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O-001
PRE-ENUCLEATION CHEMOTHERAPY IN ADVANCED INTRAOCULAR
RETINOBLASTOMA IN CENTRAL AMERICA. LONG TERM FOLLOW-UP:
AHOPCA II
S. Luna-Fineman1, A. Alejos2, G. Amador3, S. Alabi4, M. Barnoya5, R. Benavides6,
M. Castellanos7, R. Dominguez8, J. Gamboa9, L. Fu10, C. Maldonado3, R.A. Morales11,
R. Ortiz12, G. Mendez12, G. Chantada13, C. Rodriguez-Galindo14
1Stanford University, Pediatric Hematology/Oncology, Palo Alto, USA; 2Unidad
Nacional de Oncologia Pediatrica, Ophthalomogy, Guatemala, Guatemala; 3Hospital
Escuela, Ophthalmology, Tegucigalpa, Honduras; 4Hospital Bloom,
Hematology/Oncology, San Salvador, El Salvador; 5Unidad Nacional de Oncologia
Pediatrica, Ophthalmology, Guatemalag, Guatemala; 6Hospital Seguro Social,
Ophthalmology, San Jose, Costa Rica; 7Unidad Nacioal de Oncologia Pediatrica,
Hematology/Oncology, Guatemala, Guatemala; 8Hospital Bloom, Ophthalmology, San
Salvador, El Salvador; 9Hospital Seguro Social, Pediatric Hematology/Oncology, San
Jose, Costa Rica; 10Hospital Escuela, Pediatric Hematology/Oncology, Tegucigalpa,
Honduras; 11Hospital La Mascota, Ophthalmology, Managua, Nicaragua; 12Hospital La
Mascota, Hematology/Oncology, Managua, Nicaragua; 13Hoslpital Garrahan, Pediatric
Hematology/Oncology, Buenos Aires, Argentina; 14Dana-Farber Cancer
Institute/Harvard Medical School, Pediatric Hematology/Oncology, Boston, USA
Background/Objectives: A significant percentage of patients in Central America present
with buphthalmos, carrying a high risk of globe rupture and orbital contamination. In
2007, the protocol AHOPCA II introduced a study of chemotherapy before enucleation
in children with buphthalmos and for families who refused enucleation at diagnosis.
This is the final report.
Design/Methods: Patients with advanced intraocular disease were considered
standard-risk and underwent enucleation. Those with diffuse invasion of choroid,
post-laminar optic nerve, or anterior chamber invasion received 4-6 cycles of adjuvant
chemotherapy (vincristine 1.5 mg/m2 and, carboplatin 500 mg/m2 day 1, and etoposide
100 mg/m2 days 1-3). Patients with buphthalmos or perceived to be at risk for refusal or
abandonment were considered high risk and given 2-3 cycles of chemotherapy before
scheduled enucleation and adjuvant chemotherapy to complete 6 cycles regardless of
pathology. All cases were discussed via online meetings.
Results: From 2007 to 2014, 396 patients were enrolled on AHOPCA II; 239 had IRSS
stage I (174 unilateral). There were no refusals; 143 had upfront enucleation, 95 had
pre-enucleation chemotherapy, and 1 is pending enucleation. Of 95 high-risk group, 8
abandoned, 20 had relapse/progression (13 bilateral), 6 had toxic deaths and 61 are alive
at first event. Of high risk patients, OS for 56 with unilateral disease was 80±0.06 at 7
years. For patients with buphthalmos OS was 77%±0.07. The estimated 7-year OS
(abandonment sensitive) for all IRSS 1 was 90±0.03 and 79±0.04 for standard-risk and
high-risk patients, respectively (p=0.007).
Conclusion: AHOPCA was able to address advanced intraocular disease with an
innovative approach. Histopathology at the time of enucleation can define risk. In eyes
with buphthalmos and patients with risk of abandonment, neo-adjuvant chemotherapy
is effective, when followed by post-enucleation chemotherapy. This approach saved
patients from ocular rupture and intensified therapy; and reduced refusal rate compared
to our previous experience.
O-002
OUTCOMES FOR CHILDREN AND ADOLESCENTS WITH HODGKIN
LYMPHOMA 2000-2010: A FIRST REPORT BY THE SOUTH AFRICAN
CHILDREN’S CANCER STUDY GROUP
J. Geel1, B. Rowe2, T. Chirwa3, F. Omar4, D. Stones5, Y. Goga6, D. Stefan7, B. Van
Emmenes8, O. Wedi9, M. Vaithilingum10, M. Hendricks11
1Faculty of Health Sciences- University of the Witwatersrand, Division of Paediatric
Haematology and Oncology- Charlotte Maxeke Johannesburg Academic Hospital,
Johannesburg, South Africa; 2Faculty of Health Sciences- University of the
Witwatersrand, Division of Paediatric Haematology and Oncology-Chris Hani
Baragwanath Academic Hospital, Soweto, South Africa; 3Faculty of Health Sciences-
The University of the Witwatersrand, Division of Epidemiology and Biostatistics- School
of Public Health, Johannesburg, South Africa; 4University of Pretoria, Division of
Paediatric Haematology and Oncology-Steve Biko Academic Hospital, Pretoria, South
Africa; 5University of the Free State, Division of Paediatric Haematology and Oncology-
Universitas Hospital, Bloemfontein, South Africa; 6Nelson R Mandela School of
Medicine- University of KwaZulu Natal, Division of Paediatric Haematology and
Oncology-Inkosi Albert Luthuli Central Hospital, Durban, South Africa; 7University of
Stellenbosch, Division of Paediatric Haematology and Oncology-Tygerberg Hospital,
Stellenbosch, South Africa; 8Division of Paediatric Haematology and Oncology, Frere
Hospital, East London, South Africa; 9Polokwane Provincial Hospital, Division of
Paediatric Haematology and Oncology, Polokwane, South Africa; 10Netcare Parklands
Hospital, Paediatric Haematology and Oncology Practice, Durban, South Africa;
11Faculty of Health Sciences- Department of Paediatrics and Child Health-University of
Cape Town, Division of Paediatric Haematology and Oncology-Red Cross War Memorial
Children’s Hospital, Cape Town, South Africa
Background/Objectives: A multicentre retrospective study was conducted by the South
African Children’s Cancer Study Group (SACCSG) to analyse the outcome and
prognostic factors of paediatric patients with biopsy-proven Hodgkin lymphoma (HL)
in South Africa. HL has excellent survival rates in high income countries, but there is
scant data on outcome in South African and African patients. Differing approaches to
treatment are used in centres across the country, and the SACCSG has embarked on a
programme to audit outcomes in order to harmonise treatment protocols.
Design/Methods: All dedicated paediatric oncology units participated in a retrospective
data review. All patients with Hodgkin lymphoma treated between January 2000 and
December 2010 were included. Survival analysis was conducted using Kaplan-Meier
survival plots. Prognostic factors were generated using the Cox regression model.
Results: Two hundred and ninety five patients were elligible for inclusion. The mean age
at presentation was 9.63 years (range 2.9 – 18.8). Fifty five percent of patients presented
with Stage III and IV disease. Ten percent of patients were HIV positive. First-line
therapy consisted of ABVD in 161 patients, OEPA/OPPA-COPP in 98 and
ABVD-ChlVPP in 34 patients. The five year OS was 79% (95% CI 73-84%).
OEPA/OPPA-COPP was found to be most myelosuppressive, but patients receiving
ABVD-ChlVVP had the highest rate of infections. Treatment with ABVD was
associated with higher survival rates (p = 0.028) while black race (p = 0.001), B
symptoms (p = 0.001), HIV infection (p < 0.001) and under-resourced settings (p =
0.0278) were associated with a poorer prognosis.
Conclusion: Overall survival rates are encouraging for a middle income country,
although economic disparities continue to impact negatively on outcomes. These results
will form the basis for national protocol development and will be used to lobby for
more equitable allocation of resources for paediatric cancer care.
Pediatr Blood Cancer DOI 10.1002/pbc
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O-003
PREDICTION OF PROGNOSIS BY PREOPERATIVE CHEMOTHERAPY
RESPONSE IN HEPATOBLASTOMA PATIENTS TREATED BY JPLT-2
PROTOCOL
E. Hiyama1, T. Hishiki2, I. Kohmei3, K. Watanabe4, T. Oue5, M. Yano6, K. Hoshino7,
I. Tomoko8, K. Koh9, Y. Tanaka10, K. Sho11, Y. Ueda11
1Hiroshima University Hospital, Hiroshima, Japan; 2Chiba Children’s Hospital, Pediatric
Surgery, Chiba, Japan; 3Teikyo University Mizonokuchi Hospital, Pediatrics, Kawasaki,
Japan; 4Shizuoka Children’s Hospital, Department of Hematology and Oncology,
Shizuoka, Japan; 5Hyogo Colleage of Medicine, Department of Pediatric Surgery,
Nishinomiya, Japan; 6Akita University, Department of Pediatrics, Akita, Japan; 7Keio
University, Department of Pediatric Surgery, Tokyo, Japan; 8Kyoto Prefectural University
of Medicine, Department of Pediatrics, Kyoto, Japan; 9Saitama Children’s Medical
Center, Department of Hematology/Oncology, Saitama, Japan; 10Kanagawa Children’s
Medical Center, Clinical Research Institute and Department of Pathology, Yokohama,
Japan; 11Hiroshima University Hospital, Pediatric Surgery, Hiroshima, Japan
Background/Objectives: The Japanese Study Group for Pediatric Liver Tumor(JPLT)-2
study (1999-2012) was designed to evaluate the efficacy of cisplatin/pirarubicin for
hepatoblastoma (HB). We considered HBs in 3 risk categories as follows: standard
(tumors involving three or fewer sectors of the liver), intermediate (tumors involving all
sectors of the liver or invasion into portal or hepatic vein) and high (tumor with distant
metastasis). In this study, we aimed to clarify whether preoperative chemotherapy
response represents a prognostic factor for HB.
Design/Methods: In the JPLT-2 study, 385 HB children were eligible for inclusion.
Except for primary resected cases, after 2 cycles of preoperative chemotherapy, tumor
response evaluation by imaging was classified into CR, PR, NC, PD according to
RECIST criteria and cases were defined as responsive if serum AFP levels declined by
at least 90% of the highest AFP level.
Results: Among the 385 cases, there were 31 PRETEXT I, 120 II, 145 III, and 89 IV,
including 86 metastatic HBs. The 3-year EFS/OS of standard risk HBs were 94/82%,
while those of intermediate and high risk HBs were 64/49% and 34/28%, respectively. In
the standard risk group except for primary resected cases, EFS/OS (86%/96%) of the
CR/PR cases were significantly better than other cases (58%/81%) and EFS/OS
(96%/100%) of AFP reduced cases were significantly better than others (53%/84%) (P <
0.05). In the intermediate/high risk groups, there were no significant differences in
EFS/OS when using these preoperative chemotherapeutic response classifications.
Conclusion: Evaluation of efficacy of preoperative chemotherapy after two cycles is
useful for standard risk HB. Therefore, to improve the prognosis and to reduce side
effects in this risk group, it may be beneficial for responders to undergo primary tumor
resection and for non-responders to reconsider their chemotherapeutic regimen after
two cycles. In intermediate/high risk HBs, other response criteria should be adopted for
evaluation of treatment efficacy.
O-004
SHORT (STI) AND LONG TERM INFUSION (LTI) OF CH14.18/CHO
IMMUNOTHERAPY: TOXICITY PROFILES AND OUTCOMES IN 530 HIGH
RISK NEUROBLASTOMA (HR-NBL) PATIENTS IN TWO SIOPEN TRIALS
R. Ladenstein1, U. Poetschger2, J. Gray3, D. Valteau Couanet4, R. Luksch5, V. Castel6,
I. Yaniv7, G. Laureys8, M. Elliott9, J. Michon10, C. Owens11, T. Trahair12, G. Chi Fung
Chan13, E. Ruud14, H. Schroeder15, M. Beck Popovic16, E. Glogova2, G. Schreier17,
H. Loibner18, H. Lode19
1St. Anna Children’s Hospital and St. Anna Kinderkrebsforschung e.V., Paediatric
Haematology and Oncology / Studies & Statistics for Integrated Research and Projects,
Vienna, Austria; 2St. Anna Kinderkrebsforschung e.V., Studies & Statistics for Integrated
Research and Projects, Vienna, Austria; 3University of Southampton, Paediatric
Haematology and Oncology, Southampton, United Kingdom; 4Institut Gustave Roussy,
Paediatric Haematology and Oncology, Villejuif, France; 5Istituto Nazionale Tumori di
Milano, Paediatric Haematology and Oncology, Milan, Italy; 6Hospital La Fe Valencia,
Pediatric Hematology and Oncology- Pediatric Oncology Unit, Valencia, Spain;
7Schneider Children’s Medical Center of Israel, Paediatric Haematology Oncology, Petah
Tikva, Israel; 8University Hospital Gent, Paediatric Haematology and Oncology, Gent,
Belgium; 9Leeds Teaching Hospitals NHS Trust, Paediatric Haematology Oncology,
Leeds, United Kingdom; 10Institut Curie, Paediatric Haematoloy and Oncology, Paris,
France; 11Our Lady’s Children’s Hospital, Paediatric Haemtology and Oncology, Dublin,
Ireland; 12Syndney Children’s Hospital, Paediatric Haematology and Oncology,
Randwick, Australia; 13Queen Mary Hospital, Paediatric Haematology and Oncology,
Hong Kong, Hong Kong- China; 14Rikshospitalet, Paediatric Haematology and
Oncology, Oslo, Norway; 15University Hospital of Aarhus- Skejby, Paediatric
Haematology and Oncology, Aarhus, Denmark; 16University Hospital, Paediatric
Haematology Oncology Unit, Lausanne, Switzerland; 17AIT Austrian Institute of
Technology GmbH, Safety & Security Department, Graz, Austria; 18Apeiron Biologics
AG, CEO, Vienna, Austria; 19Ernst Moritz Arndt University of Greifswald, Paediatric
Haematology and Oncology, Greifswald, Germany
Background/Objectives: Design of a tolerable and effective immunotherapy with
ch14.18/CHO monoclonal antibody immunotherapy (IT) ± subcutaneous interleukin 2
(scIL2).
Design/Methods: The HR-NBL1/SIOPEN Phase III trial
(APN311-302)(EudraCT:2006-001489-17) randomized 406 high risk first-line
neuroblastoma patients (HR-pts) in consolidation phase with oral 13-cis-RA
(160 mg/m2,d19-32) to receive 100 mg/m2 ch14.18/CHO (d8-12) as 5 daily 8-hour
short-term infusion (STI) alone (STIA) or combined with 6×106IU/m2 scIL2
(d1-5;8-12) (STIB). In the SIOPEN-Phase II study
(APN311-202)(EudraCT:2009-018077-31) 124 relapsed/refractory neuroblastoma pts
(VHR-pts) received a 10 day long-term infusion (LTI) of 100 mg/m2 ch14.18/CHO
(d8-17) aiming to reduce the pain profile and scIL2 and 13-cis-RA as outlined above.
Both trials planned a total of 5 IT cycles. Median follow-up was 2.1 years (0-4.5) for the
STI and 0.8 years (0-3) for the LTI trial.
Results: General tolerance improved with LTI. A Lansky performance status of 30%
was found in 10% of LTI-pts, 39% STIB-pts and 17% STIA-pts (p<0.001). CTC-grade
3&4 allergic reactions were observed in 10% LTI-pts, 20% STIB-pts and 9% STIA-pts
(<0.001). Incidence of capillary leak and CTC-grade 3&4 fever was not different
between scIL2 containing LTI (9% and 48%) and STIB (9% and 40%) but significantly
lower without scIL2 STIA (1% and 14%). Markedly reduced pain and intravenous
morphine usage was observed in the LTI setting. The 2-year EFS rates for HR-pts in
CR (or VGPR/PR) treated with STIA were 65%±5% (58%±6%) and with STIB
67%±5% (59%±6%) indicating no benefit for scIL2. The 2-year EFS rate in LTI treated
VHR-pts was 50%±7%. Early termination of IT occurred in 18% in STIA but in 44%
in STIB (36% toxicity-related, 8% progressions) and in 42% in LTI (21%
toxicity-related, 21% progressions).
Conclusion: Although disease risk-profiles differed between trials, reduced toxicities
were observed with LTI. Ongoing randomised SIOPEN trials will clarify the role of
scIL2 with the LTI scheme.
O-005
INTEGRATED GENOMIC ANALYSIS IDENTIFIES SPECIFIC ALTERATIONS
AND ACTIVATION OF YAP IN RELAPSED NEUROBLASTOMA
A. Eggert1, A. Schramm2, J. Köster3, Y. Assenov4, A. Kristina2, A. Engesser5,
Y. Kahlert5, J. Theissen5, B. Hero5, F. Roels5, M. Peifer6, K. Astrahantseff7,
K. dePreter8, H. Lode9, F. Speleman8, P. Schmezer4, F. Westermann4, S. Rahmann3,
M. Fischer5, J. Schulte7
1Charité Berlin, Berlin, Germany; 2University Duisburg-Essen, Pediatric Oncology,
Essen, Germany; 3University Duisburg-Essen, Genome Informatics, Essen, Germany;
4DKFZ Heidelberg, Epigenetics, Heidelberg, Germany; 5University Hospital Cologne,
Pediatric Oncology, Cologne, Germany; 6University Hospital Cologne, Translational
Genomics, Cologne, Germany; 7Charité Berlin, Pediatric Oncology, Berlin, Germany;
8University of Ghent, Human Genetics, Ghent, Belgium; 9University Hospital Greifswald,
Pediatric Oncology, Greifswald, Germany
Background/Objectives: Neuroblastoma is a malignancy of the developing sympathetic
nervous system that is often lethal when relapse occurs, but the molecular mechanisms
behind this process are poorly defined.
Design/Methods:We used whole-exome sequencing, mRNA expression, arrayCGH and
DNA methylation analysis to holistically characterize 16 paired samples from
neuroblastoma patients at diagnosis and relapse.
Results: Global allele frequencies at relapse indicated clonal mutation selection during
disease progression. Promoter methylation patterns were consistent over disease course
and patient-specific. No relapse tumor acquired new mutations in previously identified
neuroblastoma driver genes, but MYCN amplification was acquired in one. Inactivating
mutations in the putative PTPN14 tumor suppressor and a relapse-specific activity
pattern for the PTPN14 target gene, YAP, were identified, and represent the first hint
for Hippo/YAP signaling involvement in neuroblastoma relapse. Overexpressing a
naturally occurring mutant PTPN14 in a neuroblastoma cell line caused YAP nuclear
translocation and enhanced clonogenic survival. Recurrent new mutations in HRAS,
KRAS, DOCK8, and genes mediating cell-cell interaction in 13 of 16 relapse tumors
also point to disturbances in signaling pathways mediating mesenchymal transition.
Conclusion: Our results suggest a role for Hippo/YAP signaling and possibly
mesenchymal transition processes and their modulation by genomically altered
upstream signaling in disease recurrence.
O-006
MOLECULAR (RE-)CLASSIFICATION AND GENETIC CHARACTERIZATION
OF CNS PRIMITIVE NEUROECTODERMAL TUMORS (CNS-PNET)
M. Kool1, D. Sturm1, V. Hovestadt2, D.T. Jones1, P.A. Northcott1, P. Lichter2,
D. Capper3, A. Korshunov3, S.M. Pfister1
1German Cancer Research Center, Pediatric Neurooncology, Heidelberg, Germany;
2German Cancer Research Center, Molecular Genetics, Heidelberg, Germany; 3University
Hospital Heidelberg, Neuropathology, Heidelberg, Germany
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Background/Objectives: Childhood CNS primitive neuro-ectodermal tumors
(CNS-PNETs; WHO °IV) are poorly differentiated embryonal tumors with early onset
and aggressive clinical behavior. Histological diagnosis can be complicated by
morphological heterogeneity and divergent differentiation. Recent studies suggest the
existence of molecular subgroups of CNS-PNETs sharing biological characteristics
with other childhood CNS tumors.
Design/Methods:We analyzed 254 fresh-frozen or paraffin-embedded CNS-PNET
samples using DNA methylation (n=254) and expression (n=76) arrays. (Epi-)genetic
profiles of CNS-PNETs were compared to those of >5000 other childhood brain
tumors including embryonal, astrocytic, and ependymal entities, and their respective
molecular subgroups.
Results: DNA methylation and gene expression profiles showed a clear segregation of
pediatric brain tumors by histological entities and molecular subgroups. Interestingly,
CNS-PNET profiles showed a significant overlap with various well-defined entities,
including AT/RT, ETMR, high-grade glioma, medulloblastoma, and ependymoma,
which was validated by the presence of characteristic genetic hallmarks, such as
mutations in SMARCB1, IDH1, or H3F3A; amplification of 19q13.42; or other
established protein markers. Strikingly, a subset (25%) of CNS-PNETs, which could
not be reclassified, segregated into four distinct molecular subgroups, each with its own
characteristic pattern of DNA-methylation, copy number aberrations, gene expression,
and mutations. We also identified several cases among previously diagnosed
glioblastomas, ependymomas or other brain tumors that now classify to one of these
true CNS-PNET groups.
Conclusion: The correct classification of CNS-PNETs remains challenging. Based on
DNA methylation, many cases can be reliably re-classified, indicating that a significant
proportion of CNS-PNETs may comprise a variety of other tumor subtypes. These
findings suggest that the use of established and novel subgroup markers is needed in
order to assist the histopathological evaluation of these tumors. In addition, we have
identified a number of true CNS-PNET subtypes and are currently analyzing them in
more detail in order to elucidate the genetics and clinical behavior of these distinct
groups.
Free Papers 01: Stem Cell Transplantation
O-007
VIABILITY OF CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS
(PBSC) DOES NOT GUARANTEE FUNCTIONAL ACTIVITY: IMPORTANT
IMPLICATIONS FOR QUALITY ASSURANCE OF STEM CELL TRANSPLANT
PROGRAMMES
D. Morgenstern1, M. Brocklesby2, G. Ahsan2, M. Watts3, C. Cale2
1Great Ormond Street Hospital, Paediatric Oncology, London, United Kingdom; 2Great
Ormond Street Hospital, Cell Therapy Laboratory, London, United Kingdom; 3University
College London Hospital, Wolfson Cellular Therapy Unit, London, United Kingdom
Background/Objectives: Cryopreserved PBSC are used for myeloablative therapy
(MAT) rescue in the autologous setting, and occasionally for allografts. Standard PBSC
quality assurance (QA) uses CD34+ cell counts and viability using vital dyes. In 2013,
concerns were raised at Great Ormond Street Hospital (GOSH) about a series of
patients who experienced delayed engraftment after MAT with cryopreserved PBSC.
Design/Methods: Root cause analysis was undertaken including all aspects of the
pathway: PBSC mobilisation, apheresis, cryopreservation, reinfusion and count
recovery. Data were collected from patient and laboratory records and interviews with
staff. When initial investigations failed to identify a cause, a series of experiments were
undertaken in which a single PBSC product was divided into three and cryopreserved in
parallel using a control-rate freezer (CRF) or passive freezing method (−80°C freezer)
at GOSH, and the same passive freezing at another centre. Viability by thaw
CD34+/7AAD- flow cytometry and colony assays (CFU-GM) were undertaken.
Results: Eight consecutive patients who received PBSC cryopreserved at GOSH
experienced delayed engraftment. Although PBSC viability and cell doses were
adequate in all cases, the cryopreservation method was investigated further. Comparison
of parallel cryopreservation methods (repeated x4) revealed equivalent and adequate
PBSC viability in all experiments. However, although CFU-GM assays demonstrated
colonies from the products cryopreserved using passive freezing (both at GOSH and at
the other laboratory), products cryopreserved using the CRF did not form any colonies.
The CRF device was shown to be operating within manufacturer’s specifications.
Conclusion: The cause of the cryopreservation problem at GOSH remains unclear.
Nevertheless, this experience has important implications for quality assurance for all
transplant programmes, particularly those using cryopreserved products. The failure of
thaw CD34+/7AAD- counts, the best routine QA test available, to ensure PBSC
function is of great concern and should prompt a reassessment of protocols and QA
procedures by all centres.
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PERSISTENCE AND REACTIVATION OF HUMAN ADENOVIRUSES IN THE
IMMUNOCOMPROMISED HOST
T. Lion1, K. Kosulin1, E. Geiger1, A. Vécsei2, W.D. Huber3, M. Rauch1, E. Brenner4,
F. Wrba4, K. Hammer2, A. Innerhofer2, U. Pötschger5, G. Fritsch6, A. Lawitschka7,
S. Matthes-Leodolter7
1Children’s Cancer Research Institute, Molecular Microbiology, Vienna, Austria;
2St.Anna Children´s Hospital, Gastroenterology, Vienna, Austria; 3Medical University
Vienna, Pediatrics, Vienna, Austria; 4Medical University Vienna, Pathology, Vienna,
Austria; 5Children’s Cancer Research Institute, SIR2P, Vienna, Austria; 6Children’s
Cancer Research Institute, Flow Cytometry, Vienna, Austria; 7St.Anna Children´s
Hospital, Stem Cell Transplantation, Vienna, Austria
Background/Objectives: Primary infections with human adenoviruses (HAdVs) most
commonly occur during early childhood and can lead to viral persistence in different
tissues. Reactivation in patients with impaired immune surveillance is associated with
high morbidity and mortality, particularly in paediatric haematopoietic stem cell
transplant (HSCT) recipients. Although invasive HAdV infections are thought to
mainly arise from the gastrointestinal (GI) tract, and rising virus levels in serial stool
specimens were shown to precede disseminated disease, the specific sites of HAdV
persistence and proliferation are not well characterised.
Design/Methods:We have prospectively screened biopsies from 143 immunocompetent
children undergoing routine gastrointestinal endoscopy and monitored serial stool
specimens from 148 paediatric HSCT recipients for the presence of HAdV by real-time
PCR screening. The intracellular location and protein expression of HAdV were
determined by in-situ hybridisation and immunohistochemistry.
Results: Persistence of various HAdV species in the GI tract was identified in 31% of
the children screened, with the highest prevalence in the terminal ileum. HAdV
persistence was identified primarily in lymphoid cells of the lamina propria and
immunohistochemistry indicated low virus production. By contrast, transplant
recipients with HAdV infection revealed a high concentration of replicating HAdV in
intestinal epithelial cells. The frequency of HAdV persistence in the GI tract and the
prevalence of HAdV species in immunocompetent children were similar to the rate of
reactivation and the prevalence of HAdV species found in HSCT recipients. Detection
of intestinal HAdV shedding pre-transplant correlated with high risk of invasive
infection.
Conclusion: HAdV persistence in the GI tract is a likely origin of infectious
complications in severely immunocompromised children. Intestinal lymphocytes
represent a reservoir for HAdV persistence and reactivation, while the intestinal
epithelium is the main site of viral proliferation preceding dissemination. The findings
have important implications for assessing the risk of life-threatening invasive HAdV
infections.
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DAY+100 SURVIVAL ANALYSIS BY PRIOR HEMATOPOIETIC STEM CELL
TRANSPLANT TYPE FROM AN ONGOING US STUDY OF DEFIBROTIDE
FOR HEPATIC VENO-OCCLUSIVE DISEASE
P. Richardson1, A. Smith2, B. Triplett3, N. Kernan4, S. Grupp5, J. Antin6, L. Lehmann7,
M. Miloslavsky8, R. Hume8, A. Hannah8, B. Nejadnik8, R. Soiffer6
1Harvard Medical School, Jerome Lipper Multiple Myeloma Center- Division of
Hematologic Malignancy- Department of Medical Oncology- Dana-Farber Cancer
Institute, Boston- MA, USA; 2University of Minnesota, Division of Pediatric Blood and
Marrow Transplantation, Minneapolis- MN, USA; 3St. Jude Children’s Research
Hospital, Bone Marrow Transplantation and Cellular Therapy, Memphis- TN, USA;
4Memorial Sloan-Kettering Cancer Center, Pediatric BMT Service, New York-NY, USA;
5The Children’s Hospital of Philadelphia, Pediatric Oncology, Philadelphia- PA, USA;
6Dana-Farber Cancer Institute, Stem Cell/Bone Marrow Transplantation Program-
Division of Hematologic Malignancy- Department of Medical Oncology, Boston- MA,
USA; 7Harvard Medical School, Center for Stem Cell Transplantation- Division of
Hematologic Malignancy- Department of Medical Oncology- Dana-Farber Cancer
Institute, Boston- MA, USA; 8Jazz Pharmaceuticals- Inc., Clinical, Palo Alto- CA, USA
Background/Objectives:Hepatic veno-occlusive disease (VOD; or sinusoidal obstruction
syndrome) is an unpredictable, life-threatening complication of hematopoietic stem cell
transplant (HSCT). Severe VOD (sVOD) is associated with >80% mortality; it is
characterized clinically by multi-organ failure (MOF). In the European Union,
defibrotide is approved for treatment of sVOD in HSCT. In the United States,
defibrotide is available through an ongoing, expanded-access, protocol-directed
treatment IND (T-IND) in VOD post-HSCT/chemotherapy. T-IND day+100 survival
was analyzed in autologous/allogeneic subgroups.
Design/Methods: Patients received defibrotide 25 mg/kg/day, 21 days recommended.
Eligibility: Originally, sVOD with MOF (renal/pulmonary) by Baltimore criteria post
HSCT; amended to include patients post HSCT/chemotherapy with non-sVOD
(without MOF), VOD per modified Seattle criteria, or biopsy-proven VOD.
Results: Of 641 patients post HSCT/chemotherapy enrolled through 2013 receiving
defibrotide (median treatment, 21 days), 57% were male; median age was 13y (range
0–69y) with 58% (372/636) 16y. Most common underlying diagnoses included acute
myelogenous leukemia (27%) and acute lymphocytic leukemia (23%). Most common
graft-vs-host disease agents were tacrolimus (41%), cyclosporine (30%), and
methotrexate (29%). Of 336 patients with sVOD and HSCT, 54% were male; median
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age was 12y (range 0–69y) with 61% (204/333) 16y. For 526 patients post HSCT with
survival data, 467 received allografts and 56 received autografts (3 grafts unknown);
sVOD rates were 54% and 48%, respectively. Day+100 survival post allograft was 50%
(95% CI 46–55%) overall, 43% (37–49%) for sVOD, 58% (52–65%) for non-sVOD.
Post-autograft survival: 66% (54–79%) overall, 59% (41–78%) for sVOD, 72% (56–89%)
for non-sVOD.
Conclusion: In this study, day+100 survival rates in both allograft and autograft sVOD
subsets were consistent with prior defibrotide studies. The higher survival rates in the
non-sVOD subsets indicate further study is warranted to determine the impact of
treatment earlier in the course of VOD. Support: Jazz Pharmaceuticals.
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OUTCOME OF SALVAGE CHEMOTHERAPY FOLLOWED BY STEM CELL
TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN
LYMPHOMA IN CHILDREN- A SINGLE CENTRE EXPERIENCE
S. Panda1, G. Narula1, A. Gupta2, D. Rajamanickam2, A. Gokarn2, S. Punatar2,
L.J. Mathew3, B. Bagal3, B. Arora1, N. Khattry3, S. Banavali2
1Tata Memorial Hospital, Pediatric Oncology, Mumbai, India; 2Tata Memorial
Hospital, Medical Oncology, Mumbai, India; 3Tata Memorial Hospital, Stem Cell
Transplantation, Mumbai, India
Background/Objectives: Hodgkin Lymphoma (HL) in children is highly curable with
overall survival (OS) approaching 70% even in advanced lymphoma. Relapsed and
Refractory HL however, has poor outcomes unless managed with aggressive salvage
chemotherapy (CT) followed by Stem Cell Transplantation (SCT). Outcomes of
children with relapse/ refractory HL managed at a large tertiary center in a developing
were analyzed.
Design/Methods: Case records of patients less than 18 years age undergoing SCT for
Relapsed or Refractory HL from Jan 2008 to February 2015 were analyzed
retrospectively. Patient and disease characteristics, treatment histories and salvage/ SCT
strategies used were studied and outcomes analyzed. Progression Free Survival (PFS)
and OS were calculated by Kaplan-Meier method and univariate analysis on risk
factors was done.
Results: Thirty-five patients underwent transplant at a median age of 13 yrs (5-18 yrs).
At diagnosis, 63% had Stage III or IV disease, 66% had B symptoms and 28% had
bulky disease. Thirty-four received Adriamycin, Bleomycin, Vinblastine, Dacarbazine
(ABVD) as initial chemotherapy followed by 2 or more salvage regimens in 16. Involved
Field Radiation Therapy was given in 18 prior to SCT. All except 1 had stage III or IV
disease prior to use of salvage therapy. GDP (Gemcitabine, Cisplatin, Steroids) was
used as salvage CT pre- SCT in 43% cases followed by Mitoxantrone, Ifosamide,
Etoposide in 31%. Thirty-two children underwent autologous SCT with Lomustine,
Ara-C, Cyclophosphamide, Etoposide (LACE) conditioning while 2 underwent
allogeneic SCT. At time of SCT, 8 were not in complete remission (CR). Two (5.7%)
had transplant related mortality (TRM). PFS and OS were 60% and 68% at 4 years. On
univariate analysis, CR status pre-SCT significantly impacted outcome (p=0.001).
Conclusion: Salvage CT followed by SCT in Relapse/ Refractory HL has favorable
outcome with 2/3rd patients benefitting with low TRM. It is important to achieve CR
pre-SCT.
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A RISK-ADAPTED, RESPONSE-BASED THERAPEUTIC REGIMEN USING A
MODIFIED STANFORD V APPROACH FOR THE TREATMENT OF
CHILDRENWITH HIGH RISK HODGKIN LYMPHOMA, AHOPCA LH 2004
E.M. Castellanos1, M. Metzger2, L.F. Baez3, Y. Gamboa4, A. Pena Hernandez5,
S. Alabi6, S. Luna-Fineman7, R. Nieves8, P. de Alarcon9
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San Jose, Costa Rica; 5Hospital Escuela Materno Infantil, Oncologia Pediatrica,
Tegucigulpa, Honduras; 6Hospital de Ninos Benjamin Bloom, Oncologia Pediatrica, San
Salvador, El Salvador; 7Unidad Nacional de Oncologia Pediatrica, Oncologia Pediatrica,
Guatemala City, Guatemala; 8Hospital Universitario, Oncologia Pediatrica, Santa
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Background/Objectives: Hodgkin Lymphoma (HL) is highly curable with reported
event-free survival (EFS) estimates of greater than 90% even in high-risk patients.
Unfortunately, EFS of HL in low-income countries is much lower, about 50%. We now
report mature five-year results from this previously reported study.
Design/Methods: All newly diagnosed biopsy proven HL patients stages IIB, IIIB and
IV, that presented between April 2004 and April 2009 were eligible. Treatment consisted
of a modified Stanford V regimen with cyclophosphamide substituting for nitrogen
mustard and instead of 35 Gy involved field radiation therapy (IFRT) like in the
original regimen only gave 20Gys IFRT to subjects with a complete anatomical response
(CR) at the end of chemotherapy and 25 Gy to those with a partial response (PR).
Results: Of 221 patients enrolled in the protocol, 206 were evaluable. Male subjects
predominated (79%) with a median age of 10 years (2-19 years). Forty-nine (23%) had
stage IIB, 100 (48%) stage IIIB, 4 (2%) stage IVA and 50 (24%) stage IVB HL.
Forty-five per cent of patients had nodular sclerosis, 42% mixed cellularity, 5%,
lymphocyte predominant, 2% lymphocyte depleted and for 6% histology was not
specified. The most important grade 3 and 4 toxicities were hematological (75%) and
there were two grade 5 toxicities, one infectious and one pulmonary. EFS (±SE) at 5
years was 55.4 % (± 4.4), considering abandonment of therapy as an event.
Abandonment of therapy was 14.6%. Five-year EFS by stage was: stage IIB 79% (±
6%), IIIB 56% (± 7%) and IVB 29% (± 8%).
Conclusion: Our modified Stanford V regimen was well tolerated with acceptable
toxicities. It did not require growth factor support and was delivered in an outpatient
setting. However, the EFS of patients was less than expected for the group as a whole,
(55.4%).
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PEDIATRIC HODGKIN LYMPHOMA TREATMENTWITH CHEMOTHERAPY
ALONE: FRENCH-AFRICAN PEDIATRIC ONCOLOGY GROUP (GFAOP)
EXPERIENCE
F.B. Diagne1, C. Moreira1, N. Diouf1, C. Edan2, M.A. Raquin2, C. Patte2
1CHU Aristide Le Dantec, Service d’oncologie Pédiatrique, Dakar, Senegal; 2GFAOP,
Institut Gustave Roussy, Villejuif, France
Background/Objectives: Hodgkin lymphoma (HL) is a common childhood cancer; there
is limited information regarding its management in developing countries. Until now, the
majority of children and young adults with HL are cured with combined chemotherapy
and radiation therapy in high-income countries. Sub-Saharan Africa has the poorest
supply of radiotherapy equipment. The aim of this multicentre prospective study was
to assess the safety and effectiveness of hybrid protocol COPP/ABV alone for the
management of paediatric HL in sub-Saharan Africa.
Design/Methods:Were prospectively registered children/adolescents under 18 years,
diagnosed with a histologically confirmed classical HL in seven paediatric oncology
centers in sub-Saharan Africa. Initial work-up included physical examination, chest X
ray, abdominal ultrasonography, myelogram or bone marrow biopsy. The protocol used
was COPP/ABV regimen (Cyclophosphamide, Vincristine, Prednisone, Procarbazine,
Adriblastine, Bléomycine, Vinblastine). Number of cycles was between 4 and 8
according to stage and early response, evaluated after two cycles.
Results: Between October 1st, 2006 and November 30th, 2012, 127 children with HL
were registered. Mean age was 10 years, with the age group 5-10 years representing 40%
of cases. Males represented 3/4 of the patients. There was a majority of advanced
stages: 57.2% stages III and 78.6% with B symptoms. Overall the scleronodular form
(39%) was the most common, followed by mixed cellularity form (21.3%). 44/90 were «
good responders » after 2 courses. COPP/ABV protocol was well tolerated. Overall
survival (OS) rate was 82% and event-free survival (EFS) rate 67% with mean follow up
of 3 years. The relapses were late with an average of 13 months.
Conclusion: Hybrid protocol COPP/AVB alone is feasible, with less toxicity and gives
satisfactory results in African low-income countries.
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OUTCOME OF PEDIATRIC HODGKIN LYMPHOMA TREATEDWITH ABVD:
A MULTICENTRIC ANALYSIS OF 335 PATIENTS
S. Bhethanabhotla1, S. Jain2, G. Kapoor2, M. Kalra3, A. Mahajan3, S. Vishnubhatla4,
S. Bakhshi1
1All India Institute of Medical Sciences, Division of Pediatric Oncology- Department of
Medical Oncology, New Delhi, India; 2Rajiv Gandhi Cancer Institute and Research
Centre, Pediatric Hematology/Oncology, New Delhi, India; 3Indraprastha Apollo
hospital, Pedaitric Hematology/Oncology, New Delhi, India; 4All India Institute of
Medical Sciences, Biostatistics, New Delhi, India
Background/Objectives:With advent of ABVD (Adriamycin, bleomycin, vinblastine,
dacabazine) as an effective regimen for Hodgkin lymphoma in adult population this
regimen has been successfully been used in pediatric population based on the
extrapolation of results. However there are very few studies which evaluated its efficacy
in pediatric population.
Design/Methods: Between January 2003 and December 2013, 359 patients diagnosed
Hodgkin lymphoma received ABVD regimen. Early stage and patients with bulky
disease received additional radiotherapy. Data from 3 tertiary cancer centers in India
was collected andanalysis was done for freedom from treatment failure (FFTF), overall
survival (OS) after obtaining ethical clearance from the institute ethics committee of
respective centers.
Results: Of 359 patients 8 patients received treatment other than ABVD and 16 patients
were lost to follow up before treatment initiation. Of 335 patients who received ABVD,
151 and 183 were early and advanced stages respectively. Complete remission was
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attained in 92.5% of patients. While 11 (3.3%) patients achieved partial remission at the
end of treatment, 10 of them achieved complete response on observation and follow up.
Median follow up duration of the cohort was 46.5 months. Median freedom from
treatment failure (FFTF) and overall survival (OS) was not reached for cohort. FFTF
and OS at 5 yr was 89.9%± 0.02 and 96.9%±0.01 respectively. FFTF at 5 yr for early
and advanced stages was 96.9±1.5% and 83.4±3 %(logrank,p=0.003) respectively.
Total 8 patient died of whom 5 died of progressive disease and 3 had treatment related
mortality. On multivariate analysis only more than 3 nodal regions, extranodal disease
were significantly associated with inferior outcome. Patients having either of them or
both have odds ratio for treatment failure is 4.3 and 19.3 respectively.
Conclusion: Combined modality treatment with ABVD and radiotherapy results in
excellent long term outcome in children with Hodgkin lymphoma.
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ANAPLASTIC LARGE CELL LYMPHOMA IN CENTRAL AMERICA: A
REPORT FROM THE CENTRAL AMERICAN ASSOCIATION OF PEDIATRIC
HEMATOLOGY ONCOLOGY (AHOPCA)
F. Ceppi1, R. Ortiz2, F. Antillon3, A. Pena4, R. Velasquez5, W. Gomez6, J. Gamboa7,
S. Gupta8
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4Hospital Escuela-Universitario, Department of Hemato-Oncology, Tegucigalpa,
Honduras; 5Hospital Benjamin Bloom, Department of Onco-Hematology, San Salvador,
El Salvador; 6Department of Hematology-Oncology, Children’s Hospital Robert Reid
Cabral, Santo Domingo, Dominican Republic; 7Hospital Nacional de Niños “Dr. Carlos
Sáenz Herrera”, Department of Hematology, San José, Costa Rica; 8Hospital for Sick
Children, Hematology Oncology, Toronto, Canada
Background/Objectives:While anaplastic large cell lymphoma (ALCL) is curable in
high-income countries (HICs), data from low- and middle-income countries (LMICs)
are lacking. We therefore conducted a retrospective study of the Central American
Association of Pediatric Hematology Oncology (AHOPCA) experience in treating
ALCL.
Design/Methods:We included all patients age <18 years newly diagnosed with ALCL
treated between 2000 and 2013 in 7 AHOPCA institutions. Retrospective data were
extracted from the Pediatric Oncology Network Database.
Results: 28 patients met inclusion criteria. 22 (79%) had advanced disease (stage III and
IV), 4 (14%) were treated on the APO (doxorubicin, prednisone, vincristine) regimen,
and 24 (86%) on the European-based treatment regimens. 5-year overall EFS and OS
were respectively 69.5% ± 9.1% and 69.0% ± 9.3%. 5-year EFS in patients treated with
an APO regimen was 100% ± 0% compared to 65.2% ± 10.0% in patients treated with
European-based regimens; the difference was not statistically significant (P=0.24). All
10 events occurred in patients treated on European-based treatment regimens: 2
patients experienced relapse, 6 treatment related mortality (TRM), and 2 abandonment.
Conclusion: Treatment of ALCL in countries with limited resources is feasible with
similar outcomes as HIC, though the causes of treatment failure differ. Less intensive
regimens may be preferable in order to decrease TRM and improve outcomes.
Prospective clinical trials determining the ideal treatment for LMIC children with
ALCL are necessary.
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METASTATIC LOW GRADE GLIOMAS IN CHILDREN: 20 YEAR
EXPERIENCE AT ST. JUDE CHILDRENS RESEARCH HOSPITAL
O. Chamdine1, A. Broniscer1, S. Wu2, A. Gajjar1, I. Qaddoumi1
1St. Jude Children’s Research Hospital, Oncology, Memphis, USA; 2St. Jude Children’s
Research Hospital, Biostatisctics, Memphis, USA
Background/Objectives: Low-grade gliomas (LGG) are the most common brain tumors
during childhood. Long-term survivals are excellent with the current treatments.
Dissemination of LGG along the neuroaxis is rare. Robust data regarding true
incidence, outcome and best management approaches does not exist. In this study, we
describe the longest follow period up of a large cohort with metastatic LGG, at
diagnosis and/or at follow up, treated at St Jude Children’s Research Hospital.
Design/Methods: Data was retrospectively collected between January 1990, and
December 2010. Inclusion criteria were: diagnosis of metastatic LGG, age less than 21
years at diagnosis, MRI of the brain and/or spine at diagnosis and follow up.
Demographic, treatment and outcome data was collected and analyzed.
Results: A total of 599 patients with LGG were identified. Thirty-eight patients (6%)
had metastatic disease either at diagnosis or at follow up. Most of the tumors were
located in the brain (87%), one half had metastatic disease at presentation. Only 3
patients did not have tissue confirmation at diagnosis. The most common diagnosis was
pilocytic astrocytoma (55%). Chemotherapy was the most common initial treatment
modality. Median number of treatments per patient was 3 (range 1-5). Fifteen patients
(40%), died at a median of 6 years from diagnosis (range 0.8 to 15 years). Death
occurred due disease progression in all but 1 case. Median survival for the whole group
was 6.2 years (range 0.1-16.9). Overall survivals were 80.7 ± 6.6%, 63.0 ± 10.2%, and
50.9 ±16.0% at 5, 10 and 15 years respectively.
Conclusion: This study describes the longest follow up of metastatic LGG in children to
date. We showed that this disease is underestimated and entails major morbidity and
mortality. Large-scale studies are required to unveil the true incidence, study the
molecular characteristics, and determine the best treatment and follow up modalities.
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OUTCOME OF NEUROFIBROMATOSIS TYPE 1 PATIENTS TREATEDWITH
FIRST LINE VINBLASTINE FOR OPTIC PATHWAY GLIOMAS (OPG): A
CANADIANMULTICENTER STUDY
A. Lassaletta1, K. Scheinemann2, S.M. Zelcer3, J. Hukin4, B. Wilson5, N. Jabado6,
A.S. Carret7, L. Lafay-Cousin8, V. Larouche9, C. Hawkins10, G.R. Pond11, K. Poskitt12,
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Children’s Hospital at Hamilton Health Sciences, Pediatric Hematology-Oncology,
Hamilton, Canada; 3Children’s Hospital of Western Ontario, Pediatric
Hematology-Oncology, London, Canada; 4British Columbia Children’s Hospital,
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Background/Objectives: Vincristine and carboplatin continues to be the first-line
chemotherapy for children with NF-1 and OPG in the majority of countries.
Vinblastine has shown promising activity in a phase-II study in children with
recurrent/refractory low-grade glioma (LGG). The aim of this study was to assess the
activity of vinblastine in chemotherapy naïve children, and to assess the toxicity profile.
Design/Methods: Patients <18 years-old with unresectable or progressive LGG were
eligible if no previous treatment with chemotherapy or radiation. Vinblastine was
administered weekly at a dose of 6 mg/m2 over a period of 70 weeks.
Results: Overall, the study enrolled 54 patients with LGG. A total of 13 patients
(24.1%) had NF-1. Patients with NF-1 were younger at diagnosis: median age 3.84
years (range, 1.74-16.36) vs. 7 years in non-NF-1. Tumor location in all NF-1 patients
was the optic pathway. Treatment was very well tolerated, however, 5 patients (38%)
needed dose reductions. Most common toxicity was hematological: 1 patient with grade
3+ neutropenia (vs. 10 patients non-NF1). There were only 2 episodes of febrile
neutropenia, no RBC transfusions and no toxic death. Best response to chemotherapy
was assessed centrally by an independent radiologist: 2 PR, 1 MR, 8 SD, and 2 PD, for
a response rate of 23.1%. At a median follow-up of 5.37 years (3.45 – 6.57y): Only two
NF-1 patients had progression. Five-year progression free survival (PFS) was
85.1±9.7% (vs. 42±7,9% for all non-NF1, p=0.01; and 41.7±14% for non-NF1 with
OPG, p=0.01). None of the NF1 patients received radiation (0 vs. 6 non-NF1). No
patients died of progression (0 vs. 3 non-NF1).
Conclusion:Weekly vinblastine is well tolerated and can be used in NF-1 children with
OPG as first line chemotherapy with good results. The toxicity profile is lower than with
other chemotherapies, offering a better quality of life to these patients.
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A CONSENSUS WORKSHOP TO DEVELOP RISK-BASED SELECTION
CRITERIA FOR THE NEXT SIOP TRIAL OF “SIGHT-SAVING THERAPY” FOR
CHILDRENWITH NF1-ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG)
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Hey Children’s NHS Foundation Trust, Department of Radiology, Liverpool, United
Kingdom; 25University Medical Center Hamburg-Eppendorf, Department of
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Background/Objectives: The natural history of children with NF1-OPG is
unpredictable, indications for therapy to save vision, using patient, imaging and visual
factors have not been studied in Europe. In order to promote a revised and
standardised approach for the next SIOP LGG trial, a multi-disciplinary workshop
using a cohort of patients with complete imaging and clinical datasets from
SIOP-LGG2004 trial was conducted.
Design/Methods: The workshop involved specialists in neuro-radiology, ophthalmology,
NF genetics and neuro-oncology from 8 centres participating in SIOP-LGG2004 trial.
Each centre contributed cases of NF1-OPG with complete imaging, visual and clinical
datasets. Eighty -three patients were recruited (age at diagnosis: median 4.8 yrs range
1.1-13.1; m:F 37:46, median follow-up 19.2 months range 1.8-121 months). Severe
visual impairment/blindness (LogMAR >=1.0) at diagnosis and last follow up,
respectively: unilateral 16,21; bilateral 3,7. Anatomical distribution at diagnosis: Dodge
Stage A (nerves) 35; Stage B (chiasm) 16; Stage C (nearby structures) 32. Imaging
evidence of: response 31: no change:46; progression 6. Analysis of the dataset informed
consensus discussion and voting of representative cases for proposed trial criteria for
observation, treatment and randomisation, subsequent development of a web-based
survey was piloted with workshop participants.
Results: Consensus on imaging and visual classification was achieved, including a
schematic for recording patient, visual and imaging details. Criteria for case selection
were: age, history of visual decline, presence of severe visual symptoms, unreliable
visual assessment, proptosis and post-chiasmatic tumour involvement. A subsequent 19
case web-based questionnaire, supported by a podcast summary of the cohort
(http://goo.gl/aTSdaK) was completed by 15 workshop participants. The respondents
allocated 8 cases to observation; 8 to immediate treatment and 3 for consideration for
randomization.
Conclusion: This workshop has achieved a new consensus on selection criteria using a
contemporary trial cohort. We have piloted a web-based questionnaire to assess
feasibility of a randomised trial in this disease group.
O-018
CHILDRENWITH BIALLELIC MISMATCH REPAIR DEFICIENCY DEVELOP
RAPID ONSET OF ULTRA-HYPERMUTANT TUMORSWHICH ARE
RESISTANT TO CURRENT CHEMOTHERAPIES
B. Campbell1, A. Shlien1, R. de Borja1, R. Dvir2, R. Farah3, V. Larouche4, S. Afzal5,
N. Jabado6, A. Huang7, R.G. Grundy8, C. Pearson1, M.D. Taylor9, C. Durno10,
M. Aronson11, D. Malkin12, M.R. Stratton13, C. Hawkins9, P.J. Campbell13,
E. Bouffet12, U. Tabori12
1Sick Kids Peter Gilgan Centre for Research and Learning, Genetics and Genome Biology,
Toronto, Canada; 2Tel Aviv Medical Center, Pediatric Hemato-Oncology Department,
Tel Aviv, Israel; 3Saint George Hospital University Medical Center, Paediatric Oncology,
Beirut, Lebanon; 4Centre Mère-Enfant Soleil du CHU de Québec, Department of
Oncology, Quebec City, Canada; 5Dalhouse University, IWK Health Centre, Halifax,
Canada; 6McGill University, Pediatric Hematology-Oncology, Montreal, Canada; 7Sick
Kids Peter Gilgan Centre for Research and Learning, Haematology/Oncology, Toronto,
Canada; 8University of Nottingham, Children’s Brain Tumour Research Centre,
Nottingham, United Kingdom; 9Sick Kids Peter Gilgan Centre for Research and Learning,
Labatt Brain Tumour Research Centre, Toronto, Canada; 10The Hospital for Sick
Children, Division of Gastroenterology- Nutrition and Hepatology, Toronto, Canada;
11Mount Sinai Hospital, The Familial Gastrointestinal Cancer Registry at the Zane
Cohen Centre for Digestive Disease and Department of Surgery, Toronto, Canada; 12The
Hospital for Sick Children, Department of Haematology/Oncology, Toronto, Canada;
13Wellcome Trust Sanger Institute, Cancer Genome Project, Cambridge, United Kingdom
Background/Objectives: Biallelic Mismatch Repair Deficiency (bMMRD) is a cancer
predisposition syndrome caused by germline mutations in MSH2, MSH6, MLH1, and
PMS2. Children with bMMRD develop early onset brain, hematological and
gastrointestinal malignancies and rarely reach adulthood. The genomic landscape and
response to current therapies of bMMRD cancers are unknown.
Design/Methods:We analyzed 27 cancers and corresponding normal tissues from
bMMRD patients using genome, exome sequencing and SNP-arrays. Additionally, we
developed a novel functional assay to detect bMMRD and examined sensitivity of
bMMRD cells to current chemotherapies.
Results: BMMRD cancer harbored massive numbers of substitution mutations
(>100/Mb), greater than all childhood and most adult cancers (>7,000 analyzed). This
hypermutation signature is diagnostic for cancers arising from germline bMMRD
(p<10−13). The functional assay confirmed that out of eight families, all patients with
biallelic mutations in MMR genes tested negative for mismatch repair activity.
Conversely, nine family members with heterozygous mutations and no cancer
phenotype had normal MMR function. Hypermutated bMMRD brain cancers
acquired early and conserved somatic mutations in DNA polymerases ε or δ and
sequential tumor analysis revealed that brain tumours acquired over 20,000 mutations
in less than 6 months during malignant transformation. Importantly, recurrent
glioblastomas did not display a higher mutation load than ultra-hypermutant primary
tumors with a polymerase mutation. bMMRD cells were resistant to current
chemotherapies such as antimetabolites and temozolomide.
Conclusion: Early-onset bMMRD cancers have a unique mechanism of malignant
progression through secondary mutations in DNA polymerases and rapid mutation
accumulation quickly reaching a threshold. Although bMMRD cancers are resistant to
current chemotherapies, the high mutation load and threshold of bMMRD cancers
may be it’s Achilles’ heel, exploitable for diagnosis and therapeutic
intervention.
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O-019
NEUROBLASTOMA IMMUNOTHERAPY TARGETING CSF-1R REVERSES
INDUCTION OF SUPPRESSIVE MYELOID CELLS AND CONTROLS
AGGRESSIVE TUMOR PROGRESSION
N. Eissler1, Y. Mao2, J.I. Johnsen1, R. Kiessling2, P. Kogner1
1Karolinska Institute, Department of Women´s and Children´s Health, Stockholm,
Sweden; 2Karolinska Institute, Department of Oncology-Pathology, Stockholm, Sweden
Background/Objectives: High-risk neuroblastoma is a significant clinical challenge.
Despite progress in survival due to intensified multimodal therapy, aggressive metastatic
disease induces severe impairments of anti-tumor immunity and has poor clinical
outcome. M-CSF (CSF-1) is produced at high levels by neuroblastoma tumors and
infiltration of CSF-1R+ myeloid cells is associated with poor clinical survival.
Design/Methods: Human and murine in vitro culture models, exploiting CD34+
progenitor cells derived from cord blood, primary human monocytes, and murine bone
marrow cells, as well as human and murine neuroblastoma cells, were established to
analyze the CSF-1/CSF-1R axis in the induction of tumor-induced immune
suppression. Preclinical studies evaluating CSF-1R as therapeutic target were
conducted in transgenic TH-MYCN mice.
Results: In vitro, neuroblastoma-derived factors hamper myelopoiesis of human
CD34+ progenitor cells, and induce suppressive myeloid cells from primary human
monocytes and murine bone marrow cells through M-CSF/CSF-1R interaction. In the
spontaneous TH-MYCN model resembling aggressive high-risk human neuroblastoma,
we observe significant accumulation of myeloid-derived suppressor cells of the
granulocytic (p < 0.01, grMDSCs, Ly6G+Ly6Clow) and monocytic (p < 0.0001,
moMDSCs, Ly6GnegLy6Chigh) lineage, as well as F4/80+ macrophages (p < 0.01).
Sorted from spleens of tumor-bearing mice, Gr1+ cells conduct potent inhibition of T
cells through production of indolamine-2,3-dioxygenase (IDO, p<0.04) and inducible
nitric oxide synthase (iNOS, p<0.04). Of note, antagonizing CSF-1R with a selective
chemical inhibitor (BLZ945; Novartis) abolishes the induction of human and murine
MDSCs and TAMs in vitro, and overcomes their induction in vivo. Strikingly, treatment
in vivo with BLZ945 elicits robust anti-tumor immune responses and efficiently limits
progression of established tumors (p<0.01) including complete response and
eradication of macroscopic neuroblastoma tumors.
Conclusion: Our results demonstrate the essential clinical role of the
M-CSF/CSF-1R-axis during the induction of suppressive myeloid cells and suggest the
therapeutic potential of targeting this pathway in high-risk neuroblastoma.
O-020
TELOMERASE ACTIVATION BY RECURRENT GENOMIC
REARRANGEMENTS IN HIGH-RISK NEUROBLASTOMA
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M. Peifer1, F. Roels2, F. Hertwig2, R. Menon3, A. Kraemer2, R. Buettner4, S. Perner3,
A. Schramm5, J.H. Schulte5, B. Hero2, R.J. O’Sullivan6, F. Westermann7,
R.K. Thomas1, M. Fischer2
1University of Cologne, Translational Genomics, Cologne, Germany; 2University of
Cologne, Pediatric Oncology, Cologne, Germany; 3University of Bonn, Institute of
Pathology, Bonn, Germany; 4University of Cologne, Institute of Pathology, Cologne,
Germany; 5University of Essen, Pediatric Oncology, Essen, Germany; 6University of
Pittsburgh Cancer Institute, Department Pharmacology & Chemical Biology, Pittsburgh,
USA; 7German Cancer Research Center, Neuroblastoma Genomics, Heidelberg, Germany
Background/Objectives: Neuroblastoma shows a broad spectrum of clinical courses,
ranging from spontaneous regression to fatal tumor progression. The genetic basis of
the various clinical subtypes of the disease has remained largely elusive.
Design/Methods:We performed whole-genome and RNA sequencing of 57 primary
neuroblastomas (high-risk, n=40; low-risk, n=17), and targeted sequencing and FISH
of an independent cohort of 160 primary neuroblastomas. Six neuroblastoma cell lines
representing different genetic subtypes were examined for activity of telomerase and
alternative lengthening of telomeres (ALT).
Results:We identified genomic rearrangements affecting chromosome 5p15.22 in a 50
kb region centromeric of the human telomerase reverse transcriptase gene (TERT) in
13/57 tumors. The rearrangements occurred only in high-risk neuroblastomas (13/40) in
almost mutually exclusive fashion withMYCN amplifications and ATRX mutations,
which are known genetic events in this tumor type. While the structure of the
rearrangements varied greatly, they consistently induced massive transcriptional
up-regulation of TERT and three additional genes located in close proximity to the
chromosomal breakpoint. By contrast,MYCN-amplified tumors showed only
up-regulation of TERT itself, suggesting that bothMYCN amplification and TERT
rearrangements converge on TERT activation. In the validation cohort, we identified 15
additional tumors with TERT rearrangements. In total, TERT rearrangements
occurred in 13% of primary neuroblastomas and were strongly associated with poor
patient outcome (5-year EFS, 0.188±0.098, 5-year OS, 0.429±0.161), independent of
the established prognostic markers stage, age andMYCN amplification. Supporting a
functional role of TERT, bothMYCN-amplified neuroblastoma cell lines and cell lines
bearing TERT rearrangements exhibited elevated TERT expression and enzymatic
telomerase activity, while ALT was detected in cell lines without these aberrations.
Conclusion: Our findings show that remodeling of the genomic context abrogates
transcriptional silencing of TERT in high-risk neuroblastoma, and places telomerase
activation in the center of transformation in a large fraction of these tumors.
O-021
MYCN TRANSCRIPTIONALLY REPRESSES CD9 TO TRIGGER AN
INVASION-METASTASIS CASCADE IN NEUROBLASTOMA
H. Deubzer1, J. Fabian2, D. Opitz2, K. Althoff3, M. Lodrini1, K. Astrahantseff1,
B. Hero4, R. Volland4, A. Beckers5, K. De Preter5, N. Patil6, M. Abba6, J. Wünschel1,
T. Thole1, J. Hu2, L. Schweitzer7, G. Mechtersheimer8, D. Carter9, B. Cheung9,
O. Popanda10, A. von Deimling7, K.O. Henrich11, F. Westermann11, M. Schwab11,
J. Koster12, R. Versteeg12, G. Marshall9, F. Speleman5, M. Zoeller13, H. Allgayer6,
M. Fischer4, F. Berthold4, A. Kulozik14, O. Witt2, J. Schulte3, A. Eggert1
1Charité Berlin, Department of Pediatric Hematology & Oncology & Bone Marrow
Transplantation, Berlin, Germany; 2German Cancer Research Center, Clinical
Cooperation Unit Pediatric Oncology, Heidelberg, Germany; 3University Children’s
Hospital Essen, Department of Pediatric Hematology and Oncology, Essen, Germany;
4University of Cologne, Department of Pediatric Hematology and Oncology, Cologne,
Germany; 5Ghent University Hospital Medical Research Building MRB, Center for
Medical Genetics Ghent CMGG, Ghent, Belgium; 6German Cancer Research Center,
Molecular Oncology of Solid Tumors Unit, Heidelberg, Germany; 7University of
Heidelberg, Department of Neuropathology, Heidelberg, Germany; 8University of
Heidelberg, Department of Pathology, Heidelberg, Germany; 9Children’s Cancer
Institute, UNSW, Randwick, Australia; 10German Cancer Research Center, Division of
Epigenomics and Cancer Risk Factors, Heidelberg, Germany; 11German Cancer Research
Center, Neuroblastoma Genetics, Heidelberg, Germany; 12University of Amsterdam-
Academic Medical Center, Department of Oncogenomics, Amsterdam, Netherlands;
13University of Heidelberg, Experimental Surgery and Tumor Cell Biology, Heidelberg,
Germany; 14University of Heidelberg, Department of Pediatric Hematology and
Oncology, Heidelberg, Germany
Background/Objectives: The systemic and resistant nature of neuroblastoma
metastasized to distant organs makes it largely incurable with current multimodal
treatment. Clinical progression stems mainly from an increasing burden of metastatic
colonization. Novel therapeutic perspectives may be won by blocking as yet poorly
understood pathways triggering the migration-invasion-metastasis cascade in
neuroblastoma.
Design/Methods: The CD9 cell surface glycoprotein was decoded as a major
downstream player and direct target of the recently described GRHL1 tumor
suppressor in in-depth transcriptome analyses and ChIP-qRT-PCR. CD9 is known to
facilitate carcinoma cell motility and metastasis.
Results: High-level CD9 expression in primary neuroblastomas correlated with patient
survival and established markers for favorable disease. Low-level CD9 expression was
an independent risk factor for adverse outcome and predicted poor treatment response
in patients with the worst outcome. MYCN and HDAC5 colocalized to the CD9
promoter and repressed transcription. CD9 expression was strongly reduced during
progressive development of murine tumors in the TH-MYCN transgenic mouse model
of neuroblastoma compared to expression in ganglia from wildtype mice, further
supporting MYCN involvement in CD9 transcriptional repression in neuroblastoma
cells. We detected differential CD9 methylation in 450K methylation array analyses of
primary neuroblastomas, and CD9 hypermethylation was associated with reduced CD9
expression, supporting epigenetic regulation. Inducing CD9 expression in a SH-EP cell
model inhibited migration and invasion in Boyden chamber assays. Enforced CD9
expression in neuroblastoma cells transplanted onto chicken chorioallantoic
membranes strongly reduced metastasis to chicken embryo bone marrow. Combined
treatment of neuroblastoma cells with inhibitors for HDACs and DNA
methyltransferase induced CD9 expression.
Conclusion: Our results show CD9 is a critical and indirectly druggable mediator of
neuroblastoma cell invasion and metastasis.
O-022
COMPREHENSIVE ANALYSIS OF BONEMARROW (BM) INVOLVEMENT
ANDMINIMAL RESIDUAL DISEASE (MRD) IN NEUROBLASTOMA
PATIENTS BYMOLECULARMARKERS
A. Druy1, E. Shorikov2, G. Tsaur1, A. Popov3, L. Saveliev4, L. Fechina2
1Regional Children’s Hospital/Research Institute of Medical Cell Technologies,
Molecular biology laboratory, Yekaterinburg, Russia; 2Regional Children’s
Hospital/Research Institute of Medical Cell Technologies, Pediatric oncology ward,
Yekaterinburg, Russia; 3Regional Children’s Hospital/Research Institute of Medical Cell
Technologies, Immunophenotyping laboratory, Yekaterinburg, Russia; 4Ural State
Medical University, Chair of laboratory medicine, Yekaterinburg, Russia
Background/Objectives: BM involvement detection in neuroblastoma (NB) is crucial for
staging; MRD defines tumor response and could be associated with unfavorable
outcome.
Design/Methods: Expression of 4 tumor-associated genes (TAGs): PHOX2B, TH,
ELAVL4, GD2 was analyzed in NB cell lines, in 26 intact BM samples, in discovery
(331 BM samples from 57 patients) and validation (311 samples from 55 patients)
cohorts. Threshold levels (TLs) of expression were established using ROC-analysis and
applied for overall correct prediction (OCP) computation. Criteria of BM positivity
were PHOX2B expression or tumor cells in BM smears. Event-free (EFS) and overall
survival (OS) rates were calculated with median of follow-up 2.45 years.
Results: Neither PHOX2B nor TH expression was detected in intact BM, expression of
ELAVL4 was revealed in 20, GD2 – in 15/26 samples. In the discovery cohort 105/107
positive samples had PHOX2B expression; 101/107 positive and 5/224 negative
samples- TH. ELAVL4 and GD2 expression was detected in all 107 positive samples
and in the majority of negative (209 and 197/224, respectively). OCP values for TH,
ELAVL4, GD2 achieved 0.952, 0.828, 0.767 correspondingly, for PHOX2B- 0.994. In
the validation cohort OCPs were 0.997 for PHOX2B, 0.939 for TH. Presence of
PHOX2B/TH expression in BM at the time of diagnostics decreased EFS
(0.31±0.12vs.0.81±0.06,p<0.01) and OS (0.31±0.13vs.0.87±0.05,p<0.01).
Predominance of PHOX2B expression over TH >1.68 in BM had adverse prognostic
significance: EFS 0.00vs.0.56±0.12,p=0.017, OS 0.00vs.0.72±0.11,p=0.006. Persistence
of TAGs expression during treatment demonstrated trend to reduced EFS
(0.27±0.12vs.0.43±0.19,p=0.08). Positivity of BM for PHOX2B/TH before stem cells
apheresis had strongly negative prognostic impact (EFS 0.00vs.0.35±0.14,p=0.04; OS
0.00vs.0.36±0.15,p=0.03) despite of CD34+ selection.
Conclusion: PHOX2B and TH are the most appropriate markers for BM involvement
and MRD detection. Theirs expression at the time of diagnostics and before PBSC
apheresis had strongly adverse prognostic impact. Predominance of PHOX2B
expression over TH can define high risk patients.
O-023
IMPACT OF RESPONSE TO PRIOR THERAPY ON OUTCOME FOR
REFRACTORY VS. RELAPSED NEUROBLASTOMA PATIENTS TREATED
WITH 131I-METAIODOBENZYLGUANIDINE (131I-MIBG)
K.K. Matthay1, M. Zhou1, M. Doral1, J. Villablanca2, G. Yanik3, S. DuBois1
1University of California San Francisco, Pediatrics, San Francisco-CA, USA; 2Children’s
Hospital of Los Angeles and University of Southern California, Pediatrics, Los
Angeles-CA, USA; 3University of Michigan and Mott Children’s Hospital, Pediatrics,
Ann Arbor, USA
Background/Objectives: 131I-metaiodobenzylguanidine (131I-MIBG) is a targeted
radiopharmaceutical with significant activity in high-risk relapsed and
chemotherapy-refractory neuroblastoma. The primary aim of this study was to
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determine if there are differences in response rates to 131I-MIBG between patients with
relapsed and treatment-refractory neuroblastoma.
Design/Methods: This was a retrospective cohort analysis of 218 patients with
refractory, persistent, relapsed, or progressive neuroblastoma treated with 131I-MIBG
at UCSF between 1996 and 2014. Results were obtained by chart review and database
abstraction. Baseline characteristics and response rates between relapsed/progressive
and refractory/persistent patients were compared using Fisher exact and Wilcoxon rank
sum tests, and differences in OS were compared using the log-rank test. Subanalyses
were performed including only patients treated on MIBG monotherapy protocols, and
on patients treated on MIBG protocols that did not included myeloablative
chemotherapy.
Results: The response rate (complete and partial response) to 131I-MIBG based
therapies for all patients was 27%. There was no difference in response rates between
relapsed and refractory patients in either univariate or multivariate analysis However,
after 131I-MIBG, 24% of relapsed patients had progressive disease compared to only 9%
of refractory patients, and 39% of relapsed patients had stable disease compared to
59% of refractory patients (p = 0.02). The median follow up for surviving patients was
61 months. Among all patients, the 24-month OS was 47.0% (95% CI 39.9%-53.9%).
The 24-month OS for refractory patients was significantly higher at 65.3% (95% CI
51.8%-75.9%), compared to 38.7% (95% CI 30.4%-46.8%) for relapsed patients (p <
0.001).
Conclusion: Although there was no significant difference in overall response rates to
131I-MIBG between patients with relapsed and refractory neuroblastoma, more
patients with prior relapse developed progressive disease and had a lower 2-year overall
survival after 131I-MIBG compared to patients with refractory disease. Our results can
be used to guide stratification on future 131I-MIBG clinical trials.
O-024
RELAPSE IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA AFTER
TREATMENTWITH 3F8+GM-CSF+CIS-RETINOIC ACID IN FIRST
COMPLETE/VERY GOOD PARTIAL REMISSION: PATTERNS,
MANAGEMENT AND LONG-TERMOUTCOME
S. Modak1, B.H. Kushner1, K. Kramer1, E. Basu1, S.S. Roberts1, E. Chamberlain1,
S. Wolden2, M. LaQuaglia1, N.K.V. Cheung1
1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, USA; 2Memorial
Sloan Kettering Cancer Center, Radiation Oncology, New York, USA
Background/Objectives: Anti-GD2 immunotherapy is now standard of care for
high-risk neuroblastoma (HR-NB). However, prognosis after first relapse
post-immunotherapy is deemed dismal; patients are often enrolled on early phase
studies without curative intent.
Design/Methods: HR-NB patients relapsing post-3F8+GMCSF+cis-retinoic acid
(CRA) in first complete (CR) or very good partial remission (VGPR) (NCT00072358)
underwent the following reinduction strategies: (1) Isolated CNS relapse (CNS-R):
multimodality therapy including intra-Ommaya radioimmunotherapy (MM-RIT) (J
Neurooncol 97:409). (2) Disseminated (D-R) or focal soft-tissue relapse (FS-R):
High-dose chemotherapy using active agents as previously described (Cancer 119: 665;
Bone Marrow Transplant 48:642; Pediatr Blood Cancer 56: 403; Eur J Cancer 47: 84;
Cancer 116: 3054) ±surgery (±IORT)±radiation. (3) Focal bone relapse (FB-R):
low-dose chemotherapy (J Clin Oncol 24:5271) ± radiation. Patients achieving second
CR/VGPR were retreated with 3F8+GM+CRA (Oncoimmunol In Press 2015)
±anti-GD2/GD3 humoral vaccine (ClinCanRes 20:1375). Progression-free (PFS) and
overall survival (OS) analyses were performed (Kaplan-Maier method) and prognostic
variables compared (log-rank test).
Results: Of 145 consecutive patients treated with 3F8+GM+CRA in first CR/VGPR,
64 (44%) relapsed (median follow-up 60 months from starting 3F8): 17 CNS-R, 24
D-R, 12 FS-R, 11 FB-R. 39 (61%) achieved second CR. 19 (29%) continued in
remission >5 years after relapse. Respective five-year PFS and OS rates (%) for groups
CNS-R receiving MM-RIT, D-R, FS-R and FB-R were 77±12 and 68±13, 6±7 and
6±7, 25±13 and 30±7, 54±15 and 62±15. Adverse prognostic factors for survival
post-relapse included failure to achieve second CR, D-R as opposed to other relapse
patterns, and early (<6mo from starting 3F8 ) relapse (p<0.05 for each), but not
MYCN amplification (p=0.4).
Conclusion: Long-term PFS and OS are possible in HR-NB patients post-relapse if
CR/VGPR can be achieved, especially when relapse is focal. Agents with proven
anti-NB activity should be considered initially at first relapse rather than purely
experimental approaches.
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O-025
A CONSERVATIVE STRATEGY IN INFANTILE FIBROSARCOMA IS
POSSIBLE: THE EUROPEAN PEDIATRIC SOFT TISSUE SARCOMA GROUP
(EPSSG) EXPERIENCE
D. Orbach1, B. Brennan2, G.L. De Salvo3, M. Van Noesel4, N. Francotte5, A. Kelsey6,
R. Alaggio7, D. Ranchere8, M. Casanova9, C. Bergeron10, J.H. Marks11, M. Jenney12,
M. Stevens13, G. Bisogno14, A. Ferrari9
1Institut Curie, Pediatric-Adolescent-Young Adult Department, Paris, France; 2Royal
Manchester Children’s Hospital, Department of Pediatric Oncology, Manchester, United
Kingdom; 3IRCCS Istituto Oncologico Veneto, Clinical Trials and Biostatistics Unit,
Padova, Italy; 4Prinses Maxima Center for Pediatric Oncolog, Pediatric Oncology
Department, Utrecht, Netherlands; 5CHC-Clinique Esperance, Department of Pediatrics,
Montegnée, Belgium; 6Royal Manchester Children’s Hospital, Department of Diagnostic
Paediatric Histopathology, Manchester, United Kingdom; 7Padova University, Pathology
Department, Padova, Italy; 8Institut d’Hematologie et d’Oncologie Pediatrique,
Pathology Department, Lyon, France; 9Fondazione IRCCS Istituto Nazionale Tumori,
Pediatric Oncology Unit, Milan, Italy; 10Institut d’Hematologie et d’Oncologie
Pédiatrique, Department of Pediatric Oncology, Lyon, France; 11Emma Children’s
Hospital-Academic Medical Cente, Department of Pediatric Oncology, Amsterdam,
Netherlands; 12Children’s Hospital for Wales, Department of Pediatric Oncology, Cardiff,
United Kingdom; 13Royal Hospital for Children-University of Bristol, Department of
Pediatric Oncology, Bristol, United Kingdom; 14Padova University, Pediatric Hematology
and Oncology Division, Padova, Italy
Background/Objectives: Infantile fibrosarcoma (IFS) is a very rare disease occurring in
young infants characterized by high local aggressiveness but also an overall favorable
survival. To try to reduce the total burden of therapy, the European pediatric Soft
Tissue Sarcoma Group (EpSSG) has developed conservative therapeutic
recommendations according to initial resectability.
Design/Methods: Between 2005 and 2012, children less than 2 years, with localized IFS
were prospectively registered. Initial surgery was suggested only if possible without
mutilation. Patients with initial complete (IRS-group I) or incomplete (IRS-group II)
resection had no further therapy. Patients with an initial inoperable tumor (IRS-group
III) received first-line vincristine-actinomycin-D chemotherapy (VA). Delayed
conservative surgery was planned after tumor reduction. Aggressive local therapy
(mutilating or external radiotherapy) was discouraged.
Results: A total of 54 infants (median age 1.8 months [0.0-18.7]; 7 % of all
Non-rhabdomyosarcoma-soft-tissue-sarcoma), were included in the study, 37%
occurred before birth or during the first month of life. ETV6-NTRK3 transcript was
present in 73% of all assessed cases. Primary sites were predominantly limbs (55.6%)
and trunk (27.8%). At initial surgery, 12 patients were classified as IRS-group I, 8 as
IRS-group II, 34 as IRS-group III. VA chemotherapy was delivered to 31 children. An
additional drug (alkylating/anthracycline) was necessary for 9 patients. Only 3 survivors
need mutilating surgery and 1 radiotherapy. After a median follow-up of 51.5 months,
3-year event free and overall survival were respectively 90.7 (95%CI 79.2-96.0) and 94.4
(95%CI 83.8-98.2).
Conclusion: Conservative strategy is possible in IFS without jeopardizing survival.
Mutilating surgery could be avoided in 94%. Alkylating or anthracycline based
chemotherapy could be avoided in 65% of patients needing chemotherapy. This study
does not support a “wait and see” strategy in this tumor. VA should be regimen of first
preference in order to reduce long term effects.
O-026
PEDIATRIC ONCOMINE: A CHILDHOOD CANCER NGS PANEL TO DIRECT
DIAGNOSIS AND THERAPY
T. Triche1, R. Arceci2
1Children’s Hospital Los Angeles, Los Angeles, USA; 2Phoenix Children’s Hospital,
Pediatrics, Phoenix, USA
Background/Objectives: Chemotherapy of childhood cancer has shown little
improvement in outcome over the past several decades. In contrast, adult cancer
increasingly employs targeted therapeutics chosen on the basis of an identifiable gene
mutation, fusion, or amplification that suggests likely sensitivity to a specific agent. The
NCI MATCH (Molecular Analysis for Therapy Choice) program employs a diagnostic
panel of such genomic features (OncomineTM) in order to match drug with target in the
design of ’precision medicine’ clinical trials. Unfortunately, OncomineTM is designed for
use in adult cancer and is ill suited for use in pediatric cancer. Our objective is to
develop a pediatric version of OncomineTM, termed Pediatric Oncomine,that is
optimized for childhood cancer.
Design/Methods:We have identified 50+ genes in OncomineTM that match targeted
therapeutics for potential use in pediatric cancer. We have also identified diagnostically
and prognostically useful gene translocations, as well as copy number variants, useful in
the diagnosis of both solid tumors and hematopoietic malignancies. In addition, in
order to provide useful dosing guidance for pediatric oncologists we have added a panel
of genes like MTHFR, TPMT1, COMT, CYP2B6 UGT1A1, and others. These gene
targets have been incorporated into a next generation sequencing panel suitable for use
on FFPE tissue developed by the Center for Personalized Medicine at CHLA, which
designed the content.
Results:We have adapted a preexisting pan-cancer somatic panel, OncomineTM, for
pediatric use by re-utilizing features (largely mutations) relevant to targeted
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therapeutics while adding genomic features (largely gene translocations and
amplifications) unique to pediatric cancer, as well as a pharmacogenomic module of
particular use in pediatric oncology.
Conclusion: A pan-cancer somatic panel designed specifically for use in the diagnosis
and management of childhood cancer patients who would benefit from targeted therapy
has been created and will be useful in pediatric oncology ’precision medicine’ trials.
O-027
TRANSCRIPTOME BASED INDIVIDUALIZED THERAPY OF REFRACTORY
PEDIATRIC SARCOMA
B. Weidenbusch1, G. Richter2, T. Buch3, U. Dirksen4, T. Grunewald5, L. Lindner6,
I. Teichert-von Lüttichau2, U. Mansmann7, D. Busch3, S. Burdach2
1Technische Universität München, Munich, Germany; 2Technische Universität München,
Department of Pediatrics-Children’s Cancer Research Center, Munich, Germany;
3Technische Universität München, Institute of Medical Microbiology Immunology and
Hygiene, Munich, Germany; 4Universitätsklinikum Münster, Department of Pediatric
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Background/Objectives: Tumor biology in refractory pediatric patients is highly
heterogeneous and new approaches addressing resistance are urgently needed. Gene
expression profiling may aid in medical decision making in this setting.
Design/Methods:We enrolled patients for whom standard of care and current clinical
trials provided no further treatment options in a one arm open label prospective study
to assess survival. Tumor samples underwent transcriptome analysis with Affymetrix
arrays. We focused on genes with >1.5 fold expression vs. normal tissue, identified as
drivers by TARGETgene. Targets ranked between 1-100 were considered for therapy.
Drug selection criteria: delivery, no previous use in the patient, citations related to
disease, citations related to other cancers, side effects, drug interactions, oral
application, approval by German authorities.
Results: During 29 months 22 biopsies were obtained after informed consent from 19
eligible patients at a single institution (TUM) with a mean age of 15.1 years. Diagnosis
was sarcoma in 17 (8 Ewing sarcoma, 5 soft tissue sarcoma, 4 osteosarcoma), and
embryonal tumor in 2. Targeted therapy was administered in 12, while in 6 no
druggable targets could be identified. One patient was noncompliant. Medications
assessed: 472. Mean druggable targets per patient: 7. 21 different drugs were
recommended with an average of 3 drugs per patient, including PKIs, TKIs, TOP2Is,
HDIs, taxanes, nucleoside analogs, arsenic trioxide and ATRA. Therapy was generally
well tolerated with no adverse reactions and no side effect-related discontinuation of
treatment. In this pilot study survival was at least non-inferior to best medical care.
Conclusion: Targeted therapy is a feasible alternative to best medical care in refractory
pediatric cancer. In the majority of patients druggable targets can be identified and
therapy typically does not cause side effects. Prospective studies with appropriate
sample size to determine potential overall survival benefit are planned within the
INFORM consortium.
O-028
CORRELATION OF COPY NUMBER CHANGES AND GENE EXPRESSION IN
NEUROFIBROMATOSIS1-ASSOCIATEDMALIGNANT PERIPHERAL NERVE
SHEATH TUMOURS
M. Upadhyaya1, J. Winston2, E. Rad2, M. Mort2, K. Dodd2, A. Tee2, F. McDyer3,
S. Moore3, D. Cooper2, L. Thomas2
1Cardiff University, Institute of Cancer and Genetics, Cardiff, United Kingdom; 2Cardiff
University, Medical Genetics, Wales, United Kingdom; 3Almac Diagnostics, Belfast,
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Background/Objectives: Neurofibromatosis type1 (NF1) is a common autosomal
dominantly inherited complex neurogenetic disorder and results from the mutational
inactivation of the NF1 gene. Neurofibromin, the NF1 gene product is a tumour
suppressor protein and downregulates Ras. NF1 is characterised by the development of
benign and malignant tumours of the peripheral nerve sheath (MPNSTs). Whilst
biallelic NF1 gene inactivation contributes to benign tumour formation, additional
cellular changes in gene structure and/or expression are required to induce malignant
transformation. Although few molecular profiling studies have been performed on the
process of progression of pre-existing plexiform neurofibromas to MPNSTs, the
integrated analysis of copy number alterations (CNAs) and gene expression is likely to
be key to understanding the molecular mechanisms underlying NF1-MPNST
tumorigenesis. In a pilot study, we employed this approach to identify genes
differentially expressed between benign and malignant NF1 tumours and then
correlated this with copy number alterations.
Design/Methods: The study group comprised nine NF1-associated tumours with
biallelic NF1 genes mutations (comprising four benign plexiform neurofibromas and
five high grade MPNSTs from nine unrelated NF1 patient). DNA and RNA were
isolated from the same segment of tumour. The same tumour samples were analysed by
Affymetrix SNP array 6.0 and Affymetrix Human Exon 1.0 ST array.
Results: SPP1 (osteopontin) was the most differentially expressed gene (85-fold increase
in expression), compared to benign plexiform neurofibromas. Short hairpin RNA
(shRNA) knockdown of SPP1 in NF1-MPNST cells reduced tumour spheroid size,
wound healing and invasion in four different MPNST cell lines. Seventy-six genes were
found to exhibit concordance between CNA and gene expression level. Pathway
analysis of these genes suggested that glutathione metabolism and Wnt signalling may
be specifically involved in NF1-MPNST development.
Conclusion: Our study suggests SPP1 is associated with malignant transformation in
NF1-associated MPNSTs and could prove to be an important target for therapeutic
intervention.
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BETTER OUTCOMEWITHMAINTENANCE THERAPY: PEDIATRIC
PATIENTS WITH STAGE IV SOFT TISSUE SARCOMA BENEFIT FROM LONG
TERM THERAPY COMPARED TO SCT OR NO FURTHER THERAPY
K. Bochennek1, T. Dantonello2, A. Borkhardt3, U. Dirksen4, A. Eggert5, J. Greiner6,
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Background/Objectives: Despite advances in the treatment of soft tissue sarcoma (STS),
the prognosis of patients with metastatic disease remains daunting. While high dose
chemotherapy (HDC) and allogeneic stem cell transplantation (aSCT) did not result in
a therapeutic breakthrough, maintenance therapy (MT) following a multimodal therapy
was shown in the CWS-96 study to be a promising approach and has been
recommended therefore for metastatic disease in the CWS 2002 P and CWS-IV-2002
international studies conducted in Germany, Sweden, Swiss, Poland and Austria from
2002-2009. We present a retrospective analysis of patients with metastatic
Rhabdomyosarcoma (RMS) and RMS-like STS registered in both studies.
Design/Methods:Multimodal therapy according to protocol included
polychemotherapy (Vincristine, Actinomycine D, Ifosfamide, Carboplatin, Etoposide,
Epirubicine), surgery and/or radiation, followed by oral MT with a combination of
Trofosfamide, Idarubicine, and Etoposide (O/TIE). Many patients however, received
other type of consolidation therapy based on individual decision of the treating centers:
i.e. HDC, aSCT or the combination of Cyclophosphamide and Vinblastine (Cyc/Vbl).
Results: 176 patients were inlcuded (alveolar RMS n=91, embryonal RMS n=60,
RMS-like n=25). The probabilities of overall (pOS) and event free survival (pEFS) were
35%, and 29.9% respectively, with a median follow-up time of 121 weeks (all patients,
range 1 – 278). Patients who received intensive chemotherapy only (n=33), or
additional allogeneic SCT (n=22) showed a significant lower pOS (18.7% and 15.2%)
than patients who received O/TIE (n=81) or Cyc/Vbl (n=26) (pOFS 31% and 54.8%
respectively). pOS of all MT patients (n=107) was 38% vs. 17% in all non-MT patients
(n=69), p=0,002.
Conclusion: This analysis supports our previous results (CWS-96 IV Study) showing
that a MTmight improve prognosis in patients with metastatic STS in contrast to HDC,
aSCT and to no further therapy. The question what the best MT will be remains open.
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RELAPSE AFTER LOCALIZED RHABDOMYOSARCOMA: EVALUATION OF
THE EFFICACY OF SECOND-LINE CHEMOTHERAPY
S. Winter1, V. Minard-Colin2, S. Fasola3, H. Brisse4, V. Mosseri5, D. Orbach1
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Background/Objectives: About one third of patients with rhabdomyosarcoma relapse
despite appropriate treatment and experience a poor outcome. Little meaningful
improvement in the outcome of this disease has been observed over the last 30 years.
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There is no clear international recommendation concerning the use of salvage
chemotherapy at relapse. A retrospective multicenter analysis was therefore conducted
to analyze the efficacy of various second-line chemotherapy regimens in this setting.
Design/Methods: Forty-nine patients under the age of eighteen, with initially localized
rhabdomyosarcoma, who relapsed after first complete remission, treated in 3 SFCE
centers (Société Française des Cancers de l’enfant) between 1995 and 2013, were
analyzed.
Results: First relapse occurred after a median interval of 22 months and remained
localized in 71.4% of cases. All patients received second-line chemotherapy with an
overall response to this salvage therapy of 71.7%. Best specific response rates were
86.7% and 85.7% for carboplatin/epirubicin/vincristine-ifosfamide/vincristine/etoposide
(CEV/IVE) (13 patients) and vincristine/irinotecan ± temozolomide (VI(T)) (6
patients), respectively. Overall, 40 patients (81.6%) were then eligible for delayed local
treatment (surgery and/or radiotherapy) and 30 of them (61.2%) achieved second
complete remission. After a median follow-up of 5.4 years since diagnosis of first
relapse, 5-year overall survival is 49.4% (95% CI: 34.2-64.6).
Conclusion: Salvage chemotherapy plays a central role in the management of patients
with relapsed rhabdomyosarcoma. CEV/IVE and VI(T) regimens can be recommended
as neoadjuvant chemotherapy before local treatment for patients with relapsed
rhabdomyosarcoma.
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TUMOR SUPPRESSOR GENES IKZF1 AND BTG1 COOPERATE IN ACUTE
LYMPHOBLASTIC LEUKEMIA DEVELOPMENT AND GLUCOCORTICOID
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Background/Objectives: IKZF1 (IKAROS) aberrations have been shown to
independently predict poor prognosis in children with BCP-ALL and currently are
incorporated in the risk stratification of Dutch pediatric B-cell precursor acute
lymphoblastic leukemia (BCP-ALL) patients. Our recent findings show that loss of
IKZF1 function has a direct impact on chemotherapy responses by inhibiting
glucocorticoid-induced apoptosis in normal and leukemic B-cells. Furthermore, the
effect of other genetic aberrations on therapy outcome of IKZF1-deleted patients has
not been fully addressed. Our analysis has revealed that the event-free survival of
IKZF1-deleted patients is negatively affected by the co-occurrence of BTG1 deletions.
In addition, BTG1 deletions appear to occur more frequently in patients with IKZF1
gene alterations (19%) compared to an unselected cohort (9%). We studied the genetic
interaction between IKZF1 and BTG1 in leukemia development and glucocorticoid
responses using knockout mouse models and human leukemia cell lines.
Design/Methods: Ikzf1+/− were crossed onto a Btg1 knockout background and
monitored for spontaneous leukemia development. Additionally, glucocorticoid
response was determined in lymphoid cells isolated from compound Ikzf1+/−;Btg1−/−
mice by MTS assay. Additionally, sensitivity towards glucocorticoid-induced apoptosis
was determined in human leukemia cell lines displaying loss of IKZF1 and BTG1
function.
Results:We observed a significant acceleration in the onset of T-cell acute
lymphoblastic leukemia in Ikzf1+/−;Btg1+/− which was even further enhanced in
Ikzf1+/−;Btg1−/− animals. These leukemias were characterized by clonal TCRβ
rearrangement and aggressive infiltration into secondary organs. B-cells isolated from
Ikzf1+/−;Btg1−/− animals were highly resistant against glucocorticoid-induced
apoptosis. Similarly, human leukemia cell lines displaying loss of IKZF1 and BTG1
function showed a glucocorticoid-resistant phenotype that was even stronger than by
loss of IKZF1 alone.
Conclusion: Together, our findings establish BTG1 as a tumor suppressor gene that
genetically interacts with IKZF1 during leukemic transformation and strongly
potentiates the IKZF1-mediated glucocorticoid resistance phenotype in normal and
leukemic B cells.
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EFFECTS OF ETHNICITY AND SOCIOECONOMIC STATUS ON OUTCOME
IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
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Background/Objectives:Data on the effects of socioeconomic status (SES) and outcome
as it relates to race/ethnicity for children with ALL in the United States are limited.
Using two large US cancer registries, we investigated the effects of race/ethnicity and
community-level SES for children with ALL.
Design/Methods: Patients diagnosed with ALL between 1995-2008 at the age of 1-18
years old were eligible for inclusion. Community level poverty data were calculated for
each patient using United States Census data and categorized as a community in which
<5%, 5-<20% or 20-100% of households live below the poverty level.
Results: A total of 4,719 patients were included. Race/ethnicity consisted of
non-Hispanic White (NHW) (47.6%), Hispanic (H) (43.9%) and non-Hispanic Black
(NHB) (8.5%). 5-year overall survival (OS) for NHW, H and NHB patients was 87.7%,
82.9% and 79.2%, respectively (NHW versus H, p<0.001; NHW versus NHB,
p=0.008). 5-year OS for patients living in a community with <5% poverty, 5-20%
poverty and >20% poverty was 90.5%, 86.3% and 78.4%, respectively (<5% versus
5-20% poverty, p=0.006; <5% versus 20-100% poverty, p<0.001). Patients were
categorized into two age groups (1-9 years, 10-18 years) based on the National Cancer
Institute’s stratification of standard risk and high risk patients. Multivariate analysis of
patients 1-9 years of age revealed that race/ethnicity was not independently associated
with OS after adjusting for gender, treatment era and socioeconomic status. Patients in
communities with >20% poverty experienced worse OS (HR 1.84 [95% CI 1.3-2.6]). For
patients age 10-18 years of age, multivariate analysis demonstrated that early treatment
era, Hispanic ethnicity and SES were all associated with worse OS. NHB race/ethnicity
was not independently associated with worse outcome after adjusting for other factors.
Conclusion: Lower SES has significant adverse effect on OS in children with ALL.
Further research into the causes for worse outcome for these patients is warranted.
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ETP ALL IN AIEOP CHILDREN TREATEDWITH THE AIEOP-BFM ALL 2009
STUDY
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Background/Objectives: To evaluate the outcome of AIEOP (Italian Association of
Pediatric Hematology Oncology) patients with Early T-cell Precursor (ETP) Acute
Lymphoblastic Leukemia (ALL) treated in AIEOP-BFM ALL 2009 Study.
Design/Methods: Immunophenotipic criteria for ETP-ALL definition: CD1a and CD8
negative, CD5 weak positive or negative and positive at least one of CD34, CD117,
HLADR, CD13, CD33, CD11b, or CD65 antigens. Treatment: BFM protocol I; 4
HDMTX courses (5 g/sqm over 24 hrs) and protocol II in non-high risk (HR) or 3
poly-chemotherapy blocks and protocol III x3 in HR patients; intrathecal therapy ±
cranial radiotherapy; maintenance therapy up to 2 years of treatment. Peg-L-Asp is
used.
Results: Of the 201 T-ALL eligible patients, 33 (16.4%) had ETP ALL. ETP ALL had
lower WBC counts (<20,000/mmc 61% vs 20%, p-value<0.001; median 5600 vs 95200);
frequent absence of molecular markers for PCR-MRD (61% vs 5%); more PPR (52%
vs 36%), MRD-HR at day+15 (BM blasts 10% by FCM, 61% vs 27%), resistance to
phase IA (BM blasts 5% morphologically, 15% vs 5%), high PCR-MRD ( 10−3) at
day+33 (85% vs 45%) and at day 78 (23% vs 14%) for those with markers (13/33), and
HR allocation (76% vs 44%). After a median follow-up of 2.3 years 29/33 patients
(88%) are in CCR, including 8/10 after HSCT, with 2 deaths in Induction and 2 after
HSCT. 2 yrs EFS in ETP is 85.9%(6.7) vs 79.1%(3.6) in non-ETP T-ALL.
Conclusion: ETP is characterized by poor initial treatment response; phase IB is
effective in reducing MRD. Although follow-up and number of patients are limited,
these data suggest that ETP and non-ETP ALL patients treated with current BFM
stratification and treatment strategy have comparable outcomes, as recently reported
for UKALL and COG protocols using Peg-L-Asp. The role of innovative therapies and
HSCT in ETP ALL needs to be further investigated.
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INADEQUATE LUNG SHIELDING IN CHILDRENWITH ALL UNDERGOING
ALLO-HSCT IS ASSOCIATEDWITH INFERIOR SURVIVAL: REPORT FROM
THE CHILDREN’S ONCOLOGY GROUP/PEDIATRIC BLOOD ANDMARROW
TRANSPLANT CONSORTIUM
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Background/Objectives: Lung shielding has not been standardized during total body
irradiation (TBI) preparative regimens for hematopoietic stem cell transplantation
(HSCT), leading to differences in pulmonary radiation dose. We examined the
relationship between lung radiation dose, transplant-related mortality (TRM),
relapse-free (RFS) and overall survival (OS) in children undergoing TBI-based HSCT
for acute lymphoblastic leukemia (ALL) on COG trial ASCT0431/PBMTC ONC051.
Design/Methods: The lung radiation dose received during TBI (1200 or1320 cGy given
bid in 6 or 8 fractions) was analyzed in relation to: total TBI dose, TBI dose per
fraction, TBI dose rate, TBI fields, patient position, pulmonary toxicity, acute graft
versus host disease (GVHD), veno-occlusive disease (VOD), TRM, donor type,
minimal residual disease (MRD) levels, RFS and OS.
Results: Of 143 enrolled, 109 patients had lung doses available for analysis. Patients
treated with lateral fields were significantly more likely to receive lung doses  800cGy
(p < 0.001). Patients receiving lung dose  800cGy had higher rates of relapse or TRM
(p = 0.034), and a trend for higher rates of death (p = 0.078). There was no association
between lung dose and rates of pulmonary toxicity (p = 1.000). In univariate analysis,
lung dose  800cGy, grade IV vs. grade I-III GVHD, VOD, pulmonary toxicity, MRD,
higher disease risk group and unmatched donor types were associated with inferior
RFS and OS. Multivariate analysis identified lung dose  800cGy to be significantly
associated with inferior RFS (HR 1.9; p = 0.031) and OS (HR 2.1; p = 0.023) while
controlling for risk group and donor type.
Conclusion: This data showed that lung irradiation dose  800 cGy during TBI was
associated with inferior RFS and OS. Understanding the mechanisms underlying these
results will require more research, but shielding to reduce the lung dose to 800cGy for
TBI regimens administering  1200cGy is recommended.
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LEUKEMIA
M. den Hoed1, S.M.F. Pluijm1, M.L. te Winkel1, H.A. de Groot-Kruseman2, M. Fiocco3,
P. Hoogerbrugge4, J.A. Leeuw5, M.C.A. Bruin6, I.M. van der Sluis1, D. Bresters7,
M.H. Lequin8, J.C. Roos9, A.J.P. Veerman9, R. Pieters10, M.M. van den
Heuvel-Eibrink10
1Erasmus University Medical Center - Sophia Children’s Hospital, Pediatric Oncology,
Rotterdam, Netherlands; 2Dutch Childhood Oncology Group, Pediatric Oncology, The
Hague, Netherlands; 3Leiden University Medical Center, Department of Medical
Statistics and Bioinformatics, Leiden, Netherlands; 4Radboud University Medical Center
Nijmegen, Department of Pediatric Hemato-Oncology, Nijmegen, Netherlands; 5Beatrix
Children’s Hospital- University of Groningen, Department of Pediatric
Oncology/Hematology, Groningen, Netherlands; 6University Medical Center Utrecht,
Department of Pediatric Hemato-Oncology, Utrecht, Netherlands; 7Leiden University
Medical Center, Department of Pediatric Hemato-Oncology, Leiden, Netherlands;
8Erasmus MC-Sophia Children’s Hospital, Radiology, Rotterdam, Netherlands; 9Vrije
Universiteit Medical Center, Department of Pediatric Hemato-Oncology, Amsterdam,
Netherlands; 10Princess Maxima Center, Oncology, Utrecht, Netherlands
Background/Objectives: Osteonecrosis (ON) and decline of bone mineral density
(BMD) are serious side effects during and after treatment of childhood acute
lymphoblastic leukemia (ALL). It is unknown whether ON and low BMD co-occur in
the same patients, and whether these two osteogenic side-effects can mutually influence
each other’s development.
Design/Methods: BMD and the incidence of symptomatic ON were prospectively
assessed in a national cohort of 466 patients with ALL (4-18 years of age) who were
treated according to the dexamethasone-based Dutch Child Oncology Group-ALL9
protocol. Bone mineral density of the lumbar spine (BMDLS)(n=466) and of the total
body (BMDTB)(n=106) were measured by dual X-ray absorptiometry. BMD was
expressed as age- and gender-matched standard deviation scores.
Results: Thirty patients (6.4%) suffered from symptomatic ON. At baseline, BMDLS
and BMDTB did not differ between patients who developed or who did not develop ON.
At cessation of treatment, patients with ON had a lower mean BMDLS and BMDTB
than patients without ON (respectively, ON+:-2.16 vs. ON-:-1.21, p<0.01 and
ON+:-1.73 vs. ON-:-0.57, p<0.01). Multivariate linear models showed that patients
with ON had a steeper BMDLS and BMDTB decline during follow-up than patients
without ON (interaction group time, p<0.01 and p<0.01).
Conclusion:We conclude that BMD status at ALL diagnosis does not seem to influence
the occurrence of symptomatic ON. BMD decline occurs from the moment of ON
diagnosis, this suggest that the already existing BMD decline during ALL therapy is
further aggravated by factors such as restriction of weight bearing activities and
destruction of bone architecture due to ON. Therefore ON can be considered as a risk
factor for low BMD in children with ALL.
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EFFECTIVE TARGETING OF B-CELL PRECURSOR ACUTE
LYMPHOBLASTIC LEUKEMIA BY CD70 DIRECTED IMMUNOTHERAPY
Q. Sun1, K.M. Debatin1, L. Meyer1
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Background/Objectives: Despite successful treatment of acute lymphoblastic leukemia
(ALL), relapse of the disease remains a major problem and is associated with poor
prognosis. This emphasizes the need for novel treatment strategies in addition to
established chemotherapy without increasing general toxicity. Previously, we identified
up-regulated CD70 transcript levels in a subgroup of B-cell precursor (BCP) ALL
associated with poor prognosis and patient outcome. CD70 is involved in T/B cell
priming and generation of memory B cells and only expressed on activated immune
cells. In this study, we aimed to evaluate CD70 as a therapeutic target for directed
immunotherapy.
Design/Methods: CD70 surface expression was analyzed by flowcytometry on
patient-derived xenograft samples. Effectivity and mechanisms of anti-CD70 directed
immunotherapy on BCP-ALL cells were evaluated in vitro and in vivo using different
xenograft mouse models.
Results: CD70 surface expression was analyzed on all together 28 patient-derived
BCP-ALL xenograft samples. Interestingly, CD70 surface expression was found to be
higher in leukemias associated with poor outcome compared to ALL with favorable
outcome while very low CD70 expression was observed in non-leukemic bone marrow
control samples. Taking advantage of increased CD70 expression in BCP-ALL, the
efficacy of monoclonal antibody based CD70-directed immunotherapy was evaluated.
A marked reduction of leukemia load in peripheral blood, bone marrow and spleens of
the animals was detected after transplantation of anti-CD70 treated CD70hi primograft
ALL cells onto NOS/SCID mice. This effect could be abrogated by both depletion of
NK-cells in NOD/SCID mice and by using NK-cell deficient NSG mice as recipients,
indicating that decreased in vivo leukemia growth upon anti-CD70 treatment is
mediated by NK-cell induced cytotoxicity. In line, antibody-dependent cell-mediated
cytotoxicity (ADCC) was observed to mediate the anti-leukemic effect in vitro.
Conclusion: Thus, we identified significantly up-regulated CD70 expression in
BCP-ALL providing a novel target for directed immunotherapy.
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ACUTEMYELOID LEUKEMIA: A REPORT OF AML-BFM STUDY 2004
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Background/Objectives: Conflicting data on poor risk factors in pediatric acute myeloid
leukemia (AML) hamper risk stratification systems. The aim was to evaluate the
prognostic impact of specific chromosomal aberrations, especially a complex or
monosomal karyotype, in uniformly treated children to improve risk-adapted therapy.
Design/Methods: 707 patients <18 years with de novo AML (WHO criteria, no Down
Syndrome, no t(15;17)) were included in Study AML-BFM-2004. In 644 (91%) patients
genetic data were conclusive for either cytogenetic, FISH analyses or RT-PCR (initial
bone marrow or blood samples). Monosomal karyotype (MK) was defined as 2
autosomal monosomies or one autosomal monosomy associated with one structural
abnormality, excluding favorable cytogenetics. Complex karyotype (CK) was defined as
Pediatr Blood Cancer DOI 10.1002/pbc
SIOP ABSTRACTS S155
3 aberrations and one structural aberration, without favorable genetics or mixed
lineage leukemia (MLL)-rearrangement.
Results: In addition to several known cytogenetic prognostic factors a trisomy 8 was
associated with a reduced probability of 5-year event-free survival (pEFS) (n=16, pEFS
25%, SE 11%, P=0.0089), but not if it was combined with other aberrations (n=48,
pEFS 50%; SE 8%, P=0.83). Patients with MK showed a dismal outcome (n=25, pEFS
23%, SE 9%, P=0.0080), even after excluding patients with involvement of
chromosome 7 (n=19; pEFS 25%; SE 10%, P=0.0066). Although patients with MK
had high complete remission rates (80%), the cumulative incidence of relapse was
enhanced (CIR 49%, SE 11%, P=0.05). Multivariate analysis of EFS revealed MK as
independent high risk factor (Hazard ratio 2.07, 95% Confidence Interval 1.20 – 3.57,
Pχ 2=0.009). In contrast the complex karyotype alone had no prognostic significance
(n=47, pEFS 47%, SE 7%, P=0.33) after excluding patients with MK.
Conclusion:We identified the monosomal karyotype and trisomy 8 (without additional
cytogenetic aberrations) as potentially poor prognostic factors in pediatric AML,
thereby diminishing the impact of the complex karyotype. These results might affect
future risk stratification and risk-adapted therapy in childhood AML.
O-038
OPTIMIZING RISK STRATIFICATION OF JUVENILE MYELOMONOCYTIC
LEUKEMIA USING NEXT GENERATION SEQUENCING
E. Stieglitz1, A. Taylor-Weiner2, T. Chang1, G. Laura1, Y.D. Wang3, E. Esquivel1,
A. Yu1, T. Gruber3, K. Stegmaier2, M. Loh1
1Benioff Children’s Hospital- University of California- San Francisco, Pediatrics, San
Francisco, USA; 2Broad Institute of MIT and Harvard, Cancer genomics, Cambridge,
USA; 3St. Jude Children’s Research Hospital, Oncology, Memphis, USA
Background/Objectives: Juvenile myelomonocytic leukemia (JMML) is an aggressive
myeloproliferative neoplasm of childhood, with an event free survival of 50% after
hematopoietic stem cell transplantation (HSCT). Next generation sequencing was
performed in a large cohort of patients in order to identify additional genetic
alterations in this disease.
Design/Methods:Whole exome sequencing was carried out in 29 patients with
germline-tumor pairs including seven patients who also had relapsed samples available
for analysis. Targeted, deep sequencing was then carried out in an additional 71
patients. Genome wide DNA methylation and RNA-seq analyses were also performed
on samples of particular interest.
Results: Pathogenic mutations from exome sequencing were identified in 16 genes,
several of which were only detected in a clonal fashion at relapse. The recurrent
mutations involved genes regulating signal transduction, gene splicing, the polycomb
repressive complex and transcription. Importantly, the number of somatic alterations
present at diagnosis was the major determinant of outcome with patients harboring
two or more somatic alterations at diagnosis having a significantly inferior survival
compared to those with less than two despite treatment with HSCT. The 10-year event
free survival rates for patients with zero to one somatic events at diagnosis was 60.6% ±
6.2% versus 22.7% ± 7.4% for those with two or more (p=0.003). In addition, when
modeled in a multivariate analysis, only the number of somatic alterations remained
independently prognostic of poor outcome. By focusing on patients with relapsed
disease, we also established that the model for disease progression in JMML is
surprisingly simplistic, with a linear acquisition of mutations compared to the
branching model seen in other cancers.
Conclusion: Patients with JMML harboring two or more somatic alterations at
diagnosis have unacceptably poor outcomes with conventional treatment and should be
risk stratified to receive tailored treatments based on their genetic profile.
O-039
PHF6 MUTATIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA
J. de Rooij1, M. van den Heuvel-Eibrink1,2, N. van de Rijdt1, V. de Haas3, J. Trka4,
A. Baruchel5, D. Reinhardt6, R. Pieters2, M. Fornerod1, C.M. Zwaan1
1Erasmus University Medical Center - Sophia Children’s Hospital, Pediatric Oncology,
Rotterdam, Netherlands; 2Princess Máxima Center for Pediatric Oncology, Utrecht,
Netherlands; 3Dutch Childhood Oncology Group, DCOG, The Hague, Netherlands; 42nd
Medical School-Charles University, Pediatric Hematology/Oncology, Prague, Czech
Republic; 5Hôpital Robert Debré AP-HP, Pediatric Hematology-Immunology, Paris,
France; 6Universitätsklinikum Essen, AML-BFM Study Group-Pediatric
Hematology/Oncology, Essen, Germany
Background/Objectives: Acute myeloid leukemia (AML) is characterized by the
presence of different cytogenetic and molecular aberrations, which may influence
prognosis. PHF6, a gene located on Xq26.3, is a tumor suppressor mutated in 20% of
the T-ALL cases (Van Vlierberghe, 2010). In adult AML mutations of PHF6 are found
in 3% of the cases, all classified as FAB-M0, M1 and M2 (Van Vlierberghe, 2011). In
T-ALL and adult AML mutations were found almost exclusively in male patients,
probably due to the sex-chromosome localization of the gene. Studies show that
suppression of PHF6 promotes myeloid tumor cell growth in vivo (Meacham, 2015).
Our aim was to investigate the frequency of PHF6 mutations in patients with pediatric
AML.
Design/Methods:We investigated a pediatric AML cohort (n=318), enriched for
FAB-M0, M1 and M2 (n=143), for the presence of mutations in the complete encoding
region of PHF6 with direct sequencing. Moreover, we analyzed mRNA expression
levels of PHF6 with quantitative PCR, and analyzed outcome.
Results:We identified 5 cases with a PHF6 frameshift mutation, and one case harboring
a point mutation, predicted as damaging by SIFT/PolyPhen analysis. All mutated cases
were classified as FAB-M0, M1 and M2. In contrast to adult AML, 4/6 mutated
patients were female, of which 1 female showed –X based on conventional karyotyping
and XIST expression. The frameshift mutated cases showed significantly lower PHF6
expression compared to other pediatric AML cases, indicating a loss-of-function. Of
the 6 patients with a mutation, one was refractory, and 4 relapsed. Four patients died
due to leukemia and two are in CCR. Other genetic aberrations found in these patients
were RUNX1/RUNX1T1, NUP98/KDM5A, and mutations in RAS, WT1, TET2,
IDH1, BCORL1 and ETV6, none of which were recurrent.
Conclusion:We identified recurrent loss-of-function PHF6 mutations in pediatric
AML, in both male and female patients, exclusively found in FAB-M0, M1 and M2.
O-040
IMPLEMENTATION OF ADAPTED AML TREATMENT IN LIMITED
RESOURCES COUNTRY (INDONESIA NATIONAL AML PROTOCOL):
INTERIM RESULTS
!
E. Supriyadi1, I. Purwanto1, P.H. Widjajanto1
1Dr. Sardjito Hospital - Faculty of Medicine- Universitas Gadjah Mada, Pediatric
Hematology Oncology, Yogyakarta, Indonesia
Background/Objectives: Childhood acute myeloblastic leukemia (AML) treatment has
significantly improved over the past decades. In developing countries the success of
treatment was estimated below 10% while in developed countries treatment success has
reached 65%. Starting 2011 we developed and used the National Protocol for AML.
The aim of this study was to determine the profile of childhood AML in Dr. Sardjito
Hospital and evaluate the results of three different AML treatments protocols: ADE
(Ara-C, Doxorubycine and Etoposide) versus modification of the Nordic Society of
Pediatric Hematology Oncology and Indonesia National AML Protocol.
Design/Methods: The health records of children 0 – 18 years of age, newly diagnosed
with AML from March 1999 – February 2015 were retrospectively reviewed. The
diagnosis of AML was confirmed based on morphological and histochemical
examinations of marrow samples. Survival analysis was performed on patients treated
on ADE (ara-C, doxorubicinand etoposide) versus m-NOPHO (6-mercaptopurine,
cytarabine, etoposide, anthracycline, methotrexate and L-asparaginase) and National
AML protocol (doxorubycine, cytarabine and etoposide plus tripel drugs intrathecal:
metothrexate, hydrocortison and Ara-C).
Results: Of 301 patients diagnosed with AML, 217 (72%) patients received
chemotherapy: 139 (64%) used ADE or m-Nopho protocol, 66 (30%) with National
AML protocol and the rest used other protocol 12 (6%). The OS after 2-years in
patients who were treated with National AML protocol was 18.6% whereas in the ADE
and m-Nopho protocol group, was 3.9% (p=0.05).
Conclusion: Treatment with National AML protocol had a higher survival compared to
the ADE and m-NOPHO protocol. Supportive care including infection control has
considerable influence to the success in the treatment of AML.
O-041
IMATINIB PHARMACOKINETICS, ITS GOOD EFFICACY BUT ALARMING
TOXICITY IN CHILDRENWITH CHRONIC MYELOID LEUKEMIA IN INDIA
B. Arora1, N. Thacker1, G. Narula1, M. Prasad1, N. Patkar2, P.G. Subramaniam2,
S. Gujral2, P. Tembhare2, P. Amare3, V. Gota4, S. Banavali1
1Tata Memorial Hospital, Pediatric Oncology, Mumbai, India; 2Tata Memorial
Hospital, Hematopathology, Mumbai, India; 3Tata Memorial Hospital, Cytogenetics,
Mumbai, India; 4Tata Memorial Hospital, Clinical Pharmacology, Mumbai, India
Background/Objectives: Imatinib has limited data on efficacy and toxicity, which is
mostly from mostly Caucasian children. Imatinib’s potential risk of chronic toxicity due
to inhibition of c-kit and PDGF-R involved in normal organ functions in growing
children and its metabolism through cytochrome P450 with significant genetic
polymorphism, necessitates evaluation of its pharmacokinetics, efficacy as well as
chronic toxicity in large cohorts from all ethnic groups.
Design/Methods: Children with CML in chronic-phase on Imatinib (300 mg/m2)
underwent monitoring for plasma trough levels by HPLC, efficacy, and acute as well as
chronic toxicity (> 1 year of Imatinib usage) for growth, immunological, cardiac,
endocrine, musculoskeletal, pulmonary, ophthalmological and auditory functions.
Results: Ninety six children were evaluated (M: F - 2.2:1; median age- 12 years &
median follow-up- 55 months). Of these, 84.3% achieved complete cytogenetic response
at 12months and 69% Major Molecular response at 18 months. The event free and
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overall survival of group was 84.1% and 93.8% respectively.Common acute toxicities
were anemia -100%, neutropenia-81.2% & thrombocytopenia 57.3%, hepatic-83.3%,
and skin depigmentation in 80.2%. In chronic toxicity, 60 evaluable children had
significant growth deceleration at 12 and 24 months which continued till at least 48
months of follow-up. CPK elevation (65%), hypogammaglobulinemia (8%), moderate
restrictive airway dusfunction (7%) were also observed. Imatinib trough levels showed
significant variability (mean±SD- 1,375ng/ml±715ng/ml, range 430ng/ml-4,980ng/ml)
but were comparable to published data. Children with higher median
levels(>1,000ng/ml) had better cytogenetic responses at 1 year but no excess toxicity.
Conclusion: Imatinib has similar pharmacokinetics, and good efficacy but higher acute
hematological as well as non-hematological toxicity in Indian children. It causes
alarming growth retardation and significant skin depigmentation and also has probable
impact on immune, pulmonary and muscular system. A larger multicentric prospective
study with serial longitudinal testing is required to assess its impact on all organ systems.
O-042
THE CRM1 NUCLEAR EXPORT RECEPTOR IS CRITICAL FOR THE
EXPRESSION OF HOXA GENES AND CAN SUBSTITUTE FOR CALM IN
CALM-AF10 LEUKEMOGENESIS
D. Wechsler1, J. Heath1, W. Aumann1, C. Lavau1
1Duke University Medical Center, Pediatric Hematology-Oncology, Durham, USA
Background/Objectives: The CALM-AF10 chromosomal translocation is associated
with overexpression of HOXA genes, which are effectors of oncogenic transformation
that are frequently upregulated in pediatric acute leukemias. We have previously shown
that a nuclear export signal within CALM interacts with the CRM1 nuclear export
receptor and that the CRM1/CALM-AF10 interaction is essential for leukemia
development in mice. The goals of the present work are to investigate the molecular
mechanisms by which CRM1 participates in HOXA upregulation, and to determine
whether CRM1 can substitute for CALM in leukemogenic fusions.
Design/Methods:We measured Hoxa transcript levels in murine leukemia cells treated
with the CRM1 inhibitor Leptomycin B (LMB). We created artificial retroviral CRM1
fusion constructs and assessed their leukemogenic potential in vitro and in vivo.
Results:We found that brief LMB treatment of CALM-AF10 leukemia cells causes a
significant reduction of Hoxa7, Hoxa9 and Hoxa10 levels. In an in vitro murine bone
marrow (BM) clonogenic assay, native CRM1 overexpression did not transform, while
CRM1-AF10 fusions resulted in immortalization. To investigate leukemogenic potential
in vivo, we transplanted mice with retrovirally transduced BM progenitors.
CRM1-AF10 induced myeloid neoplasms with a low penetrance and long latency (7/20
mice developed leukemias between 160-350 days). These primary leukemias were
transplantable, causing leukemias with a shorter latency, and leukemia blasts expressed
elevated levels of Hoxa genes.
Conclusion:Our results demonstrate that CRM1 regulates the expression of Hoxa genes
in murine leukemia cells, and that CRM1 fusions can drive murine leukemogenesis. Of
note, a CRM1-AF10 fusion gene was recently identified in a T-ALL patient (BLOOD,
2014). Novel CRM1 inhibitors are currently being tested in clinical trials. Our data also
suggest that the efficacy of these inhibitors could be mediated in part by their ability to
block CRM1-dependent transcriptional activation of HOXA genes.
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BURKITT LYMPHOMA : LONG TERMOUTCOME IN 738 PATIENTS
TREATEDWITH CYCLOPHOSPHAMIDE-BASED PROTOCOLS IN RURAL
CAMEROON FROM 2003 T0 2013
P. Hesseling1, F. Kouya2, G. Mbah3, P. Wharin4, P. McCormick4, E. Katayi2, P. Achu5,
R. Bardin2
1Stellenbosch University, Peadiatric Child and Health Department, Cape Town, South
Africa; 2Cameroon Bapist Convertion Health Board, Cameroon Bapist Convertion Health
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Bapist Convention Health Board, Bamenda, Cameroon; 4Beryl Thyer Memorial Africa
Trust-UK, Beryl Thyer Memorial Africa Trust-UK, Kettering, United Kingdom; 5Mezam
Clinic, Mezam Clinic, Bamenda, Cameroon
Background/Objectives: A 50% to 60% one year event free survival was previously
reported with Burkitt lymphoma protocols which use 3 doses of weekly
cyclophosphamide and intrathecal methotrexate as induction followed by one to three
more pulses of cyclophosphamide ± vincristine and IV methotrexate for advanced or
non – responsive disease. Rescue treatment for early relapses consisted of 3 weekly
pulses of cyclophosphamide + vincristine and full retreatment for relapses beyond one
year. Patients were all treated at Banso (BBH), Mbingo (MBH)and Mutengene (BHM)
Baptist Hospitals in Cameroon. To record the incidence of early deaths, deaths during
treatment, relapses and long term survival in this cohort.
Design/Methods: All patients with complete treatment records were followed - up in
hospital, by telephone or home visits to ascertain outcome. The diagnosis was based on
clinical presentation, fine needle aspirates, cerebrospinal fluid, bone marrow and
abdominal ultrasound examinations.
Results:Median age was 8 (range 3 – 15) years. Forty two deaths (5.7%) occurred during
induction, and a total of 120 (16.3%) during the total 3 to 8 week treatment period.
Deaths during treatment ranged from 10% at BBH to 26% at MBH, because of lapses in
standardized supportive care at MBH. One or more relapses occurred in 219 (29.7%) of
all patients, with 53 (24%) long term survivors. Follow – up beyond 12 months of onset
of treatment in 405 patients in remission, was achieved in 336 (83%) of patients. Overall
survival was 55% after median follow – up of 3.7 yrs (range 2 months to 11.8 yrs).
Conclusion: Long term overall survival of 55% was achieved with low cost, low toxicity,
high frequency cyclophosphamide based regimens. Relapses can be successfully treated
with a 3 week rescue protocol or full retreatment.
Acknowledgements: BTMAT, Swiss Cancer League, WCC, our nurses.
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CHILDHOOD BURKITT LYMPHOMA IN NORTH AFRICA: THEMATII
STUDY OF THE FRENCH-AFRICAN PEDIATRIC ONCOLOGY GROUP
(G.F.A.O.P.)
M. El Kababri1, S. Cherkaoui2, L. Hessissen1, M. Khattab1, A. Madani2, A. Quessar2,
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Villejuif, France; 6University Hospital of Bicetre, Biology and Haematology Department,
Villejuif, France; 7Gustave Roussy Institute, Pediatric Oncology, Villejuif, France;
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Background/Objectives: A first prospective multicentre study was performed by GFAOP
in 2001-2004 to evaluate the feasibility of modified LMB 89 chemotherapy regimens in
Burkitt lymphoma (BL) in Africa. Two schemes were proposed: the MAT
(Morocco-Algeria-Tunisia) and the GFA2001. North African units except Rabat used
the MAT protocol and the other units the less intensive GFA 2001 protocol (without
doxorubicin). Overall survival (OS) was 61% with better results with the MAT regimen
(74%) (Harif, BPC, 2008).In order to improve outcome of patients with BL in North
African GFAOP units, it was decided to extend the MAT protocol to the four North
African units for the second study, including Rabat.
Design/Methods: All patients with BL were prospectively registered in a common
database in Casablanca. They were stratified in 3 risk groups (A, B, C), and treated with
polychemotherapy of progressive intensity.
Results: From 04/2005 to 05/2014, 431 patients were evaluable: sex ratio 2.5/1 Median
age was 51/2 years. There were: 18 stages I (4%), 65 stages II (15%), 266 stages III (62%),
67 stages IV (19%) and 15 Burkitt leukaemia, corresponding to 13 patients in group A,
338 in group B and 80 in group C. Any grade III-IV toxicity was observed in 702/2225
courses (31%). Sixty one pts died of toxicity (14%). Fifty three patients relapsed (12%).
The event free and OS were respectively 83% and 91% in group A, 71% and 74% in
group B, 29% and 32% in group C. OS was 68% for all patients, but increased for stage
III patients from 63% in 2005-2008 period to 80% in 2008-2014 period.
Conclusion: Except in group C, a high cure rate was achieved in BL in North Africa
with the LMB-based MATII protocol. Improvement in supportive care and increased
experience of healthcare teams contributed to the better outcome in the second period.
O-045
A MULTICENTER STUDY FOR TREATMENT OF CHILDRENWITH BURKITT
LYMPHOMA IN SUB SAHARAN PAEDIATRIC UNITS. A STUDY OF THE
“GROUPE FRANCO AFRICAIN D’ONCOLOGIE PÉDIATRIQUE” (GFAOP)
C. Bouda1, F. Traore2, J.J. Atteby3, K.M. Guédénon4, A. Pondy5, C. Moreira6,
M. Harif7, C. Patte8
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7CHUMohammed VI, Paediatrics, Marrakech, Morocco; 8Gustave Roussy, Paediatric
Oncology, Villejuif, France
Background/Objectives: To evaluate the results of an intense chemotherapy for the
treatment of Burkitt lymphoma (BL) in sub-Saharan paediatric units (PU).
Design/Methods: Following 2 previous GFAOP protocols (Harif, PBC 2008; Traore,
PBC 2011), 6 PU started in April 2009 a common protocol based on a modified LMB
regimen. Treatment starts with a prephase with cyclophosphamide, followed by 2
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induction COPM courses (cyclophosphamide-Vincristine-high dose (HD)
Methotrexate(HDMTX)) and 2 consolidation CYM courses (cytarabine-HDMTX).
HDMTX, associated with intrathecal MTX, is given at the dose of 3g/m2.
Recommendation was to initiate the following course when neutrophil count >500 in
ascending phase. We focus the analysis on stage III which represent 80% of all patients.
In April 2014, there were 231evaluable cases (sex ratio 2/1). Median age: 7.5 y (12 m-17.5
y). 95% pts had an abdominal tumour and 51% of them had also a facial tumour.
Results: 104 patients are alive in CR1 (94 after protocol treatment and 10 despite early
treatment stop), 5 in CR2 and 14 in unknown status. 72 died: 22 (9%) from toxicity
during protocol treatment and the others from lymphoma progression or toxicity of 2nd
line treatment. In total, 36 (15%) were lost to FU, 8 of them in CR.Overall survival
(OS) is 61% (53-68) at 12m (median FU: 9m). Among the 196 pts who achieved
induction, OS was significantly better: 73% (61-83) versus 55% (42-67), (p=0.02) when
the delay between treatment start and COPM2 start was < or > 34 days.
Conclusion: A prospective multicentre study for treatment of BL is feasible in
sub-Saharan Africa. Dose intensity during first weeks of treatment is an important
prognostic factor. Although improvements still have to be done, results are encouraging
with increase of cure rate and lower percentage of patients lost to FU compared to
previous studies.
O-046
CLINICAL SPECTRUMOF LYMPHOMA IN CHILDREN AND ADOLESCENTS
IN CENTRALMALAWI
M. Mutai1, I. Mtete1, P. Mehta2, S. Gopal3, G. Liomba4, Y. Fedoriw5, R. Krysiak4,
P. Kazembe6, N. El-Mallawany7
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Background/Objectives:While Burkitt lymphoma (BL) is the most common pediatric
lymphoma in sub-Saharan Africa, Hodgkin lymphoma (HL) and other non-Hodgkin
lymphomas (NHL) occur. Diagnosing lymphomas presenting without classical jaw
masses is challenging given limitations in radiology and pathology. We describe
presentations and outcomes for diverse pediatric lymphomas in central Malawi.
Design/Methods:We retrospectively characterized 121 children with lymphoma from
12/2011 – 6/2013. Diagnosis was pathologically confirmed in 50 patients and clinical in
the remainder. Chemotherapy regimens were: stage I/II BL, INCTR 03-06; stage III/IV
BL and other NHL, CHOP; HL, ABV-PC.
Results:Median age was 8.4 years (2.1-16.8). Seventy-eight (64%) were male. Clinical
sites of presentation were: abdominal mass 50%, jaw mass 35%, peripheral
lymphadenopathy (LAD) 34%, cranial nerve palsy and/or lower extremity weakness
(CNS+) 17%, peri-orbital mass 13%, mediastinal mass 12%, and severe cytopenias 9%.
Diagnoses included: BL 64%, HL 18%, lymphoblastic lymphoma (LBL) 12%, diffuse
large B-cell lymphoma (DLBCL) 5%. HL commonly presented with long-standing
LAD (21/22). The majority of LBL presented with mediastinal mass (12/15). Murphy
NHL stage distribution was: 27% stage I/II, 44% stage III, 29% stage IV. HIV testing
was routinely performed; 4 were HIV-infected (3 BL, 1 DLBCL). Chemotherapy was
completed in 65%, while 16% were lost to follow-up. At last evaluation, 31% were in
complete remission (CR) after median follow-up of 18 months (range 3-31). Four
children with CNS+ BL were in CR after 18-31 months. Sustained CR rates were: LBL
0% (0/15), HL 23% (5/22), DLBCL 17% (1/6), and BL 40% (31/78).
Conclusion: Stage I/II BL accounted for only 21.5% of pediatric lymphomas. The
majority of lymphomas (>70%) presented with advanced stage III/IV disease, and
abdominal primary sites were most common. Outcomes were poor for LBL, DLBCL,
and HL. Treatment paradigms accounting for pediatric lymphoma diversity in our
setting are urgently needed to improve survival.
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RELAPSES OR REFRACTORY FORMS OF LYMPHOBLASTIC LYMPHOMAS
IN CHILDREN: RESULTS AND ANALYSIS OF 23 PATIENTS IN THE EORTC
58951 AND LMT96 PROTOCOLS
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Background/Objectives: The treatment of children with T-cell (T-LBL) and precursor
B- (pB-LBL) lymphoblastic lymphomas has improved during the last few decades.
However, the patients who relapse or the refractory patients still have poor prognosis.
Design/Methods:We report the characteristics and evolution of T-LBL and pB-LBL
relapses in two multicentric prospective studies, LMT 96 and EORTC 58951.
Results: From 1997 to 2008, 194 patients were included in these studies (157 T-LBL and
37 pB-LBL); and 23 patients underwent relapse or progression (18 T-LBL and 5
pB-LBL). The median age was 7.7 years [range 1.4; 16.3]. The survival rate at 8 years
was 8.7% (21 deaths). The median duration from diagnosis to relapse was 9 months
[range 1; 69], and 11 months [range 1; 45] for T-LBL and pB-LBL respectively.
Twenty-two patients received a second line treatment (VANDA) but remission was
achieved in 7 patients only. In ten patients, intensification with hematopoietic stem cell
transplantation (HSCT) was performed and 4 of them had a second relapse. The two
living patients had T-LBL, experienced relapses at 15 and 69 months after diagnosis,
and received a HSCT as consolidation. Relapse during the intensive phase and second
line treatment without HSCT were identified as risk factors for bad prognosis (p=0.01).
Statistic of immuno-genetic parameters could not be obtained.
Conclusion: Results of the second line treatment, including intensive chemotherapy and
HSCT, are still disappointing in controlling refractory forms. The early identification of
these aggressive forms is mandatory to improve the prognosis with early intensification
in first remission. Valid prognostic parameters, such as prognostic biological features
are needed with multicentric international cooperation for collecting information on
these rare diagnoses.
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TARGETING THE PI3K/AKT/MTOR PATHWAY IMPROVES
CHEMORESPONSIVENESS IN CELL LINE MODELS OF CHEMOTHERAPY
SENSITIVE AND RESISTANT BURKITT LYMPHOMA
T. Ippolito1, N. Czuczman2, C. Mavis3, D. Rolland4, M. Lim4, A. Tiwari5, M. Cairo5,
R. miles6, M. Barth1
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Background/Objectives: Relapsed/refractory Burkitt lymphoma (BL) has a dismal
prognosis with <20% survival, stressing the need for development of novel therapeutic
approaches. Recently published data implicated PI3K in Burkitt lymphomagenesis.
Chemotherapy-resistant Raji BL cell lines (Raji-2R and Raji-4RH) developed in our
laboratory exhibit increased basal PI3K/Akt/mTOR pathway activation, suggesting a
possible role of PI3K/Akt/mTOR in chemoresistance.
Design/Methods: The efficacy of targeting the PI3K/Akt/mTOR pathway was
investigated in BL Raji, Raji-2R, Raji-4RH, Daudi and Ramos cells. Cell viability, cell
cycle progression, and induction of apoptosis were evaluated following exposure to
PI3K/Akt/mTOR pathway inhibitors alone and in combination with chemotherapy.
Results: In vitro exposure to inhibitors of PI3K (idelalisib), Akt (MK2206) or
mTORc1/2 (INK128) resulted in dose- and time-dependent decreases in viability by
AlamarBlu assay. BL cells were most sensitive to the mTORc1/2 inhibitor with IC50s in
the low nM range. Exposed Raji cells exhibited G1 cell cycle arrest, while G2/M arrest
was observed in Raji-2R and Raji-4RH cells. The combination of MK2206 and either
doxorubicin or dexamethasone resulted in synergistic decreases in viability in all cell
lines tested including both sensitive and resistant cells, by Chou-Talalay method. In Raji
and Ramos, MK2206 and doxorubicin in combination resulted in a higher degree of
PARP cleavage compared to single agents. No PARP cleavage was noted in Raji-2R and
Raji-4RH cells, likely related to impaired apoptotic potential previously reported in
these cells. Analysis of phosphoproteomics and gene expression profiling identified
B-cell receptor (BCR) activation while miR array and qRT-PCR identified increased
expression of Akt activating miR 17 as potential mechanisms of Akt activation in the
chemoresistant cells.
Conclusion: Our data suggests constitutive activation of the PI3K/Akt/mTOR pathway,
through activation of the BCR pathway and/or over-expression of miR17, is associated
with development of resistance in BL cell lines, and inhibition of PI3K/Akt/mTOR can
sensitize BL cells to chemotherapeutic agents.
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PHASE I STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH
RELAPSED OR REFRACTORY SOLID TUMORS: A POETIC GROUP STUDY
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L. Shen8, C. Herzog9, C. Veyrat-Follet10, J. Zhang11, S. Chi1
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Background/Objectives: Purpose: To determine the dose limiting toxicity (DLT) and
maximum tolerated dose (MTD) of cabazitaxel in pediatric patients with relapsed or
refractory solid tumors including brain tumors. Background: Cabazitaxel is a novel
taxane with increased activity against other taxane resistant tumors in vitro; with
demonstrated penetration through the blood brain barrier, making it a potential
therapy for brain tumors. A phase I study was conducted through the Pediatric
Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) to
determine the MTD of cabazitaxel. This study also characterized the safety, tolerability
and pharmacokinetic (PK) profile of cabazitaxel.
Design/Methods: Patients with refractory or recurrent solid tumors were enrolled in a
standard 3+3 design. The DLT period encompassed the first cycle. The starting dose of
cabazitaxel was 20 mg/m2, which was 80% of the MTD in adult studies. Cabazitaxel
was administered IV once every 3 weeks. PK studies were performed during the first
cycle and tumor assessment every 9 weeks. Patients could remain on study drug if they
had no evidence of progressive disease or unacceptable toxicity.
Results: 26 patients were enrolled at 8 POETIC institutions with 3 screen failures. 19
patients had brain tumors and 4 had solid tumors. 6 of 23 patients had stable disease or
partial response for > 3 treatment cycles. Common adverse events were fatigue,
diarrhea, nausea and vomiting, febrile neutropenia and hypersensitivity reactions. A
total of 3 DLTs (febrile neutropenia) were reported, and after previous dose level
expansion, the MTD was determined to be 30 mg/m2. Slightly higher plasma clearance
compared to adult trials was observed.
Conclusion: Cabazitaxel was generally well tolerated in this phase I study and the MTD
in children is 30 mg/m2, which is higher than the adult MTD but with a slightly higher
plasma clearance of cabazitaxel. A phase II trial in brain tumors is ongoing.
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ENROLLMENT IN AN EARLY PHASE CLINICAL TRIAL IN PEDIATRIC
ONCOLOGY: FACTORS THAT INFLUENCE DOCTORS’ PROPOSAL AND
PARENTS’ DECISION
A. Surun1, M.E. Dujaric2, D. Orbach1, I. Jimenez1, I. Aerts1, H. Pacquement1,
F. Bourdeaut1, G. Schleiermacher1, J. Michon1, J.C. Dupont1, F. Doz1
1Institut Curie, Department of Pediatric Oncology, Paris, France; 2Institut Curie,
Department of Biostatistics, Paris, France
Background/Objectives: Since 2007, the Pediatric Regulation was launched in Europe to
facilitate access to new medicines for children. Little research has focused on
early-phase trials’ availability in Pediatric Oncology and reasons for failure to enroll. In
this study, we aimed to explore accessibility of early-phase trials for children in
palliative phase, and to identify reasons for non-proposal to enroll, parents’ refusal or
failure of inclusion.
Design/Methods:We conducted a retrospective chart review at Curie Institute for all
patients less than 18 years at diagnosis, whose cancer progressed despite known effective
treatments between July 2010 and December 2013. Data were recorded anonymously.
Results: This study involved 100 patients (in the same period, the median number of
new patients yearly cared for cancer in our Department was 249 [220-265]). Fifty-two
experienced at least one early-phase trial’s proposal. Despite proposal, 20 parents
refused the inclusion, preferring a conventional treatment (n=5/18 reported reasons,
data not available in 2 cases), or due to quality of life priority and fear of constraints
(n=13/18). Fourteen inclusions failed despite parents’ approval, due to rapid
deterioration (n=6), non-inclusion criteria (n=6), and unavailability of the trial a
posteriori (n=2). No enrollment’s proposition was done for 48 patients: no early-phase
trial available during the palliative phase (n=5), non-inclusion criteria (n=26), other
physical factors (n=5), medical choice for a conventional treatment (n=5), trial’s
constraints (n=4), psychological factors (n=2), and follow-up in another hospital
(n=1).
Conclusion: Availability of early-phase trials has recently increased, thanks to the
Pediatric Regulation. Decision not to propose early-phase trials to children is
multifactorial, in line with the complexity of palliative care. Better selection of timing
to propose, opening less constraining early-phase trials, limiting waiting lists, and
improving parents’ and children’s information may facilitate children’s access to new
medicines.
O-051
TARGETING ACUTE LYMPHOBLASTIC LEUKEMIA WITH TRANSGENIC
MondoA-SPECIFIC ALLORESTRICTED T-CELLS
A. Sipol1, T. Grünewald2, G. Richter1, C. Wernicke1, S. Burdach1
1Technischen Universitaet Muenchen, Children’s Cancer Research and Roman Herzog
Comprehensive Cancer Centers-Department of Pediatrics, Munich, Germany;
2Ludwig-Maximilians-Universitaet, Institute of Pathology-Laboratory for Pediatric
Sarcoma Biology, Munich, Germany
Objectives: Oncogene addiction provides ideal targets for immunotherapy. We
previously assessed MondoA (also known as MLXIP, MAX like protein X interacting
protein) as a metabolic stress sensor, required for leukemogenesis (Wernicke et al. 2012).
MondoA dimerizes with MLX within the MYC interactome, promotes longevity in C.
elegans (Johnson et al. 2014) and regulates cancer cell metabolic reprogramming
(Carroll et al. 2015). MondoA induces stemness, proliferation and B cell receptor
signaling pathway in common ALL (cALL,Wernicke et al. 2012). Here we report on
the role of MondoA in malignancy of cALL in vivo and targetability by allorestricted T
cell receptor (TCR) transgenic T cells (ATRs).
Design/Methods: NALM6, 697 and Reh cALL lines were lentivirally transduced with
MondoA short hairpin RNA (shRNA) and tested in our xenotransplantation model
(Richter et al. 2009). MondoA specific T cells were generated by priming of donor
HLAA0201 negative (A2-) T-cells with A2+ dendritic cells bearing MondoA peptides,
multimer-based sorting and subcloning of A2-CD8+ T-cells. Specificity and
functionality of T cell clones were tested by ELISpot interferon g (IFg) and granzyme B
assays with leukemia lines (A2+, A2-). Transgenic ATRs were generated by infection of
lymphocytes with retroviral vector system containing TCR construct.
Results:We found MondoA to be overexpressed in both ALL and AML. MondoA
knock down (kd) in cALL cell lines reduced the transcript by 80%. Importantly, in vivo
MondoA maintained 90-99% of CD10+ leukemic blasts in blood, marrow and spleen.
Spleen size and weight normalized by MondoA kd. Our transgenic MondoA specific
ATRs successfully recognized and killed A2+ MondoA expressing cALL cell lines.
Peptide dependent and independent off target alloreactivity was low compared to
reactivity against NALM-6 cALL.
Conclusion: These findings demonstrate that MondoA maintains leukemic burden and
malignancy of cALL in vivo. Moreover, we identified MondoA as a promising target for
immunotherapy of cALL.
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PHASE II PROSPECTIVE, OPEN LABEL STUDY OF EVEROLIMUS IN
CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY
OSTEOSARCOMA, RHABDOMYOSARCOMA AND OTHER SOFT TISSUE
SARCOMA
S. Epelman1, R. Melaragno1, E. Gorender1, R.S.S. Medeiros1
1Santa Marcelina Hospital, Pediatric Oncology Department, Sao Paulo, Brazil
Background/Objectives: Everolimus is an oral inhibitor of the mammalian target of
rapamyn (mTOR). Inhibition of mTOR has been shown to inhibit sarcoma cells in
vitro and also inhibit the growth of xenografs of rhabdomyosarcoma and osteosarcoma
cell lines in vivo. Mestastic soft-tissue sarcoma and bone sarcomas are typically
associates with limited therapeutic options and poor outcomes.
Design/Methods: There were enrolled 17 patients, whom 11 were osteosarcomas and 6
rhabdomyosarcoma, median age of 13 years (range of 4 - 21 years), 14 boys and three
girls. Everolimus was given at 5 mg/m2/ day until progression, which each cycle was
defined as 30 days of treatment and after 2 cycles responses were evaluated. All patients
were previously heavly treated with a median of three (1 to 6) chemotherapy regimens
with three or four drugs.
Results: There were administered 42 cycles in which partial response was reached in two
patients (one osteosarcoma and one rhabdomyosarcoma) that lasted for 5 and 11
months respectively, stable disease in other one patient for 4 months and progression in
14 patients. There were adverse events related to everolimus in five patients in which
only one patient had grade 3 toxicity. Despite 14 from 17 had disease progression,
everolimus therapy was well tolerated with little severe toxicity.
Conclusion: Based on these results, everolimus is safe and well tolerated and displayed
some clinical activity. Further studies will be necessary to evaluate efficacy of
everolimus as adjuvant therapy in a cohort of pediatric patients enrolled at diagnosis.
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VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE TREATMENT FOR
RECURRENT/PROGRESSIVE PEDIATRIC SOLID TUMORS
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1Istanbul University- Cerrahpasa Medical Faculty, Pediatric Hematology Oncology,
Istanbul, Turkey; 2Bezmialem Vakif University Medical Faculty, Pediatric Hematology
Oncology, Istanbul, Turkey; 3Istanbul University Oncology Institute, Radiation Oncology,
Istanbul, Turkey
Background/Objectives: The combination of irinotecan and temozolomide has shown
activity against manyrecurrent/progressivepediatric solid tumors. We evaluated our
experience with vincristine, irinotecan and temozolomide (VIT) given to children with
recurrent/progressive solid tumors.
Design/Methods:We retrospectively evaluated 30 patients treated with a combination of
vincristine 1.5 mg/m2/1st day; temozolomide 150 mg/m2 orally on days 1-5; irinotecan
intravenously 50 mg/m2 on days 1-5, every 21 days. Cefixime prophylaxis was used to
reduce irinotecan associated diarrhea in all patients.
Results: A total of 123 courses of VIT were given to 30 patients (27 progressive/3
relapse) with a median of 3 courses per patient. The diagnosis were Ewing sarcoma
(13), rhabdomyosarcoma (8), neuroblastom (7) and Wilms tumor (1), osteosarcoma (1).
All patients received VIT at second or further relapses. Median time from diagnosis to
recurrent/progressive time when VIT was initiated, was 21.8 months (5-63 months). We
observed 1 complete (Ewing sarcoma-8 months +), 2 partial responses (1
neuroblastoma 4 mo.+, 1 Ewing sarcoma 4 mo.+) and 9 stable disease in our patients.
Median duration of stable disease for all patients was 2 months (1-8mo.). In Ewing
sarcoma patients, median duration of stable disease was 6 months (3-8mo.).
Radiotherapy was used in 11 patients as local therapy. The main adverse effect of the
VIT combination was diarrhea.
Conclusion: In this heavily pretreated cohort, VIT was tolerated and had some effect in
recurrent/progressive solid tumors. It may have more effect if used at first relapse.
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PHASE I STUDY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN
CHILDRENWITH RECURRENT/REFRACTORY HIGH GRADE GLIOMA
P. Chastagner1, B. Devictor2, B. Geoerger3, I. Aerts4, P. Leblond5, D. Frappaz6,
J.C. Gentet7, S. Pall-Kondolff1, N. André7
1Children University Hospital, Paediatric Oncology Department, Vandoeuvre, France;
2University Hospital la Timone-AP-HM, Pharmacokinetic and Toxicology Laboratory,
Marseille, France; 3Gustave Roussy, Paediatric and Adolescent Oncology Department,
Villejuif, France; 4Curie Institute, Paediatric Adolescent and Young Adults Oncology
Department, Paris, France; 5Oscar Lambret, Paediatric Oncology Department, Lille,
France; 6Institut d’Hémato-Oncologie Pédiatrique, Institut d’Hémato-Oncologie
Pédiatrique- Lyon, Lyon, France; 7University Hospital la Timone-AP-HM, Paediatric
Oncology Department, Marseille, France
Background/Objectives: To determine the maximum tolerated dose and
pharmacokinetics (PK) of non pegylated liposomal doxorubicin (Myocet R©), in
children with recurrent or refractory high grade gliomas.
Design/Methods: Children previously treated with surgery, radiotherapy and
chemotherapy were eligible. Cohort of at least 3 patients each received escalating doses
of Myocet R© starting at 60 mg/m2, administered IV over 1 hour, at 3-week intervals for a
maximum of 6 courses. If no dose-limiting toxicity occurred, dosages were escalated to
75 mg/m2 corresponding to the adult recommended dose. Periodic blood samples were
collected and plasma DXR concentrations were quantified to characterize the PK.
Results: Between October 2010 and January 2013, 13 patients aged 6-17 years entered
the study. Patients received 1 to 6 courses (median 2) corresponding to 60 to 360 mg/m2
cumulative doses (median 120 mg/m2). In total, 27 courses were administered, at the 60
mg/m2 dosage level in 7 patients without dose-limiting toxicity (DLT), and at 75 mg/m2
in 6 patients who experienced 2 DLT (grade 4 neutropenia). The most common grade 3
to 4 toxicities reported were neutropenia and thrombocytopenia. No cardiac toxicity
occurred. No response was observed, however, 2 patients in stable disease after 4 and 6
courses and who received additional chemotherapy and surgery are alive in PR and CR
at 45 and 46 months from the start of Myocet R©.60% of the circulating DXR was
encapsulated. Median estimates of PK values of T1/2 (h), Cl (L/h/m2), and Vss (L),
were respectively: 32.9, 33.7, and 527 for free DXR; 34.8, 15, and 24.8 for total DXR.
Conclusion: The recommended dose of Myocet R© administered every 3 weeks to
pediatric patients was 60 mg/m2. The efficacy of Myocet R© on paediatric patients with
high grade glioma remains to be determined and should be studied in paediatric Phase
II trials.
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REFLECTIVE PRACTICE AND GLOBAL LEADERSHIP IN PEDIATRIC
HEMATOLOGY/ONCOLOGY: A MODEL FOR “ON THE JOB” TRAINING
P. Mehta1, E. Fruge2, J. Slone2, A. Slone2, G. Airewele2, E. Ishigami3
1Baylor College of Medicine, Houston, USA; 2Baylor College of Medicine, Pediatrics,
Houston, USA; 3Texas Children’s Hospital, Pediatrics, Houston, USA
Background/Objectives: TXCH Global HOPE operates projects in sub-Saharan Africa
(SSA). Placement in leadership positions in such settings can present significant
challenges beyond the scope of pre-service orientation. We adapted our evidence-based
Reflective Practice & Leadership Seminar (RP&L) methods1 to provide “on the job”,
ongoing leadership mentoring and training for team members in SSA. 1 Frugé, E.,
Mahoney, D.H., Poplack, D.G. & Horowitz, M.E. Leadership: “They Never Taught Me
This in Medical School”. JPHO, 2010, 32, No. 4, 304-308.
Design/Methods: A one-hour, bi-monthly teleconference seminar was conducted with
the Botswana and Angola teams of TXCH Global HOPE. In the Global RP&L
method, team members present current challenges and seasoned faculty guide the
discussion through a disciplined, step-wise analysis including a “diagnosis” of the
situation and a plan for strategic action – the leadership dimension of the African team
member’s role.
Results: Topics covered in the seminar included the challenges of bringing new staff
members onto the team, negotiating care delivered by an ancillary in-country service,
petitioning for resources within the context of a larger local organization, negotiating
for the change of medical personnel provided through a separate institution, and
negotiating change within an external institution that directly affects program function.
Self-report post-seminar questionnaires indicated participants strongly agreed (5 on 1-5
scale) with the following statements: the seminar improved their ability to 1) analyze
complicated clinical service situations 2) navigate inter-institutional politics, and 3)
effectively build cross-service relationships to improve patient care.
Conclusion: This Global Leadership Seminar has demonstrated success in helping our
SSA program teams improve leadership capacity and negotiate change effectively. This
Seminar is a novel and effective strategy to mentor international medical leaders in the
global setting. As our next phase, we plan to include local leaders in future seminars.
Finally, this novel model has proven to be cost-effective.
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CAPACITY BUILDING THROUGH TWINNING IN PAEDIATRIC ONCOLOGY:
CANADA AND THE CARIBBEAN AS AMODEL FOR SUCCESS
C. Bodkyn1, S. Weitzman2,3, C. Sin Quee4,5, E. Adler3, C. Alexis6, Z. Ali1, U. Allen7,
J. Bird-Compton8, R. Boyle9, B. Datta9, S. de Young3, B. Fleming-Carroll10, T. Gibson11,
S. Gupta2, P. Ingram-Martin12, M. Kirby-Allen2, J. Knight-Madden13, I. Odame2,
S. Read3,7, M. Reece-Mills14, M. Richards-Dawson15, B. Smith3, M. Thame16,
G. Wharfe11, V. Blanchette2,3
1University of the West Indies- St Augustine Campus, Department of Clinical Medical
Sciences- Faculty of Medical Sciences, Port of Spain, Trinidad and Tobago; 2The
Hospital for Sick Children, Department of Paediatrics-University of Toronto and Division
of Haematology/Oncology, Toronto, Canada; 3The Hospital for Sick Children, Centre for
Global Child Health, Toronto, Canada; 4Princess Margaret Hospital, Pediatrics, Nassau,
The Bahamas; 5University of the West Indies, SCMR, Nassau, The Bahamas;
6University of the West Indies- Cavehill Campus, Pediatrics, Bridgetown, Barbados; 7The
Hospital for Sick Children, Department of Paediatrics-University of Toronto and Division
of Infectious Diseases, Toronto, Canada; 8Ministry of Health, Community Child Health
Service, Castries, St Lucia; 9Milton Cato Memorial Hospital, Pediatrics, Kingstown, St
Vincent and the Grenadines; 10The Hospital for Sick Children, Collaborative for
Professional Practice, Toronto, Canada; 11University of the West Indies- Mona Campus,
Department of Pathology, Kingston, Jamaica; 12Bustamante Hospital for Children,
Nursing Services, Kingston, Jamaica; 13University of the West Indies, Sickle Cell
Unit-Tropical Medicine Research Institute, Kingston, Jamaica; 14University Hospital of
the West Indies, Department of Child Health, Kingston, Jamaica; 15Bustamante Hospital
for Children, Pediatrics, Kingston, Jamaica; 16University of the West Indie, Department
of Obstetrics-Gynaecology and Child Health, Kingston, Jamaica
Background/Objectives: In 2013, the SickKids Center for Global Child Health at the
Hospital for Sick Children (SickKids), Toronto, Canada launched a 5-year,
not-for-profit initiative with Caribbean countries to build capacity for care of children
with cancer and blood disorders. Formalized through a Memorandum of
Understanding with the University of the West Indies (UWI) and with respective
Ministries of Health, the SickKids-Caribbean Initiative (SCI) has partnered with in 6
Caribbean countries: The Bahamas, Barbados, Jamaica, St. Lucia, St. Vincent and the
Grenadines and Trinidad and Tobago.
Design/Methods: Support from Caribbean and SickKids physician and nursing leaders
in the aforementioned territories has helped facilitate formally contracted agreements
with academic, hospital and government agencies in the Caribbean, and with the
SickKids Division of Haematology/Oncology. Funding secured by SickKids
Foundation is used to finance local SCI activities, through contracts between SickKids
and Caribbean hospital administrations. Key paediatric oncology deliverables include:
(1) establishing a hospital-based database; (2) conducting case consultations with
additional diagnostic studies as needed; (3) enhancing diagnostic services; and (4)
finalizing a nursing curriculum with UWI School of Nursing.
Results: Integral to the success of SCI, communication is maintained through a
standardized network of telemedicine facilities, installed or upgraded by SCI in all
participating countries. All of the above elements have been key to building the
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foundation of SCI with relationships at the university, hospital and government levels,
in collaboration with a strong donor-base, support from Canadian Embassies in the
Caribbean and the Caribbean Diaspora in Toronto.
Conclusion: SCI has achieved its goals for the first phase of this ambitious project
establishing the formal links between six countries and SickKids. This will now pave the
way for the second phase of the project to assure that SCI can contribute to improving
diagnosis and management of children with cancer and blood disorders in the partner
Caribbean countries.
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ERICC (ELECTRONIC REGISTRY IN CHILDHOOD CANCER)
L. Burns1, P. Bird1,2
1World Child Cancer, Operations, London, United Kingdom; 2GlaxoSmithKline, Medical
Business Operations, London, United Kingdom
Background/Objectives: The burden of paediatric cancer is rising, but few
population-based registries exist in Low &Middle Income Countries (LMIC), hence
there is limited understanding of baseline statistics or the scale of the problem.
Collecting data on incidence, mortality and survival is crucial for service planning,
demonstrating progress and making a robust case for support to funders and local
policy makers. Many treatment centres in LMIC have neither the facilities available nor
sufficient capacity of trained staff to be able to plan for reliable electronic data
collection.
Design/Methods:World Child Cancer (WCC) supports 8 twinning partnerships around
the globe and has come to understand the need for a freely available, uncomplicated
and offline electronic patient registry which can be wholly owned by local teams.
Through GlaxoSmithKline’s ‘PULSE’ skills-based volunteering programme, a member
of the company’s medical department with experience in data management and
programming joined WCC for 6 months with the purpose of developing such a registry.
A consultation period was undertaken with healthcare professionals and data collection
experts on site at WCC’s partner hospital in Bangladesh, and with WCC’s medical
trustees, to obtain advice on the essential fields required for storing paediatric oncology
data. The patient registry was then designed and programmed in Microsoft Excel with
Visual Basic.
Results: The system was tested at WCC’s partner hospitals in Ghana, by trained and
experienced local database managers. A training manual was also developed to support
the use of the system. Both are available free of cost for any interested LMIC paediatric
oncology centre.
Conclusion: A simple, reliable and safe database system has been created and introduced
to a number of local paediatric oncology teams. Each database is owned and controlled
by local teams and will permit them to log and analyse patient data systematically.
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ROLE OF TRADITIONALMEDICINE IN BURKITT LYMPHOMA DIAGNOSIS
ANDMANAGEMENT IN CAMEROON - NECESSITY FOR COLLABORATION
G. Afungchwi1, G. Afungchwi2, P. Hesseling3, C. Kimbi4, P. Nfor5, J. Kaah2, F. Kouya4,
P. Wharin6, E. Tanni2
1Banso Baptist Hospital, Kumbo, Cameroon; 2Banso Baptist Hospital, Pediatric
Oncology, Kumbo, Cameroon; 3Stellenbosch University, Tygerber Children’s Hospital,
Cape Town, South Africa; 4Mbingo Baptist Hospital, Pediatric Oncology, Mbingo,
Cameroon; 5Baptist Hospital Mutengene, Pediatric Oncology, Mutengene, Cameroon;
6Beryl Thyer memorial Africa Trust, Beryl Thyer Trust, London, United Kingdom
Background/Objectives: Childhood cancers constitute an important public health
concern in Cameroon. Burkitt Lymphoma (BL) is the most common childhood
malignancy. There are four centres in the country where children with Burkitt
lymphoma are treated, with reported cure rates between 50 and 60%. Traditional
medicine is a choice of many Cameroonians for health care. The scope of knowledge
and practice of traditional healers is undefined, and often entraps children with
malignancies. This study looks at the diagnosis, methods and costs of treatment, and
parent’s attitudes in relation to traditional medicine in the setting of BL.
Design/Methods: The study involves Children diagnosed with BL in Banso Baptist
Hospital and Mbingo Baptist Hospital in the Northwest region, and Baptist Hospital
Mutengene in the Southwest region. A questionnaire was used to interview parents on
the use of traditional medicine in their child’s disease. Patients diagnosed between 2010
and 2014 were analysed.
Results: 117 parents were interviewed. 56% were male and 44% female. The modal age
group was 6-10. 46.15%(54) had visited a traditional healer. Common diagnosis
provided by the traditional healers include: liver problem, abscess, witch craft, poison,
hernia, side pain, spleen, mushroom in the belly, toothache, mumps. Methods of
management include: massage, cuts, concoctions, and incantations. The charge for these
services include domestic animals, farm tools, and cash ranging from 200FCFA
(0.4USD) to over 100,000FCFA (200USD). The choice of traditional medicine was
based on failure of earlier attempts in a hospital, recommendation of relatives, and
belief that some diseases can only be treated by traditional medicine.
Conclusion: Traditional healers are significantly involved in BL management in
Cameroon. There is widespread ignorance about BL amongst traditional healers,
resulting in non-referral, and thus delay in diagnosis and management. Collaboration
with traditional healers could reduce late diagnosis and improve cure rates of BL.
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IMPACT OF PRIMARY SURGERY IN PEDIATRIC HEPATOCELLULAR
CARCINOMA
K. Becker1, C. Furch1, J. Hubertus1, D. von Schweinitz1, B. Häberle1
1University Children’s Hospital at Dr. v. Haunersches Kinderspital-Ludwig Maximilian
University, Pediatric Surgery, München, Germany
Background/Objectives: Complete tumor resection is essential for prognosis in pediatric
hepatocellular carcinoma (HCC). Aim of the following analysis was to evaluate the
impact of agressive primary surgery on survival in HCC in our study and in
comparison with other HCC series.
Design/Methods: From 1999 to 2008 60 pediatric patients with HCC were registered in
the German Cooperative Liver Tumor Study HB99, a prospective, single arm study
from the German Society of Pediatric Oncology and Hematology (GPOH). Initial
complete tumor resection, if somehow feasible, was aim for all patients. Histology of
tumor specimens was zentrally reviewed. After resection patients received two courses
of adjuvant chemotherapy with Carboplatin and Etoposid (CARBO/VP16). In case of
unresectable tumorsize neoadjuvant high dosage chemotherapy with CARBO/VP16
was supplied.
Results: Data from 43 patients could be analyzed. 5-year OS (Kaplan-Meier) was 53%
(95%-CI 52.7 – 90.7) and EFS was 43% (95%-CI 40.9 – 76.6). OS was significantly
influenced by younger age at diagnosis, multifocality, metastasis, PRETXT-stadium
and portal vein invasion. In 25 patients (58%), mainly PRETEXT II + III-tumors,
primary surgery was performed. 19/25 (76%) survived with no evidence of disease
(NED), 6 died of disease. 17/18 patients with unresectable HCC received neoadjuvant
chemotherapy. One patient died before any treatment was started. In 11/17 (65%)
partial response to chemotherapy was observed resulting in tumor shrinkage and
secondary resection. In 9/17 cases (53%) complete tumor resection was achieved.
However, only 4 patients with neoadjuvant chemotherapy and secondary complete
resection survived with NED. Compared to other pediatric HCC series OS and primary
resection rate is superior in our study, although patients and tumor characteristics are
similar except for a higher percentage of underlying liver disease in other series.
Conclusion: Primary surgery remains the cornerstone of treatment in pediatric HCC.
Further prognostic factors such as underlying liver diesease should be analyzed in
larger trials.
O-060
CLINICAL CHARACTERISTICS AND OUTCOME OFMULTIMODALITY
TREATMENT ON HEPATOBLASTOMA IN AMULTI-CENTER PROTOCOL: A
REPORT FROM THE CHINA SOCIETY OF PEDIATRIC ONCOLOGY
X. Yuan1, M.J. Tang2, Y.M. Wu3, C.R. Shi4
1Xinhua Hospital-Shanghai Jiaotong University School of Medicine, Shanghai, China;
2Xinhua Hospital-Shanghai Jiaotong University School of Medicine, Department
Pediatric Hematology/Oncology, Shanghai, China; 3Xinhua Hospital-Shanghai Jiaotong
University School of Medicine, Department Pediatric Oncology Surgery, Shanghai,
China; 4Xinhua Hospital-Shanghai Jiaotong University School of Medicine, Department
Pediatric Surgery, Shanghai, China
Background/Objectives: Wuhan Protocol is the first national protocol in China for
children with hepatoblastoma (HB). The study retrospectively analyzed the clinical
outcome of those patients treated byWuhan protocol and assessed the feasibility and
effectiveness of this protocol, in order to provide the basis for further optimization of
treatment.
Design/Methods: A total of 127 patients with HB in 11 hospitals during Jan 2006 to Dec
2013 were enrolled in this cohort. Data about demographic characteristics, clinical
manifestations, PRETEXT stage, COG stage, pathology subtype, serum AFP,
chemotherapy regimen, surgical options and complications were analyzed. All
statistical data were evaluated by SPSS version 19.0. Survival curves were estimated
according to Kaplan Meier.
Results: There were 90 boys and 37 girls, the male to female ratio was 2.4:1, and the
median age at diagnosis was 16.0 (1.3-132.0) months. The 6-year overall survival (OS)
rate and event-free survival (EFS) rate were (85.3±3.3)% and (72.1±4.1)% respectively.
The univariate analysis of HB showed that the patients younger than three years old (P
= 0.038), PRETEXT I/II stage (P = 0.001), complete surgical resection(P = 0.000), no
metastases at diagnosis (P = 0.000) and delayed surgery after neoadjuvant
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chemotherapy (P = 0.000) had better prognosis. The multivariate analysis revealed that
metastases at diagnosis (HR 2.804, 95%CI 1.076-7.309, P = 0.035) and PRETEXT IV
stage (HR 2.640,95%CI 1.141-6.107,P = 0.023) could be regarded as independent poor
prognostic factors.
Conclusion: Neoadjuvant chemotherapy could improve the complete surgical resection
rate effectively. The primary results of multi-center showed thatWuhan Protocol is
feasible and efficacious in China, but it still should be further optimized from surgery
indications and based on risk-stratification chemotherapy.
O-061
LIVER TRANSPLANTATION (LT) FOR HEPATOCELLULAR CARCINOMA IN
CHILDHOOD AND ADOLESCENCE: THE BRUSSELS EXPERIENCE
C. Bourdeaux1, S. Hollanders1, X. Stephenne2, F. Smets2, I. Scheers2, M. Janssen1, C. de
Magnée1, E. Sokal2, B. Brichard3, J.B. Otte1, R. Reding1
1Cliniques Universitaires Saint Luc, Padiatric and Transplant Surgery, Brussels, Belgium;
2Cliniques Universitaires Saint Luc, Padiatric Gastro-Enterology, Brussels, Belgium;
3Cliniques Universitaires Saint Luc, Padiatric Oncology, Brussels, Belgium
Background/Objectives: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC)
are the most common hepatic malignancies in children. The role of LT in children with
HCC is still a matter of debate. The aim of this study was to review our experience with
total hepatectomy and liver transplantation as treatment for HCC in children.
Design/Methods:Medical records of patients who underwent LT for unresectable
primary HCC between July 1993 and October 2014 in our pediatric program were
retrospectively reviewed; follow-up ranged from 6 to 183 months.
Results: During the study period, 50 children were transplanted for a liver malignancy,
including 35 HB (70%) and 11 HCC (22%). An underlying liver disease was present in
10/11 patients. On pre-transplant assessment only 3 patients were within the Milan
criteria. Only 2 patients received systemic chemotherapy before LT. A living donor LT
was used in 8/11 patients. The actuarial disease-free survival rates at one and five year
was 90% and 79%. Two patients showed HCC recurrence (pulmonary). One patient
died of recurrent HCC.
Conclusion: Liver transplantation for unresectable HCC can be curative with optimal
long-term survival rate. There is no argument, either biological or based on evidence,
that the selection of pediatric candidates for transplantation should be based on the
same criteria as in adult patients (Milan criteria). The use of living donor LT for this
indication provides an optimal timing, avoiding HCC dissemination before a cadaveric
organ becomes available. The role of neo-adjuvant approaches, including trans-arterial
chemo-embolization, is still unclear in pediatric HCC.
O-062
INTEGRATED EXOME ANALYSIS IN CHILDHOOD HEPATOBLASTOMA:
BIOLOGICAL APPROACH FORMOLECULAR TARGETING
E. Hiyama1,2, S. Kurihara1, O. Miyuki1, U. Yuka1, N. Morihara2, I. Fukuba2,
R. Komatsu2
1Hiroshima University Hospital, Pediatric Surgery, Hiroshima, Japan; 2Hiroshima
University, Natural Science Center of Basic Research and Development, Hiroshima,
Japan
Background/Objectives: Hepatobastoma (HB) is more than 80% of childhood hepatic
malignant tumors. The outcome of the HB cases mainly depends on the biological
characteristics and disease staging, but the candidate genes correlated with HB
progression have not been identified. Sequence capture enrichment strategies and
massively parallel next generation sequencing (NGS) were used for such gene discovery.
Design/Methods: Out of approximately 400 HBL case treated according to the JPLT
(Japanese Study group for Pediatric Liver Tumor)-2 protocol, 49 cases whose
non-treated tumor and normal samples were available were analyzed by a method for
whole-exome sequencing using the Illumina DNA-sequencing platform. In these cases,
10 had lung metastatic cases and 13 of the remaining 39 cases had vascular invasion or
multifocal lesions at admission. Consequently, 14 cases had a relapse and 10 cases died
of disease.
Results: Among these 49 HBL cases, mutations and deletions compared the
corresponding normal sample were 67 and 887 (median 302) and 324 genes including
CNNB1 exon 3 was nominated as more than 10 cases had mutations. Among them,
MUC related genes including MUC4, MUC 6, and MUC12 had mutations in more
than 40 cases. The pathway analysis revealed Wnt signal genes including AXIN1 and
FAP genes as well as CNNB1, α-fetoprotein (AFP) production correlated genes, and
some imprinting genes were frequently mutated. Among the cases with metastatic
lesion and/or those derived from the consequently dead, PI3K/Akt/mTOR pathway
genes showed mutation and deletion.
Conclusion:Whole-exome sequencing using NGS in hepatoblastoma revealed several
candidates mutated or deleted genes for carcinogenesis such as MUC family genes, Wnt
signal pathway and AFP production pathway genes. Our NGS research revealed that
PI3K/Akt/mTOR inhibitors can be one of the effective molecular targeting therapies in
aggressive HB.
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MICRORNA SIGNATURES IN PEDIATRIC ADRENOCORTICAL TUMORS:
IDENTIFICATION OFMICRORNAS AND PREDICTED PATHWAYS
INVOLVED IN TUMORIGENESIS AND PROGNOSIS
P. Fedatto1, D. Marco Antonio2, M. Baroni1, R. Panepucci2, A. Goes3, C. Martinelli Jr1,
S. Antonini1, M. de Castro3, S. Tucci Jr4, L. Neder5, A. Seidinger6, M. Matellaro6,
J. Yunes6, S. Brandalise6, L. Tone1, C.A. Scrideli1
1Ribeirão Preto Medicine School - University of São Paulo, Pediatrics, Ribeirão Preto,
Brazil; 2Ribeirão Preto Medicine School - University of São Paulo, Hemocentro
Fondation, Ribeirão Preto, Brazil; 3Ribeirão Preto Medicine School - University of São
Paulo, Internal Medicine, Ribeirão Preto, Brazil; 4Ribeirão Preto Medicine School -
University of São Paulo, Surgery, Ribeirão Preto, Brazil; 5Ribeirão Preto Medicine
School - University of São Paulo, Pathology, Ribeirão Preto, Brazil; 6Centro Infantil
Boldrini/State University of Campinas, Pediatrics, Campinas, Brazil
Background/Objectives: Abnormal microRNAs expression has been shown to play an
important role in development and progression of different human cancer, but data in
pediatric adrenocortical tumors (ACTs) are limited. The present study aimed to
evaluate the microRNAs signature in samples from pediatric patients with ACTs.
Design/Methods: The global expression of microRNAs was evaluated by Human
microRNAMicroarray Kit (V3) (Agilent Technologies) in 37 samples of pediatric
ACTs and 9 pediatric non-neoplastic adrenal cortices. In silico prediction of targets
were made using software Ingenuity Pathway Analysis (Qiagen Company). Nine
microRNA were validated by qRT-PCR using TaqMan probes and one microRNA was
chosen for functional in vitro studies.
Results: A significant modulation of the expression was found in 294 microRNAs with
a P  0.05 (false discovery rate corrected) between ACT and pediatric non-neoplastic
tissue. In the validation by qRT-PCR it was observed the up-regulation of miR-17-3p,
-145-5p, -146a-5p, -150-5p, -196b-5p, -495-3p and -598-3p; and down-regulation of
miR-149-3p in children with ACTs compared to non-neoplastic pediatric adrenal
cortices. The miR-196b-5p e miR-149-3p also showed up regulated in patients who had
relapsed and had lower event-free survival (EFS). To miR-146a-5p, higher expression
was associated with significant higher EFS. After miR-196b-5p inhibition by lentiviral
vector (pLV-miR-196b-Locker) in NCI-H295R ACT cell line it was observed an
increased number of cells in the clonogenic assay, and increased expression of EGF
receptor, but no change the doubling time and viability. In silico analyses showed the
MAPK, Insulin, ERBB, GNRH and mTOR signaling pathways are mRNA-target to
miR-196b-5p.
Conclusion: Our findings suggest a potential role of microRNAs in pediatric ACT
development and prognosis, which can contribute to a better understand in the
mechanisms of action of miRNAs in this tumor.
O-064
DIFFERENTIATED THYROID CARCINOMA IN CHILDHOOD AND
ADOLESCENCE: INDICATIONS FOR CONSERVATIVE SURGERY. AN
ITALIANMULTICENTRIC STUDY ON 260 PATIENTS
C. Spinelli1, L. Rossi1, S. Strambi1, M. Massimino2, A. Ferrari2, G. Bisogno3,
G. Cecchetto4, A. Inserra5, A. Antonelli6, P. Miccoli1
1University of Pisa, Department of Surgical- Medical- Pathological-Molecular and Critic
Area- Chair of Pediatric, Pisa, Italy; 2Fondazione IRCCS Istituto Nazionale dei Tumori
INT, Pediatric Unit, Milan, Italy; 3Pediatric Hematology and Oncology- University of
Padua, Department of Pediatrics, Padua, Italy; 4Pediatric Surgery Unit- University
Hospital of Padua, Department of Women’s and Children’s Health, Padua, Italy;
5Ospedale Pediatrico Bambino Gesù- IRCCS, 5Departments of Surgery, Rome, Italy;
6University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy
Background/Objectives: In the recent decades the incidence of paediatric differentiated
thyroid carcinoma (DTC) increased. DTC in paediatric age is rare and has an excellent
prognosis. Nevertheless, the best surgical treatment is unclear, and the debated focuses
on radical vs conservative surgery. Total thyroidectomy has a lower rate of recurrence
but a higher risk of complications. Our study purposes to draw-up surgical indications
to guide the choice of the surgeon between conservative or radical surgery.
Design/Methods: The authors conduced an Italian multicentric retrospective analysis
about paediatric patients suffering from DTC between 2000 and 2014. Medullary
carcinomas have been excluded. A total of 260 patients underwent surgical treatment:
conservative surgery (lobectomy associated to isthumesctomy) has been performed in
low risk patients (neoplasm limited to one lobe, no extra-thyroid spread, absence of
distant metastasis) with a tumour < 2cm; the other patients have been treated by
radical surgery.
Results: Total thyroidectomy has been performed in 236 (90.8%) patients whereas
hemithyroidectomy in 24 (9.2%) patients. Post-surgical complications occurred in 55
patients (21.2%): 37 (14.2%) transitory hypocalcaemia, 11 (4.2%) permanent
hypocalcaemia, 7 (2.7%) laryngeal nerve injury with vocal cord palsy (5 ipsilateral, 2
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bilateral). All post-surgical complications occurred after radical surgery. To date, after a
median follow-up of 5.8 years (range 1-14 years) all patients are alive (overall survival
100%); 30 patients (11.5%) had relapse, in average after 1.7 years: 29 after radical
surgery and 1 after conservative surgery (it presented lymph nodal metastasis).
Conclusion: The surgical treatment should be personalized and based on an accurate
evaluation of the risk to choose the best surgical approach. Small tumours in low-risk
paediatric patients should be treated by conservative surgery since it is not associated to
a higher risk of recurrence and it decreases the rate of post-surgical complications,
permitting a better quality of life.
O-065
EXCELLENT REMISSION RATES WITH LIMITED TOXICITY IN RELAPSED
LANGERHAN CELL HISTIOCYTOSIS WITH PULSE DEXAMETHASONE
AND LENALIDOMIDE IN CHILDREN
R. Uppuluri1, S. Ramachandrakurup2, H. Doss2, R. Raj2
1Apollo Cancer Hospitals, Chennai, India; 2Apollo Cancer Hospitals, Pediatric
Hematology-Oncology and BMT, Chennai, India
Background/Objectives: Lenalidomide which has been licensed for use in adults with
multiple myeloma and myelodysplastic syndromes is a drug with immunomodulatory
potential with antiangiogenic, proapoptotic, and anti-inflammatory activities. We
present a series of four children with refractory/ relapsing Langerhan Cell
Histiocytosis(LCH) who have achieved durable remission with a lenalidomide based
chemotherapeutic regimen with minimal toxicity.
Design/Methods: The study was conducted between June 2012 and December 2014 and
the children aged between 31/2 to 51/2 years had a biopsy proven diagnosis of LCH
treated with steroids and vinblastine followed by second line therapy with cytarabine
and cladribine upon relapse. Consent was obtained from the families after detailed
explanation of the potential side effects of lenalidomide including neuropathy and pulse
dexamethasone including osteoporosis as per institutional guidelines. The regimen
consisted of 6 cycles of pulse dexamethasone and lenalidomide with each cycle being 28
days. Lenalidomide was given continuously for 21 days at a dose of 15 mg / m2 and
dexamethasone at 0.8 mg/kg on days 1,8,15 and 21 of each cycle. The children were
monitored carefully for potential neurological side effects, constipation, headache,
myalgia and cytopenias during follow up ranging from 1 month to 18 months.
Results: All 4 children managed to complete the regimen without compliance issues as
it was outpatient based and well tolerated. One child had a fracture of both bones of
forearm after a trivial fall. There were no documented grade IV cytopenias. Three out
of four children showed PET negative lesion and one has resolution of lesion on MRI.
Conclusion: Pulse dexamethasone and lenalidomide can be used with good efficacy and
safety profile in children with refractory /relapsing disease. The pilot regimen needs to
be validated with more number of patients and long term safety studies and is
particularly suited for resource poor countries.
O-066
PEDIATRIC ATYPICAL CHOROID PLEXUS PAPILLOMA REDEFINED:
INCREASEDMITOTIC ACTIVITY IS A PROGNOSTIC MARKER ONLY IN
CHILDREN OLDER THAN THREE YEARS
C. Thomas1, V. Ruland1, U. Kordes2, S. Hartung2, J. Wolff3, W. Paulus1, M. Hasselblatt1
1University Hospital Münster, Institute of Neuropathology, Münster, Germany;
2University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology
and Oncology, Hamburg, Germany; 3Cleveland Clinic Children’s, Department of
Pediatric Hematology and Oncology, Cleveland, USA
Background/Objectives: Atypical choroid plexus papilloma (WHO grade II) is
characterized by increased mitotic activity and a higher probability of recurrence.
Anecdotal evidence suggests that some younger children harboring atypical choroid
plexus papillomas experience excellent outcome. We therefore aimed to investigate the
prognostic value of increased mitotic activity in pediatric choroid plexus papillomas
according to age.
Design/Methods: Clinical details, neuropathological findings and follow-up data of 149
children harboring choroid plexus papillomas were retrieved from the CPT-SIOP
registry. The effect of increased mitotic activity (2 mitoses per 10 HPF) on
progression-free survival and overall survival was examined according to age group (<3
years vs. 3 years) using Kaplan-Meyer-Analysis.
Results:Median age at diagnosis of the 77 boys and 72 girls was 18 months. The vast
majority of these pediatric choroid plexus papillomas was located supratentorially
(119/149, 80%). On neuropathological examination, 73 (49%) of the choroid plexus
papillomas displayed increased mitotic activity. Children harboring tumors with
increased mitotic activity experienced significantly shorter progression-free survival
[108 months (94-121 months) vs. 156 months (148-164 months), mean (95% confidence
intervals), P=0.002]. Importantly, the prognostic role of increased mitotic activity was
mainly restricted to older children (3 years) [67 months (40-94 months) vs. 115
months (105-126 months), P<0.001], but not significant in younger patients (P=0.10).
Five year overall survival accounted for 97-100% in all groups.
Conclusion: In choroid plexus papillomas, increased mitotic activity is associated with a
higher probability of recurrence. Since the prognostic role of increased mitotic activity
is restricted to older children, we suggest that a diagnosis of atypical choroid plexus
papilloma according to current WHO criteria should not be made in children younger
than 3 years.
Supported by Deutsche Krebshilfe (DKH110267) and Deutsche Kinderkrebsstiftung
(DKS2012.18, 2014.22)
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O-067
IS BIOPSY A RISK FACTOR FORWILMS TUMOUR (WT) LOCAL
RECURRENCE IN THE SIOP WT 2001 TRIAL?
S. Irtan1,2, B. Sznadjer3, H. Von Tinteren3, N. Graf4, M. van den Heuvel-Eibrink5,
H. Heij5, C. Bergeron6, B. de Camargo7, T. Acha8, F. Spreafico9, M. Powis10,
B. Okoye11, J. Wilde12, J. Godzinski13,14, K. Pritchard-Jones1
1Institute of Child Health- University College London, Cancer Section-Developmental
Biology & Cancer Programme, London, United Kingdom; 2Trousseau Hospital, Pediatric
Surgery, Paris, France; 3Netherlands Cancer Institute - Antonie van Leeuwenhoekhuis
Plesmanlaan, Biostatistics, Amsterdam, Netherlands; 4Saarland University, Pediatric
Oncology & Hematology, Homburg, Germany; 5Princess Maxima Center for Pediatric
Oncology, Pediatric Oncology, Utrecht, Netherlands; 6Institut d’Hématologie et
d’Oncologie Pédiatrie, Pediatric Oncology, Lyon, France; 7Instituto Nacional de Câncer,
Pediatric Hematology and Oncology Program- Research Center, Rio de Janeiro, Brazil;
8Hospital Materno-Infantil, Pediatric Oncology, Malaga, Spain; 9Fondazione IRCCS
Istituto Nazionale dei Tumori, Pediatric Oncology Unit-Department of Hematology and
Pediatric Oncology, Milan, Italy; 10Leeds Teaching Hospitals NHS Trust, Pediatric
Surgery, Leeds, United Kingdom; 11St. Georges Healthcare NHS Trust- Tooting,
Pediatric Surgery, London, United Kingdom; 12Hôpitaux Universitaires de Genève, Child
and Adolescent Department-Division of Pediatric Surgery, Geneva, Switzerland;
13Marciniak Hospital, Pediatric Surgery, Wroclaw, Poland; 14Medical University, Chair
of Emergency Medicine, Wroclaw, Poland
Background/Objectives: The implications of biopsying WT at diagnosis are
controversial. Multivariable analysis (MVA) in the UKW3 trial showed that biopsy was
not significantly associated with increased risk of local relapse but was limited by the
small number of events. To further address this important clinical question, we
performed a similar analysis on patients registered in the SIOPWT2001 trial.
Design/Methods: 3,009 patients with unilateral WT (stages I-IV) treated by total
nephrectomy after pre-operative chemotherapy were eligible with 392 relapses,
including 137 local relapses. ‘Local’ was defined as relapse within the abdomen except
for liver metastases, considered as ‘distant’ relapse together with other haematogenous
routes. Risk factors for recurrence were analyzed by Cox proportional hazard methods.
Results: Biopsy was performed in 970/3,009 (32%) patients (64% cutting needle, 30%
fine needle aspiration (FNA), 6% open biopsy). Only open biopsy required treatment as
stage III. In MVA that included all factors associated with local recurrence in univariate
analysis (age, high-risk histology, abdominal stage III, lymph node involvement (LNI),
tumour rupture, tumour volume at diagnosis and after pre-op chemo, any biopsy-FNA
of marginal significance), only high-risk histology (hazard ratio, HR=8.9); age2years
(HR=2.2) and tumour volume after chemo (HR=1.06/100ml) remained significant.
The HR for the association with [KP1] biopsy was not significant
(1.31;0.76-2.25,p=0.33). In MVA of event-free survival, high-risk histology (HR=8.17),
stage IV (HR=2.13), age2years (HR=1.6), tumour volume after chemo
(HR=1.08/100ml) and LNI (HR=1.41) were significantly associated with adverse EFS,
the HR for biopsy was not significant (1.24;0.91-1.71,p=0.18). In MVA of overall
survival, high-risk histology (HR=11.1), age>4years (HR=1.8), stage IV (HR=3.6),
abdominal stage beyond stage I (HR=2.1) and tumour volume after chemo
(HR=1.1/100ml) were associated with excess hazard for death, the HR of
1.33(0.85-2.07) for biopsy was not significant (p=0.21).
Conclusion: This posthoc analysis did not show a significant association of biopsy with
risk of local recurrence.
O-068
MINIMALLY-INVASIVE SURGERY FORWILMS TUMOUR: HOWOFTEN
WILL IT BE FEASIBLE?
M.D. Leclair1, A. Floret2, I. Pellier3, K. Renaudin-Autain4, T. Lefrancois2, E. Thebaud5
1Children University Hospital, Pediatric Surgery, Nantes, France; 2Children University
Hospital, Pediatric Radiology, Nantes, France; 3University Hospital, Pediatric Oncology,
Angers, France; 4Children University Hospital, Histo-pathology, Nantes, France;
5Children University Hospital, Pediatric Oncology, Nantes, France
Background/Objectives: In the process of writing future protocols guidelines, the
SIOP-Renal Tumour Study Group has defined criteria, which would allow to perform
laparoscopic total nephrectomy (MIS) in Wilms’ tumours (WT). We aimed to
investigate in what proportion of renal tumours these criteria were present.
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Design/Methods: Inclusion criteria: Consecutive WT referred to a single institution. All
children received preoperative chemotherapy according to SIOP protocols.
Retrospective blind reviews of preoperative post-chemo CT-scans and pathology
reports, to determine the prevalence of the following criteria : tumour volume, invasion
of surrounding organs/main vessels, vascular thrombus, extension beyond the ipsilateral
edge of the vertebral body.
Results: Among 86 consecutive tumours (79 patients), one or more criteria excluding
potential feasibility of MIS were present in 60% of cases. The main reason for ruling
out MIS was tumour volume (54%), invasion of renal vessels (19%), extension to
surrounding organs (17%), or suspected fragility of the tumour due to preoperative
retroperitoneal rupture or intra-tumoral bleeding (10%).Among 34 (40%) tumours
potentially eligible for MIS, 21 also met criteria for partial nephrectomy (NSS) (either
predisposed syndromic patients n=10, or new SIOP-RTSG criteria for elective NSS in
unilateral WT, n=11).Analysing pathology reports of the 24 cases eligible for total
nephrectomy by MIS (without SIOP mandatory indication for NSS), 25% had open
incomplete microscopic resection after open nephrectomy, 25% had positive lymph
nodes and 20% were high-stage histology.
Conclusion: Among a population of 86 consecutive WT, the proportion of tumours
potentially amenable to MIS was 40%. After exclusion of tumours eligible for NSS,
there remained a subset of 13/86 tumours (15%) with no contra-indication to
laparoscopic total nephrectomy. Considering the increased risk of local relapse related
to microscopic residue, this finding suggests that these cases should be centrally
reviewed and discussed, and the procedures be performed in a limited number of
institutions.
O-069
NEPHRON-SPARING SURGERY FOR UNILATERAL UNSCREENEDWILMS
TUMOUR: HOWOFTEN IS IT FEASIBLE?
M.D. Leclair1, A. Floret2, I. Pellier3, K. Renaudin-Autain4, M.P. Quere2, E. Thebaud5
1Children University Hospital, Pediatric Surgery, Nantes, France; 2Children University
Hospital, Pediatric Radiology, Nantes, France; 3University Hospital, Pediatric Oncology,
Angers, France; 4Children University Hospital, Histo-pathology, Nantes, France;
5Children University Hospital, Pediatric Oncology, Nantes, France
Background/Objectives: In the process of writing future protocols guidelines, the
SIOP-Renal Tumour Study Group has defined criteria, which would allow to perform
partial nephrectomy (NSS) in Wilms’ tumours (WT). We aimed to investigate in what
proportion of unscreened renal tumours these criteria were present.
Design/Methods: Inclusion criteria: Consecutive unscreened paediatric WT referred to a
single institution. Predisposed syndromic children, and bilateral WT with diffuse
nephroblastomatosis were excluded. All children received pre-operative chemotherapy
according to SIOP protocols. Retrospective blind reviews of preoperative CT-scans
were correlated with postoperative pathology reports, to determine the prevalence of
the following criteria: potential for sparing healthy kidney, peripheral location, invasion
of calyces, surrounding organs, main vessels, or renal sinus. In eligible cases, 3D-volume
rendering analyses calculated tumour and renal parenchyma volumes, preservable
parenchyma volume being expressed as percentage of contralateral healthy kidney
volume.
Results: Among 75 consecutive patients, one or more criteria excluding potential
feasibility of NSS were observed in 85% of cases. The main reason for ruling out NSS
was central tumour location (77%), extension to surrounding organs (5.5%), or vascular
thrombus (3%).NSS was deemed feasible in 11/75 children (15%), with a volume of
potentially preservable parenchyma of 63% [34-113]. Histopathology review of these
cases showed evidences of perilobar or intralobar nephrogenic rests in 5/11 specimens
(including 2/5 in distant healthy parenchyma), microscopic incomplete resection (n=1),
and high risk histology (n=2). Had NSS been performed, secondary total nephrectomy
would have been recommended after pathology analysis in at least 3/11 cases.
Conclusion: Among the population of sporadic WT, the proportion of tumours
potentially amenable to NSS is 15%. Considering the increased risk of local relapse, this
finding suggests that these cases should be centrally reviewed and discussed, and the
procedures be performed in a limited number of institutions.
O-070
THE SIOP AFRICA / PODC COLLABORATIVE WILMS TUMOUR PROJECT –
BASELINE EVALUATION AND PROGRESS
L. Renner1,2, F. Kouya3,4, J. Kambugu5, V. Paintsil6, H. David7, G. Chagaluka8,
R. Arora9,10, L. Burns11, J. Orem5, T. Eden12, P. Hesseling4, G. Kaspers13,
E. Molyneux8, T. Israels8,13
1University of Ghana Medical School, Accra, Ghana; 2Chair SIOP Africa; 3Mbingo
Baptist Hospital, Cameroon; 4Stellenbosch University, Cape Town, South Africa;
5Uganda Cancer Institute, Kampala, Uganda; 6Komfo Anokye Teaching Hospital,
Kumasi, Ghana; 7Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia; 8College
of Medicine, Blantyre, Malawi; 9Max Super-Specialty Hospital, New Delhi, India;
10SIOP PODC Co-Chair; 11Head of Operations, World Child Cancer; 12University of
Manchester, UK; 13VU University Medical Center, Amsterdam, the Netherlands
Background: The SIOP Africa PODC Collaborative Wilms tumour project comprises
eight centres in Ghana, Malawi, Cameroon, Uganda and Ethiopia. The project is
implementing SIOP PODCWilms tumour and supportive care adapted treatment
guidelines as a prospective clinical trial. Projected two year event free Wilms tumour
survival in Malawi increased from < 30% to 46% after introducing a similar guideline.
Baseline Wilms tumour outcome and causes of treatment failure in the other
participating centres had not been reported. Methods: A retrospective chart review was
performed of patients admitted with Wilms tumour in the three years (2011-2013)
preceding the collaborative trial. Patient outcome at the end of treatment was
documented for all patients diagnosed in 2011 and 2012. Enrolment to the prospective
trial started January 2014.
Results: In the baseline evaluation the mean disease free survival at end of treatment
was 39% (69/176) ranging from 11% to 61% between participating centres. Overall two
year survival is estimated at 25%. Incomplete treatment (31%) is the most common
cause of treatment failure, ranging from 14% to 48%. Twenty six percent of patients
died during treatment, ranging from 13% to 37%. In the prospective trial so far 97
children have been included, data of 63 patients have been entered into the central
database. Of these 63, 5 patients were misdiagnosed and are excluded. Of the remaining
58 patients with a Wilms tumour 7 (12%) did not complete treatment, 8 (14%) died
during treatment, 4 (7%) had progression and / or relapse of disease and 39 (67%) are
alive and well, either on or after treatment.
Conclusion: Sharing similar local challenges in this regional collaborative project helps
to identify and implement feasible, sustainable and successful strategies. We are
working towards our aim to increase survival to 50% with <10% incomplete treatment
and <10% treatment related deaths.
O-071
RESULTS OF THE SECONDWILMS TUMOUR STUDY OF THE “FRANCO
AFRICAIN ONCOLOGIE PEDIATRIQUE GROUPE” (GFAOP) IN
SUB-SAHARAN AFRICA
B. Mallon1, J.J. Atteby2
1Institut Gustave Roussy, villejuif, France; 2Hôpital de Treicheville, Unité
d’Onco-Hématologie Pédiatrique, Abidjan, Côte d’Ivoire
Background/Objectives: Following the first Nephroblastoma feasibility study of
GFAOP (Moreira PBC 2011), this second trial was run from 2005-2011 in 8 centers in
sub-Saharan Africa. The objectives were to evaluate the progress in existing centers and
assess the capacity of the new centers to follow the protocol, and observe its effect on
the overall survival.
Design/Methods: The study was conducted in 8 centers, 5 of which were new. This
prospective single arm study registered all children suspected of having renal tumor, but
included in the trial only patients whose diagnosis of standard risk nephroblastoma was
assessed. The protocol is identical to the initial GFAOPNEPHRO 01 study, based on
the SIOP2001 protocol. Data was collected locally and sent for analyses to Gustave
Roussy.
Results: Three hundred and thirteen children were registered, 55 of whom did not fulfill
study criteria, 89 were excluded secondarily (31 preoperative deaths, 21 unfavorable
histology, 18 abandoned treatment, 11 not Wilms, 08 poor response to initial treatment)
leaving a trial study group of 169 (158 localized and 11 metastatic). During the
preoperative period 167 (99%) were treated according to protocol. Histological staging
is known for 105 children and surgical staging for 153. Histological review was carried
out in only 7% of cases. Post-operative treatment was carried out for 146 (86%). None
of the 68 patients with stage III (60 localized, 8 metastatic) were irradiated due to
absence of radiotherapy. The 3 year post-surgery overall survival is 73% and EFS 55%.
Conclusion: Clearly there remains work for our group and caution must be observed
because of the number of deaths in the preoperative phase and the small number of
histologically reviewed cases. However our results are encouraging given that no
dedicated protocol existed for the treatment of nephroblastoma in 5 of the 8
participating centers prior to this study.
O-072
LONG-TERM FOLLOW-UP OF SOLITARY FUNCTIONING KIDNEY (SFK) IN
WILMS TUMOR SURVIVORS
A. Mavinkurve-Groothuis1, F. van de Kracht2, R. Westland3, A. van Wijk3, J. Loonen4,
M. Schreuder5
1Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands; 2Radboud
University Medical Center, Department of Hematology and Oncology, Nijmegen,
Netherlands; 3VU University Medical Centre, Department of Pediatric Nephrology,
Amsterdam, Netherlands; 4Radboud University Medical Center, Department of Pediatric
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Hematology and Oncology, Nijmegen, Netherlands; 5Radboud University Medical
Center, Department of Pediatric Nephrology, Nijmegen, Netherlands
Background/Objectives: Children with unilateral Wilms tumor (WT) treated with
chemotherapy and/or radiotherapy and nephrectomy have excellent survival rates. A
solitary functioning kidney (SFK) is associated with renal injury at late follow-up. This
study aims to investigate the additional effect of Wilms tumor treatment on renal
function compared to children with a SFK for non-oncological reasons.
Design/Methods: A single center retrospective cohort study on renal injury markers of
79 survivors of unilateral WT was performed and compared to a matched group of
children with a SFK for non-oncological reasons. Mean age at follow-up was 12.4 years,
mean follow-up duration was 9.1 years.
Results: During follow-up, mean estimated glomerular filtration rate (eGFR) and blood
pressure z-scores remained stable at an acceptable level. However, in the group of 31
WT patients with a follow-up of 15 years, 23% showed signs of renal injury, defined as
high blood pressure, proteinuria, drug use to treat either condition, and/or an
eGFR<60 ml*min−1*1.73m−2. This proportion of renal injury was significantly less
(p=0.004) then the 54% in a group of SFK patients based on non-oncological causes.
Conclusion: Renal injury in survivors of WT occurs comparable to children with SFK
for non-oncological reasons but with a lower overall incidence after long-term
follow-up. This may be due to absence of information on proteinuria. As with patients
with a non-oncological SFK, long-term follow-up is essential to monitor, inform and
deliver adequate treatment for survivors of WT.
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THE GENOMIC LANDSCAPE IN OSTEOSARCOMA
M. Nathrath1, J. Smida2, D. Baumhoer3, M. Kovac3
1Clinical Cooperation Group Technische Universität München/Helmholtz Center
München and Klinikum Kassel, Pediatric Oncology, Kassel, Germany; 2Clinical
Cooperation Group Technische Universität München/Helmholtz Center München,
Pediatric Oncology, München, Germany; 3University Hospital Basel, Pathology and Bone
Tumor Reference Center, Basel, Switzerland
Background/Objectives: Osteosarcoma recurrences come up to 40% in a 5-year period.
An explanation of this dismal figure may be that different etiologies are responsible for
the underlying chromosomal breakage resulting in mutations in many genes. To develop
future targeted treatment strategies it is crucial to have a clear understanding of the
molecular complexity of this tumor. Understanding of mutation ordering poses
another challenge that has now become possible to tackle using deep next-generation
sequencing and machine learning models.
Design/Methods:We used exome sequencing to explore the fine-scale clonal structure
and hierarchy of osteosarcoma from 25 patients. We aimed to identify genetic causes
underlying chromosomal instability that drives the onset of the disease, explore whether
linear or branching models better explain osteosarcoma evolution and single out rare
clones with potential roles in therapy resistance and disease recurrence. We analyzed the
clonal diversity by building an evolutionary history of each tumor on a fine scale with
phylogenetic and advanced statistical models.
Results:We confirmed previous findings of TP53 and RB1 as the main cancer drivers
together with RET, MUTYH, NUMA1 and FANCA as novel drivers. The mutations
in these genes occur in both somatic as well as in germ-line settings with predicted
effects on the stability of proteins that carry out DNA repair and control cell cycle
checkpoints. The TP53/FANC-driven susceptibility for DNA damage in osteosarcoma
is amplified by parallel evolution of cancer clones carrying mutations in genes which
maintain chromosomal segregation and recombination repair (e.g. BRCA1, BRCA2,
PALB2, ATM), mismatch repair (MLH1, MSH2), single and double-strand DNA
break repair (XRCC1, RAD50), and telomere integrity maintenance (TERT).
Conclusion: The project provides an insight into the complexity of osteosarcoma with
the specific aim to model its clonal composition. This knowledge will assist to introduce
more individualized treatment approaches in this heterogeneous tumors.
O-074
FUNCTIONAL OUTCOME AND DAILY-LIFE ACTIVITY IN 603 LONG-TERM
SURVIVORS OF EWING SARCOMA
A. Ranft1, C. Hoffmann1, C. Seidel2, D. Rosenbaum2, U. Dirksen1, H. Jürgens1
1University Children’s Hospital, Pediatric Hematology and Oncology, Muenster,
Germany; 2University Hospital, Institute for Experimental Musculoskeletal Medicine,
Muenster, Germany
Background/Objectives: Since 1980 patients with Ewing sarcoma have been treated
according to consecutive protocols of the German Society of Pediatric Oncology and
Hematology (GPOH). Rising survival rates have raised the question of the quality of
long-term survivorship. Objective and subjective measurement tools are used to
evaluate the actual health status and daily-life activity level as an indicator for
restitution of function.
Design/Methods: Long-term outcome of 603 survivors of the CESS81, CESS86,
EICESS92, and EURO-E.W.I.N.G.99 trials, diagnosed between 1980 and 2009, was
assessed by the Toronto Extremity Salvage Score (TESS), Short-Form Health Survey
(SF-36), and Brief Symptom Inventory (BSI) questionnaire scales, and by the
StepWatch Activity Monitor (SAM) accelerometer device. A 1:2 non-random peer
control group was selected to compare results with healthy individuals. Median age of
former patients was 28.7 years, 56% were males. Median observation time was 12.9
years (range 3.7-31.2).
Results: Former patients were less active than the control group, contributing to a mean
step count difference of 1,758 steps per day (10,394 vs. 12,152; p<0.01), but have
reached the recommended level for an active life-style (>10,000). Negative prognostic
factors were pelvic tumors (9,265; p<0.01) and primary metastatic disease (9,322;
p<0.05). Correlations between self-reported scales and the step measurement were
rather low (r<0.30). The TESS score (>90), BSI somatization, anxiety and depression
scales (raw values<0.50), and the SF-36 (Physical/Mental Component Summary
scores=47.9/49.7) showed no major clinical or functional limitations. Around 15% of
former patients rated their health status as less good or poor compared to 2% of the
controls.
Conclusion: The present study comprised a follow-up period of up to 30 years after the
treatment of Ewing sarcoma. Former patients seemed to return to a normal lifestyle
with minor limitations. The generally positive outcome is an encouraging finding for
patients with this severe disease.
*Supported by BMBF/DLR 01ER0807.
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ASSOCIATION OF PHARMACOGENETIC VARIANTS WITH EFFICACY AND
TOXICITY IN PATIENTS WITH OSTEOSARCOMA
H.I. Vos1, M.J.H. Coenen2, H. Gelderblom3, T. van der Straaten4, E.S.J.M. de Bont5,
W.T.A. van der Graaf6, H.W.B. Schreuder7, L.C.M. Kremer8, F.N. van Leeuwen1,
H.J. Guchelaar4, D.M.W.M. te Loo9
1Radboud University Medical Center, Laboratory of Pediatric Oncology, Nijmegen,
Netherlands; 2Radboud University Medical Center, Human Genetics, Nijmegen,
Netherlands; 3Leiden University Medical Center, Medical Oncology, Leiden,
Netherlands; 4Leiden University Medical Center, Clinical Pharmacy and Toxicology,
Leiden, Netherlands; 5University Medical Center Groningen, Pediatric Hematology and
Oncology, Groningen, Netherlands; 6Radboud University Medical Center, Medical
Oncology, Nijmegen, Netherlands; 7Radboud University Medical Center, Orthopedic
Surgery, Nijmegen, Netherlands; 8Emma Children’s Hospital/Academic Medical Center,
Pediatric Oncology, Amsterdam, Netherlands; 9Radboud University Medical Center,
Pediatric Hematology and Oncology, Nijmegen, Netherlands
Background/Objectives: Pharmacogenetics can be used to optimize treatment of
patients with osteosarcoma. We have previously identified genetic markers predictive of
treatment outcome in genes of cisplatin and doxorubicin metabolic pathways. However,
the complex metabolism of the drugs used in osteosarcoma treatment involves a
broader range of drug metabolic enzymes and transporters. Therefore we have
performed large scale screening of 1,936 genetic variants in 231 genes involved in drug
metabolism and transport.
Design/Methods: Germline DNA of 2 cohorts (n=139 and n=177) of patients with
osteosarcoma treated with cisplatin and doxorubicin-based chemotherapy was
genotyped using the DMET Plus array. Associations between genetic variants and
ototoxicity (SIOP grade 1-4) and 5-year Disease Free Survival (DFS) were assessed
using logistic regression models and Cox proportional hazards models respectively.
Additionally, patients with refractory/progressive disease (primary tumor growth/
growth or development of new metastases, up to 3 months post chemotherapy) were
compared to control patients (without refractory/progressive disease or recurrence)
using logistic regression models, as were patients with recurrent disease (local or distant
relapse). As the number of patients available for this analysis was limited, we analyzed
the data as 1 cohort.
Results: After standard quality control, 669 markers and 310 patients remained for
analysis. Upon meta-analysis, 16 markers were significantly associated (P < 0.05) with
ototoxicity and 23 variants showed association with 5-year DFS. Furthermore, of 280
eligible patients, 36 experienced progression and 76 recurrence. Twenty-five genetic
markers were significantly associated (P <0.05) with refractory/progressive disease. Of
these, 18 genetic variants in 13 genes were uniquely associated with
refractory/progressive disease and not with recurrent disease or DFS in this cohort.
Conclusion:We have detected significant associations of treatment response and
ototoxicity with genes previously unknown to be related to cisplatin and doxorubicin
metabolism and transport. Upon validation, these markers are of potential interest for
optimizing current therapy for patients with osteosarcoma.
O-076
EWING SARCOMAS EXPRESS IMMUNE-INHIBITORY HLA-G IN THEIR
TUMORMICROENVIRONMENT
Pediatr Blood Cancer DOI 10.1002/pbc
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C. Spurny1, B. Altvater1, S. Kailayangiri1, M. Ahlmann1, U. Dirksen1, J. Hardes2,
H. Wiendl3, W. Hartmann4, C. Rossig1
1University Children´s Hospital Muenster, Pediatric Hematology and Oncology, Münster,
Germany; 2University of Muenster, Department of Orthopedic Surgery, Münster,
Germany; 3University of Muenster, Department of Neurology, Münster, Germany;
4Gerhard-Domagk Institute of Pathology, Pathology, Münster, Germany
Background/Objectives: Novel therapies are needed to cure disseminated, relapsed or
refractory Ewing sarcoma (EwS). Identification of mechanisms by which EwS cells
manipulate the immune system may allow to develop strategies that reverse
tumor-induced immunosuppression and sensitize tumor cells to lysis by preexisting or
therapeutic effector cells. We hypothesized that the non-classical, immune-inhibitory
molecule HLA-G may contribute to immune escape of EwS.
Design/Methods:We used flow cytometry to detect HLA-G expression in EwS cell lines,
and ELISA to quantify soluble HLA-G isoforms in cell culture supernatants and in
serum. To study HLA-G expression within their tumor microenvironment, we analyzed
paraffin-embedded pretherapeutic tumor biopsies from 35 EwS patients by
immunohistochemistry. For functional experiments addressing the immune-inhibitory
properties of HLA-G in EwS, we expressed HLA-G1 in two EwS cell lines by retroviral
gene transfer.
Results:Membrane-bound HLA-G1 was not identified in any of 14 EwS cell lines even
after interferon-γ stimulation, but one of the cell lines (TC-32) responded to cytokine
stimulation by significant upregulation of soluble HLA-G1 and G5 (p=0.004). In 19
EwS patients, serum HLA-G was not increased compared to 15 healthy controls.
Moreover, no significant differences in the proportions of naturally occurring HLA-G+
CD4+ or CD8+ suppressor T cells among peripheral blood lymphocytes were found.
HLA-G expression was detected in 12 of 35 EwS biopsies (34%), either on the tumor
cells (10/35) and/or on infiltrating lymphocytes (7/35). Coincubation of gene-modified,
HLA-G-expressing EwS cells with freshly isolated allogeneic NK-cells resulted in
suppression of EwS cell lysis in 3 of 6 NK cell donors in a flow cytometry based
cytotoxicity assay.
Conclusion:We conclude that local expression of HLA-G within the tumor
microenvironment in EwS is a candidate mediator of immune escape and a potential
barrier to cellular immunotherapeutics. Strategies that modulate HLA-G expression
may be effective to overcome local immune suppression in this cancer.
O-077
TUMOR DIVERSITY: A CHALLENGE OF GENOMIC CANCER THERAPY
S. Burdach1
1Klinikum Rechts der Isar, Department of Pediatrics, Munich, Germany
Genomics engendered the promise of targeted therapies. So far, targeted therapies have
failed in childhood cancer. They rather prime for resistance. An exception may be the
targeting of oncogene addiction. The promise of targeted therapies was provoked by
the cancer stem cell model. This model may not represent intratumoral diversity.
Pediatric cancer display genomic and particularly, epigenomic plasticity, when under
selective pressure, yielding subclones that are non-dominant at one point in time and
dominant at another. Employing longitudinal biopsies we observed activation of
oncogenic pathways during individualized expression-based targeted therapy in
advanced Ewing Sarcoma (ES). Simultaneous targeting of both the EWS/FLI1
dependent catalytic subunit polycomb repressor complex 2 enhancer of zeste
homologue 2 (EZH2) as well as reactive oxygen species (ROS) independent pathways
yielded loss of EWS/FLI1 target genes expression and up regulation of ROS signaling.
Cytotoxic drugs can have specific effects on oncogene signaling. Increase of sensitivity
due to repression of oncogene down stream targets widens the therapeutic index; i.e.
the sensitivity of the tumor as compared to normal cells. In ES, trabectedin interferes
with EWS-FLI1 driven expression of the Werner (WRN) protein in ES cells (Grohar
2014). Since WRN-deficient cells are known to be hypersensitive to irinotecan, we have
performed a pilot trial using trabectedin to block EWS-FLI1 activity, and selectively
sensitizing ES cells to the DNA damaging effects of irinotecan (Herzog 2015). This
molecular precision chemotherapy is capable of controlling, with persistent quality of
life, about half of the cases of advanced pediatric sarcomas refractory to any
established therapy. The contribution of molecular precision therapy vs. more general
cytotoxic effects remains to be elucidated.
In Conclusion: Intratumoral diversity may require strategies of molecular precision
chemotherapy with synergistic effects and some collateral damage. Such oncogene
addiction directed precision chemotherapy can overcome resistance to selective targeted
therapies.
O-078
PHASE II TRIAL DESIGNS IN OSTEOSARCOMA RELAPSES: REVIEW OF
PAST EXPERIENCE
N. Omer1, M.C. Le Deley2, L. Brugières1, N. Gaspar1
1Gustave Roussy, Cancérologie de l’Enfant et de l’Adolescent, Villejuif, France; 2Gustave
Roussy, Biostatistiques, Villejuif, France
Background/Objectives: Optimal Phase-II design to evaluate new therapies in
osteosarcoma is not defined yet. Our objective is to study the consistency between
protocols evaluating new anticancer treatments in osteosarcoma in terms of eligibility
criteria, response assessment, endpoints, statistical design and reported results.
Design/Methods: Systematic review of clinical trials registered on clinicaltrials.gov,
eudrapharm.eu, and French National Cancer Institute website, or referenced in
PubMed or ASCO website, between 2003 and 2014. Relevant trials were identified using
the following criteria: (osteosarcoma OR bone sarcoma OR sarcoma) AND (phase II)
AND (relapsed OR recurrence OR metastatic).
Results: 54 trials were identified, described as Phase-II (n=45), I/II (n=8) and II/III
(n=1) evaluating mostly chemotherapy (n=24) and/or targeted therapies (n=21).
Results were published for 22 and partially published (abstract) for 4 trials. Sixteen
trials included osteosarcoma only. Eligibility criteria greatly varied in terms of disease
presentation. Inclusion ages were either children only (n=1), children to adults (n=24),
adolescents to adults (n=16) and adults only (n=13). Overall, 34 trials were run in a
multicentre setting, including 7 international trials. Only 8 trials were randomised,
including 2 with a cross-over at progression. Primary endpoint was tumour response in
34 trials, either response rate at a given timepoint (n=15) or best response (n=19), with
various definitions of “success” (complete+partial+/-minor response and stable
disease), mainly evaluated with RECIST criteria (n=25). Main endpoint was
Progression-Free Survival in 17 trials and Overall Survival in 3, evaluated at various
timepoints. In single-arm trials evaluating response rate, the null hypothesis that was
tested (when available, n=11) varied from 5% to 25%. In single-arm osteosarcoma trials,
the sample size varied from 15 to 50. Reporting has also greatly varied across trials.
Conclusion: No stable historical data can be derived from past efficacy Phase-II trials in
osteosarcoma relapses. This pleads in favour of trans-age randomised Phase-II
trials.
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THERAPEUTIC DRUGMONITORING APPROACHES TO THE TREATMENT
OF PRETERM AND FULL-TERM NEONATES WITH CANCER - A UK
EXPERIENCE
G. Veal1, J. Errington1, J. Hayden2, D. Hobin3, D. Murphy4, R. Dommett5, D. Tweddle1,
H. Jenkinson3, S. Picton6
1Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne,
United Kingdom; 2Alder Hey Children’s Hospital, Paediatric Oncology, Liverpool,
United Kingdom; 3Birmingham Children’s Hospital, Paediatric Oncology and
Haematology, Birmingham, United Kingdom; 4Royal Hospital for Sick Children,
Paediatric Oncology, Glasgow, United Kingdom; 5Bristol Royal Hospital for Children,
Paediatric Oncology, Bristol, United Kingdom; 6Leeds General Infirmary, Children’s
Oncology and Haematology, Leeds, United Kingdom
Background/Objectives: Defining chemotherapy dosing regimens for the treatment of
neonates with cancer is particularly challenging and commonly not standardized based
on any scientific rationale. The Newcastle Cancer Centre Pharmacology Group
(NCCPG) provide a national therapeutic drug monitoring (TDM) service to optimize
treatment in challenging patient populations. As an example of the potential benefits of
this approach, we report on the use of carboplatin TDM in preterm and full-term
neonates within the first month of life and use the data generated to provide guidance
for future treatment.
Design/Methods: Carboplatin TDM was performed to achieve target drug exposures
(AUC values) in nine preterm and full-term neonates diagnosed with retinoblastoma or
neuroblastoma. Carboplatin was administered over 3 days of treatment with TDM
utilized to target AUC values of 5.2-7.8 mg/ml.min.
Results: AUC values achieved following TDM were within 15% of target values in all
but one patient (12/13 treatment courses), with dose modifications up to 215% required
to achieve target AUC values, based on initial mg/kg dosing schedules. Carboplatin
clearance determined across three consecutive courses of chemotherapy in two patients
increased from 3.4-7.1ml/min and 7.2-16.5ml/min, representing >2-fold increases over
several weeks of treatment. Complete remission was observed in 8/9 patients, with no
renal toxicity reported and only one patient experiencing ototoxicity.
Conclusion: The study highlights the benefits of utilising TDM to achieve cumulative
target carboplatin AUC values in preterm and full-term neonates, particularly in view
of marked increases in drug clearance observed during the first weeks of life. Reducing
the likelihood of sensorineural hearing loss may be particularly important in terms of
quality of life in the case of neonates with retinoblastoma, who may also have some
degree of visual impairment. This treatment approach may be beneficial for a range of
chemotherapeutics, with a view to optimising the balance between clinical response and
toxicity.
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GLOBAL PHARMACOGENOMIC DIVERSITY AND ITS IMPLICATIONS FOR
CHILDHOOD CANCER TREATMENT
G. Wright1, B. Carleton2, M. Hayden1, C. Ross2
1University of British Columbia, The Canadian Pharmacogenomics Network for Drug
Safety-Medical Genetics, Vancouver, Canada; 2University of British Columbia, The
Canadian Pharmacogenomics Network for Drug Safety-Pediatrics, Vancouver, Canada
Background/Objectives: Inter-individual differences in response to medications are
known to have a strong genetic component. Pharmacogenomics involves the study of
this genetic contribution and aims to improve drug safety and efficacy by predicting
optimal treatment regimes on an individual basis. Research has identified several genes
that influence response to anticancer agents relevant to the management of paediatric
patients with cancer. By leveraging publically available genomic data, the spectrum of
genetic variation in such genes can be extensively investigated and can be used to
inform the clinical implementation of pharmacogenomic tests.
Design/Methods: Genes included in this study were selected based on relevance to
pharmacogenomics and paediatric oncology. Variants in these regions of interest were
extracted from the 1000 Genomes Project sequencing data for 2504 samples from 26
global populations. Variants were subsequently annotated using the Ensembl Variant
Effect Predictor and analysed in further detail utilising the program, VCFtools and the
software environment, R.
Results: A total of 12050 genetic variants were identified in the 62 genes that met
inclusion criteria. Pharmacogenomic variation tended to be most similar within
continental populations and all samples carried a median of five clinical variants with a
high level of scientific evidence. Genetic variants that would severely impair protein
function were found in genes associated with adverse drug reactions encountered in
paediatric oncology settings, including vincristine-induced peripheral neuropathy,
methotrexate-induced mucositis and cisplatin-induced ototoxicity.
Conclusion: The results of the current study have the potential to inform future
pharmacogenomic studies and ultimately improve cancer management in paediatric
patients. For example, the current data can be incorporated into research conducted by
the Canadian Pharmacogenomics Network for Drug Safety, which is conducting
several genomic studies of adverse drug reactions in paediatric patients with
cancer.
O-081
GENOME-WIDE ASSOCIATION STUDY OF L-ASPARAGINASE-INDUCED
PANCREATITIS IN PAEDIATRIC PATIENTS
B. Drogemoller1, H. Fujii2, S. Ito2, B. Carleton1, C. Ross1
1University of British Columbia, Canadian Pharmacogenomics Network for Drug
Safety-Pediatrics, Vancouver, Canada; 2The Hospital for Sick Children, Division of
Clinical Pharmacology and Toxicology, Toronto, Canada
Background/Objectives: L-asparaginase is highly effective in the treatment of paediatric
acute lymphoblastic leukemia. Unfortunately, this treatment is accompanied with
debilitating adverse drug reactions, such as pancreatitis. This severe adverse drug
reaction impacts on the quality of life of paediatric patients and is a frequent cause of
treatment discontinuation. As treatment dose and formulation have not been able to
explain the inter-individual differences that are observed, it seems likely that genetic
factors may play an important role in the development of pancreatitis. Therefore, this
study aims to identify the genetic variants associated with L-asparaginase-induced
pancreatitis.
Design/Methods: A total of 123 patients who have been treated with L-asparaginase
were recruited from 13 oncology units across Canada. Extensive demographic and
clinical data have been collected for all patients and genotyping of 740,000 genetic
variants spread throughout the entire genome has been performed using the Illumina
HumanOmniExpress array. Statistical analyses were performed using the Golden Helix
SNP and Variation Suite v8 and packages from the programming environment, R.
Results: Investigation of the clinical variables revealed that factors such as gender,
treatment dose and formulation were not significantly associated with the development
of L-asparaginase-induced panceatitis (P < 0.05). Initial genome-wide association
analyses did, however, identify nine regions in the genome that are nominally associated
with L-asparaginase-induced pancreatitis (P < 1×10−5), including one
non-synonymous variant that was predicted to exert a deleterious effect on the gene in
which it occurred.
Conclusion: This study has identified a subset of genetic variants that may be involved
with the development of L-asparaginase-induced pancreatitis. If these results can be
replicated, these data can ultimately be used to design and implement a predictive
pharmacogenetic test, which will allow for the tailoring of treatments in order to
prevent the occurrence of pancreatitis.
O-082
NOVEL CLINICAL TRIAL DESIGNS IN PAEDIATRIC CANCER:
PROBABILITY-BASED INTERPRETATION
K. Wheatley1, V. Moroz1, A. Houlton1, P. Kearns1
1University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham,
United Kingdom
Background/Objectives: It is often considered impossible to undertake randomised
controlled trials (RCTs) in children’s cancers because of their rarity. This is because,
using a conventional approach to sample size calculation (e.g. alpha=5%, power=80%),
the numbers needed are not considered feasible. This leads to new therapies being
evaluated via single arm studies, which may be biased for many reasons. In order to
obtain more reliable evidence on the efficacy of treatments, reconsideration of the
conventional approach is needed and novel RCT designs should be implemented.
Design/Methods: Probability-based interpretation involves plotting Bayesian posterior
probability distributions, using non-informative priors and observed data. Based on
this distribution, the probabilities that one treatment is better than the other, or better
by specified amounts, can be calculated. This information can then be taken in
conjunction with other relevant data (e.g. toxicity) to come to a clinical judgement as to
which arm is better. In the case of two treatment comparisons, the level of evidence
needed to conclude that one treatment is preferable may be lower; e.g. in absence of
substantial toxicity differences, a probability of 75% that survival is better with one
regimen may be sufficient to select that treatment. In the context of rare diseases, a 90%
(or lower) chance that adding a new treatment is better may be adequate (cf. 97.5% with
conventional two-sided p=0.05).
Results: Probability-based interpretation will be used in several current and planned
trials, covering a range of disease areas and treatment stages. Examples of trials
include: frontline (EE2012) and relapsed (rEECur) Ewing sarcoma, comparing the
standard European and US chemotherapies, and four widely used chemotherapy
regimens respectively; relapsed neuroblastoma (BEACON); acute myeloid leukaemia
(MyeChild).
Conclusion: The use of probability-based interpretation in RCTs, based on clinically
acceptable levels of certainty, will produce unbiased evidence on the comparative
efficacy of treatments.
O-083
BIOMEDE TRIAL: A RANDOMISED TRIAL FROM THE INNOVATIVE
THERAPIES FOR CHILDRENWITH CANCER (ITCC) CONSORTIUM TO
EVALUATE NEW DRUGS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
M.C. Le Deley1, A. Chevance2, P. Capolino2, A. Giljean2, T. Motreff3, G. Le Teuff1,
C. Jannin3, M. Angokai2, D. Vuillier3, F. Bautista4, K. Nysom5, P. Leblond6, D. van
vuurden7, D. Hargrave8, G. Vassal3, J. Grill9
1INSERM U1018 - Gustave Roussy, Service de Biostatistique et d’Epidémiologie,
villejuif, France; 2Institut Gustave Roussy, Service de Biostatistique et d’Epidémiologie,
Villejuif, France; 3Institut Gustave Roussy, Direction de la Recherche Clinique, Villejuif,
France; 4Hospital Infantil Universitario Niño Jesús, Unidad de Oncología Pediátrica,
Madrid, Spain; 5Rigshospitalet, Paediatric Haematology-Oncology, Copenhagen,
Denmark; 6Centre Oscar Lambret, Unité d’Oncologie Pédiatrique et Inserm U908 "Cell
Plasticity and Cancer", Lille, France; 7Vrije Universiteit Amsterdam, Paediatric
Haematology Oncology, Amsterdam, Netherlands; 8Great Ormond Street Hospital,
Paediatric Haematology and Oncology, London, United Kingdom; 9Institut Gustave
Roussy, Paediatric and Adolescent Oncology, Villejuif, France
Background/Objectives: Treatment of children with DIPG remains challenging. Besides
radiotherapy, no validated treatment exists, and most children die within two years of
diagnosis. Survival rate has not improved over the last three decades despite many
clinical trials. More efficient strategies in pediatric oncology new drug development are
needed, considering the multiple hurdles that include disease rarity and limited
knowledge about tumour biology.
Design/Methods: Following a biopsy-based translational research program, 3 drugs
were selected for clinical evaluation: erlotinib, everolimus and dasatinib. EGFR
overexpression (50%) may be predictive of erlotinib efficacy and PTEN-loss (90%)
predictive of everolimus efficacy. We designed a “targeted-driven” randomised trial
where dasatinib is compared to erlotinib and/or everolimus according to biomarker
profile defined on immunohistochemical analysis of the tumour. The main efficacy
endpoint is overall survival.
Results: This innovative academic trial will recruit 250 patients over 4 years in an
international setting. Drugs are provided by 3 pharmaceutical companies. A
stereotactic biopsy will be performed at diagnosis to define biomarker profile. The 3
treatments will be allocated by randomisation, stratified by biomarker profile, excluding
erlotinib if EGFR-negative and everolimus if no PTEN-loss. The analysis will include
pairwise comparisons (erlotinib-versus-dasatinib, everolimus-versus-dasatinib, and
erlotinib-versus-everolimus, between randomised subsets, with an expected number of
100, 185 and 90 patients for each of these comparisons) and comparison to historical
control.This trial is the first stage of a larger rolling evaluation program in DIPG,
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allowing for the evaluation of new drugs that would later become available for
testing.The initial biopsy and its associated translational research program will also
provide genetic information that may be used for further treatment, and will contribute
to increase the knowledge on this disease.
Conclusion: This innovative approach of personalised medicine with randomised
comparisons should provide useful information on the effect of new drugs in DIPG.
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INVESTIGATING THE HETEROGENEITY OF ALKYLATING AGENTS’
EFFICACY AND TOXICITY BETWEEN GENDERS: A META-ANALYSIS OF
RANDOMIZED TRIALS COMPARING CYCLOPHOSPHAMIDE AND
IFOSFAMIDE (MAIAGE STUDY)
B. Fresneau1, M. Paulussen2, A. Hackshaw3, D.S. Hawkins4, J.R. Anderson5,
I.R. Judson6, U. Dirksen7, I.J. Lewis8, H. Van Den Berg9, N. Gaspar1, H. Gelderblom10,
J. Whelan11, J. Boos7, K. Wheatley12, J.P. Pignon13, M.C. Le Deley13, G. Le Teuff13
1Gustave Roussy, Pediatric Oncology, Villejuif, France; 2University Children’s Hospital,
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Centre, Epidemiology and Medical Statistics, London, United Kingdom; 4Seattle
Children’s Hospital, Hematology/Oncology, Seattle, USA; 5University of Nebraska
Medical Center, Medical Statistics, Omaha, USA; 6Royal Marsden Hospital, Sarcoma
Unit, London, United Kingdom; 7Westfälische Wilhelm’s - Universität Münster, Pediatric
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Services, Leeds, United Kingdom; 9Emma Children Hospital / Academic Medical Center,
Pediatric Oncology, Amsterdam, Netherlands; 10University Medical Center, Department
of Medical Oncology, Leiden, Netherlands; 11University College Hospital, Oncology,
London, United Kingdom; 12University of Birmingham, Cancer Research UK Clinical
Trials Unit, Birmingham, United Kingdom; 13Gustave Roussy, Epidemiology and
Biostatistics, Villejuif, France
Background/Objectives: A marginal interaction between gender and type of alkylating
agent (cyclophosphamide or ifosfamide) on event-free survival was observed in the
randomized controlled trial (RCT) Euro-EWING99-R1 for Ewing sarcoma. To better
judge of the reliability of this interaction on efficacy and to investigate this interaction
on toxicity, we performed a meta-analysis of RCTs assessing cyclophosphamide vs.
ifosfamide.
Design/Methods: A systematic review and meta-analysis on individual patient data for
any type of cancer were performed. The endpoints were progression-free survival
(PFS), overall survival (OS) and maximum grade of acute toxicity. The hazard-ratios
(HR) and odds-ratios (OR) [95% confidence interval] of the treatment-by-gender
interactions were assessed using multivariable regression models stratified on trial and
gender. Heterogeneity of interaction between trials was evaluated using a 3-order
interaction term.
Results:Meta-analysis included 1,528 patients from three RCTs, in pediatric and young
adult sarcomas: Euro-EWING99-R1 (n=856), EICESS92 (n=155) and IRS-IV
(n=517).
With a median follow-up of 6.8 years, 424 failures and 325 deaths, a marginal
(p=0.065) overall difference for PFS was observed between the four groups defined by
treatment arm and gender. Multivariable analysis tended to identify poorer PFS in
males treated with cyclophosphamide vs. ifosfamide (HR=1.26 [0.99;1.61] p=0.06),
whereas PFS was not significantly different in females receiving cyclophosphamide vs.
ifosfamide (HR=0.96 [0.70;1.31] p=0.80). However, the treatment-by-gender
interaction was not significant (HR=1.31 [0.89;1.95] p=0.17) without heterogeneity
between trials (p=0.36). Similar results were observed with OS. Concerning acute
toxicity (leuco-neutropenia, infection and renal toxicity), the treatment-by-gender
interactions were not significant (OR=0.82 [0.49;1.37] p=0.45, 1.11 [0.72;1.71] p=0.64,
1.70 [0.76;3.83] p=0.20) without heterogeneity between trials. Significantly more severe
leuco-neutropenia and infections were observed with cyclophosphamide (OR=1.47
[1.14; 1.88] p=0.003, 1.55 [1.25; 1.93] p< 0.0001) and in females (OR=0.72 [0.56; 0.93]
p= 0.013, 0.80 [0.64; 0.99] p= 0.041).
Conclusion: The meta-analysis could not confirm the hypothesis of treatment-by-gender
interactions on efficacy or toxicity outcomes.
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RESULTS OF A CCLG RANDOMISED CONTROLLED TRIAL COMPARING
BOLUS INJECTIONWITH INFUSED AND/OR LINE-LOCKED TEICOPLANIN
IN THE TREATMENT OF COAGULASE-NEGATIVE STAPHYLOCOCCAL
SEPTICAEMIA
B. Pizer1, P. Donachie2, S. Hemsworth1, S. Picton3, L. Phelan3, H. Traunecker4,
A. McCarthy5, M. Millar6
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Background/Objectives: Coagulase-negative staphylococci (CoNS) are the most
common cause of septicaemia in children treated for cancer. Teicoplanin is the UK’s
first line antibiotic in the treatment of Gram positive organisms. After two 12 hour
loading doses, it is given on a daily basis, generally by bolus injection. Concern exists,
however, that teicoplanin when given by bolus injection, may be limited in sterilising
contaminated central venous catheters (CVCs), with biofilm-forming organisms such as
CoNS. CCLG SC 1999 01 was a multi-centre RCT that examined the method of
administration of teicoplanin in CoNS bacteraemia.
Design/Methods: Following CVC insertion, children (<18y) were randomised to receive
teicoplanin by either bolus injection (BI) or a 2 hour infusion and/or line locks
(PE-prolonged exposure). For dual lumen CVCs, teicoplanin was given via each lumen
on alternate days. Patients received teicoplanin by the randomised route in the
subsequent management of suspected CVC-associated CoNS infection.
Re-randomisation was performed for each CVC inserted.
Results: 992 CVCs were randomised from 832 patients; 465 - BI and 457 - PE. One
hundred and thirty four CVCs became infected (infection rate 16.1%). The success or
failure of antibiotic therapy was predefined and recorded. The overall success rate was
107/134 (79.9%) – BI: 51/69 (73.9%), PE 56/65 (86.2%). The success rate for single
lumen CVCs was not significantly different between the two arms (p = 0.323). There
was, however, a significantly superior success rate for dual lumen CVCs treated with PE
teicoplanin: 28/41 (68.3%) for BI against 42/45 (93.3%) for PE (p = 0.003).
Conclusion: This RCT showed a benefit for teicoplanin given by infusion or line-lock in
children with dual lumen CVCs treated for CoNS bacteraemia. This may reflect a
sub-optimal drug exposure as a result of the alternate day approach to teicoplanin
administration when given by bolus injection in children and young people with dual
lumen CVCs.
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A MULTI-CYCLE PHASE III STUDY EVALUATING PALONOSETRON VERSUS
ONDANSETRON AT PREVENTING CHEMOTHERAPY-INDUCED NAUSEA
AND VOMITING IN PEDIATRIC PATIENTS RECEIVING
MODERATELY/HIGHLY EMETOGENIC CHEMOTHERAPY
G. Kovacs1, A. Wachtel2, E. Basharova3, T. Spinelli4, P. Nicolas4, E. Kabickova5
1Second Department of Pediatrics, Semmelweis University, Budapest, Hungary;
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Background/Objectives: To demonstrate that palonosetron is non-inferior to
ondansetron at preventing chemotherapy-induced nausea and vomiting (CINV) in
pediatric patients receiving up to four moderately/highly emetogenic chemotherapy
(MEC/HEC) cycles.
Design/Methods: Palonosetron doses (10, 20 μg/kg) were evaluated versus ondansetron
(3×150 μg/kg). Statistics were used to demonstrate non-inferiority (δ=-15%) for
complete response (CR, no emesis/rescue) rates during the acute phase of cycle 1. CR
rates during delayed and overall phases, and safety, were assessed.
Results: In 493 patients aged 2.1 months–16.9 years, CR rates (%) in the acute phase
(cycle 1) were 59.4, 54.2 and 58.6 in the palonosetron 20 μg/kg, 10 μg/kg and
ondansetron groups, with non-inferiority demonstrated for palonosetron 20 μg/kg
(97.5% Cl [CR] -11.7–12.4; p=0.0022). CR rates (acute phase, cycles 2–4) were 65.6,
81.4 and 64.5 in the palonosetron 20 μg/kg group, 66.7, 44.2 and 47.4 in the 10 μg/kg
group, and 59.3, 63.6 and 52.6 in the ondansetron group. CR rates (cycles 1–4) were: in
the delayed phase, 38.8, 38.9, 42.4 and 32.3 in the palonosetron 20 μg/kg group, 28.9,
35.8, 30.2 and 31.6 in the 10 μg/kg group, and 28.4, 32.6, 27.3 and 26.3 in the
ondansetron group; in the overall phase, 32.7, 35.6, 40.7 and 29.0 in the palonosetron
20 μg/kg group, 23.5, 33.3, 27.9 and 21.1 in the 10 μg/kg group, and 24.1, 29.1, 27.3
and 21.1 in the ondansetron group. Treatment-emergent adverse events (TEAEs [%],
cycles 1–4) were fewer in the palonosetron 20 μg/kg group (69.3, 64.4, 55.9, 48.4) versus
the 10 μg/kg (80.2, 76.2, 72.1, 75.0) and ondansetron (81.7, 82.6, 68.2, 72.2) groups. All
withdrawals/fatal TEAEs were not considered drug-related.
Laboratory/electrocardiogram evaluations raised no concerns.
Conclusion: In pediatric patients, palonosetron 20 μg/kg was non-inferior to
ondansetron in the acute phase (cycle 1) and numerically superior to ondansetron
across all cycles, with no significant safety risks.
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IMPACT OF BEST PRACTICES TO DECREASE CENTRAL LINE ASSOCIATED
BLOOD STREAM INFECTIONS (CLABSI) AMONG ONCOLOGY PATIENTS
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Background/Objectives: CLABSI adversely affects clinical outcomes by increasing
morbidity, mortality and waste of healthcare resources. Standardized practices for
central venous line (CVL) care have been reported to significantly decrease risk of
CLABSI. Primary objective was institutional CLABSI rate reduction to < 2.9/1000 line
days from historical rate of 5.8/1000 line days within 12 months and to sustain rate
reduction.
Design/Methods: Strategies to decrease risk of CLABSI include implementation and
long-term compliance with standardized practices for CVL care. These included CVL
insertion guidelines and standardized maintenance care bundles. In 2009, to further
decrease CLABSI rate and improve clinical outcomes, our institution adopted
standardized best practices under the auspices of the NACHRI Hematology-Oncology
Transformation Collaborative. Effectiveness of these interventions was analyzed by
comparing pre-interventional (2006-2008) CLABSI rate to post-interventional
(2009-2014) rate. To implement new practice and measure its outcome, the institutional
CLABSI Core-Working Group used “Model for Improvement” by introducing
“test-of-change” through Plan-Do-Study-Act (PDSA) cycles (listed below). Root Cause
Analyses (RCA): RCA performed on all positive blood cultures to identify any
“preventable” cause, analyze system failure, study trends and possible associations.
Nurse/Physician Education: A tailored approach to education was adopted. CVL
maintenance bundles:During 2009, several elements of standard CVL care bundles were
implemented systematically in multiple stages. Line Audits: Weekly line audits and
“snap audits” were introduced to measure compliance and to ensure appropriate CVL
line maintenance techniques. CVL Cart: This carried all necessary supplies needed for
CVL maintenance care bundle.
Results:During 2010-2014, serial annual institutional CLABSI rate was 3.9, 1.8, 1.0, 1.3
and 1.4 per 1000 line days respectively. CLABSI reduction resulted in preventing
(estimated) 88 CLABSIs and 11 deaths with institutional cost saving of approx. $ 3.01
million.
Conclusion: Systematic introduction of best practices and CVL insertion and
standardized maintenance bundles results in significant reduction in CLABSI rate and
corresponding morbidity and mortality.
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RISK-SCORING IN PEDIATRIC FEBRILE NEUTROPENIA: EXPERIENCE
FROM A SINGLE CENTRE IN INDIA
A. Das1, A. Trehan1, S. Oberoi1, D. Bansal1
1Postgraduate Institute of Medical Education and Research PGIMER, Pediatric
Hematology-Oncology unit- Department of Pediatrics, Chandigarh, India
Background/Objectives: Risk-prediction models for pediatric febrile neutropenia enable
early discharge/outpatient management for ‘low-risk’ patients. This reduces cost and
nosocomial infections, while improving quality of life. We formulated and prospectively
assessed a simple risk-scoring model, and compared its performance to 6 previously
published decision-rules.
Design/Methods: A prospective study (n=320) identified predictor-variables at
admission for a predefined set of complications. Logistic-regression models were used
to formulate a risk-score. Scoring was performed as follows: under-nutrition (2),
duration from last chemotherapy 7-days (2), clinical focus of infection (2), absolute
neutrophil count 100/μL (2) and C-reactive protein >60 mg/L (5). A total score <7
identified episodes as ‘low-risk’. The model’s performance was assessed and compared
with the published rules on a prospective cohort.
Results: Complication(s) were documented in 109/414 (26.3%) episodes. Two-hundred
and eight (50.2%) episodes were classified as ‘low-risk.’ Accuracy of prediction was
78.5%. Hosmer-Lemeshow test demonstrated adequate calibration (p=0.26).
Nagelkerke’s R2 was 34.4%. Discriminatory-performance was comparable for the
derivation (c-statistic=0.86; 95% CI 0.82-0.9) and validation-sets (0.81; 95% CI
0.76-0.85). Logistic recalibration using a novel predictor variable identified in the
validation-set (albumin <2.5 g/dL) failed to better the c-statistic (0.81; 95% CI
0.76-0.85). Sensitivity was 86.24% (95% CI 78.32-92.08) and negative predictive value
was 92.79% (95% CI 88.38-95.91). Odds-ratio for a ‘high-risk’ episode to develop
complications was 10.8 (95% CI 5.97-19.53). Comparing with published rules, the
highest c-statistic was 0.69 for a score predicting sepsis. C-statistic for a homogenized
outcome (including complications, mortality, sepsis, pneumonia) for the index rule
(0.79) was better than the other predictive models (best c-statistic=0.68).
Conclusion: Risk-stratification models validated in developed nations are not applicable
in developing countries. Predictors for complications in this setting include
under-nutrition and focus of infection. The impressive performance of the index model,
incorporating relevant and easily assessable variables, warrants its validation in centres
across developing economies.
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SYSTEMATIC REVIEW OF REDUCTIONS IN THERAPY FOR CHILDREN
WITH LOW RISK FEBRILE NEUTROPENIA
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Background/Objectives: Reductions in therapy for children with febrile neutropenia at
low risk of complications may provide benefits to both patients and the health service.
Previous systematic reviews concluded outpatient and oral antibiotic regimens were
effective, but did not address the clinical heterogeneity of the studies. We further
explored the safety of these regimens and the effect of timing of discharge.
Design/Methods:Multiple electronic databases, conference abstracts and reference lists
were searched. Prominent authors were contacted. Randomised controlled trials (RCT)
and prospective observational cohorts examining the location of therapy and/or the
route of administration of antibiotics in patients with febrile neutropenia, younger than
18 years old, were included. Studies were screened, appraised and data extracted by one
researcher and independently checked by a second. Data were combined in a
meta-analysis using a random effects model. Heterogeneity was examined using
Chi-squared tests, I2 and by visual inspection of forest plots. Registration: PROSPERO
(CRD42014005817).
Results: Thirty-seven studies (including 3205 episodes of febrile neutropenia) were
included in the review, including 13 RCTs and 24 observational cohorts. Two deaths
occurred in children receiving inpatient intravenous therapy. Two intensive care
admissions occurred in children receiving outpatient oral antibiotics. In the included
RCTs, the odds ratio for treatment failure with outpatient treatment was 0.98
(confidence interval (CI) 0.44-2.19, I2=0%) and with oral treatment was 1.05 (CI
0.74-1.48, I2=0%). When considering all prospective data, the estimated risk of failure
using outpatient therapy was 8.57% (CI 8.54-8.61%, I2=85.4%) and using oral
antibiotics was 8.1% (CI 8.1-8.2%, I2=85.9%). The rate of failure for patients receiving
reduced therapy after 48 hours was lower than these estimates, and for patients treated
entirely with reduced therapies the rate of failure was higher.
Conclusion: Reductions in therapy for specified groups are safe with low rates of
treatment failure.
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PERIPHERALLY INSERTED CENTRAL CATHETERS ARE SIGNIFICANTLY
ASSOCIATEDWITH SYMPTOMATIC VENOUS THROMBOTIC EVENTS IN
PEDIATRIC ONCOLOGY PATIENTS: A POPULATION-BASED STUDY FROM
MARITIMES, CANADA
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M. Bernstein2, S. Afzal2, B. Crooks2
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Background/Objectives: The care of pediatric oncology patients (PCPs) has been
supported by central venous catheters (CVCs); although with a risk of symptomatic
venous thrombotic events (sVTE). There are limited data addressing the association of
type of CVC and sVTE in childhood cancer patients. We describe the association of
type of CVC with sVTE in PCPs.
Design/Methods:We abstracted data from the case records of all PCPs from the
Maritime provinces managed by the IWK Health Center in Halifax. Patients were <20
years of age and cared for between January 2000 to December 2014. Data were
combined from: (i) pediatric oncology hospital database, (ii) Provincial Cancer in
Young People database, (iii) Electronic medical records, (iv) Pharmacy database (v)
IWK central line database and (v) Hospital Health records. All subjects had signs or
symptoms of VTE, radiologically proven VTE and were treated with anticoagulants.
The CVCs were categorized by method of insertion and included peripherally insertion
central catheters (PICC), totally implanted devices (TID), tunneled lines (TL), and
others. Type of first CVC was analyzed.
Results: Forty (5.4%) of the 731 PCPs had sVTE. Among the 459 patients with TID, 67
patients with TL, and 110 patients with other types of CVCs, 25 (5.4%), 4 (6%) and 2
(1.8%) developed sVTE respectively. In comparison, 9 (15.5%) of the 58 patients who
received PICC line developed sVTE (p=0.001). Presence of PICC line increased odds of
sVTE 4.4 (95% confidence interval: 2.0-9.8) times as compared to other types of CVC.
The mean time to sVTE in patients with PICC versus other types of CVC was 59.5±40
days (median=17 days) and 335.7±120 days (median=257 days) respectively (p=0.001).
Conclusion: This pediatric population based study provides evidence that PICC lines
are associated with sVTE and confirms adult patient observations in PCPs. This
underscores the need for judicious use of PICC lines.
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CARDIOVASCULARMEDICATION IN PATIENTS DIAGNOSEDWITH
CANCER AT EARLY AGE IN FINLAND: A NATIONWIDE REGISTRY LINKAGE
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Background/Objectives: Advanced therapies of childhood and young adulthood (YA)
cancer have led to excellent survival results nowadays. Nevertheless, this growing group
of surviving cancer patients faces elevated risks for possibly life-threatening
morbidities, especially cardiovascular complications.
Design/Methods: Our nationwide registry linkage study investigated the purchase of
cardiovascular medication in early onset cancer patients (N=8,197) diagnosed with
cancer below the age of 35 years between 1993 and 2004 and in healthy siblings (born
between 1958 and 2004) (N=29,974). Purchase data on cardiovascular medication from
1993 to 2011 were extracted from the national drug purchase registry. Regarding the
purchase of cardiovascular medication, cumulative incidences and hazard ratios (HR)
were analyzed after early onset cancer compared to healthy siblings.
Results: Cumulative incidences for purchasing cardiovascular medications prevailed
after both YA and childhood cancer. A markedly increasing trend over time was visible
for all investigated medication groups, especially for the purchase of any cardiovascular
or specifically cardiac medication.HRs for purchasing cardiovascular medication were
elevated especially after childhood, but also after YA cancer compared to siblings. The
highest HR stood out for purchasing anticoagulants after childhood cancer (HR 19.8,
95%CI 8.5-45.9), however, with very low purchase numbers among siblings. The next
highest HRs were found for any cardiovascular (HR 7.2, 95% CI 5.1-10.1) and cardiac
medication (HR 4.8, 95% CI 3.3-6.9) after childhood cancer. Regarding YA cancer
patients, the respective increased values were HR 2.5 (2.0-3.2) for anticoagulants, HR
1.7 (1,5-1,9) for any cardiovascular, and HR 1,5 (1,3-1,7) for cardiac medication.
Conclusion: Using a new alternative registry linkage approach, our study demonstrated
higher purchases of cardiovascular medication after cancer at young age, reflecting
elevated cardiovascular morbidity. This knowledge postulates the need for
implementation of long-term cardiovascular control guidelines for this patient group at
risk to prevent, detect and adequately treat cardiovascular late effects.
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MATERNAL RESIDENTIAL PROXIMITY TO ROADWAYS DURING
PREGNANCY AND CHILDHOOD CENTRAL NERVOUS SYSTEM TUMORS: A
POPULATION-BASED ASSESSMENT IN TEXAS, 2003-2009
H. Danysh1, K. Zhang2, L. Mitchell2, M. Scheurer1, P. Lupo1
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Background/Objectives: Due to increasing concerns over the impact of traffic-related air
pollution on childhood cancers, we evaluated residential proximity to major roadways
and risk for developing a childhood central nervous system (CNS) tumor in Texas.
Design/Methods:We obtained information on all children diagnosed with a CNS tumor
at <5 years of age and born in Texas (USA) during the period of 2003-2009 (n=315)
from the Texas Cancer Registry. A random sample of birth certificate controls was
frequency matched to cases (5:1) on birth year (n=1,575). Based on the maternal
residence at the time of the child’s birth, we assessed exposures to traffic-related air
pollution using residential proximity to major roadways derived from Geographic
Information System (GIS) applications. Logistic regression was used to generate odds
ratios (OR) and 95% confidence intervals (CI) adjusted for the child’s sex and year of
birth, maternal education and race/ethnicity, and area-level poverty. We evaluated CNS
tumors as a group and by histologic type (e.g., ependymoma, primitive
neuroectodermal tumor [PNET]).
Results:Maternal residential proximity to major roadways during pregnancy was
statistically significantly associated with CNS tumor risk in offspring. Specifically, risk
increased by 30% for every kilometer [km] closer to a major roadway (OR [95% CI]: 1.3
[1.0-1.7]). Moreover, mothers who lived in areas of high roadway density (>1.5-km
length of major road segments within a 500-m residential radius) were 1.5-times more
likely (95% CI: 1.1-2.1) and 4.2-times more likely (95% CI: 1.2-14.9) to have offspring
with any CNS tumor and ependymomas, respectively, when compared mothers in low
density areas.
Conclusion: In this large population-based assessment, we found that mothers who live
close to major roadways or who live in areas of high roadway density were more likely
to have offspring who develop a CNS tumor, particularly an ependymoma.
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NO SOCIOECONOMIC VARIATION IN SURVIVAL FROM SOFT TISSUE
SARCOMAS OF CHILDREN AND YOUNG ADULTS IN NORTHERN
ENGLAND
J. Liu1, N. Basta1, P. James1, R. McNally1
1Newcastle University, Institute of Health & Society, Newcastle upon-Tyne, United
Kingdom
Background/Objectives: Although survival from soft tissue sarcoma (STS) in children
has improved, about 30% die within 5-years of diagnosis. This study investigates the
association between socio-economic status (SES), using paternal occupation at birth,
and survival from STS in children, teenagers and young adults (TYA).
Design/Methods: All cases of STS in children and TYA (0-14 & 15-24 years) diagnosed
1968–2008 were extracted from a population-based specialist registry in Northern
England. Paternal occupational social class at the time of the child’s birth was obtained
and classified into 3 categories: class I/II (professional/managerial), class IIIN/M
(skilled non-manual/skilled manual) and class IV/V (semiskilled/unskilled).
Kaplan-Meier methods were used to calculate survival and Cox regression used to
investigate associations between survival and SES, site of tumour, stage and age at
diagnosis.
Results: There were 425 cases of STS; 216 (50.8%) children and 209 (49.2%) TYA, 231
(54.4%) males and 194 (45.7%) females, 158(37.2%) rhabdomyosarcoma and
267(62.8%) non-rhabdomyosarcoma, 135 (31.8%) had tumours in the head and neck,
107 (25.2%) in the trunk, with 97(22.8%) in the extremities. Social class was category
I/II for 78 (18.4%) cases, IIIN/M for 197 (46.4%), IV/V for 108 (25.4%) and missing for
42(9.9%). Five-year survival for all cases significantly improved from 37.2% (1968-1977)
to 74.8% (1998-2008). Survival was worse for rhabdomyosarcomas versus
non-rhabdomyosarcomas (hazard ratio (HR)=2.39, 95%CI 1.71-3.35; P < 0.001), for
tumour site trunk versus head and neck (HR=2.71, 95% CI 1.86-3.93; P < 0.001), for
TYA versus children (HR=1.45, 95% CI 1.04-2.00; P = 0.03) and for males versus
females (HR=1.50 95% CI 1.11-2.03, P = 0.008). However, SES was not significantly
associated with survival from STS (HR=1.12, 95% CI 0.74-1.69 and HR=1.32, 95% CI
0.85-2.06 for class IIIN/M and IV/V respectively versus class I/II).
Conclusion: This study has shown that site of disease, age and sex, but not SES, are
important predictive factors for survival from STS in children and TYA.
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Background/Objectives: Population-based cancer registries (PBCRs) generate estimates
of incidence and survival that are essential for cancer surveillance, research, and
developing cancer control strategies. Though cancer stage data allow for meaningful
assessments of the effectiveness of prevention and early diagnosis campaigns, as well as
changes in cancer incidence and outcomes, stage is not collected by most PBCRs. The
principal method of staging adult cancers is the tumor, node, metastasis (TNM)
classification. The collection of paediatric cancer stage however is more complicated
however because it is defined by malignancy-specific parameters and multiple
classifications from different research groups have evolved overtime. Thus collection of
paediatric stage data represents a significant challenge for PBCRs.
Design/Methods:We assembled key experts and stakeholders (oncologists, cancer
registrars, epidemiologists) and utilized a modified-Delphi approach to establish
principles guiding paediatric cancer stage collection. Using these principles,
recommendations were made on which staging systems should be adopted by PBCRs
for the major childhood cancers, including adaptations for low-income countries.
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Results: 28 panelists representing multiple stakeholder groups, 17 countries and 6
continents ultimately participated in the Delphi questionnaires and the face-to-face
meeting. 12 principles guiding the collection of paediatric stage were identified in 4
categories: rationale for collection, relationship to adult cancer staging, specificities of
paediatric staging systems, and adaptation to resource-limited settings. Using these
recommendations, staging systems for collection by population-based cancer registries
for 18 major childhood malignancies were endorsed, with different tiered systems
recommended for different resource settings.
Conclusion:Wide adoption of these recommendations among cancer registries will
facilitate international comparative studies of incidence and outcome. We recommend
that the tiered, paediatric-specific staging systems endorsed in this paper be adopted for
paediatric cases by cancer registries in both LMICs and HICs.
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CHILDHOOD CANCERMORTALITY IN INDIA: DIRECT ESTIMATES BASED
ON A NATIONALLY REPRESENTATIVE SURVEY OF CHILDHOOD DEATHS
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Background/Objectives: Though the majority of children with cancer live in low- and
middle-income countries (LMICs), estimates of LMIC mortality rates attributable to
childhood cancer are few and reliant upon non-representative cancer registries.
Design/Methods:We examined childhood cancer deaths (one month-14 years) in the
ongoing Million Death Study (MDS), a representative study of over 27,000 paediatric
deaths in India that uses enhanced verbal autopsies. All cases potentially due to
childhood cancer were identified. Two paediatric specialists (one in oncology, the other
in infectious disease) independently reviewed and categorized cases as definite, probable,
possible, or unlikely cancer. Definite and probable cases were assembled and used to
estimate national and regional mortality rates attributable to childhood malignancies.
Data on symptoms, duration of symptoms, and healthcare seeking behaviour were
abstracted from verbal autopsy closed ended questions and caregiver narratives.
Results: Of 700 cases meeting inclusion criteria, 189 were ultimately classified as definite
or possible cancer. The kappa statistic of agreement between reviewers was 0·75 (95%
confidence interval [CI] 0·71-0·78). Based on these deaths, we estimated that in 2010,
13,726 deaths due to childhood cancer occurred in India, leading to a mortality rate of
3·7 per 100,000 live births per year (95%CI 2·3-5·0), which exceeds prior estimates
provided by Indian population-based cancer registries. Disparities between MDS
estimates and registry estimates were widest among children in Northeast India, and
those with brain tumours. A preponderance of male deaths was seen (male:female ratio
1·6:1). 158 (83·4%) of cohort patients experienced symptom durations of greater than
one month.
Conclusion: The burden of childhood cancer mortality in India is substantially higher
than previous estimates based on registries. National childhood cancer strategies are
warranted in order to improve outcomes for Indian children with cancer.
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Background/Objectives: Childhood cancer is a public health issue in Mexico, being the
leading cause of death between ages five and 14. Mortality rates have remained
suboptimal for over 25 years. Understanding outcome disparities is essential to create
newer health policies to improve the outlook for these children. Describe how clinical,
epidemiological and social factors, affect survival in Mexican children with cancer.
Design/Methods:We evaluated patients registered at the National Childhood Cancer
Database between June 2008 and February 2015. Cox proportional hazards model was
used to estimate adjusted hazard ratios (HR) for death by clinical and social variables.
Cases were grouped according to International Classification of Childhood Cancer
(ICCC-3). Significance was set at < 0.05.
Results: From 18,721 registries, 11,410 patients could be enrolled into the model, with
4,177 deaths observed. Five year overall survival was 51.8%. In the Cox model
(p<0.0001), HR (95% C.I.) for clinical features: Female / male 1.07 (1.01-1.14), every
year of age 1.03 (1.02-1.03), every increasing stage 1.46 (1.41-1.52).By type of cancer
(leukemia as reference): Lymphomas 0.42 (0.37-0.47), CNS 2.98 (2.51-3.54),
neuroblastoma 1.39 (1.16-1.67), renal 0.60 (0.49-0.72), hepatic 1.35 (1.09-1.67) and
germ cell tumors 0.31 (0.22-0.43). HR for social context: Treatment in foreign state /
own state 1.11 (1.01-1.22), treatment at State Healthcare / Ministry of Health 4.28
(2.22-8.26), education index 0.47 (0.240-0.93), and financial income index 0.56
(0.36-0.84). Other health care institutions, retinoblastoma, sarcomas, carcinomas and
other tumors were not statistically significant.
Conclusion: This is the first national study ever made to correlate social and clinical
variables with survival for Mexican children with cancer. Adjusted hazard ratios enabled
us to estimate the effect of social variables. Age, type of cancer and stage, point of care
and geographic location, education and income, significantly affect the prognosis and
outcome of childhood cancer. It is time for health policy rethinking and adjustment.
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Background/Objectives: Platinum administration may lead to hearing impairment or
even deafness. Data on the prevalence of hearing impairment after platinum
administration in very long-term childhood cancer survivors (CCS) are scarce and the
role of co-medication is uncertain. The aim is to identify non-genetic risk factors for
ototoxicity, including co-medication, in a multi-center cohort of very long-term CCS
treated with platinum-based chemotherapy.
Design/Methods:We analyzed clinical and audiological data after a median follow-up
time of 10.2 years [2.0-32.1 years] of all non-cranial irradiated CCS, treated with
platinum agents between 1981 and 2013 in 2 of the 7 pediatric oncology centers in the
Netherlands. Median age at diagnosis was 3.8 years [0.1-18.9 years]. Hearing function
was measured by pure tone audiometry. Severe hearing impairment was defined
according to Münster (grade 2b) as well as Brock (grade 2) classification.
Results: In total, 252 patients received platinum-based chemotherapy, of which 137
were treated with cisplatin alone (median dose: 400 mg/m2), 75 with carboplatin alone
(median dose: 1600 mg/m2), and 40 with both cisplatin (median dose: 327 mg/m2) and
carboplatin (median dose: 1590 mg/m2). Overall, the prevalence of hearing impairment
was 29.8% (Brock grade 2), respectively 30.5% (Münster grade 2b). Severe hearing
impairment was shown in 49/137 (Münster) / 47/137 (Brock) cisplatin-treated patients,
in 8/75 (Münster) / 7/75 (Brock) carboplatin-treated patients, and in 20/40 (Münster) /
21/40 (Brock) patients treated with both agents. In univariate analysis, exposure to
cisplatin, higher cumulative doses of cisplatin, and exposure to furosemide and
vancomycin were associated with hearing impairment. This study is now being further
extended to complete the national cohort to determine the role of co-medication on
platinum-related ototoxicity.
Conclusion: About one third of the CCS who received platinum-based chemotherapy
had severe hearing impairment. Co-medication (furosemide and vancomycin) was
associated with platinum-related ototoxicity in long-term survivors of childhood cancer.
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Background/Objectives: Survivors of childhood cancer treated with platinum-based
chemotherapy and/or cranial radiation are at high risk of treatment-induced hearing
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loss. The effects of hearing loss on social attainment in adult survivors of childhood
cancer have not been well elucidated.
Design/Methods: Three hundred twenty two adult survivors of pediatric central nervous
system (CNS; n=152, mean[SD] age at evaluation=26.9[5.5] years, time since
diagnosis=18.4[5.4] years) and non-CNS solid tumors (n=170, mean[SD] age at
evaluation=31.1[7.3] years, time since diagnosis=22.0[6.1] years) treated with
potentially ototoxic cancer therapy completed audiologic evaluations and
questionnaires assessing perception of social functioning and attainment (i.e.
independent living, marriage, employment). Audiograms were assigned a grade based
on the Chang Ototoxicity Grading Scale. Serious hearing loss was dichotomized as no
or yes (Chang grade 2a vs. 2b). All analyses were stratified by tumor type (i.e. CNS
vs. non-CNS). Multivariable logistic regression models, adjusted for age, sex, and IQ
impairment (for CNS models only), were conducted to examine associations between
serious hearing loss and social outcomes. Adjusted odds ratios (OR) and 95%
confidence intervals (CI) are reported.
Results: Serious hearing loss (hearing levels requiring a hearing aid or deafness), was
prevalent in 38% of CNS and 41% of non-CNS tumor survivors. Serious hearing loss
was associated with increased risk of perceived negative impact on social functioning
for both CNS (OR=1.84, 95% CI, 0.79-4.30) and non-CNS (OR=2.11, 95% CI,
1.07-4.16) tumor survivors. Among non-CNS tumor survivors, serious hearing loss was
associated with 2-fold increased risk of non-independent living (OR=2.31, 95% CI,
1.17-4.57), unemployment (OR=1.91, 95% CI, 0.99-3.71) and history of never being
married (OR=2.07, 95% CI, 0.98-4.37).
Conclusion: A substantive proportion of adult survivors of childhood cancer treated
with potentially ototoxic therapy had serious hearing loss. Treatment-induced hearing
loss was associated with reduced social attainment, both perceived and actual, in this
large study sample.
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Background/Objectives: There is growing evidence that platinum-based
chemotherapeutic agents may up-regulate genes involved in mitochondrial superoxide
detoxification leading to cochlear oxidative stress and ultimately ototoxicity. Based on
this, we hypothesize that epigenetic mechanisms leading to differential expression of
these genes may play a role in treatment-related ototoxicity. Therefore, we evaluated the
role of methylation profiles within six mitochondrial superoxide metabolism genes on
ototoxicity susceptibility among childhood survivors of medulloblastoma.
Design/Methods: Peripheral blood samples were collected from 63 childhood survivors
of medulloblastoma at Texas Children’s Cancer Center between 2005 and 2010, with a
mean time since diagnosis of 5.2 years. Patients requiring hearing aids 1 year
following primary therapy were assigned a diagnosis of ototoxicity. DNA methylation
profiles were obtained using the Illumina HumanMethylation450 BeadChip array. We
assessed probes in promoter-associated CpG sites within the following genes: SOD2,
GPX4, GSR, PRDX3, TXN2, and TXNRD2. Ototoxicity-associated differential
methylation at these probes was assessed using linear regression adjusting for age,
gender, cranial radiotherapy, amifostine, cisplatin dose, and cellular composition. The
false discovery rate (FDR) was used to account for multiple comparisons.
Results: Among the 54 probes included in the final analysis, two were associated with
ototoxicity (FDR q<0.1): GPX4 (cg18061485; q=0.079) and GSR (cg07077080;
q=0.044). Relative to ototoxic cases (n=23), the mean beta methylation values were
12.6% and 7.8% higher in control patients (n=40) for cg18061485 and cg07077080,
respectively.
Conclusion: As DNA methylation at CpG sites in promoter regions is associated with
decreased gene expression, our results are consistent with evidence that up-regulation
of genes involved in mitochondrial superoxide detoxification is associated with
ototoxicity. Our study provides preliminary evidence that epigenetic mechanisms may
play a role in treatment-related ototoxicity. This information may potentially inform
improved risk stratification and chemoprotective strategies for hearing loss among
those undergoing therapy for childhood medulloblastoma.
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Background/Objectives:Many childhood cancer survivors develop neurocognitive
impairment impacting education and psychosocial functioning. Consensus guidelines
recommend assessment of at-risk patients, but conventional assessment is
time-consuming, costly and requires specialized expertise. Computerized
neurocognitive batteries are potential alternatives requiring further study. We evaluated
feasibility and validity of the 20-minute Cogstate R© computerized battery.
Methods: In this cross-sectional study, childhood cancer survivors, diagnosed at 21
years and 2 years since diagnosis, completed Cogstate R© plus conventional
neuropsychological measures at two U.S. cancer centers (8/9/2012-5/14/2014).
Standardized Connecticut academic achievement test scores were obtained from
schools. We measured 1) administration feasibility 2) convergent validity (associations
with conventional measures), 3) concurrent validity (ability to differentiate between
groups with known cognitive risk-factors) and 4) predictive validity (associations with
academic achievement).
Results: Participants (N=111) were a mean age of 8.0 ±5.1 (range 0.2-18.3) years at
diagnosis and 16.7±7.6 (range 8.1-53.9) years at evaluation, 63% male, previously
diagnosed with leukemia (52%), lymphoma (14%), brain tumors (20%), and other
tumors (14%). Participation and completion rates were 96% and 94%, respectively.
Spearman’s correlations revealed associations between Cogstate R© and conventional
measures for attention (p < 0.01), executive functioning (p < 0.01), and self/parent
report of executive functioning (p = 0.01). Linear regression confirmed expected
associations between younger age at diagnosis and worse Cogstate R© performance in
executive functioning (r2=−1.01, p < 0.01) and processing speed (r2=−0.02, p < 0.01);
and brain tumor diagnosis (r2=0.05, p < 0.01) and worse Cogstate R© performance in
processing speed (r2=−0.02, p < 0.01), attention (r2=0.10, p < 0.01), and working
memory (r2=0.05, p < 0.01). T-tests revealed differences between survivors above and
below Connecticut-defined reading goals on Cogstate’s R© processing speed (p = <0.01)
and working memory (p < 0.01) tasks, and between those above and below math goals
on Cogstate’s R© executive functioning task (p = 0.04).
Conclusion: Results suggest Cogstate R© is a feasible, valid method to identify patients at
risk for neurocognitive difficulties, potentially useful for clinical and research
assessments.
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Background/Objectives: Adult survivors of childhood cancer are at risk for seizures and
reduced functional outcomes. The direct impact of seizures on function in cancer
survivors has not been well explored.
Design/Methods:We examined seizure characteristics among 2,022 childhood cancer
survivors (48.3% female; median [range] age=31.5[18.4-65.9] years; time since
diagnosis=23.6[10.4-51.1] years). Frequency and persistence of seizures and
anti-epileptic medications following cancer diagnosis were abstracted from medical
records, and reviewed by board-certified neurologists. Survivors completed
neurocognitive testing and surveys to assess health-related quality of life (HRQOL) and
social attainment. Neurocognitive performance was converted to z-scores (M=0,
SD=1.0) based on population norms. Multiple logistical regression and Poisson
regression models with robust variance were used to examine associations between
seizure characteristics and functional outcomes, stratified by tumor group (i.e. CNS vs.
Non-CNS) and adjusted for age, gender, and prior cancer therapy (CNS: cranial
radiation [CRT]; Non-CNS: CRT, intrathecal and high-dose intravenous methotrexate).
Results: Seizures were identified in 232 (11.5%) survivors, and were most frequent
among survivors of CNS tumor (29.9%) and leukemia (12.6%) compared to lymphoma
(4.1%) and solid tumor (4.5%). In multivariable models, seizures were associated with
poorer performance on cognitive flexibility (CNS tumor effect size [ES]=-0.74, p=0.02;
non-CNS tumor ES=-0.68, p<0.001), fluency (non-CNS tumor ES=-0.37, p<0.001)
and short-term memory (CNS tumor ES=-0.63, p=0.001; non-CNS tumor ES=-0.46,
p<0.001). Similar effects were observed for attention and processing speed, though
seizures were generally not associated with HRQOL. Seizures were associated with less
than full time employment for survivors of CNS (ES=1.09, p=0.03) and non-CNS
(ES=1.11, p=0.001) tumors. Seizures persisted in 84/232 (36.2%) survivors within the
last year of long-term follow-up. Among seizure characteristics, seizure resolution was
the most common predictor of poor outcome.
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Conclusion: Seizures in cancer survivors impact neurocognitive outcome and
employment, independent of prior cancer therapy. Optimal clinical management by
achieving seizure control may improve neuro-cognitive function.
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Background/Objectives: Long-term survivors of childhood cancer treated with cranial
radiation (CRT) or antimetabolites are at risk for neurocognitive dysfunction. Many
also develop cardiovascular complications, though the impact of cardiovascular health
on neurocognitive function is not well understood.
Design/Methods: Adult survivors of childhood cancer (n=1,479; 47% female;
median[range] age 31.0[18-61] years; median time since diagnosis 24.6[11-49] years)
were recruited from the St. Jude Lifetime Cohort Study. Survivors completed
comprehensive medical assessments and neurocognitive testing for attention, memory,
processing speed and executive function. Survivors with history of
neurologic/neurodevelopmental conditions unrelated to cancer diagnosis or treatment
were excluded. Multivariable logistic regression was used to examine relative risk (RR,
95% confidence interval [CI]) for neurocognitive impairment, defined as age-adjusted
standard scores <10th percentile of population norms. Predictors included current
smoking status, abdominal obesity, and the presence of or treatment for hypertension,
impaired fasting cholesterol, and impaired fasting glucose, controlling for demographic
and neurotoxic treatment variables.
Results: Survivors demonstrated high frequency of hypertension (48.8%), dyslipidemia
(64.0%), obesity (67.8%), impaired fasting glucose (32.7%) and current smoking
(23.6%). High frequency of neurocognitive impairment was identified in attention
(27.6%), memory (28.6%), processing speed (32.4%) and executive function (43.3%). In
multivariable models controlling for treatment exposures (CRT dose, cumulative
intrathecal methotrexate, cumulative high-dose methotrexate, cumulative high-dose
cytarabine and corticosteroids), gender, race, and current age, obesity was associated
with risk of attention problems (RR=1.38, CI 1.14-1.67) and slow processing speed
(RR=1.37, CI 1.14-1.63). Current smoking was associated with impaired attention
(RR=1.50, CI 1.25-1.79), memory (RR=1.49, CI 1.25-1.78), processing speed
(RR=1.40, CI 1.19-1.65) and executive function (RR=1.31, CI 1.16-1.49), while
hypertension, dyslipidemia, and impaired fasting glucose were not significantly
associated with neurocognitive outcomes.
Conclusion: Long-term survivors of childhood cancer are at increased risk for
neurocognitive impairment, which may be influenced by risk factors typically
associated with poor cardiovascular health.
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Background/Objectives: Accurate histopathological grading is challenging for
ependymal tumors resulting in poor inter-observer reproducibility. In addition, suitable
prognostic markers for reliable risk stratification are lacking. We therefore aimed to
establish a uniform molecular classification of all ependymal tumors that adequately
reflects the full biological, clinical and histopathological heterogeneity across the major
anatomical CNS compartments, age groups, and grades.
Design/Methods: Genome-wide DNA methylation profiles for 500 ependymal tumors
were generated using the Illumina 450k methylation array followed by unsupervised
hierarchical clustering for subgroup identification. Copy-number aberrations, gene
expression patterns and signaling pathways as well clinical data were analyzed to
validate and further characterize identified molecular subgroups.
Results: Nine distinct molecular subgroups of ependymal tumors across all age groups,
three in each anatomical compartment of the CNS, spine (SP), posterior fossa (PF),
and supratentorial (ST), were identified. We found that these molecular subgroups are
genetically, epigenetically, transcriptionally, demographically, and clinically distinct.
One of the subgroups within each compartment was enriched with grade I
subependymomas (SP-SE, PF-SE, ST-SE). Previously described molecular subtypes of
hindbrain ependymomas (EPN), Group A and B, could be confirmed (PF-EPN-A,
PF-EPN-B). Two supratentorial subgroups were characterized by prototypic fusion
genes involving RELA (ST-EPN-RELA) and YAP1 (ST-EPN-YAP1), respectively.
Molecular subtypes of the spinal cord showed a good concordance with the
histopathological diagnoses myxopapillary ependymoma (SP-MPE) und grade II
ependymoma (SP-EPN). Analysis of clinical and demographical data revealed that the
vast majority of high-risk patients (mostly children) were restricted to just two of the
nine molecular subgroups, PF-EPN-A and ST-EPN-RELA.
Conclusion: The described analyses can be performed from minute amounts of DNA
extracted from archived material and are therefore ideally suited for routine clinical
application. Regarding clinical associations, the molecular classification proposed
herein outperforms the current histopathological classification and thus might serve as
a basis for the next WHO classification of CNS tumors.
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Background/Objectives: To evaluate feasibility and clinical results of a RT boost for
children with Ependymoma and measurable residual disease after first line or second
look surgery.
Design/Methods: The second AIEOP protocol for childhood ependymoma opened in
2003. After centralized pathological review, children were stratified to receive: 1) 3D
conformal RT, 59.4 Gy/33 fractions, to the tumor bed if completely resected and grade
II; 2) same RT followed by four cycles of VEC chemotherapy if completely resected
and anaplastic; 3) VECx4, second look surgery, local RT as in 1) followed by an
hypofractionated (8 Gy/2 fractions) boost to the residue if still measurable.
Results: 143 children entered the study (median follow-up 60 months). In 24 children
out of 46 with residue, second look wasn’t feasible or incomplete and thus received
VEC and 59.4 Gy to the tumor bed plus 8 Gy to the residue. Fifteen/24 children are
alive without progression at a median of 51 months (range 11-120 months) from
diagnosis, five/6 died of local progression, three died after distant relapse. No iatrogenic
death or major toxicity occurred: 4 children developed radiation related MRI changes
regressing with steroids within 8 months. In the 46 children with residual disease, 3 and
5 years PFS was 64% and 55%, and OS 80% and 68% respectively. Three and 5-year
survival free from local relapse was 71% and 64% respectively. 5 year-EFS for children
receiving the RT boost was 57%.
Conclusion: Hypofractionated RT boost was feasible and contributed to obtain durable
local control in 15/24 children with measurable residue after first line or second look
surgery. An aggressive and integrated local treatment strategy, multiple surgeries and
RT including an hypofractionated boost in case of residual disease, is required to
improve outcome in children with Ependymoma. This background will be the basis of
the next opening SIOP trial for Ependymoma.
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SEVERE NEUROTOXICITY FOLLOWING HYPERFRACTIONATED
ACCELERATED RADIOTHERAPY AND THIOTEPA IN THE TREATMENT OF
HIGH-RISK MEDULLOBLASTOMA: THE UK EXPERIENCE
J. Hayden1, S. Vivekanandan2, N. Thorp3, H. Mayles4, A. Baker4, B. Pizer1, G. Horan5
1Alder Hey Children’s NHS Foundation Trust, Paediatric Oncology, Liverpool, United
Kingdom; 2Cambridge University Hospitals NHS Foundation Trust, Paediatric Oncology,
Cambridge, United Kingdom; 3The Clatterbridge Cancer Centre NHS Foundation Trust,
Oncology, Wirral, United Kingdom; 4The Clatterbridge Cancer Centre NHS Foundation
Trust, Clinical Radiotherapy, Wirral, United Kingdom; 5Cambridge University Hospitals
NHS Foundation Trust, Clinical Oncology, Cambridge, United Kingdom
Background/Objectives: The prognosis for children who develop medulloblastoma
associated with high-risk features (metastasis, large cell anaplasia,MYCN amplification
or post-operative residuum >1.5cm2) remains poor.A strategy developed for high-risk
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medulloblastoma using induction chemotherapy, Hyperfractionated Accelerated
Radiotherapy (HART) followed by either maintenance chemotherapy or two
myeloblative courses with thiotepa and stem cell rescue (patients with persistent disease
prior to HART), was reported by the Milan group in 2009 with favourable outcomes
(5-year event-free and overall survival of 72% and 73% respectively). The approach was
subsequently adopted in the UK as a recommended treatment strategy in this disease.
We undertook a UK-wide service evaluation to review outcomes following the
introduction of this strategy into standard care.
Design/Methods: Neuro-oncologists in all paediatric oncology Primary Treatment
Centres in the UK were contacted and an anonymised questionnaire completed for
those treated using the strategy from February 2009 to May 2014. Neurotoxicity was
defined as  Grade 3 as defined by the Common Terminology Criteria for Adverse
Events (CTCAE), version 4.0.
Results: In total, 83 patients were treated from 17 UK centres according to the strategy;
3-year overall survival rate was 54%. Three patients died before receiving HART. In the
55% (n=44) of patients who did not receive thiotepa, none developed severe
neurotoxicity. Of those that received thiotepa (n=36) 12 received 1 and 24 two courses;
severe neurotoxicity was observed in 33.3% (n=4) and 16.7% (n=4) respectively.
Observed neurotoxicities associated with the use of thiotepa and HART included
global changes (n=5) and myelitis pattern (n=3).
Conclusion: The favourable survival seen in the original reported series is not replicated
in the UK multi-centre setting. The combination of high-dose thiotepa following
HART in high-risk medulloblastoma is associated with an unacceptable rate of severe
neurotoxicity (22%); suggesting a neurotoxic interaction between these treatment
modalities. An international trial in high-risk medulloblastoma is urgently required.
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ATYPICAL TERATOID/RHABDOID TUMORS ARE CHARACTERIZED BY
HIGH LEVELS OF EZH2 AND DNMT THAT CORRELATE WITH
DNA-METHYLATION AND ARE AMENABLE TO THERAPEUTIC INHIBITION
K. Kerl1, P. Johann2, N. Moreno3, J. Mertins3, J. Ahlfeld4, S. Erkek2, D. Jones2,
P. Northcott2, M. Frühwald5, S. Pfister2, U. Schüller4, M. Meisterernst3, M. Kool2
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Background/Objectives:Atypical Teratoid/Rhabdoid Tumors (AT/RT) are characterized
by SMARCB1/SMARCA4 mutations. Being devoid of other mutations we investigated
whether epigenetic mechanisms may contribute to the genesis of these tumors.
Design/Methods: As SMARCB1 is an epigenetic antagonist of the H3K27me3 histone
methyltransferase EZH2, we tested by using genome wide analysis of primary tumors
(geneexpression- methylom anaysis and ChIP-sequencing), as well as in in vitro and in
vivo models if EZH2 may be suitable for therapeutic inhibition in AT/RT.
Results: In gene expression profiles of 76 primary AT/RT, EZH2, as well as the
DNA-methyltransferases DNMT1, DNMT3a and DNMT3b were overexpressed in
comparison to normal brain. To epigenetically characterize these tumors, we analyzed
genome-wide methylation by Illumina 450k-methylation arrays for 100 AT/RT and
Whole Genome Bisulfite Sequencing of 17 cases and found that they display global
hypermethylation which might be a result of DNMT overexpression. Moreover, high
expression of EZH2 significantly correlated to high expression of DNMTs and
DNA-methylation. In line with this, EZH2 co-immunoprecipitated to DNMT1 and
DNMT3a in AT/RT cell lines. Secondly, the expression of EZH2 stabilized DNMT
expression and recruited DNMTs to promoter regions of tumor suppressor genes. To
identify EZH2 targets in primary tumours, 12 AT/RT were subjected to
ChIP-sequencing for EZH2 and H3K27me3. Consistent with the EZH2 overexpression
in primary tumors, genome wide H3K27me3 occupancy was higher in AT/RT than in
various control samples from fetal and adult brain and particularly pronounced at
promoter regions. Finally, in vitro and in vivo tumor cell growth was inhibited and
apoptosis was induced either by the genetic inhibition of EZH2 using RNA
interference or pharmaceutic inhibition of EZH2 or DNMT.
Conclusion: In conclusion EZH2 is upregulated in AT/RT and can be inhibited
therapeutically. Since H3K27me3 and DNA-methylation modifying compounds are
accessible for clinical use, these results may impact on therapeutic regimens for patients
with AT/RT.
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UPDATING THE PROGNOSTIC IMPORTANCE OF RESECTION STATUS AND
CHROMOSOME 1Q GAIN IN CHILDREN TREATED ACCORDING TO THE
FIRST SIOP 1999-04 TRIAL FOR PAEDIATRIC INTRACRANIAL
EPENDYMOMA
J.P. Kilday1, R. Chapman2, L. Storer2, J. Lowe2, T. Jacques3, T. Jaspan2,
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Background/Objectives: Robust clinical and biological correlates of outcome for
childhood intracranial ependymoma are still required. Previous analysis of European
paediatric trial cohorts suggested that incomplete surgical resection and chromosome
1q25 gain were markers of recurrence for very young patients, but not for older patients
(SIOP ependymoma I). This may have reflected limited cases undergoing biological
scrutiny in the latter group. Therefore, biological re-evaluation was performed on an
expanded SIOP cohort.
Design/Methods: 89 patients were originally enrolled on the SIOP ependymoma I
clinical trial. Following central pathology review, 10 were excluded. Tissue micro-arrays
were generated from formalin-fixed, paraffin-embedded material for 71 cases which
were then subjected to 1q25 FISH analysis. We also investigated 1q status by Multiplex
ligation-dependent probe amplification (MLPA) in a sub-cohort. Results were then
correlated with clinical, histological and updated survival data and with MLPA results.
Results: Of the 79 children enrolled, complete surgical resection (CR) was achieved at
initial surgery for 35 children (44%). 10-year EFS and OS for CR cases was 52.2% (SE
8.8%) and 70.4% (SE: 7.9%), yet 30.2% (SE 7%) and 46.5% (SE 7.6%) respectively for
those with incomplete resection (IR). Of the 71 cases with accompanying tissue, 54
(76%) generated 1q25 results. Both IR (HR 2.12, 95% CIs 1.02 – 4.39, p = 0.04) and
1q25 gain (HR 2.26, 95% CIs 1.04 – 4.89, p = 0.04) were independent predictors of
tumour progression. Indeed, integrating these two markers enabled stratification of
cases into three disease progression risk groups (p=0.004). The only independent
marker of adverse OS was anaplastic histology (HR 2.34, 95% CIs 1.16 – 4.74, p =
0.02).
Conclusion: 1q gain is an independent predictor of poor outcome and in combination
with IR identifies a very high risk group. Optimal methodology for identifying 1q gain
(FISH vs MLPA) on SIOP II trial will be presented.
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A NEW CLINICAL GUIDELINE (2007) AND NATIONAL AWARENESS
CAMPAIGN (2011) ACCELERATED BRAIN TUMOUR DIAGNOSIS IN UK
CHILDREN (HEADSMART - BE BRAIN TUMOUR AWARE)
D. Walker1, T. Chu1, A. Shah2, S. Wilne3, M. Coleman2
1University of Nottingham, Children’s Brain Tumour Research Centre, Nottingham,
United Kingdom; 2London School of Hygiene and Tropical Medicine, Department of
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University Hospitals NHS Trust, Department of Paediatric Oncology, Nottingham,
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Background/Objectives: Public and professional concern about delays in diagnosis of
childhood brain tumours has led to new referral guidelines and a campaign to raise
awareness of early features and the need for timely imaging.
Design/Methods:We investigated the referral pathways of children with a brain tumour
1989-2013 using (a) cancer registrations linked to routine records from primary care
and secondary care, (b) referral practice data from a multi-centre audit, and (c) data on
total diagnostic interval (TDI) from a service evaluation of HeadSmart.
Results: In a cohort of 181 patients (England, 1989-2006), primary care consultation
rates rose 40-fold, from 3.1 per 100 person-months (pm) one year before diagnosis to
148.9 at diagnosis. In a cohort of 3,959 patients (England, 1997-2006), hospital
admission rates rose 100-fold, from 1.3 per 100pm at one year before diagnosis to 134.0
at diagnosis. Emergency admissions rose from 35% to 55%. Long delays, repeated
presentations in primary care and many ineffective referrals, especially in patients with
low-grade brain tumours, were also identified in a multi-centre audit (2006). Headaches
or convulsions were the commonest first symptoms at age 4+ years. Ophthalmic signs
were more prominent in younger children, and changed most between onset (23% of
patients) and diagnosis (46%). Raised intracranial pressure was the most common
hospital presentation (40% of patients). During the period 2006-11, the median TDI fell
from 13.4 to 6.3 weeks. The greatest impact of HeadSmart is a 65% reduction in
median interval between first clinical contact and diagnosis (p<0.01; 730 children in 19
UK specialist centres, 2011-13).
Conclusion: Delays in diagnosis were associated with repeated presentations, ineffective
referrals and increasing likelihood of urgent admission. The referral guidance and
awareness campaign shortened the interval from first contact to scanning. The
campaign is ongoing, and it will be disseminated to primary care in 2014-15.
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SPERM BANKING IN ADOLESCENTS NEWLY DIAGNOSEDWITH CANCER:
RESULTS FROM THE SBANK10 STUDY
J. Klosky1, K. Wasilewski-Masker2, W. Landier3, M. Leonard4, K. Albritton5,
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Background/Objectives: To describe the prevalence of sperm banking among adolescent
males newly diagnosed with cancer in the US and Canada, and to identify factors
predictive of banking outcomes.
Design/Methods: A prospective single group quasi-experimental study design was
utilized to test the contributions of psychological, demographic, developmental, parent,
provider, and medical factors on sperm banking outcomes. At-risk adolescent males
from 8 leading pediatric oncology centers (13-21 years of age, Tanner stage  3,
N=146), their parents, and medical providers completed self-report questionnaires
within one week of treatment initiation. Logistic regression with single covariates was
utilized to test each factor as a potential correlate of the two binary sperm banking
study outcomes (bank/no bank and attempt/no attempt), and multi-covariate logistic
regression was used to calculate odds ratios (OR) and 95% confidence intervals for
specified banking outcomes.
Results: Among adolescents (Mean age = 16.49 years, SD = 2.02), 43.8% banked sperm
(64/146) and 56.2% did not (82/146). Of those not banking, 14 attempted but were
azoospermic (n=3) or unsuccessful (n=11). As such, 53.4% made a sperm banking
attempt (78/146), whereas 46.6% (68/146) did not. The overall banking model revealed
adolescent history of masturbation (OR=12.23, CI: 2.22-67.37, p<.01) and increased
parental self-efficacy to coordinate sperm banking (OR=1.24, CI: 1.03-1.49, p=.02)
associated with an increased likelihood of banking. The overall attempt model revealed
that higher Tanner stage (OR=23.13, CI: 2.20-243.59, p<.01) associated with an
increased likelihood for banking attempt, whereas higher perceived barriers to banking
by adolescents associated with a decreased likelihood (OR=0.74, CI: 0.59-0.93, p=.01).
Conclusion: This is the first large study to describe sperm banking practices among
newly diagnosed adolescents in the US and Canada. Although findings suggest that
banking is underutilized, modifiable factors such as parental self-efficacy and
adolescent perceptions of banking barriers were identified. Implications for sperm
banking interventions will be discussed.
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FACTORS ASSOCIATEDWITH AGING PHENOTYPES IN ADULT SURVIVORS
OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
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Background/Objectives: Childhood cancer survivors are at risk for accelerated aging.
We evaluated associations between lifestyle and hormonal status with risk of low bone
mineral density (BMD) and frailty among adult survivors of childhood acute
lymphoblastic leukemia (ALL).
Design/Methods: Participants included 862 ALL survivors (median age, 31.3 [range:
18.4-59.7] years) who received evaluation at St. Jude Children’s Research Hospital as
participants in the St. Jude Lifetime Cohort study. Bone density was measured using
quantitative computed tomography of L1-L2 vertebrae; low BMD was defined as an
age- and sex-standardized Z-score < -1. Prefrailty and frailty were defined as having 2
and 3 of the following conditions, respectively: low muscle mass, self-reported
exhaustion, low energy expenditure, slow walking speed, and weakness. Logistic
regression, stratified by sex, was used to examine associations (odds ratios (OR) and
95% confidence intervals (CI)) between lifestyle (smoking, alcohol consumption, and
activity levels) and hormonal status with low BMD and frailty.
Results: Thirty percent of survivors met criteria for low BMD, 3.6% for frailty and
18.6% for prefrailty. After adjusting for body mass index, males with growth hormone
deficiency (GHD; OR=1.6, 95% CI=1.0-2.5) or who were current smokers (OR=1.7,
95% CI=1.0-2.9) had increased odds of low BMD compared to those without GHD or
non-smokers. Among females, GHD (OR=2.2, 95% CI = 1.3-3.8) and moderate
alcohol consumption (OR=2.1, 95% CI=1.1-3.8) were associated with low BMD. After
adjusting for current age, the odds of prefrailty/frailty were increased among males with
GHD (OR=3.0, 95% CI=1.6-5.7) and who smoked (OR=3.3, 95% CI=1.6-6.4) and
among females who were risky drinkers (OR=2.0, 95% CI=1.0-3.8). Survivors with low
BMD did not have increased odds of prefrailty/frailty when compared to survivors with
normal BMD (p>0.05).
Conclusion: ALL survivors should receive counselling regarding lifestyle habits and
undergo screening for hormonal deficits to minimize the risk of low BMD and frailty.
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LATE MORTALITY AND CAUSES OF DEATH AMONG LONG TERM
SURVIVORS OF CHILDHOOD CANCER REGISTERED IN THE ITALIAN OFF
THERAPY REGISTRY (OTR)
R. Haupt1, M. Jankovic2, F. Bagnasco3, M. Terenziani4, C. Casella5, A. Andreano6,
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Background/Objectives: To analyze long term survival and causes of death among
5-year survivors of childhood cancer.
Design/Methods: The Off-Therapy Registry (OTR) of the Italian Association of
Pediatric Hematology/Oncology (AIEOP) started in 1980 prospectively enrolling
children with cancer (age 0-21 years) at treatment completion. Prevalent cases were also
included with the first case diagnosed in 1960. During 2012-14 vital status was
ascertained through census offices, and causes of death retrieved from death certificates.
Survival analysis allowed for left truncation to limit possible bias due to prevalent cases
at the start of OTR. Causes of death other than the one under study were treated as
competing risks.
Results: A total of 13,920 5-year survivors were evaluated (M:F ratio 1.24). The median
age at diagnosis was 5.2 years (IQR 2.7-9.7). Tumour type distribution was comparable
with other series except for a lower frequency of CNS tumours (n=1215; 8.7%). Era of
diagnosis was <1980 for 14.0% of the population, 1980-89 for 27.0%, 1990-99 for
46.7%, and 2000-09 for 12.3%.Length of follow-up ranged between 5.0 and 52.9 years,
median 19.6 years. At follow-up, 1,162 (8.4%) subjects were dead with a cumulative
probability of survival (95%CL) at 20, 30 and 40 years of 92.3% (91.8-92.8); 89.3%
(88.6-90.0); 84.6% (83.0-86.1), respectively. Significant reduction in the cumulative risk
of death was observed by treatment era, and female gender.Cause specific mortality at
35 years was 5.7% for primary cancer (n=672); 3.4% for secondary malignancy
(n=223), 2.5% for other causes (n=132) and 0.6% for external causes (n=44). It was
unknown for 91 subjects.
Conclusion: After 30 - 35 years since diagnosis mortality is more likely to be due to
other causes of death other than recurrence. We confirm a reduction in late mortality
for survivors treated in recent eras.
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POPULATION EVIDENCE TO SUPPORT AMODEL OF CHILD CANCER
SURVIVOR CARE
M.L. McBride1, K. Goddard2, S. Pritchard3, C. Fryer3, F. Walks4, P. Byron5, K. Blain6,
P. Rogers3
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Safety Quality and Supportive Care, Vancouver, Canada; 5BC Children’s Hospital,
Patient Care Services, Vancouver, Canada; 6BC Cancer Agency, Cancer Survivorship
Program, Vancouver, Canada
Background/Objectives: Follow-up of adult-age childhood cancer survivors in British
Columbia (BC) occurs mainly in the primary care setting, with little coordination and
support. Results from a research program, linking clinical records of all child cancer
cases diagnosed in BC from 1970 to mortality, cancer, and health administrative
databases for up to 40 years, were used to inform recommendations for strategies to
meet the ongoing healthcare needs of this survivor population.
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Design/Methods: Results from the BC Childhood, Adolescent, Young Adult Cancer
Survivor Research Program were used in a needs assessment; evaluation of ongoing
healthcare demand and costs; identification of gaps in care; and determination of the
size and characteristics of subgroups requiring different levels of care.
Results: There were approximately 3000 adult-age survivors. The number of survivors
transitioning to adult-age care increased each year by 3%. Over 40% lived more than 70
km from the main pediatric hospital. The proportion of at-risk survivors receiving at
least one recommended follow-up surveillance test ranged from 0.8% (TSH) to 87%
(CBC). At 20 years post-diagnosis, 20% of survivors had no reported hospital-related
conditions, and 35% had four or more types of hospital-related conditions. High users
of later outpatient services were survivors of CNS tumours, bone sarcomas, or
non-ALL leukemia; and those with previous cranial radiation; combination
chemotherapy and radiation; combination surgery, chemotherapy and radiation; or
autologous or allogenic HSCT. These data contributed to the development of
risk-stratified models of care and a business case for implementation.
Conclusion:Working group recommendations led to funding for a formal risk-tiered
adult-age childhood cancer survivor follow-up program in BC. This original research
demonstrates that population-based longitudinal database linkages of clinical and
health administrative data provide high-quality evidence to inform the development of
models of quality, sustainable, childhood cancer survivor care, that can improve health
care policy and practice.
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VALIDATING PROMIS ANXIETY AND DEPRESSION SHORT-FORMS IN
YOUNG ADULT CANCER SURVIVORS: COMPARISONWITH A
STRUCTURED DIAGNOSTIC INTERVIEW
C. Recklitis1, J. Blackmon1, G. Chang2
1Dana-Farber Cancer Institute, Pediatric Oncology, Boston, USA; 2VA Boston
Healthcare System, Psychiatry, Brockton, USA
Background/Objectives: To evaluate PROMIS Anxiety and Depression short-forms as
screening measures for young adult cancer survivors (YACS), by comparing these
measures to results of a structured diagnostic interview.
Design/Methods: 249 YACS (29.50 ±7.33 years) completed the PROMIS Anxiety and
Depression Short-forms, and an in-person Structured Clinical Interview for the
DSM-IV (SCID). Based on the SCID, participants were classified as having: 1) No
significant symptoms; 2) Significant symptoms but no SCID diagnosis; or 3) SCID
diagnosis. ROC analyses were used to evaluate concordance between the short-form
measures and the SCID and to determine if short-form cut-off score met study criteria
for sensitivity (.85) and specificity (.75).
Results: The Anxiety Short-form had good overall agreement with SCID on anxiety
diagnosis (AUC = .81) and moderate agreement on presence of significant anxiety
symptoms (AUC = .78). The Depression Short-form had good agreement with SCID
on both depression diagnosis (AUC = .89) and presence of significant depressive
symptoms (AUC = .83). For detecting a depression diagnosis, a Depression short-form
cut-off of T .53.2 came close to meeting study criteria with sensitivity .85 and
specificity .73. For detecting an anxiety diagnosis, the Anxiety short-form cut-off T 
52.1 had good sensitivity (.90) but only marginal specificity (.64) indicating many
survivors would erroneously screen-in with this cut-off. For identifying survivors with
significant anxiety and depression symptoms with or without a diagnosis, the
short-form scales performed similarly, but with less robust specificity, and no potential
cut-off approached study criteria. Of note, 6 participants with depression symptoms on
the SCID reported suicidal ideation not detected on the Depression Short-form which
lacks a relevant item.
Conclusion: The PROMIS Short-forms may be useful in assessment of anxiety and
depression in YACS but using them as stand-alone screening instruments is likely to
misclassify many survivors, particularly those with anxiety disorders.
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GENETIC VARIATION INFLUENCES IMPAIRMENT OF BONEMINERAL
DENSITY IN LONG-TERM ADULT SURVIVORS OF CHILDHOOD CANCER
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Background/Objectives: Despite similarities in upfront treatment, impairment of bone
mineral density(BMD) varies in long-term adult survivors of childhood cancer(CCS).
Because no data are available on the role of genetic variation, we studied whether
genetic variation influences this impairment of BMD in CCS.
Design/Methods: This cross-sectional single-center cohort study included 334 adult
CCS(median follow-up time after cessation of treatment: 15 years(range 5-39); median
age at follow-up: 26 years(range 18-49)). Total body BMD(BMDTB) and lumbar spine
BMD(BMDLS) were measured by dual-X-ray absorptiometry(DXA), and BMD was
expressed as age-matched and gender-matched standard deviation scores
(SDS;Z-score). We selected 12 candidate single nucleotide polymorphisms(SNPs) in 11
genes based on results of previous studies in the healthy population(COL1A1,
TNFSF11, TNFRSF11, TNRFSA11B, VDR, ESR1, WLS, LRP5, MTHFR, MTRR,
IL6). Multivariate analyses included, apart from candidate SNPs, patient and treatment
characteristics that were univariately associated with BMD values.
Results:Multivariate analyses revealed that lower BMDTB/LS was associated with lower
weight at follow-up(p<0.01), and BMDTB was associated with previously administered
radiotherapy(p=0.01). Survivors with the homozygous minor allele(GG) genotype of
rs2504063(in ESR1: estrogen receptor type 1) had a lower BMDTB(-1.17 vs. -0.84;
p=0.01) than those with the AG/AA genotype, however BMDLS was not different.
Carriers of two minor alleles(GG) of rs599083 (LRP5: low-density lipoprotein
receptor) revealed lower BMDTB(-1.18 vs. -083; p=0.04), and lower BMDLS(-0.97 vs.
-0.54; p=0.02) values than those with the TT/TG genotype. Carriers of VDR(vitamin D
receptor) haplotype 3 had a lower BMDLS than non-carriers(-0.86 vs. -0.64, p=0.05),
but BMDTB was not altered.
Conclusion: CCS who are carriers of candidate SNPs in the VDR, ESR1 or LRP5 genes
seem to be more vulnerable to impaired bone mass at an early adult age. In addition to
patient and treatment related factors, information on genetic variation may be helpful
in identifying survivors who are at risk for low bone density after childhood cancer
treatment.
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LONGITUDINAL STUDY IDENTIFIES 3 MIRNA SIGNATURES ALLOWING
DIFFERENTIATION BETWEEN PATIENTS WITHWILMS TUMORS AND
CONTROLS AT DIAGNOSIS, AFTER SURGERY AND AT TIME OF RELAPSE
N. Ludwig1, N. Nourkami-Tutdibi2, C. Backes3, N. Graf2, A. Keller3, E. Meese1
1Saarland University, Human Genetics, Homburg, Germany; 2Saarland University,
Pediatric Hematology and Oncology, Homburg, Germany; 3Saarland University, Clinical
Bioinformatics, Saarbruecken, Germany
Background/Objectives:Wilms Tumor (WT) is the most common childhood kidney
cancer. As treatment according to SIOP includes preoperative chemotherapy without
histological confirmation of WT by biopsy, minimal-invasive diagnostic markers
confirming WT diagnosis or relapse are highly warranted.
Design/Methods: In our study, we compared miRNA profiles of peripheral blood in
patients with WT at five different time points (diagnosis, after preoperative
chemotherapy, after surgery, end of therapy, recurrence), with profiles of patients with
other malignancies and controls with non-malignant diseases to identify miRNAs with
biomarker potential for WT. We measured expression of 883 miRNAs using
microarrays in a total of 138 samples and identified differential expressed miRNAs
using t-test and miRNA signatures using a Support-Vector-Machine approach.
Results: Our longitudinal study detected 37 significantly deregulated miRNAs in
patients with WT compared to controls with 6 miRNAs upregulated (including
miRs-197, -320a/b/c/d, and -93*) and 31 miRNAs downregulated (including
miRs-144/144*, -18a/b, -20a/b, and -93). We found the highest number of deregulated
miRNAs in the comparisons between the first three time points (i.e. at diagnosis, after
preoperative chemotherapy, and after surgery) and the controls (i.e. patients with
non-malignant diseases or patients with other malignancies). Furthermore, we
identified 3-miRNA-signatures that allowed differentiation between patients with WT
from non-malignant controls with a classification accuracies of 81%, 92%, and 83% for
time points at diagnosis, after surgery and at time of relapse, respectively.
Conclusion:We identified a miRNA profile in peripheral blood of patients with WT
under therapy that is significantly different from patients with other malignancies and
non-malignant diseases. We report miRNA signatures that show promise as
minimal-invasive biomarkers to differentiate WT patients from controls with high
accuracies at different time points including the initial WT diagnosis and WT
recurrence.
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MODE OF DIAGNOSIS AND OUTCOMES FOR CHILDREN DIAGNOSED
WITH RENAL TUMOURS IN THE UK AND IN GERMANY
K. Pritchard-Jones1, M. Weeks1, D. Edwards1, S. Irtan1, V. Pavasovic1, H. van
Tinteren2, V. Moroz3, A. Craft4, N. Graf5
1University College London, Institute of Child Health, London, United Kingdom;
2Netherlands Cancer Institute, Biostatistics Department, Amsterdam, Netherlands;
3University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham,
United Kingdom; 4University of Newcastle, Northern Institute for Cancer Research,
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Background/Objectives: Publication of geographical comparisons of childhood cancer
survival across Europe raised concerns whether the UK had lower population survival
rates than countries of similar socio-economic status. For Wilms tumour (WT), this
difference reaches 3-6%. Since 2002, the UK participated in a single European clinical
trial for renal tumours, allowing direct comparison of possible indicators of late
diagnosis.
Design/Methods: The SIOPWT2001 trial enrolled 849 WT patients from UK (to Dec
2011) and 1,507 WT from Germany (ongoing). Since Sept 2012, UK children (n=186)
are registered in the clinical observational study (Improving Population Outcomes of
Renal Tumours of childhood, IMPORT).
Results: In the SIOPWT2001 trial, median tumour volume (572ml vs 381ml) and
proportion with metastases at diagnosis (13% vs 10%) showed an adverse comparison
between UK and Germany, suggesting more advanced disease at diagnosis. This was
further interrogated by a retrospective casenote review of 360 patients at 3 UK centres
on their mode of diagnosis showing only 14.7% were diagnosed through screening,
routine child health surveillance or as an incidental finding when examined for
non-tumour related symptoms compared to 27.5% of 947 patients in Germany. 5yr
event free survival was not significantly different (84.1% vs 82.3%) for children
diagnosed in the former group compared to those with tumour-related symptoms in the
UK, though the small screening group had 100% EFS. A similar univariable
comparison for children diagnosed in Germany showed 90% vs 84% EFS (p=0.05) in
favour of those diagnosed without tumour-related symptoms. The IMPORT study
collects prospective information categorising the route to diagnosis and so far shows
8% diagnosed following screening/routine surveillance, 14% with non-tumour related
symptoms.
Conclusion: International comparisons of route to diagnosis and mode of detection of
a common abdominal tumour in relation to routine child health surveillance practices,
can inform approaches to improving earlier detection of cancer in children in the UK.
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TCF21 IS HYPERMETHYLATED IN CLEAR CELL SARCOMA OF THE
KIDNEY: A GENOME-WIDE TARGET STUDY
S.L. Gooskens1, S. Gadd2, J. Guidry Auvil3, D.S. Gerhard3, J. Khan4, R. Patidar4,
D. Meerzaman5, Q.R. Chen5, C.H. Hsu6, C. Yan6, C. Nguyen6, Y. Hu6,
C.G. Mullighan7, J. Ma7, R. de Krijger8, M.M. van den Heuvel-Eibrink9, M.A. Smith10,
N. Ross11, J.M. Gastier-Foster11, E.J. Perlman2
1Erasmus MC Sophia Children’s Hospital, Department of Pediatric Hematology and
Oncology, Rotterdam, Netherlands; 2Northwestern University’s Feinberg School of
Medicine and Robert H. Lurie Cancer Center, Department of Pathology, Chicago- IL,
USA; 3National Cancer Institute, Office of Cancer Genomics, Bethesda-MD, USA;
4Genetics Branch, Oncogenomics section, Bethesda-MD, USA; 5National Cancer
Institute-National Institutes of Health, Center for Biomedical Informatics and
Information Technology, Bethesda-MD, USA; 6National Cancer Institute-National
Health Institutes, Center for Biomedical Informatics and Information Technology,
Bethesda-MD, USA; 7St. Jude Children’s Research Hospital, Department of Pathology,
Memphis-TN, USA; 8Josephine Nefkens Institute-Erasmus MC, Department of
Pathology, Rotterdam, Netherlands; 9Princess Maxima Center for Pediatric Oncology,
Department of Pediatric Oncology, Utrecht, Netherlands; 10National Cancer Institute,
Cancer Therapy Evaluation Program, Bethesda-MD, USA; 11Nationwide Children’s
Hospital- Ohio State University College of Medicine, Department of Pathology and
Laboratory Medicine, Columbus-OH, USA
Background/Objectives: Clear Cell Sarcoma of the Kidney (CCSK) is a rare childhood
renal tumor. By using whole genomic and mRNA sequencing, we showed that no
recurrent genetic mutations or segmental gains/losses could be identified in CCSK.
Therefore, we performed genome-wide gene expression- and DNA methylation analyses
to find clues pointing to the pathogenesis of the majority of CCSKs.
Design/Methods: Through the “Therapeutically Applicable Research to Generate
Effective Treatments” (TARGET) initiative, 13 CCSKs were analyzed for changes in
genome-wide gene expression and DNA methylation, in addition to previously
performed SNP array analysis, whole genome sequencing and mRNA sequencing.
Methylation changes were verified and validated by real-time quantitative polymerase
chain reaction following bisulfite conversion in an independent set of 8 CCSK tumor
samples.
Results: Integrated analysis of gene expression and DNA methylation identified
promoter hypermethylation and low expression of TCF21 (Pod-1/capsulin/epicardin) in
all CCSK cases except for one case with a t(10;17)(q22;p13). To verify and validate the
methylation status of TCF21, sequencing following bisulfite conversion was performed,
showing higher TCF21 methylation levels in CCSKs (3 CCSK samples from the
discovery set, 8 CCSK samples from an independent validation set) compared with
other pediatric renal tumors (n = 12) and normal kidney samples (n = 2). Expression
of TARID, the long non-coding RNA responsible for demethylating TCF21, was
virtually undetectable in CCSKs. Immunohistochemical staining and functional studies
are currently being performed.
Conclusion:We raise the hypothesis that hypermethylation of the tumor suppressor
gene TCF21, a transcription factor involved in mesodermal development which has
been shown to be hypermethylated in many adult cancers, and/or decreased TARID
expression lies within the pathogenic pathway of CCSK.
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TREATMENT AND OUTCOME OF PATIENTS WITHWILMS TUMOUR (WT)
REGISTERED IN THE ASSOCIAZIONE ITALIANA EMATOLOGIA
ONCOLOGIA PEDIATRICA (AIEOP)-WT-2003 PROTOCOL
F. Spreafico1, P. D’Angelo2, A. Di Cataldo3, L. Gandola4, M. Bianchi5, P. Indolfi6,
M. Nantron7, A. Pession8, D. Perotti9, M. Provenzi10, D. Biasoni11, C. Morosi4,
M. Terenziani12, S. Catania12, P. Collini13
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 2Ospedale dei Bambini
G. di Cristina Palermo, Pediatrics, Palermo, Italy; 3Policlinico di Catania, Pediatrics,
Catania, Italy; 4Fondazione IRCCS Istituto Nazionale dei Tumori, Radiology and
Radiotherapy, Milano, Italy; 5Ospedale Infantile Regina Margherita Torino, Pediatric
Hematology and Oncology, Torino, Italy; 6Seconda Università degli Studi di Napoli,
Pediatrics, Napoli, Italy; 7Istituto G. Gaslini Genova, Pediatric Hematology and
Oncology, Genova, Italy; 8Policlinico S. Orsola Malpigli Bologna, Pediatrics, Bologna,
Italy; 9Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Experimental
Oncology and Molecular Medicine, Milano, Italy; 10Ospedali Riuniti Bergamo,
Pediatrics, Bergamo, Italy; 11Fondazione IRCCS Istituto Nazionale dei Tumori, Surgery,
Milano, Italy; 12Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology and
Pediatric Onco-Hematology, Milano, Italy; 13Fondazione IRCCS Istituto Nazionale dei
Tumori, Department of Pathology and Laboratory Medicine, Milano, Italy
Background/Objectives: The AIEOP-WT-2003 protocol aimed at: reducing
chemotherapy for stage I/II WT; improving the outlook for stage III/IV WT (balancing
radiotherapy timing/indications and doxorubicin (D) dose reduction), and for
anaplastic tumours (designing a new “high-risk” regimen); implementing tumour
banking for research purposes and centrally reviewed diagnosis.
Design/Methods:We analysed outcome in 449 unilateral WTs, of 649 newly-diagnosed
renal tumours since 10/2003. Treatment was assigned as follows: stage I (including
anaplastic cases) and II, 6-week or 22-week vincristine/actinomycin-D (VA),
respectively; stage III, 34-week VAD and abdominal radiotherapy; stage IV,
preoperative 6-week VAD, abdominal a/o metastatic sites radiotherapy (the last one
based on metastatic-response modulation) plus VAD. Stage II-IV anaplastic cases:
alternating courses of ifosfamide/D and carboplatin/etoposide in an intensive schedule,
plus radiotherapy.
Results: The local diagnosis was reviewed in 81% of cases, and 67% of frozen tumour
samples were centrally banked. Five-year DFS and OS for non-anaplastic WT were
86% ±2 and 94% ±1, respectively, after median follow-up of 72 months. DFS (OS)
according to tumour stage: stage I (n=117), 90% ±3 (97% ±2); stage II (n=146), 86%
±3 (94% ±2); stage III (n=83), 88% ±4 (97% ±2); stage IV (n=61), 75% ±6 (86% ±5).
Five children died without relapsing (3 from secondary cancers, from hepatic
venoocclusive disease and surgical complications in 1 case each). For 33 metastatic
complete responders to preoperative VAD, for whom lung radiotherapy was omitted,
DFS (OS) was 83% ±7 (96% ±4) compared with 65% ±9 (73.5% ±9) for incompletely
responders. DFS (OS) was 70% ±7 (74% ±7) in 43 cases with diffuse anaplasia.
Conclusion: These results are comparable with other international studies, however
more accurate questions on specific issues deserve larger cooperation to significantly
answer. Further reduction of treatment for stage I-II non-anaplastic WT must face with
the risk of metachronous tumour.
Acknowlegements: Associazione Bianca Garavaglia onlus.
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GENETIC LANDSCAPE OF ANAPLASTIC WILMS TUMORSWITH DIFFUSE
VERSUS FOCAL ANAPLASIA
G. Malouf1, L. Dainese2, X. Su3, A. Vershuur4, C. Bergeron5, C. Croppet5,
R. Mouawad6, F. Allanick6, S. Bensalma6, A. Blaise7, S. Irtan8, Y. Le Bouc9,
D. Khayat10, A. Coulomb11
1AP-HP- Groupe Hospitalier Pitié-Salpêtrière-Department of Medical
Oncology-UPMC Univ Paris 06- Institut Universitaire de Cancérologie GRC5, Oncology,
Paris, France; 2P-HP- Hôpital Armand Trousseau-Department of Pathology-UPMC
Univ Paris 06, Pathology, Paris, France; 3MD Anderson Cancer Center-Department of
bioinformatics and Computational Biology, Bioinformatics, Houston, USA; 4Hôpital
d’Enfants de La Timone-Department of Pediatric Oncology, Oncology, Marseille, France;
5Centre Léon Bérard-Institut d’Hématologie et d’Oncologie Pédiatrique IHOP,
Oncology, Lyon, France; 6P-HP- Groupe Hospitalier Pitié-Salpêtrière-Department of
Medical Oncology-UPMC Univ Paris 06- Institut Universitaire de Cancérologie GRC5,
Oncology, Paris, France; 7INSERM- UMR_S 938- CDR Saint-Antoine-Sorbonne
Universités-UPMC Univ Paris 06, INSERM UMR_S938, Paris, France; 8AP-HP-
Hôpital Armand Trousseau-Department of Pediatric Surgery-UPMC Univ Paris 06,
Pediatric Surgery, Paris, France; 9NSERM- UMR_S 938- CDR Saint-Antoine-
Sorbonne Universités-UPMC Univ Paris 06, INSERM UMR_S 938, Paris, France;
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Oncology-UPMC Univ Paris 06-Institut Universitaire de Cancérologie GRC5, Oncology,
Paris, France; 11APHP- Hôpital Armand Trousseau, Pathology, Paris, France
Background/Objectives: Presence of anaplasia is a potent marker for adverse outcome
in patients with Wilms tumors (WT). While WT patients with focal anaplasia (FA) have
identical survival to those with nonanaplastic WT, patients with diffuse anaplasia (DA)
show poor outcomes. Beside TP53 mutations, the genome-wide genetic basis of these
tumors remains unknown.
Design/Methods:We performed whole-exome sequencing on genomic DNA derived
from 12 WT and matched normal DNA from the same patients, using Agilent human
V5 (51Mb) capture and the HiSeq sequencing platform. Overall, 9 and 3 matched pairs
with DA and FA were assessed, respectively. Chromosome 17p copy number, where
TP53 is located, was assessed by a MLPA assay.
Results: Overall, we identified 125 (median 9, range 5-25) non-synonymous somatic
single nucleotide variants, of which 54 were predicted to lead to a deleterious protein.
No difference was observed in term of total number of mutations between WT with DA
and FA, respectively. TP53 mutations were identified in 5 DAWT. In addition, 2 DAWT
and 2 FAWT harbored identical hotspot DROSHA mutation (E1147K). Ingenuity
Pathway Analysis revealed enrichment for mutations in genes involved in embryonal
tumor development (ARMCX3, BCOR, FLT4, KMT2C, REST and TP53)
(p=2.7×10-4). All but one case of DAWT with TP53 mutations harbored TP53
deletion; the case without TP53 deletion had in addition both DROSHA and SIX1
mutations. The 5 patients with TP53 mutations died as compared to one out of 7
without mutation (p=0.01).
Conclusion: Our results reveal an exceptionally low mutational load in anaplastic WT,
consistent with previously reported results in pediatric solid tumors. DROSHA and
TP53 are likely to be mutually exclusive mutations in WT. Updated results with an
independent validation dataset will be presented at the meeting.
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OUTCOME OF PATIENTS EXPERIENCING A RELAPSE OFWILMS TUMOUR
TREATED BY THE SIOP2001/SFCE PROTOCOL
D. Cuzzubbo1, C. Cropet2, J. Michon3, A. Verschuur4, M.D. Leclair5, S. Supiot6,
A. Coulomb-L’Hermine7, A. Notz-Carrere8, C. Pasqualini9, P. Chastagner10,
M.D. Tabone11, E. Thebaud12, M.P. Castex13, F. Dijoud14, G. Audry15,
C. Bergeron1
1IHOP/Centre Léon Bérard, Pediatric, Lyon, France; 2Centre Léon Bérard, Statistics,
Lyon, France; 3Institut Curie, Pediatric, Paris, France; 4Marseille Hospital, Pediatric,
Marseille, France; 5Nantes Hospital, Pediatric Surgery, Nantes, France; 6Institut de
Cancerologie de l’Ouest, Radiotherapy, Nantes, France; 7Hopital Trousseau, Pathology,
Paris, France; 8Bordeaux Hospital, Pediatric, Bordeaux, France; 9Gustave Roussy,
Pediatric, Villejuif, France; 10Nancy Hospital, Pediatric, Nancy, France; 11Hopital
Trousseau, Pediatric, Paris, France; 12Nantes Hospital, Pediatric, Nantes, France;
13Toulouse Hospital, Pediatric, Toulouse, France; 14Hospices Civils de Lyon, Pathology,
Lyon, France; 15Hopital Trousseau, Pediatric Surgery, Paris, France
Background/Objectives: Overall modern treatment combinations have improved the
outcome after Wilms Tumour (WT) recurrence up to 80% for those who relapse after
minimal first line therapy and 50% for patients at high risk (unfavorable histology,
combined chemo- and radiotherapy regimen). We report the outcome of French
patients with relapsed WT included in SIOP2001/SFCE Protocol.
Design/Methods: 772 patients were treated in France between May 2002 and May 2013.
Fifty-five patients (7.1%) who experienced a relapse or a progressive disease received a
combination of chemotherapy, surgery, radiotherapy according to SIOP2001
guidelines. Intensification treatment as Myeloablative Therapy (MAT) was not formally
recommended by SIOP2001 Protocol at relapse.
Results: Forty (72.7%) patients had localized WT (19 stages I/ II; 21 stages III) and 15
(27.3%) had metastatic WT at diagnosis, respectively. Twenty-one patients (38.2%) had
unfavorable histology at diagnosis (diffuse anaplasia or blastemal-type), thirty-four
(61.8%) favorable. Six (10.9%), 45 (81.8%), 4 (7.3%) patients had a local relapse, a
metastatic relapse, or both respectively. Eighteen progressions or relapses occurred
during the first-line treatment, 18 relapses within the first 6 months following the end of
first-line therapy and 18 after more than 6 months (1 missing data). Thirty-six (65.4%)
patients received ICE (ifosfamide, carboplatin, etoposide) or CCE (cyclophosphamide,
carboplatin, etoposide) regimens as second line treatment. Twenty-four (43.6%)
patients received MAT as intensification treatment. Two-year EFS and OS were 66%
and 69.5% respectively. For the patients who underwent MAT the OS was 83.6% and
for those who didn’t was 58.1%.
Conclusion: Our analysis confirms that more than 65% of relapsed patients can be cured
by a combination of chemotherapy, surgery and radiotherapy. The role of
intensification treatment with MAT needs a prospective study to find its right place in
the treatment of relapsed Wilms tumour.
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CHANGES IN THE CLINICAL FEATURES OF NEUROBLASTOMA 10 YEARS
AFTER THE CESSATION OFMASS SCREENING IN JAPAN
A. Yoneda1, T. Tajiri1, E. Hiyama2, T. Iehara3, T. Hishiki1, K. Sugito1, Y. Hayashi1,
K. Maeda1, T. Yonekura1
1Committee on Tumor Registration of the Japanese Society of Pediatric Surgeons,
Pediatric Surgery, Tokyo, Japan; 2Hiroshima University, Pediatric Surgery, Hiroshima,
Japan; 3Kyoto Prefectural University, Pediatrics, Kyoto, Japan
Background/Objectives:Mass screening (MS) for neuroblastoma at 6 months of age in
Japan has been halted since 2004. In order to evaluate the effectiveness of MS, we
compared the clinical features of neuroblastoma before and after the cassation of MS.
Design/Methods: Six hundred and seventy patients with neuroblastoma who were born
and diagnosed between 2004 and 2013 were obtained from the neuroblastoma registry
data of the Japanese Society of Pediatric Surgeons (JSPS) (group A: post MS cohort).
Two thousand and thirty-six patients with neuroblastoma who were born and
diagnosed between 1988 and 1997 were obtained from the data of the Japanese MS
study group (group B: during MS cohort). Clinical features such as age at diagnosis,
stage andMYCN status were compared between the two groups.
Results: There was a significant decrease in the number of patients younger than one
year of age (295, group A; 1754, group B) and a significant increase in the number of
patients two to three years of age (164, group A; 88, group B) after the cessation of MS.
In the patients with stage IV disease (281, group A; 278, group B), there were a
significant decrease in the number of patients aged <18 months (91, group A; 159,
group B) and a significant increase in the number of patients aged 18 months or older
after the cessation of MS (187, group A; 122, group B). As a result, there was a
significant increase in the number of patients with stage IV high-risk disease after the
cessation of MS (219, group A; 153, group B).
Conclusion: The number of patients aged 2-3 years and patients with stage IV high-risk
disease significantly increased after the cessation of MS.
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FEASIBILITY/ TOXICITY AND RESPONSE OF UPFRONT 131I-MIBG
THERAPY FOLLOWED BY STANDARD ARM GPOH NB 2004 PROTOCOL IN
NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA PATIENTS
K. Kraal1,2, G. Bleeker2, B. van Eck-Smit3, M. van Noesel1,4, G. Tytgat1,2, H. Caron2
1Princess Máxima centre for Pediatric Oncology, Department of Pediatric Oncology,
Utrecht, Netherlands; 2Emma Children’s Hospital, Department of Pediatric Oncology,
Amsterdam, Netherlands; 3Academic Medical Centre AMC, Department of Nuclear
Medicine, Amsterdam, Netherlands; 4Erasmus MC EMC-Sophia Children’s Hospital,
Department of Pediatric Oncology/Hematology, Rotterdam, Netherlands
Background/Objectives:Meta-iodobenzylguanidine (MIBG) is effective in
neuroblastoma (NBL) patients, with response rates (RR) between 20- 60%. To evaluate
feasibility, toxicity, efficacy of upfront 131I-MIBG and induction treatment in high-risk
(HR) NBL patients.
Design/Methods: In a prospective, multi-centre (AMC and EMC) pilot study (1/1/2005-
2011), newly diagnosed HR NBL patients, were treated with 2 courses of 131I-MIBG (if
MIBG avid), standard arm of HR GPOH 2004 NBL protocol, myeloablative therapy
(MAT) and autologous stem cell rescue (ASCT). 131I-MIBG fixed dose; 1st 7.4 GBq
(200 mCi) and 2nd 5.5 GBq (150 mCi). The feasibility of giving 131I-MIBG within 2
weeks after diagnosis, dose intensity of chemotherapy, toxicity of platelets and
hematological recovery post MAT ASCT were tested. Response was according to
International Neuroblastoma Response Criteria.
Results: Of thirty-two included patients, (age median (range) 35 (0- 137) months),
twenty-one patients received the first 131I-MIBG course and 16 patients the second.
Eleven patients did not receive MIBG therapy because of; insufficient MIBG uptake,
poor clinical condition and hypertension. 131I-MIBG within 2 weeks from diagnosis was
feasible in 20/21 (95%) patients. Median cumulative 131I-MIBG dose/ kg was 0.77 GBq
(21,0 mCi). Interval between chemotherapy courses was longer in the 131I-MIBG group
(median 26 days) than in non 131I-MIBG group (median 23 days). The median nadir of
platelets was statistically significant lower at 4 time points in the 131I-MIBG group
(11-18 vs. 38-109). Stem cell harvest in both groups was feasible (median harvest CD34
> 2x 106/ kg), hematological recovery post MAT ASCT was slower for platelets (>20 ×
109/L) 25 vs. 14 days but not for neutrophils in the 131I-MIBG group. The RR post
131I-MIBG was 8/21 (38%), post MAT ASCT 15/21 (71%) and overall RR 20/32 (63%).
Conclusion: Combination therapy is feasible/ tolerable and effective in newly diagnosed
HR NBL patients.
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EXOME SEQUENCING OF ULTRA-HIGH RISK NEUROBLASTOMA
IDENTIFIES MUTATED GENES INVOLVED IN NEURON DEVELOPMENT
AND DIFFERENTIATION
V.A. Lasorsa1, P. Pignataro1, F.M. Calabrese1, M.R. Esposito2, L. Longo3, G.P. Tonini2,
A. Iolascon1, M. Capasso1
1University of Naples Federico II, Department of Molecular Medicine and Medical
Biotechnologies, Napoli, Italy; 2Pediatric Research Institute IRP – Fondazione Città della
Speranza, Neuroblastoma Laboratory, Padova, Italy; 3National Cancer Research
Institute, U.O. Biotherapy- IRCCS AOU San Martino-IST, Genova, Italy
Background/Objectives: Neuroblastoma often presents with widespread metastatic
disease, resulting in survival rates of less than 50%. The mutated genes associated with
highly aggressive tumors remain unknown.
Design/Methods: To determine the spectrum of somatic mutations in ultra-high-risk
neuroblastoma (high-risk patients with any adverse event within 36 months from
diagnosis), we performed whole-exome sequencing (110x coverage) by Illumina
sequencer on a discovery set of 19 tumor/blood DNA pairs from patients with
ultra-high-risk neuroblastoma. As validation set, we used whole-exome sequencing data
from 14 and 11 tumor/blood DNA pairs of ultra-high-risk and of non-ultra-high-risk
patients (with no adverse events after 36 months from diagnosis) sequenced by a
different platform (Ion Proton, 80x coverage). The putative deleterious mutations
(missense, frameshift, stop gain/loss) and cancer driver genes were selected by using
Cravat and CHASM programs.
Results:We identified 134 genes with deleterious mutations and 37 of these were
predicted to be cancer driver genes; only ALK was mutated in two different patients.
Five genes were annotated as known therapeutic targets (ALK, ERBB3, PTEN, PTK2,
FGFR1). We found numerous pathways and biological processes implicated in neuron
development and differentiation. In a separate validation set of 14 tumor/blood DNA
pairs of ultra-high-risk neuroblastomas, 64 out of 134 genes carried deleterious
mutations. Pathway analysis confirmed the enrichment of neuron development and
differentiation-related functions. Conversely, in a set of 11 non-ultra-high-risk patients,
60 out of 134 genes carried deleterious mutations and were highly enriched in canonical
carcinogenesis-related pathways such as receptor tyrosine kinase signaling, response to
oxidative stress and DNA repair. An ultra-deep targeted sequencing of the selected 134
genes on 50 additional tumor/blood DNA pairs from ultra-high-risk and
non-ultra-high-risk patients is currently on-going.
Conclusion: Our study identifies mutated genes and highlights the dysregulation of
neuron development and differentiation in a sub-set of patients with a highly aggressive
neuroblastoma.
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BENIGN COURSE OF DISEASE IN LOCALIZED NEUROBLASTOMA
SHOWING RELAPSE OR PROGRESSION
B. Hero1, T. Simon1, R. Volland1, A. Eggert2, M. Fischer1, F. Berthold1
1University of Cologne, Pediatric Oncology, Cologne, Germany; 2Charité Berlin,
Pediatric Oncology, Berlin, Germany
Background/Objectives: Recent strategies for localized Neuroblastoma aim to reduce
cytotoxic treatment. This may lead to an increase of progressions manageable with
limited treatment. On the other hand some patients may experience multiple
progressions with a fatal outcome. We were interested in the differences between these
groups.
Design/Methods: Patients with localized Neuroblastoma without MYCN-amplification
registered between 1995 and 2010 in the German Neuroblastoma trials were analysed.
Progressions and relapses were classified as locoregional, progression to stage 4S or to
stage 4. Locoregional events were further classified into those manageable with one line
of surgery or chemotherapy versus multiple episodes requiring more than one line of
therapy.
Results: Of 896 patients with localized neuroblastoma, 161 experienced relapse or
progression (124 locoregional, 16 to stage 4S, 21 to stage 4; 5-year-EFS 0.81±0.01;
5-year-OS 0.95±0.01). Five patients with locoregional progression died during or
shortly after the first event, 78 were managed with one line of relapse treatment (surgery
only in 28 patients), and 41 patients experienced more than one event (two events:
n=16, three events: n=9, >3: n=16). Thirteen patients developed distant metastases in
consecutive events. Compared to patients with multiple episodes of progression,
patients with only one episode were younger (8 vs. 59 months, p<0.001), showed less
freqently 1p aberrations (7% vs. 24%, p=0.02) and tended to present less often with
stage 3 tumors (44% vs. 63%, p=0.054).Overall survival was excellent for patients with
progression to stage 4S and with manageable locoregional events (one patients died
from secondary malignancy), but unsatisfactory for patients with multiple locoregional
events (5-year-OS: 0.59±0.08) or with progression to stage 4 (5-year-OS: 0.57±0.11).
Conclusion: In a substantial portion of patients, locoregional progressions or
progressions to stage 4S were manageable assuring an excellent prognosis. Due to such
“benign progressions”, event-free-survival estimates in localized neuroblastoma may be
misleading and have to be interpreted with caution.
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METRONOMIC THERAPY AS LOW TOXIC AND EFFECTIVE TREATMENT
FOR RECURRENCES OF HIGH RISK NEUROBLASTOMA
F. Berthold1, R. Volland2, I. Proleskovskaya3, P. Mazanek4, M. Belogurova5,
M. Hömberg2, T. Simon2, B. Hero2, J. Sterba6
1University of Cologne- Childrens’ Hospital, Pediatric Oncology and Hematology, Köln,
Germany; 2University of Cologne, Pediatric Oncology and Hematology, Köln, Germany;
3University of Minsk, Pediatric Oncology and Hematogy, Minsk, Belarus; 4University of
Brno, Pediatric Oncology and Hematogy, Brno, Czech Republic; 5University of St.
Petersburg, Pediatric Oncology and Hematology, St. Petersburg, Russia; 6University of
Brno, Pediatric Oncology and Hematology, Brno, Czech Republic
Background/Objectives:Many patients with recurrences from high risk neuroblastoma
have been treated with very limited success utilizing the “maximum tolerated dose
(MTD) concept”. It is known from breast and other cancers that low toxic continuous
use of cytostatic and other drugs may overcome resistances. This metronomic approach
is thought to target the microenvironment (immune cells, vasculature, stroma) and the
cancer cells. Here we report the first results with pilot patients of a new metronomic
concept.
Design/Methods: 20 patients with recurrences from high risk neuroblastoma (HR-NB)
were treated with metronomic concept (celecoxib 2×200 mg/m2xd oral cont.,
cyclophosphamide 25 mg/m2xd oral cont., vinblastine 3 mg/m2xd every 2 weeks,
etoposide 25 mg/m2xd oral d1-21 every 2nd month x4) up to 24 months. The secondary
progression free and overall survival was compared to 307 patients with recurrent stage
4 neuroblastoma >18 months at diagnosis treated according to the MTD concept
(palliative excluded) and weighted by time from diagnosis to recurrence (18 months)
and number of sites of recurrences (1 vs.>1).
Results: One of the patients had 1 and 19 had 2-4 recurrences before start of
metronomic therapy. 5 patients had one site, 11 two, and 1 three sites of recurrence
(primary tumor 12, osteomedullary 12, CNS 3, liver 1, lymph nodes 1). Three patients
were in CR after pretreatment of the relapse and therefore not included in the survival
analyses. The 1 year EFS of the metronomically treated patients was 64±12% compared
to 37±3% of the control group (logrank p=0.271) and the 1 year OS was 79±11% for
the metronomic and 59±3% for the control patients (logrank p=0.052). The reported
toxicity was minimal except grade 2-3 thrombocytopenia/ leukopenia/anemia (all
heavily pretreated) and treatment was realized in an outpatient setting.
Conclusion: The metronomic approach is promising concept regarding outcome in HR
neuroblastoma and has minimal toxicity. A prospective study is underway.
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DEVELOPMENT OF A SCORING SYSTEM BASED ON A PROGNOSTIC
INDEX FOR RISK ASSESSMENT OF PATIENTS WITH NEUROBLASTOMA
C. Rosswog1, R. Schmidt2, A. Oberthuer1, D. Juraeva3, B. Brors3, F. Westermann4,
F. Berthold1, T. Simon1, B. Hero1, A. Faldum2, M. Fischer1,5
1University of Cologne, Department of Pediatric Oncology and Hematology, Cologne,
Germany; 2University of Muenster, Institute of Biostatistics and Clinical Research,
Muenster, Germany; 3German Cancer Research Center, Department of Theoretical
Bioinformatics, Heidelberg, Germany; 4German Cancer Research Center, Department of
Tumor Genetics, Heidelberg, Germany; 5University of Cologne, Center for Molecular
Medicine Cologne CMMC, Cologne, Germany
Background/Objectives: Accurate risk stratification for patients with neuroblastoma still
remains a challenge. While current algorithms consider a variety of clinical,
histopathological and genetic markers for treatment allocation, the ideal strategy to
combine these markers has remained elusive. We here aimed to develop a risk
assessment system that is built on a computational model taking hazard ratios of
individual prognostic markers into account.
Design/Methods: To develop a prognostic model for predicting event free survival
(EFS), a large cohort of patients with neuroblastoma was divided into a training set for
model building (n=411) and a validation set (n=209). Potential prognostic factors
comprised stage, age,MYCN status, 1p status and four different gene expression-based
classifiers that had been generated previously on an independent cohort. To build a
reliable prognostic index (PI), variables were selected by the LASSO method (Least
Absolute Shrinkage and Selection Operator), followed by backward selection using
multivariable Cox regression. A risk score with three groups (low-, intermediate- and
high-risk) was built based on an optimal stratification of the PI.
Results: Variable selection by LASSO identified stage,MYCN status, age and two gene
expression-based classifiers as the most accurate variables for prediction of EFS. These
variables were considered for further selection by multivariable analysis to finally build
a new scoring system based on hazard ratios of the best performing markers. The final
risk score was determined by two different gene expression-based classifiers (SVM_th24
and SVM_th44) only, showing highly accurate outcome prediction of patients of the
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training cohort (5-year EFS, low-risk 83.2±2.6, intermediate-risk, 64.8±9.0, high-risk
32.0±4.0; p<0.001).
Conclusion: Results from the training set indicate that our approach provides an
innovative scoring system that is highly accurate in predicting outcome of patients with
neuroblastoma, and that gene expression-based classifiers are key determinants of the
disease course. Validation of these findings in the independent validation cohort is
pending.
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HAILEY FISH - A ZEBRAFISHMODEL OFMALIGNANT RHABDOID TUMOR
S. Sredni1, E. Rabinovich1, A. Halpern1, K. Patel1, S. Evans2, U. Shafi1, R. Anderson2,
T. Tomita1, J. Topczewski2
1Ann and Robert H. Lurie Children’s Hospital of Chicago, Pediatric Neurosurgery,
Chicago, USA; 2Stanley Manne Children’s Research Institute, Developmental Biology,
Chicago, USA
Background/Objectives:Malignant Rhabdoid Tumor (MRT) is one of the most
aggressive and lethal pediatric malignancies. While kidney and brain are the most
frequent primary sites of origin, MRT can develop at any anatomical location. Biallelic
inactivation of the tumor suppressor gene SMARCB1 (also known as
INI1/BAF47/SNF5), is well recognized as the primary recurrent genetic event involved
in the development of MRT. SMARCB1 encodes a subunit of the SWI/SNF
ATP-dependent chromatin-remodeling complex, The zebrafish (Danio rerio) is an
important vertebrate organism used in biomedical research. In recent years, zebrafish
has emerged as an attractive animal model in the study of cancer biology. In contrast to
other vertebrates (including humans) bony fish (teleost) have two paralogues of smarcb1
gene: smarcb1a and smarcb1b. The Smarcb1 proteins are highly conserved; suggesting
shared cellular functions in fish and mammals. Because MRT is rare, a zebrafish model
would be significant to explore questions regarding tumor biology and in developing
new therapeutic strategies.
Design/Methods: Using TALEN and CRISPR mediated genome editing we have
successfully mutagenized smarcb1a and smarcb1b genes.
Results:We have observed tumor development in smarcb1b mutagenized fish.
Histological analyses revealed that zebrafish develop tumors that are morphologically
similar to their human counterparts. We are expanding this study by targeting smarcb1a
gene to compare tumors developed by individual and compound heterozygotes. We
expect that double heterozygotes will develop tumors more easily and in the broader
range of tissue than each individual heterozygote.
Conclusion: By comparing the expression profile of fish tumors and human MRT we
hope to illuminate novel pathways involved in disease pathogenesis. In addition, our
zebrafish model of MRT will be used to determine the cell of origin of this tumor and
will serve as an in vivo drug-screening tool.
Acknowledgements: Rally Foundation for Childhood Cancer Research in Memory of
Hailey Trainer.
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TGF-BETA SIGNALING IS INVOLVED IN THE DETRIMENTAL EFFECTS OF
SMARCB1 DEFICIENCY IN ATYPICAL TERATOID/RHABDOID TUMORS
A. Jeibmann1, J. Schulz1, K. Thiel1, I. Tegeder1, P. Johann2, M. Kool2, W. Paulus1,
M.C. Frühwald3, M. Hasselblatt1
1University Hospital Münster, Institute of Neuropathology, Münster, Germany; 2German
Cancer Research Center DKFZ, Division of Pediatric Neurooncology, Heidelberg,
Germany; 3Childrens’ Hospital Augsburg and EU-RHAB Registry working group,
Swabian Childrens’ Cancer Center, Augsburg, Germany
Background/Objectives: In the majority of atypical teratoid/rhabdoid tumors (AT/RT)
inactivation of chromatin remodeling complex member SMARCB1 is the sole recurrent
genetic event. Little is known, however, on downstream pathways which might
represent targets for treatment.
Design/Methods: Using Drosophila melanogaster and the Gal4-UAS system, modifier
screens were performed in order to identify pathways involved in the lethal phenotype
associated with knockdown of snr1, the fly homolog of SMARCB1. The role of human
homologs of identified genes was next investigated in human rhabdoid tumor cell lines
as well as AT/RT tumor samples from the European Rhabdoid Tumor Registry
EURHAB.
Results: The lethal phenotype associated with snr1 knockdown in Drosophila
melanogaster could be shifted to later stages of development upon additional
knockdown of babo, the fly homolog of TGFbeta receptor type I. Similarly,
pharmacological inhibition of TGFbeta receptor type I using SB431542 reversed the
detrimental effect of snr1 knockdown in the fly model. TGFbeta signaling is transduced
to the nucleus by SMAD proteins. In human AT/RT samples, SMAD family members
were found to be highly expressed. In SMARCB1-deficient AT/RT cells, silencing of
SMAD3 and SMAD6 expression reduced TGFbeta signaling activity (luciferase assay)
and resulted in decreased proliferation (MTT and BrdU assay).
Conclusion: TGFbeta signaling is involved in the detrimental effects of
SMARCB1-deficiency. Our results demonstrate that fly models can be employed for the
identification of clinically relevant pathways in human cancer and provide a rationale
for the investigation of TGFbeta directed treatments in AT/RT. Supported by Deutsche
Krebshilfe (DKH110266) and IZKFMünster (Ha3/019/15).
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BRENTUXIMAB VEDOTIN PRESENTS PROFOUND ANTI-TUMOR
EFFICACY IN CD30+ AND CO-CULTURED CD30- GERM TUMOR CELLS
B. Götz1, C. van Beekum1, D. Nettersheim2, H. Schorle2, G. Calaminus3, I. Leuschner4,
U. Göbel5, D.T. Schneider6, D. Dilloo1, S. Schönberger1
1University Children’s Hospital Bonn, Department of Pediatric Hematology and
Oncology, Bonn, Germany; 2University of Bonn Medical School- Institute of Pathology,
Department of Developmental Pathology, Bonn, Germany; 3University of Münster,
Department of Pediatric Hematology and Oncology, Münster, Germany; 4University of
Kiel, Institute of Pathology, Kiel, Germany; 5University of Düsseldorf, Department of
Pediatric Oncology- Hematology and Clinical Immunology, Düsseldorf, Germany;
6Municipal Hospital Dortmund, Clinic of Pediatrics, Dortmund, Germany
Background/Objectives: Brentuximab vedotin (BV) consists of the potent antimitotic
drug monomethylauristatin E (MMAE) attached to an anti-CD30 monoclonal
antibody and thereby rendered inactive. After CD30-binding, internalization and
linker-cleavage cytotoxic MMAE is intracellularly released and diffuses in the tumor
microenvironment. While demonstrating significant activity in lymphoma, the efficacy
of BV is yet unexplored in other CD30+ cancers such as germ cell tumors (GCT).
Thus, in children with CD30+GCT who are at particular risk for treatment-related
sequelae, BV may be a therapeutic option.
Design/Methods: CD30 was analyzed in 12 human GCT cell lines by quantitative
RT-PCR and immunohistochemistry. Cytotoxicity of BV and free MMAE was
measured by cytometry-based Hoechst assay differentially measuring viable
CD30+GCT27 and CD30-JAR cells over time.
Results: CD30 is expressed in 7/12 GCT cell lines and is predominately detectable in
embryonal carcinoma (EC) compartments. Treatment of CD30+GCT27 led to a time-
and BV dose-dependent reduction of cell viability down to 68.6±6.9%(48h),
14.2±1.0%(72h) and 3.1±0.1%(96h) compared to daily controls at 250 ng/ml BV. In
contrast, CD30-JAR cells unable to internalize BV only respond to free MMAE with
residual cell viability of 86.2±18.1%, 19.2±2.5% and 7.0±2.2%, respectively. Of note, in
co-culture not only CD30+GCT27 but also CD30-JAR cells exhibit a profound
cytotoxic response to BV in a time and dose-dependent manner. After 96h of treatment
with 250 ng/ml, 500 ng/ml and 1000 ng/ml BV 80.9±6.7%, 42.8±4.7% and 16.5±2.9%
of CD30+GCT27 cells were still alive while viability of CD30-JAR cells was reduced to
56.1±22.5%, 34.5±18.1% and 18.8±11.7%, respectively. This indicates that MMAE
released from CD30+GCT27 cells not only destroys the targeted cell population but
also co-cultured CD30-JAR in a bystander fashion with comparable potency.
Conclusion: Based on these in vitro findings, Brentuximab vedotin may constitute a
novel treatment approach warranting future clinical evaluation in children with
malignant GCTs not only of pure but also mixed CD30+/CD30-histology.
O-130
MYC ANDMITOCHONDRIAL METABOLISM IN CHILDHOOD
NEUROBLASTOMA
M. Arsenian Henriksson1, G. Oliynyk1, H. Zirath1, H. Johansson2, J. Lehtiö2
1Karolinska Institutet, MTC, Stockholm, Sweden; 2Karolinska Institutet, Onc/Path.,
Stockholm, Sweden
Background/Objectives: Neuroblastoma, which arises from the sympathetic nervous
system is one of the most aggressive solid tumors of early childhood. Amplification of
theMYCN oncogene has been found in around 30% of neuroblastoma patients and it
is associated with rapid tumor progression and poor prognosis. New treatment options
are urgently needed for this group of patients. As metabolic adaptations are crucial for
cancer cell survival during tumor progression, identifying metabolic discrepancies of
aggressive tumors may be central in order to find new treatment strategies.
Design/Methods:We have treated neuroblastoma cells with a small c-MYC inhibitor,
10058F4, or with shMYCN-RNA and analyzed apoptosis, cell cycle progression, and
differentiation. We have also performed proteomic analyses and used the results from
these data for further functional studies including Seahorse experiments using a set of
metabolic inhibitors.
Results: Our findings suggest that a small chemical molecule, 10058-F4, previously
identified as a c-MYC inhibitor also targets the MYCN/MAX complex resulting in
apoptosis and neuronal differentiation inMYCN-amplified neuroblastoma cells.
Importantly, we found that inhibition of MYCN results in changes in neuroblastoma
cell metabolism including mitochondrial dysfunction leading to accumulation of
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intracellular lipid droplets. Using functional assays we found that MYCN contributes
to metabolic plasticity in neuroblastoma cells.
Conclusion: Taken together, our results highlight that MYCN regulates important
metabolic pathways inMYCN-amplified neuroblastoma, which may be the basis for
development future therapies for this patient group.
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SYNERGISTIC ANTITUMOR ACTIVITY OF TOPOTECAN AND
EVOFOSFAMIDE (TH-302) MEDIATED BY OXIDATIVE STRESS IN
PEDIATRIC SOLID TUMORS
L. Zhang1
1The Hospital for Sick Children, Toronto, Canada
Background/Objectives: Previous studies have shown that topoisomerase I inhibitor,
topotecan, induces oxidative stress in breast cancer cells. Topotecan treatment may
yield increased hypoxia in tumors, and potentiate antitumor effects of evofosfamide
(TH-302), a hypoxia-activated prodrug of bromo-isophosphoramide mustard. In this
study, we assessed the oxidative stress in pediatric tumor cells after topotecan
treatment. We also investigated the antitumor efficacy of combined topotecan and
evofosfamide treatment in preclinical tumor models.
Design/Methods: A panel of twelve neuroblastoma (NBL), rhabdomyosarcoma (RMS),
osteosarcoma and Ewing’s sarcoma cell lines were cultured and exposed to topotecan,
both as a single agent and in combination with evofosfamide, for 72 hours. Cell viability
was measured using AlamarBlue assay. Tumor cell oxidative stress was determined by
the 2, 7’-dichlorofluorescein diacetate (DCFDA) assay under topotecan treatment
with/without the presence of evofosfamide. In vivo antitumor activity was evaluated in
NOD/SCID mouse models. Cleaved caspase-3 was used as the apoptotic marker in vivo.
Results: All tested tumor lines showed anti-proliferative responses to topotecan with the
IC50s ranging from 3.6nM to 3.7μM. Adding topotecan to the evofosfamide treatment
significantly increased cytotoxicity in all tumor cells (p<0.05). Our data indicated
increased oxidative status, as revealed by increased reactive oxygen species measured by
DCFA assay in tumor cells exposed to topotecan when compared with control cells
(p<0.01). In NBL and RMS xenograft models, adding topotecan more significantly
inhibited tumor growth comparing to single-agent evofosfamide or topotecan
treatment (p<0.01). Complete tumor regression was observed in CHLA-20,
SK-N-BE(2) and RH4 xenograft models with combined treatment. In the SK-N-BE(2)
metastatic model, combined treatment group also showed improved animal survival
than single-agent treatments (p<0.01). Increased tumor apoptosis was confirmed by
cleaved caspase-3 immunostaining with combined treatment.
Conclusion: Topotecan increases oxidative stress in pediatric solid tumor cells.
Synergistic therapeutic efficacy can be achieved when combining topotecan with
hypoxia-activated prodrug evofosfamide.
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BIOMARKER IDENTIFICATION IN CEREBROSPINAL FLUID PROTEOME
FROM CENTRAL NERVOUS SYSTEM (CNS) PEDIATRIC TUMOURS
F. Spreafico1, I. Bongarzone2, S. Pizzamiglio3, R. Magni4, E. Taverna2, M. De Bertoli2,
C.M. Ciniselli3, E. Barzanò1, V. Biassoni1, A. Luchini4, L. Liotta4, P. Verderio3,
M. Massimino1
1Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology and Pediatric
Onco-Hematology, Milano, Italy; 2Fondazione IRCCS Istituto Nazionale dei Tumori,
Laboratory of Proteomics, Milano, Italy; 3Fondazione IRCCS Istituto Nazionale dei
Tumori, Biometry and Bioinformatics, Milano, Italy; 4George Mason University,
Proteomics, Manassas, USA
Background/Objectives: Sensitivity of combined cerebrospinal fluid (CSF) cytology and
neuroimaging studies to diagnose leptomeningeal dissemination in CNS tumours
–which is a key information to drive treatment- is relatively low. Changes in CSF
proteome have been shown to reflect CNS pathological processes. We seek to
characterize the CSF proteome of pediatric CNS tumours, to identify CSF biomarkers
predictive of tumour proclivity to leptomeningeal spread, of patient recurrence, other
than to assist diagnosis.
Design/Methods: CSF samples collected by lumbar puncture (18 medulloblastoma, 1
high-grade glioma, 5 ependimoma, 2 PNET, 1 atypical teratoid rhabdoid tumor), either
at initial diagnosis (n=27) or at tumour recurrence (n=3), and 13 controls (extra-CNS
non Hodgkin lymphoma) were processed with core-shell hydrogel nanoparticles and
then analyzed with reverse-phase liquid chromatography/electrospray tandem mass
spectrometry (MS/MS). Several physiological, technical and statistical challenges were
considered and faced.
Results: Among the 559 non redundant proteins identified by MS/MS analysis, 147 were
not present in the CSF database (http://www.biosino.org) and 91 were expressed or not
in all the 40 subject (not discriminant proteins). The univariate selection procedure
identified 47 significant proteins in at least one of the performed comparisons (cases
versus controls, metastatic or not metastatic cases versus controls, respectively).
Twenty-six 26 proteins out of 47 were afterwards selected because of their biological
relevance. Fourteen of them were subjected to quantitative expression analysis on an
independent validation cohort (60 cases, 14 controls), using western blotting, reverse
phase protein arrays (RPPA) and Enzyme-Linked Immunosorbent Assay (ELISA).
Conclusion:Measuring biomarker performance in CNS pediatric tumours
demonstrated to be a difficult task. Combining a unique dataset of CSFs from pediatric
CNS tumours with a novel enabling nanotechnology allowed us to identify promising
CSF proteins, possibly linked to CNS tumors.
Aknowledgments: Italian Ministry of Health; Associazione Bianca Garavaglia onlus
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CRANIO-FACIAL SECOND PRIMARY TUMORS IN HEREDITARY
RETINOBLASTOMA PATIENTS PREVIOUSLY TREATEDWITH EXTERNAL
BEAM RADIOTHERAPY
I. Jiménez1, M. Laé2, A. Savignoni3, L. Dejardins4, F. Doz1, H. Brisse5, I. Aerts1
1Institut Curie, Pediatric Oncology, Paris, France; 2Institut Curie, Pathology, Paris,
France; 3Institut Curie, Biostatistics, Paris, France; 4Institut Curie, Ophtalmology, Paris,
France; 5Institut Curie, Imaging, Paris, France
Background/Objectives: About half of children diagnosed with retinoblastoma (Rb) are
carriers of a constitutional alteration of the Rb1 gene. The prognosis of Rb is excellent,
but carriers of this mutation have higher risk than general population to develop
further malignancies, particularly in irradiation field if they have been previously
treated by external beam radiotherapy (EBRT). These cranio-facial second primary
tumors (SPTs) in irradiation field have a very poor prognosis.
Design/Methods: This retrospective monocentric study includes 219 patients diagnosed
with hereditary Rb and treated by EBRT between 1968 and 2011 in the Institut Curie.
Clinical, therapeutical, radiological and histological data were recorded. Radiological
and histological centralized reviews were performed. Cranio-facial SPTs rate was
estimated using the Kaplan-Meier method.
Results:Median follow-up was 241 months [5.3 - 461.2]. During the follow-up, 52
patients developed a cranio-facial SPT and a third tumor was diagnosed in 4 patients.
Among the 52 SPTs, 46 were malignant (88%) and 6 benign (12%). Histologically, the
most frequent subtypes were undifferentiated sarcomas in 22 patients (42%) and
osteosarcomas in 17 patients (33%). Predilection sites were: facial bones (38%), orbit
(33%) and ethmoid sinus (12%). At 10, 15 and 20 years after EBRT, the SPT rate was
equal to 6.7% CI95% [3.3% – 10.0%], 12% CI95% [7.5% – 16.5%] and 24% CI95% [17.5% –
30.0%] respectively. At 1, 2 and 5 years after STP diagnosis the overall survival was
estimated to 81.6% CI95% [71.5% - 93.2%], 75.0% CI95% [63.5% - 88.3%] and 52.3%
CI95% [39.1% - 69.8%], respectively.
Conclusion: Undifferentiated sarcomas and osteosarcomas are the most common
cranio-facial SPTs in irradiated hereditary Rb, which develop in specific locations. Their
poor prognosis explains why current protocols avoid using EBRT –actually its
indication has become exceptional– and justifies the efforts in early detection to try to
improve their outcome.
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CONSERVATIVE TREATMENT OF INTRAOCULAR BILATERAL
RETINOBLASTOMA: A PROSPECTIVE PHASE II TRIAL FORMACULAR OR
PARAMACULAR INVOLVEMENT ON BOTH EYES OR ON THE ONLY SAVED
EYE
I. Russo1, C. Levy2, A. Dupont3, F. Doz4, A. Savignoni3, I. Aerts4
1CURIE, Paris, Italy; 2CURIE, Ophthalmology, Paris, France; 3CURIE, Statistics,
Paris, France; 4CURIE, Pediatric Oncology, Paris, France
Background/Objectives: Chemotherapy associated with focal treatments for intraocular
retinoblastoma, has allowed to achieve a higher rate of eye preservation without the use
of external beam radiotherapy (ebrt). In order to decrease the possible long term
sequels of laser scars for macular-paramacular tumors, a protocol of laser reduction
was initiated.
Design/Methods: Children affected by intraocular bilateral macular-paramacular
retinoblastoma (defined by a distance to macula of 3mm of less), on both eyes or on
the only saved eye, were included in a prospective, nonrandomized, phase ii trial,
conducted at the Institute Curie. The protocol combined 6 cycles of 3 drugs
(vincristine, carboplatin and etoposide), with thermotherapy macula-sparing associated
from the third cycle.
Results: Nineteen patients (26 eyes) were included from July 2004 to November 2009.
Median age at diagnosis was 6 months. According to Reese-Ellsworth classification, 13
eyes were group I-IV and 13 group V (Vb for 5 eyes). According to international
retinoblastoma classification, 16 eyes were group b-c and 10 group d.
Macular-paramacular tumours were treated with chemotherapy alone in 9 eyes,
chemotherapy associated to thermotherapy macula-sparing from the third cycle in 17
eyes. Four eyes experienced macular relapse during the first year from the end of
treatment. At a median follow-up of 77 months, 23 eyes (88.5%) were salvaged without
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EBRT or enucleation (2 eyes needed enucleation and 1 EBRT). The median visual
acuity (VA) of the 24 eyes preserved was 20/50 at a median age of 7.2 years. Nine eyes
presented VA  20/40, 9 between 20/40 and 20/200, and 6 eyes had VA < 20/200. No
severe treatment side effect was observed.
Conclusion: Six cycles of 3 drugs chemotherapy associated with macula-sparing
thermotherapy achieves good local control, improving the rate of eye preservation
without EBRT, and moreover, decreases macular damage allowing to often obtain
satisfactory visual results.
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FEMALE SEX, BILATERAL DISEASE, AGE BELOW 3 YEARS AND
APPREHENSION FOR ENUCLEATION CONTRIBUTE TO A HIGH RATE OF
TREATMENT ABANDONMENT IN PATIENTS WITH RETINOBLASTOMA
A. Bhargav1, D. Bansal1, U. Singh2, A. Trehan1, Z. Zadeng2
1Advanced Pediatrics Centre- Postgraduate Institute of Medical Education and Research,
Pediatrics. Hematology-Oncology unit, Chandigarh, India; 2Advanced Eye Centre-
Postgraduate Institute of Medical Education and Research, Ophthalmology, Chandigarh,
India
Background/Objectives: Aim was to study the rate and cause of treatment abandonment
in patients with retinoblastoma, a major obstacle to treating retinoblastoma in
developing countries.
Design/Methods: The study was retrospective and conducted in a referral center in
North India. Non-compliance was defined as adherence to <3 cycles of chemotherapy
and/or defiance of recommended local treatment. Two cohorts of patients were studied.
One was a larger cohort (n=602) of all patients diagnosed with retinoblastoma in the
institution from 2000 to 2014. Limited variables (Age, sex, laterality) were examined in
the larger cohort, as it was unfeasible to explore all factors influencing compliance due
to incomplete data or lost contact. Detailed interview was performed with care-givers in
a smaller cohort of 104 patients (compliant: 60; non-compliant: 44), with whom
contact was possible.
Results: One-hundred and seventy (28%) patients were non-compliant. Patients below
3-years were more likely to be non-compliant (32.5%) compared to older patients
(22.8%) (p=0.01). Compliance was greater among males (64%) than females (36%)
(p=0.017). Patients with unilateral disease were more compliant (72%) compared to
those with bilateral disease (28%) (p=0.009). Apprehension for enucleation was
expressed more frequently in the non-compliant (64%) than the compliant group (8%)
(p=0.0001). A larger proportion (61.4% vs. 13.3%) of non-compliant patients stated
difficulty in attending outpatient services of different departments for multimodality
treatment (p=0.003). The mortality in compliant versus non-compliant patients was 7%
and 68%, respectively (p=0.0001). Variables that did not influence compliance included,
symptom-to-diagnosis interval (p=0.59), residence-to-hospital distance (p=0.49), rural
background (p=0.35), financial limitation (p=0.23), socio-economic status (p=0.7),
number of siblings (p=0.41) or extra-ocular disease (p=0.32).
Conclusion: The rate of treatment abandonment in 602 patients over a 15-year period
was a sizable 28%. The factors that contributed to non-compliance included, female
sex, bilateral disease, age <3-years, apprehension for enucleation and difficulty in
attending outpatient services of different departments.
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PARENTS’ PERSPECTIVE OF QUALITY OF LIFE IN RETINOBLASTOMA
SURVIVORS: A CROSS-SECTIONAL STUDY OF 122 PATIENTS
S. Bakhshi1, A. Batra2, M. Kumari2, R. Paul2, M. Patekar2, D. Dhawan2
1Dr. BRA IRCH- AIIMS, Medical Oncology, Delhi, India; 2Dr. BRA IRCH- AIIMS,
Medical Oncology, New Delhi, India
Background/Objectives: Retinoblastoma (Rb) is the most common intraocular tumor in
childhood. With current modalities, the cure rates are high and hence the number of
survivors is increasing. However, the data on quality of life (QOL) in this population
are minimal.
Design/Methods:We analyzed the QOL in 122 retinoblastoma survivors using the
parent-proxy report of PedsQLTM 4.0 generic core scale in local language, which has
been validated in Indian population. The questionnaire was filled by parents of children
of more than 5 years of age who had completed treatment for more than 12 months.
The questionnaire consists of 23 questions on physical, social, emotional and school
domains on a scale from 0 to 4. This was converted to a scale from 0 to 100, where
higher values represented better QOL. This was compared with parent-reported QOL
of 50 siblings. Factors predicting the QOL were assessed.
Results: The median age of Rb survivors was 98 (range, 60-247) months and 68% were
males. Seventy-nine percent were International Retinoblastoma Staging System stage 1
and 25% had bilateral disease. Fourteen percent had extraocular involvement and 22%
had received radiotherapy. The overall parent-reported QOL was significantly worse in
Rb survivors as compared to controls (74.4 ± 8.5vs85.1 ± 4.6, p< 0.001). All the 4
health domains (physical, emotional, school and social) were found to be significantly
affected when compared with controls. None of the baseline and treatment related
factors predicted worse QOL in the survivor group.
Conclusion: QOL is often a neglected aspect in survivors of pediatric solid tumors. We
found a significantly worse parent-reported QOL in Rb survivors, including the
physical and psychosocial aspects. However, no predicting factors for worse QOL were
found in this group. Although a high survival rate has been achieved in early stage Rb,
efforts need to be made to improve QOL.
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LONG TERM NON-VISUAL OUTCOMES IN SURVIVORS OF
RETINOBLASTOMA
A. Batra1, A. Thakar2, M. Patekar1, S. Bakhshi1
1All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; 2All India
Institute of Medical Sciences, Otolaryngology, New Delhi, India
Background/Objectives:With multi-modality approach, the outcomes of patients with
retinoblastoma have improved. With increasing number of survivors, the long-term
aspects need to be addressed. Sensory-neural hearing loss has been reported in 0-79%
of retinoblastoma survivors, attributed to carboplatin. However, data on short-stature
in retinoblastoma survivors are limited.
Design/Methods:We conducted a cross-sectional study to assess height and hearing loss
in retinoblastoma survivors, who had completed therapy for more than 1 year and were
more than 5 years of age. Clinical and treatment related data were obtained from the
database.The recorded height was compared with median height for age and sex as per
the WHO growth standards. Z-scores were calculated for all patients and a patient with
z-score of less than -2 was considered short-statured. Baseline clinical and treatment
related factors were analyzed for any association with short-stature. Hearing loss was
assessed by pure tone audiometry upto 8,000 Hz.
Results: One-hundred thirty-eight patients with a median follow-up was 5 years were
assessed.One-third (46/138) of retinoblastoma survivors were short-statured. The mean
height of this group was significantly shorter than the mean 50th percentile height for
same age and sex (119.7 ± 14.8 cm vs 129.9 ± 15.5 cm, p<0.001). Previous
chemotherapy was found to be associated with short stature (36% vs 11%, p=0.04),
whereas no association was observed with radiotherapy (32% vs 38%, p=0.57). Pure
tone audiometry was performed in 116 survivors. One of 116 survivors (<1%) was
found to have sensory-neural hearing loss at high frequency (6,000- 8,000 Hz). The
cumulative dose of carboplatin received by this patient was 3360 mg/m2.
Conclusion: Short stature affects a significant number of retinoblastoma survivors and
is significantly associated with previous chemotherapy. Sensory-neural hearing loss is
uncommon, affecting less than 1% of survivors. We therefore recommend assessment of
stature and appropriate endocrinology referral at follow-up visits of retinoblastoma
survivors.
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DOMITOCHONDRIAL D-LOOPMUTATIONS PLAY A ROLE IN HUMAN
RETINOBLASTOMA?
L. Singh1, N. Pushker2, S. Bakhshi3, N. Saini4, S. Sen1, A. Sharma5, S. Kashyap1
1All India Institute of Medical Sciences, Ocular Pathology, Delhi, India; 2All India
Institute of Medical Sciences, Ophthalmology, Delhi, India; 3All India Institute of
Medical Sciences, Medical Oncology, Delhi, India; 4Institute of Genomics and Integrative
Biology IGIB, Functional Genomic Biology, Delhi, India; 5All India Institute of Medical
Sciences, Ocular Microbiology, Delhi, India
Background/Objectives: Preserving vision remains a challenge for ophthalmologists
treating children with retinoblastoma. Alteration in mitochondrial DNA plays an
important role in the development and progression of cancer. The Displacement Loop
(D-loop) region of mitochondrial DNA is the regulatory region for its replication and
transcription. It is considered to be a mutational ‘‘hot spot’’ in human cancers. It is the
most polymorphic region of human mtDNA genome. Mutation rate is much faster in
mitochondrial genome than nuclear genome. We aimed to characterize somatic
variations/mutations in the D-loop region of mitochondrial DNA and their impact on
survival in retinoblastoma patients.
Design/Methods: The entire D-loop region of mtDNA was amplified in polymerase
chain reaction and variations were evaluated in 60 retinoblastoma patients by direct
DNA sequencing and their results were analyzed by Mitomap database. Somatic
mutations were correlated with clinical, histopathological parameters and patient
survival. Kaplan-Meier method was used to draw the survival curves.
Results: In 60 retinoblastoma patients, 516 variations in 441 positions were found when
compared to Mitomap database. All variations were single nucleotide substitutions.
Majority of these somatic mutations of mtDNA were homoplasmic as compared to
heteroplasmic. The most common variations were T to C and C to T followed by A to
G. 368/441 (83.44%) variations was found in hypervariable regions of mitochondria.
There were 5.81% novel variations observed on comparison with the MITOMAP
database. The most common instabilities observed at the first polymorphic C track.
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A73G (83.33%) were the most frequent variations in which A263G was statistically
significant with overall survival of patients.
Conclusion: This is the first study to show a high frequency of mtDNA variations in
retinoblastoma. Our results strongly indicate that pathogenic mtDNA mutations may
be a potential prognostic marker for retinoblastoma. Furthermore, dysfunctional
mitochondria may play an active role in cancer development and the patient’s response
to radiotherapy/chemo-radiotherapy.
IPSO - Session 1: Sarcoma
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UROLOGICAL OUTCOME AFTER HIGH DOSE RATE BRACHYTHERAPY
FOR BLADDER-PROSTATE RHABDOMYOSARCOMA IN CHILDREN
J. Stenman1, M. Jalnäs1, P.J. Svensson1, N. Pal2, G. Wickart-Johansson3, C. Mercke3
1Karolinska University Hospital, Department of Paediatric Surgery, Stockholm, Sweden;
2Karolinska University Hospital, Department of Paediatric Oncology, Stockholm,
Sweden; 3Karolinska University Hospital, Radiumhemmet, Stockholm, Sweden
Background/Objectives: To evaluate urological outcome after high dose rate
brachytherapy (HDR-BT), as part of multi-modality treatment for Bladder-Prostate
Rhabdomyosarcoma in children.
Design/Methods: Five children, 1 girl and 4 boys, aged 0-8 years, received primary
treatment for Bladder-Prostate Rhabdomyosarcoma (BP-RMS) with multimodality
treatment including HDR-BT at the Karolinska University Hospital between 2004 and
2014. The tumor size was 1.5-5.5 cm and none of the patients had neither local invasion
outside of the bladder and prostate nor metastases at diagnosis. All patients were
pre-treated according to CWS protocols. Surgery was limited to placement of
BT-catheters in 3 out of 5 patients. HDR-BT was given twice daily during the first five
post-operative days (HDRMicro-Selectron, Nucletron, The Netherlands) to a total
dose of 24-42 Gy. Additional external beam radiation was given in 3 cases and the
combined total radiation dose was 39-58 Gy.
Results: After follow-up of 12-132 months, all 5 patients are alive with no evidence of
disease. One patient has undergone total cystoprostatectomy due to incomplete
response to primary treatment. Follow-up with ultrasonography has shown no upper
tract dilatation or residual urine in 4 patients and mild non-progressive upper tract
dilatation in one patient after cystoprostatectomy with temporary
ureter-cutaneostomies. Plasma creatinine levels (range 31-59) and Cystatine-C based
GFR estimates (>90) are normal for age in all patients. Urine flow measurements have
shown bell shaped curves and maximal flow rates in the normal range (13.8-19.3 ml/s)
in 4/4 patients treated without radical surgery. 3 out of 4 boys report normal erections.
Conclusion:We report the medium-term urological outcome after HDR-BT for
BP-RMS in children. The occurrence of urological squelae in this cohort of patients is
surprisingly low. Avoidance of surgery to the bladder neck and trigonum might
contribute to this finding.
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PREDICTORS FOR OUTCOME AND IMPACT OF LYMPH NODE SURGERY IN
LOCALIZED EMBRYONAL PARATESTICULAR RHABDOMYOSARCOMA – A
REPORT FROM THE CWS-86, -91, -96, AND -2002P TRIALS
G. Seitz1, J. Fuchs2, K. Thomas3, L. Ivo4, S. Andreas5, D. Tobias6, K. Ewa6
1University Children’s Hospital, Department of Pediatric Surgery and Urology, Tübingen,
Germany; 2University Children’s Hospital, Department of Pediatric Surgery and Urology,
Tuebingen, Germany; 3University Children`s Hospital, Department of Pediatric
Hematology and Oncology, Frankfurt, Germany; 4Institute of Pathology, Department of
Pediatric Pathology, Kiel, Germany; 5University Hospital, Department of Radiation
Oncology, Muenster, Germany; 6Olgahospital, Department of Pediatric Hematology-
Oncology and Immunology, Stuttgart, Germany
Background/Objectives: Patients with paratesticular rhabdomyosarcoma (PRMS) are
known to have an excellent prognosis. Retroperitoneal lymph node (LN) involvement is
common in patients > 10 years, but the optimal treatment of retroperitoneal LN
disease remains unclear. The aim of the study was to evaluate predictors for outcome
and the role of LN surgery in patients with localized embryonal rhabdomyosarcoma
(eRMS) treated within four consecutive Cooperative Soft Tissue Sarcoma (CWS) trials
between 1986 and 2008.
Design/Methods: 147 patients with PRMS and complete data set suitable for this
analysis were included. All patients were treated according to the treatment protocols
of the CWS trials including multiagent chemotherapy, tumor resection and / or
radiotherapy. IRB approval was obtained for all trials.
Results: The outcome of the patients was excellent (5-year-EFS: 89.8%±2.6). Positive
predictors for outcome were age 10 years and a tumor size <5cm (EFS: 96.7%±2.3,
p=0.008). Primary lymph node sampling of inguinal / iliacal lymph nodes was done in
15/147 patients, of which 12 were positive and 3 were pNx. The EFS (85.1%±9.7) was
comparable to patients, who did not undergo inguinal lymph node surgery (EFS:
88.5%±3.2, p=0.619) without additional local therapy in most patients. Thirty-two
patients underwent secondary retroperitoneal lymph node dissection. Viable tumor was
only found in 8/32 patients, who had an inferior outcome compared to the 24 other
patients (EFS: 50%±17.7 vs. 76.8%±9.2). 4/8 patients were >10 years.
Conclusion: The outcome of patients suffering from PRMS is excellent and is hardly
improvable. Positive predictors for outcome are age 10 years and tumor size <5cm.
Primary lymph node sampling seems to have no impact on the EFS and should not be
recommended. Secondary retroperitoneal lymph node dissection revealed a high
number of unnecessary procedures, but patients with positive lymph nodes had a poor
prognosis and require additional local therapy.
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FDG-PET/CT IMPROVES STAGING IN EXTREMITY
RHABDOMYOSARCOMA
S. Terwisscha van Scheltinga1, M. Wijnen1, H. Heij1, R. Wijnen2, R. van Baren3,
H. Merks4, M. van Noesel5
1Prinses Maxima Center of Pediatric Oncology, Pediatric Surgery, Utrecht, Netherlands;
2Erasmus Medical Center, Pediatric Surgery, Rotterdam, Netherlands; 3UMCG, pediatric
surgery, Groningen, Netherlands; 4Academic Medical Center, Pediatric Oncology,
Amsterdam, Netherlands; 5Prinses Maxima Center of Pediatric Oncology, Pediatric
Oncology, Utrecht, Netherlands
Background/Objectives: The objective of this retrospective study was to compare
FDG-PET/CT with conventional imaging (CI) in initial staging and evaluate if the
staging modality is associated with a difference in event free and overall survival.
Design/Methods:We included all patients with extremity rhabdomyosarcoma from
2000-2014 in the 4 surgical pediatric oncology centers in the Netherlands. Patients
charts were evaluated for patient and tumor characteristics, radiology reports and
outcome.
Results:We included 20 patients with a rhabdomyosarcoma of the extremities. In 10
patients a FDG-PET/CT scan was performed in addition to conventional imaging. In
the other 10 patients staging was performed by conventional imaging (ultrasound, MRI
and/or CT scan) only. Patient and tumor characteristics were comparable in the two
groups. Follow up of surviving patients was different in the two groups (median of 30
(11-73) vs 96 (17-47) months) because FDG- PET/CT was only performed since 2007.
No patients had distant metastases. In the FDG-PET/CT staged group 5/10 patients
were staged as N0 (without lymph node metastases) and 5/10 patients as N1 (with
lymph node metastases). In the CI staged group 8/10 patients had no lymph node
metastases and 2/10 had lymph node metastases. Of the 5 N0 patients in the
FDG-PET/CT group no patient had a relapse and all patients are alive. Of the 8 N0 CI
staged group 6 patients had a relapse and 4 of these patients died.In N0 patients the
EFS was significantly better in FDG-PET/CT staged patients (p=0.01), OS was not
significantly better (p=0.06).
Conclusion: Patients without lymph node metastases staged with FDG-PET/CT have a
significantly better outcome than N0 patients staged with conventional imaging only. So
FDG-PET/CT should be a part of staging patients with extremity rhabdomyosarcoma.
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TREATMENT AND OUTCOME OF PATIENTS WITH THORACIC
RHABDOMYOSARCOMA – A REPORT FROM THE COOPERATIVE SOFT
TISSUE SARCOMA TRIALS CWS-81, -86, -91, -96, -2002P AND SOTISAR
J. Fuchs1, C. Urla2, E. Hallmen3, I. Leuschner4, T. Klingebiel5, A. Schuck6, G. Seitz2,
E. Koscielniak3
1University Children`s Hospital, Tuebingen, Germany; 2University Children`s Hospital,
Department of Pediatric Surgery and Urology, Tuebingen, Germany; 3Olgahospital,
Germany; 4Institute of Pathology, Department of Pediatric Pathology, Kiel, Germany;
5University Children`s Hospital, Department of Pediatric Hematology and Oncology,
Frankfurt, Germany; 6University Hospital, Department of Radiation Therapy, Muenster,
Germany
Background/Objectives: Rhabdomyosarcoma (RMS) is the most common pediatric soft
tissue sarcoma and can also be observed at the thoracic wall or within the chest.
Surgical management of these tumors can be challenging. The aim of the study was to
analyze patients treated within six different Cooperative Soft Tissue Sarcoma (CWS)
trials suffering from intrathoracic and chest wall RMS regarding treatment, outcome
and surgical procedures.
Design/Methods: 2525 pediatric patients suffering from rhabdomyosarcoma were
enrolled into five different CWS trials from 1981 to 2014. 53 patients with localized
disease were identified with diagnosis of intrathoracic or chest wall RMS, of which 20
were male and 33 were female. One patient was excluded due to an incomplete data set.
A retrospective chart analysis was carried out. IRB approval was obtained for all trials.
Results: The median age of the patients was 8.6 years [0-19]. The 5-years overall survival
rate was 58.7%±7.4. The 5-years event free survival (ES) was 47.8%±7.4. 34 patients
had tumors located at the chest wall (ES: 58%±8.6) and 18 patients within the thoracic
cavity (ES: 23.2%±11.6). 31 patients were younger than 10 years (ES: 43.6%±9.6) and
21 were older (ES: 54%±11.4). Patients with a tumor size 5 cm (n=17) had a better
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outcome (ES: 70.1%±11.2) compared to those with a size >5 cm (ES: 36.5%±8.8).
Interestingly, patients with embryonal RMS had a worse outcome (n=29; ES:
38.1%±9.7, relapse: 14/29) compared to alveolar RMS (n=23; ES: 57.5%±11.2, relapse:
4/23). Incomplete primary and secondary resections were performed in 44%.
Conclusion: Thoracic RMS belongs to the sites with unfavorable prognosis with a high
rate of incomplete resections and relapses. Local control of these tumors needs to be
urgently improved regarding completeness of resections and local radiotherapy.
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STAGE III DISEASE IN PEDIATRIC NON-RHABDOMYOSARCOMATOUS
SOFT TISSUE SARCOMA IS AN INDEPENDENT PREDICTOR OF POOR
OUTCOME DESPITE SURGICAL RESECTION
S. Bakhshi1, N. Iqbal2, S. Agarwala3, N. Shukla4, S. Deo4, D. Sharma5, M. Sharma6
1Dr. BRA IRCH- AIIMS, Delhi, India; 2Dr. BRA IRCH- AIIMS, Medical Oncology,
Delhi, India; 3AIIMS, Pediatric Surgery, Delhi, India; 4Dr. BRA IRCH- AIIMS,
Surgical Oncology, Delhi, India; 5Dr. BRA IRCH- AIIMS, Radiation Oncology, Delhi,
India; 6AIIMS, Pathology, Delhi, India
Background/Objectives: Pediatric non-rhabdomyosarcomatous soft tissue sarcomas
(NRSTSs) are rare tumors which are not well studied.
Design/Methods: All children with NRSTSs treated between June 2003 and December
2012 were analysed for treatment outcome and prognostic factors.
Results: A total of 70 patients were analysed with median age of 15 years (range;1-18
years).The most common histological subtypes were synovial sarcoma (34%),
neurofibrosarcoma (13%) and fibrosarcoma (8%). Median tumor size was 7.6 cm (2-20
cm), with 69% patients having tumor size > 5 cm. Staging was done according to
American Joint Committee on Cancer Staging System generally used for adult
sarcomas. Forty-nine (70%) patients underwent surgical resection, out of which 45
patients had localized disease. The 5-year EFS and OS rates were 42% and 55%,
respectively for whole cohort and 55% and 69% respectively for surgically resected
group. For surgically resected group, univariate analysis identified stage III disease (p
-0.01, HR 2.89; 95% CI 1.2 -6.9) associated with poor EFS. For OS, univariate analysis
identified tumor size > 5cm (p-0.05) and stage III disease (p <0.001) as adverse
prognostic factors, however in multivariate analysis, only stage III disease ( p - 0.002;
HR 5.3; 95% CI 1.8-15.5) emerged as poor prognostic factor for OS.
Conclusion: Stage III tumors faired worse even after curative resection. Thus, this
subgroup of NRSTSs requires careful patient selection for therapeutic decision making
if any mutilating surgery is being considered. There is also a need for development of
better staging system for children with NRSTSs.
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EXTREMITY AND NON-EXTREMITY SYNOVIAL SARCOMA IN CHILDREN
S. Qureshi1, M. Bhagat2, S. Kembhavi3, S. Laskar4, T. Vora5, M. Ramadwar6,
N. Khanna4, M. Prasad5, G. Chinnaswamy5, P. Kurkure5
1Tata Memorial Hospital, Mumbai, India; 2Tata Memorial Hospital, Pediatric Surgical
Oncology, Mumbai, India; 3Tata Memorial Hospital, Radiology, Mumbai, India; 4Tata
Memorial Hospital, Radiotherapy, Mumbai, India; 5Tata Memorial Hospital, Pediatric
Oncology, Mumbai, India; 6Tata Memorial Hospital, Pathology, Mumbai, India
Background/Objectives: Synovial sarcoma is the most common non-rhabdomyosarcoma
soft tissue sarcoma in children and adolescent, accounting for 10% of all soft tissue
sarcomas. The outcome of patients with non-extremity SS is generally poor than that
of patients with extremity tumours.
Design/Methods: The records of patients with extremity (n=20) and non-extremity
(n=9) synovial sarcomas treated between February 2006 and October 2014 were
analysed.
Results: Complete surgical resection with histological clear margins was achieved in all
patients with extremity tumour, 14 as initial and 6 as delayed surgery after
chemotherapy. In patients with non-extremity tumours, initial excision was performed
in five and delayed surgery in four patients. The median follow up duration was 47
months. There were no local recurrences in patients with extremity tumours while
distant metastases occurred in five patients. Two patients with non-extremity tumours
had local recurrences and one had distant metastases. The 5-year overall survival and
event free survival was 80% and 67.8% respectively for the entire cohort. The 5-year
overall survival and event free survival were, respectively 88.2% and 69% for extremity
tumours and 62.5% (p=0.2) and 63.5% (p=0.7) for non-extremity tumours.
Conclusion: Local recurrence was the commonest failure in non-extremity tumours
while distant relapses were the only failures in patients with extremity tumours.
Although there was a trend towards better survival in patients with extremity tumours,
it was not statistically significant.
IPSO Session 2: Renal Tumours
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NUTRITIONAL STATUS OF CHILDRENWITHWILMS TUMOUR ON
ADMISSION TO A SOUTH AFRICAN HOSPITAL AND ITS INFLUENCE ON
OUTCOME
L. Lifson1
1Inkosi Albert Luthuli Central Hospital, Dietetics, Durban, South Africa
Background/Objectives: In developing countries the prevalence of malnutrition on
admission amongst paediatric patients with cancer can be as high as 69%. High rates of
malnutrition occur due to factors such as poverty, co-morbidities, late presentation and
advanced disease process. Weight has been shown to be an inaccurate parameter for
nutritional assessment of patients with solid tumours as it is influenced by tumour
mass. This study aimed to assess the prevalence of malnutrition amongst our patients
with Wilms Tumour (WT) and the level of nutritional support received within 2 weeks
of admission, as well as the influence of nutritional status on outcome.
Design/Methods: Seventy six children diagnosed with WT and admitted to Inkosi
Albert Luthuli Central Hospital between 2004 and 2012 were studied prospectively.
Nutritional assessment took place before starting treatment and included weight,
height, Mid-Arm Circumference (MAC) and Triceps Skinfold Thickness (TST).
Outcome was determined at 2 years after date of admission. Time until commencement
of nutritional resuscitation, and nature thereof, were recorded.
Results: Stunting and wasting were evident in 12 and 15% of patients respectively. By
including MAC and TST, the prevalence of malnutrition was shown to be 57%.
Malnourished children had significantly larger tumours than those who were well
nourished. Malnutrition was not a predictor of poor outcome and did not predict
advanced disease. In relapse-free patients, nutritional status was not related to treatment
toxicity. Eighty four percent of patients received nutritional resuscitation within 2
weeks of admission.
Conclusion: Nutritional assessment in children with solid tumours should include MAC
and TST. Malnutrition at the time of admission was not shown to be related to poorer
outcome after 2 years. This may be due to the effects of early aggressive nutritional
resuscitation as part of management by a multidisciplinary team, although numbers are
small.
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THE CHALLENGE OF DIFFERENTIAL DIAGNOSIS BETWEENWILMS
TUMORS, NEUROBLASTOMAS AND NON-WILMS RENAL TUMORS
T. Kobayashi1, A. Duarte1, M. Cypriano2, H. Lederman3, V. Tostes3, S. Abib1
1Pediatric Oncology Institute - GRAACC/Unifesp, Pediatric Surgery, São Paulo, Brazil;
2Pediatric Oncology Institute - GRAACC/Unifesp, Pediatric Oncology, São Paulo, Brazil;
3Pediatric Oncology Institute - GRAACC/Unifesp, Radiology, São Paulo, Brazil
Background/Objectives: To evaluate cases that have been initially treated as WT and in
fact proved to be another histology, in order to reduce the mistaken diagnosis thereby
avoiding neuroblastoma or non-Wilms renal tumors to receive unnecessary
preoperative chemotherapy.
Design/Methods: Retrospective analysis of 446 medical records and images of WT,
neuroblastoma and non-Wilms renal tumors diagnosed in children admitted at
Pediatric Oncology Institute-GRAACC/ UNIFESP from 1984 to 2012. The clinical
characteristics and the image exams of the patients who attended to the inclusion
criteria were studied and reviewed.
Results: 5 patients were mistakenly diagnosed and treated as a WT. They had
neuroblastoma or another renal tumor, showing a 98.87% accuracy on the diagnosis
performed. All 5 patients were males and less than three years old. Among the studied
patients, 4 presented unilateral renal involvement and 1 presented bilateral renal
involvement. None had metastasis at diagnosis.
Conclusion: In some cases it can be difficult to perform the differential diagnosis
between WT, neuroblastoma and other renal tumors based only on the clinical and
image data. We had 1,12% of mistakenly diagnosed cases, which demonstrates the
efficacy on the diagnosis performed at IOP-GRAACC/UNIFESP. Certainly, future
studies with more patients will enable a deeper view of neuroblastoma or other
non-Wilms renal tumors treated as a WT frequency, as well as their impact in survival.
O-147
OUTCOME OF CHILDRENWITH STAGE IV WILMS TUMOR TREATED ON
AIIMS-WT-99 PROTOCOL
S. Agarwala1, V. Jain1, S. Bakhshi2, M. Srinivas1, V.K. Iyer3, S. Mathur3, M. Jana4,
A.K. Gupta4, M. Bajpai1, V. Bhatnagar1, D.K. Gupta1
1All India Institute of Medical Sciences, Pediatric Surgery, Delhi, India; 2All India
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Background/Objectives: To evaluate the outcome of children with stage IV Wilms tumor
(WT) on AIIMS-WT-99 study.
Design/Methods: All children with Stage IV WT registered from October 2000 through
December 2012 were included. Tumors deemed resectable, underwent upfront
resection. Unresectable/inoperable tumors received pre-resection chemotherapy
(Vincristin+Dactinomycin+Doxorubicin). Adjuvant pulmonary and flank
radiotherapy was advised to all patients. Metastatectomy was performed for lung
nodules that remained after chemotherapy and radiotherapy. Kaplan Meier survival
estimates for 5-year overall survival (OS) and event free survival (EFS) were calculated.
Events were defined as death, recurrence or progression of disease.
Results: Of 219 children of WT, during this period, 36 (16%) were stage IV tumors.
Pulmonary metastases were present in 33 of whom 5 also had concomitant liver
metastases. Isolated liver metastases were present in 3. Nine patients underwent upfront
resection followed by adjuvant chemotherapy and radiotherapy. Radiotherapy for
metastatic disease was administered to 26/36 patients. Pulmonary metastatectomy was
performed in 5 patients. Eighteen of 36 (50%) patients were alive at last follow-up,
giving a 5-year OS of 48%(95CI 41.3-75.9) with a mean survival time of 59
months(limited to 115months). Of these 18 alive, only 15 were disease free, while the
remaining 3 had recurrent or progressive disease. 16/28 (57%) patients with lung only
metastases achieved a disease free status while of the 8 with liver metastases only 1
achieved disease free status. Twenty events were recorded (11 recurrences and 9 disease
progression). The 5-year EFS was 42.4% (95% CI 33.4-67.6) with a mean survival time
of 50.49 months limited to 115 months.
Conclusion: On the current multimodal therapy, Stage IV WT had a poor 5-year EFS
(42.4%), especially those with liver secondaries. Fifty-five percent of patients developed
progressive or recurrent disease. This highlights the need for more aggressive therapy
for these patients.
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MINIMALLY INVASIVE TUMOR NEPHRECTOMY FOR NEPHROBLASTOMA
S. Warmann1, G. Seitz1, M. Ebinger2, S. Jürgen3, J. Fuchs1
1University Children’s Hospital of Tübingen, Pediatric Surgery and Pediatric Urology,
Tübingen, Germany; 2University Children’s Hospital of Tübingen, Pediatric Oncology,
Tübingen, Germany; 3University Hospital, Diagnostic and Interventional Radiology,
Tübingen, Germany
Background/Objectives: Despite the lack of guidelines within current treatment
protocols, minimally invasive nephrectomy is increasingly being used as technique for
tumor removal in nephroblastoma. Several issues have to be considered concerning this
approach. We analyzed children undergoing laparoscopic WT resection at our
institution. Technical aspects for a safe procedure and an adequate Lymph node
sampling are highlighted.
Design/Methods: IRB approval was obtained. Between August 2010, and March 2015, 8
children underwent transperitoneal laparoscopic nephrectomy for WT. Patients’ data,
tumor characteristics, surgical, and oncological outcome were assessed. LN sampling
was reviewed with special emphasis.
Results:Mean age at surgery was 28.31 months (range 12-57.5). All children received
neoadjuvant Actinomycin-D/Vincristin. All tumors showed response to chemotherapy;
mean tumor volume was 296.13 ml (162-850) at diagnosis and 81.13 ml (15-207) at
surgery. Complete tumor resection was achieved via a 4 trocar-technique in all children,
resulting in local stage 1 in all cases. No tumor rupture occurred. Resected specimens
were retrieved from the abdomen via Pfannenstiel incision using a retrieval bag.
Adequate lymph node sampling (6 or more) was performed before dissection of the
kidney and was realized in all cases by applying surgical steps similar to other
procedures on the upper urinary tract (elevation with stay sutures, vascular dissection
before tumor mobilization, positioning of trocars, and others). Mean operating time
was 147 minutes (93-190). There were no complications and all children are alive
without evidence of disease after a mean follow up of 24.1 months (0-54).
Conclusion:Minimally invasive surgery is a safe option for WT resection provided that
patients are carefully selected and operating surgeons have sufficient expertise in
pediatric oncology and minimally invasive urology. Adequate LN sampling is possible
via the minimally invasive approach. However the laparoscopic technique must not be
reason for not complying with the general guidelines for WT surgery.
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DEVELOPMENT OF RENAL DYSFUNCTION LONG AFTER NEPHRECTOMY
FOR CASES WHERE ADJUVANT THERAPYWAS NOT A CONFOUNDING
PROGNOSTIC FACTOR
D. Cozzi1, S. Ceccanti2, F. Simone2, I. Falconi2, M. Vallorani3, C. Francesco2
1Sapienza University of Rome, Rome, Italy; 2Sapienza University of Rome, Pediatric
Surgery Unit, Rome, Italy; 3Sapienza University of Rome, Pediatrica Surgery Unit, rome,
Italy
Background/Objectives: The prevalence of mild-to-moderate renal dysfunction in Wilms
tumor patients surviving beyond the age-related physiological renal function decline
may be due to adjuvant therapy rather than 50% reduction in renal parenchyma. We
aimed to evaluate renal function in adult patients who underwent nephrectomy during
childhood and received or did not receive postoperative radiotherapy.
Design/Methods:We assessed the estimated glomerular filtration rate (eGFR) and
blood pressure in 13 patients older than 30 years who underwent nephrectomy during
childhood for medical causes (Group A), and in 13 Wilms tumor patients surviving
beyond the age of 30 years after nephrectomy and postoperative radiotherapy (Group
B). The primary outcome of the study was the evaluation of renal function amongst the
two groups. Data are expressed as mean±SD or numbers.
Results: There were no significant differences in age at surgery (2.41±4.1 vs. 3.88±2.8
years; p=0.3) and age at follow-up (40.92±7.74 vs. 43.15±6.46 years; p=0.43) between
Group A and Group B. Likewise, eGFR (85.69±19.22 vs. 78.30±20.62 mL/min/1.73
m2; p=0.35), systolic blood pressure (117±11.19 vs. 124.23±16.81 mmHg ; p=0.22)
and diastolic blood pressure (74.9±7.31 vs. 80 ± 9.12 mmHg; p=0.14) were similar at
follow-up. Renal dysfunction was documented in 8 patients of Group A and 11 of
Group B (p=0.37). Systolic hypertension (blood pressure 130 mmHg) and diastolic
hypertension (blood pressure  80mmHg) were found in 2 vs. 5 (p=0.37) and in 4 vs. 9
patients (p=0.11), respectively.
Conclusion: Present data suggest that children who undergo nephrectomy for
oncological or non-oncological causes, require a life-long nephrologic surveillance
because renal dysfunction is a dose-dependent predictor of morbid cardiac events and
overall mortality.
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DECREASING THE INCIDENCE OF POST OPERATIVE INTESTINAL
OBSTRUCTION IN WILMS TUMOR: A MODIFIED SURGICAL APPROACH
G. Ahmed1,2, H. Hafiz3,4
1Children’s Cancer Hospital - Egypt, Surgery, Cairo, Egypt; 2helwan University, Surgery,
Cairo, Egypt; 3Children’s Cancer Hospital - Egypt, Pediatric Oncology, Cairo, Egypt;
4National Cancer Institute - Cairo University, Pediatric Oncology, Cairo, Egypt
Background/Objectives: Intestinal obstruction is one of the main postoperative
complications in Wilms tumors. The authors postulate that manipulation of the small
intestine (SI) and cutting of anatomical peritoneal reflections opens a way for SI
migration to the the retroperitoneal space and predisposes for obstruction. The
modified approach describes a technique that entails a conservative approach towards
SI manipulation and cutting of the peritoneal reflections/evaluating the role of the
aforementioned surgical approach regarding its technical utility and the incidence of
postoperative intestinal obstruction.
Design/Methods: A retrospective review of all patients with Wilms tumor who
underwent surgery between January 2012 and December 2014 using this approach.
Data collected included demographic data, tumor characteristic(size, stage),
intraoperative tumor rupture, post operative radiotherapy and postoperative intestinal
obstruction.The technique used the transverse incision , once in the peritoneal cavity we
cut the peritoneal reflections short of the ceacum or short of the sigmoid . The
phrenocolic ligament is as well reserved. The colon is reflected over SI packing it,
proceeding to nephrectomy and lymph node sampling.
Results: The study included 65 patients (31 male,34 female).Mean age was 3.2 years (0.6
- 11). Upfront surgery were done in 24 patients(36.9%) while 41 patients (63.1%)
received preoperative chemotherapy .The mean tumor largest diameter was 13 cm. (9 -
18 ). Local staging were, I 10 patients(15.4%) , II 9 patients (13.8%) III 46
patients(70.8%) . forty nine patients (75.4%) received Post operative flank irradiation.
No intraoprtative tumor rupture occurred. During the follow up period (3 months - 3
years) one patient (1.5%) developed postoperativ inusssusception.
Conclusion: The modified surgical approach allows minimal manipulation of SI and
prevents it’s migration to the retroperitoneal space which contributes to decreasing the
incidence of postoperative intestinal obstruction with no increased risk of tumor
rupture.
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GASTROSTOMY COMPLICATIONS IN PEDIATRIC CANCER PATIENTS: A
RETROSPECTIVE SINGLE-INSTITUTION REVIEW
I. Fernandez-Pineda1, J.A. Sandoval2, R.M. Jones2, N. Boateng3, J. Wu3, B.N. Rao2,
A.M. Davidoff2, S.J. Shochat2
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Memphis, USA
Background/Objectives: Complications in pediatric cancer patients after a gastrostomy
(GT) placement have not been widely investigated. We aimed to evaluate the
complication rate and nature of complications in this population.
Design/Methods:Medical records of pediatric cancer patients having a GT placed at
our institution between 1998 and 2013 were retrospectively reviewed. Variables analyzed
included gender, age at procedure, primary cancer diagnosis, surgical procedure,
duration of GT usage, ANC level at procedure and complications.
Results: One hundred seventy-one patients (92 males, 79 females) who underwent 181
GT placements (110 open, 59 endoscopic and 12 laparoscopic) were identified. Median
age was 6.0 years (range, 0.2-21). One hundred one patients had a central nervous
system tumor, 45 had a solid tumor and 25 had leukemia/lymphoma. Median ANC
level was 3300/mm3 (range, 0-38988). Median duration of GT usage was 8.0 months
(range, 0.2-142). Complications occurred in 106 patients (61.9%). Major complications,
including intrabdominal complications (2.2%) and GT site infections (23.7%) occurred
in 46 patients (11 perioperative). Minor complications occurred in 64 patients, the most
common of which were granulation tissue (28.8%) and GT site leakage (21.4%).
Younger age at GT placement was associated with increased risk of developing a
complication (0.048) and open GT was associated with increased risk of GT site
infection (0.003). No statistical significance was observed between complications and
gender, primary cancer diagnosis, surgical procedure, duration of GT usage and ANC
at procedure.
Conclusion: A significant number of complications are seen after GT placement in
pediatric cancer patients, however the incidence of complications in our report is
similar to previously reported series in non-cancer patients. Younger patients were more
likely to have complications and GT site infections were more common after open GT
procedures. New guidelines have been established in order to decrease the complication
rate in this specific population.
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EFFICIENCY OF PHOTODYNAMIC TREATMENT FOR RECURRENT SOLID
TUMORS IN CHILDREN
N. Rostovtsev1, V. Polyakov2, A. Kotlyarov3, S. Kovalenko4
1Chelyabinsk Regional Clinical Children’s Hospital, Surgical Department, Chelyabinsk,
Russia; 2Blokhin Russian Cancer Research Center RAMS, Scientific and Research
Institute of Pediatric Oncology and Hematology, Moscow, Russia; 3South Ural State
Medical University, Chair of Children’s Surgery, Chelyabinsk, Russia; 4Chelyabinsk
Regional Clinical Children’s Hospital, Oncohematological Department, Chelyabinsk,
Russia
Background/Objectives: To assess results of photodynamic treatment (PDT) with
photosensitizers of chlorine family in children with solid tumors.
Design/Methods: PDT was conducted to 9 patients with recurrent solid tumors. The
mean age was 1.8.PDT was intraoperative after tumor removal. We used laser
equipment "Lakhta Milon" (Russia). Output laser power was 2.5 W. During treatment
the laser power density ranged from 0.1 to 0.8 W/sm2. We used different doses of photo
energy - from 300 to 400 J/sm2, and for tumors deep infiltrating growth - up to 500
J/sm2.Administered photosensitizer dosage was 0.6-0.8 mg/kg of the patient’s body
weight. Exposure duration depended on tumor size and was from 10 to 30 min. For
tumor exposure we used the light guide with end-formed microlens. Case follow-up and
dressing changes were outpatient. Number of appointments starting with primary
inspection and up to results of assessment of the chosen treatment (3 years later) was
from 10 to 15, in average.
Results: Assessment of PDT efficiency involved the following criteria: full absence of
local recurrence of the tumor; absence of visible and palpable sings of the tumor
growth; local recurrence in 6 months; no effect - continued tumor growth within near
post-operational period. Direct results of PDT were assessed during 1 year. For most
cases, this period was long enough for recurrent tumor detection. Absence of recurrent
tumor was observed in 7 (77.7%) patients, recurrence was observed in 2 patients.
Recurrence was detected only in patients with Wilms’ tumor of neuroblastoma.
Follow-up monitoring of 7 patients for 6 months to 3 years did not reveal any
recurrence.
Conclusion: The study shows high efficiency of PDT for solid tumors in children at
advanced stages. In this respect, 82.4% children had no tumor recurrence within 3 years.
PDT should be implemented more widely in treatment for residual and recurrent
tumors.
IPSO Session 4: (PBC-Session): Best of IPSO
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A SUBSET OF IMAGE DEFINED RISK FACTORS PREDICTS
COMPLETENESS OF RESECTION IN CHILDRENWITH HIGH-RISK
NEUROBLASTOMA: AN INTERNATIONALMULTICENTER STUDY
J. Nuchtern1, R. Bagatelle2, K. McHugh3, A. Naranjo4, C. Van Ryn4, Y. Rojas5,
K. Lyons6, P. Guillerman6, C. Kirby7, P. Brock8, S. Volchenboum7, T. Simon9,
L. States10, A. Miller2, B. Krug11, S. Sarnaki12, D. Valteau-Couannet13, D. von
Schweinitz14, B. Kammer15, C. Granata16, L. Pio17, J. Park18
1Texas Children’s Hospital/Baylor College of Medicine, Surgery, Houston, USA;
2Children’s Hospital of Philadelphia, Pediatrics, Philadelphia, USA; 3Great Ormond
Street Hospital for Children, Radiology, London, United Kingdom; 4University of Florida
Colleges of Medicine and Public Health & Health Professions, Biostatistics, Gainesville,
USA; 5TexasChildren’s Hospital/Baylor College of Medicine, Surgery, Houston, USA;
6TexasChildren’s Hospital/Baylor College of Medicine, Radiology, Houston, USA;
7University of Chicago, Pediatrics, Chicago, USA; 8Great Ormond Street Hospital for
Children, Pediatrics, London, United Kingdom; 9University of Cologne, Pediatrics,
Cologne, Germany; 10Children’s Hospital of Philadelphia, Radiology, Philadelphia, USA;
11University of Cologne, Radiology, Cologne, Germany; 12Gustave Roussy Institute,
Surgery, Paris, France; 13Gustave Roussy Institute, Radiology, Paris, France; 14Dr. von
Hauner Children’s Hospital/University of Munich, Surgery, Munich, Germany; 15Dr. von
Hauner Children’s Hospital/University of Munich, Radiology, Munich, Germany;
16Giannina Gaslini Children’s Hospital, Radiology, Genoa, Italy; 17Giannina Gaslini
Children’s Hospital, Pediatric Surgery, Genoa, Italy; 18Seattle Children’s Hospital,
Pediatrics, Seattle, USA
Background/Objectives: Image defined risk factors (IDRFs) were promulgated as a
means for predicting the feasibility and safety of complete primary tumor resection in
children with neuroblastoma (NB). It is unknown whether the presence or absence of
individual IDRFs has a differential effect on resectabilty or patient outcome. A
multicenter database of patients with high-risk NB was interrogated to answer this
question.
Design/Methods: Patients with high-risk neuroblastoma (age <20 years) were eligible if
cross-sectional imaging was performed at least twice prior to resection. IDRFs and
primary tumor measurements were recorded for each imaging study. Extent of
resection was determined from imaging studies and/or operative reports.
Results: There were 211 of 229 patients with IDRFs at diagnosis and 169 patients with
IDRFs present at pre-surgery. Although there was no significant correlation between
the overall presence or absence of IDRFs and completeness of resection, a >90%
resection was significantly more likely in the absence of two overlapping subsets of
IDRFs either at diagnosis or pre-surgery. Both subsets of nine included invasion of the
pancreaticoduodenal block or porta hepatis; encasement of the aorta, its major
abdominal branches, the vena cava or iliac vessels; and invasion of both renal vascular
pedicles. In addition, involvement of the diaphragm was significant at diagnosis and
encasement of the origin of the superior mesenteric artery (vs. its branches) was
significant at pre-surgery. There were no significant differences in 5-year event-free and
overall survival when patients were stratified by the presence vs. absence of any IDRF
either at diagnosis or pre-surgery.
Conclusion: A subset of IDRFs present either at diagnosis or after induction
chemotherapy significantly influences the probability of a complete resection in
children with high-risk NB. There were no significant differences in 5-year event-free
and overall survival when patients were stratified by the presence vs. absence of any
IDRF at diagnosis or pre-surgery.
O-154
DEATH RECEPTOR EXPRESSION AND SENSITIVITY TARGETED IN
DESMOPLASTIC SMALL ROUND CELL TUMOR
A. Hayes Jordan1, X.Y. Ma2, C. Kingsley3, C. Lockworth4, S. Craig4
1University of Texas MD Anderson Cancer Center, Surgical Oncology, Houston, USA;
2ApoCell, Biotechnology, Houston, USA; 3University of Texas MD Anderson Cancer
Center, Sarcoma Research Lab, Houston, USA; 4University of Texas MD Anderson
Cancer Center, Veterinary Medicine, Houston, USA
Background/Objectives: Background: Desmoplastic Small Round Cell tumor is a rare
tumor of childhood and adolescence for which cytotoxic chemotherapy, aggressive
surgery, and radiotherapy have improved the survival only to approximately 50-60%.
There is no known targeted chemotherapy for DSRCT. Here we describe a death
receptor dependent apoptosis pathway in DSRCT cells that has not previously been
described.
Design/Methods:Methods: JN-DSRCT cells were confirmed to have the t11;22
translocation and Wilms characteristic fusion protein. Flow cytometry was used to
confirm expression of death receptor 4 and 5, and decoy receptors 1 and 2.
Immunohistochemistry and immunofluorescence was used in DSRCT tissue to verify
expression of DR-4 and DR-5. Clonogenicity assay was used to assess cytotoxicity of a
novel DR-5 antibody, ONC 201. Expression of cleaved caspase 3 and 8, and cleaved
PARP levels of JN-DSRCT cells after ONC201 treatment, were assessed using Western
Blotting. An orthotopic xenograft model of luciferase transfected DSRCT in
NOD-SCID-Gamma mice was then used in ONC201 treatment.
Results: DR-5 and less so DR-4 are highly expressed in DSRCT cells. Dose dependent
cytotoxicity was demonstrated in vitro using ONC-201. The mechanism of cell death
was confirmed to be the intrinsic pathway as verified by dose dependent increased levels
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of cleaved caspase 3, 8, and PARP. ONC201 treatment of mice in-vivo showed at least
stable disease.
Conclusion: In DSRCT, the death receptor 5 is highly expressed and the intrinsic
apoptosis pathway are activated and sensitive to ONC201. This novel finding shows
ONC201 and other DR-5 targeted therapy may be effective in the treatment of DSRCT.
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HIGHER INCIDENCE OF SURGERY-RELATED COMPLICATIONS IN WILMS
TUMOR NEPHRECTOMY FROM CLINICAL RECORDS ANALYSIS
COMPARED TO CENTRAL DATABASE REGISTRATION
J. Wilde1, D. van Poll2, H. Heij3, M. Wijnen4, C. van de Ven5, B. Sznajder6, L. Tytgat4
1Geneva University Hospitals, Geneva, Switzerland; 2AMC, Paediatric Surgery,
Amsterdam, Netherlands; 3Princes Maxima Center of Paediatric Oncology, Paediatric
Oncology, Utrecht, Netherlands; 4Princes Maxima Center of Pediatric Oncology,
Pediatric Oncology, Utrecht, Netherlands; 5Erasmus MC Sophia, Pediatric Surgery,
Utrecht, Netherlands; 6Netherlands Cancer Institute AVL Amsterdam, Statistics,
Amsterdam, Netherlands
Background/Objectives: Reliable data about surgical complications in the treatment of
Wilms tumors (WT) is essential in the evaluation and implementation of treatment
protocols. The purpose of this study is to address the question whether central database
registration is reliable and a useful tool to estimate and compare figures concerning
surgery-related complications in WT nephrectomy.
Design/Methods: Clinical records of all patients treated according to the SIOP 2001
protocol in the 3 major centers in the Netherlands were analyzed for surgery-related
complications. These were compared to the prospectively reported data collected in the
central SIOP 2001 database. Data from the clinical records was considered the gold
standard. Complications were graded according to the Common Terminology Criteria
for Adverse Events version 4.0.
Results: One hundred and sixty-six patients treated between 2001 and 2013 were
included. Baseline characteristics between patients with and without complications
were similar. From the clinical records, a total of 38 patients with 53 surgery-related
complications of which 8 peri-operative were identified compared to 8 patients
(p<0.001) with 18 complications of which 3 peri-operative (p=0.52) respectively from
the SIOP 2001 database. Forty-one short term (<30 days) and 4 long-term
complications were observed from the clinical records compared to 15 (p<0.01) and
none (p=0.045) respectively identified from the SIOP 2001 database (p<0.1). The most
frequently observed complications were post-operative ileus (n=9) and
chyloperitoneum (n=5). Intra-operative tumor rupture occurred in 4 (2.4%) patients.
Patients with complications received the first post-operative chemotherapy on average
15.3 days after surgery. This was significantly longer than patients not experiencing
surgery-related complications: 13.1 days (p=0.031).
Conclusion: Central reporting of surgical complications appears to be inaccurate.
Treatment policies should therefore be based on clinical records rather than on the
central database.
IPSO Session 5: Miscelleanous
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GENETICS OF FAMILIAL OVARIAN TERATOMA IN CHILDREN
S. Sarnacki1, C.O. Muller2, C. Gordon3, J. Amiel3
1Université Paris Descartes-Sorbonne Paris Cité Institut Imagine, Paris, France;
2Université Paris Descartes-Sorbonne Paris Cité Institut Imagine, Pediatric Surgery,
Paris, France; 3Université Paris Descartes-Sorbonne Paris Cité Institut Imagine, Genetic
Department, Paris, France
Background/Objectives: Owing rarity of data about the genetics of familial forms of
ovarian teratoma, the aim of this study was to review 12 years of our experience in their
management and to perform genetic studies in familial cases.
Design/Methods:We retrospectively reviewed all the ovarian tumors operated on in a
single center between 2000 and 2012. We focused on ovarian teratoma and looked for
familial forms by systematically reviewing clinical notes and re-contacting patients.
Capture of exons from genomic DNA was performed with the 51 Mb SureSelect
Human All Exon Kit V5 (Agilent technologies) and sequencing was performed on a
HiSeq2500 (Illumina) machine. An in-house software (PolyWeb) was used for filtering
variants under relevant genetic models in each family.
Results: 110 ovarian tumors were operated on between 2000 and 2012. 19 were
malignant (germ cell tumors, yolk sac tumors, and immature teratoma), 91 were benign
tumors from which 74 were teratomas. We identified 10 cases with a familial history of
ovarian tumors: 8 benign and 2 with malignant component. Familial history consisted
in: mother with a unilateral or bilateral synchrone mature teratoma (n=3), maternal or
paternal aunt with unilateral mature teratoma (n=2), paternal cousins with mature
teratoma or serous cystadenoma (n=2), Prader Willi syndrome (n=1), maternal uncle
with testicular seminoma (n=1), maternal grandfather with testicular seminoma (n=1).
All patients are disease free at a mean follow up of 3.7 years (range 1-8). An exome
sequencing was performed in 8 families but failed to identify any common variant.
However, we found an interesting variant in the gene p53-induced protein with a death
domain (PIDD1), known to act in the DNA-damage response, within one family.
Conclusion:We failed to find a frequent genetic cause of familial forms because there
may be a high genetic heterogeneity underlying ovarian teratoma. Enlargement of this
cohort is now mandatory
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RISK FACTORS FOR SEVERITY IN PATIENTS DIAGNOSEDWITH
NEUTROPENIC ENTEROCOLITIS
M.B.L.M. Henne1, V.S. Tostes2, F.A.M.C. Carlesse1, M.L. Lee1, A.A.B. Duarte3,
R.C. Ribeiro3, H.M. Lederman2, S.D.C.V. Abib3
1Pediatric Oncology Institute-UNIFESP/GRAACC, Pediatric Oncology, Sa¯o Paulo,
Brazil; 2Pediatric Oncology Institute-UNIFESP/GRAACC, Pediatric Radiology, Sa¯o
Paulo, Brazil; 3Pediatric Oncology Institute-UNIFESP/GRAACC, Pediatric Surgery
Oncology, Sa¯o Paulo, Brazil
Background/Objectives: To characterize the episodes of Neutropenic Enterocolitis (NE)
that occurred in the Pediatric Oncology Institute – GRAACC/ UNIFESP, Brazil.
Design/Methods: A retrospective descriptive cohort study. 38 patients with NE from
2007 to 2013. Age; sex; diagnosis; clinical presentation; chemotherapy interval;
neutropenia history in interval less than 30 days; use of stimulating factor colonies and
corticosteroids; realization of radiotherapy and transplantation; Complete blood count
and absolute reactive protein c diagnosis; Computed tomography (CT); Conservative or
surgical treatment; length of stay; use of NPP; fasting time more than 5 days; and
clinical outcome. We used the logistic regression method with the SPSS21 program for
univariate (UV) and multivariate (MV) analysis.
Results: One thousand five hundred twenty two patients were analyzed (25% were
leukemias), 2.49% had a diagnosis of NE. The average age was 11.4 years, with no
gender predominance. 40% of cases are related to hematological malignancies and 60%
with solid tumors. ICU stay was required in 58.3% of the episodes and was associated in
the UV analysis of neutropenia history in interval less than 30 days (p = 0.014); fasting
time more than five days (p = 0.01); PCR (p = 0.037); and ascites valued at initial CT (p
= 0.024). The same factors were significant in MV analysis, except for ascites. Surgery
was performed in 11.6% of cases and the death rate due to NE was 7.9%.
Conclusion: An increased incidence of NE in patients with solid tumors was observed
and may be associated with the intensity of current chemotherapy protocols. Clinical,
laboratory and radiological factors are associated with ICU admission and recent
neutropenia, absolute value of CRP, fasting time and ascites indicate severity. This
experience led to a standardized follow up protocol.
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SURGICAL APPROACHES AND OUTCOME IN PEDIATRIC SUPERIOR
MEDIASTINALTUMORS
G. Ahmed1,2, A. Fathalla3, T. Raafat4, H. Hafez5,6, M. Elshafiey1
1Children’s Cancer Hospital, Surgery, Cairo, Egypt; 2Helwan University, Surgery, Cairo,
Egypt; 3National Cancer Institute, Surgery, Cairo, Egypt; 4National Cancer Institute,
Radiology, Cairo, Egypt; 5National Cancer Institute, Pediatric Oncology, Cairo, Egypt;
6Children’s Cancer Hospital, Pediatric Oncology, Cairo, Egypt
Background/Objectives: Superior mediastinal tumors in pediatric are heterogeneous
group of tumors with marked variation in pathology,extension and response to
chemotherapy. Different surgical approaches were described for resection of these
tumors. Objectives: To evaluate the indications, advantages, limitations and outcome of
different surgical approaches to tumors originating from or extending to superior
mediastinum in pediatric.
Design/Methods:We retrospectively reviewed all cases who had surgery for superior
mediastinal tumors in our hospital between Jan. 2008 to Dec.2013. We reviewed
demographic data, clinico-pathological features, radiologic findings, operative
techniques and outcome in all cases.
Results: The study included 18 patients (11males, 7 females). The age range was (0.2-16
years). The commonest pathology was germ cell tumors (6 cases), followed by
neuroblastoma (4 cases), soft tissue sarcoma (STS) (3 cases), thymolipoma (2 cases),
infantile fibromatosis (1 case), calcified fibrous tumor (1 case) and thymic carcinoma (1
case). The mean of largest tumor diameter at time of resection was 11 cm (5-26 cm).
Extended lateral thoracotomy was used in 6 cases. Other approaches included trapdoor
incision (5 cases), clamshell incision (4 cases), cervical approach (2 cases) and double
level lateral thoracotomy (1 case). Fourteen cases had initial biopsy while 4 cases had
upfront surgery based on radiologic findings. Neoadjuvant chemotherapy was given in
10 cases. There was no perioperative mortality and post operative morbidity was 16%.
At the end of Dec. 2014, 16 cases were alive free of disease while one case with STS
developed local recurrence and the case of thymic carcinoma died of distant metastases.
Conclusion: Tumors originating or extending to superior mediastinum in pediatric are
challenging. Every case should be evaluated according to tumor extension and
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pathology for proper selection of the best surgical approach which achieve best
exposure for adequate resection and least morbidity.
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MALIGNANTMELANOMA IN CHILDREN AND ADOLESCENTS – A
NATIONWIDE OUTCOME REPORT
P. Losty1, V. Poirier2, J. Verne2
1University of Liverpool, Liverpool, United Kingdom; 2Cancer Intelligence, Public Health
England, Bristol, United Kingdom
Background/Objectives: The incidence of skin cancer notably Malignant Melanoma
(MM) and Non Melanoma Skin Cancer is increasing in England and while it remains
predominantly an adult cancer (4% of overall paediatric cancers) - timely referral,
treatment and advice must be clearly established. This study reports nationwide data for
patients under 18 years who presented with MM in England during the era(s) 2005
-2013.
Design/Methods: Skin cancer data (ICD10 C43 – malignant melanoma - MM) - were
extracted from the National Cancer Registry Service. Tumour morphology, anatomical
site, gender, type of first treatment, Breslow thickness at presentation and lymph node
operation(s) including mortality rate(s) were analyzed.
Results: Two hundred thirty one patients with MM were diagnosed in England and of
these seventy seven were superficial spreading melanoma and twenty nodular
melanoma(s). The majority of index cases occurred in 11-17 year old patients (n= 204)
with a male to female ratio of 1 : 1.6 for MM. Anatomical site showed 34% of MMs in
males were on the trunk region while 35% were on the lower limb(s) in females. Thirty
four percent of patients had a Breslow thickness > 2mm with 18% also > 4mm. Main
procedures undertaken were excision of which 44% had at least two operations
performed. Thirteen percent of patients underwent varied lymphadenectomy
operations(s). Eighteen deaths ( 8%) occurred within 0 - 6 years from primary diagnosis.
Conclusion: This study highlights national data, clinical management and outcomes(s)
of MM in a paediatric population. The findings usefully serve a public health warning.
Whilst a ban on sun bed use has been introduced in the UK for those < 18 years this
policy has not led to an overall decline in ‘tanning burns’ for young people who
continue this practice(1).
1N.Bowtell et al, NCIN Conference 2014.
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PULMONARY PLEUROBLASTOMA IN CHILDREN: IS A CONSERVATIVE
SURGICAL STRATEGY POSSIBLE?
N. Khen-Dunlop1, D. Orbach2, M. Larroquet3, P. Philippe-Chomette4, B. Fresneau5,
Y. Reguerre6, H. Martelli7, Y. Aigrain1, S. Sarnacki8
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Roussy, Pediatric Oncology, Villejuif, France; 6CHU la Réunion, Pediatric Oncology,
Saint Denis de la Réunion, France; 7Hopital Bicêtre, Pediatric Surgery, Le Kremlin
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Background/Objectives: Due to the rarity of this tumor, management and surgical
treatment for pulmonary pleurobalstoma (PPB) are not completely defined, as attested
by recent discussions in the EXPERT group. The aim of this study was to analyze a
homogenous series treated for PPB in order to propose some surgical principles of
treatments.
Design/Methods: From 2000 to 2014, nine patients were operated. There were 6 boys
and 3 girls with a median age at diagnosis of 2.3 years (range 6 months – 13 years).
Results: PPB classification was 2 subtype I, 6 subtype II and 1 subtype III.
Circumstances of diagnosis were congenital lung malformation in 3 cases,
pneumothorax in 2 cases and thoracic mass in 4 cases. In 4 patients, chest tube was
placed at diagnosis. First surgery was considered as complete in 4 cases and incomplete
in 5 cases and was followed by chemotherapy in all(IVA=2 or IVADo=7). Four of these
five incomplete resections underwent a second look procedure, avoiding radiotherapy.
The fifth, aged 13 years at diagnosis, died after 11 months from uncontrolled tumoral
progression. Two patients presented recurrence, one initially considered as complete
resection and the other as incomplete. They were treated both by complementary
surgery, second line chemotherapy and radiotherapy. None had chest tube insertion at
diagnosis. 8/9 patients are alive, without disease, with a median follow-up of 16 months.
Conclusion: Rupture of PPB at diagnosis is frequent, either spontaneous or linked to a
chest tube insertion, but does not seem to impair the prognosis. Second look surgery is
of high interest for the decision of adjuvant radiotherapy. Regarding the high
chemosensitivity of PPB, complete pneumonectomy is discouraged at diagnosis and
should be discussed in case of persistent unresectable tumor or residual viable cells at
second look surgery. Multidisciplinar discussion should then balance irradiation risks
with those of total pleuro-pneumonectomy.
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PREOPERATIVE EVALUATION OF PAEDIATRIC ADNEXALMASSES WITH
PAEDIATRIC RISK OF MALIGNANCY INDEX IMPROVES OVARIAN
CONSERVATION AND SURGICAL MORBIDITY
C.Z.B. Kho1, Y.W. Chong1, Y.T. Lee2, G. Krishnaswamy3, C.L. Ong4, S.L. Lam4,
A.H.P. Loh2
1NUS Yong Loo Lin School of Medicine, NUS Yong Loo Lin School of Medicine,
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Background/Objectives: To validate the paediatric risk of malignancy index (PRMI),
and examine its impact on surgical practices in the management of paediatric adnexal
masses.
Design/Methods: Retrospective review of clinical charts and electronic records were
performed for girls aged 18 years and under, who were managed for adnexal masses in
our institution from January 2004 to December 2014. Surgical approaches adopted for
patients managed before and after the introduction of the PRMI were compared.
Results: One hundred and fifteen patients were analysed - 76 were managed before, and
39 after the introduction of the PRMI. A score value of <7 predicted a benign
histological diagnosis in children with adnexal masses with a sensitivity of 97.0% and
93.9%, and a positive predictive value of 98.5% and 91.2% in the two groups,
respectively (P<0.001, and 0.011). Elevated serum AFP, βHCG, CA-125 and CEA were
associated with non-benign pathology (P=0.004, 0.004, <0.001, and 0.002,
respectively). Following its introduction, patients with PRMI <7 who had an initial
laparoscopic surgical approach increased from 83.1% to 91.2%, and those who had
ovarian sparing surgery increased from 72.3% to 97.1%. Patients with PRMI <7 who
underwent surgical staging procedures, which included omentectomy, contralateral
ovary inspection or biopsy, and lymph node biopsy, decreased from 7.7% to 2.9%.
Conclusion: The PRMI was validated in a post-implementation cohort to be sensitive in
predicting benign pathology in paediatric adnexal masses. Since its introduction to our
centre, more girls predicted to have benign pathology received an initial laparoscopic
approach, ovarian-sparing surgery, and were spared unnecessary surgical staging
procedures.
IPSO Session 6: Liver Tumors / Neuroblastoma
O-162
IMAGING-BASED RESPONSE AND EFFECT OF PRE-OPERATIVE
CHEMOTHERAPY ON HEPATOBLASTOMAS
S. Kembhavi1, S. Qureshi2, G. Chinnaswamy3, T. Vora3, S. Shah1, P. Popat1,
M. Ramadwar4, M. Prasad3, S. Laskar5, N. Khanna5, P. Kurkure3
1Tata Memorial Centre, Radiodiagnosis, Mumbai, India; 2Tata Memorial Centre,
Paediatric Surgery, Mumbai, India; 3Tata Memorial Centre, Paediatric Medical
Oncology, Mumbai, India; 4Tata Memorial Centre, Pathology, Mumbai, India; 5Tata
Memorial Centre, Radiotherapy, Mumbai, India
Background/Objectives: To document changes between PRETEXT to POSTEXT on
CT scan and correlate with serAFP.
Design/Methods: 18 patients treated between 2010-13 had pairs of pre and
post-induction chemotherapy scan on PACS. We documented SIOPEL staging, serAFP
levels within 2 weeks of the scans, tumor volume, presence of calcifications, percentage
change in volume and serAFP.
Results: The pretext stages were I,II,III and IV in 0,8,7 and 3 patients. Only 1 Stage II
patient was down-staged to I. 4 patients with pretext III got down-staged to II, 2
remained stage III and one showed progression to IV. Of 3 stage IV patients, only one
shifted to III. Thus only 33.33 % got down-staged. Four patients had portal vein
thrombosis, 1 showed resolution of the thrombus while 3 showed reduction in size of
thrombus. Of 9 patients with multifocal disease, 4 converted to unifocal disease (F0), 4
remained multifocal and one progressed. All of those with residual F0 disease showed
>99% drop in serAFP. 6/11 patients with extra-hepatic extension had reduction in size
with no extra-hepatic extension after chemo. 2 patients progressed on chemotherapy.
Surgery was performed in 15 patients. Percentage fall in AFP was always more than
percentage fall in tumor volume, except in one patient (this patient died of disease). 6
patients developed new calcifications and 2 showed increase in pre-existing calcifications
post-chemotherapy. There was no correlation between calcification and response.11/13
are disease free (median follow up of 21/2 year) and 2/13 are alive with recurrent
disease. 5 patients died of disease. 9 /11 patients with >90% fall in AFP post induction
chemotherapy followed by complete treatment are doing well, the other two are alive
with treated recurrence (p value 0.049).
Conclusion: Down-staging doesn’t occur commonly after chemotherapy. The response
in tumor volume is usually less than the fall in SerAFP.
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HEPATOBLASTOMA: OUTCOMES OF 72 PATIENTS TREATED IN A SINGLE
CENTRE
S. Agarwala1, D. Mittal1, V.K. Iyer2, S. Mathur2, M. Jana3, M. Srinivas1, M. Bajpai1,
V. Bhatnagar1, A.K. Gupta3, D.K. Gupta1
1All India Institute of Medical Sciences, Pediatric Surgery, Delhi, India; 2All India
Institute of Medical Sciences, Pathology, Delhi, India; 3All India Institute of Medical
Sciences, Radiodiagnosis, Delhi, India
Background/Objectives: To evaluate the outcomes of hepatoblastoma(HB) patients
treated atour centre over last 14 years.
Design/Methods: Prospective study of all patients of hepatoblastoma registered from
January 1999 to December 2013. Pretext staging system and risk categorization were
used. All were treated with either Cisplatin+Doxorubicin (PLADO) or Cisplatin
monotherapy (Mono). Kaplan Meier estimates of overall survival (OS) and event free
survival (EFS) was made where death and recurrence of tumor was taken as event.
Results: Of the 72 patients of HB there were 6(8.3%); 35(48.6%); 26(36.1%) and 5(7%)
PRETEXT I; II; III and IV respectively. Forty one (57%) were SR and 31(43%) HR.
Neoadjuvant chemotherapy was given to 69(95.8%) patients and 3(4.2%) underwent
upfront resection. Of the 41SR patients, 38(92.7%) received neoadjuvant chemotherapy
(26 PLADO; 11 Mono; 4 Mono+PLADO) and 35(92.1%) had good response to
chemotherapy. Of the 31HR patients, all received neoadjuvant PLADO and only
20(64.5%) had good response to chemotherapy. Sixty four (89%) patients [40/41(98%)
SR; 24/31 (77%)HR] underwent resection while 8(11%) [1 SR; 7HR] could not be
operated [2 lost to FU and 6 preoperative deaths]. Fourteen (19.4%) patients had lung
metastasis and of these only 5(35.7%) achieved CR while 5 died, 2 were lost to follow
up and 2 had progressive disease. Sixteen of 64 (25%) resected patients [5/40 (13%)
among SR; 11/24 (46%) among HR] had recurrence. Overall 20/72 (28%) patients died
[6/41 (15%) among SR; 14/31 (45%) among HR]. The 5-year OS was 68.5% (95CI
100-136, mean survival time of 118m) [83.4% for SR; 44.9% for HR(p= 0.0006)] and
5-year EFS was 56.4%(95CI 79-117, mean survival time of 98m) [78.4%for SR and
26.1% for HR(p=0.000)].
Conclusion: Even with neoadjuvant chemotherapy, 11% patients could not be resected.
There was significant difference in the 5-yr OS (p=0.0006) and EFS (p=0.000) between
SR and HR patients.
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SURVIVAL AFTER COMPLETION OF THERAPY FOR PRIMARY AND
METASTATIC LIVER TUMORS IN CHILDREN
R.B. Interiano1,2, N. Hinkle1,2, M.E. McCarville3, M. Bachier-Rodriguez1,
A.H.P. Loh2,4, W.L. Furman5,6, M.R. Langham1,2
1Department of Surgery, University of Tennessee Health Science Center, Memphis, TN,
USA; 2Department of Surgery, St. Jude Children’s Research Hospital, Memphis, TN,
USA; 3Department of Radiological Sciences, St. Jude Children’s Research Hospital,
Memphis, TN, USA; 4Department of Paediatric Surgery, KK Women’s and Children’s
Hospital, Singapore; 5Department of Oncology, St. Jude Children’s Research Hospital,
Memphis, TN, USA; 6Department of Pediatrics, University of Tennessee Health Science
Center, Memphis, TN, USA
Background/Objectives: To examine the relationship between completion of therapy
and outcomes for children with primary and metastatic liver tumors treated at a single
program.
Design/Methods: Records of children with primary or metastatic liver tumors treated at
our institutions between 1/1/2005 to 12/31/2014 were reviewed. Completion of therapy
was defined as no evidence of disease (NED) off chemotherapy.
Results: Thirty five children were treated for 19 hepatoblastomas (HB), 5 hepatocellular
carcinomas (HCC), 2 rhabdoid tumors, 1 embryonal sarcoma, 2 metastatic Wilms
tumors, 1 metastatic adrenocortical carcinoma (ACC), and 5 benign lesions. Eighteen
with HB underwent biopsy with neoadjuvant therapy, and 1(PRETEXT 2 V1P1)
underwent primary resection. Two died without resection. Three changed  1 sector
from PRE to POSTTEXT with therapy. Seventeen were resected and achieved NED.
Of 16 non-HB patients, 2 with extensive HCC and 1 with metastatic rhabdoid tumor of
the liver died without resection. One child underwent two resections 13 months apart.
NED status was achieved in 11 of 13.
The 31 resections included 17 conventional, 11 extreme and 3 treated with total
hepatectomy and liver transplantation at referral hospitals. Extreme resections included
reconstruction of the vena cava (4), hepatic veins (1), bile ducts (2), mesohepatectomy
(1), trisectorectomies (7), and hyperthermic intraperitoneal chemotherapy (1). There
were no perioperative deaths. Eight patients had Common Terminology Criteria for
Adverse Events (CTCAE) grade 3 or 4 postoperative complications. Three patients died
of recurrent (rhabdoid) or progressive (HCC, ACC) disease .75, 1.1, and 2.5 years after
resection. There have been no late deaths from HB or benign disease. Twenty seven of
twenty eight children completing therapy with NED are alive at a median of 2.6 years
(range: 0.1-8.8).
Conclusion:Most hepatic tumors in children can be successfully resected or referred for
transplantation. Children completing therapy with NED have excellent survival.
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AN APPRAISAL OF MINIMALLY INVASIVE SURGERY FOR THORACIC
NEUROGENIC TUMOUR. A MULTICENTER STUDY
F. Guérin1, S. Sarnacki2, F. Varlet3, P. Delagausie4, J. Rod5, M. Demarche6,
M. Alkhamis1, G. Rodesch7, A.L. Luis Huertas8, E. Habonanima9, H. Martelli1,
S. Irtan10
1Bicêtre Hospital, Pediatric Surgery, Le Kremlin Bicêtre, France; 2Necker Hospital,
Pediatric Surgery, Paris, France; 3Hôpital Nord, Pediatric Surgery, Saint-Etienne,
France; 4Hôpital la Timone Enfants, Pediatric Surgery, Marseille, France; 5Centre
Hospitalier Universitaire Côte de Nacre, Pediatric surgery, Caen, France; 6Centre
Hospitalier Régional Citadelle, Pediatric Surgery, Liège, Belgium; 7Hôpital Universitaire
des Enfants Reine Fabiola, Pediatric Surgery, Bruxelles, Belgium; 8Hospital Universitario
Infantil Niño Jesús, Pediatric Surgery, Madrid, Spain; 9Centre Hospitalier Universitaire
de Rennes, Pediatric Surgery, Rennes, France; 10Hôpital Armand Trousseau, Pediatric
Surgery, Paris, France
Background/Objectives: To assess the outcome and efficacy of thoracoscopy for
children with mediastinal neurogenic tumours.
Design/Methods: Retrospective review from 9 centres between 2000 and 2014 of
patients who underwent thoracoscopy for a neurogenic mediastinal tumour. We
assessed preoperative data, operative complications, and outcome. Results are
expressed in median and range.
Results:We identified 68 patients aged 3 years [5 months-15 years]. The median
diameter at diagnosis was 5cm [1.5-15]. INRG stratification was L1: n=41, L2 n= 16,
Ms n= 3, M n= 8. Eighteen patients with image defined risk factors (IDRF) had a
preoperative chemotherapy which allowed a 12% decrease of the largest diameter in 13
patients. Among them, 7 had still IDRF preoperatively. Median diameter at surgery
was 4.7cm [1-12]. Thoracoscopy was performed with insufflation in 19 patients. Tumour
spillage occurred in 10 patients and conversion to thoracotomy was necessary in 8
patients: for vascular encasement in 4 and a difficult location or dissection in 4. Median
operative time was 2 hours [1-6]. Fifty-seven patients had a chest drain for 2 days [1-11].
Pathology was 32 Neuroblastomas, 17 Intermixed Ganglioneuroblastoma, and 19
Ganglioneuromas). Immediate post-operative adverse events consisted of 3 Horner
syndromes, 5 Pneumothorax, 3 chylothorax. Length of hospital stay was 4 days [2-15].
Median follow-up was 23 months [1-109]. Long term complications consisted of 2 more
Horner syndromes, 3 scoliosis/back pain, and 1 delayed chylothorax. Forty patients had
a residual disease on post-operative imaging, among them 5 (4 were L1 and 1
Mestatatic) had a recurrence at 10 months [2-60]: 1 local, 3 local plus metastatic, 1 pure
metatstaic. Two patients died at 9 and 10 months after surgery.
Conclusion:Minimally invasive surgery is safe for thoracic neurogenic tumours without
vascular IDRF, however, relapse is mainly local without identified preoperative risk
factor.
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RECOVERY OF NEUROLOGICAL DEFICITS IN PATIENTS WITH
NEUROBLASTOMAWITH INTRASPINAL EXTENSION: IS SURGICAL
DECOMPRESSION REALLY REQUIRED?
S. Agarwala1, D.K. Yadav1, D. Mittal1, S. Bakhshi2, M. Srinivas1, M. Jana3,
A.K. Gupta3, M. Bajpai1, V. Bhatnagar1, D.K. Gupta1
1All India Institute of Medical Sciences, Pediatric Surgery, Delhi, India; 2All India
Institute of Medical Sciences, Medical Oncology-BRAIRCH, Delhi, India; 3All India
Institute of Medical Sciences, Radiodiagnosis, Delhi, India
Background/Objectives: To evaluate the outcome of patients with neuroblastoma with
intraspinal extension.
Design/Methods: All children of neuroblastoma with intraspinal extension registered
from June 1996 through June 2014 were included in the study. INSS was used for
staging. All patients were treated with chemotherapy
(Cyclophosphamide+Doxorubicin+Etoposide+Cisplatin). Neurological recovery and
survival were evaluated.
Results: Of the 264 patients registered in our clinic 29(11%) had intraspinal extension
of the tumor. There were 1(3%), 15(52%), 13(44%) patients in Stage 1, 3, 4 respectively.
Primary site was abdominal in 13(45%), pelvic 2(7%) and thoracic 14(48%). Twenty
(69%) of the patients had neurological symptoms at presentation [13(65%) paraplegia;
2(10%) limping, 1(5%) unstable gait, 2(10%) root pain and 10(50%) neurogenic
bladder/bowel]. The history of neurologic symptoms was from 8 weeks to 20 weeks. Of
the 20 patients with neurological symptoms 17(85%) received chemotherapy alone and
3(15%) underwent laminectomy and decompression of spinal canal. Neurological
recovery was seen in 17/20(85%) patients [10(50%) partial; 7(35%) complete] and in
1(5%) there was no recovery while 2(10%) had progressive disease and discontinued
treatment early in the course and so neurological recovery could not be assessed.
Among 17 patients who received initial chemotherapy 16 (95%) recovered neurologically
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[10(59%) partial; 6(36%) complete] and in 1(6%) there no recovery. All the 3 patients
who underwent initial laminectomy recovered neurologically [2(67%) partial and 1(33%)
complete]. Of these 29 patients with intraspinal extension 27 were alive (93%) [16(59%)
disease free, 9(33%) stable disease and 2(7%) progressive disease] while 2(7%) had died
of progressive disease. Of 15 patients with paraplegia 13 were ambulatory [12 without
support;1 with calipers] while 1 showed no improvement and 1 could not be assessed.
Conclusion: Even late presenting neurologic deficits, due to intraspinal extension of NB,
improves with chemotherapy in a substantial number of patients and surgical
decompression may not be required.
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EFFICACY OF THREE-DIMENSIONAL PRINTINGMODEL BASED ON
PREOPERATIVE CT IMAGES FOR THE SURGERY OF PEDIATRIC
MALIGNANCIES
R. Souzaki1,2, Y. Kinoshita1, S. Ieiri1, N. Kawakubo1, Y. Koga3, T. Jimbo1, S. Obata1,
K. Miyoshi4, K. Kohashi4, Y. Oda4, T. Hara3, M. Hashizume2, T. Taguchi1
1Kyushu University, Department of Pediatric Surgery, Fukuoka, Japan; 2Kyushu
University Hospital, Department of Advance Medicine and Innovative Technology,
Fukuoka, Japan; 3Kyushu University, Department of Pediatrics, Fukuoka, Japan;
4Kyushu University, Department of Anatomic Pathology, Fukuoka, Japan
Background/Objectives: 3-dimensional (3D) printing model based on preoperative
computerized tomography (CT) images facilitate visualization of complex structures
such as vessels and tumors and it is useful for understanding anatomies of the variety
of organs preoperatively. We report our experience with the preoperative surgical
simulation using a 3D printing model based on preoperative CT images for pediatric
malignancies.
Design/Methods: The multi-detector CT images were transferred to a 3D workstation
and 3D volume data were obtained by reconstructing the sections. A 3D model was
made with 3D printer using acrylic ultraviolet curable resin. The variety of organs such
as the tumor, kidney, liver, spleen, vessels and outer body were selected to fabricate in
each case.
Results:We used 3D model for 9 cases with pediatric malignancies (3 neuroblastoma
(NB) cases, 2 soft tissue sarcoma cases, one hepatoblastoma case, one mediastinal yolk
sac tumor case and 2 cases with local recurrence of Wilms tumor and clear cell sarcoma
of kidney). The tumor and vessels can be seen through the translucent body such as
liver and we can evaluate patient’s anatomies, especially tumor location from all angles
using this model. For laparoscopic surgery, 3D model was made it possible to be
inserted trocars and the pneumoperitoneum, so that we can discuss the port layout
before the operation and to simulate the laparoscopic view and range of forceps
movement using 3D model. The laparoscopic view in the 3D model almost completely
matched the real laparoscopic view during surgery. All nine cases performed surgical
treatment without any complications.
Conclusion: The surgical simulation using 3D printing models based on preoperative
CT images for pediatric malignancy was very useful for understanding the patient’s
anatomy and for planning the surgical strategies.
Nurses - Free Papers Session 1: Nursing Across the Spectrum of Paediatric Oncology
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PAEDIATRIC ONCOLOGY SPECIALIZATION IN AFRICA: COLLABORATION
BETWEEN CAMEROON AND SOUTH AFRICA
B. Ramaru1, G. Mbah Afungchwi2
1Walkerville, South Africa; 2Banso Baptist Hospital, Pediatrics, Kumbo, Cameroon
Background/Objectives: This is a collaboration between Cameroonian and South
African nurses on various challenges facing nurses regarding paediatric oncology
specialization in Africa. The collaboration resulted from a nursing roundtable during
SIOP Africa 2014. Neither country has formal paediatric oncology nursing training in
higher education, so both countries participate in twinning programs to try to bridge
the gap. We identify the learning needs of nurses caring for children with cancer in each
country.
Design/Methods:We explored the experiences of nurses caring for children with cancer
at Banso Baptist Hospital and Charlotte Maxeke Johannesburg Academic Hospital. We
compared the local nursing challenges and training needs while highlighting the
importance of a needs analysis.
Results: In Cameroon, there is a need for specialized paediatric oncology nurses,
training in palliative care, counselling techniques and advocacy skills to raise public
awareness since in general practice, 26% of nurses were found to have no knowledge of
childhood cancer. In South Africa, general nurses lack interest in paediatric oncology
nursing believing that these children all die, and those working in the field need further
training to support children’s compliance with treatment and advocacy skills for
awareness as well. There is a critical need for a paediatric oncology nursing certificate in
higher education for nurses to truly partner with physicians. The success of any
twinning program depends on the directive of the nurses in that low-income country.
Conclusion: African nurses must identify and communicate their learning needs to
twinning partners, rather than remain passive recipients of Western/Northern teaching.
There is a great need for dissemination of information between African countries as
well as from high-income countries. Ownership of the learning process by African
nurses will make twinning programs and curriculum development more relevant and
beneficial to all parties, including the children and families who come for care.
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BEING HOME AFTER A CHILDS’ HEMATOPOETIC STEM CELL
TRANSPLANTATION. THE EXPERIENCES AND COMMITMENTS PARENTS
FACE, THE INFLUENCING FACTORS AND THEIR NEEDS AS A RESULT
V. Van de Velde1, F. Mussche2, C. Dhooge1, M. Grypdonck3
1University Hospital Ghent, Pediatric Hemato - Oncology, Ghent, Belgium; 2University
Hospital Ghent, Pediatric department, Ghent, Belgium; 3University Ghent, Nursing
Science and Midwifery, Ghent, Belgium
Background/Objectives: To understand how parents experience the post-transplant
period of their child, to get an insight in their commitments and to describe the
influencing factors and the needs of the parents in order to improve overall support of
the parents during post-transplant hospital visits.
Design/Methods: A descriptive qualitative study was conducted in which semi
structured interviews were held with 15 parents. During a two year period at least one
parent of all HSCT patients participated. The interviews were transcribed and coded
(NVivo7). Constant comparison was used to analyse the data.
Results: Once home, parents face the total responsibility of care of their child. The
continuous monitoring implies a great burden and it requires a great of effort to
integrate the rules received from the professionals into their daily routine. Not only are
the parents confronted with an insecurity in the medical evolution but also with the
qualtity of life of their child.
Factors which can influence the experiences to a greater or lesser extent are: the disease
progression, the duration of the post transplant period, the relationship with the
partner, the family situation, social environment, personal factors, personal
background, practical and financial situation, … Parents adjust their lifestyle to take
care of their child, prioritizing it over their own needs. Depending on these influencing
factors, parents have different needs. A trustful relationship is needed with
professionals, and, above all, they need to receive all the information they require. They
need psychosocial and practical support, as well as when making decisions.
Parentsappreciate help in the education of the siblings. Some of them need a
professional life and time for themselves.
Conclusion: Parents face an immense, very complex and extensive commitment when
they return home with their child after HSCT.
Results: The results of this study create an awareness in professionals and are a first step
towards improved post-transplant consultations.
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NURSING CARE FOR PATIENT WITH RETINOPLASTOMA IN ANGKOR
HOSPITAL FOR CHILDREN
R. Sinketh1, C. Sinn2, V. Kumar3, S.N. Sath2
1Angkor Hospital for Children, Siem Reap, Cambodia; 2Angkor Hospital for Children,
Emergency Room/ICU, Siem Reap, Cambodia; 3Angkor Hospital for Children, Medical
Education Supervisor, Siem Reap, Cambodia
Background/Objectives: Angkor Hospital for Children (AHC) is a pediatric referral
hospital in Cambodia which started a new Retinoblastoma treatment program in late
2013. This involved providing chemotherapy agents which had never been used before
at AHC. Contrary to many developing countries, nursing at AHC played an essential
role in planning and implementing this new initiative and continues to be
fundamentally involved in the ongoing oncology activities.
Design/Methods:We provide a detailed description of the role of nursing in a new
developing world cancer treatment service.
Results: Nursing was identified early on as a priority for the AHC oncology service and
as such, two senior AHC nurses were among the AHC core cancer team leaders during
program development. As the program progressed, three more nurses were included
and nurses now make up 50% of the cancer team. The role of the nurses includes
general clinical nursing, mixing and administering the chemotherapy, and maintaining
close communication with the patients/parents in hospital and at home. In addition the
oncology nursing team provides cancer related education to the general clinical staff at
AHC. The nurses have also taken key roles in providing guidance for patients’ pain and
palliative management. To date, 21 patients with Retinoblastoma patients have
undergone chemotherapy treatment, 6 of whom were for palliative purposes with 4
deaths, and one who abandoned treatment. The remaining are still alive.
Conclusion: Including nursing in the planning and implementation of any new
oncology program is essential to the success and survival of such initiatives.
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Furthermore, the experience at AHC highlights the value of including nursing in more
than just a supportive role. Plans to extend this program to other cancers will continue
to emphasize the important role of nursing.
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THREE YEAR EXPERIENCE OF PAKISTAN’S FIRST PEDIATRIC
HEMATOLOGY ONCOLOGY INTENSIVE CARE UNIT
A. Qidwai1, S. Punjwani2
1Afzaal Memorial Thalassemia Foundation, Pediatric Hematology Oncology, Karachi,
Pakistan; 2Afzaal Memorial Thalassemia Foundation, Nursing, Karachi, Pakistan
Background/Objectives: Hematology-oncology diseases are becoming a major health
care problem in Pakistan. The actual size of the problem is unknown since there is no
national population-based hematology-oncology registry. Global statistics depicts
rising cases of children suffering through haemoglobin disorders and early childhood
cancers as the leading cause of morbidity and mortality worldwide. Looking at these
statistics AMTF took initiative in establishing Pakistan’s First Pediatric Hematology
Oncology ICU (PHOICU) with generous support from Government of Japan.
PHOICU project was started in 2011 and was open for services in February 2012. This
year PHOICU have completed 3 years of successful running in February 2015. The
primary objective of this study is to review clinical data and outcomes of patient with
hematology oncology diseases in PHOICU. The article will illustrate organizational
and clinical work carried out in 3 year activity of first specialized Pediatric Hematology
Oncology ICU in Pakistan.
Design/Methods: Descriptive exploratory study was conducted and retrospective data
regarding patient admission was reviewed from patient’s chart and ICU record registers
from February 2012 to January 2015. Data was obtained regarding patient age, sex,
diagnosis, date and reason of ICU admission, comorbidities, length of ICU, and
outcome and in case of mortality cause of death.
Results: Total number of admissions were 558, 762 and 652 in year 2012, 2013 and 2014
respectively. The admission trend over the period of three years is 67.1% pediatric
oncology and 32.9% hematology in year 1, 49.6% pediatric oncology and 50.4%
hematology in year 2, and 60.4% pediatric oncology and 39.5% hematology in year 3.
Mean age of patients admitted is 8.26 years. Average length of stay in ICU was of 6.83
days.
Conclusion:More specialized ICU for pediatric patients diagnosed with
hematological/oncological diseases are highly required for providing quality care.
Pakistan’s first hematology/oncology ICU can serve as a model for future projects.
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OUTCOMES FOR CHILDRENWITH NEPHROBLASTOMA IN
JOHANNESBURG. NURSING ANDMEDICAL PERSPECTIVES FROM A
SINGLE CENTRE
G. Mnisi1, T. Ngcana2, J. Geel3
1Department of Nursing Education-University of the Witwatersrand, Division of
Paediatric Haematology and Oncology-Charlotte Maxeke Johannesburg Academic
Hospital, Johannesburg, South Africa; 2Faculty of Health Sciences-University of the
Witwatersrand, Department of Paediatrics and Child Health, Johannesburg, South
Africa; 3Faculty of Health Sciences-University of the Witwatersrand, Division of
Paediatric Haematology and Oncology-Charlotte Maxeke Johannesburg Academic
Hospital, Johannesburg, South Africa
Background/Objectives: Patients with nephroblastoma have excellent survival rates in
high income countries. South Africa, as an upper middle income country, has access to
most chemotherapy agents, and excellent radiation, paediatric surgical and intensive
care services. However, many patients with paediatric malignancies present late and
have poor outcomes. This study aimed to characterise a cohort of patients with
nephroblastoma in Johannesburg in order to determine nursing priorities.
Design/Methods: A retrospective review was conducted of patients with
nephroblastoma treated at Charlotte Maxeke Johannesburg Academic Hospital from
January 1999 to December 2009. Descriptive statistical methods were employed.
Results: Records from 65 patients were eligible for inclusion. The male to female ratio
was 1.27:1 and the mean age was 3.5 years. The distribution by stage was: 21 Stage I, 8
Stage II, 21 Stage III, 12 Stage IV and 3 Stage V. Patients were treated according to the
SIOP 9 nephroblastoma protocol, using vincristine, actinomycin and adriamycin. The
crude five year survival rate was 69%. Causes of death included infection (7/15), disease
(6/15) and post-operative complications (2/15). Eight patients relapsed, of whom only
one was successfully salvaged.
Conclusion: The survival rate in this cohort is encouraging for a middle income country
and most likely reflects tumour biology rather than access to care or quality of care.
The lack of successful salvage therapies in South Africa dictates that first line therapies
be aggressive. Nursing staff should be aware of the high rate of infection and make
every effort to prevent infections, and to treat them proactively when they occur.
Outreach efforts by nurses should concentrate on malignancies such as nephroblastoma
as they are under-diagnosed in South Africa but have a good prognosis.
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PARENTAL CHALLENGES FOR OBTAINING AN ACCURATE DIAGNOSIS
FOR THEIR CHILDWITH CANCER AND REACHING AN APPROPRIATE
TREATMENT CENTRE IN INDIA
A. Mahajan1, B. Agarwal2, Y. Amdekar3, M. Varughese4
1B.J.Wadia Hospital for Children, Mumbai, India; 2B.J.Wadia Hospital for Children,
Department of Haematology and Oncology, Mumbai- Maharashtra, India; 3B.J.Wadia
Hospital for Children, Hospital Academic Administration, Mumbai- Maharashtra, India;
4B.J.Wadia Hospital for Children, Department of Pediatric Haematology and Oncology,
Mumbai- Maharashtra, India
Background/Objectives: Purpose: In a low - resource country like India, the child and
family often stagger from hospital to hospital, city to city before hopefully reaching an
appropriate childhood cancer treatment centre. Our objective was to identify delays in
recognising cancer symptoms and diagnosis, lack of referral pathways and above all the
large vacuum of information and guidance.
Design/Methods: A retrospective study and review of the topic was performed during
2013-2014 with 60 parents of newly diagnosed pediatric cancer patients (all ages, recent
diagnosed) in a hospital in Mumbai. Information was obtained from patient files, initial
outside consultation records and individual parent interviews.
Results: 90% of our patients were from rural areas and their parents had little education
and low economic status. 10% from urban areas, well educated with middle economic
status. 100% of the parents interviewed had experienced the following challenges: Did
not recognize the signs of cancer; Treated child’s on and off fevers locally and child
remain undiagnosed; An absence of clear referral pathways; Did not have the resources
to get their child to a medical facility; Once at a clinic or hospital, a lack of resources or
medical equipment meant a diagnosis was not made. Even when cancer was recognized,
a further referral was made; Large vacuum of information and guidance; Parents
experienced 5 -6 referrals before reaching our pediatric oncology ward.
Conclusion: One of the huge challenges facing low - income countries, including India,
is a timely diagnosis, referral and treatment. Lack of awareness among parents and
health professionals hampers timely presentation for cancer treatment. This adversely
affects the outcome requiring greater treatment intensity, supportive care, costs,
treatment toxicity, treatment abandonment rates and poorer outcomes. Nursing must
assume a strong role in improving childhood cancer awareness and advocating for a
more streamline referral process.
Nurses - Free Papers Session 2: Training & Supporting the Nursing Workforce
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CAPACITY BUILDING STRATEGIES FOR CRITICAL PEDIATRIC
ONCOLOGY NURSING IN A LIMITED RESOURCE SETTING: A REPORT OF
CHILDREN CANCER HOSPITAL, KARACHI, PAKISTAN
S. Bana1, R. Punjwani2, A. Khatoon3
1Children Cancer Hospital, Nursing Services, Karachi, Pakistan; 2Children Cancer
Hospital, Nursing Education Services, Karachi, Pakistan; 3Children Cancer Hospital,
Infection Control, Karachi, Pakistan
Background/Objectives: The High Dependency Unit (HDU) provides intermediate care
between the general ward and Intensive Care Unit (ICU) and serves as a step-up or
step-down facility. As per critical care standards by the UK Royal College of
Paediatrics and Child Health (2014),our HDU is appropriate for level 2 critical care, in
which more intricate nursing care is provided to critically ill children who require close
monitoring and supervision by more proficient nursing and medical staff with relevant
specialized training.
Design/Methods: Due to the needs of pediatric oncology at the Children Cancer
Hospital (CCH), the HDU facility was expanded from 2 to 5 beds as of January
2015.Currently, CCH collaborates with an out-sourced ICU to manage patients
requiring advanced airway support. But, to provide quality healthcare to patients
within the facility and to reduce the cost of the out-sourced ICU, the HDU had to be
expanded.To build the capacity of pediatric oncology nurses and technicians working
in the HDU, an extensive and thorough one-week critical care course was designed by
the Head Nurse and Nursing Education Department and included theory and clinical
training. This staff was also recertified for core oncology nursing processes.
Results: Currently, 78% of the HDU nurses and technicians in CCH have been trained
to provide quality focused critical nursing care to pediatric oncology patients. The
impact of aggressive capacity-building activity of HDU nurses is in the process of
being monitored and evaluated. To motivate nursing staff further, an HDU
supplemental allowance is given.
Conclusion: CCH has extended their capacity to provide advanced nursing care,
optimized resources for providing quality nursing care and increased the skills and
knowledge of critical care nurses caring for pediatric oncology patients.
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CHEMOTHERAPY/BIOTHERAPY NURSING EDUCATION IN LATIN
AMERICA: AN INITIATIVE OF THE ASSOCIATION OF PEDIATRIC
HEMATOLOGY/ONCOLOGY NURSES
C. Sullivan1, L. Abramovitz2, J. Gattuso3, J. Brace O’Neill4, J. Challinor5
1St. Jude Children’s Research Hospital, International Outreach Program, Memphis,
USA; 2UCSF Medical Center, Oncology, San Francisco, USA; 3St. Jude Children’s
Research Hospital, Nursing Research, Memphis, USA; 4Dana-Farber Cancer Institute,
Pediatric Oncology, Boston, USA; 5University of California San Francisco, School of
Nursing, San Francisco, USA
Background/Objectives: Literature has documented a lack of standardized,
comprehensive pediatric oncology nursing education in Latin America. The
Association of Pediatric Hematology/Oncology Nurses (APHON) has received
numerous requests from international nurses to participate in the APHON
Chemotherapy/Biotherapy certification course. Recently, the supplementary course text
was translated into Spanish and distributed complimentarily to 13 institutions in 9
countries. To increase access to this standardized education/training course, APHON’s
International Task Force recommended transculturally adapting and offering a Spanish
APHON certificate course.
Design/Methods: A 43-item needs assessment in Spanish was created by expert nurse
educators and clinicians with relevant international experience. Using a snowball
methodology, an online survey was initially sent to 43 stakeholders from 24 hospitals, in
17 countries, to assess: current chemotherapy education, common chemotherapies, and
supportive resources. Two bi-lingual Chilean nurse educators will take the English
course and provide feedback for cultural adaptation. Final Spanish content will be
determined through survey results, expert feedback, and peer-review. The course will be
piloted in Chile and then offered across Latin America.
Results: In preliminary survey results from 14 nurses, representing 14 hospitals in 12
countries, one-third reported no chemotherapy education/training for new nurses.
Two-thirds offered orientation with variable duration (2-4 weeks) and content. Many
existing orientation programs lacked APHON course content that the Latin American
nurses also identified as important: biotherapies (75%), cancer genetics (37.5%), drug
half-life (44%), late effects (44%), legal and ethical issues (56%), psychosocial issues
(44%), and navigating research protocols (87.5%). Fifty-percent lacked chemotherapy
continuing education programs. The majority (71%) of nurses prepare chemotherapy.
All wished to participate in the APHON course.
Conclusion: Based on preliminary survey results, there is significant demand for a
standardized, comprehensive, and transculturally appropriate chemotherapy course for
Latin American nurses. APHON’s Spanish Chemotherapy/Biotherapy course will offer
essential nursing education to enhance safe chemotherapy practices and improve
treatment-related outcomes.
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PERCEPTIONS OF PAKISTANI ONCOLOGY NURSES REGARDING THEIR
ROLE IN SUPPORTIVE CARE: CHALLENGES AND NEEDS - A PILOT STUDY
R. Punjwani1, J. challinor2, A. Khatoon3, N. Ansari4, S. Bana5
1Children Cancer Hospital, Karachi, Pakistan; 2University of California, Associate
Adjunct Professor of Nursing, San Francisco-California, USA; 3Children Cancer
Hospital, Infection Control, Karachi, Pakistan; 4The Indus Hospital, Indus Hospital
Research Center, Karachi, Pakistan; 5Children Cancer Hospital, Nursing services,
Karachi, Pakistan
Background/Objectives: Globally, meeting the supportive care needs of children and
their families remains a challenge in the continuum of cancer care. Pediatric oncology
nurses play a major role in supportive care and several studies have suggested that
nursing education contributes to improved patient outcomes, including reduced
mortality. In contrast to the extensive supportive care education and clinical training
provided to nurses in high-income countries, pediatric oncology nursing education is
largely unavailable in Pakistan. This study is designed to determine Pakistani pediatric
oncology nurses’ perceptions of their role in supportive care; identify challenges; and
explore learning needs.
Design/Methods: An experienced pediatric oncology nurse educator interviewed nine
nurses in a childhood cancer center in Karachi as a pilot for a planned in-depth study.
The center treats APPROX 350 children/year cared for by 49 nurses. The nurses were
questioned about their understanding of supportive care and how they saw their ability
to provide this care. Phase two of the study will include in-depth interviews with nurses
from pediatric oncology units in public and private sector hospitals (face-to-face or via
telephone) in Islamabad, Karachi, and Lahore.
Results:Major themes that emerged during the pilot study included knowledge deficits
and communication challenges when providing psychosocial support—uncertainty of
doctor-nurse boundaries for what can and cannot be communicated to the child and
family. Time constraints and staff shortages were challenges and hindered the nurses’
psycho-social support versus activity-based clinical care. Nurses also stressed a need for
supportive care education to decrease their knowledge gap and build confidence.
Conclusion: This study provides a much needed initial assessment of the gaps in
Pakistani nurses’ understanding of their role in supportive care and highlights areas
that need to be further explored. Study findings from phase two will be used to design a
curriculum to address supportive care nursing education needs.
O-177
LOW SELF-REPORTED RATES OF BURNOUT IN JOHANNESBURG NURSES
IN ONE PAEDIATRIC ONCOLOGY UNIT
P. McCusker1, J. Geel2
1Charlotte Maxeke Johannesburg Academic Hospital, Division of Paediatric
Haematology and Oncology, Johannesburg, South Africa; 2Faculty of Health
Sciences-University of the Witwatersrand, Division of Paediatric Haematology and
Oncology-Charolotte Maxeke Johannesburg Academic Hospital, Johannesburg, South
Africa
Background/Objectives: Burnout is a syndrome of emotional exhaustion and
depersonalisation which can result in reduced personal accomplishment. In a busy and
under-staffed paediatric oncology unit in Johannesburg, a high rate of absenteeism and
staff turnover was noted. This population of highly skilled nursing staff had not
previously been assessed for signs of burnout. The primary objective of this study was
to assess the permanent nursing staff working in the paediatric haematology/ oncology
unit at Charlotte Maxeke Johannesburg Academic Hospital to determine the prevalence
of signs of burnout, and secondly, to determine if any intervention was required.
Design/Methods: A questionnaire based on the Maslach Burnout Inventory (MBI) was
administered to all permanent nursing staff in both the in- and out-patient units by a
single researcher. The MBI, validated as a measure of burnout, measures emotional
exhaustion, depersonalisation and personal achievement. A high score in the first two
sections and a low score in the last section may indicate burnout. Nursing staff
completed the questionnaires and the results were scored and interpreted.
Results: The response rate was 25/27 (93%). Eight respondents (32%) fulfilled no
criteria for burnout, while the remainder of the participants showed varying levels of
emotional exhaustion, depersonalisation and decreased personal achievement, though
none met the criteria for full blown burnout. This indicates a population at risk. Senior
staff members encourage debriefing and freedom of expression, possibly contributing
to the low rate of burnout, although burnt out nurses may leave the unit.
Conclusion: The results of this study do not confirm the hypothesis that nurses in this
unit demonstrate high levels of burnout. Nevertheless, nursing staff are susceptible and
we recommend that nurses in paediatric oncology units be made aware of the
possibility of burnout, be mindful of self-care and access available support services.
O-178
EXPLORING CHALLENGES FACED BY ONCOLOGY NURSES IN A
TERTIARY CANCER CARE HOSPITAL IN INDIA
S. Joshi1
1Tata Memorial Hospital, Nursing Administration, Mumbai, India
Background/Objectives: High quality nursing is central to the care of children with
cancer. However nurses in India face many challenges while providing nursing care to
children. Which are the different challenges they face?
Design/Methods: Exploratory Survey. Structured interview schedule.
Results:Majority of nurses were from age group of 31-40 years(60%) 20% were
educated up to Nursing degree, 40% have undergone oncology training and 15% have
attended special training of pediatric nursing. Nurse patient ratio is inadequate and
absenteeism put the pressure on the nurses to complete the task. Nurses try to complete
job with trial and error. 65% agreed lot of time is utilized for non nursing job like
controlling relatives, computer work etc.Nurses sometimes face challenges with new
equipments (65%). But they (100%) agreed that they were trained with functioning of
equipments. Most of them agreed that they do functional assignments especially in
evening and night when there is shortage of staffs. They are sometimes (55%) counseled
and supported by superiors. They accepted that (75%) they sometimes face difficulty in
communicating with superiors, father of child, and subordinates. But never had
problem in communicating with mother.60% had fear of unsafe environment:
occupational and psychological hazards.70% of them also expressed fear of medico
legal issues. As team member are confident to take decisions during emergency but
emotionally upset (65%) while dealing with parents of terminally ill child.90% shown
concern with family of children who are coming from far distance for treatment and
face difficulty with food and residential arrangements.Very few nurses( 3) said that they
are involved in treatment plans and counseling of parents.
Conclusion: Nurses in pediatric oncology setup in India face lots of challenges which
can be cause of stress. We need to identify these factors and prepare them to face these
challenges in positive way. Thus they can provide quality care to children with cancer.
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STRATEGIES TO REDUCE BLOOD CULTURE CONTAMINATION IN THE
IN-PATIENT AND EMERGENCY DEPARTMENTS OF THE CHILDREN
CANCER HOSPITAL, KARACHI-PAKISTAN
S. Bana1, K. Arifa2, R. Punjwani3
1Children Cancer Hospital, Nursing Services, Karachi, Pakistan; 2Children Cancer
Hospital, Infection Control, Karachi, Pakistan; 3Children Cancer Hospital, Nursing
Education Services, Karachi, Pakistan
Background/Objectives: Blood culture sampling is an essential tool for patient
investigation and treatment plans, but improper technique can lead to false results
eventually causing unnecessary patient suffering, morbidity and additional healthcare
costs.The rate of blood culture contamination at Children Cancer Hospital in 2011 was
30.5%, 2012 - 27.7%, 2013 - 20.1%, and in 2014 - 19.6%. Although the rate is
decreasing, our benchmark for blood culture contamination in healthcare is 3%
(Clinical and Laboratory Standards Institute, 2007).
Design/Methods: A quality-improvement strategy was designed to reduce blood culture
contamination based on earlier findings that when new nurse inductees began working
on the unit, the blood culture contamination rate increased. The intervention had two
components: 1) planning and implementing an intervention to reduce blood culture
contamination in in-patient and Emergency departments and 2) monitoring and
evaluating the effectiveness of the intervention. The planning was done through a
plan-do-study-act model.The Head Nurse designed and implemented the intervention
sessions, an extensive exercise of certifying and re-certifying the nursing staff for blood
culture sampling through innovative teaching techniques. The monitoring and
evaluation are in process in coordination with the laboratory department by analyzing
the rate of contamination and identifying the nursing staff responsible for
contamination to reevaluate their practice and take appropriate action.
Results: Since January 2015, 53% of the nursing staff (including registered nurses and
technicians)working in the above-mentioned departments have been re-certified for
blood culture sampling and the target is to eventually train 100% of the nursing staff.
Conclusion: In the 14 weeks from October 2014 to mid-January 2015, there were 26
contaminated cultures, whereas, after re-certification of 53% of the nursing staff only
five blood culture contaminations were reported in February 2015. The trend is
expected to further decrease when 100% of the nursing staff is trained.
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A SOCIAL NETWORKING TOOL FOR COLLABORATIVE CARE FOR
ADOLESCENTS AND YOUNG ADULTS WITH CANCER, CAREGIVERS, AND
HEALTH CARE PROFESSIONALS: A USABILITY STUDY
J. Stinson1, A. Hussain2, J.A. Cafazzo3, A. Gupta1, D. Hodgson4, T. Jamieson5,
A.L. Chong1, P.C. Nathan1, M. van Wyk1, S. Luca1
1The Hospital for Sick Children, Toronto, Canada; 2Mount Sinai Research Institute,
Temmy Latner Centre for Palliative Care, Canada; 3University Health Network, Centre
for Global eHealth Innovation, Toronto, Canada; 4Princess Margaret Cancer Centre,
Radiation Oncology, Toronto, Canada; 5St. Micheal’s Hospital, Internal Medicine,
Toronto, Canada
Background/Objectives:We aimed to develop and test the usability of a secure,
cross-setting, cross-institutional, and inter-professional online clinical care collaborative
system (LOOP) for adolescents and young adults with cancer, their caregivers and
various healthcare professionals (HCP).
Design/Methods: A qualitative approach with semi-structured audiotaped interviews
and observation by a trained observer was undertaken. Three iterative cycles (conducted
until data saturation) determined the usability of the LOOP interface. A purposive
sample of 10 English-speaking adolescents (17.5±3.0 [M±SD]) and 2 young adults
(22.8±2.1 years) were recruited from two Canadian tertiary care centers for individual
interviews. In addition, a purposive sample of English-speaking HCP specializing in
pediatric oncology (n = 7) and pediatric complex medical care (n = 5) were recruited
for 2 respective focus groups. Descriptive statistics and simple content analyses were
used to organize data into categories that reflected emerging usability themes.
Results: All participants had access to a computer and Internet at home and reported
high levels of comfort using each. Overall, participants liked the appearance of LOOP,
valued its purpose, and felt it was easy to use, navigate, and understand. Identified
usability issues: (1) problematic navigation, (2) needed interface-related changes
(format, layout and aesthetics), and (3) necessary additional functionalities. To address
these issues the following design solutions were implemented: (1) the message stream
was changed to present messages from all users (e.g., HCP, patients) to enhance
collaboration between parties, (2) ‘new message’ notifications were made more obvious,
and (3) the search function capacity was enhanced. No new issues were identified
following the third cycle of testing.
Conclusion: Usability testing was a crucial first step in refining the clinical collaboration
system to meet the various end-users needs. Future work will focus on examining the
impact of LOOP on patient and health service utilization outcomes using a randomized
controlled trial.
O-181
INFORMATION TECHNOLOGY AS A TOOL TO ENGAGE AND DEMYSTIFY
CANCER IN CHILDREN AND ADOLESCENTS
S. Mozzilli1
1Instituto Beaba, Sao Paulo, Brazil
Background/Objectives: Technological evolution, equipment modernization and
internet accessibility are contributing to the increase of Information Technology,
especially in the oncology area, where patients and family members are eager for
information.However, the exponential growth in the amount of information does not
guarantee the quality and responsiveness of it, highlighting the inadequacy and
inappropriateness of information as a cause of fear, insecurity and even lack of
commitment to treatment.This study aims to inform the current situation of renowned
Pediatric Oncology Hospitals websites.
Design/Methods: Ten websites were analyzed in Normative Descriptive Model.The
Descriptive Model contemplates the existence and specificity of the areas: Lexi-Visual
content, organic search and advanced search. (Yes/No)The Normative Model was
based on principles and heuristics proposed by Ergonomics Areas, Human-Computer
Interaction and Information Design: information structure, simplicity, clarity, unity,
usability and acessibility. (Appropriate/Partially Appropriate/Inappropriate).
Results: Twenty percent of the evaluated websites do not have any information.
Twenty-five percent of the websites that have information do not have search.
Thirty-five percent of the websites do not comply with usability principles and a
hundred percent do not comply with accessibility principles. None of the analyzed sites
comply with the adequacy of the Normative Model.
Conclusion: The increase in the search for information is a natural trend of Information
Technology advancement. Whereas cancer patients are more likely to be involved in the
treatment of other chronic disease groups (The Center for Studying Health System
Change, 2010), there is the need to improve the websites of Pediatric Oncology
Hospitals.The appropriate production of information facilitates learning, providing
greater identification, understanding, and ensuring the message quality. All Information
Technology resources should have as its main goal to assist the understanding of
treatment, which is assumed to be humanized and effective, meeting the needs,
providing relief and improving the patient and family quality of life.
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USABILITY TESTING OF THE PAIN SQUAD+ SMARTPHONE-BASED
REAL-TIME CANCER PAIN MANAGEMENT APP FOR ADOLESCENTS WITH
CANCER
L.A. Jibb1, C. Nguyen2, J. Cafazzo3, P.C. Nathan4, E. Seto3, B.J. Stevens2, J.N. Stinson2
1The Hospital for Sick Children, Hematology/Oncology, Toronto, Canada; 2Hospital for
Sick Children, Child Health Evaluative Sciences, Toronto, Canada; 3University Health
Network, Centre for Global eHealth Innovation, Toronto, Canada; 4Hospital for Sick
Children, Hematology/Oncology, Toronto, Canada
Background/Objectives: This study utilized a user-centered design approach to develop
and test the usability (acceptable, understandable, easy to navigate, and not prone to
error-making) of a smartphone-based real-time cancer pain management app (“Pain
Squad+”) for adolescents.
Design/Methods: Three iterative cycles of usability testing involving user observation
were used to refine the Pain Squad+ app. Sixteen adolescents (14.8±2.0 [M±SD] years)
with cancer, and pain in the previous week were recruited from 1 pediatric tertiary care
center. A brief app demonstration was provided and the entire usability testing session
was audio-recorded. Participants used the app while “thinking aloud” about issues
encountered with the interface and content. Two experienced observers recorded
difficulties and navigation errors. Participants then answered open-ended questions
addressing their experience and recommendations for app improvement. Using a
rapid-analysis approach, the observers discussed session content and developed
consensus on emerging themes related to app usability and refinements were made.
Audio-recordings were referred to as necessary.
Results: Overall, adolescents liked Pain Squad+ aesthetics and content, endorsed its
clinically utility, and made few errors. Cycle 1 usability issues related to: (1) streamlining
navigation (recommendation for fewer taps to navigate), and (2) improving access to
gamification elements (ability to review compliance-encouraging videos). Changes were
made to address these recommendations. Cycle 2 issues related to the need to clearly:
(1) distinguish the meaning of pain assessment questions, and (2) present information
related to the dose and timing of recommended pain advice. Changes were made and
no new issues were identified in Cycle 3.
Conclusion: The multifaceted usability approach utilized provided insight into how a
real-time pain management app can be made amenable to adolescents with cancer. Next
steps will include feasibility testing before testing intervention effectiveness in a
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randomized controlled trial. It is expected that an acceptable and usable app will
improve pain outcomes for adolescents with cancer.
O-183
RADIATION THERAPY IN LOW- ANDMIDDLE-INCOME COUNTRIES:
NURSING’S ROLE IN THE FACE OF COMING TECHNOLOGY
J. Challinor1
1Amsterdam, Netherlands
Background/Objectives: An estimated <30% of patients needing radiation therapy (RT)
have access in low- and middle-income countries (LMIC) (Samiei 2013). Efforts such as
the International Atomic Energy Agency’s PACT and AGaRT program and global
twinnings are addressing this critical situation. Despite efforts to explore eliminating RT
through clinical trials in high-income countries, it remains an essential tool for curing
diseases such as retinoblastoma, Hodgkin lymphoma, Ewing’s sarcoma and central
nervous system tumors, and palliation (particularly relevant in LMIC where children
present with late-stage disease).
Design/Methods: Literature from 2009-2015 was reviewed to identify RT currently
available in LMIC and nursing’s role in this specialized area. Search terms included a
combination of key words “radiation therapy”, “nursing”, “developing countries”, and
“low- and middle-income countries”. Additional articles were identified in article
reference lists.
Results: Twenty-six relevant articles were identified: current and historical RT
technology and applications (7), state of RT in LMIC (12), support for RT side effects
and survivorship (7). Nursing was mentioned in 4/26 articles. Despite significant efforts
in LMIC to improve RT, including government equipment purchases and physician and
technician training, there is a significant lack of information on nursing’s role or
training.
Conclusion: Pediatric oncology nurses in LMIC provide many specialist services (e.g.,
nutritional guidance and psychosocial support), due to the severe shortage of allied
professionals. LMIC nurses should have basic knowledge of RT’s capabilities and
associated risks, because their governments and twinning partners are scaling up RT,
children have particular vulnerability to RT, and RT’s suitability for palliation. Low
public awareness of childhood cancer extends to the myths and fears surrounding RT in
LMIC. Whether or not an LMIC unit currently has RT, preparing nurses for the future
of RT in LMIC will ensure that children and their families are informed and supported
to achieve an optimal outcome during childhood cancer RT.
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DEVELOPING AN ONLINE COLLABORATIVE CARE TOOL FOR
ADOLESCENTS WITH CANCER, THEIR CAREGIVERS AND HEALTHCARE
PROFESSIONALS: A CLINICAL USABILITY TEST
J. Stinson1, A. Hussain2, J. Cafazzo3, N. D’Agostino4, D. Hodgson5, T. Jamieson6,
A.L. Chong1, P.C. Nathan1, M. van Wyk1, S. Luca1
1The Hospital for Sick Children, Toronto, Canada; 2Mount Sinai Hospital, Temmy
Latner Palliative Care Centre, Toronto, Canada; 3University Health Network, Centre for
Global eHealth Innovation, Toronto, Canada; 4Princess Margaret Cancer Centre, Cancer
Clinical Research Unit, Toronto, Canada; 5Princess Margaret Cancer Centre, Radiation
Oncology, Canada; 6St Michael’s Hospital, Internal Medicine, Canada
Background/Objectives: The care of adolescents with cancer, both during and after
treatment, requires the collaborative skills and efforts of the adolescent, their caregiver,
and various healthcare professionals (HCP), who are often based in different settings.
Effective communication between these parties is critical to achieving optimal health
outcomes for patients. We have therefore developed a cross-setting and
inter-professional online system (LOOP) to support collaborative care between
adolescents with cancer, caregivers and HCP. The aim of this study was to test the
usability of LOOP in a real-world setting.
Design/Methods:We assembled 3 collaborative teams to each test the clinical usability
of LOOP. Teams used LOOP from home and work to consult with each other about the
adolescent’s care for 4-6 weeks. Individual interviews by a trained interviewer were
conducted at the mid-point and end-point of the testing period. Each team member
answered open-ended questions related to: (1) overall impressions of the clinical
communication system, (2) perceived challenges and benefits of its use, and (3) personal
patterns of interaction with the system. Simple content analyses were used to organize
data into categories that reflected emerging themes.
Results: The assembled teams included 3 adolescents (mean age: 16.3 years), 3
caregivers, 6 HCP (2 oncologists, 1 oncology fellow, 2 nurses, 1 social worker). All
participants had access to a computer at home. Analysis of interview data indicated
that participants found LOOP acceptable and would use it if available. Specific
endorsements related to LOOP included: (1) ease of use, (2) privacy and security, (3)
team composition, and (4) design feedback. HCP raised concerns regarding the
integration of LOOP into their daily workflow.
Conclusion: Overall, this research established the clinical usability of the LOOP clinical
communication system. Future work will focus on examining the system impact on
patient and health service utilization outcomes using a randomized controlled trial.
O-185
DEVELOPMENT OF THE PARENT CARING RESPONSE SCORING SYSTEM
(P-CARESS) USING SWANSON’S THEORY OF CARING AND ITS
PRELIMINARY RELIABILITY AND VALIDITY
J. Bai1, K. Swanson2, S. Santacroce1
1The University of North Carolina at Chapel Hill, School of Nursing, Chapel Hill, USA;
2Seattle University, College of Nursing, Seattle, USA
Background/Objectives: Children with cancer are regularly subjected to procedures that
can be distressing and even traumatic for them and their parents. Parents play essential
roles in caring physically and emotionally for their children. Parent behaviors can
influence child’s procedure experiences in both the short- and long-term run. A reliable
and valid theory-based coding scheme could provide a means to categorize parent
behaviors and inform theory-based nursing interventions that aim to support parents in
caring for their child during painful procedures. Existing schema are neither
theory-based nor are non-verbal behaviors amply represented. Thus, the purpose of this
study is to develop the Parent Caring Response Scoring System (P-CaReSS) based on
Swanson’s Theory of Caring and to test its preliminary reliability and validity.
Design/Methods: Six video clips showing parents’ behaviors with their daughter as she
underwent procedures during her visit to an Emergency Room were extracted from the
documentary, “The Waiting Room”. The video clips were used to inductively generate
preliminary observational codes for the P-CaReSS. Parent behavior codes were
generated every 20 seconds. Then, these codes were deductively structured into domains
consistent with the five caring processes of Swanson’s Caring Theory. The inter-rater
reliability and criterion validity of P-CaReSS are tested in children during cancer
treatment-related port starts.
Results: A 28-item P-CaReSS was developed. Three types of parent behaviors were
represented: verbal (13 items), non-verbal (9 items), and emotional indicators (6 items).
These behaviors comprised seven domains: Knowing (2 items), Being With (5 items),
Doing For (4 items), Enabling (3 items), Maintaining Belief (3 items), Non-Caring (8
items), and Irrelevant (3 items). The validation of P-CaReSS is in the process.
Conclusion: Developing an observational coding scheme to measure parent caring
interacting behaviors based on Swanson’s Caring Theory is feasible. Future research
should test the P-CaReSS in a larger sample of children with cancer.
O-186
EXPLORING THE HEALTH EDUCATIONAL NEEDS AND CONCERNS OF
PARENTS OF CHILDRENWITH CANCER AT THE KOMFO ANOKYE
TEACHING HOSPITAL, KUMASI
M. Barnabas1, C. Asiamah2, M. Holison2, V. Paintsil2, L. Osei-Tutu2, J. Dogbe2
1Komfo Anokye Teaching Hospital, Kumasi, Ghana; 2Komfo Anokye Teaching Hospital,
Child Health, Kumasi, Ghana
Background/Objectives: Cancer in children may profoundly affect parents in terms of
psychological stress and increased care burden. In spite of the emotional impact that
occurs when one’s child is diagnosed with cancer, most families receive limited
information and support to assist them. Many factors may interfere with the ability of
a parent to cope with his or her child’s diagnosis. Nurses should be aware of the
parents’ teaching needs and their concerns during this critical moment.
The purpose of this study was to identify the educational needs and concerns of
parents of children with cancer.
Design/Methods: A total of fifteen parents were recruited from the parents association
of children with cancer for this study. A focus group discussion was held on clinic days
with each group comprising of five participants. The discussions were recorded and
later transcribed and analyzed.
Results: The nurses identified a lack of comprehension of the disease process as a
principal challenge even though parents are counseled before treatment begins. Also
parents had concerns with the high cost of treatment as childhood cancer is not covered
under the national health insurance scheme. The distance that parents have to travel to
treatment centre is yet another concern raised by parents since there are only two
cancer treatment centers in the country-Accra and Kumasi. Coping with changes in
body image from treatment, outcome of diagnosis and duration of treatment emerged
as the key elements that required further education and support for parents.
Conclusion: Even though the educational needs of parents of children with cancer will
not drastically change overnight. Nurses can improve the quality of life of both parents
and children with cancer by providing additional psychosocial support and cancer
information in our daily interactions with the parents.
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FORCING AND PROTECTING - PARENTS´ LIVED EXPERIENCE DURING
THEIR CHILD´S RADIOTHERAPY TREATMENT
J. Gårdling1, I. Hallström1, E. Törnqvist1, M. Edwinson Månsson1
1Health Sciences, Faculty of Medicine-Lund university, Lund, Sweden
Background/Objectives: Radiotherapy treatment aims to cure or/and relieve symptoms
for children with cancer and is a daily treatment, 5 days per week, during a period of
10-35 days. Leaving the child alone in the treatment room and expose them to radiation
is a challenging experience for many parents. To gain an understanding of parents lived
experience, parents were asked to write a diary during their child’s radiotherapy
treatment.
Design/Methods: A descriptive inductive design with a hermeneutical
phenomenological approach was chosen to analyze the diaries. The parents were asked
to write their lived experiences, thoughts and reflections during their child’s
radiotherapy treatment and could involve e.g. the impact on family, child, sibling or
others. Daily notes, both short and long, were desirable.
Results: The parents described the radiotherapy treatment as a twin-pan balance where
they constantly were balancing between forcing and protecting their child to increase
the child’s chances of survival. The parents were fighting for their child and lived
through their child’s emotions and agonies when they at the same time had to face their
own. Meanwhile the parents themselves were struggling with their own despair and
feeling of powerless. While protecting their child they experienced a sense of hope and
that they gained control.
Conclusion: Parent’s daily written reflections are important for clinical practice and give
important knowledge. Parents need support when focusing on forcing and protecting
their child and they need help with information and to find routines to gain more
control over the situation.
Acknowledgements:We would like to express our gratitude to the parents who agreed to
share their lived experiences with us and to the Swedish Childhood Cancer Foundation
for funding.
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PROFESSIONAL COMPETENCE FORWORKINGWITH TEENAGERS AND
YOUNG ADULTS WITH CANCER: CONSENSUS AND DISSENSION
REVEALED IN THE BRIGHTLIGHT DELPHI SURVEY
N. Aslam1, F. Gibson2, R. Taylor3, J. Whelan4, R. Raine5, R. Feltbower6
1University College London Hospitals NHS Foundation Trust, Cancer Clinical Trials
Unit, London, United Kingdom; 2Great Ormond Street Hospital for Children NHS
Foundation Trust and London South Bank University, Centre for Nursing and Allied
Health Research and Evidence Based Practice, London, United Kingdom; 3University
College London Hospitals NHS Foundation Trust and London Southbank University,
Cancer Clinical Trials Unit, London, United Kingdom; 4University College London
Hospitals NHS Foundation Trust and London Southbank University, Department of
Oncology, London, United Kingdom; 5University College London, Epidemiology & Public
Health, London, United Kingdom; 6University of Leeds, Division of Epidemiology &
Biostatistics, Leeds, United Kingdom
Background/Objectives: Teenage and young adult medicine is emerging as a distinct
speciality, acknowledging the core tasks required to enable a young person to transition
successfully to adulthood. The aim was to provide international consensus on the
competencies required by healthcare professionals providing specialist cancer care for
this population.
Design/Methods: A modified, international e-Delphi survey was conducted over 2
rounds. Experts were defined as professionals having worked in this field of cancer care
for more than 12 months. They were identified through publications and invitations via
professional organisations. There were 87 closed-ended questions (9-point Likert scale
responses) and further open-ended responses to identify skills, knowledge and attitudes.
Round 2 contained only items with no consensus in round 1 and additional suggested
items of competency. Consensus was defined as a median score ranging from 7-9.
Descriptive statistics were used.
Results: A total of 179 registered to be members of the expert panel, with valid
responses available for 158 (88%) in round 1 and 136 (86%) for round 2. Most
participants were nurses (35%) or doctors (39%) from Europe (55%) or North America
(35%). All 87 items in round 1 reached consensus with an additional 15 items identified
for round 2. There were significant differences in what doctors, nurses and allied
professionals felt were important skills, areas of knowledge and attitude. For example
100% nurses vs. 79% doctors and 74% others agreed providing holistic care was
important, whereas 80% doctors vs. 54% nurses and 44% others agreed being able to
consent to a clinical trial was important.
Conclusion: Consensus was reached for the competencies required by healthcare
professionals caring for this population. There were some notable differences across
professional groups. Variation according to profession highlights important distinctions
to explore further in pursuit of effective multi-disciplinary team working.
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CONSTRUCT VALIDITY AND RELIABILITY OF AMULTIDIMENSIONAL
ELECTRONIC PAIN DIARY FOR SCHOOL-AGED CHILDREN AND
ADOLESCENTS WITH CANCER
J. Stinson1, L.A. Jibb1, P.C. Nathan1, A.M. Maloney1, L. Dupuis2, J.T. Gerstle3,
S. Hopyan4, B. Alman3, C. Strahlendorf5, C. Portwine6, D. Johnston7, J.C. Victor8,
C. Nguyen2
1Hospital for Sick Children, Toronto, Canada; 2Hospital for Sick Children, Child Health
Evaluative Sciences, Toronto, Canada; 3Hosptial for Sick Children, Surgery, Canada;
4Hospital for Sick Children, Orthopedic Surgery, Canada; 5BC Children’s Hospital,
Vancouver, Canada; 6McMaster Children’s Hospital, Hamilton, Canada; 7Children’s
Hospital of Eastern Ontario, Ottawa, Canada; 8University of Toronto, Institute of
Clinical Evaluative Sciences, Toronto, Canada
Background/Objectives: The aim of this study was to evaluate the construct validity and
reliability of a multidimensional smartphone-based electronic pain diary (Pain Squad)
in school-aged children and adolescents with cancer.
Design/Methods:Momentary pain data were collected twice daily (morning and
evening) for 2-weeks from 99 participants (8-18 years, with various cancer diagnoses,
recruited at 4 Canadian pediatric tertiary care centers) using the Pain Squad
smartphone diary. The Pain Squad diary is a 22-item measure assessing the
multidimensional construct of pain (sensory, affective, and evaluative dimensions).
Construct validity was assessed using Pearson’s correlations between average weekly
pain (intensity, bothersomeness and interference) scores on the Pain Squad diary and
scores of: (a) recalled average weekly pain scores (convergent validity); and (b) overall
and disease-specific health-related quality of life (HRQL; discriminant validity) for each
week. Reliability (internal consistency) was assessed using Cronbach’s alpha
correlations between average weekly pain intensity, bothersomeness and interference
scores for Weeks 1 and 2.
Results: Adolescents reported moderate levels of pain intensity (4.2±2.8[M±SD]/10),
pain bothersomeness (5.6±2.9/10), and pain interference (4.4±2.7/10). As
hypothesized, the Pain Squad diary displayed correlations between average weekly pain
intensity, pain bothersomeness, and pain interference that were: (a) moderate in
magnitude and positive in direction (0.46r0.61) with recalled pain; and (b) low in
magnitude and negative in direction with overall HRQL (r-0.30 for all) and
disease-specific HRQL (r-0.12 for all). Regarding the reliability of the tool, as
predicted, the correlations for each of average weekly pain intensity, bothersomeness
and interference were high (Cronbach’s α0.88) for Weeks 1 and 2.
Conclusion: These findings provide evidence of the construct validity and reliability of
the Pain Squad smartphone-based diary in adolescents with cancer. Use of real-time
data capture approaches should be considered in future studies of self-reported pain in
pediatric cancer.
Nurses - Free Papers Session 5: Ethical Issues & Quality of Life in Paediatric Oncology
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HEALTH CARE PROFESSIONALS PERCEPTIONS OF THE PEDIATRIC
HOSPITAL ETHICAL CLIMATE IN CHILDHOOD CANCER CARE
C. Bartholdson1, M. af Sandeberg1, K. Lützén1, K. Blomgren1, P. Pergert1
1Karolinska Institutet, Department of Children´s and Women´s Health, Stockholm,
Sweden
Background/Objectives: The overall aim of this study was to describe perceptions of the
paediatric hospital ethical climate among healthcare professionals treating and caring
for children with cancer.
Design/Methods: A study-specific questionnaire including a modified version (17 items)
of the Hospital Ethical Climate Scale, developed by Olsson, was used to collect data.
Descriptive statistics were performed to analyse perceptions. Physicians, nurses and
nursing-assistants (n=89) working at three paediatric units, where children with cancer
are admitted, participated.
Results: In 6 of the 17 items, less than 25% selected a positive alternative, indicating
perceptions of a poor ethical climate. In 5 of the 17 items, more than 75% selected a
positive alternative. Nurses rated the ethical climate positively to a lesser extent than
physicians in all items. One third of the participants stated that they were able to
practice ethically good care and also to a greater extent that nurses and physicians
trusted one another and that guardian’s wishes were respected. The two-thirds that
stated inability to practice ethically good care also to a lower extent stated that they had
access to the necessary tools to be able to solve ethical issues/problems; that conflicts
concerning ethical issues/problems were openly dealt with and not avoided; and that
there was an atmosphere that encouraged them in questioning, learning, and seeking
creative responses to ethical problems/issues in treatment/care.
Conclusion: A positive perception of the possibility to practice ethically good care
seems to be related to inter-professional trust and listening to guardians/parents. A
negative/neutral perception appears to be influenced by a lack of ethical support as well
as the experience of ethical conflicts and might be a risk of developing moral stress.
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Clinical ethics support needs to be implemented in care where important values are at
stake.
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CONSOLIDATING CARE BY CLARIFYING PERSPECTIVES: HEALTH CARE
PROFESSIONALS EXPERIENCES OF ETHICS CASE REFLECTION SESSIONS
C. Bartholdson1, K. Lützen1, K. Blomgren1, P. Pergert1
1Karolinska Institutet, Department of Children´s and Women´s Health, Stockholm,
Sweden
Background/Objectives: The purpose of this study was to explore health care
professionals’ experiences of participating in ethics case reflection (ECR) sessions, in
childhood cancer care, in which an ethical concern was reflected on.
Design/Methods: Data were collected by observations and individual
interviews/encounters and data analysis followed grounded theory methodology.Health
care professionals working at a children’s hospital in Sweden participated in ECR
sessions in which ethical issues were reflected on, based on clinical cases. A total of 35
health care professionals participated in six ECR sessions that lasted 60-90 minutes and
were organized as meetings with an external facilitator. Health care professionals were
individually interviewed, formally and/or informally, afterwards (n=10).
Results:When health care professionals participate in ECR sessions with the care team,
their main concern is to consolidate care. The core category, clarifying perspectives, and
two related categories explain how care is consolidated. The two related categories were
named: deliberating ethics (approaches) and unifying interactions (consequences).
Different approaches for deliberating ethics are used during the sessions including
raising values and making sense, leading to increased understanding, group strengthening
and decision grounding.
Conclusion: By implementing ECR sessions, ethical concerns could be eased.
Conflicting perspectives can be shifted into unifying interactions in the health care
professional team. ECR sessions are furthermore valuable because it allows the
discussion of values regarding health care-related issues in childhood cancer care. When
the health care team is clarifying perspectives, on the ethical concerns, professionals are
enable to reflect on the most sensible and ethically defensible care for the child. A
consolidated care approach would be important both for the child and family and the
health care professionals because of shared care goals.
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RACIAL AND ETHNIC DISPARITIES IN SURVIVAL OF CHILDRENWITH
ACUTE LEUKEMIA
L. Morrissey1
1Inpatient Hematology/Oncology Nursing, Boston Children’s Hospital, USA
Background/Objectives: The dramatic increase in survival of children with acute
lymphoblastic leukemia (ALL) over the past fifty years is one of the most notable
successes in pediatric oncology. While overall survival rates of 85% or higher are
documented in contemporary data, significant racial and ethnic disparities in the
mortality rate of children with ALL persist for reasons not fully understood. Several
large cohort studies illustrate these disparities and propose that variation in survival
rates may arise from the complex interaction of economic, social, cultural, biological
and pharmacogenetic factors. Pediatric oncology nurses are well positioned to identify
patients at risk for poor outcomes and propose strategies for early intervention.
Objectives: Summarize the findings of recent cohort studies which describe survival
disparities by race in children with ALL; Discuss and analyze factors which may
contribute to suboptimal outcomes in children with ALL; Propose strategies for nurses
to mitigate risk factors that may interfere with disease-free survival in children with
ALL.
Design/Methods: The current literature on disparities in cancer outcomes highlights
possible underlying causes of ethnic and racial differences in survival for children with
leukemia. A review of the possible reasons for ethic/racial differences in outcomes as
they relate to nursing care of children with cancer will be presented.
Results: Socioeconomic and environmental factors correlated with race and ethnicity
impact factors such as early diagnosis, access to quality health care, enrollment in
clinical trials and treatment compliance. Nurses are present along the entire trajectory
of care and are uniquely positioned to recognize patients at risk for poor outcomes due
to racial and ethnic factors.
Conclusion: Educating pediatric oncology nurses to identify risk factors that are
harbingers of poor outcomes may help to mitigate the racial and ethnic gap in survival
rates and promote optimal care for children of all backgrounds.
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QUALITY OF LIFE (QOL) IN CHILDREN DYING OF CANCER: THE STATE OF
THE SCIENCE
I. Ogunlade1
1Boston Children’s Hospital, Boston, USA
Background/Objectives: Approximately 30% of children with cancer die from their
disease, with 72% dying in hospital while receiving cancer-directed therapy. They
experience impairments in QOL dimensions including pain, fatigue, dyspnea, and
uncontrolled anxiety. The purpose of this review is to identify the gaps in the literature
addressing QOL in children dying of cancer.
Design/Methods: CINAHL, PubMed and Academic Premier were searched for research
findings using the terms: childhood cancer, end of life, pediatric palliative care, QOL,
cancer, and health-related QOL published between January 2004 and September 2014
in English language. Exclusion criteria were non-research articles, literature reviews,
and participants > 18 years old. Data were extracted from included studies and content
analyses were done to synthesize the results of the review.
Results: Sixteen articles met the inclusion criteria. All studies focused on aspects of
QOL including physical, psychosocial, social, and spiritual functioning in children who
were dying of cancer. However, most studies emphasized physical and psychosocial
functioning more than other dimensions. The most commonly negatively correlated
QOL domain was physical functioning; specifically fatigue, pain and dyspnea. Children
who died due to treatment-related symptoms experienced disproportionate pain,
vomiting, sleepiness, weight loss, poor appetite, and physical fatigue than children who
died of progressive disease. Children who received more intensive therapies (stem cell
transplant) suffered more than those who received less intensive therapies
(chemotherapy with surgery, chemotherapy with radiation or chemotherapy alone).
Conclusion: This scoping literature review indicated that children with terminal cancer
experienced changes in QOL related to treatment approach. Impairments in two QOL
dimensions, physical and psychosocial functioning, were most often associated with
decreased QOL. Terminally ill children’s adaptation was ineffective, which indicates that
QOL was compromised. Strategies facilitating adaptive responses and enhancing QOL
are needed.
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IMPACT OF NURSING ON TREATMENT ABANDONMENT IN CHILDREN
WITH CANCER
S. Day1, L. Mckeon2
1Cordova, USA; 2University of Memphis, Nursing, Memphis, USA
Background/Objectives: Purpose: A comprehensive nursing program was implemented
at a pediatric oncology unit in Central America, to improve the quality of nursing care.
Twenty-four new nursing positions were created, decreasing nurse patient ratio from 1:7
to 1:5, and a full-time nurse educator was hired to provide pediatric oncology
education. In addition, processes were established to improve 20 nursing quality
standards. The purpose of this study was to assess the program’s impact on treatment
abandonment in children with cancer. Treatment abandonment is a critical problem in
developing countries and a leading cause of death for children with cancer.
Design/Methods: Pre-program cumulative incidence (CIN) of treatment abandonment
was compared to post-program CIN at the intervention site and to a control site in
which no new nursing interventions were implemented during the study period. The
sample included 1,936 patients diagnosed with cancer during study period.
Results: Pre-program CIN of treatment abandonment for the intervention site (10.2 ±
1.2) was significantly higher (p = .045) than post-program CIN (6.5 ± 1.3). Post-
program CIN of treatment abandonment for the intervention site (6.5 ± 1.3) was
significantly lower (p = 0.0003) than post-program CIN for the control site (14.7 ± 2.7).
Conclusion: Significant improvement in the CIN of treatment abandonment within the
intervention site and as compared to the control site was found. Several factors may
have contributed to the study’s findings. Well educated nurses are better able to provide
parents with insight regarding the need to continue therapy, and the improved
nurse-patient ratio allowed more time for nurses to provide individualized parent
education. In developing countries, abandonment is seen as the primary domain of
psychologists and social workers. A combined effort of nursing and psychosocial
intervention may be the best option for preventing abandonment.
O-195
A NUTRITION SCREENING TOOL FOR CHILDHOOD CANCER (SCAN)
A. Murphy1, M. White2, K. Viani3, T. Mosby4
1The University of Queensland, Children’s Nutrition Research Centre, Brisbane,
Australia; 2Lady Cilento Children’s Hospital, Department of Nutrition and Dietetics,
Brisbane, Australia; 3Hospital das Clínicas- University of Sao Paulo’s Medical School,
Hematology-Oncology Department and Hematopoietic Stem Cell Transplant
Unit-Institute for Treatment of Childhood Cancer – Hematology-Oncology Department
of Instituto da Criança, São Paulo, Brazil; 4Tennessee Technological University College
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Dietetics, Tennessee, USA
Background/Objectives: Nutrition screening is a simple alternative to nutrition
assessment for identifying children with cancer who are at risk of malnutrition. A new
nutrition screening tool for childhood cancer, SCAN, has been developed. SCAN aims
to identify the need for nutritional intervention by identifying patients that are currently
undernourished or are at high risk of becoming malnourished. SCAN consists of 6
scored questions, a total score 3 identifies patient ‘at risk of malnutrition’ who should
be referred to a dietician or clinician. This study aims to assess SCAN in children and
adolescents with cancer.
Design/Methods: SCAN was used to screen 91 children with cancer (n=47 females;
n=49 solid tumors), between 0.75 and 17.1 years of age. Subjects were classified as ‘at
risk of malnutrition’ and ‘not at risk of malnutrition’ according to SCAN. Measures of
height, weight, body mass index (BMI), mid upper arm circumference and triceps
skinfolds were taken in each subject and measures were compared between the
malnutrition risk groups. Survival at 1 year post screening was recorded.
Results: SCAN classified 59% of the subjects as ‘at risk of malnutrition’. Subjects who
were identified as ‘at risk of malnutrition’ had significantly lower values for weight Z
score (p<0.001) BMI Z score (p<0.001) and triceps skinfolds (p<0.01) than subjects
who were ‘not at risk of malnutrition’. There were significantly more children with a
solid tumor who were classified as ‘at risk of malnutrition’ (p=0.01). The number of
patients surviving 1 year after screening was not significantly different between the risk
groups (p=0.85).
Conclusion: SCAN is a new tool available to screen children with cancer for risk of
malnutrition, enabling early identification and treatment of malnutrition. Children
screened as ‘at risk of malnutrition’ have reduced weight and body size and are more
likely to be diagnosed with a solid tumor.
Nurses - Free Papers Session 6: Psychosocial Care for Parents, Survivors & Nurses
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TO ASSESS THE LEVEL OF SATISFACTION AMONG PARENTS OF
CHILDRENWITH CANCER REGARDING NURSING CARE IN PEDIATRIC
WARD
R. Yadav1
1TATA Memorial Hospital, Mumbai, India
Background/Objectives: Background: Patient satisfaction has become an important
indicator to measure the quality of care rendered to the patients while in hospital.
Patient satisfaction surveys can help identify ways of improving nursing and health care
services. The study was planned to assess the parent satisfaction with nursing care in
selected hospital. Objective: To identify level of parent satisfaction in various aspects of
nursing care and thereby improve the quality of care and approach. Set Up: Pediatric
Ward of Tertiary Hospital.
Design/Methods: Design: Descriptive Exploratory study.Methodology & Data
Collection: The study tool was a questionnaire which had four aspects of nursing care:
communication, physical, psychological and socioeconomical and assessment biographic
data of the parents.
Results: The overall rating scale was 4.5 on an average (on a Likert scale of 1-5 where 1
was poor rating and 5-excellent). The mean score was 93.1. Highest scores (109) was for
infection control practices communicated well and timely reinforcement given. Lowest
scores (63) was given for explanation during orientation phase and diagnosis,
physiology of disease, treatment and prognosis of the child. It is important for the
nurses too to improve on their stereotype views and expectations of parents to enhance
satisfactory level. There was a trend seen with the patients admitted first time were
more satisfied than those admitted more than once. The nurse scored 2.4 mean score
(out of 5) for reference given to social help given by hospital and various NGOs.
Conclusion: Nurses are pivotal in communicating and counseling about all aspects of
nursing care. Hence this could help to reduce the fear, anxiety and uncertainty among
parents and children.
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PERCEIVED CONTROL IN MOTHERS OF CHILDRENWITH CANCER: A
LONGITUDINAL STUDY DURING THE FIRST YEAR POST-DIAGNOSIS
E. Sulkers1, W. Tissing2, A. Brinksma1, R. Sanderman3, A. Ranchor3, J. Fleer3
1University of Groningen-University Medical Center Groningen UMCG, School of
Nursing and Health, Groningen, Netherlands; 2University of Groningen-University
Medical Center Groningen UMCG, Department of Paediatric Oncology/Haematology
Beatrix Children’s Hospital, Groningen, Netherlands; 3University of
Groningen-University Medical Center Groningen UMCG, Department of Health
Psychology, Groningen, Netherlands
Background/Objectives: Perceived control (i.e. the belief that one is personally able to
influence important outcomes in life) is an important stress-coping resource that has
been associated with better mental health. Perceived control however, may be
undermined by critical life events such as the diagnosis of pediatric cancer. Little is
known how (potentially shattered) control beliefs develop over time. The current study
aimed to examine the course and adaptive value of perceived control (PC) in mothers
of children with cancer during the first year post-diagnosis.
Design/Methods:Mothers (N= 95, 86% response rate) of consecutive newly diagnosed
pediatric cancer patients (0–18 years) completed measures of general and
domain-specific PC, depressive symptoms, and anxiety at diagnosis, and 3, 6, 12
months thereafter. The data were analyzed by linear mixed model analysis.
Results: General PC, which was relatively high at diagnosis, remained stable during the
study period. Likewise, PC over the child’s illness, PC over the child’s symptoms and PC
over one’s emotions did not change over time (all p’s >.05). In contrast, PC over
medical care (ß=.04, SE=.02, t240=2.0, p = .05), PC over relationships (ß=.03, SE=.01,
t250=2.4, p = .02), and PC over daily life (ß=.10, SE=.02, t249=5.9, p < .001) increased
over time. Depressive symptoms and anxiety over time were predicted by general PC
and domain-specific PC. Regarding the latter, only PC over one’s emotions and PC over
daily life were significant in the final equation. The final models explained 38% of the
variance in depressive symptoms and 40% in anxiety.
Conclusion: The results confirm previous findings in adult oncology which suggest that
individuals maintain perceptions of general PC by feeling efficacious in areas less
affected by the disease. The study further supports that PC is an important resource for
mothers of children with cancer. Helping mothers to enhance their feelings of control
may improve mothers’ capacity to adapt.
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ENHANCING THE SELF-EFFICACY OF CHILDHOOD CANCER SURVIVORS
TO PERFORM PHYSICAL EXERCISE THROUGH ADVENTURE-BASED
TRAINING
H.C.W. Li1, O.K.J. Chung2
1The University of Hong Kong, Hong Kong, Hong Kong-China; 2The University of Hong
Kong, School of Nursing, Hong Kong, Hong Kong-China
Background/Objectives: Physical activity is of paramount importance to enhance the
quality of life of cancer survivors. Nevertheless, there is growing concern about
declining levels of physical activity in childhood cancer survivors. The objectives of this
study were to examine the effectiveness of an adventure-based training in enhancing the
physical activity levels, self-efficacy, and quality of life of childhood cancer survivors.
Design/Methods: A randomized controlled trial, two-group pretest and repeated
post-test, between-subjects design was conducted to 69 childhood cancer survivors (9-
to 16-year-olds). Participants in the experimental group joined a 4-day integrated
adventure-based training and health education program. Control group participants
received the same amount of time and attention as the experimental group but not in
such a way as to have any specific effect on the outcome measures. Participants’ exercise
behavior changes, levels of physical activity, self-efficacy, and quality of life were
assessed at the time of recruitment, 3, 6, and 9, 12 and 18 months after starting the
intervention.
Results: From baseline to 18 months after the intervention, the experimental group
reported statistically significant differences in the stages of change in physical activity
and higher levels of physical activity, self-efficacy, and quality of life than did the
control group.
Conclusion: The adventure-based training was found to be effective in enhancing the
physical activity levels, self-efficacy, and quality of life among childhood cancer
survivors over at least 18 months. Healthcare professionals should consider adopting
such training to promote the regular physical activity among childhood cancer
survivors.
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CULTURAL ADAPTATION AND VALIDATION OF THEMORAL DISTRESS
SCALE TO THE PEDIATRIC ONCOLOGY CONTEXT
M. af Sandeberg1, K. Lützén1, M. Wenemark2, P. Pergert1
1Karolinska Institutet, Childhood Cancer Research Unit- Department of Women’s and
Children’s Health, Stockholm, Sweden; 2Linkopings universitet, Division of Community
Medicine-Department of Medicine and Health Sciences, Linkoping, Sweden
Background/Objectives: Research has shown that value conflicts can arise in childhood
cancer care and contribute to moral stress. The Moral Distress Scale (MDS) has
recently been revised (MDS-R) to fit pediatric settings and multiple disciplines. Our
objectives were to translate and culturally adapt the MDS-R to the context of Nordic
pediatric oncology care.
Design/Methods: The MDS-R was translated by both a certified translator and by
specialists in ethics and pediatric oncology. The translated versions were compared and
processed in a focus group with experts (n=5). Cognitive interviewing was performed
with pediatric oncology nurses (n=6) with ethical competence to test face validity, item
relevance and respondent friendliness. Based on these results, modifications were made
and thereafter the questionnaire was tested in a focus group with consultant pediatric
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oncology nurses (n=14) which led to a few more modifications. All modifications were
discussed with a skilled researcher on instrument design and the final version has been
translated back to English to ensure equivalence.
Results: The aim was to keep the Swedish version close to the original but some
adjustments were necessary. For example, the statement, “Increase the dose of
sedatives/opiates …that I believe could hasten the child’s death” caused confusion
because nurses do not increase the dose without prescription and moreover,
associations were made to euthanasia. Another statement included “fears of a lawsuit”,
which within a Nordic context are unusual while fears of being reported to authorities
are more relevant.
Conclusion: Cultural adaptation is time consuming but necessary to ensures a
respondent-friendly and relevant instrument. The process has required expertise in
pediatric oncology nursing, linguistics, ethics as well as questionnaire design.
Parents/Survivors - Cancer Control Workshop
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THE ROLE OF CHILDHOOD CANCER SUPPORT GROUPS IN IMPROVING
CANCER CARE IN SOUTH AFRICA AND ETHIOPIA
B. Wondu1, W.B. Woldemariam2, W.B. Woldemariam2
1Mathiwos Wondu-YeEthiopia Cancer Society, Cancer Society, Ethiopia, Ethiopia;
2Mathiwos Wondu-YeEthiopia Cancer Society, Cancer Society, Addis Ababa, Ethiopia
Background/Objectives: The death rate of children with cancer in Africa is far higher
than in upper middle income countries. As part of the intervention to decrease the
mortality and morbidity of cancer in children, support groups in South Africa and
Ethiopia started to collaborate with their national governments, ensuring that
childhood cancer be placed on the national government agenda, improving intersectoral
collaboration and proper cancer care.
Design/Methods: An assessment was made of the current policies. Stakeholder meetings
were attended, ensuring that childhood cancer was part of the national strategy and
policy environment. Deficiencies in the system, and potential solutions, were identified
to improve cancer care.
Results: The South African national cancer control plan did not address childhood
cancer and there is evidence that this situation is similar to other English speaking
countries in Africa. Through its contacts in the non-profit sector, CHOC ensured that
they represented the interests of the childhood cancer society, including: early and
accurate diagnosis, appropriate treatment; and more emphasis on quality survival. In
Ethiopia the MWECS seconded a professional consultant to the ministry of health to
coordinate the development of the national cancer care control plan through their
intervention. The political dynamics in Ethiopia have been dramatically changed in
favor of NCD and have contributed to the policy changes at national level.
Conclusion:While it is essential to remain part of the ongoing development of the
national cancer control plan, groups in both countries have exerted additional efforts to
ensure that it is mandatory that a separate national cancer care management plan for
children is devised by the relevant stakeholders and adopted by all departments of
health on the Africa continent. This plan should conform to WHO, UICC and
international childhood cancer norms. This exercise demonstrates proof positive that
joint, multi-sector efforts truly can make a difference.
Parents/ Survivors - Nutrition Workshop
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FOOD AHOY! A PIRATE GAME HELPS CHILDREN ENJOY EATING AGAIN
A. Brinksma1, M. Groenewold2, M. Vingerhoets3, B. Janssen4, K. Krosien5,
R. Tigchelaar6, F. Montijn7, M. Roumen8, F. Verhoeven6, W. Tissing9
1University Medical Center Groningen, Department of Pediatric Oncology and
Hematology Beatrix Children’s Hospital/School of Nursing and Health, Groningen,
Netherlands; 2University Medical Center Groningen, Department of Dietetics Beatrix
Children’s Hospital, Groningen, Netherlands; 3Avans University of Applied Science,
Academy for Entrepreneurship Marketing and Innovation, Breda, Netherlands; 4Avans
University of Applied Science, Academy for Media & User Experience, Breda,
Netherlands; 5Fontys University of Applied Sciences, Industrial Product Design, Venlo,
Netherlands; 6Utrecht University of Applied Sciences, Research Group Co-Design,
Utrecht, Netherlands; 7Sparckl Learning, Designer, Delft, Netherlands; 8Rhinofly
Concepts & Codes, Designer, Utrecht, Netherlands; 9University Medical Center
Groningen, Department of Pediatric Oncology and Hematology Beatrix Children’s
Hospital, Groningen, Netherlands
Background/Objectives: Cancer and cancer treatment affects children’s appetite and
disrupts normal eating behavior. The pressure to ensure adequate intake is stressful for
parents and child and cause a struggle for control within the family. To date,
appropriate interventions that support families are lacking. Therefore, this study aimed
to develop an intervention to reduce feeding stress and to support children and families
to get a healthier eating behavior.
Design/Methods: Scientists and designers worked together in a so called “participatory
design-science” project. Based on qualitative interviews with children and parents and
expert sessions with health care providers, designers and students generated ideas for an
intervention. Prototypes of the intervention were tested among families, improved by
designers, and tested again in an iterative way.
Results: The developed intervention is a Pirate game for children 3-10 years of age. In
this explorative story-telling game, children and their families travel around the world
guided by a treasure map. Visiting different continents of the world, participants have
to fulfill exciting food-related tasks i.e.: “Pirates try to steal your food. Prevent stealing
by making a fruit-cactus, so that pirates who try to steal your fruit will prick
themselves.” By fulfilling tasks, children can earn special rewards. Every continent
represents a main group of foods (i.e. dairy products). The game teaches unconsciously
that food is fun and stimulates positive food associations. Additionally, the game
provides practical tips for parents how to stimulate and reward healthy eating behavior.
Pilot tests revealed that families enjoyed the game, children spontaneously tried new
foods, and parents felt renewed inspiration to deal with their child’s eating behavior.
The coming months, the game will be tested by more families.
Conclusion: Preliminary results look promising. The pirate game might be an effective
manner to reduce feeding stress and to develop healthy eating behavior among children
with cancer.
Parents/ Survivors - Abandonment & Follow-up Care
O-202
PATIENT NAVIGATION AND TRACKING TO REDUCE ABANDONMENT AND
ENSURE FOLLOW-UP IN CHILDRENWITH CANCER (PANTRACC) IN INDIA:
A PILOT STUDY
R. Arora1,2, S. Ahuja2, S. Gupta3, P. Bagai2
1Max Super-Speciality Hospital, Medical Oncology, New Delhi, India; 2Cankids,
Quality Care-Research and Impact, New Delhi, India; 3Hospital for Sick Children,
Division of Haematology/Oncology, Toronto, India
Background/Objectives: Patient navigation and tracking has shown to improve
outcomes in adult cancers, HIV and tuberculosis. A similar approach could be helpful
in reducing treatment abandonment and ensure follow-up in childhood cancer and we
developed a log book for this. The pilot’s aim was to test use of log book and a
secondary aim was to investigate impact on outcomes.
Design/Methods: 81 patients (73% males, median age 6 years) in four childhood cancer
centres in New Delhi, India who contacted Cankids (a national support advocacy
group) for assistance were recruited. A specific parent support group member (PSGM)
established initial contact with every child shortly after diagnosis and maintained
contact at least on a weekly basis for 12 weeks after recruitment. The PSGM kept a
record of successful/unsuccessful contacts and treatment status with an algorithm
leading to necessary actions (more frequent contact, counselling, financial assistance,
etc.).
Results: On a five-point Likert scale, all PSGM strongly agreed that the log book was
simple to use, decreased work load, and delivered better patient assistance. Of 986
contact attempts (62% phone, 38% in-person), successful contact was made at first
attempt in 88% attempts and in the reminder, on subsequent attempts. In 4 instances,
there was dissatisfaction expressed with ongoing treatment and in 1 instance there was a
wrong phone number. At end of 12 weeks, 70/81(86.41%) patients are alive and on
treatment, 6(7.40%) patients have died, 2(2.46%) were not offered further treatment and
3(3.70%) have abandoned treatment. Of those abandoned, 1 returned subsequently to
continue treatment, in 1 carers refused to provide information, and in 1 the contact
does not know the status.
Conclusion: The pilot demonstrates that patient navigation and tracking is feasible and
acceptable. The potential use of the log book to reduce abandonment rates and ensuring
follow-up would be investigated in a larger prospective multi-centre study in India.
O-203
NEURO-ONCOLOGY SURVIVORSHIP PROJECT (NOSP) TO SUPPORT
TRANSITION TO HOME, REHABILITATION, EDUCATION AND
VOCATIONAL DEVELOPMENT
K. Dickinson1, M. Parr1, L. Robinson1, E. Bennett1, T. Hancox1, P. White1,
R. Spencer1, N. Webb1, D. Walker2
1East Midlands Children’s and Young Persons’ Integrated Cancer Service EMCYPICS,
East Midlands, United Kingdom; 2University of Nottingham, Children’s Brain Tumour
Research Centre, Nottingham, United Kingdom
Background/Objectives: The NOSP aimed to identify needs and solutions for children,
young people and their families moving from the “safety blanket of hospital to home"
in order to help rebuild family life.
Design/Methods: Eighteen standardised interviews were conducted with parents or
young people (1-14 years post diagnosis) treated previously within EMCYPICS.
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Thematic analysis of the interviews was conducted to inform and prioritise the design
of interventions to accelerate and support transition.
Results: Thematic analysis identified: a) preparation for discharge, b) learning to live
with disability, c) moving to a new normality, d) fostering emotional support, e)
accessing educational and vocational support and f) promoting awareness of late
effects. These highlighted the need for information and training for families, signposting
access to local support services and promoting coping strategies for young people.
These needs were addressed through the development of Awareness Day training
course(s), Family Support Information Directory and a Local Sport and Activity
Directory. Refinements to discharge planning were recommended by early referral to
local services. New partnerships between health, psychology and education services
were strengthened and knowledge shared to enhance awareness of the patients’ needs
through a Teacher Training day. “The Way Forward“ course has been designed by a
multi professional group, which included nurses, allied health professionals, CLIC
Sargent social care team, youth workers, parent and patient representatives and
voluntary organisations to help young people learn coping strategies and set goals to
support them. New partnerships with a local brain injury organisation (Headway) has
enhanced access to learning and support for those over 18years.
Conclusion: Collecting evidence from parents and young people living with brain
tumours has provided new insights and led to the development of initiatives providing
information and targeted support. The assessment of the impact of these interventions
will be the focus of future research.
O-204
COMPREHENSIVE REHABILITATION PROGRAM FOR ONCOLOGY
PATIENTS NUESTROS HIJOS FOUNDATION
E. Vogel1, M. Zubieta2, A. Vargas3, V. Celedon3
1Fundación Nuestros Hijos, Extensión y Desarrollo, Santiago, Chile; 2Fundación
Nuestros Hijos, Junta Directiva, Santiago, Chile; 3Fundación Nuestros Hijos, Centro de
Rehabilitación Oncologico Infantil, Santiago, Chile
Background/Objectives: In Chile, such as high income countries, 7 of 10 children survive
cancer and 80% of them are going to survive with consequences from treatment and
disease itself. Rehabilitation is very important for upcoming quality of life of these
children. Chemotherapy, radiation therapy and surgery are priority for survival of
patients, and rehabilitation needs are satisfied after treatment. There is no specialized
center for the attention of children with consequences in Chile. During September
2014, Nuestros Hijos Foundation create the first Oncology Rehabilitation Center.
Purpose: To give a comprehensive oncology rehabilitation to children with cancer
attended in the public system of health. The center provide assistance in hospitals,
houses and outpatient clinics from the first stage of disease and medical treatment.
Design/Methods: The pilot program create an Oncology Center with a team comprised
of physiatrist, kinesiology, speech therapist, occupational therapist, psychologist, social
workers. They evaluate patients from the oncology service and create an individualized
work plan according their needs. The therapy is provided where children are, in the
hospital, house or Foundation shelter.
Results: 15 patients have been treated; from 1 to 23 years old; frequent diagnostic is
central nervous system tumor (n6) followed by Leukemia (n4); from 2 to 10 weekly
sessions according to the specialist. Gait disorders, swallowing and language are the
most frequent consequences.
Conclusion: Children survival cancer presenting consequences can be rehabilitated with
special programs designed to each patient. Early rehabilitation is essential for the
quality of life in the future.
O-205
FOLLOW-UP OF THE IMPROVED FRAMEWORK FOR CHILDHOOD
CANCER HOSPITALS, AND A REPORT ON A NEWMOVEMENT FOR
ADVANCEMENT OF CLINICAL RESEARCH PROGRAM IN JAPAN
K. Yamashita1
1Childrens Cancer Association of Japan, Tokyo, Japan
Background/Objectives: To share information on the latest situation concerning
childhood cancer in Japan from the perspective of policy frameworks and clinical
research will surely provide fellow parents organizations in CCI with ideas useful for
their activities in their respective countries.
Design/Methods: 1. As reported in SIOP-2014 in Toronto, there had been
changes/improvements in the framework of childhood cancer hospitals in Japan
recently; 2. Coinciding with the improvement of the framework of childhood cancer
hospital, a new movement for the advancement of clinical research on childhood cancer
in Japan has taken place. In the past, there have been several separate study groups
conducting clinical researches. Although all groups have been constantly exchanging
information and coordinating research programs, inefficiency is undeniable in terms of
human and financial resources.
Results: 1. By the end of March 2015, all actions necessary to activate the new
framework have been completed; 2. A new organization called Japan Children’s Cancer
Group (JCCG) integrating existing clinical research group across Japan was established
in Dec. 2014.
Conclusion: 1. Such actions include formation and implementation of regional council
to coordinate networks of hospitals treating childhood cancer led by the designated
hub hospital in each of the 7 regions, designation of central institution and nomination
of advisory board for which the author of the presentation is a member representing
parents organizations. The presentation also reports as to how such actions affect the
frontline of childhood cancer treatment, and what are the expectations of
patients/parents for furtherance of level of medical treatment of childhood cancer in
Japan; 2. Medical professionals as well as patients/parents expect that this integration
will be a turning point for the advancement of clinical researches of childhood cancer
in Japan.
Parents/ Survivors - Psychosocial Support – Mechanisms and Practices
O-206
SIBLINGS – THE SILENT SUFFERERS - A SUPPORT PROGRAMME
T. Cuntu1
1CHOC Childhood Cancer Foundation S A, Johannesburg, South Africa
Background/Objectives: Siblings are often referred to as the “silent sufferers” as the
diagnosis of childhood cancer or life threatening blood disorders places a tremendous
strain on the entire family system including the siblings. Children are perceptive; they
can see their parents taking strain and do not want to burden them further; so they
rather keep quiet. Parents in turn do not know how to communicate this difficult
information and with the intention of protecting them, do not talk to the siblings either.
This in turn creates many conflicting emotions for the siblings. On the one hand they
feel concern and anxiety for their sick sibling and yet, they also experience anger and
resentment.
Design/Methods: The CHOC Psychosocial Support team developed a workbook for
siblings of children on treatment. The workbook takes them through all aspects of their
journey and the impact of their siblings’ illness on the family system. It explores their
understanding of the diagnosis, the treatment and its implications and provides a safe
space in which they can be with their feelings. It can be used on a one-on-one basis as
well as in a group. The programme has also been incorporated in a camp context;
combining the group fun element of a camp while working through the workbook. A
workbook has also been developed for bereaved siblings.
Results: Parents expressed their gratitude and commented on the change in their
children.
Conclusion: Professionally it is humbling to see the transformation in the siblings as
they work through the workbook. They learn they are not alone, that it is good for
them to express their thoughts and feelings and that they may have fun without feeling
guilty about their sick brother or sister.
O-207
VOLUNTEERMANAGEMENT - A DOUBLE-EDGED SWORD – DEVELOPING
AND SUSTAINING A VOLUNTEER PROGRAMME
A. Bence1
1CHOC Childhood Cancer Foundation, Johannesburg, South Africa
Background/Objectives: In the NGO world, where keeping within a budget is essential,
it is often necessary to seek assistance with non-professional tasks by using volunteers.
However, it should be borne in mind, prior to starting a volunteer programme, that the
necessary infrastructure should exist within the organisation in order to support the
successful management of a volunteer programme.
Design/Methods: There are several key elements to address when developing a volunteer
programme: what motivates people to volunteer; identifying and recruiting volunteers,
especially in regions where historically the community does not have a high level of
volunteering; screening, selection and training; and most importantly, retention and
recognition. The management and empowerment of volunteers through providing
regular support, supervision and on-going evaluation is essential to protect both the
beneficiary and the volunteer.
Results: A well-managed volunteer programme results in a greater retention of
volunteers who in turn, can provide essential support to the organisation, patients and
families. It is important to recognise that the management of volunteers takes significant
resources, and is essential to ensure that there is a net gain to the organisation.
Conclusion: Volunteer mobilisation and coordination should become an essential part
of any NGO’s strategic planning; however a poorly designed or managed programme
can be counterproductive and detrimental to the organisation.
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SURVIVORS AUSTRIA: NOTHING ABOUT US – WITHOUT US
Z. Tomášiková1, M. Willi2, S. Karner2
1Österreichische Kinder-Krebs-Hilfe, Vienna, Austria; 2Österreichische
Kinder-Krebs-Hilfe, Österreichische Kinder-Krebs-Hilfe, Vienna, Austria
Background/Objectives: 280 children and young adolescents come down with cancer
each year in Austria. Due to a survival rate of over 80% about 235 survive. Some of
these former patients have the need to meet people who have made similar experiences
and/or want to give something back to patients and families.
Design/Methods: This spirit of some Austrian survivors resulted in the establishment of
the Austrian survivors group in 2003. Within the last twelve years the organizational
structure as well as the offer for survivors and patients strongly developed.
Results: It is not obvious that former pediatric childhood cancer patients get active, set
up a survivors network/group/organization and offer activities for survivors/patients.
The Austrian survivors group consists of regional groups and one umbrella group. The
regional survivors groups focus on offering meetings on a regular basis for survivors.
Especially this offer is adapted to individual needs and for personal exchange. In
addition, once a year a big summer party for survivors from all over Austria is
organized. On contrary to those fun activities, workshops to all survivors are offered
twice a year and this year group members organize the first symposium for survivors
about medical late effects. Beside these offers for survivors, mentoring for
patients/families is offered in three Austrian hospitals and is coordinated by the regional
survivors groups. Moreover, group representatives contribute in a project for long-term
after care, in which medical professionals, psychologists and parents organizations are
involved. Last but not least individual survivors get the possibility to actively
participate on European and international meetings.
Conclusion: One major aim is the recruitment of more survivors and the encouragement
to get active members. Furthermore, an additional objective is to expand the offer of
seminars and activities for survivors from all over Austria and focus on the special
needs of childhood cancer survivors.
Parents/Survivors - Impacts of Childhood Cancer on Families, Siblings & Caregivers
O-209
A NATIONAL COHORT STUDY OF THE EFFECTS OF CHILDHOOD CANCER
ON PARENTS’ INCOME FROM EMPLOYMENT AND EMPLOYMENT STATUS
A. Lindahl Norberg1, S. Montgomery2, M. Bottai3, M. Heyman1, E. Hovén1
1Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm,
Sweden; 2Karolinska Institutet, Department of Medicine, Stockholm, Sweden;
3Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
Background/Objectives: There is insufficient knowledge about the economic effects on
the family of childhood cancer. The objectives of this study were to investigate the
short- and long-term impact of childhood cancer on mothers’ and fathers’ income from
employment and employment status.
Design/Methods: The study included parents of all children ( 18 years of age)
diagnosed with a primary cancer during 2004-2009 in Sweden (n=3638 parents of 1900
children). Data on income from employment and employment status (employed/not
employed) were obtained from the Longitudinal integration database for health
insurance and labour market studies. The database integrates data from the labour
market, educational and social sectors and is updated each year. Outcomes in the study
cohort were compared using regression models with a closely matched reference group
of parents (n=35096) sampled from the general population.
Results: Initial analyses confirmed equivalent average starting values (two years before
diagnosis) between case- and referent parents for: civil status, parental age, number of
children living at home, county of residence, disposable income, and educational level.
Parents’ income from employment decreased significantly following the child’s cancer
diagnosis (P < .001), and this association was most pronounced for mothers’ income.
This reduction in income of mothers who had a child with cancer continued for six
years post-diagnosis (P < .05). Fathers’ income was comparable to referent fathers at
three years post-diagnosis. Mothers were also more likely to stop working following a
child’s cancer diagnosis, compared with referent mothers. Importantly, no association
with fathers’ employment status was identified.
Conclusion: Parents’ income from employment and employment status are adversely
affected by a child’s cancer in Sweden. However, familial socioeconomic consequences
of childhood cancers are still not equally distributed between men and women. Fathers’
incomes catch up after a few years, while mothers tend to be disadvantaged regarding
their professional life for several years after a child’s cancer diagnosis.
O-210
CHILD SYMPTOM BURDEN AND DEPRESSIVE SYMPTOMS AMONG
CAREGIVERS OF CHILDRENWITH CANCERS
A. Olagunju1, F. Sarimiye2, T. Olagunju3, O. Aina4
1Lagos University Teaching Hospital/College of Medicine-University of Lagos,
Psychosocial Oncology, Lagos, Nigeria; 2University College Hospital-Ibadan,
Radiotherapy and Oncology, Ibadan, Nigeria; 3Health Service Commission, Mainland
Hospital, Lagos, Nigeria; 4Lagos University Teaching Hospital/College of
Medicine-University of Lagos, Psychiatry, Lagos, Nigeria
Background/Objectives: The burden of symptoms among children with cancers evokes
various emotional reactions in caregivers that include depressive symptomatology.
Given that depression in caregivers can impair their wellbeing and their caregiving
roles; this study was set to investigate the relationship between child’s symptom burden
and depressive symptomatology among caregivers of children with cancers.
Design/Methods: This is a cross-sectional study among 72 consenting caregivers of
children with cancers. A designed questionnaire was administered to elicit
socio-demographic profile of the children with cancers and their caregivers.
Subsequently, the child’s symptom was profiled with questions adapted from Memorial
Symptom Assessment Scale; while depressive symptomatology in caregivers was elicited
using CES-DR. Data were analyzed using SPSS-16.
Results: All the caregivers in this study were all made up of parents with majority
(83.7%) being mothers. The mean age of caregivers was 39±2(years). The common
symptoms in the children with cancer include pain, feeling drowsy, hair loss and lack of
energy among others. More than one third of caregivers (38.2%) had significant
depressive symptomatology based on CES-DR interview. Symptom burdens in children
with cancers was significantly associated with the experience of depressive symptoms in
caregivers (p<0.05).
Conclusion: Active management symptoms in children with cancers and psychosocial
support services for their caregivers are desirable.
O-211
FROM LANGUISHING TO FLOURISHING: EXPLORINGWELL-BEING IN
YOUNG ADULTS SURVIVORS OF CHILDHOOD CANCER AND IN THEIR
SISTERS AND BROTHERS
M. Scrignaro1, F. Nichelli2, L. Cattaneo2, M. Spinelli2, D. Fraschini2, A. Biondi2,
M. Jankovic2
1Milano, Italy; 2MBBM Foundation-San Gerardo Hospital, Pediatric Hematology,
Monza, Italy
Background/Objectives: One in every sixty hundred and forty young adults is estimated
to be a survivor of childhood cancer. Survivors may have long-term side effects which
can reduce quality of life. Further, the family’s system becomes a ‘second-order
survivor’. Data on long term psychosocial adjustment specific to this population are
lacking and studies that explore simultaneously both patients and their family members
were uncommon. The majority of existing researches used an impairment model of
adjustment (i.e. absence of diagnosed psychological disorders). However, the current
psycho-oncology research has directed its attention toward a multidimensional and
flourishing model of well-being (i.e. growth, purpose, realization of personal capacities,
life satisfaction). The aim was to explore both adjustment and well-being in a group of
thirty-two young adult survivors (five years from the stop therapy) of child-hood
leukemia and their forty-three sisters and brothers.
Design/Methods: The measures administrated were: the SCL-90-R, the Psychological
Well-being Scale, the Satisfaction with Life Scale and the General Self-efficacy Scale.
Results: T-test analyses showed no difference in all measures between patients and their
sisters and brothers. The twelve percent of participants had psychological disorders and
symptoms. However the thirty-nine percent had a general self-efficacy below to the
twenty percentile. The fifty-five percent showed low-to-moderate levels of
self-acceptance and approximately the forty percent exhibited low-to-moderate levels of
autonomy, environmental mastery, purpose in life and positive relationship. Only the
thirty-nine percent were highly satisfied of their life.
Conclusion: These findings showed the effectiveness of a thriving model of well-being to
a deeper understanding of the psychosocial long-term side effects after cancer
experience.
O-212
PREPARING CHILDREN AND CAREGIVERS FORMEDICAL TREATMENT
PROCEDURES
P. Raleting1
1CHOC Childhood Cancer Foundation, Johannesburg, South Africa
Background/Objectives: Any child undergoing treatment for childhood cancer or a life
threatening blood disorder is confronted with a variety of invasive medical treatment
procedures. These can result in a vast array of feelings such as fear, anxiety, anger and
this is often expressed in obstructive behaviour and resistance in cooperating with
treatment procedures.
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Design/Methods: Through networking with professionals in the field of child trauma
and mental health, the psychosocial team received the necessary training to deal with
this situation. Methods used include distraction, sharing of information, play and other
therapeutic techniques. The children are also oriented to equipment and treatment
facilities.
Results: This preparation gives the children a sense of control over the situation which
in turn releases stress and anxiety and helps them to cooperate. The information and
choices they are presented with empowers them and aids the treatment and recovery
process.
Conclusion: Less trauma is experienced by all involved, especially the child; medical
treatment is delivered timeously; and long term scarring is alleviated.
Parents/ Survivors - Palliative Care and Bereavement
O-213
PALLIATIVE CARE SUPPORTING PROGRAM NUESTROS HIJOS
FOUNDATION
E. Vogel1, M. Zubieta2, J. Fernandez3
1Fundación Nuestros Hijos, Extension y Desarrollo, Santiago, Chile; 2Fundación
Nuestros Hijos, Junta Directiva, Santiago, Chile; 3Fundación Nuestros Hijos, Servicios
Medicos y Sociales, Santiago, Chile
Background/Objectives: Each year in Chile, 500 new children are diagnosed with cancer,
75% surviving for five years. Likewise, around 90 children are admitted in the Palliative
Care Program of the Public Health Care System. This program subsidizes the costs
associated with the use of morphine and other medicines. However, this is not sufficient
for all demands of these children and their families in this stage of disease. In 2003,
Nuestros Hijos Foundation create a complementary model of care that provides
medical, social and spiritual support for children and their families.
Purpose: to contribute with supporting on palliative care (PC) through complementary
comprenhensive care for children and their families, with a supplementary role to the
Public Health Care.
Design/Methods: Foundation helps through delivery of medicines, loan of medical
equipment (electric beds, anti-bedsore mattresses, continuous subcutaneous medicines
infusion pump, etc), economic bonus (transportation and special meals), death fee,
among others. Besides, Nuestros Hijos Foundation works with the hospital PC group,
supporting medical assistance through home visits, 24 hours of telephone service, home
improvements, spiritual accompaniment, etc.
Results: From the beginning, 385 children have been helped from 12 national oncology
units; Last year, 112 children received some medical care, 23% patients from Exequiel
González Cortés Hospital. This program have allowed that 80% of attended patients
have died at home.
Conclusion: It is posible to generate a complementary work to public health system, a
comprehensive care to children with palliative care. This help children allowing to live
with their families until the last day.
O-214
DEBRIEFING PARENTS/CAREGIVERS WITHIN THEWARD COMMUNITY
AFTER THE DEATH OF A CHILD
B.J. Herbert1
1CHOC Childhood Cancer Foundation, Johannesburg, South Africa
Background/Objectives: The death of a child within the ward community of a paediatric
haematology oncology unit has a significant impact on not just the other parents but
also the children. The emotional bond that forms amongst parents while sharing the
ordeal of their child being treated for cancer is seriously tested. Conflicting feelings of
trauma, grief and sadness, but at the same time relief that it is not their child, create an
atmosphere of sombreness and withdrawal. At the same time parents are anxious that
their child may be the next to die. As it is difficult to verbalise these feelings, the
psychosocial team have created a safe space for the debriefing of this community.
Design/Methods: The parents are grouped together to provide a safe space in which to
explore and verbalise their feelings. Through the foundation of non-judgmental
listening within the group, these feelings are normalised and resources both internally
and externally can be accessed. Different skills and techniques are used to further
empower the parents to answer their children’s questions around these matters. The
sessions close with parents sharing an act of kindness through a gentle physical
massage.
Results: The results that have been identified following these debriefing sessions are that
parents are calmer and empowered to focus on and be emotionally available for their
child.
Conclusion: These debriefing sessions provide the parents with a sense of hope and the
confidence to move forward positively.
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NURSE-INTERPRETERS IN THE PAEDIATRIC ONCOLOGY UNIT. BAD
NEWS OR BADMEDICINE?
K. Ndlovu1, J. Geel2
1Charlotte Maxeke Johannesburg Academic Hospital, Division of Paediatric
Haematology and Oncology, Johannesburg, South Africa; 2Faculty of Health Sciences-
University of the Witwatersrand, Division of Paediatric Haematology and
Oncology-Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South
Africa
Background/Objectives: Pronounced economic disparities and the lingering effects of
Apartheid continue to hinder effective communication in hospitals in South Africa, a
country with 11 official languages. Many caregivers struggle to communicate with
medical staff as most doctors do not speak the same first languages as their patients.
Paediatric oncology nurses are often required to interpret and assist doctors to deliver
bad news, despite a lack of specific training in this task. This study aimed to explore
barriers to effective counselling when nurses double as interpreters, identify common
feelings experienced by nurses and to ascertain possible areas of improvement in this
process.
Design/Methods: Internal audit of nursing staff in the Haematology / Oncology Unit at
Charlotte Maxeke Johannesburg Academic Hospital using a structured questionnaire,
consisting of 12 “Yes/ No” questions and 7 open-ended questions. Participants were
asked to suggest recommendations. Descriptive statistical methods were employed.
Results: The participation rate by permanent nursing staff was 15/20 (75%) and all
(100%) had been required to act as interpreters. The majority (11/15) reported
discomfort during the process of interpreting and felt inadequately prepared prior to
the delivery of bad news. They felt that effective communication between doctors and
nurses could improve the process of interpreting. Many felt that there should be more
sensitivity towards the feelings of these nurse-interpreters, as they often experience
great emotional stress when children are involved. Additional concerns raised were lack
of awareness of specific cultures and African family structures.
Conclusion: The interpretation of bad news is more distressing to interpreters than
previously recognised. Nurse-interpreters would like doctors to acknowledge the vital
role they play in the delivery of bad news. Prior preparation is vital, as are improved
communication between medical and nursing staff. Enrichment of the process for
health care workers should improve the experience for families and patients.
O-217
EMOTIONAL STRESS AMONG NURSES AT THE PAEDIATRIC ONCOLOGY
WARD KORLE BU TEACHING HOSPITAL, ACCRA, GHANA
F. Amoako1, L. Renner2
1Korle Bu Teaching Hospital, Department of Child Health, Accra, Ghana; 2University of
Ghana School of Medicine and Dentistry, Department of Child Health, Accra, Ghana
Background/Objectives: Emotional stress among nurses on Paediatric Oncology Wards
differs from what occurs on other Paediatric wards in many ways, including the fact that
nurses come face to face with the death of patients they may have known over a
relatively long period of time. The objective of the study was to find out more about
emotional stress amongst Paediatric Oncology nurses and make recommendations that
would help address this issue effectively.
Design/Methods: This study was undertaken at the Paediatric Oncology ward of the
Korle Bu Teaching Hospital in Accra, Ghana. A questionnaire with open-ended
questions was distributed to all the nurses currently working on the Paediatric
Oncology Ward in February 2015.
Results: Twelve of the fifteen questionnaires were returned completed. All respondents
were female. Forty-two percent had over 10 years’ experience in nursing, only 17% over
10 years’ experience on the oncology ward. Ninety-two percent admitted work related
emotional stress. This was mostly due to palliative care and deaths of the children (50%)
and financial difficulties of families (33%). Stress led to feelings of helplessness and
poor concentration (42%). The main symptoms were headache and palpitations. Most
reduced stress by resting or talking to colleagues about it (58%). Most nurses, 75%, were
motivated in their work by seeing children improve (33%), being given financial
incentives (33%) and appreciation of their services. Sixty-seven percent felt like leaving
the ward. Reasons included deaths of children and perceived risks from chemotherapy.
Nurses’ recommendations to reduce emotional stress included psychological
counseling, increasing staff numbers and instituting recreational activities.
Conclusion: Emotional stress is highly prevalent amongst nurses working on the
Paediatric Oncology ward in Ghana with serious potential for staff attrition. Strategies
to address this should include psychological counseling sessions and increasing staff
numbers so as to reduce the work load.
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A COST-EFFECTIVE AND CARE-EFFICIENT BEHAVIORAL CHANGE
STRATEGY: HEALTH CAREWORKERS HAND HYGIENE COMPLIANCE IN
PEDIATRIC ONCOLOGY CENTER IN LOWMIDDLE INCOME COUNTRY
A. Khatoon1, R. Punjwani2, S. Bana3, R. Rafiq1
1Children Cancer Hospital, Infection Control, Karachi, Pakistan; 2Children Cancer
Hospital, Nursing Education, Karachi, Pakistan; 3Children Cancer Hospital, Nursing
Service, Karachi, Pakistan
Background/Objectives: Improvement in hand hygiene compliance and change in
behavior is very difficult task in hospitals. Hands are the most common mode of
transmission of infection amongst patients and health care workers. According to
Center of Diseases Control and Prevention (CDC) proper hand hygiene is single most
effective strategy to reduce Health Care Associated Infections (HAI). The objective was
to bring out behavioral change in hand hygiene practices among Health Care Workers
(HCW). For that reason, Infection Control Nurse Manager (ICNM) designed and
implemented care efficient and cost effective intervention in the pediatric oncology
center.
Design/Methods: The intervention planned by ICNM had three components: 1)
availability of resources; 2) teaching and training sessions for HCW; and 3) monitoring
and evaluation of the applied intervention. To optimize the available resources and
realizing the financial constraints ICNM advised to place wall mounted hand rubs on
intravenous (IV) stands providing intravenous therapy to keep it on elbow distance, as
indicated by WHO. Moreover, the hand washing stations were also placed in every unit
to reinforce hand hygiene practices. All the HCW participated in hand hygiene teaching
sessions organized by ICNM. And the audits and feedback system was designed to
monitor and evaluate the compliance of hand hygiene.
Results: The behavioral change strategy had massive impact and hand hygiene practices
increased by 50% amongst HCW after implementing the strategy. Though the strategy
had great impact, High Dependency Unit (HDU) had reservation to attach hand rubs
on IV stands because in critical care areas already IV poles are occupied with
equipments such as infusion and syringe pumps. Alternative strategy was planned to
overcome the issue in HDU.
Conclusion: Behavioral modification needs constant reinforcement. Frequent on-going
monitoring and evaluation is required to keep this strategy sustainable.
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INDIAN PEDIATRIC ONCOLOGY GROUP - AN INITIATIVE OF THE
PEDIATRIC HEMATOLOGY ONCOLOGY CHAPTER OF INDIAN ACADEMY
OF PEDIATRICS
R. Arora1, A. Trehan2, D. Bansal2, T. Seth3, V. Radhakrishnan4, B. Arora5, N. Shah6,
A. Rau7, S. Bakhshi8
1Max Super-Speciality Hospital, Medical Oncology, New Delhi, India; 2Postgraduate
Institute of Medical Research, Pediatric Hematology Oncology, Chandigarh, India; 3All
India Institute of Medical Sciences, Hematology, New Delhi, India; 4Cancer Institute,
Medical Oncology, Chennai, India; 5Tata Memorial Hospital, Pediatric Oncology,
Mumbai, India; 6PD Hinduja National Hospital, Pediatrics, Mumbai, India; 7MS
Ramaiah Medical College, Pediatric Hematology Oncology Unit, Bangalore, India; 8All
India Institute of Medical Sciences, Medical Oncology, New Delhi, India
Background/Objectives: Formation of co-operative groups has been critical in
improving paediatric cancer outcomes. These can be country specific (e.g. COG-USA
and CCLG-UK) or disease specific (e.g. SIOPEL for liver tumours) and have research
at their core.Similarly, the Indian Paediatric Oncology Group (INPOG) was established
in September 2008. The primary objective was promoting regionally relevant paediatric
cancer research, including multicentre clinical trials in India (which had so far been
limited to ALL) so as to generate evidence in the local population and to improve
outcomes.
Design/Methods: INPOG was restructured recently to lend impetus to meeting its
objectives including election of a larger executive committee. Several working groups
were proposed. All members of the Paediatric Haematology Oncology Chapter of the
Indian Academy of Paediatrics were invited to complete a survey in Jan 2015 to express
their interest in the activities of INPOG and its working groups, both as contributors
of patients in relevant clinical studies, as well as more active participants in the design
and conduct of new studies.
Results: Applications were received from 62 members from 46 institutes. From these 21
groups were created including 17 disease specific (e.g. ALL, CNS tumours, etc.) and
groups on supportive care, epidemiology, access to care and late effects. Interested
individuals were allocated specific groups maintaining a balance of representation from
high volume (annual new childhood cancer patients >150) and low volume centres.
Each group chose its own chair and has had to invite key relevant allied specialities e.g.
radiation oncologists, surgeons, pathologists, etc. The groups then have the task to
define research priorities for their respective group and create a roadmap.
Conclusion: An organized effort been made to address the long-standing need of a
cooperative paediatric oncology research group in India with involvement of
stakeholders from all disciplines and public as well private pediatric cancer units.
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TREATING AWIDE SPECTRUMOF CHILDHOODMALIGNANCIES DESPITE
LIMITATIONS IN DIAGNOSTIC AND THERAPEUTIC RESOURCES IN
CENTRALMALAWI
I. Mtete1, M. Mutai1, P. Mehta2, M. Chasela1, M. Mtunda1, M. Kim3, P. Kazembe3,
N. El-Mallawany4
1Baylor College of Medicine Children’s Foundation Malawi, Pediatric Oncology,
Lilongwe, Malawi; 2Baylor College of Medicine, Pediatric Oncology, Houston, USA;
3Baylor College of Medicine Children’s Foundation Malawi, Pediatrics, Lilongwe,
Malawi; 4New York Medical College, Pediatric Oncology, Valhalla, USA
Background/Objectives:While most pediatric oncology programs worldwide employ
treatment regimens based upon pathology-proven diagnoses, many hospitals in
low-income countries struggle to choose protocols due to severe limitations in
laboratory, radiology and pathology services. With this scenario in mind, we aim to
describe the clinical characteristics and treatment outcomes in central Malawi.
Design/Methods:We retrospectively analyzed records of 271 children with cancer from
12/2011 – 6/2013. Diagnosis was based on cytology/histology in 102 patients.
Consistently available chemotherapeutic agents include cyclophosphamide (C),
doxorubicin (D, H, or A), vincristine (V or O), bleomycin (B), low-dose methotrexate
(M), and prednisone (P). Chemotherapy regimens varied; stage I/II Burkitt lymphoma
(BL): COMP, stage III/IV BL and other non-Hodgkin lymphoma (NHL): CHOP,
Hodgkin lymphoma (HL): ABV-PC, solid tumors (VDC+surgery), Kaposi sarcoma
(KS): BV.
Results: There were 111 females, 160 males. Most common clinical sites of presentation
were: abdominal mass 38%, peripheral lymphadenopathy 30%, jaw mass 16%,
peri-orbital/orbital mass 15%, central nervous system abnormalities 9%, mediastinal
mass 6%, and extremity mass 4%. HIV testing was performed routinely; 49/271 (18%)
were HIV-infected (45 KS, 3 BL, 1 NHL).Diagnoses include: BL 28.7%, KS 20.3%,
solid tumors of the abdomen 15.5% (Wilms tumor most commonly, then
neuroblastoma and germ cell tumors), HL 8.1%, non-Burkitt NHL 7.7%,
retinoblastoma 6.6%, rhabdomyosarcoma/soft-tissue sarcomas 4%, bone sarcomas
2.9%, acute leukemias 2.2%, and nasopharyngeal carcinoma 1.5%. Chemotherapy
regimens were completed by 55%, while 13% were lost to follow-up. At last evaluation,
complete remission (CR) was found in 74 (27%) patients (median follow-up 19
months). Sustained CR rates were highest for children with KS (49%), Wilms tumor
(42%), and BL (40%).
Conclusion: The three most common childhood cancers have the highest cure rates.
Treatment paradigms focusing on risk stratification can improve outcomes for common
diseases and may offer long-term cures to significant numbers despite severe limitations
in diagnostic and therapeutic resources.
O-221
ARE ESSENTIALMEDICINES AVAILABLE, RELIABLE AND AFFORDABLE IN
LOW-MIDDLE INCOME COUNTRIES?
T. Eden1, E. Burns2, C. Chunda-Liyoka3, M. Dolendo4, A. Islam5, A.A. Khaing6,
F. Kouya7, E. Molyneux8, V. Paintsil9, M. Pina10, L. Renner11, T. Scanlan12
1University of Manchester, Academic Unit of Paediatric and Adolescent oncology,
Edinburgh, United Kingdom; 2World Child Cancer, Head of Operations, London, United
Kingdom; 3National Children’s Hospital, Paediatric Oncology, Lusaka, Zambia; 4St
Jude partner Hospital, Pediatrics-oncology, Davao City, Philippines; 5Bangabandhu
Sheikh Mujib Medical University, Paediatric Oncology, Dhaka, Bangladesh; 6Yangon
Children’s Hospital, Department of Haematiology and Oncology, Yangon, Myanmar
Burma; 7Mbingo Baptist Hospital, paediatrics, Mbingo, Cameroon; 8College of
Medicine, Paediatrics, Blantyre, Malawi; 9Komfo Anokye Teaching Hospital, Paediatrics,
Kumasi, Ghana; 10Instituto Nacional de Cancerologia, Clinica de Pediatria, Bogota,
Colombia; 11Korle Bu Teaching Hospital, Paediatric Oncology, Accra, Ghana;
12Muhimbili National Hospital, Paediatrics, Dar es Salaam, Tanzania
Background/Objectives: A critical challenge for reducing the cancer survival disparity
between children living in low- middle income countries (LMICs) and those in high
income countries is the lack of consistent supplies of reliable ,effective and affordable
essential medicines.
Design/Methods: Using a semi-structured seventeen point questionnaire we sought the
perceptions of ten clinical leads from nine LMIC units regarding the availability,
importation, efficacy and costs of curative, supportive and palliative medicines within
their countries (Cameroon, Ghana, Tanzania, Malawi, Zambia, Bangladesh, Myanmar,
Philippines, Colombia).
Results: Collectively they see over 2000 new cases annually of whom a median of
65%(range 5-90%) receive curative intent therapy. No treatment relates to late diagnosis
and perceptions of incurability but predominantly to the family cost involved.
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Subsequent therapy abandonment ranged from <5% -50%( mean 20%), the lowest in
three countries with free drugs and the highest where no subsidy was available.
Philanthropic help has reduced abandonment somewhat. Only Bangladesh produces
any cyto-toxics and all depend on importation. In three countries the Government
directly controls importation, in five the role is delegated to a specific Pharmacy or
adult hospital , and in one free market forces operate.All reported inconsistent supplies
of key drugs mercaptopurine, methotrexate, cytosine, asparaginase, vincristine,
antibiotics and morphine and quality doubts were expressed about Branded generic
drugs. The principal sources of these were India (7/9), China, Argentina, Brazil, Korea,
Cyprus and Malaysia.
Conclusion: All of the respondents identified that World Health Organisation (WHO)
Listed Essential drugs were not consistently being produced, distributed reliably and/or
imported into their country. Unless there is state funding of drugs many families can
not afford the treatment costs. Internal and external drug subsidies have ameliorated the
problem to a degree but are not sustainable in the long term .Only a Global effort by all
interested parties including WHO and Pharma can remedy this problem.
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IMPACTMEASUREMENT - A SUSTAINABLE APPROACH
L. Burns1, J. Dixon2
1World Child Cancer, London, United Kingdom; 2World Child Cancer, Operations
Department, London, United Kingdom
Background/Objectives: The vast majority of paediatric oncology units in low-middle
income countries (LMIC) are underfunded, not prioritised by governments, and
frequently rely on outside support. Those making a case for additional support for
paediatric oncology units are not often trained fundraisers and so have little experience
in securing grants to help them develop their services. Attracting funding becomes
difficult when data collection techniques are not established and when the importance
of measuring impact and recording overall change is understated.The relationship
between donor and the paediatric oncology unit is often ‘top down’, with little
communication regarding monitoring and evaluation (M&E) processes and procedures,
often leaving the unit ‘muddling through’.
Design/Methods: Donors must realise that it is the paediatric oncology unit which is
best placed to develop long-term sustainable project goals, identifying realistic
indicators based on both qualitative and quantitative data. They must avoid the
temptation to focus solely on quantitative information and encourage local teams to
collect a variety of data, enabling a comprehensive picture of overall project
effectiveness to be built. It is through this process that paediatric oncology units learn
the true importance of measuring impact, whilst donors benefit from a wealth and
diversity of data. Accountability and transparency is fundamental to the overall success
of securing and maintaining funding. Regular reporting/feedback templates and
schedules should be developed in a collaborative process between both parties, with
training provided where necessary.
Results: A realistic and sustainable approach to impact measurement will strengthen the
overall M&E process, increasing a paediatric oncology unit’s chances of securing
long-term funding and support. This support will develop the services a unit provides,
ultimately resulting in better outcomes for patients.
Conclusion: It can be fairly easy to secure one-off intervention but long-term support
requires evidence-based progress to be reported. Sustainability is built through
long-term investment and impact measurement.
PPO - Opening Symposium
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UNDERSTANDING CONSENT IN PAEDIATRIC PHASE I/II CLINICAL TRIALS
FOR THE PARENTS AND THE CHILDREN
H. Chappuy1, A. Beranger2, A. de Haut de Sigy2, A.C. Foubert2, F. Doz3
1Pierre and Marie Curie University, Paris, France; 2APHP, Clinical Research Unit, Paris,
France; 3Curie Institute, Oncology, Paris, France
Background/Objectives: To assess parents and children’s comprehension of the
information given when seeking for consent to their child’s participation to phase I/II
clinical oncology trial, and to identify the factors of significant influence on parents’
decision making process.
Design/Methods: one hundred nineteen parents who had been approached for enrolling
their child in a clinical oncology study were asked to complete an interview. Their
understanding was measured by a score which included items required to obtain a valid
consent according to French legislation.
Results: Items that were best understood by parents were the risks (88%), the
procedures (85%), the potential benefits to other children (76%), the right to withdraw
(76%) and the duration of participation (70%). Items that were least understood were
the possibility of alternative treatments (48%), the aims of the study (38%), the
potential benefits to their child (25%). Seventy parents (59%) reported their decision as
evident. Thirty two parents (27 %) declared that they made their decision together with
the investigator. Thirty three parents (27%) took the decision on their own. Forty three
parents (36%) felt that the level of quantity of information given was satisfactory, even
when the level of information quality was up to 69%. Sixteen children (47%)
understood that the protocol was a phase I/II clinical trial.
Conclusion: There was a diversity of level of understanding between the evaluated items.
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ENCCA – EUROPEAN ACTIVITIES AND ACHIEVEMENTSWITH POTENTIAL
INTEREST OUTSIDE OF EUROPE
R. Ladenstein1, M. Schrappe2, K. Pritchard-Jones3, Z. Dobai4, S. Essiaf5, P. Kearns6,
A. Eggert7, M. Stanulla8, R. Haupt9, C. Kennedy10, G. Schreier11, M.G. Valsecchi12,
S. Bielack13, A. Cañete14, P. Czauderna15, R. Riccardo16, I. Lewis17, D. Stark17,
F. Doz18, J.C. K. Dupont18, E. Steliarova-Foucher19, G. Vassal20
1Children’s Cancer Research Institute, Studies and Statistics on Integrated Research,
Vienna, Austria; 2University Medical Center Schleswig-Holstein Campus Kiel,
Department of General Pediatrics, Kiel, Germany; 3UCL Institute of Child Health and
Great Ormond Street Hospital NHS Trust, Molecular Haematology and Cancer Biology
Unit, London, United Kingdom; 4Children’s Cancer Research Institute, Grant
Management & Research Support, Vienna, Austria; 5European Society for Paediatric
Oncology, Brussels, Belgium; 6School of Cancer Sciences-University of Birmingham,
Cancer Research UK Clinical Trials Unit CRCTU, Birmingham, United Kingdom;
7Charité - Universitätsmedizin Berlin, Department of Pediatric Oncology / Hematology,
Berlin, Germany; 8Hannover Medical School, Department of Paediatric Haematology
and Oncology, Hannover, Germany; 9Istituto Giannina Gaslini, Epidemiology and
Biostatistics Unit, Genova, Italy; 10University of Southampton, Faculty of Medicine,
Southampton, United Kingdom; 11Austrian Institute of Technology, Safety & Security
Department, Graz, Austria; 12University of Milano Bicocca, Centre of Biostatistics for
Clinical Epidemiology- Department of Clinical Medicine and Prevention, Milano, Italy;
13Klinikum Stuttgart, Olgahospital, Stuttgart, Germany; 14Fundación para la
Investigación Hospital Universitario La Fe, Grupo de Investigación Clínica y Traslacional
en Cáncer IIS La Fe, Valencia, Spain; 15Medical University of Gdansk, Gdansk, Poland
Department of Surgery and Urology for Children and Adolescents, Gdansk, Poland;
16Università Cattolica del Sacro Cuore, Department of Pediatric Oncology, Milano, Italy;
17The Leeds Teaching Hospitals NHS Trust, Children’s and Teenage Oncology and
Haematology Unit, Leeds, United Kingdom; 18Institut Curie, Paediatric Oncology
Department, Paris, France; 19World Health Organization, International Agency for
Research on Cancer, Lyon, France; 20Institut de Cancérologie Gustave-Roussy, Research
Clinical Division, Villejuif, France
Background/Objectives: The European Network for Cancer research in Children and
Adolescents’ (ENCCA - funded by the European Union’s FP7 program) aims to
improve the quality of life of children, teenagers and young adults with cancer by
efficiently structuring collaboration within the paediatric oncology community.
Design/Methods: The project was driven by 34 organizations in 11 countries and
together with the SIOPE community the following areas of interest were developed:
biology, bio-banking, drug development, policy actions to improve the clinical trial
framework, population-based cancer registries, special needs of teenager and young
adult patients (TYA), innovative statistical methodology, and close collaboration with
European Parent and Patient Groups, including ethical aspects in clinical research.
Results: ENCCA established important platforms for Paediatric Oncology: a European
Clinical Research Council as a community voice, the CDDF – ITCC- ENCCA- SIOPE
platform to facilitate collaborative partnership with Pharma (re-enforcing
mode-of-action driven drug developments), a European Parents and Patients Forum,
an Ethical Advisory Committee and a TYA network. The new platforms engage
successfully in European policy initiatives including new Clinical Trial Regulation
(completed) and forthcoming EU Data Protection Regulation. ENCCA designed an
“Advanced Biomedical Collaboration Domain”, a cloud-based solution for the
“European Virtual Institute” and the ENCCA Unified Patient Identity (EUPID), a
context–based identity management concept. ENCCA developed a survivorship
passport prototype providing long-term guidance to the patients’ journey of cancer
treatment, an on-line neuro-oncology module in eight languages where patients can
enter their outcomes in a standard dataset for future outcome research, a new Syllabus
for PHO education and organised several collaborative training courses (including
e-learning).ENCCA published 54 research and advocacy papers.
Conclusion: The manifold ENCCA activities have greatly improved the visibility of
paediatric oncology in Europe and paved the way towards long-term sustainable
research structures in Europe. Lessons learned could benefit other SIOP continents.
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CANKIDS PEDIATRIC PSYCHO-ONCOLOGY PROGRAM: A
FAMILY-CENTERED CARE PRACTICE FOR INDIA
H. Anis1
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Background/Objectives: The CanKids Pediatric Psycho-oncology Program is an integral
part of our objective to improve the quality of life for children with cancer. In India,
annually there are 40-50,000 new cases of childhood cancer. The cancer treatment
process can be psychologically devastating for children and families and psychological
support is an essential component of treatment. Throughout most of India, very few
resources are available for psychological support; this lack of emphasis and
understanding has often meant that children and families will not receive proper
treatment and therefore may have unnecessary fear, anxiety, and confusion, potentially
leading to the abandonment of treatment.
Design/Methods: CanKids has initiated a pediatric psycho-oncology program, serving
as a low cost model for other cancer institutions and organizations. We operate with a
focus on providing family centered care viewing cancer diagnosis as impactful to the
whole family. This initiative outlines a set protocol for child friendly wards,
explanation/clarification of diagnosis, disease oriented counseling for parents and the
child, bereavement support, informational tools for patients and caregivers, capacity
building for the social support team and sensitization workshops for healthcare
providers.
Results:Measurable results included advanced patient and family support services via
the aforementioned protocols, sensitization and increased knowledge for those
concerned with pediatric psycho-oncological care and advocacy for an enhanced
standard of pediatric psychosocial care in India. Results for the child and family
showed higher rates of compliance with treatment and long term psychological and
emotional well-being.
Conclusion: The CanKids Pediatric Psycho-oncology model is providing a family
centered care approach that works in collaboration and bridges the gap between the
psychosocial approach and treatment-centric approach. When uniting these two
approaches, the child and family facing cancer is provided with a comprehensive
healthcare experience for the best possible outcome.
PPO - Care Issues in the Developing World
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GAPS IN ESSENTIAL RETINOBLASTOMA CARE IN AFRICA
L. Hampejsková1, C. Bascaran1, M. Zondervan1
1London School of Hygiene and Tropical Medicine, International Centre for Eye Health,
London, United Kingdom
Background/Objectives: Retinoblastoma is one of the most common childhood cancers
with about 25% of the global burden in Sub-Saharan Africa, due to Africa’s vast
population and high birth rates. An early sign of retinoblastoma can be detected by
leukocoria and about 70% can be treated by unilateral enucleation with early detection.
However, many barriers in Sub-Saharan Africa prevent children from reaching
treatment in a timely manner causing high mortality. This study aims to evaluate the
gaps in providing essential care to retinoblastoma patients in 11 VISION2020
Paediatric LINKS across 8 African countries.
Design/Methods: A descriptive cross-sectional study was conducted in Ethiopia,
Malawi, Ghana, Nigeria, Uganda, Tanzania, Zambia and Zimbabwe on essential
retinoblastoma care. Ophthalmologists were identified through the LINKS and
snowballing technique was used to identify oncologists and pathologists totaling 45
participants. Participants answered Internet-based questionnaire addressing
comprehensive retinoblastoma care based on Canadian Retinoblastoma Strategy.
Ophthalmology participants were followed up with telephone/Skype interviews and
fieldwork was conducted in Tanzania and Zimbabwe. Through questionnaire/interview
analysis and literature review of retinoblastoma in developing countries, an
Africa-based retinoblastoma tool and scoring method was developed including 5
sections, 23 essential components and 66 descriptors. Data collected from each LINK
was input into the planning tool and rated using devised scoring method (a rating out
of 100% based on availability of each essential component) to determine the gaps in
essential retinoblastoma care in each VISION 2020 Paediatric LINK.
Results: An overall gap of 38% across the 11 VISION2020 LINKS was determined
using devised scoring method. Zimbabwe had the smallest gap at 18% and Ethiopia the
largest with 51%. The main gap was found at the primary health care level with lack of
training in detection of retinoblastoma to health care workers.
Conclusion: Further research is required to investigate an association between the
essential components and survival rates.
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COMMUNITY PLATELET DONOR DRIVES & ESTABLISHMENT OF A
VOLUNTARY DONOR REGISTRY: A NOVEL STRATEGY TO ENHANCE
TREATMENT COMPLIANCE & OUTCOMES OF CHILDHOOD CANCERS IN
LMIC
S. Jatia1, B. Arora1, T. Vora1, S. Banavali1, S. Rajadhyaksha2, D. Patil2, P. Motwani3,
P. Dutt3, D. Shah4, B. Sanadhya4, S. Sharma4
1Tata Memorial Centre, Pediatric Oncology, Mumbai, India; 2Tata Memorial Centre,
Transfusion Medicine, Mumbai, India; 3NDMCT, Mumbai, India; 4Gunvati J Kapoor
Foundation, Mumbai, India
Background/Objectives: Lack of adequate & affordable supply of blood products and
psychological as well as financial stress on families to ensure blood products availability
by donation from family members or from expensive private blood banks is common in
LMIC including India and is an important cause of treatment abandonment. Hence,
we started a novel campaign called “Save a Life” to motivate, recruit, and retain
voluntary non remunerated blood donors.
Design/Methods: “Save a Life was aimed at identifying target groups, conducting
platelet donation drives in community and creating a voluntary donor registry which
was first such effort in India. The campaign was initiated in November 2009 by a team
consisting of transfusion medicine specialists, pediatric oncologists and 3 NGO
(non-government organizations). In 5 years, 17 platelet drives were organized in
colleges, and corporate offices in which the audience were motivated through talks on
need, impact and process of donations. No incentives were offered but donors were
appropriately felicitated in addition to ensuring that donors get a holiday on the day of
donation through arrangement with college principals or employers.
Results: A total of 1483 donors were enrolled in registry. Of 1352 eligible donors,
369(27%) donated platelets and 123 of these (33 %) donated more than once. This led
to addition of 657 SDP units to hospital inventory in 5 years. The donor numbers
increased from 228 in 2009 to 1306 in 2014. Treatment abandonment in the same period
reduced from >20% to less than 5% due to multipronged approach including platelet
support.
Conclusion: Timely delivery of adequate, safe and free platelets from volunteers through
registry had a positive impact in the reduction of treatment abandonment as well as
reduction in morbidity & mortality associated with bleeding. This model can be easily
adopted in other LMIC with blood products shortage.
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HEALTH-CARE PROVIDERS’ PERSPECTIVES ON TRADITIONAL,
COMPLEMENTARY AND ALTERNATIVE TREATMENT IN CHILDHOOD
CANCER IN KENYA
G. Olbara1, J. Parigger2, F. Njuguna1, J. Skiles3, M. Sitaresmi4, G. Kaspers2,
S. Mostert2
1Moi Teaching and Referral Hospital, Eldoret, Kenya, Department of Child Health and
Pediatrics, Eldoret, Kenya; 2VU University Medical Center, Amsterdam, Netherlands,
Department of Pediatric Oncology-Hematology and Doctor 2 Doctor program,
Amsterdam, Netherlands; 3Indiana University School of Medicine-Indianapolis,
Department of Pediatrics- Division of Hemato-Oncology, Indiana, USA; 4Dr Sardjito
Hospital, Department of Pediatrics, Yogyakarta, Indonesia
Background/Objectives: Our study explores health-care providers’ (Hcp) perspectives on
TCAM in childhood cancer. Personal experience with TCAM, health beliefs,
components of TCAM, recommending or discouraging TCAM, communication
between Hcp, parents, and TCAM practitioners and knowledge of TCAM were
assessed.
Design/Methods: This cross-sectional study used semi-structured questionnaires. Hcp
involved in the care of children with cancer at an academic hospital between July 2014
and October 2014 were interviewed.
Results: Out of total 179 Hcp, 155 Hcp (response rate, 79 %) returned the
questionnaire. Hcp describe their view on TCAM as: cautious (39%), skeptic (33%),
positive (18%), and undecided (11%). TCAM can cure cancer according to (9%) of the
Hcp. More doctors (90%) than other Hcp (56%) think that chemotherapy can cure
cancer (P=<0.001). Hcp (97%) think that their patients should inform them if they use
TCAM. Only 5% of Hcp always openly discuss the topic TCAM with their patient,
Doctors mostly recommend vitamin supplements (66%), self-prayer (58%), and special
food intake (58%). Most discouraged forms of TCAM are: witchcraft (85%),
scarification (68%) and ritual sacrifice (68%). Communication between doctors and
TCAM practitioners is required (91%). Most Hcp feel that their knowledge about the
safety and efficacy of CAM is inadequate (71%), Hcp want to learn more about CAM
(87%).
Conclusion: A majority of Hcp have a negative attitude towards the use of TCAM.
Communication about TCAM between Hcp and parents should be improved so
parents feel safe to discuss their interest in TCAM. More attention should be given in
updating knowledge of Hcp on safety and efficacy of TCAM in medical training
institutions and through continued medical education programs.
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TREATMENT ABANDONMENT IN PEDIATRIC CANCER PATIENTS DURING
WARTIME IN SYRIA
O. Fawaz1
1Al Bairouni University Hospital for Cancer, Damascus, Syria
Background/Objectives: Treatment abandonment of pediatric cancer patients represents
a crucial reason for their low survival rate in limited resources countries. The study aims
to discuss this problem and how it is further worsen by fighting acts and war conditions
in Syria.
Design/Methods: Syria has three hospitals to treat pediatric patients. Al Bairouni
hospital is the specialized center for cancer treatment. Department of pediatric
oncology was opened in 2010. Examples of Analyses include: comparison of numbers
of newly accepted patients each year before and after the eruption of the conflict,
2011-present time. Statistic of patient’s follow-up and medication adherence. Changes
in treatment cost during this period and percentage of drug availability. Family
residence and transport accessibility to and from hospital location.
Results: Cancer is a national public health problem in Syria with growing incidence,
according to the statistics of the cancer registry of the Ministry of Health, already
before the Syrian crises in 2011. The number of newly accepted cancer patients
decreases. Half of the patients have stopped coming to the hospital to continue their
treatment. Decline of available drugs offered. Increase in the treatment cost for each
patient.
Conclusion: Deterioration in medical Infrastructure, leakage of doctors and nurses and
shortage of affordable low cost therapeutic agents are important causes of treatment
abandonment in pediatric cancer patients during wartime in Syria.
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HEALTH-CARE PROVIDERS’ PERSPECTIVES ON HEALTH-INSURANCE
ACCESS, WAIVING PROCEDURES AND HOSPITAL DETENTION PRACTICES
IN KENYA
S. Mostert1, F. Njuguna2, R. van der Burgt3, J. Musimbi2, S. Langat2, J. Skiles4,
A. Seijffert3, M. Sitaresmi5, G. Kaspers3
1VU University Medical Center, Amsterdam, Netherlands; 2Moi Teaching and Referral
Hospital, Pediatrics, Eldoret, Kenya; 3VU University Medical Center, Pediatric
Oncology-Hematology, Amsterdam, Netherlands; 4Indiana University Schoolof
Medicine, Pediatric Hemato-Oncology, Indianapolis, USA; 5Dr Sardjito Hospital,
Pediatrics, Yogyakarta, Indonesia
Background/Objectives: Patients at Kenyan public hospitals are detained if families
cannot pay the medical bills. Access to health-insurance and waiving procedures to
prevent detention may be limited. This study explores the perspectives of health-care
providers (HCP) on health-insurance access, waiving procedures and hospital detention
practices.
Design/Methods: A self-administered structured questionnaire was completed by 104
HCP (response rate 78%) in January and February 2013.
Results: All children with cancer should have health-insurance according to 96% of
HCP. After parents apply for health-insurance, it takes too long before treatment costs
are covered (67%). Childhood cancer patients without health-insurance have a higher
chance to abandon treatment (82%). Hospitals should waive bills of all children with
cancer when parents have payment difficulties (69%). Waiving criteria are unclear
according to 45% of HCP, and 15% are uncertain. Waiving procedures take too long
(75%). Social workers’ approach toward pressuring parents to pay is too aggressive
according to 44% of HCP, and 19% are uncertain. Parents are scared by waiving
procedures and may decide never to return to hospital again (68%). Families’
experiences with waiving procedures contribute to high treatment abandonment rates
(64%). Poor families delay visiting hospital because they fear hospital detention and
first seek alternative sources of treatment instead (92%). When poor families finally
come to hospital the disease may be in an advanced stage already (94%). Parents
sometimes have to abandon their child in hospital if they cannot pay hospital bills
(68%). Children should not be left alone in hospital, if their parents cannot pay hospital
bills (84%). Detention of children at hospitals if parents cannot pay medical bills is
disapproved by 84% of HCP.
Conclusion: HCP acknowledge that access to health-insurance needs improvement and
that waiving procedures contribute to treatment abandonment. Most HCP disapprove
of hospital detention practices. These factors warrant urgent attention and adjustment.
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REDUCING ABANDONMENT OF TREATMENT IMPROVES QUALITY OF
CARE FOR ALL PATIENTS: THE SALVADORAN EXPERIENCE
N. Rossell1
1University of Amsterdam, Institute of Social Science Research, Amsterdam, Netherlands
Background/Objectives:When evaluating pediatric cancer in low and middle-income
countries, abandonment of treatment is a main cause of treatment failure and death.
Beyond cure rates, abandonment reveals complex issues of culture and life conditions
across multiple social strata, and speaks to health systems and health teams working in
childhood cancer.
Design/Methods: A long-term qualitative research study in El Salvador explored
parents’ explanations for abandonment revealing relevant specifics of multidisciplinary
health care.
Results: During the past decade, each year, approximately 20/200 children diagnosed
with cancer abandoned treatment. Despite representing a small proportion of the total
number of children on treatment, these families had an impact on the way medical care
for paediatric cancer is provided in El Salvador. In the process of attempting to reduce
treatment abandonment, the multidisciplinary team optimized resources to provide
money for public transportation and meals for patients and parents, reorganized tasks
and responsibilities to improve close follow-up of families, and focused most of its
energy on refining detection of risk factors in families vulnerable to abandonment. As a
result of the various initiatives and dedication, abandonment rates decreased from 13%
to approximately 3%. The ‘at risk’ families became the main force to push the
multidisciplinary team to re-examine their care, humanizing their relationships, and
improving the quality of care for all patients.
Conclusion: Since it is impossible to identify with absolute certainty in advance which
parents will stop bringing their child for treatment, the consequences of the team’s
efforts in trying to prevent abandonment have had direct benefits on all patients as well
as developed the professional and human quality of the multidisciplinary team.
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ABANDONMENT OF TREATMENT: A CALL FOR QUALITATIVE RESEARCH
ON CANCER, CULTURE, AND PSYCHOSOCIAL SERVICES
N. Rossell1
1University of Amsterdam, Amsterdam Institute of Social Science Research, Amsterdam,
Netherlands
Background/Objectives: Abandonment of treatment represents a substantial obstacle
for curing children with cancer in low-income countries (LIC). Initial research focused
on finding measurable factors and cause-effect relationships among quantifiable
variables. Socio-economic issues were linked to abandonment, and interventions based
on the provision of material resources to parents had a positive impact in reducing the
problem. As interventions for reducing abandonment become more effective, qualitative
research is needed to understand and solve the minority of cases that continue to defy
health team efforts.
Design/Methods: Based on the analysis of the multidisciplinary team interventions and
data collected through an ethnographic study on abandonment of treatment in El
Salvador, research and clinical practice together offered valuable sources of knowledge
for improvement.
Results: The families’ experiences of socioeconomic and emotional stress and cultural
and religious beliefs, interplay as components of the doctor-parent encounter, and are
involved in abandonment of treatment. Equally important, the results show that a
committed multidisciplinary team working on individualized approaches to families at
risk of abandonment probed to be effective. The data in this study show the value of
qualitative research in the medical setting, and the significance of psychosocial teams in
oncology. The need for understanding abandonment puts psychosocial teams in the
forefront, challenging and promoting their role inside the medical practice and
personnel. The same occurs in qualitative research, which is essential for explaining the
meanings and relationships like family dynamics, living circumstances, and emotions,
involved in the experience of a child’s undergoing cancer treatment.
Conclusion: Abandonment of treatment is a cruel reminder for health teams to
recognize the impact of socio-cultural meanings in the treatment of cancer and its
outcomes. This highlights the need for approaches and practices informed by
qualitative research, and mobilizes the enhancement of psychosocial teams.
PPO - Resilience & Social Skills in ALL & Brain Tumours
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RESILIENCY OF CHILDREN AND ADOLESCENTS DURING TREATMENT
OF ACUTE LYMPHOBLASTIC LEUKEMIA: THE USE OF 5-HTT AND BDNF
POLYMORPHISMS AS BIOMARKERS
J. Blom1, L. Pomicino2, C. Migliozzi1, L. Montanari1, G. Rigillo3, G. Zanazzo2,
M. Cellini1, C. Benatti3, F. Tascedda3
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1University of Modena and Reggio Emilia, Department of Pediatric Oncology, Modena,
Italy; 2IRCCS Burlo Garofolo, Pediatric Hematology and Oncology, Trieste, Italy;
3University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy
Background/Objectives:Why are some children more likely than others to develop
resilience in the face of similar levels of trauma exposure as compared to others who do
not. It is increasingly clear that there are critical roles for predisposing genetic and
environmental influences in differentially mediating psychological risk. Resilience differs
from traditional concepts of risk and protection in its focus on individual variations in
response to comparable experiences. Here, we tested the hypothesis that anxiety and
depression as well as neural repair and plasticity related polymorphisms may partly
account for the difference in resilience observed during treatment for acute
lymphoblastic leukemia (ALL).
Design/Methods: Forty-five patients (1-18 yrs old) diagnosed with ALL were enrolled in
two centers (protocol AIEOP-BFM-2009) and genotyped for 5HTT and BDNF
(val66met). Patients and their family were subjected to a short screening battery,
psychosocial testing (PAT2.1) and a specific assessment of their resiliency during
treatment. The resiliency scale was composed of three subscales: Sense of Mastery
(MAS), Sense of Relatedness (REL), and Emotional Reactivity (REA).
Results: Patients with the SL allele of 5HTTLPR had a more compromised score in
some areas of resiliency than patients with the LL allele; the presence of the S allele
most affected emotional reactivity REA and sense of mastery MAS. Furthermore, age
was an important factor, as younger children displayed a reduced trust and tolerance
versus their surroundings. This then contributed importantly to an overall reduction in
their overall resiliency. Also, resiliency was reduced one year into therapy while
vulnerability was significantly enhanced.
Conclusion: Genes regulating susceptibility to stress, such as 5HTTLPR and BDNF,
may help to predict susceptibility towards the development of resiliency in children and
adolescents treated for cancer, and may play a critical role as a predisposing factor in
differentially dealing efficiently with the emotional risks related to cancer and its
treatment.
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IS TUMOUR TYPE A CRITICAL FACTOR IN PEDIATRIC BRAIN TUMOUR
PATIENTS’ SOCIAL SKILLS AND QUALITY OF LIFE?
B. Maru1, U. Bartels2, A. Rokeach3, A. Saleh3, K. Hancock3, D. Cataudella4,
F. Schulte5, J. Chung6, J. Hukin6, A. Downie4
1Hospital for Sick Children, Toronto, Canada; 2Hospital for Sick Children, Paediatrics,
Toronto, Canada; 3Hospital for Sick Children, Psychology, Toronto, Canada; 4Children’s
Hospital of Western Ontario, Oncology, London, Canada; 5Alberta Children’s Hospital,
Haematology/Oncology, Calgary, Canada; 6BC Women and Children’s Hospital,
Haematology/Oncology, Vancouver, Canada
Background/Objectives: Paediatric brain tumour patients (PBTP) treated for
medulloblastoma are at increased risk for neurocognitive deficits compared to other
PBTP, with radiation doses being a critical factor. Less is known about the effect on
their social behaviour and quality of life (QOL) compared to other tumour types. We
investigated the differential effect of pediatric brain tumour type/treatment [low grade
gliomas (LGG), medulloblastoma (MEDBL), other brain tumours (OBT, including
astrocytoma)] on PBTP’s social skills and QOL.
Design/Methods: Eighty PBTP (LGG=35, MEDBL=18, OBT=27), ages 8 to 16 years,
in stable medical condition, and attending school participated. Parent and Self-reported
questionnaires were used to assess social skills (Social Skills Rating System; SSRS), and
QOL (PedsQL4.0 generic). PBTPs were on average 5 years post-diagnosis. One way
ANOVAs (using diagnosis/treatment type) were conducted for each outcome measure.
Alpha levels with Bonferroni correction and effect sizes are reported.
Results: Social Skills. There were significant differences between diagnosis type on both
Self and Parent-reported Total Social Skills (p = 0.034, 0.032; η2 =0.08,0.09) and
Assertion scores (p = 0.004, 0.001; η2 =0.13, 0.19); Self-reported Empathy Subscale (p
= 0.009; η2 =0.12); and Parent-reported Self-Control subscale (p = 0.045; η2 =0.08).
Parents reported the poorest Self-Control scores for LGG. QOL. Parent-reported QOL
indicated a significant effect for the Emotional (p = 0. 015; η2 =0.10) and Social
domains (p = 0.03; η2 =0.09), with LGG experiencing poorer emotional QOL and
MEDBL experiencing poorer social QOL. Self-reports showed no significant effects.
Conclusion: Patients treated for MEDBL may experience more social skills difficulties
than other PBTPs, while emotional QOL is a major concern for LGG patients
compared to other PBTPs. These findings emphasize the importance of examining in
detail what factors of diagnosis/treatment might be critical for these outcomes.
Acknowledgements: The Canadian Cancer Society Research Institute funded this study.
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A RANDOMIZED CONTROL TRIAL OF THE EFFICACY OF A GROUP
SOCIAL SKILLS INTERVENTION FOR PAEDIATRIC BRAIN TUMOUR
PATIENTS
B. Maru1, A. Rokeach2, K. Hancock2, U. Bartels3, A. Saleh2, F. Schulte4,
D. Cataudella5, L. Sung6, J. Chung7, A. Downie5, J. Hukin7, D. Strothers8
1Hospital for Sick Children, Toronto, Canada; 2Hospital for Sick Children, Psychology,
Toronto, Canada; 3Hospital for Sick Children, Paediatrics, Toronto, Canada; 4Alberta
Children’s Hospital, Haematology/Oncology, Calgary, Canada; 5Children’s Hospital of
Western Ontario, Oncology, London, Canada; 6Hospital for Sick Children,
Haematology/Oncology, Toronto, Canada; 7BC Women and Children’s Hospital,
Haematology/Oncology, Vancouver, Canada; 8Alberta Children’s Hospital, Oncology and
Transplant Program, Calgary, Canada
Background/Objectives: Paedatric brain tumour patients (PBTP) typically experience
social competence deficits and yet, treatment for these deficits has received little
attention. The study objective was to assess the efficacy of a manualized group social
skills training intervention program (SSIP) for PBTP by evaluating whether the
Experimental Group (EG) demonstrated improved social skills when compared to a
Control Group (CG).
Design/Methods: A multisite, randomized control trial (RCT) with repeated measures
(baseline, post-intervention, six months later) was employed. PBTP aged 8-16 years in
stable condition- on or off therapy - and attending school regularly, were block
randomized to either the EG or CG. Both groups underwent 8 two-hour weekly
sessions. EG (n = 40) received manualized social skills training through activities and
crafts. CG (n = 42) received activities and crafts only. Social skills were assessed using
the Social Skills Rating System (SSRS; Parent and Self Reports) – subscales include
Cooperation, Assertion, Self-Control, and Problem Behaviours (Externalizing,
Internalizing). ANCOVAs controlled for baseline scores.
Results:No significant groups or time effects were found in self-reports. Parental ratings
of Total Problem Behaviours and Internalizing subscale yielded a group by time
interaction, (p = 0.032, n2 = 0.06), suggesting a reduction of Internalizing problems in
the EG. Parent reports for both groups indicated a significant time effect (p = 0.005, n2
= 0.10) and group effect (p = 0.013, n2 = 0.08, p = 0.015, n2 = 0.07) in the Cooperation
subscale, suggesting improvements within this subscale.
Conclusion: Both groups were offered opportunities for social interactions, but based on
parental reports, the SSIP seems to have the added potential for improving PBTP’s
cooperative behaviour and internalizing changes in social skills. It is unclear whether
self-reports reflect true finding or a lack of insight.
Acknowledgements: This study was funded by the Canadian Cancer Society Research
Institute.
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PSYCHOLOGICAL ISSUES IN ADOLESCENTS AND YOUNG ADULTS WITH
CANCER REFERRED TO PSYCHO-ONCOLOGY SERVICE IN A TERTIARY
CARE CANCER CENTER
S. Goswami1, J. Deodhar1, L. Sonkusare1
1Tata Memorial Hospital, Psychiatric Unit, Mumbai, India
Background/Objectives: Adolescent and young adults (AYA) who are diagnosed with
and treated for cancer have distinctive psychosocial concerns that set them apart from
pediatric and older adult populations. They have different needs and treatment
challenges from children or older adults. There is a dearth of literature in the Indian
setting on emotional issues expressed by this population. Our paper studies the
psychological concerns in adolescents and young adult cancer patients referred to our
psycho-oncology service in a tertiary care cancer hospital.
Design/Methods: A clinical audit of AYA cancer patient referrals to psycho-oncology
service was conducted for the period of January to December 2014.Information was
collected from prospectively maintained data in the department along with patient
charts. Details about diagnosis, treatment, demography, reason for referrals, patients
concerns and coping skills were noted. Relevant statistics were used.
Results: 84 out of 553 AYA cancer patients were referred to psycho-oncology service in
the study period, a referral rate of about 15%. Out of 84 AYA cancer patients referred,
38 (45%) were from pediatric and 46 (55%) from adult care setting. 55 (65%) were male
and 51(61%) were outpatients. Common reasons for referral were counseling and
evaluation of mood. The main cancer diagnoses were hematolymphoid (43%) and solid
tumors (56%) of which (19%) CNS tumors.Majority of AYA cancer patients had
psychological/ emotional issues (anxiety, distress related to physical state, worries about
school, missing home) and 75% had multiple concerns (physical, emotional, family,
practical, and spiritual). 53 (63%) had adjustment difficulties and mood/ emotional
disturbances.
Conclusion: The psychological issues faced by AYA patients referred to our service were
related to mood disturbances, distress and adjustment difficulties. More effective
monitoring of psychosocial needs of AYA cancer patients is essential to empower them
with specialized psycho-therapeutic interventions and to improve their coping and
adjustments throughout the cancer treatment and after treatment.
Pediatr Blood Cancer DOI 10.1002/pbc
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MATCH OF PSYCHOSOCIAL CARE AND PSYCHOSOCIAL RISK IN
FAMILIES OF CHILDREN DIAGNOSEDWITH CANCER
S.M. Sint Nicolaas1, S.A. Schepers2, E.M.M. Meijer-van den Bergh1, Y. de Boer2,
E.M. van Dijk-Lokkart3, I.C. Streng4, M.A. Grootenhuis2, C.M. Verhaak1
1Radboud University Medical Centre, Medical Psychology, Nijmegen, Netherlands;
2Emma Children’s Hospital Academic Medical Center, Psychosocial Department,
Amsterdam, Netherlands; 3VU Medical Center, Medical Psychology, Amsterdam,
Netherlands; 4Sophia Children’s Hospital Erasmus Medical Center, Medical Psychology,
Rotterdam, Netherlands
Background/Objectives: This study aims to describe psychosocial care provided to
families of a child with cancer, and to what extent this care matches with families’
psychosocial risk profiles as measured with the Psychosocial Assessment Tool (PAT).
Design/Methods: In this multicenter longitudinal Dutch study, 83 families (response
rate 73%) of newly diagnosed children with cancer (0-18 year) participated. The PAT
was assessed at diagnosis, and their need for psychosocial care was assessed six months
later. Families were considered at low risk (PAT0.99), medium risk (PAT1.00-1.95), or
high risk (PAT1.96) for psychosocial problems. Subsequent matched psychosocial
care was defined as child care specialist for all families, social worker for medium risk
families, and psychologist for high risk families. When parents wanted help from a
psychosocial care specialist, but had not received it, it was defined as an unmet need.
Results: 65% of families had low, 30% medium, and 5% high risk for developing
psychosocial problems according to the PAT. Of low-risk families, 17% of the children
and 26% of the parents received care by a psychologist, and 49% got help from a social
worker. In families with medium risk, 48% of the children and 40% of the parents
received psychological care, and 72% got care from a social worker. In high-risk families,
50% of the children and 50% of the parents got psychological care, and 75% received
help from a social worker. Unmet needs regarding psychosocial help were highest
among families at medium (16%) or high risk (25%) regarding a child psychologist.
Conclusion: Results indicate that psychosocial care is only partly matched to risk
profiles. It seems that low risk families tend to get more specialized care than their risk
profile would suggest, while families with severe risk get less care than risk profiles
suggested. Feedback of the risk profile could optimize this match.
PPO - Patients, Parents & Sibling Subjective Perspectives on the Childhood Cancer
Journey
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VOICINGMY CHILD CANCER IN SENEGAL: CHALLENGING THE
ASSUMPTIONS WEMAKE ABOUT CHILDREN’S PERCEPTION OF THE
CANCER EXPERIENCE BY ALLOWING THEM TO NARRATE IT
S. Ndiaye1, S.M. Ndiaye2, M.T. Sagna3, C. Moreira3, F.B. Diagne3, M.N. Diouf3
1University Hospital Aristide Le Dantec, Dakar, Senegal; 2Hopital Principal de Dakar,
Psychiatry, Dakar, Senegal; 3University Hospital Aristide Le Dantec, Pediatric Oncology,
Dakar, Senegal
Background/Objectives: This qualitative study challenged assumptions made by adults
in a culture where silence is supposed to be golden for children.Our purpose was to
offer a cathartic space for young cancer patients to describe their experience from
diagnosis through remission.
Design/Methods:We’ve collected data from therapeutic groups in which children
hospitalized of the only pediatric oncology unit in Senegal described the treatment
process, the hospitalization, and their repercussions on their regular lives. The
instruction was to write a letter to a newly diagnosed patient to prepare her for the
upcoming cancer experience (original idea from Dr Wiener). We’ve collected data from
10 hospitalized patients aged between 6 and 15.
Results: Our patients reported a detailed description of the physical explorations
necessary for diagnosis; the treatment process including the frequent blood draws;
chemotherapy and the "colored" infusions; surgery and its painful aftermath. Young
patients have also addressed the bodily changes provoked by the chemotherapy, all their
interactions and appreciations of the staff as well as the hospital stay day-by-day.
Unexpectedly, they paid special attention to the temperature in the rooms, the quality
of food, the distinctions in the quality of care amongst the medical practitioners and
depending on the time of day. For their newly diagnosed pair, young patients focused
deeply on the painful procedures, the emotional experience of being away from home,
having depressive phases during treatment, being stigmatized at school and at
home…etc.
Conclusion: In Senegal we assume that children are too fragile to be informed, yet we
were surprised of how mindful and aware they were about their cancer experience.
Contrarily to popular belief assuming that young patients can’t talk about their disease,
we’ve demonstrated that children were at ease in describing their pathology with more
details than their parents and with focus on aspects oblivious to the adult eye.
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BEREAVEMENT AND END OF LIFE CARE ISSUES OF CHILDRENWITH
CANCER AND THEIR PARENTS
E. Khan Ghazi1, A. Abbas1, R. Waheed1
1Children Cancer Unit-Indus Hospital, Psychosocial Oncology, Karachi, Pakistan
Background/Objectives: Children Cancer Unit- Indus Hospital, provides free of cost
services to children with cancer who come for treatment from all over Pakistan and
Afghanistan. Since there is a paucity of human and financial resources, visits could not
be made to homes of bereaved families to offer condolences or support. Therefore a
protocol was devised which would include offering condolence calls via telephone, to
bereaved families and to identify areas of further improvement in end of life care
services being offered.
Design/Methods: Sixty-five bereaved families were approached and interviewed by the
spiritual counselor and psychotherapists trained in person centered care, over the
telephone.
Results: A qualitative analysis was carried out in which the themes that were prevalent
in end of life care, were of excruciating pain that children with cancer faced and
parents’ trauma as well as the post traumatic experiences that the parents faced from
seeing the death of their child. Relying on divine will as the reason for the end of
suffering through death and the subsequent relief, were also factors that came up.
Moreover some parents wanted there to be a way to ease the death of the child. In the
bereavement phase the factors that were identified were that the more supportive the
families felt health professionals in the Children Cancer Unit, Indus Hospital were, the
better their coping mechanisms were with the grief of losing their child. There was
gratitude and a sense of calm at getting condolence calls from the counselors, and the
ones who showed distress were given grief counseling.
Conclusion: Further research into non pharmacological and pharmacological means of
pain alleviation, needs to be carried out to ensure that children with cancer receive
effective pain reduction treatment in end of life care. And the distress of the parents
whose children have died can be lessened further.
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SIBLINGS’ EXPERIENCES OF THE BROTHER’S OR SISTER’S CANCER
DEATH: A NATIONWIDE FOLLOW-UP 2-9 YEARS LATER
M. Lövgren1,2, L. Jalmsell3, A. Eilegård Wallin2, G. Steineck4, U. Kreicbergs1,5
1Karolinska Institutet, Department of Children’s and Women’s Health, Stockholm,
Sweden; 2Dalarna University, School of Education- Health and Society, Falun, Sweden;
3Uppsala University, Centre for Research Ethics & Bioethics, Uppsala, Sweden;
4Karolinska Institutet, Department of Oncology-Pathology, Stockholm, Sweden; 5Ersta
Sköndal University College, Palliative Research Centre, Stockholm, Sweden
Background/Objectives: Even though siblings of a child who dies from cancer live the
illness experience with the same intensity as the parents, they often stand outside the
spotlight of attention, and until recently, little research has focused on the sibling’s
situation. The aim of this study was therefore to examine siblings’ experiences of their
brother’s or sister’s cancer death and if these experiences influenced levels of anxiety 2-9
years later.
Design/Methods: This nationwide survey was conducted in Sweden 2009. All siblings
who had a brother/sister who was diagnosed with cancer before the age of 17 and who
died before the age of 25 during 2000-2007 were invited. Of those, 174 siblings
participated (participation-rate: 73%). Mixed data from the survey about the siblings’
experiences of death were included as well as data from the Hospital Anxiety and
Depression Scale. To examine the experiences, descriptive statistics and content analysis
were used. Mann-Whitney U-test was conducted to investigate if the experiences
influenced anxiety 2-9 years later.
Results: The siblings reported poor knowledge and experienced a lack of
communication about their brother’s/sister’s death, e.g. about the time frame and bodily
changes near death. Siblings who reported that no one talked with them about what to
expect when the brother/sister was going to die reported higher levels of anxiety 2-9
years after the loss. Seventy percent reported that they witnessed their brother/sister
suffering the last hours in life. Stressful situations during end-of-life care and poor
communication within the family were described as influencing the siblings’ grieving
process. Many of those who were not present during the illness trajectory and at the
time of death regretted that.
Conclusion: It is important to prepare siblings for their brother’s/sister’s illness and
death in order to prevent anxiety and regrets later on.
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INCORPORATING GOOD PATIENT, PARENT, AND PROVIDER DEFINITIONS
TO IMPROVE CARE INTERACTIONS AND PSYCHOSOCIAL OUTCOMES
FOR CHILDRENWITH CANCER, THEIR FAMILIES, AND THEIR CARE
TEAMS
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1St Jude Children’s Research Hospital, Pediatric Oncology, Memphis, USA; 2Children’s
National Health Systems, Pediatric Intensive Care, Washington DC, USA; 3Children’s
National Health Systems, Department of Nursing Research and Quality Outcomes,
Washington DC, USA
Background/Objectives: Understanding how adolescents with cancer define “good
patient” and “good child” roles and how parents abide by a “good parent” definition
may improve care interactions and decisional approaches for children with cancer.
Design/Methods: The study team engaged in three prospective, face-to-face qualitative
interview studies at two pediatric hospitals in the United States. Parents (n=43 in urban
PICU setting, n=62 in cancer hospital setting) were asked to describe factors important
for parenting their ill child and how clinicians could help them achieve their definition
of “being a good parent” to their child. Adolescent-age cancer patients (n=40 in two
separate cancer centers) were asked to describe their definition of “being a good
patient” and “being a good child” during times of illness. Parent and patient responses
were analyzed thematically with strict adherence to consolidated criteria for reporting
qualitative research (COREQ) guidelines.
Results: A concept of good child and good patient exists for adolescents undergoing
cancer treatment and the ill child is conscious of these in care interactions, family
dynamics, and medical decisions. A concept of good parent exists and influences end of
life treatment decision-making in at least two different parent groups: parents of
children with incurable cancer parents of children in the PICU who may or may not
survive. Participants identified key staff interactions that support or hinder these good
parent, child, and patient roles.
Conclusion: As the concept of good patient and good child exists for adolescent cancer
patients and the concept of good parent exists for their care guardians, the concept of
good doctor and good nurse has been reported in the literature as influencing care
delivery. A better understanding of the interactions resulting from these concepts and
“good role” beliefs may improve medical care, decision support, and psychosocial
outcomes in pediatric cancer.
PPO Free Papers Session
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SIOP PODC GLOBAL TASK FORCE ONHOSPITAL DETENTION PRACTICES:
COLLABORATING INTERNATIONALLY TO RAISE AWARENESS AND
ENCOURAGE ADVOCACY AND ACTION TO END HOSPITAL DETENTION
A. Patenaude1, C.G. Lam2, C. Salaverria3, S. Mostert4, F. Njuguna5, K. Kulkarni6
1Dana-Farber Cancer Institute, Department of Psychosocial Oncology and Palliative
Care, Boston MA, USA; 2St. Jude Children’s Research Hospital, Department of
Oncology, Memphis TN, USA; 3Hospital Nacional de Ninos Benjamin Bloom,
Department of Pediatric Oncology, San Salvador, El Salvador; 4VU University Medical
Center, Department of Pediatric Hematology-Oncology, Amsterdam, Netherlands; 5Moi
University, Department of Child Health and Pediatrics, Eldoret, Kenya; 6IWK Health
Center- Dalhousie University, Department of Pediatrics, Halifax-Nova Scotia, Canada
Background/Objectives: Data on repeated detention of children with cancer in Kenyan
public hospitals presented by Mostert and Njuguna at SIOP Hong Kong and published
in Pediatric Blood and Cancer and Psycho-Oncology led to the 2014 creation of the
SIOP PODC Global Task Force on Hospital Detention Practices. The goal is to
advocate for awareness and find solutions to end hospital detention practices, where
patients are kept in hospital due to families’ inability to pay hospital costs.
Design/Methods: Starting with online meetings in existing PODC working groups, the
Task Force encompasses 32 members from 12 countries. An online repository was
initiated to highlight hospital detention practices in the literature and lay media and to
extrapolate lessons from advocacy efforts for patients across diverse settings. Monthly
meetings included reports of detention in Africa, Asia, South America and Eastern
Europe. Lack of consistent nomenclature was noted to hinder descriptions and
comparisons, as did challenges to open reporting by professionals. Outreach to Human
Rights Watch and other organizations helped define need for collaborative and creative
means to effectively end hospital detention.
Results: The Task Force established use of consistent nomenclature, preferring
“hospital detention” to “hospital retention.” A Position Statement on Hospital
Detention was prepared for publication. Recognition of the Task Force’s work led to a
Statement of Support from the International Psycho-Oncology Society (IPOS), posted
on the IPOS website and reflected in a Presidential Plenary talk at the July 2015
IPOS/APOSWashington meeting. A session hosted by Childhood Cancer International
at SIOP/Asia in Jordan in April 2015 was organized to raise awareness and increase
international collaboration.
Conclusion:More research and action are needed to document the extent and impact of
hospital detention on lowering survival and reducing quality of life for families of
cancer patients. International collaboration is essential to finding solutions to end this
practice.
O-244
POOR IMPACT OF POST-ABANDONMENT TRACKING AND COUNSELLING
PATIENTS WHO DEFAULTED TREATMENT OF CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA: THE NEED OF PRE-EMPTIVE STRATEGIES
N. Roy Moulik1,2, K. Kulkarni3, A. Kumar4
1Saroj Gupta Cancer Centre and Research Institute, Pediatric Hematology and Oncology,
Kolkata, India; 2King George’s Medical University, Division of Pediatric
Hematology-Oncology-Department of Pediatrics, Lucknow, India; 3IWK Health Centre,
Division of Hematology/Oncology-Department of Pediatrics, Halifax, Canada; 4King
George’s Medical University, Division of Pediatric Hematology-Oncology-Department of
Pediatrics, Lucknow, India
Background/Objectives: Treatment abandonment is an important hurdle in the
optimum outcome of children from low/middle income countries with malignancies.
Tracking of patients who abandon therapy is being recongized as a useful
interventional tool. We herein describe our experience with post-abandonment tracking
and its effect on the outcome of children who abandoned ALL therapy.
Design/Methods: All ALL patients managed at author’s institution from 2007-2013 who
abandoned therapy were tracked telephonically. Postal communication was used
whenever telephone communication failed. The contacted families were called weekly
till they returned for treatment or until the child died. During the contact,
parents/responders were counselled by the social worker/physician regarding the
importance of resuming treatment and urged to return immediately.
Results: 77 of 418 patients abandoned therapy. Telephonic calls were made to 60 of
these families, of which 29 could be contacted (give median/mean and range of no of
telephone calls).Of those who could not be contacted, 15 telephone-numbers were
invalid, calls to 10 went unattended, and 6 were told to be wrong numbers. Letters were
sent to48 families, only 10 of which evoked responses.In total 39/77 (50.6%) families
could be contacted. Upon contact, 20 patients were reported to have expired and 19
patients were told to be well. Only 8 of these 19 patients returned on repeated
counselling and assurance of all possible support (after an average of 6 calls made to
each family), 4 with relapse. Recurrent abandonment was seen in 3 patients who
returned (1 of them died of relapse, 2 still on treatment).
Conclusion: Tracking patients post-abandonment was unsuccessful in more than half of
the patients. Outcome of abandonment remained grim despite our efforts, as
post-abandonment counselling failed to ensure compliance in majority of the contacted
families. Future efforts will need to be focussed on preemptive strategies.
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MEDICAL AND PSYCHOSOCIAL CORRELATES OF INSOMNIA IN
PEDIATRIC BRAIN TUMOR SURVIVORS
E. Zhou1, P. Manley2, K. Marcus3, C. Recklitis1
1Dana-Farber Cancer Institute, Perini Family Survivor’s Center, Boston, USA;
2Dana-Farber Cancer Institute, Pediatric Neuro-Oncology, Boston, USA; 3Dana-Farber
Cancer Institute, Radiation Oncology, Boston, USA
Background/Objectives: Improving survival rates for children diagnosed with brain
tumors have resulted in a growing population at risk for medical and psychosocial late
effects of treatment. In particular, children treated for a brain tumor commonly report
suffering from insomnia. There has been limited literature examining insomnia within
the pediatric brain tumor survivor population. We used a clinically significant indicator
of insomnia (sleep efficiency) to evaluate insomnia rates, medical and psychosocial
correlates, and medical documentation of sleep-related issues during survivorship visits.
Design/Methods: 98 adult survivors of pediatric brain tumors provided self-report data
about sleep, psychological distress, and health-related quality of life. Medical records
were reviewed for all participants to examine treatment-related information (surgery,
chemotherapy, CNS-directed radiation therapy), and for documentation of
sleep-related issues if the participant completed study measures on the same day as a
survivorship medical visit.
Results: 26% of the sample reported clinically significant insomnia. Insomnia status was
associated with a migraine headache history, but not with any other medical or
psychosocial outcomes. Approximately 1 in 3 medical providers did not document a
discussion about sleep during the survivorship visit.
Conclusion: A sizeable minority of survivors of pediatric brain tumors experience
insomnia. With the exception of migraine headaches, there were limited medical or
psychosocial risk factors identified. Thus, medical providers must use the survivorship
visit as an opportunity to conduct a thorough evaluation of sleep-related issues for this
at risk population, and to provide appropriate intervention or referrals.
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REPRODUCTIVE STRATEGIES IN FAMILIES WITH CHILDHOOD CANCER
SURVIVORS
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1D.Rogachev Federal Research Centre of Pediatric Hematology-Oncology and
Immunology, Rehabilitation, Moscow, Russia; 2M. Lomonosov Moscow State University,
Sociology of Family and Demography-Sociology Department, Moscow, Russia
Background/Objectives: The objective is to study reproductive strategies of families with
children-cancer survivors and various social, medical and psychological factors
contributing to changes in reproductive behavior and family planning.
Design/Methods: Data from the families were collected in 2009-2013 through interviews
and questionnaires of 1085 mothers from 78 regions of the Russian Federation;
mothers aged 25–49 (average 36.6), with a cancer child aged 5–17, in remission from
1–12 years (average 4.2). The results were compared with the data of the Russian state
statistics agency’s demographic research of the same period (1118 female respondents
of the same age range) – comparable with the population.
Results: The study revealed the gap between our and control group according to the
number of children - born, desired and expected. The number of children born per
woman increased in our group versus control group: 1 child - 39.7% vs 58.3%; 2 –
48.7% vs 27.8%; 3 – 9.6% vs 3.8%; 4 and more – 2.1% vs 0.7% respectively. The main
demographic indices - reproductive attitudes in our group were significantly higher
versus control group: average desired number of children – 2.59 vs 2.28; average
expected – 2.05 vs 1.72 respectively. This has been linked to changing social and family
values in our group. The study proved the higher level of family values in the system of
value orientations in our group versus control group. Oncological diseases in children
and long-term treatment made considerable impact on family relations: 25.3% -
improved; 10.7% - deteriorated; 9% - divorced; 55% - not changed. This data inversely
correlated with the level of education of respondents (Р<0.05) and with nosology of
cancer - family relations worse in children with solid tumors versus hemoblastoses
(Р<0.05).
Conclusion: Childhood cancer can change the meanings and life priorities towards
pro-family orientation. The families need psychological, social and medical support.
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INTENSIVE TREATMENT OF HIGH-RISK MEDULLOBLASTOMA (HR-MB):
HOW TO LEARN FROM TOXICITIES IN A EUROPEAN SETTING OF
RADIOTHERAPISTS AND PHYSICISTS OF THE SIOP BRAIN TUMOR
WORKING GROUP
L. Gandola1, G. Horan2, S. Meroni3, J. Giralt4, H. Mayles5, A. Baker6, N. Thorp7,
S. Bailey8, B. Pizer9, M. Ramos4, L. Padovani10, C. Malet11, F. Doz12, G.O. Janssens13,
M. Kusters14, F. Oldenburger15, R.D. Kortmann16, S. Rutkowski17, M. Massimino18,
T. Giandini3, E. Pignoli3
1Fondazione IRCCS Istituto Nazionale dei Tumori, Diagnostic Imaging and Radiation
Oncology, Milano, Italy; 2Addenbrookes Hospital, Radiation Oncology, Cambridge,
United Kingdom; 3Fondazione IRCCS Istituto Nazionale dei Tumori, Diagnostic
Imaging and Radiation Oncology-Medical Physics, Milano, Italy; 4Hospital Universitari
Valld’Hebron, Radiation Oncology, Barcelona, Spain; 5Clatterbridge Cancer Centre,
Physics Department, Bebington, United Kingdom; 6Clatterbridge Cancer Centre,
Radiation Oncology, Bebington, United Kingdom; 7Clatterbridge Cancer Centre,
Radiation Oncology, Wirral, United Kingdom; 8Sir James Spence Institute of Child
Health Royal Victoria Infirmary Queen, Pediatric Neuro-Oncology, Newcastle upon
Tyne, United Kingdom; 9Alder Hey Children’s Hospital, Pediatric Oncology, Liverpool,
United Kingdom; 10Timone Hospital Center, Radiation Oncology, Marseille, France;
11Léon Bérard Cancer Center, University of Lyon, Lyon, France; 12CLCC Institut Curie,
Pediatric Oncology, Paris, France; 13University Medical Centre Utrecht & Princess
Maxima Center for Pediatric Oncology, Radiation Oncology, Utrecht, Netherlands;
14Radboud University Medical Centre, Radiation Oncology, Nijmegen, Netherlands;
15Academic Medical Center, Radiation Oncology, Amsterdam, Netherlands; 16University
of Leipzig, Radiation Oncology, Leipzig, Germany; 17University Medical Center
Hamburg-Eppendorf, Pediatric Hematology and Oncology, Hamburg, Germany;
18Fondazione IRCCS Istituto Nazionale dei Tumori, Pediatric Oncology, Milano, Italy
Background/Objectives: Survival of HR-MB has historically been poor despite full-dose
CSI and chemotherapy. In 2009, very promising 5-year results were published in JCO
concerning an intensive regimen including post-operative sequential high-dose
chemotherapy, hyperfractionated-accelerated radiotherapy (HART), 39 Gy CSI plus 60
Gy posterior fossa boost, and two cycles of high-dose tiothepa in case of non-CR
before HART. Since then, several Centers in Europe adopted the regimen, not as a GCP
protocol, and the HART approach became the backbone to develop a new SIOP study.
In 2014, “unexpected” neurotoxicities were reported in different European countries: to
address these issues, a meeting was held in Milan in November 2014 during which
Radiation Oncologists and Physicists from most European countries collegially
reviewed the treatment plans of children showing neurotoxicity after intensive
treatment for HR-MB to highlight any possible correlation with radiotherapy
technique and dosimetry.
Design/Methods: From 2009, about 240 HR-MBL children were treated according to
an HART approach and 27 showed grade 3-4 neurotoxicity as follow: 18 global
neuro-functional impairments, 4 myelitis, 5 brainstem/cerebellum radionecrosis.
Clinical charts and seventeen treatment plans of children with neurotoxicity were
reviewed and discussed in Milan.
Results: Global neurotoxicity occurred in children younger than 10 receiving high-dose
thiothepa after HART but no correlation with radiotherapy technique and dosimetry
was established. Myelitis was associated with inclusion of upper cervical spine in
posterior fossa boost volumes, while brainstem/cerebellum radionecrosis occurred after
delivery of an additional 9 Gy boost to posterior fossa residuum not contemplated in
the original HART approach.
Conclusion: Global neurotoxicity should be evaluated as a benefit/risk issue in the
context of a high risk disease. The joint international discussion and face to face
confrontation of radiotherapists and physicists allowed to highlight important clinical
and radiotherapy-linked risk factors that will be valuable in developing a new SIOP
protocol for HR-MBL and high-standard radiotherapy guidelines.
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LATE TOXICITIES IN CHILDRENWITH NASOPHARYNGEAL CARCINOMA
(NPC) TREATEDWITH INTENSITY MODULATED RADIOTHERAPY (IMRT):
DOSE VOLUME RELATIONSHIPS
S. Laskar1, A. Bindal1, N. Khanna1, T. Vora2, G. Chinnaswami2, S. Kembhavi3,
M. Ramadwar4, S. Qureshi5, S. Chaudhari6, M. Muckaden7, P. Kurkure2
1Tata Memorial Hospital, Radiation Oncology, Mumbai, India; 2Tata Memorial
Hospital, Pediatric Oncology, Mumbai, India; 3Tata Memorial Hospital, Radiodiagnosis,
Mumbai, India; 4Tata Memorial Hospital, Pathology, Mumbai, India; 5Tata Memorial
Hospital, Surgical Oncology, Mumbai, India; 6Tata Memorial Hospital, Medical Physics,
Mumbai, India; 7Tata Memorial Hospital, Palliatve Care, Mumbai, India
Background/Objectives: Evaluation of late toxicities and their correlation with dose
volume relationships in children with NPC treated with IMRT.
Design/Methods: Seventy three children [median age 14 years] treated with IMRT and
Cisplatin based chemotherapy from Jan 2004 to Dec 2013 were analysed. Response
assessment PETCT was done at 3 months post treatment. Follow up evaluation was
done 3 monthly for 2 years and 6 monthly thereafter. Pure tone audiogram and thyroid
function tests was done at 3 months, 1 year and thereafter as indicated. Ototoxicity was
graded using the SIOP Scale 2012.
Results: At a median follow up of 26.7 months [4-136 months], the overall survival (OS)
and disease free survival (DFS) were 89% and 70% respectively. Serial audiometric
evaluations revealed Gr II ototoxicity in 63%. ROC analysis showed an increased risk
of SNHL with cochlea receiving Dmean  46Gy [p=0.035] or total Cisplatin dose
>400 mg [p=0.041]. An improvement in SNHL by at least 2 grades was observed after
2 years. Mandibular remodelling was also significantly affected. A measurable decrease
in bigonial and bicondylar width was observed along with absolute halting of
mandibular body growth. Significant correlation was found with age at time of
radiotherapy [Spearmann’s correlation ρ-0.469, p= 0.014], maximum mandibular dose
[ρ-0.500, p= 0.008], and V25 [ρ-0.419, p=0.03]. The reduction being greatest in
pubertal age group, Dmax > 72Gy, and V25 > 53cc. Subclinical hypothyroidism was
seen in 73% after a minimum of 12 months post IMRT. Baseline thyroid gland volume
was a significant predictor of hypothyroidism. Children with thyroid dose <30Gy to
<2cc volume had a significantly lesser risk of developing hypothyroidism [p= 0.046].
Conclusion: Late radiation toxicities like SNHL, mandibular hypoplasia and
hypothyroidism following IMRT for childhood NPC demonstrates a significant dose
volume relationship. Appropriate dose constraints should be considered during IMRT
planning.
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QUALITY OF LIFE IN TODDLERS TREATEDWITH PENCIL BEAM
SCANNING PROTON THERAPY FOR PEDIATRIC TUMOURS
G. Calaminus1, B. Timmermann2, K. Baust1, C. Teske3, R. Schneider4, U. Kliebsch5,
D. Weber6
1University Childrens Hospital Münster, Department of Pediatric Hematology and
Oncology, Münster, Germany; 2Universitätsklinikum Essen, Westdeutsches
Protonenzentrum, Essen, Germany; 3Univeristy Childrens Hospital Münster, Department
of Pediatric Hematology and Oncology, Münster, Germany; 4Paul Scherrer Institute,
Department of Proton Therapy, Villingen, Switzerland; 5Paul Scherrer Institute,
Department of Proton Beam Therapy, Villingen, Switzerland; 6Paul Scherrer Institute,
Department of Proton Beam Therapy, Villingen, Switzerland
Background/Objectives: Assessment of Quality of Life (QoL) in standard therapies for
childhood cancer has become an integral part in many studies. Little is known about
QoL in patients treated with proton beam therapy (PT).
Design/Methods: PATIENTS ANDMETHODS: Longitudinal and cross-sectional
QoL data (proxy-assessment) including a baseline-assessment before PT were provided
for childhood patients treated at the Paul-Scherrer-Institute (Villingen/CH) during the
years 2005-2014. Data of a homogenous sub-sample (n =49) defined by age group and
proxy-assessed by the PedsQL (patients aged 2-4) were compared to an age-adapted
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reference sample. This represent 71% of all patients treated with PT during this
time-period in the according age range.
Results:When compared to the norm (n=256), toddlers with cancer (n=49) had a
significant decrease of QoL in all domains except in Emotions before the initiation of
PT. During PT, the overall QoL (total mean scores, 26.5 vs. 27.9; p>0.1) did notably
increase for these patients. A trend toward statistical significance was observed with
decreasing QoL in the Social domain (total mean scores, 84.8 vs. 78.8; p=0.06). One
year after PT, a significant increase of the overall QoL was observed (total mean scores,
73.6 vs. 76.6; p=0.05), especially so in the Emotional domain (total mean scores, 67.9
vs. 74.8; p=0.02).
Conclusion: Although QoL of toddlers with cancer is significantly decreased when
compared to normative data, PT has no impact on the QoL of these very young
patients. One year after therapy, QoL increased significantly in all domains.
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SCOLIOSIS IN CHILDREN RECEIVING CRANIOSPINAL IRRADIATION FOR
MEDULLOBLASTOMA
A. Paulino1, H. Suzawa2, Z. Dreyer2, R. Bryant2, M.F. Okcu2, M. Chintagumpala2
1MD Anderson Cancer Center, Radiation Oncology, Houston, USA; 2Texas Children’s
Hospital, Pediatric Hematology/Oncology, Houston, USA
Background/Objectives: Scoliosis is a recognized complication in children receiving
radiotherapy to the hemiabdomen. Care is taken by radiation oncologists to ensure
delivery of homogeneous radiation to the width of the vertebra to minimize this
complication. In craniospinal irradiation (CSI), the entire width of the vertebra is
usually given a homogenous dose. We examined the incidence of scoliosis in our
long-term survivors with medulloblastoma.
Design/Methods: Since 1996, 37 children have survived at least 5 years after photon
radiotherapy for medulloblastoma at one institution. Twenty-two children had routine
spinal X-rays to detect scoliosis and the subject of this report. Seventeen were male, and
twelve were  5 years of age at CSI. All of them were treated using a 3-dimensional
photon technique to the craniospinal axis (18 to 39.6 Gy) followed by an IMRT boost
to the posterior fossa and/or tumor bed. Patients also received chemotherapy according
one of 3 multiinstitutional protocols.
Results: Scoliosis was seen in 15 patients (40.5% of all patients followed for at least 5
years and 68.2% of patients who had routine spine X-rays). Median time to scoliosis
was 108 months after CSI (range, 42 to 128 months). Scoliosis was not associated with
gender, age at time of CSI, CSI dose, length of follow-up or presence of hemiparesis.
Degree of scoliosis was < 10 degrees in 5, 10-19 in 7 and  20 in 3 patients. Scoliosis
involved the thoracolumbar region in 8, thoracic spine only in 3, thoracolumbosacral
region in 3 and cervicothoracolumbar region in 1. None of the patients had surgical
intervention for the scoliosis.
Conclusion: Scoliosis is an under-reported complication of CSI and was found in more
than two-thirds of children treated for medulloblastoma. Despite its high frequency,
most are minimal and do not require intervention; however, longer follow-up is needed
regarding the significance of this finding.
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PROGRESSIVE TECHNIQUES TO EFFECTIVELY PREPARE CHILDREN FOR
RADIOTHERAPY: A SUPPORTIVE FRAMEWORK COMBINING
INFORMATIVE FILMSWITH AMINIATUREWORKINGMODEL LINAC
R. Alexander1, L.K. Walter1
1University College Hospital- London, Paediatric Radiotherapy, London, United Kingdom
Background/Objectives: The aim of this project is to provide a comprehensive
preparation framework that incorporates patient involvement and peer support with
the practical facility of a working miniature model LINAC (Linear Accelerator) for
therapeutic play. By increasing understanding and familiarity of radiotherapy and its
planning procedures prior to commencement of treatment, anxiety levels are lowered,
and the need for general anaesthetics may be decreased. Demystifying the process of
radiotherapy also increases compliance, which can result in reduced time spent in the
treatment room.
Design/Methods: Over an 18 month period 17 children and adolescents, aged 3-16 years,
were filmed and interviewed throughout their radiotherapy procedures. These films
have been organised into four stages; introduction to radiotherapy, immobilisation, CT
planning, and treatment. Downloaded onto the IPad, the films can be taken to the
patient at the bedside, into a clinic consultation, to another hospital or on a home visit.
The child and family view each step of the radiotherapy process via the preparation
film, and can then practice and familiarise themselves with their individual treatment
plan on the miniature machine, which has been commissioned within our department.
Results: Feedback from questionnaires for the adolescent film were overwhelmingly
positive, with 100% of patients and parents reporting an increase in their understanding
of the radiotherapy process. Results are currently being obtained for the paediatric
version using age-appropriate questionnaires for children and their parents/carers. The
opportunity to view children of similar ages going through the same procedures allows
for peer learning and support, while the practical play activities on the miniature
LINAC help to normalise the experience.
Conclusion: The supportive framework ensures that all paediatric patients coming for
radiotherapy have equal access to tools and equipment that can appropriately and
effectively prepare each individual child for their treatment, regardless of language and
cultural differences.
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PROTON BEAM THERAPY IN CHILDHOOD - INITIAL RESULTS FROM THE
WEST GERMAN PROTON THERAPY CENTER ESSEN (WPE)
A.L. Steffen1, S. Frisch1, M. Christiaens2, C. Hüer2, G. Fleischhack3, R. Dankwart2,
D. Geismar1, B. Timmermann2
1West German Proton Therapy Center Essen, University Hospital Essen, Essen,
Germany; 2Clinic for Particle Therapy-West German Proton Therapy Center, University
Hospital Essen, Essen, Germany; 3Paediatric Haematology/Oncology-Paediatrics III,
University Hospital Essen, Essen, Germany
Background/Objectives: Proton beam therapy (PT) has experienced increasing interest
over time especially in pediatric malignancies as PT may be able to reduce
post-treatment late effects. The West German Proton Therapy Center Essen (WPE)
started treatments for pediatric tumors in June 2013. Initial findings are presented.
Design/Methods: Between September 2013 and March 2015, 82 children (40 males, 42
females, aged 1.3-16.8 years (median 5.4 years)) were enrolled into the prospective
registry study for children (KiProReg) at WPE. Diagnoses were CNS (n=44),
sarcomatous (n=37) and nasopharyngeal tumors (n=1), respectively. Treatment sites
were head or neck (n=64), spine (n=9), or pelvis (n=9). In 75.6% of the patients,
macroscopic residual disease was present before PT. The median total dose of PT was
54 Gy (range 30.6-74.0 Gy). Only one patient had a mixed beam technique. In 56.1% of
the children, concurrent chemotherapy was applied. Side-effects were classified
according to Common Terminology Criteria for Adverse Events (CTCAE) V4.0
grading system.
Results:Median follow-up (FU) was 7.0 months (range 0.4-16.0 months). In 76
children (92.7%), no or only mild to moderate acute side-effects (grade 1 or 2) were
documented (skin disorders, mucositis). Only 6 children presented with grade 3
treatment-related toxicities (mucositis, fatigue, anorexia); five of them receiving
chemotherapy simultaneously. No grade 4 or 5 side-effect was observed. In 50 patients,
information on early late effects after at least 3 months (range 3.0-13.5 months) is
available. In this group, no toxicities grade 3 or higher were revealed. So far, 12 children
failed due to tumor recurrence or progression (local n=7; systemic n=5). Five of them
died of disease.
Conclusion: Prospective data from WPE registry suggest good feasibility with only mild
or moderate side-effects in the majority of children even when administering high doses
at critical sites. Longer FU time is needed to assess late effects and long-term outcomes.
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USE OF HYPNOSIS IN RADIOTHERAPY AS AN ALTERNATIVE TO
GENERAL ANESTHESIA IN PEDIATRIC RADIATION ONCOLOGY
A. Duncan1, S. Mancini2, P. Marec-Bérard1, S. Roche2, M. Morelle3,4, C. Carrie2,
L. Claude2
1Institut d’Hémato-Oncologie Pédiatrique-IHOP, Lyon, France, Département
d’Oncologie-Pédiatrique, Lyon, France; 2Centre Léon Bérard, Départment de
Radiothérapie, Lyon, France; 3Cancer Centre Léon Bérard, Lyon, France, Clinical
Research and Innovation Direction DRCI, Lyon, France; 4GATE Lyon-St Etienne- UMR
n°5824-69130, Ecully, France, University of Lyon, Lyon-CNRS, Lyon, France
Background/Objectives: Even though general anesthesia (GA) is effective and has proof
of safety for the necessary immobilization of patients during radiotherapy (RT)
sessions, it stays a timely and costly method on which we know little about the
consequences on the long run of repeated use in childhood. The use of rituals and/or
hypnosis has been encouraged in multiple fields of medicine, enabling distraction for
uncomfortable moments of treatment and it seems children have a natural propensity
for it. This observational study which took place in the RT children cancer department
(Leon Berard regional center, Lyon, France) aimed to evaluate the place of the
alternative of rituals and/or hypnosis in RT.
Design/Methods: Two time periods, before and after 2008 (2003 – 2013) have been
compared, the second one introducing accompaniment methods such as hypnosis
systematically. 137 children < 5 years benefited from RT in that period and were
included (70 pts before 2008, 64 after 2008).
Results: There was no significant difference between the two populations for age, sex
and localization of the RT. There was significantly more high-technicity RT in the
second period (17% vs 44% p<0.001). There was no significant reduction in the use of
GA (57% vs 53%, p = 0.235) globally but the techniques used on the second period
were more sophisticated (longer sessions, optimal asset, limited margins…) and GA
should have been more frequent. The pts more likely to undergo RT without GA were
the oldest and the patients treated for abdominal lesions.
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Conclusion: Also globally this study did not find a significant reduction in the use of
GA after introduction of extra accompaniment and hypnosis in young children
receiving RT, this drug – free technique could limit its logical increasing use in a world
where in parallel RT techniques have greatly evolved in precision.
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PROTONTHERAPY IN CHILDRENWITH LOCALIZED INTRACRANIAL
GERMINOMA: DOSIMETRIC ADVANTAGEWITH USE OF NEW PENCIL
BEAM SCANNING (PBS) IN COMPARISON TO DOUBLE-SCATTERING (DS)
S. Vennarini1, M. Kirk2, Z. Huifang2, D. Ravanelli3, R.A. Lustig2, Z. Tochner2
1APSS-Trento Italy, Proton Therapy Center, Trento, Italy; 2The Perelman Center for
Advanced Medicine, Department of Radiation Oncology, Philadelphia, USA;
3APSS-Trento Italy, Health Physics, Trento, Italy
Background/Objectives: In children with a localized intracranial germinoma, due to the
complex clinical target volume, defined as whole ventricle system (WV) and tumor bed,
and the excellent long-term survival after induction chemotherapy and radiotherapy,
there is a need for the investigation of the dosimetric advantage of new delivery
technology such as with pencil-beam scanning (PBS) proton therapy compared with the
more common double-scattering (DS) technique.
Design/Methods: Five children with localized intracranial germinoma treated with
protons at Hospital of the University of Pennsylvania were retrospectively studied. PBS
and DS proton plans were generated for each patient prescribing dose of 23.40Gy to
WV, with 21.60Gy boost at primary site (protocol COG ACNS 0232). Dose-volume
histogram parameters of clinical organs at risk were compared with Wilcoxon
matched-pair signed-rank test. For target coverage assessment, the conformity index
and homogeneity coefficient were evaluated.
Results: The V10Gy, V20Gy, V30Gy and integral dose to normal brain tissue of PBS
plans showed a significant dose reduction of 22%, 35%, 41% and 4% compared to DS
plans (P<0.05). There was also a reduction by 14% for the V20Gy and by 8% for mean
doses to the temporal lobes (P<0.05). No significant differences were found for the
mean dose of the hypothalamus and pineal gland (P>0.05). For PBS plans the mean
doses to the hippocampi and cochlea were also significantly reduced by 6% and 16%
(P<0.05). The average conformity index was 0.69 for PBS plans, while was 0.62 for DS
plans, showing a significant better conformity (P<0.05). There was no significant
difference in target coverage homogeneity between the two plans (P>0.05).
Conclusion: As compared to DS proton therapy for pediatric localized intracranial
germinoma, PBS proton delivery technique achieved significantly better target
conformity, allowing more dose sparing to normal brain tissue, temporal lobes,
hippocampi and cochlea.
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PRINCIPLES AND ADVANCES OF 223-RADIUM AND PROTON PARTICLE
THERAPY IN BONE-FORMING TUMORS INCLUDING OSTEOSARCOMA
P. Anderson1, M. Ladra2, V. Subbiah3, E. Murphy4, M.F. McAleer5, E. Rohren6
1Cleveland Clinic, Pediatric Hematology/Oncology and Pediatrics Institute, Cleveland,
USA; 2Provision Center For Proton Therapy, Pediatric Program, Knoxville, USA;
3University of Texas MD Anderson Cancer Center, Investigational Cancer Therapeutics,
Houston, USA; 4Cleveland Clinic, Radiatoin Oncology, Cleveland, USA; 5University of
Texas MD Anderson Cancer Center, Radiation Oncology, Houston, USA; 6University of
Texas MD Anderson Cancer Center, Nuclear Medicine, Houston, USA
Background/Objectives: It is estimated that >2/3 of cancers arise from accumulation of
mutations in tissue stem cells. More effective elimination of cancer stem cells can be
accomplished using varieties of particle radiation that have high Linear Energy
Transfer (LET) values, causing >100x more double-strand DNA breaks which are hard
to repair than lower LET radiation (photons or electrons including beta-emitting
pharmaceuticals). Radium-223, an alpha particle emitter, is now US FDA and EMA
approved for prostate cancer, and improves both pain from bone metastases and
prolongs survival.
Design/Methods:We have now successfully reached the dose expansion cohort using
Radium-223 for osteosarcoma: 100 kBq/kg monthly x6.
Results: At 2x the standard dose used for prostate cancer, hematologic toxicity has been
minor; no significant (grade 2) toxicities were seen. Preliminary imaging data of
osteoblastic tumors has shown fluoride-PET/CT to be better than FDG-PET/CT or
Tc-99m MDP bone scans in evaluating response. One patient with brain metastases
showed Radium-223 can traverse the blood brain barrier. New technology can provide
image guided proton beam therapy, with techniques rapidly improving. Also, the cost
of building a new proton center with enhanced precision and capabilities is estimated to
be a tenth of the cost a decade ago. With improved immobilization and
image–guidance, proton therapy is evolving to allow delivery of precision particle
therapy with larger fractions. Hypo-fractionated proton plans are currently in
development; examples will be shown.
Conclusion: Since relapse at sites of non-osteoblastic metastases continue to be a
problem, other means to more specifically target Radium-223 and protons to tumor
stem cells is needed. Because of less toxicity, decreased cost, and potential increased
efficacy, particle therapy with alpha particles and/or protons will become more widely
used in children, adolescents, and adults with malignancies that rely on radiation for
durable local control (e.g. axial osteosarcoma, Ewing sarcoma, bone and brain
metastases).
Poster Discussion: Acute Lymphoblastic Leukaemia
PD-001
THE NEDD8 ACTIVATING ENZYME INHIBITOR PEVONEDISTAT (MLN4924)
INDUCES ER STRESS/UPR-MEDIATED CELL DEATH AND ALTERS THE
APOPTOTIC THRESHOLD FAVORING CELL DEATH IN ACUTE
LYMPHOBLASTIC LEUKEMIA
J. Barredo1, G. Leclerc2, S. Zheng2, J. DeSalvo2, G. Leclerc2, R. Swords3
1University of Miami Miller School of Medicine, Pediatrics and Biochemistry and
Moleuclar Biology, Miami, USA; 2Univeristy of Miami Miller School of Medicine,
Pediatrics, Miami, USA; 3University of Miami Miller School of Medicine, Medicine,
Miami, USA
Background/Objectives: Acute lymphoblastic leukemia (ALL) is the main cause of
cancer-related death in children and adolescents, and effective treatment strategies for
relapsed/refractory ALL remain elusive. In search for novel strategies, we investigated
the anti-leukemic activity of the NEDD8-activating enzyme (NAE) inhibitor
pevonedistat, an investigational agent that interferes with cullin-RING E3
ligase-(CRL)-dependent protein degradation by preventing CRL neddylation.
Design/Methods:We used pharmacological, molecular, and genetic approaches
targeting the NEDD8, UPR, and mTOR pathways in ALL cell lines and primary cells.
Results: Our data showed that pevonedistat induced dose-dependent ER
stress/UPR-mediated cell death in ALL cell lines and primary cells, as evidenced by
increased expression of UPR markers (GRP78, ATF4, CHOP) and cleaved-PARP.
Mechanistically, pevonedistat led to p-eIF2a de-phosphorylation via up-regulation of
the PERK inhibitor p58IPK, causing proteotoxic/ER stress from failure to halt protein
translation. Pevonedistat also led to up-regulation of mTOR/p70S6K, further
increasing protein synthesis and augmenting proteotoxic/ER stress. Additional studies
into the mechanism of pevonedistat-induced apoptosis revealed that homeostasis of
pro- and anti-apoptotic proteins was rebalanced in favor of cell death through
decreased Mcl-1 pro-survival activity, via sequestration by NOXA and BIM. Activation
of the MEK/ERK/Mcl-1 pathway following pevonedistat-induced cell death was also
noted, possibly as a compensatory mechanism. Further, we demonstrated in vitro
synergy between pevonedistat and effective anti-leukemic drugs and showed that NSG
mice harboring human ALL cells treated with pevonedistat plus dexamethasone had
statistically significant increased survival when compared to single agent therapy,
lending support for the clinical investigation of pevonedistat as part of a multi-agent
approach.
Conclusion: Our data demonstrate that the NAE inhibitor pevonedistat alters the cells’
translational machinery, leading to in vitro and in vivo ER stress/UPR-mediated cell
death, and suggest pevonedistat may have a “priming” effect on ALL cells by affecting
the apoptotic threshold through modulation of Mcl-1’s pro-survival activity.
PD-002
TREATMENT COST FOR CHILDRENWITH ACUTE LYMPHOBLASTIC
LEUKAEMIA IN BANGLADESH
T. Eden1, A. Akhter2, A. Islam3
1University of Manchester, Academic Unit of Paediatric and Adolescent Oncology,
Manchester, United Kingdom; 2Combined Military Hospital, Paediatrics, Dhaka,
Bangladesh; 3Banglabandhu Sheik Mujib Medical University, Paediatric Haematology
and Oncology, Dhaka, Bangladesh
Background/Objectives: Acute Lymphoblastic Leukaemia(ALL), the most common
childhood malignancy in Bangladesh, is potentially curable but high rates of treatment
refusal and abandonment are seen. The principal reason is the cost burden on families
who pay for all drugs. This is the first study performed in Bangladesh to assess the cost
of having a child with ALL.
Design/Methods: A cross-sectional study of costs incurred by 50 families of a child with
ALL at the BSMMU hospital was conducted over a six month period. 10 parents were
requested to keep and submit receipts for all costs of drugs, transport, food and
accommodation at each of five treatment phases: initial investigation, remission
induction, intensification, consolidation and maintenance. All the children were treated
on the same modified UKMedical Research Council ALLX1 protocol.
Results: The mean age of the boys was 6yrs and 7.8yrs for girls. The identified mean
basic cost of all therapy was $ 4443(range $3234-$7672).49%of costs were for cytotoxic
drugs,9% for investigations,2.5% for procedures, 0.6% for blood and blood
products,12.9% for general treatment and 26% for other aspects including transport
,food and parental lodging. On average each episode of febrile neutropenia added
$1200 and for this cohort the mean number of episodes was three .With refractory fever
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requiring changes in antibiotics a further $1740 was required. This mean cost in local
currency was BDT 311028(226400-537040 BDT). 33%of Bangladeshi families live
on<5000BDT per month and 51% between 5000 and 20,000 BDT per month.
Conclusion: Although the costs reported are considerably less than in high income
countries they remain prohibitively high for most families in Bangladesh leading to
treatment abandonment in 15-20% of cases. Internal and external philanthropic
subsidies have ameliorated the problem to some extent but long term solutions to the
cost of treatment both in Bangladesh and worldwide are required.
PD-003
IMPACT OF ASPARAGINE-DEPLETION ON TREATMENT OF RELAPSED
CHILDHOOD ALL: RESULTS OF THE ALL-REZ BFM 2002 TRIAL
C. Chen-Santel1, S. Illig1, A. Eggert1, G. Henze1, A. von Stackelberg1, P. Hundsdoerfer1
1Charité University Medicine, Pediatric Oncology, Berlin, Germany
Background/Objectives: About 15-20% of patients with childhood acute lymphoblastic
leukemia (ALL) suffer from relapse after frontline therapy. The significance of
asparaginase treatment during frontline therapy is well known. We here describe the
impact of asparagine depletion (using native E.coli-, PEGylated E.coli, or Erwinia
asparaginase) on outcome of patients with relapsed childhood ALL treated according
the ALL-REZ BFM 2002 trial.
Design/Methods:We retrospectively analysed the outcome of patients who were treated
according to ALL-REZ BFM 2002 trial from January 2002 until December 2014. Only
patients with first relapse were included in the analysis. From a total of 908 patients
registered within the ALL-REZ 2002 trial, sufficient data on type and extend of
treatment with asparaginase were available for 789 patients.
Results: Asparagine depletion at the first induction cycle of relapse treatment was
performed using native E.coli, PEG- and Erwinia asparaginase in 51%, 38%, and 7%
respectively. In 30% of patients type of asparaginase was changed due to allergic
reactions or silent inactivation. Recurrent severe allergic reactions precluded
continuation of asparaginase treatment in 17% of patients. Substitution of native E.coli
by PEG- or Erwinia asparaginase did not result in reduced 5y-EFS (56% ± 3% vs. 55%
± 2%). In contrast, univariate analysis revealed discontinuation of asparaginase
treatment as risk factor for poor outcome (5y-EFS 46% ± 4% vs. 57% ± 2%, p=0.05).
During induction therapy, asparaginase treatment was of particular significance.
Incomplete asparaginase application was associated with poor morphological response
after induction (rate of morphological remission: 34% vs. 65%, p<0.001) as well as
poor outcome (5y-EFS 41% ± 7% vs. 56% ± 2%, p=0.01).
Conclusion: Asparagine depletion is an important component of treatment of relapsed
childhood ALL according to the ALL-REF BFM 2002 trial. The type of asparaginase
used has no impact on outcome, but sustained asparaginase treatment during the
complete relapse therapy is required.
PD-004
A REVIEW OF NEW AGENTS TESTED BY THE PEDIATRIC PRECLINICAL
TESTING PROGRAM AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA
XENOGRAFTS
R. Lock1, P. Houghton2, M. Smith3
1Children’s Cancer Institute, UNSW Australia, Randwick, Australia; 2UT Health
Science Center, Greehey Children’s Cancer Research Institute, San Antonio, USA;
3National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, USA
Background/Objectives:While the overall cure rate for pediatric acute lymphoblastic
leukemia (ALL) is approximately 90%, patients with high-risk subtypes remain
relatively intractable and new treatments are required. The objective of the Pediatric
Preclinical Testing Program (PPTP) is to utilize panels of patient-derived xenografts
(PDXs) to prioritize new agents for clinical evaluation in pediatric malignancies.
Design/Methods: PDXs were established from biopsies of pediatric patients with ALL
by direct transplantation into immune-deficient mice. PDX panels represent the
heterogeneity of pediatric ALL and high-risk subtypes. Drugs are selected based on
demonstrated activity against adult cancers, as well as rationale for efficacy against
pediatric ALL. In vivo testing is conducted in a blinded fashion against panels (n=8) of
PDXs, with responses evaluated by event-free survival (T/C) measurements and
stringent objective response criteria modeled after the clinical setting.
Results: Over 70 new agents/combinations have been evaluated, including small
molecules, antibodies, and antibody-drug conjugates. Less than 25% of the new agents
tested elicited objective responses in  50% of PDXs, despite several drug classes being
represented by multiple agents. For example, 6 agents representing the
PI3K/AKT/mTOR pathway were completely ineffective. The antimitotic agent eribulin,
the kinesin spindle protein inhibitor ispinesib, and the Aurora Kinase A inhibitor
alisertib (MLN8237) were highly effective. The most consistently active drug class was
MDM2 inhibitors, with MK-8242 and RG7112 inducing objective responses in 6/7 and
7/8 ALL PDXs, respectively.
Conclusion: In vivo efficacy testing of novel drugs against panels of pediatric ALL
xenografts has identified several candidates for clinical evaluation. Moreover, reporting
of all PPTP testing results has highlighted numerous drugs that are unlikely to be active
in the clinical setting. The p53/MDM2 axis appears to be of particular interest as a
target for the development of novel treatment strategies in pediatric ALL. Supported by
NCI NO1CM91001 and NO1CM42216.
PD-005
ACUTE LYMPHOBLASTIC LEUKEMIA OF THE CENTRAL NERVOUS
SYSTEM IS MEDIATED BY VASCULAR ENDOTHELIAL GROWTH FACTOR
INDICATING A NOVEL TARGET FOR COMPARTMENT-SPECIFIC THERAPY
V. Muench1, L. Trentin1, J. Herzig1, J.M. Kraus2, H.A. Kestler2,3, G. te Kronnie4,
K.M. Debatin1, L.H. Meyer1
1Ulm University Medical Center, Department of Pediatrics and Adolescent Medicine,
Ulm, Germany; 2Ulm University, Research Group Bioinformatics and Systems Biology,
Ulm, Germany; 3Fritz Lipmann Institute, Leibniz Institute for Age Research, Jena,
Germany; 4University of Padua, Department of Women’s and Children’s
Health-Laboratory of Oncohematology, Padua, Italy
Background/Objectives: Involvement of the central nervous system (CNS) in acute
lymphoblastic leukemia (ALL) is associated with adverse prognosis. CNS directed
therapy is indispensable in all ALL patients, indicating subclinical CNS manifestation
in many patients. Therefore, we aimed to characterize mechanisms mediating CNS
leukemia and to identify targets for directed treatment.
Design/Methods: Primary B-cell precursor ALL cells were xenografted into NOD/SCID
mice. At onset of disease, leukemia cells were isolated from bone marrow (BM) and
CNS and analyzed by transcriptome profiling. ALL cells with VEGF knockdown,
overexpression and in response to VEGF or an antagonizing antibody were further
analyzed.
Results: In a subset of patient-derived xenograft ALL samples we observed leukemia
manifestation in BM, spleen, and peripheral blood along with meningeal infiltration in
contrast to absent CNS manifestation despite high infiltration in BM, spleen, and
blood. In line, meningeal enhancement was detected by magnetic resonance imaging.
Expression profiling comparing CNS to BM-derived ALL cells identified vascular
endothelial growth factor A (VEGF) to be significantly upregulated in CNS-ALL cells.
Interestingly, increased levels of VEGF known to mediate vascular permeability and
trans-endothelial migration have been reported in cerebrospinal fluid of CNS-positive
acute leukemia patients. VEGF overexpression, down-regulation, or exposure of
leukemia cells to VEGF or the anti-VEGF antibody bevacizumab did not affect cellular
proliferation and survival. In brain endothelial cells, VEGF induced signaling activity
mediating endothelial permeability. Interestingly, in a trans-well model of brain
endothelial cells VEGF-dependent trans-endothelial leukemia cell migration was
observed. Moreover, in an in vivo model of CNS-positive ALL anti-VEGF treatment
significantly reduced leukemia load in the CNS but not in other organ compartments.
Conclusion: In summary, we identified VEGF as a mediator of CNS manifestation in
ALL. Importantly, in vivo VEGF inhibition significantly decreased involvement of
CNS ALL indicating a novel therapeutic strategy to control CNS leukemia.
PD-006
RAPID LUNGMRI: PARADIGM SHIFT IN EVALUATION OF FEBRILE
NEUTROPENIA IN CHILDRENWITH LEUKEMIA
K. Sodhi1, N. Khandelwal1, A. Saxena1, D. Bansal2, A. Trehan2
1Post Graduate Institute of Medical Education & Research, Radiodiagnosis, Chandigarh,
India; 2Post Graduate Institute of Medical Education & Research, Pediatrics,
Chandigarh, India
Background/Objectives: Immunocompromised children with hematological
malignancies are at increased risk of developing potentially fatal pulmonary infections.
Early detection and prompt treatment is critical to combat morbidity and mortality in
these children. Computed tomography (CT) scan has inherent radiation risks, which are
more harmful in children. We performed this study to determine the technical
feasibility and sensitivity of a new rapid magnetic resonance imaging (MRI) protocol
compared with high resolution computed tomography for the detection of pulmonary
findings in febrile neutropenic children with leukemia.
Design/Methods: Twenty Six children with leukemia (age range: 5-13 years) presenting
with fever and neutropenia were included in this prospective study, which was approved
by the institutional ethics committee. All patients underwent CT scan and MRI of the
chest on the same day. The findings were recorded as nodules, consolidations and
ground glass opacity areas. The findings of CT scan and MRI were compared, with CT
as the standard of reference.
Results: For the detection of nodules and consolidations, MRI had100% sensitivity,
specificity, PPV and NPV, when compared with CT scan.
For the detection of ground glass opacity, MRI had sensitivity, specificity, PPV and
NPV of 66.67%, 100%, 100% and 90.91% respectively. There was perfect agreement
between MRI and CT examination findings by kappa test (κ=1). No significant
difference was observed between the two modalities by the McNemar test (p >0.05).
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Conclusion: Rapid lung MRI is technically feasible; has a high correlation, sensitivity
and specificity to CT scan; and can emerge as the first line modality for the detection of
pulmonary nodules in children with leukemia and persistent febrile neutropenia.These
children shall be thus saved from unnecessary radiation involved with CT scans.
PD-007
GENOMIC DNA BREAKPOINTS INMLL GENE AND TREATMENT
OUTCOME IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
ENROLLED INTOMLL-BABY TRIAL
G. Tsaur1, C. Meyer2, A. Popov1, A. Kustanovich3, T. Riger1, Y. Olshanskaya4,
E. Matveeva4, E. Fleischman5, O. Sokova5, O. Streneva1, L. Saveliev6, R. Marschalek2,
A. Solodovnikov1, E. Shorikov1, L. Fechina1
1Regional Children’s Hospital/Research Institute of Medical Cell Technologies, Pediatric
Oncology and Hematology, Yekaterinburg, Russia; 2Institute of Pharmaceutical Biology
ZAFES Goethe-University of Frankfurt, Diagnostic Center of Acute Leukemia,
Frankfurt am Main, Germany; 3Belarusian Research Center for Pediatric Oncology
Hematology and Immunology, Molecular Biotechnology Laboratory, Minsk, Belarus;
4Federal Research Institute of Pediatric Hematology Oncology and Immunology,
Cytogenetics and Molecular Genetics laboratory, Moscow, Russia; 5N.N. Blokhin Russian
Cancer Research Center Russian Academy of Medical Science, Cytogenetics Laboratory,
Moscow, Russia; 6Ural State Medical University, Chair of Laboratory Medicine,
Yekaterinburg, Russia
Background/Objectives: Acute lymphoblastic leukemia (ALL) in infants is characterized
by high incidence of MLL gene rearrangements. The purpose of this work was to
evaluate the relation between genomic DNA breakpoints inMLL gene and treatment
outcome in infant ALL treated according to MLL-Baby multicenter trial.
Design/Methods: 62 infants (22 boys and 40 girls with median age of 4.4 mo) with
MLL-rearranged ALL were included in the current study. Genomic DNA breakpoint
detection inMLL gene was performed by long-distance inverse PCR. Exon-intron
numbering of MLL gene was done according to I. Nilson et al, 1996. Among our cohort
there were 35 patients withMLL-AF4 fusion gene (56%), 14 ones withMLL-MLLT1
(23%), 8 withMLL-MLLT3 (13%), 4 withMLL-EPS15 (6%), 1 withMLL-AFF3 (2%).
Results: The most common breakpoint location withinMLL gene was intron 11,
detected in 31 cases (50%), less frequently breakpoints in intron 10 (n=13;21%), intron
9 (n=8;13%) and others (n=10;16%) were found. We estimated prognostic significance
of MLL breakpoint locations in 46 cases homogenously treated by MLL-Baby
protocol. 5-year event-free survival was significantly lower in patients with breakpoints
in intron 11 (n=29) in comparison to patients with breakpoint localized from intron 7
to exon 11 (n=17) (0.16±0.07 vs 0.38±0.14 p=0.035). While cumulative incidence of
relapse was remarkably higher in the first group of patients (0.80±0.33 vs 0.56±0.20
p=0.020). However in Cox regression model including breakpoint location in intron 11
together with age, immunophenotype, initial WBC count, initial CNS involvement, type
of MLL rearrangement, absolute blast number at day 8 of dexamethasone profase,
minimal residual disease (MRD) at time point 4 (TP4) of MLL-Baby protocol, the only
significant covariate associated with unfavorable outcome was the presence of MRD at
TP4 (HR 5.994, 95% CI 2.209-16.263, p<0.001).
Conclusion: Our data provide additional information of molecular genetic features of
MLL-rearranged infant ALL.
PD-008
PREVALENCE OF INVASIVE FUNGAL INFECTIONS (IFI) IN CHILDREN
WITH FEBRILE NEUTROPENIA BETWEEN 1- 12 YEARS TREATED FOR
ACUTE LEUKEMIA- A PROSPECTIVE STUDY
J. Yadav1, A. Singh1, R. Seth1, S.K. Kabra1, I. Xess2, M. Jana3
1ALl India Institute of Medical Sciences, Pediatrics, Delhi, India; 2ALl India Institute of
Medical Sciences, Microbiology, Delhi, India; 3ALl India Institute of Medical Sciences,
Radiology, Delhi, India
Background/Objectives: The objective of our study was to ascertain the prevalence,
determinants, etiological species of invasive fungal infections (IFI) and outcome
(discharge/ death) during febrile neutropenia episodes in children with acute leukemia
between 1-12 years age group during chemotherapy.
Design/Methods: Episodes of febrile neutropenia of duration 96 hrs were enrolled
and investigated for fungal infection. Blood investigations including Galactomannan
antigen, aspergillus serology, Bactac fungal culture and radiological investigations were
done. Serial monitoring of Galactomannan Ag was done to assess treatment response.
Revised definitions of IFI from the European Organization for Research and Treatment
of Cancer (EORTC) were used for analysis.
Results: Total 319 febrile neutropenic episodes were screened and 74 patients fulfilled
the enrollment criteria. Out of 74, seventeen (23%) had IFI. As per EORTC criteria’s
out of seventeen, three (17%) classified as proven, eleven (65%) probable and three
(17%) possible. Seven (9.5 %) patients died during same admission. Commonest fungal
isolate was Aspergillus (79%) followed by Candida. Radiological findings suggestive of
IFI were present in fourteen patients; well circumscribed nodules in lungs were most
consistent finding. On multivariate analysis clinical sinusitis and abnormal chest X -ray
at admission were significant predictors of IFI.
Conclusion: IFI’s are associated with significant morbidity and mortality in leukemia.
We found clinical sinusitis and abnormal chest radiograph as significant predictor of
IFI in leukemia. Aspergillus was most common fungus causing IFI. Galactomannan
Ag was found to be useful in early diagnosis and monitoring of response to antifungals.
Sputum for Aspergillosis, Chest tomograph and Galactomannan antigen test strongly
correlate with each other. EORTC guidelines has limitations; as children with
nasal/Oral swab or urine culture showing fungal growth, Tomograph showing fungal
ball in solid organs( Kidney) with positive Galactomannan Ag test also benefited with
antifungal therapy suggesting likely systemic fungal infection although these were not
included in criteria of IFI.
Poster Discussion: Bone Tumours
PD-009
PREDICTORS OF SURVIVAL IN PEDIATRIC PATIENTS WITHMETASTATIC
OSTEOSARCOMA TO THE LUNGS
R. Antiel1, R. Chaudhry1, C. Moir2, M. Ishitani2, C. Arndt3, A. Zarroug2
1Mayo Clinic, General Surgery, Rochester, USA; 2Mayo Clinic, Pediatric Surgery,
Rochester, USA; 3Mayo Clinic, Pediatric Hematology/Oncology, Rochester, USA
Background/Objectives: Surgical resection of lung metastases is a treatment option for
select pediatric patients with metastatic osteosarcoma. We aim to describe outcomes
following pulmonary metastasectomy in patients with metastatic osteosarcoma and to
determine which factors contribute to improved survival.
Design/Methods: Between 2002 and 2012, 30 patients ( 21 years old) underwent
pulmonary resection for metastatic osteosarcoma at the Mayo Clinic Rochester.
Demographics, survival, metastasis location, primary tumor size, number of nodules,
unilateral versus bilateral disease, and tumor histology were evaluated. Survival was
calculated using Kaplan-Meier estimates, and Cox proportional-hazards regression
analysis was used to compare differences in survival between various groups.
Results: The mean age of our sample was 14 years (60% male). Of these patients, 27
(90%) underwent wedge resections and 3 (10%) underwent lobectomy or
pneumonectomy. There were no deaths from surgery. The median overall survival was
2.2 years. Survival at 1 and 5 years was 68% and 48%, respectively. Patients’ risk of
death was 5.8 times greater if they had central or central and peripheral disease
compared to patients with peripheral disease alone (p=0.01, 95% CI: 1.52-22.5). Tumor
size, number of nodules, unilateral versus bilateral disease, and tumor histology did not
have a significant effect on overall survival. Median recurrence-free survival was 10.3
months. Recurrence of pulmonary metastases at 1 and 5 years was 49% and 77%,
respectively. There was not a significant difference in recurrence-free survival between
patients with central or central and peripheral disease compared to patients with
peripheral disease alone (p=0.48).
Conclusion: Pulmonary metastasectomy in select patients with metastatic osteosarcoma
can be associated with improved survival. The location of lung nodule is significant for
overall survival but not for recurrence-free survival.
PD-010
NON-HIGH-DOSE-METHOTREXATE (HD-MTX) BASED DOSE-DENSE
(DD)CHEMOTHERAPY(CT) IN OSTEOSARCOMA: IS IT EFFECTIVE,
ECONOMIC AND EASY?
J. Bajpai1, A. Chandrasekharan2, N. Pande2, S. Gupta2, T. Vora2, B. Rekhi3, S. Banavali2
1Tata Memorial Hospital, Mumbai, India; 2Tata Memorial Hospital, Medical Oncology,
Mumbai, India; 3Tata Memorial Hospital, Pathology, Mumbai, India
Background/Objectives: There is still no worldwide consensus on a standard
chemotherapy approach in osteosarcoma.Concept of dose-density has proven
effectiveness in breast cancer.Considering, mandatory complex pharmacokinetic
monitoring (labor-intensive & costly) and unpredictable toxicity of HD-MTX,
Non-HDMTX based DD,CT merits exploration.
Design/Methods: This prospective study evaluated OGS-12 regimen comprising DD-CT
with Doxorubicin, Ifosfamide, & Cisplatin. Neoadjuvant-chemotherapy (NACT)
response was evaluated with histological-necrosis (HN) grading; wherein, 90% HN
defined good-responders (GR). Baseline tumor-burden and nutritional parameters were
correlated with outcomes and toxicity. Survival analysis was performed using the
Kaplan–Meier method and compared with Log-rank test.
Results: There were 325 patients enrolled from 2011-2014, of which 26% were
metastatic. At presentation, 74% were malnourished, 38% anemic, and 57% were iron
and vitamin-B12 deficient.Mean lesion size was 11cm, all had high LDH and 37% had
high SAP.Among 239 nonmetastaic patients 190 completed NACT and underwent
surgery at the analysis. 60% were GR. At a mean follow-up of 15(3-38) months, median
disease-free-survival (DFS) and overall-survival (OS) is not reached .Estimated 2-year
DFS is 79 % and OS is 98%. Incidence of grade III/IV chemo-toxicities were
febrile-neutropenia (FN)(30%), thrombocytopenia (18%), GI-toxicity (6%), and
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Cardiac-toxicity (4.7%),however none toxic death occured. In uni-variate analysis, age
(>12yrs), LDH (>500U/L), SAP (>500 U/L), Thrombocytopenia, and cardiotoxicity
were found as poor prognostic variables; however in multivariate analysis only
cardiotoxicity was identified as independent variable for DFS. For OS, LDH and SAP
were found as poor prognostic markers. SAP, LDH and Albumin were found as
predictors for GI toxicity, and SAP alone for thrombocytopenia.
Conclusion: Non-HDMTX based OGS-12 regimen was proven as Effective, Economic
and Easy to manage, even in nutritionally challenged and high tumor- burden
osteosarcomas. LDH, SAP and Albumin are identified as non-conventional potential
prognostic markers for toxicity prediction at baseline, and cardiotoxicty was identified
as novel marker for DFS and merits further exploration.
PD-011
THE CHALLENGE OF GENOMIC CANCER THERAPY: COPINGWITH
TUMOR DIVERSITY AND T CELL PROMISCUITY
S. Burdach1
1Technische Universität München, Department of Pediatrics-Children’s Cancer Research
Center, Munich, Germany
Background/Objectives: High throughput genomics technologies generated great hopes
of targeted therapies (TT). Targeting by tumor specific T cells was particularly
looked-for to overcome resistance and avoid side effects due to its specificity. So far, TT
have widely failed in cancer of childhood. They seem to prime for resistance. T cell
therapy is not specific since one T cell receptor (TCR) has to recognize many peptides.
An exception to the TT prime for resistance rule is targeting oncogene addiction.
However, many addiction targets such as mutated P53 or EWS-FLI1 are not actionable
by drug based TT.
Design/Methods:We have assessed gene ontology (GO) annotated expression as well as
pathway activation by gene set enrichment analysis (GSEA) under selective pressure of
expression based TT yielding resistance. In addition, we assessed specificity and
cytotoxicity of HLA-A2 allorestricted T cells against those oncogene addiction targets,
identified by expression profiling and validated in vivo by knock down in refractory
sarcoma, specifically Ewing sarcoma (ES).
Results: Upon simultaneous targeting of both the EWS/FLI1 dependent catalytic
sunbunit polycomb repressor complex 2 enhancer of zeste homologue 2 (EZH2) and
reactive oxygen species (ROS) independent pathways with Vorinostat, Paclitaxel and
Vincristin, we found a loss of expression of EWS/FLI1 target genes and up regulation
of ROS dependent (i.e. STEAP1) signaling. Moreover, we discovered up regulation of
oncogenic pathways from 10 to 18 pathways. (NomP >0.70 vs. 0.40, FDR q value >0.80
vs. 0.40; both for NES 1.0). Finally, A2 allorestricted T cells against oncogene addiction
targets displayed cytolytic functionality against STEAP1. STEAP1 A2 allorestricted
TCR transgenic T cell clones displayed also significant off-target reactivity.
Conclusion: Intratumoral heterogeneity in pediatric malignancy may require strategies
capable of generating synergy between expression based molecular precision
chemotherapy and T cells restricted to addiction gene products in an parental HLA
diversity context by individualized longitudinal profiling.
PD-012
GENOMICS AND ALLORESTRICTION BASED IMMUNOTHERAPY: COPING
WITH T CELL PROMISCUITY…
S. Burdach1
1Klinikum rechts der Isar, Department of Pediatrics, Munich, Germany
Background/Objectives: EWS/ETS dependent genes (EDG) are not actionable by
targeted drug therapies, but potentially by T cells. Though perceived as specific,
chimeric antigen receptor T cells (CARs) are rather increasing the therapeutic index,
while bypassing evolutionary safety features, restricting recognition of
surface-molecules to immuoglobulins. Accepted CAR expenses are unwanted
activation of innate immunity and agammaglobulinemia.
Design/Methods:We employed allorestricted T-cell receptor (TCR) transgenic T-cells
(ATRs) from donor parents recognizing peptides presented by the non-inherited human
leukocyte antigen (HLA)-disparate haplotype (Vigor of Defense against Non-Self,
Burdach & Kolb 2013). ATRs recognize intracellular targets; their target-pool is
unlimited. T-cell activation and deregulation of innate immunity are low, while
off-targets effects are more frequent. Most important, ATRs target antigens essential
for survival. Regulatory authorities tweak science, requiring specificity of ATRs but not
of CARs: TCR promiscuity is imperative, given that 1011 human TCRs have to
recognize 1020 peptides.
Results: Functionality of ATR targets, identified by genomics, as addiction oncogenes
in Ewing Sarcoma (ES) was verified by RNA interference in vivo, including EDG
EZH2 (Histone methyltransferase) and ChM1 (osteochondrous differentiation
regulator): ChM1 specific ATRs are capable of killing ES in vivo, without target down
modulation in bulky tumors, whereas EZH2 specific ATRs killed in vitro, but not in
vivo. STEAP1 (ROS signaling receptor) specific humanized ATR clones showed
off-target reactivity as assessed by alanine/threonin scan, while killing ES efficaciously
(Schirmer 2015). ADRB2 (adrenergic receptor) specific ATRs committed fratricide
(Kirschner 2015). Last not least, EDG ATRs killed ES irrespective of donor source
(Thiel 2015). Autologous T cells are not inferior to allogeneic in HLA-disparity based
killing, making haplodisparate transplants dispensable.
Conclusion: Taken together, some addiction oncogene peptides are actionable by ATRs,
whereas fratricide may be a cause why others are not. Specificity is not required.
Epitope spreading and evolutionary conserved strength of alloreactivity may help to
overcome resistance.
PD-013
IMPACT OF ZOLEDRONIC ACID ON CHILDREN GROWTH: RESULTS OF
THE OS2006 RANDOMISED TRIAL
A. Chevance1, L. Brugières2, P. Marec-Berard3, H. Pacquement4, C. Lervat5,
J.C. Gentet6, N. ENTZ-WERLE7, N. Corradini8, M.D. Tabone9, V. Gaveikaite1,
N. Bonnet10, F. Redini11, S. Piperno-Neumann12, M.C. Le Deley1
1Gustave Roussy, Service de Biostatistique et d’Epidémiologie, Villejuif, France; 2Gustave
Roussy, Département de Pédiatrie, Villejuif, France; 3Centre Léon Berard, Institut
d’Hématologie et d’Oncologie, Lyon, France; 4Institut Curie, Département d’Oncologie
Pédiatrique-Adolescent Jeunes Adultes, Paris, France; 5Centre Oscar Lambret, Unité
d’Oncologie Pédiatrique, Lille, France; 6Hôpital de la Timone, Service d’Oncologie
Pédiatrique, Marseille, France; 7Hôpital de Hautepierre, Onco-Hématologie Pédiatrique,
Strasbourg, France; 8Hôpital Mère-Enfant, Service d’Oncologie Pédiatrique, Nantes,
France; 9Hôpital A. Trousseau, Service d’Hémato-Oncologie Pédiatrique, Paris, France;
10Unicancer, R&D, Paris, France; 11Faculté de Médecine, INSERM UMR957, Nantes,
France; 12Institut Curie, Medical Oncology Department, Paris, France
Background/Objectives: Evaluation of Zoledronic acid (ZA) efficacy is ongoing in
children and adult with Ewing sarcoma. Concerns were raised from preclinical data
about a possible impact of ZA on children growth. This question was evaluated within
the OS2006 randomised trial in osteosarcoma patients.
Design/Methods: The OS2006 trial recruited patients from 5 to 50 years, with a newly
diagnosed osteosarcoma, from 2007 to 2014. We selected for the current study patients
<18 years at study entry, recruited >1 year ago, alive free of disease 1 year after
inclusion. Patients received methotrexate-etoposide-ifosfamide chemotherapy, +
doxorubicin-platinum post-operatively if poor histological response, +/- 10
ZA-injections according to randomisation. Height was normalised by age and gender
using WHO growth curves, and transformed into Z-score. Repeated Z-scores over time
were modelled using mixed models considering time during treatment and follow-up
time separately. Covariables included treatment (ZA+ versus ZA-), initial Z-score, age
and pubertal status.
Results: The current study is focused on 161 patients; mean initial z-score =+0.45,
significantly higher than 0 (p<0.0001). After a mean follow-up duration of 3.1 years,
the mean height increase was 6.9 cm, lower than expected, leading to a mean decrease
in Z-score of -0.40, with no significant difference between randomised groups (-0.33 in
ZA+ versus -0.46 in ZA-,p=0.18). In multivariable model, Z-scores significantly
decreased over time, even after the end of treatment although the slope was less steep
than during treatment (slope= -0.661/year during treatment and -0.342/year during
follow-up, interaction test, p<0.0001). Decrease was significantly more important in
younger patients (p<0.0001) and in patients with a high Z-score at study entry
(p=0.0001). We did not observe any significant impact of ZA on patient growth
(interaction between treatment and time, p=0.21).
Conclusion: Patients with osteosarcoma may be taller than healthy peers. Osteosarcoma
and its treatment appear to impact children growth, regardless of zoledronic acid.
PD-014
NATURAL KILLER CELL TARGET OSTEOSARCOMA TUMOR INITIATING
CELLS USING NKG2D-NKG2DL INTERACTIONS
L. Fernández1, J. Valentin2, A. Patiño3, W. Leung4, A. Pérez-Martínez5
1Centro Nacional Investigaciones Oncológicas CNIO, Clinical Research, Madrid, Spain;
2IdiPAZ, Innate Immunity, Madrid, Spain; 3Clínica Universitaria de Navarra, Pediatría.
Genética Clínica., Pamplona, Spain; 4St. Jude Children’s Research Hospital, Bone
Marrow Transplant and Cell Therapy, Memphis, USA; 5Hospital Universitario La Paz,
Pediatric Hemato-Oncology, Madrid, Spain
Background/Objectives: Tumor-initiating cells (TICs) have been described in
osteosarcoma, and are responsible for drug resistance, recurrence and metastasis.
Current therapies fail to cure recurrent or metastatic osteosarcoma and to target this
compartment. Natural Killer (NK) cells are lymphocytes with cytotoxic activity toward
virus-infected or malignant cells. In this study we have explored the ability and the
pathways involved in the NK cell elimination of osteosarcoma TICs.
Design/Methods: TICs in osteosarcoma cell lines 531MII, 654M and MG-63 were
identified phenotypically by the expression of c-kit and CXCR4 markers using Flow
Cytometry (FCM) and functionally by Sphere Formation Assays (SFA). NK cells
capacity to reduce TICs was assayed by co-culture of MG-63, 654M and 531MII and
NK cells for 4 and 24 hours and FCM analysis. To evaluate if NK cells could impair OS
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cells ability to grow as spheres, MG-63 GFP+ cells were co-cultured with NK cells for 4
and 24 hours, GFP+ live cells were then sorted and re-plated for SFA. One week later
spheres were counted using an inverted Nikon Ti microscope (Tokyo, Japan). The role
of NKG2D receptor and its ligands interactions was assayed using NK cells treated
with an NKG2D blocking antibody.
Results:We found osteosarcoma cells have a TICs compartment with expression of
c-kit and CXCR4, and ability to grow as spheres. Co-culture with NK cells showed to
reduce TICs subset. Specific antibody blockade showed NKG2D receptor and its
ligands interactions have a role in the elimination of osteosarcoma TICs by NK cells.
Conclusion: TICs can be identified in osteosarcoma cell lines. NK cells show ability to
reduce this compartment both in phenotype and in function. NKG2D and NKG2DL
have a role in the NK cell elimination of osteosarcoma TICs. Our data suggest
osteosarcoma patients could benefit from NK cells based therapies.
PD-015
CO-AMPLIFICATION OFMYC/PVT1 AND HOMOZYGOUS DELETION OF
NLRP1 LOCUS ARE THE FREQUENT GENETICS CHANGES IN MOUSE
OSTEOSARCOMA
P. Rao1, L. Kurenbekova1, Y.J. Zhao1, A. Yu1, N. Rainusso1, M. Trucco1,
W. Allen-Rhoades1, V. Borra1, T.K. Man1, L. Donehower2, J. Yustein1
1Baylor College of Medicine, Pediatrics, Houston, USA; 2Baylor College of Medicine,
Molecular & Cellular Biology, Houston, USA
Background/Objectives: High-grade osteosarcomas (OS) are characterized by high
levels of genomic instability compared to almost any other cancer. To gain insights into
the genomic instability and its contribution towards understanding the genetic basis of
osteosarcoma, we characterized 19 primary and 13 metastatic mouse tumors in a
genetically engineered novel mouse model of osteosarcoma by a combination of
genomic techniques.
Design/Methods:We established two osteosarcoma-susceptible lines of genetically
engineered mice (GEMM) utilizing osteoblast-specific Cre allele crossed with floxed p53
or LSL-p53 R172H alleles to generate localized or metastatic OS. Subsequent tumors
were isolated and established tumor cell lines from primary bone and/or distal
metastatic lesions, e.g. lung and liver. Several genomic techniques such as SKY, CGH,
array CGH, FISH and qRT-PCR were employed to characterize the complex
chromosomal aberrations in OS.
Results: Based on SKY/G-Banding analysis, genomic instability (GI) score was
estimated for each tumor and similar to human osteosarcoma, a wide spectrum of GI
was found, with some tumors displaying few changes (2) and others displaying > 40
chromosomal aberrations. We identified frequent amplification of 15D1 and loss of
11B4 by SKY/CGH and subsequent array CGH, FISH and qRT PCR analysis
demonstrated co-amplification and overexpression of Myc/Pvt1 transcripts from the
15D1 amplicon and loss and decreased expression of the Nlrp1 from 11B4. Both 15D1
and 11B4 has homology with human chromosomal bands 8q24 and 17p13, respectively.
Conclusion:We have shown a compelling homology between the genomic changes
identified in mouse tumors and several human cancers. This study also demonstrated
the co-amplification and overexpression of Myc andPvt1 genes and regulation of high
Myc protein levels through the Pvt1 non-coding micro RNAs may provide considerable
therapeutic targets in Myc-driven Osteosarcoma. In addition, we identified novel tumor
suppressor gene Nlrp1 with proapopotic properties and the functional significance of
this gene needs to be ascertained in OS.
Poster Discussion: Brain Tumours
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CLINICAL ANDMOLECULAR RESULTS OF THE GERMAN PHASE II STUDY
HIT-HGG-CILMETRO: CILENGITIDE ANDMETRONOMIC
TEMOZOLOMIDE FOR RELAPSED/REFRACTORY HIGH GRADE
GLIOMAS/DIPG IN CHILDREN AND ADOLESCENTS
C.F. Classen1, T. Pietsch2, C. Kramm3
1University Childrens Hospital-Rostock, Oncology Hematology, Rostock, Germany;
2Department of Neuropathology-University of Bonn, Department of Neuropathology,
Bonn, Germany; 3University Medicine Göttingen, University Childrens Hospital,
Göttingen, Germany
Background/Objectives: Relapsed high-grade gliomas (HGG) in pediatric patients like
glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), diffuse intrinsic
pontine glioma (DIPG) represent a dismal prognosis group currently without standard
salvage therapy. In this population, a combined protocol was investigated: Cilengitide
1800 mg/m2 twice weekly; temozolomide 75 mg/m2/d for 6 weeks with one week rest,
given for one year.
Design/Methods: Between 02/2012-03/2013 28 patients were recruited (3 AA, 9 GBM,
15 DIPG, one anaplastic oligoastrocytoma), 27 after first-line temozolomide
radiochemotherapy.
Results: 3/28 patients completed the full 52 weeks of treatment without signs of active
disease (all GBM); one of these patients died due to pneumonia without clinical tumor
progression 20 months after relapse; the two other patients are alive and
progression-free (follow-up 23/34 months). The following serious adverse events (SAE)
were observed: Intracranial hemorrhage (n=4); neurological deterioration (n=4),
seizures (n=3), pneumonia (n=2); and edema, severe obstipation, pain, cellulitis (each
n=1). No suspected unexpected serious adverse reaction (SUSAR) occurred.
Recruitment was prematurely stopped due to an altered risk assessment after negative
clinical data employing cilengitide in HGG. Survival was compared to historical relapse
patients from our database treated individually (n=417). Median overall survival in
HIT-HGG-CilMetro was 0.397 (0.181-0.613) vs. 0.507 (0.451-0.562) years (not
significant). Since our three GBM longterm survivors might represent true responders,
molecular analyses were done. The therapeutic targets (i.e. beta-5 integrins) were
expressed on all GBMs without a difference between survivors and the others. Most
interestingly, all CilMetro responders demonstrated an unmethylated MGMT promoter
status. Other molecular analyses including EGFR, PDGFRA, p53, H3F3AK27 status,
ATRX, IDH1, BRAFV600, CDKN2A, and MYCN-amplification, were inconclusive.
Conclusion: HIT-HGG-CilMetro offered a feasible salvage treatment approach with
tolerable toxicity for pediatric patients with relapsed HGG and might induce an
increased progression-free survival in a GBM subgroup, potentially with unmeythylated
MGMT promoter status.
PD-017
SURVIVAL AND PROGNOSTIC FACTORS IN 211 INTRACRANIAL
EPENDYMOMAS - 13 YEARS EXPERIENCE OF CHILD’S CANCER FRENCH
SOCIETY
A. Ducassou1, X. Murraciole2, L. Chaltiel3, S. Bolle4, L. Claude5, B. Coche-Dequeant6,
C. Alapetite7, S. Supiot8, A. Huchet9, V. Bernier10, E. Le Prise11, C. Kerr12, T. Nguyen13,
G. Truc14, A. Sevely15, A.I. Bertozzi-Salomon16, F. Tensaouti17, S. Liceaga17,
T. Filleron3, A. Laprie1
1Institut Claudius Regaud-Institut Universitaire du Cancer-Toulouse Oncopole, Radiation
Oncology, Toulouse, France; 2Hopital La Timone, Radiation Oncology, Marseille,
France; 3Institut Claudius Regaud-Institut Universitaire du Cancer-Toulouse Oncopole,
Biostatistics, Toulouse, France; 4Gustave Roussy, Radiation Oncology, Villejuif, France;
5Centre Léon Bérard, Radiation Oncology, Lyon, France; 6Institut Oscar Lambret,
Radiation Oncology, Lille, France; 7Institut Curie, Radiation Oncology, Paris, France;
8ICO, Radiation Therapy, Nantes, France; 9CHU, Radiation Therapy, Bordeaux, France;
10Centre Alexis Vautrin, Radiation Oncology, Nancy, France; 11Centre Eugène Marquis,
Radiation Oncology, Rennes, France; 12ICM, radiation Oncology, Montpellier, France;
13Centre Jean Godinot, Radiation Oncology, Reims, France; 14Centre Georges-François
Leclerc, Radiation Oncology, Dijon, France; 15CHU, Pediatric Neuro-Radiology,
Toulouse, France; 16CHU - Hopital des Enfants, Pediatric Onco-Hematology, Toulouse,
France; 17INSERM UMR 825, Neuroimaging, Toulouse, France
Background/Objectives: To analyze the outcome and assess the prognostic impact of
clinical characteristics for pediatric patients with localized ependymoma in a French
muticentric cohort.
Design/Methods: 211 patients with newly diagnosed intracranial ependymoma were
treated with adjuvant radiation therapy (RT) in the 13 French major radiation
oncology centers between January 2000 and December 2013. Clinical data were
retrospectively gathered on a web-based national database until January 2015. Median
age was 5 (range1;23). Location was posterior fossa in 74%, supratentorial in 26%, with
anaplastic features in 63%. The extent of resection was gross-total in 86%. The median
delivered dose was 58.7 Gy. Sixty-six patients received pre-RT chemotherapy. RT was
3D conformal in 121 patients, intensity-modulated (IMRT) in 71 (13 tomotherapy) and
protontherapy in 17. With a median follow up time of 43.7 months, the estimation of
cumulative incidence of local relapse at 3 years was 24.7%. Recurrences were mainly
local (strictly local in 66% of recurrences, local and distant in 23% and strictly distant in
11%). The estimated 3-year overall survival (OS) and event-free survival (EFS) rates
were respectively 86 % and 62% for patients who received a dose > 54Gy vs 77% and
53% with dose 54 Gy (both p= 0.03). Three-year OS and EFS were respectively 87
and 65% for patients older than 3 years at the initiation of RT and 72 and 47% for
children less than 3 years (p=0.009 and p=0.002). Three-year OS was better after
gross-total resection (85 vs 68%; p=0.02).
Conclusion: In this large multicentric French cohort, children with a localized
intracranial ependymoma had a significant better survival with a dose > 54 Gy. Age
younger than 3 years at initiation of RT and incomplete surgery were significant
prognostic factors of worse outcome.
PD-018
RE-IRRADIATION IN PATIENTS WITH DIFFUSE INTRINSIC PONTINE
GLIOMAS. THE CANADIAN EXPERIENCE
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A. Lassaletta1, U. Bartels1, M. Issaivanan2, D. Strother3, D. Ku1, L. Lafay-Cousin3,
N. Laperriere4, J. Adamski1, R. Rajagopal1, V. Ramaswamy1, U. Tabori1, A. Huang1,
T. McKeown1, E. Bouffet1
1Hospital for Sick Children, Pediatric Neuro-Oncology, Toronto, Canada; 2Cancer Care
Manitoba, Pediatric Oncology, Winnipeg, Canada; 3Alberta Children´s Hospital,
Pediatric Hematology-Oncology, Calgary, Canada; 4Princess Margaret Cancer Centre,
Radiation Oncology, Toronto, Canada
Background/Objectives:More than 90% of the children diagnosed with diffuse intrinsic
pontine gliomas (DIPG) will succumb within two-years of diagnosis. Clinical-trials
over the last four decades failed to demonstrate a survival benefit of adjuvant
chemotherapy. Radiotherapy is the only effective treatment thus far but of limited
duration. The aim of this study is to determine the safety and efficacy of re-irradiation.
Design/Methods: Since September 2013, patients with DIPG showing clinical and
radiological progression were considered for re-irradiation. We retrospectively reviewed
demographic, clinical and radiation data of all patients with DIPG treated in Canada
with re-irradiation.
Results: Since September 2013, 10 patients with progressive DIPG received
re-irradiation in Canada. Median age at diagnosis was 4.9 years (range, 2.2-13y).
Median time from diagnosis to progression was 12 months (range, 4-37m).
Re-irradiation total dose varied between institutions from 21.6 Gy (2 patients), 30.6 Gy
(6 patients), and 36 Gy (2 patients), in 1.8 Gy daily fractions. Re-radiation was focal
except in two patients who received whole-brain irradiation due to distant/disseminated
relapse. One patient received a third course of focal radiation (21.6 Gy) 6 months after
re-radiation. Re-irradiation was very well tolerated by all children. Dexamethasone was
avoided where feasible but necessary in 4 patients. Four patients had transient tiredness
and decrease of appetite during treatment. All but one showed neurological
improvement, with 4 patients showing full-recovery. With a median follow-up from
diagnosis of 19.5 months (range, 9-45m), seven patients died, with a median time from
re-irradiation to death of 9 months (range, 5-13m). When compared to an historic
cohort of 46 patients, median time from progression to death was 91.5 days in the non
re-irradiated patients, vs. 171 days in the re-irradiated ones (p<0.05).
Conclusion: In this limited experience re-irradiation was safe and feasible in patients
with progressive DIPG, providing neurological recovery and a prolonged life span.
PD-019
UK NATIONAL AUDIT REVEALS UNEXPECTED NEUROTOXICITY OF
CHILDRENWITH STPNET TREATEDWITH INTENSIVE CHEMOTHERAPY,
HYPER FRACTIONATED RADIOTHERAPY (HART) AND TANDEMHIGH
DOSE THIOTEPA CONSOLIDATION
J. Sastry1, B. Pizer2, N. Thorp2, R. Taylor3, D. Walker4, A. Michalski5, G. Horan6,
H. Traunecker7
1Royal Hospital for Sick Children-Yorkhill, Glasgow, United Kingdom; 2Alderhey
Children’s Hospital, Haemato-Oncology, Liverpool, United Kingdom; 3Singleton
Hospital, Oncology, Swansea, United Kingdom; 4University of Nottingham, Paediatric
Oncology, Nottingham, United Kingdom; 5Great Ormond Street Hospital, Paediatric
Oncology, London, United Kingdom; 6Addenbrookes Children’s Hospital, Oncology,
Cambridge, United Kingdom; 7University Hospital of Wales, Paediatric Oncology,
Cardiff, United Kingdom
Background/Objectives: Supratentoral Primitive Neuroectodermal Tumour (StPNET) is
rare in children. Prognosis is poor with various series reporting 20-40% survival. The
Milan group published improved outcomes with intensive chemotherapy, HART
followed by tandem high dose thiotepa consolidation in 2006 and 2013. The 5-year
PFS, EFS, and OS rates were 62%, 53%, and 52%. UK CCLG adapted this treatment
as recommended strategy for all patients with stPNET in 2009.
Design/Methods: A national audit was undertaken in the UK in 2014 to evaluate the
outcome and the toxicity of this treatment. Information collected included details of
the diagnosis, treatment, outcome and toxicity. All patients with StPNET, metastatic
pineoblastoma, above the age of 36 months at diagnosis, treated as per the
recommendation between Jan 2009 to May 2014 were included.
Results: A total of 19 patients (2 Pineal and 17 non-Pineal PNETs) were identified.
Mean age was 9.81 (range 5-16.5) and M:F ratio was 2:1(M13). All patients received
recommended induction chemotherapy and radiotherapy. 14 patients received the 1st
thiotepa consolidation and 9 of them received the 2nd dose thiotepa consolidation. 7
(36%) patients had died by the end of study period with a follow up ranging from 8-56
months (mean 9.81):6 from progressive disease, 1 from toxicity of treatment. Grade 3/4
neurotoxicity was noted in 8 patients. 7 of these developed fairly rapid onset global
neural deterioration with bulbar dysfunction. All these patients were neurologically
intact before the thiotepa consolidation. MRI brain showed varying degree of
leucoencephalopathy changes in these patients.
Conclusion: This audit shows severe unexpected neurotoxicity with the use of intensive
chemotherapy, HART and high dose thiotepa consolidation. The treatment strategy
was discontinued in the UK immediately following the audit. Further research is
urgently needed to improve outcomes in this enigmatic disease.
PD-020
A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY APPEARS
TO BE SUPERIOR TO HIGH-DOSE CHEMOTHERAPY IN RECURRENT
MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR
I. Slavc1, A. Peyrl2, M. Chocholous2, A.A. Azizi2, T. Czech3, K. Dieckmann4
1Medical University of Vienna, Vienna, Austria; 2Medical University of Vienna,
Pediatrics, Vienna, Austria; 3Medical University of Vienna, Neurosurgery, Vienna,
Austria; 4Medical University of Vienna, Radiotherapy, Vienna, Austria
Background/Objectives: Prognosis of patients with recurrent medulloblastoma and
atypical teratoid rhabdoid tumor (ATRT) is dismal despite intensive therapy including
high-dose chemotherapy with stem cell rescue. An evolving alternative approach to
conventional chemotherapy is to target neovascularisation by interfering with tumor
angiogenesis at various levels. We report on 20 patients with recurrent medulloblastoma
and ATRT treated with an antiangiogenic combination therapy.
Design/Methods: From 11/2006 to 09/2014, 20 patients were diagnosed with recurrent
embryonal tumors, 13 with a recurrent medulloblastoma (8 first, 5 multiple recurrences)
and seven with recurrent ATRT (4 first, 3 multiple), three had germ line mutations.
Treatment consisted of an antiangiogenic multidrug-regime including IV bevacizumab,
oral thalidomide, celecoxib, fenofibrate, and etoposide alternating with
cyclophosphamide, and augmented with intraventricular therapy (etoposide and
liposomal cytarabine). Median age at start of antiangiogenic therapy was 13 (1-24)
years for medulloblastoma and 4 (1-13) years for ATRT.
Results: As of 03/2015, 7/13 patients with medulloblastoma are alive at a median of 48
(5 to 78) months after their last recurrence. 6/13 surviving patients are currently in CR
for 78, 75, 74, 48, 9, and 7 months, four off therapy for 60, 43, 39 and 18 months, one
has stable disease after 5 months. 3-year and 5-year-OS is 57.1±14.8%. One patient
died of an accident in CR 23 months after initiation of antiangiogenic therapy. 3/7
patients with ATRT are in CR, one in PR. Follow-up since last recurrence is 42, 41, 8
and 5 months, two are off therapy for 36 and 32 months. Therapy was generally well
tolerated and toxicities were manageable.
Conclusion: The proposed antiangiogenic regimen is currently being evaluated for
medulloblastomas in a formal international phase II protocol (MEMMAT;
ClinicalTrials.gov Identifier: NCT01356290). The same approach seems to be also
efficacious in recurrent ATRTs and warrants further evaluation.
PD-021
DISPOSITION OF HIGH-DOSEMETHOTREXATE IN VERY YOUNG INFANTS
WITHMALIGNANT BRAIN TUMORS
V. Daryani1, K. Wright2, A. Broniscer2, G. Robinson2, I. Qaddoumi2, G. Armstrong2,
A. Gajjar2, C. Stewart3
1St. Jude Children’s Research Hospital, Pharmaceutical Sciences, Memphis, USA; 2St.
Jude Children’s Research Hospital, Oncology, Memphis, USA; 3St. Jude Children’s
Research Hospital, Memphis, USA
Background/Objectives: Little is known about the use of high-dose methotrexate
(HDMTX) in very young infants (< 1 year) with malignant brain tumors who have
immature renal function by virtue of their age alone. Developmental changes in renal
function likely introduce inter- and intra-patient variability with drug therapy, and in
the absence of any data, no specific dosing guidelines or supportive care measures have
been proposed or optimized for this patient population.
Design/Methods:We investigated MTX pharmacokinetics in a clinical trial evaluating
risk-adapted therapy for infants and young children with brain tumors
(NCT00602667). During induction therapy, all patients received HDMTX as a 24-hour
infusion of 5 g/m2 and we empirically decreased the dosage to 2.5 g/m2 for infants  31
days of age on the first day of each 28 day cycle. Serial pharmacokinetic sampling was
obtained after HDMTX infusion, and MTX concentrations were measured by a
fluorescence polarization immunoassay. Population parameters for a two-compartment
pharmacokinetic model were estimated by nonlinear-mixed effects modeling
(NONMEM).
Results: Thirty-eight patients with a median age of 7.3 months (range: 0.2 - 11.6
months) contributed 817 MTX pharmacokinetic samples to the data set. The
population MTX clearance estimate (CLt) in the base structural model was 68.2
ml/min/m2 with inter-individual variability (IIV) of 23.3% (R2=0.32). MTX Clt
appears to increase linearly during the first year of life, paralleling the physiological
maturation in renal function that occurs during infancy. Future studies will include a
full covariate analysis for the prediction of MTX CLt, including age, gender, race, total
body weight, body surface area, and estimated GFR.
Conclusion: This preliminary analysis suggests incorporation of a maturation function
on clearance will improve the dosing of MTX in infants and young children with
malignant brain tumors.
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IMPACT OF INDUCTION CHEMOTHERAPY, HYPERFRACTIONATED
ACCELERATED RADIOTHERAPY AND HIGH DOSE THIOTEPA ON BRAIN
VOLUME LOSS AND FUNCTIONAL STATUS OF CHILDRENWITH
PRIMITIVE NEUROECTODERMAL TUMOUR (PNET)
E. Szychot1, K. Mankad2, S. Thust3, K. Seunarine4, C. Clark4, A. Michalski5
1University College Hospital, Children and Young People’s Cancer Services, London,
United Kingdom; 2Great Ormond Street Hospital for Children, Neuroradiology
Department, London, United Kingdom; 3UCL Institute of Child Health, Institute of
Neuroradiology, London, United Kingdom; 4UCL Institute of Child Health,
Developmental Imaging and Biophysics Section, London, United Kingdom; 5Great
Ormond Street Hospital for Children, Paediatric Oncology, London, United Kingdom
Background/Objectives: Aggressive chemo-radiation treatments have been introduced to
improve the dismal prognosis of high risk PNETs. There is increasing concern that
combination therapies may result in neurotoxicity, but the clinical impact of these
findings remains to be determined. The aim of this analysis was to investigate the
relationship between brain volume loss and functional status in children treated with
sequential chemotherapy, hyperfractionated accelerated radiotherapy (HART) and
high-dose thiotepa with autologous stem-cell rescue.
Design/Methods:We retrospectively reviewed clinico-radiological data of children with
primitive neuroectodermal tumours (including supratentorial PNET, high risk
medulloblastoma and pineoblastoma) treated at our national referral centre between
2009-2013 according to the Milan Cancer Centre protocol published by Gandola et al.
(J Clin Oncol 2009 Feb 1;27(4):566-71). Serial MRI scans from presentation until the
end of treatment were qualitatively analysed by two board certified neuroradiologists
assessing for brain volume loss and signal abnormality. A quantitative brain volume
analysis was undertaken using FSL’s Sienax toolkit. Functional status was determined
using the Lansky Performance Scale.
Results: Thirteen of 14 children developed generalised brain volume loss with moderate
or severe volume loss in 7 of 14 children. Of 11 children who received thiotepa, 7
suffered moderate to severe brain volume loss. Mean brain volume loss of all subjects
was 8.9% (4.2-17.4%) averaged over 2 years from presentation. Two children developed
transverse myelitis and 1 patient suffered peripheral neuropathy, urinary incontinence
and seizures. Performance status was severely restricted in 4 of 14 children (Lansky
score 10-40). Mild to moderate impairment was noted in 7 of 14 children (Lansky score
50-70).
Conclusion: Substantial brain volume loss was evident in our cohort of children
following treatment. Of 14 children 4 had severe and 7 mild to moderate impairment of
clinical performance status. The presence of imaging changes was associated with a
greater performance decline at the end of therapy.
Poster Discussion: Epidemiology
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UTILIZATION OF THEWHOMODEL LIST OF ESSENTIAL MEDICINES
(EML) FOR ANTI-NEOPLASTIC DRUGS IN LOW ANDMIDDLE INCOME
COUNTRIES (LMICS)
R. Barr1, J. Robertson2
1McMaster University, Pediatrics, Hamilton, Canada; 2University of Newcastle, School
of Medicine and Public Health, Newcastle, Australia
Background/Objectives: The lower survival rates in children with cancer in LMICs, by
comparison with those in high income countries, is related in part to limited availability,
access and affordability with respect to anti-neoplastic drugs. The objective of this
study was to determine alignment of national Essential Medicines Lists (NEMLs) with
the panel of essential and ancillary anti-neoplastic medicines recommended by the
SIOP Working Group on Essential Medicines.
Design/Methods: NEMLs are available on the WHO website
http://www.who.int/selection_medicines/country_lists/en The number of the medicines
included on NEMLs available on the website in 2015 was correlated with three indices –
gross national income per capita (A), average government expenditure on health care
per capita (B), and the number of physicians per million population (C); indices
obtainable from WHO and World Bank websites.
Results: Information was available for 116 LMICs. Availability of individual essential
non-steroidal anti-neoplastic drugs – X n=18) ranged from 25.0% for thioguanine to
86.2% for methotrexate (also listed in EMLs for non-cancer purposes). The median
number of drugs available was 11.6, range 0-18. In the ancillary list - Y (n=8) the
median was 1, range 0-7. For the variables A, B and C the medians and ranges are US
$3735, $123-$25,000 (A); $113, $1.7-$1423 (B); 650, 8-4236 (C) respectively.
Remarkable exceptions notwithstanding, the Pearson correlations (r) were as follows: X
v A 0.19, p=0.0411; Y v A 0.36, p<0.0001; X v B 0.03, p=0.7492; Y v B 0.26,
p=0.0048; X v C 0.20, p=0.0314; Y v C 0.43, p<0.00001 (p values are two-tailed).
Conclusion: The availability of anti-neoplastic drugs for children with cancer in LMICs
is highly variable and generally limited. While there are correlations between listing as
essential medicines and variables A, B and C, the strongest is between ancillary
(non-essential) drugs and the number of physicians per million people.
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CHILDHOOD LYMPHOMA INCIDENCE IN THAILAND FROM 1990-2011
K. Demanelis1, H. Sriplung2, R. Meza3, S. Wiangnon4, L. Rozek1, M. Scheurer5,
P. Lupo5
1University of Michigan, Environmental Health Sciences, Ann Arbor, USA; 2Prince of
Songkla University, Epidemiology Unit, Hat Yai, Thailand; 3University of Michigan,
Epidemiology, Ann Arbor, USA; 4Khon Kaen University, Pediatrics, Khon Kaen,
Thailand; 5Baylor College of Medicine, Pediatrics, Houston, USA
Background/Objectives:While lymphoma is one of the most common childhood
malignancies, the incidence overall and by subtype varies significantly worldwide. This
variability may be due to differences in both genetics and environmental factors.
However, more work is needed to elucidate patterns of childhood lymphoma in
developing countries. Therefore, we analyzed childhood lymphoma incidence trends
from 1990 to 2011 in Thailand and compared these results to United States (US) data.
We evaluated the following childhood lymphoma subtypes: Hodgkin lymphoma (HL)
and non-Hodgkin lymphoma (NHL).
Design/Methods:We used population-based cancer registry data from five provinces in
Thailand (n=402). Data from the US were obtained from the Surveillance,
Epidemiology, and End Results program (n=3,948). We computed age-standardized
incidence rates (ASIR) using the WHO 2000 standard population. We evaluated
temporal changes in incidence by year of diagnosis using joinpoint regression and
reported the annual percent changes (APC).
Results: The ASIR of lymphoma was 1.1 and 2.4 cases per 100,000 in Thailand and the
US, respectively. The proportion of NHL and HL in Thailand was 52.5% and 20.4%,
respectively, vs. 35.6% and 50.1% in the US (p<0.001). In Thailand, the mean age at
diagnosis was younger compared to the US (11.5 vs. 13.4 years, p<0.001). The
incidence of HL increased by 4.1% per year (p=0.006) in Thailand while it remained
stable in the US (APC=-0.24%, p=0.589). While the incidence of NHL increased in the
US by 1.9% per year (p<0.001), it increased in Thailand by 3.5% per year (p <0.001).
Conclusion: Our findings suggest that while lymphoma incidence is lower in Thailand
than the US, NHL and HL incidences are more rapidly increasing and the proportion
of these subtypes differs significantly when compared to the US. These patterns
warrant comparing these results to the Asian population within the US and
investigating novel risk factors within Thailand and Southeast Asia.
PD-025
NON COMPLIANCE OF CHILDREN CANCER PATIENTS WITH THERAPY: A
SINGLE CENTER EXPERIENCE IN A DEVELOPING COUNTRY
A. Farrag1, M. Ghzaly2
1South Egypt Cancer Institute-Assiut University, Pediatric Oncology Department, Assiut,
Egypt; 2Faculty of Medicine-Assiut University, Department of Pediatrics, Assiut, Egypt
Background/Objectives: To evaluate risk factors affecting compliance of childhood
cancer patients with therapy.
Design/Methods: The following data were collected by retrospective reviewing of
reports of all patients who were diagnosed and started treatment between 2006 and
2010 in the pediatric oncology department, South Egypt Cancer Institute (SECI): Age,
sex, diagnosis, duration of travel from patient’s home to SECI, time lag between first
symptom till first visit to SECI and between first visit till start of treatment, first
evaluation after initial course of therapy, compliance with therapy. Non-compliance
with therapy was defined when patients missed their determined appointment for
therapy for 1 week or more, or who refused or escaped therapy.
Results: About 15% (n=75) of the included patients (N=502) were non-compliant. As
40 patients missed their determined appointment for therapy; 7 refused; and 28 escaped
further therapy. There was not a significant difference between non-compliant patients
vs. compliant patients in the following factors: the travel time from home to SECI, 1.35
(0.28 - 6.8) vs. 0.85 (0.17 – 9) hours; from first symptom till first presentation, 4 (0.43 –
96) vs. 4 (0.14 – 96) weeks; and from first presentation till start of treatment 5 (0 – 60)
vs. 5 (0 – 210) days, respectively. Although 14% of patients who were not in complete
remission at time of first evaluation after initial therapy, and 13.5% of patients who
suffered severe complications were non-compliant with the further therapy, these
differences were not significant. In addition, within the excluded patients, 2.4% (n=17)
escaped from the hospital just after initial suspicion of cancer; 0.8% (n=6) refused
chemotherapy after reaching a final diagnosis of cancer; and 0.3% (n=2) escaped after
doing initial surgeries as a primary step in therapy.
Conclusion: Treatment refusal and abandonment are still big problems facing cancer
management in developing countries.
Pediatr Blood Cancer DOI 10.1002/pbc
SIOP ABSTRACTS S217
PD-026
RECURRENCE OF GRAM-NEGATIVE INFECTIONS AMONG PATIENTS
WITH PEDIATRIC CANCER
R. Ojha1, S. Stallings-Smith1, P. Asdahl2, E. Bittner1, S. Gomez3
1St. Jude Children’s Research Hospital, Department of Epidemiology and Cancer
Control, Memphis, USA; 2Aarhus University Hospital, Department of Pediatrics, Aarhus,
Denmark; 3Hospital de Niños Sor Maria Ludovica, Department of Hematology, La
Plata, Argentina
Background/Objectives: Gram-negative pathogens are a widespread concern because of
their potential for developing antibiotic resistance. Prior studies of Gram-negative
infections among patients with pediatric cancer have focused on the risk of first
infection. The paucity of data about recurrent Gram-negative infections limits
understanding the continuum of infection risk. Therefore, we aimed to estimate the risk
of recurrent Gram-negative infections among patients with pediatric cancer.
Design/Methods: Individuals eligible for our longitudinal cohort study were aged <20
years and treated for a malignancy at Hospital de Niños Sor Maria Ludovica (La Plata,
Argentina) between January 2011 and June 2013. Patients contributed person-time to
the cohort until end of therapy, death, loss to follow-up, or end of study. We estimated
the incidence rate (IR) of microbiologically-documented Gram-negative infections and
corresponding 95% jackknife confidence limits (CL) to account for within-patient
clustering. The IR was subsequently used to estimate the risk of recurrent
Gram-negative infections, assuming a random Poisson distribution.
Results: Our study population comprised 159 patients with pediatric cancer. We
observed 35 Gram-negative infections during 47,245 person-days at risk (IR per 1,000
person days=0.74, 95% CL: 0.50, 1.1). The overall estimated risks of having one, two,
or three Gram-negative infections during a one-year period were 21%, 2.8%, and
0.25%, respectively. The risk of recurrence differed by subgroups. In particular, patients
with pediatric acute myeloid leukemia (AML) had the highest estimated risks of having
one, two, or three Gram-negative infections during a one-year period, which were 34%,
11%, and 2.3%, respectively.
Conclusion: Our results suggest considerable risk of recurrent Gram-negative infections
among patients with pediatric cancer, particularly among patients with pediatric AML.
Our findings may be useful for promoting discussion about antimicrobial stewardship
strategies for subgroups with high risks of recurrent Gram-negative infections and
repeated exposures to antibiotic therapy.
PD-027
CAREGIVERS WHOMISS APPOINTMENTS TO THE PEDIATRIC CANCER
CLINIC OF A TEACHING HOSPITAL IN GHANA
L. Osei-Tutu1, V. Paintsil1, J. Dogbe1, A. Osei Akoto1, E. Amuzu2
1Komfo Anokye Teaching Hospital, Child Health Department, Kumasi, Ghana; 2Komfo
Anokye Teaching Hospital, Research and Development Unit, Kumasi, Ghana
Background/Objectives: At Komfo Anokye Teaching Hospital (KATH), Kumasi,
Ghana, over one-third of caregivers of children with cancer miss their children’s
scheduled clinic appointments. Our goal was to describe the demographic and
socioeconomic characteristics of caregivers who had missed their clinic appointments.
Design/Methods: This is a prospective cross-sectional survey of caregivers attending the
paediatric cancer clinic who had a history of previously missing clinic visits.
Respondents completed a questionnaire of closed and open-ended questions. Data was
collected over a 3 months period (1st November, 2014 to 31st January, 2015) and
analyzed using STATA IC 12.0 R© software.
Results: Twenty-five respondents had previously missed clinic visits; 72% females and
28% males. Sixty percent were married, 16% were divorced and 12% cohabiting.
Christians constituted 80% while 20% were Moslems. There was an average of 3
children per household with a mean age of 7 years. Overall, 72% had Primary and/or
Junior High School education and 28% had Senior High School education/higher.
Most, 68% were self-employed traders and farmers, 24% were unemployed and 8%
were government employees. Majority (72%) reside outside Kumasi. The mean travel
time to the Clinic was 2 hours, 8 minutes and 60% required at least 2 vehicles to reach
the Clinic. Reasons for missed appointments included lack of money for investigations
and/or treatment as given by 24% of respondents, with 20% reporting an inability to
afford transportation cost. While 12% were absent due to miscommunication of dates,
8% forgot their appointment dates.
Conclusion:Most of the respondents were females of low socioeconomic status,
resident outside the city and requiring an average of 2 hours and at least two vehicles to
reach the Clinic for appointments. Majority attributed their absence to lack of money
for transportation and clinical care, and others to miscommunication and forgetfulness.
PD-028
ENVIRONMENTAL RADON EXPOSURE AND INCIDENCE OF PEDIATRIC
LYMPHOMA IN TEXAS, 1995-2011
E. Peckham1, M. Scheurer1, H. Danysh1,2, J. Lubega1, P. Langlois3, P. Lupo1
1Baylor College of Medicine, Pediatrics-Hematology-Oncology Section, Texas Children’s
Cancer Center, Dan L. Duncan Cancer Center, Houston, USA; 2University of Texas
School of Public Health, Epidemiology-Human Genetics and Environmental Sciences,
Houston, USA; 3Texas Department of State Health Services, Birth Defects Epidemiology
and Surveillance Branch, Austin, USA
Background/Objectives: There is consistent and growing interest in assessing the
association between environmental exposure to radon and the risk of childhood cancer.
However, previous studies have been largely equivocal. Therefore, we sought to evaluate
the association between indoor radon exposure and the incidence of pediatric
lymphoma in Texas, a state characterized by a large population-based cancer registry
and variable concentrations of radon.
Design/Methods: Information on childhood lymphoma cases was obtained from the
Texas Cancer Registry (n=2,147) for the period 1995-2011. Denominator data were
obtained from the 2000 United States Census. Exposure to radon was estimated using
data from the Texas Indoor Radon Survey. Specifically, arithmetic mean radon
concentrations (picoCuries/liter; pCi/l) were obtained from 13 geologic regions in the
state and linked to the residence at diagnosis. Exposure was assessed both on a
continuous scale and dichotomously (<90th percentile [low exposure] vs. 90th
percentile [high exposure]). Poisson regression was used to generate incidence rate ratios
(IRR) and 95% confidence intervals (CI) adjusted for sex, race/ethnicity, and area-level
poverty. We evaluated the following lymphoma outcomes: Hodgkin (HD; n=1,248),
Burkitt Lymphoma (BL; n=241), and Non-Hodgkin excluding Burkitt Lymphoma
(non-BL NHL; n=658).
Results: The mean radon concentration across regions was 1.24 pCi/l (range: 0.25-3.30).
For every one pCi/l increase in radon exposure, there was a modest, but non-significant,
increase in the incidence of non-BL NHL (IRR [95% CI]: 1.07 [0.93-1.24]).
Additionally, areas with high radon concentrations had a 26% higher incidence of
non-BL NHL (95% CI: 0.88-1.81) compared with areas of low radon concentrations.
Associations were not detected for HD or BL.
Conclusion: Overall, there was little evidence to suggest radon is strongly associated
with childhood lymphoma incidence. However, the incidence of non-BL NHL was
modestly increased in areas of the highest concentrations.
PD-029
DELAYS IN CANCER DIAGNOSIS AND TREATMENT AMONG CHILDREN
WITH CANCER COMPARATIVE STUDY BETWEEN EGYPTIAN AND SAUDI
CENTERS
L. Sherief1, S. Arafa2, E. Abdelkalek1, N. Kamal3, N. Al Tehewi2
1Zagazig University, Pediatric, Zagazig, Egypt; 2Benha University, pediatric, Benha,
Egypt; 3Cairo University, Pediatric, Cairo, Egypt
Background/Objectives: Childhood cancer outcome is greatly affected by delay in
diagnosis. Our objective was to explore factors underlying delay in diagnosis as an
important step to establish control measures.
Design/Methods:We carried out retrospective study on 300 children suffering from
different types of malignancies from two Arab countries; Egypt and Saudi Arabia.
One-hundred-fifty children were enrolled from Egyptian oncology centers and another
150 children from Saudi Arabian oncology centers. They were studied for different
possible factors influencing timing of diagnosis which were categorized as patient
related factors, disease related factors and health care related factors. Correlations
between all possible factors and total delay time to final diagnosis were carried.
Results: The median total diagnosis delay period was longer in Saudi Arabia than in
Egypt; 59 versus 42 days respectively. In both countries, health care related factors
significantly contributed to delay in diagnosis. Patients’/ parents’ related factors (child
age, parental age, education, socioeconomic status, maternal work) caused 3 times more
delay in Saudi patients as compared to Egyptian patients with obvious significant
negative effect of different factors during patient pathway till final diagnosis is
obtained. Disease related factors including; disease type, presenting symptoms and
stage of malignancy at the time of presentation, also played an important role.
Conclusion: Significant correlations were detected between delay in childhood cancer
diagnosis and patients’ factors and disease related factors. Health care related factors
were the most delaying factor in both countries. Efforts should be carried to raise
awareness of parents, improve health care providers’ skills and health care centers
facilities to achieve early diagnosis and best outcomes for childhood cancers.
PD-030
FACTORS ASSOCIATEDWITH TIME TO DIAGNOSIS OF CHILDHOOD
CANCER: A RETROSPECTIVE COHORT STUDY
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L. Vasquez1, M. Oscanoa1, M. Tello1, I. Maza1, G. Paredes1, J. Geronimo1
1Rebagliati Hospital, Pediatric Oncology, Lima, Peru
Background/Objectives: Time to diagnosis (TD) or “lag time” is the time between a
patient’s first symptom recognition to a diagnosis of cancer. Delayed TD allows tumor
progression and poor outcome in childhood cancer in many studies, although it remains
controversial. In our country, high rate of metastatic presentation and poor survival has
been described. The aim of this study was to define clinical and socio-demographic
factors associated to TD, which includes “Parents delay” (PD) and “Medical delay”
(MD) in children and adolescents diagnosed with cancer in Lima, Peru.
Design/Methods: A total of 314 patients younger than 18 years of age diagnosed with
lymphoma and solid tumors between January 2012 and December 2014 were
retrospectively evaluated. Clinical and demographic variables such as type of diagnosis,
clinical stage, sex, age and parental characteristics were analyzed to evaluate their effects
on TD, PD and MD.
Results: The TD ranged between 1 week and 26 months (median, 9.75 weeks), with a
median of PD and MD of 2 and 5.5 weeks, respectively. Among type of disease, we
found significant differences in TD (longer in patients with Hodgkin disease and
osteosarcoma and shorter in patients with Wilms tumor and hepatoblastoma). A
greater TD was found in children first diagnosed by a general physician or surgeon than
by a pediatrician (p=0.004). Advanced parental age (p=0.035), low mother´s level of
education (p=0.013) and older children (p<0.01) was significantly associated with
delayed TD. Children of divorced or separated couples (p=0.008) had longer TD than
their counterparts. Metastatic disease, clinical stage and sex did not affect significantly
TD.
Conclusion: In our country, median TD was comparable to described in developing
countries, where index of suspicion of childhood cancer remains low. It is necessary to
establish strategies for optimizing early diagnosis based on associated factors.
Poster Discussion: Late Effects
PD-031
HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF
BRAIN TUMOURS IN CHILDHOOD AND ADOLESCENCE: A SERIAL STUDY
SPANNING A DECADE
T. Nayiager1, J. Duckworth1, E. Pullenayegum2, A. Whitton3, J. Horsman4,
R. Hollenberg5, W. Furlong4, R. Spitzer6, R. Barr7
1McMaster Children’s Hospital, Service of Hematology-Oncology, Hamilton, Canada;
2Hospital for Sick Children, Child Health Evaluative Services, Toronto, Canada;
3Juravinski Cancer Centre, Radiation Oncology, Hamilton, Canada; 4Health Utilities
Inc, Health Utilities Inc, Dundas, Canada; 5McMaster Children’s Hospital, Service of
Surgery, Hamilton, Canada; 6Mount Sinai Hospital, Obstetrics and Gynaecology,
Toronto, Canada; 7McMaster University, Pediatrics, Hamilton, Canada
Background/Objectives: Survivors of brain tumours in childhood experience adverse
sequelae from their disease and its treatment that are greater in prevalence and severity
than those encountered by survivors of all other forms of cancer in early life. This is
reflected in burdens of morbidity reported by cross-sectional surveys using instruments
measuring health-related quality of life (HRQL). However, there are few studies of
change in HRQL over time in such populations; the objective of this study.
Design/Methods: Patients 5 years of age or older, at least two years from completion of
therapy and able to communicate in English were eligible for survey by the generic,
preference-based multi-attribute Health Utilities Index Mark 2 (HUI2) and 3 (HUI3) at
study initiation (T1) and again 5 (T2) and 10 (T3) years later. HUI provides utility
scores of single-attribute (domain/dimension) morbidity and multi-attribute HRQL.
HRQL scores are on a scale such that 0.00=dead, 1.00=perfect health and negative
scores represent states of health considered worse than being dead. Responses were
collected from patients and their proxies.
Results: An initial cohort of 40 patients decreased to 37 and 25 at T2 and T3
respectively, though only one death occurred during the study period. Overall HRQL,
derived from the responses of patients, showed a progressive and clinically important
size decline over the decade. Median HRQL scores at T1, T2 and T3 respectively for
HUI2 were 0.93, 0.90 and 0.88; and for HUI3 were 0.88, 0.85 and 0.77. Cognition was
the attrubute compromised most often (T1=67%, T2=62% and T3=60%). Pain was
also reported frequently (T1=35%, T2=25% and T3=52%).
Conclusion: Decreased HRQL in survivors of brain tumours in childhood is
multifaceted. Cognitive deficits and pain are prominent problems. Pain represents an
unexpected burden of morbidity. Further studies should be undertaken to explore
problems with pain and potential therapeutic intervention.
PD-032
ECONOMIC INDEPENDENCE IN ADULTHOOD AMONG SURVIVORS OF
CANCER IN YOUNG AGE
M. Gunnes1, D. Moster1, R.T. Lie1, T. Bjørge1, S. Ghaderi2, E. Ruud3, F. Wesenberg4,
A. Syse5
1University of Bergen, Department of Global Public Health and Primary Care, Bergen,
Norway; 2Norwegian Institute of Public Health, Norwegian Institute of Public Health,
Bergen, Norway; 3Oslo University Hospital Rikshospitalet, Department of Pediatric
Medicine, Oslo, Norway; 4Cencer Registry of Norway, Cancer Registry of Norway, Oslo,
Norway; 5Statistics Norway, Department of Research, Oslo, Norway
Background/Objectives: Several studies demonstrate that survivors of cancer in young
age have a variety of long term challenges, both medical and social. We wanted to study
whether a cancer diagnosis in young age affected future earnings and need for
short-term financial assistance from the government.
Design/Methods: By linking national registries (the Norwegian Cancer Registry, the
Central Population Registry, the Medical Birth Registry, the Norwegian Labour and
Welfare Administration and Statistics Norway) we defined a cohort of all live births in
Norway from 1965-1985 followed up through 2007. The cancer group and the
non-cancer group were compared using logistic regression models for outcomes of
high- and low-income (defined as 80th- and 20th income percentile (sex specific) per year
of birth), as well as need for financial assistance.
Results: After excluding individuals with a disability pension and those who died or
emigrated, our final cohort consisted of 1,054,375 individuals, of whom 3,617 had been
diagnosed with cancer before the age of 25. Men surviving a cancer diagnosis in young
age had no altered likelihood of being in either the high income, OR=0.92 (95% CI
0.82-1.03), or the low income, OR=1.09 (0.98-1.2), category. For women in the cancer
group, there was a 25% increased risk of being in the low income category, OR=1.25
(1.11-1.41), and no altered risk for being in the high income category, OR=0.95
(0.83-1.08), compared with the non-cancer group. Men with cancer had a reduced risk
of receiving financial assistance from the government, OR=0.87 (0.79-0.96), whereas
there were no differences for women with cancer, OR=1.00 (0.90-1.12), compared with
the non-cancer group.
Conclusion: In this population-based cohort, we demonstrated an economic
disadvantage for women surviving cancer in young age, whereas no such association
was found for male cancer survivors.
PD-033
TREATMENT AND OUTCOMES OF RADIATION INDUCEDMENINGIOMAS
(RIM) FOR CHILDHOOD CANCER SURVIVORS RECEIVING CRANIAL
IRRADIATION
N. Logie1, C. Corriveau-Bourque2, M. Disciglio2, S. Ghosh3, F. van Lendeghem4,
M. Spavor2, S. Chafe1
1Cross Cancer Institute, Radiation Oncology, Edmonton, Canada; 2Stollery Children’s
Hospital, Pediatric Oncology, Edmonton, Canada; 3Cross Cancer Institute, Statistics,
Edmonton, Canada; 4University of Alberta Hospital, Neuropathology, Edmonton,
Canada
Background/Objectives: Secondary meningiomas after the treatment of central nervous
system (CNS) with radiotherapy (RT) are serious complications and therapeutic
strategies are complex. We reviewed our institutional experience of treatment and
outcomes for patients with RIM.
Design/Methods: A review of all patients followed in the Childhood Cancer Survivor
Program showed 17 patients developed RIM after cranial irradiation for non-CNS
tumors. We reviewed demographics, histology, tumor location, treatment, latency
interval, time to first intervention and time to subsequent interventions.
Results: Of 17 patients diagnosed with RIM, 58.8% were female. All patients received 
20 Gy PCI and systemic chemotherapy and 88.2% received intrathecal methotrexate.
Demographics revealed that RIM was solitary in 58.8% and multiple in 41.2%.The
meningiomas were WHO grade 1 in 73.3% and 26.7% grade 2, skull base in 35.3%,
35.3% convexity, 17.6% parasagittal and 11.8% multiple locations. Median latency to
development of RIM was 25.6 yrs (95%CI=20.5-27.6yrs). Sixteen patients had
symptoms prior to diagnosis; headache in 88.2% and cranial nerve deficits in 35.3%.
Fifteen patients had surgery, 46.7% gross total resection (GTR) of all lesions, 33.3%
GTR of some lesions, and 20.0% with subtotal resection (STR) and 2 patients had no
intervention. Median time to first intervention was 25.6 yrs (95%CI=19.2-27.8yrs). Ten
patients (58.8%) required further intervention with median time to second intervention
was 2.7 yrs (95%CI=1.0-5.8yrs). All patients with STR recurred. Eight patients received
further surgical resection and 2 patients were treated with RT alone. Four patients had
further progressive disease.
Conclusion: RIM is a significant complication for pediatric patients receiving cranial
irradiation. Multiple interventions were required in 58.8% patients. RIM reviewed had
a higher proportion of being multiple, grade 2, and skull base than seen in the literature
for spontaneous meningiomas. These factors may impact treatment of RIM, although
further study is required.
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PROSPECTIVE ANALYSIS OF LONG-TERM RENAL FUNCTION IN
SURVIVORS OF CHILDHOODWILMS TUMOR (NEPHROBLASTOMA)
M. Neu1, A. Russo1, A. Wingerter1, F. Alt1, J. Theruvath1, B. Kron1, M. Dittrich1,
J. Lotz2, P. Gutjahr1, R. Stein3, J. Faber1
1University Medical Center of the Johannes Gutenberg University Mainz, Pediatric
Hematology/ Oncology/ Hemostaseology, Mainz, Germany; 2University Medical Center
of the Johannes Gutenberg University Mainz, Institute of Clinical Chemistry and
Laboratory Medicine, Mainz, Germany; 3University Medical Center of the Johannes
Gutenberg University Mainz, Department of Urology and Pediatric Urology, Mainz,
Germany
Background/Objectives:Wilms tumor (WT) is the most common renal malignoma in
childhood. Considering improved outcome, a better understanding of late effects in
WT survivors (WT-S) is needed. The aim of this study was to evaluate renal function
and to determine the prevalence of subclinical renal impairment in a cohort of WT-S
using a clinical, sonographic and biomarker approach.
Design/Methods: Fourty-nine former WT-S were enrolled in this prospective single
center study. Glomerular filtration rate (GFR) was measured by creatinine clearance
and estimated using creatinine-based and Cystatin-C-based approximations. In
addition, urinary excretion of total protein, albumin, α1-microglobulin and neutrophil
gelatinase-associated lipocalin (NGAL) were assessed. Clinical examination included
kidney sonomorphology and blood pressure measurement.
Results: All examined WT-S (mean age 23.8 years, range 1.68-48.8 years; mean
follow-up 18.3 years) were treated with a combination of surgery (total/partial
nephrectomy) and chemotherapy; 57% received adjuvant radiotherapy. A creatinine
clearance below age norm was detected in 32% of WT-S. Moreover, applying
age-adjusted Cystatin-C-based GFR-estimation, a GFR below age norm was identified
in 56% of the WT-S studied. In 7 patients with low GRF, glomerular selective
proteinuria (micro- or macroalbuminuria) was identified. Pathological urinary NGAL
excretion as a marker of renal tubulary dysfunction was detected in 13%. Ultrasound
revealed a compensatory contralateral renal hypertrophy > 95th percentile in 81% of the
patients. Fifteen (31%) WT-S presented with hypertension and 6 (12%) with
high-normal blood pressure (according to WHO definition).
Conclusion: Even though it is believed that WT-S have a low risk for end stage renal
disease, in this study a remarkable part of former WT-S presents with previously
unidentified subclinical signs of renal function impairment and secondary morbidity
with no ceiling of the cumulative incidence after WT-therapy over time. Further studies
are needed to define optimal long-term follow-up of WT-S, especially with regard to
subclinical disease and risk stratification.
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SKELETAL LATE EFFECTS IN CHILDHOOD CANCER SURVIVORS
T. Oskarsson1, R. Niinimäki2, A. Harila-Saari3, J. Winther4, J. Olsen4, H. Hasle5,
H. Anderson6, L. Tryggvadottir7, S. Montgomery8, M. Heyman9
1Karolinska University Hospital, Stockholm, Sweden; 2Oulu University Hospital, Clinic
for Children and Adolescents, Oulu, Finland; 3Karolinska University Hospital,
Department of Pediatric Oncology, Stockholm, Sweden; 4Danish Cancer Society
Research Center, Survivorship Unit, Copenhagen, Denmark; 5Aarhus University,
Department of Clinical Medicine - The Department of Paediatrics, Aarhus, Denmark;
6Lund University, Cancer Epidemiology, Lund, Sweden; 7Icelandic Cancer Registry,
Icelandic Cancer Registry, Reykjavik, Iceland; 8Karolinska Institute, Department of
Medicine, Stockholm, Sweden; 9Childhood Cancer Research Unit-Karolinska Institute,
Department of Women´s and Children´s Health, Stockholm, Sweden
Background/Objectives: A significant number of childhood cancer survivors develop
treatment related health problems that manifest early to years after completion of
cancer treatment. The purpose of this study was to assess the risk and spectrum of
skeletal late effects in childhood cancer survivors.
Design/Methods: A cohort of 19.970 one-year cancer survivors diagnosed before 20
year of age was identified in the national cancer registries of Denmark, Iceland and
Sweden and a cohort of 123.680 population controls was selected from the respective
national population registries. By linking study participants to national hospital
registries the observed numbers of first-time hospital contacts for acquired skeletal
disorders were compared with the expected numbers in the population cohort.
Standardized hospitalization rate ratios (SHRRs) and absolute excess risks per 100.000
person-years (AERs) were calculated from the observed and expected numbers among
the study participants.
Results: In total, 1457 childhood cancer survivors (7.3%) were diagnosed with skeletal
disorders, yielding a SHRR of 1.30 (95% CI, 1.23-1.37) and an overall AER of 114
(88-141). We observed an increased risk among the survivors for osteonecrosis SHRR
14.6 (8.9-24.3), osteoporosis 3.6 (2.5-5.2), osteochondropathies 1.6 (1.2-2.0),
osteoarthritis 1.3 (1.1-1.6) and fractures 1.2 (1.16-1.31), especially osteoporotic
fractures 1.5 (1.4-1.7). The risk and pattern of skeletal disorders varied between
different cancer groups and age groups but the increased risk continued throughout life.
Conclusion: Childhood cancer survivors have a lifelong increased risk of skeletal
disorders. To decrease the burden of late effects in childhood cancer survivors,
assessment of skeletal health is important both during treatment and in the long-term
follow-up.
PD-036
CHILDHOOD CANCER SURVIVORSHIP CLINIC ATTENDANCE IN A
REGIONAL SAMPLE: PATTERNS AND PREDICTORS
D. Zheng1, K. Sint2, H.R. Mitchell1, N. Kadan-Lottick1,3
1Yale University School of Medicine, Pediatric Hematology-Oncology, New Haven,
USA; 2Yale University, Department of Biostatistics, New Haven, USA; 3Yale Cancer
Center, Pediatric Hematology-Oncology, New Haven, USA
Background/Objectives: Even when specialty survivorship clinics are available, many
childhood cancer survivors do not receive recommended surveillance for late effects of
treatment. We sought to characterize clinic attendance in a regional sample and identify
predictive factors.
Design/Methods: Using the Connecticut Tumor Registry and Yale hospital records, we
identified all patients diagnosed with cancer at age 18 years from 3/1/1998-3/1/2008,
still in follow-up 5 years post-diagnosis, and living <100 miles from Yale. Survivorship
clinic attendance, demographics, disease characteristics, and treatment exposures were
ascertained from medical records. Vital status was confirmed using the National Death
Index. Kaplan-Meier curves and hazard ratios were calculated for survivorship clinic
attendance; patients were censored upon attending clinic, death, or 3/1/2013.
Results: 489 eligible survivors were diagnosed at a mean age of 9.1±5.8 years with
leukemias/lymphomas (47.2%), brain tumors (16.4%), sarcomas (11.2%), thyroid
cancers or melanomas (7.8%), other solid tumors (17.4%). The Kaplan-Meier estimated
5- and 10-year post-diagnosis clinic attendance probabilities were 27.8% (SE=2.3%)
and 35.5% (SE=3.1%) respectively. The attendance probabilities were 36.9%
(SE=4.4%) after radiation and 40.8% (SE=3.8%) after anthracycline therapy at five
years. After adjusting for age at diagnosis, gender, and insurance, patients treated with
anthracyclines (HR=3.047;p<0.0001) and radiation (HR=1.902;p=0.0004) were
significantly more likely to attend clinic. Patients with a history of brain tumors
(HR=0.298 compared to leukemia; p=0.0008), surgery without radiation or
chemotherapy (HR=0.023 compared to chemotherapy only; p=0.0002), no insurance
(HR=0.345;p<0.0001), and no primary care physician (HR=0.060;p<0.0001) were
significantly less likely to attend clinic. Income, travel time to clinic, clinical trial
enrollment, and race were not significant predictors.
Conclusion: The majority of childhood cancer survivors in our regional sample,
including high-risk groups who received radiation or anthracyclines, had not attended
survivorship clinic. Factors related to health care access, including having a primary
care physician and insurance, were important predictors of clinic attendance.
Poster Discussion: Liver Tumours
PD-037
GENOME-WIDE ANALYSIS OF DNAMETHYLATION IN
HEPATOBLASTOMA TISSUES
X. Cui1, B. Liu1, S. Zheng1, R. Dong1, K. Dong1
1Children’s Hospital of Fudan University, Pediatric Surgery, Shanghai, China
Background/Objectives: DNA methylation has a crucial role in cancer biology. We
performed a genome-wide analysis of DNA methylation in hepatoblastoma (HB)
tissues to verify differential methylation levels between HB and normal tissues. As
alpha-fetoprotein (AFP) has a critical role in HB, we also detected AFP methylation
levels, using pyrosequencing.
Design/Methods: Normal and HB liver tissue samples were obtained from patients with
HB. Genome-wide analysis of DNA methylation in these tissues was performed using
an Infinium HumanMethylation 450 BeadChip, and results confirmed with quantitative
RT-PCR (q-PCR).
Results: The Infinium HumanMethylation 450 BeadChip showed distinctively less
methylation in HB tissues than in non-tumor tissues. We also found methylation
enrichment in positions near the transcription start site of AFP, which exhibited lower
methylation levels in HB tissue than in non-tumor liver tissues. Lastly, we found a
significant negative correlation between AFP mRNA expression and DNA methylation
percentage, using linear Pearson’s R correlation coefficients.
Conclusion: Our results demonstrate differential methylation levels between HB and
normal tissues, and imply that aberrant methylation of AFP in HB could reflect HB
development. Expansion of these findings could provide useful insight into HB biology.
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THE ANALYSIS OF THE FACTORS AFFECTING THE RESULT OF THE
HEPATOBLASTOMA TREATMENT IN CHINA - ONE SINGLE CENTER
EXPERIENCE
K. Dong1, G. Liu2, K. Li2, X. Xiao2, Z. Shan2
1Children’s Hospital of Fudan University, Shanghai, China; 2Children’s Hospital of
Fudan University, Surgery, Shanghai, China
Background/Objectives: The mortality of hepatoblastoma remains worse in developing
country. This study aims to introduce the experience and outcome of hepatoblastoma
at a local children’s medical center in China.
Design/Methods: The study was a retrospective analysis of 98 children with
hepatoblastoma between January 2006 and December 2014 in one center. The standard
treatment of hepatoblastoma is composed of PLADO or C5V chemotherapy and
surgery. Patients who were not sensitive to primary regimen, the other regimen could be
changed to alternatively.
Results: Two-year/5-year overall survival (OS) of this study was 68.8%/65.7%,
respectively, while patients with PRETEXT stage IIII were 83.3%/83.3%,
100%/92.9%, 68.8%/66.1%, respectively. The 3-year OS of stage IV was 10.3%. 18
patients (23.1%) recurrenced after surgery. PRETEXT III/IV, vascular invasion and
resection margin <5mm are three high risk factors of recurrence with univariate
analysis (P<.05). Age >5 years old, vasulcar invasion, tumors resection, PRETEXT
stage are four prognostic factors of survival with univariate analysis (P<.05). Tumor
resection is the only one prognostic factors with multivariate analysis (p<.001,
HR=0.049, 95%Cl (0.013, 0.175).
Conclusion: Surgery plays the central role of the treatment. The survival of stage IV and
unresectable tumor with stage III is lower than those reported in developed country.
The restriction of liver transplantation is the main reason for this difference. Although
PLADO and C5V had similar efficiency, when patients who were not sensitive to one
regimen, the other regimen is could be effective.
PD-039
MICELLAR CURCUMIN EFFECTIVELY REDUCES AFP AND TUMOR
GROWTH IN AN ORTHOTOPIC MURINE MODEL OF PEDIATRIC
HEPATOCELLULAR CARCINOMA
V. Ellerkamp1, N. Bortel1, S. Armeanu1, E. Schmid1, J. Frank2, A. Kocher2,
C. Schiborr2, S. Warmann1, J. Fuchs1
1University Hospital Tuebingen, Pediatric Surgery and Pediatric Urology, Tuebingen,
Germany; 2Universitiy of Hohenheim, Biofunctionality and Safety of Food, Hohenheim,
Germany
Background/Objectives: In children with hepatocellular carcinoma (pHCC) the 5-year
overall survival rate is poor. Effects of cytostatic therapies such as cisplatin (CDDP)
and doxorubicin are limited due to chemoresistance and tumor relapse. In adult HCC
several antitumor properties are described in in vitro models for the use of curcumin.
Curcumin is one of the best investigated phytochemicals in complementary oncology
without relevant side effects, but its use is limited by the low bioavailability.
Design/Methods: Orthotopic growth of the pediatric hepatocellular carcinoma cell line
HC-AWF1 in NOD/LtSz-scid/IL-2Rgamma(null)mice was induced by intrasplenic cell
injection and splenectomy. By the increase serum alpha fetoprotein AFP >5 U/mL mice
were randomly assigned to one of four groups: control (no treatment); curcumin
(micellar curcumin, 60 mg/Kg body weight 3 weeks); Cisplatin (CDDP, 1 mg/Kg
bodyweight on days 1 and 2), and micellar curcumin + CDDP (combination therapy
CDDP + curcumin micelles). Curcuminoid levels in serum and organ lysates as well as
AFP serum levels were investigated.
Results: Tumor uptake was 91.5%. Serum curcumin decreased from 3514 ± 2792
nmol/L two hours after administration to 770 ± 449 nmol/L after five hours. Curcumin
concentrations significantly differed between organs (p=0.000) and the highest
concentrations were observed in the lungs 11.33 ± 9.17 nmol/Kg and the lowest in the
brain 0.16 ± 0.24 nmol/Kg. The concentrations in the tumor tissue (2.57 ± 1.49
nmol/Kg) were higher than in the liver (1.77 ± 1.50 nmol/Kg). The combination
therapy (micellar curcumin + CDDP) significantly reduced AFP concentrations
compared to control group (week 3: 1.04 ± 0.67 vs. 2.73 ± 0.64, p = 0.004; week 4: 2.05
± 1.01 vs. 3.35 ± 0.43, respectively, p = 0.02).
Conclusion: These data prove the potential of micellar curcumin as a complementary
agent in pediatric oncology to enhance the overall survival of patients with pediatric
liver tumors.
PD-040
LOW EXPRESSION OF N-MYC DOWNSTREAM-REGULATED GENE 2
(NDRG2) CORRELATES WITH POOR PROGNOSIS IN HEPATOBLASTOMA
J. Goedeke1,2, E. Luxenburger2, F. Trippel2, K. Becker2, B. Häberle2, J. Müller-Höcker3,
D. von Schweinitz2, R. Kappler2
1University Medical Center Mainz, Pediatric Surgery, Mainz, Germany; 2Dr. von Hauner
Children´s Hospital-Ludwig-Maximilians-University Munich, Pediatric Surgery, Munich,
Germany; 3Ludwig-Maximilians-University Munich, Institute of Pathology, Munich,
Germany
Background/Objectives: Besides mutation of the beta-catenin gene epigenetic alterations
are heavily discussed to play a major role in the development of hepatoblastoma (HB).
Here, we investigated whether epigenetic silencing of the N-myc downstream-regulated
gene 2 (NDRG2) may contribute to HB development.
Design/Methods: The methylation status and mRNA expression level of 38 human HB
and normal liver tissue samples was evaluated by pyrosequencing and real-time PCR,
respectively. Subsequently, we analyzed whether NDRG2 promoter methylation and
expression are clinically relevant by correlating the molecular findings with clinical data
obtained from the German Liver Tumor Registry.
Results: Downregulation of NDRG2 is a common event in HB (28/38 cases) and
NDRG2 transcription is potentially down-regulated through promoter
hypermethylation. NDRG2 expression was significantly lower in patients with
metastatic disease and NDRG2 downregulation significantly correlated with poor
prognosis.
Conclusion: Our findings suggest that NDRG2 expression may be an important factor
for maintenance of normal condition of infantile liver tissue. Its epigenetic silencing
could contribute to HB formation and its downregulation might be used as a marker
for poor prognosis.
PD-041
CONGENITAL HEPATOBLASTOMA IN JPLT-2 STUDY
K. Watanabe1, T. Hishiki2, K. Ida3, T. Oue4, M. Yano5, K. Hoshino6, T. Iehara7,
K. Koh8, Y. Tanaka9, E. Hiyama10
1Shizuoka Children’s Hospital, Department of Hematology and Oncology, Shizuoka,
Japan; 2Chiba Children’s Hospital, Department of Pediatric Surgery, Chiba, Japan;
3Teikyo University Mizonokuchi Hospital, Department of Pediatrics, Kawasaki, Japan;
4Hyogo College of Medicine, Department of Pediatric Surgery, Nishinomiya, Japan;
5Akita University, Department of Pediatrics, Akita, Japan; 6Keio University, Department
of Pediatric Surgery, Tokyo, Japan; 7Kyoto Prefectural University of Medicine,
Department of Pediatrics, Kyoto, Japan; 8Saitama Children’s Medical Center,
Department of Hematology/Oncology, Saitama, Japan; 9Kanagawa Children’s Medical
Center, Clinical Research Institute and Department of Pathology, Yokohama, Japan;
10Hiroshima University Hospital, Department of Pediatric Surgery, Hiroshima, Japan
Background/Objectives: Congenital hepatoblastoma was previously thought to have
poor prognosis and different characteristics compared to hepatoblastoma in children
beyond neonatal period. However, recent reports demonstrated it could have similar
prognosis by standard therapeutic strategy consisted of hepatectomy and
chemotherapy.
Design/Methods:We analyzed the clinical characteristics and outcome of the neonatal
patients with hepatoblastoma enrolled to a protocol of the Japanese Study Group for
Pediatric Liver Tumor, JPLT-2 study, which enrolled a total of 279 children with
malignant liver tumors. In this study, primary chemotherapy consisted of cisplatin and
pirarubicin (CITA), and for unresectable or unresponsive disease, the combination of
ifosphamide, pirarubicin, etoposide, and carboplatin (ITEC) was used.
Results: Seven (2.5%) developed hepatoblastoma in the neonatal period (6 males, 1
females). All patients were born with normal birth weight and no associated congenital
abnormalities. Tumors were classified as PRETEXT II (5), III (2). All had no metastatic
disease. The median α-fetoprotein level was 462,700 ng/ml (range, 182,490 to 1,390,000
ng/ml). Two of the three patients who underwent primary resection received adjuvant
chemotherapy. Four patients underwent partial hepatectomy after neoadjuvant
chemotherapy followed by postoperative chemotherapy. In all patients who received
chemotherapy, it consisted of cisplatin and pirarubicin (CITA) with 30 to 50% dose
reduction. No patients received the salvage regimen ITEC. Grade 3 to 4 neutropenia
was documented in three patients, and cardiac dysfunction (ejection fraction 60%)
occurred in one patient. One patient who underwent primary resection without
adjuvant chemotherapy had metastatic recurrence in the lungs after five months from
diagnosis and died after brain metastasis. All other patients were alive without evidence
of disease with median follow-up of 36 months (range, 14 to 159 months).
Conclusion: Congenital hepatoblastoma could be successfully treated by surgical
resection and standard cisplatin-based chemotherapy with dose reduction.
Poster Discussion: Lymphomas & Histiocytosis
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RESULTS OF TREATMENT OF LYMPHOBLASTIC LYMPHOMA AT THE
CHILDREN CANCER HOSPITAL EGYPT- A SINGLE CENTER EXPERIENCE
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H. Abdel Rahman1, M. Sedky2, A. Hamoda3, N. El Kinaai4, M. El Wakeel5, D. Hesham6
1Cairo, Egypt; 2National Research Centre, Pediatric, Egypt; 3National Cancer Institute,
Cairo University, PediatricOncology, Cairo, Egypt; 4National Cancer Institute, Cairo
University, Pathology, Cairo, Egypt; 5National Cancer Institute, Radiodiagnosis, Cairo,
Egypt; 6Children Cancer Hospital Egypt, Clinical Research, Cairo, Egypt
Background/Objectives: Lymphoblastic lymphoma (LL) and acute lymphoblastic
leukemia (ALL) and are neoplasms of immature B or T-cell precursors. They are
considered as a unique biological entity in the 2008 World Health Organization
Classification of Hematologic Neoplasm. Treatment of LL has evolved over time from
conventional high-grade NHL schedules to ALL- derived protocols. The aim of this
work is to estimate the EFS, OS, and common chemotherapy toxicities of LL patients
treated at the Children Cancer Hospital Egypt during 5.5 years period.
Design/Methods: A Retrospective review of patients charts diagnosed and treated as LL
during the period between July 2007 till end of December 2012 was done. Patients were
treated according to St. Jude Children Research Hospital ALL Total Therapy XV
protocol, standard risk arm.
Results: This study included 77 patients. T- cell LL patients were 87%, while and B-cell
were 13%. The median age was 9 years (range 1–17 years). The majority were males
(70.1%). Stage III was the most common at presentation (74%). Complete remission
post induction chemotherapy was seen in 25.3% of the patients, partial remission in
72%. Progressive disease was the event in 6.6%, while 5.3% suffered from a disease
recurrence. The most common chemotherapy toxicities were cerebral venous
thrombosis (20%), followed by bone infarcts ((10.6%), and avascular necrosis of head
of femur (9.3%). Disease recurrence was local in 4% and systemic in 5% of the patients.
By the end of the study, 84% of the patients were alive in CR, 16% were dead. Mean
duration of follow up was 48.6 months (range 1-89 months). The 4 years overall
survival was 82.7% while event free survival was 82.2%.
Conclusion: Disease progression and chemotherapy related toxicity are the main causes
of death in pediatric LL patients. While cerebral vascular thrombosis and steroids
induced musculoskletal complications are the major chemotherapeutic adverse events.
PD-043
CHANGE TO OEPA/COPDAC AND PET-CT BASED STRATEGY FROM
FORMER ABVD/COPP FOR TREATING HODGKIN LYMPHOMA: LESSONS
LEARNT FROM CHANDIGARH, INDIA
S. Mohapatra1, D. Bansal1, A. Trehan1, B.R. Mittal2, A. Bhattacharya2, R. Kapoor3,
R. Srinivasan4, A. Rajwanshi4, N. Kakkar5, A. Das5
1Advanced Pediatric Centre, Postgraduate Institute of Medical Education and Research,
Hematology-Oncology Unit-Department of Pediatrics, Chandigarh, India; 2Postgraduate
Institute of Medical Education and Research, Department of Nuclear Medicine,
Chandigarh, India; 3Postgraduate Institute of Medical Education and Research,
Department of Radiotherapy, Chandigarh, India; 4Postgraduate Institute of Medical
Education and Research, Department of Cytology, Chandigarh, India; 5Postgraduate
Institute of Medical Education and Research, Department of Histopathology,
Chandigarh, India
Background/Objectives: Reduced anthracycline/alkylating-agent, non-bleomycin and
PET-CT response based protocols are being evaluated to reduce long-term toxicity in
Hodgkin lymphoma (HL). Aim was to analyze short-term outcome of patients with
HL treated with Euronet-PHL-C1 based strategy as ‘off-study’ from 2010-14. A
comparison was performed with institute’s earlier published study using chemotherapy
(ABVD, ABVD/COPP/MOPP) alone, non-radiotherapy, non-PET based approach. In
the older strategy, the mean number of cycles administered in early and late-stage were
5 and 6.5, respectively.
Design/Methods: Retrospective study.
Results: Forty-nine patients were treated. The mean age was 7.7±2.4 years (range:
2-12). The number of patients in TG-1, 2 and 3 were 18, 15 and 16, respectively. A
PET-CT was performed at diagnosis and following OEPA-2. Two/four courses of
COPDAC were administered in treatment-groups (TG) 2/3, respectively. Radiotherapy
was indicated for inadequate PET-response. The mean duration of follow-up was
25.6±14 months (range: 0.3-52). An inadequate PET-response was observed in 23
(46.9%) patients. Radiotherapy was administered to 8. Radiotherapy was ‘replaced’ by
2 courses of COPDAC in 9 patients, due to physician preference. In the remaining 6
patients, radiotherapy or additional chemotherapy was not administered due to
misinterpretation of PET.There were 17 episodes of febrile neutropenia: 2 (4%) patients
died. Two patients relapsed. One had progressive disease and another had
secondary-AML. The 4-year-EFS and OS were 86.4% and 95.9%, respectively. It is
comparable to the 5-year-EFS (77.7%) and OS (92.7%) of the institute’s previous study.
The 4-year-EFS in TG-1, 2 and 3 was 88.9%, 100% and 72.7%, respectively. The
relatively lower EFS in TG-3 was probably contributed in part by misinterpretation of
PET in the early period of the study.
Conclusion: Chemotherapy with OEPA/COPDAC and decision for radiotherapy based
on re-evaluation PET-CT, permits reduction of therapy with excellent short-term
outcome. Efforts should be made to adopt risk-stratification and response based
therapy in developing countries as well.
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ANTHRACYCLINE-BASED THERAPY AMONG CHILDRENWITH ENDEMIC
BURKITT LYMPHOMA IN LILONGWE, MALAWI
B. Heimlich1, C. Stanley1, N. El-Mallawany2, I. Mtete3, M. Butia3, B. Kaimila1,
S. Itimu1, M. Chikasema1, F. Chimzimu1, C. Kampani1, S. Mzumara4,
N.D. Montgomery5, Y. Fedoriw5, P.N. Kazembe3, B.M. Dhungel4, R. Krysiak1,
N.G. Liomba1, S. Gopal1
1University of North Carolina-Chapel Hill, UNC Project Malawi, Lilongwe, Malawi;
2New York Medical College, Pediatric Hematology Oncology, Valhalla, USA; 3Baylor
College of Medicine, Children’s Foundation Malawi, Lilongwe, Malawi; 4Kamuzu
Central Hospital, Department of Radiology, Lilongwe, Malawi; 5University of North
Carolina-Chapel Hill, Department of Pathology and Laboratory Medicine, Chapel Hill,
USA
Background/Objectives: Endemic Burkitt lymphoma (eBL) is highly curable in
resource-rich settings with anthracycline-based chemotherapy, but such approaches
have not been widely adopted in sub-Saharan Africa (SSA) due to toxicity concerns.
Design/Methods:We describe children 18 years with eBL enrolled June
2013-December 2014 in a prospective observational cohort. Due to frequent relapses
historically with less intense regimens, children were uniformly treated during this
period with an institutional protocol involving COP prephase followed by CHOP for 6
cycles as tolerated. Patient monitoring and supportive care were standardized. We
summarize treatment course and toxicities for this approach.
Results: Sixty-two children with eBL [median age 8.6 years, 41 (67%) male, 46 (74%)
stage III/IV] received first-line CHOP. As of December 31, 2014, 24 (40%) were alive
after completing treatment, 8 (13%) were alive while receiving CHOP, 29 (47%) had
died, and one patient was lost to follow-up. Median follow-up was 10.8 months among
children still alive. For the cohort overall, median absolute neutrophil count remained
>1.5 × 109/L, absolute lymphocyte count >1.5 × 109/L, hemoglobin >8 g/dL, and
platelets >300 × 109/L throughout treatment. Excluding 8 children still receiving
first-line CHOP at censoring, significant neutropenia occurred in 11/54 (20%, 7 grade 3,
4 grade 4) and anemia in 25/54 (44%, 21 grade 3, 4 grade 4). Chemotherapy delay >7
days occurred in 33/54 children (61%) mostly due to incomplete blood count recovery
prior to scheduled treatment. Of 29 deaths, 15 were attributed to disease, 10 to
treatment, and 4 to unknown causes.
Conclusion: CHOP for predominantly advanced-stage eBL in Lilongwe resulted in
overall similar outcomes compared to historical experience using less intensive
regimens. CHOP may be appropriate for some children, and many deaths were from
disease rather than therapy. Better risk-adapted, response-guided strategies can help
optimize treatment for individual children with eBL in SSA.
PD-045
PRIMARY BONE LYMPHOMAS IN HIV- INFECTED CHILDREN
G. Naidu1, R. Wainwright2, S. Poyiadjis2, D. MacKinnon2, B. Rowe2
1University of the Witwatersrand and Chris Hani Baragwanath Academic Hospital,
Johannesburg, South Africa; 2University of the Witwatersrand and Chris Hani
Baragwanath Academic Hospital, Pediatric Oncology, Johannesburg, South Africa
Background/Objectives: Background Diffuse Large B- Cell and Burkitts Lymphoma
which account for 90% of lymphomas in the HIV- infected patient are aggressive
cancers with a high morbidity and mortality. Primary Bone Lymphoma (PBL) is a rare
disease and accounts for 3-5% of all pediatric lymphomas.
Design/Methods: This is a retrospective review of the presentation, results, treatment
and outcome of four HIV-infected children who presented with PBL.
Results: There were two males and the mean age was 11.5 years. All presented with
lymphadenopathy, one had scalp lumps, one had a mass in the left hip and one had a
swelling of the left face. All were stunted and wasted with HFA and WFA between -2
and -3 SD. The laboratory investigations: a mean Hb= 10.8g/dl, WCC= 5.2 × 109/l,
PLT= 446 × 109/l and LDH=639 u/L. The mean CD4 number was 364 × 106/l and the
CD4% was 13.4%. None had metastatic disease to the bone marrow or CSF, but
radiology and bone scans revealed extensive bulky disease. The immunophenotypic
analysis: two CD20+, CD79a +, BCL2 +, BCL6 +, MMI +; and one CD10 +, all
strongly positive for K167, negative for TdT and CD3. All were stage 3, risk group 4
and treated with the NHL-BFM 1998 protocol and ARVs. All four patients completed
therapy successfully.
Conclusion: PBL is a rare tumour. NHL in the HIV-infected, ARV naïve group of
patients is associated with a high morbidity and mortality due to disease progression,
relapsed disease, infectious complications and poor compliance. We describe a group of
ARV naive patients with advanced disease with a good outcome. The numbers are
limited to draw conclusions, but may represent a group of patients in whom we could
dose-reduce treatment to minimise chemotherapy related toxicity.
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SUPERIOR OUTCOMES AT A LOWER COSTWITH COG BASED PROTOCOL
FOR ANAPLASTIC LARGE CELL LYMPHOMA: EXPERIENCE FROM INDIA
S. Ramachandrakurup1, D. Boddu2, R. Raj3, Uppuluri4, Doss5, Mathew2
1Apollo Speciality Hospital, Chennai, India; 2Christian Medical Mollege, Haematology,
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Background/Objectives: Anaplastic large cell lymphoma has excellent treatment
outcomes in children. We discuss the treatment outcome in resource limited setting,
using BFM and COG based protocols.
Design/Methods: This is a retrospective descriptive study in patients diagnosed to have
Anaplastic large cell lymphoma treated with BFM protocol or COG protocol between
2002 and 2014 in two cancer centres.
Results: Out of a total of 30 patients, 19 patients received treatment as per BFM –NHL
90 protocol .The mean age was 8.7 years (range 1.5 to 16 years). Patients in high risk
group 70%, standard risk 26% and 4% were in low risk group. Thirteen patients are in
complete remission, three died of infection during treatment, 3 had progressive disease
of which one achieved remission after second line treatment. The mean febrile
neutropenic episode in this group was 1.8 (ranged 0-5).Twenty six percentage of these
patients developed septicaemia. Severe mucositis and hospitalisation needed for 10% of
patients. Mean duration of follow up of those in CR is 25.4 months (range 3-56
months). Three (16%) patients had relapse with the mean time to relapse was 36.6
months. Eleven patients were treated with COG ALCL protocol with mean age
9.3(range 2to 16). Patients in high risk group 77% and 23% were standard risk. The
mean duration of follow up is 2.6 months (range 1- 4 months). There have been no
deaths and no documented relapses till date. No documented bacteraemia or severe
mucositis in this group.
Conclusion: Patients from developing countries fared better with a COG based protocol
for Anaplastic Large Cell Lymphoma. We would recommend this outpatient based
protocol including treatment over 15 months requiring less supportive care and
superior outcome due to lack of regimen related toxicity to all cancer centres in our
country based on our pilot study.
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EVENT FREE SURVIVAL OF PATIENTS WITHMULTISYSTEM-RISK
LANGERHANS CELL HISTIOCYTOSIS IS SUBOPTIMALWITH LCH-III
PROTOCOL: 8-YEARS CHANDIGARH, INDIA EXPERIENCE
S. Totadri1, D. Bansal1, A. Trehan1, R. Srinivasan2, N. Varma3, N. Kakkar4,
A.K. Saxena5, P. Bhatia1
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Background/Objectives: Langerhans cell histiocytosis (LCH) III trial recruited patients
worldwide from 2001-08. Experience with LCH-III, with patients enrolled as ‘off-study’
is presented from a pediatric oncology unit in India.
Design/Methods: Retrospective (2006-2013) chart review was performed. Patients in
group-1 (Multisystem-risk) received initial treatment of 6-12 weeks, followed by
continuation treatment to complete 12-months. Drugs included, vinblastine,
prednisolone and 6-MP. Patients in group-2 (Multisystem-low-risk) received similar
treatment, except 6-MP. Group-3 (Single-system/multifocal-bone-disease) patients were
treated for 6 months. An event was defined as relapse, progressive disease or death. No
patient received a liver or hematopoietic transplant due to limited accessibility.
Results: Forty-nine patients were diagnosed in the 8-year-period: 24 (49%), 14 (29%)
and 11 (22%) in Group 1, 2 and 3, respectively. The mean age was 31.6±28.4 months
(range: 4-120). Patients in Group-1 were younger (p=0.001). The median follow-up
duration was 25 months (range: 0.5-120). Five patients abandoned treatment. There
were 7 deaths (all in Group-1), at a median duration of 22 days (range: 14-213) from
treatment; from progressive disease (4), febrile neutropenia (2) or meningoencephalitis
(1). All patients who died had partial response or progressive disease following
induction (p<0.001). Disease relapsed in 12 (24.5%) patients, at a mean duration of
17.2±7.6 months. Incidence of relapse was similar in 3 groups (p=0.83).There was no
increase in deaths in patients with respiratory involvement (22.2% vs. 12.5%, p=0.45).
Sclerosing cholangitis was an independent predictor of mortality (OR: 85.8, p=0.01).
Five-year-EFS was 34.5±11.3%, 63.5±15% and 77.9±14.1% in groups 1, 2 and 3,
respectively (p=0.027). Five-year-OS was 68.9±9.8% and 100% in Group 1 and 2/3,
respectively (p=0.01).
Conclusion:Majority (49%) of patients presented with multisystem-risk disease. Partial
response and progressive disease is a major concern in patients with multisystem-risk
disease, resulting in a suboptimal five-year-EFS of 34.5±11.3%. The 5-year-OS of
patients with multisystem low-risk and multifocal bone disease is 100%.
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COMBINED BIOMODULATORY THERAPY TARGETING THE TUMORS´
BIOLOGY AS AN ALTERNATIVE TREATMENT IN CHEMOREFRACTORY
PAEDIATRIC MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS
K. Rehe1, A. Reichle2, J. Foell1, M. Jakob1, S. Corbacioglu1
1University Hospital Regensburg, Paediatric Haematology/Oncology, Regensburg,
Germany; 2University Hospital Regensburg, Department of Internal Medicine III,
Regensburg, Germany
Background/Objectives: Nearly half of the patients with systemic Langerhans´cell
histiocytosis (LCH) relapse, mostly within 2 years from diagnosis (Minkov et al, 2008).
For patients failing to achieve stable remission under conventional chemotherapy
according to the LCH III protocol we applied a multi-targeted therapeutic approach
simultaneously directed at tumor metabolism, inflammation, angiogenesis and immune
response.
Design/Methods: An 18 months old girl presented with LCH of the skin, bones and
spleen. She started on vinblastine and prednisone according to the LCH III protocol.
After recurrence of skin and bone lesions during treatment the relapse was treated with
vincristine, cytarabine and prednisone. Due to severe adverse effects the chemotherapy
was interrupted. An 11 months old boy presented with LCH of the skin, liver and small
bowels. He also was treated according to the LCH III protocol. With refractory disease
he received a salvage therapy with prednisolone, cytarabine and cladribine. In
maintenance therapy with indomethacin he again relapsed with multiple bone lesions.
As for increasing liver failure (cirrhosis) a third line conventional chemotherapy was
unfeasible.
Both patients were started on a metronomic biomodulatory therapy approach in
analogy to an adult melanoma trial, consisting of low dose trofosfamide, a PPAR
alpha/gamma agonist (pioglitazone), a COX-2 inhibitor (etoricoxib) and low-dose
dexamethasone.
Results: Both patients treated with a combined biomodulatory therapy in a
compassionate use approach responded to the treatment as determined clinically, by
MRI scans and biopsies and are still in stable remission after one and two years
respectively. So far the liver cirrhosis of the boy came to a halt.
Conclusion: A combination of anti-inflammatory and angiostatic drugs is a
well-tolerated and feasible treatment option for children with refractory systemic LCH.
Confirmation of efficacy should be evaluated prospectively in patients who fail to stably
respond to conventional therapy.
Poster Discussion: Myeloid Leukemias, Myelodysplastic & Myeloproliferative
Syndromes
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BENZENE EXPOSURE FROM A BP REFINERY FLARING INCIDENT
INCREASES THE RISK OF DEVELOPING HEMATOLOGICAL
MALIGNANCIES IN CHILDREN
M. D’Andrea1, G.K. Reddy2
1University Cancer and Diagnostic Centers, Houston, USA; 2University Cancer and
Diagnostic Centers, Radiation Oncology, Houston, USA
Background/Objectives: Benzene is a recognized environmental carcinogen and causes
serious adverse hematological effects. Especially, benzene exposure increases the risk of
developing lleukemias and lymphomas. Children are highly vulnerable to the toxic
effects of benzene exposure. The objective of this study was to evaluate the health
consequences of benzene exposure among children from a flaring incident that
occurred at the British petroleum (BP) refinery in Texas City, Texas, USA.
Design/Methods: The study included both children aged <17 years who had been
exposed and unexposed to benzene. Using medical charts, clinical data including white
blood cell (WBC) counts, platelets counts, hemoglobin, hematocrit, blood urea nitrogen
(BUN,) creatinine, alkaline phosphatase (ALP), aspartate amino transferase (AST), and
alanine amino transferase (ALT) were reviewed and analyzed.
Results: A total of 899 children (benzene exposed, n=641 and unexposed, n=258) were
included. Hematological analysis indicated that WBC (X 103 per μL) counts were
significantly decreased in the benzene exposed children compared with the unexposed
children (7.1±2.2 versus 7.6±2.1, P=0.001). Similarly, the mean hemoglobin (g/dL)
levels were decreased significantly in the benzene exposed group compared with the
unexposed group (12.7±1.3 versus 13.1±1.5, P=0.001). Conversely, platelet (X 103 per
μL) counts were increased significantly in the benzene exposed group compared with
the unexposed group (318.6 ± 79.8 versus 266.9 ± 58.8, P=0.001). Similarly, benzene
exposed children had significantly higher levels of ALP (264.6 ± 64.6 versus 192.1±55.1
IU/L, P=0.001), AST (28.2±9.5 versus 22.9±14.6 IU/L, P=0.001) and ALT (20.9±7.4
versus 16.2±6.5 IU/L, P=0.001) compared with the unexposed children.
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Conclusion: Children exposed to benzene had significant alterations in their
hematological and liver functions indicating that these children are at a higher risk of
developing both soft tissue and bone marrow related malignant disorders.
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EFFECT OF SEVEN ANTIFUNGAL AGENTS AGAINST CANDIDA SPP.
ISOLATED FROMORAL CAVITY OF PEDIATRIC PATIENTS WITH
LEUKEMIA
A. Dehghani Nazhvani1, P. Haddadi2, P. Badiee3
1Shiraz University of Medical Sciences, Oral & Maxillofacial Pathology, Shiraz, Iran;
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Center, Shiraz, Iran
Background/Objectives: Oropharyngeal candidiasis is a frequent problem in patients
with leukemia, associated with different clinical presentations including
pseudomembranous and erythematous forms. Nevertheless, azole antifungal drugs are
frequently prescribed for the treatment of these infections. The aim of this study was
the analysis of susceptibility pattern of Candida spp., isolated from oral cavity of
pediatric patients with leukemia, against seven antifungal agents.
Design/Methods: A total of 88 Candida strains were obtained from oral cavity of
pediatric patients with leukemia. Samples were plated on Sabouraud dextrose agar and
incubated at 24°C for 10 days. The identification of Candida strains was performed
using carbohydrate assimilation reactions on the API 20 C AUX system. Candida
parapsilosis ATCC 22019 was used as control. The minimum inhibitory concentrations
(MICs) against amphotericin B, fluconazole, ketoconazole, voriconazole, itraconazole,
caspofungin, and posaconazole were analyzed by E-test method.
Results: Among the Candida (C) strains, C. albicans (60%) was the most prevalent
Candida spp. followed by C. dubliniensis (6.8%), C. tropicalis (6.8%), C. krusei (6.8%),
C. parabsilosis (6.8%), Other Candida spp. (12.5%). Most of the patients had acute
leukemia including acute lymphoblastic leukemia and acute myeloid leukemia, and
underwent chemotherapy and/or hospitalizations. Many of patients had a history of
antifungal prophylaxis administration. Candida Krusei was the most resistant isolated
yeast, which was 40% resistant to fluconazole and 30% to itraconazole, 11% to
ketoconazole, and 1% to amphotericin B. All the tested species were mostly sensitive to
caspofungin.
Conclusion: Knowledge about the susceptibility patterns of Candida spp., colonized in
oral cavities of high risk patients can help more effective management and treatment of
the conditions. In this study, caspofungin and amphotericin B were revealed as the most
potent agents against the colonized Candida spp.
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DNMT3AMUTATION IN CHINESE CHILDHOOD ACUTEMYELOID
LEUKEMIA
W. Li1, Z. Li1, C. Gao1, L. Cui1, S. Li1, X. Zhao1, R. Zhang1, H. Zheng1, M. Wu1
1Beijing Children’s Hospital, Department of Hematology, Beijing, China
Background/Objectives: DNMT3A mutation has been found in approximately 20% of
adult AML patients and in 01.4% childhood AML. The prognosis of adult patients
with DNMT3A mutation is worse, however, the prognosis of DNMT3A mutation in
childhood AML is still dismal. Here, we tried to determine the incidence and prognostic
significance of DNMT3A mutation in Chinese childhood AML.
Design/Methods:We detected the mutation in DNMT3A exon 23 by PCR and direct
sequencing in 343 children with AML (range: 016 years old, M1:4, M2:143, M3:75,
M4:43, M5:33, M6:11, M7:30, unclassified: four patients) from January in 2005 to June
in 2013, treated on BCH-2003AML protocol. Details regarding the clinical
characteristics, fusion gene, and other molecular characteristics (FLT3-ITD, NPM1,
C-KIT andWT1) of the study cohort were analyzed.
Results: DNMT3A mutations were detected in 1.17% (4/343) of patients. Of them with
DNMT3A mutated, Pt 1. (M/6, M4) harbored a S892S mutation was diagnosed
leukemic infiltration of the gastrointestinal tract, and gave up after 38 days; Pt 2. (F/12,
M3) harbored a V912A mutation and PML-RARA fusion gene got continuous
complete remission for 60 months; Pt 3. (M/1, M5) harbored a R885G mutation and
two inrtonic mutations (c.2598-15C>T and c.2739+55A>C) was newly diagnosed
myeloid sarcoma and was combined with testicular leukemia and CNS leukemia after 2
months. After 10 months, he undertook the BM Transplant but got relapsed in
testicular after 39 days and then died after 8 months; Pt 4. (F/2, M3) harbored a Q886R
mutation was found to be PML-RARA and FLT3-ITD positive, and dead of retionic
acid syndrome after 22 days.
Conclusion: DNMT3A mutation can be found in 1.17% Chinese childhood AML. The
mutation positions were different from the hotspots reported in dult AML. We
supposed that DNMT3A mutations may have adverse prognostic impact at earlier ages
in childhood AML.
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DOES HDARA-C IMPROVE THE OUTCOME OF DOWN SYNDROME
PATIENTS WITH ACUTEMYELOID LEUKEMIA?
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1King Faisal Specialist Hospital and Research Centre, Pediatric Hematology / Oncology,
Riyadh, Kingdom of Saudi Arabia; 2King Faisal Specialist Hospital and Research Centre,
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Background/Objectives: Patients of Down syndrome with AML have an overall good
outcome but are at increased risk to chemotherapy related toxicities.
Design/Methods:Medical records of 27 DS AML patients who received chemotherapy
on two different protocols between 1998 and 2013 were reviewed. Data extracted
included those related to clinical characteristics of patients and their outcome.
Results: 20 patients were males (74%). Median age at diagnosis was 24 months (range
1.31-152.98). Four patients were below the age of 12 months (14.81%).7 were FAB M7.
Mean WBC count was 32.73(range 1.80-219.96). Six patients had trisomies in addition
to ct21. Fifteen patients received Japanese protocol (No HDAra-C)JAP (55.55%), 10
POG (Containing HDAr-C) (27%) and 1(3.7%) other protocol.14 patients (93%) on
JAP achieved remission at the completion of induction, 3 relapsed (2 in BM and 1 in
BM+CNS) with a median relapse free time of 4.2 months (range1.92 -16.08). 3 died (2
due to Progressive disease and one to infection). 3(20%) patients admitted in PICU. 8
patients (80%) on POG achieved remission at the completion of chemotherapy. 3(30%)
relapsed in bone marrow with a median relapse free time of 3.96 months (range
01.8-4.44). Three patients (30%) expired due to progressive disease. 2(20%) patients
needed PICU admission. There were more post induction infectious toxicities in the
POG group compare to JAP (F/N episodes 9 vs 2, Invasive Fungal Infection 6 vs 0,
Bacterial 4 vs 2, Viral 1 vs 0 and mucositis 1 vs 0). Statistically there was no significant
difference in the OS (JAP 75.4% vs POG 70%, p-value= 0.262) and EFS (JAP 65.5% vs
POG 70%, p-value = 0.412) between the two protocols.
Conclusion: The use of HDAra-C in treatment of DS-AML patients did not improve
outcome and is associated with higher infectious complications.
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ACUTEMYELOID LEUKEMIA: TREATMENT RELATEDMORTALITY IS A
BANE IN A DEVELOPING COUNTRY
J. Ramamoorthy1, A. Trehan2, D. Bansal2, N. Varma3, R. Jain2
1Post Graduate Institute of Medical Education & Research, Chandigarh, India; 2Post
Graduate Institute of Medical Education & Research, Pediatrics, Chandigarh, India;
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Background/Objectives: To determine the outcome of children treated for Acute
Myeloid Leukemia (AML) in a university hospital in India.
Design/Methods: Hundred children were treated for AML (Non M3) from January
2004 to December 2013. AMLMRC X protocol was followed before 2007 & AML
MRC XII subsequently. Baseline characteristics, response rate and complications were
analyzed from case records.
Results: The mean age was 7.3±3.6years. There were 76 boys and 24 girls. FAB subtype:
M0: 2; M1: 12; M2: 46; M4: 17; M5: 14; M6: 3; M7: 6. Cytogenetics were not available.
Seven patients had gum hypertrophy and 14 granulocytic sarcoma. Median TLC:
26,500 /mcL (8,200-67,000); Platelets 30,000/mcL (13,500 -69,700). Eight patients had
central nervous system (CNS) involvement.Remission: Bone marrow in 75 patients
after course 1: 64% in remission (M1), 76% : <15% blasts. Five children had refractory
AML. Three defaulted therapy. Treatment related mortality (TRM): Forty eight
children died. Twenty five (53%) deaths occurred during course 1, with 8, 7 & 8 deaths
after course 2, 3 & 4. Cause of death: 25(52.1%) severe sepsis; 13(27.1%) bacterial
culture positive sepsis, 6(12.5%) probable fungal infection, 3(6.3%) proven fungal
infection, 1(2.3%) leukostasis related. Relapses: Twenty patients relapsed; ¾ being early
relapses. . Survival: The overall survival is a dismal 27.2% (665.47± 130.24). Disease
free survival (DFS) is 34.7% (845±160.62). There was no difference in DFS between
those who had >15% /<15 % blasts after course 1 (31.6% vs. 35.5%; p=0.916). Age,
gender, FAB subtype & CNS positivity had no association with outcome.
Conclusion: High TRM precludes satisfactory outcomes in AML. Infections are
responsible for the majority of TRM. One fourth of the cohort died during the first
induction. Improving supportive care and combating infection is the need of the hour
for decreasing TRM to improve survival in a developing country set up.
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CHILDHOOD ACUTEMYELOID LEUKEMIA: AIIMS EXPERIENCE
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Background/Objectives: From India, the data of outcome in childhood acute myeloid
leukemia (AML) is below par and still not adequate as compare to west. There are
modest survival outcomes 23% to 53.8%.To evaluate the outcome of childhood acute
myeloid leukaemia (AML) treated during 2011-2014 at our centre.
Design/Methods: Case records of AML patients treated (MRC10 protocol) at our
centre were reviewed.
Results: A total of 63 patients were enrolled during 2011-2014. 98% patients presented
with fever. Bleeding was present in 18/63, proptosis 10/63 and CNS disease in 4/63
patients. Median duration of the disease related symptoms was one month. Karyotypes
of 27 patients were available. 50% had cytogenetics abnormalities with good prognosis
(inv 16, t(8;21) or t(15;17)). Fifteen patients presented with cytogenetics abnormalities
with intermediate prognosis. Patients in intermediate cytogenetic risk group fared
poorly than patients in favourable cytogenetic risk group in terms of both event free
survival and overall survival (p = 0.0059). Of 63 patients 15 declined therapy, 3 were
lost to follow up. Fifteen (31%) patients died before completion of therapy while rest
completed treatment. Initial presentation with bleeding came out to be significant for
poorer event free survival (p = 0.0071). Higher TLC count at diagnosis is also a poor
prognostic factor in terms of event free survival (p = 0.01). Among survivors the
median duration to the first neutopenic episode is 8 weeks. In 86% survivors the time to
first neutropenic episode was > 1.5 weeks after induction (p = 0.02). Overall survival
probability came out to be higher for patients who completed treatment (p = 0.0001).
Conclusion: It was noticed that initial presentation without bleeding, absence of high
TLC delayed occurrence of first neutropenic episode is associated with significantly
better outcome. Those who took treatment and completed it have performed better in
terms of overall survival.
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EPIGENETIC ALTERATIONS COMMON TO ADULT AND PEDIATRIC
MYELOID MALIGNANCIES PREDICT SURVIVAL AND RELAPSE IN BOTH
AGE GROUPS SIGNIFICANTLY BETTER THANMUTATIONAL OR
CYTOGENETIC PROFILES ALONE
T. Triche1, D. Wai2, R. Ries3, T. Alonzo4, S. Meshinchi3, R. Arceci2
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Hematology/Oncology, Phoenix, USA; 3Fred Hutchinson Cancer Research Center,
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Background/Objectives: Both adult and pediatric acute myeloid leukemia (AML) are
characterized by diverse mutational and cytogenetic profiles, poor outcomes, and high
incidence of relapse, as well as relatively few advances in treatment over the past 30
years. Given the high incidence of fusions and mutations affecting components of the
epigenetic machinery, we sought to characterize features conferring better or worse
outcomes within a risk group among pediatric cases, having previously shown the
power of this approach in two large adult cohorts.
Design/Methods: The most comprehensive assay results among adults stem from the
Cancer Genome Atlas (TCGA) AML project (Ley et al., NEJM 2013); the assays in the
TARGET pediatric AML project are most comparable to those conducted in the
TCGA AML cohort, allowing direct transfer of DNA methylation signatures, copy
number variation, and gene expression markers from the former to the latter and vice
versa. Without any modification or refitting, we applied to the pediatric cases a DNA
methylation signature derived from the adults (non-FABM3 cases) which outperformed
all known mutational and cytogenetic markers as well as the standard of care.
Results: The risk scores in pediatric cases (derived from the adult risk panel)
significantly and profoundly separated a higher-risk subgroup of children from a
standard- or low-risk subgroup, as we had previously observed in the adults. Further,
the association with time to relapse was stronger in the pediatric cases than we had
observed in the adults, suggesting that further analysis of the pediatric cases may
uncover predictors which can also be applied to the treatment of adult cases.
Conclusion:We suggest that our approach uncovers significant, clinically relevant
aspects of leukemic progression, which have been overlooked by studies focusing solely
or primarily on mutational covariates, and may provide a means to better stratify
patients in both age groups for more effective treatment.
Poster Discussion: Neuroblastoma
PD-056
MXI1 ANDMXI0 HAVE DIFFERENTIAL IMPACT ON N-MYC FUNCTION IN
NEUROBLASTOMA GROWTH AND CHEMOSENSITIVITY
D.C. Ellis1, S. Kirchner1, J. Bartram1, D. Wechsler1, M. Armstrong1
1Duke University, Pediatrics, Durham, USA
Background/Objectives: Neuroblastoma is the most common extracranial malignancy
of childhood. The Myc family of proteins, implicated in the etiology of many cancers,
regulates cell growth and proliferation.MYCN amplified neuroblastoma is associated
with a poor prognosis. Mxi1 is a member of the MAD family that inhibits N-Myc
activity. We identified Mxi0, an alternatively spliced variant of Mxi1 with a different
first exon (Exon 0), whose function is unknown. Our hypothesis is that Mxi1 and Mxi0
differentially impact N-Myc-dependent neuroblastoma cell proliferation.
Design/Methods:We expressed Mxi1 and Mxi0 in SHEP neuroblastoma cells and
SHEP cells stably transfected to express high levels of MYCN (SHEP/MYCN). We also
utilized native neuroblastoma cell lines with inducible expression of Mxi1 and Mxi0.
Cell proliferation and survival were quantified. Apoptosis was measured by propidium
iodide staining and caspase-3 immunohistochemistry. Subcellular localization of Mxi1
and Mxi0 proteins was detected by immunofluorescence.
Results: Overexpression of Mxi1 inhibits N-Myc mediated cell proliferation and
improves chemosensitivity. In the absence of N-Myc, Mxi1 overexpression
independently inhibits cell proliferation and induces cell apoptosis. Conversely,
overexpression of Mxi0 leads to enhanced proliferation and chemoresistance,
suggesting that Mxi0 is counter-regulatory to Mxi1. Finally, examination of Mxi1 and
Mxi0 subcellular location reveals that Mxi1 resides in the nucleus while Mxi0 is found
in the cytoplasm; this differential localization appears to be determined by the presence
of Exon 0.
Conclusion: Overexpression of Mxi1 in neuroblastoma cell lines leads to inhibition of
N-Myc-mediated cell proliferation while Mxi0 appears to promote cell growth. Mxi1
expression enhances chemosensitivity of neuroblastoma cells, while Mxi0 has the
opposite effect. Exon 0 may play an important role in the differential function. A better
understanding of the interaction between Mxi1 and Mxi0 and how they affect
neuroblastoma physiology may aid in developing more effective targeted therapies to
improve outcomes in children with neuroblastoma.
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INTERLEUKIN-2 ADDS TOXICITY BUT NOMEASURABLE ACTIVITY IN
RELAPSED/REFRACTORY NEUROBLASTOMA PATIENTS TREATEDWITH
LONG-TERM INFUSION OF ANTI GD2 ANTIBODY CH14.18/CHO
H. Lode1, N. Siebert1, C. Eger1, M. Schuster2, E. Janzek2, H. Loibner2
1University Medicine Greifswald, Pediatric Hematology / Oncology, Greifswald,
Germany; 2Apeiron Biologics, Pediatric Oncology, Vienna, Austria
Background/Objectives: Long-term infusion (LTI) of ch14.18/CHO emerges as a
promising treatment concept for relapsed/refractory neuroblastoma patients. The role
of additional stimulation of the immune system by concomitant treatment with scIL2 is
unclear in this setting.
Design/Methods: Pts (74) were treated with 5 cycles of LTI with 100 mg/m2
ch14.18/CHO (d8-17) combined with 6×106 IU/m2 sc IL-2 (d1-5; 8-12) (53 Pts) and
without IL2 (21Pts) in a single center program. Surrogate parameters for activity and
pain toxicity were determined using the whole blood cytotoxicity test (WBT) (d1, 8, 15)
and analysis of the intravenous (iv) morphine usage (d8-17).
Results: GD2 specific killing of neuroblastoma cells analyzed in the WBT assay was
found in all patients and cycles. The cytotoxic activity in base line samples preceding
subsequent ch14.18 applications increased over cycles, indicating persistent lytic activity
over the entire treatment period of 6 months. Interestingly, there was no difference in
GD2 specific cytotoxic activity against neuroblastoma target cells at any time point
between patients treated with or without IL2.Analysis of iv morphine usage in cycle 1
of patients treated in combination with scIL2 revealed a cumulative dose of 2.5
mg/kg/cycle in contrast to patients treated with ch14.18/CHO only (1 mg/kg/cycle).
This corresponds to a >60% increase of the ch14.18/CHO associated pain toxicity by
additional scIL2 treatment. Reduction of iv morphine usage in subsequent treatment
cycles was observed in both cohorts. However, in patients treated without additional
scIL2, 0% of patients required iv morphine in cycles 3 or greater in contrast to 29% in
the scIL2 combination group.
Conclusion: Neither the surrogate WBT activity parameter nor the higher pain toxicity
profile support the combined treatment in above pilot studies. Ongoing SIOPEN trials
(EudraCT 2009-018077-31; EudraCT2006-001489-17) randomizing LTI ch14.18/CHO
± scIL2 in front line and relapsed/refractory patients will clarify the optimal approach.
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RELAPSED/REFRACTORY NEUROBLASTOMA PATIENTS RESPOND TO
ANTI GD2 ANTIBODY CH14.18/CHO DELIVERED BY LONG-TERM
INFUSION COMBINEDWITH INTERLEUKIN-2 AND SHOW IMPROVED
SURVIVAL RATES COMPARED TO HISTORICAL CONTROLS
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Background/Objectives: Patients (pts) with high risk relapsed/refractory neuroblastoma
(NB) may benefit from treatment with long-term infusion (LTI) of ch14.18/CHO.
Design/Methods: 97 pts were treated with LTI of 100 mg/m2 ch14.18/CHO (d8-17),
6×106 IU/m2 sc IL-2 (d1-5; 8-12), and 160 mg/m2 oral 13-cis-RA (d19-32) (SIOPEN
Phase II; APN311-202; EudraCT 2009-018077-31; 44 pts; single center program;
APN311-303; 53 pts). Response assessments followed INRG criteria. Fcγ -receptor
polymorphisms FCGR2A (H131R), -3A (V158F) and -3B (NA1/NA2) were
determined.
Results: Clinical overall responses were 30% (APN311-303) and 31% (APN311-202).
The survival update of the APN311-303 cohort revealed a 1-y & 4-y OS of 94.2±3.2%
& 60.9±9.0% (median FU 2.9 y [0.7-5.2 y]) and a 1-y & 4-y PFS of 54.4±6.9% & 32.3%
±6.9% (median FU 2.8 y [0.7 - 4.9 y]). Median TTP was 571 d (95% CI: 232.7 d). The
comparator is the reported historical gold standard with 1-y & 4-y PFS of 19±2% &
8±3% and OS of 56±3% & 14±4% and a median TTP of 63 d (95% CI: 56.8 d). NB pts
with high affinity FCGR alleles and an increase in ADCC (cut off 15%) had better PFS
and OS rates (p<0.03; p<0.005), which supports NK-cell mediated ADCC as the
mechanism of action.PK of ch14.18/CHO was analyzed in cycle 1: Cmax=12.2±0.4
μg/ml, t½=8.4±1.1 d, AUC=145.3± 5.8 μg*d/ml, Vd=9.3±0.5 L/m2. A
pro-inflammatory cytokine response (IL-2, IL-6, IL-8, IFNγ ) translated into the
expansion of effector NK- (3x) and T-cells (2x). We observed HACA in 17/97 pts
(17.5%) of which only 9/97 (9.3%) were neutralizing with respect to the inhibition of
CDC and WBT activity. In HACA negative patients, levels of ch14.18/CHO and
functional parameters (CDC, WBT) analyzed before subsequent treatment cycles
indicate persistent anti-NB activity for the entire treatment period.
Conclusion: High-risk relapsed/refractory NB patients respond to LTI of ch14.18/CHO.
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MOLECULAR PROFILING INCLUDING GENOMIC ABERRATIONS CAN
REVEAL ULTRA HIGH-RISK GROUP IN THE JAPAN NEUROBLASTOMA
STUDY GROUP’S CLINICAL TRIAL FOR HIGH-RISK NEUROBLASTOMA
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Background/Objectives: The Japan Neuroblastoma Study Group (JNBSG)
prospectively enrolled patients with high-risk neuroblastoma according to the
Children’s Oncology Group risk group for a phase II clinical trial JN-H-07. The trial
consisted of five courses of induction chemotherapy (vincristine, cyclophosphamide,
cisplatin, pirarubicin and operation), followed by high-dose chemotherapy (melphalan,
etoposide and carboplatin with autologous PBSCT) and radiation therapy.
Design/Methods: FromMarch 2007 to February 2009, 50 patients were enrolled.
Median age at diagnosis was 36 months (range: 13-174 months). Array comparative
genomic hybridization (CGH) was used for genomic grouping in 45 patients.
Results: The five-year overall survival (OS) and progression-free survival (PFS) for 50
patients were 48.4 ±7.2% and 32.2 ±6.8%, respectively. The five-year PFS of patients
withMYCN amplification (n=20) was 40.0 ±11.0%, while the PFS of MYCN
non-amplified cases (n=30) was 26.7 ±8.4% (p=0.62). Thirty-nine tumors were in
partial chromosomal gain/losses (GG-P), four were in whole chromosomal gain/losses
(GG-W), and two were in silent with no obvious losses and gains exceptMYCN
amplification (GG-S). The five-year PFS of GG-W (0.0 ±0.0%) was significantly
poorer than that of GG-P (37.5 ±7.9%; P=0.018). In GG-P, 13 tumors were P1a
(1p-loss,MYCN amplification) and 13 were P3s (11q-loss,MYCN single). The five-year
PFS for P1a and P3s were 33.3 ±27.2% and 34.2 ±13.8%, respectively. Notably, the
five-year PFS of P1s (1p-loss,MYCN single; n=4) was 0.0 ±0.0%, which was
previously reported as having 71% of OS in all stages of neuroblastoma. Of 45 cases
analyzed, the ALK gene was mutated in five cases whose PFS was 40.0 ±21.9 %, similar
to 34.0 ±7.6% of non-mutated cases.
Conclusion: PFS of high-risk neuroblastoma according to the genomic classification
has been improved in comparison with the previous report. Molecular profiling
including genomic aberrations could reveal ultra high-risk neuroblastoma, which
should be required further analysis by genomic sequencing.
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NATIONAL NEUROBLASTOMA NETWORK (NNN): A WAY FORWARD FOR
NEUROBLASTOMA CARE IN INDIA
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Background/Objectives: In India, exact epidemiology and outcome of neuroblastoma
(NB), is not known due to the lack of appropriate network and reporting system.
National Neuroblastoma Network (NNN) has been formed to bridge this gap. The
objectives of NNN are to study epidemiology, establish diagnostics, prepare uniform
risk group stratification and to create uniform therapeutic protocols to improve
outcomes of NB.
Design/Methods: In July 2014, NNN was formed amongst the members of Indian
Pediatric Hematology Oncology group and started the fortnightly online meetings
using the St. Jude hospital’s website portal www.cure4kids.org. Participating centres are
reporting data every month but final data analysis will be done on yearly basis.
Results: Over 7 months (July2014-Jan2015), NNN held 9 online and 2 physical meetings
(attended by 64 members). Fourteen case based discussions were held covering
histopathology, staging, role of N-myc, risk stratification and treatment. From 37
centres across 13 states, 120 new cases were reported (range 12-23/month). Sixteen
centers provided details of 57cases. Male to female ratio was 1.28:1. Sixteen (28%) aged
less than 18 months. N-myc could be done in 32/57 (56.14%) cases and it was amplified
in 8/32. Twenty six (65%) had stage 4 disease with bone marrow involvement seen in
18/57. Risk stratification at presentation could be done in 53 children, 31 (58.49 %)
were high risk, 13 intermediate and 9 were low risk. Further data is being collected and
will be analysed at 1 year. Treatment protocols for low & intermediate risk NB have
been finalized while those for high risk and relapsed NB are being prepared.
Conclusion: NNN has successfully linked 37 centres reporting data to a centralized
registry. NB care is being improved across these centres by online tumor board
meetings. As majority of cases are high risk so co-operative group like NNN is needed
to improve outcomes.
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Yekaterinburg, Russia; 3Ural State Medical University, Laboratory Diagnostic,
Yekaterinburg, Russia
Background/Objectives: To investigate the copy number variations (CNVs) and
determine their prognostic significance in neuroblastoma patients aged less than 18
months. The retrospective study has been conducted in Pediatric Oncology and
Hematology Center, Regional Children’s Hospital, Ekaterinburg, Russia.
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Design/Methods: Among 103 children under 18 months (median of age 6 months) with
primary neuroblastoma admitted to our clinic since April 1993 till November 2014
74(72%) were undergone CNV investigation by MLPA. All the investigated patients
were treated according to NB90, NB97 and NB2004 protocols: 2(3%), 15(20%) and
57(77%) correspondingly.
Results: Patients’ distribution by stage was as follow: stage I–18(24,3%); stage
II–6(8,1%); stage III–22(29,7%); stage IV–15(20,3%); stage IVS–13(17,6%). In
univariate analysis in the whole group of investigated children only stage IV of disease
and MYCN-amplification had the prognostic significance. 15-years event free survival
(EFS) in patients with stage IV was 29%±21% and overall survival (OS) was 65%±12%
in comparison with other children: 82%±5% and 89%±4% (p=0,03) respectively.
8(10,8%) patients with MYCN-amplification had significantly worse prognosis: EFS
did not exceed 25%±15% vs. 78%±7% and OS 37%±17% vs. 89%±4% (p<0,001).
Among 66(89,2%) patients without MYCN amplification prognostic significance had
following CNVs: 1p deletion and 2p23-24 gain. EFS in children with 1p deletion was
26%±20% vs. 89%±7% and OS 53%±17% vs. 96%±2% (p<0,01). In patients with 2p
gain EFS was 31%±23% vs. 87%±4% and OS 62%±17% vs. 94%±3% (p=0,02).
Multivariate analysis demonstrated only MYCN-amplification has prognostic
significance in EFS and OS of whole group of patients: 6,74 (95%CI 2,355-19,291;
p<0,001) and 9,084 (95%CI 2,618-31,521; p=0,001). Presence of 1p deletion had a
significant negative influence on EFS: 4,409 (95%CI 0,993-19,565; p=0,05).
Conclusion: The results of this study demonstrate that MYCN-amplification and 1p
deletion are significantly influencing on outcome in children with neuroblastoma under
18 months.
PD-062
MINIMAL BONEMARROW DISEASE IS FREQUENTLY DETECTED IN
LOCALIZED NEUROBLASTOMA PATIENTS
E. van Wezel1, B. Decarolis2, J. Stutterheim1, L. Zappeij-Kannegieter1, B. Hero2,
F. Berthold2, T. Simon2, R. Schumacher-Kuckelkorn2, M. van Noesel3, M. Fiocco4,
H. Caron5, C.E. van der Schoot1, G. Tytgat5
1Sanquin Research, Experimental Immunohematology, Amsterdam, Netherlands;
2Children’s Hospital-University of Cologne, Pediatric Hematology and Oncology,
Cologne, Germany; 3Erasmus Medical Center, Pediatric Oncology, Rotterdam,
Netherlands; 4Leiden University Medical Center and Dutch Childhood Oncology Group,
Biostatistics, The Hague, Netherlands; 5Academic Medical Center, Pediatric Oncology,
Amsterdam, Netherlands
Background/Objectives: The clinical importance of minimal disease detection in bone
marrow (BM) of localized neuroblastoma patients at diagnosis remains unclear. In this
prospective multicenter study, BM samples at diagnosis of a large cohort, were studied
using Real-time quantitative PCR (qPCR).
Design/Methods: In total 160 BM samples from localized patients were prospectively
collected at Dutch and German centers between 2009 and 2013. qPCR was performed
by using five neuroblastoma specific markers: PHOX2B, TH, DDC, GAP43 and
CHRNA3. The association with other biological factors and the prognostic impact of
BM positivity and clinical response were assessed.
Results: In 58 out of 160 patients neuroblastoma mRNA was detected in BM. In 47 of
the 58 positive samples only one marker was found positive. BM positivity was
significantly associated with MYCN amplification (p=0.02) and deletion of
chromosome 1p (p=0.04). In total 31 patients had an event, of which only 5 patients
had progression to stage 4. BM positivity was not associated with an unfavorable
outcome. However, the detection of more than one marker was associated with an
unfavorable outcome (systemic or local relapse) (EFS 48% vs 85%; p=0.03) in the whole
cohort and in the observation group.
Conclusion: BM positivity was associated with unfavorable biological factors and might
represent more aggressive tumors. Patients with qPCR positive BM should not be
upstaged, because of very few systemic events in the cohort. However, for patients in
the observation group with more than one marker positive a more careful follow-up
might be required.
PD-063
CONFIRMATION OF THE INRG SURVIVAL TREE ANALYSIS BY A
DIFFERENTLY COMPOSED REPRESENTATIVE NATIONAL COHORT OF
PATIENTS
R. Volland1, T. Simon1, F. Berthold1, B. Hero1
1University of Cologne- Childrens’ Hospital, Department of Pediatric Oncology and
Hematology, Köln, Germany
Background/Objectives: In 2009 a new International Neuroblastoma Risk Group
(INRG) classification system was introduced by Cohn et al. This system was based on a
large international cohort. Our aim was to apply this classification system on a
representative independent national cohort with respect to event free (EFS) and overall
survival (OS).
Design/Methods: Data of 1,209 patients from the German trials NB97 and NB04,
diagnosed between 01.01.2002 and 31.12.2010, age at diagnosis <21 years were
compared with the published INRG data for the risk factors: INSS stage, histology, age
at diagnosis (</12 and </18 months), LDH, ferritin, MYCN, 1p, 11q and 17q
status. In addition, survival trees based on EFS and OS including these risk factors were
calculated.
Results: Differences between distribution of the German and INRG cohort were not
found for ferritin, age </ 12 months, 11q and MYCN status but for age </ 18
months (p=0.003), INSS stage (p<0.001), LDH (p=0.001), histology (p=0.017), 1p
(p<0.001) and 17q status (p=0.026). Both survival trees assigned stage (localized, 4S vs.
4) as first node. As in the INRG tree, the branch of localized and 4S stage was split for
EFS into unfavorable and favorable histology followed by MYCN status as third node
which was second node for OS. Subgroup of stage 4 was separated into age <12 vs. 12
months for EFS and OS, while branching for EFS stopped here. For OS the younger
group was divided according to MYCN (normal vs amplified) while the older group
was divided according to LDH (</ 587 U/L).
Conclusion: Applying survival tree analysis on a differently distributed neuroblastoma
cohort with diverse endpoints resulted in similar selection and ranking of risk factor as
in the published INRG survival tree. Interestingly in our cohort, cutoff of 12 months
instead of 18 months was chosen by the survival tree method.
Poster Discussion: New Drugs/Experimental Therapeutics
PD-064
SEARCHING FOR TARGETED TREATMENT FOR PEDIATRIC TUMORS BY
DNA SEQUENCING
B. Herrero1, B. Angulo2, I. Martinez1, S. Hernandez2, M. Villa1, F. Lopez-Rios2,
B. Lopez-Ibor1
1HM Hospitales, Pediatric Hematology and Oncology Unit, Madrid, Spain; 2HM
Hospitales, Laboratorio Dianas Terapeuticas, Madrid, Spain
Background/Objectives: Sequencing pediatric tumors in order to identify any druggable
alteration in patients with incurable tumors with conventional therapy.
Design/Methods: A prospective study that includes pediatric patients with incurable o
relapsed tumors, has been designed to search for druggable gene alterations since 2014.
For targeted next generation sequencing analysis we used the PGMTM-Ion Torrent
Systems platform and a targeted gene panel assay, (Ion AmpliSeqTM Cancer Hotspot
Panel v2). DNA was extracted from a formalin-fixed and paraffin-embedded tissue
sample from patient’s tumor and peripheral blood sample (normal control). When
needed, other molecular techniques such as in situ hybridization, were used in order to
characterize genetic alterations not covered by the targeted gene sequencing panel.
Results:We have studied to date 18 pediatric tumors either at relapse or at diagnosis
when prognosis is dismal. Eleven patients had a brain tumor. We have made sequencing
analysis with Ion-Torrent System in 12 patients. Also, we have applied other molecular
studies. We have found druggable gene alterations in four patients, all of them with
CNS tumors: two V600E BRAF mutations, one PDGFRA gene amplification and one
mutation in CDKN2A. We have treated three patients with targeted therapy:
Dabrafenib to BRAF mutation, Dasatinib to amplification of PDGFRA and Vorinostat
with retinoic acid to CDKN2A mutation.
Conclusion: The pediatric tumors highlight the current molecular heterogeneity of
cancer and prove the need for further understanding of molecular biology in order to
identify any druggable alteration which can improve the clinical management of these
patients, especially those affected by the most aggressive types. It is not about
sequencing the whole tumor, but only about searching the mutations which have
targeted therapy.The massive sequencing panels are initially oriented to adult tumors.
Our goal is to redesign these studies to include all relevant alterations in pediatric
tumors.
PD-065
TRABECTEDIN FOLLOWED BY IRINOTECAN CAN STABILIZE DISEASE IN
ADVANCED TRANSLOCATION-POSITIVE SARCOMAS
J. Herzog1, F. Klot-Heydenfeldt1, C. Rossig2, U. Dirksen2, J. van den Brande3,
M. D’Incalci4, P. Grohar5, I. von Luettichau1, W. Berdel6, S. Burdach1
1Kinderklinik München Schwabing-Klinikum rechts der Isar-Technische Universität
München, Department of Pediatrics-Division of Pediatric Hematology/Oncology,
München, Germany; 2University Children’s Hospital Muenster, Department of Pediatric
Hematology and Oncology, Muenster, Germany; 3University of Antwerp, Antwerp
University Hospital, Edegem, Belgium; 4IRCCS-Istituto di Ricerche Farmacologiche
Mario Negri, Laboratory of Cancer Pharmacology- Department of Oncology, Milan,
Italy; 5Vanderbilt University School of Medicine, Pharmacology & Cancer
Biology-Division of Hematology/Oncology, Nashville, USA; 6University of Muenster,
Department of Medicine A-Hematology and Oncology, Muenster, Germany
Background/Objectives: Preclinical data indicate that trabectedin followed by irinotecan
has strong synergistic effects in Ewing sarcoma. This is presumably due to
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hypersensitization of the tumor cells to the camptothecin as an effect of trabectedin. A
strong synergistic effect was also reported in a human rhabdomyosarcoma xenograft.
Twelve patients with end-stage, refractory translocation-positive sarcomas were treated
with trabectedin followed by irinotecan within a compassionate use program.
Design/Methods: Twelve patients with refractory sarcomas, all heavily pretreated with
chemotherapy were treated with trabectedin followed by irinotecan. Diagnosis was
Ewing sarcoma in eight and soft tissue sarcoma in four patients.
Results: As of February 20, 2015, partial remission according to RECIST criteria was
achieved in one patient, stable disease in five patients, progressive disease was seen in six
patients. Median survival was 0.7 at three months after start of this therapy. In the
majority of patients significant hematological toxicity (grade 3 and 4) was observed.
Reversible liver toxicity and diarrhea also occurred. Only one patient suffered from dose
limiting diarrhea and severe prolonged neutropenia, so that irinotecan had to be
omitted in subsequent courses.
Conclusion: Our experience with the combination of trabectedin followed by irinotecan
in patients with advanced sarcomas showed promising results in controlling refractory
solid tumors. While the hematological toxicity was significant, it was reversible. Quality
of life during therapy was maintained. These observations encourage a larger clinical
trial.
PD-066
TROUGH LEVEL MONITORING OF INTRAVENOUS BUSULFAN TO
ESTIMATE THE AREA UNDER THE PLASMA DRUG
CONCENTRATION-TIME CURVE IN PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANT RECIPIENTS
T. Nishikawa1, E. Watanabe2, K. Ikawa3, Y. Kodama1, T. Tanabe1, K. Matsumoto2,
Y. Okamoto1, Y. Takeda2, Y. Kawano1
1Kagoshima University, Pediatrics, Kagoshima, Japan; 2Kagoshima University, Clinical
Pharmacy and Pharmacology, Kagoshima, Japan; 3Hiroshima University, Clinical
Pharmacotherapy, Hiroshima, Japan
Background/Objectives: Optimizing systemic busulfan exposure, the area under the
concentration-time curve (AUC), improves the outcomes for hematopoietic stem cell
transplantation (HSCT). The AUC is conventionally calculated using six plasma
concentrations (AUC0-) drawn after the first of 16 intravenous busulfan doses given as
a two-hour infusion every six hours. The aim of this study was to develop limited
sampling strategies (LSSs) using three or fewer busulfan concentrations with which to
reliably calculate AUC0- in children undergoing HSCT.
Design/Methods: Following the administration of a single dose of busulfan as a test
dosing and the first dosing of busulfan for the conditioning regimen, blood samples
were collected from each patient at six time-points (1, 2, 2.25, 2.5, 3 and 6 hours from
the start of the infusion). The busulfan concentrations in the plasma were measured
using high performance liquid chromatography. The busulfan AUC0- was calculated
according to the trapezoidal method using MOMENT program, employing all six of
the available data points. LSSs using one, two, or three plasma busulfan concentrations
were developed by multiple linear regression.
Results: Pharmacokinetics samples (total: 46 AUCs) were collected from all 29 patients.
LSSs using one (C6: busulfan plasma concentration six hours after the start of the
infusion), two (C2 and C6), or three (C2, C3, and C6) plasma busulfan concentrations
were developed by multiple linear regression that showed excellent agreement with
actual AUC0-. The AUC0- predicted based on C6 was significantly correlated with,
and not statistically different from, actual values as follows: AUC0- = 2556.5 C6 +
320.9 (r2 = 0.929, P < 0.0001, mean bias 0.282%, precision 7.91%). In contrast, the
predicted AUCs derived from the other sampling single points did not meet the criteria.
Conclusion: In single-point sampling strategies, the AUC0- predicted by the LSS (C6)
and AUC0- using the six data points demonstrated excellent agreement.
PD-067
NOVEL CLINICAL TRIAL DESIGNS IN PAEDIATRIC CANCER: MULTI-ARM
MULTI-STAGE (MAMS) DESIGNS
K. Wheatley1, V. Moroz1, A. Houlton1, P. Kearns1
1University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham,
United Kingdom
Background/Objectives:Most children’s cancers are rare and, with increased
understanding of the underlying genetic features of many tumour types, increasing
numbers of targeted therapies may become available and need to be evaluated reliably.
There also remains a need to identify the optimal conventional therapies (e.g.
chemotherapy, radiotherapy, surgery), given the frequent paucity of reliable evidence.
Design/Methods:Most randomised controlled trials (RCT) consist of two arms, while
many single arm studies are also undertaken. Running a trial is a long process from
concept to publication, including a substantial set up period. If several treatments are
of interest, rather than just selecting one (possibly the wrong one) for evaluation against
the standard, a MAMS design permits all of the treatments to be assessed, with
insufficiently active treatments in terms of intermediate outcome being dropped after
Phase II, with recruitment continuing to the remaining arms for Phase III evaluation.
Furthermore, as novel agents or regimens of interest come along, they can be
incorporated into the trial. This adaptive design is a much more efficient process than
setting up separate trials to test each new agent, and being randomised and comparative
avoids the biases on single-arm Phase II trials.
Results:MAMS trials are underway or planned in several tumour types, including: the
rEECur trial for relapsed Ewing sarcoma, comparing four widely used chemotherapy
regimens; a trial in relapsed rhabdomyosarcoma evaluating several novel agents added
to a conventional chemotherapy backbone; a trial in newly diagnosed
rhabdomyosarcoma comparing three novel regimens; a trial in neurofibromatosis-1 low
grade glioma; the BEACON trial in neuroblastoma, which is being adapted to become
a MAMS design by adding two new arms as the initial step.
Conclusion: The more widespread use of MAMS designs will enable the quicker
identification of effective therapies, leading to improved outcomes for children with
cancer.
Poster Discussion: Rare Tumours
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GORHAM-STOUT SYNDROME: A RARE DISEASE AND DIFFICULT TO
TREAT
C. Akyuz1, B. Aydin1, I. Bajin1, H. Susam Sen1, S. Ocak1, B. Yalcin1, A. Varan1,
M. Buyukpamukcu1, T. Kutluk1
1Hacettepe University Faculty of Medicine, Pediatric Oncology, ANKARA, Turkey
Background/Objectives: Gorham-Stout syndrome is characterized by lymphatic
vascular malformation leading to progressive osteolysis. Chylothorax is the most
serious component. Because of the rarity there is limited treatment experience.
Design/Methods: Four patients diagnosed with Gorham-Stout syndrome in our
department were evaluated regarding clinical findings and treatment experience.
Results: Patients were diagnosed median 9-year-old and were followed-up 17-113
months (median 56). All had extensive bone lesions. Three patients were presented with
chylothorax and one with abdominal lymphangioma. Interferon was used as first-line in
two patients, second-line in other two patients. Sirolimus was used with minimal
response. Calcitonin was used in one, pamidronate and zoledronic acid was used in two
patients for osteopenia and bone lesions. There was no response to propranolol. First
patient had progression in bone lesions and chylothorax with interferon. Second-line
treatment was started with bevacizumab. Chylothorax regressed but due to pathological
fracture bevacizumab had to be stopped after 10 months. Sirolimus was 3-line treatment
and she has stable disease with restrictive lung disease.Second patient had spleen cysts,
abdominal macrocystic lymphangioma and bone lesions. After 3 months with
interferon treatment new bone lesions occurred, sirolimus was given and she remained
stable with sirolimus.Third patient with chylothorax and bone lesions received sirolimus
as first-line treatment. Within 3 months chylothorax increased, treatment changed with
interferon. He still has been receiving interferon with stable disease.The last patient had
massive chylothorax and bone lesions. Chylothorax didnot respond sirolimus but
decreased with interferon. She is off-therapy and has severe restrictive lung disease.
Conclusion: There is no standard treatment recommendation for Gorham-Stout
syndrome. Interferon seems to have some benefit but sirolimus and propranolol showed
no positive effect. Bevacizumab might help chylothorax but bone lesions might be
worsen. Biphophonates might have some effect on bone lesions. Multicenter studies for
prospective trials of treatment regimens should be undertaken.
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ENDEMIC KAPOSI SARCOMA IN HIV-NEGATIVE CHILDREN IN CENTRAL
MALAWI: CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES
J. Villiera1, W. Kamiyango1, P. Mehta2, C. Kovarik3, S. Ahmed4, P. Kazembe4,
N. El-Mallawany5
1Baylor College of Medicine Children’s Foundation Malawi, Pediatric Oncology,
Lilongwe, Malawi; 2Baylor College of Medicine, Pediatric Oncology, Houston, USA;
3University of Pennsylvania, Dermatology, Philadelphia, USA; 4Baylor College of
Medicine Children’s Foundation Malawi, Pediatrics, Lilongwe, Malawi; 5New York
Medical College, Pediatric Oncology, Valhalla, USA
Background/Objectives: Endemic Kaposi sarcoma (eKS) was first described in Africa
well before the HIV-epidemic. However, the clinical characteristics and outcomes of
children with eKS are not well described. We aimed to describe our experience with
pediatric eKS.
Design/Methods:We retrospectively analyzed 10 HIV-negative children with eKS
between 8/2010 – 6/2013 in Lilongwe, Malawi. Diagnosis was established clinically
except in two patients who underwent confirmatory biopsies. HIV-serostatus was
confirmed with rapid antibody test as well as DNA PCR methodology. Local 1st-line
chemotherapy included bleomycin and vincristine.
Results:Median age was 11.7 years (2.0-16.3); one female & nine males. Common sites
of presentation were: woody edema (70%), skin (60%), subcutaneous nodules (40%),
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lymph node (40%), oral (10%). Utilizing our previously described pediatric KS staging
classification, 2/10 were stage 2 (lymphadenopathic subtype), 6/10 were stage 3 (woody
edema subtype), and 2/10 were stage 4 (based upon widespread involvement of the skin
with > 20 skin lesions). None of the patients presented with visceral disease. Overall
survival was 60% with a median follow-up of 24.5 months (range 20-34). Four patients
died, with median time to death of 4 months (range 0.5-19). The two stage 2 patients
achieved long-term CR, however one died in CR of another cause. Of the six stage 3
patients, 1 achieved long-term CR, 1 died of progressive KS at 19 months after multiple
relapses, and 4 are alive with stable disease. Amongst the 4 with stable disease, 3
experienced relapse and required further chemotherapy to stabilize. The two stage 4
patients died < 2 months from KS diagnosis with refractory and progressive disease.
Conclusion: This case series demonstrates the high rate of woody edema subtype in
HIV-negative children with eKS. Outcomes stratify according to the severity of clinical
presentation, however long-term survival is possible with moderately-intense
chemotherapy regimens.
PD-070
KAPOSI SARCOMA INFLAMMATORY CYTOKINE SYNDROME IN
HIV-INFECTED CHILDREN IN CENTRALMALAWI, A DISTINCT CLINICAL
PRESENTATION CHARACTERIZED BY INTERLEUKIN-6 RELATED VIRAL
PATHOPHYSIOLOGY
W. Kamiyango1, D. Dittmer2, C. Kovarik3, D. Frank4, J. Villiera1, P. Mehta5,
P. Kazembe6, N. El-Mallawany7
1Baylor College of Medicine Children’s Foundation Malawi, Pediatric Oncology,
Lilongwe, Malawi; 2University of North Carolina, Virology, Chapel Hill, USA;
3University of Pennsylvania, Dermatology, Philadelphia, USA; 4University of
Pennsylvania, Pathology, Philadelphia, USA; 5Baylor College of Medicine, Pediatric
Oncology, Houston, USA; 6Baylor College of Medicine Children’s Foundation Malawi,
Pediatrics, Lilongwe, Malawi; 7New York Medical College, Pediatric Oncology, Valhalla,
USA
Background/Objectives: The NIH first described Kaposi sarcoma (KS) inflammatory
cytokine syndrome (KICS) in HIV-infected adults in 2010. Interleukin-6 (IL-6)-related
pathophysiology is driven by human herpesvirus-8 (HHV-8). KICS has never been
described in children or in Africa. We aimed to describe our pediatric KICS experience.
Design/Methods:We retrospectively analyzed 6 HIV-infected children diagnosed with
KS between 8/2010 – 6/2013 in Lilongwe, Malawi that fit the clinical presentation
characterized by KICS. Local 1st-line chemotherapy included bleomycin and vincristine
(BV). HAART was prescribed according to national guidelines.
Results:Median age was 3.5 years (range 2.2–6.2); 3 females & 3 males. All 6 patients
presented with the following constellation of clinical findings: (1) bulging
lymphadenopathy, (2) persistent fevers, (3) massive hepatosplenomegaly, and (4) severe
cytopenias. At diagnosis, median hemoglobin was 5.1 (range 4–6.2) and median platelet
count was 13 (6–24). Additionally, 2 patients had KS skin lesions, 3 had subcutaneous
nodules, and one had facial edema. Lymph node biopsy was obtained in one patient
revealing KS histology without evidence of multicentric Castleman disease (spindle cell
infiltrate with immunohistochemical stains positive for HHV-8 LANA and CD31,
CD20-negative). Virologic testing was available for one patient and was characteristic
of KICS, revealing HHV-8 viral load of 1.9 × 104 copies/106 cells, IL-6 level 450
pg/mL, and interleukin-10 level 320 pg/mL. Failure to BV was apparent, so prednisone
was added to treat the systemic inflammatory syndrome. Cytopenias dramatically
improved 2 weeks after starting prednisone with median platelets reaching 587 (range
148–789) without transfusion. Four patients achieved long-term complete remission
with median follow-up of 35.5 months (range 24-50 months). Two patients died early
due to complications of other opportunistic infections.
Conclusion: This case series demonstrates the distinct and severe clinical presentation of
IL-6 related KICS in HIV+ children. Long-term cures can be achieved by adding
prednisone to BV plus HAART.
PD-071
CHEST WALL EWING SARCOMA; A POPULATION BASED ANALYSIS
A. Jacobs1, J. Fishbein2, C. Fein Levy3, R. Glick4
1Hofstra University, School of Medicine, Hempstead, USA; 2Feinstein Institute for
Medical Research, Biostatistics Unit, Manhasset, USA; 3Cohen Children’s Medical
Center, Department of Pediatric Hematology/Oncology, New Hyde Park, USA; 4Cohen
Children’s Medical Center, Division of Pediatric Surgery, New Hyde Park, USA
Background/Objectives: The globally low incidence of pediatric chest wall Ewing
sarcoma (CWES) has limited prior studies of this disease to mostly small, single
institution reviews. Our objective was to assess incidence, demographics, treatment
patterns, and long-term survival of this disease through a population based analysis.
Design/Methods: The Surveillance, Epidemiology, and End Results (SEER) database
was used to identify patients aged 0-21 diagnosed with CWES from 1973-2011. Patients
were grouped by decade to assess changes in treatment patterns and outcomes. The
effects of clinical, demographic, and treatment variables on overall survival were
assessed by the computation of Kaplan-Meier curves and the log-rank test, with Cox
proportional hazard regression used for multivariate analysis.
Results: A total of 193 pediatric patients with histologically-confirmed CWES were
identified. The disease was more common in males (60.6%), whites (92.2%), and 11-17
year-olds (48.7%). It was metastatic at presentation in 36.8% of patients. When grouped
approximately by decade, 10-year overall survival improved progressively from 38.2% in
1973-1979 to 65.4% in 2000-2011 (p=0.033). The use of radiation decreased from
84.2% in the earliest time period to 40.0% in the most recent, while the proportion of
patients receiving surgery increased from 75.0% to 84.9%. When controlling for
covariates on multivariate analysis, male patients were found to have a higher mortality
than female patients (HR: 2.4; CI: 1.4, 4.4; p=0.0028).
Conclusion: This population-based analysis of CWES demonstrated an impressive
trend of improving overall survival, with increasing use of surgery and decreasing use
of radiation therapy. As has been previously noted for Ewing sarcoma in general, our
study demonstrated a gender difference in survival of CWES, with girls having a better
prognosis.
PD-072
PAPILLIARY UROTHELIAL NEOPLASMS OF LOWMALIGNANT
POTENTIAL IN CHILDREN AND YOUNG ADULTS.TREATMENT AND
FOLLOW UP GUIDELINES
D. Murphy1, S. O’Toole2, M. Diana1, M. Ronghe1, J. Sastry1, C. Willis1, G. Oades3,
P. French4
1Royal Hospital for Sick Children-Yorkhill, Oncology, Glasgow, United Kingdom; 2Royal
Hospital for Sick Children-Yorkhill, Urology, Glasgow, United Kingdom; 3Southern
General Hospital-Glasgow, Urology, Glasgow, United Kingdom; 4Southern General
Hospital-Glasgow, Pathology, Glasgow, United Kingdom
Background/Objectives: To describe the Scottish experience of Papilliary Neoplasia of
Low Malignant Potential (PUNLMPS) in Children and Young Adults and to produce
treatment and follow up guidelines.
Design/Methods: A search of the Scottish Cancer Registry of the Information Services
Division and a Systematic Review of the Literature.
Results: The Scottish data combined with a search of PUBMED, CINAHL and
EMBASE using the terms Papilliary Neoplasia of Low Malignant Potential
(PUNLMPS), child and young adult revealed 9 publications and 32 cases under the age
of 20. All tumours were superficial and did not invade muscle. 2 studies confirmed the
rarity of genetic aberrations in these tumours in children and young adults under the
age of 20.
Conclusion: PUNLMP was introduced to describe the histology of urothelial
neoplasms of low biological risk of progression in 2004. PUNLMPS are increasingly
recognised in children and young adults. The diagnosis of PUNLMP is subject to
significant controversy and registry data may under estimate true incidence. Although
locally aggressive they do not metastasise. A malignant cancer diagnosis with attendant
psychological burdens can be avoided. Staging for spread is unnecessary making painful
procedures such as bone marrow trephines redundant. Exposure to ionising radiation is
similarly not needed. PUNLMPS should be completely excised. Overall survival is
excellent (100%) but close follow up with ultrasound is necessary to guard against
recurrence. Routine, frequent cystoscopy should be avoided to prevent trauma to the
growing urethra.
PD-073
LIPOBLASTOMA: AN HETEROGENOUS ENTITY
J. Shalkow1, I. Guzman2, L. Bornstein3, G. Espino4, J. Palacios5, M. Esparza6
1Secretariat of Health, Childhood Cancer, Mexico, Mexico; 2National Institute of
Pediatrics, Surgery, Mexico City, Mexico; 3InmunoQ, Pathology, Mexico City, Mexico;
4Anahuac University, School of Medicine, Mexico City, Mexico; 5National Institute of
Pediatrics, Surgical Oncology, Mexico City, Mexico; 6Secretariat of Health, Childhood
Cancer, Mexico City, Mexico
Background/Objectives: Background: Lipoblastomas (LB) are rare benign tumors of
embryonic fat, mostly found in extremities of children before age three. They represent
less than 1% of neoplasms, but 30% of adipocitic tumors in children. Objective: To
present our experience treating pediatric patients with LB at a single center. We describe
clinical and epidemiological factors, as well as follow up.
Design/Methods: Pediatric patients with histologic confirmation of LB were evaluated
between 2004 and 2014. Age, sex, history, clinical findings, primary site, surgical
procedure, pathology reports and outcomes were evaluated.
Results: There were nine boys and three girls, with ages ranging from 4 to 38 months
(median age of 13 months). Time to diagnosis ranged from three days to 21 months.
Most common primary sites were head and neck (5 patients) and trunk (5 patients),
followed by extremities and scrotal (1 patient each). Preoperative evaluation included
USG in six, CT scan in seven, and MRI in four patients. All presented with increased
volume. Fourteen resections were performed. Tumor size ranged from 3.5 to 18 cm. All
lesions were completely resected, with histologic confirmation. There was one local
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recurrence.Surgical time ranged from one to four hours. Blood loss was minimal.
Average hospital length of stay was 1.5 days.There were no surgical complications and
no perioperative mortality. Follow up from one month to 7 years.
Conclusion: LB are rare, benign tumors of embryonic fat, affecting children under three
years of age. There is a marked male preponderance. Initial diagnosis is seldomly
suspected by the primary care physician. MRI is the study of choice for extremity and
paraspinal tumors. CT scan is optimal for head and neck, and retroperitoneal lesions.
Our study differs from previous reports, since we found larger lesions, with most tumors
in the head and neck. Interestingly, recurrence occurred only in one girl.
PD-074
EBSTEIN-BARR VIRUS ASSOCIATED SMOOTHMUSCLE TUMOURS IN
CHILDRENWITH AIDS AT CHRIS HANI BARAGWANATH ACADEMIC
HOSPITAL
R. Wainwright1, S. Pather2, B. Rowe3, D. Mackinnon3, G. Naidu3, S. Poyiadjis3
1Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa; 2Chris Hani
Baragwanath Academic Hospital, Anatomic Pathology, Johannesburg, South Africa;
3Chris Hani Baragwanath Academic Hospital, Paediatric Oncology, Johannesburg, South
Africa
Background/Objectives: Despite the AIDS epidemic that has ravaged the South African
population EBV-associated smooth muscle tumours have remained rare. These
tumours are associated with severe immune suppression and were previously diagnosed
as myofibroma. The objective was to review patients with biopsy proven disease.
Design/Methods: The study was initiated from pathology and the children were traced
from their biopsy records. Our paediatric oncology unit’s patient files were also
reviewed from 2003 to 2014 for any additional cases. Six cases were found in total and
the data extracted. Ethical consent for retrospective data collection was obtained.
Results: A strong female predominance (6/0) was noted, the age range at presentation
was 10 to 15 years, with a mean of 12 years 9 months. Symptoms featured pain
predominantly - abdominal or back, 3 patients had spinal compression, 1 a paraspinal
mass, 1 gallbladder involvement, 1 an eye mass (iris). Prior treatment for suspected TB
contributed to delay with diagnosis. The CD 4 count varied from 3 to 1331, 5 patients
were virally suppressed, 1 was in virological failure. Tumour site was single (2) patients
-spinal (1), eye(1); multiple (4) patients, spinal(3), adrenal(2), ribs(1) and 1 had an
unproven basal ganglia lesion.Therapy included surgery (3), radiation(3),
chemotherapy (1), and palliation(4). Survival ranged from 5 months to 109 months.
One patient died of AIDS related sepsis, one is lost to follow up, 4 are alive, but 1 is
deteriorating, weight 13kg at 13years.
Conclusion: EBV-associated tumours may have a prolonged survival but AIDS related
comorbidities contribute to mortality. A spinal lesion presentation was most frequently
found.
PD-075
A PERSONALIZED, MOLECULAR-BASED APPROACH TO THE TREATMENT
OF RARE, RECURRENT, OR REFRACTORY PEDIATRIC AND ADOLESCENT
CANCERS
K. Zabokrtsky1,2, C. Garner3, T. McEachron4, J. Carpten4, D. Craig5, L. Sender3,6,7,8
1CHOC Children’s Hospital, Hyundai Cancer Genomics Center, Orange, USA;
2University of California-Irvine, Medicine, Irvine, USA; 3University of California-Irvine,
Epidemiology, Irvine, USA; 4Translational Genomics Research Institute, Integrated
Cancer Genomics Division, Phoenix, USA; 5Translational Genomics Research Institute,
Neurogenomics Division, Phoenix, USA; 6University of California-Irvine, Medicine,
Orange, USA; 7University of California-Irvine, Pediatrics, Orange, USA; 8CHOC
Children’s Hospital, Hyundai Cancer Institute, Orange, USA
Background/Objectives:Many pediatric patients with cancer are cured of their disease,
yet there is a subset of patients for whom therapy is unsuccessful. The primary goals of
our research program are to collect tumor and germline specimens from patients with
rare, recurrent, or refractory cancer and to perform whole genome sequencing (WGS)
on both tumor and germline samples and mRNA sequencing on the tumor sample.
Sequencing data is used to characterize the molecular signature of the cancers, to assess
how the disease may have circumvented therapy, and to identify ways in which the
cancer may be treated.
Design/Methods: Sequencing data is analyzed in independent bioinformatics pipelines
to maximize validity of results. Genomic variation, identified by WGS, is integrated
with gene expression information from mRNA sequencing, to develop a molecular
profile of each tumor. The process culminates with a multidisciplinary team meeting
where results are interpreted and a clinical action plan is developed.
Results: Through the end of 2014, 314 potential participants have been identified. Of
those, 224 participants and/or families provided consent; 83 had suspect recurrent or
refractory disease and 141 had a suspect new diagnosis. WGS of the tumor and normal
genomes has been undertaken for 70 patients; of the patients for whom sequencing has
been performed, 11 cases are from patients newly diagnosed with cancer. Whole
genome data has been obtained from the following: brain tumors (n=11), acute
leukemias (n=16), sarcomas (n=14), lymphomas (n=4), ganglio/neuroblastomas
(n=4), mixed germ cell tumors (n=3), and carcinomas (n=3). The remaining data
include that obtained from one each of hemophagocytic lymphohistiocytosis (HLH),
hepatoblastoma, melanoma, myelodysplastic syndrome (MDS), and Wilms tumor.
Conclusion: Our experience has demonstrated the feasibility and effectiveness of clinical
sequencing in pediatric and adolescent oncology and has yielded results that have
informed treatment choices as well as refined diagnoses.
Poster Discussion: Renal Tumours
PD-076
LATE EFFECTS IN CHILDREN TREATED FORWILMS TUMOR AT A SINGLE
CENTER IN BRAZIL
M. Cypriano1, A. Spinola e Castro2, E. Caran1, A. Siviero-Miachon2, A.L. Pires3,
S. Campos Vieira Abib4, A.S. Petrilli1
1Pediatric Oncology Institute/GRAACC/UNIFESP, Pediatric Oncology, Sao Paulo,
Brazil; 2Pediatric Oncology Institute/GRAACC/UNIFESP, Endocrinology, Sao Paulo,
Brazil; 3Pediatric Oncology Institute/GRAACC/UNIFESP, Epidemiology, Sao Paulo,
Brazil; 4Pediatric Oncology Institute/GRAACC/UNIFESP, Pediatric Surgery, Sao Paulo,
Brazil
Background/Objectives: Over 80% of patients with Wilms tumor (WT) can be cured
from their disease, most of them with minimal late effects; nonetheless, patients with
advance stage tumor, unfavorable histology or disease relapse are at increased risk of
long-term complications. Objectives: to assess renal dysfunction, cardiomyopathy,
musculoskeletal deformities, puberal problems, infertility and second neoplasm in WT
survivors.
Design/Methods: From 1991 to 2001, 204 patients with WT were registered and 126
were eligible for the study: 70 from group 1 (patients treated from 1991 to 2001, on the
Brazilian Cooperative Group protocol - GCBTTW) and 56 from group 2 (treated from
2002 to 2011, on SIOP protocol). We reviewed the medical charts, performed a full
physical exam (vital signs, anthropometric measurements, body composition, puberal
development and musculoskeletal deformities), and assessed renal and cardiac function.
Results: Initial treatment was different between the two groups: GCBTTW indicated
initial surgery and SIOP preoperative chemotherapy. Intraoperative tumor rupture,
abdominal radiation and use of doxorubicin were more common in group 1.
Seventy-nine patients underwent a complete evaluation: 32 from group 1 and 47 from
group 2. No differences between the groups were noted regarding weight and BMI
z-scores, abdominal fat, musculoskeletal deformities, pubertal development,
cardiomyopathy or renal dysfunction. Group 1 patients had shorter standing height and
sitting height than group 2. Radiation affected the growth in both groups; however, this
effect was statistically worse in group 1 patients, who had already reached their final
height. Hypertension (29.1%) was the most common late effect, followed by reduction
of the glomerular filtration rate (26.6%), musculoskeletal deformities (24.1%), cardiac
(21.9%) and pubertal abnormalities (2.5%).
Conclusion: At least one late effect was found in 63.3% patients; 39.2% presented only
one complication; 20.3% two and 3.8% three. Despite high cure rates, long-term
follow-up is required in survivors of WT.
PD-077
REDUCED USE OF RADIOTHERAPY IN THEMANAGEMENT OF
METASTATIC WILMS TUMOR
H. Halalsheh1, T. Ismael1, K. Ghandour2, A. Almousa3, M. Qandeel4, F. Alajlouni4,
N. Alshawabkeh5, M. Albouhisi5, I. Sultan1
1King Hussein Cancer Center, Pediatric, Amman, Jordan; 2King Hussein Cancer Center,
Pediatric Surgery, Amman, Jordan; 3King Hussein Cancer Center, Rdaiation Oncology,
Amman, Jordan; 4King Hussein Cancer Center, Radiology, Amman, Jordan; 5King
Hussein Cancer Center, Nursing, Amman, Jordan
Background/Objectives: It is recognized that lung radiation can be avoided successfully
in the management of metastatic Wilms tumor(WT). We report our experience in
treating stage IV WT at our institution.
Design/Methods:We conducted a retrospective analysis of children (<18years) with
stage IV WT who presented from July 2006 until December 2014. Patients’
characteristics, treatment modalities and outcome were analyzed. All cases were
discussed in multidisciplinary clinic that included pediatric oncologists, radiologists,
pediatric surgeons and radiation oncologists. According to our local protocol,
radiotherapy (RT) was decided based on radiologic response after 5-6weeks of
initiating chemotherapy.
Results:We identified 21 patients (9males) who presented with stage IVWT. The median
age at diagnosis was 4.3years (range1.7to11.3). Fifteen patients (71%) had locally stage
III disease, 2 stage I, one stage II, and three had bilateral disease. Lung only metastasis
was present in 19 patients (90%); the other three had metastasis to: ovary in one patient,
lung and skin in the second, and lung and liver in the third. Four patients were treated
according to SIOP protocol while the rest were treated according to NWTS5. Upfront
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nephrectomy done only in three patients. Preoperative tumor rupture detected in four
patients; all of them received whole abdomen RT. Ten patients had complete response
in lung metastasis after 5-6weeks of chemotherapy and didn’t receive lung RT; the
other ten had partial response and were given whole lung RT. The estimated 5-yearEFS
and OS were 83%±8.9% and 89%+/-11%, respectively. Although not statistically
significant, there were less percentage of patients irradiated among those diagnosed
after 2010(42%vs.56%) and those treated with SIOP protocol (25%vs.53%).
Conclusion: Patients with metastatic WT had excellent outcome despite omitting
radiotherapy in half of our patients. Use of radiotherapy decreased over time, possibly
related to our team experience with response assessment. It might be decreased further
with judicious use of metastectomy to accurately assess response.
PD-078
CENTRAL RADIOLOGY REVIEW FORWILMS TUMOUR (WT) PATIENTS
REGISTERED IN THE UK IMPORT STUDY: A CHALLENGING BUT USEFUL
PROCESS
S. Irtan1,2, V. Pavasovic1, M. Weeks1, D. Edwards1, K. Pritchard-Jones1, Olsen3
1Institute of Child Health-University College of London, Cancer section- Developmental
Biology &Cancer Programme, London, United Kingdom; 2Trousseau Hospital–Paris
Sorbonnes Universités-UPMC Paris VI, Pediatric Surgery, Paris, France; 3Great Ormond
Street Hospital for children NSH Trust- London-UK., London, United Kingdom
Background/Objectives: Central Pathology Review introduced in the SIOP WT 2001
trial proved successful with rapid review allowing clinicians to modify treatment when
discrepancies were found. In the UK, Improving Outcome for Renal Tumours of
Childhood (IMPORT) study, started in 2012, Central Radiology Review (CRR) was
initiated with the ultimate goal to improve the definition of metastatic and bilateral
disease through standardisation of radiological techniques, and promote use of MRI.
Design/Methods: Images (CT and/or MRI scans) from diagnosis and preoperative
assessment are requested on all patients registered and a proforma’d report compiled
for each case reviewed. We report herein the first experience of CRR in WT in the UK.
Results: From September 2012 to March 2015, 192 patients were registered in the
IMPORT study from 21 centres. A hundred and twenty-two patients (63%) have had
imaging submitted for radiology review. Eighty-Nine patients (46%) had both
diagnostic and pre-operative images submitted, 32 patients (17%) only at diagnosis and
a single neonatal case had ultrasound alone. Diagnosis of lung nodules was done on
113 chest CT and 5 X-Ray. Abdominal assessment was performed on 41 CT and 83
MRI at diagnosis, four patients having had both. Discrepancies in the reporting of
possible lung metastases and bilateral lesions have been found in 12% of the patients
considered as metastatic or having CT only nodules and 3.5% of the patients
considered to have bilateral disease by either local or review radiologist. Only 4 patients
had insufficient imaging for formal assessment.
Conclusion: CRR has been shown feasible and useful when complete imaging sets were
received to influence clinical decision-making process. The next step will be to
implement ‘real-time’ feedback review as an integrated report combining radiology and
oncology contextual review.
PD-079
EFFECTS OF PROVIDING FINANCIAL SUPPORT TO PATIENTS WITH
WILMS TUMOR IN KENYA ON ABANDONMENT AND SURVIVAL RATES
J. Libes1, J. Musimbi2, F. Njuguna2, K. Patel3, O. Oruko4, F. Abdallah5, J. Githanga5,
J. Ndung’u6, E. Hansen7, M. Newton7, M. Mwachiro8, R. White8, J. Axt9, J. O’Neill10,
H. Lovvorn10
1Children’s Hospital of Illinois, Pediatrics, Peoria, USA; 2Moi Teaching and Referral
Hospital, USAID-Ampath Partnership, Eldoret, Kenya; 3Moi Teaching and Referral
Hospital, Immunology, Eldoret, Kenya; 4University of Nairobi, Pathology, Nairobi,
Kenya; 5University of Nairobi, Haematology and Transfusion, Nairobi, Kenya;
6University of Nairobi, Surgery, Nairobi, Kenya; 7AIC Kijabe Hospital, Surgery, Kijabe,
Kenya; 8Tenwek Mission Hospital, Tenwek Mission Hospital, Bomet, Kenya; 9Mbingo
Baptist Hosptial, Surgery, Bamenda, Cameroon; 10Vanderbilt University Children’s
Hospital, Pediatric Surgery, Nashville, USA
Background/Objectives: Survival from Wilms tumor (WT) in Kenya is a dismal 36% due
to on-therapy mortality and a 25% treatment abandonment rate. Parents who answered
multi-center surveys and tracing calls confirmed financial constraints as a barrier to
treatment completion. We therefore aimed to study the impact of financial support on
treatment abandonment and survival rates.
Design/Methods: In this prospective cohort study, we planned for all patients newly
diagnosed with WT at 4 collaborating Kenyan hospitals between 2012-2013 to be
offered $500 U.S. dollars toward their treatment in exchange for paraffin blocks of their
tumors at the time of resection. Patient visits and treatments were recorded in the
Kenyan WT registry and patients were called by our research nurse if they abandoned
therapy.
Results: Twenty-four patients were enrolled on this study, but due to poor
documentation, 1 was excluded from analysis. Ten patients abandoned treatment with
curative intent (43.5%). Nine patients died while on-therapy (39.1%) and 4 patients
remained alive and adherent to treatment (17.4%). Of the patients who abandoned
treatment, 10% abandoned prior to post-operative chemotherapy, 60% abandoned
during post-operative chemotherapy and 30% abandoned prior to radiation therapy.
Fifty percent of patients who abandoned care were confirmed alive, giving a known
survival rate of 39.1% at 18 months after the last patient was consented. While
abandonment occurred slightly later than in our previous study, it actually occurred at a
higher frequency. This intervention therefore failed to reduce treatment abandonment
or increase survival.
Conclusion: Survival remains dismal despite provision of funding. Hospital
administrative issues with releasing funds were problematic at one site. Tracing calls
made to patients from all sites revealed continued financial barriers and parental beliefs
that the children were healthy and no longer needed therapy as the reasons for
abandonment. Financial provision without improved infrastructure and education is
insufficient to reduce treatment abandonment.
PD-080
LONG TERM FOLLOW-UP IN CHILDREN UNDERGOING NEPHRON
SPARING SURGERY FOR NON-SYNDROMIC UNILATERALWILMS TUMOR
R. Nerli1, S. Patil2, A. Patil2, S. C2, S. B2
1Belgaum, India; 2KLE’S Dr. Prabhakar Kore Hospital, Department of Urology,
Belgaum, India
Background/Objectives:Wilms tumor (WT) represents approximately six to seven
percent of all pediatric cancers and accounts for more than 95 percent of all tumors of
the kidney in the pediatric age group. Recently some centers have explored the role of
nephron sparing procedures in children with unilateral Wilms tumors because of the
concern about late occurrence of renal dysfunction after unilateral nephrectomy. We
assessed the long term renal functional outcome after parenchymal-sparing procedure
for non-syndromic unilateral Wilms tumor at our center.
Design/Methods:We retrospectively reviewed the records of all children with unilateral
Wilms tumor who had undergone nephron sparing surgery at our center. Patient’s
long-term renal function, tumor recurrence, and survival, were determined from a
review of each patient’s medical record.
Results: A total of eight patients underwent partial nephrectomy (PN) and the
remaining three with polar tumors underwent hemi-nephrectomy (HN) following
chemotherapy. Smaller tumor volumes were associated with not only preservation of
renal function but also increase in eGFR during the follow-up period. The median
preoperative eGFR was 106 and median eGFR at the last follow-up was 131.0.
Conclusion: In properly selected children with non-syndromic unilateral Wilms tumor,
nephron sparing surgery provides excellent renal function preservation.
PD-081
ABANDONMENT OF TREATMENT AT BASELINE IN THE COLLABORATIVE
WILMS TUMOUR AFRICA PROJECT
V. Paintsil1, L. Renner2, P. Hesseling3, L. Burns4, J. Kambugu5, M. Amoah6, F. Kouya7,
D. Haileyesus8, E. Molyneux9, T. Israels10
1Komfo Anokye Teaching Hospital, Kumasi, Ghana; 2Korle-bu Teaching Hospital, Child
Health, Accra, Ghana; 3Stellenbosch University, Paediatrics and Child Health, Cape
Town, South Africa; 4World Child Cancer, Head of Operations, London, United
Kingdom; 5Uganda Cancer Institute, Paediatric Oncology, Kampala, Uganda; 6Komfo
Anokye Teaching Hospital, Paediatric Surgery, Kumasi, Ghana; 7Mbingo Baptist
Hospital, Paediatric Oncology, Bamenda, Cameroon; 8Tikur Anbessa Specialized
Hospital, Paediatric Oncology, Addis Ababa, Ethiopia; 9College of Medicine,
Paediatrics, Blantyre, Malawi; 10VU University Medical Center-Amsterdam, The
Netherlands K, Paediatric Oncology, Amsterdam, Netherlands
Background/Objectives: Incomplete treatment (often called abandonment of treatment)
is a major cause of treatment failure in low-income countries. Poverty, direct cost of
treatment and associated costs for the family play a major role. A consensus adapted
Wilms tumour treatment guideline is implemented in 8 centres in sub-Saharan Africa.
The treatment guideline includes strategies to prevent incomplete treatment. We
performed a baseline evaluation of the situation before the start of the project to help
decide on priorities to improve outcome and to assess improvements over time.
Design/Methods: A retrospective chart review was performed of patients admitted with
Wilms tumour in the three years (2011-2013) preceding the collaborative project. The
percentage of patients who did not start or complete their treatment was documented.
We interviewed representatives from the participating institutions about costs of
medical treatment, health insurance, government and external support and remaining
treatment costs for the parents. Availability of money for travel to the hospital and
accommodation and food during the stay in the hospital was documented as was the
availability of adequate counseling.
Results: Average rate of incomplete treatment was 31% (54/176) ranging from 14%
(8/59) to 48% (26/54). All centres have strategies in place to prevent incomplete
treatment but lack the funds to completely cover the costs for parents. The remaining
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costs of treatment for the parents range from around US$ 100 in Malawi to US$ 1100
in Ghana. Some centres pay for travel and provide food during the hospital stay.
Conclusion: Incomplete treatment is the most common cause of treatment failure and
this is preventable. We aim to reduce incomplete treatment to less than 10%. Our
strategy includes funding of medical treatment and associated costs, adequate
counseling and careful documentation of contact details to enable active follow up.
Poster Discussion: Retinoblastoma
PD-082
IMPROVEMENT IN THEMANAGEMENT AND OUTCOME OF
RETINOBLASTOMA AT CHILDREN CANCER HOSPITAL, KARACHI,
PAKISTAN AFTER INITIATION OF AMULTIDISCIPLINARY TEAM
M. Ashraf1, M.R. Khan2, M.H. Chatni3, U. Vayani3
1Children Cancer Hospital, Karachi, Pakistan; 2Children Cancer Hospital, Oncology,
Karachi, Pakistan; 3Patel Hospital, Eye, Karachi, Pakistan
Background/Objectives: To analyze data of children with Retinoblastoma treated after
initiation of a multidisciplinary team of ophthalmologist, oncologist, radiotherapist,
psychologist, social worker ocularist and compare it with the historical control.
Design/Methods: Before initiation of a multidisciplinary team the outcome of
Retinoblastoma at our institution had been dismal with abandonment rate up to 50%,
poor eye salvage, lack of rehabilitation and a dismal overall survival (including
abandonment) of 25%. In July 2012 collaboration began between pediatric oncology
and ophthalmology departments of two hospitals in Karachi to develop a
multidisciplinary Retinoblastoma team. Retinoblastoma treatment guidelines were
finalized. All new cases were discussed in monthly tumor board. Data were
prospectively collected. Implants were put at the time of enucleation and prosthesis
were put after the completion of treatment. The documentation of staging, protocol
compliance, enucleation, adverse histopathology factors, eye salvage, abandonment,
placement of implant and prosthesis, screening of siblings and follow up visits were
analyzed and compared with the historical control.
Results: Abandonment rate has reduced from 53% to 33%. More parents agreed for
upfront enucleation. The documentation of staging in diseased eye has improved from
75% to 94%. More children are treated according to the protocol guideline.
Histopathology is now reported as per guideline. Overall survival (including
abandonment) has increased from 23% in historical data to 48% in this study. Previously
less than 10% children were getting implant and prosthesis and there was no screening
of younger siblings. Now almost all children have implant at the time of enucleation
and more than 80% have eye prosthesis. Screening of siblings is offered to all families.
Conclusion: After initiation of multidisciplinary team there has been significant
improvement in treatment, outcome and rehabilitation of children with
Retinoblastoma.
PD-083
SUPERSELECTIVE OPTHALMIC ARTERY CHEMOINFUSION (SOAC) FOR
INTRAOCULAR RETINOBLASTOMA: AN EFFECTIVE STRATEGY FOR
GLOBE SALVAGE AND PREVENTION OF TREATMENT ABANDONMENT IN
LOW ANDMIDDLE INCOME COUNTRIES (LMIC)?
G. Chinnaswamy1, N. Shetty2, M. Prasad1, T. Vora1, N. Shetye1, A. Polnaya2,
S. Qureshi3, S. Kulkarni2, S. Kembhavi4, S. Banavali1
1Tata Memorial Hospital, Pediatric Oncology, Mumbai, India; 2Tata Memorial
Hospital, Intervention Radiology, Mumbai, India; 3Tata Memorial Hospital, Pediatric
Surgery, Mumbai, India; 4Tata Memorial Hospital, Radiology, Mumbai, India
Background/Objectives: Retinoblastoma(RB) continues to pose challenges in LMIC.
Unlike the developed world where cure rates are over 95%, outcomes in LMIC are
suboptimal due to delayed diagnosis and advanced disease. Additionally, a significant
factor for poor outcomes is therapy abandonment, reported to be upto 20% in Indian
subcontinent-primarily due to sociocultural non-acceptability of enucleation. Hence it
is only imperative that strategies for globe salvage without compromising survival
would have a beneficial impact in the overall outcomes of this highly curable disease.
We evaluated the role of SOAC for intraocular retinoblastoma in this context.
Design/Methods: This is a retrospective analysis of children with Group B-E
retinoblastoma who underwent SOAC between Jan’2013 to Dec’2014. All children
underwent standard baseline diagnostic and staging evaluation. Children with
extraocular disease, optic nerve involvement or metastatic disease were excluded.
Melphalan and Carboplatin were the drugs administered in age dependent doses.
Results: A total of 63 sessions of SOAC were performed on 21 eyes of 19 children. The
procedure was successful 92.06%. Favourable response (CR/PR) with resultant globe
salvage was seen in 17 eyes giving a globe salvage rate of 80.95% at median follow up of
11.7 months (1-22). 3/21 eyes ultimately needed enucleation and one eye underwent
EBRT due to inadequate response. 92% of treatment naïve eyes were salvaged and in
62.5% of previously treated eyes enucleation was avoided. Eye salvage rates were 100%
in sporadic retinoblastoma and 42% in familial retinoblastomas. Treatment
abandonment rate reduced from 26% (2010) to 2.6% (2014). Complications were
minimal (<10%) and included lid edema, opthalmic artery spasm and conjunctival
chemosis. Grade III neutropenia was seen in 5% of the procedures performed. The
results were comparable with Western published literature.
Conclusion: SOAC is a feasible and successful strategy for globe salvage in LMICs. It is
a powerful tool in the strategy to prevent treatment refusal and abandonment.
PD-084
INTRA-ARTERIAL CHEMOTHERAPY (IAC) AND/OR INTRA-VITREAL
CHEMOTHERAPY (IVC) AS AN ALTERNATIVE TO AVOID ENUCLEATION IN
INTRA-OCULAR RETINOBLASTOMA (RB) PATIENTS
S. Epelman1, P.L.B.J. Meirelles1, L.F. Teixeira1, R.S.S. Medeiros1, M.P. Vilas Boas1,
L.M. Silva1, F.M. Ferraz1, J.C. Aguirre Neto2, M.C.P. Marques1, E. Gorender1,
R. Melaragno1
1Santa Marcelina Hospital, Pediatric Oncology Department, Sao Paulo, Brazil; 2Santa
Casa de Misericordia, Pediatric Oncology Deparment, Belo Horizonte, Brazil
Background/Objectives: To evaluate efficacy and safety of IAC and IVC as first-line or
salvage therapy to patients with locally advanced RB.
Design/Methods: Retrospective observational cohort study with review of charts of RB
patients from 01/2012 to 12/2014. One to five cycles every three weeks of IAC with
melphalan for newly diagnosed patients or melphalan and topotecan for salvage
treatment ; with carboplatin to all patients with no response or progression after 2
drugs. Addition of local therapy was indicated between IAC procedures. IVC was
performed for all patients with vitreous seeds after IAC. Primary outcome was defined
as rate of enucleating after IAC and IVC. Secondary outcome was defined as objective
response of therapy by Retcam every one cycle of IAC/IVC. The safety was defined as
number of moderate to adverse events (grades 2 to 4).
Results: There were enrolled 33 patients (37 eyes), median age at diagnosis was 8,8
months ( 1 month to 3,5 years), 43% as salvage therapy and 57% as first-line therapy.
According to international classification was : 3% group B, 19% C, 67% D, 11% E. 18
were bilateral, four patients received IAC to both eyes. Median of cycles was 2 (1-5) and
drugs were 2 (1-3). 30 eyes were preserved and 7 eyes were enucleated, 3 received as
first-line and 4 as salvage. 24% had no response to IAC. Seven patients with vitreous
seeds received IVC, with no response in 1 eye. Six (18%) patients had ocular adverse
events, (grade 3 and 4) Neither haematologic event nor metastasis occurred.
Conclusion: IAC and IVC as first-line and salvage treatment were feasible and well
tolerated with high rate of response and preservation of eye (30/37). IAC and IVC can
be included in multimodal treatment strategy for RB patients.
PD-085
SMALL BLUE ROUND CELLS TUMORS AFTER HEREDITARY
RETINOBLASTOMA : LATE METASTATIC RELAPSE OR SECONDARY
TUMOR?
F. Pierri1, P. Fréneaux2, H. Brisse1, C. Dehainault3, I. Aerts1, N. Corradini4,
D. Frappaz5, O. Mariani3, K. Aitrais3, G. Pierron3, C. Houdayer3, F. Doz1,
F. Bourdeaut1
1Institut Curie, Pediatric Oncology, Paris, France; 2Institut Curie, Pathology, Paris,
France; 3Institut Curie, Genetic Oncology, Paris, France; 4CHU, Pediatric Oncology,
Nantes, France; 5CHU, Pediatric Oncology, Lyon, France
Background/Objectives: Long-term survivors of hereditary retinoblastoma (Rb) are at
an increased risk of developing and dying from a subsequent non-ocular cancer. Among
these late occurring secondary tumors, we observed rare cases of small blue round cells
tumors (SBRCTs), raising the issue of late metastatic relapse versus secondary tumors.
Design/Methods: From 1981 to 2014, we identified 8 children carrying a RB1
constitutional mutation and/or bilateral and/or familial Rb who developed a secondary
extra-CNS (Central Nervous System) tumor, labeled as SBRCT. 7/8 SBRCTs were
localized; 7 developed in bones and one in the ovary. Clinical, pathological, radiological
and genetic features of these 8 SBRCTs were centrally reviewed.
Results: The median age at SBRCT diagnosis was 12.8 years (y) [5.8-25.6] ; the median
time between last Rb treatment and SBRCT diagnosis was 11.5y [3.1-20.3]. The analysis
of pathological and radiological features could not discriminate between true secondary
SRBCT and late Rb metastatic relapse. The comparison between RB1 mutations in Rb
and matched SBRCT in 3/8 patients showed that i) the normal RB1 allele was
constantly lost, confirming that SBRCT development was due to the predisposition
context, and ii) the second RB1 hit in SBRCT and matched Rb were different, thus
proving that the former tumor was not derivative from the latter. Similarly, when
available (in 2/8 cases), the comparison of aCGH profiles from Rb and matched
SBRCT were strikingly different.
Conclusion: Our results argue in favor of SBRCT not being late Rb metastases, but
rather secondary undescribed tumors, linked to the RB predisposition syndrome.
Further analyses, such as transcriptome profilings and exome sequencings are ongoing
to better characterize this emerging type of SBRCTs.
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SECOND PRIMARYMALIGNANCIES IN CHILDREN AND ADOLESCENTS
AFTER RETINOBLASTOMA TREATMENT
P. Temming1,2, A. Viehmann3, M. Arendt3, L. Eisele3, C. Spix4, N. Bornfeld2,5,
W. Sauerwein6, K.H. Jöckel3, D. Lohmann2,7
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3University Hospital Essen, Institute for Medical Informatics- Biometry and
Epidemiology, Essen, Germany; 4University Medical Centre of Johannes Gutenberg
University Mainz, Institute of Medical Biostatistics-Epidemiology and Informatics,
Mainz, Germany; 5University Hospital Essen, Ophthalmology, Essen, Germany;
6University Hospital Essen, Radiotherapy, Essen, Germany; 7University Hospital Essen,
Human Genetics, Essen, Germany
Background/Objectives: Children with retinoblastoma carry a high risk to develop
second primary malignancies already in childhood and adolescence. This study
characterizes the type of pediatric second primary malignancies after retinoblastoma
treatment and investigates the impact of different treatment strategies and genetic
predisposition.
Design/Methods: All national patients treated for retinoblastoma at the German
reference center with a current age of 6-27 years were invited to participate in a study to
characterize late effects.
Results: Data on pediatric second primary malignancies were recorded from 488
patients. Ten developed a malignancy before the age of 18 years. For children
heterozygous for oncogenic variants of RB1 in germline, the cumulative incidence to
develop a second malignancy at the age of 10 years was 5.2 +/-1.8%. This results in an
elevated risk for sarcoma (SIR 147.98; 95% confidence interval: 39.81-378.87) and
leukemia (SIR 41.38, 11.13-105.95). The type of RB1 mutation or its origin showed no
significant impact. Previous radiotherapy increased the risk. Three of 91 children with
chemotherapy or combined radio- and chemotherapy developed acute leukemia.
Treatment modality influenced incidence, latency and type of malignancy, but 2
children with heterozygous RB1 germline mutation developed a second primary
malignancy without previous chemotherapy or external beam radiotherapy.
Conclusion: Screening for second primary malignancy is a critical part of pediatric
oncological follow-up in patients with RB1 germline mutation. Especially for patients
with sporadic unilateral retinoblastoma, genetic information is important for treatment
decisions and allows tailoring of follow-up schedules.The Deutsche Kinderkrebsstiftung
financed this study.
Poster Discussion: Soft Tissue Sarcomas
PD-087
TUMOR EXPRESSION OF SURVIVIN, P53, CYCLIN D1 AND OSTEOPONTIN
PREDICTS RESPONSE TO CHEMOTHERAPY IN CHILDRENWITHMPNST
G. Karpinsky1, M. Krawczyk2, E. Izycka-Swieszewska3, B. Kazanowska4, J. Godzinski5,
E. Adamkiewicz-Drozynska2, E. Szurowska6, R. Tuszynski7, E. Bien2
1Medical University of Gdansk, English Division Paediatric Oncology Scientific Circle,
Gdansk, Poland; 2Medical University of Gdansk, Department of
Paediatrics-Haematology and Oncology, Gdansk, Poland; 3Medical University of
Gdansk, Laboratory of General Pathology and Neuropathology, Gdansk, Poland;
4Medical University of Wroclaw, Department of Paediatric Oncology-Haematology and
Bone Marrow Transplantation, Wroclaw, Poland; 5Marciniak Hospital, Department of
Paediatric Surgery, Wroclaw, Poland; 6Medical University of Gdansk, 2nd Department of
Radiology, Gdansk, Poland; 7Hospital Health, Department of Paediatrics, Kwidzyn,
Poland
Background/Objectives: A number of altered cell cycle regulators and extracellular
matrix glycoproteins have been recently found involved in the development,
proliferation and progression of adult sarcomas. Their roles in pediatric malignant
peripheral nerve sheath tumours (MPNST) have not been investigated. The aim of the
study was to determine whether the tumor expression of survivin, p53, cyclin D1,
fibronectin (FN) and osteopontin (OPN) at diagnosis, correlate with the response to
neoadjuvant CHT in children with MPNST.
Design/Methods: Twenty six children (14M/12F; median age: 130 months), diagnosed
with MPNST and treated with CWS protocols between 1992 and 2013 in Poland were
included. Response to CHT was assessed after 3 cycles and defined as good (tumor
reduction 33% <100%) and poor (tumor reduction <33% or progression).
Immunohistochemical expression of analyzed markers was assessed on tissue
microarrays and determined as negative or positive based on semiquantitative criteria.
Results: Response to neoadjuvant CHT was assessable in 21 patients, of whom ten
(48%) achieved good response and 11 - poor response. It was significantly worse in NF1
patients.Survivin was expressed in 16/21 (76%) patients, OPN in 14 (67%), cyclin D1 in
11 (52%) and p53 in 11. Expression of p53, survivin and OPN was significantly more
frequent in poor responders than in good responders (p=0.00892, p=0.0124, p=0.0183
respectively). The correlation for cyclin D1 was borderline and FN not significant.
Most of good responders (8/10) expressed maximum of two markers and only one
patient expressed all 4 markers. The majority of poor responders (9/11) expressed at
least 3 markers and none of them had all markers negative.
Conclusion: It is suggested that survivin, p53, cyclin D and OPN are important in the
biology of MPNST and their tissue expression may help to identify patients prone to
benefit from neoadjuvant CHT.
PD-088
KAPOSI’S SARCOMA IN CHILDREN IN CAMEROON BEFORE AND DURING
THE HIV EPIDEMIC
B. Nkegoum1, D.C. Stefan2
1University Hospital center,Yaounde, Cameroon; 2Department of Paediatrics and Child
Health, Tygerberg Hospital and Stellenbosch University, Tygerberg, Cape Town, South
Africa
Background: Kaposi’s sarcoma was endemic in Cameroon before the AIDS epidemic,
involving lymph node, with poor prognosis. With the onset of AIDS increased
frequency of Kaposi sarcoma (KS) has been reported. However, studies in sub Saharan
Africa are scarce.
Patients and methods: This retrospective study included 78 cases of children with Kaposi
sarcoma observed in Cameroon within a period of 25 years. The study analyzed the
demographics, clinical presentation, laboratory investigations, treatment and prognosis.
Results: The demographic results showed 50 males and 28 females. The mean age is 5,9
years. Lymph node is the most common site of involvement and the diagnosis of early
cases is not easy. Skin lesions are found amongst 20% of the children.4 children in this
seies had eyes involvement. HIV serology was performed only in 50 % of the cases as
the parents usually refuse testing. Out of 50% of performed tests, 20% of the children
are HIV positive. The treatment for KS included chemotherapy and was based on
Cyclophosphamide, anthracycline and prednisone. The chemotherapy was associated
with HAART when the child is HIV positive. The prognosis of HIV negative children
after treatment is better than in HIV positive children.
Conclusion: Children with Kaposi sarcoma in Cameroon is a common finding before
and during AIDS epidemic.
PD-089
PEDIATRIC RHABDOMYOSARCOMA; CLINICOPATHOLOGICAL
FEATURES AND OUTCOME; A SINGLE INSTITUTION EXPERIENCE IN
PAKISTAN
S.A. Hamid1
1Indus Children Cancer Centre, Pediatric Hematology and Oncology, Karachi, Pakistan
Background/Objectives: To study clinico-pathological characteristics, and outcome of
Rhabdomyosarcoma in a tertiary care hospital in Pakistan.
Design/Methods: A retrospective chart review of children less than 18 years with initial
diagnosis of Rhabdomyosarcoma from 1998 till 2014. Most were treated with IRS
protocol, some received alternating courses of CVD (Cyclophosphamide, Vincristine,
Doxorubicin,) and IE (Ifosphamide, Etoposide). Local control (surgery and
radiotherapy) was based on protocol guideline. Demography, clinical presentation,
primary site, histopathology, stage, treatment received and outcome were analyzed.
Results: Total 155 children included with male to female ration of 1.5: 1. Median age
was 5 years (range 0.3 -18 years). Swelling and pain in the local site were the most
common clinical presentation. Head and neck (41%) was the most common primary
site followed by extremities (20%) genitourinary (13%), orbital (9%) and abdomen and
pelvis 7% each. Majority children presented with advanced stage disease (61% stage III
and 11% stage IV). Embryonal histology was the most common type. 43% children
received radiation to local site. 53/155 (35%) abandoned treatment,15/155(10%) were
given palliative treatment, 83/155 (55%) complied with protocol treatment. 18/155 (
12%) died due to toxicity 20/155 (13%) due to disease progression and relapses. Overall
survival with and without abandonment is 30% and 54%. Because second treatment
were not offered there was no difference between event free (EFS) and overall survival
(OS).
Conclusion: The outcome of rhabdomyosarcoma in our study is suboptimal. High rate
of abandonment, toxicity death and advanced disease at presentation are major adverse
factors.
PD-090
NEOADJUVANT ALTERNATING INTRAARTERIAL AND SYSTEMIC
CHEMOTHERAPY FOR TREATMENT OF ADVANCEDMALIGNANT
ABDOMINAL AND PELVIC TUMORS IN CHILDREN
M.J. LI1
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1Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, China
Background/Objectives:We present our experience of neoadjuvant alternating
intra-arterial and intravenous chemotherapy for the treatment of advanced malignant
abdominal and pelvic tumors in children.
Design/Methods: From 1999 to 2012, twenty-two patients aged 5 months to 14 years
with advanced malignant abdominal or pelvic tumors (not including hepatic and renal
tumors) received neoadjuvant alternating intra-arterial infusion chemotherapy and
systemic chemotherapy. There were rhabdomyosarcoma of urinary bladder in 5 cases,
ovarian yolk sac tumor in 5 cases, sacrococcygeal malignant germ cell tumor in 4 cases,
vaginal rhabdomyosarcoma in 3 cases, vaginal endodermal sinus tumor in 1 case,
endodermal sinus tumor of omentum in 1 case, pelvic rhabdomyosarcoma in 1 case,
pancreatoblastoma originating from mesentery in 1 case, and abdominal promoting
proliferation connective tissue tumor in 1 case.The selected artery for intra-arterial
infusion chemotherapy were bilateral iliac arteries for pelvic tumors and superior
mesenteric artery for abdominal tumors. The drugs were cisplatin 80 mg/m2,
pirarubicin 40 mg/m2, and vindesine 3 mg/m2. Intravenous chemotherapy using
vindesine, ifosfamide and etoposide administered 3 weeks after arterial chemotherapy.
Alternating arterial and intravenous chemotherapy with a 3-week interval repeated each
1 to 3 courses before operation. After operation the patients underwent intravenous
chemotherapy or radiotherapy.
Results: The most common side effects after alternating arterial and intravenous
chemotherapy were grade Ⅱ-Ⅲ bone marrow suppression. No drug-induced
cardiotoxicity, nephrotoxicity or hepatic dysfunction were observed. All patients were
followed-up 2 to 13 years (median 5 years). Disease-free survival rate was 86.4%
(19/22), and overall survival rate 90.9% (20/22).
Conclusion: Neoadjuvant alternating arterial and intravenous chemotherapy is safe and
effective for the treatment of advanced malignant abdominal and pelvic tumors in
children.
PD-091
DECLINE IN SURVIVAL IN PEDIATRIC RHABDOMYOSARCOMA IN
SWEDEN? CHARACTERISTICS AND OUTCOMES IN CHILDRENWITH
RHABDOMYOSARCOMA DIAGNOSED IN SWEDEN DURING THE YEARS
1984 -2010
S. Lychou1, G. Göran2, L. Gustaf1
1Uppsala University, Childrens University Hospital-Pediatric Oncology, Uppsala,
Sweden; 2Karolinska Insitute, Pediatric Oncology, Stockholm, Sweden
Background/Objectives: The outcome for paediatric rhabdomyosarcoma (RMS) in
Sweden was high during the nineties. During the last decade we have seen decreasing
trends in Overall Survival (OS). The aim was to investigate incidence, patient and
disease characteristics, treatment and outcome, and whether any reason for the possible
decline in OS could be found.
Design/Methods: Two hundred and ten children aged 0-14 years diagnosed with RMS
in the population-based Swedish Childhood Cancer Registry during the years
1984-2010 were included in the study. Complementary information was collected from
medical charts.
Results: The overall annual incidence was 4.9 per million. The 5-year OS for the periods
1984-1989, 1990-1999 and 2000-2010 was 59±7%, 78±5 % and 71±5% respectively.
When patients with localised disease were analysed separately, there was no difference in
outcome between the periods 1990-1999 and 2000-2010 (5-year OS 82±5% and
81±5%), but outcome in 1984-1989 (5-year OS 53±8%) was significantly worse. The
prevalence of metastatic disease was unexpectedly high during the last period with a
metastasis rate of 28% (p=.010), in contrast to 18% for the material in total.
Conclusion: The results suggest that a higher rate of metastatic disease may explain the
declining trend in OS in paediatric RMS in Sweden over the last decade. The reason for
this higher rate remains unclear but could be due to coincidence.
Poster Discussion: Supportive Care/Palliative Care
PD-092
THE IMPACT OF COMMUNICATIONWHEN A BROTHER OR SISTER IS
DYING OF CANCER AND THEREAFTER - A NATIONWIDE LONG-TERM
FOLLOW-UP IN SWEDEN
A. Eilegard Wallin1, G. Steineck2, T. Nyberg3, U. Kreicberg4
1Dalarna University College, Falun, Sweden; 2Sahlgrenska Academy- University of
Gothenburg, Oncology, Gothenburg, Sweden; 3Karolinska Institute, Clinical Cancer
Epidemiology, Stockholm, Sweden; 4Ersta Skondal University College, Palliative
Research Centre, Stockholm, Sweden
Background/Objectives: The purpose of this study was to examine siblings’ long-term
psychological health in relation to their perception of communication with their family,
friends and health-care professionals during their brother or sister’s last month of life.
Design/Methods: A questionnaire study was conducted nationwide in Sweden in 2009,
of individuals who had lost a brother or sister to cancer two to nine years earlier. Of the
240 siblings contacted, 174 (73%), participated. The Hospital Anxiety and Depression
scale (HADS) was used to assess psychological health. Data are presented as
proportions (%) and relative risks (RR) with 95% confidence interval (95% CI).
Results: Siblings who were not satisfied with the amount they talked about their feelings
with others during their brother or sister’s last month of life were more likely to report
anxiety, 15/58 (26%) than those who were satisfied, 13/115 (11%), RR=2.3 (1.2-4.5).
The same was true for those who had been unable to talk to their family after
bereavement, RR=2.5 (1.3-4.8). Avoiding health-care professionals for fear of being in
their way increased siblings’ risk of reporting anxiety at follow-up, RR=2.2 (1.1-4.6),
especially avoidance in the hospital setting, RR=6.7 (2.5-18.2). No such differences
were seen when the ill brother or sister was cared for at home.
Conclusion: Lack of communication was associated with a higher risk of anxiety in
bereaved siblings long-term, and so was avoiding health-care professionals, especially
when the brother or sister was cared for at the hospital.
PD-093
QUALITY OF CLINICAL PRACTICE GUIDELINES FOR FERTILITY
PRESERVATION IN CHILDRENWITH CANCER
A. Font-Gonzalez1, R.L. Mulder1, E.A.H. Loeffen2, J. Byrne3, E. van Dulmen-den
Broeder4, M.M. van den Heuvel-Eibrink5, W.J.E. Tissing2, M.D. van de Wetering1,
L.C.M. Kremer1, and on behalf of the PanCareLIFE Consortium
1Emma Children’s Hospital/Academic Medical Center, Pediatric Oncology, Amsterdam,
Netherlands; 2Beatrix Children’s Hospital-University Medical Center Groningen-
University of Groningen, Department of Pediatric Oncology/Hematology, Groningen,
Netherlands; 3Boyne Research Institute, Drogheda, Ireland; 4Department of Pediatric
Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands;
5Department of Pediatric Oncology/Hematology, Princess Máxima Center for Pediatric
Oncology, Utrecht, The Netherlands
Background/Objectives: There is little uniformity in fertility preservation care for
children diagnosed with cancer. To ensure high-quality care, evidence-based clinical
practice guidelines are essential. As a step towards guideline development, we aimed to
identify existing guidelines for fertility preservation in children and young adults
diagnosed with cancer, evaluate their quality, and explore differences in
recommendations.
Design/Methods:We performed a systematic search in PubMed (2000-October 2014),
guideline databases and websites of cancer, paediatric and fertility organisations. Two
reviewers evaluated the quality of the identified guidelines using the Appraisal of
Guidelines Research and Evaluation Instrument (AGREE II). From the high quality
guidelines, we evaluated areas of concordance and discordance among the
recommendations.
Results:We identified 26 guidelines, 20 guidelines focused on adults and children and 6
on adults only. Five guidelines were not appraised, as these were older versions from
other identified guidelines. Of the 21 guidelines that underwent a full critical appraisal,
the average AGREE-II domain scores varied from 0% on applicability and editorial
independence to 100% on clarity of presentation. We found areas of discordance
regarding the clinical questions “Who should receive fertility preservation?”, “What
fertility preservation method should be used?”, “When should fertility preservation be
discussed and initiated?”, “Who should be involved in the discussion and decision for
fertility preservation? and “What are the ethical aspects?”.
Conclusion: Our findings show that variations in fertility preservation recommendations
exist, which can affect the quality of care. Clinical practice guidelines including a
transparent decision process for fertility preservation at the start of cancer treatment
can help health care providers deliver optimum care and improve the quality of life of
children with cancer.
PD-094
INFECTIOUS COMPLICATIONS IN CHILDRENWITH ACUTE
MYELOGENOUS LEUKEMIA: INCREASEDMORBIDITY, BUT DECREASED
MORTALITY IN MULTICENTER TRIAL AML-BFM 2004
T. Lehrnbecher1, C. Perner2, J. Gilfert2, T. Klingebiel2, D. Reinhardt3, U. Creutzig4,
K. Bochennek2
1Frankfurt, Germany; 2University of Frankfurt, Children´s Hospital, Frankfurt,
Germany; 3University of Essen, Children´s Hospital, Essen, Germany; 4Medizinische
Hochschule Hannover, Children´s Hospital, Hannover, Germany
Background/Objectives: Infectious complications are an important cause of morbidity
and mortality in children undergoing therapy for acute myelogenous leukemia (AML).
Therefore, specific recommendations for the prevention and treatment of infectious
complications had been implemented in the protocol of the multicenter trial
AML-BFM 2004. In addition, since 1999, training courses on anti-infective strategies
are regularly offered to pediatric hematologists.
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Design/Methods: The medical records of children treated according to AML-BFM
2004 were reviewed and data on infectious complications were gathered by two of the
authors (CP and JG) in the hospital where the patient was treated. Patients with Down
syndrome were excluded from the analysis.
Results: Overall, 1,361 infections occurred in 405 patients [203 girls, 202 boys; median
age (range) at diagnosis 8 years (0-18)]. The median number of infections (range) per
patient was 3.3 (0-11). Specifically, fever of unknown origin (FUO) was observed in
55.5% of the infectious episodes (n=756), clinically documented infections in 10.6%
(n=144), and microbiologically documented infections in 33.9% (n=461). Neutropenia
was present in 1,251 (90%) of all infectious episodes. Bacteremia was diagnosed in 325
episodes, of which were 18 (5.5%) polymicrobial. Overall, 245 Gram-positive and 101
Gram-negative pathogens were isolated in the blood. A total of 9 children died due to
infectious complications (median time after diagnosis of AML: 23 days). As compared
to the multi-institutional trial AML-BFM 93, which had a lower dose-intensity than
BFM-AML 2004, the incidence of infectious complications was significantly higher
(2.8 versus 3.3 infectious episodes per patient; P=0.046), whereas the infection-related
mortality had significantly decreased (6.6% versus 2.2%; P=0.004).
Conclusion: Specific anti-infective recommendations in the treatment protocol and the
implementation of training courses in the education of pediatric hematologists may be
the reason of reduced infection-related mortality in children with AML. However,
further studies are needed in order to decrease infection-related morbidity.
PD-095
NON-PHARMACOLOGICAL ANTI-INFECTIVE MEASURES MAY
INFLUENCE INFECTIOUS COMPLICATIONS IN CHILDRENWITH ACUTE
MYELOGENOUS LEUKEMIA
T. Lehrnbecher1, E. Salzmann-Manrique2, T. Klingebiel2, D. Reinhardt3, U. Creutzig4,
L. Sung5, L. Tramsen2
1Frankfurt, Germany; 2Children´s Hospital, Pediatric Hematology and Oncology,
Frankfurt, Germany; 3Children´s Hospital, Pediatric Hematology and Oncology, Essen,
Germany; 4Medizinische Hochschule Hannover, Pediatric Hematology and Oncology,
Hannover, Germany; 5The Hospital for Sick Children, Division of
Haematology/Oncology, Toronto, Canada
Background/Objectives: Infections are an important cause of morbidity and mortality
in children treated for acute myelogenous leukemia (AML). Although most centers
apply non-pharmacological anti-infective measures, little is known on their impact on
infectious outcomes.
Design/Methods:We surveyed sites to determine institutional standards regarding
recommended restrictions of social contacts (6 items), pets (5 items), and food (8 items)
in children treated for AML according to AML-BFM 2004. A scoring system was
developed with a restriction score for each item (2 for always restricted, 1 for sometimes
restricted, and 0 for no restriction), resulting in a total restriction score ranging from 0
to 38. Univariate and multiple Poisson regression were used to estimate the impact of
the restrictions on the incidence ratios of fever, bacteremia, pneumonia and diarrhea
during intensive treatment.
Results: Data on non-pharmacological anti-infective measures were available from 37
institutions treating 429 children with AML. Median (range) of the overall restriction
score was 29 (13-37). When combining all items (social contacts, pets, and food), there
was a small, but significant influence of the restriction score on the incidence of fever
[IRR (incidence rates ratio) 0.98 (95%CI 0.978-0.998); P=0.022] and bacteremia [IRR
1.02 (1-1.046); P=0.045]. Further analysis demonstrated that a higher restriction score
of social contacts increased the incidence of bacteremia [IRR 1.21 (1.074-1.377);
P=0.002], whereas a higher restriction score of pets decreased the incidence of
pneumonia [IRR 0.877 (0.755-0.993); P=0.038]. No other non-pharmacological
anti-infective measures had an impact on the incidence of any of the infectious
complications analyzed.
Conclusion: Our data suggest that non-pharmacological anti-infective measures may
have some impact on the incidence of fever and bacteremia. However, since we did not
include potential confounders such as antibiotic prophylaxis, results may be
confounded by other supportive care practices. More research is required to identify the
independent effect of non-pharmacological interventions.
PD-096
EXPERIENCES OF EARLY DISCHARGE, WITH A FOCUS ON PAEDIATRIC
FEBRILE NEUTROPENIA: A META-ETHNOGRAPHY
J. Morgan1, J. Cleminson1, L. Stewart1, R. Phillips1, K. Atkin2
1University of York, Centre for Reviews and Dissemination, York, United Kingdom;
2University of York, Department of Health Sciences, York, United Kingdom
Background/Objectives:Many children have no significant sequelae of febrile
neutropenia. A systematic review of clinical studies demonstrated patients at low risk
of septic complications can be safely treated as outpatients using oral antibiotics, with
low rates of treatment failure. However, this review raised concerns that reductions in
therapy, particularly outpatient treatment, may not be acceptable to patients, parents
and healthcare professionals.
Design/Methods: This meta-ethnography explored qualitative studies to inform theories
of experiences of early discharge in paediatric febrile neutropenia, including reports a)
from studies of adult febrile neutropenia, for its disease specific data, and b) from other
paediatric conditions, to provide a broader social context. Systematic literature
searching preceded our analysis which used an adapted version of Noblit and Hare’s
phases of meta-ethnography.
Results: Nine papers were included. The overarching experience of patients, parents
and healthcare professionals is that decision making in early discharge is complex and
difficult. This experience is influenced by various common factors, including fear,
timing and resources. Within this decision making, we identified two distinct themes.
First, families struggled with some practical aspects associated with maintaining
successful treatment regimens, namely childcare, finances and attendance at follow-up.
Second, parents struggled with various social and emotional issues raised by early
discharge. These included social isolation, relational and environmental issues. In
linking these two themes, participants noted the importance of continuity of care and
the need for information if they accepted early discharge. Participants described
strategies that might circumvent some of the practical challenges faced and alleviate
some of the feelings of isolation experienced.
Conclusion: Decision making about accepting early discharge is complex, featuring
practical, social and emotional considerations along with a desire for more information
and continuity of care. This work should inform the design of supportive care services
and the development of future research strategies.
PD-097
GASTROSTOMY COMPLICATIONS IN ONCOLOGY PATIENTS – A
NATIONAL STUDY
H. Thakkar1, S. Lane2, K. Lakhoo1
1John Radcliffe Hospital- Oxford University Hospitals NHS Trust, Department of
Paediatric Surgery, Oxford, United Kingdom; 2John Radcliffe Hospital- Oxford
University Hospitals NHS Trust, Department of Paediatric Haematology/Oncology,
Oxford, United Kingdom
Background/Objectives: Survival from childhood cancers has substantially increased
over the decades. Up to 50% experience some degree of malnutrition. This is related to
the both the disease and it’s treatment. Gastrostomy feeding provides a means of
supplemental nutritional support. Neutropenia can increase the risk of gastrostomy
complications. We sought to assess the incidence of such complications nationally
across paediatric surgical oncology centres.
Design/Methods: All national paediatric surgical oncology centres were contacted for
participation through a national committee. An audit pro-forma was designed for data
collection. This included patient demographics, patient diagnosis, treatment protocol,
dates of gastrostomy insertions/changes, need for granulocyte colony stimulating factor
(GCSF) treatment and any complications. All patients with a gastrostomy sited
between January 2012 and December 2013 were included in the study.
Results: Four centres responded for participation in the study with a total of 49 patients
in the study period. 71% of patients had a diagnosis of either central nervous system
(primarily medulloblastoma) or other solid extra-cranial malignancies. The median age
at insertion of gastrostomy was 8 years (10months-17yrs). Median duration between
last chemotherapy and gastrostomy insertion was two weeks (1-30 weeks). 25% of
patients were given GCSF prior to gastrostomy insertion in line with reducing counts.
47% of patients had their gastrostomies removed within two years of insertion with a
median duration of use of 9 months (2-31 months). Only one patient had their
gastrostomy removed for recurrent infections when neutropenic. Overall there was a
16% infection rate, mainly with Staphylococcus aureus causing superficial skin
infections. One other patient developed a local myositis and one patient suffered from a
blocked gastrostomy.
Conclusion: Gastrostomy feeding appears to be safe in oncology patients with minimal
complications. The duration of use is often short providing an effective means of
supporting nutrition in a catabolic state.
PD-098
RESTING ENERGY EXPENDITURE AND BODY COMPOSITION IN
CHILDRENWITH CANCER: RESULTS OF A CROSS-SECTIONAL
COMPARATIVE STUDY
G. Tseitlin1, M. Konovalova1, A. Vashura1, S. Rudnev2, O. Starunova3, D. Nikolaev3
1D.Rogachev Federal Research Centre of Pediatric Hematology-Oncology and
Immunology, Rehabilitation, Moscow, Russia; 2Institute of Numerical Mathematics of
the Russian Academy of Sciences, Moscow, Russia; 3Scientific Research Centre ‘Medas’,
Moscow, Russia
Background/Objectives: The assessment of body composition and energy requirements
in children with cancer is necessary for the development of individualized nutritional
support regimens and recommendations. Our aim was to estimate body composition of
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children with cancer, to compare measured versus predicted energy requirements, and
to develop new predictive equations for use in pediatric oncology.
Design/Methods: Resting energy expenditure (REE) by indirect calorimetry and body
composition by bioimpedance analysis (BIA) were accessed in three groups of children
aged 5–18 years. Group 1 (n=181) – patients in remission of cancer, group 2 (n=55) –
children with cancer receiving chemotherapy or in the early period after hematopoietic
stem cell transplantation, group 3 (n=63) – hospitalized children with non-malignant
diseases of the gastrointestinal tract. To eliminate the influence of age and gender on the
intergroup comparison, body composition parameters were expressed as standardized
values (z-scores) relative to a reference group of healthy Russian children (n = 138,191).
Results: Group 1 was characterized by excess fat content and intact fat-free mass
(FFM). Groups 2 and 3 showed significant FFM depletion more pronounced in group
2 and masked by the increase in percentage fat. In groups 1 and 3, all used conventional
formulae (WHO, Harris–Benedict and others) underestimated REE as compared to
indirect calorimetry. A new formula for REE providing unbiased estimate in the group
1 was proposed: REE (kcal/day) = 28.7 × BCM (kg) +10.5 × Height (cm) – 38.6 ×
Age (years) – 134, where BCM is the body cell mass according to BIA (R2 = 0.67, SD
= 196 kcal/day).
Conclusion: Significant differences in malnutrition prevalence and body composition
were observed between the study groups. The suggested formula for REE can be used in
children with cancer in remission for the assessment of the effectiveness of dietotherapy
and nutritional support.
Poster Discussion: Surgery (IPSO)
PD-099
ESTABLISHMENT AND PRELIMINARY CHARACTERIZATION OF NOVEL
CELL LINES IN RARE PEDIATRIC TUMORSWITH PERITONEAL
DISSEMINATION
A. Duarte1, K. Gimenes2, M. Souza2, T. Sellani2, S. Tomaz2, S. Toledo3, M.T. Seixas
Alves4, E. Rodrigues2, S. Abib1
1Pediatric Oncology Institute - GRAACC/ Federal University of São Paulo- Brazil,
Pediatric Surgery, São Paulo, Brazil; 2Paulista School of Medicine-Federal University of
São Paulo EPM-UNIFESP, Laboratory of Cancer Immunobiology-Department of
Microbiology-Immunology and Parasitology, São Paulo, Brazil; 3Pediatric Oncology
Institute - GRAACC/ Federal University of São Paulo- Brazil, Genetic Laboratory, São
Paulo, Brazil; 4Pediatric Oncology Institute - GRAACC/ Federal University of São
Paulo- Brazil, Pathology, São Paulo, Brazil
Background/Objectives: Introduction: There is a lack of information about primary and
metastatic pediatric peritoneal tumors, which impair the diagnosis and treatment of
these children diseases. The inexistence or the low number of established and
well-characterized cell lines representative of these tumors contributes greatly to this
scenario. Tumor cell lineages can be studied in vitro, and novel targets for inhibition of
proliferation, metastasis and/or survival can be determined. Moreover, the sensitivity
for chemotherapeutic agents can also be analyzed in vitro, improving the preclinical
evaluation of novel treatment protocols. Objective: to establish cell lines of pediatric
tumors with peritoneal dissemination.
Design/Methods: Primary and metastatic pediatric peritoneal tumors were collected
immediately after surgeries, and samples were subjected to mechanical separation of the
cells and/or preparation of explants. In vitro cultures in enriched medium allowed the
isolation of 2 cell lines, out of 5 samples.
Results: Cell lines from a peritoneal desmoplasic tumor and from a peritoneal ovary
tumor metastasis were established and expanded. Preliminary characterization of these
cell lineages showed a high tumorigenic potential in immunosuppressed animals,
growing after subcutaneous and intraperitoneal inoculation. Markers of these
xenografted tumors were evaluated by immunohistochemistry, which highly expressed
human vimentin, and will be compared to the original human tumors. Sensitivity to
chemotherapeutic agents was also evaluated, and both cell lines showed resistance to
commonly used chemotherapeutic drugs.
Conclusion:We will continue our efforts on the complete characterization of these cells
lines, and will also pursue the isolation of other representative cell lines of peritoneal
dissemination of pediatric tumors.
PD-100
PREVALENCE OF C-KIT COPY NUMBER VARIATIONS (CNVS) IN
NEUROBLASTOMA
S. Agarwala1, R. Kapoor2, P. Chattopadhyay3, D. Gupta2
1All India Institute of Medical Sciences, Delhi, India; 2All India Institute of Medical
Sciences, Pediatric Surgery, Delhi, India; 3All India Institute of Medical Sciences,
Biochemistry, Delhi, India
Background/Objectives: Immunopositivity for c-kit has been observed by us in a number
of tissues of neuroblastoma patients. This study aimed at evaluating the prevalence of
c-kit copy number variations (CNVs) and its prognostic significance in neuroblastoma.
Design/Methods: Thirty-seven histologically confirmed neuroblastoma (NB) specimens
were evaluated. Genomic DNA was amplified through real-time PCR. Relative copy
number of c-kit gene was calculated with respect to three housekeeping genes, Succinate
dehydrogenase (SDH-C), N-acetylglucosamine kinase (NAGK), and Rnase P. Patient’s
samples having values 10, at least with respect to two reference genes, were considered
as amplified.
Results: Age ranged from 1-132 months (mean 38.48; SD±33.26). Seven (18.9 %) of 37
patients were below 12 months. There were 10 (27%) females and 27 (70.3%) males. The
location of tumors was adrenal in 26 (70.3%) and non-adrenal in 11 (29.7%). There
were 19 (51.3%) stage 4 and 18 (48.6%) non-stage 4 patients. Out of 37 cases 33 (89.2%)
received neo-adjuvant chemotherapy (NACT), of which 2 (5.7%) achieved CR, 27
(77.1%) PR, 2 (5.7%) NR and 2 (5.7%) had PD. Final response was assessed in 36
(97.3%) patients, of which CR was achieved in 21 (58.3%), PR in 3 (8.3%), NR in 3
(8.3%) and PD in 9 (25%). Out of 37 patients, 10 (27%) died while the rest 27 (73%)
survived till the end of the study.Real-time PCR, showed that c-kit CNVs was present
in only one case. Patient was 8 months old male with adrenal neuroblastoma, stage 4;
undifferentiated histology and high mitosis-karyorrhexis index (MKI). Making it
unfavorable histology. The patient died soon after presentation during workup without
receiving any treatment.
Conclusion: c-kit gene amplification was observed in only one case (2.7%). This suggests
that c-kit amplifications are rare events in neuroblastoma and may not be responsible
for the observed immunopositivity of c-kit. It may not be helpful in prognostication.
PD-101
GLYPICAN-3 AS A NOVELMARKER OF PROGNOSIS IN WILMS TUMOR
A. Vallonthaiel1, N. Wari1, A. Ahmed1, D. Saxena1, R. Walia1, V. Iyer1, S.R. Mathur1,
S. Agarwala2
1All India Institute of Medical Sciences, Pathology, Delhi, India; 2All India Institute of
Medical Sciences, Delhi, India
Background/Objectives: Glypican-3 (GP3), is a heparan sulfate proteoglycan, found in
fetal tissues and in some cancers, playing role in cell growth and differentiation and
tumorigenesis. Increased levels of GPC3 correlate with poor outcome in hepatocellular
carcinoma and hepatoblastoma. This study aimed to evaluate the expression of GPC3
in Wilms tumor and to correlate it with histopathology and outcome, and thereby
establish its prognostic role.
Design/Methods: A prospective study on 75 cases of Wilms tumor from 2009 to 2012.
Real time Polymerase chain reaction (RT-PCR) for Glypican mRNA was performed on
tumor and normal samples collected from fresh nephrectomy specimens. GPC-3 gene
expression in fold change was determined and was compared with adjacent normal
kidney and GAPDH. GPC-3 fold change of >1.5 was considered elevated. GPC3
expression was correlated with each of the prognostic variable independently.
Results: GPC3 was overexpressed in 37/75 (49.3%) cases. Stage was not significantly
related to GPC3 overexpression (p=0.2). GPC3 was overexpressed in 25/45 (56%) cases
that received neo-adjuvant chemotherapy while it was overexpressed in only 12/30
(40%) of those who were operated upfront (p=0.03). GPC 3 was found overexpressed
in 82% cases with blastema predominant histology while it was overexpressed in around
50% of the other histologies. All the 5 deaths among blastema predominant tumors and
4/5 deaths among triphasic tumor had overexpressed GPC3. The only death among the
stroma and epithelial predominant tumors did not have GPC3 overexpression. The
overall survival (OS) was 73% among those with GPC3 overexpression and 93% among
those without overexpression (p= 0.016;HR 5.3; 95CI 1.1-24.8). However, the event
free survival (EFS) was not significantly different among those with GPC3
overexpression (p=0.11;HR 2.09; 95CI 0.82-5.3).
Conclusion: Overexpression of GPC3 levels correlated with poor OS (p=0.016) but not
with EFS (p=0.11) among Wilms tumor. It might serve as a molecule for targeted
therapy in future.
PD-102
OUTCOME OF PULMONARYMETSTASECTOMY IN PEDIATRIC SOLID
TUMORS
V. Khanna1, S. Agarwala1, S.S. Panda2, S. Bakhshi3, M. Jana4, A.K. Gupta4,
M. Srinivas1, M. Bajpai1, V. Bhatnagar1, D.K. Gupta1
1All India Institute of Medical Sciences, Pediatric Surgery, Delhi, India; 2All India
Institute of Medical Sciences, Pediatric Surgery, Odhissa, India; 3All India Institute of
Medical Sciences, Medical Oncology-BRAIRCH, Delhi, India; 4All India Institute of
Medical Sciences, Radiodiagnosis, Delhi, India
Background/Objectives: To evaluate surgical management and outcome of patients
undergoing pulmonary metastasectomy.
Design/Methods: Retrospective review of patients operated for pulmonary metastases
from September 2001 till January 2015 for their presentation, surgery and outcome.
Results: A total of 46 patients underwent 69 thoracotomies for removal of 196 lung
metastases (range 1-20 metastases). Primary diagnosis was Osteosarcoma (OSa) 23;
Wilms tumor (WT)11, hepatoblastoma (HB)5, malignant germ cell tumor (MGCT)3
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and 1 each had Ewing sarcoma (EW), malignant mesenchymal tumor (MMT),
rhabdomyosarcoma (RMS) and synovial sarcoma (SS). Thirty-eight thoracotomies
were done for lung metastases that were already present at the time of diagnosis while
31 thoracotomies were done when lung metastases that presented as recurrence. Sixteen
patients (12 OSa, 3 HB and 1 WT) had bilateral metastases and 12 of them underwent
staged metastasectomy. One patient with bilateral re-recurrence followed by surgery on
one side and other whose metastases resolved with alternate chemotherapy did not
undergo second metastasectomy. Three patients with bilateral disease are waiting for
contralateral surgery following unilateral metastasectomy. Nine repeat thoracotomies
were required in 7 patients (5 OSa, 1 WT and 1 HB). Fifteen patients underwent
lobectomy (>1 lobe was removed in 4 patients), 31 patients had wedge resections, 9 had
subpleural resections and 11 had both wedge and subpleural resections. Only biopsy
was performed in 1 patient for an unresectable tumor. Two had negative thoracotomy.
Ten patents died and 20 patients (9 OSa, 5 WT, 4 HB, 1 MMT and 1 MGCT) had
re-recurrence in the lungs giving a 3-year overall survival of 77%(95 CI 58-88) and
3-year event-free survival of 43%(95CI 26-59).
Conclusion: Pulmonary metastasectomy, even when done for bilateral and
metachronous disease, is a viable option for achieving survival in patients. It leads to
acceptable event-free (43%) and overall survival (77%) rates in patients who otherwise
would have progressed and died.
PD-103
COMPARATIVE EFFICACY OF ULTRASOUND INVESTIGATION IS IN THE
DIAGNOSIS OF MALIGNANT ABDOMINAL TUMOR IN CHILDREN IN
OUTPATIENT CONDITIONS AND IN A SPECIALIZED ONCOLOGY
HOSPITAL
I. Begun1, R. Tarasevich1, I. Papkevich1
1Belarusian Research Center for Pediatric Oncology-Hematology and Immunology,
Functional diagnostic, Minsk region, Belarus
Background/Objectives: Ultrasonography is method of choice for primary diagnosis of
abdominal solid tumors in pediatric patients. However, there are significant proportion
of advanced forms of cancer among children admitted for inpatient treatment. The
purpose of this study was to compare the effectiveness of ultrasonic method for
primary diagnosis of pediatric abdominal malignancies on for outpatient phase and in
specialized clinic.
Design/Methods: Analyzed the medical records of 216 patients of both sexes aged 1 day
- 13 years (median 2.1 years), successively admitted for further examination and/or
treatment to pediatric oncology hospital. The spectrum of disease consisted from:
retroperitoneal neoplasms - 49 patients; tumor and tumor-like processes of the liver -
35, kidneys - 101, adrenal - 31. Was evaluated the diagnostic accuracy of the ultrasonic
method.
Results: The results of a comprehensive analysis of the data for the presence of solid
malignancies in a child using the estimates of the aggregate of the classical signs of
ultrasound are detailed documented in outpatient conditions in only one-fifth of cases,
and in the hospital - in three-quarters of cases. Accuracy of the method in evaluation of
the diagnostic data levels (differentiation of the tumors and tumors-like processes;
differentiation benign and malignant tumors; assumptions about the nosological form)
in these cases was in the range of 82% -31% and 95% -53% in outpatient conditions and
in the hospital respectively. With regard to nosological forms - the most lowest
effectiveness of ultrasound diagnosis according with these criteria was set for
retroperitoneal tumors.
Conclusion: The effectiveness of ultrasound diagnosis to outpatient phase was lower
than that in a specialized medical facility. It is necessary to make more use of the
possibility of comprehensive assessments of ultrasound data according to diagnostic
criteria of malignancy successively from ascertaining the existence of the tumor till to
assess the symptoms of malignant growth.
PD-104
OUTCOMES OF PRETREATMENT RE-EXCISION AFTER UNPLANNED
EXCISIONS FOR NONRHABDOMYOSARCOMA SOFT TISSUE SARCOMAS
IN CHILDREN
M. Bhagat1, S. Qureshi2, T. Vora3, S. Kembhavi4, S. Laskar5, M. Prasad6,
M. Ramadvar7, G. Chinnaswamy3, P. Kurkure8
1Tata Memorial Hospital, Mumbai, India; 2Tata Memorial Hospital, Division of
Pediatric Surgical Oncology, Mumbai, India; 3Tata Memorial Hospital, Pediatric
Oncology, Mumbai, India; 4Tata Memorial Hospital, Department of Radiology,
Mumbai, India; 5Tata Memorial Hospital, Department of Radiation Oncology, Mumbai,
India; 6Tata Memorial Hospital, Department of Pediatric Oncology, Mumbai, India;
7Tata Memorial Hospital, Department of Pathology, Mumbai, India; 8Tata Memorial
Hospital, Pediatric Oncology, Mumbai, India
Background/Objectives: It is not uncommon to come by children with initial unplanned
surgical intervention for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS). The
aim of this study was to evaluate the presence of residual disease, the treatment
outcomes in terms of local and distant recurrence and survival in patients with
unplanned excision of NRSTS treated with pretreatment re-excision (PRE).
Design/Methods: The records of 35 patients presenting with unplanned excision of
NRSTS between January 2006 and October 2014 were reviewed. The records were
compared with 25 patients with planned excision of NRSTS in the similar period.
Results: Total 33 patients underwent PRE and two were considered unsuitable for PRE.
Tumor was present in the PRE specimen of 16 (48.5%) patients. Brachytherapy was
offered to 12 of the 21 patients who received radiotherapy following PRE. On
comparison with planned excision, patients with extremity (p=0.01) and invasive
tumors (p=0.03) more often had a PRE. There were four relapses (distant: 3, local: 1) in
the PRE group and seven relapse in the planned excision (distant: 5, local: 1 and
progression: 1) group (p=0.17). The 5-year overall and event free survival were,
respectively 95.5% and 83.6% for the PRE group and 86.6% (p=0.3) and 65.7%
(p=0.08) in the planned excision group.
Conclusion: The probability of residual disease following unplanned excision of
NRSTS is high therefore PRE should be considered whenever feasible. The outcomes
following PRE are similar to that with planned excision. An associated advantage is the
feasibility of brachytherapy during PRE which could minimize the morbidity
associated with external radiotherapy.
PD-105
NEOADJUVANT THERAPY FOR LOCALISED, INITIALLY UNRESECTABLE
NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS
M. Bhagat1, S. Qureshi2, S. Kembhavi3, V. Tushar4, M. Ramadwar5, G. Chinnaswamy4,
S. Laskar6, P. Kukure4
1Tata Memorial Hospital, Mumbai, India; 2Tata Memorial Hospital, Pediatric Surgical
Oncology, Mumbai, India; 3Tata Memorial Hospital, Department of Radiodiagnosis,
Mumbai, India; 4Tata Memorial Hospital, Pediatric Oncology, Mumbai, India; 5Tata
Memorial Hospital, Department of Pathology, Mumbai, India; 6Tata Memorial
Hospital, Radiation Oncology, Mumbai, India
Background/Objectives: Treatment of localised initially unresectable
non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) is challenging considering the
unavailability of robust neoadjuvant therapy. The aim of this study was to describe the
neoadjuvant therapy and the outcomes in children with initially unresectable NRSTS.
Design/Methods: The records of patients with initially non-metastatic and unresectable
NRSTS treated between January 2006 and March 2014 were analysed.
Results: Non-extremity tumours (n=15) were the commonest amongst the 22 patients
analyzed. More than 80% of the patients had tumours with high-risk features (tumour
size > 5 cm, high grade, invasiveness). Neoadjuvant therapy included chemotherapy
alone in 20 patients while one patient each received radiotherapy alone or along with
chemotherapy. None of the patients had a complete response while major responses
(>50 regression) were recorded in 23.8% and minor (<50% regression) in 47.6% of
cases. Stable or progressive disease was seen in 28.6%. The 3-year event-free and overall
survival was 42.6% and 49.4% respectively. Of the nine relapses, three each were at the
local site, abdominal cavity and lung respectively. The response to neoadjuvant therapy
did not predict outcome.
Conclusion: Initially unresected NRSTS commonly present with high-risk features and
respond poorly to neoadjuvant therapy. The outcomes remain dismal, which compels
the need for more effective therapy for these patients.
PD-106
IS BLEOMYCIN EFFECTIVE ANTI- ANGIOGENIC AGENT FOR VASCULAR
ANOMALIES?
S. Bhatnagar1
1Mumbai, India
Background/Objectives: Vascular anomalies many a times pose a tremendous
therapeutic challenge due to type, site, rapid growth, disfigurement and complications.
Objectives: 1) To emphasize the need for early intervention in patients with vascular
anomalies especially of the head and neck. 2) To establish the efficacy of Injection
Bleomycin as sclerosant for vascular anomalies.
Design/Methods: Children with vascular anomalies (malformations) of varying sizes,
sites and behaviour, were selected for Injection Bleomycin therapy and subjected to
sclerotherapy regime three weeks apart in the dose 0.66units to 1unit/kg/dose diluted in
1:1 normal saline and not exceeding more than 1 unit/kg per session, between January
2004 till December 2014. The lesions were measured and photographed serially. The
clinical response and complications were recorded. Regression of lesions were termed
excellent (>75%), significant (50-75%) or poor (<50%).
Results: Total 117 children were included in the study, mean age being 16.3 months
(range, 2 months to 9 years ).The mean number of injections given was 5.6( range, 3-8).
The mean total dose administered was 30 mg (range, 15-42). 73 patients (62.4%)
achieved a response of greater than 75% reduction in size (51 had complete resolution).
28 (24%) showed 50-75% reduction in the size of the lesion while 16 (13.7%) showed <
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50% reduction in size. Ulceration occurred in 5 children and 78% developed patchy
hyperpigmentation. None developed pulmonary fibrosis.
Conclusion: Vascular lesions traditionally were left alone for spontaneous regression to
occur for which was neither certain nor complete and occurred if at all over many years,
or were treated surgically or with steroids giving partial responses and recurrences.
Moreover the lesions over head, face, neck cause disfigurement and are often rapidly
progressive. The anticancer, antiangiogenic agent Bleomycin cause permanent cure in a
large number of children providing excellent cosmetic results and with resolving minor
side effects of the drug.
PD-107
MANDATORY COCCYGECTOMY IN SURGICAL MANAGEMENT OF
SACROCOCCYGEAL TUMOURS
A. Coetzee1, R. Fisher2, L.C. Peres1
1Sheffield Children’s Hospital, Histopathology, Sheffield, United Kingdom; 2Sheffield
Children’s Hospital, Paediatric Surgery Unit, Sheffield, United Kingdom
Background/Objectives: Sacrococcygeal tumours are germ cell tumours within a diverse
group of masses that may occur within the region of the pericoccygeal area. At the time
of surgical resection the exact diagnosis is not always known. The UKCCLG guidelines
on resection of sacrococcgeal teratomas mandates coccygectomy, either primary or
delayed, due to risk of malignant recurrence.
Design/Methods: In a tertiary paediatric surgical centre, a retrospective review was
undertaken of all lesions resected from the pericoccygeal region to determine
compliance with mandatory coccygectomy for suspected or potential saccrococcygeal
teratoma. Cases were identified from pathology reports and SNOMED codes for
relevant topography and morphology within a 15 year period to 2014. Each case was
assessed to tabulate the precise diagnosis and presence or otherwise of coccygectomy
specimen.
Results: There were 19 tumours excised. Coccygectomy was performed in 10 cases. In 8
cases there was no evidence of coccygectomy and in one the presence or absence of a
coccyx was not apparent from the wording of the report. There were 14 germ cell
tumours resected; 11 mature teratomas and 3 immature teratomas. The remaining cases
were retrorectal cystic hamartomas (3), fibrolipoma (1), and lipoblastoma (1) In 43% of
germ cell tumours, mandatory coccygectomy was not performed. To date there has
been no tumour recurrence.
Conclusion: This review shows poor compliance with UKCCLG guidelines for
mandatory coccygectomy in suspected or potential germ cell tumours. The evidence
base for this guideline is controversial and practice worldwide varies. The implications
and a literature review will be presented.
PD-108
NEPHRON-SPARING SURGERY FOR UNILATERAL RENAL TUMOR IN
CHILDHOOD: TWENTY-TWO YEARS EXPERIENCE AT A SINGLE CENTER
D. Cozzi1, S. Ceccanti1, S. Frediani1, I. Falconi1, S. Bosco2, F. Cozzi1
1Sapienza University of Rome, Pediatric Surgery Unit, Rome, Italy; 2Sapienza University
of Rome, Pathology Unit, Rome, Italy
Background/Objectives:Whether the adverse effects of nephrectomy for unilateral renal
tumor (URT) in childhood outweigh the adverse effect of nephron-sparing surgery
(NSS) remains controversial. The aim of present study was to evaluate the adverse
effects of nephrectomy and NSS in our cohort of children with URT.
Design/Methods:We conducted a retrospective review of the records of all children with
URT who underwent surgery at our institution between 1992 and 2014. All patients
older than six months of age had neo-adjuvant chemotherapy and delayed surgery.
Nephrectomy was performed in 31 children, partial nephrectomy in 8 children, and
tumor enucleation in 6 children. Renal dysfunction (RD) was defined as eGFR < 90
ml/min/1.73m2.
Results: One child treated with multiple Wilms tumor enucleations underwent
unnecessary completion nephrectomy elsewhere. Another child, with stage II disease
after partial nephrectomy, developed local recurrence and underwent completion
nephrectomy and pericaval lymphadenectomy associated with radiotherapy and
chemotherapy (stage III disease). In both instances, kidney remnants were tumor-free.
Three children who underwent partial nephrectomy presented positive margins and
were successfully treated with chemotherapy alone (stage II disease). At mean ± SD age
of 14.6 ± 6.4 years after NSS the overall and the event-free survival rates were both
100% (one patient is still under treatment). None of the patients treated with NSS
presented with renal dysfunction, whereas 9 of 23 patients with stage I-III who
underwent nephrectomy presented with RD (p=0.01).
Conclusion: In our experience partial nephrectomy or tumor enucleation for treatment
of children with URT appear to be oncologically safe at a reasonable therapy price. At
short-term follow-up, more than 1/3 of the patients who underwent nephrectomy may
be at the increased risk for cardiovascular disease and overall mortality.
PD-109
ASSESSMENT OF DURATION OF THEMAIN STEPS OF NEPHRECTOMY
FORWILMS TUMOUR
J. Godzinski1,2, K. Bronowicki2, M. Krzeszewski2, R. Malgorzata2
1Wroclaw Medical University, Chair of Emergency Medicine, Wroclaw, Poland;
2Marciniak Hospital, Department of Paediatric Surgery, Wroclaw, Poland
Background/Objectives: Since 1950-ties, the nephrectomy for Wilms tumour (WT) has
been composed of well specified steps performed the similar way. Aim of the study was
to assess the importance and the duration of the particular steps.
Design/Methods: 55 WT patients submitted to post-chemotherapy nephrectomy by the
same operating team within last 4 years. Nephron sparing resections and patients with
the IVC thrombus were excluded (21 cases). Further analysis was conducted on 34 pts
with unilateral WT. The surgical steps analysed were: approach, abdominal inspection,
access to the renal pedicle, identification and ligation of renal vessels, resection of the
tumour, lymph nodes sampling and closure of the abdomen.
Results: The approach used was transvers trans-abdominal and lasted 10-15 minutes
(M=12). As all the patients had CT or MRI prior to surgery, the abdominal inspection
focused on searching for peritoneal implants and lasted 3-7 minutes (M=4). The
Kocher manoeuvre (right side) or laterocolonal (left sided) access to the renal pedicule
lasted 5-15 minutes (M=12), the identification and ligation of renal vessels - 5-22
minutes (M=12), resection of the tumour in together with the adipose capsule - 12-25
minutes (M=14), the lymph nodes sampling (>6) - 8-20 minutes (M=14), closure of the
abdomen - 12-30 minutes (M=20). The duration of the whole procedure lasted from 60
minutes to 2 hrs (M=80 minutes). There were no major intra operative complications
(tumour ruptures or major vascular injuries).
Conclusion: Summary: Post-chemotherapy nephrectomy for WT is well organised
procedure usually lasting less than 2 hrs. Time consuming appeared the closure of the
abdomen (M=20, 25% of the whole operating time), whereas so called crucial steps as
ligations of the renal vessel and dissection of the mass were shorter (M=12 and 14
respectively). This seems to confirm the need of comfortable exposure and adequate
order of steps.
PD-110
INNOVATIVE PROTON AND CARBON ION-BASED RADIOTHERAPEUTICAL
PROGRAM. PERSPECTIVES AND BUSINESS PLAN OF A FUTURE FRENCH
PROGRAM, INCLUDING A PÆDIATRIC POPULATION
J.L. Habrand1, D. Stefan1, P. Lagalle2, O. Letac3, S. Longuemarre4, O. Minckes5,
K. Meflah6
1Department Radiation Oncology, Chief Department, Centre François Baclesse;
Department Radiation Oncology, Centre François Baclesse; 2CYCLAD Company,
Director, Centre François Baclesse; 3Biology Department, Chief Manager, Centre
François Baclesse; 4Business Department, Chief Department, Centre François Baclesse;
5Department Paediatric Oncology, University Hospital; 6Director, Centre François
Baclesse
Background/Objectives: Initiating a new program of hadrontherapy in France,
providing both protons and carbon ions, including a mixed adult (Ad) and pædiatric
(Ped) patients (pts) population. Assess the financial viability of the proton project,
based on current clinical indications, and expected availability of 3 French Centers
within 5 years (Y).
Design/Methods: ARCHADE is a project that aims to develop hadrontherapy from
bench to bedside. It is estimated to 120 M€. It should become partially operational in
2018, for protontherapy (PT), in Ad and Ped pts, and fully operational 3 to 4 years later
for both particles. This ramping-up has been considered necessary to account for the
learning curve of this innovative technology. Financially, it will be supported by the
Sécurité Sociale national agency, based on an estimated 1,009 € reimbursement cost per
fraction in French pts and approx. 2,000€ in foreigners, and conventional fractionation.
This program will concern both currently validated indications, with emphasis on Ped,
and new indications. 345 pts /Y are expected in full capacity. Main Ped indications, have
been anticipated, as follows: sarcomas of bones (15), and soft tissue (20), brain (30),
neuroblastomas (15), others (10).
Results: Various simulations were realized. The expected optimal solution, is presented
for a mixed French (85%), and foreign (15%) population. Total “beam cost” (including
staff salaries) is estimated 2,300 to 2,500€/hr. Y1: 150pts (Ad: 125, Ped: 25); Total/Y:
#fractions: 4,500; beam time: 1,500; income: 4,900M€; expenditures (exp): 4,660
M€Y2: 250pts (Ad: 200, Ped: 50); Total/Y: #fractions: 7,500; beam time: 2,500; income:
8,100M€; exp: 7,450 M€Y1: 345 pts (Ad: 255, Ped: 90); Total/Y: #fractions: 10,750;
beam time: 3,790; income: 11,750M€; exp: 11,000 M€.
Conclusion: This ambitious project combining protons and carbon ions, looks
financially viable. A large proportion of foreign patients is recommended, since it allows
substantial financial flexibility. It seems not compatible with a clinical program devoted
entirely to paediatric patients.
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THE PERIPHERAL PORTACATH PROVIDES SAFE AND CONVENIENT
VENOUS ACCESS IN PAEDIATRIC AND ADOLESCENT PATIENTS
F. Herd1, F. Van Delft2, J. Goring3, K. Windebank2, H. Gabra3
1Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom; 2Great North
Children’s Hospital, Paediatric Onoclogy, Newcastle upon Tyne, United Kingdom; 3Great
North Children’s Hospital, Paediatric Surgery, Newcastle upon Tyne, United Kingdom
Background/Objectives: Adolescent patients with chronic conditions rely on permanent
venous access for safe treatment and supportive care. Traditionally venous access is
provided by a Hickmann or portacath (PaC) inserted in a central vein under general
anaesthetic. Lymphomas represent the most frequent malignancy in adolescents often
presenting with mediastinal masses, which complicates general anaesthetic (GA). We
explored the safety and feasibility of insertion of peripheral PaC which could be
performed under local anaesthetic. We present our case series of 18 patients.
Design/Methods: Eighteen patients underwent insertion of peripheral PaC into the
antecubital fossa of the non-dominant arm under ultrasound guidance at our
institution since Jan 2012. The medical records were reviewed to ascertain diagnosis,
age at insertion, mode of anaesthetic, time to removal and complications. Patients and
nursing staff were given a questionnaire to assess their experience and satisfaction with
peripheral PaC.
Results: Since 2012, 18 peripheral PaC were inserted by two consultants at our
institution. There were 11 female and 7 male patients aged between 13.58 years and 18.4
years. 4 PaC were inserted under local anaesthetic in patients who were not fit for GA
due to mediastinal mass or lung disease. At the time of analysis 7 ports remained in
situ, with a mean duration of 7.35 months (range 3 - 14.5 months). Removal of x PaC
was under LA in 7 cases and under GA in 2. Complications were observed in 7 cases
but only necessitated early removal or replacement in 2 cases (blockage and
disconnection). Thrombosis was not observed.
Conclusion: This study shows that the use of peripheral PaC is safe with acceptable
complications. The experiences and feedback from patients and nursing staff fully
supports the use of the peripheral PaC. We are exploring additional patient groups that
might benefit from this device.
PD-112
PROFILE OF SURGICAL TUMOURS PRESENTING TO A TERTIARY CENTRE
IN GHANA
A. Hesse1, W. Appeadu-Mensah1, V. Etwire2, S. Osei-Nketiah1, H. Glover-Addy2
1University of Ghana School of Medicine and Dentistry, Department of Surgery, Accra,
Ghana; 2Korle Bu Teaching Hospital, Department of Surgery, Accra, Ghana
Background/Objectives: Paediatric Surgical tumours span quite a diverse presentation.
The frequency of occurrence of such tumours differs from developed to developing
countries.
Design/Methods:We have reviewed the cases presenting to the Paediatric Surgery Unit
at the Korle-Bu Teaching Hospital in Accra, Ghana from 1st January 2013 to 31st
December 2014.
Results: There were 49 cases with a female to male preponderance of 1.7:1. Forty-two
percent of patients were under the age of 2 years. Seventy-one percent of cases had
Wilms tumour with only 29% being from other causes. Fifty-nine percent of surgeries
were for some form of nephrectomy. Of the final outcomes recorded, 60% were
discharged from the wards whilst 40% were transferred to the Paediatric Oncology
service or other specialised units.
Conclusion: In Ghana, the majority of paediatric surgical tumours seen are Wilms
tumours. A large number of the tumours seen are in patients presenting below the age
of 2 years. Late presentation is still a feature and more public education needs to be
undertaken at all levels.
PD-113
STEP BY STEP RESULTS OF 15 YEARS SURVEILLANCE OF PERMANENT
CENTRAL VENOUS CATHETERS IN PATIENTS WITHMALIGNANT TUMOR
Z. Jenovari1, B. Tamas1, Z. Sukosd1
1Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary
Background/Objectives: There are some problems of insertion and using Permanent
Central Venous Catheters (CVC). The aim of the study is to find the best personalized
method for the CVC insertion and line management based on the long term
surveillance of the CVC insertion technique.
Design/Methods: This is a longitudinal single center study from 2000 to 2014. We
collected the data of indication for CVC insertion, technique and complications of
insertions and problems developed during the treatment including infections,
thrombosis and mechanical failure.
Results: All together 1065 CVCs have been inserted in 912 patients. The indication of
CVC insertion in ratio of the patients: 27% in 2001, 91% in 2014. The technique of
insertion, ratio of per cutaneous insertion: 20% in 2001, 98,9% in 2014. The type of
CVC: 25% port-a-cath, 75% Hickmann line in 2001, 78% port-a-cath, 8% Hickmann
line, 7% peripheric miniport, 6% PICC line in 2014.Complications of insertion,
haemothorax, pneumothorax: 10% 2003, 1,2% in 2014.Malposition, kinking: 20% in
2001, 6% in 2014. Removal due to infection: 40% in 2001, 3,7% in 2014. Thrombus,
septic thrombosis: 20% in 2001, 3% in 2014.Occlusion: 15% in 2001, 2% in 2014.
Mechanical failure, disconnected port-a-cath: 5% in 2001, 5% in 2014.
Conclusion: The longitudinal surveillance led us to improve the result of insertion and
outcome of CVC, such as decreased complication rate of insertion, increased rate of
using port-a-cath, longer event free period of CVCs and more usage of peripheric
permanent lines. All the steps behind the improvement were well concerned based on
the previous results. The main steps of improvement were: standardized procedures, per
cutaneous insertion, widened indication, application peripheric lines. Currently we are
on to decrease the mechanical failure using the preconnect port and to decrease the
complications of insertion using US guidance.
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WHETHER LAPAROSCOPY ASSISTED POSTERIOR SAGITTAL EXCISION
OF PRESACRALMASS IS BETTER OVER CONVENTIONAL APPROACH?
B. Jindal1, B.K. Naredi1, A. Rijhwani1, D.S. Barathi2, D. Basu3, B. Dubashi4,
V. Radhakrisna1, K. Govindarajan1, K. Sambadan1
1Jawaharlal Institute of Postgraduate Medical Education and Research, Department of
Pediatric Surgery, Puducherry, India; 2Jawaharlal Institute of Postgraduate Medical
Education and Research, Department of Radiology, Puducherry, India; 3Jawaharlal
Institute of Postgraduate Medical Education and Research, Department of Pathology,
Puducherry, India; 4Jawaharlal Institute of Postgraduate Medical Education and
Research, Department of Medical Oncology, Puducherry, India
Background/Objectives: Pelvic neuroblastoma (NB) includes 2-6% of all NB and most
of these arise from organ from Zuckekandl. Presacral neuroblastoma is a rare tumor
with very few case reports. We report our experience in managing two cases of presacral
NB. Complete resections by one of the open abdominal or sacral/posterior sagittal were
traditionally advocated as the best treatment for these presacral /retrorectal tumor but
resection of these tumors often entails combined abdomino-sacral or
abdomino-posterior sagittal approach with morbidity in terms of neurovascular
damage. We share our innovative idea of laparoscopy assisted posterior sagittal removal
of a presacral neuroblastoma.
Design/Methods: Retrospective study of all the presacral neuroblatoma treated in the
department of Paediatric Surgery, JIPMER from February 2009 to February 2015, and
were analyzed in terms of their clinico-pathological profile and postoperative outcome
in terms of hospital stay, wound infection and neurogenic bladder if any.
Results: A total of 3 cases presacral mass was operated over this period. Of these, one
was presacral teratoma (Altman type III) and the other two were presacral
neuroblastoma. One of the case with presacral NB was operated via combined
abdomino-posterior sagittal approach and one was operated by laparoscopy assisted
posterior sagittal approach. It was observed that the case that had laparoscopy assisted
posterior sagittal excision of presacral mass had less postoperative pain, shorter
hospital stay and no neurogenic bladder involvement in the postoperative period.
Conclusion:We feel that laparoscopic mobilization of the pelvic part of presacral mass
followed by mobilization of the lower part via posterior sagittal approach and excision
of the presacral mass has the definitive advantage over conventional abdomino-sacral
and abdomino-posterior sagittal approach in terms of pain relief, morbidity and risk of
neurovascular damage as it provides better and magnified view of pelvis in the presacral
area.
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URINARY RETENTION IN CHILDREN: AN UNUSUAL PRESENTATION
WHICHMAY HERALD A BLADDER TUMOUR - A 20-YEAR REVIEW
D. Lim1, P. Hammond1, C. Hajivassiliou1, R. Ball1, R. Carachi1, N. Brindley1,
D. McIntosh2, D. Murphy2, M. Ronghe2, J. Sastry2
1Royal Hospital for Sick Children, Surgical Paediatrics, Glasgow, United Kingdom;
2Royal Hospital for Sick Children, Paediatric Oncology, Glasgow, United Kingdom
Background/Objectives: Recent institutional experience highlighted the frequency of
urinary retention as a presenting symptom of children with bladder tumours. Unlike in
the adult population, urinary retention is rare in children and should always precipitate
detailed investigation to identify any underlying cause. Earlier tumour diagnosis
generally improves clinical outcome. Modes of presentation of patients with bladder
tumours were reviewed.
Design/Methods: A retrospective case-note review was undertaken of all children
diagnosed with bladder/prostate rhabdomyosarcoma (RMS) in the West of Scotland
between 1994 and 2014 inclusive. Initial presenting symptoms and clinical signs were
noted.
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Results: Twelve children (two girls) with a mean age of 6 years (range 1 to 15 years)
were diagnosed in the study period with bladder/prostate RMS. Five children initially
presented in urinary retention. Two of these were also in obstructive renal failure. Other
presenting symptoms included dysuria/urinary tract infections (4), abdominal
swelling/distension (4), frank haematuria (3), abdominal pain (3), change of bowel habit
(constipation/diarrhoea) (3), and urinary frequency/urgency (2). Ten children had
embryonal RMS, one child had alveolar RMS, and one child had undifferentiated
RMS. Neither IRS staging nor tumour size were associated with presentation in
urinary retention. Patients who had a delay in diagnosis of the underlying
bladder/prostate tumour following treatment for symptomatic relief of urinary
retention or presumed urinary tract infection are presented.
Conclusion: Urinary retention in children is rare and may have a varied aetiology
including bladder/prostate tumours. Other causes include bladder outlet obstruction
secondary to external compression from constipation or a pelvic mass, intra-vesical
calculi or debris, prolapsed ureterocele, posterior urethral valves or neurogenic causes.
Therefore all children presenting with urinary retention should undergo a course of
urgent investigation following a structured protocol. Our protocol includes initial
imaging with renal tract ultrasound scan.
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EWINGS SARCOMA OF THE CHEST WALL IN CHILDREN – A SURGEON’S
PERSPECTIVE
S. Misra1, S. Jain2, G. Kapoor2
1Rajiv Gandhi Cancer Institute, Pediatric Surgical Oncology, Delhi, India; 2Rajiv Gandhi
Cancer Institute, Pediatric Hematology Oncology, Delhi, India
Background/Objectives: Pediatric Ewings Sarcoma of chest-wall(ESCW) is rare. Wide
local excision (WLE) and reconstruction can be challenging. We describe our
experience over 17 years.
Design/Methods: Retrospective chart-review of 21 patients with ESCW from June-1997
to August-2014 revealed 15 boys and 6 girls with a mean-age of 9.9-years (range 3-20
years). Presenting symptoms were respiratory-distress(n=9), pain(n=9), mass(n=7),
fever(n=6), cough(n=4), Horner’s syndrome(n=2) and cord compression(n=1). Three
patients needed initial respiratory intensive supportive care. The site of origin was
ribs(n=20) and sternal-body(n=1). Sixteen tumors measured >8cms (8 occupying the
entire hemithorax) and 5 were metastatic at presentation. Fifteen underwent
neoadjuvant-chemotherapy(NACT) followed by local therapy(POG#9354/CCG#7942
protocol). Four had upfront resection and adjuvant chemotherapy. Seven received
radiotherapy for: inoperable tumor(n=1), positive resection margins(n=1),
palliative(n=1) and large tumors with Huvos grade I/II necrosis(n=4). Surgery entailed
resection of average 2.35 ribs in 17 patients (range 1-4 ribs). Reconstruction involved
synthetic materials (prolene mesh, biopore) and musculucutaneous flaps (latissimus
dorsi, pectoralis major/minor). One patient was inoperable despite second line
chemotherapy, hence given radiotherapy.
Results: Two metastatic patients progressed before local therapy. Another 3 had
progression during therapy. One patient succumbed to Adriamycin-induced
cardiotoxicity. Three patients are currently on, and 12 have completed therapy. Two of
12 had fatal local relapse at 24 and 32 months; 1 of which was metastatic at
presentation. No metastatic ESCW survived beyond 24-months. Mean Follow-up in 13
surviving patients was 29.1 months (range 7-87 months). Event free survival was 91.6%
(24 months) and 88.8% (36 months). Cosmetic appearance was acceptable in all and
2/13 had minimal chest-wall deformity. None had respiratory compromise at the time
of last follow-up.
Conclusion: Newer prosthetic materials enable the surgeon to achieve free resection
margins without physiological compromise even in large ESCW. Tumor stage is the key
prognostic factor for survival. Aggressive multimodality approach can facilitate better
survival in localized ESCW.
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RELAPSED SYNOVIAL SARCOMA IN CHILDREN AND ADOLESCENTS:
PROGNOSTIC FACTORS, TREATMENT AND OUTCOME
S. Qureshi1, M. Bhagat2, S. Kembhavi3, T. Vora3, M. Ramadwar4, S. Laskar5,
N. Khanna3, G. Chinnaswamy6, M. Prasad6, P. Kurkure6
1Tata Memorial Hospital, Mumbai, India; 2Tata Memorial Hospital, Pediatric Surgical
Oncology, Mumbai, India; 3Tata Memorial Hospital, Radiology, Mumbai, India; 4Tata
Memorial Hospital, Pathology, Mumbai, India; 5Tata Memorial Hospital, Radiotherapy,
Mumbai, India; 6Tata Memorial Hospital, Pediatric Oncology, Mumbai, India
Background/Objectives: The outcomes following relapse in synovial sarcoma are dismal.
The treatment, outcomes and prognostic factors in this setting are not clearly defined.
Design/Methods: The records of patients with initially non-metastatic synovial sarcoma
treated between June 2006 and May 2013 who experienced relapse were analysed.
Results: Of the total 18 patients with relapse, local recurrence occurred in 10 patients,
distant metastases in seven and regional metastases in one patient. The time to relapse
ranged from seven to 39 months (median 17 months). Treatment of relapse consisted of
surgery in 15 patients, second-line chemotherapy in 14 and radiotherapy in 9 patients.
The projected 5-year overall and event free survival was 47.2% and 41.3% respectively.
The factors significantly influencing survival were local relapse only, complete surgical
excision and use of chemotherapy at relapse and chances of a secondary remission.
Conclusion: The overall outcome of patients with relapsed synovial sarcoma is poor
especially with distant relapse. Complete surgical excision and chemotherapy at relapse
is associated with a better outcome.
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HOW DEEP SHOULD THE PUNCTURE BE TO OBTAIN CENTRAL VENOUS
ACCESS IN PEDIATRIC ONCOLOGY?
R.C. Ribeiro1, L.B. Lima2, A.A.B. Duarte3, F.Y. Takamatsu4, A.C.Y. Imada4,
S.D.C.V. Abib3
1Barretos Cancer Hospital, Pediatric Suregry, Barretos, Brazil; 2Federal University of
São Paulo, Medical Student, São Paulo, Brazil; 3Pediatric Oncology Institute. Federal
University of São Paulo, Pediatric Surgery, São Paulo, Brazil; 4Federal University of São
Paulo, Pediatric Surgery, São Paulo, Brazil
Background/Objectives: Central venous puncture with Seldinger technique is often used
to obtain short and long-term catheters. Although safe, this technique can have some
complications and the depth that the needle is inserted is not standardized. In order to
avoid such problems, we developed a study to determine the maximum depth that
should insert the needle in an internal jugular vein catheter insertion.
Design/Methods: Anthropometric data of pediatric patients submitted to long-term
catheter implantation were collected. A portable ultrasound evaluated the
morphometric parameters of the internal jugular during surgery and the needle
insertion depth was calculated. Relationship between depth, weight and age were
analyzed by scatter plots and linear correlation coefficients of Pearson. Age and weight
were categorized and constructed graphs of average depth (with respective 95%
confidence intervals). For the comparison between age groups and depth was used
analysis of variance technique (ANOVA). The results were analyzed by the software
"STATISTICA".
Results: The study included 275 patients. The depth of needle insertion was positively
correlated with age (r = 0.433670, p <0.05) and weight (r = 0.595541, p <0.05). Mean
graphs show that the depth increases with age and weight rise. This result was confirmed
by ANOVA that showed statistically significant differences (p <0.001) between the
subgroups of age categories. By multiple regression analysis, unsatisfactory quality
adjustment was observed (R2 = 0.382) to develop a mathematical model. However,
linear regression could be a guide to know which depth we can insert the needle
securely. The formula to calculate how insert the needle is 1,7 + 0,017X weigh (Kg).
Conclusion: This study showed a positive relationship between depth of needle
insertion, age and weight. Moreover it is possible to know which depth insert the needle
in a jugular vein puncture. An approximate formula is 1,7 + 0,017X weight (Kg).
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REMNANT LEFT LOBE TORSION CAUSING INFERIOR VENA CAVA
OBSTRUCTION AFTER HEPATIC RIGHT LOBECTOMY FOR
FIBOLAMELLAR HEPATOCELLULAR CARCINOMA
R.C. Ribeiro1, V. Kremer2, E. Boldrini3, R.Z.M. Silva3, A.G.S. Vieira3, L.F. Lopes3
1Barretos Cancer Hospital, Barretos, Brazil; 2Barretos Cancer Hospital, Pediatric
Suregry, Barretos, Brazil; 3Barretos Cancer Hospital, Pediatric Oncology, Barretos,
Brazil
Background/Objectives: Hepatic venous outflow obstruction is a recognized lethal
complication after living donor transplantation. A torsion of liver can cause
obstruction in hepatic vein. This condition is very rare after hepatectomy. The previous
related cases had obstruction in hepatic vein (Budd-Chiari syndrome). Obstruction just
in vena cava is extremely rare, justifying this description.
Design/Methods:We report the case of a 14-year-old boy with left lobe torsion causing
acute inferior vena cava obstruction after right hepatectomy, which was successfully
treated with surgery.
Results: A 14-year-old boy underwent a right hepatectomy for PRETEXT II
fibrolamellar hepatocellular carcinoma. After mobilization of right lobe, bilateral
section of triangular ligament, and section of falciform ligament, the operation was in a
standard fashion with both inflow (right hepatic artery and portal vein) and outflow
(right hepatic vein) ligation prior to hepatic section. After right hepatectomy, he
developed edema of lower limb and inferior abdominal wall. He increased the weight by
10 kg. The patient had diuresis just with furosemide. Doppler ultrasonography did not
find any vein obstruction. Abdominal computed tomography (CT) revealed that
remnant liver was dislocated in the right subphrenic space and a narrow retrohepatic
vena cava. After surgical repositioning of the left lobe into its anatomical position, the
venous congestion disappeared progressively. The falciform and round ligaments were
fixed to the anterior abdominal wall to keep the remnant liver in the anatomical
position. His postoperative course was uneventful. The posoperative CT showed
improvement in inferior vena cava flow.
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Conclusion: Fixation of remnant liver may be effective for preventing hepatic venous
outflow obstruction after right hepatectomy.
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VIDEO-ASSISTED PERICARDIOSCOPY AND INTRAPERICARDIAL
AMPHOTERICIN FOR INVASIVE ASPERGILLOSIS IN BONEMARROW
TRANSPLANTAION PATIENT
R.C. Ribeiro1, V. Kremer1, N. Villela2, P.S. Ikeuti2, P. Tarso3, M.C. Pinto4, L.F. Lopes5
1Barretos Cancer Hospital, Pediatric Surgery, Barretos, Brazil; 2Barretos Cancer
Hospital, Pediatric Bone Marrow Transplantation, Barretos, Brazil; 3Barretos Cancer
Hospital, Infection Disease, Barretos, Brazil; 4Barretos Cancer Hospital, Thoracic
Surgery, Barretos, Brazil; 5Barretos Cancer Hospital, Pediatric Oncology, Barretos,
Brazil
Background/Objectives: Invasive fungal infections have become an important problem
in patients undergoing bone marrow transplantation. Pericardial aspergillosis is an
uncommon and lethal condition.
Design/Methods:We describe a patient with invasive aspergillosis that had an
evaluation with video-assisted pericardioscopy and intrapericardial amphotericin.
Results: A 13-year-old boy, diagnosed with myelodysplastic syndrome (RAEB type 2)
associated with left leg lymphedema (agenesis of lymphatic vessels). He started
treatment with azacitidine (5 cycles) while waiting for an unrelated donor for bone
marrow transplantation. He underwent allogeneic unrelated bone marrow transplant.
The myeloablative conditioning regimen was done with busulfan, cyclophosphamide,
melphalan and thymoglobulin. The graft versus host disease prophylaxis was performed
with cyclosporine and methotrexate. He presented grafting of leukocytes on D+17, but
evolved with graft dysfunction from D+41, holding periods of neutropenia since that
time. The patient developed pulmonary aspergillosis treated with oral voriconazole,
with stabilization of the clinical signs, but without falling levels of galactomannan,
requiring several changes in the antifungal scheme (liposomal amphotericin,
intravenous voriconazole, voriconazole associated with micafungin). He presented
significant pericardial effusion on echocardiography with indirect signs of cardiac
tamponade. He underwent pericardiocentesis, with exudate with galactomannan levels
quite high. Video-assisted pericardioscopy was performed. This procedure allowed
visibility of the pericardial sac and a good site to be biopsied. An intrapericardial
catheter was inserted. He received intra-pericardial infusion of amphotericin B for 5
days, while keeping systemic treatment with voriconazole. Aspergillus fumigatus was
isolated in the pericardial fluid culture. Currently, the patient is receiving systemic
treatment with voriconazole, even with positive galactomannan, but clinically stable.
Conclusion: Video-assisted pericardioscopy is a minimally invasive technique that allows
prognosis evaluation of pericarditis, do a pericardial biopsy and insert pericardial
catheter. Intrapericardial amphotericin is an option for pericardial invasive aspergillosis.
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RISK FACTORS ASSOCIATEDWITH IRS CLINICAL GROUPS AND
CHARACTERISTICS OF SOFT TISSUE SARCOMAS OVER A PERIOD OF 13
YEARS IN A NATIONAL REFERENCE CENTER
C. Sánchez-Montenegro1, G. Chocarro-Amatriain1, L. Martínez-Martínez1,
P. García-Miguel2, M. López-Santamaría1
1Hospital Universitario La Paz, Pediatric Surgery, Madrid, Spain; 2Hospital
Universitario La Paz, Pediatric Hematology & Oncology, Madrid, Spain
Background/Objectives: This study aims to characterize pediatric soft tissue sarcomas in
a national referral hospital in Spain and to analyze the risk factors associated with the
degree of surgical resection and their evolution.
Design/Methods: Pediatric patients belonging to the group of soft tissue sarcomas
newly diagnosed from 2002 to 2014 were included. Clinical charts were reviewed to
assess their characteristics and risk factors associated with the possibility of degree of
surgical resection based on their clinical grouping system developed by the Intergroup
Rhabdomyosarcoma Group (IRS). Comparisons were made using SPSS 12.0 with a
threshold of significance of 0.05.
Results: Sixty seven patients (35 males and 32 females) aged 6.36 (range 0-17 years) at
diagnosis were included. Fifty three (79.1%,) remain alive today, albeit 17 of all the
cases (25.4%) presented metastases and 10 relapsed during their evolution . There were
18 different histological types, being the most frequent embryonal rhabdomyosarcoma
(29.9%) and alveolar rhabdomyosarcoma (14.9%). Non-survivors patients died after a
mean follow-up of 21.14 (range 7-55 months). Mean follow-up was 69.04 months
(range: 6-149 months). Tumor location was in the lower limbs (22.4%), head (20.9%),
abdomen (17.9%), liver (8.95%), chest (8.95%), upper limbs (7.5%) and others (13.4%).
The IRS surgico-pathologic grouping system was strongly associated with survival
(P=0.002): I 40 cases (92.5% alive), II 3 cases (100% alive), III 13 cases (61.5% alive)
and IV 11 cases (45.5% alive). Twenty out of the 57 known-risk factors were presented
among the patients but none of them were associated with IRS group.
Conclusion: Only IRS group was associated with survival, probably due to the wide
histological variety of these tumors. Multicenter and supranational studies are
necessary to draw conclusions about other risk factors probably associated to prognosis.
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RARE NEONATAL AND EARLY INFANTILE TUMOURS: CHALLENGES IN
MANAGEMENT
S. Sharma1, R. Rahman1, A. Gupta1, D. Gupta1
1All India Institute of Medical Science, Paediatric Surgery, Delhi, India
Background/Objectives: Neonatal tumours and infantile tumours have varied
presentations and diagnosis. The management is challenging and should be tailored
case-based. We describe our experience with challenging tumours.
Design/Methods: To retrospectively review cases of challenging malignancies
encountered in neonates and infants.
Results: Four cases of malignancies presented in the infantile age group over a period
of nine months. The age at presentation varied from 34 weeks gestation to 3 months
age. There were three females and one male. The presenting complaints included
respiratory distress, poor urinary stream, haematuria with abdominal lump, neck mass
and a sacral mass. The patient with abdominal lump had a large heterogenous
enhancing mass occupying pelvic cavity in presacral region displacing Urinary bladder
with rectal luminal compromise. Biopsy was suggestive of Embryonal
Rhabdomycosarcoma. He was given half dose Vincristin, Adriamycin,
Cyclophosphamide (VAC) chemotherapy. He did not tolerate chemotherapy and
succumbed. Three patients were operated. The baby with respiratory distress had a
thoracic mass occupying the whole hemithorax. He was started on VAC chemotherapy
with a probable diagnosis of Neuroblastoma. However, the distress worsened and the
baby was subjected to emergency thoracotomy. The final diagnosis was Congenital
peribronchial myofibroblastic tumour. The 3 month old child with a neck mass was
initially given bleomycin with a diagnosis of cystic hygroma outside before being
referred to us. He was operated with a suspicion of cervical teratoma. The final
diagnosis was infantile fibrosarcoma. The preterm girl with sacral mass was operated at
1 week age and diagnosed as a mature sacrococcygeal teratoma.
Conclusion: Neonatal tumours may present as thoracic, abdominal, sacrococcygeal or
neck masses. Surgical excision should be the main crux of management in neonatal and
infantile tumours. The histopathological report is more confirmatory after surgery.
Neonates do not tolerate chemotherapy well and it should be reserved only for selected
non-operable cases.
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TREATMENT AND PROGNOSIS OF SOLID MALIGNANT TUMORWITH
PULMONARYMETASTASES IN CHILDREN
Y. Wu1
1Xinhua Hospital, Shanghai, China
Background/Objectives: To discuss the treatment and prognosis of malignant solid
tumors with lung metastasis in children.
Design/Methods: Cases of malignant solid tumor with pulmonary metastasis in
children enrolled from 2009 to 2014 were collected from department of pediatric
surgery of Shanghai Xinhua Hospital. The Results were discussed including
classifications, treatment, prognosis.
Results: A total of 10 cases (7 male and 3 female) age ranged from 21 months to 6 years
with a median of 5 years, including 2 cases of hepatoblastoma, 5 cases of
nephroblastoma, 2 cases of rhabdomyosarcoma, 1 case of medulloblastoma. In 9 cases,
patients underwent biopsy or primary resection before chemotherapy. After 6-8 course
of treatment, pulmonary metastasis was localized and stable which usually become 1 - 2
of peripheral pulmonary nodules. After thoracoscopic lung metastases resection,
malignant tumor cells were detected with the same primary pathology in 9 cases while
no active tumor cell was discovered in 1 case. After the surgery, chemotherapy was
continued according to the plan. Patients were followed up for 2 months to 5 years.
Conclusion: Children with stage IV malignant solid tumors still should be treated
actively. Resection and pathological examination is helpful in the evaluation of
prognosis and making further treatment options in patients whose lung metastases is
stable after chemotherapy and removal of primary tumor. Thoracoscopy- a minimally
invasive technique, provides an acceptable option for parents.
Posters: Acute Lymphoblastic Leukaemia
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MTHFR C677T, PT G20120A AND FV LEIDEN AS RISK FACTORS FOR
THROMBOSIS IN EGYPTIAN PEDIATRIC ALL PATIENTS
Pediatr Blood Cancer DOI 10.1002/pbc
SIOP ABSTRACTS S241
M. Ahmed1, I. Sidhom2, A. Amleh3, N. Hamdy4
1Children Cancer Hospital, Pharmaceutical Services, Cairo, Egypt; 2Children Cancer
Hospital, Pediatric Oncology, Cairo, Egypt; 3The American University in Cairo,
Department of Biology-School of Sciences and Engineering SSE, Cairo, Egypt;
4National Cancer Institute-Cairo University, Clinical Pathology, Cairo, Egypt
Background/Objectives: Thrombosis is a well-known side effect associated with Acute
Lymphoblastic Leukemia (ALL) treatment leading to significant morbidity rates.
Thrombosis occurrence in ALL patients seems to be due to the interaction between the
disease, therapy and inherited thrombophilia. We aimed to assess the prevalence of FV
Leiden, MTHFR (Methylene Tetra HydrofolateReductase enzyme) C677T
&prothrombin (PT) G20210A mutations in Egyptian pediatric patients with ALL and
its impact on the risk of thrombosis onset as well as to evaluate the impact of single
versus multiple prothrombotic mutations on thrombosis.
Design/Methods: Sixty three pediatric ALL patients with thrombotic event treated with
Total XV protocol at the Children’s Cancer Hospital in Egypt and 63 matched ALL
control patients were enrolled in the study. Restriction fragment length polymorphism
technique was used to assess the prevalence of the FV Leiden and MTHFR C677T
while Allele specific PCR was used for Prothrombin G20210A.
Results:MTHFR C677T prevalence between the ALL patients with and without
thrombosis was 65% and 38.1% respectively (p value = 0.002), while FV Leiden
prevalence was 17.5% and 15.9 % respectively, (p value= 0.81). Prothrombin G20210A
prevalence was 3.2% in both groups.Patients who were older than 10 years or on
SR/HR treatment protocol or in induction treatment phase showed higher risk of
thrombosis. The risk of thrombosis was 3 folds more in patients with MTHFR C677T
(OR =3.02), while FV Leiden and PT G20210A didn’t affect the thrombosis risk.
Having more than one mutation didn’t show a significant effect on increasing the risk
of thrombosis (p= 0.087).
Conclusion:MTHFR C677T is an important risk factor for thrombosis in Egyptian
pediatric ALL patients. These results may help in the prediction of the thrombosis
susceptibility for ALL patients and a prophylaxis therapy may be considered before
having the thrombosis.
P-002
MATURE B CELL ACUTE LYMPHOBLASTIC LEUKEMIA PRESENTING
WITH HYPERCALCEMIA
M. Akin1, Y. Isik Balci2, A. Polat2, H. Sarbay2, B. Ozhan3, S. Guler2
1Pamukkale University-Medical School, Denizli, Turkey; 2Pamukkale Univercity Faculty
of Medicine, Pediatric Hematology and Oncology, Denizli, Turkey; 3Pamukkale
Univercity Faculty of Medicine, Pediatric Endocrinology, Denizli, Turkey
Background/Objectives: Hypercalcemia is rarely observed in acute lymphoblastic
leukemia. So far, all cases presenting with hypercalcemia are pre-B cell ALL. In this
case, a mature B-cell ALL patient presenting with hypercalcemia is discussed.
Design/Methods: A three-year-old boy had a history of fever, weakness, swelling and
pain in both kness. In the patient’s blood smear, 93% L3 type blasts were seen and 90%
L3 type large blasts with vacuoles were seen in the bone marrow aspiration smear.
Results: The flow cytometry results were as follows: CD10: 87%; CD19: 85%; KAPPA:
66%; and Lambda: 35% was compliant with mature B cell ALL. His calcium level: 15
mg/dl. Although previous cases imply that hypercalcemia is usually treated with
pamidronate, calcium levels gradually decreased to normal levels within five days with
intravenous fluid therapy, furosemide, and steroids in our case.
Conclusion: Consequently, hypercalcemia is rare in leukemia. So far, all cases presenting
with hypercalcemia are pre-B cell ALL. It is important to know that hypercalcemia
could be seen in the mature B-cell ALL.
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NUTRITIONAL ASSESMENT AND SERUM ZINC CONCENTRATION IN
CHILDRENWITH ACUTE LYMPHOBLASTIC LEUKAEMIA
M. Akma1, S. Ikram1, S. Islam2
1Dhaka Medical College Hospital, Paediatric Haematology and Oncology, Dhaka,
Bangladesh; 2Dhaka Medical College Hospital, Paediatric Surgery, Dhaka, Bangladesh
Background/Objectives: Acute lymphoblastic leukaemia(ALL) is a common malignancy
in children which may cause significant nutritional deficiency and affect the outcome of
the patient.The study was done to identify the relationship of height, weight and serum
zinc in children with acute lymphocytic leukemia (ALL).
Design/Methods: This observational study was carried out in the Department of
Pediatric Haematology and Oncology, Dhaka Medical College Hospital, Dhaka over a
period of one year from July 2013 to June 2014. All children ranging from 1 – 10 years
with newly diagnosed ALL were enrolled as case. The diagnosis was made by means of
bone marrow smears and immunophenotyping. An equal number of healthy children
of similar age and sex were also included as control. The outcome measures
werewasting and stunting in children< 5 years and BMI in children > 5 years of age.
The serum zinc level was also studied as a measure of micronutrient status.
Results: The mean ages of the children of cases and controls were almost similar ( p =
0.265). The groups were significantly different in terms of male/ female(p = 0.028).
Majority (83.3%) of the children in the case group was wastedas opposed 22.2% in the
control group (p < 0.001). About 38% the children in the case group were stunted as
opposed to 16.7% in the control group (p = 0.031). The mean BMI was significantly
lower in the case group than that in the control group ( p < 0.001). Serum zinc level was
also much lower in the ALL group than that in control (0.7 ± 0.1 vs. 1.5 ± 0.5 mg/dl, p
= 0.003).
Conclusion: Children with Acute Lymphoblastic leukaemia may present with wasting
and stunting and low BMI. Serum zinc level may also be reduced which may hamper
various enzymatic functions in the body thereby reducing growth.
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SERUM LEAD LEVEL IN CHILDRENWITH ACUTE LYMPHOBLASTIC
LEUKEMIA
M. Akm1, T. Ahmed2, S. Islam3, T.R. Chowdhury4
1Dhaka Medical College Hospital, Dhaka, Bangladesh; 2Bangabandhu Sheikh Mujib
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Background/Objectives: There are some reports where serum lead levels were measured
and change in concentration of serum lead level was found among acute Lymphoblastic
leukemia (ALL) patients. The aim of this prospective study was to determine serum
lead levels in patients with ALL.
Design/Methods: In this cross sectional study all children suffering from acute
lymphoblastic leukemia ranging 2 to 12 years (30 patients) were evaluated for serum
lead levels who were admitted at the Department of Pediatrics in DMCH, from
February 2013 to January 2014. Serum level of age and sex matched healthy children
were taken as control. Serum measurements for lead were performed by Atomic
absorption spectrophotometer in Analytical Chemistry Laboratory of Atomic Energy
Centre Ramna, Dhaka.
Results: Among the 63 children there was no significant difference in age and sex
between the patients and control. The mean serum lead level of Acute lymphoblastic
Leukemia patient group (234.8±162.9 g/L) was significantly higher than that of the
control group (23.6±12.6 μg/L). There was significant difference of serum lead level in
children with ALL and control group (p<0.05).
Conclusion: From the findings of the study it can be concluded that there is significant
difference between Acute lymphoblastic Leukemia patient and normal control in terms
of serum Lead (pb) level.
P-005
RESPONSE TO RE-VACCINATION IN CHILDREN AFTER TREATMENT FOR
ACUTE LEUKEMIAS
S. Anak1, E. Erdem Ozcan1, A. Kilic2, M. Onel3, A. Ozguven1, A. Unuvar1,
Z. Karakas1, G. Ozturk1, A. Agacfidan3, O. Devecioglu1, L. Agaoglu1
1Istanbul University Istanbul Medical Faculty, Department of Pediatric Hematology
Oncology, Istanbul, Turkey; 2Istanbul University Istanbul Medical Faculty, Department
of General Pediatrics, Istanbul, Turkey; 3Istanbul University Istanbul Medical Faculty,
Department of Microbiology, Istanbul, Turkey
Background/Objectives: The aim of this study was to examine effectiveness of
vaccination in pediatric patients with leukemia at least one year after the cessation of
the treatment.
Design/Methods: The study was performed prospectively in 32 patients (28 ALL, 4
AML). Diphtheria, tetanus, acellular pertussis, hepatitis B, hepatitis A,
measles-mumps-rubella (MMR) and varicella vaccines were applied to patients.
Results: Among leukemia patients, 71.8% of patients had complete protection against
diphtheria, 84,3% against tetanus and 37,5% against hepatitis A before vaccination. All
of seronegative patients achieved protective antibody levels after one dose against
diphtheria, tetanus and hepatitis A. Forty-nine percent of patients were protected
against pertussis and 37% against hepatitis B before vaccination. For pertussis, 66,7%
achieved protective antibody levels after one dose, but only 55,5% for Hepatitis B.
Thirty-four point four percent of patients were seropositive against measles before
vaccination. 73,3 % of seronegative patients achieved protection after one dose.
Seventy-eight point five percent and 71,9 % of patients were seropositive against rubella
and mumps respectively before vaccination, all seronegative patients achieved full
protection against rubella and mumps after one dose. Fifty-nine point four percent of
patients were seropositive against varicella before vaccination. 87,5 % became
seropositive after one extra dose.
Conclusion: In our study, patients had very good antibody response against to
diphtheria, tetanus, hepatitis A, rubella and mumps vaccines at least 12 months after
the cessation of therapy. Performing one booster dose appeared to be sufficient for all
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groups. Protection after pertussis, hepatitis B, measles and varicella zoster vaccines were
in moderate levels. The patients showed different antibody responses to vaccines,
depending on age, the time passed after the cessation of treatment and their primary
vaccination status. Antibody levels should be followed to evaluate the response
obtained. A booster should be considered when there is a decrease or loss in these
levels.
P-006
CNS EVENTS IN CHILDHOOD HAEMATOLOGICAL MALIGNANCIES
DURING EARLY PHASE OF TREATMENT IN TERTIARY LEVEL HOSPITAL
Z. Ara1, A. Islam1, C.Y. Jamal1, M.A. Karim1, A.A. Rahman1, M. Begum1,
L.R. Molla1, F. Yasmin1, M.T. Ahammed1, M. Akter1
1BSMMU, Pediatric hematology and oncology, Dhaka, Bangladesh
Background/Objectives: The purpose of this observational study is to evaluate the
pattern of CNS complications along with risk factors during early phase of treatment
in children with hematological malignancies.
Design/Methods: This observational study was conducted in 50 children with
hematological malignancies (ALL, AML, NHL) who were admitting in paediatric
haematology and oncology department of BSMMU Dhaka, from july ,2013 to june ,
2014. After clinical examination and positive lab investigation findings, the diagnosed
patients were treated according to specified protocol based chemotherapy and was
evaluated during induction phase of treatment.
Results: During one year period, total 12 patients out of 50 (24%) showed CNS events.
CNS complications included convulsion were 9 (75%), peripheral neuropathy 8(66.6%),
change in mental status 8(66.6%), altered consciousness 8(66.6%), L-asperginase related
suspected complication 5(41%), IT therapy related toxicity 4(33.2% ), cerebral infection
2( 16.6% ), cranial nerve involvement with unilateral hemiplegia 2(16.6% ). Based on
history, clinical lab finding different possible risk factor or co-morbid conditions for this
events were expected like thrombocytopemia ( 75% ) with coagulation disorder , severe
febrile neutroperia ( 66.6%) , history of traumatic IT therapy 3-4 days before CNS
event (33.2% ) , dyselectrolytaemia with hypocalcemia (16.6%), history of ear
infection(16.6%), L-asperginase related complication (41% ) and metabolic
abnormalities (8.3%). Only 7 (58.3%) of out of 12 patients were recovered from
complications.
Conclusion: Central nervous system (CNS) complications during treatment of
childhood haematological malignancies remain a challenging clinical problem. This
may be related to various factors like disease itself, chemotherapy induced neurotoxicity
and to some co- morbid conditions along with the treatment method. As many of these
neurological complications are treatable, early diagnosis and prompt treatment is
essential to limit permanent damage.
P-007
OBESITY IMPACT ON SURVIVAL PROGNOSTIC AND RELAPSE IN
MÉXICO’S STATE LINFOBLASTIC LEUKEMIA ACUTE CHILDREN’S
L. Araceli1, I. Tejocote2, C. Rodriguez C2, Y. Jaimes3
1Hospital Materno Infantil ISSEMYM, Toluca, Mexico; 2Hospital Materno Infantil
ISSEMYM, Pediatric Oncology, Toluca, Mexico; 3Hospital Materno Infantil
ISSEMYM, Oncology, Toluca, Mexico
Background/Objectives: In Mexico childhood cancer and obesity are public health
problems. Malnutrition but not obesity, had been associated with a lower chance of
survival and relapse. Objective: Assess the impact of obesity on the prognosis of
survival and relapse in children with Lymphoblastic Acute Leukemia (LAL).
Design/Methods:We included in a cohort study, children with LAL. There were
evaluated nutritional status at diagnosis, according to BMI in children, in search of
Association of obesity and other factors with the presence of relapse of disease and
survival using Kaplan-Meier and Cox regression.
Results:We evaluate 161 patients, 70% of patients with obesity of male gender of these
43% with all of very high risk. Obesity increased the risk of relapse (OR 3.6,
IC95%1.7-7.6,p 0.001) of death (OR 3.4 95% 1.51-7.48 p0.002) and limited 52% to 77
months survival an Exp β of 3.35 in the Cox regression was obtained for patients with
obesity and high risk leukemia.
Conclusion: In our patients, obesity increases the risk of relapse and decreases the
survival time. Perhaps due to considerable increase in toxicity and some growth factors
that determines poor response to the chemotherapy in neoplastic cells. Biological
factors influencing the prognosis of the disease may not be modifiable however is
essential to establish health policies aimed at early diagnosis and prevention of obesity
and overweight.
P-008
DETERMINING FREQUENCY OFMORTALITY AND THE CAUSES OF
DEATH IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
K. Arjmandi Rafsanjani1, L. Hashami2, A. Arjmandi Rafsanjani3
1Iran University of Medical Sciences, Hematology Oncology, Tehran, Iran; 2Iran
University of Medical Sciences, Pediatric Neurology, Tehran, Iran; 3University of British
Columbia, Pathology and Laboratory Medicine, Vancouver, Canada
Background/Objectives: During three decades with recent progress in chemotherapy
regimens, the survival rate of children with ALL has improved significantly. But
developing countries still have high mortality rate of patients with ALL. The present
study examined the prevalence and causes of death in children with ALL.
Design/Methods: In this retrospective cross-sectional study, medical records of patients
with ALL who referred to Ali-Asghar hospital during 2004-2012 and died during
treatment, were studied. Information about demographic characteristics, cause of
death, age, sex, WBC count, response to treatment, type of ALL, underlying disease,
and recurrence were recorded. Data analyzing was performed using SPSS 18 software.
Results: In this study, 442 patients that have been referred to Ali Asghar hospital were
included, which 80 of them (18%) were dead. Mean age of dead patients was 6.5±3.7
years and 63.8% of them were male.2.5% also had other underlying disease (down
syndrome). WBC count in 76.2% was less than 50000 cell/mm3 and only 23.8% have
more than 50000 cell/mm3. 61.25% of the patients had a relapsed during treatment.
35% had recurrence after treatment. The most common site of relapse was bone
marrow (71.8%). Infectious causes included 72% of the causes of death. Among the
infections, sepsis and pneumonia were the most common causes of death in patients
with ALL. Also bleeding was the cause of death in 13.8% of the patients.
Conclusion: According to this point that the most common causes of death in ALL
patients was infectious causes such as sepsis and septic shock and pneumonia,
providing appropriate treatment and infection control measures, is essential to improve
patients outcome and reduce mortality of patients.
P-009
OSTEOPOROSIS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
TREATED ONMODIFIED ST JUDE TOTAL XV THERAPY
S. Aytac1, M. Cetin2, B. Kuskonmaz2, S. Unal2, B. Tavil2, F. Gumruk2
1Hacettepe University Faculty of Medicine, Ankara, Turkey; 2Hacettepe University
Faculty of Medicine, Pediatric Hematology, Ankara, Turkey
Background/Objectives: Today,one of the challenges faced in treating children with
acute lymphoblastic leukemia is steroid induced osteonecrosis which can be detected
during and/or after therapy.
Design/Methods: To determine the incidence, risk factors and morbidity, we
retrospectively collect the data in our single center on which Modified St Jude Total XV
therapy was given since 2008. The St Jude Total XV protocol was adapted with minor
modification which include high dose methylprednisolone (HDMP) treatment during
remission induction, all other therapy was the same with the original one.
Results: There were 130 newly diagnosed ALL patients aged 1-17 years between 1 Jan
2008 and 1Jan 2014 at Hacettepe University Pediatric Hematology Department. Of
these 130 patient, 4 were deceased during induction because of severe infection(n=2),
tumor lysis syndrome(n=1) and traffic accident(n=1) and from those remaining 126
patients, there were 15(11.9%) patients diagnosed with osteonecrosis during the
treatment period. The incidence was significantly higher among adolescent
females(p<0.05).The hip was the most frequently involved site however 5 patient had
multiple skeletal sites involvement.
Conclusion:When we compare our results with the original protocol, the incidence of
osteonecrosis seems to be much more higher (11.9% vs 6.4%)in our group. As we don’t
know the osteonecrosis associated genotype of these patients, we can not argue the
genetic susceptibility. However, not only steroid but also L-Asparaginase and other
known risk factors such as age, gender may facilitate this devastating complication.
P-010
IDENTIFICATION OF CHILDRENWITH ACUTE LYMPHOBLASTIC
LEUKEMIA AT LOW RISK FOR TUMOR LYSIS SYNDROME
G. Bahoush Mehdiabadi1, K. Arjmandi Rafsanjani2
1IUMS, Tehran, Iran; 2IUMS, Pediatrics, Tehran, Iran
Background/Objectives: Tumor lysis syndrome (TLS) could occur before, during or
after the initiation of chemotherapy in patients with hematologic malignancies. This
study was designed to determine the prevalence and predictors of TLS in children with
acute lymphoblastic leukemia (ALL) and to develop a sensitive prediction rule to
identify patients at low risk of TLS.
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Design/Methods: In this cross-sectional retrospective analytic study, one hundred and
sixty children diagnosed as ALL in Ali-Asghar Children Hospital, Tehran were
recruited from 1996-2010. Predictors of TLS were determined using univariate and
multiple logistic regression analyses.
Results: TLS was diagnosed in 41 (25.6%) cases. The most common laboratory
abnormality was hypocalcaemia observed in 30% of cases. Univariate analysis showed
that splenomegaly [odd ratio(OR)= 2.38; P=.005], mediastinal mass (OR= 4.45;
P=.003), T-cell phenotype (OR= 4.66; P=.001), central nervous system involvement
(OR= 10.93; P=.001), lactate dehydrogenase 2000 U/L (OR= 3.88; P=.003), and
white blood count (WBC) 20×109/L (OR= 4.18; P <.001) were predictors of TLS in
these cases. Multiple regression analysis of variables that were available at presentation
identified CNS and renal involvement, mediastinal mass, and initial WBC  20 × 109/L
as independent predictors of TLS. When all 4 of those predictors were absent at
presentation (n = 83 patients), the negative predictive value of developing TLS was
92.22%, with a sensitivity of 82.93%.
Conclusion: The above predictors could be used to evaluate the risk of TLS in patients
with hematologic malignancies before initiative chemotherapy. Finding a model of
independent factors to define a group of ALL children at low risk of TLS could be used
to prevent excessive the monitoring and high cost of prophylactic treatment modalities.
P-011
CHROMOSOME 7 ABNORMALITIES IN CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKAEMIA
J. Bate1, P. Guerra-Garcia1, J. Swansbury2, D. Lancaster1
1Royal Marsden NHS Foundation Trust, Paediatric Oncology, Sutton, United Kingdom;
2Royal Marsden NHS Foundation Trust, Department of Cytogenetics, Sutton, United
Kingdom
Background/Objectives: Losses involving chromosome 7 are a rare cytogenetic
abnormality in paediatric patients with acute lymphoblastic leukaemia (ALL) with
unclear prognostic significance when treated on UK protocols.
Design/Methods: Cytogenetic results were obtained for all patients under 20 years of
age with a confirmed diagnosis of ALL who were treated at the Royal Marsden,
England from January 1995 to January 2015. Bone marrow and/or blood samples for
cytogenetic study were processed for G-banded chromosome analysis following
short-term culture using standard procedures.
Results: There were 279 patients with ALL for whom a chromosome study was
successful. There were 15 patients (5.4%) with complete or partial loss of chromosome
7 involving 7q with median age at diagnosis of 10.6 years (range 3.1-19.9 years). Three
patients had isolated monosomy 7 and one patient had 53 chromosomes. The other
eleven patients had a complex karyotype including two patients with Philadelphia
chromosome (Ph) in addition to monosomy 7 and two patients with abnormalities
resulting in 7q-. Of 14 patients with available data, 3 had a diagnostic WBC > 50x
109/L and 9 patients (including both patients with Ph) had a rapid response to
induction characterised by <25% blasts at Day 8/15. Both patients with Ph proceeded
to transplant in first remission. 7 patients experienced a relapse (6) or had initial
refractory disease (1). 3 of these patients subsequently died – one with refractory
disease, one with secondary myelodysplastic syndrome post transplant and one with
transplant-related hepatic failure. 12 patients remain alive to date (5 on maintenance
treatment, 4 completed treatment in remission, 2 patients with relapsed disease
currently undergoing allogeneic transplant, 1 Ph relapsed patient on nilotinib).
Conclusion: Chromosome 7 abnormalities in ALL patients in this series are observed
more frequently in patients > 10 years and almost half of these patients experienced a
relapse or had refractory disease.
P-012
POSSIBILITIES OF OVERCOMING DRUG RESISTANCE OF BLAST CELLS IN
CHILDRENWITH RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA
N. Batmanova1
1Moscow, Russia
Background/Objectives: Relapses of childhood ALL are the main causes of treatment
failures. Bortezomib (Velcade R©) can modify the sensitivity of tumor cells to
chemotherapy.
Design/Methods: From June 2011 to January 2015 21 patients with relapsed ALL aged
2–21 years (8.6 years) were enrolled in this study. Boys were 15 (71,4%), girls – 6 (28,6
%). Very early revealed in 4 (26,7%), early in 4 (26,7%) children, late -in 7 (46,7%) pts.
Chemotherapy consisted on induction (VCR 1.5 mg/m2 N4, DNR 60 mg/m2 N1,
PEG-ASP 2,500 IU/ m2 N4, PRED 40 mg/m2 1–28 days, and bortezomib 1.3 mg / m 2
N4); two courses of post induction: 1) VP-16 100 mg/m2 N5, CPM 440 mg/m2 N5,
MTX 5000 mg/m2 N1, bortezomib 1.3 mg/m2 N3 and 2) ARA-C 6000 mg/m2 N4, ASP
6000 IU/m2 N2.
Results: After induction CR achieved 12 (57,1%) children. After the second course – 2
(9,5%) pts. Three (14,4%) pts didn’t achieve CR, one (4.8%) died from sepsis on day 23.
Evaluation of MRD after the first course of chemotherapy performed in 10 patients
(47,6%), and the level of MRD was less than 0.001% in 8 pts (38,1%).Now 6 pts
(28.6%) are alive in CR, 1 of them relapsed after BMT. 4 (19.0%) had late isolated BM
relapse B-ALL, two pts with late relapse of T-lymphoblastic lymphoma. Three (14.3%)
pts with BM relapse underwent a SCT. Relapse developed in 2 (13.4%) children, both
died, 6 (40%) died from sepsis (1 – induction death, 5 – in CR).
Conclusion: Thus, bortezomib in combination with standard chemotherapy allowed
achieve CR in 66,6% pts, PR in 14,3%, and possibly long remission in pts with late
relapse. This therapy is more effective for late relapses ALL and lymphomas.
P-013
NORMALIZATION OF LENGTH SPLEEN ON THE GROWTH OF PATIENT
INCREASES IT STATISTICAL SIGNIFICANCE FOR FORECAST OUTCOME
OF THE DISEASE IN CHILDRENWITH ACUTE LYMPHOBLASTIC
LEUKEMIA
I. Begun1, O. Budanov2, I. Papkevich1, R. Tarasevich1
1Belarusian Research Center for Pediatric Oncology-Hematology and Immunolog,
Functional Diagnostics, Minsk Region, Belarus; 2Belarusian Research Center for
Pediatric Oncology-Hematology and Immunolog, Statistics, Minsk Region, Belarus
Background/Objectives: Prognostic factors are used in oncology for selecting
appropriate treatment regimens and for the comparative evaluation of it.
Results: The objective of the present study was to identify ways to elaborate
independent prognostic indicators for patients with acute lymphoblastic leukemia
(ALL) on the basis of the linear spleen size.
Design/Methods: In a retrospective study including 102 children of both sexes with
acute lymphoblastic leukemia at the age of 1 to 18 years (median 5.42 years) who
underwent the abdominal ultrasound before receipt of protocol treatment MB-2002,
was evaluated the significance of ultrasonographic determination of the length of the
spleen as of predictor of outcome of diseases. In order to mitigate influence of growth
parameters in children of different ages the data were evaluated on based normalized
value of the length of the spleen - NLS ((Normalized the Length of the Spleen)=spleen
length/patients height). Calculation of the cumulative incidence of relapse was
performed by the method of competing risks. Data were censored on 01.01.2014.The
statistical differences between measures of frequency of relapse were determined using
the Gray test. The differences between the compared parameters were considered
statistically significant at p <0.05.
Results: In the level of surveillance for 8 years cumulative incidence of relapse in ALL
patients depending on the absolute size of the original length of the spleen in Groups
less than or equal and more 12 cm (65 and 37 patients) was 13,2±4,5% and 25,9±7,5%;
p=0.0308. In another groups formation (55 and 47 children) with normalized of the
spleen length less than or equal 0.093 and more 0.093 they statistically more
significantly were different for a cumulative incidence of relapse (8,7±4,4% and
29,1±6,9%; p=0.009).
Conclusion: The findings show prospects elaboration of morphometric normalized
indicators associated with survival rates of children with hematologic malignancies.
P-014
VINCRISTINE HURTS!
A. Beukhof1, M. van de Wetering2, H. van den Berg2
1Emma Children’s Hospital/Academic Medical Center, Amsterdam, Netherlands; 2Emma
Children’s Hospital/Academic Medical Center, Pediatric Oncology, Amsterdam,
Netherlands
Background/Objectives: Vincristine is an important chemotherapeutic agent in the
treatment of children with acute lymphoblastic leukemia (ALL). One of the side effects
of vincristine is severe painful neuropathy, which is difficult to treat. In our unit this
neuropathic pain is often treated with amitriptyline. So far, there is hardly anything
described about the treatment of neuropathic pain in children with cancer. Purpose:
The aim of this cohort study is to show how many children with ALL develop a
neuropathy during the treatment with vincristine, how many children are treated with
amitriptyline for this neuropathic pain and what is the effect of this treatment.
Design/Methods:We performed a retrospective cohort study, using questionnaires. The
study population was a random sample; children (0-18 years) with ALL diagnosed and
treated in the period from January 1, 2009 to November 1, 2011 at the Academic
Medical Centre, Amsterdam.
Results: Thirty-four patients were enrolled, 71% completed the questionnaire (N = 24).
95.8% developed a symptomatic neuropathy, in 41.7% neuropathic pain was found.
33.3% were using pain medication for this neuropathic pain. Only one respondent used
amitriptyline in combination with acetaminophen and tramadol. The mean pain score
measured by VAS scale (scale range 0-10) without medication, was 5.6, (N=24). With
medication they gave a score of 4.0 (N = 8).
Conclusion: Almost all children with ALL develop symptomatic neuropathy during the
treatment with vincristine and give high scores in pain. Vincristine does hurt and there
is yet a big profit to win in the fight against this neuropathic pain.
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COMPARISON OF DIFFERENTMETHODS FORMINIMAL RESIDUAL
DISEASE CALCULATION IN B LINEAGE ACUTE LYMPHOBLASTIC
LEUKEMIA CASES AND DETERMINATION OF THE EASIEST METHOD FOR
INDIAN LABORATORIES
A. Bibi1, P. Tembhare1
1Tata Memorial Hospital, Hematopathology Laboratory, Mumbai, India
Background/Objectives: Flow cytometric minimal residual disease (MRD) evaluation is
being widely used for evaluating treatment response and risk stratification in B-acute
lymphoblastic leukemia (B-ALL). Level of 0.01% is considered prognostically
significant. Different methods of MRD calculation are being used worldwide but no
study has been published comparing these methods. In this study, we compared
different methods of MRD calculation and its implication for Indian laboratories.
Design/Methods: Post-induction bone marrow specimens from 56 MRD positive
B-ALL cases were studied for calculation of MRD using different methods. These
methods include calculation of MRD out of M1] total nucleated cells (TNC) using
3-tubes assay, M2] TNC using 2-tubes assay, M3] TNC by Children Oncology Group
(COG) method, M4] all viable cells using single-tube assay M5] all CD45+ cells using
single-tube assay. M1 was considered as a method of reference. For statistical analysis
(SPSS-16.0v), level of 0.01% and 0.1% were used for comparison of these methods.
Results:MRD value ranged from 0.002% to 19.386%. Mean, median and standard
deviation values for M1 were 1.16%, 0.104% and 2.93% respectively. No statistically
significant difference was found between methods M1, M2 &M3. For level 0.1%, M4
calculated 5.4% cases as negative and M5 calculated 2% cases as positive against M1.
For level 0.01%, M4 calculated 2% cases and M5 calculated 5.4% cases as positive
against M1. Technically M1 was time consuming and complex compared to M2 and
M3. Although, M4 &M5 were quick and simple but showed minor discrepancies and
were prone for subjective errors.
Conclusion: TNC based MRD calculation methods using Syto-dye are objective, of
them M2 and M3 are easy and simple methods. M4 and M5 are cost effective, quick &
simple however, prone for subjective variation and needs to be used cautiously.
P-016
PREVALENCE AND RISK FACTORS OF IRON OVERLOAD AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDHOOD
ACUTE LEUKEMIA: AN LEA STUDY
S. Bohrer1, A. Sirvent2, F. Garnier3, P. Auquier3, M. Jehanne1, Y. Reguerre1, G. Michel4
1University Hospital of Saint-Denis, Department of Pediatric Haematology-Oncology,
Saint-Denis, Reunion; 2University Hospital of Montpellier, Department of Pediatric
Haematology, Montpellier, France; 3University Hospital Marseille- Aix-Marseille
University, Department of Public Health -EA 3279 Research Unit, Marseille, France;
4University Hospital Marseille-Aix-Marseille University, Department of Paediatric
Haematology-Oncology, Marseille, France
Background/Objectives: Iron overload (IO) is a common transplant-related
complication in adulthood and is associated with an increased long-term morbidity and
mortality. However there is no consensus on definition, incidence, risk factors,
treatments and complications of IO after hematopoietic stem cell transplantation
(HSCT) for childhood acute leukemia (AL). We conducted a prospective multi-centric
long-term study to determine the prevalence and risk factors of IO in this population.
Design/Methods: All children under 18 years of age at diagnosis of AL undergoing
HSCT (allogeneic or autologous) between 1980 and 2011 and included in the Leucémie
de l’Enfant et de l’Adolescent program were eligible. IO was assessed by a serum ferritin
level (SFL) 350μg/L without any inflammatory process. Among the 420 eligible
patients, 379 (90.24%) had at least one recorded measure of serum ferritin and could be
included.
Results: Prevalence of IO was 43.80% (166 patients) with a mean SFL at diagnosis of
1336.44μg/L (352-9052μg/L) at a mean of 3.56 years (1-22.8 years) post-HSCT. In
univariate and multivariate analysis, independent risk factors of IO were age at HSCT
(Odds Ratio (OR)=7.63 and 6.33 respectively for patients older than 12.68 years and
aged between 8.23 years and 12.68 years; p<0.001), an allogeneic transplantation
(OR=5.47 and 3.01 respectively for donors other than matched sibling donors and for
matched related donors; p<0.001), and a significant graft versus host disease in
allografted patients (OR=2.06; p<0.005). Recent transplantation period (p<0.001) and
total body irradiation in preparative regimen (p=0.043) were significantly associated
with a higher risk of IO only in univariate analysis.
Conclusion: IO is a frequent complication in pediatric long-term survivors post-HSCT
for AL and its prevalence seems to increase over time. Further studies and prolonged
follow-up of our cohort are warranted to confirm this and to determine the impact of
IO on long-term morbidity and mortality in this population.
P-017
ROLE OF EZH2 IN LEUKEMOGENESIS AND DZNEP AS A THERAPEUTIC
OPPORTUNITY IN HIGH RISK AND/OR RELAPSED PEDIATRIC B-CELL
ACUTE LYMPHOBLASTIC LEUKEMIA
A. Iannotta1, M. Ramaglia1, V. D’Angelo1, D. Di Pinto1, C. Ficociello1, M. Di
Martino1, S. Pettotta1, F. Rossi1, E. Pota1, P. Indolfi1, F. Casale1
1Second University of Naples, Department of Woman-Children and General and
Specialized Surgery, Naples, Italy
Background/Objectives: Epigenetic alterations carried out an important role in
leukemogenesis and Polycomb group proteins (PRC2) represent a major class of
epigenetic regulators in development and transcriptional repression. Deregulation of
this histone modification can lead to epigenetic silencing of genes that promote
differentiation and leads to leukemogenis. Evidences suggest that over-expression of the
histone metil transferasi Enhancer of Zeste Homologue 2 (EZH2) is strongly associated
with haematologic cancer progression and poor outcome. 3-Deazaneplanocin (DZNep)
is the first molecular inhibitor of EZH2. We have studied EZH2 expression and
pharmacological effect of DZNep with conventional chemotherapic agents as
Daunoblastine (DBN) and Vincristine (VCR) in pediatric B-cell Acute Lymphoblastic
Leukemia (B-ALL).
Design/Methods:We analyzed EZH2 expression levels by Real time PCR and Western
Blot analysis in SUP-B15 cell line and in 33 B-ALL patients treated to Paediatric
Oncology Service of Second University of Naples. SUP-B15 cell line were treated with
DNB, DZNep and VCR, single and in combination. Cell viability assay was analyzed
by MUSE 1.4 analyzer (Millipore). Apoptotic cell death and cell cycle were analyzed by
Annexin-V- FITC staining and PI fluorescence.
Results: Our preliminary data show that EZH2 RNA was markedly expressed in our
high risk samples ( >1.2 fold) compared to normal bone marrow. SUP-B15 cell line
expressed the highest value. EZH2 protein was detected in 9/33 samples B-ALL and in
SUP-B15 cell line. IC50 value at 48 h was 12.5 μM, 1.5 μg and 12 ng for DZNep, VCR
and DNB, respectively.
Conclusion: Pharmacological targeting of EZH2 might represent a potential feasible
approach to be used as adjuvant treatment for making conventional therapy more
effective on pediatric high risk B-ALL or in relapsed B-ALL.
P-018
OSTEONECROSIS : A COMPLICATION OF TREATING CHILDHOOD
CANCER: A REPORT OF ZOLEDRONIC ACID THERAPY
T. Celkan1, N. Ozdemir1, I. Adaletli2, H. Botanlıoglu3, F. Kantarci2
1Istanbul University-Cerrahpasa Medical Faculty, Pediatric Hematology-Oncology,
Istanbul, Turkey; 2Istanbul University-Cerrahpasa Medical Faculty, Pediatric Radiology,
Istanbul, Turkey; 3Istanbul University-Cerrahpasa Medical Faculty, Orthopedics,
Istanbul, Turkey
Background/Objectives: Purpose: To determine the incidence, risk factors, and
morbidity for osteonecrosis (ON) in children with acute lymphoblastic leukemia (ALL)
and Hodgkin lymphoma(HL) treated with intensive chemotherapy including multiple,
prolonged and high dosis courses of corticosteroid. Patients and Methods: The
occurrence of symptomatic ON was investigated retrospectively in 278 ALL and 152
HL children ages 1 to 18 years old receiving therapy for their cancer during 1995-2015
in I˙stanbul university Cerrapasa Medical Faculty pediatric Hematolgy-Oncology.
Results: ON was diagnosed in 4 patients 3 ALL and 1 HL (0.9%). All of the children
were >12 years. Two of them were male. The symptoms were diagnosed within 6
months chemotherapy ended. ON was multifocal in all of patients. Girls’ ON were
found in hip junction while boys had in ankle and knee. Symptoms of pain and
immobility were chronic in all, with only one having undergone an orthopedic
procedure but three of them considered candidates for surgery in the future. Zoledronic
acid was used in all except one for 6 times monthly and for 3 times for the other.
Radiological and clinical relevant was achieved in all, only one had undergone
operation.
Conclusion: Children ages >10 years who receive multiple courses of corticosteroid, are
at significant risk for developing ON. These children must be given information for ON
and be careful for extremity pain especially after their chemotherapy finished. Although
fur ther evidence-based studies will be needed to precisely define the benefit of
zoledronic acid in ON, our clinical experience on 4 children suggest that zoledronic acid
may be safely used.
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THE CLASSIFICATION AND COMMON GENETIC ABNORMALITIES IN
CHILDRENWITH NEWLY DIAGNOSED ACUTE LEUKEMIAS AT HUE
CENTRAL HOSPITAL, VIETNAM
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Background/Objectives: Traditionally acute leukemias (AL) was classified on the basis
of morphology and cytochemistry. Accurate subclassification of leukemia is essential to
guide therapy and to improve patients’ outcome. The aim of this study was to
implement immunophenotyping and detect the common genetic abnormalities to
classify different subtypes of acute leukemia at Hue Central Hospital.
Design/Methods: This is a single institutional prospective study of 50 children newly
diagnosed with AL fromMay 2012 to May 2014 at HueCentral Hospital. The diagnosis
was confirmed by morphological FAB criteria, cytochemistry, immunophenotype.The
molecular genetic screening test using Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR) was performed to detect fusion gene transcripts.
Results: Of 50 patients analyzed, there were 38 children with ALL and 12 children with
AML, median age was 3.7 year( range 2 months to 15 years).Regarding ALL : L1 was
common with 60.5%, L2 was less with 39.5% and L3 was rare.B cell ALL was common
with 84.2%, T cell ALL was 15.8%. The frequencies of the genetic abnormalities were
as follow: 9(23.7%) with t(12;21)/TEL-AML1, 2(5.3%) with t(9;22)/BCR-ABL ,
3(7.9%) with t(4;11)/MLL-AF4, 4 (10.5%) with t(1,19)/E2A-PBX1.Regarding AML :
M2 was common with 41.6%. M1 was 25.0%, M4 was 16.7%. M6 was 16.7%., The
frequencies were :1(8.3%) with t(8;21)/AML1-ETO, 2(16.6%) with
t(15;17)/PML-RARA, 1(8.3%) with t(16,16)/CBFB-MYH11, 2 (16.6%) with
t(9;11)/MLL-AF931.6% of ALL and 41.7 % of AML had been chromosomal
abnormalities. Hyperdiploidy were 21.1% of ALL and 25.0% of AML.
Conclusion: Diagnosis and classification of acute leukemia in Hue Central Hospital
have improved by implementing immunophenotyping and detecting genetic
abnormalities which can determine the subtypes of acute leukemia and to decrease
errors of morphologic classification.The frequencies of the genetic abnormalities of our
patients are higher than in the reported literatures.Our sample size is small; therefore,
further study with larger sample size will be necessary to have the true frequencies.
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DEATH ASSOCIATEDWITH ACUTE LYMPHOCYTIC LEUKEMIA IN
CHILDREN IN HEMATOLOGY AND PEADIATRIC ONCOLOGY UNIT
N. Chellakhi1, S. Cherkaoui2, A. Madani2, A. Quessar2
1Casablanca, Morocco; 2Hospital August 20th, Hematology and Oncology Paediatric
Unit, Casablanca, Morocco
Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most common
malignant disease in children. It represents 80% of acute childhood leukemia, with a
frequency peak of 2 to 10 years. It is more common in boys (sex ratio 1.3 / 1). The
purpose of this study is to describe the clinical and epidemiological profile and then
deduct mortality’s causes of ALL in children.
Design/Methods: It’s a retrospective study over nine years (2006-2014), collecting
patients aged from 3 months to 20 years. Diagnosis was confirmed by cytology and
immunophenotyping. All of the patients were initially included in the MARALL
protocol 2006.
Results: Three hundred and thirty-eight patients were treated for ALL from January
2006 to September 2014, with a male predominance (sex ratio: 1.70).The median age
was 11.25 years. Hyperleukocytosis was found in 66.3% of cases. Sixty percent were of
phenotype B and 34% of phenotypeT. Death occurs in 31.9%, relapse in 6.8%,
Complete remission was obteined in 53.5% and 7.7% were lost of sight. In dead
patients, 60% were aged over 10 years and 9.2% under 3 years. Two patients had a
neurological localization and 5 tumor lysis syndrome. ALL T represents 20.3% and
ALL B 33.3%. Hyperleukocytosis was in 19.4% with nine percent of non response to
corticosteroid in prephase. A complex karyotype was found in 22 patients with the
Philadelphia chromosome in 3 patients. . Eleven percent died in prephase, 25% in
induction phase and 63% after remission. Death occurs after relapse (56.4%), after
septic shock (13.8%), following drug toxicity (10.18%), before treatment (5.55%),
hemorrhage (3.7%), lysis syndrome (0,92%) and non specific causes (14.8%).
Conclusion:Mortality associated with ALL remains a serious complication. Its rate still
increased in our unit; so it is important to individualise prognostic groups and to adapt
treatment protocol.
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OPTIMIZATION OF FOUR COLORMULTIPARAMETRIC FLOW
CYTOMETRY PANEL TO DIAGNOSE PEDIATRIC LEUKEMIAS
M. Cubbage1, A. Marcogliese2, K. McClain1, M. Redell1, J. Margolin1, A. Gaikwad1,
R. Kulkarni1, T. Goltsova1
1Texas Children’s Hospital/Baylor College of Medicine, Cancer and Hematology
Centers, Houston, USA; 2Texas Children’s Hospital/Baylor College of Medicine,
Pathology, Houston, USA
Background/Objectives: Acute leukemia remains an alarming problem and the second
leading cause of death in children even with improvement in current chemotherapy
regimens. Flow cytometry plays a vital role in the diagnosis and detection of this
disease. At Texas Children’s Cancer and Hematology Centers, a multiparametric flow
cytometry approach using six color panel and 33 antibodies is used for the diagnosis
and follow-up of pediatric leukemias. We investigated the diagnositc potential of a four
color panel using 18 antibodies. Potentially, the six-color 33 antibody panel may be
reduced to a four color 18 antibody panel without compromising diagnostic potential.
A reduced panel would be better for diagnosis in developing countries.
Design/Methods: Retrospective analysis of thirty cases was independently performed by
three clinicans. The immunophenotypic expression of 18 antibodies was employed for
diagnosis. The cases used for this study consisted of 11 patients previously diagnosed
with pediatric B-acute lymphocytic leukemia (B-ALL), nine with T-ALL, and ten with
acute myeloid leukemias (AML) using the 33 antibody panel.
Results: The diagnosis of both B- and T-ALL cases by using the 18 antibody panel
matched with the previous diagnosis. While 50% of the myeloid cases were diagnosed as
AML using the 18 antibody panel by all three clinicians, the remaining 50% cases were
grouped mostly as T-ALL.
Conclusion: This study shows that pediatric B- and T-ALL can be diagnosed with the
limited 18 antibody panel. However, immumophenotypic abberencies of pediatric
AML pose a challenge with the limited panel. Inclusion of intracytoplasmic staining
should improve AML diagnosis.
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IDENTIFICATION OF HOST GENETIC VARIANTS ASSOCIATEDWITH
MINIMAL RESIDUAL DISEASE IN PATIENTS WITH PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA
M. Dawidowska1, M. Kosmalska1, Ł. Se˛dek2, M. Twardoch2, A. Sonsala2,
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Background/Objectives:Minimal residual disease (MRD) is the most significant
prognostic factor in acute lymphoblastic leukemia (ALL). We aimed at identification of
host genetic variants associated with MRD in patients with pediatric ALL.
Design/Methods: The study group included 174 patients treated according to ALL-IC
BFM 2002 protocol, with informed consent and approval of local review board. The
study combined a candidate gene approach and a replication of Genome-Wide
Association Study (GWAS). It included 24 genetic variants; potentially involved in
metabolism of drugs used in ALL:MDR1 (rs3789243,rs2235046,rs1045642), VDR
(rs2228570,rs1544410), NR3C1 (rs6198,rs41423247), GSTP1 (rs1695), GSTM1 and
GSTT1 gene deletion, TPMT (rs1800460,rs1142345),MTHFR (rs1801133), TYMS
(rs3474033–TSER*2, TSER*3, TSER*3G>C), RFC (rs1051266); in anti-tumor
immunity: CCR5 (rs333) and MRD-associated variants as revealed by GWAS: IL15
(rs10519613), NALCN (rs7992226), CCDC85C (rs11160533), 3 intragenic variants
(rs9871556,rs3862227,rs4888024). For genotyping High Resolution Melting (HRM),
TaqMan Genotyping Assays, PCR/PCR-RFLP were used. Flow cytometry was used
for MRD assessment at day 15, 33 and week 12.
Results: Significant differences were found in genotypes distribution of CCR5 (rs333;32
bp deletion) between patients with high vs. low/negative MRD levels (cut off 10-3) at
day 15 (p=0.014; Freeman-Halton extension of Fisher exact test for 2×3 contingency
tables). Homozygous wild-type genotype was associated with low/negative MRD
(p=0.029; Z-test). Significant differences were also found in MRD levels (as a
continuous variable) at day 33 and week 12 between patients presenting different
genotypes of IL15 rs10519613 (p=0,037) and RFC rs1051266 (p=0.015) variants,
respectively (Kruskal-Wallis ANOVA on ranks). For both IL15 and RFC variants the
highest MRD levels were observed in patients with AA genotypes, although post hoc
Pediatr Blood Cancer DOI 10.1002/pbc
S246 SIOP ABSTRACTS
tests for verification of genotypes associated with highest/lowest MRD levels were
inconclusive (p>0.05).
Conclusion: Host germline variation is a potential source of prognostic markers,
available at the time of diagnosis, which might aid the improvement of risk assessment
in ALL through their association with MRD.
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CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: REFUSAL AND
ABANDONMENT OF TREATMENT IN SOUTHEAST OF IRAN
A. Dorgalaleh1, H. Soudabeh2
1Tehran University of Medical Sciences, Tehran, Iran; 2Iran University of Medical
Sciences, Hematology and Blood Transfusion, Tehran, Iran
Background/Objectives: Acute Lymphoblastic leukemia (ALL) accounts for one –fourth
of all malignancies in children. ALL treatment is based on standard protocols and
treatment abandonment is the main cause of treatment failure. Different factors such as
treatment regimen, Socioeconomic Status (SES) and family cultural and educational
background are the main cause of treatment abandonment in children with ALL.
Therefore, this study aimed to assess effect of SES on the rate of treatment
abandonment in children with ALL in southeast of Iran.
Design/Methods: This cross-sectional study was carried out in ALL patients in Zahedan
city within April 2011 to May 2013. Study population including 22 children with
different subtypes of ALL whom abandoned treatment. A structural questionnaire was
filled up by patients or their parents, and the association of these factors with treatment
abandonment were assessed with descriptive and analytical tests.
Results: Ninety patients that were diagnosed with ALL within April 2011 to May 2013
in Zahedan Ali Asghar hospital. The rate of treatment abandoned was 22(24.4%) in this
area. majority of the patients were boys 60.9 % and with regard to ethnicity, 20 persons
(90.9% ) were Baluch and the other two, one was Fars and the other Afghan origin
.Based on French–American–British (FAB) classification system, we had 18 patients
(78.3%) ALL_L1 and 4(17.4%) had ALL_L2.The reasons of treatment abandonment
in our study population was low family income, transportation difficulties, father´s
education status, belief about cancer as a whole an incurable and life terminating
disease and most of them relied on religious and spiritual beliefs for cure.
Conclusion: It seems that low income of patients’ parents was the main reason for
treatment abandonment in southeast of Iran. Financial problems in this area cause a
high rate of treatment abandonment that can impose higher costs to the health care
system of this country.
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ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS WITH
β-THALASSEMIA MAJOR
A. Dorgalaleh1, S. Hosseini2
1Tehran University of Medical Sciences, Tehran, Iran; 2Iran University of Medical
Sciences, Hematology and Blood Transfusion, Tehran, Iran
Background/Objectives: β-Thalassemia major is a severe form of anemia that can causes
new complications including malignancy. The immune imbalance is responsible for
occurrence of different malignancies such as leukemia and lymphomas. In the condition
like thalassemia multiple transfusions cause excess iron accumulation and result in
generating toxic oxygen free radicals and therefore immune system modification and
stimulate growth of infectious organisms. Thus, we assessed rate of malignancy in
patients with β-Thalassemia major.
Design/Methods: This long-term (5 years) study was carried out on 30 patients with
β-Thalassemia major as well as 30 healthy individuals as control groups. Both groups
were regularly checked up for any malignancy with standard protocols in 6 months
intervals. In any suspected case to malignancy, further confirmatory tests were
performed.
Results: The mean age were 5.2 and 4.9 years in case and control groups respectively
(0.08). Seventeen patients were male and all of patients were received defroxamine
(DFO) for iron chelating therapy. The mean number of transfused packed cell during
the study time was 108 and mean serum ferritin level was 570 (ng/dl). During the time
of the study, we found two (a 3.5 years old male and 11years old female) out of thirty
cases of patients with β-Thalassemia major who developed Acute Lymphoblastic
Leukemia (ALL) while in control group we did not find any evidence of malignancy.
Microscopic examination of both patients revealed ALL-L1 (FAB classification).
Immunophenotypic analysis revealed the lymphoblast with following phenotypes:
CD10-positive, CD19-positive, CD20-positive and CD22-positive in both cases.
Molecular analysis demonstrated homozygous mutations that in female patient was
IVSI-6 and in male one it was IVSI-5.
Conclusion: Co existence of thalassemia with leukemia emphasize that the possibility of
occurrence of malignancy in thalassemia major patients that one possibility for this
phenomena is the carcinogenic and toxic effects of excess iron resulted from multiple
transfusions.
P-025
DISEASE OUTCOME FOLLOWING THERAPYMODIFICATIONS FOR
METHOTREXATE NEUROTOXICITY IN ACUTE LYMPHOID LEUKEMIA
Z. Dreyer1, J. Brackett2, T. Horton2, K. Kamdar2, A. Stevens3, J. Margolin2, J. Theis2,
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Background/Objectives: Central nervous system (CNS) therapy is a significant
management problem for patients with acute lymphoid leukemia (ALL) who develop
methotrexate neurotoxicity (MTX-N). Symptoms include transient events, seizures,
hemiparesis or severe necrotizing encephalopathy. Few have reported clinical outcomes
following therapy modifications for MTX-N. We report the clinical outcomes of 22
patients with ALL and MTX-N diagnosed between 2011-2014.
Design/Methods: Twenty five events were reported in 22 patients with ALL risk status
defined as: high risk or very high risk -16; standard risk – 6; CNS 1 -19; CNS 2 – 2;
CNS 3 – 1. Treatment was on or according to COG AALL0232, AALL0932 or
AALL1131. Our institutional guidelines include: MRI at time of event and 4-6 weeks
later; withholding intrathecal (IT) therapy for 4-6 weeks. If physical findings and MRI
changes (diffusion restriction / acute changes) resolve, retreatment with IT MTX plus
leucovorin (ITM/LCV) is considered. If physical findings resolve but minor MRI
changes remain, IT hydrocortisone / araC (ITH-A) are recommended until MRI
normalizes. IT therapy is withheld in patients with persistent physical findings or acute /
worsening MRI changes.
Results:MTX-N events by phase of therapy: Consolidation (4), Interim maintenance I
(IM-I) - high dose MTX (8), IM-I - Capizzi MTX (2), Delayed intensification (5), IM-II
(3), Maintenance (3). Management for patients included: ITM/LCV (4); ITH-A (8);
ITH-A and ITM/LCV (10). Events included: Mild TIA/weakness (11), severe TIA (10)
and seizure (4). Three patients had second events post ITM/LCV. Eleven patients have
been off therapy a median of 9 months. Eleven remain on therapy and 8/11 will
complete therapy within one year. One patient had a CNS relapse following ITM/LCV.
Conclusion:Modifications as described for MTX-N are adequate to maintain disease
control while posing minimal risk. ITM/LCV may offer a greater risk of a second event
occuring.
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PROFILE OF CHILDHOOD CANCER IN CENTRAL SUDAN
M. Elhassan1
1National Cancer Institute - University of Gezira, Wad Madani, Sudan
Background/Objectives: In Sudan it is still difficult to know the extent of cancer and its
profile among children. This study was conducted to find out the pattern of childhood
cancer in a tertiary referral center in a sub Saharan African country.
Design/Methods: It was a retrospective descriptive study. Data was retrieved from
medical records of all paediatric patients who were registered at the National Cancer
Institute, Sudan over the period from January 1999 to December 2013.
Results: During the study period a total of 766 children below 15 years of age were
registered. The predominant age affected was observed in 0 to 5 years age group. The
frequency of cancer was found to be higher among boys with a male to female ratio of
1.3:1. Majority of the children were from rural areas. Leukemia (36.9%), lymphoma
(26.3%), retinoblastoma (9.8%) and nephroblastoma (9.5%) were the commonly found
childhood cancers among the study population. Other less commonly found cancers
were neuoroblastoma (7%), central nervous system tumours (6.4%), soft tissue sarcoma
(3.7%), bone tumours (3.4%) and nasopharyngeal carcinoma (3.4%). Lymphoma and
central nervous system tumours occurred in higher frequency in boys (27 % and 7%
respectively) compared to girls (17% and 4 % respectively), whereas retinoblastoma and
nephroblastoma occurred less frequently in boys (7% and 6.5% respectively) than girls
(11% and 10% respectively).
Conclusion: This study provided some knowledge about the situation of childhood
cancer in Sudan and showed that leukaemia and lymphoma represent about 60% of all
cases. A dedicated paediatric cancer registry is essential to find out the real incidence,
types and survival of childhood malignancies Sudan.
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HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
USING A REDUCED-INTENSITY CONDITIONING REGIMENWHICH
CONSIST OF RITUXIMAB ANDMESENCYMAL STEM CELL CO-INFUSION
IN CHILDREN: PRELIMINARY RESULTS
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Background/Objectives: Haploidentical stem cell transplantation (haplo-HSCT) has
been developed as an alternative transplant strategy for children with hematological
disorders without a HLA matched donor. Reduced-intensity conditioning (RIC)
regimens allow haplo-HSCT with less toxicity, but graft versus host disease (GVHD)
remains still an actual problem. T cell receptor (TCR) α and β/CD3 depletion for the
prophylaxis of GVHD achieved a significant success in haplo-HSCT. The aim of our
study is to investigate the efficacy of rituximab (RTX) and mesencymal stem cell (MSC)
administration for GVHD prevention in haplo-HSCT.
Design/Methods:We analyzed the outcome of fifteen pediatric patients who underwent
haplo-HSCT using a RIC regimen and TCRαβ /CD3 depletion from January 2014 to
March 2015. To prevent EBV related posttransplant lymphoproliferative disease and
GVHD, RTX was added into conditioning regimen. MSC was co-infused to suppress
alloreactive donor anti-host T-cell responses and to use their ability to promote
angiogenesis and support micro-environment, which facilitate engraftment.
Results: Reducing α/ β of the graft was 99.9%. The grafts contained a median of
28.91×106 CD34+ cells. Ten patients engrafted with full donor chimerism. Two
patients were mix chimeric. Graft rejection occurred in three patients. Three patients
developed grade 3-4 acute GVHD. CMV, Adeno and BK virus reactivation were seen in
3, 3 and 4 patients respectively. None of the patients developed EBV reactivation after
HSCT. Severe bacterial infection was seen in three patients after HSCT. Two patients
were died and transplant related mortality at day 100 was 13.3%. Our data at +30, +60
and +90 from engraftment showed delayed immune reconstitution.
Conclusion: These data indicate that a selective graft manipulation and MSC results
into effective prevention of acute GVHD, rapid recovery of neutrophil and platelet
counts without severe complication at acute phase of HSCT and low TRM. Following
investigation of advantages and risks of Rituximab and MSC application are required.
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IMPACT OF TRAUMATIC LUMBAR PUNCTURE ON CLASSIFICATION OF
CNS LEUKEMIA AND OUTCOME FOR CHILDRENWITH ACUTE
LYMPHOBLASTIC LEUKEMIA TREATED UNOP PEDIATRIC HOSPITAL IN
GUATEMALA
J. Flerlage1, S. Howard1, F. Antillon-Klaussman2, A. Zapata2, M. Arreola2, D. Borrayo2,
C. Garrido2, J. Baker1
1St Jude Children’s Research Center, Oncology, Memphis, USA; 2Universidad
Internacional de Oncologia Pediatrica, Oncology, Guatemala City, Guatemala
Background/Objectives: Background: Traumatic lumbar puncture (LP) at diagnosis of
acute lymphoblastic leukemia (ALL) can confound the classification of central nervous
system (CNS) status and increase the risk of CNS relapse. Traumatic LP rates can be
decreased by performing procedures under anesthesia, assuring an adequate platelet
count prior to the procedure, and allowing only experienced practitioners to perform
the first LP, but implementation of such measures is not universal.
Design/Methods: Procedure: Lumbar puncture practices, the incidence of traumatic LP,
CNS risk classification, and outcomes of patients with ALL consecutively diagnosed
from May 2007 through December 2012 at the National Pediatric Oncology Unit of
Guatemala were analyzed to identify opportunities to improve the quality of care.
Traumatic lumbar puncture was defined as at least 10 red blood cells per microliter of
cerebrospinal fluid.
Results: Of 587 consecutively diagnosed patients, 3 died prior to their first LP and 114
(19.5%) of the remaining 584 evaluable patients had a traumatic LP. Rates of traumatic
LP varied by year ranging from 13.1% (n=130) to 23% (n=103).
Conclusion: A quality improvement project is needed to improve modifiable risk factors
for traumatic LP at diagnosis in Guatemala to avoid unnecessary classification to a
higher CNS status and extra chemotherapy/radiation secondary to traumatic LP and
decrease the rates of CNS relapse that may be secondary to traumatic LP at diagnosis.
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HAS THE TIME COME FOR EFFECTIVE TREATMENT OF CHILDRENWITH
PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA IN CHINA? A RETROSPECTIVE STUDY FROM CHINESE
CHILDHOOD CANCER GROUP
Y.J. Gao1, X.F. Zhu2, S.Y. Hu3, Y.P. Zhu4, Q. Hu5, Y. Jie6
1Shanghai Children’s Medical Center, Department of Hematology and Oncology,
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University, Department of Hematology and Oncology, Suzhou, China; 4West China
Second University Hospital of Sichuan University, Department of Pediatric Hematology
& Oncology, Chengdu, China; 5Tongji Hospital- Tongji Medical College-Huazhong
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Wuhan, China; 6Chongqing Children’s Hospital- Chongqing Medical University-
Chongqing, Department of Hematology, Chongqing, China
Background/Objectives: This study was designed to provide descripitive review then
improve our understanding of barriers to effective treatment of pediatric Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China.
Design/Methods:We collected and centrally reviewed medical records of children with
Ph+ ALL who were treated by 6 large single institutions in China between 2005 and
2012. Follow-up observations extended through September 30, 2014. All patients were
assigned to therapy for high-risk ALL or very high-risk ALL. Allogeneic hematopoietic
stem-cell transplantation (alloHSCT) was indicated for all patients in first complete
remission. Post-induction imatinib was introduced into the chemotherapy regimens
recently.
Results: One hundred and seventy-nine patients (118 boys and 61 girls) with Ph+ ALL
were identified from 4439 patients who were newly diagnosed at the 6 participating
institutions. Of the 127 patients who achieved remission by the end of initial phase of
induction therapy, 87 were treated with chemotherapy alone, 22 underwent alloHSCT
with or without imatinib and 18 treated with chemotherapy combined with continuous
imatinib. Abandonment (42.1%) was the leading cause of therapeutic failure. However,
the abandonment rate decreased by 25% from 2005 to 2010 (50.5%) to 2011 to 2012
(25.7%). The mortality related to transplant was 20.8%. There is no toxic death related
to imatinib. The 2-year event free survival (EFS) was 36.8± 6.1% in chemotherapy only
cohort, 61.8± 10.7% in alloHSCT cohort and 72.2 ± 10.6% in imatinib cohort (P =
0.002). The difference in EFS was not significant between the alloHCST and imatinib
cohort (P = 0.92).
Conclusion: AlloHSCT is not readily available for children with Ph+ ALL in China.
The growing evidence for the benefit of imatinib for pediatric Ph+ ALL and the
economic growth most contribute to the abandonment rate decline between 2005 and
2012. With the generic imatinib getting into market, including imatinib in the therapy
would be feasible in China.
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POLYMORPHISMS IN MICRORNAS COULD AFFECT MTX CLEARANCE IN
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
M. Umerez1, A. Gutierrez-Camino1, I. Martin-Guerrero1, E. Lopez-Lopez1,
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Oncohaematology, Bilbao, Spain; 4University Hospital La Paz, Department of
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Background/Objectives:Methotrexate (MTX) is a key component in the treatment of
childhood Acute Lymphoblastic Leukemia (ALL). Treatment with high-dose MTX
often causes toxicity, requiring a dose reduction or cessation of treatment, which has
been demonstrated to reduce survival. Therefore, it would be useful to identify a
predictor of the adverse effects of MTX. In the last years, several studies have
investigated the relationship between genetic variations and MTX toxicity. Nevertheless,
most of these studies have focused on coding regions. Nowadays, it is known that genes
that do not codify proteins, like microRNAs (miRNAs), can regulate genes involved in
drug transport. Recently, it has been described that SNPs in miRNAs could alter
miRNA function. In fact, MiRNA related-SNPs have been already associated with
MTX toxicity. Therefore, the aim of this study was to determine if SNPs in miRNAs
could be useful as new MTX toxicity markers in pediatric B-ALL treatment.
Design/Methods: DNA from blood of 180 children with B-ALL during complete
remission and treated with the LAL/SHOP protocol were analyzed. MTX plasma levels
were used as an objective and quantifiable marker of toxicity. 235 SNPs in 222 miRNAs
were studied. VeraCode GoldenGate platform was used.
Results: Interestingly, we found 2 SNPs in one miRNA targeting the transporter
SLC46A1 gene, significantly associated with MTX clearance.
Conclusion: Our results suggest that polymorphisms in miRNA genes may affect the
risk of MTX toxicity in childhood ALL. Acknowledgements This project was
supported by RETICS (RD/12/0036/0060 and RD/12/0036/0036) and Basque
Government (IT661-13, S-PE12UN060).
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POLYMORPHISMS AND VINCRISTINE TOXICITY IN PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA
A. Gutierrez-Camino1, I. Martin-Guerrero1, E. Lopez-Lopez1, N. Bilbao-Aldaiturriaga1,
N. Garcia de Andoin2, A. Navajas3, P. Garcia-Miguel4, A. Carbone Bañeres5,
A. Garcia-Orad6,7
1University of the Basque Country, Department of Genetics-Physic Anthropology and
Animal Physiology, Leioa, Spain; 2University Hospital Donostia, Department of
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Pediatrics, San Sebastian, Spain; 3University Hospital Cruces, Department of
Oncohaematology, Bilbao, Spain; 4University Hospital La Paz, Department of
Oncohaematology, Madrid, Spain; 5University Hospital Miguel Servet, Department of
Paediatrics, Zaragoza, Spain; 6University of the Basque Country, Department of Genetics
Physic Anthropology and Animal Physiology, Leioa, Spain; 7BioCruces Health Research
Institute, UPV/EHU, Leioa, Spain
Background/Objectives: Vincristine is an important component of treatment protocols
for acute lymphoblastic leukemia (ALL). However, vincristine can cause neurotoxicity,
a disabling adverse effect that can affect the quality of life of the patients. This
neurotoxicity can lead to dose reduction or treatment discontinuation, which can have
an impact on survival. Nowadays, one of the challenges in medicine is to predict which
patients are going to respond to a treatment based on their genetic characteristics in
order to adjust the treatment from the beginning.The mechanism of action of
vincristine is based on its binding to beta-tubulin, which causes the inhibition of
microtubule assembly and cell cycle arrest. In the nervous system, the binding of
vincristine to beta-tubulin leads to severe alterations in axonal microtubules, resulting
in axonal swelling and nervous fiber damage that disturbs both sensory and motor
functions that are characteristics in neurotoxicity. Recently, a genome-wide association
study in 2 independent cohorts of childhood ALL patients found a polymorphism in
the promoter region of CEP72 that was associated with increased risk of
vincristine-related neurotoxicity. CEP72 gene encodes a centrosomal protein essential
for microtubule formation, and vincristine exerts its pharmacologic effects by inhibiting
microtubule formation.The aim of this study was to replicated the polymorphism of
CEP72 in a spanish cohort of childhood B-ALL patients and determine if other
polymorphism in microtubule-related genes are associated with vincristine
neurotoxicity.
Design/Methods: DNA from blood of 152 children with B-ALL during complete
remission and treated with the LAL/SHOP protocol were analyzed. 22 SNPs in 7 genes
were studied.
Results:We found several polymorphisms in these genes significantly associated with
vincristine toxicity.
Conclusion: Our results suggest that polymorphisms in microtubule-related genes may
affect the risk of vincristine toxicity in childhood ALL. This project was supported by
RETICS (RD/12/0036/0060 and RD/12/0036/0036) and Basque Government
(IT661-13, 2012111053).
P-032
MORBIDITY ANDMORTALITY DURING INDUCTION CHEMOTHERAPY OF
PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA: REPORT FROM
COMBINEDMILITARY HOSPITAL RAWALPINDI, PAKISTAN
T. Ghafoor1, T. Ashraf1
1Combined Military Hospital, Paediatric Oncology, Rawalpindi, Pakistan
Background/Objectives: To analyze pattern of morbidity and mortality during
induction chemotherapy of paediatric Acute Lymphoblastic Leukaemia (ALL).
Design/Methods: Prospective descriptive study conducted at Paediatric Oncology
department, Combined Military Hospital Rawalpindi, Pakistan. All newly registered
cases of ALL between 1 to 18 years of age during three years of study from 1st January
2012 to 31st December 2014 were included.
Results: Out of 241 patients with ALL, 169 (70%) were males and 72 (30%) were
females. The mean age was 6.2 years with a range from 15 months to 17 years. The
mean duration of symptoms before reporting to oncologist was 41 days with a range
from 3 to 305 days. Diagnosis was Pre-B ALL in 176 (73%), T-ALL in 26 (10.8%),
Lymphoblastic lymphoma in 10 (4.2%) cases, 29 (12 %) cases were diagnosed as ALL
on basis of morphology only. Cytogenetics was available in 72 (29.8%) cases. Only 11
(4.6%) cases had CNS disease at the time of diagnosis. The patients were treated
according to standard arm of UKALL2011 protocol. One hundred and twenty seven
(52.7%) cases were categorized as high risk and were treated with four drugs (regimen B
induction) and 114 (47.3%) patients were of standard risk and were treated with three
drugs (Regimen A). the major problems in induction were; infection in 158 (65.6%)
cases, proximal myopathy in 75 (31.1%) cases, drug induced hepatotoxicity in 18 (7.5%)
cases and neuropathy in 12 (5%) cases. Eighteen (7.46%) patients died during induction
chemotherapy, 12 (66.6%) due to infection, 3 (16.7%) due to bleeding and 2 (11.1%) due
to hepatic failure and one (5.5%) due to Anthracycline induced cardiotoxicity.
Conclusion: Infection and proximal myopathy are the major concerns during induction
chemotherapy. Infection alone or in combination with other factors is the major cause
of death during induction chemotherapy.
P-033
PENTOXIFYLLINE INCREASES APOPTOSIS AND REGULATES A
PROAPOPTOTIC GEN EXPRESSION PROFILE IN CHILDRENWITH ACUTE
LYMPHOBLASTIC LEUKEMIA DURING INDUCTION TO REMISSION
PHASE (STEROID WINDOW)
O. Gonzalez-Ramella1,2, J. Meza-Arroyo3, L.F. Jave-Suarez3, P. Ortiz-Lazareno3,
F. Medina -Barajas1, G. Hernadnez-Flores3, X. Jimenez-Lopez1,
S. Gallegos-Castorena1, F. Sanchez-Zubieta1,2, A. Bravo-Cuellar3
1Hospital Civil de Guadalajara, Departamento de Hematologia y Oncologia Pediatrica,
Guadalajara, Mexico; 2Universidad de Guadalajara, Instituto de Investigacion de Cancer
Infantil y de la Adolescencia, Guadalajara, Mexico; 3Instituto Mexicano del Seguro
Social, Centro de Investigacion Biomedica de Occidente, Guadalajara, Mexico
Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most common
childhood cancer. Pentoxifylline (PTX) increases chemotherapy-induced apoptosis. A
pre-treatment window clinical trial was developed to evaluate whether PTX increases
apoptosis and gene expression profile in ALL during the induction steroid window
phase.
Design/Methods: Thirty-two children with a new diagnosis of ALL were randomly
assigned to receive prednisone (PRD 40 mg/m2/day) only during the 7-day treatment
pre-phase (PRD group, n=11) or to receive PRD with PTX (10 mg/kg/day) (PTX
group, n=11); the control group included children with normal bone marrow (n=10).
Bone marrow aspiration was performed at diagnosis in all groups, and at the end of
PRD window for patients with ALL (PRD and PTX groups). Apoptosis was evaluated
by flow cytometry using Annexin V-Flourescein isothiocyanate /Propidium iodide
stains. Gene expression profile was performed by microarray and sq-PCR.
Results: Apoptotic index at diagnosis was similar in all groups. After treatment,
apoptosis was significantly higher in the PTX group than in the Prednisone group (p <
0.04). There were no serious adverse effects observed for PTX. Expression of wide
number of genes was regulated by PTX between the PRD group and the PTX group
(170 and 875 genes respectably p<0.01). PRD and PTX groups showed a proapoptotic
gene expression profile. PTX when added to PRD induced the expression of
proapoptotic genes involved in the death inducing signaling complex formation
(CASP8, RIPK1 and TNFIP3L). The intrinsic pathway was also affected by the
BNIP3L and p53 regulator BCL11A.
Conclusion: PTX potentiates blast apoptosis induced by PRD in children with ALL
during steroid window phase. Experimental reports suggest that PTX induce inhibition
of NF-ĸB, inhibiting survival genes facilitating apoptosis. PTX promote apoptosis by
inducing the expression of extrinsic as well as intrinsic pathway genes. At the present
time we are conducting a study to conclude this hypothesis.
P-034
RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
HIGH RISK PEDIATRIC LEUKEMIA: THE EXPERIENCE IN A
SINGLE-CENTER IN MÉXICO
R. Navarro-Martín del Campo1, O. Gonzalez-Ramella1,2, A.L. Orozco-Alvarado1,
M. Ortiz-Sandoval1, S. Gallegos-Castorena1, F. Sanchez-Zubieta1,2
1Hospital Civil de Guadalajara, Departamento de Hematología y Oncología Pediatrica,
Guadalajara, Mexico; 2Univiersidad de Guadalajara, Instituto de Investigación de cáncer
infantil y de la adolescencia, Guadalajara, Mexico
Background/Objectives: Hematopoietic stem cell transplantation (HSCT) offers an
opportunity to cure children with high-risk leukemia. We describe the results of this
procedure in our Center.
Design/Methods: FromMarch 2003 to May 2014, fifty-nine pediatric patients with
high-risk leukemia aged 1 to 20 years underwent HSCT. Status disease were: ALL 1st
CR:10, ALL 2nd CR:13, ALL 3rd CR:4 , AML: 22, CGL non responsive to imatinib:8,
MMJL:1, Secondary LLA:1. All conditioning regimens were myeloablative. GVHD
prophylaxis consisted in cyclosporine plus methotrexate.
Results: Stem cell sources included: Bone Marrow (BM) in 71%, Peripheral Stimulated
Blood (PSB) in 12% and Cord blood (CB) in 17%. Fifty patients received Allogenic
HSCT while 9 AML patients autologous HSCT. Medium infused CD34 cells/Kg for
Bone Marrow group were 3ˆ6, in CB group 0.21ˆ6 and in PSB group 5ˆ6. Engraftment
succeed in 53 patients, 6 patients had graft failure. Average Neutrophil engraftment
occurred on day +17 in BM and PSB patients while in UCB on day +28. Platelet
recovery was achieved in average at day +20 in BM and PSB patients while in UCB at
day +34. Acute GVHD was diagnosed in 45% of patients being grade I-II in 60% and
Grade IV in 40%. Mild cGvHD occurred in 10 patients. Currently, 61% of patients are
disease free with a follow-up of 45 months. Main cause of death was Leukemic
progression in 52% followed by aGVHD in 22%, CMV infection after day 100 in 9%,
graft failure in 9%, sepsis in 4% and VOD 4%.
Conclusion: HSCT is a valuable treatment in high-risk pediatric leukemia, reaching 61%
of cure in our series. Mean cause of death post transplantation still being leukemic
relapse. In our population most cases of chronic GvHD were mild to moderate,
probably because we use BM and CB a source of hematopoietic progenitors.
P-035
ACUTE LYMPHOBLASTIC LEUKEMIA PRECEDED BY STEROID RESISTANT
NEPHROTIC SYNDROME – CASE REPORT AND REVIEW OF LITERATURE
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V. Gunasekaran1, N. Radhakrishnan2, A. Sachdeva2
1Sir Gangaram Hospital, New Delhi, India; 2Sir Gangaram Hospital, Pediatric
Hematology-Oncology, New Delhi, India
Background/Objectives: Infections, tumour lysis, leukemic infiltration and drug toxicity
usually account for renal involvement in Acute Lymphoblastic leukemia (ALL). Mostly,
renal disease develops following the onset of ALL.
Design/Methods:We describe the clinical course and management of a child, in whom
nephrotic syndrome (NS) preceded the diagnosis of ALL, with a review of pertinent
literature.
Results: A 6 year old boy presented with fever, abdominal pain, vomiting, oliguria,
pallor, anasarca and hypertension. Investigations revealed deranged renal functions,
albuminuria(++++) and hypoalbuminemia(1.9 g/dL). Initial blood counts showed:
Haemoglobin 8.2g/dL, platelet count 1,98,000/μL, total leucocyte count 6000/μL, with
a differential count of neutrophils 60%, lymphocytes 27%, eosinophils 4% and
monocytes 8%. Peripheral smear showed no abnormal cells. Ultrasonography showed
bilateral bulky kidneys. P-ANCA was positive by immunoenzymatic assay (repeated
twice). Renal biopsy showed gross tubular necrosis with mesangial and segmental
sclerosis. He showed initial improvement on steroids and intermittent hemodialysis.
However, proteinuria persisted. Later, Tacrolimus was added for steroid resistant NS.
During 4th month of treatment, he developed fever. Investigations showed
thrombocytopenia with peripheral smear showing 11% blasts. Bone marrow evaluation
confirmed precursor B-cell ALL. He was started on induction chemotherapy (BFM95
protocol). He developed sepsis on day 10 of chemotherapy, requiring antimicrobials,
ventilation and inotropes. He developed intracranial haemorrhage on day 15, requiring
decompressive craniotomy. He continued to receive non-myelosuppressive
chemotherapy. His progressively worsening renal function required hemodialysis.
Despite all, he developed septic shock, multi-organ failure and finally succumbed on
day 34 of chemotherapy. Previously, 5 children were reported to develop ALL, 5 – 84
months after a diagnosis of NS. All 5 achieved remission, though renal problem
persisted in all.
Conclusion: This child had no clinical or laboratory clues of malignancy at initial
presentation. The exact pathogenesis for the co-incidence of these two disorders is still
not clear. High index of suspicion is essential.
P-036
IMMUNOPHENOTYPIC, CYTOGENETIC AND CLINICAL FEATURES OF
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A DEVELOPING
COUNTRY EXPERIENCE
V. Gupta1, A. K M2, V. Tilak3, J. Shukla3
1Banaras Hindu University, Varanasi, India; 2Banaras Hindu University, Pediatrics,
Varanasi, India; 3Banaras Hindu University, Pathology, Varanasi, India
Background/Objectives: Immunophenotyping has great importance for diagnosis,
classification and prognosis of acute lymphoblastic leukemia (ALL). However, with
resource constraints the complete work up can not be carried out in many cases. We
investigated the immunophenotypic subtype of ALL and its association with
cytogenetics and clinical features.
Design/Methods: A total of 210 children with ALL were studied for their clinical
presentation. Immunophenotyping was carried out in 165 children by flow cytometry
using a panel of monoclonal antibodies. 56 patients were also subjected to karyotype
analysis by G-banding technique.
Results:Mean age of the patients was 6.4 years .with male to female ratio of 1.6:1.
28.1% patients had cell count >50 × 10 9 /L of which more than half had counts of
>100 × 10 9 /L. 3.3% patients had prominent musculoskeletal manifestations. 5.7% had
nephromegaly. 2.9% had central nervous system symptoms. Another 3% patients had
positive blats in CSF without CNS symptoms. 18.8% were identified as T-ALL and
81.2% as B-ALL. Among B-ALL, 4.4% were identified as Pro-B ALL, 69.2% as
Common ALL, 24.2% as Pre-B ALL and 2.4% as mature-B ALL. Myeloid antigen
(MyAg) expression was documented in7.9% of patients. Myeloid positivity was more in
patients with T-ALL (12.9%) than B-ALL (6.7%). Myeloid positivity was associated
with high cell count (>50 × 10 9 /L). CD13 was the most commonly expressed antigen.
Of the 56 patients karyotyped, 3 (5.4%) were positive for ph chromosome. 6 had
hypoploidy, 2 had hyperploidy, 5 had monosomy and 7 had trisomy.
Conclusion:More number of patients showed high risk features such as
hyperleucocytosis and T cell disease compared to previously reported studies from
developed countries.
P-037
IMPACT OF EARLY INVASIVE FUNGAL INFECTIONS ON CHILDHOOD
ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY AND OUTCOME
H. Hafez1, A. Emad2, A. Hamed2
1National Cancer Institute-Cairo University, Pediatric Oncology, Cairo, Egypt; 2Ain
Shams University, General Pediatrics, Cairo, Egypt
Background/Objectives: The objectives of this study were to investigate the frequency
and mortality rates of invasive fungal infections and to assess the impact of these
infections on the timely application of chemotherapy regimens during induction and
consolidation therapy in pediatric patients with acute lymphoblastic leukemia (ALL).
Design/Methods: This is a retrospective cohort study analyzed patients below the age of
18 years with ALL, receiving chemotherapy for remission induction and consolidation
therapy from January 2012 to December 2012. Patients were evaluated for frequency of
invasive fungal infection (either probable or proven fungal infection). Also dates of
chemotherapy that given during these phases and any changes in the schedule was
reported.
Results: During the study period, 96 patients were enrolled with median age of 5 years,
and male/female ratio was 1.5:1. According to Total XV St. Jude protocol, 48 patients
(50%) were low risk, 47 patients (49%) standard risk, and one high risk. Infection was
the most common complication during induction and consolidation as it was reported
in 42 patients (43.7 %), 19 patients (19.8%) had probable fungal infection, 13 (13.5%)
with documented bacterial sepsis, and 10 (10.4%) with soft tissue infections. The total
deaths during induction and consolidation were 16 patients (16.70%) (All of them died
during induction), the most common cause of death was sepsis (9.4%), followed by
fungal infection (3.1%). Median duration of treatment delay during induction and
consolidation therapy was 31 days in patients with invasive fungal infection compared
to 8 days without IFI (P.valu <0.001).
Conclusion: Infectious complications during induction therapy are still a major problem
affecting the outcome of the childhood ALL. High incidence and the attributable
mortality rate of fungal infections during ALL induction as well as their impact on
chemotherapy schedule may call for the antifungal prophylaxis during this phase of
treatment.
P-038
LUNG TRANSPLANTATION OF PEDIATRIC BRONCHIOLITIS OBLITERANS
PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION : A SINGLE CENTER EXPERIENCE
S.M. Hahn1, H.S. Kim1, J.W. Han1, H.C. Paik2, C.J. Lyu1
1Severance hospital, Pediatric Hematology & Oncology, Seoul, Korea; 2Severance
hospital, Thoracic and Cardiovascular Surgery, Seoul, Korea
Background/Objectives: Bronchiolitis obliterans (BO) is a lung involvement of chronic
graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation
(HSCT). In severe progressive BO unresponsive to immunosuppressant therapy, lung
transplantation (LTx) can be a treatment option for patients. There are only a few
reports about pediatric LTx for BO hence we here present patients who have undergone
LTx with BO in our center.
Design/Methods:We retrospectively reviewed data of patients who had allogeneic HSCT
from 2008 to 2014 and developed BO. Clinical characteristics, treatment modality,
imaging studies as well as results of pulmonary function test (PFT) have been collected.
Results: Among 119 patients who received allogeneic HSCT, 18 (15.1%) were diagnosed
as BO. Their primary diagnosis were ALL in 9 patients, AML in 5, lymphoma in 2,
Krabbe’s disease in 1 and Ewing sarcoma in 1 patient. As one patient with relapsed
ALL had been transferred for the BO treatment, total 19 patients were evaluated.
Median duration of BO development is 7.3 months (range, 3.6-19.3) after HSCT. There
were two who had been enrolled to LTx candidate and died before surgery and five
patients (26.3%) with continuous falling of PFT parameters were able to received LTx.
One patient expired because of pneumonia which progressed to multi-organ failure
after 102 days of LTx, three has been shown improved lung function after LTx, and one
patient just received LTx three weeks ago. The longest survival after LTx is 10.5 months.
Among 12 patients who were not on waiting list of LTx, five patients expired, all due to
direct or indirect influence of BO.
Conclusion: The mortality of BO is 42.1% in our study, 25% in LTx patients. Patients’ 5
year overall survival rate is 48.0 ± 5.4%. LTx could be considered as effective treatment
for pediatric patients with BO, although long term follow up of patients are needed.
P-039
PEDIATRIC-INSPIRED VERSUS HYPERCVAD PROTOCOLS FOR
PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN
ADOLESCENTS AND YOUNG ADULTS (AYA): AN NNT ANALYSIS
K.F. Villa1, G.F. Guzauskas2, D.L. Veenstra2
1Jazz Pharmaceuticals-Inc, Health Economics & Outcomes Research, Palo Alto-CA,
USA; 2University of Washington, Pharmaceuticals Outcomes Research and Policy,
Seattle- WA, USA
Background/Objectives: ALL treatment outcomes in adolescents and young adults
(AYAs, ages 16-39 years) are poorer relative to children due to age-associated
cytogenetic features and treatment differences. Compared with adult protocols,
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pediatric treatment protocols generally contain higher cumulative doses of
nonmyelosuppressive agents including L-asparaginase. HyperCVAD is an
asparaginase-free chemotherapeutic regimen widely used to treat AYAs and adults with
ALL. The hyperCVAD regimen consists of 2 alternating cycles: fractionated
cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Cycle-A); and
high-dose methotrexate and cytarabine (Cycle-B). While treatment of AYA patients
with hyperCVAD is common in the US, noncomparative data suggest that outcomes
may be inferior to pediatric-inspired treatment protocols, which include L-asparaginase.
Objective was to calculate the number-needed-to-treat(NNT) to prevent 1 relapse or
death for pediatric-inspired treatment versus hyperCVAD in AYA patients with ALL.
Design/Methods: No comparative clinical trials were found in a comprehensive review
of published literature to identify outcomes for AYA patients with
Philadelphia-negative ALL undergoing pediatric-inspired versus hyperCVAD first-line
treatments. Progression-free survival (PFS) was estimated for these regimens based on 2
studies with similar patient populations (Kantarjian et al, Cancer, 2004; Storring et al,
BJH, 2009) by fitting Weibull curves to the published PFS rates. The NNT was
calculated using these estimates. NNT is the inverse of the absolute risk reduction
(ARR) associated with experimental intervention relative to controls (1/ARR), where
ARR equals control event rate (CER) minus experimental event rate (EER), ie,
ARR=CER-EER (Laupacis et al, NEJM, 1988).
Results: Five-year PFS estimated from the relative survival curves were 0.44 for
hyperCVAD and 0.62 for pediatric-inspired regimens, translating into an NNT of 6.
Conclusion: An indirect comparison of published literature in similar populations
suggests that pediatric-inspired regimens containing asparaginase may have better
clinical outcomes than treatment with the asparaginase-free hyperCVAD protocol, with
an NNT of 6 (for every 6 patients treated, one relapse or death is averted).
P-040
INVASIVE CANDIDIASIS IN PEDIATRIC PATIENTS WITH HEMATOLOGIC
DISORDERS
Z. Hashemizadeh1, P. Badiee1, S.A. Shamsdin2
1Prof Alborzi Clinical Microbiology Research Center, Shiraz University of Medical
Sciences, Shiraz, Iran; 2Gasterohepathology Research Center, Shiraz University of
Medical Sciences, Shiraz, Iran
Background/Objectives: Invasive Candidiasis (IC) is one of the major infectious
complications in pediatric patients with hematologic disorders. Several techniques
based on the detection of Candida species –specific DNA, circulating serum
biomarkers and Candida antigens have been developed. The aim of this prospective
study is to determine the incidence of IC in pediatric patients with hematologic
disorders by nested PCR, Galactomannan and Beta -D- glucan Tests.
Design/Methods: All the patients were classified according to the diagnostic criteria of
the European Organization for Research and Therapy of Cancer and Mycoses Study
Group (EORTC/MSG) consensus revised definitions draft, presented at PMC, 2009.
BDG measurement using the glucan detection kit and MN antigen using Platelia
Candida Ag, were used with cut-off value of 80 pg/mL and 0.5ng/mL, respectively.
Two sets of primers universal were used for Candidas identification.
Results: Between Oct. 2006 and Jun. 2008, two hundred two sera from 124 pediatric
patients with hematologic disorders, hospitalized in Nemazee hospital , southern Iran,
Shiraz, who were febrile, neutropenic or on chemotherapy, followed up for Invasive
Candidiasis. Mean age was 9.3 years (range 1—14 years). Seventy seven were male and
forty seven were female. The underlying diseases were ALL (n=43), AML (n=31),
aplastic anemia (n=7), pancytopenia (n=9), CLL (n=16) and CML (n=18). The
incidence of IC in the patients was 29 %( 36/124), with 6/124 being proven and 30/124
probable. The sensitivity of the assays for the patients with candidemia were as follows:
Candida nested PCR 88%, BDG 47%, Mannan 41%.
Conclusion: On the basis of our data, commercially available BDG and GM assays
besides molecular methods such as PCR can offer diagnostic help in patients with
suspected IC. Developing nucleic acid based tests and other novel technologies is
warranted to promote the accuracy of IC diagnosis.
P-041
MONITORING OFMINIMAL RESIDUAL DISEASE AND IT’S SIGNIFICANCE
IN DISEASE OUTCOME IN CHILDRENWITH ACUTE LYMPHOBLASTIC
LEUKEMIA
N. Hazarika1, P. Dwivedi1
1Fortis Memorial Research Institute-Gurgaon-India, Pediatric Medical Oncology, Delhi
NCR, India
Background/Objectives: Purpose: Minimal residual disease (MRD) monitoring has
become an integral part of the management of ALL in children. MRD has an essential
role in predicting relapse and overall survival.
Design/Methods:Methods: It is a retrospective analysis of MRD levels and its
correlation with the disease outcome in children with Acute Lymphoblastic Leukemia.
We have analysed 33 children with ALL who has received treatment with from Jan 2010
to Dec 2014. All of these children were treated with BFM 95 protocol based on risk
stratification. MRD levels were done by flow cytometry method at D33 of induction
chemotherapy and at the end of reinduction chemotherapy.
Results:MRD at D33 of induction was done in twenty four patients out of thirty three
(73%) and at the end of reinduction in twenty patients (60%). MDR at D33 was
<0.01% in twenty patients out of twenty four (83%) and >0.01% in four patients
(17%).In nine patients (27%) MRD level couldnot be done as two patients died during
induction, and four had already received some treatment at local centres before coming
to us and initial flow cytometry was not available and in three patients cost burden was
the cause. All four patients with high MRD levels at D33 of induction had poor
prognosis in spite of treatment intensification, two had very early relapses, one died due
to progressive disease and one had late relapse.Out of twenty patients who had MRD
<0.01% at D33 of induction only two had late relapses.
Conclusion:MRD monitoring has become a standard of care in the treatment of ALL
in children. But in developing countries still many centers have to rely on bone marrow
morphology only due to lack of facility for MRD testing and associated cost burden.
P-042
TREATMENT RESULTOF CHILDREN ACUTE LYMPHOBLASTIC LEUKEMIA
IN VIET NAM NATIONAL CANCER HOSPITAL FROM 4/2006 TO 8/2010
P. Huong1
1National Cancer Hospital, Ha Noi, Vietnam
Background/Objectives: Background: Acute lymphoblastic leukemia (ALL) is the most
common malignant disease in children, accounts for 30 – 35% children cancers.
Purpose: To evaluate the result of treatment of childhood standard risk ALL by the
modified CCG-1991 protocol. Objective: 40 children with previously untreated
standard risk ALL in Peadiatric Oncology Department, Viet Nam National Cancer
Hospital from April 2006 to August 2010.
Design/Methods: Prospective study, apply the protocol.
Results: After 52 months of follow - up, disease free survival rate is 65%, overall survival
rate is 67,5%.
Conclusion: Treatment of childhood standard risk ALL by the modified CCG-1991
protocol has good results.
P-043
RESULTS OF THERAPY OF ACUTE LYMPHOBLASTIC LEUKEMIA IN
CHILDREN ACCORDING TO PROTOCOLMB 2008 IN UZBEKISTAN
S. Ibragimova1, N. Aripova2
1Tashkent, Uzbekistan; 2Scientific Research Institute of Hematology and Blood
Transfusion, Pediatric, Tashkent, Uzbekistan
Background/Objectives: Since 2009, Clinic Research Institute and Mr. PC have been
starting to apply a protocol MB-2008 for the treatment of children with ALL.The
optimization of treatment acute lymphoblastic leukemia in children on the basis of the
application and effectiveness analysis of protocol ALL-MB-2008.
Design/Methods:We analyzed 222 patients with primary diagnosed ALL treated on
protocol ALL-MB-2008, admitted to the hospital of the Institute of Hematology and
Blood Transfusion (Tashkent) in the period from 01.01.2009 on 01.01.2014.
Results: There was held an analysis of treatment in 222 patients who received treatment
according to protocol ALL-MB-2008. Frequency of induction deaths is quite high and
amounts to 4.0% for all patients; with the performance of the induction of mortality
did not differ between patients SRG (standard risk group) and ImRG (intermediate risk
group). During the observation 11 patients of the 222 were lost to follow-up. 200 of 222
(90%) patients achieved PR. Mortality in remission differed in SRG and ImRG and
amounted to 1.2% and 5.7%, respectively. In all patients who died during the remission
had developed severe sepsis, bacterial and fungal etiology. In 2 patients reported the
development of secondary tumors by 2.2 and 3.4 months after treatment of ALL,
respectively. In 17 patients (7.6%) reported relapse of ALL. During the phases of
consolidation infectious complications developed in 93 patients ImRG (80,1%), and 22
patients (18.9%) developed severe sepsis.
Conclusion: The effectiveness of the protocol ALL-MB 2008 proved to be quite high.
The 5-year EFS was 72 ± 13%, OS - 75 ± 2%. Thus, patients in SRG EFS were 80,7 ±
13%, OS -82 ± 2%, in the levels of ImRG EFS and OS were 68% ± 2 and 72 ± 2%,
respectively, for the patients HRG EFS were only 18.1 ± 6%, and OS - 19,7 ± 6%.
P-044
CLINICOPATHOLOGICAL PROFILE AND TREATMENT OUTCOMES IN
INFANT LEUKEMIAS (IL) – A SINGLE CENTRE EXPERIENCE FROM LOW
ANDMIDDLE INCOME COUNTRY (LMIC)
Pediatr Blood Cancer DOI 10.1002/pbc
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S. Java1, N. Thacker2, P. Subramanian1, G. Narula2, P. Kadam Amare3, P. Tembhare1,
N. Patkar1, B. Arora2, M. Prasad2, A. Kumar1, Y. Badrinath1, S. Ghogale1,
S. Banavali2, S. Gujral1
1Tata Memorial Hospital, Hematopathology, Mumbai, India; 2Tata Memorial Hospital,
Pediatric Oncology, Mumbai, India; 3Tata Memorial Hospital, Cytogenetics, Mumbai,
India
Background/Objectives: Infant leukemia (IL) is rare high-risk leukemia with poor but
improving outcomes in High Income Countries. The aim is to study the
clinicopathological profile and treatment outcomes of IL in a LMIC setup.
Design/Methods:We retrospectively studied case records of 88 patients with age<1year
diagnosed as leukemia (WHO-2008 criteria) from 2005-2014 for demographic,
hematological, immunophenotypic, cytogenetic and treatment outcome data.
Results: Eighty-eight patients (M:F=1.75:1; median age=9 months) of IL were studied,
however 3 were excluded from further analysis due to incomplete workup. Mean
hemoglobin, WBC, platelet and blast count was 9gm/dl (range:4-17gm/dl), 120×109/L
(range:2-554×109/L), 83×109/L (range:3-1077×109/L), and 67.5% (range:2-100%)
respectively. Serum LDH was raised in 81.4% cases (mean=1632U/L,
range:115-6470U/L). Immunophenotyping of acute leukemias (76/85) revealed
following subtypes– ALL (50/76; B-ALL=48, T-ALL=2), AML (24/76; FAB subtypes:
AML-M4/M5=8; AML-M7=6; Others=10) and acute undifferentiated leukemia
[AUL] (2/76). JMML was diagnosed in 9 male patients. On cytogenetics study, MLL
gene was rearranged in 50% (B-ALL=20, T-ALL=1, AML-M4/M5=7, AML-M1=1,
AUL=1); further subtyped as t(4;11) (20%), t(9;11) (20%), t(11;19) (3.3%) and
unknown partner (56.7%). Of 76 patients of acute leukemia, only 35 (46.1%) opted for
treatment (ALL-26; AML-9). Of 26 patients of ALL, 16 attained remission (4 relapsed;
12 sustained remissions), median follow-up was 24 months (range:3-91months). Factors
like female sex, age<6 months, hyperleucocytosis, Pro-B phenotype and MLL-gene
rearrangement correlated with adverse outcomes. Of 9 patients of AML who received
treatment, 5 attained remission (2 relapsed; 3 sustained remissions), median follow-up
was 17 months (range: 2-122months). Infants with JMML received only cytoreductive
therapy.
Conclusion: Though 42.9% of those treated have achieved long-term remissions, in
LMIC setup with limited infrastructure/resources, only the better risk patients get
treated. Overall only 17.7% of our patients are in sustained remission. Hence, there is a
need to explore newer treatment modalities to improve the survival of patients with IL
in LMIC setup.
P-045
INTERFERON ALPHA2B PLUS RIBAVIRIN THERAPY FOR HEPATITIS C
(HCV) INFECTION IN CHILDRENWITH CANCER ON CHEMOTHERAPY:
EFFICACY AND OUTCOME
S. Jayabose1, V. Kumar2, A. Annamalai2, K. Viswanathan3
1Rutgers Cancer institute of New Jersey, New Jersey, NJ, USA; 2Meenakshi Mission
Hospital & Research Centre, Pediatric Oncology, Madurai, India; 3Meenakshi Mission
Hospital & Research Centre, Madurai, India
Background/Objectives: To study the efficacy of interferon-alpha2b plus ribavirin for the
treatment of HCV infection in children with cancer on chemotherapy.
Design/Methods: This study is a retrospective analysis of data collected on 39 children
treated (2011-2014) for HCV infection, while on chemotherapy: ALL, 30; AML, 3;
Hodgkin lymphoma, 2; Non-Hodgkin lymphoma, 4. Median age, 5 yrs (range 2-19);
M:F, 22:17. Treatment included recombinant interferon-alpha 2b (rIFNa) or
peginterferon-alpha2b (pIFN); plus ribavirin p.o in standard doses. The response was
followed by HCV –RNA by PCR.
Results: At the time of diagnosis of HCV, 36 of 39 were in remission from the
malignancy; the median HCV RNA was 2.26×106; (range 0.12 to 50.3×106); the
median (range) AST/ ALT values were 60 (26-748) and 92 (19-708) respectively; only
five patients had bilirubin values above 1.2 mg/dl. Initial treatment consisted of rIFNa
in 23 and pIFN in 16. For patients without significant response to rIFNa, the treatment
was changed to the pIFN and vice versa. In total, 8 of 39 (20. 5%) patients achieved a
sustained virologic response (SVR); 4 responses occurred on rIFNa and the other four
on pIFN. The median time to achieve negative HCV RNA was 32 weeks (range, 8-74).
All eight patients continue to be negative for HCV RNA for 7 to 25 months (median, 16
months). Five of the 31 non-responders have died; one from acute liver failure; two
from infections during neutropenic period; and two from relapsed malignancy. All of
the 26 surviving non-responders continue to have high HCV-RNA counts, but without
any clinical signs of liver failure.
Conclusion: Inteferon plus ribavirin combination offers sustained virologic response to
only a minority of children with active HCV infection and on chemotherapy; thus
newer more effective drug therapy should be studied in this group of patients.
P-046
SIBLING SUPPORTERS´ SUPPORT FOR SIBLINGS WHO HAVE A BROTHER
OR A SISTERWITH CANCER
M. Jenholt Nolbris1, T. Berisa2, H. Jungerby Larsson3, M. Petersson3, S. Nilsson4
1Queen Silvia’s Children’s Hospital-Sahlgrenska University & University of
Gothenburg-Gothenburg, Sweden, Centrum for Childrens Right & Centre for
Person-Centred Care GPCC, Gothenburg, Sweden; 2Queen Silvia’s Children’s
Hospital-Sahlgrenska University, Pediatric Cancer Centrum, Gothenburg, Sweden;
3Queen Silvia’s Children’s Hospital-Sahlgrenska University, Play Therapy and Library,
Gothenburg, Sweden; 4University of Gothenburg-Gothenburg, Sweden & Work Life and
Social Welfare- University of Borås, Borås, Sweden, Institute of Health and Care
Sciences & Child- Faculty of Caring Science, Göteborg & Borås, Sweden
Background/Objectives: Siblings of a child with cancer have rights under the United
Nation´s Convention on the Rights of the Child concerning the promotion of their
own welfare. For siblings it is important to get a sense of the context of what is
happening from their own perspective. Given each sibling support with person-centred
care, means that each child is treated respectfully regardless of its resources and to act
in the child’s best interests. In Sweden have sibling supporters became a part of the staff
since 1990 and are included in the support group around the family. They are available
at all children´s cancer centers, the child hospice, play therapy and Ronald Mc Donald
house.The aim of the study was to describe both the short and long term support,
sibling supporters provide for siblings with a brother or a sister who has a cancer.
Design/Methods: The study was qualitative descriptive in design. The sibling supporters
were individually interviewed via Skype by two authors (MJN, SN). Data were collected
during autumn 2014. Twelve Swedish sibling supporters (9 women, 3 men) participated
at the time of the interview. The interviews were conducted as communication between
the interviewers and sibling supporter which included 20 questions with follow-up
questions. A qualitative content analysis was used to draw a systematic conclusion from
the text and to extract the message.
Results: The result comprises two domains, i.e. possibilities and challenges, which were
analyzed further into 11 categories.
Conclusion: This study shows the importance of having sibling supporters to support
siblings, a support that provide the siblings with person-centred care and promote
health.
P-047
PLASMAMIRNAS PREDICT THE CURATIVE EFFECT AND PROGNOSIS OF
PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
Q. Jiang1
1Bei Jing Children’s Hospital, Beijing, China
Background/Objectives: To investigate the expression level of plasma miRNAs of
hsa-miR-197-3p and hsa-miR-652-3p in childhood acute lymphoblastic leukemia
(ALL) samples, BCP- ALL cell lines and healthy children.
Design/Methods: First, We performed micro-array analysis in 12 samples, which
included 9 ALL plasma samples from new diagnosis (ND), complete remission (CR),
and relapse (RE) in 3 patients and additional 3 plasma samples from healthy children.
Second, we validated the results of micro-array analysis by stem-loop reverse
transcriptional real-time PCR in independent samples. One set is paired bone marrow
(n = 29, 12 paired ALL samples of ND and CR from the same patient, and 5 samples
of RE), and the other is matched plasma samples (n=100, 30 pair ALL plasma samples
of ND and CR, and 10 samples of RE).The level in REH and Nalm-6 BCP-ALL cell
lines were also analyzed.
Results: The expressions levels of hsa-miR-197-3p and hsa-miR-652-3p in childhood
ALL plasma exhibited a specific characteristic: healthy > CR > RE > ND. Significant
differences were observed between each group (P<0.05). The miR-197-3p and
miR-652-3p in plasma and bone marrow samples were expressed consistently (P<0.05).
Compared to the normal adult common B cell line, the expression levels of miR-197-3p
and miR-652-3p in REH and Nalm-6 were much lower (P < 0.05).
Conclusion: Hsa-miR-197-3p and hsa-miR-652-3p maybe act as cancer suppressor
genes through leukemogenesis and progression of pediatric ALL. Furthermore, our
research indicates the possibility of miRNA as the biomarker in the diagnosis,
treatment and prognosis of pediatric ALL.
P-048
ROUTINE CEREBROSPINAL FLUID EXAMINATION DURING
INTRATHECAL CHEMOTHERAPY IN PEDIATRIC ALL: IS IT REALLY
NECESSARY?
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1Ludhiana, India; 2Dayanand Medical College, Department of Pediatrics, India
Background/Objectives: The success rate of pediatric ALL has reached > 95%. CNS
relapse still occurs in 3 -8% of patients. Most ALL protocols recommend a routine CSF
examination during the intrathecal chemotherapy. Each patient undergoes 22-25
intrathecal during the treatment. CSF analysis during all of these adds to approx INR
10,000 per patient to the cost of therapy. We wish to analyze the value of performing
CSF examination during intrathecal chemotherapy in diagnosing isolated CNS relapse.
Design/Methods: Between Jan 2013 to Dec 2014, 32 patients underwent treatment for
ALL in our unit. 19 (59 %) of these were on regimen A of UK ALL 2003 protocol and
13 (41%) on regimen B. The medical records of these patients were reviewed and reports
of CSFexamination done during were evaluated. Patients in whom CSF was done due
to CNS complaints were excluded.
Results: Total 225 CSF samples were collected from 32 patients during the study period.
Out of these, 141 (63%) samples were taken from patients undergoing treatment in
regimen A (n=19) and rest 84 (37%) from patients under regimen B (n=13). In regimen
A, 78 (55%) samples were collected during intensive phase and 63 (44.6%) during
maintenance. None of these CSF samples were found to be positive for malignant cells.
In regimen B, 84 CSF samples were collected. Seventy- two (85.7%) samples were
collected during intensive phase and twelve (14.2%) during maintenance. Two of these
samples were detected to be positive for lymphoblasts. One patient was undergoing
interim maintenance and the other was in maintenance. Bone marrow was normal in
both the patients.
Conclusion: Occult CNS relapses are more common in high-risk pediatric ALL.
Continued CSF surveillanceis recommended in this group of patients and can be
omitted in standard risk patients.
P-049
DIFFUCULTIES IN DIAGNOSING AND TREATMENT OF INTRACRANIAL
FUNGAL INFECTIONS: REPORT OF THREE CASES
S. Karaman1, S. Aydogdu1, A. Sencer2, Y. Yilmaz3, A. Somer4, N. Salman4, Z. Erturan5,
H. Aktürk4, A. Demirel3, O. Devecioglu1, Z. Karakas1
1Istanbul University Istanbul Medical Faculty, Pediatric Hematology-Oncology, Istanbul,
Turkey; 2Istanbul University Istanbul Medical Faculty, Neurosurgery, Istanbul, Turkey;
3Istanbul University Istanbul Medical Faculty, Pediatrics, Istanbul, Turkey; 4Istanbul
University Istanbul Medical Faculty, Pediatric Infectious Disease, Istanbul, Turkey;
5Istanbul University Istanbul Medical Faculty, Department of Infectious Diseases and
Clinical Microbiology, Istanbul, Turkey
Background/Objectives: Invasive fungal infection (IFI) of the CNS is life-threatening
disease in patients with malignancies.We report three IFI cases during chemotherapy.
Design/Methods: Case 1: Ten-year-old male patient was diagnosed T-cell ALL. At the
nineteenth day of the chemotherapy, the thoracicCT revealed nodular lesions,
Liposomal amphotericin B(LipAmpB)was given. At the thirty third day ofthe
fungotherapy, patient had consciousness andconvulsion. The cranialMRI demonstrated
several lesions localized on temporal lobe.The voriconazole was added to the therapy.In
the follow up, the patient developed convulsion. The cerebrospinal fluid examination
demonstrated fungal hyphes. The stereotaxic biopsy was done.The third antifungal,
flucytosine, was added to dual therapy. The minimal regression on cranialMRI was
observed after one month.However, bone marrow relapse occurred withinfour month
and patient died.Case 2: Elevenyear-old female patient was diagnosed CommonB-ALL.
At thirty sixth day LipAmpBwas given as galactomannan test positive.At the eighteen
dayof the fungotherapy, abscess detected.LipAmpB was ceased, voriconazole started.
During follow-up, regression of lesion demonstrated. Patient continues chemotherapy
and is now onfifth month of treatment. Case 3: Fiveyear-old male patient was
diagnosedCommonB-ALL. Patient developed headache at twentieth day of
chemotherapy. The cranial MRI showed abscess on frontal region.LipAmpB was given.
Patient developed consciousness and intracranial bleeding was detected and patient
undergone urgent neurosurgical intervention. As progression of lesion was shown, the
voriconazole was added to the treatment. As lesion culture demonstrated tricoderma
species with characteristics of resistance to amphotericinB and sensitive to
voriconazole.We began caspofungin with voriconazole administered together.Patient
continues his therapy with severe neurological sequel.
Results: One of the patients performed combination therapy was died due to
progressive disease, the other lives with severe neurological sequel.Our one case
responded to antifungal therapy well and is followed-up regularly.Two patient
undergone stereotaxic biopsy.The early stage surgical intervention could not be
performed in our cases and 2 patients undergone surgery when they had hydrocephaly
and intracranial bleeding respectively.
Conclusion: The Intracranialfungal infections show highmortality in patients receiving
chemotherapy. There aresome studies showing positive effect of early surgical
intervention on prognosis beside antifungal therapy.The combined antifungal therapy is
still controversial.
P-050
HAIR, URINE AND SERUM SELENIUM STATUS IN PEDIATRIC CANCER
PATIENTS
S. Karaman1, S. Vural2, B. Mansuroglu3, Y. Yıldırmak2, K. Kızılbey4, S. Derman5,
A.B. Hazar6
1Istanbul University Istanbul Medical Faculty, Pediatric Hematology-Oncology
Department, Istanbul, Turkey; 2Istanbul Sisli Etfal Education and Traininig
Hospital-Pediatric Hematology-Oncology Department, Istanbul, Turkey; 3Yildiz
Technical University-Faculty of Science and Letters, Molecular Biology and
Genetics-Faculty of Science and Letters, Istanbul, Turkey; 4Yildiz Tecnical University,
Science and Technology Application and Research Center, Istanbul, Turkey; 5Faculty of
Chemical and Metallurgical Engineering, Yildiz Technical University, Department of
Bioengineering, Istanbul, Turkey; 6Yildiz Technical University, Faculty of Chemical and
Metallurgical Engineering, Department of Metallurgical and Materials Engineering,
Istanbul, Turkey
Background/Objectives: The role of different trace elements in normal vital activities
and initiation of some disease has long been known.Selenium (Se) is a trace element
which has multiple functions including plays a key role in ptotecting cells against
oxidative damage.Low Se amounts in serum and hair have been reported in pediatric
and adult cancer patients.
Design/Methods: Eighty eight pediatric patients with newly diagnosed cancer including
acute leukemia(n=58),Hodgkin’s lymphoma (n=4) non-Hodgkin’s lymphoma (n=12)
and solid tumors(5neuroblastoma,5medulloblastoma,1 wilms,1
hepatoblastoma,1rhabdomyosarcoma and 1 osteosarcoma)admitted to the
hospital.Age and sex-matched 32 healthy children(brothers or sisters of patients) were
enrolled to the study as the control group.There were 51 male and 37 female (mean age:
6.79±3.88 years)in the study group and 19 male and 13 female (mean age: 6.52±2.52
years) in the healthy control group.2 ml of venous blood were collected from 120
children by using cleaned syringe and needles,into heparinized pretreated clean
polypropylene tubes,carefully avoiding external metal contamination and
hemolysis.Hair samples were collected by hair clippings from the back of the head and
near the scalp with a stainless-steel scissor and put in clean plastic bags.Blood and urine
measurements were obtained from patients and controls at 08.00 am.Serum was
separated with centrifugation at 3500 rpm and stored-80 °C.Selenium levels were
determined by ICP-MS spectroscopy.
Results: In this study we found that Se levels in serum and hair of children with cancer
were significantly lower than those of controls.There are no differences in the leukemia,
lymphoma and solid tumors group.On the other hand,Se levels of urine samples were
slightly elevated in cancer patients compared with control groups.There was no marked
difference in Se levels of patients who had different types of cancer.
Conclusion: Se deficiency might be associated with the development of pediatric cancer.
Especially in children, additional studies are needed to define whether low levels of Se
may play a role in cancer pathogenesis.
P-051
IS SERUM PHOSPHOR LEVEL ASSOCIATEDWITH HIGH RISK OF
MORTALITY IN PEDIATRIC FEBRIL NEUTROPENIC PATIENTS WITH
MALIGNANCY?
S. Karaman1, S. Vural2, Y. Yildirmak2
1Istanbul University Istanbul Medical Faculty, Pediatric Hematology-Oncology, Istanbul,
Turkey; 2Istanbul Sisli Etfal Education and Training Hospital, Pediatric
Hematology-Oncology, Istanbul, Turkey
Background/Objectives: Phosphor is a basic intracellular anion required for many
biological functions. Hypophosphatemia has been informed to be related to sepsis and
has been associated with sepsis severity.There are several studies showing that severe
hypophosphatemia can increase the mortality in septicemia.There is no study about
serum level of phosphor in the febril neutropenic attacks (FNA) in pediatric cancer
patients. In this prospective study, we aimed to determine whether hypophosphatemia
associated with mortality in febril neutropenic patients with malignancy. Also we assess
the relationship between serum level of phosphor and characteristics of attacks and
treatment modification in cases of febrile neutropenia.
Design/Methods: The study included febrile neutropenic children with malignancy who
were hospitalized during one year (2013-2014).The study group consisted of 27 female
and 49 male with median age of 5 years (5months-16years).The number of febril
neutropenia was 129 among 76 patients.The 23%of cases was ALL, 7% of them
AML,52%of them Burkitt lymphoma,8%of them neuroblastoma and10% of cases was
other solid tumors.The patients were examined,we performed the hematological and
biochemical analyses including phosphor,cultures of blood and urine in febril attack.
One hundred twenty nine FNA were observed in76 patients.They were were divided
into 2 groups:group 1 comprised 45 attacks with severe hypophosphatemia(serum
inorganic phosphate (Pi)<1 mg/dl); group 2 comprised 84 attacks without severe
hypophosphatemia(Pi>1 mg/dl).
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Results: In 45 attacks(35%), serum level of phosphor was under normal level,and in 84
attacks(65%) level was normal range.There is no significant differences duration of
antibiotics, microbiologically documented number of attacks,number of fever with
unknown origin,number of attacks with treatment modification and death between two
groups.
Conclusion: Hypophosphatemia occurs in the sepsis and can be associated with the
life-threatening condition.In our study,we showed that the lower level of serum
phosphor did not increase the mortality and length of stay in hospital in cases of febrile
neutropenia.The relationship between serum level phosphor and mortality in FEA need
to be confirmed in further studies.
P-052
EXPRESSION OF CD133.2, AS A PROSPECTIVE MARKER, PREDICTING
MINIMAL RESIDUAL DISEASE (MRD) LEVEL AT DAY 15, IN CHILDREN
WITH CD45-DIM B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
M. Khvedelidze1, A. Shengelaia1, T. Javakhadze1
1Children Central Hospital, Hematology/Oncology, Tbilisi, Georgia
Background/Objectives: To address predictive value of CD133.2 receptor expression on
CD45-dim B-ALL cells at initial diagnosis, in the context of minimal residual disease
monitoring at day 15 in children with B-ALL.
Design/Methods: Nine newly diagnosed children with CD45-dim B-ALL were assessed
for MRD levels on the day 15 of remission induction. We arbitrarily assigned the
patients to either relatively ’high or low CD133.2’ groups based on percentage of
CD133.2 positive events at initial diagnosis. Phenotyping was performed in agreement
with ALL-ICBFM-2009 recommendations using 4-color flow cytometry, with an
acquisition number of at least 300.000 nucleated cells per tube and MRD of 30 cellular
events was considered as positive.
Results: Among study subjects there were four males and five females with an average
age of 3.1 (95%CI: 1.9 – 4.3). Median percentage of CD133.2 positive cells in ’low
CD133.2’ group were defined as 0.8% (Interquartile range (IQR): 0,115 – 1.70) and as
42.85% (IQR: 29,01 – 70) in ’high CD133.2’ group gated on CD19+ ALL cells.
Comparison between these groups revealed statistically significant difference in minimal
residual disease levels at day 15 (p=0.02); Median percentage of MRD in ’high
CD133.2’ group was 1.75% (IQR: 1.18 – 6.6), while a median of 0.04% of residual
leukemic cells (IQR: 0.04 – 0.08) was observed in ’low CD133.2’ group. Correlation
analyses revealed significant positive correlation between CD133.2 and CD45 receptor
expression (Mean Fluorescent Intensity) at diagnosis (r2= 0.86; p=0.029). Percentage
of CD133.2 positive B-ALL cells also positively correlated with leukocyte count at
initial diagnosis (r2= 0.83; p=0.04).
Conclusion: Study showed that, CD133.2 receptor expression at initial diagnosis might
be exercised as a surrogate marker to predict MRD levels at day 15 in children with
CD45-dim B-ALL, although further, larger cohort studies are needed to address this
question.
P-053
CLOFARABINE TOXICITY IN RELAPSED OR REFRACTORY ACUTE
LEUKEMIA IN CHILDREN
U. Kocak1, N. Oner1, M. Isık1, A.E. Sal1, F. Tekkesin1, I. Altan1, Z. Kaya1, I. Yenicesu1,
T. Gursel1
1Gazi University School of Medicine, Pediatric Hematology and Oncology, Ankara,
Turkey
Background/Objectives: Although modern treatment of acute leukemia in children had
a dramatic success during the last decades same results could not be reproduced in
relapsed and refractory patients to standard chemotherapy. Clofarabine which could be
used in such patients for salvage therapy is a second-generation purine nucleoside
analogue inhibiting DNA synthesis and repair. Despite its efficacy when combined with
other DNA damaging agents it has significant toxicity.
Design/Methods:We have given combined chemotherapy consisting of clofarabine to 4
relapsed (2 AML, 2 ALL), 6 refractory (3 AML, 3 ALL) leukemia patients for 12 times.
AML patients received clofarabine combined with cytarabine whereas ALL patients
had clofarabine along with cyclophosphamide and etoposide. One of the resistant
AML and one of the resistant ALL patients received their clofarabine therapies after
their relapses from stem cell transplantation (SCT).
Results: All of the patients experienced hematological toxicity as grade IV
myelosupression, grade II/III infectious toxicity, grade II/III nausea, vomiting and
mucositis. Mucositis was grade IV in 2 patients. During 6 cycles, hypokalemia which
was resistant to therapy was observed with a 10 days duration. None of the patients had
veno occlusive disease. One of the patients died on the 3rd day of treatment probably
due to capillary leak syndrome. Two of the patients died on 40th and 45th day of after
clofarabine therapy with severe intracranial fungus infection and disease progression.
Of the remaining 7 patients 5 were immediately undergone SCT whereas 2 patients who
received clofarabine after SCT relapse have been prepared for a second transplant.
Conclusion: Clofarabine is a potent and efficient chemotherapeutic agent in relapsed
and refractory leukemic children. However due to its substantial toxicity profile it could
be used as a salvage therapy bridging to SCT.
P-054
DEXTROMETHORPHAN IS A SIMPLE BUT EFFECTIVE TREATMENT AND
PROPHYLAXIS FOR HIGH DOSEMETHOTREXATE RELATED
NEUROTOXICITY
S. Kohli1
1Gurgaon, India
Background/Objectives:Methotrexate induced neurotoxicity is a frequent complication
of methotrexate (MTX) therapy and can occur after intrathecal or systemic
administration. The pathogenesis of MTX neurotoxicity is multifactorial, though one
potential biochemical pathway leading to neurotoxicity involves the folate dependent
remethylation of homocysteine (Hcy). MTX therapy is known to cause elevations of
both plasma and CSF Hcy levels. Hcy is directly toxic to vascular endothelium and Hcy
and its metabolites are excitatory agonists of the N-methyl-D-aspartate (NMDA)
receptor. Competitive or noncompetitive antagonists might afford protection from or
reversal of neurotoxicity. Dextromethorphan, a noncompetitive antagonist of the
N-methyl-1-aspartate (NMDA) receptor may be able to reverse or prevent methotrexate
related toxicity.
Design/Methods: 14 years old female, follow up case of Pre B ALL with previous
history of seizure disorder, being treated as per the BFM 95 protocol. After the
administration of high dose MTX (@ 5gm/m2) with intrathecal MTX she developed
altered behavior, agitation, insomnia within 48 hrs of therapy and had a brief seizure
with unconsciousness on 7th day. She had delayed excretion of MTX resulting in rise in
creatinine and acute renal injury. She was managed with leucovorin (Folinic acid) and
dextromethorphan. Her MTX level was serially monitored till it was below 0.3ng/ml. In
subsequent 3 cycles of high dose MTX, she was given dextromethorphan prophylaxis
along with reduced dose of MTX (2gm/m2). This regimen was tolerated well by her and
prevented neurotoxicity on subsequent cycles.
Results: The patient’s symptoms resolved dramatically after starting dextromethorphan
in the first course and she had no further seizures, vomiting stopped and her agitated
behavior settled and she could sleep well. She did not develop any signs/symptoms of
neurotoxicity in subsequent 3 cycles of high dose MTX with dextromethorphan
prophylaxis.
Conclusion: Dextromethorphan is an effective agent for treatment and prevention of
MTX related neurotoxicity.
P-055
METABOLIC SYNDROME IN CHILDRENWITH ACUTE LYMPHOBLASTIC
LEUKEMIA, PRELIMINARY RESULTS
I. Spichak1, E. Zukovskaya2, E. Teplykh1, M. Bogacheva1, S. Kovalenko1
1Chelyabinsk Regional Children’s Clinical Hospital, Oncohematological Department,
Chelyabinsk, Russia; 2Dmitry Rogachev’s Federal Scientific and Clinical Centre of
Pediatric Hematology and Oncology and Immunology, Treatment and Rehabilitation
Center, Moscow, Russia
Background/Objectives: The aim of the study was to find out the impact of metabolic
syndrome (MS) on realization of program of treatment in children with Acute
Lymphoblastic Leukemia (ALL).
Design/Methods: The objects of our study were two groups of patients. The 1st one
consisted of 173 children with ALL treated according to the ALL-MB scheme from
01.01.2000 to 31.12.2012. The 2nd retrospective group in our study included 462
children with ALL which received treatment for the last 20 years according modified
ALL-BFM scheme for period from 01.01.1994 to 31.12.1999.
Results: Among 173 children with ALL in the period of 01.01.2000 till 31.12.2012 we
diagnosed MS in 57 (32,9%) patients but we did not disclose it in other 116 (67.1%).
During this period 35 (20.2%) patients from the 1st group died because of disease
progression or lethal complications which occurred in the course of treatment. Among
died patients there were 25(71.4%) children with MS and 10 (18.6%) without it. The
percentage of fatal outcomes of patients without MS was 8,6% (10/116) but it was 43,8
% (25/57) of patients with MS. The treatment of ALL was complicated by steroid
diabetes in 13 (2.8%) cases from 462 and 12 of them came to children with MS. There
was manifestation of complication in 12 (92.3%) cases at the repetitive courses of
glucocorticosteroid drug usage where 9 (69.2%) patients took anti-relapse treatment.
Conclusion: The patients with MS have complications more often when curing ALL
and these complications lead to deviations from the program chemotherapy. For that
reason we should rate MS as factor which works on course and results of treatment.
Pediatr Blood Cancer DOI 10.1002/pbc
S254 SIOP ABSTRACTS
P-056
CNS FUNGAL INFECTION DURING ALL INDUCTION: HOW LONG TO
CONTINUE ANTI FUNGAL TREATMENT?
N. Fernandes1, H. Lashkari2
1Kasturba Medical College, Paediatrics, Mangalore, India; 2Kasturba Medical College,
Mangalore, India
Background/Objectives: Brain abscesses in children though rare, remains a
life-threatening complication in those with haematological malignancies. As prognosis
is dismal and with little information on the appropriate management of this
complication, we reviewed literature on the management for children who developed
multiple fungal brain abscesses while on anti-leukemic therapy to try and find out an
ideal treatment recommendation.
Design/Methods: A six year old girl with ALL was started on UKALL 2003 regimen B
(4 drug) induction. While on induction she developed prolonged febrile neutropenia
and later had an episode of status epilepticus which on investigation revealed multiple
brain abscesses. All the bacterial work up were negative including that for tuberculosis.
Among the fungal work up only CSF galactomannan was positive in high titres. She
was started on conventional Amphotericin (1.5 mg/kg/day) and Voriconazole (7 mg/kg
12 hrly) for 6 weeks and then Voriconazole alone was continued for 9 months. During
the course of her treatment, a repeat titre showed decreased levels in 6 months. As she
was stable, her anti-leukaemic therapy continued and she is currently in remission and
receiving maintenance chemotherapy. Detailed literature review showed one study in
which a child received Voriconazole for 17 months for multiple fungal brain abscesses.
Results: Our case will be the first documented survived case from the Indian
subcontinent. Right antifungal treatment need to be continued until the lesions get
smaller or disappear. However if the child becomes neutropenic during the treatment
for ALL, that needs to be addressed aggressively.
Conclusion:We conclude that patients with ALL and multiple fungal brain abscesses
can be salvaged by developing a rigorous febrile neutropenic protocol. At the moment
there is no consensus about the duration of antifungal therapy in children with
leukaemia and fungal CNS infection.
P-057
CRITICAL ILLNESS POLYNEUROPATHY AND ACUTE LYMPHOBLASTIC
LEUKEMIA
S. Walia1, T. Pai1, H. Lashkari2
1Kasturba Medical College, Paediatrics, Mangalore, India; 2Kasturba Medical College,
Mangalore, India
Background/Objectives:Muscle weakness and peripheral neuropathy is common in
children with Acute Lymphoblastic Leukaemia (ALL) during induction therapy mainly
due to steroids and vincristine . Critical Illness Polyneuropathy (CIPN) appears to be a
common complication of severe sepsis and is thought to represent a neurologic
manifestation of the systemic inflammatory response syndrome (SIRS).
Design/Methods: A 22 month old boy with Pre- B ALL, whilst on UK-ALL03 Regimen
A Induction ( 3 drugs) presented to us on day 22 of induction with Right sided
pneumonia and septic shock . He required multiple fluid boluses (150 ml/kg), packed
red cell (30ml/kg), platelet transfusion, inotropic support (for 72 hours). He was on
mechanical ventilation under sedation for 5 days. Two attempts at extubating him on
day 6 and 13 of ventilation were unsuccessful. It was due to poor muscle tone and
power. He has had generalized hypotonia & areflexia with muscle power of <2/5 in
upper and lower limb muscle groups. As he was well and this onset of hyptonia
happened following the septic shock a possibility of CIPN was considered. The other
differential diagnosis such as vincristine induced neuropathy, steroid myopathy,
Guillaine Barre Syndrome (GBS) and malnutrition aggravating the pathology were
thought of. On day 21 he was successfully extubated to non invasive BiPAP. He was
treated with antibiotics, antifungal and IV IgG medications.
Results:Many toddlers with ALL during induction period stop walking due to muscle
weakness. It would be difficult to differentiate between CIPN, drug induced neuropathy
and GBS. Following the regular physiotherapy, vitamin and nutritional support, his
muscle tone and power is improving.
Conclusion: CIPN is seen in children who are admitted in intensive care units especially
with septic shock. Following multidisciplinary team approach we would be able to
manage these children.
P-058
TREATMENT OF TUMOUR LYSIS SYNDROME RELATED
HYPERPHOSPHATEMIA; ROLE OF SEVELAMER HYDROCHLORIDE
H. Lashkari1
1Kasturba Medical College, Mangalore, India
Background/Objectives: Tumour lysis syndrome (TLS), the commonest oncological
emergency seen in children, is associated with high levels of uric acid, phosphate and
potassium along with low levels of calcium and abnormal renal function needing
dialysis in some cases.The standard treatment of hyperleukocytosis with TLS in
majority of the centres in India are hyper hydration, alkalinisation of urine and
allopurinol.In some cases haemodialysis is performed to improve the renal function and
control the high uric acid and phosphate levels. Calcium based phosphate binders are
not used due to increased chance of developing calcium phosphate crystals. Sevelamer
hydrochloride, an oral phosphate-binder is used in the treatment of hyperphosphatemia
in children and adults on haemodialysis for chronic kidney disease.
Design/Methods:We hereby report two cases of T-cell ALL who presented with a high
white cell count (49000cells/cc and 375000cells/cc), bulky disease and proceeded to
spontaneous tumour lysis syndrome.Both cases received Rasburicase and Sevelamer
hydrochloride which reduced the serum uric acid and phosphate level respectively.
Results: In both cases serum phosphate levels were high (12.5 mg/dl and 22 mg/dl)
enough to initiate haemodialysis, however, performing haemodialysis in newly
diagnosed ALL with TLS is challenging in view of low platelet counts. In both these
cases received hyperhydration 5lit/m2 and urine output was achieved with regular
diuretics, however their serum creatinine levels were abnormal (1.9 mg/dl and 2.4 mg/dl)
for the initial 72 hrs. Following the introduction of Sevelamer hydrochloride we
successfully avoided hemodialysis and reduced the serum phosphate levels within 48 hrs.
Conclusion: In developing countries like India children with these diseases present late
when the disease has progressed to an advanced stage with a high tumour load.
Sevelamer hydrochloride appears to be effective and safe treatment for
hyperphosphatemia associated with tumour lysis syndrome.
P-059
IMPACT OF ALLERGY TO L-ASPARAGINASE ON OUTCOME OF ACUTE
LYMPHOBLASTIC LEUKAEMIA (ALL) IN CHINESE CHILDREN
C.K. Li1, A.K. Chiang2, C.W. Luk3, C.H. Li4, S.C. Ling5, A.W. Leung1, V. Lee1,
D.K. Cheuk2
1Prince of Wales Hospital, Paediatrics, Hong Kong, Hong Kong-China; 2Queen Mary
Hospital, Paediatrics, Hong Kong, Hong Kong-China; 3Queen Elizabeth Hospital,
Paediatrics, Hong Kong, Hong Kong-China; 4Tuen Mun Hospital, Paediatrics, Hong
Kong, Hong Kong-China; 5Princess Margaret Hospital, Paediatrics, Hong Kong, Hong
Kong-China
Background/Objectives: L-asparaginase (L-asp) is standard anti-leukaemia agent for
treatment of ALL. Allergy to L-asp is common and associated with antibody
production. Patients allergic to native E Coli L-asp need alternative L-asp preparations.
Outcome of patients recruited into two Hong Kong PHOSG ALL protocols with or
without allergy to L-asp was analysed.
Design/Methods: From 2002 to 2008, 159 patients were recruited into IBFM-IC ALL
2002 Study, and 132 patients into the CCLG 2008 Study from 2008-2012. First line
L-asp was leunase, 2nd line was PEG-asp (Oncaspar), Erwinia asp (Erwinase) was 3rd
line. Induction, early intensification and consolidation treatment was similar in both
protocols. In 2002 Study, standard risk (SR) patients were randomized to 1 or 2 delayed
intensification (DI), Intermediate Risk (IR) to 1 or 3 DI, high risk (HR) patients
received 3 pulse blocks and 2 DI. In 2008 study, SR patients received 1 DI, IR received
2 DI and HR received 6 blocks and 1 DI. All the DIs and blocks included L-asp
treatment.
Results: L-asp allergy developed in 28.9% patients (17.6% in 2002, 42.4% in 2008
Study). HR patients had significantly higher incidence of allergy (HR 59.3% vs IR
20.6% vs SR 23.8%, p<0.001). Relapse risk was similar in those with/without allergy
(10.7% vs 15%), there was no difference in EFS (78.6% vs 78.6% in 2002 Study, and
92.9% vs 85.5% in 2008 Study). According to risk groups, there was no difference in
EFS for those with/without allergy in SR and IR (SR 83.3% vs 85.7%, IR 89% vs
80.6%) but better EFS in HR (90.6% vs 68.2% , p=0.021).
Conclusion:More exposures to treatment phases with L-asp increased incidence of
allergy. Switching from leunase to alternative L-asp did not affect outcome nor
increased risk of relapse. Oncaspar with higher dose activity may overcome silent
asp-antibody with good outcome.
P-060
IS IT REALLY USEFUL AS A PROGNOSTIC FACTOR THE ABSOLUTE
LYMPHOCYTE COUNT AT THE END OF INDUCTION THERAPY IN IN
PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA?
R. Lopez-Almaraz1, J. Udaondo1, R. Rubio-Rojas1, O. Zubiaur1, M. García-Ariza1,
A. Echebarria-Barona1, R.M. Adán-Pedroso1, I. Astigarraga1, A. Navajas1
1Hospital Universitario Cruces, Pediatric Oncology and Hematology, Barakaldo, Spain
Background/Objectives: Several recent studies have suggested that the prognostic utility
of absolute lymphocyte count (ALC) may be a prognostic indicator in children with
hematologic malignancies, with low ALC associated with adverse outcome. We studied
whether the ALC at the end of remission induction in children with acute
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lymphoblastic leukemia (ALL) treated on two consecutive protocols have been useful as
a prognostic factor, independent with respect to minimal residual disease (MRD).
Design/Methods:We reviewed 96 newly diagnosed cases of pediatric ALL treated on the
Hospital Universitario de Cruces enrolled in two trials: ALL SHOP-99 (August
1999-April 2005) and ALL SHOP-2005 (May 2005-May 2013). Variables analyzed
included: age and gender at diagnosis, initial leukocyte count, lineage, cytogenetics, risk
group, MRD status at the end of remission induction therapy (MRD-34) only in the
ALL SHOP-2005 trial, and ALC at day +34 of induction (ALC-34) in both trials.
Results: Thirty six cases were treated with ALL SHOP-99 and sixty with SHOP-2005.
The mean age at time diagnosis was 5 years (range 1-15); 59 males (61.5%) and 37
females (38.5%). The initial leukocyte count was 50,000/mm3 in 24%. ALL linage: B;
82.4% (n: 79), T; 15.6% (n: 15), and biphenotypic; 2% (n: 2). Cytogenetic negative; 54%,
and alterations in the rest; being the most common TEL-AML (19%). The risk groups
were: standar risk (29%), high risk (52%) and ultra-high risk (19%). Overall survival
(OS) was 91% in ALL SHOP-99 and 88.3% in SHOP-2005, and event-free survival
(EFS) 85.3% and 83.3% respectively. In our patients, 1,250/mm3 in was the median
ALC-34 value for patients who relapsed or died (53.5%; <1,000/mm3). All of relapse
cases in ALL SHOP-2005 trial; has negative MRD-34.
Conclusion: In our study, the ALC and MRD at the end of induction were not
significant and independent prognostic factor in childhood ALL comparing the
number of cured cases.
P-061
HIGH INCIDENCE OF HYPERTENSION IN YOUNG CHILDRENWITH
ACUTE LYMPHOBLASTIC LEUKEMIA DURING INDUCTION REMISSION
P. Malhotra1, S. Jain1, G. Kapoor1
1Rajiv Gandhi Cancer Institute and Research Centre, Pediatric Hematology and
Oncology, Delhi, India
Background/Objectives: High doses of corticosteroids form the backbone of acute
lymphoblastic leukemia (ALL) induction therapy and contribute to most of the
non-life threatening side effects. Steroid induced hypertension is an often
under-reported toxicity. We report high incidence of hypertension in young children.
Design/Methods: Induction data of 133 consecutive pediatric ALL patients treated per
BFM95 protocol, between January 2011 and December 2013, was retrieved from
physician notes, blood pressure (BP) records and medication orders. All patients
received prednisolone at 60 mg/m2 for 7 days and 40 mg/m2 for 21 days. Hypertension
was defined as BP measurement of more than 95th percentile for age, sex, height (3
separate occasions). Statistical analysis was done using SPSS version 21.
Results: Demographic and disease characteristics revealed median age 6 years
(4months-18years), male preponderance (102/133,77%), extramedullary disease in
(6/133,4.5%), B immunophenotype (115/133,86%) and unfavourable (t(9,22),t(4;11))
molecular genetics in (10/133,7.5%) patients. BFM standard, moderate and high risk
occurred in 31/133(23%), 71/133(54%) and 31/133(23%) cases respectively.
Hypertension was observed in 51/133(39%) patients, requiring one (42/51) or
more(9/51) antihypertensive drugs. Most patients were asymptomatic. Incidence did
not vary by sex (males 36/102, females 15/31) or risk group. Incidence of hypertension
in children <1year, 1-9 years and >9 years was 0/3, 42/89 and 8/43 respectively (p,0.02).
The odds ratio of having hypertension in 1-9 year age group was 10.7 and all patients
requiring 2 or more antihypertensive agents belonged to this group. Malnourished
(WHO, BMI <3,>85 percentile) patients were more likely to have hypertension as
compared to normally nourished (BMI >3,<85 percentile) patients (22/36,61% versus
20/53,38%;p0.03) with an odds ratio of 5. Complete remission rate was 95%(126/133)
with an induction mortality of 2/133(1.5%).
Conclusion: Hypertension during ALL induction is common. Children aged 1-9 years
and those with under-/over-nutrition are more predisposed. Frequent and careful
monitoring of blood pressure is recommended as this condition can be managed
medically.
P-062
LONG-TERM FUNCTIONAL OUTCOMES OF HYPERFRACTIONATED
RADIATION ON CHILDHOOD ALL SURVIVORS: A PILOT STUDY
A. Tang1, C. Alyman2, L. Anderson3, I. Hodson4, S. Marjerrison3,5
1McMaster University, Life Sciences, Hamilton, Canada; 2McMaster University,
Psychiatry and Behavioural Neurosciences, Hamilton, Canada; 3McMaster Children’s
Hospital, Pediatric Hematology/Oncology, Hamilton, Canada; 4McMaster University,
Oncology, Hamilton, Canada; 5McMaster University, Pediatrics, Hamilton, Canada
Background/Objectives: Cranial radiation in acute lymphoblastic leukemia (ALL) has
irreversible neurocognitive effects. A hyperfractionated radiation (HFX) strategy was
randomized against conventional radiation (CFX) in the DFCI 87-01/91-01 trials
attempting to minimize these effects. Neurocognitive test results 8 years after therapy
demonstrated no difference, and this strategy was abandoned. The objective of this
pilot study was to evaluate whether patients who received HFX as part of the DFCI
87-01/91-01 trials have better late functional outcomes than those who received CFX.
Design/Methods: This retrospective study reviewed all patients treated according to the
DFCI 87-01/91-01 trials at the McMaster Children’s Hospital in Hamilton, Canada.
Inclusion criteria required that patients were <18 years at diagnosis and have attended
at least one follow-up visit since Jan 1, 2000. Data were collected from patient charts.
The primary outcomes examined were functional outcomes. IQ test results were
examined for trends. Demographics and outcomes were presented with descriptive
statistics.
Results:We identified 57 DFCI 87-01/91-01 trial participants; 14 received HFX, 29
CFX and 14 had no radiation. There were no demographic differences between the
HFX and CFX groups. Survivors who received HFX were more likely to be living
independently (64% vs 28%, p=0.02) and to be engaged in long-term relationships (57%
vs 25%, p=0.04) than those who received CFX. Non-statistically significant trends
suggested HFX survivors may be more financially independent (67% vs 36%, p=0.09),
employed full-time (57% vs 34%, p=0.16), and less likely to have experienced
educational difficulties in school (23% vs 45%, p=0.30). Patients who received HFX
also had a trend toward higher scores on neuropsychological IQ testing.
Conclusion: ALL survivors who received HFX appeared to have better overall
long-term functional outcomes than those who received CFX. A wider study involving
all patients enrolled on DFCI 87-01/91-01 protocols should be done to reconsider
radiation protocols for ALL.
P-063
MORTALITY IN CHILDRENWITH ALL: A 10-YEAR REVIEW
F. Durão1, T. Martins2, P. Costa Reis1, X. Duarte3, M.J. Ribeiro3, A. Neto3,
A. Teixeira3, G. Caldas3, C. Mendes3, C. Constantino3, A. Lacerda3, F. Pereira3
1Hospital de Santa Maria- Centro Hospitalar Lisboa Norte-EPE, Departamento de
Pediatria, Lisboa, Portugal; 2Hospital Garcia de Orta-EPE, Almada, Portugal; 3Instituto
Português de Oncologia de Lisboa Francisco Gentil-EPE, Departamento de Oncologia da
Criança e Adolescência, Lisboa, Portugal
Background/Objectives: Despite improvements in cure rates of children with acute
lymphoblastic leukemia (ALL), 15-20% die of disease or treatment-related
complications (TRC). We aimed to analyze cause of death in children with ALL.
Design/Methods: Retrospective review of clinical data of children who died between
Jan’05-Dec’14 in a Pediatric Oncology Unit (POU) that admits about 30 ALL annually,
0-15y, using DFCI 2005 as first-line protocol.
Results: Forty children with ALL died, representing 12.6% of all deaths. Most were
boys (26/40) and B-lineage (22/40). Fifteen died after a TRC (G1) and 25 from
incurable disease (G2). Most children were high or very-high risk (G1-11/15, G2-17/25).
Genetic abnormalities were rare (G1-6/15, G2-5/25), including 1 trisomy-21 and 1
ataxia-telangiectasia in G1. Almost all (G1-13/15, G2-25/25) were under intensive
cycles (levels 3/4 of the Intensity of Treatment Rating Scale 2.0). In G1 6/15 died during
induction, 3/15 first consolidation, 1/15 second consolidation, 2/15 maintenance, 3/15
second-line protocol. Cause of death was infection (9/15), organ toxicity (3/15),
graft-versus-host disease (2/15) and anaphylaxis (1/15). Within infections, 5/9 occurred
in aplasia; primary site was blood (5/9), gastrointestinal tract (2/9), lung (1/9), skin (1/9).
Pathogens were identified in 6/9 (3 Gram- bacteria, 4 fungus, 1 virus), 2 co-infections
(bacteria+fungus). In G2, 22/25 died under second or third-line protocols, 2/25 with a
second malignancy (glioblastoma, rhabdomyossarcoma) and 1/25 in first consolidation.
Median interval between diagnosis and death was 0.8y in G1 (IQR 0.2-2y) and 2.9y in
G2 (IQR 1.3-6.7y). In G1 11/15 children died in intensive care units (ICU), 3/15 at
home, 1/15 in the ward. In G2 12/20 died at home, 5/20 in ICU, 3/20 in the ward.
Conclusion: Despite improvements in supportive care, TRC remain a major challenge
for POU. Many deaths are potentially preventable and efforts must be directed towards
educating professionals and patients at risk.
P-063A
DE NOVOMYC AND BCL2 DOUBLE-HIT B CELL PRECURSOR ACUTE
LYMPHOBLASTIC LEUKEMIA (B-ALL) IN PEDIATRIC PATIENTS AND
YOUNG ADULTS ASSOCIATEDWITH POOR PROGNOSIS
X. Lu1, W. Liu1, S. Hu1, P. Lin1, J. Medeiros1
1University of Texas-MD Anderson Cancer Center, Hematopathology, Houston, USA
Background/Objectives:MYC and BCL2 translocations in B cell lymphomas are
defined as “double-hit” associated with poor prognosis. Such double-hit events are
extremely rare in B cell precursor acute lymphoblastic leukemia (B-ALL), especially in
pediatric patients or young adults. This study is to investigate the clinical manifestation
of double-hit B-ALL in young patients.
Design/Methods: This study was designed to perform a retrospective data review and to
identify the patients with de novo double B-ALL. Flow cytometry immunophenotypic,
cytogenetic, pathologic, immunohistochemistry and clinical outcome data are collected
and summarized. Additional literature cases were reviewed.
Results: Three patients were identified and there were two females and one male, with
15, 18 and 24 years of age, respectively. All patients had an unremarkable medical
history before presenting with extensive bone marrow and central nervous system
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involvement at diagnosis. Flow cytometry immunophenotypic analysis showed an
immature BCP-cell immunophenotype in all cases (CD10+, CD19+, TdT+, surface
Ig-) and immunohistochemistry showed high expression of MYC and BCL2 in all cases.
All patients showed complex karyotypes associated with 8q24 abnormalities in the form
of t(8;9)(q24;p13) or t(8;14)(q24;q32) and t(14;18)(q32;q21). Fluorescence in situ
hybridization confirmed MYC and BCL2 rearrangements. Two patients died of
refractory disease or disease progression 7 and 13 months after initial diagnosis,
respectively, and the third patient was treated with protocol AALL0232 under the
Children’s Oncology Group study, achieved complete remission and remained in
remission for 53-month at last follow-up. Combining our cases with previous
documented cases in literature, we found that the de novo double-hit B-ALL occurs
predominately in young patients with a medium age of 27 years.
Conclusion: Our study showed that MYC and BCL2 double-hit rearrangements exist in
pediatric or young adult patients with B-ALL and, such double-hit events associated
with complex karyotypes and poor prognosis. Younger patients may benefit from
intensified chemotherapy.
P-064
HEALTH RELATED QUALITY OF LIFE, DEPRESSION, ANXIETY AND SELF-
CONCEPT IN CHILDHOOD ALL SURVIVORS IN TURKEY
A. Meral Gunes1, Ç. As¸ut2, M. Sezgin Evim1, B. Baytan1, A. Çırpan Kantarcıog˘lu1
1Uludag University Faculty of Medicine, Ped. Hematology, Bursa, Turkey; 2Uludag
University Faculty of Medicine, Pediatri, Bursa, Turkey
Background/Objectives:With the advance in childhood acute lymphoblastic leukemia
(ALL) survival rate, long-term side effects of the treatment which contains high doses
of asparaginase, vincristine, and corticosteroids have become more important. As
previously reported ALL treatment might adversely affect health-related quality of life.
Besides health related quality of life our aim was to investigate, depression, anxiety and
self-concept among ALL survivors.
Design/Methods: 50 patients who have been diagnosed Pre B ALL at least 4 years ago
and their siblings were enrolled (n=100). Kovacs depression scale, State-Trait anxiety
inventory, Offer Self Image Questionaire, Quality of life scale for children and
adolescent were used for collecting data. The data were collected in a single session.
Results: There are significant differences between Quality of life scores among groups.
The physical health (p< 0.05), psychological health (p<0.03) and total scores of the
scale (p<0.05) of ALL survivors were significantly lower than the score of the siblings
and reported significantly lower self-concept (p<0.00) than controls. ALL survivors
have significant difficulty in the impulse control, level of emotion, body and self-image,
social relations, professional purposes, sexual attitudes, family relationships, mental
health and environmental compliance. Finally the results show that ALL survivors have
significantly higher depression (p<0.00) and anxiety (p<0.00) symptoms when
compared with their siblings.
Conclusion: A continuous diagnostical and interventional mental health services might
be necessary for possible emotional side effects of treatment during and after the
treatment. Adequate rehabilitation and follow-up programmes should be implemented
for children during the treatment and after remission from ALL. When consedering
parents child interaction is reciprocal, parents should recieve mental /psychological
counseling too.
P-065
LEUKEMIA INITIATING CELLS IN ACUTE LYMPHOBLASTIC LEUKEMIA
ARE ENRICHED IN EARLY CELL CYCLE AND CHARACTERIZED BY LOW
CELLULAR ENERGYMETABOLISM
L. Trentin1, K.M. Debatin1, L. Meyer1
1Ulm University Medical Center, Pediatrics and Adolescent Medicine, Ulm, Germany
Background/Objectives: In acute lymphoblastic leukemia (ALL), the nature of leukemia
initiating cells (LIC) remains undefined, although of key clinical relevance since LICs
need to be eradicated in order to cure the disease. The hierarchical concept with few
LIC being able to propagate leukemia upon transplantation onto immunodeficient mice
has been challenged by data showing LIC-activity also in committed cells supporting a
stochastic model. As a common strategy, these studies are based on defining
sub-populations by distinct surface marker profiles. In order to alternatively
characterize and define LIC in ALL, energy metabolism and cycle phases were
addressed in patient derived xenograft B-cell precursor (BCP) ALL samples.
Design/Methods: ALL cells were analyzed for levels of reactive oxygen species (ROS)
along with DNA and RNA staining allowing determination of cell cycle phases.
Repopulating activities of sorted cellular sub-fractions were investigated upon
transplantation onto NOD/SCID mice.
Results: All cell cycle fractions showed LIC-activity and led to NOD/SCID/huALL
engraftment. However, cells of early G0/G1 cell cycle phases showed increased
repopulation activity compared to later/G2-M cell cycle phases. Interestingly, a low
oxidative state (ROSlow) was identified in cells of early cell cycle in contrast to ROShigh
cells originating from later cell cycle suggesting that the ALL cells’ oxidative state is
indicative for its leukemia initiating activity. To functionally address this hypothesis,
sorted ROShigh and ROSlow cells were transplanted. Interestingly, ALL cells of low
oxidative state (ROSlow) cells showed higher repopulating activity with short leukemia
free survival of recipients compared to ROShigh ALL cells leading to significantly
prolonged leukemia engraftment.
Conclusion: Our data indicate that all cells in ALL show LIC activity, with cells of early
cell cycle and low energy metabolism representing the driving leukemia initiating cell
compartment, thus pointing to redox modulation as a potential therapeutic target in
ALL.
P-066
INFECTIONS DURING HIGH DOSEMETHOTREXATE THERAPY IN
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
T. Mosleh1, A. Islam1
1BSMMU, Department of Pediatric Hematology & Oncology, Dhaka, Bangladesh
Background/Objectives: High-dose methotrexate (HDMTX) therapy as an effective
therapy for childhood ALL, which is frequently associated with side effects like
infection in our centre . It prolongs hospital stay, delays chemotherapy and causes more
economic burden on patients.Objective of this study is to identify the incidence, risk
factors , and severity of infection during HDMTX therapy.
Design/Methods: This prospective observational study included fifty patients, aged 1-15
years scheduled to receive HDMTX 2.5gm/m2 in B cell leukemia and 5gm/m2 in Tcell
leukemia at Department of Pediatric Hemato-oncology of BSMMU .With the approval
of the local institutional review board, study was done over a period of six months from
January,2012 to June 2012. Baseline investigations were done prior to therapy
.Follow-up was done in daily basis from day of infusion upto recovery or 7 days after
discharge from hospital. Demographic, clinical, pathological and microbiological data
were collected according to a pre-defined Patient Data Form.
Results: Out of 50 patients, infection occurred in 19 (38%) patients. Gastro intestinal
tract (GIT) was the most common site 8(42.11%). Microbiologically documented
infections found in 9 occations, where Gram negative bacilli - E.coli 4(44.4%),
Pseudomonus 3(33.33%) were predominant organisms. The rate of infection is
significantly higher (P value =0.01) in children <5 yr(78.94%). Male child 15(78.94%)
are more prone to infection then female child 4 (21.05%) (P value =0.01). Total 3
patients died during study period due to infection, the mortality rate was 6%.GIT
symptoms as vomiting, mucocitis, diarrhea were the commonest features after
HDMTX administration.
Conclusion: Infection (38%) as well as fatality rate (6%) is high with HDMTX
chemotherapy, specially in younger children. Gram negative organism (E. coli,
Pseudomonus) are the main pathogen in our center.
P-067
THE EFFECT OF CNS INVOLVEMENT AND CNS IRRADIATION ON
SURVIVAL IN CHILDRENWITH ACUTE LYMPHOBLASTIC LEUKEMIA
M. Taskinen1, T. Oskarsson2, M. Levinsen3, M. Bottai4, M. Hellebostad5, O. Jonsson6,
P. Lähteenmäki7, K. Schmiegelow8, M. Heyman2
1Children’s Hospital-Helsinki University Central Hospital, Pediatric Hematology and
Oncology, Helsinki, Finland; 2Childhood Cancer Research Unit-Karolinska Institute,
Department of Women´s and Children´s Health, Stockholm, Sweden; 3Institute of
Gynegology-Obstetrics-and Pediatrics, The University of Copenhagen, Department of
Pediatrics, The University Hospital Rigshospitalet, Copenhagen, Denmark; 4Karolinska
Institute, Biostatistics Core, Stockholm, Sweden; 5Ullevål Hospital, Department of
pediatrics, Oslo, Norway; 6Children´s Hospital-Landspitali University Hospital, Pediatric
Hematology and Oncology, Reykjavik, Iceland; 7Turku University Hospital, Department
of Pediatrics, Turku, Finland; 8Institute of Gynegology-Obstetrics and Pediatrics, The
University of Copenhagen, Department of Pediatrics, The University Hospital
Rigshospitalet, Copenhagen, Denmark
Background/Objectives: Central nervous system irradiation (CNS-RT) has been an
important modality in the treatment of acute lymphoblastic leukemia (ALL).
Nevertheless, most recent ALL protocols have omitted CNS-RT due to concerns
regarding the long-term late-effects. Our aim was to estimate the effect of CNS
involvement and CNS-RT on survival in children with ALL.
Design/Methods: In total, 2735 children aged 1-14.9 years with pre-B and T-cell ALL
were treated according to the NOPHO ALL-92 and 2000 protocols. Patients stratified
as High Risk, were included in the study (n=836). Prophylactic CNS-RT was
prescribed to a subgroup of HR-patients older than 5 years. We evaluated the effect of
CNS status at diagnosis and CNS-RT on the risk of death (overall survival, OS) and
any event (event-free survival, EFS). Outcome estimations were calculated with the
Kaplan-Meier method, Poisson regression and competing risks regression.
Results: CNS involvement was detected in 56/836 HR-patients (6.7%). Complete
remission rate was similar in patients with or without CNS involvement. The central
nervous system was more frequently involved at relapse if CNS positive at diagnosis.
There were no differences in the OS (69.3% vs. 74.4%), EFS (60.6 vs. 61.9%) and
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cumulative incidence of relapse (30.5% vs. 30.8%) at 10 years in patients with or
without CNS involvement. CNS-RT was given to 170 patients. Overall survival was
similar in patients with or without CNS-RT (84.4 ± 2.8% and 88.3 ±1.5%) but the
hazard ratios in the irradiated patients for relapse, CNS-involving relapse and isolated
CNS relapse were 0.36 (p<0.001), 0.35 (p<0.01) and 0.22 (p<0.05), respectively.
Conclusion: CNS involvement at diagnosis is a strong risk factor for CNS involving
relapses, especially CNS involving relapses but is not an independent risk factor for
overall survival or event-free survival. CNS-RT does not increase overall survival in
general but decreases the risk of relapse and CNS involving relapses.
P-068
SECONDARYMALIGNANT NEOPLASMS AMONG CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED USING THE
KYUSHU-YAMAGUCHI CHILDREN’S CANCER STUDY GROUP
PROTOCOLS: A RETROSPECTIVE STUDY
S. Ozono1,2, H. Inada1, H. Moritake3, S. Kamimura3, Y. Koga4, Y. Shinkoda5,
H. Nakayama6, S. Suenobu7, M. Shimomura8, Y. Nomura9, J. Inagaki10, Y. Okamoto11,
Y. Kawano11
1Kurume University, Pediatrics, Kurume, Japan; 2University of British Columbia,
Developmental Neuroscience and Child Health, Vancouver, Canada; 3Miyazaki
University, Pediatrics, Miyazaki, Japan; 4Kyushu University, Pediatrics, Fukuoka, Japan;
5Kagoshima City Hospital, Pediatrics, Kagoshima, Japan; 6Fukuoka East Medical
Center, Pediatrics, Fukuoka, Japan; 7Oita University, Pediatrics, Oita, Japan;
8Yamaguchi University, Pediatrics, Yamaguchi, Japan; 9Fukuoka University, Pediatrics,
Fukuoka, Japan; 10National Kyushu Cancer Center, Pediatrics, Fukuoka, Japan;
11Kagoshima University, Pediatrics, Kagoshima, Japan
Background/Objectives: To investigate the cumulative incidence of secondary malignant
neoplasms (SMN) and related factors among childhood acute lymphoblastic leukemia
(ALL) patients treated using the Kyushu-Yamaguchi Children’s Cancer Study Group
(KYCCSG) protocols.
Design/Methods: A retrospective cohort study including 509 children diagnosed with
ALL and registered in 3 consecutive multicenter KYCCSG protocols between June
1988 and July 2002 was conducted. The cumulative incidence of SMN and related
factors including treatment protocol, irradiation, stem cell transplantation, and other
features of primary ALL, were analyzed. Approximately two-thirds of patients (n=338)
received cranial irradiation, and 90 patients received stem cell transplantation.
Results: Fifteen of 509 patients were diagnosed with SMN, including acute myeloid
leukemia (AML)/ myelodysplastic syndrome (MDS) (n=7), brain tumor (n=5),
malignant schwannoma (n=2), and basal cell carcinoma (n=1), within a median
follow-up duration of 12.7 years. The cumulative incidence of any SMN was 2.5% (95%
CI, 1.7-3.3%) at 10 years and 4.3% (95% CI, 3.1-5.5%) at 20 years, respectively. The
standardized incidence rate ratio (SIR) of all SMN was 28.6. The SIRs of AML/MDS
and brain tumor were 13.4 and 6.3, respectively. Univariate analysis revealed that
cranial irradiation had a tendency to be associated with an increased risk of all SMN
(chi-square=3.0, p=0.08). However, we an increased risk was not found for the type of
protocol or stem cell transplantation.
Conclusion: Despite exposure to intermediate chemotherapy and cranial irradiation
(including stem cell transplantation in some patients), the cumulative incidence of
SMN was unexpectedly low. However, the SIR of SMN in childhood ALL was
significantly higher than that of the age-matched general population. Risk-based
follow-up and health check education for ALL survivors, and collaboration between the
survivors’ physician and a clinical oncologist should be encouraged for prevention and
early detection of SMN.
P-069
BONEMINERAL DENSITY DEFICIT IN ADULT SURVIVORS OF
CHILDHOOD CANCER: A SYSTEMATIC LITERATURE REVIEW
S. Pluijm1, M. Den Hoed2, C. Wilson3, S. Neggers4, R. Pieters5, M. Van den
Heuvel-Eibrink5
1Erasmus University Medical Center - Sophia Children’s Hospital, Department of
Paediatric Oncology, Rotterdam, Netherlands; 2ErasmusMC, Department of Pediatric
Oncology/Hematology, Rotterdam, Netherlands; 3St Jude Children’s Research Hospital,
Department of Oncology, Memphis, Netherlands; 4ErasmusMC, Department of Internal
Medicine- section Endocrinology, Rotterdam, Netherlands; 5Princess Maxima Center for
Pediatric Oncology, Pediatric Oncology, Utrecht, Netherlands
Background/Objectives: Childhood cancer treatment may lead to diseases of the
skeleton characterized by low bone mineral density (BMD), and a consequent increased
fracture risk. A comprehensive review on the occurrence of BMD deficit, and its risk
factors in childhood cancer survivors (CCS), has never been pursued.
Design/Methods: An electronic literature search was performed using PubMed,
Medline, Scopus and Web of Science databases. Studies were included if survivors of
childhood cancer (median age at diagnosis 18 years) were at least a median period of
5 years after stop therapy and had a median age of 18 years old at BMD
measurement. Outcome measures were total body BMD (BMDTB), lumbar spine BMD
(BMDLS) and hip BMD (femoral neck (BMDFN), total hip (BMDTH), expressed as
Z-scores or Standard Deviation Scores (SDS).
Results: Literature search revealed 29 studies. All studies were retrospective and most of
them used samples with less than 50 survivors; only 5 studies included more than 100
survivors. Most studies measured BMD in survivors of pediatric acute lymphoblastic
leukaemia (ALL); fewer studies assessed BMD in survivors of solid tumors. The
majority of the studies found lower BMD values in survivors in comparison with
healthy peers. In one large study, the percentage of all survivors with BMD<-1 SDS
was about 40%. Especially, survivors of ALL and acute myeloid leukemia (AML),
brain tumor, and osteosarcoma seemed to have a high risk of a BMD deficit. Lower
body weight at adult age, cranial radiotherapy and treatment with glucocorticosteroids
or chemotherapeutic agents seemed risk factors for BMD deficit.
Conclusion: Long-term childhood cancer survivors are prone to BMD deficit already at
a relatively young adult age. These results indicate that greater awareness is needed,
especially in survivors of leukemia, brain tumor and osteosarcoma, who have
underweight and were treated with cranial radiotherapy or glucosteroids.
P-070
HIGH INCIDENCE OF HYPERDIPLOIDY AND BETTER PROGNOSIS FOR
HIGH HYPERDIPLOIDY IN OUR COHORT OF PEDIATRIC B-ACUTE
LYMPHOBLASTIC LEUKEMIA: FLOW CYTOMETRY BASED STUDY FROM
NORTHERN INDIA
B. Prateek1, D. Bansal1, A. Trehan1
1PGIMER, Pediatric Hematology Oncology Unit- Department of Pediatrics,
Chandigarh, India
Background/Objectives: Introduction: DNA ploidy assessment forms an important
method to detect numerical genetic abnormalities in B-ALL and patients are
categorized into favorable or unfavorable risk groups based on high hyperdiploid (>51
chromosomes) or hypodiploid (<46 chromosomes) DNA index respectively. Aims &
Objectives: To standardize and note the frequency of DNA ploidy abnormalities in
pediatric B-ALL and to correlate the same with early response to chemotherapy.
Design/Methods: DNA ploidy assessment was done in 40 pediatric B-ALL cases
confirmed on bone marrow and immunophenotyping before start of chemotherapy. 40
non-leukemic controls were run with each sample. Samples were processed using DNA
ploidy kit reagents (Cycletest DNA ploidy kit; BD biosciences) and analysis was done
on a flow cytometer (LSR-II; BD biosciences). The DI (DNA index) was calculated
using the Mofit software. The results were compared with standard risk criteria and
chemotherapy outcome (modified UK-ALL protocol).
Results: A hyperdiploid cell line was noted in 33/40 (82.5%). 7/40 (17.5%) cases had
diploid cell line. None of the cases showed a hypodiploid population. DI of 1.01-1.15
(Hyperdiploid A) was seen in 17/33 (51.5%), DI between 1.16-1.6 in 11/33 (33.3%) and
4/33 (15.2%) had a DI>1.90 (tetraploidy range). Cases with DI >1.16 had significantly
better response to treatment than with those having diploid DI or DI between 1.06-1.16
(P<0.05). Significant prognostic factors on Cox analysis were DI>1.16, age between
2-9 years, WBC count< 50,000 and Hb<9.0.
Conclusion: There is a relatively high frequency of hyperdiploidy cell line in our cohort
of B-ALL patients. Cases with DI>1.16 and WBC count <50,000 at presentation are
likely to respond better to chemotherapy with less risk of relapse. However, prospective
studies on a large cohort of B-ALL cases in our population are needed to derive
definitive conclusions and make individualized treatment decisions.
P-071
STUDYING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)
MINIMAL RESIDUAL DISEASE (MRD) USING TEN COLOR FLOW
CYTOMETRIC ASSAY
N. Rabade1, K. Ghodke1, A. Bibi1, S. Ghogule1, Y. Badrinath1, N. Patkar1,
P.G. Subramanian1, S. Gujral1, S. Banawali2, P. Tembhare1
1Tata Memorial Hospital, Hematopathology, Mumbai, India; 2Tata Memorial Hospital,
Medical Oncology, Mumbai, India
Background/Objectives:MRD is a well establish prognostic factor in the management
of T-cell acute lymphoblastic leukemia (T- ALL) and flow cytometry (FC) is easily
available and widely used for MRD evaluation. Currently standardized FC based MRD
assays are 4 to 6-color assays and have analytic limitations leading to decreased efficacy.
With aim to overcome these limitations and to improve sensitivity and specificity, in this
study we standardized a 10-color FC T-ALL MRD assay.
Design/Methods:We studied 68 MRD tests in 50 pediatric T-ALL patients from
January 2014 to January 2015 at different time points. Of these 50 were post-induction
(day 33), 15 were post-consolidation (day 78) and three maintenance samples. T-ALLs
were diagnosed as per WHO 2008 criteria using a comprehensive antibody panel.
Ten-color T-MRD assay was standardized and all the samples were analyzed by the
Navios flow cytometer (Beckman Coulter) using Kaluza analysis software Antibodies
for T-MRD panel included CD5-BV421, surfaceCD3-BV510, CD8-FITC, CD7-PE,
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cytoplasmicCD3-ECD, CD34-PCcy5.5, CD16+CD56-PC7, CD4-APC, CD45-AF700,
CD38-AF750, and Syto13 for nuclear staining.. MRD results were correlated with
other high risk factors.
Results: Fifty T-ALL cases (M:F ratio 7.3 :1) including 5 early precursor T-ALLs
(ETPALL) were studied. Seventeen (34%) of 50 post-induction and 3 (17.5%) post
consolidation samples were MRD positive (mean - 0.78%, median - 0.1% & range -
0.002% to 24.5%). Two (40%) of 5 ETPALLs were positive post induction but negative
post consolidation. Lowest level of MRD detected by this assay was 0.002%, which
indicates very high sensitivity (2 in 106) of 10-color FC-T-MRD as equal to MRD by
molecular assay.
Conclusion: Ten-color T-ALLMRD assay provides high level of sensitivity and helps in
better monitoring of response to therapy.
P-072
OUTCOME OF TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA IN DOWN AND NON DOWN SYNDROME. EXPERIENCE AT A
SINGLE TERTIARY CARE CENTER
A. Khairy1, S. Al-Sweedan1, K. Alkayed1, R. Jafri2, A. Al-Ahmari1, I. Ghemlas1,
K. Siddiqui3, H. El-Solh1, N. Farhan1, M. Saleh1
1King Faisal Specialist Hospital and Research Centre, Pediatric Hematology / Oncology,
Riyadh, Kingdom of Saudi Arabia; 2King Faisal Specialist Hospital and Research Centre,
CDU- Pediatric Hematology / Oncology, Riaydh, Kingdom of Saudi Arabia; 3King Faisal
Specialist Hospital and Research Centre, CDU- Pediatric Hematology / Oncology,
Riyadh, Kingdom of Saudi Arabia
Background/Objectives: Outcome of Acute Lymphoblastic Leukemia (ALL) in children
with Down syndrome (DS) remains poor mainly because of high relapse rate and
treatment related toxicities.
Design/Methods:Medical records of 34 DS patients with ALL between 1997 and 2013
were reviewed. Data extracted included those related to clinical characteristics of
patients and their outcome.
Results: Twenty One patients were males (61.76%). Median age at diagnosis was 60.96
months (range17.16-162.24). Thirty one patients were below the age of 10 years (91%).
Mean WBC count was 33.95(range 1-500), CBC blasts mean was 40.51. Twenty Five
patients were CNS1, Five were CNS2 and one patient was CNS 3. Thirty three patients
had precursors B- (97%) and one had Biphenotype ALL. Three patient had additional
trisomy (9.6%). Twenty eight patients were evaluated for BM response. Twenty five
(89.28%) achieved remission at day 14 while 28(100%) achieved remission at the
completion of induction. Seven Patients (20.5%) relapsed (4 on therapy and 3 off
therapy) at a median time of 20.22 months (range 3.57-86.59). Fourteen patients
(41.1%) died, 10 due to progressive disease and 4 due to infections. Twenty three
patients developed chemotherapy related infectious toxicities in induction and
22(64.8%) in post induction phase. OS was 50.1% and EFS was 48.8% compare to OS
of 85% and EFS of 71.9% in non-DS ALL patients who received treatment at our
institution during the same period. Age at diagnosis, gender, WBC count and Blasts in
CBC did not significantly affect the probability of OS and EFS in our cohort.
Conclusion: Our results show a relatively poor outcome in DS ALL patients which is
comparable to published data.
P-073
IS NUTRITIONAL STATUS AT DIAGNOSIS RELATED TO CLINICAL
OUTCOME IN ACUTE LYMPHOBLASTIC LEUKEMIA?
J. Ramamoorthy1, A. Trehan2, D. Bansal2, R. Jain2
1Post Graduate Institute of Medical Education & Research, Chandigarh, India; 2Post
Graduate Institute of Medical Education & Research, Pediatrics, Chandigarh, India
Background/Objectives: Undernutrition is considered to be an adverse prognostic factor
in the outcome of treatment in patients with acute lymphoblastic leukemia (ALL),
influencing the course of the disease and chances of survival. This analysis was
performed to evaluate the effect of undernutrition on outcome in children with ALL.
Design/Methods:We analyzed 286 children treated for ALL from January 2010 to
December 2012. Weight for age, height for age, BMI (WHO classification) and serum
albumin at diagnosis were recorded. Anthropometric parameters were correlated with
outcome.
Results:Mean age: 5.82 ± 3.14 years. There were 199 boys and 87 girls. Standard risk
(NCI): 177, Intermediate/High risk: 108. Weight < -3 z score: 11.8%, between -3 & -2 z
score: 14.6% and normal weight: 73.5% children. Height < -3 z score: 8.3%, < -3 & -2 z
score: 8.3% and normal height: 83.4%. BMI < -3 z score: 12.3%, between < -3 & -2 z
score: 12.3% and normal BMI: 66.4%. Serum albumin < 3 gm/dl: 33.4% of patients.
Event free survival (EFS) is 63.9% (Events: relapse, death, default). Event free survival
was not affected by weight (65.1% vs. 60.5% in underweight patients p=0.513); height
(65% vs. 58.3% in stunted children p=0.710); BMI (EFS being equal in both groups)
Hypoalbuminemia had a significant effect on EFS (56.1% vs. 68.4% p=0.035). Weight,
height and BMI did not affect death independently (p= 0.386, 0.207 & 0.6) No
difference in undernutrition, stunting and BMI was observed across gender and the
standard/intermediate/high risk groups of disease.
Conclusion: There are conflicting results as to the outcome in undernourished children
with cancer. There is a trend towards a lower outcome in undernourished children, with
hypoalbuminemia at diagnosis having significantly lower EFS. Collaborative
prospective studies using a common algorithm for assessment are needed to assess the
impact on morbidity and mortality.
P-074
COGNITIVE OUTCOME IN CHILDREN AND ADOLESCENTS IN REMISSION
FROM ACUTE LYMPHOBLASTIC LEUKAEMIA, TREATEDWITH
CHEMOTHERAPY ONLY
T. Reinfjell1, G.E. Lofstad1, M.E.B. Eilertsen2, K. Hestad1, T.H. Diseth3
1Norwegian University of Science and Technology NTNU, Department of Psychology,
Trondheim, Norway; 2Sør-Trøndelag University College-Research Centre for Health
Promotion and Resources HIST/NTNU, Nursing Faculty, Trondheim, Norway; 3Oslo
University Hospital-Section of Child and Adolescent Psychiatry, Department of
Pediatrics, Oslo, Norway
Background/Objectives: The cognitive functioning in survivors of childhood acute
lymphoblastic leukaemia (ALL) treated with chemotherapy only protocols has been
evaluated by comparison to different groups, but results have been inconclusive. Studies
that compare to matched healthy controls are still scarce. The aim of the present study
was to assess cognitive outcome in children and adolescents in remission from ALL,
treated with chemotherapy only, compared to healthy controls.
Design/Methods: Thirty-five children and adolescents, between the ages of 8-15 years
and in long-term remission from ALL, 4-12 years post diagnosis, without relapse and
no prediagnosis history of neurodevelopmental disorder, were compared with 35
healthy controls matched for gender and age. The survivors of ALL were recruited from
Oslo University Hospital and St. Olav’s University Hospital in Trondheim, Norway.The
Wechsler Intelligence Scale for Children-Third Edition (WISC-III, Wechsler, 1989,
2004) was used to test cognitive outcome.
Results: All but two of the ALL survivors treated by chemotherapy only, obtained
WISC-III Total Intelligence Quotient (IQ) scores in the normal range (M = 95.3).
However, their scores were significantly below levels for their matched controls and
below normative standards for WISC-III. The difference between the patient and
controlgroup was significant at the p < 0.001 level for the measures Total IQ, Verbal IQ,
Verbal Comprehension Index, Freedom from Distraction Index and three verbal subtest
scores.
Conclusion: The results indicate impairment in global cognitive functions. They also
indicate that verbal function, processing speed, as well as attention and complex
visual-spatial problem-solving may be affected in the group of children receiving only
chemotherapy, and should be taken into account by schools and health care providers.
Therefore, it will be essential to implement adequate rehabilitation and follow-up
programs for children in remission from ALL.
P-075
NEUROPSYCHOLOGICAL OUTCOME IN CHILDREN AND ADOLESCENTS
AFTER TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKAEMIA WITH
CHEMOTHERAPY ONLY
T. Reinfjell1, G.E. Lofstad1, M.E.B. Eilertsen2, K. Hestad1, T.H. Diseth3
1Norwegian University of Science and Technology NTNU, Department of Psychology,
Trondheim, Norway; 2Sør-Trøndelag University College-Research Centre for Health
Promotion and Resources HIST/NTNU, Nursing Faculty, Trondheim, Norway; 3Oslo
University Hospital-Section of Child and Adolescent Psychiatry, Department of
Pediatrics, Oslo, Norway
Background/Objectives: The main treatment for children with acute lymphoblastic
leukamia (ALL) is chemotherapy only (CTO), however the cognitive functioning over
time in long-term survivors has been inconclusive. Further evaluation and records of
their neuropsychological function are scarce. The aim of the present study is to examine
neuropsychological differences between survivors of childhood ALL treated with CTO
compared to matched healthy controls.
Design/Methods: Neuropsychological performances in 36 children and adolescents, age
8.4 - 15.3 years, in long-term remission from ALL, 4.3 -12.4 years post diagnosis,
without relapse and no pre-diagnosis history of neurodevelopmental disorder, were
compared with the performance of 36 healthy controls matched for gender, age and the
parents socio-economic status. The former patients and the healthy controls completed
an extensive battery of standardized neuropsychological tests. The children and
adolescents treated for ALL, were recruited from Oslo University Hospital and St.
Olav’s University Hospital in Trondheim, Norway. The treatments were initiated from
May 1992 through 1999, in accordance with protocols developed in 1992 by the Nordic
Society of Pediatric Hematology Oncology-ALL (NOPHO-1992).
Results: Survivors treated by CTO obtained significantly lower scores than healthy
controls on tests of visual-spatial construction, working memory, memory span and
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processing speed in tactile stimuli. The ALL survivors obtained a steeper rising learning
slope with lower scores after single-trial memory and problem solving tasks, but catches
up with the controls when the stimuli were repeated.
Conclusion: The results indicate neuropsychological long-term sequelae in ALL
survivors limited to specific domains, especially processing novelty. Intervention
programs and school programs should take into account the deficit in processing new
information, and a focus on repetition may prevent that survivors fall behind their peers.
P-076
LONG TERM FOLLOW-UP OF 6-THIOGUANINE-INDUCED
HEPATOTOXICITY IN CHILDREN TREATED ON UKALL 97/99 PROTOCOL;
THE ROYALMARSDEN EXPERIENCE
N. Roy Moulik1,2, E. Potter2, S. Height3, S. Vaidya2, D. Lancaster2, M. Taj2
1Saroj Gupta Cancer Centre and Research Institute, Department of Pediatric
Hematology and Oncology, Kolkata, India; 2The Royal Marsden Hospital, Department
of Paediatric Oncology, Sutton, United Kingdom; 3King’s College Hospital NHS
Foundation Trust, Department of Paediatric Haematology, London, United Kingdom
Background/Objectives: The use of 6-thioguanine (6-TG) for treatment of ALL during
UKALL 97/99 was associated with hepatotoxicity in a small subset of patients treated
at the Royal Marsden hospital. We report the long term follow-up of these children
with regard to their hepatic status.
Design/Methods: The case sheets and follow-up records of all these childrenwere
revisited and data retrieved. Conventional descriptive statistics was used to analyse the
data.
Results: Of the 11 children (boys-8, girls-3) with documented 6-TG induced
hepatotoxicity in our database, 6 became symptomatic during treatment whereas 5
presented after a median of 24 (range 1-72) months from the end of therapy. The
former group (n=6) presented with features of veno-occlusive disease (4) and
transaminitis (2), whereas the latter group (n=5) had low counts with
hepatosplenomegaly (4) or isolated splenomegaly (1) at presentation. After a median
follow-up of 132 (72-168) months, 8 of 11 children had persistent problems; isolated
splenomegaly was noted in 6 and hepatic involvement as evidenced by altered hepatic
echo-texture on ultrasound was seen in 7 of these 8 patients. Of the 5 patients who
underwent upper gastrointestinal endoscopy, 4 had oesophageal varices and 1 required
banding. Liver biopsy performed in 4 of these 8 children showed nodular regenerative
hyperplasia in all 4. Thrombocytopenia, present in 7 of these 8 children was associated
with menorrhagia and pregnancy loss in 1.
Conclusion: Hepatic involvement in the majority of the patients with 6-TG induced
hepatotoxicity in this cohort progressed to chronicity, highlighting the importance of
continuing long-term hepatology and haematology follow-up in these patients.
P-077
FOLATE DEFICIENCY AND NEED FOR SUPPLEMENTATION DURING
MAINTENANCE THERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) - A PILOT STUDY
N. Roy Moulik1,2, A. Kumar2, N. Verma2, A.A. Mahdi3
1Saroj Gupta Cancer Centre and Research Institute, Pediatric hematology and oncology,
Kolkata, India; 2King George’s Medical University, Division of Pediatric
Hematology-Oncology-Department of Pediatrics, Lucknow, India; 3King George’s
Medical University, Division of Biochemistry, Lucknow, India
Background/Objectives: Folate deficiency is common in children from resource limited
settings. We had previously observed the association of folate deficiency with increased
complications during maintenance chemotherapy for ALL. This prompted us to
supplement folic acid in deficient children during maintenance, the effects of which are
being reported.
Design/Methods: All children currently undergoing maintenance chemotherapy for
ALL in our centre were enrolled, provided they had completed at least one cycle (84
days). Folate levels were assessed prior to each cycle or following unexplained
cytopenias. Children were supplemented with 2.5 mg folic acid daily for 7days whenever
their levels fell below <4ng/ml. The clinico-haematological parameters were recorded
and analysed.
Results: Sixty-three children were included with a mean follow-up of 15.45(±9.69)
months. 285 cycles of maintenance were studied. Folate deficiency was noted in the
beginning of 51 cycles where folic acid was supplemented upfront. Folate deficiency was
documented following screening for unexplained cytopenia in another 18 cycles (out of
the 25 cycles screened). A higher incidence of febrile neutropenia (10 of 18 vs. 8 of 51;
p=0.02) and longer duration of chemotherapy interruption (15.49±6.32 vs. 8.45±1.49
days; p<0.001) were noted in children of the latter group during a given cycle despite
supplementation than children who were detected deficient and supplemented on
routine screening. Ten deaths were seen during maintenance, of which 8 occurred in
folate deficient children and 5 of these during episodes of unexplained cytopenias
(p=0.04). None of the children studied had relapse of disease till last follow-up.
Conclusion: Folate deficiency was common in children during maintenance therapy of
ALL and was a common cause of unexplained cytopenias in them. Pre-emptive
detection of folate deficiency by frequent periodic screening and supplementation may
decrease the incidence of complications and improve the outcome of maintenance
therapy in these children, particularly in the resource limited countries.
P-078
MICRORNA EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA: IDENTIFICATION OFMICRORNAS INVOLVED IN
LEUKEMOGENESIS AND PROGNOSIS
C. Grecco1, D. Marco Antonio2, J. Oliveira3, P. Fedatto1, R. Panepucci2, A. Goes4,
A.B. Silveira5, J. Yunes5, S. Brandalise5, L. Tone1, C.A. Scrideli1
1Ribeirão Preto Medicine School - University of São Paulo, Pediatrics, Ribeirão Preto,
Brazil; 2Ribeirão Preto Medicine School - University of São Paulo, Hemocentro
Fondation, Ribeirão Preto, Brazil; 3Ribeirão Preto Medicine School - University of São
Paulo, Genetics, Ribeirão Preto, Brazil; 4Ribeirão Preto Medicine School - University of
São Paulo, Internal Medicine, Ribeirão Preto, Brazil; 5Centro Infantil Boldrini/State
University of Campinas, Pediatrics, Campinas, Brazil
Background/Objectives: Abnormal microRNAs expression has been shown to play an
important role in development and progression of different human cancer, but data in
pediatric acute lymphoblastic leukemia (ALL) are limited. The present study aimed to
evaluate the differential expression of miRNAs in children with ALL and correlate the
expression levels with features of diagnosis and clinical outcome.
Design/Methods:We aimed to evaluate the miRNAs expression profile by microarray
using the Human miRNAMicroarray Kit (V3, 8×15K, Agilent) in 81 consecutive bone
marrow samples from children with ALL at diagnosis (39 T-ALL and 42 CD10
B-lineage ALL). Changes in miRNA expression levels were detected using empirical
Bayesian approach corrected by False Discovery Rate. Ten miRNA of the most
differentially expressed were chosen to be validated by qRT-PCR using TaqMan probes
in the 81 ALL samples and 8 pediatric non-neoplastic bone marrow (BM). The
difference in expression between the groups was analyzed by Mann-Whitney test and
event free survival (EFS) and overall survival (OS) by Kaplan-Meier plots and log-rank
test, median of the expression values were used as cut-off and P < 0.05 considered as
significant.
Results: The unsupervised hierarchical clustering evidenced two main clusters clearly
identifying B-lineage and T-ALL. From the 10 validated mIRNA 5 were
down-expressed (miR-148, -151, -550, - 497 and -765) and 1 overexpressed (miR-213) in
ALL when compared with non-neoplastic BM. When compared B-lineage vs T-ALL
overexpression was observed to miR-151, -455 and -574, and down-expression to
miR-141, -148, -213 and -765. Overexpression of miR-455 and -574 were associated
with death in B-lineage ALL. A higher expression level of miR-574 in B-ALL was also
associated with lower EFS and OS. In children with T-ALL overexpression of miR-141
was associated with higher EFS.
Conclusion: The present results suggest a role of miRNAs in leukemogenesis and their
potential prognostic in childhood ALL.
P-079
EFFECT OF THE INHIBITION OF THE XPO7 GENE IN RESPONSE TO
METHYLPREDNISOLONE IN A CORTICORESISTANT T ACUTE
LYMPHOBLASTIC LEUKEMIA CELL LINE
V. Suazo1, V. Silveira2, A. Andrade2, R. Queiróz1, L. Tone1, C.A. Scrideli1
1Ribeirão Preto Medicine School - University of São Paulo, Pediatrics, Ribeirão Preto,
Brazil; 2Ribeirão Preto Medicine School - University of São Paulo, Genetics, Ribeirão
Preto, Brazil
Background/Objectives: In a previous study we observed a higher expression of XPO7
gene at diagnosis in children with acute lymphoblastic leukemia (ALL) and poor
response to induction treatment. The present study aimed in to investigate the effect of
the silencing of XPO7 gene by shRNA and the response to methylprednisolone
(MPRED) in a T-ALL cell line.
Design/Methods: The corticoresistant CCRF-CEM T-ALL cell line was transduced by
the RNA interference (shRNA) using 5 specific lentiviral clones to XPO7. After
verification of gene knockdown (by qRT-PCR) and protein inhibition (by western
blot), treatments were made with MPRED at different concentrations (1, 5, 50 e 100
μg/mL) at the times 24, 48, 72 and 96 hours of exposition followed by in vitro
functional studies. Cytotoxicity was evaluated by the method of resazurin at all times
and apoptosis by flow cytometry using anexin and propidium iodide at 96 h.
Results: Due to the resistance of the cell line to MPRED the IC50 was not possible to
be evaluated, once 73% of the cells were viable with 100 μg/mL of MPRED. After
silencing, there was a significant decreased of the proliferation with the dose of
100μg/mL in 24 h when compared with the pLKO non-silenced control (P<0.05).
Interestingly the opposite occurred at the times 48, 72 and 96 h with increase of
proliferation compared to control. No differences were observed with the other
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concentrations used. A significant increase of apoptosis was observed with the dose of
100μg/mL at 96 h (P<0.05).
Conclusion: The inhibition of XPO7 can be an interesting target for the treatment of
corticoresistant T-ALL.
P-080
CNS-DIRECTED TREATMENT AND ITS EFFECT ON VISUOMOTOR
CONTROL IN THE SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKAEMIA: A PRELIMINARY RESULT
D. Lau Sie Chong1, N.M. Ranai1, C.K. Loh1, Z. Latiff1, R. Jamal2, I. Schuitema3,
L.M. de Sonneville3, A.J. Veerman4, H. Alias1
1University Kebangsaan Malaysia, Paediatric, Kuala Lumpur, Malaysia; 2University
Kebangsaan Malaysia, UMBI, Kuala Lumpur, Malaysia; 3Leiden University,
Department of Clinical Child and Adolescent Studies, Netherlands, Netherlands; 4VU
University Medical Centre, Paediatrics, Amsterdam, Netherlands
Background/Objectives: Central nervous system(CNS)-directed treatment is an integral
part of childhood ALL protocol, leading to marked improvement in prognosis and
survival over the last few decades. However, major chemotherapeutic agents used as
CNS prophylaxis have central neurotoxic side effects, thus, evaluations to determine the
late effects of the treatment to the survivors were of great concern.
Design/Methods: A single centre, cross sectional study was conducted in Paediatric
Oncology Unit, UKMMC from 1st May 2014 until 28th February 2015 to evaluate the
effect of chemotherapy on visuomotor control in survivors of childhood ALL. A total
of 40 survivors who were off-treatment for at least 1 year and were in remission, and 40
healthy controls were enrolled into the study. Three subtests from Amsterdam
Neuropsychological Task(ANT) program were administered to assess the subjects’
visual reaction time (baseline speed) and their cognitive control/processing(tracking and
pursuit).
Results:Majority of the patients recruited were treated using the UKALL 97(99)
protocol (87.1%, n=34) while the rest were treated using UKALL 2003 protocol.
Median age at diagnosis was 3.87 years (IQR 2.95-5.45) while mean duration
off-treatment was 6.03 years (SD±2.76). Twenty five patients (62.5%) were of Standard
Risk group and 15 patients were High Risk group. Four patients had relapse while 2
patients had CNS involvement and received craniospinal irradiation. There were
statistically significant difference between the survivors of childhood ALL and healthy
controls on the measures of tracking accuracy(p = 0.020) and pursuit stability(p =
0.035). Higher cumulative intrathecal Methotrexate dose predicted poorer performance
for the pursuit stability. There were no significant correlation between gender and age at
diagnosis with the visuomotor deficit in our study cohort.
Conclusion: Survivors of childhood ALL in our centre showed components of
visuomotor control deficits compared to healthy controls. Remedial actions should be
offered to improve the survivors’ neuropsychological performances.
P-081
URINARY TRACT INFECTIONS IN PEDIATRIC ONCOLOGY PATIENTS –
SINGLE CENTER EXPERIENCE
K. Suh1
1Yeungnam University Hospital, Daegu, Korea
Background/Objectives: Infectious complications of chemotherapy are common and
potentially severe, especially in neutropenic patients. Urinary tract infection (UTI) is
one of the most prevalent bacterial infection in pediatric oncology patients. But most
febrile neutropenic patients had any sign and symptoms of inflammation. Aims of this
study are to find distinguishing characteristics of UTI in pediatric oncology patients.
Design/Methods: UTI was defined as a positive urine culture in the absence of another
focus in a febrile patient. Urine culture was considered positive if >105 CFU/ml of
single urine pathogen was found in a clean catch urine sample or by clean
catheterization. Nine episodes of UTI on 9 patients enrolled in this study (UTI group).
Control group consists of febrile neutropenia with negative urine culture, and 34
episodes of 24 patients were enrolled in this group. We compared clinical features, lab
findings between two groups and analyze characteristics of UTI group.
Results: Compared to controlgroup, UTI group shows high level of total IgG, lower
creatinine level, and have shorter duration of fever. In UTI group, E. coli was the most
common pathogen. In UTI group, patients with pyuria tend to appear abnormal
finding in renal Doppler and DMSA.
Conclusion: Urinalysis and urine culture should be obtained routinely as part of the
diagnostic evaluation of patients with fever and neutropenia.
P-082
SIGNIFICANT PROGNOSTIC VALUE OFMINIMAL RESIDUAL DISEASE
DETECTED BYMULTICOLOR FLOW CYTOMETRY DURING INDUCTION
TREATMENT IN CHILDRENWITH ACUTE LYMPHOBLASTIC LEUKEMIA
T. Szczepanski1, L. Sedek1, W. Mlynarski2, A. Sonsala1, J. Bulsa1, M. Twardoch1,
I. Olejnik3, M. Wieczorek3, K. Derwich4, I. Malinowska5, J. Trelin´ska2,
E. Niedzielska6, M. Niedzwiecki7, K. Muszynska-Roslan8, G. Sobol-Milejska9,
G. Karolczyk10, W. Badowska11, A. Kołtan12, T. Ociepa13, J. Kowalczyk14
1Medical University of Silesia, Department of Pediatric Hematology and Oncology,
Zabrze, Poland; 2Medical University of Lodz, Department of Pediatric
Oncology-Hematology and Diabetology, Lodz, Poland; 3Chorzów Center of Pediatrics
and Oncology, Chorzów, Poland; 4University of Medical Sciences Poznan, Department of
Pediatric Hematology-Oncology and Transplantology, Poznan, Poland; 5Medical
University of Warsaw, Department of Pediatric Hematology and Oncology, Warszawa,
Poland; 6Wroclaw Medical University, Department of Bone Marrow
Transplantation-Pediatric Hematology and Oncology, Wroclaw, Poland; 7Medical
University of Gdansk, Department of Pediatric Hematology-Oncology and
Endocrinology, Gdansk, Poland; 8Medical University of Bialystok, Department of
Pediatric Oncology, Bialystok, Poland; 9Medical University of Silesia, Department of
Pediatrics, Katowice, Poland; 10Regional Specialistic Pediatric Hospital, Kielce, Poland;
11Regional Specialistic Pediatric Hospital, Olsztyn, Poland; 12Collegium Medicum in
Bydgoszcz-Mikolaj Kopernik University, Department of Pediatric Hematology and
Oncology, Bydgoszcz, Poland; 13Pomeranian Medical University, Department of
Pediatrics-Hematology and Oncology, Szczecin, Poland; 14Medical University of Lublin,
Department of Pediatric Hematology and Oncology, Lublin, Poland
Background/Objectives: The study aimed at assessment of prognostic value of
multicolor flow cytometric MRD detection during induction treatment of childhood
ALL according to ALL-IC BFM 2002 protocol.
Design/Methods: The study group consisted of 371 children treated for ALL in centers
of the Polish Pediatric Leukemia/Lymphoma Study Group. Bone marrow samples
obtained at initial diagnosis were analyzed with multiparameter flow cytometry
according to the EuroFlow protocols. Based on the immunophenotype at diagnosis, the
2-3 flow cytometric 6-8 color tubes were selected to detect MRD in bone marrow
samples obtained at day 15, day 33, and at week 12. The median follow-up for the
whole group was 5.4 years. Equality of continuous variables was analyzed by
Mann-Whitney’s U test. For multivariate analysis, the Cox regression model was
applied. The probability of event-free survival and of overall survival was determined
by Kaplan–Meier analysis. p < .05 was considered significant.
Results: On day 15 MRD levels were <0.1% in 31% of patients. Only 2 patients in this
group relapsed. Moreover, in 14.2% of patients MRD was undetectable at D15. None
of the MRD-negative children relapsed. In 34 patients (12.4%) MRD at D15 exceeded
10%. At D33 MRD was detectable in 40.2% of patients. In 42 patients MRD levels
were > 0,1%, which was associated with unfavorable events in 15 patients. At week 12
MRD was present in 15.9% of patients; 8 MRD+ patients experienced unfavorable
events. Event-free survival was significantly influenced by leukocyte count at diagnosis
(p<0.001), prednisone response (p<0.05), MRD D15 (p<0.001) and MRD D33
(p<0.001). Age and leukocyte count at diagnosis (p<0.05), steroid response (p<0.05),
MRD D15 (p<0.001), MRD D33 (p<0.001) and MRD at week 12 (p<0.05) were
significantly associated with overall survival.
Conclusion:MRD detection based on multicolor flow cytometry gives significant
prognostic information and can be applied for improved risk group assignment in
pediatric ALL.
P-083
LOW COST INNOVATIONS IN SUPPORTIVE CARE IN CHILDREN
UNDERGOING HIGH DOSE CHEMOTHERAPY
R. Uppuluri1, S. Ramachandrakurup2, H. Doss2, R. Raj2
1Apollo Cancer Hospitals, Chennai, India; 2Apollo Cancer Hospitals, Pediatric
Hematology-Oncology and BMT, Chennai, India
Background/Objectives: Low cost innovations in supportive care will result in improved
outcomes in children undergoing cancer chemotherapy in developing countries.
Design/Methods: Our study included all children from 0 to 18 years of age diagnosed at
our centre treated for a malignancy from 2002 to 2014. Their outcomes in terms of rates
of sepsis, mortality and durable remission rates were analyzed.
Results: The first intervention was with respect to neutropenic diet based on the fact
that translocation of gut bacteria resulted in systemic sepsis especially hospital acquired
resistant bacteria like Klebsiella. Neutropenic children were put on a strict diet program
including double boiled rice, vegetables, pulses, yogurt and lactose free milk
supplements. Wheat, lactose and meat products were eliminated from the diet. This
intervention has resulted in decrease in infections rates from 22% down to 8 %. The
second intervention was related to central line associated blood stream infections
(CLASBI). Biopatch placed over the central line entry site has decreased rates of
CLASBI by 32% and central line dressing is done only once in 5 days. The cost of the
biopatch is 500 Indian rupees, while the cost incurred on antibiotics for treatment of
CLASBI amounts to over 12,000 Indian rupees a day for a 15kg child. The third
intervention was related to the universal use of Peg Asparaginase for all children with
acute lymphoblastic leukaemia regardless of their economic background. Two or three
children shared the cost of each vial (Rs 120,000), ensuring availability of this expensive
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yet highly efficacious chemotherapeutic drug to all children irrespective of their
economic condition.
Conclusion: Effective use of simple low cost innovations in supportive care of our
children help reduce rates of hospital acquired infections and ensure equitable
treatment for all children with improved survival.
P-084
PAEDIATRIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE
EXPERIENCE FROM THE DEVELOPINGWORLD
A.L. Van Eyssen1, A. Davidson1, M. Hendricks1, T. Schlaphoff2, P. De Witt3,
N. Novitzky3
1University of Cape Town, Paediatric Oncology-Red Cross War Memorial Children’s
Hospital, Cape Town, South Africa; 2South African Bone Marrow Registry, Deputy
Director, Cape Town, South Africa; 3University of Cape Town, Division of
Haematology-Department of Medicine-Groote Schuur Hospital, Cape Town, South
Africa
Background/Objectives: To review paediatric patients who underwent allogeneic
haematopoietic stem cell transplant (AHSCT) at Groote Schuur/University of Cape
Town Private Academic Hospital Transplant Unit with post-transplant care at Red
Cross War Memorial Children’s Hospital from December 1999 to December 2014.
Design/Methods: A retrospective analysis of paediatric patient charts who underwent
AHSCT between December 1999 and December 2014.
Results: Fifty children received AHSCT. Indications varied: 25 for haematologic
malignancies, 13 for bone marrow failure syndromes, 8 for transfusion dependant
haematological disorders, 3 for life threatening immunodeficiency and 1 for
adrenoleukodystrophy. There were 31 male (median age 93.9 months range 1.67-135.9
months) and 19 female (median age: 104.6 months range 9.2-141.5 months) patients.
Thirty three received HLA identical mobilised peripheral blood stem cell (PBSC) graft
from a sibling and 1 a maternal haplo-matched bone marrow (BM) graft. Eight received
10/10 HLA matched unrelated grafts: 6 were PBSC grafts and 2 were BM grafts. Eight
umbilical cord blood (UCB) transplants were performed. Only 3 of the unrelated PBSC
grafts were from local donors. The cords were all from international registries. Five
patients died of complications of graft versus host disease (GvHD) and 1 due to graft
failure. Two patients died due to severe infections within 6 months of transplant. 3
patients died of relapsed leukaemia after transplant. Thirty nine patients are alive in
remission (sixteen oncology patients and 23 non-oncologic patients). Three patients are
living with chronic graft versus host disease (GvHD) necessitating ongoing
immunosuppression.
Conclusion: Fifty children underwent AHCST, 25 for haematological malignancies and
25 for benign haematological conditions. The majority of stem cells were from siblings.
These results are promising for a resource limited setting especially for patients
transplanted for benign diseases.
P-085
ERWINIA ASPARAGINASE USE IN CHILDRENWITH ACUTE
LYMPHOBLASTIC LEUKAEMIA ALLERGIC TO PEGASPARGASE
E. van Rijswijk1, J. Mycroft2
1Royal Marsden Hospital, Paediatric Haematology & Oncology, Sutton, United
Kingdom; 2Royal Marsden Hospital, Pharmacy, Sutton, United Kingdom
Background/Objectives: Asparaginase is an effective drug and essential part of the
combination treatment of children with acute lymphoblastic leukaemia (ALL) and the
5-year survival rate has increased significantly since it was introduced into treatment
protocols. Failure to complete treatment with asparaginase leads to poorer outcomes
and it is therefore important to identify patients with clinical and subclinical allergy.
In the UK, patients receive between 3 and 8 doses of pegaspargase 1000IU/m2/dose
intramuscularly (IM) depending on their risk stratified treatment group. UK Protocols
(UKALL 2003, Interim guidelines and UKALL 2011) all advise to change each dose of
pegaspargase to 6 doses of 20,000IU/m2 IM Erwinia Asparaginase in case of systemic
allergy. Prior to November 2005 Erwinia asparaginase was not available in the UK and
patients allergic to pegaspargase discontinued asparaginase treatment altogether.
Design/Methods:We retrospectively identified and evaluated patients (aged 1-24 years)
with a systemic pegaspargase allergy who were treated for ALL from October 2003 to
March 2015 at The Royal Marsden Hospital. A systemic allergy was defined as Grade 2
or more using the common terminology criteria for adverse events.
Results:During this time 453 patients received treatment for ALL as per UKALL 2003,
2011 Interim Guidelines and UKALL2011 trials. We identified 24 (5.3%) patients with
pegaspargase allergy who needed to switch to Erwinia asparaginase. The severity of the
reactions varied from a generalised rash to full-blown anaphylaxis. There were no
deaths related to the allergic reactions.
Conclusion: The incidence of children who developed pegaspargase allergy was 5.3%.
No children reacted to Erwinia asparaginase after switching.
P-086
A STUDY OF SERUM AND CSF METHOTREXATE LEVELS FOLLOWING
HIGH DOSEMETHOTREXATE INFUSION IN ACUTE LYMPHOBLASTIC
LEUKEMIA AND ITS CORRELATION TO RELAPSE
S. Vasanna1, N. Radhakrishnan2, V. Dinand3, T. khanna3, S. Bhargava2, A. Sachdeva2
1Sir Ganga Ram Hospital, Delhi, India; 2Sir Ganga Ram Hospital, Pediatric Hematology
Oncology Unit-Institute of Child Health, Delhi, India; 3Sir Ganga Ram Hospital,
Pediatric Hematology Oncology Unit-Institute of Child Health, Delhi, India
Background/Objectives: High dose methotrexate is a major component of most
contemporary acute lymphoblastic leukemia (ALL) treatment protocols as a
CNS-directed therapy.
Design/Methods:We describe a retrospective analysis of ALL cases diagnosed between
January 2007 to December 2013. 114 children (378 cycles) who received high dose
methotrexate infusion were analyzed. Children were treated using two ALL protocols
(BFM- 95 protocol(5 gm/m2/cycle x 4) and UK ALL XI (6 gm/m2/cycle x 3)) at our
center during this period. Serum and CSF methotrexate levels were measured at the end
of 24 hours, with additional serum levels at 48 and 72 hours as required.The data was
analyzed for the correlation of serum and CSF methotrexate levelsachieved to
occurrence of medullary and extramedullary relapse.
Results:Median age at diagnosis was 4 years (1 – 18). 12 patients had T cell, rest had B
cell lineage. Median 24-hour and 48-hour levels achieved were comparable between
both protocols. Significant variability was noted in the 24-hour values. 48-hour serum
level and CSF level remained homogenous. There was good correlation observed
between 24-hour serum level and CSF level. >90% patients achieved a protective level
of Mtx in the CSF in all cycles. A total of 7 relapses (2 CNS, 2 medullary, 3 medullary
+ testes) occurred during a median follow up of 3.7 years. There was no statistically
significant difference in the any serum or CSF drug level between patients who relapsed
and those who did not. In patients who relapsed CSF and serum levels were significantly
less than average. None developed any major complications during HDMtx cycles.
Conclusion: HDMtx is definitely feasible in India. Although our follow up is short, it
has definitely helped us in reducing the incidence of CNS relapse. 48 hour Methotrexate
values were homogenous and close to statistical significance in preventing relapse.
P-087
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME TREATMENT
BASED ON SYMPTOMS AND IMAGING FINDINGS IN PEDIATRIC PATIENTS
WITH ACUTE LYMPHOBLASTIC LEUKEMIA
M. Velázquez-Aviña1, J.G. Peñaloza-González1
1Hospital Juárez de México, Pediatric Oncology, Mexico City, Mexico
Background/Objectives: Posterior reversible encephalopathy syndrome (PRES) is an
uncommon side effect of some chemotherapeutic agents, particularly methotrexate. The
clinical presentation depends on the area of brain hypoperfusion. To date there is no
standardized treatment, but a myriad of drugs and procedures have been proposed. The
purpose of this study is to report our experience in the treatment of this síndrome in
patients with acute lymphoblastic leukemia (ALL).
Design/Methods:We performed a retrospective chart review and included patients with
lymphoblastic leukemia with neurologic focal symptoms two weeks after methotrexate
treatment regardless route of administration. The study period was from October 2004
to December 2014.The demographic and clinical characteristics are described as means
or proportions according to variable type.
Results:We reviewed 176 charts of eligible patients, of which eight (4.5%, 4 female, 4
male) had PRES. The average age was 11.2 years. Seven patients had high-risk ALL
(87.5%) and 1 (12.5%) standard risk ALL. The onset of symptoms started at an average
of 7.3 days after intravenous (n=6; 75%), or intrathecal (n=2; 25%) methotrexate. None
of the cases had simultaneous routes of administration.Patients with localized ischemia
(n=3) were treated citicoline (10-20 mg/kg/d) for 5-7 days, with seizures (n=2) were
treated with valproate for 6 months (15 mg/kg/d); and with areas of brain edema were
treated with dexametasone (0.5 mg/kg/d) for 5 days. All patients with brain ischemia
without seizures (n=3) were treated with hyperbaric oxygen therapy. Five patients had
multiple simultaneous therpay according to clinical and imaging characteristics.
Symptoms recovery was present at 10 days postreatment average. None of the patients
had permanent neurological sequelae.
Conclusion: According to our findings, complete recovery of PRES can be achieved if
therapy is started early based on symptoms and MRI findings. If no contraindication is
present, multiple simultaneous therapy can be safely prescribed.
P-088
IS IT REASONABLE TO USE HIGH INTENSITY PROTOCOLS FOR ACUTE
LYMPHOBLASTIC LEUKEMIA IN COUNTRIES WITH LIMITED
RESOURCES? EXPERIENCE WITH ST JUDE HOSPITAL TOTAL XV
PROTOCOL
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E. Villanueva1, G. Sanchez1, J. Acebo1, C. Vicuña1, J. Eguiguren1
1SOLCA Hospital- Hospital Metropolitano, Department of Hematology-Oncology,
Quito, Ecuador
Background/Objectives: Implementing high intensity protocols in pediatric patients with
Acute Lymphoblastic Leukemia (ALL) in countries with limited resources has been
debated. We analyzed the survival of our patients using the Total XV St Jude protocol
in SOLCA Hospital.
Design/Methods:We reviewed medical records and POND online database for a 9 year
period from January 2006 to December 2014.
Results: A total of 191 patients were diagnosed with ALL; from these, 138 were elegible.
We excluded patients previously treated in other hospitals, with prior malignancies and
infants. There were 63 females and 75 males. Common ALL (97) was the predominant
lineage, T-cell (18), early pre B (8), bilineal (T&B) 8, and biclonal 7 (AML/ALL).
Hyperleukocytosis (>100.000/mm3) was identified in eleven patients (7.9%).
Twenty-nine (21%) had translocations: t(1;19), t(12;21) and t(9;22) were the most
common. Fourty-two (30.4%) were considered low risk patients, 81 (58.7%) standard
risk and 15 (10.9%) high risk according to the stratification used in the original
protocol. Twenty patients (14.5%) relapsed. Bone marrow and isolated Central Nervous
System (CNS) were the most common sites, from these, 10 are alive in treatment or post
stem cell transplant. Twelve patients (8.6%) abandoned treatment. Thirty-three (24%)
patients died. Overall survival is 76% and if we exclude abandonment, 83%. Ten
patients (7%) died during induction. One with CNS hemorrhage and nine with bacterial
(6) or fungal (3) infections.
Conclusion: High intensity protocols can be used in middle income countries if the
hospital provides a multidisciplinary team, Intensive Care Unit, broad spectrum
antibiotics, antifungals, blood products, and if protocols are implemented for
management of febrile neutropenia. We have to find strategies to decrease the
abandonment of treatment and improve the education of parents for early arrival to the
hospital in emergencies.
P-089
PHONE-BASED PALLIATIVE CARE FOR CHINESE PEDIATRIC PATIENTS
WITH CANCER
C. Wang1, X. Zhou2
1Beijing Children’s Hospital-Capital Medical University, Beijing-PR. China, Beijing,
China; 2Beijing Children’s Hospital, Hematology/Oncology Center, Beijing, China
Background/Objectives:More than 60000 pediatric patients in China were diagnosed
cancer each year. However, only few cancer patients can receive palliative care even
though almost 25% of them are incurable. With the development of China, more and
more patients and families have the demand of palliative care especially at the end of
life.
Design/Methods: From Nov. 2013 to Dec. 2014, patients with incurable cancer were
received palliative care by a multidiscipline team in hematology/oncology center of
Beijing Children’s Hospital. The support was operated by experienced nurses and
oncologists. Phone support is the main method to communicate with families.One
phone call by nurses every two weeks if patient was stable. Updating of the patients’
condition, quality of life evaluating, pain management and psychological counseling
were the majority of calls. For sure parents could call back to team at anytime they
need. A routine round by team members were held every month in order to discuss
patients’ situation and make plans for the next step.
Results: 38 patients with incurable cancer were enrolled.Patients’ average age was
5.96±5.16 years, 75% patients were leukemia, 22.5% were solid tumor.52.6% (20/38)
patients experienced pain which could be controlled by team. 30 patients died peacefully
by now, the median survival time was 30 days, the average score of quality of life was
increased 21.08% during hospice care. 93.3% (28/30) families could accept children’s
death without long term depression, .all families satisfied with palliative support.
Conclusion: Because of the different culture background, parents would like to bring
incurable children back to hometown, phone-based palliative care can be the important
and effective method in China.
P-090
DETERMINE THE GENOMIC BREAKPOINT OF TEL-AML1 BY NEXT
GENERATION SEQUENCING
X. Wang1, Y. Jin2, L. Cao2, L. Ding1, H. Liang1, Y. Miao1, J. Tang1, B. Li1, Y. Chai2
1Shanghai Children’s Medical Center, Department of Hematology & Oncology, Shanghai,
China; 2Soochow University Affiliated to Children’s Hospital, Department of
Hematology & Oncology, Suzhou, China
Background/Objectives: The most common chromosomal translocation observed in
childhood acute lymphoblastic leukemia (ALL) is t(12;21)(p13;q22), which leads to an
ETV6-RUNX1 gene fusion and associated with favorable prognosis following
conventional therapeutic strategies. To TEL-AML1 positive leukemia, the genomic
breakpoint and flanking sequence from the translocation of chromosome 12 and 21 is
one of the best markers of minimal residual disease (MRD) monitoring by quantitative
real-time polymerase chain reaction (QRT-PCR).
Design/Methods: In this study we established the next-generation sequencing (NGS)
based TEL-AML1 translocation capturing and sequencing method. Moreover, we
compared patient-specific breakpoint and flanking sequence on paired diagnostic and
relapsed samples.
Results:We found patient-specific breakpoints in 24 cases of childhood ALL samples.
Besides, we found the three-way translocation including TEL-AML1 in 5 patients, and
4 of them relapsed on the late or after the cessation of treatment. In contrast, 19
patients without three-way translocation were still in remission (P<0.0001). The
three-way translocation may reflect the degree of genetic instability or gene damage.
Moreover, by comparing patient-specific breakpoint and flanking sequence on paired
diagnostic and relapsed samples, we also found that relapsed clone mainly derived from
primary leukemia clone at diagnosis.
Conclusion: The three-way translocation maybe an important risk factor of
TEL-AML1 positive leukemia relapse, and this method could be further developed and
become a new MRD monitoring method.
P-091
COMPLETE BLOOD COUNTS AND PERIPHERAL SMEAR REVIEWS IN
YOUNG CHILDRENWITH ANDWITHOUT ACUTE LEUKEMIA
I. Yaniv1, P. Froom2, S. Elitzur1, M. Zoldan1, E. Isakov2, M. Barak2
1Schneider Children’s Medical Center of Israel, Pediatric Hematology Oncology,
Petach-Tikva, Israel; 2Haifa and the Western Galilee-Clalit Health Service, Central
Laboratory, Nesher, Israel
Background/Objectives: The proportion of young children with leukemia but without
blasts found on peripheral smear review is unclear as are results on the automated
complete blood count (CBC) that best differentiate between those with and without
acute leukemia.
Design/Methods:We recorded the clinical presentations, and results of CBC, and
peripheral smear reviews in 87 consecutive children aged <5 years with acute leukemia.
We then compared the CBC results to those from 739 consecutive outpatients of the
same age.
Results: In patients with acute leukemia 77% (95% CI – 67.1%-84.6%) had blasts found
on the peripheral smear review, and those without blasts had a bone marrow
examination because of combinations of presenting symptoms and findings on the
automated CBC. Retrospectively, we found that a combination of four criteria had the
best sensitivity and specificity in differentiating patients with and without acute
leukemia; 94.3% (95% CI- 87.2-97.5%) of the young children with leukemia but in only
2.3% (1.4-3.7%) of those without leukemia had at least one of four criteria (a white
blood cell count >30 × 109 cells/L, an absolute neutrophil count < 1 × 109 cells/L as
well as a platelet count less than 120 × 1012 /L, or a hemoglobin value < 80 gm/L). All
the children not identified by at least one of the four criteria had clear clinical
indications for a bone marrow examination.
Conclusion: A significant number of young children with leukemia will not have blasts
found on the peripheral blood smear review, and physicians should rely on the
automated CBC test results and the presenting symptoms to determine the need for a
bone marrow examination. Prospective studies with larger numbers of young children
are warranted to confirm these preliminary findings that suggest automated CBC
criteria that are most helpful in determining the need for a bone marrow examination.
P-092
AUTOPHAGY-DEPENDENT RESTRICTION OF GLUCOSEMETABOLISM IN
PRIMARY ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
X. Zhao1
1Beijing Children’s Hospital, Beijing, China
Background/Objectives: Clinical evidence indicated that favorable Glucocorticoids
(GCs) sensitivity of childhood acute lymphoblastic leukemia (ALL) tended to associate
with high periodic acid-Schiff (PAS) scores for glycogen staining, inhibition of
glycolysis, and activation of autophagy.
Design/Methods: To investigate whether GC-induced cytotoxicity was influenced by
autophagy and manifested by the interruption of glycogen metabolism and glycolysis,
primary cells were isolated from patients and tested for glucose utilization under
cultured conditions, without or with rapamycin pretreatments. The levels of IL-1β
secretion in vitro, as well as in the plasma of original patients, were examined by
ELISA. The cellular existence and distribution of glycogens was evaluated by PAS
scores, and cross-examined with transmission electron microscopy (TEM).
Results: Rapamycin treatments were able to activate autophagy and restrict the glucose
utilization in cultures from patients with different PAS scores. However, there seemed to
lack the direct correlation between levels of autophagy activation and the morphological
changes of glycogens. Interestingly, the IL-1β levels in poor GC-responsive group with
low autophagy activities were higher than others with statistical significance.
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Conclusion: As autophagy was increasingly recognized as a key process to regulate
glucose metabolism, the approach of using primary cultures for probing the autophagy
activation capacity could be an attractive and practical method for clinical outcome
evaluations. Despite no direct association between the glycogen and autophagy
activation of ALL cells was established from this study, the discovery of IL-1β for the
indication of glucose metabolism changes implied potential diagnostic values. The
dependence of IL-1β secretion to the activation of autophagy has enabled IL-1β as a
candidate marker of autophagy in other tissue types, its application potential in
leukemia remained to be further investigated.
Posters: Bone Tumours
P-093
EWING SARCOMA AND PRIMITIVE NEUROECTODERMAL TUMORS OF
THE CHEST WALL IN CHILDREN: HACETTEPE EXPERIENCE
C. Akyuz1, B. Yalcin1, S. Ekinci2, Z. Akcoren3, B. Oguz4, F. Yildiz5, H.A. Demir1,
S. Ocak1, B. Aydin1, A. Varan1, T. Kutluk1, M. Buyukpamukcu1
1Hacettepe University Faculty of Medicine, Pediatric Oncology, ANKARA, Turkey;
2Hacettepe University Faculty of Medicine, Pediatric Surgery, Ankara, Turkey;
3Hacettepe University Faculty of Medicine, Pediatric Pathology, Ankara, Turkey;
4Hacettepe University Faculty of Medicine, Radiology, Ankara, Turkey; 5Hacettepe
University Faculty of Medicine, Radiation Oncology, Ankara, Turkey
Background/Objectives: Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET)
is the most common malignant tumor of chest wall in children. We aimed to review our
institutional experience to document clinical and pathological characteristics and
treatment results of our cases.
Design/Methods: Hospital files of 36 children with chest wall ES/PNET diagnosed
between 1972-2014 were reviewed. Demographic characteristics, presenting symptoms,
physical examination findings, laboratory and radiological data, extent of disease,
treatments and outcome were analyzed.
Results:Median age was 9.8 years (2-17; male/female: 20/16). Most common presenting
complaints were chest wall masses and pain, respiratory problems followed; fever and
weight loss were less common. Primary tumor sites were ribs in 33/36, soft tissues in
3/36 cases. Histopathology was PNETs in 16/36 (45%), ES in 20/36 (55%). Eleven cases
(30.5%) had distant metastases (lungs 9, bones 3). Primary tumor resection was
performed in 12 cases (33%) at our hospital or outside; in 13 cases (36%) tumors were
resected following chemotherapy; in 11 cases (31%) surgery was not attempted. All
cases received multiagent combined chemotherapy regimens depending on year of
diagnosis. Twenty-five cases (70%) received external irradiation to primary tumor sites.
In the follow-up, 25 cases (70%) experienced tumor recurrence or progression mostly in
primary sites, recurrences in lungs or bones were less frequent. A boy who had a
recurrence 44 months after initial diagnosis received further treatment and was in
remission for 7 years. At a median follow-up of 76 months, 23 cases died, 5 were lost to
follow-up and 8 cases were under follow-up (6 disease-free). Five-year event-free and
overall survival rates were 22.7% and 30.2%, respectively.
Conclusion:Most patients had advanced disease and complete resection wasn’t possible
in the majority. Local and/or distant failures were frequent. Preoperative chemotherapy
may facilitate total resection. More intensive standard chemotherapies and effective
local therapies, especially surgery, should be encouraged to improve prognosis.
P-094
IMPACT OF GENTAMICIN USE ON CISPLATIN-INDUCED HEARING LOSS
IN PATIENTS WITH OSTEOSARCOMA
A. am Zehnhoff-Dinnesen1, K. Richter1, R. Parfitt1, D. Deuster1, C. Rössig2,
C. Lanvers-Kaminsky2
1University Hospital Münster, Clinic for Phoniatrics and Pedaudiology, Münster,
Germany; 2University Hospital Münster, Department of Pediatric Hematology and
Oncology, Münster, Germany
Background/Objectives: Patients treated with the ototoxic anticancer drug cisplatin
often receive aminoglycosides to treat febrile neutropenia or gram-negative infections.
The additional impact of the use of aminoglycoside on the hearing loss risk of patients
who already receive cisplatin for cancer treatment is not fully resolved yet.
Design/Methods:We investigated the use of gentamicin in 20 patients with
osteosarcoma (aged 9-24 years, median: 15.4 years). Patients received 120 mg/m2
cisplatin per cycle as a continuous infusion over 72h according to the COSS96 (6
patients) or EURAMOS-1 (14 patients) protocol. Ototoxicity was graded according to
the Muenster Classification for Early Detection of Cisplatin-Induced Hearing Loss
(MS).
Results: Patients were classified in hearing loss MS grade 2b (9 patients, group A) and
<MS grade 2b (11 patients, group B). Among group A, 5 of 9 patients were treated
according to COSS-96, while only 1/11 patients of group B received COSS-96 (p=0.05;
Fisher’s exact test). The cumulative cisplatin doses ranged between 240-480 mg/m2.
Patients of group A tolerated significantly less cisplatin until onset of hearing loss
compared to patients of group B (group A: median: 240 mg/m2; range: 120-360 mg/m2
vs. group B: median: 480 mg/m2; range: 360-480 mg/m2, p<0.001 Mann-Whitney Rank
Sum Test). Seventeen of 20 patients received gentamicin for supportive care (8/9 in
group A und 9/11 in group B). Two of 9 patients in group A already developed
ototoxicity before any gentamicin was administered. Altogether no significant
differences were observed between group A and B with respect to tolerated gentamicin
administrations and cumulative gentamicin doses. However, the interval between
ototoxic medications (cisplatin/gentamicin) was significantly shorter in patients of
group A (group A: median: 26.5 days; group B: median 40.3 days) (p=0.002,
Mann-Whitney Rank Sum Test).
Conclusion: Regarding the long half-life of aminoglycosides their ototoxic impact has
to be considered in the course of platinum treatment of patients with osteosarcoma.
P-095
CLINICOPATHOLOGIC CHARACTERISTICS AND OUTCOME OF
CHILDHOOD EWING’S SARCOMA IN CENTER OF TUNISIA
N. Ammar1, I. Chabchoub1, H. Bhiri1, F. Ezzairi1, M.O. Bellamlih1, I. Belaid1,
M. Hochlef1, O. Gharbi1, L. Ben Fatma1, H. Zaghouani2, M. Benmaitig3, S. Ben
Ahmed1
1Farhat Hached University Hospital, Medical Oncology Department, Sousse, Tunisia;
2Farhat Hached University Hospital, Radiology Department, Sousse, Tunisia; 3Sahloul
University Hospital, Surgical Orthopedy, Sousse, Tunisia
Background/Objectives: Ewing sarcoma (ES) is the second most common tumor of
bone in childhood. Survival of patients with ES has increased since 1970.
At present 5 year overall survival rate of localized disease is approximately 75%. The
aim of this study is to evaluate clinicopathologic characteristics and outcome of ES in
children in center of Tunisia.
Design/Methods: Thirteen patients under 18 years with documented pathology of ES
referred to Farhat Hached center through 2002 to 2013 were enrolled in this
retrospective study. Overall survival and disease free survival and prognostic factors
were evaluated.
Results: The median age at the time of diagnosis was 12 years (range, 3–17 years).The
sex ratio was 2. 25. Primary tumor sites were flat bone and log bone respectively in 54%
and 31%. The median size of primary tumor was 16 cm (range, 5cm-49cm). Seven
patients (54%) presented with localized disease and 6 patients (46%) had metastatic
disease at presentation, including 2 patients (33.3%) with multiple metastatic sites. All
children achieved partial responses with induction chemotherapy. Complete surgical
resection was done in 84.6 %. Histological good response was obtained in 27.2 %. Four
patients (50%) received radiation therapy after surgery. Eight relapses (61.6%) have
occurred (five metastatic and three local).The overall 5-year year survival was 60%.
Conclusion:Marked improvements in survival have been reported during the past 40
years for patients with localized disease with chemotherapy combined with local
treatment. However, lesser improvements have been seen for patients with metastatic or
recurrent disease. A better understanding of the complex biology of Ewing’s sarcoma
may lead to the successful development of biologically targeted therapies.
P-096
FACTORS RELATED TO YEARS POTENTIAL LIFE LOST IN CHILDREN
WITH OSTEOSARCOMA OF THE VALLEY OF TOLUCA, MEXICO
A. Lopez Facundo1, I. Tejocote2, Y. Jaimes Garcia1, M. Laffont Ortiz2
1Hospital Materno Infantil ISSEMYM, Pediatric Oncology, Toluca, Mexico; 2Hospital
Para el Niño del Instituto Maternoinfantil del Estado de México, Pediatric Oncology,
Toluca Estado de México, Mexico
Background/Objectives: In Mexico, infant mortality due to cancer is a public health
problem. Osteosarcoma is a tumor with high probability of premature death, so it is
important to study its causes. Potential years of life lost (YPLL) index compares the
relative importance of the causes of more relevant deathObjective: To assess factors
related to potential years of life lost in children with osteosarcoma treated in the Valley
of Toluca, Mexico.
Design/Methods:Material and methodsIn a retrospective study, we included patients
with diagnosis of osteosarcoma in the Toluca Valley, We estimated the YPLL and
clinical and paraclinical factors related were studied in bivariate analysis.
Results: Of were evaluated 30 of 36 patients with diagnosis of osteosarcoma which 20
died. The YPLL estimated was 1502 years (0-78) average of 50 ± 36, median of 73. The
age, the gender, histological type, type of chemotherapy were not correlated with
greater or lesser number of YPLL, the presence of bulky disease as well as lung
metastases at diagnosis and localization at sites other than the femur increased the
years lost. Treatment with amputation it seems to reduce years of life lost.
Conclusion: The rate of YPLL estimated in patients with osteosarcoma in our
environment is extremely high, despite high costs exerted by social protection in health
schemes, should be considered for planning new programs of care, define priorities for
action and research that include actions aimed at early diagnosis and to establish
strategies to improve treatment such as the use of biological therapies whose cost limits
Pediatr Blood Cancer DOI 10.1002/pbc
S264 SIOP ABSTRACTS
their use in our country. YPLL related factors are mainly secondary to late diagnosis
and reference.
P-097
METASTATIC EWING SARCOMA TREATEDWITHMIFAMURTIDE. A CASE
REPORT FROMMEXICO CITY
F. Arreguin1, A.C. Garcia-Espinoza2, F. Miranda-Castañon2, O. Campell2
1Centro Medico Nacional "20 de Noviembre" ISSSTE, Pediatric Oncology, Mexico City,
Mexico; 2Chihuahua´s State Cancer Center, Pediatric Oncology, Chihuahua, Mexico
Background/Objectives: Ewing sarcoma (ES) belongs to the family of malignant, small,
round cell neoplasms of soft tissue or bone origin. The treatment is characterized by
multi-disciplinary collaboration. Outcomes for patients with metastatic ES remains
poor. Mifamurtide is an orphan drug approved for the treatment non-metastatic
osteosarcoma. We present the case of a child with Ewing sarcoma and pulmonar
metastasis that was treated with multiagent chemotherapy and mifamurtide, with good
response.
Design/Methods:We report the case of a 6 year old male, with a femur bone lesion and
pulmonary metastases. Pathological anaylisis was consistent with Ewing sarcoma. The
patient received neoadyuvant chemotherapy with posterior limb-salvage, and we added
mifamurtide to the adyuvant chemotherapy. The pulmonary metastasis were considered
unresectable .After 24 months of treatment, we resected the pulmonary metastasis with
pathological report of necrosis.
Results: Last image study PET-CT was reported without tumoral activity.Mifamurtide
is currently an investigational agent that holds orphan drug status for the treatment of
osteosarcoma,it is an immunomodulator with antitumor effects that appears to be
mediated via activation of monocytes and macrophages, so its main use remains in
pulmonary metastasis. Even though it is only used in osteosarcoma we presume that it
can also be used in metastatic solid tumors.
Conclusion:Mifamurtide had a manageable safety profile. So we consider that this drug
can be used in other solid tumors with pulmonary metastatic disease. More experience
is needed to prove efficacy.
P-098
18F-FDG-PET / CT AND DIFFUSIONMRI IN BONE SARCOMA: HISTOLOGIC
AND IMAGING CORRELATION
B. Aydin1, M. Caglar2, B. Ergen3, I. Bajin1, N. Kurucu1, B. Yalcin1, A. Varan1,
T. Kutluk1, M. Buyukpamukcu3, C. Akyuz1
1Hacettepe University Faculty of Medicine, Pediatric Oncology, Ankara, Turkey;
2Hacettepe University Faculty of Medicine, Nuclear Medicine, Ankara, Turkey;
3Hacettepe University Faculty of Medicine, Radiology, Ankara, Turkey
Background/Objectives: 18F-FDG-PET/CT and diffusion-weighted MRI were used for
predicting response to treatment in patients with bone sarcomas in this study.
Correlation between PET and MRI parameters with histopathological response and
clinical outcome was assessed.
Design/Methods: Sixteen patients (5 osteosarcoma, 11 Ewing’s sarcoma) aged between
5-16 years were included in study. All patients underwent 18F-FDG-PET/CT and
diffusion MRI before (PET1 and MR1) and after preoperative chemotherapy (PET2
and MR2) to assess the radiological tumor response. The number and localization of
18F-FDG involvements, "maximum standardized uptake" value (SUVmax), metabolic
tumor volume (MTV) and total lesion glycolysis (TLG) in 18F-FDG-PET/CT, and
tumor volume and diffusion coefficients (ADC) from three separate areas within tumor
on MRI were measured. Changes in parameters before and after treatment were
compared with histopathological tumor response.
Results: PET/CT at diagnosis revealed 18F-FDG uptake in 1-32 different anatomical
regions. Median SUVmax1 and TLG1 values were 6.0 (ranged between 2.6-9.4) and
127.0 (ranged between 8.2-573.3), respectively. Eight patients with good histologic
response had lower median post-chemotherapy FDG-PET/CT parameters compared to
those with poor response (1.7 vs 3.0 for SUVmax2 and 5.0 vs 62.5 for TLG2,
respectively). The correlation coefficients between tumor necrosis and SUVmax2 and
TLG2 were -0,647 and -0,656 respectively, p<0,05).Based on ROC curve analysis,
SUVmax2 and TLG2 predicted a good pathological response. The optimal cut-off
values for SUVmax2 and TLG2 were 2,25 and 43,85 which yielded a
sensitivity/specificity of 0,83/0,75 and 0,67/100 respectively.Median diffusion MRI
ADC changes were found 27.6 and 46.9 in poor and good responders, respectively
(p>0.05, 8 patients).
Conclusion: PET/CT can be used for identification of metastasis in patients with bone
tumors on diagnosis and can predict the histopathological response after neoadjuvant
therapy. Although statistically non-significant, due to small number of patients,
diffusion MRI may predict tumor response.
P-099
DEMOGRAPHIC PROFILE AND PREDICTORS FOR CHEMO TOXICITY IN
OSTEOSARCOMA: A TERTIARY CARE CENTER EXPERIENCE FROM INDIA?
J. Bajpai1, A. Chandrasekharan2, A. Pande2, S. Gupta3, B. Rekhi4, T. Vora5, J. Ghosh3,
N. Jambhekar4, S. Banavali3
1Tata Memorial Hospital, Mumbai, India; 2Tata Memorial Hospital, Medical Oncology,
Mumbai, India; 3Tata Memorial Hospital, Department of Medical Oncology, Mumbai,
India; 4Tata Memorial Hospital, Department of Pathology, Mumbai, India; 5Tata
Memorial Hospital, Pediatric Medical Oncology, Mumbai, India
Background/Objectives: Osteosarcoma is the most common primary malignant bone
tumor in children. There is sparse data from India regarding the disese characterstics
and is worth exploring.
Design/Methods: This prospective study evaluated demographic profile and risk factors
for chemotoxicity in patients enrolled on OGS-12 regimen comprising DD-CT with
Doxorubicin, Ifosfamide, & Cisplatin. Baseline tumor burden and nutritional
parameters were studied and correlated with chemotoxicities. CT response was
evaluated with histological-necrosis (HN) grading. Good responders (GR) were defined
as those with  90% HN.
Results: There were 325 patients enrolled between December 2011 and December 2014,
out of which 86(26%) were metastatic and 239(74 %) nonmetastatic.Median age was
17(6-56) years.There were 164(69%) male and 75(31%) female patients. In the
nonmetastatic cohort,baseline median values of Albumin-4.4gm/dl, Iron-57mcg/dl,
TIBC-329mcg/dl, Transferrin saturation 17%, Vitamin B12 172pg/ml, BMI 17, LDH
233U/L, SAP 332U/L.At presentation, 74% were malnourished (higher or lower BMI),
38% anemic, 57% iron deficient, and 57% were B12 deficient. Mean lesion size was
11cm, all had high LDH and 37% had high SAP.Most common histologic varient was
conventional(82%), followed by chondroblastic(11% ).Most common site of disese was
lower end femur (42%) followed by upper end Tibia(28%).There were 60% good
responders to chemotherapy.Incidence of grade III/IV chemotoxicity was
febrile-neutropenia (FN) (30%), thrombocytopenia (18%), GI-toxicity (6%), and
cardiac (4.7%), however there was no toxic death.Chemo toxicity was found to be
correlated with the variables like serum levels of SAP, LDH and Albumin which were
identified as predictors for GI toxicity. For thrombocytopenia, SAP was found as
predictor.
Conclusion: The study underlines the challenging to treat population in developing
world with features of higher tumor burden at presentation with coexisting
malnurishment. Chemotoxicity could be predicted by LDH, SAP and Albumin at
baseline, and these novel markers merits further exploration.
P-100
LIMB SALVAGE FOR OSTEOSARCOMA: FUNCTIONAL EVALUATION IN
PEDIATRIC PATIENTS
J. Cabezas1, U. Marcelo2, P. Gabriela2, M. Cores2, L. Francisco3, A. Fernandez4,
M. Garcia Lombardi5
1R. Gutierrez Children Hospital, Resident, CABA, Argentina; 2R. Gutierrez Children
Hospital, Oncology, CABA, Argentina; 3R. Gutierrez Children Hospital, Traumatology,
CABA, Argentina; 4Hospital de Niños Ricardo Gutierrez, Traumatology, Buenos Aires,
Argentina; 5Hospital de Niños Ricardo Gutierrez, Oncology, Buenos Aires, Argentina
Background/Objectives: To evaluate the quallity of life in patient with limb preservation
surgery, to compare the local relapse betwen these group and the mutilation one and its
influence on the survival, in patients with osteosarcoma treated at “Hospital de niños
Ricardo Gutiérrez“.
Design/Methods:We retrospectively evaluated the medical records of patient with
osteosarcoma admitted between January 1990 and December 2013. Patient were
evaluated with an adapted version of the functional system accepted by the
Musculoskeletal Tumor Society (MSTS).
Results: Total 2349 patients were admitted with a diagnosis of solid tumors, 127
patients with osteosarcomas The average age was 176 months (range 23 a 236 months),
H / M 1.3/1.The most frequent location was: femur (67) (52.7%), tibia (25) (19.6%),
humerus (12) (9.44%), fibula (5) (3.93%), other locations (18) (14.1% ). Localized stages
(98) (77.1%) non metastatic (29) (22.8) Surgical intervention received were:
disarticulation (12) (9.44%), amputation (32) (25.1), salvage surgery (63) (49.6%)
refused to receive treatment or were lost to follow-up (20) (15.7 %).). neo adjuvant
chemotherapy (122) (96.1%), adjuvant (5) (3.9%). Local relapse was: patients with
conservative surgery (5) (8%), disarticulated patients (2) (10%), in amputed patients (3)
(10%). Five of the patients initially treated with conservative surgery that relapsed
locally, were amputed. And three of the them are alive Funtional results in patients with
conservative surgery were good: 84%.
Conclusion: The functional results with conservative surgery are good.The local
recurrence rate is comparable to non-conservative surgeries with the possibility of
rescue patients with a second surgery.Our results are accord with publish dates.
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IMPACT OF RECOMMENDATIONS FROM THE INTERDISCIPLINARY
TUMOR BOARD OF THE CESS GROUP ON THE OUTCOME IN PATIENTS
TREATEDWITHIN THE EUROEWING99 TRIAL
U. Dirksen1, J. Kreyer1, M. Paulussen2, H. Jurgens1, V. Vieth3, S. Scobioala4,
J. Hardes5, A. Streitbürger5, C. Wiebe6, A. Ranft1
1University Hospital Münster, Pediatric Hematology and Oncology, Muenster, Germany;
2Witten/Herdecke University, Vestic Children’s Hospital Datteln, Datteln, Germany;
3University Hospital Münster, Radiology, Muenster, Germany; 4University Hospital
Münster, Radiotherapy and Radiooncology, Muenster, Germany; 5University Hospital
Münster, Orthopedics and Tumororthopedics, Muenster, Germany; 6University Hospital
Münster, Thoracic Surgery, Muenster, Germany
Background/Objectives: The prognosis in patients with Ewing sarcoma localized disease
has improved up to 70%. While the value of systemic treatment is systematically
analyzed in clincial trials, a systematic investigation on the value of different local
treatment approaches is lacking. Local treatment in Ewing Sarcoma is a crucial step in
the treatment and must be planned carefully and individually. The trial office of the
cooperative Ewing sarcoma study group offers the support of an interdisciplinary
tumor board (ITB).
Design/Methods: Between 2006 and 2009, 1,234 patients were discussed in the ITB in
Münster. Of these, 696 were not registered into the EuroEWING99-trial (EE99). 538
(43.6%) of these patients participated in the EuroEWING99 study and were included in
our analysis. Fiftyseven patients were excluded because of missing information or
missing follow up (N=481).
Results:Median age at diagnosis was 15 years. The ITB discussedmore patients with
metastases at the time of diagnosis than with localized disease (39.5% vs 34.1%;
p=0.149). A combined local therapy was done in 45.6% of the patients who were
discussed in the ITB vs 33.7% in patients who were not discussed in the ITB (non-ITB)
(p=0.010). The ITB had no significant impact on the survival of the patients: non-ITB
(N= 307) 3y-EFS: 0.57 (SE=0.03); ITB (N=174) 3y-EFS: 0.58 (SE=.04); p=0.948.
Neither in patients with primary localized disease non-ITB (N= 217) 3y-EFS: 0.70
(SE=0.03) ITB (N=114) 3y-EFS: 0.73 (SE=0.04) ; p=0.966) nor in patients with
metastases at the time of diagnosis the ITB had an impact on the survival non-ITB
(N= 90) 3y-EFS: 0.25 (SE=0.05); ITB (N=60) 3y-EFS: 0.31 (SE=0.06) ; p=0.353.
Conclusion: The recommendations given by the ITB had no impact on the event free
survival. A detailed subgroup analysis has been undertaken, in order to analyze
additional clinical prognostic factors such as site, size, number of metastases and
histological response.
P-102
POOR PROGNOSTIC FEATURES ANDMETASTATIC DISEASE AT
PRESENTATION CONTRIBUTION TO LOW SURVIVAL RATE OF CHILDREN
WITH OSTEOGENIC SARCOMA IN JOHANNESBURG
T. Ngcana1, J. Geel2, J. Poole2
1Faculty of Health Sciences- University of the Witwatersrand, Department of Paediatrics
and Child Health, Johannesburg, South Africa; 2Faculty of Health Sciences-University of
the Witwatersrand, Division of Paediatric Haematology and Oncology-Department of
Paediatrics and Child Health, Johannesburg, South Africa
Background/Objectives: Survival rates of South African children with osteogenic
sarcoma (OS) are known to be poor. An audit was performed at Charlotte Maxeke
Johannesburg Academic Hospital (CMJAH) to assess the prognostic features and
survival rates in patients treated at one centre.
Design/Methods: A retrospective folder review was conducted of all children with
documented OS at CMJAH over a 20 year period. Kaplan-Meier survival analysis,
Pearson’s chi square and Cox regression tests were performed.
Results: Sixty four patients with histologically proven OS were identified, representing
3.3% of the total paediatric malignancies. Ten files were excluded as records were
incomplete. The ratio of male to female was 1:1. The majority of patients (40/55) were
black. The mean duration of symptoms was 90 days (range 21 to 180 days). Most
patients presented with poor prognostic features: 47(85%) has masses larger than 8cm
diameter; 55(100%) presented with high alkaline phosphatase and 46(83.6%) had
elevated lactate dehydrogenase (LDH). Histology included osteoblastic (37/55) and
chondroblastic OS (24/55). Thirty five of the patients were underweight for age at
presentation (63.6%). Forty one patients were treated with ifosfamide, doxorubicin,
methotrexate and cisplatinum, while 14 (25%) did not receive chemotherapy (6/14
declined chemotherapy while 8/14 were treated palliatively). Four patients refused
surgery. The intent-to-treat 5 year survival rate was 42%. Causes of death included
disease (22/41) and treatment complications (5/41). The following factors were found to
impact significantly on survival: nutrition (p=0.05), LDH (p= 0.05), stage (0.048) and
response to chemotherapy (p=0.05).
Conclusion: The poor survival rate in this population may be improved by increased
attention to modifiable factors such as nutrition and diagnostic lag time. Delayed
presentation is common in the South African setting; lag time is longer than in high
income countries and this study will be used to increase awareness of OS to be part of a
broader education programme.
P-103
SKIP METASTASIS IN OSTEOSARCOMA: EXPERIENCE FROM A SINGLE
INSTITUTION
H. Halalsheh1, A. Shehada2, T. Ismael3, R. Deebajah3, M. Alarini4, N. Alshawabkeh5,
I. Sultan3
1King Hussein Cancer Center, Amman, Jordan; 2King Hussein Cancer Center, Surgery,
Amman, Jordan; 3King Hussein Cancer Center, Pediatric, Amman, Jordan; 4King
Hussein Cancer Center, Radiology, Amman, Jordan; 5King Hussein Cancer Center,
Nursing, Amman, Jordan
Background/Objectives: Skip metastasis (SM) is defined as synchronous regional bone
metastasis. Using new imaging modalities, detection of SM is easier and possibly more
common. We reviewed patients with SM and compared their characteristics and
outcome to other patients with osteosarcoma (OS) treated at our center.
Design/Methods:We reviewed retrospectively children (<18years) with newly diagnosed
high grade OS who presented from July2006 until December2014. Patients’
characteristics, treatment modalities, and outcome were analyzed. All cases were
discussed in multidisciplinary clinic that included two experienced radiologists.
Results:We identified 60 patients diagnosed with OS; among them 10 patients (16%)
had SM detected by MRI. Patients with SM had a median age at diagnosis of 9.8 years
(range, 7.4-17). Three patients had metastasis at diagnosis (2 had lung only and 1 had
lung and bone). Bone scan was positive for the skip lesion in three patients only. Nine
patients underwent primary tumor resection after neo-adjuvant chemotherapy
(amputation in three, limb salvage surgery in six). One patient did not have local control
due to disease progression. Resection margin was negative in all but one, and four had
post chemotherapy necrosis 90%. Two patients relapsed (one local and one in the
lung) and died of disease.Compared to the rest of the patients, those with SM were
younger at diagnosis (median age 9.8 vs.14.2 years, P=0.0052) but otherwise had
similar clinical features. Outcome was similar in the two groups with no significant
differences in EFS and OS (P=0.84 and 0.86, respectively).
Conclusion: In this study, we identified higher than expected number of patients with
SM, possibly due to improved sensitivity of imaging studies. Bone scan detected only 3
skip lesions (out of 10) and only 1 patient had combined distant bone metastasis.
Patients with SM were younger; otherwise had similar clinical features and outcome to
the rest of our patients.
P-104
OSTEOSARCOMA IN CHILDREN RETROSPECTIVE STUDY IN THE CENTER
OF TUNISIA
B. Hanen1, C. Imen2, A. Nouha2, E. Faten3, B.M. Oumlreit2, B. Imtinen2, H. Makram2,
G. Olfa2, B.F. Leila2, B.Z. Hounaida4, M. Mahmoud5, B.A. Slim6
1Farhat Hached University Hospital, Medical Oncology Department Farhat Hached
University Hospital, Sousse, Tunisia; 2Farhat Hached University Hospital, Medical
Oncology Department, Sousse, Tunisia; 3Medical Oncology Department Farhat Hached
University Hospital, Medical Oncology Department, Sousse, Tunisia; 4Farhat Hached
University Hospital, Radiology Department, Sousse, Tunisia; 5Sahloul University
Hospital, Surgical Orthopedy Department, Sousse, Tunisia; 6Farhat Hached University
Hospital, Medical Oncology Departments, Sousse, Tunisia
Background/Objectives: Osteosarcoma (OS) is the most common malignant bone tumor
in children. Survival for these patients was poor with surgery and/or radiotherapy. The
introduction of multi-agent chemotherapy improved the outcome of these patients with
a PFS of 60%-70%. This study was conducted to investigate presentation, treatment,
and outcome in young children with OS.
Design/Methods:We retrospectively analyzed the data of 26 consecutive children with
high-grade bone OS, with histological confirmation treated with RosenT10, OS94 or
OS2005 protocol, through a period of 10 years (2002-2013). Epidemiologic and
therapeutic result was analyzed with SPSS software and Kaplan Meier method.
Results: The median age at diagnosis was 13 years (range, 6-17 years). The Sex ratio was
2.25. The majority of the tumor was located in the long bones of lower limb (60%).
Most of them had conventional OS histology (77%). The median size of primary
tumors was 24 cm (range, 3cm-56cm). Tow patients had metastasis at diagnosis. All
patients received primary chemotherapy. Of the 26 patients, 7 patients underwent limb
salvage surgery (35%), 13 underwent amputation (65%). Only 20% analyzed tumors
responded well (>95% necrosis) to neo adjuvant chemotherapy. On follow-up, 7
patients were still alive at last clinical contact. Four patients never achieved a complete
remission and 8 developed recurrences (local, N=01; metastatic, N=07) and 07 died.
The overall 04-year survival was 40%. Metastasis at diagnosis was associated with
poorer outcome. Better survival was correlated with good response to chemotherapy.
Conclusion: A lot of progress has been made in the treatment of the OS over the last 30
years, due to introduction of chemotherapy and multi-disciplinary collaboration.
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Relapsing and refractory tumor, need new effective drugs, new therapeutic targets and
new strategies.
P-105
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR
REFRACTORY EXTRACRANIAL PRIMITIVE NEUROECTODERMAL TUMOR
OF CHILDREN AND ADOLESCENTS: A MULTICENTER SURVEY STUDY
V. Hazar1, M. Karakükcü2, A. Küpesiz3, V. Kesik4, E. Ünal2, Ü. Koçak5, N. Eker3,
E. Atas¸4, S. Aksoylar6, N. Taçyıldız7, M. Elli8, S¸.Y. Bengoa9, Z. Kaya5, S. Kansoy6,
E. Ünal7, F. Erbey10, S. Emir11, H. Öniz12, A. Yes¸ilipek13,14
1Medipol University Faculty of Medicine, Pediatric Hematology&Oncology and BMT
Unit, I˙stanbul, Turkey; 2Erciyes University Faculty of Medicine, Pediatric
Hematology&Oncology and BMT Unit, Kayseri, Turkey; 3Akdeniz University Faculty of
Medicine, Pediatric Hematology&Oncology and BMT Unit, Antalya, Turkey; 4Gülhane
Military Medical Academy, Pediatric Hematology&Oncology and BMT Unit, Ankara,
Turkey; 5Gazi University Faculty of Medicine, Pediatric Hematology&Oncology and
BMT Unit, Ankara, Turkey; 6Ege University Faculty of Medicine, Pediatric
Hematology&Oncology and BMT Unit, I˙zmir, Turkey; 7Ankara University Faculty of
Medicine, Pediatric Hematology&Oncology and BMT Unit, Ankara, Turkey; 8On Dokuz
Mayıs University Faculty of Medicine, Pediatric Hematology&Oncology and BMT Unit,
Samsun, Turkey; 9Dokuz Eylül University Faculty of Medicine, Pediatric
Hematology&Oncology and BMT Unit, I˙zmir, Turkey; 10Bahçes¸ehir Medical Park
Hospital, Pediatric BMT Unit, I˙stanbul, Turkey; 11Ankara Child Health and Diseases
Hematology and Oncology Training and Research Hospital, Pediatric
Hematology&Oncology and BMT Unit, Ankara, Turkey; 12Tepecik Training and
Research Hospital, Pediatric Hematology&Oncology and BMT Unit, I˙zmir, Turkey;
13Bahçes¸ehir University Faculty of Medicine Medical Park Göztepe Hospital,
Department of Pediatric Hematology&Oncology and BMT Unit, I˙stanbul, Turkey; 14On
behalf of, the Turkish Pediatric Bone Marrow Transplantation Study Group TPBMT-SG,
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Background/Objectives: The objective of this study was to evaluate the outcomes
experienced by children with relapsed or refractory extracranial Primitive
Neuro-Ectodermal Tumor (rr-ePNET) following high-dose chemotherapy and
hematopoietic stem cell transplantation (HSCT).
Design/Methods:We retrospectively analyzed the outcomes of 44 patients with
rr-ePNET. Of 44 patients underwent HSCT, 18 had high-risk, non-relapsed disease and
7 had primary refractory disease. At the time of transplantation, only 66% of the
patients were chemosensitive. The majority of patients received busulphan+melphalan
for conditioning (28/44), and peripheral blood (41/44) was used as a source of stem cells.
Results: After a median follow-up period of 18 months, 20 patients were alive. At 2
years, the probabilities of overall survival (OS), event-free survival (EFS),
progression-free survival (PFS), the cumulative non-relapse mortality (NRM) and the
crude relapse rate (RR) were 35.6±8.8%, 35.3±8.2%, 43.2±8.4%, 14.6±8.2% and
52.3%, respectively. The probability of PFS in chemosensitive and chemoresistant
patients at 2 years was 63.7±10.0%, and 13.3±8.8%, respectively (p=0.001). Although
patients with only lung metastases had better OS than those with other or combined
metastases (2-year OS 53.6±18.0% vs 40.0±13.9%), it did not reach statistical
significance. Multivariate analysis showed that chemoresistant disease at the time of
transplantation was the factor predicting limited PFS (odds=2.739, p=0.026).
Conclusion:HSCT increased PFS in a significant proportion of children with rr-ePNET.
Survival rates were better for patients with chemosensitive disease at the time of HSCT.
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POSTOPERATIVE CARE AFTER TUMOR ORTHOPEDIC SURGERY ON A
PEDIATRIC ONCOLOGYWARD
V. Hielscher1, H. Sowade2, E.M. Luedeke2
1University Hospital Muenster, Muenster, Germany; 2University Hospital Muenster,
Department of Pediatric Hematology and Oncology, Muenster, Germany
Background/Objectives: Purpose: In the Department of Pediatric Oncology at
University Children´s Hospital Muenster, 130 newly diagnosed pediatric cancer patients
are admitted per year. Of these patients, 20 to 25 are children and adolescents with
malignant bone sarcomas (Ewing sarcoma, Osteosarcoma) and require bone
replacement surgery. Limb saving surgery is possible in the majority of patients, but
around 10% still require amputation. Postsurgical complications under continuing,
adjuvant chemotherapy include delayed wound healing, local infections and phantom
limb pain. Here we address how the Pediatric Oncology nursing team can support
patients in this situation.
Design/Methods:Method: Among the members of an interdisciplinary team, including
orthopedic and pediatric oncology nurses, wound care experts, physiotherapists,
occupational therapists, social workers, psychologists and physicians (pediatric
oncologists and orthopedic surgeons), we designed and evaluated a nursing care plan
for the postoperative management of patients continuing chemotherapy following
tumor orthopedic surgery.
Results: Close interdisciplinary cooperation allows to optimize wound management and
overall patient care in this specific situation. Written standards of care are helpful for
the training of less experienced nurses and enhance an overall feeling of safety among
both the members of the nursing care team and the patients and their families.
Conclusion: The experienced and standardized care and management of a patient
readmitted to a pediatric oncology ward after bone tumor surgery is a critical
prerequisite for an optimal recovery and quality of life, especially under conditions of
continuing chemotherapy, and to allow transition towards rehabilitation and a normal
daily life. Close cooperation of various disciplines is essential to meet the general and
individual challenges of this situation.
P-107
EXTRASKELETAL OSTEOSARCOMA AFTER BONEMARROW
TRANSPLANTATION
R. Kebudi1, H. Ozger2, S. Bay Buyukkapu3
1Istanbul University-Cerrahpasa Medical Faculty and Oncology Institute, Pediatric
hematology Oncology, Istanbul, Turkey; 2Istanbul University-Istanbul Medical Faculty,
Orthopedics, Istanbul, Turkey; 3Istanbul University-Oncology Institute, Pediatric
Hematology Oncology, Istanbul, Turkey
Background/Objectives: Hematopoietic stem cell /bone marrow transplant
(HSCT/BMT) recipients carry a risk for developing secondary malignancies, either
lymphoproliferative disorders or solid tumors. There has been only seven osteosarcoma
cases reported as second malignancies after HSCT/BMT to date.
Design/Methods: Retrospective case and literature review.
Results: A 17-year-old girl presented with a three-month history pain and one-month
history of swelling in the right lower thigh. She had underwent allogeneic HSCT from
his full-match donor, his brother for MDS when she was 4 years old. Imaging studies
(x-ray, MRI) revealed a mass surrounding the femur. A trucut biopsy revealed
osteosarcoma. She underwent limb sparing surgery after thre courses of neoadjuvant
chemotherapy consisting of ifosfamide, cisplatin, pirubicin, followed by three more
courses of the same regimen and mifamurtide. She is followed up with no evidence of
disease 17 months after termination of chemotherapy.
Conclusion: Children treated for maignancies should be followed-up for late effects,
including second malignancies. Osteosarcoma as a secondary malignancy after MDS is
very rare. Treatment as primary osteosarcoma seems to be effective.
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SIX COURSES OF NONMETHOTREXATE 3-DRUG CHEMOTHERAPY AND
SURGERY IN OSTEOSARCOMA IS EFFECTIVE: 25 YEAR EXPERIENCE
R. Kebudi1, I. Ayan2, H. Ozger3, F.B. Cakir4, O. Gorgun1, S. Buyukkapu Bay1,
B. Bilgic5
1Istanbul University-Cerrahpasa Medical Faculty and Oncology Institute, Pediatric
Hematology Oncology, Istanbul, Turkey; 2Istanbul University-Oncology Institute,
Pediatric Hematology Oncology, Istanbul, Turkey; 3Istanbul University Istanbul Medical
Faculty, Orthopedics, Istanbul, Turkey; 4BezmiAlem Vakif University, Pediatric
Hematology Oncology, Istanbul, Turkey; 5Istanbul University Istanbul Medical Faculty,
Pathology, Istanbul, Turkey
Background/Objectives: Chemotherapy and surgery are the mainstay of osteosarcoma
(OS) treatment. Using 2-4 drugs and short/long duration in chemotherapy protocols
have been evaluated in various trials. A metaanalysis (Anninga JK, 2011) has reported,
3-drug regimen is better than 2, not inferior than 4-drug. Our study aims to evaluate the
outcome of Osteosarcoma (OS) patients treated with a nonmethotrexate 3-drug
regimen and surgery.
Design/Methods: Children and adolescents with oteosarcoma treated between
January,1990 - January, 2015 at Istanbul University, Oncology Institute were
retrospectively evaluated for demographic features and outcome. Patients recieved 6
courses of a 3 drug regimen comprising of ifosfamide 1.8 g/m2/d x 3 days, epirubicin 90
mg/m2/d and sisplatinum 100 mg/m2/d administered 3-pre and 3-postoperatively.
Methotrexate was not in the protocol because drug levels could not be monitored in the
1990’s at our center. Since 2012, mifamurtide was added to the protocol postoperatively
for nonmetastatic patients.
Results: 189 children (105M, 84F), median age 12 years (3-18yrs) were evaluated. 151
(80%) were non-metastatic. Median follow-up was 3,6 years (1mo.-24 yrs). 91.5 % had
limb salvage surgery. Relapse/progressive disease was observed in 69 patients at a
median 15 months (1mo-63 mo). The 5 and 10-year survival and event free survival for
all were (OS) 63.1% and 60.5%, and (EFS) 58.8% and 57% respectively. In
non-metastatic and in metastatic patients, 5-year OS was 73.8 and 23.9%, 5-year EFS
was 69.4% and 20.8%; respectively (p = 0.0001). In 25 nonmetastatic patients recieving
chemotherapy and mifamurtide 2-year OS and EFS were 90.9% and 85.5% respectively
at a median of 20 months.
Conclusion: A 3-drug combination of cisplatin,epirubicin,ifosfamide given for 6 courses
is an effective, well tolerated regimen for osteosarcoma; and with surgery results in
survival rates comparable in the literature. Longer follow up is needed to assess the
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contribution of mifamurtide on outcome. Presence of metastasis is associated with
poor outcome.
P-109
CHILDHOOD EWING SARCOMA FAMILY TUMORS: 25-YEAR EXPERIENCE
OF A SINGLE CENTER IN TURKEY
R. Kebudi1, O. Gorgun1, F.B. Cakir2, F. Yaman Agaoglu3, S. Buyukkapu Bay4, B. Koc1,
B. Zulfikar5, H. Ozger6, I. Ayan5, E. Darendeliler3
1Istanbul University, Cerrahpasa Medical Faculty and Oncology Institute, Pediatric
Hematology Oncology, Istanbul, Turkey; 2Bezmialem Vakif University, Pediatric
Hematology Oncology, Istanbul, Turkey; 3Istanbul University Oncology Institute,
Radiation Oncology, Istanbul, Turkey; 4Istanbul University Oncology Institute, Pediatric
Hematology Oncology, Istanbul, Turkey; 5Istanbul University, Cerrahpasa Medical
Faculty, Pediatric Hematology Oncology, Istanbul, Turkey; 6Istanbul University Istanbul
Medical Faculty, Orthopedics, Istanbul, Turkey
Background/Objectives: Our study aims to evaluate the demographic features and
survival outcome of Ewing sarcoma family tumors (ESFT) treated in a tertiary
pediatric oncology center.
Design/Methods: Patients, under 19 years old, with the diagnosis of ESFT treated
between January 1989 and January 2015 at Istanbul University Oncology Institute were
retrospectively evaluated in terms of demographic features and survival outcomes.
Results: One hundred ninety-seven children (100 boys, 97 girls) with a median age of
12.3 years (0.4-18 yrs) were evaluated. There were 119 (60%) non-metastatic and 78
metastatic patients. Primary localisation was in the extremities in 136 (69%) patients, in
other sites in 61 patients. Initial treatment consisted of 3 or 4 courses of neoadjuvant
alternating IE/VAC chemotherapy given every 3 weeks, followed by surgery and or
radiotherapy (RT) to the primary site and adjuvant chemo for a total of 1 year. Surgery
was performed to 121 (61%) patients; RT was given to 125 (63%) patients as the local
therapy. Median follow-up time was 3 years (2mo.-25 yrs). Relapse or progressive
disease was observed in 53 patients (27%) at a median of 17 months (1mo-70 mo.).
Presence of metastasis was significantly associated with poor prognosis in terms of
overall survival (OS) and event free survival (EFS) (p=0.0001). OS at 2yrs and 5 yrs
were %80 and %71.1 in the nonmetastatic group and %61.3 and %30.4 in the metastatic
group. EFS at 2 yrs and 5 yrs were %70.2 and %60 in the nonmetastatic group; %50.3
and %24.1 in the metastatic group.
Conclusion: Survival of our study group is consistent with the other studies in the
literature. Presence of metastasis was significantly associated with poor outcome both
in EFS and OS.
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MIFAMURTIDE (L-MTP-PE) IN CHILDRENWITH OSTEOSARCOMA: THE
TURKISH EXPERIENCE
R. Kebudi1, N. Sari2, M. Kantar3, F.B. Cakir4, E. Guler5, N. Olgun6, T. Celkan7,
S. Vural8, O. Gorgun1, N. Cetingul3, I. Ilhan2
1Istanbul University-Cerrahpasa Medical Faculty and Oncology Institute, Pediatric
Hematology Oncology, Istanbul, Turkey; 2Ankara Oncology Training and Research
Hospital, Pediatric Oncology, Ankara, Turkey; 3Ege University Medical Faculty,
Pediatric Oncology, Izmir, Turkey; 4Bezmialem Vakif University Medical Faculty,
Pediatric Hematology Oncology, Istanbul, Turkey; 5Akdeniz University Medical Faculty,
Pediatric Hematology-Oncology, Antalya, Turkey; 6Dokuz Eylul University Oncology
Institute, Pediatric Oncology, Izmir, Turkey; 7Istanbul University Cerrahpasa Medical
Faculty, Pediatric Hematology-Oncology, Istanbul, Turkey; 8S¸is¸li Etfal Training and
Research Hospital, Pediatric Oncology, Istanbul, Turkey
Background/Objectives:Mifamurtide (liposomal muramyl tripeptide), activates
macrophages, provides antitumor effect in lungs. Mifamurtide+chemotherapy
improved survival in nonmetastatic osteosarcoma patients, in phase III study. After
EMA approved mifamurtide for nonmetastatic osteosarcoma, it could be used off-label
by the approval of the Ministry of Health on a patient basis, in Turkey. This
multicentric study aims to evaluate the demographic characteristics, adverse effects,
outcome of adding mifamurtide to chemotherapy in children with osteosarcoma in
Turkey.
Design/Methods: From September 2011-January 2015, in 45 nonmetastatic, 4 metastatic
(after metastasectomy) osteosarcoma patients, mifamurtide was added to
chemotherapy after surgery in 8 centers in Turkey. Chemotherapy regimens used were
epirubicin/ifosfamide/cisplatin in 29 patients (Istanbul University Oncology
Institute-IUOI) and other in 20 (MayoPilotII, EURAMOS, ICE etc.). Mifamurtide
was given i.v.2 mg/m2, twice weekly for 12 weeks, followed by once weekly for 24 weeks.
Results:Median age was 14 years (4-17 years). The most frequent adverse affects were
chills and fever especially in initial doses. Median follow-up time for all was 23 months
(5-57mo.). Twenty-seven of 45 (60%) nonmetastatic patients completed mifamurtide.
Thirty-three patients have no evidence of disease (NED) at median 23mo. (5-38 mo.).
Twelve relapsed at median 15 months (9-26mo.), 2 are dead of disease, 8 are alive with
disease; 2 NED. Two of 4 metastatic patients died (28, 57 months). For nonmetastatic
patients 2 year event free survival was 71.3%, overall survival was 92.1%.
Conclusion: In this multicentric study, mifamurtide could be administered safely with
no major side effects. The experience with mifamurtide in patients with nonmetastatic
osteosarcoma is promising; a longer follow up is needed to make further conclusions for
survival benefit.
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IL-6 SECRETED BY EWING SARCOMA TUMORMICROENVIRONMENT
CONFERS ANTI-APOPTOTIC AND CELL-DISSEMINATING PARACRINE
RESPONSES IN EWING SARCOMA CELLS
U. Kontny1, A. Lissat2, M. Jörschke3, D. Shinde4, T. Braunschweig5, A. Meier3,
R. Bortnick3, P. Henneke6, G. Herget7, T. Gorr8
1University Medical Center, Division of Pediatric Hematology and Oncology, Aachen,
Germany; 2Charite-University Medical Center, Division of Pediatric Hematology and
Oncology, Berlin, Germany; 3University Medical Center, Division of Pediatric
Hematology and Oncology, Freiburg, Germany; 4IOR, Institute of Oncolgy Research,
Bellinzona, Switzerland; 5University Medical Center, Institute of Pathology, Aachen,
Germany; 6University Medical Center, Division of Infectious Diseases, Freiburg,
Germany; 7University Medical Center, Orthopedics and Trauma Surgery, Freiburg,
Germany; 8University of Zurich, Institute of Veterinary Physiology, Zurich, Switzerland
Background/Objectives: The prognosis of patients with Ewing sarcoma (ES) has
improved over the course of the last decades. However, those patients suffering from
metastatic and recurrent ES still have only poor chances of survival and require new
therapeutic approaches. Interleukin-6 (IL-6) is a pleiotropic cytokine expressed by
immune cells and a great variety of cancer cells. It induces inflammatory responses,
enhances proliferation and inhibits apoptosis in cancer cells, thereby promoting
chemoresistance.
Design/Methods:We investigated expression of IL-6, its receptors and the IL-6 signal
transduction pathway in ES tumor samples and cell lines applying reverse transcriptase
PCR, immunoblot and immunohistochemistry. The impact of IL-6 on cell viability and
apoptosis in ES cell lines was analyzed by MTT and propidium iodide staining,
migration assessed by chorioallantoic membrane (CAM) assay.
Results: Immunohistochemistry proved IL-6 expression in the stroma of ES tumor
samples. IL-6 receptor subunits gp80 and gp130 were expressed on the surface of ES
cells. Treatment of ES cells with rhIL-6 resulted in phosphorylation of STAT3. rhIL-6
protected ES cells from serum starvation-induced apoptosis and promoted migration.
IL-6 blood serum levels were elevated in a subgroup of ES patients with poor prognosis.
Conclusion: These data suggest that IL-6 contributes to ES tumor progression by
increasing resistance to apoptosis in conditions of cellular stress, such as serum
starvation, and by promotion of metastasis.
P-112
ASSOCIATION OF VITAMIN D RECEPTOR GENE POLYMORPHISMWITH
OSTEOSARCOMA RISK AND PROGNOSIS
N. Kurucu1, G. Sahin2, N. Sari3, S. Ceylaner4, I. Ilhan3
1Hacettepe University Institute of Oncology, Department of Pediatric Oncology, Ankara,
Turkey; 2Dr. Sami Ulus Children’s Hospital, Depertment of Pediatric Oncology, Ankara,
Turkey; 3A.Y. Ankara Oncology Training and Research Hospital, Department of
Pediatric Oncology, Ankara, Turkey; 4Intergen Genetics Center, Department of Genetic
Research, Ankara, Turkey
Background/Objectives: Vitamin D receptor (VDR) plays an important role in a wide
variety of cellular process. Polymorphisms in VDR gene have been linked to risk of
various cancers and their prognosis. We conducted a case-control study to analyze
relationship of VDR gene polymorphisms with occurrence and prognosis of
osteosarcoma.
Design/Methods: Fifty-eight osteosarcoma patients diagnosed in Ankara Oncology
Training and Research Hospital and 75 sex- and age-matched healthy controls were
included the study. Single nucleotide change polymorphism in Cdx2, FokI, BsmI, ApaI,
TaqI regions of VDR gene were examined by SNAPshot mini-sequencing technique.
Allele and genotype frequencies in patient and control groups were compared.
Association of polymorphic genotypes with osteosarcoma was evaluated. Relationship
of prognostic parameters and survival rates with the presence of polymorphisms were
also analyzed.
Results: Allele frequencies in Cdx2, FokI, BsmI, ApaI and TaqI regions of VDR gene of
patients and controls were not different. The differences in genotype frequencies of
patient and control groups were not significant. The VDR gene Cdx2, FokI, BsmI, ApaI
and TaqI polymorphisms were not associated with osteosarcoma risk. Tumor volume
was greater (p=0.041), metastases was more common (p=0.042) and histopathological
response to chemotherapy was worse (<90%)(p=0.044) in patients having Cdx2
polymorphic allele. All patients carrying BsmI homozygote polymorphic genotype had
more than 90% necrosis after induction chemotherapy (p=0.037). Median follow-up
time was 46 months. The three-year event free survival rate significantly higher in the
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presence of homozygote polymorphic ApaI than heterozygote polymorphic and wild
type (87.2% vs. 51.2% p=0.015). The other polymorphic genotypes have not an effect
on survival rates.
Conclusion: Although an association of VDR gene polymorphisms with various cancer
risks has been described, we did not find any relationship in osteosarcoma risk. We
showed the relationship of Cdx2 polymorphism with bad prognosis, BsmI
polymorphism with good prognosis and ApaI polymorphism with better survival rates.
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EVEROLIMUS/SORAFENIB DRUGS COMBINATION IN TREATMENT OF
REFRACTORY CHILDHOOD OSTEOSARCOMA: SINGLE CENTER
EXPERIENCE
E. Senzhapova1, A. Dzampaev1, M. Aliev1
1Pediatric Hematology and Oncology Institute N.N.Blokhin Russian Cancer Research
Center, Children’s surgery№3, Moscow, Russia
Background/Objectives: The results of treatment refractory childhood osteosarcoma are
not satisfactory. According to the data of different pilot trials progression-free survival
(PFS) curves dramatically tend to zero with a median follow-up in 6-8 months.
Possibility of using these drugs combination in children is unknown.
Design/Methods: FromMay 2013 to March 2015 eight children and adolescents with
refractory osteosarcoma were included in this pilot trial. Male/female ratio was 1/1.
Median age - 12.7 years (range from 7 till 17). T2bN0M0 stage was revealed in 3
patients, T2bN0M1a stage – in 5 patients. All patients had received first-line
chemotherapy PHOI-OS-2006, second-line therapy - high-dose ifosfamide and
third-line therapy – gemcitabine/docetaxel before they were enrolled in this trial.
Sorafenib was administered orally at the starting dose 150 mg/m2 (with following
possible escalation up to 200 mg/m2) every 12 hours, everolimus - orally at the starting
dose 2.5 mg/m2 (with following possible escalation to 5 mg/m2) once a day for
consecutive 28-day cycles until disease progression or unacceptable toxic effects. The
primary endpoint was 6 month PFS.
Results: The most common toxicity was skin syndrome, oral mucositis. Hematological
toxicity was not more than grade I-II. Three out of 6 patients were progression free at 6
months. Maximum PFS was 12 months, a median follow-up was 4.3 months (range
from 1,3 till 12,5).
Conclusion: The combination of sorafenib and everolimus showed therapeutic effect as
a further-line treatment for children and adolescents with refractory osteosarcoma.
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ROLE OF HIGH DOSEMETHOTREXATE (HDMTX) IN PEDIATRIC
OSTEOSARCOMA: A RETROSPECTIVE STUDY
P. Mallya1, C.P. Raghuram1, P. Chinder2, I. Mehdi1, C. Sreenath1, D. S1
1Bangalore Institute of Oncology, Pediatric Oncology, Bangalore, India; 2Bangalore
Institute of Oncology, Orthopedic Oncology, Bangalore, India
Background/Objectives: The four major chemotherapeutic agents used for treatment of
Pediatric Osteosarcoma are Doxorubicin, Cisplatin, Ifosfamide and High dose
Methotrexate. MTX seems to be the most active agent however this had not been
unambiguously proven. Objectives: To compare the survival, percentage of tumour
necrosis and rate of complications in patients with Osteosarcoma receiving
chemotherapy regimens with and without HDMTX.
Design/Methods: Case notes of 23 children with Osteosarcoma who were treated at a
tertiary cancer hospital in Bangalore, India were retrospectively analysed. Details about
symptoms, signs, chemotherapy, surgery, complications and survival were collected.
These were compared between patients who received chemotherapy regimens with and
without HDMTX.
Results:M:F ratio was 1.8:1 with mean age of 14.78 years (8-18 years). Pain and
swelling were the most common symptoms and distal femur was the most common site.
35% were metastatic. Forty percent of children received chemotherapy with HDMTX
containing MAP (Cisplatin, Doxorubicin, and HDMTX) regimen. Other received
regimens which did not contain HDMTX. The percentage of tumour necrosis was
more than 90% in 77.7% in HDMTX receiving children as compared to 37.5% with
other protocols. Overall survival in localized Osteosarcoma was better in children
receiving HDMTX compared to those receiving regimens without HDMTX 60% vs
40%. Overall survival in metastatic Osteosarcoma was better in children receiving HD
MTX compared to those receiving regimens without HDMTX 50% vs 0%. Rate of
admissions for febrile episodes (88% vs 57%) and need for PRBC (66% vs 50%) and
platelet transfusions (66% vs 57%) were more in children receiving HDMTX.
Conclusion: HDMTX improves the survival and percentage of tumour necrosis in
pediatric patients with Osteosarcoma.
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METHOTREXATE AND ALL-TRANS RETINOIC ACID COMBINED
TREATMENT FOR INDUCTION OF OSTEOSARCOMA CELL LINES
DIFFERENTIATION IN VITRO
J. Neradil1,2, M. Sramek1,2,3, M. Mrkvicova2,3, K. Zitterbart1,2,3, J. Sterba2,3,
R. Veselska1,2,3
1Masaryk University, Department of Experimental Biology, Brno, Czech Republic;
2Masaryk Memorial Cancer Institute, RECAMO, Brno, Czech Republic; 3Masaryk
University, Department of Pediatric Oncology, Brno, Czech Republic
Background/Objectives: Induced differentiation of tumor cells into mature phenotypes
is a promising strategy in cancer therapy. All-trans retinoic acid (ATRA) and its
derivatives can induce cell differentiation in many types of hematological malignancies
and solid tumors including osteosarcoma. Methotrexate (MTX; amethopterin;
4-amino-10-methylfolic acid), a structural analogue of folic acid, is still one of the most
effective compounds used in osteosarcoma treatment. MTX is an inhibitor of enzyme
dihydrofolate reductase (DHFR) which catalyses the reduction of folate to
tetrahydrofolate. The inhibition of DHFR results in tetrahydrofolate depletion, leading
to the inhibition of purine and pyrimidine precursor synthesis. Besides these cytostatic
and cytotoxic effects of MTX, there is also an evidence of differentiation effect of this
compound. MTX was found to be a potent differentiation inducer in HL-60 human
promyelocytic leukaemia cells.
Design/Methods:We studied the potential of ATRA and MTX to induce differentiation
of osteosarcoma cell lines in vitro and further we studied if MTX is able to modulate
ATRA induced differentiation. The detection of the activity of mitochondrial
dehydrogenases by MTT assay was used for the evaluation of cell proliferation. The
expression of cell differentiation markers and genes involved in ATRA signalling (e.g.
RAR, RXR, CRABP) was assessed using qPCR. The level of extracellular matrix
mineralization was evaluated using Alizarin Red S staining.
Results: Treatment with ATRA alone enhanced the expression of the middle and late
differentiation markers and ATRA alone enhanced the extent of mineralization.
Combined application of ATRA and MTX slightly increased the effect of ATRA in
terms of differentiation.
Conclusion: Our results suggest that MTX and ATRA could be a new promising
combination in treatment of osteosarcoma.
Acknowledgements: This study was supported by grant IGAMZCR NT14327-3 and by
the European Regional Development Fund and the State Budget of the Czech Republic
(RECAMO, CZ.1.05/2.1.00/03.0101).
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EXPERIENCE IN THE TREATMENT OF EWING’S SARCOMAOF THE PELVIS
IN CHILDREN. EAST EUROPEAN SARCOMA GROUP
O. Nisichenko1, A. Dzampaev1, V. Khayrullova1, D. Hestanov1, M. Aliev1
1Russian Oncology Research Center N.N.Blokhin, general oncology, Moscow, Russia
Background/Objectives: The aim of our study was to determine treatment outcomes in
two protocols: 1) using high-dose chemotherapy and autologous peripheral blood stem
cell transplantation (HDCT/autoPBSCT) and 2) protocol with decreasing doses of
chemotherapy in pediatric patients with Ewing’s sarcoma of pelvis treated at the East
European Sarcoma Group (Russian oncology research center N.N.Blokhin).
Design/Methods:We retrospectively analyzed the data of patients with Ewing’s sarcoma
of pelvis between 1997-2011. All patients receive the same mode neoadjuvant
chemotherapy regimens 5 courses (VAC and IE).
Results: The first group included 31 children. Metastatic disease was found in 42% of
patients. The average tumor volume was 345ml. Middle age was 11.5 y.o. The second
group included 21 patients with a reduction in drug dosage. Metastatic disease was
found in 33% of patients. The average tumor volume was 298ml. Middle age was 12.7
y.o. Overall 1-,3-,5-y survival after HDCT/autoPBSCT were 70%, 39%, 39%. Median
was 17.2 months in first group. With metastatic disease overall 1-,3-,5-y survival were
46%, 7%, 7%. Median was 10.2 months. With non metastatic disease overall 1-,3-,5-y
survival were 88%, 64%, 64%. Median not reached. Overall 1-,3-,5-y survival in the
second group were 100%, 70.5%, 58.8%. With metastatic disease overall 1-,3-,5-y
survival were 100%, 68.5%, 34.2%. With non metastatic disease overall 1-,3-,5-y survival
were 100%, 71.4%, 71.4%. Median not reached. Data is valid (p=0.008).
Conclusion: Although we obtained the best survival data in the second group than the
first using HDCT/autoPBSCT, are different by selection the data volume of the
primary tumor and rate of metastatic disease. Requires further study and monitoring
of patients undergoing treatment for Ewing’s sarcoma of the pelvis.
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IDENTIFICATION OF CANCER STEM CELLS IN OSTEOSARCOMA CELL
LINES: CHARACTERIZATION OF CANCER STEM CELLMARKERS
EXPRESSION AND IN VIVO TUMORIGENICITY
J. Skoda1,2, J. Neradil1,3, I. Zambo4, M. Hermanova4, J. Sterba2,3, R. Veselska1,2
1Masaryk University - Faculty of Science, Department of Experimental Biology, Brno,
Czech Republic; 2University Hospital Brno, Department of Pediatric Oncology, Brno,
Czech Republic; 3Masaryk Memorial Cancer Institute, RECAMO, Brno, Czech
Republic; 4St. Anne‘s University Hospital, First Department of Pathological Anatomy,
Brno, Czech Republic
Background/Objectives: Despite modern treatment protocols, survival for patients with
metastatic or relapsed osteosarcoma remains poor. Recent studies found that cancer
stem cells (CSCs) are present in osteosarcoma and could be the cause of observed
clinical pattern. However, reported proportions of CSCs vary between the studies as
different groups used different marker or method singly to identify CSCs.
Design/Methods: To evaluate the relevance of putative CSCs markers in osteosarcoma,
we examined their expression in 8 osteosarcoma-derived cell lines and 1 established
osteosarcoma cell line SAOS-2. Immunofluorescence, flow-cytometry and RT-PCR
were employed to analyze expression of following markers: CD133, ABCG2, CD117,
ALDH1A1, nestin, Oct3/4, Sox2 and Nanog. All 9 cell lines were tested for the presence
of CSCs using in vivo tumorigenicity test. In the xenograft assay, 1 million unsorted
cells of each cell line were injected in triplicate into NSG mice.
Results: Only 1 of 9 tested osteosarcoma cell lines was able to form xenograft tumors –
OSA-13. The presence of CSCs in OSA-13 was further confirmed in serial
xenotransplantations. Unexpectedly, we identified high expression of at least some of
the putative CSCs markers among all of the examined cell lines. However, only OSA-13
cells expressed all of the examined CSCs markers including Sox2, which has been
recently reported as crucial for self-renewal and tumorigenicity of CSCs in
osteosarcoma. Moreover, OSA-13 cells expressed CSCs markers at overall higher level
compared to other non-tumorigenic cell lines.
Conclusion: Our results indicate that use of previously reported osteosarcoma CSCs
markers singly is limited because even high expression of the single marker does not
necessary reflect the tumorigenic phenotype of the cells. CSCs are more likely
characterized by simultaneous expression of multiple markers, including Sox2, and
multi-marker strategies should therefore be applied for their identification in
osteosarcoma.
Acknowledgements: This study was supported by IGAMZCR NT13443-4 and
RECAMO, CZ.1.05/2.1.00/03.0101.
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METHOTREXATE INDUCES EPIGENETIC ALTERATIONS IN
OSTEOSARCOMA CELL LINES
M. Sramek1,2,3, J. Neradil2,3, M. Mrkvicova1,3, K. Zitterbart1,2,3, J. Sterba1,3,
R. Veselska2,3
1Masaryk University - Faculty of Medicine, Department of Pediatric Oncology, Brno,
Czech Republic; 2Masaryk University - Faculty of Science, Department of Experimental
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Czech Republic
Background/Objectives:Methotrexate (MTX) is one of the most frequent
chemotherapeutic drug and is still used in the treatment of osteosarcoma. MTX is able
to inhibit dihydrofolate reductase, but it also interferes with the enzymes
methylenetetrahydrofolate reductase, methionine synthase and methionine
S-adenosyltransferase. It is therefore probable that MTX can be involved in reduction
of S-adenosylmethionine level which subsequently leads to depletion of
5-methylcytosine. Moreover, it was shown that MTX can act as inhibitor of histone
deacetylases due to its shared structural similarity with some other histone deacetylase
inhibitors.
Design/Methods: In this study we used MTT assay for basic assessment of MTX
cytotoxicity. Gene expression was measured using qPCR after MTX treatments.
Differences of DNA methylation resulting from MTX and 5-aza-2’-deoxycytidine (the
DNA demethylating agent) treatments were studied using ELISA assay. Histone
acetylation levels were detected by ELISA and western blotting.
Results:MTX treatments influenced expression of some genes involved in drug
metabolism and transport. In several cell lines MTX was able to decrease level of
5-methylcytosine in DNA and MTX was almost as effective as 5-aza-2’-deoxycytidine
at the same concentration. In some cells MTX also increased level of acetylated histone
H3.
Conclusion: To conclude, MTX alone is able to modify gene expression and epigenetic
determinants in osteosarcoma cell lines. Acknowledgements: This study was supported
by grant IGAMZCR NT14327-3 and by the European Regional Development Fund
and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101).
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STEM CELL RESCUE FROM IRRADIATION OF TUMOR SITES COMBINED
WITH HIGH-DOSE CHEMOTHERAPY YIELDS LONG TERM SURVIVAL IN
PATIENTS WITH ADVANCED PEDIATRIC SARCOMASWITHOUTMARROW
INVOLVEMENT
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Background/Objectives: Ewing’s sarcomas (ES), metastatic to more than one bone or
marrow or early relapse as well as stage IV rhabdomyosarcomas (RMS) have poor
prognosis. We assessed toxicity, relapse free survival (RFS) and overall survival (OS) of
advanced ES and RMS patients treated with the MetaEICESS protocols.
Design/Methods: From 1992 to 2014, 20 patients, 18 with advanced ES (AES,  three
bones/organs or marrow involved at diagnosis, n=4 or relapse <24 months after
diagnosis, n=3) and 2 with stage IV RMS, were enrolled in the two subsequent
MetaEICESS 1992 and 2007 protocols consisting of induction-chemotherapy,
whole-body MRI or MRI/PET directed radiotherapy to the primary tumor and to all
metastases, as well as surgery, tandem high-dose chemotherapy with autologous rescue
(both groups) plus allogeneic stem cell transplantation (allo-SCT, only MetaEICESS
2007). OS was also compared to outcomes of 26 historical AES patients treated with
conventional protocols. Data was censured on March 1st 2015.
Results: 11/20 patients are surviving in CR. This is significantly better than historical
controls. CR rates did not differ between MetaEICESS 2007 (5/9) versus MetaEICESS
1992 (3/11). 4/9 patients in the MetaEICESS 2007 group had bone marrow (BM)
involvement in contrast to 3/11 in the MetaEICESS 1992 group.
Altogether, 11/14 patients without BM involvement survived in contrast to 0/7 patients
with marrow involvement. There were 3 DOC, all in MetaEICESS 1992. When patients
suffering DOC were excluded (n=3), 6/6 patients who had BM involvement at diagnosis
had died of disease, whereas 3/11 patients without BM involvement had died of disease,
leaving 8/11 patients in CR (median: 66 months).
Conclusion: The MetaEICESS protocols yield long term survival in patients with
advanced ES/RMS. Allo-SCT was not associated with DOC increase. Given the higher
incidence of BM involvement in the allogeneic transplant group, it remains open
whether the addition of allo-SCT improves the prognosis.
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IMPACT OF PATHOLOGICAL FRACTURES ON THE PROGNOSIS OF
PRIMARYMALIGNANT BONE SARCOMAS IN CHILDREN AND ADULTS. A
SINGLE CENTER RETROSPECTIVE STUDY
M. Schlegel1, M. Zeumer1, H. Rechl2, K. Woertler2, M. Steinborn3, P. Prodinger2,
R. von Eisenhart-Rothe2, S. Burdach1, I. von Luettichau1
1Childrenshospital München Schwabing- Technical University Munich-Wilhelm Sander
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Sarcoma Unit-Comprehensive Cancer Center Munich, Department of Orthopedic
Surgery, Munich, Germany; 3Childrens Hospital München Schwabing-Technical
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Background/Objectives: The purpose of this study was to investigate whether a
pathological fracture (PF) has an effect on the prognosis of patients with osteosarcoma
and Ewing tumor regarding 5-year survival, occurrence of metastases and local
recurrence.
Design/Methods:We retrospectively analyzed 205 patients with the histological
diagnosis of either osteosarcoma or Ewing sarcoma. Survival analysis was performed
for all patients and differentiated for adult and pediatric (<18 years at diagnosis)
patients.
Results: Out of all patients, 127 were diagnosed with osteosarcoma and 78 with Ewing
tumor. At time of diagnosis, 51% of all patients were under the age of 18 years. The age
ranged from 3 to 79 years (median age 17). In 20% a pathological fracture was
observed. Patients with PF showed lower survival rates with 5-year survival rates of
64% compared to 83% without PF (p= 0.023). The difference in development of
metastases between patients with and without PF was not statistically significant. Local
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recurrence occurred in 7% of the patients without and in 24% with PF (p= 0.023). In
pediatric patients, the 5-year survival rate was 87% in patients without and 77% with PF
(p= 0.806). The rate of local recurrence was not different in children with and without
PF (10% vs. 11%, p= 0.573). In contrast, the survival rate in adults with PF fracture
decreased from 78% to 51% (p= 0.004) and local recurrence increased from 13% to 42%
(p= 0.001). None of the subgroups showed a statistically significant correlation
between pathological fractures and metastases.
Conclusion: The present study suggests that the overall occurrence of PF in primary
malignant bone sarcomas has a negative impact on survival rates and implicates an
increased risk of local recurrence. Of note, in pediatric patients, PF did not have
prognostic impact.
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INHIBITION OF DNA-REPAIR ENZYMES (DNA-PK AND PARP) TO
SENSITIZE EWING SARCOMA TO CHEMO-AND RADIOTHERAPY
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Background/Objectives: Exposure to DNA-repair inhibitors can render malignancies
more susceptible to chemo- and radiotherapy. DNA dependent protein kinase
(DNA-PK) and poly(ADP-ribose)polymerase (PARP) inhibitors are in clinical trials,
both as single agents and in combinations. Metastatic and relapsed Ewing sarcoma is
associated with a poor outcome and there is an urgent clinical need to improve
treatment strategies. Recently, ETS transcription factors, such as EWS-FLI1, were
described as biomarkers for PARP-inhibitor sensitivity in Ewing sarcoma, which had
previously been limited to homologous recombination repair (HRR) deficient tumours.
Design/Methods:We assessed DNA-PK (NU7441) and PARP-1/-2 (rucaparib)
inhibitors as single and as chemo- or radiosensitising agents in 3 Ewing sarcoma cell
lines by performing growth inhibition and clonogenic assays, and evaluating cells for
their ability to repair DNA double strand breaks by HRR. Single agent rucaparib
(10 mg/kg i.p. daily) was evaluated in an in vivo orthotopic model with serial
bioluminescent imaging.
Results: NU7441 caused chemosensitisation (etoposide, doxorubicin) and
radiosensitisation (2-7 fold increase in cytotoxicity). Chemosensitisation of rucaparib
was profound for temozolomide (15-29 fold) and modest for camptothecin and ionizing
radiation (1.4–2 fold). Depending on the type of clonogenic assay used, single agent
rucaparib activity differed with LD50 values ranging from 0.5-1 μM to 5-8 μM
(continuous versus 24h drug exposure, respectively). After induction of DNA double
strand breaks, the cells showed a significant increase in rad51 foci formation indicating
intact HRR. In vivo testing of rucaparib was non-toxic but failed to show any tumour
responses or survival advantages.
Conclusion: Ewing sarcoma cell lines are functional for HRR but nevertheless sensitive
to PARP-1/-2 inhibition. Despite in vitro activity, monotherapy with a PARP inhibitor
was not efficacious in vivo. Given the chemo- and radiosensitising effects of both
inhibitors, our findings strongly support further evaluation of these agents in
combination with chemo– or radiotherapy in preclinical models and clinical trials.
Posters: Brain Tumours
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EXPLORING POTENTIAL DRIVERMUTATIONS IN PEDIATRIC SOLID
TUMORS
A. Wilzen1, T.T. Tomic´2, M. Sodéus1, K. Truvé3, F. Abel1
1Biomedicine, Gothenburg, Sweden; 2Biomedicine, Clinical Genetics, Gothenburg,
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Background/Objectives: Brain tumors are the most common solid malignancies in
children. Over the past few years we have seen a dramatic change in the field of
pediatric neuro-oncology, largely because of the emergence of unbiased
high-throughput genome-wide analyses. Pediatric brain tumors have molecular features
very unique compared to their adult counterparts. One example is Pilocytic
astrocytomas driven by MAPK activation abnormalities, most often through
KIAA1549:BRAF fusions or BRAFV600E mutations. These features may serve as
diagnostic or prognostic markers or even as targets for novel therapy. The aim of this
study was to genetically characterize a pediatric brain tumor set from western Sweden,
and next, to explore the functional relevance of novel mutations identified.
Design/Methods:We are currently cloning the novel gene mutation transcripts, which
will be further transfected into neural cell lines (HEK293, RES-186, SK-N-AS) to study
cell proliferation, clonal expansion, cell adhesion, migration and invasion capabilities.
The localization, binding partners, and effect of the mutated proteins will be studied
through live-cell imaging, co-immunoprecipitation, and gene expression analysis. If our
study demonstrates a transforming capability in vitro, we will move on with in vivo
studies using a xenograft mouse model.
Results: Through RNA-sequencing and Exome-sequencing we have identified novel
point-mutations and gene fusions linked to the Rab-pathway. There is increasing
evidence that Rab regulators have an important role in tumor progression, but this is
the first time that Rab-associated mutations are linked to pediatric brain tumors.
Conclusion: In conclusion, increased knowledge of downstream effects and
pathophysiologic roles of driver mutations will facilitate the development of subgroup
or tumor-specific therapeutics. The BRAF inhibition agent Vermurafenib enacts an
example of personalized therapeutic potential of CNS tumors. These and other
targeted agents provide hope for the treatment of advanced and incurable tumors and
may radically improve current therapy.
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EMBRYONAL TUMORWITH ABUNDANT NEUROPIL AND TRUE ROSETTES
(ETANTR): LONG TERM SURVIVAL IN A CHILD TREATEDWITH INTENSIVE
CHEMOTHERAPY AND PERIPHERAL BLOOD STEM CELL RESCUE
S. Afzal1, B. Crooks2, R. Rutledge3, S. Brocklehurst2, S. Walling4, D. McNeely5,
E. Bouffet6, A. Huang6
1Dalhousie University, Division of Pediatric Haematology/Oncology, Halifax, Canada;
2IWK Health Centre, Division of Pediatric Haematology/Oncology, Halifax, Canada;
3CDHA-QEII-Dickson Centre, Department of Pediatric Radiation Oncology, Halifax,
Canada; 4IWK Health Centre-Halifax, Division of Neurosurgery, Halifax, Canada;
5IWK Health Centre, Division of Neurosurgery, Halifax, Canada; 6Hospital for Sick
Children, Department of Neuro-Oncology, Toronto, Canada
Background/Objectives: Embryonal central nervous system tumors are classified into
three subtypes: medulloblastoma, atypical teratoid/ rhabdoid tumor (ATRT) and
primitive neuro-ectodermal tumor (PNET).Embryonal tumor with abundant neuropil
and true rosettes (ETANTR) was initially described as a subtype of PNET. Recently,
described as a distinct malignant CNS tumor with dismal prognosis despite aggressive
treatment.Histologically ETANTR is characterised by presence of undifferentiated
neuroepithelial cells resembling classic PNET along with well differentiated neuropil
and ependymoblastic rosettes arising from paucicellular regions of neoplastic neuropil.
ETANTR has a specific genetic alteration, amplification of the miRNA cluster C19MC
at 19q13.42.
Design/Methods:We report a 33 months old girl with increasing irritability, balance
disturbance and neck pain. MRI scan showed a massive right occipital tumor
originating in the posterior fossa, infiltrating through the tentorium up into the cerebral
hemisphere with significant mass effect. MRI spine and CSF cytology were negative for
metastatic disease.She underwent right occipito- parietal and sub occipital posterior
fossa craniotomy with intention of gross total resection. Post surgical MRI showed
small residual tumor. Histopathological diagnosis was consistent with ETANTR. FISH
analysis showed heterogeneous pattern of distribution with 3-6 copies of the 19q13.41
in 30% nuclei, 10-15 copies in 8% nuclei and normal signal in the remaining cells. She
received three cycles of induction chemotherapy (vincristine, etoposide,
cyclophosphamide and cisplatin) followed by three cycles of thiotepa and carboplatin
with peripheral blood stem cell rescue. She had second look surgery to remove small
residual tumor post induction. No radiation was given.
Results: She tolerated her chemotherapy well. She is 3 years post treatment and has no
significant concerns.
Conclusion: Some children with ETANTR may do well with intensive chemotherapy.
Prognostic factors for variable outcome need to be identified, in particular with regard
to the heterogeneous distribution of 19q13.41 signal in our patient.
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THE ROLE OF SURVEILLANCE IN FAMILIES WITH BIALLELIC MISMATCH
REPAIR DEFICIENCY SYNDROME: CASE REPORT OF TWO SIBLINGSWITH
MULTIPLE COLON ADENOCARCINOMA AND BRAIN TUMOR
S. Afzal1, B. Crooks1, R. Romao2, R. Rutledge3, L. Penny4, M. Bernstein1, M. Rashid5,
D. McNeely6, E. Bouffet7, U. Tabori7
1IWK Health Centre, Division of Pediatric Haematology/Oncology, Halifax, Canada;
2IWK Health Centre, Division of Pediatric Surgery, Halifax, Canada;
3CDHA-QEII-Dickson Centre, Department of Pediatric Radiation Oncology, Halifax,
Canada; 4IWK Health Centre, Department of Genetics, Halifax, Canada; 5IWK Health
Centre, Division of Pediatric Gastroentrology, Halifax, Canada; 6IWK Health Centre,
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Background/Objectives: Biallelic mismatch repair deficiency syndrome (BMMRD) is a
distinct childhood cancer predisposition syndrome caused by biallelic germline
mutations in one of the four mismatch repair (MMR) genesMLH1, MSH2, MSH6, or
PMS2. BMMRD predisposes children to haematological, brain and gastrointestinal
malignancies. Surveillance protocol was developed for these children and applied where
possible.
Design/Methods:We report two siblings with BMMRD homozygous bi-allelicMSH6
mutation with focus on implementation of surveillance. Fifteen year-old male with
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cleidocranial dysplasia presented with weight loss, chronic bloody diarrhea and
hypoalbuminemia. Clinical features were suggestive of NF-1 and familial adenomatosis
polyposis (FAP). Endoscopy revealed extensive polyposis coli. He underwent
laparoscopic protocolectomy with end ileostomy. Pathology revealed multiple colonic
adencarcinoma. He was treated with oxaliplatin and 5FU for 24 weeks with complete
remission. Molecular and genetic diagnostics were negative for APC andMUTYH
genes but all colonic cancers had microsatellite instability. Tumour cells and adjacent
normal mucosa stained negative forMSH6 and positive forMLH1, MSH2 and PMS2
suggestive of BMMRD. A homozygous pathogenicMSH6 mutation was identified
(c.3202C>T). This is the first reported BMMRD with CHRPE that fits clinical criteria
for both NF-1 and FAP. After diagnosis of BMMRD, 12 years old sister underwent
genetic workup and found to have homozygous forMSH6 mutation. While awaiting
surveillance imaging she developed headache and diplopia. MRI revealed large frontal
tumor. She underwent incomplete resection of a glioblastoma multiforme (GBM)
followed by radiation therapy and retinoic acid. Colonoscopy showed numerous large
polyps with adenomatous changes and high grade dysplasia.
Results: The GBM progressed rapidly and she died within 9 months of diagnosis. Her
brother continue surveillance with recent resection of second rectal carcinoma.
Conclusion: High index of suspicion of BMMRD in children with colon cancers and
early implementation of surveillance protocol may improve survival for individuals with
this highly penetrant syndrome.
P-125
MALIGNANCY IN THE CHROMOSOME 22Q11.2 DELETION SYNDROME
(DIGEORGE SYNDROME/VELO-CARDIO-FACIAL SYNDROME)
M. Akker1, T. Stevens2, J. van der Werff ten Bosch1
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Background/Objectives:We aim to describe the correlation between malignancy and the
22q11.2 Deletion Syndrome (22q11.2DS), of which DiGeorge Syndrome (DGS) is one
of its clinical phenotypes.
Design/Methods: A 10 year old boy with a pineoblastoma was treated in our center.
Due to his past history of developmental delay, genetic analysis was done, which
detected a 2.4 Mb deletion on 22q11.21, leading to the diagnosis of 22q11.2DS. To
evaluate the correlation between 22q11.2DS and malignancies we performed an
extensive pubmed search over the last 40 years.
Results: Although a link between pineoblastoma and DGS was not described before,
several other malignancies were found in patients with 22q11.2DS including
xanthoastrocytoma, thyroid adenoma, hepatoblastoma, neuroblastoma, renal cell
carcinoma, lymphoma and wilms tumor (table overview at poster).
Interestingly, a remarkable amount of patients with a rhabdoïd tumor were described.
In this group, genetic analysis consistently showed deletions distal to the ´Typically
Deleted Region´ in 22q11.2DS. It is referred to as the Distal 22q11.2 Syndrome, which
was recently concluded to be a separate entity from the common 22q11.2DS even
though clinical overlap was described. It must be emphasized that DGS has a broad
variety in clinical manifestations. Hence, children with clinical similarities to the
common 22q11.2DS might benefit from additional tests to evaluate possible distal
deletions, considering its clinical relevance.
Conclusion: Given the high frequency of DGS, it´s important to define the risk of
malignancy. The analysis of literature, concerning malignancy in 22q11.2DS, has led us
to postulate that the overall risk of malignancy might be increased in 22q11.2DS. We
suggest that caregivers of these patients should be vigilant regarding cancer diagnosis.
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UTILIZATION OF 18F-DOPA-PET IMAGING FOR NEUROSURGICAL
PLANNING AND TARGET DELINEATION IN THE TREATMENT OF
PEDIATRIC GLIOMAS
A. Arnett1, Y. Zhang2, M. Seaberg2, D. Pafundi2, D. Brinkmann2, C. Giannini2,
N. Laack2
1Mayo Clinic, Rochester, USA; 2Mayo Clinic, Radiation Oncology, Rochester, USA
Background/Objectives: Delineation of at-risk sites is critical for radiation planning and
surgical treatment of gliomas. MRI/CT imaging is the ‘gold standard’, but this may not
reflect the true extent of disease. Anaplastic tumors can present as heterogeneous
lesions on MRI, and reliance on contrast-enhanced images alone can lead to
non-diagnostic biopsy and inaccurate grading of tumor. The tracer
3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (FDOPA) has a high sensitivity for
gliomas and may improve radiation planning and neurosurgical site selection. This
study compares FDOPA-PET/CT to conventional CT/MRI imaging utilized for
radiotherapy and resection planning in pediatric patients.
Design/Methods:MR/CT and FDOPA-PET/CT images were obtained in 5 pediatric
patients with malignant gliomas. The region of interest (ROI) was defined based on
areas of enhancement on MRI and increased FDOPA uptake. Ratios of maximum
tumor standardized uptake value (SUVmax) normalized to mean SUV (SUVmean) of
normal brain tissue (T/N) were determined using the SUVmax from each biopsy
coordinate and the SUVmean from the volume of contralateral normal brain tissue
contoured at the corresponding level.
Results: An average of 5 biopsies were obtained from each patient. The FDOPA-PET
images were utilized to guide biopsy site selection in four patients, and one patient did
not require biopsy after FDOPA-PET failed to show evidence of increased uptake.
Regions of increased FDOPA uptake extended beyond those identified with MRI in
two patients, and biopsy sites correlated with the region of highest uptake in 3 patients.
Average tumor SUVmax was 2.135 (range 2.92-1.27), and the average T/N ratio was 1.6
(range 1.92-1.18). Biopsies were consistent with Grade III or Grade IV astrocytoma in
three patients. Biopsies obtained from one patient demonstrated infiltrating glioma, but
were undiagnostic for grade.
Conclusion: FDOPA-PET imaging has utility in guiding biopsy selection and may assist
with identifying regions of higher-grade disease in patients with astrocytomas.
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QUALITY OF LIFE IN PEDIATRIC SURVIVORS OF CENTRAL NERVOUS
SYSTEM TUMORS. EXPERIENCE OF A THIRD LEVEL HOSPITAL IN A LOW
INCOME COUNTRY
F. Arreguin1, Y. Gonzalez-Paredes2, M. Palomo-Colli3, G. Frias2
1Centro Medico Nacional "20 de Noviembre" ISSSTE, Mexico City, Mexico; 2Centro
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Background/Objectives: Background: Long-term survivorship is a reality for an
increasingly number of children with cancer, and it is very important to understand and
take care of their quality of life (QoL), since many of them may experience a lot
disturbances (physical,social,cognitive and psychological). Central Nervous System
tumors (CNS) are the most common solid tumors in children with lot of morbility among
survivors. Objective: To explore the QoL of survivors of brain cancer in the Pediatric
Oncology Service in a third Level Hospital.
Design/Methods: This descriptive, cross-sectional study was conducted in a tertiary
medical center in Mexico City, and involved a total of 16 pediatric survivor patients
who had CNS tumors. They performed a validated quality of life scale for Mexican
children (PedsQLMT).
Results:We graded each area (emotional, cognitive, physical and social) using the
PedsQL scale. In a general way, QoL in our survivors is good. Emotional and cognitive
functioning of PedsQL were the most affected areas, something important was that
most of our patients felt anger. The physical area was also affected. Survivors of brain
tumors suffer from numerous endocrine and metabolic consequences, majority of them
developing within the first 5 years after brain tumor therapy.
Conclusion: An active follow-up aiming for early diagnosis and therapy is essential for
improvement of quality of life in these patients. These data support an ongoing specific
interest in the QoL of long-term cancer survivors and suggest the need for further study
of multidimensional functioning in this population, especially in brain tumor survivors.
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OUTCOME OF CHILDRENWITHMEDULLOBLASTOMA: RESULTS FROM A
SINGLE CENTER IN IRAN
G. Bahoush Mehdiabadi1, K. Arjmandi Rafsanjani2
1IUMS, Tehran, Iran; 2IUMS, Pediatrics, Tehran, Iran
Background/Objectives: Childhood primary central nervous system (CNS) malignancies
are one of the most important concerns in pediatric oncology. Therefore, study on the
outcome of Medulloblastoma as one of the most common primary CNS malignancies
in childhood can be helpful to find a better therapeutic approach for these malignancies.
Design/Methods: In this historical cohort, forty nine patients with medulloblastoma
treated in Ali-Asghar Children’s Hospital between 1999 and 2008 were evaluated for
age, gender, type of treatment, and survival.
Results: The records of twenty female (40.80%) and twenty nine male (59.20%) patients
were included. The mean age was 6.8 ± 3.39 years (6 months to 14 years). Complete
resection, radiotherapy, and chemotherapy were done in 59.2, 91.8, and 100 percent,
respectively. Estimated 5 years overall and event-free survivals (EFSs) were 69.50%
[standard error (SE) =7.40] and 37.40% (SE= 7.80), respectively. The patients with
complete resected tumors had significantly better outcome (p = 0.013).
Conclusion: The poor EFS with consideration of high number of progressive disease
among our patients suggests that children in Iran with CNS tumors had high quality of
care but availability of advanced treatment protocol and sharing of cooperative trial
study is essential for survival improvement. In addition to use more advanced methods
and equipments of radiotherapy and chemotherapeutic drugs, we should seriously
consider development of better surgical techniques to increase the rate of complete
resection of malignant CNS tumors.
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RHABDOID COMPONENT EMERGING AS A SUBCLONAL EVOLUTION OF
PEDIATRIC LOW-GRADE GLIONEURONAL TUMORS
A. Bertrand1, J. Masliah-Planchon2, P. Leblond3, P. Varlet4, L. Brugières5,
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Background/Objectives: Low-grade glioma with a rhabdoid component and loss of
BAF47 were reported in 4 pediatric cases up to now. Patients were usually young, with a
median age of 4 years, and their prognosis dismal (3 patients died).
Design/Methods:We report 5 cases of pediatric patients presenting low-grade gliomas
harboring either at diagnosis or during evolution a rhabdoid component and a
homozygous deletion of SMARCB1.
Results: Age at diagnosis ranged from 13 months to 12 years. All tumors were located in
the fronto-parietal region, and presented an avid and heterogeneous enhancement, with
edema but no necrosis. Histology of the low-grade component (LGGC) was a
ganglioglioma for two patients, an association between a ganglioglioma and an
oligodendroglioma for one patient, a pleomorphic xanthoastrocytoma for one patient,
and an unclassifiable tumor for one patient. A BRAF V600E mutation was detected in
none of the patients but the pleomorphic xanthoastrocytoma one. The rhabdoid
component (RC) was evidenced at diagnosis for 4 patients. It appeared at relapse for
one patient while he was treated by BRAF V600E inhibitor. All cells in the RC showed
a typical BAF47 loss of expression. Comparing array-CGH from the LGGC and the
RC in two patients clearly showed the similarity of the two profiles. However,
SMARCB1 deletion was hemizygous in LGG and homozygous in RC, demonstrating
that RC was a subclonal evolution of LGGC. Overall 3 patients died, one within 24
hours after diagnosis, two patients 6 months and 2 years after diagnosis, including the
patient with deletion of SMARCB1 at relapse, and 2 patients are in complete remission
2 years and 4.5 years after the initial diagnosis.
Conclusion: This short series brings evidence that a subset of pediatric glioneuronal
tumors may secondarily transform as rhabdoid tumors. CGH-profiling shows a
hemizygous SMARCB1 deletion that may underline potential aggressive
transformation of such benign tumors.
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TREATMENT OUTCOME AND PATTERNS OF FAILURE IN PATIENTS OF
SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOUR:
CLINICAL EXPERIENCE FORM A REGIONAL CANCER CENTER IN NORTH
INDIA
A. Biswas1, S. Mallick1, S. Purkait2, S. Roy1, C. Sarkar2, S. Bakhshi3, M. Singh4,
P. Julka1, G. Rath1
1All India Institute of Medical Sciences, Radiation Oncology, New Delhi, India; 2All
India Institute of Medical Sciences, Pathology, New Delhi, India; 3All India Institute of
Medical Sciences, Medical Oncology, New Delhi, India; 4All India Institute of Medical
Sciences, Neurosurgery, New Delhi, India
Background/Objectives: Supratentorial primitive neuro-ectodermal tumours (SPNET)
are high grade, embryonal tumours, which account for 2–3% of paediatric brain
tumours.
Design/Methods:We assessed the clinical features and treatment outcome in patients of
SPNET by retrospective chart review from 2003-12. Overall survival (OS) and
recurrence free survival (RFS) were analyzed by Kaplan-Meier method.
Results: Thirty two patients met the study criterion (male: female=21:11). Median age
at presentation was 12 years.Tumour location was pineal in 17 and hemispheric in 15
patients. Median KPS was 80. Surgical resection was gross-total in 12(37.5%), near-total
in 2, subtotal in 10(31.25%) and limited to biopsy in 7(21.88%) patients. Histopathology
showed sheets of small round blue cell tumour immunopositve for synaptophysin, class
III ß-tubulin and neuron specific enolase (NSE). Median MIB-1 labelling index was
35%. At presentation, 6(18.75%) patients had leptomeningeal dissemintation.
Radiation therapy was delivered in 29(90.63%) patients with majority(75%) receiving
craniospinal irradiation(CSI)(36Gy/20fractions/4weeks) followed by local boost of
20Gy/10fractions/2weeks. Systemic chemotherapy (median 6 cycles), given in
27(84.38%) patients, included VAC(vincristine,adriamycin,cyclophosphamide)
alternating with IE (ifosfamide,etoposide) regimen in non-pineal tumours and EP
(carboplatin and etoposide) regimen in pineal tumours. After a median follow-up of
29.22 months (mean 30.35 months), seven (21.88%) patients had died (6-disease
progression and 1-neutropenic sepsis). Recurrence was noted in 13(40.63%) patients
(local-3, leptomeningeal-5 and both-5 patients). Median OS was not reached (actuarial
rate of OS at 3 years-75.7%) and estimated median RFS was noted to be 5.49 years
(actuarial rate of RFS at 3 years- 59.5%). On univariate analysis, there was a trend
towards inferior RFS in patients with M+ disease (median-2.19 years) compared to
those with M0 disease (median-6.38 years) (P=0.06).
Conclusion:Maximal safe resection followed by CSI and chemotherapy with 6 cycles of
VAC/ IE (in non-pineal tumour) or EP (in pineal tumour) is a reasonable treatment
strategy in patients of SPNET in a developing nation.
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AN UNUSUAL CASE OF RHABDOID MENINGIOMA
A. Boardman1,2, S. Stivaros3,4,5, M. McCabe3,7, A. Kelsey6, V. Josan8, A. Penn3,7
1University of Manchester, School of Medicine, Manchester, United Kingdom; 2Christie
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Manchester, United Kingdom; 4Institute of Population Health-University of Manchester,
Centre for Imaging Sciences, Manchester, United Kingdom; 5Royal Manchester
Children’s Hospital-Central Manchester University Hospitals NHS Foundation Trust,
Academic Department of Paediatric Radiology, Manchester, United Kingdom; 6Royal
Manchester Children’s Hospital-Central Manchester University Hospitals NHS
Foundation Trust, Department of Paediatric Histopathology, Manchester, United
Kingdom; 7Institute of Cancer Sciences-University of Manchester, Centre for
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Foundation Trust, Neurosurgery, Manchester, United Kingdom
Background/Objectives:Meningioma accounts for approximately 1% of primary
paediatric central nervous system tumours, making these a relatively uncommon
diagnosis in childhood. Within the paediatric population, a higher than expected
proportion of these tumours are of a malignant subtype (papillary, rhabdoid,
anaplastic). We present the case of an 11 year old girl diagnosed with rhabdoid
meningioma, diagnosed incidentally during investigations following a traumatic head
injury.
Design/Methods:We reviewed the patient casenotes, identifying the patients initial
presentation, imaging results, management plan and final pathological diagnosis.
Results: Previously asymptomatic, the patient developed symptoms of headache,
vomiting, photophobia and neck stiffness over a one week period following a witnessed
fall which resulted in head injury. Whilst the CT and MRI demonstrated an extra axial
lesion, the remaining imaging phenotype was atypical for a meningioma with areas of
diffusion restriction, lack of enhancement and areas of haemorrhage, with significant
mass effect. This patient was treated with a macroscopic complete resection (Simpson
grade 2). Histologically, this tumour was composed of sheets of enlarged eosinophilic
cells, with eccentric nuclei and a high proliferative index (10-15%). Thickened dura was
noted to extend beyond the mass. Immunohistochemical staining with INI1 confirmed
the diagnosis. She is currently receiving adjuvant focal radiotherapy.
Conclusion: The results of investigations performed are in keeping with an aggressive
malignant meningioma of the rhabdoid subtype. This histological diagnosis is
extremely rare in children.
P-132
THE RESULTS OF TREATMENT OF RECURRENT ANAPLASTIC
EPENDYMOMAS (AE) IN CHILDREN
I. Borodina1, O. Geludkova2, E. Kumirova1, E. Salnikova1, V. Emtsova1, S. Ozerov3,
O. Shcherbenko4, Y. Kushel5, A. Melikyan5, O. Polushkina6
1Russian Research Center Hematology Oncology and Immunology, Neurooncology,
Moscow, Russia; 2Russian Research Center Rentgenradiology, Neurooncology, Moscow,
Russia; 3Russian Research Center Hematology Oncology and Immunology,
Neurosurgeon, Moscow, Russia; 4Russian Research Center Rentgenradiology,
Radiologist, Moscow, Russia; 5Institute Neurosurgery, Neurosurgeon, Moscow, Russia;
6Moscow Children Hospital, Oncology, Moscow, Russia
Background/Objectives: To evaluate the survival of patients in relapse of AE, and there
survival depending on the treatment scheme.
Design/Methods:We observed 57 children with AE progression after initial treatment,
39 boys and 18 girls at the age from 1 month to 19 years (median 4 years). The tumor
was located initially supratentorial in 29 patients (50.9%) and subtentorial - in 28
(49.1%). 34 patients (59.7%) had stage M0, 2 (3.5%) - M1, 2 (3.5%) - M2, 4 (7.0%) -
M3, in 15 patients (26.3%) stage was not determined. As a first-line therapy 30 patients
(52.6%) received surgery+RT+PCT, 14 (24.6%) - surgery+PCT, 9 (15.8%) -
surgery+RT, and 4 (7.0%) - only surgery.28 patients (47.8%) had a relapse as the
progression of the disease (PD), 15 (26.3%) - continued growth, 11 (19.3%) - Mts, 3
(5.3%) - relapse+Mts, 1 (1.7%) - continued growth+Mts. The median time before PD
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was 17 months (3-48 months).37 patients (65.0%) was obtained as a therapy of the 2nd
line Protocol HIT REZ 2005 with TMZ, 6 (10.5%) - only surgery, 4 (7.0%) -
surgery+RT, 4 (7.0%) - only RT, 6 (10.5%) - various non-protocol treatment.
Results: The median of follow-up after PD - 15 months (1-110 months). 5-year PFS
after 2nd line therapy - 0.30. Median PFS - 25 months. Alive 35 patients (61.0%), 17 of
them finished treatment.5-year PFS in patients treated with the protocol HIT REZ
2005 with TMZ - 0.34, in patients receiving only surgery and / or radiotherapy - 0.24,
non-protocol with treatment - 0.23, p = 0.56.
Conclusion: The best results were obtained in the group of patients treated with the
protocol HIT REZ 2005 with TMZ.
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CEREBELLAR ASTROCYTOMA IN A REGIONAL NEURO-ONCOLOGY
CENTRE; EVALUATING THE NEED FOR POST-SURGICAL IMAGING
SURVEILLANCE
H. Brophy1, B. Pizer2, C. Mallucci3, S. Avula4, S. Hemsworth2, B. Pettorini3,
D. Williams2, J. Hayden2
1Liverpool, United Kingdom; 2Alder Hey Children’s Hospital, Oncology, Liverpool,
United Kingdom; 3Alder Hey Children’s Hospital, Neurosurgery, Liverpool, United
Kingdom; 4Alder Hey Children’s Hospital, Radiology, Liverpool, United Kingdom
Background/Objectives: Cerebellar astrocytomas constitute around 15 % of CNS
neoplasms in childhood. Surgery, with the aim of complete resection, is the principal
treatment modality, although need for and duration of post-surgical MRI surveillance
is not well defined. In this respect, we conducted an evaluation of the outcome of
cerebellar astrocytomas at our regional paediatric neuro-oncology centre.
Design/Methods: Our tumour database was interrogated to identify all cases of
cerebellar astrocytoma. Variables included patient age, gender, tumour grade,
completeness of resection, duration of follow-up, remission status and adjuvant
therapy.
Results: Between 1988 and 2007, 49 patients with cerebellar astrocytoma were reviewed
- 43 pilocytic astrocytomas, 4 fibrillary astrocytomas, 1 ganglioglioma and 1 unspecified
low-grade tumour. Thirty seven patients underwent complete resection (CR), none of
whom relapsed. Of the 12 patients with incomplete resection, six patients progressed at
between 4 months and 6 years. We thus changed the duration of MRI surveillance from
5 years to a maximum of 2.5 years (scans at 6, 18 and 30 months post surgery) in those
patients who had undergone CR. Since this change in practice, a further 12 patients (all
WHO grade 1) have been treated (data until December 2012-to allow > 2 years
follow-up). Eleven tumours were completely resected and 1 had a near total resection.
None of these 12 patients have relapsed (median follow-up - 4.9 years).
Conclusion: In this service evaluation, none of the 48 patients with completely resected
cerebellar astrocytoma relapsed, supporting a change in practice to shorten the
duration of post-operative surveillance. This has resulted in a time and cost saving to
families and our health service. The data does, however, raise the question as to whether
any surveillance imaging is required in completely resected pilocytic cerebellar
astrocytoma. For incompletely resected tumours, a standard 5-year post-surgical
imaging schema should be maintained.
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SINGLE AGENT VINORELBINE IN PEDIATRIC AND ADOLESCENT
PATIENTS WITH PROGRESSIVE UNRESECTABLE LOW-GRADE GLIOMA
A. Cappellano1, E. Bouffet2, F.A. Silva3, S. Cavalheiro4, M.T.S. Alves5, S. Toledo6,
I. Dias6, N.S. da Silva7
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Brazil; 6IOP/GRAACC/UNIFESP, Genetics, Sao Paulo, Brazil;
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Background/Objectives: The management of progressive unresectable low-grade glioma
(PULGG) remains controversial. Treatment options include chemotherapy, usually
preceded by a period of observation, to delay or even avoid radiotherapy and extensive
surgery in a proportion of children. Within this context an institutional protocol for
PULGG with vinorelbine, a semi-synthetic vinca alkaloid, was conducted at
IOP/GRAACC/UNIFESP with the aim to evaluate the clinical and radiological
response, as well as its toxicity profile.
Design/Methods: From July 2007 to may 2013, 41 patients with recurrent (9) and newly
diagnosed (32) PULGG were treated with vinorelbine 30 mg/m2 on days 0, 8 and 22 for
18 cycles. Response criteria used a combination of magnetic resonance imaging,
physical and visual evaluation.
Results:Mean age 6.4 years. Tumor sites: 27 optic pathway (1 disseminated), 1
intramedullary, 3 hemispheric (1 bilateral thalamic), 7 brainstem, 2 cerebellum, 1
gliomatosis cerebri. Twenty-eight patients had neurosurgical intervention, 18 grade I
astrocytoma and 10 grade II. Ten of them were evaluated by BRAF status showing 6
BRAF fusions, 2 of them also with BRAF mutation. Four patients had diagnosis of
neurofibromatosis type 1 and three diencephalic syndrome. Of the 41 patients enrolled
in the study, 40 were assessable for response. The best objective response was observed
in 17 patients (1 complete, 10 partial, 6 minor), while 23 had stable disease. The most
important toxicity was hematologic, with grade 3/4 neutropenia in 9 patients. None of
the patients showed grade 3/4 gastrointestinal toxicity and only 1 grade 3 neurotoxicity
(lower extremity pain). With a mean follow-up of 56 months the progression-free and
overall survival for the all group in 3 years was 49.3% and 81.8%, and 5 years was
36.8%, and 81.8%, respectively.
Conclusion: The results suggest that vinorelbine may be an option for PULGG,
showing some activity with low toxicity and excellent quality of life.
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CHEMOTHERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS
F. Cedeño1, M. Nana1, M. Urbieta1, P. Gabriela1, M. Cores1, M. Garcia Lombardi2
1Hospital de Niños Ricardo Gutierrez, Oncology, Buenos Aires, Argentina; 2Hospital de
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Background/Objectives: The low-grade gliomas (LGG), WHO grade I-II, corresponding
to 50% of tumors of the central nervous system. Surgery remains the mainstay in the
treatment, and complete resection the most important prognostic factor.The decision to
treat patients with incomplete resection is controversial because of the possibility of
sequelae related to a new surgery. Chemotherapy and radiotheraphy should be reserved
for symptomatic progression tumors with no possibility of complete resection.
PURPOSETo evaluate the efficacy of chemotherapy in pediatric patients (p) with
unresectable LGG, symptomatic or progressed after surgery.
Design/Methods: Retrospective descriptive population based study of LGG at a single
center from March 2002 to March 2014.
Results: Seventy one children were diagnosed and treated for LLG. Twenty p (28.5%)
were performed chemotherapy. All patients had localized disease. In 16 p (80%) partial
resection surgery was performed. In the remaining 4 no surgery was performed (3
chiasmatic and 1 in cervical cord tumors). The most common histological subtype was
pilomyxoid Astrocytoma (8 p, 40%) followed by pilocytic astrocytoma (3 p, 15%) and
diffuse astrocytoma (2 p, 10%). Most frequent location was suprasellar 75% (15p, Optic
pathaway 6 p). Fifty percent of p (10) performed treatment with carboplatin plus
Vincristine (COG A9952) and 9 p (45%) performed vinblastine weekly. One p received
oral Temozolomide. Three p made second-line and 2 p received local radiotherapy for
progression after receiving second-line treatment. Fifteen percent had Grade III
hematologic toxicity.The mean follow-up was 44 months (range 1-132), 6p(30%) died
for progression disease,1p died for postoperative complications and 13 p (65%) are
stable or with partial remission to date. The 5 yr. OS was 85%.
Conclusion: Use of chemotherapy in children with unresectable LGG progressed or
symptomatic appear to be effective in achieving stable disease with minimal toxicity,
delaying the use of local radiotherapy and avoiding progression.
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EXPRESSION OFMRTL ANDMYCHEX1 FROM C-MYC LOCUS IN
PEDIATRIC BRAIN TUMORS
M.H. Ji1, S.K. Kim2, C.Y. Kim3, H.J. Jun1, S.W. Blume4, H.S. Choi1
1Seoul National University Bundang Hospital, Pediatrics, Seongnam, Korea; 2Seoul
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Background/Objectives: The c-myc protooncogene plays a major role in the regulation
of cell growth, proliferation, differentiation, and apoptosis. In addition to the canonical
c-Myc p64 and p67 proteins, the human c-myc locus also encodes two distinct proteins
designated “mrtl” (ORF114) and “MycHex1” (ORF188) within the 5’-“untranslated”
region of the c-myc P0 mRNA. The aim of this study is to examine simultaneously, for
the first time, mrtl, MycHex1, c-Myc p64, and p67 in pediatric brain tumor tissues.
Design/Methods: The mrtl and MycHex1 coding sequences were PCR amplified and
analyzed in medullobastoma and malignant glioma tissues. Monoclonal mouse
anti-mrtl and polyclonal rabbit anti-MycHex1 antisera were developed. Western
analysis was done with whole cell lysates and immunofluorescence (IF) staining and
confocal imaging performed following methanol fixation.
Results: Sequence analyses confirmed a known polymorphism at base 1965 (T>G) and
revealed new mutations in mrtl sequence associated with non-synonymous amino acid
substitutions. MycHex1 sequence revealed no variation from published sequence.
Western analyses visualized mrtl, MycHex1, c-Myc (N262) p64 and p67 simultaneously.
The relative intensities of mrtl and MycHex1 were positively correlated. IF staining
showed mrtl dominantly localized to the nuclear envelope, along with prominent
reticular pattern in the cytoplasm consistent with endoplasmic reticulum (ER).
MycHex1 was observed as a series of bright foci located mainly within the nucleus and
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partially colocalized with fibillarin (a nucleolar protein). MycHex1 also stains other
intranuclear structures not recognized by fibrillarin.
Conclusion: This study showed the evidence for expression and stable accumulation of
all 4 proteins (mrtl, MycHex1, c-Myc p64, and p67) encoded by three non-overlapping
reading frames within the human c-myc locus. MycHex1 from the c-myc P0 mRNA
seemed to be located to a specific domain of the nucleoli, as well as other intranuclear
structures. Further work is ongoing to elucidate the functional or regulatory
relationships between these molecules.
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CHARACTERISTICS OF METASTATIC ORMULTIFOCAL LOW GRADE
GLIOMAS OF THE CENTRAL NERVOUS SYSTEM- A TEN YEAR
INSTITUTIONAL REVIEW
M. Dandapani1, I. Colmenero2, A. Peet1,3, M. English1
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Background/Objectives: Low grade gliomas (LGG) account for 40% of childhood CNS
tumours. A minority of these are metastatic or multifocal. Aim: To study the occurrence
and characteristics of metastatic compared to localised LGG.
Design/Methods: Retrospective review of all children aged 17 years with LGG (WHO
grade I or II, which meet criteria for LGG2 study) treated in our institution between
October 2003-September 2013.
Results: There were 150 patients with LGGs(73 male,77 female). At diagnosis, 45
patients(30%) were aged 0-4 years, 62(41.3%) were >10 years and 43(28.6%) were 5-9
years of age. One hundred and forty two patients(94.67%) had localised tumours:
62(40.7%) posterior fossa, 29(19.3%) hemispheric, 29(19.3%) optic pathway gliomas{18
of these patients had neurofibromatosis type I (NF-1)}, 19(12.7%) deep midline (tectal
plate, hypothalamus, corpus callosum) and 4(2.7%) spinal cord. Twenty-four patients
had NF-1; 3 patients had tuberous sclerosis with sub-ependymal giant cell
astrocytoma(SEGA). Histopathology was confirmed in 74% patients(103 localised and
all metastatic patients). Localised diagnoses: Pilocytic astrocytoma(n=82), diffuse
astrocytoma(n=5), ganglioglioma(n=8), SEGA(n=2), gemistocytic astrocytoma(n=1),
glioneuronal(n=2), astroglial(n=1), ganglioneuroma(n=1) and angiocentric
glioma(n=1). First line treatment in localised LGG was as follows: observation
only(n=18, 1 biopsy), third ventriculostomy(n=5), surgery(n=102),
chemotherapy(n=11) and radiotherapy(n=6). Progression was seen in 36 patients
requiring further treatment and there were 6 deaths. Eight patients(5.33%) had
metastatic/multifocal disease(3 patients aged 0-4 years, 2 aged 5-9 years and 3 aged >10
years). One patient had disease restricted to the cord with leptomeningeal spread while
7 had disseminated disease. Histopathology included 3 pilocytic astrocytomas, 2
pilomyxoid astrocytomas, 1 oligodendroglioma, 1 diffuse astrocytoma and 1
glioneuronal tumour. First line treatment was surgery(n=4), chemotherapy(n=3) and
radiotherapy(n=1). Five patients progressed needing further treatment with one death
(infant with extensive pilomyxoid astrocytoma).
Conclusion:Metastatic LGGs have more varied histology than localised
tumours(pilocytic vs other pathology(p=0.04)). Most children with LGG are cured.
Therefore careful treatment selection to minimise long-term consequences is crucial.
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CHILDHOODMEDULLOBLASTOMA - EXPERIENCE FROM A TERTIARY
CARE CENTER IN NORTH INDIA
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Background/Objectives:Medulloblastoma is the most common posterior fossa tumor of
childhood. Outcome depends on risk stratification based on age at diagnosis, extent of
surgery, spread of disease and eligibility for radiotherapy.
Design/Methods: This is a retrospective analysis of 21 children diagnosed with
Medulloblastoma who were treated during August 2009 to January 2015 in our
center.Children has been treated with surgery, concurrent chemotherapy and
radiotherapy followed by adjuvant chemotherapy with Packer’s regimen or high dose
chemotherapy with stem cell rescue. Data was analyzed using SPSS 22.
Results: Age of children ranges from 2 to 25 years (Median 8 years). Out of 21 children
15 were male (71.4%), 6 were female (28.6%). Eight (38 %) were of average risk, 13/21
(62%) were of high risk. Near total resection was done in 14/21 patients and 6/21 had
residual disease post resection. All except one (age-2 year) received craniospinal
radiotherapy post-surgery. Weekly Vincristine was given to all patients, two patients
also received Carboplatin during radiotherapy. Fifteen patients (8 with average risk and
7 with high risk) were treated with Packer’s regimen. One patient received baby brain
protocol. Four patients with high risk disease were treated with high dose
chemotherapy with stem cell rescue (4 cycles). Median survival has not reached. On
median follow up of 16 months overall survival (OS) for average risk was 86%, and 62%
for high risk. Fifteen out of twenty one (71%) are alive till January 2015, fourteen are
disease free, one relapsed but alive. Five out of six died due to disease progression, one
died due to HLH. None of the mortality was due to treatment related sepsis.
Conclusion: Outcome of this rare disease is reasonably good with combined modality
treatment and it is possible to administer high dose chemotherapy with stem rescue
without significant side effects even in developing countries.
P-139
HUMAN CYTOMEGALOVIRUS INFECTIONMODIFIES PATTERN OF DNA
METHYLTRANSFERASE-1 IN CNS TUMORS AND IN NON TUMOR CELLS
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Background/Objectives: Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus
that infects and establishes latency in the majority of the human population and may
cause fatal infections in immunocompromised patients. HCMV has been detected in
90-100% of malignant glioblastoma (GBM) and in a majority of primary
meduloblastomas (MB), two of the most common type of brain tumors. Epigenetic
alterations are believed to be a basic factor behind malignancies and whole genome
methylation studies of GBM tumors suggest that GBM recurrence is linked to
epigenetic mechanisms and pathways. Previous study from our laboratory has shown
that HCMV infection of non-tumor cells affects the host cell DNA methylation
machinery (DNA methyltransferases, DNMTs) by preventing its nuclear localization.
This may be a strategy for HCMV to abrogate the host cell defense against viral
replication.
Design/Methods: The overall aim of our work is to investigate epigenetic alterations
caused by HCMV encoded viral proteins in non tumor and CNS tumor cells, and to
further investigate if viral alterations of epigenetic mechanisms contributes to
tumorigenesis. In order to investigate the mechanism(s) involved in cellular
re-localization of DNMTs following HCMV infection, we analysed the expression of
DNMT1 in non-tumor (MRC-5 and HUVEC) and tumor cells (GBM and MB) by
TaqMan and confocal microscopy.
Results: Re-localization of DNMT1 from the nucleus to the cytoplasm appeared to be
associated with cells expressing HCMV-late proteins, and which could be restored in
the nucleus by antiviral (Ganciclovir) treatment. Our results suggest that specific viral
proteins interact with host cell proteins to modulate the host cell epigenetic response.
Conclusion:We hypothesize that HCMV infection may lead to host cell epigenetic
alterations of surviving cells and eventually to neoplastic events.
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PHASE II STUDY OF NIMOTUZUMAB AND RADIOTHERAPY IN CHILDREN
AND ADOLESCENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC
PONTINE GLIOMAS (DIPG)
S. Epelman1, V. Odone2, E. Gorender1, R.S.S. Medeiros1, L. Silva1
1Santa Marcelina Hospital, Pediatric Oncology Department, Sao Paulo, Brazil; 2Clinical
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Background/Objectives: DIPG are amongst the most challenging tumors to treat in
childhood with no drug proven to be effective. Standard of care remains focal
radiotherapy alone however, rapid disease progression usually occurred. Median overall
survival is less than 1 year, and the 2-year survival is less than 10%.
Design/Methods: Patients with clinically and radiologically confirmed, centrally
reviewed newly diagnosed DIPG were eligible for this multicenter phase II study. The
anti-epidermal growth factor receptor antibody, nimotuzumab (150 mg/m2) was
administered intravenously once weekly concomitant with focal radiotherapy (54Gy)
and every 2 weeks until tumor progression. Response evaluation was based on clinical
and radiological assessments. Primary objective was to improve survival with a historic
cohort that received radiation therapy alone.
Results: Twenty one patients entered into this study (7/14, male/female; median age, 7.6
years; range 2-16 years). All received radiotherapy. Treatment was well tolerated. 40/502
cycles had adverse effects related to the drug and very mild. The majority of adverse
effects were associated with progression of disease. Disease free survival at 7.3 months
was 85.7% (CI95% - 70.7-100). Overall survival at 9 months was 71.4% and at one year,
57.1% (CI95% - 33.8-74) which demonstrated better results when compared with
historic trials.
Conclusion: This trial demonstrated some activity of nimotuzumab in DIPG. It was
well tolerated and improved overall survival. A small subset of patients appeared to
benefit from this anti-EGFR antibody and can be considered in future trials with
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synergistic drugs. An upfront biopsy can bring the prospect of a better understanding
of DIPG biology and selection of better treatment.
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CHEMOTHERAPY-ONLY STRATEGIES FOR YOUNG CHILDREN
NEWLY-DIAGNOSEDWITHMALIGNANT BRAIN TUMORS; CAN THEY BE
APPLIED SUCCESSFULLY IN DEVELOPING COUNTRIES? THEMALAYSIAN
EXPERIENCE
J.L. Finlay1, W.A. Bin Abdullah2, D. Osorio1, L.H. Peng3
1The Neuro-Oncology Program - Center for Global Outreach, Division of Hematology,
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University of Malaya Medical Center, Kuala Lumpur, Malaysia; 3The Department of
Pediatrics, Subang Jaya Medical Centre, Subang Jaya, Malaysia
Background/Objectives: Since the 1980s, treatment strategies for young children with
malignant brain tumors have focused on initially delaying and subsequently avoiding
irradiation and its profound and irreversible deleterious effects through use of intensive
chemotherapy. We report the Malaysian experience with the “Head Start”
chemotherapy-only strategy and draw comparisons with the “Head Start” Consortium
studies conducted in high-income countries between 1990 and 2009.
Design/Methods: Patients: Since 1997, 17 children under 3 years old at diagnosis of
either medulloblastoma (13) or posterior fossa ependymoma (4) were treated with
either the “Head Start” HS-I or HS-II regimens. Ten children underwent gross-total, 4
near-total and 3 sub-total resections of primary tumor. Three children had metastases
at diagnosis.
Results: Fourteen children (82.5%) completed all 5 cycles of Induction chemotherapy;
one died of candidemia following HS-I cycle #4, two developed tumor progression
during HS-II Induction. Twelve children (70.5%) proceeded with myelo-ablative
consolidation and autologous hematopoietic cell rescue; two children completing
induction declined further therapy. All 4 children with ependymoma subsequently
relapsed, while 7/8 children with medulloblastoma undergoing transplant continue alive
without recurrence between 4 and 7 years from transplant. Overall, 7/13 children with
medulloblastoma (54%) all with localized disease at diagnosis, remain alive and
irradiation-free following this strategy.
Conclusion: This experience in an upper-middle-income Asian country demonstrates
the feasibility of these chemotherapy-only regimens for young children with
medulloblastoma, with tolerance and efficacy not significantly different from that
encountered in the comparable experience in high-income countries. With expanding
and improving infrastructure and supportive care for the management of many
childhood cancers, especially given persisting substantial lack of modern
radio-therapeutic equipment and expertise, these chemotherapy-only strategies should
be evaluated prospectively and more widely throughout middle- income developing
countries.
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EFFECT OF CHEMOTHERAPY AND CHEMORADIOTHERAPY FOR
MEDULLOBLASTOMAWITHIN PROTOCOL HIT-2000/2008 AMONG
CHILDREN UNDER THE AGE OF FOUR YEARS
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Background/Objectives: To estimate the efficiency of chemotherapy and radiotherapy
and to determine the prognostic factors.
Design/Methods: From 2009 to 2014, we analyzed 36 cases who got therapy within
protocol HIT-2000/2008 after tumor resection. There were 19(53%) girls and 17(47%)
boys. Most patients were older than 1 year: 5(14%) patients 3–12 months, 18(50%) -
13–24 months, 13(36%) - 25–48 months. The histological variant of the tumor were:
16/3 (53%) DМВ/MBEN, 15 (41.5%) CMB, and 2 (5.5%) LCA. Stage M0 was in 25
(69.5%) patients; M+ in 11 (30.5%). 15 cases (42%) underwent total resection; a
residual tumor was in 10 patients (28%). Chemotherapy+radiotherapy used on 19
(53%) patients; 17 (47%) got chemotherapy. Intrathecal/intraventricular Methotrexate
used to 22 (61%) patients.
Results: PFS and OS were 0.71±0.08 and 0.86±0.06. The mean time of observation was
36 months, the median time to progression - 17 months. 35 patients completed
treatment, 9 were diagnosed with recurrence, and 4 died of PD. PFS/OS was 0.88/1.0
for patients aged 25–48 months, 0.62/0.77 for patients 13–24 months and 0.60/0.80 for
patients 3–12 months. There were no differences in PFS/OS depending on the
histological variant: 0.61/0.85 for DMB/MBEN, 0.79/0.86 for CMB, and 1.0/1.0 for
LCA. Patients with stage M0 had better PFS/OS in contrast for M+: 0.74/0.95 and
0.64/0.65 respectively. PFS/OS among patients with M0R0 were 0.64/0.92;М0R+
0.89/1.0. PFS was better in patients who received intrathecal/intraventricular MTX
(0.79) in comparison to those who didn’t (0.63). PFS was 0.67 among patients who got
radiotherapy and 0.76 among those who didn’t.
Conclusion: Chemotherapy is efficient in MB patients under the age of 4. A low survival
rate was observed among patients under 1 year and with metastases. The completeness
of the surgical resection and radiotherapy did not affect the results of treatment. The
best survival rate was found among patients who got regional MTX.
P-142
RESULTS OF HIGH-DOSE CHEMOTHERAPYWITH AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT
OFMEDULLOBLASTOMA
A. Gevorgian1, E. Morozova1, I. Kazantsev1, T. Iukhta1, S. Safonova1, Y. Punanov1,
B. Afanasyev1, O. Zheludkova2
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Background/Objectives:Medulloblastoma (MB) is one of the most common pediatric
malignant brain tumors with less than 30% 5-year overall survival rate in high-risk
group. The aim of this study was to assess the effectiveness of single or tandem
high-dose chemotherapy (HDCT) with autologous hematopoietic stem-cell
transplantation (auto-HSCT) in this patient group.
Design/Methods: From February 2006 to February 2015, 32 pediatric patients with
high-risk or relapsed MB received HDCT with auto-HSCT after induction
chemotherapy, radiotherapy and surgical treatment. At the moment of HDCT 15
patients were in complete remission (CR), 10 patients were in partial remission (PR)
and 7 patients had stable disease (SD). Patients received single or tandem auto-HSCT
depending on age. Bone marrow (N=16), peripheral blood stem cells (N=13) or both
(N=3) were used for stem cell sources.
Results: The median follow-up is 17 months (range, 2–78). The median time to
engraftment was day +15 (range, 11–30) after auto-HSCT. Six patients with SD at the
moment of auto-HSCT died of disease progression. Ten of 25 patients with CR or PR
relapsed 1-23 months after HDCT, 11 patients are currently in CR and the other 4
children died of toxicity. 2-Year overall survival (OS) was 50% and disease free survival
(DFS) was 47%. 2-Year DFS was significantly better among high-risk patients in 1st CR
compared to patients in 2nd or following CR: 80% and 38%, accordingly (p=0,05).
Patients in CR or PR at the moment of HDCT had better DFS rate than patients in
SD: 60%, 40% and 14% (p=0,003), respectively.
Conclusion: HDCT with auto-HSCT in pediatric patients with high-risk MB may be a
feasible option for patients in CR or PR after induction chemotherapy. It is ineffective
as a salvage therapy in refractory patients.
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MANAGEMENT OF PROGRESSING BRAIN STEM ANAPLASTIC
GANGLIOGLIOMAWITH AMOLECULAR BASED THERAPY
I. Martinez1, B. Herrero1, M.D. Corral2, M. Villa1, B. Angulo3, A. Duque4, C. Rubio5,
S. Garcia-Duque6, B. Lopez-Ibor1
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Background/Objectives: To show the changes in the treatment, based in molecular
studies, and the clinical evolution in a patient with a CNS tumor.
Design/Methods: A 2yo Caucasian boy diagnosed with a brain stem anaplasic
ganglioglioma is presented. Clinical summary revealed a 13 month history of gait
disturbances and several cranial nerve paresia, dismetria and left hemiparesia. The
tumor was unresectable so only a biopsy could be obtained. He was initially treated with
chemotherapy (vincristine, cisplatin, etoposide, and cyclophosphamide) but progressed
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after 5 cycles. Treatment was then started with irinotecan and bevacizumab with an
improvement over the next 10 months. After 13 cycles irinotecan was stopped because
of gastrointestinal toxicity but Bevacizumab was mantained. Three months latter
tumor progression was diagnosed. Molecular study of the tumor had been performed
at diagnosis, and showed a mutation in BRAF exon 15 (c. 1799> A, pVal600Glu).
Treatment with dabrafenib (3,75 mg/kg/day) was initiated after this 3rd tumor
progression. 4 weeks later clinical improvement was remarkable and confirmed with a
cranial NMR on week 12. Six months later the treatment was stopped 10 days because
a VP shunt infection. In this context the patient had a neurological deterioration and
tumor progression on NMR. Dabrafenib was resumed and cloroquine was added (3
mg/kg/day) with a clinical improvement that has been confirmed by a cranial NMR.
Child is 5yo, attend school and has a residual left hemiparesia and left held tilting.
Results: A personalized treatment in this patient has improved his survival and quality
of life.
Conclusion:Molecular analysis of our patient’s tumor allowed us, to identify a
druggable mutation which gave us the chance to administer Dabrafenib once several
considered standard treatments had failed. Our patient that significantly improved since
he started Dabrafenib. The rol of adding cloroquine in this context has been previously
reported in order to induce autophagy.
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EXPRESSION IN CHILDHOOD NEURAL TUMORS AND INHIBITION OF
WNT SIGNALING PREVENTS CHEMORESISTANCE
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Background/Objectives: High expression of the DNA repair enzyme
O6-methylguanine-DNA methyltransferase (MGMT) are frequently detected in
cancers and MGMT is an important factor for treatment failure and development of
cancer cell resistance against chemotherapeutic drugs. Several drugs inhibiting MGMT
have been developed but their systemic uses are limited due to lack of efficiency and
hematologic toxicity.
Design/Methods:We searched for cellular regulators of MGMT expression in cancers
of different origin as an alternative approach to inhibit MGMT. Pathway-specific gene
expression profiling, gene clustering and immunohistochemistry where used to detect
correlations between MGMT and other genes and signaling pathways. Pharmacological
or genetic inhibition of target genes where used to confirm regulation of MGMT and
restoring chemoresistance in vitro and in vivo.
Results:We show that the canonical Wnt signalling pathway regulates the expression of
MGMT in childhood neural tumors. A significant correlation between Wnt signaling
and MGMT expression in childhood gliomas, medulloblastomas and neuroblastoma
that was confirmed by gene expression analysis and immunofluorescence demonstrating
co-localization between active β-catenin and MGMT. Small molecule inhibition of key
molecules within the canonical Wnt signalling cascade or knock-down of β-catenin
downregulates MGMT expression and restore chemosensitivity to DNA alkylating
drugs in mouse models of neural tumors.
Conclusion: These findings have potential therapeutic implications for the treatment of
chemoresistant cancers, especially in brain tumors where the use of temozolomide
frequently is included in the treatment protocols.
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IMPACT OF TUMOR TYPE, LOCATION, AND TREATMENT ON PHYSICAL
AND EMOTIONAL OUTCOMES IN PEDIATRIC BRAIN TUMOR
C. Karlson1, M. Barrera2, A. Patenaude3, M.J. Kupst4, C. Gerhardt5, K. Vannatta5
1University of Mississippi Medical Center, Pediatrics, Jackson, USA; 2The Hospital for
Sick Children, Psychology, Toronto, Ontario, Canada; 3Dana-Farber Cancer
Institute-Harvard Medical School, Psychiatry, Boston, USA; 4Medical College of
Wisconsin, Psychology, Milwaukee, USA; 5The Research Institute at Nationwide
Children’s Hospital and The Ohio State University College of Medicine, Psychology /
Neuropsychology, Columbus, USA
Background/Objectives: Survivors of pediatric brain tumor suffer reduced quality of life
in both physical health and psychological health. There is a paucity of research
examining medical factors that may impact physical and psychological health outcomes.
It was the aim of this study to identify the impact of brain tumor type, primary
location, and treatment modality on parent-reported child pain, physical functioning,
and emotions.
Design/Methods: Participants included mothers of 182 children and adolescents (M age
= 11.3 years; 47.3% female;M = 3.8 years since diagnosis) diagnosed with a brain
tumor. Brain tumor types included low grade glioma/astrocytoma (LGA; 48.4%),
PNET (23.6%), ependymoma (7.7%), craniopheringioma (7.1%), germ cell (13.2%), and
other (7.7%). Primary tumor location included infratentorial (45.6%), supratentorial
(33.0%), and midline (18.7%). Parents completed the Child Health Questionnaire and
the Child Behavior Checklist. Multivariate regression and post-hoc t-tests were utilized.
Results: Controlling for age at diagnosis, tumor type was associated body pain (F = 2.5,
p < .05), physical functioning (F = 6.9, p < .01), and withdrawal/depression symptoms
(F = 3.3, p = .01). Specifically, LGA was associated with less body pain, better physical
functioning, and less withdrawal/depression compared to PNETs and
craniopheringiomas (p’s < .05). Supratentorial tumor location was associated with less
withdrawal/depression compared to infratentorial (t = -4.3, p < .01) and midline tumors
(t = −3.1, p < .01). Chemotherapy and radiation were associated with decreased
physical function (p’s < .01) and increased withdrawal/depression symptoms (p’s  .01),
while radiation was also associated with increased body pain (F = 6.1, p = .02).
Conclusion: Children with LGA and supratenorial tumors may suffer fewer negative
physical and emotional outcomes than children with other brain tumors. Chemotherapy
and radiation appears to increase the risk for both physical and emotional concerns.
Identifiable risk factors may help guide early monitoring and intervention.
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EMBRYONAL TUMORSWITH ABUNDANT NEUROPIL AND TRUE
ROSETTES: CLINICOPATHOLOGICAL REPORT OF THREE CASES
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Background/Objectives: Embryonal tumors with abundant neuropil and true rosettes
(ETANTR) are very rare childhood embryonal brain tumors with distinct
histopathological features. Standard therapy for other embryonal brain tumors is
ineffective and prognosis is dismal.
Design/Methods: Among 42 children with embryonal brain tumors treated at our
institution, three patients with ETANTR were identified. We present clinical courses
and analyze molecular characteristics including 19q13.42 amplification and LIN28A
and DNMT3B expression in three cases.
Results: Case 1: Three-month-old girl presented with increasing head circumference.
MRI showed a tumor in the fourth-ventricle, which was sub-totally resected. Complete
resolution of the tumor on images was achieved by multi-agent chemotherapy and focal
proton therapy. The tumor recurred 17 months after diagnosis. Despite sub-total
resection followed by high-dose chemotherapy with hematopoietic stem cell rescue, the
tumor progressed and the patient died 2 years after diagnosis. Case 2: One-year-old girl
presented with vomiting and CT showed a tumor in right cerebellar hemisphere. The
tumor was sub-totally resected. The tumor recurred during multi-agent chemotherapy.
Craniospinal irradiation was started, however the tumor progressed rapidly and
patients died 5 months after diagnosis. Case 3: One-year-old boy presented with left
lower extremity weakness, gait disturbance and left conjugate deviation of eyes.
Imaging studies showed a tumor invading midbrain and pons with spinal
dissemination. Tumor biopsy revealed the diagnosis. The tumor was resistant to
multi-agent chemotherapy and showed partial response to radiotherapy. However the
tumor progressed in two months after radiotherapy.
Conclusion: The MRI findings of ETANTR were iso in T1, iso-high in T2, negative for
gadolinium contrast and high in diffusion weighted image with ADC value of 0.5-0.7.
Microscopic morphology was typical and immunohistochemical staining showed
LIN28A expression in all case. DNMT3B was expressed in nuclei in case 1 and 2.
Amplification of 19q13.42 was confirmed by fluorescent in situ hybridization in case 2
and 3.
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YEAR EXPERIENCE IN A DEVELOPING COUNTRY
R. Kizyma1, Z. Kizyma1, B. Kotsay2, L. Dvornyak3, K. Biganych4, I. Lukavetskyi1,
T. Mykytyn4
1Western Ukrainian Specialized Children’s Medical Centre, Surgery, Lviv, Ukraine; 2Lviv
National Medical University, Pediatrics, Lviv, Ukraine; 3Western Ukrainian Specialized
Pediatr Blood Cancer DOI 10.1002/pbc
SIOP ABSTRACTS S277
Children’s Medical Centre, Neurology, Lviv, Ukraine; 4Lviv City Children Hospital,
Neurosurgery, Lviv, Ukraine
Background/Objectives: Pediatric CNS tumours are a heterogeneous group of
malignancies. The prognosis for children with medulloblastoma and high-grade gliomas
including anaplastic astrocytoma and glioblastoma multiforme remains poor. The
choice of treatment strategy in the realm of a developing country remains controversial.
Design/Methods: A retrospective chart review of children with CNS tumours treated
and observed at Lviv institutions from 2005 to 2014 was performed. 74 cases of
different histological subtypes were analysed. Diagnosis was confirmed by excision or
biopsy of the primary lesion or metastases. Conventional CT and MRI scans were
performed according to the site of involvement.
Results: The largest cohorts were patients with LGG (30%), medulloblastoma (23%),
HGG (16 %), anaplastic ependymomas (12%) and germ cell tumours (8%). Patients
with WHO grade III-IV tumours received multimodal treatment (surgery, distant beam
radiotherapy and adjuvant chemotherapy with cyclophosphamide, methotrexate,
carboplatin, VP-16, cisplatin, CCNU and vincristine) mainly using recommendations
of HIT2000 protocol. All patients with HGG received temozolomide as adjuvant
treatment with radiotherapy. At the end of 2014, with a median follow-up of 36
months, the 3-year OS in patients with WHO grade III-IV tumours is 50% including
47% for medulloblastoma. Patients with WHO grade I-II tumours (LGG) received
adjuvant distant beam radiotherapy after surgery in the case of residual tumour. The
3-year OS in patients with WHO grade I-II tumours is 82%.
Conclusion: Gross total resection of the primary tumour, no delay in radiotherapy after
subtotal resection and appropriate adjuvant chemotherapy were the main factors to
influence the survival without considering WHO grade. Temozolomide was a good
option as an adjuvant treatmentof HGG alongside radiotherapy. The tumour specimen
cytogenetic analysis is the next step in proper implementing of novel agents in the
treatment of unfavourable CNS tumours in low income countries.
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PRIMARY INTRACRANIAL GERM CELL TUMORS IN CHILDREN: 35-YEAR
EXPERIENCE OF SINGLE CENTRE
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Turkey
Background/Objectives: Germ cell tumors (GCT) are rare in intracranial region. We
aimed to evaluate the characteristics, treatment and outcome in patients with
intracranial GCT (IGCT).
Design/Methods: Patients with IGCT diagnosed in Hacettepe University Pediatric
Oncology Department, between1980-2014 were evaluated retrospectively. Patients’ age
and gender, complaints and signs, location and histopathological subtype of tumor,
treatment applied and survival time were recorded.
Results: There were 52 patients with a median age of 140(13–210) months. Male/female
ratio was 2.25. The most frequent complaints were headache (50%), vomiting (44%),
polydipsia/polyuria (34%). Most common signs were lateral gaze palsy (15), parinaud
syndrome (13), impairment of vision (10). Endocrinological investigation revealed
panhypopituitarism in 18 patients, diabetes insipidus in 4, precocious puberty in 2,
diencephalic syndrome in one. Hidrocephalus was diagnosed in 24 patients and half of
them required shunt. Tumor was located in sellar/suprasellar region in 40.4%, pineal
region in 38.4% and bifocal in 11.5% of patients. Pineal location was more common in
boys than girls (p=0.04). Intracranial and/or spinal seeding were observed in 9 patients.
Serum α-fetoprotein and/or β-HCG levels were high in 18 patients. Histopathological
diagnoses were germinoma in 60.8%, mixed GCT in 19.5%, yolk sac tumor in 4.34%,
immature teratoma in 8.7%, malignant teratoma in 6.5% of patients. Gross total or
subtotal excision was performed in 34 patients. Forty-three patients received platinum
based protocols, 42 received radiotherapy. Mean follow-up time was 47 months. Overall
and event free survival rates were 72.6% and 60.4%, respectively. OS and EFS rates for
germinoma were better than others subtypes (82.0% vs 68.5%, p:0.03 and 50% vs 34%,
p=0.004).
Conclusion: IGCT comprised 4.1% of 1,280 brain tumors and 8.8% of 587 GCT
diagnosed in our department in the same period. Endocrine disturbances were an
important problem. The survival rates in IGCT were similar to that of GCT in other
regions.
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RADIATION SPARING APPROACH FOR PATIENTS WITH ATRT: A MULTI
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Background/Objectives:While radiation has been included in most of the recent
multimodality strategies to treat ATRT, the concern of significant neurocognitive deficit
in these very young children has led some pediatric neurooncologists to avoid the use of
systematic adjuvant radiation. We present here a multi institutional Canadian
experience of radiation sparing approach.
Design/Methods: Retrospective review of patients diagnosed between 2001 and 2013 in
3 Canadian centers (Calgary, Vancouver, Toronto) with ATRT and treated with high
dose chemotherapy (HDC) with the intent to delay or avoid radiation.
Results: There were 16 females and 10 males. The median age at diagnosis was 21.2
months (4.2-110.2). Fourteen patients had a supratentorial tumor and 8 were metastatic
at diagnosis (1M1, 5M2, 1M2/M3, 1 M2/MRT). Fifteen achieved gross total resection
(3 underwent second look surgery). Ten patients received additional triple IT
chemotherapy. Five of the 16 patients tested had evidence of INI1 germline
mutation.Conditioning regimen for consolidation consisted in 1 cycle of
(Carbo/VP16/Thiotepa) in 6 patients, 3 cycles of (Carbo/Thiotepa) in 19 and 4 cycles of
(CPM/CDDP/VP16) in 1 patient. Ten patient received maintenance therapy with
Tamoxifen and Cis retinoic acid following high dose chemotherapy.Only 6/26 (23%)
patients received adjuvant radiation. Radiation consisted in focal radiation in 4 and
craniospinal irradiation in 2 patients. Median age at time of radiation was 50.4 months
(37.3-110.2). Eleven patients relapsed. Ten patients died of disease, one of treatment
related toxicity. At a median time of 53.8 months, 15 patients (57.6%) are alive with 11
(73.3%) of them who did not received radiation.
Conclusion: Although there is a lack of clear prognostic factor to identify patients with
ATRT who can be spare upfront radiation, our experience describe promising survival
rate for patient with ATRT in absence of adjuvant radiation. Upcoming molecular
classification in ATRT should help delineating indication of radiation.
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VINBLASTINE AS FIRST-LINE TREATMENT: A CANADIANMULTICENTER
STUDY
A. Lassaletta1, K. Scheinemann2, S.M. Zelcer3, J. Hukin4, B. Wilson5, N. Jabado6,
A.S. Carret7, L.L. Cousin8, V. Larouche9, C. Hawkins10, G.R. Pond11, K. Poskitt12,
E. Barlev1, D. Keene13, D. Johnston13, V. Ramaswamy1, U. Bartels1, U. Tabori1,
E. Bouffet1
1Hospital for Sick Children, Pediatric Neuro-Oncology, Toronto, Canada; 2McMaster
Children’s Hospital at Hamilton Health Sciences, Pediatric Hematology-Oncology,
Hamilton, Canada; 3Children’s Hospital of Western Ontario, Pediatric Hematology
Oncology, London, Canada; 4British Columbia Children’s Hospital, Pediatric
Neuro-Oncology, Vancouver, Canada; 5Universtiy of Alberta Hospital, Pediatric
Hematology Oncology, Edmonton, Canada; 6McGill University, Pediatric Hematology
Oncology, Montreal, Canada; 7Hospital Sainte Justine, Pediatric Hematology-Oncology,
Montreal, Canada; 8Alberta Children’s Hospital, Pediatric Neuro-Oncology, Calgary,
Canada; 9Centre Hospitalier Universitaire de Quebec, Pediatric Hematology Oncology,
Quebec, Canada; 10Hospital for Sick Children, Neuro-pathology, Toronto, Canada;
11Ontario Clinical Oncology Group OCOG, Statistician, Hamilton, Canada; 12British
Columbia Children’s Hospital, Pediatric Hematology Oncology, Vancouver, Canada;
13Children Hospital of Eastern Ontario, Pediatric Hematology Oncology, Ottawa,
Canada
Background/Objectives: The purpose of this prospective study is to describe the
quality-of-life (QOL) of children with low-grade glioma (LGG) treated with weekly
vinblastine as first-line chemotherapy. To our knowledge, this is the first study that
evaluates the QOL during treatment in children with LGG.
Design/Methods: QOL assessments by the PedsQLTM Brain-Tumor-Module (version
1.0) were obtained at baseline, at 26 weeks, and at the end of the 70 weeks vinblastine
therapy. Children under 2 years were not eligible. Ages consisted in: 7 patients (2-4
years); 5 (5-7y); 7 (8-12y); and 13 (13-18y). Parents were requested to fill in the
questionnaires. Items explored included: cognitive problems, pain and hurt, movement
and balance, procedural anxiety, nausea, and worry.
Results: Of the 49 patients eligible for the study, only 24.5% had all questionnaires
completed. Sixty-seven percent had at least one completed. Mean change scores at week
26 and week 70 compared to baseline for all QOL subscales showed no significant
change. At baseline, scales with lower mean scores (out of 100) were cognitive problems
(66.11) and procedural anxiety (58.33). According to age, lower scores were seen in: 2-4
years in procedural anxiety (53.33); 5-7 years in cognitive problems (64.58), movement
and balance (62.50), and procedural anxiety (54.16); 8-12 years, in procedural anxiety
(55); and teenagers 13-18y in procedural anxiety (42.70) and worry (53.64).
Conclusion: QOL of children with LGG treated with vinblastine as first-line
chemotherapy is not altered during treatment. If we take into account that the response
rates of the different chemotherapy regimens for LGG in children are relatively similar,
the assessment of quality of life should be an element of comparison when deciding
chemotherapy for first line therapy. While remaining on vinblastine, LGG patients were
able to maintain their QOL in all realms. Vinblastine may be a good choice for first line
chemotherapy in this population.
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Background/Objectives: The prognosis of children with pediatric high grade glioma
(pHGG) remains poor despite aggressive multidisciplinary therapeutic approaches.
Current standard treatment combines surgery, radiation therapy and alkylating agents,
such as temozolomide. Evofosfamide (Evo, previously known as TH-302) is a
2-nitroimidazole hypoxia-activated prodrug of the cytotoxic bromo-isophosphoramide
mustard. Evo has been shown to exhibit preclinical activity against solid tumors. We
present here the first data with Evo in pHGG cell lines.
Design/Methods: Evo was evaluated in 3 well-characterized pHGG cell lines (SF188,
UW479, KNS42), cultivated under normoxic or hypoxic conditions (1% O2). The
cytotoxicity of Evo, used as a single drug or in association with SN38, doxorubicin and
etoposide, was evaluated in vitro using a MTS assay. The synergism was analyzed by the
Chou and Talalay method. Radio-sensitizing effects were investigated in vitro using
clonogenic assays. The antitumor activity of Evo was assessed in vivo using animal
models.
Results: Growth of all cell lines was inhibited by Evo single agent, and as expected, the
cytotoxicity of Evo was higher under hypoxic conditions (IC50 were 2-8 fold higher in
normoxic vs hypoxic conditions). As previously reported, we found a strong synergism
between Evo and doxorubicin, and we also demonstrated a significant synergistic effect
with SN38 and etoposide, 2 drugs widely used in pediatric oncology (CI0.5 in every
case). Radio-sensitizing effects and in vivo evaluations are currently ongoing.
Conclusion: Hypoxia is a well-known phenomenon leading to glioma cell resistance to
cytotoxic drugs. We report here the first preclinical data about a novel hypoxia-activated
prodrug Evo in pediatric high grade glioma. Interestingly, Evo appears effective in
hypoxic glioma cells and the synergistic effects observed with SN38, doxorubicin and
etoposide are of interest for pediatric oncology.
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CONCURRENT ARHI UPREGULATION AND JAK/STAT3 INACTIVATION IN
RESVERATROL-TREATEDMEDULLOBLASTOMA CELLS
H. Li1
1Dalian Medical University, Dalian, China
Background/Objectives:Medulloblastoma (MB) is the commonest pediatric brain
malignancyand has extremely poor prognosis because of the difficulty to remove the
tumor radically and the lack of effective adjuvant therapeutic approaches.
Resveratrol/Res, a natural polyphenol compound, exerts anti-medulloblastoma efficacy
and STAT3 signaling is its major molecular target. However, the mechanism underlying
resveratrol-suppressed STAT3 activation remains obscure. ARHI has been known as a
tumor suppressor gene because of its inhibitory effect on STAT3 activation. So far, the
status of ARHI expression in medulloblastomas has not yet been known. The current
study is aimed to investigate ARHI expression patterns and its relevance with
resveratrol-caused STAT3 inactivation in medulloblastoma cells.
Design/Methods: UW228-2 and UW228-3 human medulloblastoma cell lines were
cultured in DMEM culture medium containing 10% fetal bovine serum and DAOY in
10% fetal bovine serum containing RPMI 1640 medium. The three cell lines were
treated by 100mM resveratrol for 48 hours and their sensitivities to the treatment were
determined by multiple experimental methods. Meanwhile, the cells without and with
resveratrol treatment were collected for ARHI- and STAT3-oriented
immunocytochemical/ICC, RT-PCR and Western-blotting analyses.
Results: The three medulloblastoma cell lines so far checked are sensitive to resveratrol
in terms of suppressed growth, neuronal-like differentiation and distinct apoptosis. The
level of ARHI expression is very low and STAT3 signaling is activated in those cell
lines; after resveratrol treatment, ARHI is up-regulated in them, accompanied with the
decreased frequencies of p-STAT3 nuclear translocation.
Conclusion: The situation of ARHI downregulation and STAT3 activation in three
medulloblastoma cell lines can be reversed by resveratrol, suggesting an opposite
correlation of ARHI expression and STAT3 activity in medulloblastomas and the
potential involvement of ARHI in STAT3 inactivation of resveratrol-treated
medulloblastoma cells. Acknowledgments: Supported by the grants from National
Natural Science Foundation of China (No. 81450016, 81272786, 81071971, 81072063
and 30971038) and PCSIRT Program of China.
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CD57 DEFINES A NOVEL POPULATION OF GLIOMA STEM CELLS THAT
ARE POTENTIAL DRIVERS OF GBM INVASTION
L. Qi1, H. Yulun2, M. Kogiso1, H. Lindsay1, P. Baxter1, J.M. Su1, L. Perlaky1, C. Lau1,
M. Chintagumpala1, D.W. Parsons1, X.N. Li1
1Texas Children’s Hospital- Baylor College of Medicine, Pediatrics, Houston, USA;
2Soochow University, Neurosurgery, Suzhou, China
Background/Objectives: Diffuse invasion into normal brain is one of the hallmark
features that make GBM difficult to treat. Due to the lack of biologically accurate
invasive GBM cells from patients, most of the existing studies on GBM invasion were
conducted in surgical samples that were primarily tumor core tissues. Although cancer
stem cells are shown to be critical in tumor initiation and therapy-resistance, their role
in GBM invasion has not been well understood.
Design/Methods: To identify the cancer stem cell subpopulations that drive GBM
invasion, we utilized a panel of 7 (6 pediatric and 1 adult) patient tumor-derived
orthotopic xenograft (PDOX) mouse models to isolate matched pairs of invasive GBM
cells (from the “normal” mouse brains) and tumor core GBM cells and directly
compared their stem cell features.
Results: The invasive cells exhibited stronger neurosphere forming efficiency in vitro and
displayed higher tumorigenic capacity in vivo (particularly at 100 cells/mouse). A
systemic screening of putative cancer stem cell markers (CD133, CD15, CD24/CD44,
CD57 and CD117) showed that GBM cells in the invasive front were enriched with
CD57+ cells (>2 folds than the tumor core), and most of them were CD57+ CD133-.
Direct implantation of FACS purified CD57+/CD133- cells (100 – 10,000 per mouse)
into the brains of NOD/SCID mice confirmed their tumor forming capacity in vivo. We
also showed that CD57+ cells expressed high levels of self-renewal genes and tend to
stay in G0/G1 phases. Additionally, we found that CD133+ cells were frequently
dual-positive with CD57 (CD33+CD57+) both in the xenograft tumors and in patient
GBMs.
Conclusion:We identified CD57 as a novel GBM stem cell marker and showed that
CD57+ GBM cells are particular enriched in the invasive front of GBMs. Our findings
suggest that new anti-invasion therapies should be developed to target CD57+ cells in
addition to CD133+ cells.
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THE IMAGING AND CLINICAL FEATURES OF THE INTRACRANIAL
GERMINOMA
Y. Li1
1Shanghai Jiaotong University, Shanghai, China
Background/Objectives: To understand the imaging and clinical features of the
intracranial germinoma in order to improve the diagnosis.
Design/Methods: Fourty-one cases of intracranial germinoma were reviewed. All of
them but one were convinced by pathology and one case had typical image findings and
clinical course.They were performed by both CT and MRI before operation.
Results: The age of patients ranged from 8 to 20 years old. In our study, the most
common location was suprasellar region(58%),secondly pineal region(15%),basal
ganglia region(15%) and involving two regions (10%). The CT appearance of a
germinoma was that of an iso- to hyperdense mass and uniform enhancement after IV
infusion of contrast.On MRI, the mass showed isointensity on T1W and iso-to mild
hyperintensity on T2W, iso-to hyperintensity on DWI. In suprasellar region, patients
showed 5:1 female predominance presenting mainly diabetes insipidus or visual
disturbance .None of the tumours calcified in CT scan. In pineal region, patients
showed 7:1 male predominance presenting hydrocephalus. In CT, calcification was
identified in all cases. In basal ganglia region, patients showed 6:1 male predominance
presenting hemiparesis and mental status changes.One case no mass was seen. MRI
manifested pachy abnormal intensity with ipilateral frontal and temperal lobe
atrophy.After chemotherapy and radiotherapy, the lesion disappeared and patient
recovered.
Conclusion: Intracranial germinoma usually occur in young teenagers.Tumor in
different location appeared different image findings and different clinical presentation.
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CORRELATIVE ANALYSES OF SHH SIGNALINGWITH
RESVERATROL-INDUCED DIFFERENTIATION AND APOPTOSIS OF
HUMANMEDULLOBLASTOMA CELLS
J. Liu1
1Dalian Medical University, Dalian, China
Background/Objectives:Medulloblastoma (MB) arises from neuronal progenitors with
defects in cerebellum development-related signalings. Sonic hedgehog (Shh) signaling
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plays important roles in normal cerebellum development, indicating that altered Shh
signaling may leads to dedifferentiation or undifferentiation states of brain cell
components such as medulloblastoma formation. Resveratrol/Res suppresses growth
and promotes neuronal-like differentiation of medulloblastoma cells via certain
unknown manner(s). The aims of current study are 1) the status of Shh singnaling
components (Shh, Gli1, N-Myc and cyclinD1) in medulloblastoma cells and 2) the
potential influence of resveratrol in Shh signaling when promoting neuronal-oriented
differentiation.
Design/Methods: Two human medulloblastoma cell lines, UW228-2 and UW228-3,
were treated by 100μM resveratrol and the statused of Shh signaling in the cells without
and with the treatment were analyzed by multiple experimental approaches. Selective
inhibitors and siRNA interference for Shh signaling were employed to treat UW228-2
and UW228-3 cells to elucidate the significance of Shh signaling for medulloblastoma
cell maintenance/survival and resveratrol’s anti-medulloblastoma effects.
Results: Shh, Gli1, N-Myc and cyclinD1 were expressed in normally cultured UW228-2
and -3 cells, which were respectively down-regulated in both cell lines after resveratrol
treatment along with neuronal-like differentiation and apoptosis of MB cells. Shh
selective inhibitor (GANT61; a Gli antagonist) effectively suppressed the growth but
without induction of apoptosis of UW228-2 and -3 cells in a time and dose-related
fashion. Downregulation of Gli1 expression by siRNA interference inhibited MB cell
growth.
Conclusion: The above results demonstrate that 1) activated Shh signaling is neccessary
for the growth of medulloblastoma cells; 2) Shh activation occurred in downstream of
Smo in UW228-2 and -3 cell lines and 3) the inhibition of Shh signaling is one of the
molecular events caused by resveratrol in medulloblastoma cells.
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TREATMENT OF CHILDREN’S CENTRAL NERVOUS SYSTEM (CNS)
TUMOURS: A ‘MAP’ OF THE RESEARCH EVIDENCE AVAILABLE
C. Main1
1University of Birmingham, Birmingham, United Kingdom
Background/Objectives: To determine the evidence available for undertaking systematic
reviews for the Research for Patient Benefit (RfPB) programme on the effects of
treatments for children’s central nervous system (CNS) tumours, a ‘map’ of the
evidence base was produced.
Design/Methods: Seven electronic databases were searched for interventional studies on
surgical procedures, radiotherapy (RT), chemotherapy (CT), hormone therapy (HT),
immunotherapy, biological therapies and imaging from 1985 to November 2014 across
the spectrum of children’s CNS tumours. No study design filters were applied.
Psycho-social interventions were excluded. All relevant studies were then categorised by
tumour histology type, type of intervention and study design on the basis of the
available abstract.
Results: A total of 8,448 unique references was identified; with 1,868 included in the
‘map’. Eleven systematic reviews, 29 randomised controlled trials (RCTs) including
more than 4,992 patients, and 190 single arm phase II trials were identified. Most of the
single arm phase II trials were small with less than 40 patients included. The majority
of the evidence base was limited to case series studies (1,077) or case reports with less
than 5 patients (306). Chemotherapy regimens, used alone or in combination with RT,
were the most frequently assessed interventions. Radiotherapy (RT) used alone had also
been assessed in both RCTs and single arm phase II trials. Few studies of surgery alone,
HT, immunotherapy or biological agents were identified. The highest proportion of
studies had been conducted either in patients with medulloblastoma (11 RCTs, 28 single
arm phase II trials and 188 case series) or in patients with mixed tumour histologies (29
RCTs, 68 single arm phase II trials and 273 case series).
Conclusion: ‘Mapping’ the evidence base for children’s CNS tumours has highlighted
the paucity of well conducted RCTs in this arena, with most patients being entered into
uncontrolled studies that provide lower quality evidence.
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LONG TERM FOLLOW-UP OF PATIENTS WITHMETASTATIC (M+) AND
HIGH-RISK MEDULLOBLASTOMAWITH TAILORED-DOSES
HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (HART) CSI
PLUS/MINUS HIGH-DOSE THIOTEPA
M. Massimino1, L. Gandola2, F. Spreafico1, V. biassoni1, E. Schiavello1, E. Pecori2,
E. Pignoli3, T. Giandini3, R. Luksch1, M. Casanova1, A. Ferrari1, M. Terenziani1,
G. Poggi4, M. Podda1, C. Meazza1, S. Catania1, S. Chiaravalli1, N. Puma1,
L. Boschetti1, L. Veneroni1, M. Antonelli5, F. Buttarelli6, F. Giangaspero5,7
1Fondazione IRCCS Istituto Nazionale dei Tumori, Pediatrics, Milano, Italy;
2Fondazione IRCCS Istituto Nazionale dei Tumori, Pediatric Radiotherapy, Milano,
Italy; 3Fondazione IRCCS Istituto Nazionale dei Tumori, Physics, Milano, Italy;
4IRCCS Eugenio Medea La nostra Famiglia, Acquired Lesions, Bosisio Parini Lecco,
Italy; 5Università Sapienza, Pathology, Roma, Italy; 6Università Sapienza, Dip.
Neurologia e Psichiatria, Roma, Italy; 7Neuromed, Pathology, Pozzilli, Italy
Background/Objectives: Since 1998 we launched a mono-institutional, thereafter
national strategy, for M+medulloblastoma. We report the results of 54 M+ patients
and, from 6/2008, of 6 with large cell/anaplastic (LCA) no M+ and underline
outcome/toxicity features.
Design/Methods: An intensive post-surgical treatment applied HDMTX/VCR,
HDVP16, HDcyclo, HDcarboplatin followed by HART at total neuraxis dose of 39 Gy
(1.3Gy/fraction,2 fractions/day) with posterior fossa boost 60Gy (1.5Gy/fraction,2
fractions/day). If disease persisted before HART, patients received thereafter 2 courses
of myeloablative thiotepa, done in all patients with LCA histology. Children aged under
10 years and in complete remission before HART, received reduced 31.2Gy CSI.
Results of the first 33 patients were already published.
Results: Ten/54 patients had Chang M1 disease, 9 M2, 34 M3 and one M4; ten also
LCA histology; 42(78%) had at least SD pre-HART; 83% with evaluable disease had
CR+PR after HART; 11 patients received 31.2Gy CSI; 29 had high-dose thiotepa. No
patient progressed after HART. Both responses to CT and RT were prognostic factors;
CSI doses and use of HDthiotepa, tailored to response, were not. At 100months
median follow-up for the 54 metastatic patients, EFS and OS were 71%/69% and
73%/65% at 5/10yrs, respectively. All the 6 with LCA were alive at median 55 months.
Five/60 patients– all receiving HDthiotepa –median 6 months after treatment developed
a neuro-functional impairment characterized by worsening/appearance of cerebellar
signs, hear/sight loss, seizures, with some deterioration and plateau/improvement after
intensive rehabilitation. One/5 suffered from tumor progression and died. No
correlation with radiotherapy technique and dosimetry was documented after plan
review, moreover, 3/5 had avoided, for clinical reasons, posterior fossa radiation boosts.
Conclusion: Larger patient numbers and longer follow-up confirmed good results with
no event after 5-year follow-up. Functional toxicity after HDthiotepa post-HART
represents a rare, not fully understood occurrence, probably also correlated to
individual susceptibility.
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DISTRIBUTION AND PROGNOSTIC IMPACT OF MOLECULAR SUBGROUPS
IN AN HOMOGENEOUSLY TREATED SERIES OF METASTATIC
MEDULLOBLASTOMA
M. Massimino1, F.R. Buttarelli2, C. Baldi2, S. Minasi2, M. Antonelli3, F. Giangaspero3
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 2Università Sapienza,
Neurology and Psychiatry, Rome, Italy; 3Università Sapienza, Radiological-Oncological
and Anatomo-Pathological Sciences, Rome, Italy
Background/Objectives:Medulloblastoma (MDB) is the most common malignant brain
tumor in children. The prognostic system based on clinical parameters and
histopathological variants is commonly used in clinical practice. Four different
molecular subgroups are recognized, which differ in gene expression, genomic
aberrations, histology and survival: WNT and SHH groups, having specific mutations
in the homonymous pathway, and groups C and D having several genetic alterations
and associated to a worse outcome. Such molecular classification could provide a more
consistent approach to the therapeutic stratification of patients. The purpose of this
study was to evaluate the distribution and prognostic impact of the four molecular
subgroups in a series of 39 MDB metastatic at the onset and homogenously treated in a
single institution.
Design/Methods:We investigated the protein expression of different subgroup
biomarkers by IHC, RT-PCR, cDNA sequencing and FISH; results were correlated
with patient outcomes by Kaplan-Meier statistic analysis.
Results: On the basis of molecular sub-grouping we could identify 5 WNT cases with
nuclear translocation of β-catenin and DKK1 positivity, 7 SHH cases with triple
positivity of GAB1, YAP1 and Filamin A, 9 group C cases with FSTL5
over-expression and 5 group D cases with negativity for Filamin A, positivity for
KCNA1 and negativity for NPR3; 10 cases analyzed were unclassifiable (NC) having
heterogeneous biomarkers, for 3 cases the material was not enough to be analyzed.
MYC amplification is more frequent (32.5%) compared to the amplification of MYCN
(2.7%) and compared to the literature. WNT and NC groups showed superior (but not
statistically significant) OS and PFS compared to SHH, C and D.
Conclusion:While we have previously shown that the histological variants maintain
prognostic value also in metastatic MDB, especially referring to LC/A histology,
sub-grouping into molecular classes via IHC is not efficient to allow a prognostic
stratification in our cohort of metastatic MDB.
P-159
PEDIATRIC BRAINSTEM GLIOMAS: RESPONSE AND SURVIVAL
FOLLOWING RADIOTHERAPY
T. Mehmood1, M. Irfan1, A. Rashid1, A. Ghaffar1, U. Khaleeq1
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1Shaukat Khanum Memorial Cancer Hospital and Research Centre, Radiation Oncology,
Lahore, Pakistan
Background/Objectives: Brainstem gliomas accounts for approximately 20% of all
central nervous system tumors in children and carries very poor prognosis. A
retrospective review was made to analyze the clinical presentation, diagnosis, treatment
outcome and survival in pediatric patients with brainstem gliomas treated at Shaukat
KhanumMemorial Cancer Hospital and Research Centre Lahore, Pakistan.
Design/Methods:With a median age of 8 years (range 4-13 years), we retrospectively
analyzed 76 brainstem gliomas patients (56% males, 44% females), between January
2005 to December 2011. All patients were diagnosed by CT scan or MRI Brain.
Median duration from first symptom to appear and diagnosis was 2.3 months. 19% of
the patients had focal disease and 81% had diffuse lesions. 32% of the patients
presented with long tract involvement, 8% with cranial nerves involvement and 54%
with both. 93% of the patients were treated with radiotherapy and 7% of the patients
were managed with supportive care only. Median radiotherapy dose was 51 Gy (range
30-60 Gy). Radiotherapy schedules; conventional 1.8 Gy/fraction over a period of 6
weeks in 46% of the patients and hypo fractionated radiotherapy 3 Gy/fraction over a
period of 3 weeks in 54% of the patients.
Results: Radiological response was seen in 69% of the patients (partial response 32%
and stable disease in 37% of the patients). At the time of review, 20% patients died of
tumor progression, 9% were alive with tumor progression and 71% were alive with
continuous partial response and clinical improvement. 3 years overall survival was 37%
and overall median survival was 7.5 months (range 1-45 months).
Conclusion: Radiotherapy appears to be an effective treatment modality for brainstem
gliomas in pediatric patients but with poor outcomes. New treatment strategies
including safe surgical resection, alternate radiotherapy schedules and chemotherapy
regimens are warranted to improve the outcome in this group of patients.
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GAMMA KNIFE RADIOSURGERY AS SALVAGE THERAPY FOR RECURRENT
OR RESIDUAL PEDIATRIC AND YOUNG ADULT BRAIN TUMORS
K. Merrell1, R. Planchard2, M. Link3, B. Pollock3, I. Parney3, N. Laack1
1Mayo Clinic, Radiation Oncology, Rochester, USA; 2Mayo Clinic, Mayo Medical
School, Rochester, USA; 3Mayo Clinic, Neurosurgery, Rochester, USA
Background/Objectives: Gamma Knife radiosurgery (GK) provides high dose radiation
to focal brain lesions in a single treatment. We evaluated our institutional experience for
GK in pediatric and young adult patients with recurrent or residual brain tumors.
Design/Methods: Between 1998 and 2009, 14 patients with recurrent (n=11) or residual
(n=3) brain tumors received 16 GK treatments. Primary brain tumors included
high-grade neuroepithelial (GBM=3, anaplastic astrocytoma=1), low-grade
neuroepithelial (pilocytic astrocytoma=3, oligodendroglioma=1), embryonal
(medulloblastoma=4, embryonal carcinoma=1), and germ cell (germinoma=1)
tumors. Most patients had prior fractionated radiotherapy (RT) (n=11) with a median
dose of 55.8 Gy in 1.8 Gy per fraction. Toxicity was scored using CTCAE version 4.
Local control (LC), distant brain control, and overall survival (OS) were estimated
using the Kaplan Meier method.
Results:Median age at time of GK treatment was 11.5 years (range, 2-24) and the
median follow-up was 1.9 years (range, 0.4-10 years). Median GK dose was 16 Gy
(range, 10-20 Gy) to the 50% isodose line (range, 40-50%). Treated locations include
cerebellum (n=2), ventricular system (n=6), cerebrum (n=5), and brainstem (n=3). The
median volume treated was 0.6 cm3 (range, 0.14-12.7 cm3). One- and 5-year LC was
74% and 56% for all patients, respectively. LC was similar between histologic subtypes.
Patients with embryonal tumors had more distant brain failure (80%, n=4) than other
histologies (22%, n=2) (p=0.03). The median OS after GK was 6.3 years correlating to
a 1- and 5-year OS of 84% and 50%, respectively. Patients with high-grade astrocytoma
had worse OS with a median survival of 1.4 years. Treatments were well tolerated and
with no radiation necrosis. No significant late toxicity was associated with GK use.
Conclusion: Our results suggest GK is safe and effective therapy for recurrent or
residual brain tumors in carefully selected pediatric patients. Further investigation in
the efficacy of GK for pediatric patients is warranted.
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PEDIATRIC GLIOBLASTOMAMULTIFORME
M. Mohammadianpanah1
1Colorectal Research Center, Shiraz, Iran
Background/Objectives: Glioblastoma multiforme (GBM) is the most common
astrocytoma in adults and has a poor prognosis, with a median survival of about 12
months. But, it is rare in children. We report our experience on the childhood
population (20 years or younger) with GBM.
Design/Methods: Twenty-three patients with GBM who were treated at our hospital
during 1990–2008 were evaluated.
Results: The mean age was 15.2 years, and the majority of them (14/23) were male. All
had received radiotherapy and some had also received chemotherapy. The mean
survival was 16.0 months. Two cases survived more than 5 years. Age, extent of surgical
resection, radiation dose and performance status were significantly related to survival.
Conclusion: GBM in pediatric patients were not very common in our center, and
prognosis was unfavorable.
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THALAMIC GLIAL TUMORS IN CHILDREN AND ADOLESCENTS: A SINGLE
INSTITUTION EXPERIENCE
K. Elwood1, D. Warad2, D. Daniels3, C. Giannini4, N. Laack5, S. Khan2,
A. Raghunathan6, R. Vilmarie2, A. Nageswara Rao2
1Mayo Clinic, Pediatrics, Rochester, USA; 2Mayo Clinic, Pediatric
Hematology/Oncology, Rochester, USA; 3Mayo Clinic, Neurosurgery, Rochester, USA;
4Mayo Clinic, Pathology, USA; 5Mayo Clinic, Radiation Oncology, Rochester, USA;
6Mayo Clinic, Pathology, Rochester, USA
Background/Objectives: Thalamic glial tumors account for about 5% of central nervous
system tumors. Management is often very challenging since these tumors carry a
significant risk for neurologic morbidity related to their location and treatment. We
reviewed our experience with thalamic glial neoplasms diagnosed and treated at our
institution from 1993 to 2014.
Design/Methods: Retrospective chart analysis.
Results: Our study included twenty-three patients (13 male; 10 female). Median age at
diagnosis was 11.8 years (range; 1.9-17.8 years). Hydrocephalus was noted in 43.5% of
patients at presentation. Eighteen (78.3%) patients had unilateral thalamic tumors. Five
patients had bithalamic involvement. Fifteen (65.2%) patients had low-grade histology
[pilocytic astrocytoma (n=11), fibrillary astrocytoma (n=2), and other (n=2)]. Seven
patients had high-grade histology [anaplastic astrocytoma (n=2), glioblastoma
multiforme (n=4), high-grade oligoastrocytoma (n=1)]. Extent of surgical resection
included gross total resection (7 low-grade; 2 high-grade), subtotal resection (2
low-grade; 1 high-grade), and biopsy (6 low-grade; 3 high-grade). Ten (66.6 %) patients
with low-grade tumors had new and/or worsening post-operative neurologic deficits.
All patients with high-grade histology received chemotherapy and/or radiation therapy
while 3 patients with low-grade tumors received adjuvant radiation (n=2) or
chemotherapy (n=1). No patient with a high-grade tumor was alive beyond 41 months
from diagnosis. Median follow-up for patients with low-grade tumors was 3.7 years
(range; 0.11-17.9 years). Three year progression-free survival(PFS) was 76.2%. There
was 1 patient death unrelated to tumor. Low-grade histology was significantly
associated with better PFS and overall survival (OS) outcomes (p=0.004 and p<0.0001,
respectively). Hydrocephalus at presentation, unilateral versus bithalamic involvement,
and extent of resection were not associated with PFS for low-grade tumors (p=0.4,
p=0.4, and p=0.9, respectively).
Conclusion:Majority of thalamic tumors are of low-grade histology. Though
recurrences are observed, low-grade tumors are associated with good OS and risk of
long-term morbidity should be an important consideration in the management of these
tumors.
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OUTCOME OF PEDIATRIC MEDULLOBLASTOMA IN LIMITED-RESOURCE
SETTING – EXPERIENCE FROM A TERTIARY CANCER CENTRE IN INDIA
M. Nair1, K. Parukkuttyamma2, P. Thankamony3, B. Rajeswari3, A. Ninan3,
S. Kommadath3, G. Chellappan3, R. Kesavapillai Sukumaran3, B. Sarah Mathew4, R. K4
1Regional Cancer Centre, Thiruvanathapuram, India; 2Regional Cancer Centre, Pediatric
Oncology, Trivandrum, India; 3Regional Cancer Centre, Pediatric Oncology,
Thiruvanathapuram, India; 4Regional Cancer Centre, Radiation Oncology,
Thiruvanathapuram, India
Background/Objectives: Advances in surgery and integration of multimodality therapy
has translated to improved survival in children with medulloblastoma(MB) over the
recent years. But the excellent results are not reproduced in resource-limited countries,
due to multiple factors. We sought to find out the characteristics and outcome of
pediatric medulloblastoma treated in our department.
Design/Methods: Children 0-14years of age diagnosed with medulloblastoma and
treated in Pediatric Oncology Division, RCC, Trivandrum during a 5year
period(January2008 to December2012) were identified. Patients >3 years received
postoperative craniospinal radiation(36-55Gy for average-risk and 55-60Gy for
high-risk) with concurrent Vincristine , followed by 6-8 cycles of chemotherapy.
Patients<3years received COG Baby Brain Protocol chemotherapy and delayed
radiation.
Results: There were 89 medulloblastoma patients (22%of all brain tumours).19%were
0-3years, 27%were 10-14years and peak age group was 4-9years(53%).Male
predominance was observed, male:female ratio being 1.8:1. 61patients(68.5%) were
average-risk and 28patients(31.5%) high-risk. Initial metastatic disease was found in
only10%. 74patients(83%) had adequate surgery. 19patients did not take any adjuvant
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treatment. Combined chemotherapy and radiotherapy was used for 63 patients(70%)
and chemotherapy only for 7patients.58 patients completed treatment without much
toxicity. There were 6 therapy-related deaths.11patients (12.3%)developed recurrence,
of whom 6 had disease progression while on treatment and 5 recurred after treatment
completion. No salvage therapy was given for recurrences. At median follow-up of 23
months, 56 patients(63%) are alive,17patients(19%) expired, and 16 are
lost-to-follow-up. 5-year disease-free survival(DFS) for the treated cohort was
84.5±5%. DFS was significantly low for children<3years(39%) and for high-risk
patients(41%) .There was no significant difference in outcome for patients with initial
metastatic status. Age 4-9 years, treatment received (surgery+radiation+chemotherapy)
and average-risk disease are favourable prognostic factors for survival.
Conclusion: Survival comparable to published international data is achieved in
average-risk pediatric MB patients in our institution with current multimodality
therapy.Treatment is refused by a significant minority.Outcome is poor in high-risk
patients, especially younger children.
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MEDULLOBLASTOMA IN CHILDREN: THE EXPERIENCE IN THE CENTER
OF TUNISIA
B.M. Oumlreit1, C. Imene2, F. Ezzaairi2, H. Zaghouani3, I. Belaid2, M. Hochlef2,
O. Gharbi2, L. Ben Fatma2, H. Krifa4, S. Ben Ahmed2
1Sousse, Tunisia; 2Farhet Hached Hospital, Medical Oncology, Sousse, Tunisia; 3Farhet
Hached Hospital, Radiology Department, Sousse, Tunisia; 4Sahloul Hospital, Neuro
Surgery Department, Sousse, Tunisia
Background/Objectives:Medulloblastoma tumors (MB) are the first brain malignat
tumor in the chidhood. MB are classified into high risk and standard risk categories
based on age at diagnosis, degree of surgical resection, and disease spread.
Design/Methods: It is a retrospective study of eighteen cases of children with
Medulloblastoma histologically proved treated from 1994 to 2013 in the Oncology
Department of Farhat Hached University Hospital, Sousse, Tunisia.
Results: The median age was 9.25 years (18 months - 16 years) with 2 patients aged less
than 3 year. The sex ratio was 1.25. Cranial hypertension and cerebellar syndrome were
the most frequent symptoms respectively in 94.4 % and 83.3% of cases. MB was located
in the vermis, 4th ventricle and cerebral hemisphere in respectively 50%, 33.3% and
16.7% of cases. At diagnosis, 4 patients had cerebrospinal metastases. Complete or near
complete resection (<1,5cm) was done in 66.7% of cases. Fifty per cent of patients were
classified in average risk group and 50 % in standard risk group. Eleven patients
received cranial-spinal axis irradiation (25 grey to 30 grey) with a boost to the posterior
fossa (54 grey). Fourteen patients received chemotherapy: regimen of “8 drugs a day”
for 4 cases and a regimen of etoposide-carboplatin for 9. The overall survival was 60%
at 5 years (41.9 months): 40% (27.6 months) for the high risk group and 70% (59.7
months) for the standard risk group.
Conclusion: The results of our study indicate the need of the improvement of treatment
of MB especially with the identification of novel molecular prognostic factors.
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GROWTH AND PUBERTAL DEVELOPMENT IN PEDIATRIC BRAIN TUMOR
SURVIVORS
S. Pietilä1, A. Mäkipernaa2, A.M. Koivisto3, H.L. Lenko4
1Rinnekoti Foundation, Espoo, Finland; 2Helsinki University Central Hospital,
Department of Hematology, Helsinki, Finland; 3University of Tampere, School of Health
Sciences, Tampere, Finland; 4Tampere University Hospital, Department of Pediatrics,
Tampere, Finland
Background/Objectives: To evaluate growth and pubertal development in childhood
brain tumor survivors.
Design/Methods: A population-based cross-sectional study; fifty-two (69%) out of 75
invited brain tumor survivors diagnosed below 17 years of age between 1983-1997 and
treated in Tampere University Hospital, Finland, were examined at a mean age of 14.2
(range 3.8-28.7) years after a mean follow-up time of 7.5 (1.5-15.1) years.
Results: Thirteen patients (25%) received hormone substitution, nine (17%) more than
one; thyroxine (n=10), glucorticoid (n=4), growth hormone (GH) (n=4), sex hormone
(n=7) and desmopressin (n=3). Twelve patients (23%) had GH deficiency (GHD).
Sixteen were prepubertal, 30 had normal puberty and five had puberty induced with sex
hormones and one precocious puberty. The adult height of the 16 patients who were 18
years or older ranged from 140.0 cm to 181.2 cm. In the whole group the height SDS
ranged from -4.6 SD to +2.8 SD (mean +0.1 SD). The mean difference between actual
height and target height was -0.1 SD (-4.3 SD-+2.8 SD). Shorter stature was statistically
significantly associated with tumor malignancy (p=0.005), radiotherapy (p=0.004),
chemotherapy (p=0.024), GHD (p<0.001), in pubertal/post pubertal patients sex
hormone deficiency (p=0.044) and abnormal sex hormone levels (p=0.008) during the
study. The patients who had received craniospinal irradiation or both radiotherapy and
chemotherapy were shorter than other patients. Young age at diagnosis, tumor site at
sellar region, thyroxin and glucorticoid treatment were not associated with shorter
stature. The patients who had residive/residual tumor at evaluation were taller than the
others and taller than their target height. Cranial irradiation increased the risk of GHD
(p < 0.001) and sex hormone deficiency (p=0.003).
Conclusion: Survivors who have had malignant tumor, have received radiotherapy
and/or chemotherapy, have GHD and/or sex hormone deficiency are at greater risk for
growth problems.
P-166
METRONOMIC CHEMOTHERAPY FOR PEDIATRIC PATIENTS WITH
UNTREATABLE MALIGNANCIES
M. Porkholm1, S. Toiviainen-Salo2, R. Seuri2, T. Lönnqvist3, K. Vepsäläinen4,
U.M. Saarinen-Pihkala1, V. Pentikäinen1, S.M. Kivivuori1
1Division of Hematology-Oncology and Stem Cell Transplantation, Children’s
Hospital-University of Helsinki and Helsinki University Hospital, Helsinki, Finland;
2Helsinki Medical Imaging Center-Department of Pediatric Radiology, University of
Helsinki and Helsinki University Hospital, Helsinki, Finland; 3Division of Child
Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;
4Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland
Background/Objectives: Few therapies prolong the survival and increase the quality of
life for pediatric patients with malignancies unresponsive to conventional treatments.
Metronomic administration of chemotherapy has lately emerged as an effective and
well-tolerated method to fulfill these ambitions.
Design/Methods: Fourteen pediatric patients with various untreatable malignancies
received therapy according to the anti-angiogenic Extended Angiocomb protocol
consisting of metronomic thalidomide, etoposide and celecoxib. Endpoints of the study
were overall survival, quality of life, and radiological response. Adverse effects were
monitored. Results were compared to a control group consisting of eight patients in
palliative care, with or without other maintenance therapies.
Results:Median survival after start of the study was 6.4 months for study patients and
3.8 months for controls (p = 0.002). Four study patients were long-term survivors with
overall survival over 24 months. Study patients were able to attend school or daycare
and walk without support for a significantly longer time compared to controls (school
or daycare attendance: median 4.9 months versus 0.76 months, p = 0.009; walking
without support: median 4.9 months versus 0.8 months, p<0.001). Radiologically, one
patient had a partial response and one patient stable disease during study therapy.
Conclusion: The Extended Angiocomb protocol prolonged survival and increased the
quality of life for pediatric patients with untreatable malignancies. Our results suggest
that anti-angiogenic therapy should be more thoroughly studied as a treatment option
during palliative care for cancer.
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DELAYED DIAGNOSIS OF CHILDHOOD LOW-GRADE GLIOMA: CAUSES,
CONSEQUENCES AND POTENTIAL SOLUTIONS
A. Arnautovic1, C. Billups2, A. Broniscer1, A. Gajjar1, F. Boop3, I. Qaddoumi4
1St. Jude Children’s Research Hospital, Oncology, Memphis, USA; 2St. Jude Children’s
Research Hospital, Biostatistics, Memphis, USA; 3St. Jude Children’s Research Hospital,
Surgery, Memphis, USA; 4St. Jude Children’s Research Hospital, Memphis, USA
Background/Objectives: Diagnosis of childhood brain tumors is delayed more than
diagnosis of other pediatric cancers. However, the contribution of the most common
pediatric brain tumors, low-grade gliomas (LGG), to this delay has never been
investigated.
Design/Methods:We retrospectively reviewed cases of childhood LGG diagnosed from
January 1995 through December 2005 at our institution. The pre-diagnosis symptom
interval (PSI) was conservatively calculated, and its association with race, sex, age,
tumor site, tumor grade, and outcome measures (survival, disease progression, shunt
use, seizures, extent of resection) was analyzed. Cases of neurofibromatosis type 1 were
reported separately.
Results: The 258 children had a median follow-up of 11.1 years, and 226 (88%)
remained alive. Greater pre-diagnosis symptom interval (PSI) was significantly
associated with grade I (vs. grade II) tumors (p = 0.03) and age >10 years at diagnosis
(p = 0.03). Half of the 16 spinal tumors had a PSI > 6 months. PSI was significantly
associated with progression (p = 0.02) in grade I tumors (n = 195) and in grade I
tumors outside the posterior fossa (n = 134, p = 0.03). Among children with grade I
tumors, median PSI was longer in those who had seizures (10.3 months) than in those
who did not (2.5 months) (p = 0.09).
Conclusion: Delayed diagnosis of childhood LGG allows tumor progression. To reduce
time to diagnosis, medical curricula should emphasize inclusion of LGG in the
differential diagnosis of CNS neoplasm.
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PEDIATRIC INTRACRANIAL CLEAR CELL MENINGIOMA ASSOCIATED
WITH A GERMILINE MUTATION OF SMARCE1
H. Raffalli-Ebezant1, J.P. Kilday2
1Royal Manchester Children’s Hospital, Department of Neurosurgery, Manchester,
United Kingdom; 2Royal Manchester Children’s Hospital, Department of
Haematology/Oncology, Manchester, United Kingdom
Background/Objectives: Intracranial clear cell meningioma (CCM) represents a rare and
potentially more aggressive subgroup of meningioma that is observed more frequently
in children and adolescents. Despite its characterization as a histological entity, there is
little evidence identifying tumorigenic etiologies. Recently, a novel mutation in
SMARCE1, encoding a subunit of the SWI/SNF chromatin remodeling complex, was
identified in a cohort of spinal CCMs. To date, no intracranial CCM has been subjected
to analysis.
Design/Methods:We report the case of an isolated intracranial CCM in a 14 year old
girl. Gross total resection was achieved following a two-stage approach with no
evidence of tumor recurrence eight months following presentation. Exon sequencing
identified a germline mutation in SMARCE1, which was also present in tumor DNA.
Results: Extensive literature review confirmed our study is the first to seek and report a
genetic anomaly for childhood intracranial CCMs outside of the NF2 gene locus, and
the first to make an association between a germline SMARCE1 mutation and
childhood intracranial CCMs. Together with the previous description of SMARCE1
mutations in spinal CCMs, our report suggests that SMARCE1 aberrations may be
implicated in establishing a clear cell histology irrespective of meningioma location.
Conclusion:We would advocate that, where feasible, genetic sequencing is performed on
future new cases of childhood neuraxial CCMs and includes interrogation of the
SMARCE1 gene.
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THE IMPACT OF AGE AND RACE ON LONGEVITY IN PEDIATRIC
ASTROCYTIC TUMORS: A POPULATION-BASED STUDY
M.C. Samaan1, N. Akhtar-Danesh2
1McMaster University, Department of Pediatrics-Division of Pediatric Endocrinology,
Hamilton, Canada; 2McMaster University, School of Nursing-Department of Clinical
Epidemiology & Biostatistics, Hamilton, Canada
Background/Objectives: Despite improvements in pediatric brain tumor outcomes, the
survivors of childhood brain tumors are burdened by multiple comorbidities. We report
on the relative survival ratios and excess mortality rate in children with astrocytic
tumors over the past four decades.
Design/Methods: Survival analysis was conducted using flexible parametric model to
estimate relative survival and excess mortality rate for non-white and white children
(0-19 years old, n=5,956) using the Surveillance, Epidemiology & End Results (SEER)
database. We incorporated age group and year of diagnosis into the model to estimate
these indices for the period of 1973-2010. We used mortality-to-incidence ratio (MIR)
to measure mortality ratio over the study period. The MIR is defined as the crude
number of deaths divided by the crude number of cancer incident cases.
Results: The mean age of diagnosis was 9.2±5.3 years (47% female). Caucasian
participants were the major group (82.2%). The MIR was highly significant for race
(27.4% for non-white children compared to 22.7% for white children (p-value 0.001).
Progressive decline in relative survival ratios was noted over time, with non-white
children having lower survival rates than white children, and these trends persisted over
the duration of the study. Fifty percent of non-white survivors were deceased 30 years
post diagnosis, compared to 35 years in white survivors.
Conclusion: Survivors of childhood astrocytic brain tumors have progressively lower
survival rates as they get older, and this is higher in non-white when compared to white
children. Future research efforts need to focus on understanding the factors mediating
the effect of the tumor or its treatment on survival in these patients, and the ethnic
variations that drive these survival trends.
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THE EFFECTIVENESS OF LIFESTYLE INTERVENTION,
PHARMACOTHERAPY OR BARIATRIC SURGERY ON LOWERING BMI
Z-SCORE IN OBESE SURVIVORS OF CHILDHOOD BRAIN TUMORS: A
SYSTEMATIC REVIEW
A. Fleming1, K.W. Wang1, K. Scheinemann1, M. Valencia1, J. Duckworth1, L. Banfield2,
S. Burrow3, L. Thabane1, M.C. Samaan1
1McMaster University, Pediatrics, Hamilton, Canada; 2McMaster University, Health
Sciences Library, Hamilton, Canada; 3McMaster University, Division pf Pediatric
Orthopedics, Hamilton, Canada
Background/Objectives: Over the past three decades, high survival rate of childhood
brain tumors has been accompanied by long-term cardiometabolic co-morbidities,
including obesity, cardiovascular diseases, type 2 diabetes, hypertension and metabolic
syndrome. These co-morbidities can have a significant negative impact on the lifespan
and quality of life of childhood brain tumor survivors. We conducted this systematic
review to determine the effectiveness of lifestyle intervention, pharmacotherapy and
bariatric surgery on lowering BMI z-score in survivors of childhood brain tumors.
Design/Methods: This is a systematic review.
The inclusion criteria including obese survivors of childhood brain tumor and
comparing randomized controlled trials of lifestyle intervention, bariatric surgery,
pharmacotherapy to obese non-cancer controls. The primary outcome measure is BMI
z-score.We conducted a three-step search strategy: 1.Initial search conducted in
Medline, followed by an analysis of the index terms used to describe articles 2.A second
search using all identified keywords and index terms were then conducted in Medline,
Embase, PsychINFO, CINAHL, Cochrane Review, DARE, PubMed, and Sport Discus
3.The reference lists of all identified articles were screened.
Results: Using the above search strategy, 474 records were identified. A total of 234
records were found irrelevant and therefore excluded, as they did not discuss treating
obesity in the survivors of childhood brain tumors. Instead, a majority of them
explored obesity as a late effect after treatment for the brain tumors. Only one
randomized controlled trial was identified.
Conclusion:We conclude that there is limited evidence for treatment of obesity in this
population. Based on this search strategy, we are widening the inclusion criteria to
include non-RCT study designs such as case control, prospective cohort and
retrospective cohort. This will allow us to systematically evaluate the interventions
studied, so that we can design new intervention strategies to treat and prevent obesity
and cardiometabolic disorders in the survivors of childhood brain tumors.
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A REVIEW OF OTOTOXICITY AND NEPHROTOXICITY IN CHILDRENWITH
PRIMITIVE NEUROECTODERMAL TUMOURS (PNETS) TREATEDWITH
PLATINUM BASED CHEMOTHERAPY AND CRANIAL RADIOTHERAPY:
WEST OF SCOTLAND EXPERIENCE
J. Sastry1, C. Willis2, D. Black3, M. Ronghe2, D. Murphy1, F. Cowie2, R. Jones1, J. 4
1Royal Hospital for Sick Children-Yorkhill, Glasgow, United Kingdom; 2Royal Hospital
for Sick Children-Yorkhill, Oncology Department, Glasgow, United Kingdom; 3Glasgow
University, Medical School, Glasgow, United Kingdom; 4Royal Hospital for Sick
Children-Yorkhill, Audiology Department, Glasgow, United Kingdom
Background/Objectives: Irreversible oto-toxicity and nephrotoxicity are recognised in
children with PNETs treated with high dose platinum chemotherapy and cranial
radiotherapy. We aimed to determine the number of such patients that developed
hearing impairment, identify whether the chemotherapy was changed when
deterioration in hearing was detected, to evaluate if there was a difference in audiology
outcomes in patients considered standard risk versus high risk and to determine the
number of children who had a decline in glomerular filtration rate (GFR).
Design/Methods: It is a retrospective review of patients diagnosed with PNETs since
2000, treated with platinum chemotherapy and cranial radiotherapy. Using electronic
records 32 patients were identified. Five patients were excluded (<3 years at diagnosis,
<1 year post end of treatment or insufficient information available). A proforma was
used to collate information regarding diagnosis, age of diagnosis, treatment regime used
(chemotherapy and radiotherapy doses), evidence of ototoxicity and decline in GFR,
and where relevant, any subsequent change in chemotherapy.
Results: Twenty-seven patients were included (6 supratentorial PNETs and 21
medulloblastomas). Median age at diagnosis of was 6 years. Seventeen (63%) of
patients had changes in their audiograms post treatment (2 supratentorial PNET and
15 medulloblastoma). Chemotherapy was changed accordingly in 70%. Four patients
had clinically significant hearing loss resulting in referral and or insertion of hearing
aids. There was no significant difference in proportion of children developing hearing
loss between standard, high risk medulloblastomas and supratentorial PNETs. 94% of
patients had a reduction in their GFRs post platinum chemotherapy. Of these, 44% had
a reduction in GFR of >30%.
Conclusion: Oto-toxicity was commonly seen in our cohort of patients with PNETs.
This will have a significant effect on learning and educational outcome. A decline in
GFR was also demonstrated in this particular group of patients. Future treatment
strategies should aim at reducing such toxicity.
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RADIATION NECROSIS IN CHILDREN – AN UNDERREPORTED PROBLEM?!
K. Scheinemann1,2, M. Otth2, J. Duckworth1, N. Stein3, A. Whitton4, J. Greenspoon4,
S. Singh5
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Children’s Hospital, Surgery, Hamilton, Canada
Background/Objectives: Radiation necrosis is one of the rare complications of
radiation, most likely dose and modality dependent. Multiple reports on radiation
necrosis in adults are published, reports on incidence and outcomes in the pediatric age
group are rare.
Design/Methods: Patients were identified through the pediatric neurooncology database
at McMaster Children’s Hospital.
Results: Between June 2008 and June 2013 five patients with a diagnosis of radiation
necrosis were identified, age range 1 to 16 years. Underlying diagnosis were atypical
teratoid rhabdoid tumor (ATRT) in the posterior fossa, diffuse intrinsic pontine glioma
(n = 3) and midline low grade glioma. The majority did receive intensity modulated
radiation therapy (IMRT), one patient received cyperknife irradiation. Radiation
necrosis was diagnosed by new neurological symptoms (altered level of consciousness,
regression of milestones) and subsequent multiple imaging modalities, timeline 1 – 6
months following the radiation treatment. All patients got treated with high dose
dexamethasone initially for the malignant cerebral edema. In 2 patients therapy was
escalated: one patient received bevacizumab without a bleeding complication and
improvement of the neurological symptoms, one patient received a course of hyperbaric
oxygen therapy over 1 month. Overall the outcome was poor: all three DIPG patients
died due to a combination of worsening radiation necrosis and tumor progression, one
within 3 months of their initial diagnosis. The other 2 patients have ongoing severe
neurological symptoms with major imaging findings: the patient with the ATRT has a
developmental delay (e. g. not walking yet) with a severe speech deficit. The patient with
the midline LGG has been hospitalized multiple times for severe somnolence problems.
Conclusion: International cooperation is needed to evaluate the true incidence within
the pediatric age group, identify risk factors like the role of extent of surgery or
intensive chemotherapy treatment and implement a treatment strategy especially to
improve a mainly poor prognosis.
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EARLY POST-OPERATIVE MRI FOLLOWING A RESECTION OF A
PEDIATRIC BRAIN TUMOR – WHAT IS THE RIGHT TIMEPOINT?
K. Scheinemann1,2, M. Otth2, J. Duckworth1, N. Stein3, S. Singh4
1McMaster Children’s Hospital, Pediatrics, Hamilton, Canada; 2Kinderspital Luzern,
Pediatrics, Lucerne, Switzerland; 3McMaster Children’s Hospital, Radiology, Hamilton,
Canada; 4McMaster Children’s Hospital, Surgery, Hamilton, Canada
Background/Objectives: Early post-operative imaging 24 – 72 hours following a
resection of a brain tumor is mandatory to confirm the extent of resection which
influences the further treatment in pediatric brain tumors. This time frame has been
established to avoid misinterpretation through sclerosis and edema and to recognize
immediate post-operative complications like bleeding.
Design/Methods: Over a period of 5 years pediatric brain tumor patients underwent
immediate post-operative MRI on the way to the Intensive Care Unit (ICU) following
brain tumor resection at McMaster Children’s Hospital. Data on imaging, further
treatment and outcome were collected and the economic effect calculated.
Results: Between June 2008 and June 2013 65 pediatric brain tumor patients underwent
a tumor resection/ biopsy at McMaster Children’s Hospital. In 20 patients with
posterior fossa tumors an immediate post-operative MRI intubated and still under
general anasthesia was performed on the way from the OR to the ICU. In 2 patients
residual tumor was detected and a further resection was performed in the same surgery.
All other patients showed a gross total tumor resection with no bleeding or massive
cerebral edema signs and were therfore extubated and an immediate neurological exam
performed. No imaging study needed to be repeated for immediate post-operative
complications. On average the patients were between 24 – 48 hours less intubated and
sedated and could be transferred to the peripheral ward earlier.
Conclusion: To avoid prolonged intubation and sedation for post-operative imaging and
to judge on neurological outcome earlier immediate post-operative seems feasable and
safe in our setting. Further multi-center studies are needed to confirm the results.
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DIFFERENTIAL MICRORNAS EXPRESSION PROFILE IN PRIMARY
GLIOBLASTOMAS OF CHILDREN AND ADULTS, PILOCYTIC
ASTROCYTOMAS AND NON-NEOPLASTIC WHITE MATTER:
IDENTIFICATION OF PATHWAYS INVOLVED IN TUMORIGENESIS.
L.G. Darrigo Jr1, P. Fedatto1, V. Silveira2, D. Marco Antonio3, E. Valera1,
R. Panepucci3, A. Goes4, C. Carlotti Jr5, R. Oliveira5, L. Neder6, S. Aguiar7, J. Yunes7,
S. Brandalise7, L. Tone1, C.A. Scrideli1
1Ribeirão Preto Medicine School - University of São Paulo, Pediatrics, Ribeirão Preto,
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University of São Paulo, Surgery, Ribeirão Preto, Brazil; 6Ribeirão Preto Medicine
School - University of São Paulo, Pathology, Ribeirão Preto, Brazil; 7Centro Infantil
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Background/Objectives: Changes in miRNA expression have been described in several
human tumors, including CNS tumors. This study aimed to evaluate miRNA signature
in pediatric and adult astrocytic tumors and non-neoplastic white matter.
Design/Methods:We analyzed the global expression of miRNAs in microdissected
samples at diagnosis from 29 glioblastomas (GBM) (20 adults and 9 children), 16
pediatric pilocytic astrocytoma (PA) (3 NF1-associated) and 12 non-neoplastic human
white matter (WM) using the Human miRNAMicroarray Kit (V3 8×15K, Agilent).
Ten miRNAs differentially expressed (mir-10, mir-21, mir-34, mir-124, mir-125,
mir-136, mir-139, mir-142, mir-144, mir-630) were validated by qRT-PCR using
TaqMan probes in 45 samples of GBM (35 adults, 10 children), 39 pediatric PA (4
NF1) and 12 WM. The difference in expression between the groups was analyzed by
Mann-Whitney test.
Results: The significant differential modulation of the expression was found in 40
miRNAs in GBM vs. PA, 37 miRNAs in GBM vs. WM and 112 miRNAs differentially
modulated in PA vs. WM. Differences were also observed when compared pediatric
GBM versus adults (16 miRNAs) and sporadic PA versus NF1 (32 miRNAs). From the
10 miRNA validated by qRT-PCR, significant differential expression was observed in 9
miRNAs when compared GBM vs. WM, 8 between PA vs. WM and 7 between PA vs.
GBM. Searching for the validated targets genes to the most differentially expressed
miRNAs: miR-10b, miR-34a-5p, miR-139-3p, miR-142-5p, miR-144-3p and miR-630,
using of the database miRWalk it was found 84, 226, 12, 44, 60 and 20 targets genes
respectively. By using the program Enrichr for evaluation of signaling pathways, it was
found focal adhesion, glioma, p53, apoptosis and cell cycle as the main pathways
involved.
Conclusion: Our results suggest a potential role of miRNAs in tumorigenesis and
progression of astrocytic tumors and may contribute to a better understanding and
management of these tumors.
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SILENCIG OF GDF15 GENE AND RESPONSE TO RADIOTHERAPY AND THE
TREATMENTWITH TEMOZOLOMIDE IN GLIOBLASTOMA CELL LINES
M. Baroni1, P. Fedatto1, A. Andrade2, V. Suazo1, R. Queiróz1, L. Tone1, C.A. Scrideli1
1Ribeirão Preto Medicine School - University of São Paulo, Pediatrics, Ribeirão Preto,
Brazil; 2Ribeirão Preto Medicine School - University of São Paulo, Genetics, Ribeirão
Preto, Brazil
Background/Objectives: Glioblastoma (GBM) is one of the most malignant primary
brain tumors in adults and children. In a previous study, our group described a
significant high expression of the gene GDF15 in primary GBM compared to
non-neoplastic white matter. The present study aimed in to investigate the effect of the
silencing of GDF15 by shRNA and the response to radiotherapy and temozolamide
(TMZ) in pediatric and adult GBM cell lines.
Design/Methods: The GDF15 gene expression was evaluated in 9 GBM cell lines by
qRT-PCR. The two lines with the higher expression levels of GDF15 [KNS42
(pediatric) and U343 (adult)] were transduced by the RNA interference (shRNA) using
lentiviral vector. After verification of gene (by qRT-PCR) and protein inhibition (by
western blot), independent treatments were made with radiotherapy (2, 4, 6 Gy) and
TMZ (250 to 1,500 μM) followed by in vitro functional studies: cell proliferation
(Resazurin), apoptosis (anexin/propidium iodide) and clonogenic capacity.
Results: After silencing, there was a significant decreased in the clonogenic capacity of
KNS42 compared with the control (p <0.05). The gene silencing associated with TMZ
had effect in increase the U343 cell proliferation with significant data after 72 hours of
treatment with the doses of 500, 1000 and 1500μM of TMZ (p <0.05). The KNS42
showed no change in sensitivity to TMZ after silencing. The silencing with
radiotherapy had effect on U343 line, which showed a lower fraction surviving colonies
in the silenced line at a dose of 4Gy, compared to the control (p <0.05). No correlation
was observed between silencing and sensitivity to radiotherapy in the KNS42 cell line.
Conclusion: This study showed that the silencing of GDF15 promotes different
responses in pediatric and adult GBM cell lines, reinforcing their distinct molecular
characteristics.
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DNAMETHYLATION ANALYSIS OF PAEDIATRIC LOW-GRADE
ASTROCYTOMAS IDENTIFIES A TUMOUR-SPECIFIC SIGNATURE AT A SET
OF ENHANCERS
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Background/Objectives: Low-grade gliomas (LGGs) are the most common brain
tumours in children, and are dominated by pilocytic and diffuse astrocytomas (WHO
grades I and II, respectively). Although most of the genetic changes observed in LGGs
converge on the MAPK/ERK signalling pathway, there is heterogeneity in clinical
behaviour with diffuse astrocytomas having a significantly worse outcome than
pilocytic astrocytomas. To improve our understanding of the molecular origins of
paediatric LGGs, we have conducted a genome-wide study of DNA methylation in a
large, well-characterised group of tumours.
Design/Methods: DNA methylation profiles were determined using the Illumina
Infinium HumanMethylation450 BeadChip Kit, and analysed using Illumina Genome
Studio and MethLab software. Marmal-Aid was used to compare the findings with
publicly available data from other paediatric brain tumours. Gene expression was
determined using Affymetrix U133 plus 2.0 arrays and RT-PCR.
Results:We identify a hypomethylated signature at a set of enhancers in pilocytic
astrocytomas. This profile is not present in paediatric diffuse astrocytomas,
medulloblastomas, adult low- or high-grade gliomas, or control brain tissue.
Furthermore, the AP-1 complex, which is regulated by the MAPK/ERK pathway and
is comprised of the FOS and JUN family of transcription factors, is predicted to bind
to 35% of the differentially methylated regions. In the pilocytic astrocytomas, we find
that a subset of AP-1 targets are up-regulated and show positive correlation with both
FOS and JUN expression.
Conclusion: This study has revealed a DNA methylation profile in pilocytic
astrocytomas that is not present in a broad cohort of other brain tumours, emphasizing
the unique molecular biology of pilocytic astrocytomas. When integrated with
genomics and gene expression profiles, the findings provide a comprehensive platform
for understanding differences in gene regulatory pathways in paediatric low-grade
gliomas.
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RESULTS OF PHARMACOKINETIC ANALYSIS OF INTRAVENTRICULAR
ETOPOSIDE IN A PHASE II STUDY OF RECURRENTMEDULLOBLASTOMA,
CNS-PNET AND EPENDYMOMA
S. Tippelt1, R. Mikasch1, N. Siegler1, R.A. Hilger2, U. Jaehde3, U. Bode4, R. Kwiecien5,
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Background/Objectives: Neoplastic meningitis is a common problem in malignant brain
tumor. Especially in recurrence metastatic disease occurs even more often and worsen
significantly prognosis. Limited attribution of systemic chemotherapy into CNS is one
known problem in therapy of malignant brain tumors. In contrast, intrathecal
administrations of anticancer drugs in humans have shown high concentrations in
cerebrospinal fluid (CSF) and leptomeninges by using low drug doses. Etoposide has
demonstrated in experimental and clinical data significant cytotoxic activity.
Penetration of etoposide after systemic administration into CSF is extremely poor
(<3%) and did not exceed cytotoxic level, depending on cell line and exposure time, of
0.1-10 μg/ml. In a previous study of intraventricular etoposide administration in 14
patients with leptomeningeal disseminated brain tumors our group demonstrated
etoposide concentration in CSF of 9.03, 1.31 and 0.11 μg/ml 0.25 hours, 4 hours and 24
hours after intraventricular administration.
Design/Methods: In this study we present pharmacokinetic data of a phase II trial with
intraventricular administration of etoposide according determined schedule (1 mg
etoposide on 5 consecutive days, week 1, 3 and 5). Etoposide was measured by using a
validated RP-HPLC and PK calculations were performed by TOPFIT 2.0.
Results: The pharmacokinetic of etoposide is well described in a two compartment
disposition model. Cmax was calculated to 11.11 ± 8.22 μg/ml CSF. AUC for etoposide
in CSF after 1st dose was calculated to 20.72 ± 6.71 μg/ml*h and clearance was
calculated to 0.91 ± 0.36 ml/min. Calculating the ratio of etoposide measured in CSF
to the plasma concentrations, a mean ratio (n=23) of 81 ± 64:1, with 212fold higher
concentrations as maximum ratio and a 10fold higher concentrations in CSF as a
minimum, was detected.
Conclusion: Pharmacokinetic data of this study confirmed results of feasibility study
without significant cumulation of etoposide after repetitive administration within five
weeks.
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IRRADIATION OF NECROTIC CANCER CELLS, EMPLOYED FOR PULSING
DENDRITIC CELLS (DC), POTENTIATES DC VACCINE-INDUCED
ANTITUMOR IMMUNITY AGAINST HIGH-GRADE GLIOMA
S. van Gool1, L. Vandenberk2, A. Garg3, T. Verschuere2, C. Koks2, J. Belmans2,
P. Agostinis3
1Herent, Belgium; 2KU Leuven, Microbiology and immunology, Leuven, Belgium; 3KU
Leuven, Oncology, Leuven, Belgium
Background/Objectives: Despite trimodal standard-of-care therapy, the prognosis of
patients diagnosed with high-grade glioma (HGG) remains dismal. Dendritic cell
(DC)-based immunotherapy has yielded promising results with objective responses
reported in 15 % of HGG patients. The efficacy of DC vaccinations is however abated
by the profound HGG-induced immunosuppression and a lack of attention towards
immunogenicity of the tumor lysate. Literature analysis of DC vaccination clinical
trials for HGG showed that the two most frequently used methods for preparing tumor
lysate are: freeze-thaw (FT)-induced necrosis or FT-necrosis followed by high-dose
X-ray irradiation. From the available clinical evidence, it is not clear which of the above
methodologies have a superior immunogenic potential.
Design/Methods:We made use of the GL261 glioma murine model to directly compare
the immunogenicity of FT-necrotic and irradiated FT-necrotic tumor lysates.
Results: Pulsing of DCs with irradiated FT-necrotic (compared to FT-necrotic only)
tumor lysate prolonged overall survival and increased tumor rejection in
glioma-challenged mice. This was associated with an increase in brain-infiltrating T
cells and an increase in the CD8+ T cell to Treg ratio, paralleled by a reduced
accumulation of regulatory T cells (Tregs), tumor-associated macrophages (TAMs) and
myeloid-derived suppressor cells (MDSCs). Pulsing of DCs with irradiated
F/T-necrotic tumor lysate did not influence phenotypic and functional maturation of
DCs. Further analysis showed that, the overall content of carbonylated proteins - a
surrogate of immunogenic oxidation-associated molecular patterns (OAMPs) - in the
FT-necrotic lysate, was increased by the irradiation treatment. Moreover, we found a
striking correlation between the amount of protein carbonylation in tumor lysates and
the DC vaccine-mediated tumor rejection capacity (such that the latter was partially but
not significantly abrogated by addition of bona fide anti-oxidants).
Conclusion: Together these data strongly advocate the use of protein oxidation-inducing
modalities like irradiation for increasing the immunogenicity of tumor lysate used for
pulsing DC vaccines.
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OUTCOME OF BRAIN TUMORS TREATED AT A SINGLE INSTITUTION
BETWEEN 1987-2013
A. van Zyl1, V. Netshituni1, A. Kanyamuhunga1, R. Uys1, P. Hesseling1, M. Kruger1
1Stellenbosch University, Paediatrics and Child Health, Cape Town, South Africa
Background/Objectives: To determine the disease free survival (DFS) of all children
treated with brain tumors since 1987 till 2013. A secondary objective was to determine
DFS between children treated prior to 2000 and thereafter in a single institution.
Design/Methods: All patients 0-15 years of age, diagnosed at Tygerberg Hospital were
included and divided into 2 groups: group 1 diagnosed before 2000 and group 2 from
2000 onwards. Data analysis included demographic data (age at diagnosis, sex), tumor
type, stage, treatment received and final outcome after 24 months.
Results: There were 168 children included in the study with a mean age of 6.25 years
(range: 0-14 years). Group 1 had 54 patient and group 2 114 patients. The overall male
to female ratio was 1:0.9; respectively 1:0.6 and 1:0.9 for groups 1 and 2. Astrocytoma
(22%) (respectively 31% and 18% for groups 1 and 2) was the most common brain
tumor followed by medulloblastoma (16%) (respectively 15% and 16% for groups 1 and
2). DFS improved with time from 36% for group 1 to 46% for group 2 (overall 47%).
Patients with medulloblastoma achieved a DFS of 72% for group 2 versus 38% for
group 1 (65% overall), and 70% for astrocytoma in group 2 versus 47% for group 1.
Treatment prior to 2000 included a combination of surgery-radiotherapy (24%),
surgery alone (19%); combined surgery-radiotherapy-chemotherapy (18%);
radiotherapy alone 13%, or no treatment (11%), which was similar for group 2 (surgery
alone 23%, radiotherapy alone 23%; combined surgery-radiotherapy-chemotherapy
20% or no treatment 22%) except for very few patients receiving combined
surgery-radiotherapy (6%).
Conclusion:Medulloblastoma had the best overall DFS of 65%, followed by
astrocytoma 60%. The improved survival was mainly noted IN group 2. This was
probably due to more standardized treatment protocols used from 2000
onwards.
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QUALITY OF LIFE IN LONG-TERM SURVIVORS TREATED FOR
METASTATIC MEDULLOBLASTOMAWITH A HYPERFRACTIONATED
ACCELERATED RADIOTHERAPY (HART) STRATEGY
L. Veneroni1, L. Boschetti1, C.A. Clerici1, F. Simonetti1, E. Schiavello1, V. Biassoni1,
F. Spreafico1, L. Gandola2, M. Massimino1
1Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology and Pediatric
Onco-hematology, Milan, Italy; 2Fondazione IRCCS Istituto Nazionale dei Tumori,
Diagnostic Imaging and Radiotherapy, Milan, Italy
Background/Objectives: Since 1998 we launched a therapeutic strategy, for metastatic
medulloblastoma. An intensive post-surgical treatment applied HDMTX/VCR,
HDVP16, HDcyclo, HDcarboplatin followed by HART at total neuraxis dose of 39 Gy
(1.3 Gy/fraction, 2 fractions/day) with posterior fossa boost 60 Gy (1.5 Gy/fraction, 2
fractions/day). If disease persisted before HART, patients received thereafter 2 courses
of myeloablative thiotepa. Children aged under 10 years and in complete remission
before HART, received reduced 31.2 Gy CSI. Studies that evaluate the quality of life
(QOL) of patients with metastatic disease are missing especially in a very intensive
therapeutic ground. Aim of this study is to evaluate the long-term adjustment of these
patients at least three years after the end of treatment.
Design/Methods: Patients and their parents completed standardized self-administered
questionnaires on health-related quality of life (PEDSQOL, SDQ, SF-36, EORTC
QLQ-C30/QLQ-BN20). The questionnaires were delivered to the patient’s home,
following a phone call and due consent. Data were analyzed using descriptive statistics.
Results: Data were provided by 16 of 28 eligible survivors (57%), median age years
(range 12-35 years), median interval after diagnosis 12 years (range 3,8-15,7). The QOL
in general appeared adequate, but the analysis of the single subscales revealed that
physical symptoms - principally pain and fatigue - were present only in a small
percentage of patients, ranging 25%-37%, while serious problems related to
cognitive/emotional/relational functioning occur in a percentage ranging 50%-100%.
Small numbers prevents so far correlation with clinical variables.
Conclusion: QOL results are not different from other reported series in non-metastatic
medulloblastoma treatment. Apart from disease and treatment effects, personal and
social variables mediating disease damages have a strong impact on QOL. A global care
of these patient implies therefore specific actions to support the scholastic and
relational continuity, from diagnosis to the subsequent follow-up in multi-disciplinary
day-hospital dedicated to survivors.
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DELAYED DIAGNOSIS OF PAEDIATRIC CNS TUMOURS – HEADSMART BE
BRAIN TUMOUR AWARE
J.F. Liu1, L. Murphy2, S. Alam2, S. Wilne3, D. Walker1
1University of Nottingham, Children’s Brain Tumour Research Centre, Nottingham,
United Kingdom; 2University of Nottingham, School of Medicine, Nottingham, United
Kingdom; 3Nottingham University Hospitals NHS Trust, Department of Paediatic
Oncology, Nottingham, United Kingdom
Background/Objectives: A systematic literature review in 2005 identified that UK total
diagnostic interval (TDI) ranked poorly in international comparisons. Consequently, a
new NHS Evidence accredited referral guideline was developed and disseminated
through a public awareness campaign (HeadSmart be brain tumour aware,
www.headsmart.org.uk) to raise awareness of symptoms and the need for timely
imaging. The objectives of this project were to: (1) repeat the original systematic
literature review from 2005 and conduct an international comparison of TDIs since the
launch of HeadSmart in 2011; and (2) identify the tumour subtypes with the greatest
proportion of delayed diagnostic intervals to inform the on going awareness campaigns
about patient groups at greatest risk of delays.
Design/Methods: TDI data was collected by clinical champions in eighteen regional
children’s cancer centres. Systematic literature review using PubMed, Embase, The
Cochrane Library and ISI Web of Science was undertaken to identify relevant
publications between January 2005 and December 2014. Descriptive analysis was used
to compare the difference between subgroups.
Results: The UK TDI data showed a reduction in median from 3.3 (2006) to 1.5 months
(mean 4.9 months) by May 2013. From 6,482 articles 3 were identified reporting TDI of
all brain tumour types. International comparison of published studies showed that the
UK data is second only to a 2005 Polish study reporting a median of 1.0 month (mean
4.9 months). Tumour subtypes with the greatest proportion of prolonged TDI were
craniopharyngioma, low-grade glioma, germ cell tumours and optic pathway glioma
with median TDIs of 3.5, 2.7, 1.3 and 2.4 months respectively.
Conclusion: This strategy to accelerate brain tumour diagnosis in UK using a public
and professional awareness campaign is a “world first” in paediatric cancer, producing
leading performance in referral intervals. Identifying the subgroups with most skewed
TDIs permits this information to be used to appropriately tailor further intervention.
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DEVELOPMENT OF A POTENTIAL PRE-OPERATIVE RISK
STRATIFICATION TOOL OF CEREBELLARMUTISM SYNDROME IN
CHILDRENWITH POSTERIOR FOSSA TUMOUR
R.A. Dineen1, S. Avula2, T. Chambers3, M. Dutta4, D. Macarthur5, S. Harave2,
C.C. Ong2, C. Mallucci6, R. Kumar7, B. Pizer8, D. Walker9
1Nottingham University Hospitals NHS Trust, Department of Radiology, Nottingham,
United Kingdom; 2Alder Hey Children’s NHS Foundation Trust, Department of
Radiology, Liverpool, United Kingdom; 3University of Nottingham, School of Life
Sciences, Nottingham, United Kingdom; 4University of Nottingham, School of Medicine,
Nottingham, United Kingdom; 5Nottingham University Hospitals NHS Trust,
Department of Neurosurgery, Nottingham, United Kingdom; 6Alder Hey Children’s NHS
Foundation Trust, Department of Neurosurgery, Liverpool, United Kingdom; 7Alder Hey
Children’s NHS Foundation Trust, Department of Neurology, Liverpool, United
Kingdom; 8Alder Hey Children’s NHS Foundation Trust, Department of Paediatric
Oncology, Liverpool, United Kingdom; 9University of Nottingham, Chldren’s Brain
Tumour Research Centre, Nottingham, United Kingdom
Background/Objectives: Cerebellar mutism syndrome (CMS) complicates posterior
fossa tumour (PFT) resection in 11-29% of cases. Although the mutism typically
improves over 4-8 weeks, motor and cognitive deficits persist. Previous studies have
identified potential clinical and radiological predictive factors; however, a unifying
pre-operative risk stratification model for use during surgical consent is currently
lacking. The project aims to develop a risk stratification tool via: (1) a retrospective
analysis of clinical and radiological data included paediatric patients who had
undergone PFT resection at an institution to develop a preliminary model; then (2)
validate and modify the model further in a larger cohort.
Design/Methods: Post-operative CMS status was ascertained from clinical notes.
Pre-operative MRI scans underwent structured evaluation for a 21 tightly-defined
candidate imaging risk markers based on prior literature. Logistic regression was used
to identify potential CMS predictors, and the strongest predictors were used to test
their ability to stratify the patient cohort into low, intermediate and high-risk groups.
Results: The first cohort consists of 51 patients (age: 2-23yrs, gender 14M, 37F, 24
medulloblastoma, 23 pilocytic astrocytoma, 4 ependymoma); thirteen patients (25%)
developed CMS. A risk model combining IV ventricular location and brainstem
invasion allowed separation of the cohort into low (5%), intermediate (25.5%) and
high-risk (71.5%). This model will be further validated by the inclusion of a cohort of
48 patients of which 15 had PFT recruited with similar methodology (age: 0.7-17.6yrs,
gender: 19M, 29F) in March 2015.
Conclusion: Retrospectively applying a tightly defined structured evaluation of
pre-operative imaging and clinical data has created a risk stratification model for
post-operative CMS which will inform risk pre-operatively permitting reconsideration
strategies for primary surgical intervention to limit risk of surgical damage to sensitive
parts of the brainstem in particular where the areas of post operative damage seem to
affect the inferior olivary nucleus and associated brainstem tracts.
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ATYPICAL TERATOID/RHABDOID TUMORS: A CLINICOPATHOLOGICAL
STUDY OF 22 CASES AND LITERATURE REVIEW
L. Wang1
1Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,
Shanghai, China
Background/Objectives: Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, highly
malignant tumors of the central nervous system (CNS) that affect young children and
are characterized by a low response to therapy and poor prognosis. It is essential to
distinguish AT/RTs from other pediatric embryonal tumors, although prognostic
indicators remain controversial.
Design/Methods: we describe the clinical, histological, and immunohistochemical
characteristics, along with the treatments and outcomes, of 22 cases of AT/RTs
diagnosed in our hospital between 2009 and 2014.
Results: Among the 22 cases, the age at diagnosis ranged from 5 months to 9 years
(median, 24 months). Fifteen of the patients were under 3 years old, and 15 patients
were male. A supratentorial tumor origin accounted for 45% of all cases. The
morphological characteristics were assessed in 19 cases, and rhabdoid cells were seen in
more than half of all cases (n=13). Vesicular nuclei were seen in the majority of cases
(n=12), although cytoplasmic vacuoles were not evident or scattered in most cases.
Immunohistochemical analysis revealed that all 22 cases showed loss of INI1 nuclear
expression. Therapy and follow-up data were available in 15 of the 22 cases. Seven
patients died from tumor progression within a short time following surgery without any
adjuvant treatment, all of whom were under 2 years of age. Five patients were treated
with radiation and systemic chemotherapy, four of whom were older than 3 years, and
three patients experienced longer term disease-free survival of more than 12 months.
Our study showed that rhabdoid cells have histopathological importance but are not
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inherent among AT/RTs; rather, the lack of INI1 protein is the most useful marker for
differential diagnosis.
Conclusion: Young age and infratentorial location are negative prognostic factors, while
gross total surgical resection and adjuvant therapy, such as radiation and
chemotherapy, are positive factors.
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QUALITY OF LIFE IN LONG-TERM SURVIVORS OF VERY YOUNG
PEDIATRIC LOW-GRADE GLIOMAS
R. Youland1, C. Nwachukwu1, N. Wetjen2, G. Keating3, N. Laack1
1Mayo Clinic, Radiation Oncology, Rochester, USA; 2Mayo Clinic, Pediatric
Neurosurgery, Rochester, USA; 3Mayo Clinic, Pediatric Neurology, Rochester, USA
Background/Objectives:We report quality of life and clinical outcomes in long-term
survivors of very young (<5 years at diagnosis) pediatric low-grade glioma (LGG).
Design/Methods: Sixty consecutive patients <5 years old upon diagnosis were reviewed
(1970-2009). Fourteen patients completed a mailed questionnaire including the
European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30 and QLQ-BN20) and a modified St. Jude
Long-Term Follow-Up Study. All patient records were retrospectively reviewed for
patient, tumor and treatment characteristics.
Results:Median follow-up was 7.7 years overall and 24.9 years for questionnaire
responders. Twenty-year overall survival (OS) was 81% and progression-free survival
(PFS) was 46% compared to 61% in responders. Overall and in responders, 65% had
grade I histology. Gross total resection was achieved in 73% overall, and 86% of
responders. Adjuvant radiotherapy was delivered in 17% overall, and 14% of
responders. Chemotherapy was given to 10% overall, and 7% of responders. Salvage
radiotherapy was given in 7% overall and 7% of responders. A total of 71% reported
their health as very good or excellent. Mean (standard deviation) global QOL score was
83 (17) versus 76.4 (22.8) in a reference population of healthy adults. Mean QLQ-BN20
score overall was 6.9. Learning/memory deficits were reported in 4, seizure disorders in
2, migraines in 2, imbalance in 3, transient stroke in 1, transient sensory loss in 1,
transient prolonged pain in 1, and chronic abnormal sensation in 1 responder. No
patients reported tremors, dysphagia or weakness. One patient had a significant
complication related to surgery (stroke). One patient reported a significant
complication related to radiotherapy (chronic back pain).
Conclusion: Long-term (>20 year) follow-up of very young pediatric LGG survivors
suggests a subgroup of patients have a high quality of life with chronic neurologic
symptoms in only a small portion of patients.
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OUTCOME OF INI-1 NEGATIVE CNS TUMOR IN CHILDREN: A SINGLE
INSTITUTE EXPERIENCE
S. Yurikusa1, T. Wataya2, M. Hamazaki3, O. Taemi1, Y. Horikoshi1, I. Rieko1,
H. Kitazawa1, D. Shimizu1, S. Obu1, K. Watanabe1
1Shizuoka Children’s Hospital, Hematology and Oncology, Shizuoka, Japan; 2Shizuoka
Children’s Hospital, Neurosurgery, Shizuoka, Japan; 3Shizuoka Children’s Hospital,
Pathology, Shizuoka, Japan
Background/Objectives: Atypical teratoid rhabdoid tumor (AT/RT) and marignant
rhabdoid tumor (MRT) have similar histology and similar clinical and demographic
features. AT/RT and MRT both have deletions of the INI1 gene. The overall prognosis
for AT/RT and MRT is very poor.
Design/Methods:We retrospectively reviewed five children newly diagnosed as INI-1
negative tumor(two AT/RTs, three MRTs) in our institution from 2006 to 2013.
Results: The median age at diagnosis was 44 months (range 7 to 65 months). Three
tumors were located in the spinal cord, one in the frontal lobe and the other in the
suprasellar region. Two of them had dissemination on MRI at diagnosis. Only one
patient achieved gross total resection (GTR), three underwent subtotal resection (STR)
and biopsy was performed in the other. All patients received sarcoma-oriented
chemotherapy such as ICE (ifosfamide, carbopratine and etoposide), VAC (vincristine,
actinomycin and cyclophosphamide) or VDC (vincristine, doxorubicin and
cyclophosphamide). One patient underwent high dose chemotherapy (HDCT). Two
patients without dissemination received focal radiation and two with dissemination
received cranio-spinal irradiation (CSI). The 2-year overall survival was 60% with the
median of follow-up of15 months (range 10 to 102 months). Two patients older than 5
years old at diagnosis survived for 62 and 102 months, respectively. One patient with
dissemination, who had progression disease with dissemination after HDCT, was alive
with disease after re-irradiation and maintenance chemotherapy for six months after
relapse.
Conclusion: The prognosis of young children with INI-1 negative tumor is poor but
could be improved by intensive chemotherapy and radiotherapy after surgery.
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THEMIR-17-5P EXPRESSION CORRELATES WITH GRADE AND OUTCOME
OF CHILDRENWITH EPENDYMOMA
M. Zakrzewska1, K. Zakrzewski2, W. Fendler3, B. Dembowska-Bagin´ska4, I. Filipek4,
W. Grajkowska4, P.P. Liberski5
1Medical University of Lodz, Lodz, Poland; 2Polish Mother Memorial Hospital Research
Institute, Department of Neurosurgery, Lodz, Poland; 3Medical University of Lodz,
Department of Pediatric Oncology-Hematology and Diabetology, Lodz, Poland; 4The
Children’s Memorial Health Institute, Department of Oncology, Warsaw, Poland;
5Medical University of Lodz, Department of Molecular Pathology and Neuropathology,
Lodz, Poland
Background/Objectives: Ependymal tumors are the third most common group of brain
tumors in children, accounting for 10-12% of all primary lesions, and concurrently the
most common type in children younger than 5 years of age. Approximately 70% of
tumors in children develop within the posterior fossa and usually infiltrate surrounding
vital brain structures. Lack of recurrently mutated genes observed in ependymomas
makes their molecular analyses difficult and suggest plausible epigenetic background of
this lesion. Here we focused on one of the epigenetic mechanism with plausible role in
solid tumors formation, altered miRNA expression.
Design/Methods:We performed two stage miRNAs expression study in 74 cases of
pediatric ependymomas. Primary analysis underwent profiling of miRNAs, afterwards,
the expression measurements in validation cohort of patients with complete survival
data were performed. Student’s t-test with Benjamini-Hochberg procedure was used to
compare expression data. Survival analysis was done using the log-rank test and
multivariate Cox’ proportional hazards regression. P<0.05 was considered as
statistically significant.
Results: Out of 84 profiled miRNAs, 32 showed differential expression between WHO
grade II and III tumors; grade II tumors showed lower expression of those miRNAs.
Five miRNAs chosen for validation in the full cohort (miR-200a, miR-19a, miR-17a,
miR-106b, miR-9-3p) showed the same tendency of changes. Decrease of miR-17
expression was shown to be associated with increased risk of relapse and shorter overall
survival.
Conclusion: Current study provides a better understanding of pediatric ependymomas
biology enabling to type epigenetic biomarkers helpful in discrimination between
childhood grade II and III ependymomas and in defining factors connected with
tendency to relapse and final outcome.Work supported by the Polish National Science
Centre grant No 2011/01/B/NZ4/03573.
Posters: CCI (Parent/Survivors)
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PAEDIATRIC ONCOLOGY SOCIAL WORK AND ITS ROLE IN ALLEVIATING
POSSIBLE TRAUMA FOR THE CHILD AND FAMILY
A. Bence1
1CHOC Childhood Cancer Foundation, Johannesburg, South Africa
Background/Objectives: The diagnosis of cancer or a life threatening blood disorder in a
child is devastating with far-reaching psychosocial and emotional implications for not
just the child, but also the family system as a whole.
Design/Methods: The family’s psychosocial needs are addressed through the following
key aspects of the social worker’s role: Counselling at the time of breaking the bad news
of the diagnosis; psychosocial assessments; preparation for medical treatment
procedures; ongoing individual and/or group counselling and guidance from diagnosis
to the end of treatment and palliative- end of life care and support.
Results:With the paediatric oncology social worker rendering the above key services,
the impact of the diagnosis and treatment is alleviated. Her presence can break down
the medical jargon and procedures can be simply explained in the family’s own
language. Through the psychosocial assessment, a bigger picture of what is going on in
the family is gained and possible problems further down the line can be pre-empted.
The patient is prepared for medical procedures, which alleviates fear and anxiety and
generates greater cooperation. So the family is supported from the time of diagnosis
until the end of treatment, whether it means cure or preparing the family for, and
supporting them through, the death of their child.
Conclusion: The path that the social worker walks with the families enables them to
access internal and external resources with which to come to terms with and take
ownership of their situation.
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THE EFFECT OF THE “HONG KONG – MAINLAND CHINA CHILDHOOD
CANCER EXCHANGE CAMP” IN SUPPORTING CHILDHOOD CANCER
PATIENTS IN THE TWO PLACES
H. Chan1
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1Little Life Warrior Society, Hong Kong, Hong Kong-China
Background/Objectives: The Little Life Warrior Society (LLWS) is a childhood cancer
mutual support organization in Hong Kong aiming to improve the benefits of
childhood cancer patients. Except launching the work in Hong Kong, LLWS has
started the work of supporting childhood cancer patients in China in the past 10 years.
Till now, 10 LLWSs has already been established in 10 different provinces in China with
the help of LLWS in Hong Kong. In order to closely connect the childhood cancer
patients in Hong Kong and China, the “Hong Kong – Mainland China Childhood
Cancer Exchange Camp” is held every 2 years. The study aims at finding out the effect
of the exchange camp in supporting the childhood cancer patients in the two places. Its
function as a platform for the communication among patients of the two places will
also be explicated.
Design/Methods: Since the establishment of LLWS, 3 exchange camps have been held.
Each time after the exchange camp, a questionnaire is designed for participants to
complete in order to collect useful data of participants’ views on the effect and use of
the exchange camp in serving as a platform for patients’ communication and mutual
support.
Results: Revealed that the exchange camp is very effective in supporting childhood
cancer patients in Hong Kong and China in that it can foster the communication among
patients from different places. This could help them build up a network of mutual
support. Besides, medical and nursing knowledge is shared among patients through
their communication and the intensive medical seminars provided during the camp.
Conclusion: The “Hong Kong – Mainland China Childhood Cancer Exchange Camp”
help childhood cancer patients in Hong Kong and China to establish a network of
mutual support. Ultimately, patients can gain enough support and encouragement in
fighting against childhood cancer.
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THE IMPACT OF CHOC SOCIAL WORKERS IN PUBLIC HEALTH SECTOR
HOSPITALS IN SOUTH AFRICA
T. Dube1
1CHOC Childhood Cancer Foundation, Johannesburg, South Africa
Background/Objectives: CHOC Childhood Cancer Foundation S A (CHOC) was
established in 1979 by a group of parents with the aim of supporting children
diagnosed with cancer or life threatening blood disorders and their families.
Design/Methods: Through the partnership with public health sector hospitals, CHOC
appointed its first social worker in 2004. Over the years this partnership has grown to
encompass five social workers and two social auxiliary workers employed in five state
funded academically linked hospitals throughout South Africa.
Results: The placement of CHOC employed social workers has made a significant
difference not just for the children and their families but also for the medical and
nursing teams. These differences encompass: counselling and educating parents from
the time of diagnosis until the end of treatment; creating awareness and educating
parents about childhood cancer; palliative- end of life care to ensure quality of life and
dignity in the dying process; bereavement support; support for the medical and nursing
staff, which alleviates the pressure on their already burdened workload; and educating
the medical and nursing staff on the psychosocial and emotional needs of the patients
and their families.
Conclusion: The medical Heads of the Paediatric Oncology Units have expressed their
gratitude to CHOC and acknowledged the significant impact the social workers have
made on the lives of the patients and their families. One doctor has been quoted as
saying that she cannot understand how a Paediatric Oncology Unit can function
without a designated CHOC social worker.
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USE OF BEADS/BUTTONS/SEEDS AS A REWARD FOR THE COURAGE AND
BRAVERY DISPLAYED BY CHILDREN UNDERGOING TREATEMENT FOR
CANCER
N. Gravett1
1CHOC Childhood Cancer Foundation S A, Johannesburg, South Africa
Background/Objectives: The concept of using beads to “reward” children for their
courage while undergoing treatment has been utilised at several hospitals around the
world and presented to CHOC as an idea to implement at the Frere Hospital in the
Eastern Cape. In Africa the use of beads in various ways represents their culture; the
patterns and colours denote different tribes. As the majority of the children who are
hospitalised in the Eastern Cape come from rural areas, beads are part of their everyday
lives.
Design/Methods: The bead programme was adapted for use in the Frere Hospital. It
was decided that each child should be rewarded for their courage and bravery while
undergoing the various treatment procedures. Each bead/seed/button represents a
procedure. The more painful the procedure, the greater the reward, which is reflected in
the beauty of the bead. The children then get to choose the appropriate bead and
attach it to their string. These are known as “Memory Beads”.
Results: The children enjoy spending time choosing their beads and add them to their
string with much pride. Allowing the child to choose their bead is an easy way for
Doctors, Staff and CHOC to acknowledge the child for their courage, bravery and
heritage. “Memory Beads” create a personal memory for the child and the family of
their journey travelled.
Conclusion: The children enjoy spending time choosing their beads and add them to
their string with much pride. Allowing the child to choose their bead is an easy way for
Doctors, Staff and CHOC to acknowledge the child for their courage, bravery and
heritage. “Memory Beads” create a personal memory for the child and the family of
their journey travelled.
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THE FIRST SYMPOSIUM FOR SURVIVORS ABOUTMEDICAL LATE
EFFECTS IN AUSTRIA
S. Karner1, E. Cate2, M. Willi2, Z. Tomášiková2
1Österreichische Kinder-Krebs-Hilfe, Vienna, Austria; 2Österreichische
Kinder-Krebs-Hilfe, Österreichische Kinder-Krebs-Hilfe, Vienna, Austria
Background/Objectives: 280 children and young adolescents come down with cancer each
year in Austria. Due to a survival rate of over 80% about 235 survive, which leads to an
increased number of former childhood cancer survivors in the society.
Design/Methods: Due to the vast range of different activities offered for Austrian
survivors, a regular exchange is easily possible between them. Moreover, survivors
representatives stay in contact with survivors groups from other countries and maintain
close collaborations with medical and psychosocial professionals.
Results: Through this regular exchange the need of a special symposium for survivors
about medical late effects got visible, as a lot of survivors are not aware of possible late
effects and risks. They have only little information about possible late effects and not
enough knowledge about the screenings (what, when and why are they necessary).
Cancer and its treatment can lead to chronic or late occurring problems many years
after therapy. The communication with former patient about the relevance and
challenges of medical and psychosocial follow-up for childhood cancer survivors leads
to the first symposium in Austria in 2015. The symposium was scheduled for one day,
the survivors got information from paediatric oncologists in lay language, and they had
the possibility to ask them directly.
Conclusion: It is very important to give the information to the Survivors, because this
helps them to take over the responsibility for their own health, as they are very often
lost in follow-up and they don`t know where to go if they have problems or questions
(pediatric oncologists, general practitioner or medical specialist). In the future, other
tools will be developed in Austria, which will focus on the improvement of the quality
of life of childhood cancer survivors.
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MOBILIZING OPPORTUNITIES TO SYSTEMATICALLY ADDRESS ISSUES
IMPACTING CAREGIVERS OF CHILDREN: A MULTI-SECTORAL
APPROACH TO INFLUENCE SYSTEM CHANGE IN CANADA
M. Morrison1, S. Turner1, D. Mornar2, J. Thomson3
1Canadian Cancer Action Network, MOSAIICC, Toronto, Canada; 2British Columbia
Childhood Cancer Parents Association, MOSAIICC, Vancouver, Canada; 3Ontario
Parents Advocating for Children with Cancer, MOSAIICC, Barrie, Canada
Background/Objectives: As an emerging voice for system change in Canada, caregivers
need a scientific approach to influence policy decisions. The Canadian Cancer Action
Network adopted the IAP2 Public Participation Spectrum to develop evidence-based
recommendations for system change by engaging caregivers, scientific experts and
NGOs. Namely: 1) convening a consultative session ‘Family Caregivers and childhood
cancer: understanding the issues impacting caregivers of children’ to address financial
burden/gaps in the health-care system. 2) conducting a scan of research publications
and resources 3) informing national dialogue (with over 45 stakeholders) to
develop/validate recommendations for change 4) collaborating with stakeholders to
move from dialogue to action.
Design/Methods: Two parallel processes were used to develop recommendations. An
E-Delphi process informed a collaborative caregiver national action plan. E-Delphi
participants were recruited through members of the National Steering Committee and
other key stakeholders. Simultaneously, 5 regional think tanks were held across Canada
to seek multi-jurisdictional input into draft recommendations related to caregivers of
children. Think tank participants were recruited through NGOs, support groups and
children’s hospitals.
Results: This systematic process resulted in practical, feasible recommendations to
address the high financial burden on families due to Canada’s geographical dispersion
and fragmented support systems. Participants validated the need for a unique online
portal in Canada, providing timely information concerning financial supports, complete
with the ability to personalize based on individual family needs. Further, Government
Pediatr Blood Cancer DOI 10.1002/pbc
S288 SIOP ABSTRACTS
programs (such as tax deductions and drug coverage) should be aligned with policy
goals and families’ realities with remaining gaps including a strategy to alleviate the
immediate financial burden on Canadian families.
Conclusion: There remains a need for direct financial support for families in Canada,
supported by the implementation of a collaborative model of stakeholder and caregiver
engagement. A collaborative framework for multi-sectoral/multi-jurisdictional
engagement supports efforts to ensure issues impacting caregivers of children remain a
key, shared priority.
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THE HOUSE OF THE AVENIR : 20 YEARS HOUSING PARENTS OF
CHILDRENWITH CANCER IN MOROCCO
F. Msefer Alaoui1, F. Chraibi2, F. Alillouch3
1Association l’Avenir, Rabat, Morocco; 2Association l’Avenir, Association l’Avenir,
Rabat, Morocco; 3Association l’Avenir, Maison de l’Avenir, Rabat, Morocco
Background/Objectives: In Morocco, there are about 1000 new cases of kids with cancer
each year. About 300 are treated in Rabat at the Pediatric Hematology and Oncology
Service, initiated and supported by the Foundation of parents and friends of children
with cancer “l’Avenir”. To avoid abandonment of treatment, improve the conditions of
treatment and help the families living out of Rabat, the foundation built the first house
of parents in Morocco in 1995 and runs it up to now.
Design/Methods: It is four floors house, well equipped, with 22 bedrooms (54 beds),
showers, play room, living room, kitchen, dining room, and a garden. The main floor is
occupied by the Foundation with meeting room, offices for the president, secretaries
and treasurer, computer space for the kids, and archives room. It’s also a space for
sharing, listening, helping each other, meet members of the foundation, volunteers and
a psychologist to advise and encourage them. When a new family arrives, the director
of the house explains the rules, shows them their room and gives them all they need.
They are helped by house keepers, security guards and a driver. The adult pays a
symbolic amount (10 MDH about 1 USD).
Results: Besides housing and accommodation, the Avenir provides to families foods,
clothes, toys, transport, prosthesis, communication means, drugs, entertainment…as
long as their treatment is required. During 2014, the number of families and kids who
stayed at the house of the Avenir was 641 with an average of 12 days at a stay, from 1 to
20 times a year depending on the type of the disease and its treatment. The average rate
of occupation is 75%.
Conclusion: Since 20 years, the house contributes to soften and improve social, medical
and psychological conditions of treatment and somehow makes the disease and its
constraints more acceptable.
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A YOUNG SURVIVORS’ ROLE: POSITIVELY AFFECTING CHILDREN AND
THE YOUTH IN GHANA
J. Owiredu-Okyere1
1Accra, Ghana
Background/Objectives: I am a survivor of Hodgkin Lymphoma having been diagnosed
with the condition at nine years of age. I experienced psychological trauma, some of
which was as a result of stigmatization whilst at school. Losing all my hair and having
to wear a wig to school made me look odd among my peers and I became a subject of
gossip. When I was on admission in Accra, I also noticed the stress and anxiety that my
parents and other parents go through. As a youthful survivor and a student, my
objective was to bring hope to children and the youth who are going through cancer
treatment and to educate my peers in school on cancer as well as show them that
children with cancer need love and are just like all other children.
Design/Methods: In 2014, I gave some talks to my classmates in boarding school about
childhood cancer, using my experiences. They became really interested and enthusiastic
about what they could do to help. We raised money from friends and relations. We
obtained permission from the consultant-in-charge of the Paediatric Oncology Unit
and the Korle Bu hospital authorities to spend a day with the children on the unit.
Results: In December, 2014, we made our presence felt on the ward in a big way.
Activities included a film show, music, dancing with the patients and donation of gifts.
We put broad smiles on the faces of the children and their parents. Even the nurses had
fun. Everyone, including my classmates would like us to visit again.
Conclusion: Survivors can help change perceptions by educating their peers. They can
help relieve some of the psychological distress faced by patients and parents by visiting
their former units and interacting with the children.
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IMPACT OF CHILDHOOD CANCER SURVIVORS SUPPORT
GROUP-LESSONS LEARNT FROM UGAM
P. Phad1, S. Jha2, E. Rawat-Pawar2, S. Goswami3, M. Prasad4, P. Kurkure5,
B. Sanadhya1
1Indian Cancer Society-Gunvati J Kapoor Foundation, Ugam, Mumbai, India; 2Indian
Cancer Society, Ugam, Mumbai, India; 3Tata Memorial Hospital, Psycho-Oncology,
Mumbai, India; 4Tata Memorial Hospital, Pediatric Oncology, Mumbai, India; 5Tata
Memorial Hospital-Indian Cancer Society, Pediatric Oncology-Ugam, Mumbai, India
Background/Objectives: Ugam is a support group formed by Mumbai based young
adult survivors of Childhood Cancers attending the After Completion of Therapy
(ACT) clinic at Tata Memorial Hospital (TMH). Ugam was formally launched on 7th
June 2009, first Sunday of June celebrated as Cancer Survivors Day across the world.
UGAMmeans “To Rise”, underscoring the determination of childhood cancer
survivors, to rise above all obstacles in life & be VICTORS. UGAM is affiliated to
Indian Cancer Society (ICS) under its survivorship programme. UGAM has been set
up with an aim to provide a helping hand to the survivors of childhood cancers &
become the ambassador of the message “Childhood Cancer is Curable” in society. The
present study was done to understand the impact of the support group on the quality
of life of childhood cancer survivors.
Design/Methods: Survey was conducted with the help of semi structured interview.
Interview guide (questionnaire) was designed to collect basic information & also about
psychosocial aspects (self confidence, self esteem, anxiety, coping). Responses rated on
4 point Likert scale before & after joining Ugam to understand impact of Ugam in
improving their coping skills.
Results: Of 45/195 (23%) Ugam members who participated in survey,29(64%) are male
& 16(36%) females with median age 24yrs (R 18 -50). 87% of the survivors received
psychosocial support, 56% benefitted from establishing social contact & sharing with
Ugam members.24% encountered new opportunities and 78% received guidance for
future. Ugam participants reported improvement in self confidence (59%), self esteem
(55%), and handling emotions (46%). Participants reported reduction in anxiety in
40%, fear 44% & loneliness in 79%.
Conclusion: Ugam support group helped its members significantly to bring about a
positive change in their perspective and identity as a survivor. Therefore, survivor
support group plays important role in psychosocial rehabilitation of young adult
survivors.
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SURVIVORSHIP ISSUES AND CARE IN CHILDHOOD CANCER: A HISTORY
OF GLOBAL DISPARITIES
R. Rohrer1
1Seton Hill University, Greensburg, USA
Background/Objectives: Children cancer is a rare disease which knows no boundaries of
race, gender, class or nationality. In developed countries approximately 1 in 330 children
will be diagnosed with cancer before the age of 15 years. The historical rates in many
developing nations approximate this number, although many children are undiagnosed
in these areas. With often scarce resources for treatment, survivorship issues are
minimally addressed due to extremely stretched resources.
Design/Methods: The author will use the archives of the National Cancer Institute and
published medical and psycho social students for this work. This study will focus upon
the comparative availability and characteristics of survivorship monitoring and care in
the United States and India as examples.
Results: One of the major challenges facing the families of childhood cancer patients is
financial. It is common in developed nations for one parent to take extended leave or
lose employment because of the demands of travel and time for clinic visits and
hospital stays for their child. Cost of travel, meals, parking and often lodging are also
usual costs. Two issues addressed in this study center on lack of finances and
unavailable transportation to clinic or hospital visits. This access for survivors applies to
both developed and developing nations. Travel in rural areas existence and general lack
of health centers is not only a problem of developing nations.
Conclusion: The author will conclude by examining the efforts of advocacy groups
globally to address the unique challenges faced by childhood cancer survivors.
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THEMENTORING PROGRAM IN GERMANY – DEVELOPMENT IN THE
LAST YEARS AND STATUS QUO
D. Schmid1, F. Mauersberger2
1Deutsche Kinderkrebsstiftung, Mentoren-Programm, Pliezhausen, Germany; 2Deutsche
Kinderkrebsstiftung, Mentoren-Programm, Dresden, Germany
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Background/Objectives: The presentation will be about the mentoring program in
Germany. We present the first steps that happened with this program in Germany, how
it went on during the last years and where we stand right now. Our aim is to give
information to other survivors how they can establish a mentoring program in their
home country, which barriers they may face and where they may find supporters.
Design/Methods: A mentor to a child or teenager with cancer has had cancer in young
years as well. But not every survivor is able to become a mentor. The authors are
psychologists and survivors, we are two of the trainers that train young adults to
become a mentor. We train them in special speaking and empathy skills, but also
support them in a better active listening. We present the structure of our training and
how our connection between all active survivors in Germany works.
Results: The time fighting against a cancer disease is a hard period of life – especially
for children, teenagers and young adults. We always get positive feedback of our
mentoring program from the concerned. The mentoring program is supported by the
German Childhood Cancer Foundation and well esteemed.
Conclusion: All in all, the mentoring program is a good possibility to help children and
young adults to pass their treatment with a psychosocial support got by peers who
understand what they feel. Our mentoring program in Germany is growing more and
more and we want to help other survivors to have such a program as well.
Posters: Epidemiology
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GEOGRAPHICAL DISTRIBUTION OF THREE AIDS-RELATED CANCERS
AMONG CHILDREN IN THE SIX WHO REGIONS
O. Adetokunboh1,2
1Centre for Healthcare Research and Training, Research and Training Unit, Ibadan,
Nigeria; 2Stellenbosch University, Division of Community Health, Cape Town, South
Africa
Background/Objectives: Although cancer is relatively rare in children aged 0-14 years
but it remains a significant burden for HIV-infected children. HIV infection has a link
with the development of AIDS-related cancers such as Non-Hodgkin lymphoma
(NHL), Kaposi’s sarcoma (KS), and cervical cancer. This study describes the
geographical patterns of the incidence and mortality of the three AIDS-related cancers
in the six World Health Organization (WHO) regions.
Design/Methods: Data from International Agency for Cancer Research GLOBOCAN
2012 database was used to examine the incidence and mortality rates for children aged
0-14 years old using age-specific rates and numbers as obtained in the WHO regions.
Results: African region recorded the highest incidence rates for NHL (1.3/100 000 for
female and 2.1/100 000 for male). The region also recorded the highest mortality rates
for NHL (0.7/100,000 for female) and 1.0/100,000 for male). The situation was the same
with KS with the African region having the highest incidence and mortality rates for
both gender. African region had the highest number of NHL and KS new cases [38%
(6296/16509)] and KS [96% (2081/2162)] respectively while Western Pacific region had
41% (68/165). The regions recorded 18,836 new cases (NHL – 88%, KS -11% and
cervical cancer – 0.9%) while the mortality cases followed almost the same pattern. The
total number of new cases of NHL for female was 5885, 10624 for the male (P=0.1668),
and that of KS was 963 for female and 1199 for male (P=0.8757).
Conclusion: The study shows that distribution of these three AIDS-related cancers
followed the pattern of HIV prevalence in the WHO regions. Africa being the most
affected region recorded the highest incidence and mortality in children (both
HIV-infected and non – infected). KS is majorly an African problem while cervical
cancer is rare among children despite the widespread HIV epidemic.
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CONNECTING THE CARIBBEAN: UTILIZING TELEMEDICINE TO
FACILITATE CAPACITY BUILDING FOR PAEDIATRIC ONCOLOGY PATIENT
CARE
C. Sin Quee1,2, M. Reece-Mills3, M. Abdelhaleem4, E. Adler5, C. Alexis6, Z. Ali7,
C. Bick5, V. Blanchette5,8, C. Bodkyn7, G. Chavhan9,10, M. Irwin8, M. Kirby-Allen8,
N. Laperriere8,11, S. McLean-Salmon8,12, A. Naqvi8, M. Shago13, F. Shaikh8,
G.R. Somers14, J. Bird-Compton15, B. Datta16, S. Weitzman5,8
1Princess Margaret Hospital, Pediatrics, Nassau, The Bahamas; 2University of the West
Indies, SCMR, Nassau, The Bahamas; 3University of the West Indies, Department of
Child Health, Kingston, Jamaica; 4The Hospital for Sick Children, Department of
Paediatric Laboratory Medicine- Haematopathology Division, Toronto, Canada; 5The
Hospital for Sick Children, Centre for Global Child Health, Toronto, Canada; 6University
of the West Indies, Cavehill, Bridgetown, Barbados; 7University of the West Indies- St.
Augustine Campus, Department of Clinical Medical Sciences- Faculty of Medical
Sciences, Port of Spain, Trinidad and Tobago; 8The Hospital for Sick Children,
Department of Paediatrics-University of Toronto-Division of Haematology/Oncology,
Toronto, Canada; 9The Hospital for Sick Children, Diagnostic Imaging, Toronto,
Canada; 10University of Toronto, Medical Imaging, Toronto, Canada; 11Princess
Margaret Cancer Centre, Department of Radiation Oncology, Toronto, Canada;
12Bustamante Hospital For Children, Pediatrics, Kingston, Jamaica; 13The Hospital for
Sick Children, Department of Paediatric Laboratory Medicine, Toronto, Canada; 14The
Hospital for Sick Children, Paediatric Laboratory Medicine, Toronto, Canada;
15Ministry of Health, Community Child Health Service, Castries, St Lucia; 16Milton
Cato Memorial Hospital, Pediatrics, Kingstown, St Vincent and the Grenadines
Background/Objectives: In high-income countries (HIC) childhood cancer survival is
over 80%, whereas in low- and middle-income countries (LMIC) this is lagging by 20%
or more. To address this gap in patient outcomes, established paediatric cancer
treatment centres are well positioned to share clinical expertise. Launched in March
2013 at the Hospital for Sick Children (SickKids), Toronto, Canada, the
SickKids-Caribbean Initiative (SCI) aims to enhance care for children with cancer and
blood disorders in 6 Caribbean countries: The Bahamas, Barbados, Jamaica, St. Lucia,
St. Vincent and the Grenadines and Trinidad and Tobago.
Design/Methods: To increase accessibility to healthcare services, 6 standardized
telemedicine facilities have been opened or upgraded, connecting SickKids with
participating countries. To commence telemedicine based consultative activities, an
indemnity agreement was signed by all sites, SickKids Division of
Haematology/Oncology consultant physicians were contracted, and a secure electronic
file transfer system was established to adhere with ethical and legislative obligations to
protect personal health information.
Results: Using the SCI telemedicine network, monthly Case Consultation Review
Rounds provide an educational forum for discussion of diagnostic work-up,
management challenges and local treatment plans. Fifty-eight cases have been reviewed.
Of the 42 oncological cases submitted, 17 (40.5%) were leukemia/lymphoma, 14 (33.3%)
solid tumours and 11 (26.2%) brain tumours. In the event that testing is not available at
the referring centres, imaging and pathology samples are reviewed at SickKids.
Conclusion: Telemedicine enhances opportunities for collaboration within the
Caribbean region by creating a reliable forum for education, knowledge transfer and the
development of consensus management plans. It is a valuable tool to strengthen
training by increasing the expertise of sub-specialists locally and promotes academic
exchange in paediatric specialties. By building capacity and nurturing expert knowledge
through education, SCI hopes to contribute to reducing the gap in childhood cancer
survival between Canada and the participating Caribbean countries.
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PATTERN OF CHILDHOODMALIGNANCY AND TREATMENT REFUSAL IN
A TERTIARY CARE HOSPITAL
M. Akm1, M. Akter2, S. Islam3
1Dhaka Medical College Hospital, Dhaka, Bangladesh; 2Dhaka Medical College
Hospital, Paediatric Haematology and Oncology, Dhaka, Bangladesh; 3Dhaka Medical
College Hospital, Paediatric surgery, Dhaka, Bangladesh
Background/Objectives: Refusal and abandonment is the leading cause of treatment
failure in children with cancer in the developing world. Malignant neoplasm remains
the leading cause of disease-related (non injury) mortality (12.8%) among persons 1-14
yr of age. To our knowledge Bangladesh has few studies about pediatric cancer
profile.To evaluate the pattern of pediatric cancer & causes of treatment refusal in
Dhaka Medical College Hospital.
Design/Methods: This was a prospective observational study from March’ 2014 to
February’ 2015 in Department of Pediatric Hematology & Oncology, Dhaka Medical
College Hospital. Hundred thirty nine cases were included in this study.Detailed
information’s were obtained in each cases according to protocol. Complete history was
taken from accompanying attendants. Through clinical examination was done. Relevant
investigations report was collected. All the informations were recorded in the fixed
Pediatric Oncology network database (POND). Collected data was classified, edited,
coded and entered into the computer for statistical analysis by using SPSS-17.
Results: Out of 139 patients, mean age was 6.11(±3.31) yrs, male female ratio was 1.55
:1. Common clinical features were fever , pallor, Hepatomegaly, Bleeding manifestation,
bony tenderness, weight loss, abdominal or mediastinal mass, splenomegaly and
lymphadenopathy which were 110(55%), 74(37%), 61(30%), 40(20%), 40(20%),
40(20.10), 37(19%) and 14(7%) respectively. Common pattern of child hood malignancy
were ALL, AML, Neuroblastoma, Hodgkin lymphoma, Non-Hodgkin lymphoma,
Wilms tumor and Embryonal rhabdomyosarcoma which were 98(49%), 19(9%),
13(6%), 11(5%), and 05(2%) respectively. Refused to treatment was 41(21%). Majority
28(68.29%) were due to financial crisis, followed by lack of family support 25(61%),
13(32%) lack of blood and blood product, 07(17%) had have faith on traditional
treatment or homeopathy, 05(12%) had Interested to treat elsewhere.
Conclusion: An structured database provide excellent information about childhood
malignancy/ Proper input in database identify the problem magnitude,presentation of
diseases, morbidity pattern and cause of refusal of treatment by parents.
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PERCEPTION AND ATTITUDE OF ARAB PEDIATRIC ONCOLOGISTS
TOWARD GENETIC TESTING IN CANCER
N. Amayiri1, D. Al-Rimawi1, A. Al-Omari2
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1King Hussein Cancer Center, Amman, Jordan; 2King Hussein Cancer Center, Office of
Scientific Affairs and Research, Amman, Jordan
Background/Objectives: Genetic predisposition is an increasingly accepted cause of
childhood cancers. However, little is known about the perception and attitude of
pediatric oncologists in Arab countries toward disclosure of genetic predisposition for
cancer (GPC) and genetic testing (GT).
Design/Methods:We designed a questionnaire (29 questions) which evaluates
demographics, knowledge and practices toward GPC and was emailed to a list of
oncologists. Their emails were acknowledged by one or two local oncologists. We
exclusively included replies from Arab pediatric oncologists practicing in Arabic
countries; aiming to unify the cultural background and work circumstances.
Results:We had 48 complete responses, 60% from eastern countries. Median
participants’ age was 46.5 years (range, 35-68 years) with equal male: female ratio
.Thirty one (65%) reported >10 years oncology experience and 60% had some oncology
training in Europe / North America. GT and genetic counselors are likely available in
60% of countries. Majority of oncologists (83%) believe that confirmation of a genetic
cause will change the patient management.67% of oncologists think the community
accepts GT while 29% believe cancer is stigmatized and the idea of GPC is culturally
and psychologically unbearable. Despite this, most oncologists (92%) feel ethically
obligated to tell a parent if GPC is suspected, in order to encourage GT and cancer
screening. In fact, half of oncologists had referred patients for GT and almost all
oncologists (98%) will offer a specific GT (if available) to their patients. Interestingly, no
demographic factor seemed to influence the oncologists’ perception or attitudes
(p>0.05).
Conclusion:Majority of Arab pediatric oncologists are aware of GPC and would
encourage such discussions during family encounters. They realize there are some
logistic difficulties, cultural and social challenges to such disclosures. When present,
oncologists need to utilize the genetic counselors to raise public and governmental
awareness and help overcome the challenges in countries with high consanguinity.
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PROFILE AND OUTCOME OF PEDIATRIC CNS TUMORS: EXPERIENCE
FROM A CANCER CENTER IN A LOW INCOME COUNTRY
N. Amayiri1, K. Jamal2, M. Swaidan3, M. Al-Hussaini4, H. Halalsheh5, A. Ibrahimi6,
M. Elayyan7, A. Musharbash8, E. Bouffet9
1King Hussein Cancer Center, Pediatric Department, Amman, Jordan; 2King Hussein
Cancer Center, Department of Cancer Registry, Amman, Jordan; 3King Hussein Cancer
Center, Radiology Department, Amman, Jordan; 4King Hussein Cancer Center,
Pathology Department, Amman, Jordan; 5King Hussein Cancer Center, Pediatric
Department, Amman, Jordan; 6King Hussein Cancer Center, Radiation Oncology
Department, Amman, Jordan; 7King Hussein Cancer Center, Surgical Departement,
Amman, Jordan; 8King Hussein Cancer Center, Amman, Jordan; 9Hospital for Sick
Children, Department of Hematology / Oncology, Toronto, Canada
Background/Objectives: Limited data are available about epidemiology and outcome of
pediatric CNS tumors in low income countries (LIC). A multidisciplinary pediatric
neurooncology service was established at King Hussein Cancer center (KHCC)/ Jordan
in 2004 with a twinning with Sickkids hospital /Toronto. KHCC as well is a referral
center for pediatric radiotherapy and has a hospital based cancer registry since 2006. We
aimed to utilize the registry data to profile pediatric CNS tumors treated over 7 years.
Design/Methods:We reviewed registry records between 2007 -2013. Patients diagnosed
with primary CNS tumors < 18 years at presentation were included. Clinical
characteristics, management and survival were documented for patients exclusively
treated at KHCC.
Results: CNS tumors ranked second (19%) following leukemia (29%). We identified 476
patients: 349 treated by KHCC team, 91 one-time consultation and 36 solely
radiotherapy referrals. Male: female ratio was 1.4 and 73% were Jordanians. Median age
was 6.7 years (range,0.2-18 years) with 60 children (17%)3 years. Intracranial tumors
occurred in 330 tumors (95%); 60% were infratentorial. The main histology was low
grade astrocytoma (LGG) 30%, medulloblastoma 24%, high grade astrocytoma (HGG)
20%, ependymoma 8%, craniopharyngioma 3% and germ cell tumors (GCT) 3%. More
males were reported in GCT (78%) and medulloblastoma (67%). Ten of seventeen
spinal tumors were astrocytoma (2 HGG) and six were ependymoma. Treatment
included surgery in 85% and half received radiotherapy and/or chemotherapy. 5yr OS
for intracranial LGG was (93.8±3.6%), medulloblastoma (60.2±7%), ependymoma
(53.2±12.2%), craniopharyngioma (80±12.7%) while 3yr OS for HGG was 14.1±7.2%.
Conclusion: Being a referral center, malignant CNS tumors requiring radiotherapy are
overrepresented. Cancer registries are critical to appreciate incidence and outcome and
should be encouraged in LIC. They can be enriched with data about relapse, salvage
therapy and morbidities. Multidisciplinary approach and twinning help achieve
acceptable survival rates in LIC despite local difficulties.
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DESCRIPTIVE EPIDEMIOLOGY OF CANCER IN ADOLESCENTS AND
YOUNG ADULTS IN TWO TERTIARY CANCER CENTRES IN DELHI, INDIA
R. Arora1,2, S. Chatterjee2, A. Adhana1, R. Shirali1, R. Singh2
1Max Super-Speciality Hospital Saket, Medical Oncology, New Delhi, India; 2Max
Super-Speciality Hospital Patparganj, Medical Oncology, New Delhi, India
Background/Objectives: Although, cancer in adolescents and young adults (AYA) is
increasingly an area of focus, there is paucity of clinical and epidemiological data from
developing countries. We describe the epidemiology of this group of patients from 2
hospitals in India.
Design/Methods: All patients aged 15 to 29 years with the diagnosis of cancer who were
registered with two hospitals in New Delhi during a 12 month period from January
2014 to December 2014 were included. Basic demographic information on age, sex and
nationality was available. Using cancer site and morphology codes, the cancers were
grouped by the Birch classification of AYA cancers.
Results: There were 287 patients (57.5% male, 85.4% Indian origin) registered with 54
(18.8%), 97 (33.8%) and 136 (47.4%) patients in the 15-19, 20-24 and 25-29 years age
groups respectively. The three most common cancer groups were carcinomas (40.8%),
lymphomas (12.9%) and leukemias (10.4%) overall. The pattern was similar in females
while for males most common cancer groups were carcinomas, bone tumours and
lymphomas. For the 15-19 years age group most common cancer groups were
carcinomas, lymphomas and leukemias; for the 20-24 years age group carcinomas,
leukemias and bone tumours; for the 25-29 years age group carcinomas, lymphomas
and germ cell tumours. Among carcinomas, those of the gastrointestinal tract were
most common at all ages except 15-19 years were carcinoma of the thyroid was most
common.
Conclusion: The occurrence of cancer in AYA in India has been described. The
distribution differs from the only previous report from India which may partly be
related to referral bias.
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DELAYED CANCER DETECTION ASSOCIATEDWITH A LOWER SURVIVAL
IN ONCOLOGIC CHILDREN IN QUITO, ECUADOR
A. Borja1, M.J. Pesantez2, J.D. Naranjo2, D. Franco3
1Hospital Axxis, Quito, Ecuador; 2Hospital Axxis, Pediatric Oncology, Quito, Ecuador;
3Hospital Metropolitano, Anatomopathology, Quito, Ecuador
Background/Objectives: Evaluate the mean age at diagnosis of cancer, most frequent
sex, distribution and 5-years survival rates in a group of ecuadorian children compared
to frequencies and rates in developed countries. According Pan American Health
Organization, the higher percentages of childhood cancer cases in the continent were
detected in Latin America (65%) in past years. Despite of this, cancer is not the leading
cause of disease-related death among children in many undeveloped countries. The
underestimation of childhood cancer is a public health problem in undeveloped
countries because it reflects the late diagnosis of cases, which increase mortality. While
the percentage of cancer survival in developed countries is 75%, in low income
countries is 60% due to late diagnostic and abandonment of treatment.
Design/Methods: Open, Retrospective.Medical Data of all patients between 0-14 years
old that attend to Oncology Service at BO Hospital in Quito Ecuador from January,
2007 to October, 2012. Data used includes age at diagnosis, sex, Biopsy-based diagnosis
and 5-year survival.
Results: A total of 667 (4,6%) from 14635 children were diagnosed with cancer, 56%
men and 44% women. The most prevalent age group was 1- 5 years (34%), followed by 8
- 12 years (22%), 5-7 years (19%),0- 11months(14%) and >12 years (11%). Most
frequent cancer was leukemia (30%) followed by Central Nervous System (21%),
lymphoma (14%), Wilms tumor (9%), Neuroblastoma (5%), Osteosarcoma (4%),
Retinoblastoma (4%), Rhabdomyosarcomas (2%) others (11%). The 5-year survival
rates were Leukemia 70%, Central Nervous System 60%, Lymphoma 60%, Wilms
tumors 95%, Neuroblastoma 60%, Osteosarcoma 40%, Retinoblastoma 70%.
Conclusion: The 5-year survival rates in Ecuador are lower compared to higher income
countries. A large number of patients had delayed diagnose (8 - 12 year old), which
improve the possibility of advanced stage of cancer and therefore lower survival.
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CAUSE AND PLACE OF DEATH IN A PEDIATRIC ONCOLOGY UNIT
P. Costa-Reis1, F. Durão1, T. Martins2, M.J. Ribeiro3, A. Neto3, X. Duarte3,
A. Lacerda3, M.F. Pereira3
1Hospital Santa Maria-University of Lisbon, Pediatrics, Lisbon, Portugal; 2Hospital
Garcia da Orta, Pediatrics, Almada, Portugal; 3Instituto Português de Oncologia de
Lisboa Francisco Gentil, Pediatrics, Lisbon, Portugal
Background/Objectives: Although pediatric cancer is rare, it is the leading cause of
non-accidental death in children. New treatment strategies have significantly improved
overall survival, but are associated with significant side effects, including major
infections and organ toxicity. The aim of this study was to analyze cause and place of
death in children with cancer in a Pediatric Oncology Unit.
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Design/Methods: Retrospective analysis of the clinical data of all the children who died
between January 2005 and December 2014.
Results: In 10 years 317 children died; 177 were male (56%); median age of death was 9y
(IQR 5-14y). Most of the deceased children had solid tumors (N=124, 39%), followed
by central nervous system tumors (N=108, 34%) and leukemia/lymphoma (N=85,
27%). Progression of disease was the main cause of death (N=267, 84%). Twenty nine
deaths were due to infection (9%), including 19 patients with septic shock, eight with
pneumonia, one with varicella and one with a cytomegalovirus infection. Neutropenia
was documented in 16 patients with septic shock (16/19; 84%). Eight children died after
surgery (3%). Graft-versus-host disease caused three deaths (1%). Two children died
due to neurotoxicity, one to cardiotoxicity and another to anaphylaxis. The median
time between diagnosis and death was 17m in progressive disease and 7m in toxic
deaths. The majority of deaths due to progressive disease occurred in the hospital
setting (N=226, 71%), only 33 children (13%) died at home. All toxic deaths (N=48)
occurred in the hospital, 48% (N=23) in an intensive care unit.
Conclusion: Disease progression was the main cause of death, followed by infection.
Prevention, early diagnosis and aggressive treatment of infection must be, therefore, a
main concern of Pediatric Oncology Units. There is the need to develop palliative care
services to provide alternatives to hospital death in children with disease progression.
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CHILDHOOD CANCER SURVIVAL IN A SINGLE CENTRE BETWEEN 2006
AND 2010
J. Duarte1, S. Nunes2, A.M. Neto1, M.F. Pereira1
1Instituto Português de Oncologia de Lisboa, Pediatria, Lisbon, Portugal; 2Instituto
Português de Oncologia de Lisboa, Neuropediatria, Lisbon, Portugal
Background/Objectives: Survival rates for childhood cancers have greatly improved over
the past years. In this study we compared survival data of patients treated in our centre
between 2006 and 2010 with those previously published from Southern Portugal, other
European countries and the United States.
Design/Methods:We retrospectively reviewed data for 2,193 children (aged between 0
and 14 years) admitted in our department between January 1st, 2006 and December
31st, 2010. We excluded 852 patients that did not have an oncologic disease and also
excluded 132 patients coming from Portuguese-speaking African countries. We finally
analysed data for 1,209 patients with cancer diagnosis. Neoplasic diseases were grouped
according to the International Classification of Childhood Cancer (ICCC3) and in the
case of central nervous system (CNS) neoplasms we also used a histological
classification. We described age and gender distribution and estimated 5-year overall
survival for major cancer groups.
Results: Five-year overall survival was 79.1% (95% CI 75.9–82.5). EUROCARE-5 study
(European patients diagnosed between 2000-2007) reported a 77.9% rate while SEER
(United States patients diagnosed between 1999-2006) published a 79.9% rate.
According to their survival rate we differentiated a group of diseases with a survival rate
above 90% (including renal tumours, lymphomas and hepatic tumours); a group with
survival between 75% and 85% rate (including acute leukemias, retinoblastomas, soft
tissue sarcomas and epithelial tumours) and a group with a survival rate below 70%
(including neuroblastomas, CNS tumours and malignant bone tumours).
Conclusion: Survival rates of our study cohort improved those previously reported by
national groups with the exception of malignant bone tumours. Patients with Ewing
sarcoma had more relapses than expected and those patients with metastatic disease did
not survive. Histological classification for CNS tumours was better than ICCC3 in
defining patient groups with a similar outcome. International cooperation is essential to
improve outcome of bad prognosis diseases.
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IMPROVING ACCESS TO CANCER CARE FOR CHILDREN AND
ADOLESCENT FROM DISTANT AND LOW-INCOME AREA
S. Epelman1, R. Guedes1, E. Gorender1, R. Melaragno1
1Santa Marcelina Hospital, Pediatric Oncology Department, Sao Paulo, Brazil
Background/Objectives: Brazil is a continental middle-income country but income
inequality remains at high levels. It has demographic characteristics areas that does not
demand a pediatric cancer center therefore; we demonstrated the value of prompt
referral pathways to pediatric patients with suspected malignancy to a cancer center,
despite the large geographical distances and economic diversity between them.
Design/Methods: Children and adolescents with signs and symptoms of cancer from
Amapa, a northern state of Brazil, are referred to our center in Sao Paulo, a southern
state 2.600 km from there. All necessary needs and treatment are supported by public
health insurance and NGO. There is no cost for the patient.
Results: The estimated incidence of cancer in the population under 19 years in Amapa
is 36 new cases per year. Therefore, between 2010 and 2014, 69 patients were referred
and 33 (44%), during the last year, Male/Female 38/31, median age 7 years, (1-16 years).
Mean per capita income of these patients is U$ 100/month (Sao Paulo - U$
700/month). 17% had no basic sanitation at home and their parents had informal
employment in 44%. Main diagnosis were acute leukemia (55%), lymphoma (12%),
solid tumors (12%) and non-malignant diseases (21%). Median time since they seek
medical care to referral to our center was 30 days.
Conclusion: A public health policy to the adequate diagnosis and treatment of
childhood cancer needs a comprehensive cancer center with trained staff, necessary
equipment and drugs, to improve survival, develop research, and train future workforce.
It is a priority to every country to improve access to an affordable, best standard of
care. The recognition of the unique demographic and economic characteristics areas
are mandatory to create referral routes and care pathways to improve survival. This
model can be useful in other countries.
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THE EUROPEAN ROADMAP TO HORIZON 2020 FOR CHILDREN AND
ADOLESCENTS WITH CANCER - A LONG TERM SUSTAINABLE STRATEGY
G. Vassal1, M. Schrappe2, K. Pritchard-Jones3, F. Arnold4, L. Basset5, S. Bielack6,
A. Biondi7, G. Bode8, T. Boterberg9, A. Eggert10, S. Essiaf11, H. Hasle12, L. Hjorth13,
L. Kameric´14, N. Kameric´14, S. Karner8, P. Kearns15, A. Kienesberger8, J. Kowalczyk16,
O. Kozhaeva11, P. Lack17, M. Naafs-Wilstra8, G. Perilongo18, G. Petrarulo11,
R. Pieters19, R. Riccardi20, J. Starý21, R. Sullivan22, A. Tsirou23, M.G. Valsecchi24,
R. Ladenstein25
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Department of Radiation Oncology and Experimental Cancer Research, Ghent, Belgium;
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and Haematology, Berlin, Germany; 11SIOP Europe SIOPE, The European Society for
Paediatric Oncology, Brussels, Belgium; 12Aarhus University Hospital Skejby,
Department of Paediatrics, Aarhus, Denmark; 13Skåne University Hospital- Clinical
Sciences- Lund University, Department of Paediatrics, Lund, Sweden; 14The heart for the
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FBiH/Cancer Survivor Network, Sarajevo, Bosnia and Herzegovina; 15School of Cancer
Sciences-University of Birmingham, Cancer Research UK Clinical Trials Unit CRCTU,
Birmingham, United Kingdom; 16Medical University-Lublin, Department of Paediatric
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Padua, University Hospital of Padua, Padua, Italy; 19Princess Máxima Center for
Paediatric Oncology, Princess Máxima Center for Paediatric Oncology, Utrecht,
Netherlands; 20Policlinico Universitario “A. Gemelli”, Division of Paediatric Oncology,
Rome, Italy; 21CPH Czech Working Group for Paediatric Oncology-University Hospital
Motol, Department of Paediatric Haematology and Oncology, Prague, Czech Republic;
22King’s College London, Division of Cancer Studies, London, United Kingdom;
23Kyttaro/Greek Survivors Association, Kyttaro/Greek Survivors Association, Athens,
Greece; 24Centre of Biostatistics for Clinical Epidemiology-University of
Milano-Bicocca, Department of Health Science, Monza, Italy; 25St. Anna
Kinderkrebsforschung e.V., Children’s Cancer Research Institute, Vienna, Austria
Background/Objectives:With 35,000 new cases every year, childhood cancer is an urgent
public health issue in Europe. Access to standard care is unequally available across the
continent. Survivors experience long-term effects, and, in spite of the improvements
achieved, cancer remains the leading cause of disease-related death for children beyond
one year of age. To define a long term sustainable strategy to increase both the rate and
the quality of cure in children and adolescents with cancer over the next decade.
Design/Methods: As part of the FP7 ‘European Network for Cancer research in
Children and Adolescents’ (ENCCA) project, a strategy was defined along with the
Clinical Research Council (composed of all the European Clinical Trial groups and
national societies in paediatric haematology oncology) and with parents and survivors
from the Childhood Cancer International European group.
Results: Seven medical and scientific objectives have been set up: i) Introducing safe and
effective innovative treatments into multidisciplinary standard care; ii) Driving
therapeutic decision by improved risk classification, the use of molecular characteristics
and precision medicine; iii) Increasing knowledge of tumour biology and speeding up
translation to benefit patients; iv) Increasing equal access across Europe to standard
care, expertise and clinical research; v) Addressing the specific needs of teenagers and
young adults, jointly with adult oncology; vi) Addressing the quality of survivorship;
vii) Understanding the causes of paediatric cancers and addressing prevention where
possible. The strategy achieved a broad consensus between all involved stakeholders.
The European Society of Paediatric Oncology (SIOPE) is steering the effective
implementation through dedicated programmes and cross tumour platforms, and will
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facilitate funding through European and national grants as well as from charities and
industry.
Conclusion: This European Childhood Cancer Plan is the outcome of a close
partnership among all involved stakeholders.
Acknowledgements: Funded by the European FP7 programme.
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KNOWLEDGE OF EARLYWARNING SIGNS OF CHILDHOOD CANCER IN
FINAL YEARMEDICAL STUDENTS. ENOUGH IS NOT ENOUGH
B. Stevenson1, L. Krook1, B. Katz1, F. Tamaryn1, S. Winnan1, J. Geel2
1Faculty of Health Sciences-University of the Witwatersrand, Department of Paediatrics
and Child Health, Johannesburg, South Africa; 2Faculty of Health Sciences-University of
the Witwatersrand, Division of Paediatric Haematology and Oncology-Charlotte Maxeke
Johannesburg Academic Hospital, Johannesburg, South Africa
Background/Objectives: The incidence of childhood cancer in South Africa is much
lower than in high income countries, partially attributable to under-diagnosis and
under-reporting. This study was conducted to determine the level of knowledge of
signs of childhood cancer in final year medical students and to explore correlations
between knowledge level, participant demographics and previous exposure to a patient
with cancer.
Design/Methods: A structured questionnaire based on the St SILUAN mnemonic,
testing both recall and recognition of early warning signs of childhood cancer, was
administered to final year medical students. Pearson’s chi square and Fisher’s exact test
were employed to determine correlations between demographic data, prior contact with
patients with cancer and test scores. An equality ratio compared recall and recognition
sections of the questionnaire.
Results: The mean number of signs and symptoms correctly recalled by the 84
participants was 5.7. The mean number of signs correctly recognised was 13.6/20
(68.1%), while 44.1% of respondents could correctly identify more than 75% of the
signs. There was no correlation between scores and participants’ gender, age and prior
contact with a person with cancer. When test scores were combined using an equality
ratio, a significant correlation was found between previous clinical experience and a
higher score (p = 0.044; Pearson’s chi square test).
Conclusion:Medical students demonstrated a marked inconsistency between recall and
recognition of early warning signs of childhood cancers. However, the majority of
students could recognise enough symptoms to meet the university pass standard.
Despite acceptable recognition of signs of childhood cancer in final year medical
students, the age standardised ratios of children with cancer in South Africa are
unacceptably low, indicating that long term recall in medical practitioners is poor. We
recommend increased exposure in medical school to paediatric oncology and improved
awareness programmes to increase early referrals.
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A 10-YEAR RETROSPECTIVE STUDY OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR CANCER AND BENIGN HEMATOLOGIC
DISEASES: A SINGLE REPORT FROM AMEXICAN PEDIATRIC
HEMATOLOGY-ONCOLOGY CENTER
O. Gonzalez Ramella1,2, J.L. Vazquez-Urdiano1, M. Ortiz-Sandoval1,
A.L. Orozco-Alvarado1, R. Navarro-Martin del Campo1, G. Escobedo-Melendez2,
R. Balderrama-Magallanes2, F. Sanchez-Zubieta1,2
1Hospital Civil de Guadalajara, Departamento de Hematologia y Oncologia Pediatrica,
Guadalajara, Mexico; 2Universidad de Guadalajara, Instituto de Investigacion del Cancer
Infantil y de la Adolescencia, Guadalajara, Mexico
Background/Objectives: Hematopoietic stem cell transplantation (HSCT) plays an
important role in the treatment of malignant and not malignant diseases. In our
hospital, the first HSCT was performed in 2003. The aim of this study was to evaluate
the characteristics and the outcome of HSCT in our Center.
Design/Methods: Between January 2003 to December 2013, 95 pediatric patients under
the age of 20, with either a malignant or non-malignant diseases were transplanted in
our Unit. Clinical records were reviewed and data were retrospectively analyzed.
Results: 95 pediatrics patients were transplanted. Fifty-three (55.8%) were male; average
age was 7.6 years (range 1 to 20). Twenty-two were ALL patients (23.2%), AML in 24
(35.3%), hematologic disorder (including immunodeficiencies) in 31 (32.7%), solid
tumors in 4 (4.3%) myelodysplastic syndrome in 3 (3.2%), lymphoma in 2 (2.1%), CML
in 9 (9.5%). Fourteen patients (14.7%) received an autologous transplant, a full
matched related donor (MRD) was used in 49 (51.5%) whereas 32 (33.6%) a full or
partially matched unrelated donor (MUD) was used, (4/6 to 6/6 30 cord blood units and
1 haploindentical). Conditioning regimens included myelo- and non-myelobaltive. Total
body irradiation was used in all patients with an ALL. Graft was achieved in 21.6 days
(range 8 to 71). Some grade of acute GVHD occurred in 33 patients (34.7%) whereas
chronic GVHD was seen only in 3 (3.1%). Overall survival rate was 55% with 60 follow
up time.
Conclusion: HSCT is feasible in mid-income countries like ours. Both neutrophil and
platelet engraftment time were longer compared to other HSCT Centers, this might be
explained due to the high number of cord blood units that were transplanted as well as
the use of bone marrow instead to peripheral blood. Transplant related mortality has
been decreased over the years, due principally to the multidisciplinary team expertise.
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ONCOGENETIC PEDIATRIC CONSULTATIONS: EVALUATION OF
INDICATIONS AND PRACTICES IN THE BORDEAUX
HEMATOLOGY-ONCOLOGY PEDIATRIC UNIVERSITY HOSPITAL UNIT
DURING THE 2011-2012 PERIOD
S. Gourdon1, Y. Reguerre2, M. Jehanne2, B. Doray3, Y. Perel4, S. Ducassou4
1Reunion University Hospital, Hematology-Oncology Pediatric Unit and Genetics Unit,
Saint Denis, Reunion; 2Reunion University Hospital, Hematology-Oncology Pediatric
Unit, Saint Denis, Reunion; 3Reunion University Hospital, Genetics Unit, Saint Denis,
Reunion; 4Bordeaux University Hospital, Hematology-Oncology Pediatric Unit,
Bordeaux, France
Background/Objectives: In literature, cancer genetic predispositions are present in about
10% of children suffering from cancer. Identifying such factors is an "important
requirement" to improve children’s management. Key points to identify patients with
cancer genetic predispositions should be identified.To test first and foremost children at
risk of predisposition, a tool allowing the collection of risk factors may be useful in a
pediatric oncology service. The description and quantification of these genetic risk
situations and their modality of care will help create this tool.
Design/Methods: This study was conducted on all children diagnosed with cancer
between 2011 and 2012, in the oncology-hematology pediatric unit of Bordeaux
University Hospital. The chosen risk factors included age under one year at diagnosis,
multifocal lesions, type of cancer, secondary malignancy, family history of cancer and
the call of the clinical examination points.
Results: 223 children with a cancer were treated between 2011 and 2012. There were 76
patients (33.9%) with at least one risk factor for genetic susceptibility to cancer. The
two risk factors most frequently encountered were the age under one year at diagnosis
(34.2%) and a family history of cancer (48.7%). 65.8% of our cohort presented one risk
factor. Finally, only 23 patients (30%) with risk factors were sent in an oncogenetic unit
for consultation. They were essentially patients with multifocal disease or multiple risk
factors.
Conclusion: A large proportion of children treated for cancer required an oncogenetic
consultation. However, a minority of patients with visible criteria for clinicians
benefited from it. A systematic data collection file seems useful to improve identification
of patients at risk. We proposed one example of data collection form.
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THE AFRICAN SCHOOL OF PEDIATRIC ONCOLOGY INITIATIVE: REPORT
FROM THE FRENCH AFRICAN GROUP OF PEDIATRIC ONCOLOGY
L. Hessissen1, P. Catherine2, L. Guy3, M. Helene4, V. Gilles5, C. Antoine5, H. Robert6,
H. Mhamed7
1Hemato-Oncology Pediatric Center, Rabat, Morocco; 2Gustave Roussy Institute,
pediatric oncology, Villejuif, France; 3Trousseau Hospital, Pediatric Hematology and
Oncology, Paris, France; 4Bicêtre Hospital - Paris sud University, Pediatric Surgery,
Villejuif, France; 5Gustave Roussy Institute, École du Cancer, Villejuif, France; 6French
African Group of Pediatric Oncology, Pediatric Oncology, Villejuif, France; 7Mohamed
VI University Hospital, Pediatric Hematology and Oncology, Marrakech, Morocco
Background/Objectives: To improvethe skills of pediatric oncology (PO) health-care
providersin Africa, the French African Group of Pediatric Oncology (GFAOP) set up
the African School of Pediatric Oncology.
Design/Methods: This school located in Marrakech, Morocco, develops programs not
only for physicians and nurses, but also for pathologists, surgeons, and technicians. This
project is supported by Sanofi Espoir foundation (My Child Matters program), Lalla
Salma Foundation for Prevention and Treatment of Cancer, the Moroccan Society of
Pediatric Hematology and Oncology and the Gustave Roussy Institute’s School of
Cancer.
Results: From 2011 to 2014, four intensive courses were organized in Morocco: A
three-day intensive course for nurses in 2011, afive-day course for pediatric oncologist
in 2012, a three-day course for pediatric surgeon in 2013 and afive-day course for nurse
educators in 2014.The content was adapted to address topics and issues specific to PO
in Africa. Some nurses were selected for training in France (Laurette Fugain
association scholarship).A total of 128 health-care providers, from 14 African countries
attended the courses: Morocco (62), Algeria (9), Tunisia (6), Mali (6), Burkina Faso (6),
Senegal (5), Ivory Coast (5), Togo (5), Madagascar (4), Democratic Republic of Congo
(4), Mauritania (3), Cameroun (3), Guinea Conakry (2) and Republic of Congo (1).
Among them 72 were nurses, 32 pediatric surgeons, 21 pediatric hemato-oncologists, 2
pathologists and one ophthalmologist.Each course was assessed for its scientific value,
applicability to the participants’ daily practice, quality of pedagogical material and
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interaction with the participants.According to the post course survey 90% of the
participants were satisfied or very satisfied.
Conclusion: The GFAOP continuously strives to improve the quality of the training in
Africa. Accordingly, a PO diploma was set up in 2014-2015 with the participants of 26
candidates from 9 African countries.
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RISK ASSESSMENT OF ENVIRONEMENTAL CARCINOGENS,
EPIDEMIOLOGY AND POLYMORPHISM IN CHILDHOOD LEUKEMIA AND
SOLID TUMORS: A STUDY FROM ENVIRONMENTAL HEALTH CENTER,
KOREA
H. Kook1, H.J. Baek1, H.I. Jang1, J.H. Cho1, K.M. Jeong1, D.K. Han1, H.J. Kim2,
J.D. Moon3
1Chonnam National Univ. Hwasun Hospital, Pediatrics, Chonnam, Korea; 2Chonnam
National Univ. Hwasun Hospital, Hematology, Chonnam, Korea; 3Chonnam National
Univ. Hwasun Hospital, Environmental and Occupational Medicine, Chonnam, Korea
Background/Objectives: This study is aimed to identify environmental factors and
genomic variations in the development of childhood leukemia and cancer, and their
outcome from a province of Korea with a population of 3.5 million.
Design/Methods: From 2006 to 2014, a total of 472 children were diagnosed to have
childhood leukemia and solid tumors from Gwangju-Chonnam area. A questionnaire
including parental environmental and occupational exposure, and mother-child
life-style was obtained. A total of 371 patients and 378 healthy controls were enrolled in
the study. Environmental exposure was assessed by toxicological measurement of
house-hold air and water samples. Blood and urine samples were collected from
patients and controls and their respective parents. Single nucleotide polymorphisms
(SNP) were evaluated for enzymes involved in metabolism, cell cycle regulation,
differentiation, and signal transduction.
Results: The 6-yr Kaplan-Meier estimated overall survival (OS) for all 472 patients was
76.7±3.0%. The 6-yr OS for 235 leukemia patients was 73.4±3.5%, while that for 237
children with solid tumors was 79.7±4.5%. Maternal smoking history was the most
significant factor associated with leukemia in children [Odds ratio (OR), 4.76 (95% CI,
1.23-18.46)]. Carcinogenic exposures in house-hold air and water were not significantly
different from controls. Urinary 1-hydroxypyrene concentration was higher in patients
(P<0.001), and blood cadmium concentration tended to be higher in patients and their
parents. SNP analysis showed that genomic variations of ARID5B and CDKN2A, but
not IKZF1, might play an important role in the risk of childhood acute lymphoblastic
leukemia in Korea.
Conclusion: Considering the heterogeneity of childhood cancers and complex
pathogenesis of each disease category, a large number of patients are required to
elucidate precise association with environmental carcinogens. However, parental
smoking was associated with the risk of leukemia. Moreover, ethnic difference in
genotypic polymorphism and the susceptibility to malignancies should be
contemplated.
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AN OVERVIEW OF YOUTH CANCER ISSUES IN MBINGO BAPTIST
HOSPITAL
F. Kouya1, P. Hesseling2, P. Wharin3, P. McCormick3, R. Bardin4, Y. Njoko5
1Mbingo Baptist Hospital, Mbingo, Cameroon; 2Stellenbosch University, Tygerberg
Children’s Hospital, Cape Town, South Africa; 3Beryl Thyer Memorial Africa Trust,
Beryl Thyer Trust, London, United Kingdom; 4Mbingo Baptist Hospital, Internal
Medicine/ Pathology, Mbingo, Cameroon; 5Mbingo Baptist Hospital, Internal Medicine,
Mbingo, Cameroon
Background/Objectives: Cancer in young adults has received significant world-wide
attention over the last decade. In Mbingo Baptist Hospital the care of children (0 to 15
years) with cancer has improved since 2003, to attain a cure rate of 60%. Little
attention, poor coordination of care and limited resources have been devoted to the
young adults (15-22 years) with cancer, thus accounting for a significant poorer survival
rate. This study looks at the pattern of cancer, the duration of symptoms prior to
treatment, the ability to complete treatment and survival rate.
Design/Methods: All patients’ information were collected from the hospital records. The
diagnosis was based on clinical presentation, imaging, fine needle aspirates,
Cerebrospinal fluid, bone marrow and abdominal fluid analyses. The study involves
young adults from 15 to 22 year diagnosed of cancer in Mbingo Baptist Hospital in the
Northwest region, Cameroon from 2009 to 2014.
Results: A total of 120 adolescents were recorded, from 5 patients in 2009 to 43 patients
in 2014. The majority of patients (39%) had lymphoma, followed by osteosarcoma
(11%) and hepatocellular carcinoma (10 %). Late presentation continues to be a big
problem. The duration since onset of symptoms was found to be 0,5 months to 24
months. 31 patients had recorded disease stage, with 54% being stage 3, and 32% stage
4. Chemotherapy was given only to 41(34%) patients. 53% of these completed their
treatment and 47% could not complete their treatment due to financial reasons,
progressive disease, side effects and unknown reasons. Few patients were followed up
and the survival rate less than 10 %.
Conclusion: The number of adolescents with malignancies is growing. A comprehensive
care model is needed to optimize care for this population. Resources for free treatment,
appropriate protocol for this age group have to be made available. Active follow up has
to be implemented.
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CHILDHOOD CANCER REGISTRY OF CHELYABINSK REGION
S. Kovalenko1, I. Spichak1, E. Basharova1, K. Volkova1
1Chelyabinsk Regional Children’s Clinical Hospital, Oncohematological Department,
Chelyabinsk, Russia
Background/Objectives: The Chelyabinsk region child population resides mainly in
major industrial cities and is, therefore, exposed to a variety of anthropogenic and
natural adverse factors. Active development of regional pediatric cancer calls for extra
attention in patients’ follow up and epidemiological indicators monitoring as it is
necessary for adequate care planning and therapy results improvement. The Regional
Childhood Cancer Registry was set up to address these challenges.
Design/Methods: The institutional registry was developed in 1992-1996. It provides a
retrospective pediatric cancer data collection for that period. Since 1996 prospective
data collection was initiated and starting from 2008 all cases of childhood cancer
(patients of 18 years or less) were prospectively registered.
Results: As at 1 January 2014 a total of 1545 pediatric cancer patients cases were
registered. A median patients’ age was 6.1 years, 1443 patients were younger, than 15
years. Male/female ratio was 1.26. The most common pediatric cancer type was
leukemia (32%). Central nervous system tumors accounted for about 25% of all
pediatric cancer cases, lymphoma for about 15% of cases. Age-standartized rate (ASR,
world standard) for the period of 2008-2012 was 15.72 per 100,000 child population.
We examined the geographic distribution of childhood cancer and demonstrated one
high risk cluster with statistically significant increasing of incidence in two adjacent
cities (ASR in Miass city - 20,27 per 100,000, in Zlatoust city — 22 per 100,000).
Conclusion: Our results on the regional incidence, age-sex distribution and cancer
morbidity structure correspond to previous published data. The cancer incidence
increase described by this study requires further epidemiological research and greater
observation span.
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SYMPTOMATIC VENOUS THROMBOTIC EVENTS ARE ASSOCIATEDWITH
SIGNIFICANTLY INCREASED REQUIREMENT OF CENTRAL VENOUS
CATHETERS IN PEDIATRIC CANCER PATIENTS: A POPULATION-BASED
STUDY FROMMARITIMES, CANADA
K. Kulkarni1, T. MacDonald2, C. Digout3, V. Price2, P. Cox2, C. Fernandez2,
M. Bernstein2, M. Yhap2
1IWK Health Center and Dalhousie University, Division of Paediatric Hematology
Oncology-Department of Paediatrics, Halifax, Canada; 2IWK Health Center, Division of
Paediatric Hematology Oncology-Department of Paediatrics, Halifax, Canada; 3IWK
Health Center, Division of Paediatric Hematology Oncology-APPHON, Halifax, Canada
Background/Objectives: Central venous catheters (CVCs) have revolutionized the care
of pediatric cancer patients (PCPs). CVC associated symptomatic venous thrombotic
events (sVTE) are known to occur during childhood cancer therapy and may lead to
CVC loss. Loss of a CVC typically mandates immediate replacement requiring general
anesthesia, surgical intervention and is a significant cost to health care system. The
frequency of CVC replacement post sVTE is not well described. This study was
designed to assess the requirement of CVC replacement in PCPs with and without
sVTE.
Design/Methods: All PCPs in 3 Maritime Provinces (Nova Scotia, New Brunswick and
Prince Edward Island) are treated at IWK Health Center in Halifax in a shared care
model with regional provincial hospitals. After ethics approval, case records of all
cancer patients (<20 years of age) managed from January 2000 to December 2014 were
retrieved. Data were integrated from: (i) pediatric oncology hospital database, (ii)
Provincial Cancer in Young People database, (iii) Electronic medical records, (iv)
Pharmacy database (v) IWK central line database and (vi) Hospital Health records.
Patients with signs or symptoms attributable to VTE and radiologically documented
VTE treated with anticoagulants were identified. Information of all CVCs required in
all PCPs was extracted.
Results: Forty (5.4%) of 731 PCPs had sVTE. Central venous system (81.6%) was the
most common location of sVTE.Among the patients with and without sVTE, 72.5%
and 27.5% respectively (p=0.001) required >1 CVC. The mean numbers of
CVCs/individual in patients with and without sVTE were 2.5±1.3 and 1.6±1.1
respectively (p=0.021). Presence of sVTE increased the odds of requiring >1 CVC to
3.6 (95% confidence interval: 1.76-7.3).
Conclusion: This population-based study demonstrates that increased CVC requirement
is an adverse clinical outcome of sVTE. Given the clinico-economic implications of
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CVC loss, future trials should focus on identification of “at-risk” patients and
prevention of sVTE.
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PILOT PROGRAMOF NEWBORN SCREENING FOR SICKLE CELL DISEASE
(SCD) IN ANGOLA - ANGOLA SICKLE CELL INITIATIVE (ASCI)
D. Nirenberg1, B. Santos2, P. Patel3, M. Noli3, M. Cubbage4, E. Ishigami4,
K. Wilson-Lewis4, G. Airewele5
1Baylor College of Medicine-Texas Children’s Cancer and Hematology Centers, Cancer
and Hematology Centers, Luanda, Angola; 2Hospital Pediatrico David Bernardino,
Pediatrics, Luanda, Angola; 3Baylor College Of Medicine-Texas Children’s Cancer and
Hematology Centers, Cancer and Hematology Centers, Cabinda, Angola; 4Texas
Children’s Hospital-Texas Children’s Cancer and Hematology Centers, Cancer and
Hematology Centers, Houston, USA; 5Baylor College Of Medicine-Texas Children’s
Cancer and Hematology Centers, Cancer and Hematology Centers, Houston, USA
Background/Objectives: An estimated 12,000 babies are born with SCD annually in
Angola alone. Without treatment, most of these babies die before five years of age.
Early diagnosis through newborn screening followed by treatment including daily
penicillin reduces mortality. In March 2011, the Republic of Angola entered into a
public-private partnership with Chevron and Texas Children’s Hospital/Baylor College
of Medicine to pilot a comprehensive newborn screening and treatment program in
order to reduce morbidity and mortality of children with SCD in Angola.
Design/Methods: This unique program provides screening, diagnosis, care, treatment,
health professional training, research, and community mobilization to improve care of
children with SCD in Angola. The Ministry of Health provides governmental
institutional support for execution of the project throughout the Angolan healthcare
system, including access to babies and support of maternity staff for blood spot
collection; staff, supplies and medications for the care and treatment provided in
government health facilities; and space for laboratory operationsChevron provides
funding for the projectBaylor College of Medicine and Texas Children’s Hospital
contribute expertise, personnel, training including pediatric hematology-oncology
subspecialists based in Angola and manage program funds and operations by providing
organizational capability, technical support for data management and procurement of
drugs and supplies, and leadership guidance.
Results: As of February 2015, the program has screened more than 100,000 newborns.
Of these, 2,000 were diagnosed with SCD 19 birth and health centers in Cabinda and
Luanda provinces collect samples from newborns for testingMore than 1,000 healthcare
professionals have been trained in SCD screening and treatment.
Conclusion:While the program has achieved remarkable screening results, challenges
include locating and enrolling affected babies in treatment. Moreover, competing health
priorities impede full integration of sickle cell program into the Angolan government
healthcare system. Finally, the program needs to diversify its funding source to expand
nationally.
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WHAT INFLUENCE CARE PATHWAYS BEFORE DIAGNOSIS IN CHILDREN
AND ADOLESCENTS WITHMALIGNANCIES?
S. Tatencloux1, V. Mosseri2, S. Papillard-Marechal3, B. Mesples4, B. Pellegrino5,
M. Belloy6, I. Jimenez1, N. Algret7, D. Levy1, J. Michon1, D. Orbach1
1Institut Curie, Pediatric-Adolescent and Young Adult Oncology Department, Paris,
France; 2Institut Curie, Department of Biostatistics, Paris, France; 3Hôpital Ambroise
Paré-Assistance Publique-Hôpitaux de Paris, Department of Pediatrics, Boulogne,
France; 4Hôpital Louis Mourier, Pediatric Department, Colombes, France; 5Centre
Hospitalier Intercommunal de Poissy-St Germain en Laye, Pediatric Department, Poissy,
France; 6Centre Hospitalier Robert Ballanger, Pediatric Department, Aulnay, France;
7Institut Curie, Department of Biostatistic, Paris, France
Background/Objectives: To describe the care pathways in children and adolescents with
solid cancers, in order to analyze its determinants and impact of a potential delay
before diagnosis.
Design/Methods: Retrospective study on patients aged less than 25 years at first
consultation in the oncology department of pediatric, adolescent and young adult in
Institut Curie during one year was performed and analyzed relationships between
cancer characteristics, components of care pathways, and socio-demographic
characteristics. Analyze of a relationship between delayed diagnosis and its potential
consequences was performed.
Results: A total of 106 patients were selected, diagnosed at a median age of 6 years.
Most frequent tumors were low grade cerebral tumors and sarcomas. Pain was the most
frequent initial disorder observed (34.3%). Only 27.6% of first signs were unspecific
(concerning 18.6% of patients) of cases. Median value of the time before the first
consultation was 3 days [0-1727]. Median total time to diagnosis was one month [range:
0-64] and median number of consultations before diagnosis 2 [range: 1-7]. Time to
diagnosis was shorter if father was of foreigner nationality vs. French (34 vs. 72 days, P
< 0.03), and longer if parents were separated (74.5 vs. 42.5 days, P < 0.03).
Retrospective analysis found that a shorter diagnosis may have been possible earlier in
44.3% of patients. Overall, potential vital risk due to a possible delayed diagnosis has
been estimated at 14.1 %, and functional risk at 20.7%.
Conclusion: Overall time to diagnosis is quite fast, even if first signs of pediatric cancers
are very polymorphic and seem associated to social but also age and economic status, in
a slightest measure.
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A REVIEW OF 15 YEARS OF PRIMARY CHILDHOOD CANCER DATA AT A
TEACHING HOSPITAL IN GHANA
L. Osei-Tutu1, V. Paintsil1, J. Dogbe1, A. Osei Akoto1, E. Amuzu2
1Komfo Anokye Teaching Hospital, Child Health Department, Kumasi, Ghana; 2Komfo
Anokye Teaching Hospital, Research and Development Unit, Kumasi, Ghana
Background/Objectives: Since 1998, the Paediatric Cancer Clinic of the Komfo Anokye
Teaching Hospital (KATH) had collected patient demographic and clinical data. This
primary data is relevant for internal restructuring and development of protocols for the
advancement of clinical care and research. We reviewed the data derived from patient
visits from January, 1998 to October, 2013.
Design/Methods: Data that had been collected and kept in a registry using Microsoft
Excel R© program from January, 1998 to October, 2013 was analyzed with STATA IC
12.0 statistical software.
Results: Overall, data on 1,197 patients were entered into the register; 63% males and
37% females. The age range was from 1 month to 192 months (16 years) with a mean of
84 months (7 years). On the average 75 patients were enrolled per year. Burkitt
lymphoma was the commonest cancer making up 34% of the total with; 22% being
abdominal, 8% jaw and 4% from other sites. Nephroblastoma was diagnosed in 23% of
the children, Leukaemia 16%, Non-Hodgkin non-Burkitt lymphoma 7%, and Hodgkin
lymphoma 6%. Neuroblastoma, Rhabdomyosarcoma and Retinoblastoma made up
14% of the total number of cases seen. While 33% of the patients completed their
treatments, 34% abandoned treatment and 31% died. Of those that abandoned
treatment, 81% completed half or less of their therapy and 10% completed their
treatment courses but have been lost to follow up. The rest, 9% did not start treatment
at all.
Conclusion: Burkitt lymphoma was the commonest cancer seen in our hospital between
1998 and 2013. Only a minority of the children completed their prescribed treatments
leading to high treatment abandonment rater and cancer related mortality in the clinic.
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CHILDREN ENROLLED INTO THE PEDIATRIC CANCER CLINIC OF A
TEACHING HOSPITAL IN GHANA IN 2014
L. Osei-Tutu1, V. Paintsil1, E. Amuzu2
1Komfo Anokye Teaching Hospital, Child Health Department, Kumasi, Ghana; 2Komfo
Anokye Teaching Hospital, Research and Development Unit, Kumasi, Ghana
Background/Objectives: The Komfo Anokye Teaching Hospital (KATH), Kumasi,
Ghana, enrolls an average of 75 children per year into its Paediatric Cancer Clinic. In
2005, the highest enrollment of 125 children was recorded. We reviewed the clinical
data of all new enrollments to the Paediatric Cancer Clinic from 1st January, 2014 to
31st December, 2014.
Design/Methods: The clinical data of newly enrolled children was extracted
retrospectively, from their clinical records for the period under review using Microsoft
Excel R©. The data was analyzed with STATA IC 12.0 R© statistical software.
Results: A total of 135 children were enrolled into the clinic. There were 78 males (58%)
and 57 females (42%). The highest enrollment of 18 occurred in May and the least was
5 recorded in September. The average enrollment per month was 11. The mean age was
80 months. Overall, 43% of the children enrolled were diagnosed with Burkitt
Lymphoma, followed by 14% with Leukaemias. Ten, 10% were diagnosed with
Retinoblastoma whereas 7.5% had Wilms Tumour. By the end of 2014, 20% of the
children had died. The final causes of death were advanced disease 55%,
cardiopulmonary failure 35% and Tumour Lysis Syndrome 10%. Currently, 41%
continue to access clinical care in the clinic while 39% have abandoned treatment.
Conclusion: The average patient enrollment to the Paediatric Cancer Clinic of KATH in
2014 is almost double the known average of 75 new patients per year. Treatment
abandonment rate however, has increased while the mortality rate has decreased. There
was an increase in the number of children diagnosed with leukemia and retinoblastoma
in 2014.
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CANCER IN SYRIAN REFUGEE CHILDREN
Y. Oymak1, D. Ince2, B. Demirag2, B. Ali3, Y. Yaman4, G. Ozek5, S. Unal6, S. Aydin
Koker2, T.H. Karapinar2, Y. Ay2, C. Vergin2
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1Harran University, Pediatric Hematolgy and Oncology, Sanliurfa, Turkey; 2Dr. Behcet
Uz Children’s Hospital, Pediatric Hematology and Oncology, Izmir, Turkey; 3Gaziantep
University, Pediatric Hematology and Oncology, Gaziantep, Turkey; 4Sütçü Imam
University Faculty of Medicine, Pediatric Hematology and Oncology, Kahramanmaras,
Turkey; 5Sanlıurfa Children’s Hospital, Pediatric Hematolgy and Oncology, Sanliurfa,
Turkey; 6Mersin University Faculty of Medicine, Pediatric Hematology and Oncology,
Mersin, Turkey
Background/Objectives:We aimed to determine the features of Syrian refugee children
treated due to cancer who have been followed by us.
Design/Methods: The records of Syrian refugee chidren in some regions of Turkey
treated with a diagnosis of cancer were evaluated between March 2013 and January
2015 retrospectively.
Results: The total of 36 patients (M/F: 1.6) with median age of 5(1.2-18.0) years were
analyzed. The types of cancer diagnosed in the patients were leukemia (n=27),
lymphoma (n=3), langerhans cell histiocytosis (LCH)(n=2), rhabdomyosarcoma
(n=2), neuroblastoma (n=1) and Ewing’s sarcoma (n=1). Fifteen of 27 leukemia
patients admitted with relapse. Seven of 15 relapsed leukemia patients couldn’t receive
chemotherapy because of the war. Two of the patients with lymphoma had multiorgan
metastasis. One of these patients deceased with tifilitis during induction chemotherapy.
Although all the patients with LCH and rhabdomyosarcoma were diagnosed in Turkey,
they couldn’t receive chemotherapy immediately due to problems related with
migration. The patient with Ewing’s sarcoma died with progression. The patients with
stage 4 neuroblastoma was sustaining the chemoterapy during this study.
Conclusion: Shelter, health, education and food aid for Syrian refugees in Turkey is
provided, and health services is given in the standard of Turkish
citizens.Socio-economic and accommodation problems of family is tried to be solved
by extending stay in the hospital. Althgough the translator has been supplied by
Turkish goverment, language difference has caused communication difficulties during
the treatment. However treatment of Syrian refugee children with cancer couldn’t be
apllied in time because of the war and migration. So relapses are inevitable for them. In
this study we want to call attention to Syrian children with cancer who were obligated
to migration.
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RELATIONSHIP BETWEENMULTIDRUG RESISTANCE ORGANISMS
(MDROS) AND DEMOGRAPHIC VARIABLES OF CHILDHOOD CANCER IN
TERTIARY CANCER CENTRE
N. Pereira1
1Tata Memorial Hospital, Pediatric Ward, Mumbai, India
Background/Objectives: There has been a rising prevalence MDROs bugs in the general
population. The alarming high prevalence of community acquired MDRO colonization
especially carbapenem resistant organisms was raised from 20% to 40% during the
course of the therapy. Aim: To assess the rate of MDRO carrier status at presentation
and rate of conversion to MDRO during the treatment. To find the association between
the prevalence of MDROs and demographic variables.
Design/Methods: Prospective study. Rectal swab of patients presenting to pediatric
hematolymphoid were sent within 7 days from date of registration for 2015. Also stool
cultures/rectal swabs of all patients who got admitted at presentation to the pediatric
ward were sent. Repeat rectal swabs were sent for the patients from this cohort when
they got readmitted at least 15 days from past discharge or when clinically indicated.
Results: Total of 618 baseline surveillance rectal swabs were sent the baseline no growth
was seen in 7.3% and MDROs grown in 18.7%. Follow up swabs were sent of 570
patients of which 0.5% showed no growth and 20.5% showed MDROs showing a
doubling up of MDROs from baseline culture. Of the 618 patients 46.9% were from
west, 37.5% (232) from BIMARU states (Bihar, Madhya Pradesh, Rajasthan and Uttar
Pradesh). Total MDROs 45.7% (53) were seen in patients from BIMARU. There were
27 deaths and 13 ICU admissions respectively out of these 618 patients. Of the 27
deaths, 22.2% patients had MDRO whereas only 3.7% had pan sensitivity. Of the ICU
admissions 22.5% had grown MDROs whereas only 7.3% had pansensitivity (P 0.08).
Conclusion: This illustrates the baseline MDRO colonization showing its association
with the BIMARU state which contributes MDRO buds colonization in waters of
Ganga and Yamuna flowing alongside these states and also due to poor sanitation
conditions thereby showing a significant trend in the morbidity and mortality rate being
affected.
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CHILDHOOD CANCER IN REUNION ISLAND ANDMAYOTTE
J. Ramiandrisoa1, M. Jehanne2, Y. Reguerre2, E. Chirpaz1
1Universitary Hospital of Reunion, Cancer Registry of Reunion Island, Saint Denis,
Reunion; 2Universitary Hospital of Reunion, Pediatric Hematology and Oncology
Department, Saint Denis, Reunion
Background/Objectives: Little is known about childhood cancer epidemiology in
Reunion Island (RI) and the archipelago of Mayotte, two French overseas territories
located in the Indian Ocean on either side of Madagascar, characterized by mixed
populations. This study aimed to describe the incidence and overall survival (OS) of
childhood cancers in these two areas.
Design/Methods: Data was extracted from the population-based Cancer Registry of
Reunion Island. All incident cases of cancer in children younger than 15, diagnosed
from 2005 to 2011 and living in Reunion Island or Mayotte were included. Cancers
were classified according to the International Classification of Childhood Cancer, Third
version. Incidence rates were standardized (world standard) and survival rates
estimated by the Kaplan Meier method.
Results: From 2005 to 2011, 236 cases of childhood cancers were registered in these two
populations (176 in RI, 60 in Mayotte). For RI, the age-standardized incidence rate
(ASR) for all cancers was 125.0 per million [106.3-143.7]. Leukemias, central nervous
system (CNS) tumors and soft tissues sarcomas were the most frequent malignancies
with respectively 30%, 22.7% and 8.5%. For Mayotte, ASR for all cancers was 101.8 per
million [76.0-127.6]; the most frequent cancers were CNS tumors (20%), leukemias
(15%) and both neuroblastoma (11.7%) and malignant melanomas (11.7%). For the
two regions, ASR for the main cancer groups seems lower than in mainland France
(155.8 per million), excepted for germ cell tumors and malignant melanomas for which
higher incidence was observed in Mayotte. The 5 years OS rate for all patients was
78.8% [72.2; 84.0].
Conclusion: Incidence of all childhood cancers in RI and Mayotte is lower than in
mainland France although few disparities exist in the distributions between cancer
groups, notably for Mahori patients. OS for these two territories is comparable to the
results described in mainland France.
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CHILDHOOD CANCERS IN DUBAI: PRIORITIZING ONCOLOGY SERVICES
A. Rana1
1Dubai Hospital, Dubai, United Arab Emirates
Background/Objectives: An estimated 250,000 new children are diagnosed with cancer
every year worldwide. When diagnosed early and treated with appropriate protocols,
70% of children will be cured of their cancer. Children living in Dubai and the
Northern Emirates are fortunate to have an advanced medical care center located in
Dubai Hospital where such treatment is available. We looked at our hospital based
registry to see our pattern of cancers compared to the rest of the world. There are an
estimated one and a half million children under the age of fourteen years in Dubai and
the Northern Emirates.
Design/Methods: A database was setup in October 2012 to record details of all children
presenting to the Pediatric Oncology department of Dubai Hospital for treatment. The
dataset for the years of 2013 and 2014 were analyzed.
Results:We saw sixty-three new children with cancers in two years. The number almost
doubled in 2014 as compared to the previous year. The increase in numbers was seen in
the non-Emirati group of children. Leukemia composed 62% (thirty two) of all the
cancers followed by renal tumors and then lymphomas. We fortunately had no
treatment related death during chemotherapy. Twenty three children (37%) travelled
abroad either for further therapy not available in the United Arab Emirates, back home
or as a personal choice.
Conclusion: Although the spectrum of cancers seen in childhood in Dubai is
comparable to the rest of the world, the figure is rising dramatically either due to more
awareness or net immigration. We need to prioritize and allocate more resources to
pediatric oncology services to cope with the increasing numbers.
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EPIDEMIOLOGY OF CHILDHOOD CANCER IN RUSSIA
T. Men1, M. Rykov1, V. Polyakov1
1Institute of Pediatric Oncology and Hematology FSBSI "N.N. Blokhin RCRC", General
Oncology, Moscow, Russia
Background/Objectives: To determine current rates of childhood cancer incidence and
mortality at a national level for Russia and to evaluate recent trends.
Design/Methods: Using the Annual reports of Ministry of health and Federal State
Statistics Service we calculated childhood cancer incidence and mortality rates for the
5-year period 2008–2012 and trends between 1989 and 2012 by sex, age and site. Rates
were directly age-standardised to the 2000 World Standard Population, and linear
regression was used to determine the magnitude and significance of trends.
Results: The age-adjusted incidence rate in children aged 0-17 years was 125 per
1000000 individuals per year for 2008-2012. The highest age-specific incidence (159 per
1000000 children/year) was observed in0-4 years. Between 1989 and 2012 a significant
increase in the cancer incidence was observed in children aged 0-14 years: average
annual percent change was 1.6%. The greatest increase for this period was observed for
soft tissue sarcomas (3.7%), hepatic tumors (3.6%), thyroid carcinomas (3.7%), CNS
neoplasms (2.9%), renal tumors (2.1%) и leukaemias (1.9%). The decrease of incidence
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was observed for Hodgkin (- 1.6%) and non-Hodgkin (-1.4) lymphomas. Childhood
cancer mortality for 2008-2012 was 40 cases per 1000000 children/year. The highest
age-specific mortality rate (52,3 per 1000000) was observed in infants. The significant
decrease of mortality were found from 1989 (70 per million) to 2012 (37 per million).
The greatest average annual decrease for this period was observed for leukaemias
(-3.8%) and lymphomas (-6,8%). The significant decrease of mortality in 1999-2012 was
found for malignant bone tumors( -5.9), renal tumors (-2.9%) and CNS neoplasms
(-1,1%) with the only exeption for soft tissue sarcomas (average annual increase was
3.2%).
Conclusion: The rates of cancer mortality are generally decreasing in Russia there are
still very high levels for common childhood cancer types.
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TECHNOLOGY DECIPHERED FOR PEDIATRIC ONCOLOGISTS
A. Saxena1, K. Sodhi2, N. Khandelwal2
1Post Graduate Institute of Medical Education and Research, Chandigarh, India; 2Post
Graduate Institute of Medical Education and Research, Radiodiagnosis and Imaging,
Chandigarh, India
Background/Objectives: Pediatric oncologists maintain busy schedules practicing their
speciality. This leaves them little time to understand the nuances of radiology which has
rapidly evolved during the last three decades. The objective of this presentation is to
provide a radiology primer to the pediatric oncologists.
Design/Methods: The presentation enumerates the different imaging modalities available
to the pediatric oncoligsts. The strength and weaknesses of these modalities are
elaborated. Radiation hazards for the children are also discussed.
Results: Ultrasound and chest X ray are frequently the initial modality of investigation
for a child with suspected abdominal or thoracic malignancy respectively. Computed
tomography and/or Magnetic Resonance Imaging are used for complete mapping of
the disease load. Newer modalities like Positron Emission Tomography and Whole
body Diffusion Weighted MRI are evolving promising tools.
Conclusion: A number of radiological modalities are available to the pediatric
oncologists. Local availability of equipment and expertise are important in making a
choice. All efforts should be made to keep the radiation dose to minimum.
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PEDIATRIC ONCOLOGY IN THE LAKE REGION OF TANZANIA:
EVALUATION OF CLINICAL DIAGNOSIS, TREATMENT AND OUTCOMES
K. Schroeder1, C. Chao2, N. Masalu2, S. Mafwimbo3, J. Mafwimbo3, D. Wechsler4,
N. Chao1, B. Likonda5
1Duke University Medical Center, Global Cancer, Durham, USA; 2Bugando Medical
Centre, Medical Oncology, Mwanza, Tanzania; 3Bugando Medical Centre, Social Work,
Mwanza, Tanzania; 4Duke University Medical Center, Pediatric Oncology, Durham,
USA; 5Bugando Medical Centre, Radiation Oncology, Mwanza, Tanzania
Background/Objectives: The majority of new pediatric cancer diagnoses are made in
resource poor countries where survival rates range from 5-25%, compared with 80% in
high-resource countries. This study provides a snapshot of the pediatric oncology
burden at Bugando Medical Centre (BMC), a tertiary referral center in the Lake Zone
of Tanzania, one of two cancer treatment centers in Tanzania. Results will provide pilot
data to highlight areas of need and direct future interventions to improve pediatric
oncology outcomes.
Design/Methods: Study design is a retrospective review of recorded hospital admissions
and clinic visits to the oncology ward at BMC from January 2013-December 2013. Fifty
charts were randomly selected for preliminary analyses, with 46 available for review.
Results: 32% of the patients were female (n=15), and the average age was 5.7 years old.
The most common recorded diagnoses were retinoblastoma (n=8) and Burkitt
lymphoma (n=8), followed by Wilms tumor (n=7), lymphoma (n= 5) and Acute
Lymphoblastic Leukemia (n= 5). Of these, 78% (n=36) were diagnosed clinically, and
only 22% (n=10) had available histopathologic confirmation. All patients received at
least one chemotherapy treatment. However, 78%% (n=10) did not complete prescribed
course of therapy due to progressive disease (n=13), therapy toxicity (n=4), medication
unavailability (n=1) or abandonment of care (n=28). Treatment outcomes included 9%
overall survival with documented response to treatment (n=4), 22% lost to follow up
(n=10), and 69% died (n=32). Of recorded deaths, 13% (n=4) occurred during
treatment, 41% (n=13) resulted from disease progression, and 47% (n=15) took place
following treatment abandonment.
Conclusion: Abandonment of therapy and death from progressive disease were the two
most common outcomes for this study. Future interventions to improve outcomes
should target methods to reduce factors contributing to treatment abandonment
including access to medications, transportation, reducing cost of therapy and
educational interventions.
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EPIDEMIOLOGY OFMEXICAN CHILDRENWITH CANCER: GEOGRAPHIC
VIARIABILITY AND OUTCOMES FOR 15,702 PATIENTS
J. Shalkow1, R. Rivera-Luna2, L. Castro3, S. Neme3, I. Villaseñor4, M. Esparza3
1Secretariat of Health, Childhood Cancer National Program, Mexico, Mexico; 2National
Institute of Pediatrics, Division of Pediatric Hematology-Oncology, Mexico City,
Mexico; 3Secretariat of Health, Childhood Cancer National Program, Mexico City,
Mexico; 4Secretariat of Health, Childhood and Adolescent Health, Mexico City, Mexico
Background/Objectives: Cancer is the leading cause of death in Mexican children
between five and 14 years of age, causing over 2,000 annual demises. The Federal
Government financially supports cancer treatment for all children. Patients are treated
within a network of 65 public hospitals, following national treatment protocols. To
present epidemiologic data and variability among thousands of patients treated for
cancer under the National Childhood Cancer Program.
Design/Methods: Patients registered in the Childhood and Adolescence National
Cancer Registry between 2008 and 2013 were analyzed. Prevalence, incidence, tumor
type, geographic variability, mortality, and abandonment rate were recorded.
Results: Total number of cases significantly increased annually over the study period
(p<0.05).Diagnosis was documented in 15,702 children, with a relative risk of 1.2 for
males (56%).The highest incidence was in children less than four years, with higher
mortality in adolescents. Incidence was 7.5 / 100,000 Mexicans under 18, varying by
state of residence (3.30 - 16.04). Median age was 4.9. Most common neoplasia was
leukemia (51%), followed by lymphoma (12%), CNS tumors (10%), sarcomas (10%),
and germ cell tumors (5%). Overall 5-year survival was 50.8%, varying among region,
age, gender, and diagnosis (18.7% - 64%). Overall mortality was 5.3 per 100,000, being
higher for males (5.9) than females (4.6), and also for adolescents (8.8) vs other age
groups (4.4).Abandonment was 5.0% at one-year, and 13.16% at five-year follow up,
also with great variability regarding gender, state, and type of tumor. Extensive
variability was found when disaggregating groups by tumor type, age, sex, and
geographic location.
Conclusion: There is a high incidence of childhood cancer in Mexico. Extensive
variability is seen among different groups, regarding age, gender, tumor type,
geography, survival, and mortality. Understanding such differences is paramount to
optimize care delivery and improve outcomes.
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ESTABLISHMENT OF A NATIONAL PAEDIATRIC
HAEMATOLOGY-ONCOLOGY PROGRAM IN BOTSWANA
J. Slone1, A. Agrawal2,3, S. Alisanski3, A. Slone1, J. Margolin1, E. Ishigami4, P. Mehta1
1Texas Children’s Cancer and Hematology Centers-Baylor College of Medicine, Pediatric
Hematology-Oncology, Houston, USA; 2Children’s Hospital and Research Center
Oakland, Pediatric Hematology-Oncology, Oakland, USA; 3Texas Children’s Global
Health Corps-Baylor College of Medicine International Pediatric AIDS Initiative BIPAI,
Pediatrics, Houston, USA; 4Texas Children’s Cancer and Hematology Centers, Pediatric
Hematology-Oncology, Houston, USA
Background/Objectives:Worldwide, approximately 160,000 children are diagnosed with
cancer annually. The overall cure rate is approaching 80% for children with cancer in
high income countries. In contrast, in low and middle income countries (LMICs),
where children are often diagnosed too late or remain undiagnosed, the majority die
from these curable cancers, particularly in sub-Saharan Africa.
Design/Methods: A novel partnership between the Botswana Ministry of Health, Texas
Children’s Cancer and Hematology Centers (TXCH) and the Baylor International
Pediatric AIDS Initiative (BIPAI) led to establishing Botswana’s only pediatric
hematology-oncology program in 2007 at Princess Marina Hospital (PMH), the main
government hospital in Gaborone. Since its inception, the program has been led by a
full time in-country pediatric hematologist-oncologist (PHO) from TXCH. In 2013, a
Care Coordinator position was added and a second PHO joined in 2014. In addition to
clinical services, the program provides training and education locally and nationally and
is establishing a comprehensive oncology database to research the presentation and
treatment of paediatric malignancies in Botswana.
Results: Since 2007, over 450 new haematology-oncology patients have enrolled in the
program with 94 presenting in 2014. Prior to 2007, 22 cases of paediatric cancer had
been diagnosed at PMH according to available hospital records. An average of 40
children were diagnosed with cancer per year at PMH in 2013-2014 (leukaemia [19.8%],
sarcoma [16.0%], Wilms tumor [12.3%], lymphoma [11.1%], brain tumors [9.9%],
retinoblastoma [6.2%], Kaposi sarcoma [3.7%] and others [21%]).
Conclusion: The TXCH-Botswana program demonstrates that a long-term sustainable
twinning partnership between a center in a high-income country and a resource-limited
setting in sub-Saharan Africa is achievable with resultant exponential program growth.
By focusing on high-quality clinical care in an academic environment with an emphasis
on training and education, local capacity is being created to establish a regional model
of excellence in paediatric haematology-oncology care.
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EPIDEMIOLOGY OF CHILDHOOD CANCER PRESENTING TO A TERTIARY
CARE PEDIATRIC CENTER IN INDIA
S. Arumugavelu1, A. Trehan1, D. Bansal1
1Postgraduate Institute of Medical Education & Research, Pediatrics, Chandigarh, India
Background/Objectives: Cancer incidence world over is showing an increasing trend.
Data regarding incidence, distribution of cancer with regard to age, sex, region and
death are limited in developing countries owing to lack of countrywide cancer registries.
Design/Methods: Data pertaining to age, sex, symptom diagnosis interval, type of
cancer, treatment taken, final outcome and trend of disease was retrieved from the case
records of 3568 patients who presented to our unit from January 2004 to June 2014.
Results: The common cancers seen are acute lymphoblastic leukemia (35.8%)(ALL),
retinoblastoma (9.4%), acute myeloid leukemia (7.8%), followed by neuroblastoma
(6.3%), Wilms tumour (6%)(WT), non-Hodgkin lymphoma (6.4%)(NHL), Hodgkin
lymphoma (5.2%)(HL). Brain tumours, Ewing sarcoma, hepatoblastoma & chronic
myeloid leukemia constituted 1 to 2% malignancies.The male to female ratio was 2.2:1,
being 6:1 in HL. Peak age was between 36 to 72 months. The median age of patients
with ALL was 5.2 years, 7.5 years for lymphomas whilst WT, neuroblastoma, germ cell
tumours presented below 3 years. A 25% increase was observed over 10 years. This was
consistent in all malignancies.The symptom diagnosis interval (SDI) differed. The mean
SDI for leukemia’s was 7 weeks and 11 weeks for NHL. HL had a median SDI of 24
weeks. One fourth (26.2 %) patients refused therapy. One fourth of the patients treated
defaulted. Refusal of therapy, default, death and relapse were taken as events and the
event free survival (EFS) was 35%. The EFS amongst treated patients is 47%. Sixteen
percent patients expired.
Conclusion: The demographics of malignancies are consistent with worldwide data. The
number of patients reporting has escalated by 25% over 10 years. Increased awareness
and better diagnostics may account for increase. We need to establish a countrywide
population based registry to provide good epidemiological data. To treat all and prevent
default remains a challenge.
P-231
INFECTIOUS DISEASE AGENTS IN FEBRILE NEUTROPENIA IN PATIENTS
WITH CHILDHOOD CANCER AT A NATIONAL REFRENCE HOSPITAL
M. Velázquez-Aviña1, J.G. Peñaloza-Gonzalez1
1Hospital Juárez de México, Pediatric Oncology, Mexico City, Mexico
Background/Objectives: Approximately 80% of patients with childhood cancer and
chemotherapy treatment will have an episode of febrile neutropenia (FN). The
percentage of positive blood cultures is correlated with the risk of overall infection. The
purpose of the present study is to describe the precentage of positive blood cultures and
the infectious disease agent.
Design/Methods:We reviewed all blood cultures of patients with childhood cancer from
August 2012 to December 2013 at our institution. We described percentages of negative
or positive blood cultures and identified the disease agent in case of positive testing.
The demographic and clinical characteristics are described as means or proportions
according to variable type.
Results:We included 171 blood cultures. The patient average age was 10.4 years. In 52%
of the cultures the result was negative, and 48% were positive. Fifty-one percent of our
patients were female and 49% were male. According to the type of cancer, high-risk
acute lymphoblastic leukemia representes 42.1% of our population, osteosarcoma
22.8%, 9.9% germ cell tumors and the rest were patients with Hodgkin disease and
rhabdomyosarcoma. Gram positive bacteria were isolated in 53.9% of positive cultures,
and Gram negative bacteria in 46.1% of positive cultures. The most frequent Gram
positive bacteria was Staphylococcus epidermidis folowed by Staphylococus aureus and
Staphylococcus hominis. The most frequent Gram negative bacteria was Escherichia coli
followed by Klebsiella pneumoniae, and Acinetobacter baumanii. Gram positive bacteria
were more frequently isolated in female patients, whereas Gram negative bacteria were
most frequently isolated in male patients.
Conclusion: The percentage of positive blood cultures in our practice is relatively high
compared to other series. The most frequent infectious disease was a Gram positive
agent. Although not statistically significant, we found a difference of disease agent
according to the gender.
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METHODOLOGY AND PROCESS FOR ASSESSING FEASIBILITY OF
INTRODUCING PEDIATRIC HEMATOLOGY/ONCOLOGY SERVICES IN A
RESOURCE-LIMITED SETTING: EXPERIENCE IN SUB-SAHARAN AFRICA
K. Wilson-Lewis1, P. Mehta1, E. Ishigami1, M. Cubbage1
1Texas Children’s Hospital/Baylor College of Medicine, Texas Children’s Cancer &
Hematology Centers, Houston, USA
Background/Objectives: As mentioned in recent articles, there has been a significant
increase in the incidence of cancer in Sub-Saharan Africa, (SSA), however there is poor
access to pediatric hematology-oncology (PHO) care. Consequently, a great need exists
to build capacity in the local healthcare infrastructure and workforce to meet this
evolving need. Since 2008, Texas Children’s Global HOPE has aimed to increase overall
survival and quality of life for children with cancer and blood disorders and to build
sustainable health professional capacity in PHO care.
Design/Methods: Our program recognized the importance of partnering with local
stakeholders to conduct a thorough assessment of the current capacity to better inform
a jointly developed vision and strategies to achieve the aims. We developed a systematic
methodology and detailed electronic database for conducting site assessments and
performing strategic planning. This assessment approach has been successfully utilized
in both international and domestic sites to determine the unique needs of PHO
programs and their environments. This process identifies and assesses country level and
institution specific clinical, education, research and administrative operations and
resources, identifies gaps and needs for improvement and proposes solutions to advance
PHO care at a level of excellence the partners jointly agreed to attain. A detailed
implementation plan is developed for program improvement including timelines and
budgets.
Results: This methodology has been utilized in 3 SSA countries. Outcomes include
completed country-wide assessments with sustainable intervention plans built into
agreements with LMIC governments.
Conclusion:While partnership is essential to making significant progress in the
advancement of PHO services in LMICs, we recommend utilizing helpful tools such a
systematic methodology and approach to assessment and planning, to facilitate
effective and efficient programmatic plans and outcomes.
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INDIAN PEDIATRIC HEMATOLOGY ONCOLOGY GROUP: A COOPERATIVE
EFFORT TO IMPROVE CHILDHOOD CANCER CARE IN INDIA
S. Yadav1, S. Katewa1, M. Ramzan2, S. Bhat3, M. Kalra4, M. Anjan5,
V. Chinnabhandar6, R. Misra7, N. Rastogi1, A. Prakash8, V. Dua9, G. Kharya10,
D. Khalon11, A. Gupta12, A. Kumar13, N. Dhingra14
1Fortis Memorial Research Institute, Pediatric Hemato-Oncology & Bone Marrow
Transplant Unit, Gurgaon, India; 2The Hospital for Sick Children, Bone Marrow
Transplant Unit, Toronto, Canada; 3Narayana Hyrudalaya, Pediatric Hematology
Oncology, Bangalore, India; 4Apollo Hospital, Pediatric Hematology Oncology, Delhi,
India; 5Dubai Hospital, Pediatric Hematology Oncology, Dubai, United Arab Emirates;
6Sydney Children’s Hospital, Pediatric Hematology Oncology, Sydney, Australia;
7Medanta Hospital, Pediatric Hemato-Oncology, Gurgaon, India; 8St John Medical
College, Pediatric Hematology Oncology, Bangalore, India; 9Artemis Hospital, Pediatric
Hemato-Oncology, Gurgaon, India; 10BLK Superspeciality Hospital, Pediatric
Hematology Oncology, Delhi, India; 11Deep Hospital, Pediatric Hemato-Oncology,
Amritsar, India; 12Institute of Medical Sciences-Banaras Hindu University, Pediatric
Hemato-Oncology, Banaras, India; 13Rainbow Children’s Hospital, Pediatric
Hemato-Oncology, Hyderabad, India; 14All India Institute of Medical sciences,
Hematology, Delhi, India
Background/Objectives: There is an urgent need to improve survival of children with
blood and a cancer disorder in India. Indian Pediatric Hematology Oncology Group
(IPHOG) was formed in March 2013 with goals to a) improve survival of childhood
cancer, b) improve survival of children with blood disorders, c) make hematopoietic
stem cell transplant (HSCT) available to children who need it, d) train more physicians
in pediatric haemato-oncology and e) form a cooperative study group for research in
childhood blood and cancer disorders.
Design/Methods: The members met online every fortnight through the Cure4kids
website hosted by St. Jude Hospital, USA. Group identified barriers to improve cure
and developed strategies to overcome them. Educational Seminars and Tumor Boards
were also conducted.
Results: IPHOG has 104 members now across 17-States
(Maharasthra-21,Delhi-22,Haryana-8,Karnataka-6&Tamilnadu-4) and across
7-countries (India-85,USA-9,Canada-5,Australia-2,UK-1,Singapore-1&UAE-1). They
are oncologists-88, surgeons-3, pathologists-2, radaition-oncologist-1, nuclear
medicine-1, molecular genetics-1 and fellows- 8. A total of 42 meetings were held over
2-years. It published a paper in Pediatric Hematology Oncology journal in 2104
(Barriers to cure for children in India and strategies to improve outcomes). It identified
delayed diagnosis, abandonment, sepsis, lack of uniform treatment protocols and
relapse as five major barriers. IPHOG applied for a grant to establish a LCH treatment
network in India to Histiocytosis Society in July 2013 which was unsuccessful however
a positive feedback was received from Histiocytosis Society. National Neuroblastoma
Network has been established by IPHOG to know about epidemiology and outcome of
neuroblastoma in India. So far 37 centres across 13 states have reported 120 new cases.
IPHOG has started a one-year fellowship in Pediatric Hemato-oncology (2 students)
and a one-year fellowship in Pediatric HSCT(1 student).
Conclusion: IPHOG has identified local causes of treatment failure for children with
cancer in India and has put strategies in place to improve care and outcomes in the
participating centres.
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CLINICAL FEATURES AND TREATMENT RESULTS I˙N GERM - CELL
TUMORS OF CHILDHOOD: 24 YEARS EXPERI˙ENCE OF A SINGLE CENTER
F. Akici1, D. Tugcu1, H. Sayilan Sen1, Z. Salcioglu1, G. Aydogan1, A. Akcay1,
A. Kiyak1, M. Gokce1, S. Sander2, S. Dervisoglu3
1Kanuni Sultan Suleyman Training and Research Hospital, Pediatric Hematology
Oncology, Istanbul, Turkey; 2Kanuni Sultan Suleyman Training and Research Hospital,
pedIatric Surgery, Istanbul, Turkey; 3I.U. Cerrahpasa Medical School, Patology,
Istanbul, Turkey
Background/Objectives: Germ cell tumors (GCTs) are formed an important group of
gonadal neoplasms and are also found in a number of extragonadal sites like
mediastinum, sacrococcygeal regions and retroperitoneum which represents
approximately 1-3 % of all childhood malignancies. The aim of this study was to
evaluate the demographic data of the children with GCTs in our center retrospectively
and treatment results are compare the results of the literature.
Design/Methods: Seventy two children (29 male, 43 female) from September 1991 to
September 2014, new diagnosed with GCT were enrolled to the study. Cases to the
changing surgery to radical surgical excision, biopsy approached with the multimodal
treatment approach, as well as combination chemotherapy (cisplatin, bleomycin,
etoposide) was performed. Serum alpha-fetoprotien (sAFP) on admission was studied.
Results: The study included 72 pediatric cases of histological confirmed GCTs of the
gonadal, extragonadal. Mean age of the cases was 44 month (range:1-80
month).Abdominal pain and enlargement or mass was the commonest
presentation(41% of cases).Most of the cases, the tumor site was gonadal(43 cases
gonadal, 24sacrococcygeal, 3 mediastinal, 1 labium major, 1 orbital).Histopathologic
subtypes were:19 mature teratoma, 13 immature teratoma, 29 yolk sac tumor, 5
dysgerminoma, 6 mixed GCT. POG/CCG surgical staging of the studied cases were
applied. Mature teratoma cases were not taken to be evaluated staging and survivals.
Twelve cases(23%) were in stage I, 11(21%) in stage II, 16(30%) in stage III, and
14(26%) in stage IV. The median sAFP level at diagnosis was 7900ng/L(22-123000).The
mean follow up time was 83 month (range10-287 months).Local recurrence was
observed in 8 cases, 6 patients died of recurrent.4 patients out of the follow-up after
completion of therapy while in remission.
Conclusion: Five-year overall survival rate is 87%, event-free survival rate was found to
be 84%. Survival rates in the whole group are in parallel with advances attained in the
World.
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KLINEFELTER SYNDROME AND GERM CELL TUMORS
M. van den Akker1, J. van der Werff ten Bosch1
1UZ Brussel, Pediatric Hematology Oncology, Brussels, Belgium
Background/Objectives: Klinefelter syndrome (KS) is the most common sex
chromosome disorder, occurring in about one out of 600 males. Various malignancies
have been associated with KS. Breast cancer has been most highly associated with the
47,XXY mosaics, suggesting up to 20-30 times greater incidence in patients with KS
compared to patients with normal karyotype. A large number of extragonadal germ cell
tumors (EGGCT) have been described in association with KS, most often located in the
mediastinum with a relative risk of at least 50.
Design/Methods: Our centre, seven year old boy was diagnosed with testicular mature
teratoma and a malignant mediastinal mixed germ cell tumor. Since KS is the only
known risk factor for mediastinal GCTs, karyotype was done, showing 47,XXY
compatible with KS. To review the literature on GCT associated with Klinefelter’s
syndrome, a PubMed search was conducted in the English-language literature using the
keywords ‘Klinefelter’s syndrome’ and ‘Germ Cell Tumors’. Every paper was reviewed,
and all the patients with KS and a GTS were documented by first author of the paper,
year of publication, location of primary tumor, age of the patient and histology of the
tumor.
Results: A total of 102 papers were reviewed and 124 patients with KS and GCT were
found. The median age group is 15-19 year old. The localisation is in 70% the
mediastinum, followed by the brain, testis and abdomen. Histology is principally mixed
GCT, followed by teratoma and germinoma.
Conclusion: In contrast to the GCT in adults, which are mostly gonadal, in childhood
they are more often extragonadal. In KS the principal localization of a GCT is the
mediastinum except for children under the age of 5 year in which the abdominal
location is more frequent. Mixed GCT are much more frequent in KS, while teratoma is
the most common GCT in children without KS.
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PEDIATRIC GERM CELL TUMORS IN DENMARK 1984-2013
J. Brok1, E. Madeline1, C. Rechnitzer1
1Rigshospitalet, Pediatric Department of Hematology and Oncology, Copenhagen,
Denmark
Background/Objectives: Germ cell tumors (GCTs) are a heterogeneous group of tumors
derived from primordial germ cells. GCTs are benign or malignant tumors localized
either gonadal or extragonadal. Only few reports on national population-based cohort
of GCT’s are available. We have mapped the pediatric cohort of GCTs in Denmark (5,6
mill. residents) over 30 years.
Design/Methods: All Danish pediatric GCTs diagnosed from 1984 to 2013 were
collected from the Danish Children Cancer Registry. Case records were reviewed by two
data extractors. We extracted data on localization, gender, histology, tumor markers,
treatment and clinical outcome. Updated results will be presented at SIOP 2015.
Results:We have identified 223 GCTs (45% gonadal, 20% sacrococcygeal, 13% central
nervous system and 22% other sites) in patients aged 0-15 years (crude
incidence:1.2/100.000, 64% girls). Extragonadal GCTs were mainly observed in early
childhood with sacrococcygeal localization as the most common. Gonadal GCTs were
in contrast observed in late childhood with ovaries as the most frequent site of origin.
Mature teratomas were the most frequent observed histological classification (55%) and
usually localized in the ovaries. Alfafetoprotein was elevated in 15% and 4% had
elevated beta-human chorionic gonadotropin. One third of all GCTs were malignant.
Of these, 50% were treated with chemotherapy. Almost all cases had surgery. Only
intracraniel GCT were irradiated. Relapse rate was 10%. Mortality rate was 4%. Very
few children had adverse events (oto- and nephrotoxicity) related to chemotherapy.
Conclusion: In Denmark pediatric GCTs are rare and are mainly benign with mature
teratoma being the most frequent. We identified a peak of extragonadal GCTs in early
childhood and a peak of gonadal GCTs in late childhood. In malignant GCTs
morbidity is very low but chemotherapy is administered for about 50%. The incidence
of GCTs in Denmark seems similar to other studies.
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BILATERAL JUGULAR VEIN (JV)OBSTRUCTION IN GERM CELL TUMOR
(GCT): CASE REPORT
T.M. Hnin1, A.A. Khaing2, H. Han3, A. Nge Nge4, E.E. Shwe5
1Yangon Children’s Hospital, Yangon, Myanmar Burma; 2Yangon Children Hospital,
Hematology-Oncology Unit, Yangon, Myanmar Burma; 3Yangon Children Hospital,
Pediatric Surgical Ward, Yangon, Myanmar Burma; 4Yangon Children Hospital,
Department of Radiology, Yangon, Myanmar Burma; 5Yangon Children Hospital,
Department of Pathology, Yangon, Myanmar Burma
Background/Objectives: This is a report of GCT with bilateral internal jugular vein
thrombosis without catheter related nor prior coagulation abnormalities.
Design/Methods: Treatment details and treatment responses of the patient were
summarized.
Results: Case: A 10-year-old-girl, initially present with fever, abdominal distension for 1
month with 1 week history of painful left supraclavicular fossa. Ultrasound Chest and
CT abdomen revealed thrombus in the both side of jugular vein (left: 5.1 × 1.3 ×
1.6cm), (Right: 3.6 x0.8 x0.6 cm) and mass (18×12×8 cm) occupying lower abdomen
respectively. Alpha feto protein raised upto 20000U/L. Coagulation profile; PT, PTT,
D-dimer, Protein C, Protein S, Factor V leiden, Antithrombin III, Antiphospholipid Ab
were in normal range. Treated with VCR, Bleo, CDDP(PEB) together with SC
Enoxaparin (1 mg/kg) 12 hourly. After 2 cycles with PEB, defaulted 2 weeks and back
with persistence mass, so continued enoxaparin for 21 days followed by oral wafarin
overlapping with UFH for 5 days, continuing aspirin and warfarin for 10 weeks together
with VCR, Bleo, CBDCA(JEB), four cycles and evaluation found both JV were patent
and tumor mass also reduced to 7×4.6×4.8cm with calcification is noted in right lower
abdomen. Tumor removal and right salpingoophrectomy was done, omental seedling
was also found and JEB 3 cycles was given. The patient remains well for three months.
Conclusion: Complete resolution of the thrombus can be achieved by chemotherapy
together with anticoagulants in GCT (abdomen) with thromboembolism in distant sites
like JV in a resource limited country.
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TREATMENT RESULTS OF PEDIATRIC GERM CELL TUMORS FROM A
SINGLE INSTITUTION
D. Ince1, K. Mutafoglu1, F. Yenigurbuz1, E. Ataseven1, D. Kizmazoglu1, M. Erdem1,
M. Olguner2, H. Guleryuz3, E. Ozer4, A. Demiral5, N. Olgun1
1Dokuz Eylul University, Department of Pediatric Oncology, Izmir, Turkey; 2Dokuz
Eylul University, Department of Pediatric Surgery, Izmir, Turkey; 3Dokuz Eylul
University, Department of Radiodiagnostics, Izmir, Turkey; 4Dokuz Eylul University,
Department of Pathology, Izmir, Turkey; 5Dokuz Eylul University, Department of
Radiation Oncology, Izmir, Turkey
Background/Objectives:Herein we reported our treatment results of children with GCT,
between 1988 and 2015.
Design/Methods:Medical records of patients were analyzed retrospectively.
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Results: Forty-nine patients with GCT were included in analysis, GCTs constitute 5,7%
of all our patients. The median age of diagnosis was 12years (0–18), M:F ratio was 0.5.
Primary tumor was gonadal in 63%, extragonadal in 25% and intracranial in 12% of
patients. Histopathology revealed mature teratoma (25%), immature teratoma (14%),
germinoma (8%), embryonal carcinoma (8%), yolk sac tumor (8%), mixed germ cell
tumors (21%), disgerminoma (% 8), endodermal sinus tumor (4%), sex-cord stromal
tumor (2%). Stage distribution of gonadal GCTs was stage-I (45%), stage-II (15%,)
stage-III (20%), stage-IV (20%); and extragonadal GCTs was stage-I (42%), stage-II
(8%), stage-III (25%), stage-IV (25%). On average four courses (2-10) of cisplatinum
based chemotherapy were given. Radiotherapy was performed in 7 patients. Gonadal
GCTs : Primary surgery and delayed surgery were performed in 29 and two cases,
respectively. Twenty-one patients received CT, two patients received radiotherapy. Three
of them died with progression. Ekstragonadal GCTs: Primary surgery was performed
in 7 (complete resection:5, macroscopic residue:2), with only biopsy in two patients
with sacrococcygeal GCTs (n:9). One of them had metastatic disease, four received
chemotherapy, and two died with progression. CR achieved by primary surgery in one
retroperitoneal GCT. Two metastatic patients (anterior mediastinal:1, intra-abdominal
midline:1) treated by incomplete surgical resection, chemotherapy and radiotherapy.
CR achieved in one. Median follow-up-time was 3years (1mos-20yrs); 10 and
15-years-EFS were 77% and 64%; 10 and 15-years-OS were 79%.
Conclusion: The survival rates were acceptable. High number of teratomas may have a
positive effect on these results. Due to the limited number of patients, no conclusion
can be made about the treatment success according to clinical and histopathological
subgroups. Colloborative studies are needed to define risk-based treatment strategies.
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TREATMENT OF CHILDHOOD GERM CELL TUMORS IN BELARUS-
SINGLE CENTER EXPERIENCE
I.Z. Reiman1, L. Arushkevich2
1National Research Center for Pediatric Oncology-Hematology and Immunology, Minsk,
Belarus; 2National Research Center for Pediatric Oncology-Hematology and
Immunology, Oncology department, Minsk, Belarus
Background/Objectives:Malignant germ cell tumors (GCTs) are a heterogeneous group
of neoplasms, putatively originating from the primordial germ cell. Since 2002 we have
been used GermanМАКЕI-96 andМАМО-98 treatment protocols in Pediatric
extracranial GCTs in Belarus.
Design/Methods: Totally 85 malignant extra cranial GCTs registered in 2002-2012 in
children or adolescents aged 0-18 years, were included in this study. Testicular GCTs in
18 pts were registered, ovarian - 43 and extra gonad sites in 24 cases.МАМО-98 was
implemented in all testicular GCTs and the rest extra cranial GCTs according to
МАКЕI-96. Data on tumor location, histology, stage, and detail of follow up were
collected from cancer register.
Results: All children tolerated the protocol therapy well without complications. From
18 pts with testicular GCTs only 1 relapsed and 5-years EFS was 94%. There were 2
relapses in ovarian group of pts and 95% EFS was achieved. The results of extra gonad
sites were less optimistic, and EFS was equal 77% with 6 relapsed pts. In general these
results are considerably better than we got before initiatingМАМО-98 andМАКЕI-96
protocols.
Conclusion: Therapeutic approaches included inМАМО-98 andМАКЕI-96 showed
good outcome in all types of GCTs in Belorussian children and merit further
continuation.
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SACROCOCCYGEAL TERATOMA: 33 CASES AT A SINGLE INSTITUTION
J. Palacios1, D. Hernandez1, A. Leon1, C. Leal2, D. Herrera1, J. Shalkow3
1National Institute of Pediatrics, Surgical Oncology, Mexico City, Mexico; 2National
Institute of Pediatrics, Oncology, Mexico City, Mexico; 3Secretariat of Health,
Childhood Cancer, Mexico City, Mexico
Background/Objectives: Sacrococcygeal Teratoma (SCT) is the most common
congenital neoplasm. Derive from embryonal germ cells, often containing elements
from the three germ layers. They can be prenatally detected by ultrasound. Most
common presentation is sacral mass, but they can elicit urinary, fecal, or neurologic
symptoms. They tend to become malignant as children grow older. Surgical resection is
the treatment of choice.We aim to describe our experience with surgical management of
SCT at a single institution.
Design/Methods: Retrospective review of children treated for SCT at the Surgical
Oncology Department of the National Institute of Pediatrics in Mexico City, between
1981 and 2015.
Results: There were 24 girls and nine boys, with ages between one day and 14 years,
most of them neonates.Only six patients (18%) were prenatally diagnosed with
ultrasound.Most common presentation was sacral mass. Urinary incontinence and
chronic constipation were seen in one patient each.Altman classification: type I (52%),
II (30%), III (12%), and IV (6%).Mature teratoma was histologically confirmed in 91%
of patients. Three cases had endodermal sinus elements.Surgical complications included
wound infection and dehiscence (4 patients), urologic and fecal complications in four
and two patients respectively.Blood loss was 20 ml. Average length of stay was 7
days.Two patients died, one from congestive heart failure before surgery, one due to
disease progression with lung metastases. Most (94%) are alive and free of disease.
Conclusion: Eerly surgical resection offers the best chance of cure for SCT. Most
neonates have benign tumors. Complete tumor resection excising the tip of the coccyx
is paramount to prevent recurrence. Prognosis is excellent if patients are treated at
referral centers with experience in pediatric oncology.
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PARAVERTEBRAL GERM CELL TUMORWITH INTRASPINAL EXTENSION
AND CORD COMPESSION: A RARE PRESENTATION
S. Sharma1, R. Rahman2, S. Gundapaneni2, V. Iyer3, D. Gupta2
1All India Institute of Medical Science, Delhi, India; 2All India Institute of Medical
Science, Paediatric Surgery, Delhi, India; 3All India Institute of Medical Science,
Pathology, Delhi, India
Background/Objectives: Primary malignant germ cell tumors of mediastinum account
for only 10-15% of all mediastinal tumors. The commonest site in mediastinum is
anterior mediastinum. In posterior mediastinum, neurogenic tumor and bronchogenic
tumor predominates. Posterior mediastinum germ cell tumor is rare and posterior
mediastinal germ cell tumor arising in paravertebral region with intraspinal extension
and causing cord compression is extremely rare and in our knowledge such presentation
has never been described before.
Design/Methods: To describe a case of 3 years old male child with paravertebral germ
cell tumor with intraspinal extension and cord compression in view of its rarity.
Results: A 3 years old male child presented with complaints of progressive weakness of
both lower limbs and loss of bowel and bladder control after an accidental fall from
height 15 days back. Child developed weakness of both lower limbs two days after fall.
It was followed up by loss of bladder and bowel control. MRI dorsolumbar spine
revealed a paraspinal mass from D8 to L2 level with intraspinal extension through
foramina of D10-11 and D11-12 causing cord compression and encasement with
features suggestive of Neuroblastoma. FNAC was inconclusive but possibility of germ
cell tumor could not be ruled out. Since the child had features of cord compression
child was given first course of PEB. AFP came out to be raised (146600ng/ml). Urinary
VMA/HVA were within normal limits and there were no skeletal metastasis. Child
improved following 2 courses of PEB with significant improvement in lower limb
movement and bladder and bowel control.
Conclusion: An unusual case of posterior mediastinal germ cell tumor with paraplegia
is described.
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RECURRENCE SACROCOCCYGEAL TERATOMA IN CHILDREN: 11 CASES
ANALYSIS
Y. Wu1
1Xinhua Hospital, Shanghai, China
Background/Objectives: To discuss the effects of risk factors on recurrence of
sacrococcygeal teratoma (SCT) in children.
Design/Methods: A retrospective review was made in 11 cases (8%) of recurrent tumor
in 136 children with sacrococcygeal teratoma between Jan. 2006 and Nov. 2014 in
Shanghai Xinhua Hospital. Clinic factors and pathologic analysis were identified.
Results: Eleven children had recurrence of SCT, 3 were male, 8 were female. The age
was 4 days to 11 years old, median age was 12 months while they were underwent
primary surgery. Second operation was performed in a median interval of 23 months (5
months —10 years) after first operation .The recurrence of mature teratoma was
observed in 4 patients, yolk sac tumor in 7.Third recurrence yolk sac tumor was
presented in 3 patients after second operation. Third time procedure was performed to
removed the tumor in these kids.
Conclusion: Cause of recurrence of sacrococcygeal teratoma is include incomplete
resectioni and malignant histology. Regular follow-up after surgery is important to find
tumor relapse earlier and to improve the outcome.
Posters: Histiocytosis
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LANGERHANS CELL HISTIOCYTOSIS (LCH) IN CHILDREN AND ADULTS:
A COMPARATIVE STUDY OF 40 CASES
I. Astigarraga1, L. Ceberio2, A. Gondra3, R. Adan4, A. Echebarria4, A. Canovas5,
M.V. Egurbide5, S. Garcia-Obregon6
1Hospital Universitario Cruces, Pediatrics, Barakaldo, Spain; 2Hospital Universitario
Cruces. H U Araba, Internal Medicine, Vitoria, Spain; 3Hospital Universitario Basurto,
Pediatr Blood Cancer DOI 10.1002/pbc
S300 SIOP ABSTRACTS
Pediatrics, Bilbao, Spain; 4Hospital Universitario Cruces, Pediatric Oncology, Barakaldo,
Spain; 5Hospital Universitario Cruces, Internal Medicine, Barakaldo, Spain; 6BioCruces
Health Institute, Pediatric Oncology Group, Barakaldo, Spain
Background/Objectives: Langerhans Cell Histiocytosis (LCH) can develop at any age.
Clinical presentation, severity and therapeutic approach vary in children and adults, but
few studies have analyzed the differences Aim: Review of epidemiological and clinical
LCH cases collected from 1995 to 2014 in 3 hospitals from the Basque Country (Spain)
to compare data between adults and pediatric patients.
Design/Methods: The analysis of epidemiological and clinical data was performed by
using SPSS software.
Results: Forty patients were included (22 males and 18 females). Range of age: 0-84
years-old. Pediatric cases (until 18 years-old): 18 cases, 9 females and 9 males. Median
age at diagnosis: 6.6 years-old. Initial organ involvement: 17-bones (8 unifocal), 1-skin,
1-lung, 1-gastrointestinal with multisystem disease in 8 but no risk organ.
Chemotherapy was administered in 10. Evolution: No deaths, relapses in 4. Nowadays,
16 were in complete remission. Adult cases: 22 cases, 9 females and 13 males. Median
age at diagnosis: 32.5 years-old. Clinical features: 9-bones (7-unifocal), 9-lung, 6-lymph
nodes, 3-skin, 2-spleen, 2 CNS, 1-genital, 1-liver, 1-hematopoietic-system. Multisystem
disease was found in 8. Treatment: 4-chemotherapy and 4-radiotherapy. Relapse in 2
patients. Missing data in follow-up but 2 deaths and 5 malignancies associated
(2-Hodking, 2 lung, 1 leukemia).
Conclusion: LCH was most frequent in children and in the first 40 years of life (median
of 18 and 75% cases were less than 35 years old). Bone lesions were the most common
in both groups. Multisystem involvement was detected in 40%. Pulmonary, lymph
nodes and risk organ involvement were most frequent in adults. Only children were
included in national or international studies. Chemotherapy was more used in children
and radiotherapy in adults. Prognosis was better in children and associated
malignancies and deaths were observed only in adults. A better follow up is needed to
know the long term sequelae and monitoring programs should be implemented.
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INVESTIGATION OF CENTRAL NERVOUS SYSTEM DISEASE IN PATIENTS
WITH LANGERHANS CELL HISTIOCYTOSIS. EXPERIENCE OF EGE
UNIVERSITY FROM TURKEY
N. Çetingül1, H. Hekimci Özdemir2, Ö. Kitis¸3, C. Çallı3, G. Serdarog˘lu4, S. Gökben4,
M. Kantar2, S. Aksoylar2, S. Demirel2, M. Hekimgil5, S. Kansoy2
1Ege University Facultyof Nursing, Izmir, Turkey; 2Ege University-Faculty of Medicine,
Pediatric Hematology-Oncology, I˙zmir, Turkey; 3Ege University-Faculty of Medicine,
Radiology, I˙zmir, Turkey; 4Ege University-Faculty of Medicine, Pediatric Neurology,
I˙zmir, Turkey; 5Ege University-Faculty of Medicine, Pathology, I˙zmir, Turkey
Background/Objectives: Langerhans cell histiocytosis (LCH) is a rare disease in
childhood involving clonal proliferation of CD1a positive Langerhans cells. Clinically,
its manifestations range from isolated bone lesions to multiple system disease (MSD)
and failure. CNS-LCH is a rare significant form of LCH due to its high morbidity rate.
In CNS-LCH diesase early age, craniofacial bone involvement and MSD constitute a
risk. The aim of our study was to determine via a multidisciplinary approach, the
frequency of CNS-LCH cases.
Design/Methods: This is a retrospective and cross-sectional study of 30 patients with
LCH followed in Ege University, Department of Pediatric Oncology.
Neuropsychological examination, EEG and cranial MRI was done by the departmants
of pediatric neurology and radiology.
Results: In this study, the mean age at diagnosis of patients was 81.3 months (8-192
months). Eleven (36%) patients under 36 months old were considered as early age.
Seven (63%) of them had MSD. Skeletal system was the most commonly affected
system (97%). Twenty (66%) of all cases showed single-system involvement, MSD was
seen in 10 (34%) patients. Clinical and radiological findings of CNS disease were
detected in 10 (33,3%) cases. Six of them had clinical and radiological disease findings
approved as “certain CNS disease”. Since 4 patients had developmental delays and/or
the risk of organ involvement in addition to the radiological findings, they were
approved as “highly probable CNS disease”. There were 7 cases with MRI lesions that
were compatible with LCH, but did not have a risk for CNS diease. These cases were
approved as “suspected CNS disease” and follow-ups were scheduled.
Conclusion: In patients with LCH, especially MSD and early age there is a risk in terms
of CNS disease. A multidisciplinary perspective (neuropsychiatric exams and cranial
MRI) is crucial in the diagnosis of CNS disease and management.
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EXOSOME-TRANSFERRED APOC3-NCRNA COMPLEXMEDIATES IRON
REGULATION IN β-THALASSEMIA MAJOR
C.T. Peng1,2, C.Y. Li1,3,4, F.J. Tsai1,2, C.H. Tsai1,2, K.H. Wu1, Y.N. Yu-Nan Huang1,3
1China Medical University, Children’s Hospital, Taichung, Taiwan; 2Asia University,
Biotechnology, Taichung, Taiwan; 3China Medical University, Graduate Institute of
Clinical Medical Science, Taichung, Taiwan; 4China Medical University Hospital,
Department of Anesthesiology, Taichung, Taiwan
Background/Objectives: Exosomes are small membrane vesicles (50–90 mm in diameter)
containing bioactive proteins and genetic materials that may be transferred to accept
cells, resulting in potent biological effects in the circulatory system.
Exosome-transferred APOC3-ncRNA may be a crucial function in iron regulation.
However, the role in β-thalassemia major is remains unclear. The aim of this study was
to investigate how Exosome-transferred APOC3-ncRNA adapts to iron regulation in
β-thalassemia major.
Design/Methods: Using Proteomics, RNA-sequencing and lncRNA Q-PCR array, we
demonstrated expression of exosomes-transferred APOC3-ncRNAs in plasma of
β-thalassemia major patients (n = 40). Identification of exosome by Dynamic light
scattering (DLS), Flow cytometry and western blots. Lentiviral infection, ncRNAs
transfection and in vitro studies revealed that knockdown or overexpression obviously
increased or ameliorated exosomes-induced iron regulation. Bioinformatics analysis,
luciferase assay and in vitro studies revealed that ncRNAs functioned as a repressing
mediator and formed a feedback loop with ncRNAs and target gene to mediate iron
regulation.
Results:We observed that ncRNA is differential expressed in the exosomes of
β-thalassemia major. We analyzed the effects of ex vivo-derived exosomes for iron
regulation by monocytes/hepatocytes model. In vitro model showed that exosomes were
internalized by THP-1/HuH-7 cells, and regulates the IRP1/FPN/HAMP. In turn,
Exosome-transferred APOC3-ncRNA mediates inflammatory cytokine expression and
iron regulation via p38/pAKT/TRAF6/NF-kB pathway. Knockdown of
APOC3-ncRNA reversed IRP1/FPN/HAMP expression.
Conclusion: This is the first example of extracellular APOC3/ncRNA regulating gene
expression via circulatory exosomes-transferred to accept cells. Increased
Exosome-transferred APOC3-ncRNA expression is one of the key factors that might
have contributed to abnormal iron regulation in β-thalassemia major patients.
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ROSAI DORFMAN DISEASE: ANALYSIS OF CLINICAL AND
PATHOLOGICAL CASES IN PEDIATRICS IN A SINGLE CENTER
M. Perez1, M. Berdugo1, P. Bove2, M. Urbieta1, M. Garcia Lombardi1
1R. Gutierrez Children Hospital, Oncology, CABA, Argentina; 2R. Gutierrez Children
Hospital, Pathology, CABA, Argentina
Background/Objectives: Sinus histiocytosis with massive lymphadenopathy or Rosai
Dorfman disease (RDD) is considered a benign pathology of unknown cause. Presents
with unilateral or bilateral cervical lymph node involvement, painless, fever and various
hematological disorders. The diagnosis is pathological. Usually treatment is not
necessary.Therapy is required, however, for patients with extranodal RDD having vital
organ involvement or those with nodal disease causing life-threatening complications.
The purpose is review the pathological and diagnostic clinical features of patients (p)
with RDD.
Design/Methods: Report of seven cases of patients treated at Hospital de Niños
Ricardo Gutierrez, analyzing the clinical, immuno histochemical and pathological
features between October 1992 and october 2013.
Results: Seven cases are reported, mostly male (5), aged between 1 and 18 years. All of
them had single or multiple cervical lymphadenopathies, with concomitant symptoms
like fever (2 p), and lymphadenopathy in different locations (4 p). Histologically, lymph
nodes show dilated sinuses, heavily infiltrated with large histiocytes, lymphocytes and
plasma cells. The presence of the engulfment of lymphocytes and erythrocytes by
histiocytes that express CD68 (6/6p) and S-100 (5/6p), was considered diagnostic of
RDD. CD1a was typically negative (1/6p). In 4 cases, treatment was not necessary.
Three patients were treated with corticosteroids for one month and 1 with vinblastine
for bad response.
Conclusion: Rosei Dorfman disease is a histiocytic proliferative benign
idiopathicdisorder characterized by sinus histiocytosis with massive lymphadenopathy.
It is a clinicaland specific pathology. Cervical location is the most common. The
definitive diagnosis is histological. Currently there is no standardized treatment. The
evolution is usually favorable.
P-247
PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: THE
EXPERIENCE OF A TERTIARY CARE CENTRE IN SOUTH INDIA
A. Prakash1, S. Mathew2
1St Johns Medical College, Bangalore, India; 2St Johns Medical College, Pediatrics,
Bangalore, India
Background/Objectives: Hemophagocytic lymphohistiocytosis (HLH) is a rare, often
life threatening syndrome characterized by reactive, systemic proliferation of benign
histiocytes throughout the reticuloendothelial system. In a tropical developing country,
the diagnosis may be missed as there are other more common causes for the triad of
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high fever, splenomegaly and cytopenia. We describe the profile and outcome of
children with primary HLH in a pediatric unit of a developing country.
Design/Methods: Retrospective review of all cases of Primary HLH diagnosed over a 3
year period in the Pediatric hematology oncology unit.
Results: Eleven cases of primary HLH were diagnosed as per the HLH 2004 diagnostic
criteria. All the cases were referred as cases of pyrexia of unknown origin (PUO). A
syndromic diagnosis was made in 8 patients; 7 had Griscelli syndrome and 1 had
Chediak Higashi. All were treated as per HLH 2004 protocol. Two children had
neurological involvement of HLH. Seven children responded to induction therapy. One
expired before treatment could be initiated and two expired due to refractory HLH
while on induction chemotherapy. Stem cell transplant was advised to all patients once
HLH was under control but the only child who underwent SCT at another centre,
succumbed to sepsis. Four cases are on continuation therapy and on follow up. Three
were lost to follow up while on continuation therapy.
Conclusion: HLH should be considered as a diagnostic possibility in a child who
presents with PUO, especially if there are dysmorphic features suggestive of Griscelli or
Chediak Higashi syndromes. While therapy with HLH 2004 protocol is successful in the
majority of cases, access to stem cell transplant is still a challenge in the developing
world.
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LANGERHANS CELL HISTIOCYTOSIS: PERSPECTIVE FROM THE
DEVELOPINGWORLD
Y.R. Chopra1, A. Prakash2, V. Chakravarthi2, S. Katewa1, S.P. Yadav1
1Fortis Memorial Research Institute, Pediatric Hematology-Oncology, Gurgaon, India;
2St Johns Medical College, Pediatrics, Bangalore, India
Background/Objectives: Langerhans cell histiocytosis (LCH) is a rare disorder.
Outcome data is lacking from developing countries like India. We present our
experience of diagnosing and managing LCH.
Design/Methods: Cases of LCH diagnosed at two Pediatric Hematology-Oncology
Units in India over a period of 4 years were retrospectively reviewed. Demographic
details, clinical features, histopathology radiological findings, details of therapy and
outcomes were analyzed.
Results: Nineteen cases of LCH were diagnosed. Mean age of presentation was 29
months. Male to female ratio was 2.8:1. All cases were confirmed by biopsy and CD1a
stain. Ten presented with multisystem disease and 9 had single system disease. Risk
organ involvement was seen in 9 cases (liver 37%, spleen 21%, bone marrow 16%). Eight
cases had single system involvement (bone) with 4 cases of multifocal disease and 4
with single lesions. Both axial and appendicular skeletal involvement was seen. Lung
involvement was seen in 42%. Isolated mediastinal mass and nail involvement were seen
in one case each. Multiple hypoechoic lesions in the liver mimicking abscess and lung
lesions mimicking tuberculosis were seen. Radiological findings assisted in diagnosis in
all the cases.Therapy was given as per LCH-III protocol. Eight cases required two
induction cycles and two children required salvage chemotherapy. Curettage was done
for single site bone lesion in four cases and one child required spine stabilization.
Fourteen children have completed treatment and are on follow up (Median 20 months ;
range 3 -84 months). Progressive sclerosing cholangitis requiring liver biopsy was seen
in two children of which one opted for liver transplant. One child developed
staphylococcus aureus meningitis while on continuation treatment and abandoned
treatment.
Conclusion: A high index of suspicion and familiarity with the clinical and radiological
findings of LCH will ensure prompt diagnosis and therapy. Good treatment outcomes
are possible in developing world also.
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FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN:
SINGLE CENTRE RESULTS
Z. Salcioglu1, H. Sayilan Sen1, D. Tugcu1, A. Akcay1, G. Aydogan1, M. Gokce1,
C. Bayram1, F. Akici1
1Kanuni Sultan Süleyman Education and Research Hospital, Pediatric Hematology and
Oncology Clinic, Istanbul, Turkey
Background/Objectives: Familial hemophagocytic lymphohistiocytosis (FHL) is an
autosomal recessive disorder characterized with uncontrolled activation of T-helper
lymphocytes and macrophages and over-release of inflammatory cytokines. The only
curative treatment is hematopoetic stem cell transplantation (HSCT). This study
evaluates the clinical and laboratory data of children with FHL.
Design/Methods: Twenty five FHL cases followed and treated at our clinic between 2005
and 2015 were retrospectively evaluated in our study.
Results: Fourteen of the cases were boys and eleven were girls. The age at presentation
for patients was two week-36 months (mean 4.2 months). There was a history of
consanguineous marriage in 20 of the families (80%). Fever, anemia, and
hypertriglyceridemia were present in all patients. Hepatomegaly was detected in 72%.
Splenomegaly was more frequent in patients (88%). Hypofibrinogenemia was detected
in all patients. All patients had neutropenia and thrombocytopenia. Hyperferritinemia
was present in 92%% of patients. Only seven patient found to have hemophagocytosis
in the cytological evaluation of the cerebrospinal fluid (29.2%). Mutation analysis were
performed in 17 patients and of these, 3 had UNC13D, 6 had PRF1 and 2 had STX11
gene mutation. All patients vere treated with HLH-2004 protocol. HSCT was
performed in 8 patients (%32). The overall mortality rate was 56 % (14 cases) in our
series. Fourteen children died due to opportunistic infection (n = 8) or disease
progression (n = 6).
Conclusion: In conclusion, FHL is a disease with high mortalite rates and the only
curative treatment is HSCT. Donor search for HSCT must be started and HSCT should
be performed after the remission.
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OUTCOME AND DISABILITIES IN CHILDHOOD LANGERHANS CELL
HISTIOCYTOSIS
R. Seth1, A. Singh2, R. Phulia3
1All India Institute of Medical Sciences, New Delhi, India; 2All India Institute of
Medical Sciences, Pediatrics, New Delhi, India; 3All India Institute of Medical Sciences,
Nuclear Medicine, New Delhi, India
Background/Objectives: Langerhans cell histiocytosis (LCH) is characterized by
abnormal proliferation and accumulation of bone marrow–derived Langerhans cells
(histiocytosis) juxtaposed against a backdrop of hematopoietic cells, including T-cells,
macrophages, and eosinophils. Data on sequelae /disabilities on children having
completed treatment for LCH is scarce. This study describes the varied clinical profile,
outcome and disabilities in children treated for LCH followed at a tertiary center in
India. The role of PET CT in evaluation of LCH is also highlighted.
Design/Methods: Case records of children diagnosed and treated for LCH at our center
were evaluated. Symptom profile, lag period between onset of symptoms and diagnosis
were ascertained. Extent of disease was ascertained according to LCH 2009 guidelines
after relevant investigations including PET CT. Details of treatment response and
reactivation were recorded. Follow up details and sequelae described.
Results: 45 children were diagnosed with LCH in last three years. Most children had
multisystem involvement.23 completed treatment and are under follow up. Mean
period of follow up 23 months. LCH was often a missed diagnosis. Sequelae was seen in
14 patients (60%).Reactivation was seen in 5 patients (4 had multisystem involvement:
risk organ involvement was seen in 3) All children with disease reactivation had onset
of symptomatology at less than two years of age. Sequalae included short stature,
Diabetes insipidus, Chronic liver and lung disease, sclerosing cholangitis, bony defects,
ear discharge/hearing defect and proptosis. Pulmonary artery hypertension and nail
changes were also seen.
Conclusion: LCH, often a missed diagnosis, has varied clinical presentation and
treatment outcomes. Reactivation of disease does occur and is seen more often in
children with disease onset at less than 2 years of age. Sequalae are common.PET CT
emerged a useful modality to assess treatment response in both newly diagnosed and
refractory cases of LCH.
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HYPERFERRITINEMIA IN SEVERELY ILL PATIENTS: ASSOCIATIONS WITH
CLINICAL AND LABORATORY FINDINGS
T. Von Bahr Greenwood1, K. Palmkvist Kaijser2, S.C.C. Chiang3, T. Huang3, B. Tesi4,
E. Rudd4, M. Nordenskjöld4, H. Hjelmqvist5, Y.T. Bryceson3, J.I. Henter1
1Karolinska Institutet, Childhood Cancer Research Unit-Department of Women’s and
Children’s Health-Karolinska University Hospital Solna, Stockholm, Sweden;
2Karolinska Institutet, Department of Neonatology-Karolinska University Hospital
Solna, Stockholm, Sweden; 3Karolinska Institutet, Center for Infectious
Medicine-Department of Medicine- Karolinska University Hospital Huddinge,
Stockholm, Sweden; 4Karolinska Institutet, Clinical Genetics Unit-Department of
Molecular Medicine and Surgery and Center for Molecular Medicine- Karolinska
University Hospital Solna, Stockholm, Sweden; 5Karolinska Institutet, Department of
Clinical Science-Intervention and Technology and Department of Anaesthesiology and
Intensive Care-Karolinska University Hospital Huddinge, Stockholm, Sweden
Background/Objectives: Hyperferritinemia has been identified as an important
biomarker of the genetic (primary) form of hemophagocytic lymphohistiocytosis
(HLH), a disease associated with excessive inflammation and characterized by defect
lymphocyte cytotoxicity function. HLH may also develop in a secondary (acquired)
form in severely ill patients, a potentially treatable hyperinflammatory condition. In
children, the extent of hyperferritinemia can help identify and distinguish HLH from
other conditions. Furthermore, increasing levels of ferritin has been correlated to
increased risk of intensive care unit (ICU) admission and death. We analyzed ferritin
levels in patients admitted to ICU in order to correlate hyperferritinemia to clinical and
other laboratory parameters in this group of severely ill patients.
Design/Methods: Thirty-two adult patients with ferritin levels >500 μg/L were
prospectively studied at an ICU with regard to clinical and laboratory features on
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admission, including soluble CD25 (sCD25) and detailed lymphocyte cytotoxicity
analyses and genetic studies in some.
Results: Hyperferritinemia and elevated sCD25, both markers of inflammation, were
positively associated to each other in patients with septicemia, a state of known
excessive inflammation. Here, hyperferritinemia was also associated with elevated CRP.
Ferritin and sCD25 levels were inversely correlated to platelet counts in the total cohort
and in patients with septicemia. Notably, thrombocytopenia is a sign of severe illness
that affects outcome and mortality of ICU patients. Similarly, elevated sCD25 was
inversely correlated to hypoalbuminemia. Interestingly, hyperferritinemia (>5,000
μg/L) was also associated with decreased cytotoxic function. Notably, of four patients
with abnormally low cytotoxic function, three had <5% circulating NK cells and one
had a heterozygous variant in an HLH-causing gene (STXBP2).
Conclusion: Our study suggests a correlation between hyperferritinemia and other
laboratory values indicative of inflammation and of poor outcome in severely ill
patients at intensive care units.
Posters: Late Effects
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CARDIAC PROBLEMS IN PATIENTS WHO UNDERWENT TO
HEMATOPOIETIC STEM CELL TRANSPLANTATION
E. Atas1, V. Kesik1
1Gulhane Military Medical Academy, Pediatric Oncology, Ankara, Turkey
Background/Objectives: Cardiac complications may be observed after hematopoietic
stem cell transplantation (HSCT). Despite significant improvement in supportive care,
HSCT may be associated with significant morbidity and mortality. In this study, we
aimed to evaluate the frequency of serious cardiac complications with clinical
characteristics after HSCT in our patients.
Design/Methods: This is a single instutional study. The demoraphic and clinical
characteristics of patients with cardiac complication were recorded among 69 subjects
who underwent to HSCT, retrospectively.
Results: The frequency of subjects with cardiac events among 69 subjects who
underwent to HSCT was 5.8%. In addition, 5 events were detected after HSCT in 69
subjects who underwent to HSCT (7.25%). Autologous HSCT in 3, and allogeneic in a
case were performed. The median age was 12.5 years (range 12-15) and M/F ratio was
1/3=0.33. The disease distributions were the following: Hodgkin lymphoma (HL)
nodular sclerosis (NS) variant: 2 (50%), PNET: 1 (25%), T cell lymphoblastic
lymphoma: 1 (25%). Primary localizations of disease were cervical lymph node in 2
subjects, pelvic mass in 1 subject and pelvic bone in 1 subject. All of the subjects had
Stage IV disease.Pericardial effusion in 3 subjects, and sinus bradycardia and
ventricular tachycardia in 1 patient were detected. The mortality rate was 50%, and
both of them were with pericardial effusion. Poor risk factors, myocarditis, pericarditis
and heart failure owing to cumulative doses of anthracycline, cyclophosphamide, CMV
infection or other infections, mediastinal irradiation, and cryopreserved stem cell
product with DMSO were the main reasons in this study.
Conclusion: Cardiac complications after HSCT are very important side effects. Early
intervention can prevent death related to this complication. They should be followed-up
closely for this complication.
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SURVIVORS OF ALL ARE AT INCREASED RISK OF BEING
OBESE/OVER-WEIGHT, BUT NOT FORMETABOLIC SYNDROME AT A
MEAN DURATION OF 3.8-YEARS FROM END OF TREATMENT
S. Mohapatra1, D. Bansal1, A.K. Bhalla2, S.V. Attri3, N. Sachdeva4, A. Trehan1,
R.K. Marwaha1
1Advanced Pediatrics Centre-Postgraduate Institute of Medical Education and Research,
Hematology-Oncology Unit-D Department of Pediatrics, Chandigarh, India; 2Advanced
Pediatrics Centre-Postgraduate Institute of Medical Education and Research, Child
Growth and Anthropology Unit- Department of Pediatrics, Chandigarh, India; 3Advanced
Pediatrics Centre-Postgraduate Institute of Medical Education and Research,
Biochemistry Unit- Department of Pediatrics, Chandigarh, India; 4Postgraduate Institute
of Medical Education and Research, Department of Endocrinology, Chandigarh, India
Background/Objectives:Metabolic syndrome (MS) has been commonly reported in
survivors of childhood ALL from developed countries. Data from developing countries
is lacking.
Design/Methods: Survivors of childhood ALL at a referral hospital in North India were
evaluated for MS. Anthropometric measurement (weight, height, waist-circumference,
triceps/sub-scapular skin fold thickness), biochemistry (fasting glucose/insulin,
lipid-profile, thyroid function, CRP), measurement of blood pressure and SMR staging
were performed. MS was defined by the IDF, as well as NCEP ATP-III criteria
modified by Cook et al, and ford et al.
Results: The median age of 76 survivors was 11.9 years (range 7.4-19). The mean time
from completion of chemotherapy was 3.8±1.9 years (range: 2-11). Cranial irradiation
was administered to 15 (20%) patients. The mean BMI at diagnosis, completion of
treatment and at study enrolment was 14.2±1.7, 16.2±2.8 and 18.3±3.7, respectively
(p<0.0001). Twenty-four (32%) survivors were obese or overweight. The fasting blood
sugar and insulin level were within range in all the survivors. CRP was elevated (>3
mg/L) in 19 (25%) survivors; a marker of subclinical inflammation and risk factor for
cardio-vascular disease. Subclinical hypothyroidism was observed in 14 (18%) survivors.
The prevalence of insulin resistance (17%), hypertension (7%), hypertriglyceridemia
(20%) and a low HDL (37%) was comparable to the prevalence in children/adolescents
in earlier cross-sectional population based studies from India.The prevalence of MS
ranged from 1.3% to 5.2%, as per different defining criteria. Cranial radiotherapy, age
at diagnosis, sex, socio-economic status or dose of anthracycline were not observed to
be a risk factors for MS.
Conclusion: The prevalence of MS in survivors of childhood ALL, at a mean duration
of 3.8 years from completion of chemotherapy, was 1.3% - 5.2%. It was similar to the
prevalence in children/adolescents in earlier cross-sectional population based studies
from India. Twenty-four (32%) survivors were obese or overweight, a prevalence higher
than population based data.
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MARKERS OF TUBULAR RENAL INJURY IN CHILDRENWITH CANCER
RECEIVING CISPLATIN AND/OR IFOSFAMIDE
C. Barton1, D. Hawcutt1, M. Pirmohamed2, B. Pizer1
1Alder Hey Children’s Hospital, Paediatric Oncology, Liverpool, United Kingdom;
2University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom
Background/Objectives: Children with cancer receiving nephrotoxic chemotherapeutic
agents such as cisplatin and ifosfamide are at risk of both acute and chronic, and
reversible and irreversible, kidney injury. Monitoring for changes in glomerular
function is now routine, with biochemical markers of glomerular function such as
serum creatinine (sCr), and the use of chromium 51-labelled
ethylenediaminetetraacetate (51 Cr-EDTA) to measure glomerular filtration rate
(GFR). Markers of tubular injury are however less well defined.
Design/Methods: A two-step systematic review was undertaken to determine which
markers, if any, have been described in studies relating to children with cancer, and then
specifically those receiving cisplatin and/ or ifosfamide. EMBASE, MEDLINE and
CINAHL were searched. Search terms were independently matched to the thesaurus of
each database. An initial search was conducted to generate a list of markers of renal
tubular injury that had been identified or explored in either in vitro and or in vivo
biological or clinical studies. Only biochemical, genetic, peptide, and microRNA
markers were included. A second literature search was conducted to identify articles
relating to renal injury in paediatric patients receiving cisplatin or ifosfamide. The two
searches were cross-referenced.
Results: A total of 97 markers of tubular injury were identified from the defined search
terms. Of these, 14 were cross-referenced to the defined population, including fractional
excretion of phosphate, cystatin C, interleukin-18 and variance in amino acid and
metabolite profiles.
Conclusion: The clinical utility of potential biomarkers is currently limited by
considerations such as small sample size in studies conducted, the requirement for
specialist modalities (e.g. nuclear magnetic resonance spectroscopy), complexity of
analysis (e.g. urine amino acid profiles) and cost of assays (e.g. ELISA). Further work is
needed to identify new biomarkers of tubular kidney injury arising from nephrotoxic
chemotherapy, with studies in larger cohorts of patients to validate their utility,
sensitivity and specificity.
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ACUTE KIDNEY INJURY IN PAEDIATRIC ONCOLOGY PATIENTS
RECEIVING CISPLATIN
C. Barton1, D. Hawcutt1, M. Pirmohamed2, B. Pizer1
1Alder Hey Children’s Hospital, Paediatric Oncology, Liverpool, United Kingdom;
2University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom
Background/Objectives: Paediatric cancer patients receiving cisplatin are at risk of
developing acute kidney injury (AKI). Routine markers for monitoring transient and
permanent changes in glomerular function (GF) include serum creatinine (sCr) and
glomerular filtration rate (GFR) measurement. Markers of tubular injury are however
less well defined. Using routine clinical data, the current study aimed to identify the
incidence of the AKI in patients being treated within a tertiary paediatric oncology,
and potential markers for future studies.
Design/Methods: Core data including sCr levels, gentamicin levels and magnesium
supplementation were collated from the electronic and pharmacy records of 68 children
who had received cisplatin. AKIN scores were given based on biochemical data alone.
Results: Complete data was available on 63 patients; 35/63 (56%) of patients had an
AKIN score of 0, 21/63(33%) had an AKIN score of I, and 7/63 (11%) had an AKIN
score of II. A total of 71% of patients with AKIN II had received gentamicin (number
of courses: range 1–12, mean 5.8) between commencing chemotherapy and data
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collection, compared with 33% of patients with AKIN 1 (range 1–8,mean 3.14). 86% of
those patients with AKIN II required magnesium supplementation on treatment (vs
24% of AKIN I patients), with 71% of those patients with AKIN II requiring
magnesium supplementation after treatment(vs 19% of AKIN 1 patients).
Conclusion: 44% of patients had an AKIN score of I or II. Those patients withan
AKIN score of II received a higher mean number of courses of aminoglycosides than
other groups (AKIN Ior 0), and were more likely to require magnesium
supplementation, both on and off treatment. This suggests that cumulative
aminoglycoside doses may have a role in the stratification of patients at risk of AKI for
researchand follow-up purposes, and that the utility of magnesium supplementation as
a marker of AKI merits further investigation.
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DISCUSSIONS ABOUT REPRODUCTIVE AND SEXUAL HEALTH AMONG
YOUNG SURVIVORS OF CANCER
W. Cheung1, L. Chen2, Y. Wang2
1British Columbia Cancer Agency, Vancouver, Canada; 2British Columbia Cancer
Agency, Medical Oncology, Vancouver, Canada
Background/Objectives: Infertility and sexual dysfunction can result from many cancer
treatments and may become a source of significant distress for young cancer survivors.
Our aims were to 1) characterize the frequency in which reproductive and sexual health
discussions occur in a population-based cohort of young cancer patients and 2) identify
clinical factors associated with such discussions.
Design/Methods: All patients aged 18 to 39 years who were diagnosed with solid tumors
from 2008 to 2010, evaluated at any 1 of 5 regional cancer centers in British Columbia,
Canada and alive at 2 or more years after their original diagnosis were included.
Demographics, tumor and treatment characteristics, and information on
patient-physician conversations regarding reproductive and sexual health were
analyzed. Using regression models, we explored the relationships between clinical
factors and whether or not discussions had occurred.
Results:We identified 453 patients: median age 35 years (IQR 31-38), 28% men, 88%
ECOG 0, and 73% reported being in a relationship. Tumor sites included breast (50%),
testicular (27%), gynecological (17%), and colorectal (6%). A significant proportion of
patients received chemotherapy and radiation that posed the potential risk of infertility
or sexual dysfunction. However, only 224 (56%) and 24 (6%) of individuals had a
discussion about reproductive and sexual health, respectively, within the first month of
their diagnosis. At 6 months, an additional 25 (6%) and 16 (4%) patients had discussed
these concerns with their physicians. Age, gender, ECOG, relationship status, and type
of chemotherapy and radiation were not correlated with whether or not discussions had
occurred (all p>0.05). In regression models, tumor site was associated with differences
in reproductive and sexual health discussions where individuals with gynecological
cancers were most likely to engage in such conversations.
Conclusion: Among young survivors of cancer, fertility and particularly sexual function
are inadequately addressed near the time of initial cancer diagnosis.
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COGNITIVE FUNCTIONING OF CHILDHOOD ALL OR NHL SURVIVORS
AND LINKS WITH BIOMARKERS DURING TREATMENT
I. Elens1, S. Van Gool2, L. Jurgen2, B. Elise3, V.S. Charlotte3
1Leuven, Belgium; 2KUL, Child Hemato-Oncology, Leuven, Belgium; 3KUL,
Psychology, Leuven, Belgium
Background/Objectives: Contemporary treatment can cure children with NHL or ALL.
However, chemotherapy-induced neurotoxicity causes long-lasting functional deficits in
some survivors. Besides primary cure, early identification and subsequent care for these
individuals must therefore be focus of research in child oncology. Individuals with
polymorphisms causing lower activity of the methyltetrahydrofolate reductase
(MTHFR) enzyme have a higher risk for methotrexate-induced neurotoxicity, since this
enzyme plays a key role in the folate metabolism. Previously, we reported increased
levels of biomarkers of neurotoxicity in the cerebrospinal fluid (CSF) of patients during
and information processing difficulties in survivors after treatment. We aim to link 1/
MTHFR genotype, 2/ biomarkers during treatment and 3/ long-term neurocognitive
function in survivors of ALL and NHL.
Design/Methods: CSF-Tau and phospho-Tau were consecutively measured during
treatment in respectively 28 and 7 patients with ALL and NHL. After a median time
since treatment of 13.03 years, the outcome of neurocognitive tests and questionnaires
was compared with sex- and age-matched controls, and the genotype on position 677
and 1298 of the MTHFR-gene was analyzed in survivors.
Results: Survivors performed significantly slower as compared to controls on tasks
assessing memory, focused attention, cognitive flexibility and inhibition. These
observations were reflected in higher scores on self-reported cognitive dysfunctions.
The MTHFR1298 CC genotype displayed the highest levels of biomarkers. Combined
with age below five at diagnosis, biomarkers helped us to detect patients with more
severe neurocognitive problems.
Conclusion: To our knowledge, this is the first study to link genetic susceptibility with
biomarkers and final neurocognitive outcome. We developed tools to identify early
during chemotherapy children at risk for more severe late neurocognitive difficulties.
These patients can be supported at an early stage with appropriate learning plans. The
results of this study can also be applied to assess neurotoxicity in future treatment
protocols.
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PAEDIATRIC CANCER SURVIVORS IN JOHANNESBURG DEMONSTRATE A
HIGH RATE OF SUBCLINICAL RENAL DYSFUNCTION
A. Mudi1, J. Geel2, J. Poole3, C. Levy4
1Department of Paediatrics-Aminu Kano Teaching Hospital, Kano, Nigeria, Division of
Paediatric Nephrology-Charlotte Maxeke Johannesburg Academic Hospital,
Johannesburg, South Africa, Kano, Nigeria; 2Faculty of Health Sciences-University of
the Witwatersrand, Division of Paediatric Haematology and Oncology, Johannesburg,
South Africa; 3Faculty of Health Sciences-University of the Witwatersrand, Division of
Paediatric Haematology and Oncology-Charlotte Maxeke Johannesburg Academic
Hospital, Johannesburg, South Africa; 4Faculty of Health Sciences-University of the
Witwatersrand, Division of Paediatric Nephrology-Charlotte Maxeke Johannesburg
Academic Hospital, Johannesburg, South Africa
Background/Objectives: Clinical manifestations of renal dysfunction in children who
have completed treatment for cancer include hypertension, proteinuria and renal
insufficiency. This cross sectional study aimed to determine the prevalence, extent and
factors associated with residual effects of cancer therapy on the renal system.
Design/Methods: A descriptive cross sectional study was performed to assess 130
children between the age of 1 and 18 years who completed treatment at a single
institution and who were followed up at the paediatric oncology unit of the hospital.
Physical examination, blood pressure and screening urine dipstick were performed on all
patients by a single researcher. Blood results of samples routinely drawn, as part of the
current standard follow up protocol of the unit (full blood count, calcium, magnesium
and phosphate, and urea, electrolytes and creatinine), were analysed. Patients with
abnormal results were referred to the paediatric renal clinic for further evaluation.
Results: After a median follow-up post treatment of 2 years, the various manifestations
of renal dysfunction included decreased glomerular filtration rate (GFR),
hypomagnesaemia, hypophosphataemia, proteinuria, haematuria and hypertension. In
total, 34 survivors (26.15%) had at least one manifestation of renal dysfunction after
completing treatment, of which none were clinically significant. The most prevalent
manifestation of renal dysfunction detected was decreased GFR (17.69%).
Hypomagnesaemia and hypophosphataemia were present in 8 (6.15%) and 6 (4.62%) of
the survivors respectively. Patients who had pre-existing renal dysfunction were three
times more likely to have renal dysfunction post-treatment (p=0.02). Ifosfamide,
carboplatinum, and nephrectomy were significantly associated with a reduction in GFR
(p = 0.03, 0.02, <0.01).
Conclusion: Although the rate of renal dysfunction was relatively high, it was not
clinically significant. Patients with pre-existing renal dysfunction should be assessed by
a nephrologist prior to initiation of cancer therapy, and nephro-protective measures
should be employed stringently in all children with cancer.
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HEALTH-RELATED FITNESS IN LONG-TERM SURVIVORS OF CHILDHOOD
CANCER
A. Hartman1, S. Pluijm1, M. Wijnen1, E. Clemens1, R. Pieters2, M. van den
Heuvel-Eibrink2
1Erasmus MC Sophia Children’s Hospital, Pediatric Oncology and Hematology,
Rotterdam, Netherlands; 2Princess Maxima Centre for Pediatric Oncology, Pediatric
Oncology, Utrecht, Netherlands
Background/Objectives: In long-term childhood cancer survivors (CCS) adverse effects
of treatment may result in impaired health-related fitness. Most studies in CCS assessed
level of physical functioning subjectively with questionnaires. Only one study assessed
survivors of acute lymphoblastic leukemia (ALL) objectively, using tests. The current
study investigated health-related fitness in CCS in survivors other than of ALL.
Design/Methods: Cardiopulmonary endurance, mobility and muscle strength of
survivors of acute non lymphocytic leukemia (ANLL), neuroblastoma or Wilms tumor
(WT), aged 18 years, were investigated using 9 standardized validated tests. The Short
Questionnaire to Asses Health-enhancing physical activity (SQUASH) was also used.
Results were compared to healthy controls using multivariate analysis of covariance
(ANCOVA), adjusted for age, sex and educational level.
Results: CCS had poorer cardiopulmonary endurance (mean (standard error; se) of
standardised difference score (SDS) on six minute walking test: CCS: -0.53 (0.12) vs
controls: -0.05 (0.12), p=0.008), less mobility (side flexion trunk; CCS: 20.1 cm (0.4) vs
controls: 22.4 cm (0.4), p<0.001), and less muscle strength (vertical jump: CCS: 39.7 cm
(0.8) vs 43.8 cm (0.8), p<0.001) than healthy controls. Survivors of ANLL had poorer
cardiopulmonary endurance (-1.06 (0.3) SDS) than survivors of neuroblastoma: -0.59
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(0.2) SDS and WT: -0.21 (0.2) SDS) (p=0.04). CCS with a scoliosis (25%) performed
poorer on side flexion of the trunk (p=0.02), performing push ups (p=0.006) and
sit-ups (p=0.01) compared to CCS without a scoliosis. Being a survivor (p=00.1),
higher body mass index (BMI) (p<0.001) and lower levels of physical activity (p=0.03)
were the most important predictors of physical functioning.
Conclusion: CCS seem to have impaired health-related fitness, in particular
cardiopulmonary endurance. Survivors of ANLL and those with a scoliosis appear to
have the highest risk of impaired health related fitness. Life style interventions may help
to improve health-related health related fitness in CCS.
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NEUROCOGNITIVE AND NEUROIMAGING OUTCOMES FOLLOWING
CHEMOTHERAPY-ONLY TREATMENT FOR PAEDIATRIC LEUKAEMIA: A
SELECTIVE REVIEW
S. Hearps1,2, M. Seal1,2, V. Anderson2,3,4, M. McCarthy5,6, C. DeLuca5,6,7
1Murdoch Childrens Research Institute, Developmental Imaging, Melbourne, Australia;
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3Murdoch Childrens Research Institute, Clinical Sciences, Melbourne, Australia; 4The
Royal Children’s Hospital, Mental Health, Melbourne, Australia; 5Murdoch Childrens
Research Institute, Social and Mental Health Aspects of Illness, Melbourne, Australia;
6The Royal Children’s Hospital, Psycho-oncology Program-Children’s Cancer Centre,
Melbourne, Australia; 7The University of Melbourne, Department of Obstretics and
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Background/Objectives: Neurocognitive late-effects are reported in up to 50% of acute
lymphoblastic leukaemia (ALL) survivors. Exploring the neurological underpinnings of
such deficits would provide important information on the mechanism by which
chemotherapy affects brain maturation. Few studies have successfully explored the
relationship between functional cognitive outcomes and neuroimaging findings. This
paper will review this literature for children treated with chemotherapy-only for ALL.
Design/Methods: Keyword searches were performed on electronic databases (Scopus
and PubMed) for peer-reviewed journal articles. Papers were retained if: (i) participants
were aged 0-18 years at time of chemotherapy-only treatment, (ii) they included original
research on the association between cognitive and neuroimaging outcomes, and (iii)
were published in the year 2000 or later.
Results: Ten papers meet all 3 inclusion criteria. A significant relationship was found
between cognitive and neuroimaging measures in 6 studies. Significant correlations were
found between hippocampal size and visual memory, hippocampal structural integrity
and IQ, amygdala size, verbal memory and sustained attention, and structural integrity
of the frontal lobes and processing speed. Significant relationships were found between
abnormal white matter connectivity, IQ and response inhibition and greater activation
in the dorsolateral prefrontal cortex and working memory. Imaging findings include
gross volumes, structural integrity and functional activation.
Conclusion: Despite heterogeneity in study methodologies, the current literature
suggests that brain regions in the limbic system that are responsible for new learning
may be particularly sensitive to chemotherapy treatment, as well as white matter tracts
that deliver information between cortical regions. These findings have significant
implications for intervention and treatment planning for future ALL treatment
protocols. In particular, the inclusion of sensitive imaging techniques, the exploration
of imaging biomarkers that may predict functional risk, and the use of neuroprotective
agents and/or the decreased use of neurotoxic agents in vulnerable ALL subgroups
need to be further explored.
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IS CISPLATIN OTOTOXICITY RELATEDWITH GENOTYPE OF DNA REPAIR
GENES ERCC1, ERCC2, XRCC1?
C. Turan1, M. Kantar2, C. Aktan3, B. Kosova3, M. Orman4, T. Kose4, C. Bilgen5
1Ege University School of Medicine, Pediatrics, Izmir, Turkey; 2Ege University School of
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Biostatistics and Medical Informatics, Izmir, Turkey; 5Ege University School of
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Background/Objectives:We aimed to investigate the relationship between hearing loss
during cisplatin treatment and DNA repair genes, namely ERCC1/XPD, ERCC2 and
XRCC1.
Design/Methods: Fifty patients treated with cisplatin were included in the study. The
healthy control group consisted of 59 patients. The polymorphism in DNA repair genes
was studied by Light Cycler after DNA isolation by PCR.
Results: Among the patients, 22 had hearing loss (HL) documented in their charts. For
ERCC1 gene, the patients with HL had 50% (11) of GG (wild type), 32% (7) of AG
(heterozygous), and 18% (4) of AA genotypes (homozygous), while the patients
without HL had 30% (8) of GG, 59% (16) of AG, and 11% (3) of AA genotypes. In
control group, there were 49% (29) of GG, 42% (25) of AG, and 8.4% (5) of AA
genotypes. For ERCC2 gene, the patients with HL had 18% (4) of GG (wild type), 45%
(10) of TG (heterozygous), and 36% (8) of TT genotypes (homozygous), while the
patients without HL had 11% (3) of GG 37% (10) of TG, and 52% (14) of TT
genotypes. In control group, there were 17% (10) of GG, 44% (26) of TG, and 39% (23)
of TT genotypes.For XRCC1 gene, the patients with HL had 14%(3) of CC (wild type),
64%(14) of CT (heterozygous), and 23% (5) of TT genotypes (homozygous), while the
patients without HL had 37% (10) of CC, 48% (13) of CT, and 15% (4) of TT
genotypes. In control group, there were 31% (18) of CC, 54% (32) of CT, and 15% (9)
of TT genotypes.No difference was found among the groups in the distribution of each
3 genes evaluated according to the result of Chi square test.
Conclusion: Genotype of DNA repair genes is not related with hearing toxicity due to
cisplatin.
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“THE TIME OF YOUR LIFE” LIFESTYLE OF ADOLESCENTS AFTER
CHILDHOOD CANCER TREATMENT
R. Koning1, H. Calsbeek2, A. Mavinkurve-Groothuis3
1Radboud University Medical Center, Pediatric Oncology, Nijmegen, Netherlands;
2Radboud University Medical Center, IQ Scientific Institute for Quality of Healthcare,
Nijmegen, Netherlands; 3Princess Maxima Center for Pediatric Oncology, Pediatric
Oncology, Utrecht, Netherlands
Background/Objectives: Adolescents after childhood cancer treatment can, just as their
peers, come into contact with an unhealthy lifestyle including smoking, drinking
alcohol, using cannabis, lack of exercise and unhealthy nutrition. Due to the possible
(late) effects of their treatment, they might be more vulnerable to the consequences of
an unhealthy lifestyle than their peers without a cancer treatment history. The purpose
of this study was to explore the lifestyles of adolescents after childhood cancer
treatment and to compare them with lifestyles of adolescents without a history of
cancer treatment.
Design/Methods:We included 37 adolescents (aged 12-17 years) within a five year
period after their cancer treatment in our study. Data was collected using a written
standardized questionnaire on obesity, physical activity, smoking, drinking alcohol and
cannabis use. Results were compared with national figures of the general population in
the same age group.
Results: Adolescents after childhood cancer treatment reported to spend significantly
less time on physical activity per week (cycling in leisure time P= 0.00, sports P= 0.00)
compared to the reference data and were three times more often underweight (11.4% vs.
3.6%, respectively). Adolescents after childhood cancer treatment stated to know
significantly less cannabis users than the reference group (P= 0.00). The percentage of
adolescents who reported to have smoked in the past was significantly higher compared
with the reference group (P = 0.01). Both groups were similar with regard to alcohol
use.
Conclusion: Adolescents after childhood cancer treatment generally show comparable
lifestyles as their peers from the general population. However, they have a lower
physical activity rate than healthy adolescents. Given the fact that adolescents treated
for childhood cancer are probably more vulnerable for the consequences of an
unhealthy lifestyle, monitoring and advise regarding lifestyle is essential.
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SYSTEMIC INFLAMMATION, OXIDATIVE STRESS AND NEUROCOGNITIVE
FUNCTION IN LONG-TERM SURVIVORS OF CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL)
Y.T. Cheung1, Y. Mzayek1, W. Liu2, A. Panoskaltsis-Mortari3, T.M. Brinkman1,
C. Kimberg1, D.K. Srivastava2, L.L. Robison1, C.H. Pui4, M.M. Hudson4, K.R. Krull1
1St. Jude Children’s Research Hospital, Epidemiology and Cancer Control, Memphis,
USA; 2St. Jude Children’s Research Hospital, Biostatistics, Memphis, USA; 3University
of Minnesota, Pediatrics-Bone and Marrow Transplantation, Minneapolis, USA; 4St.
Jude Children’s Research Hospital, Oncology, Memphis, USA
Background/Objectives: Limited data are available on associations among chronic
inflammation, oxidative stress and neurocognitive function in long-term survivors of
childhood ALL. This study evaluated these associations in children treated on an
institutional protocol without cranial irradiation.
Design/Methods: Long-term survivors of ALL (n=71; 50.7% male; mean[SD] age
14.3[4.7] years; 7.4[1.9] years post-diagnosis), completed neurocognitive testing at >5
years post-diagnosis. Serum collected on the day of testing was assayed for markers of
inflammation (interleukin-6, tumor necrosis factor-alpha [TNF-α], C-reactive protein
[CRP]) and oxidative stress (oxidized low-density lipoprotein [OxLDL],
myeloperoxidase, and malondialdehyde). Pharmacological and physiological
treatment-related factors were collected during therapy, including serum concentrations
of high-dose IV methotrexate (HD-MTX), plasma homocysteine following HD-MTX,
and dexamethasone, all quantified as area under the curve (AUC). Serum cortisol was
measured once following oral dexamethasone. Spearman’s correlation and
Mann-Whitney U tests were used to assess associations among treatment-related
factors, inflammatory and oxidative stress biomarkers, and neurocognitive function.
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Results: Survivors demonstrated excess impairment (defined as an age-adjusted score
<10th percentile) on two measures of executive function: cognitive flexibility (37.1%)
and verbal fluency (42.9%). Homocysteine AUC was positively correlated with CRP (r
= 0.31; p = 0.012), OxLDL (r = 0.27; p = 0.026) and interleukin-6 (r = 0.27; p =
0.035). Elevated CRP was found in survivors who had impaired cognitive flexibility
(median[IQR] 3759.75 ng/ml [435.84–10309.36] vs. 638.43 [157.25–2198.55]; p = 0.025)
and verbal fluency (2832.80 [253.85 – 9681.45] vs. 584.03 [149.59–1621.56]; p = 0.028),
as compared to survivors without impairment. MTX AUC was negatively correlated
with TNF-α (r = −0.305; p = 0.012) and myeloperoxidase (r = −0.282; p = 0.019). No
association was identified between biomarkers and dexamethasone AUC or cortisol
level.
Conclusion: These findings suggest that homocysteine levels following HD-MTX may
be related to chronic inflammation, which is associated with executive dysfunction in
long-term survivors of childhood ALL. Future research will assess whether the effects
of treatment factors on neurocognitive function are mediated by chronic systemic
inflammation.
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OSTEOPOROSIS IN OSTEOSARCOMA SURVIVORS AND ITS
RELATIONSHIP WITH VITAMIN D GENE POLYMORPHISM
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Pediatric Oncology, Ankara, Turkey; 4Intergen Genetic Center, Department of Genetic
Research, Ankara, Turkey
Background/Objectives: Osteoporosis is an important late side effect seen in cancer
survivors. Polymorphisms in Vitamin D receptor (VDR) gene increase the risk of
osteoporosis. Here we analyzed the relationship between VDR gene polymorphisms
and osteoporosis in osteosarcoma survivors.
Design/Methods: Forty osteosarcoma patients treated in Ankara Oncology Training
and Research Hospital were included the study. Bone mineral density (BMD) of
proximal femur of the non-operated side was measured by dual energy x-ray
absorptiometry (DEXA). Patients were defined as osteoporotic and osteopenic when
BMD z-score was less than -2 and between -1 and -2, respectively. Single nucleotide
change polymorphism in Cdx2, FokI, BsmI, ApaI, TaqI regions of VDR gene were
examined with SNAPshot mini-sequencing technique. The relationship between VDR
genotypes and BMD was evaluated.
Results: There were 24 boys and 16 girls with a mean age of 12.75±3.1 years. In 50% of
patients, the tumor was located in the femur. Patients received CCG94-7921 protocol
(methotrexate+cisplatinium+doxorubicin). Extremity sparing surgery was performed
in 27 patients and amputation in 13. A median 23 months after the end of treatment,
the mean BMD score was -0.93±1.35. Reduction in BMD was present in 45 % of
patients (27.5% osteoporotic, 17.5% osteopenic). Frequency of osteoporosis was higher
in patients having Fok I polymorphic allele than patients with wild FokI genotype (50%
vs. 7.7%, p:0.004). Fifty-five percent of patients having heterozygous or homozygous
ApaI polymorphic allele were osteopenic, while osteopenia was observed only 18% of
patients with wild type ApaI (p=0.038). There were no relationships between the BMD
score and other VDR gene polymorphisms.
Conclusion: Vitamin D and its receptor have an important role in regulation of bone
metabolism. An association between variation in VDR gene and decreased BMD has
been reported. We showed that Fok I and Apa I region polymorphisms in VDR gene
are related with osteoporosis in osteosarcoma survivors.
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A PHYSICAL ACTIVITY INTERVENTION IN SURVIVORS OF CHILDHOOD
CANCER: A PILOT STUDY
A. Le1, H. Mitchell1, L. Balsamo1, J. Rotatori1, J. Fahey2, K. Ness3, N. Kadan-Lottick1
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Background/Objectives: About 70% of childhood cancer survivors develop medical late
effects of previous therapy, many of which can be prevented or mitigated by physical
activity. However, survivors exercise at similar or lower levels than their already
sedentary healthy peers. We studied the 1) feasibility, and 2) effectiveness of a novel
home-based six-month exercise intervention with a motivational activity tracker.
Design/Methods: Pediatric oncology survivors currently 15 years and exercising less
than the U.S. Department of Health and Human Services physical activity guidelines
were enrolled and instructed to wear the Fitbit One (a 4.8 × 1.8 cm motivational
activity tracker) daily for 6 months. Baseline and follow-up evaluations included a VO2
maximum test by cardiac stress test, an Actigraph accelerometer for 7 days, and
self-report surveys.
Results: Of 145 eligible participants, 19 enrolled (13.1% participation rate) with a mean
age of 24.3 ± 5.8 years (range 15-35); 74% were female. Three participants withdrew
with an 84% retention rate. Patients wore the Fitbit an average 19.0±4.7 days/month for
months 1-3, and 15.0±7.9 days/month for months 4-6. Post-intervention, all (100%)
participants “believed that regular exercise will help with long term effects of therapy”
and 92% were inclined to exercise at home. All participants would recommend the Fitbit
to other survivors: 25% suggested patients receive it during therapy and 75% suggested
it off therapy. Overall, cardiorespiratory fitness as measured by VO2 maximum test
increased from 25.7±7.3 ml/kg/min to 27.2±7.0 ml/kg/min, and total weekly moderate
vigorous physical activity increased from 250.6±63.4 minutes to 295.6±133.5 minutes,
but the changes were not statistically significant (p=0.69 and 0.35, respectively).
Conclusion: This pilot study of a motivational activity device demonstrated feasibility
as measured by retention, receptivity, and belief of utility. There was some
improvement in cardiorespiratory fitness and weekly physical activity, though the
results were not statistically significant with this small sample.
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EVALUATION OF IMMUNE RESPONSE AFTER VACCINATIONS
POST-CHEMOTHERAPY IN CHILDHOOD CANCER SURVIVORS
Y.H. Lee1, E.J. Shin2, W.J. Rah2, S. Oh2
1Hanyang University Medical Center, Seoul, Korea; 2Hanyang University Medical
Center, Department of Pediatrics, Seoul, Korea
Background/Objectives: Survivors of childhood cancers are recommended to receive
revaccinations post-chemotherapy, although the universally recommended vaccination
schedule for such children has not been established. We evaluated immune response
following post-chemotherapy vaccinations in childhood cancer survivors.
Design/Methods: The study included 59 patients who had survived at least 5 years
off-chemotherapy without evidence of recurrence. The study patients received hepatitis
B and MMR vaccines since 1 year after finishing chemotherapy according to our
institutional protocol. Immune response to hepatitis B and MMR vaccines was
measured and seropositivity rate and factors hindering immune response to hepatitis B
and MMR vaccines were analyzed.
Results: Among 59 childhood cancer survivors, 41 children received hepatitis B and
MMR vaccines post-completion chemotherapy. Their age was 63±52 (range, 1-206)
months at diagnosis and 90±54 (range, 12-221) months at off-chemotherapy. Fifty
eight percent of patients had hematologic malignancies and 42% non-hematologic
malignancies. The seropositivity for hepatitis B virus was 88%; with higher rate in
non-hematologic malignancies (100%, 18/18) than in hematologic malignancies (78.3%,
18/23) (p = 0.05) and reciprocally associated with the duration of chemotherapy (p =
0.0043). The seropositivity for measles, mumps, and rubella viruses was 61%, 37% and
83% respectively, showing significantly lower response to mumps virus and was not
differ between patients with hematologic malignancies and those with non-hematologic
malignancies. Unlike hepatitis B virus, the duration of chemotherapy did not affect
seropositivity for measles, mumps, and rubella viruses. Ten children who failed to be
immune to any of measles, mumps, and rubella viruses received booster MMR
vaccination which resulted seropositive rates of 77.8%, 60%, 100% respectively.
Conclusion: Longer duration of chemotherapy and hematologic malignancies were
adversely associated with achieving immune response to hepatitis B vaccine, but not to
MMR vaccine. Our results also underline the need for booster vaccinations in no
responders to vaccinations post-chemotherapy in childhood cancer survivors.
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SECONDMALIGNANT NEOPLASMS IN CHILDHOOD CANCER SURVIVORS
IN A PAEDIATRIC ONCOLOGY CENTRE IN SINGAPORE
J.W. Lim1, F.S.H. Yeap2, Y.H. Chan3, A.E.J. Yeoh2,4, T.C. Quah2,4, P.L. Tan2,4
1National University of Singapore, Yong Loo Lin School of Medicine, Singapore,
Singapore; 2National University Health System, Khoo Teck Puat-National University
Children’s Medical Institute, Singapore, Singapore; 3National University of Singapore,
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Background/Objectives: One of the most feared complications of childhood cancer
treatment is second malignant neoplasms (SMNs). This study aims to evaluate the
incidence, risk factors and outcomes of SMNs in a tertiary paediatric oncology centre
in Singapore.
Design/Methods: A retrospective review was conducted on patients diagnosed with
childhood cancer under age 21 and treated or consulted for a second opinion at the
National University Hospital, Singapore, between Jan 1990 and Nov 2013. Case records
of patients who developed SMNs were reviewed.
Results: A total of 1,227 cases of childhood cancers were identified in this 23-year study
period with a median follow-up period of 2.98 years (range: 0-24.06 years). The most
common primary malignancies were leukaemia (46.4%), central nervous system
tumours (11.3%) and lymphoma (11.1%). Fifteen cases developed SMNs and the most
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frequent SMNs encountered was acute myeloid leukaemia/ myelodysplastic syndrome
(n=7). Overall 20-year cumulative incidence was 5.3% (95% CI: 0.2-10.4%). The
median interval period between diagnosis of primary and secondary malignancy was
3.41 years (range: 0.24-18.30 years). Overall 5-year survival rate for SMNs was lower
than that of primary malignancies.
Conclusion: Reduced exposure to radiotherapy may have contributed to a smaller
proportion of secondary solid tumours as compared to Western cohorts. Significant
risks of SMNs were found especially in survivors of childhood ALL and osteosarcoma,
and are likely to be therapy-related. This suggests a need to review our current treatment
protocols in relation to potential pharmacogenetics and genetic predispositions.
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COMMUNICATION ABOUT LATE EFFECTS DURING ROUTINE
FOLLOW-UP CONSULTATIONS BETWEEN PEDIATRIC ONCOLOGISTS
AND ADOLESCENTS: A VIDEO-BASED OBSERVATIONAL STUDY
A. Mellblom1, H. Lie2, L. Korsvold2, A. Finset2, E. Ruud3
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Hospital-Rikshospitalet, Oslo, Norway
Background/Objectives: Survivors of childhood cancers benefit from information about
late effects for optimal health self-management, yet many lack such knowledge. We
investigated 1) to what extent potential late effects were discussed at routine follow-up
consultations with adolescent survivors; 2) to what extent the paediatric oncologists
(P.O.s) informed about late effects.
Design/Methods:We video-recorded consultations with 10 P.O.s and 66 adolescents,
aged 12-20 years, who had been treated for leukaemia (72.7%), lymphoma (21.2%) or
received hematopoietic stem-cell transplantation for a benign disease (7.6%). We
identified and coded discussions of potential late effects during the consultations and
then categorised the amount of information about late effects provided into three levels:
none, basic and extended information.
Results: Potential late effects were discussed in 85% of the consultations. Of these, 71%
were P.O. initiated, and 60% concerned existing health problems. The P.O.s provided
none, basic and extended information about late effects in 41%, 30% and 29% of these
discussions. Consultation length, type of potential late effect (physical vs.
patient-reported and current vs future risk), and P.O. were associated with amount of
information provided, whilst patient’s age, time since treatment and late effect
risk-stratification were not.
Conclusion:We identified a clear bio-medical focus of information practices, and many
missed opportunities to provide information about late effects. The results suggest that
a standardization of information provision practices regarding late effects is needed to
ensure adequate patient education.
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INEQUALTIES IN CHILDHOOD CANCER SURVIVORSHIP
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Background/Objectives: Inequalities in patient-reported outcomes of survivors of
childhood cancers and their supportive care needs are not often investigated and not
well understood. The aims of this study are to identify inequalities in childhood cancer
survivors based on individual-level data, and to investigate inequalities in late effects
among adult childhood cancer survivors.
Design/Methods: Data will be extracted from the National Cancer Registry Ireland on
people under the age of 18 when diagnosed from 1994 through 2012 with invasive
cancer (ICD10 00-C96), excluding non-melanoma skin cancer. This data will be linked
to family socio-economic status (SES) using information on parental occupation at the
child’s birth. Data will be analysed to estimate discrepancies in mortality based on SES.
Additional data will be collected from survivors currently over 18 years of age
(anticipate n=800). Data will be collected on supportive care needs, health-related
quality of life, functional status and cancer symptoms, and Depression Anxiety and
Stress Scale. These survey data will be linked to registry data to provide rich
information on social inequality in childhood cancer survivors.
Results: In 2012 there were 2,356 childhood cancer survivors in Ireland, of which 1,102
are female and 1,254 are male. Of these, 1,186 were 18 or older. The most cancer among
childhood cancer survivors of all ages is lymphoid leukaemia (n=534) followed by
Hodgkin disease (n=259) and brain tumour (n=232). Further data on types of cancer,
discrepancies in survivorship and inequalities in late effects will also be presented.
Conclusion: This study will collect data directly from a large number of childhood
cancer survivors in Ireland. Findings from this study will highlight inequalities in late
effects, providing critical information on the health needs and inequalities among
long-term childhood cancer survivors.
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MOROCCAN CHILDHOOD CANCER SURVIVORS : A MEDICAL AND
DEMOGRAPHIC SURVEY
F. Msefer Alaoui1, N. Benaicha2
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Background/Objectives: Childhood cancer is curable but survivors are at risk of
numerous late effects. Among children treated from cancer between 1978 and 2004 at
the Children hospital of Rabat, 1000 were considered cured by their last news. The
present survey aims to establish a database of Moroccan childhood cancer survivors
and to lay-out a strategy of long-term monitoring in order to improve their outcome.
Design/Methods: The survey type is transversal, exhaustive and descriptive. The data
collected include initial and current medical and demographic status. To reach the
survivors, we have used several means including phone, email, social networks, and
postal mail. The questionnaire was completed by the survivors themselves, their parents
or their physician.
Results: Two hundred and eight survivors’ questionnaires had been gathered until
February 2015; In average, 16 years had passed since the diagnosis. Initial demographic
data are as follows: 77% were under 10 years of age, sex ratio 1.7; 75% have been
diagnosed from 1995 to 2004 and were from urban areas. Initial medical data show that
the majority of patients had acute lymphoblastic leukemia, lymphoma, and
nephroblastoma; almost all patients received chemotherapy, 1/3 was operated and 1/3
irradiated; the great majority has never relapsed. Currently, the survivors are aged from
10 to 44 years, with a good level of education (50 % are more than high school), are
living with their parents (77%), student (36%) or employed (39%), single (78%) and
have physical activity (60%). Medical findings show that 68% of survivors have medical
issues, mostly physical, aesthetic and psychological issues. Six second cancers and five
deaths are found.
Conclusion: This first study on the Moroccan childhood cancer survivors, establishing a
database, is the first step of a long-term follow up strategy, including side effects
prevention, early diagnosis, and adequate treatment in order to improve survivors
outcome.
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ELECTROCARDIOGRAPHY AND ECHOCARDIOGRAPHY ARE BOTH
IMPORTANT IN THE FOLLOW-UP OF LONG-TERM SURVIVORS OF
CHILDHOOD CANCER
M. Pourier1, A. Mavinkurve-Groothuis2, J. Loonen1, J. Bökkerink1, N. Roeleveld3,4,
G. Beer5, L. Bellersen6, L. Kapusta5,7
1Radboud University Medical Center, Department of Pediatrics-Subdivision Hematology
and Oncology, Nijmegen, Netherlands; 2Princess Maxima Center, Pediatric Oncology,
Utrecht, Netherlands; 3Radboud University Medical Center, Department for Health
Evidence, Nijmegen, Netherlands; 4Radboud University Medical Center, Department of
Pediatrics, Nijmegen, Netherlands; 5Tel-Aviv Sourasky Medical Center, Pediatric
Cardiology Unit, Tel Aviv, Israel; 6Radboud University Medical Center, Department of
Cardiology, Nijmegen, Netherlands; 7Radboud University Medical Center, Children’s
Heart Center, Nijmegen, Netherlands
Background/Objectives: Non-invasive screening plays an important role in early
detection of subclinical heart failure after anthracycline treatment for childhood cancer.
Our aims were to describe ECG abnormalities in a group of asymptomatic long-term
survivors of childhood cancer and to determine the agreement between ECG and
echocardiography abnormalities in follow-up.
Design/Methods: ECG and echocardiography were routinely performed in 414 survivors
visiting our center during a period of 4 years. Inclusion criteria were past exposure to
anthracyclines and both an echocardiography and a 12- lead ECG at follow-up.
Exclusion criteria were clinical heart failure, congenital heart disease and use of cardiac
medication. The level of agreement between ECG and echocardiography was calculated
by Cohen’s kappa.
Results: Seventy-four survivors were excluded. The mean follow-up period was 14.5
years (range 5-32 years), while mean age was 21.4 years (range 6-43 years). ECG was
abnormal in 52 patients (15.3%). The most common abnormalities were conduction
disorders and high left ventricle voltages. A prolonged QTc (>0.45 milliseconds) was
found in only 2 survivors, both with a cumulative anthracycline dose above 300 mg/m2.
Echocardiography was abnormal in 44 patients (12.9%), mostly because of mild
valvular abnormalities with normal FS and EF. The level of agreement between ECG
and echocardiography abnormalities was low (kappa=0.10). In the group with normal
ECG and echocardiography compared to the group with abnormalities detected by one
or both methods, the LVIDs/BSA was lower (p=0.03). End systolic wall stress was
higher in the group with one or more abnormalities compared to the group without
abnormalities (62.6 versus 57.6 g/m2, p=0.04). The number of abnormalities was not
related to anthracycline dosage.
Conclusion: ECG and echocardiography abnormalities are quite common in survivors
of childhood cancer. Their level of agreement corrected for chance is low indicating the
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importance of both tests in the long-term follow-up of asymptomatic survivors treated
with anthracyclines.
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AUDIT OF PLATINUM INDUCED OTOTOXICITY IN SURVIVORS OF
CHILDHOOD CANCERS IN LATE EFFECT CLINIC AT TERTIARY CANCER
CENTRE
N. Pradhan1, N. Thacker1, S. Panda1, S. Tandon1, M. Prasad1, G. Chinnaswamy1,
T. Vora1, P. Kurkure1
1Tata Memorial Hospital, Department of Pediatric Oncology, Mumbai, India
Background/Objectives: Ototoxicty is a frequent and dose limiting side effect of
platinum compounds, and is often compounded by other risk factors such as
concurrent cranial radiotherapy (CRT), coexistent ear pathologies, renal impairment
and use of other ototoxic drugs. Aim: To find out the incidence of sensorineural hearing
loss (SNHL) among the survivors ( 2 years after cessation of therapy and disease free)
of childhood malignancies who had received platinum agents and are followed up in
After Completion of Therapy (ACT) clinic at Tata Memorial Hospital, Mumbai.
Design/Methods: ACT clinic database from February 1991 to December 2014 was
analysed for ototoxicity among survivors who had received platinum agents.
Results: Of 1714 survivors enrolled during the period, 269 (15.6%) had received
platinum compounds with or Without CRT. Median age at diagnosis was 4 years
(Range 1 to 30 yrs). Median age at follow up was 14 years (Range 3 to 45 yrs). Male to
female ratio was 1.5:1. 217 survivors received cisplatin, 29 carboplatin and 23 received
both. Twenty one survivors received CRT along with platinum agents. Mean dose of
cisplatin was 348 mg/m2 and carboplatin was 1461 mg/m2. Audiometry data was
available only in 67 survivors as pure tone audiometry (PTA) could not be done in large
cohort of younger (<5 yrs) survivors. Among survivors who received only cisplatin
(n=40) incidence of SNHL was 35%, only carboplatin (n=13) 23% and who received
both (n=14) incidence was 28.5%. With concomitant use of CRT incidence of
ototoxicity was 50%, 33% and 60% respectively in the above group.
Conclusion: Although platinum agents are indispensable part of various
chemotherapeutic regimens for childhood malignancies, sensorineural hearing loss is
major late effect on long term follow up. Detection of ototoxicity in younger survivors
is a challenge and early detection may help in earlier interventions to minimize
developmental delay.
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DOSE REDUCTION IN CRANIAL PROPHYLAXIS IRRADIATION FOR HIGH
RISK CHILDHOOD LYMPHOBLASTIC LEUKEMIA, THE IMPACT ON
OUTCOME: SECI EXPERIENCE
K. Riad1, D. Osama2, A. Ali2
1South Egypt Cancer Institute, Pediatric Oncology, Assiut, Egypt; 2South Egypt Cancer
Institute, Radiotherapy, Assiut, Egypt
Background/Objectives: Pediatric oncologists have steadily reduced the use of this
treatment modality since the late 1970s.But they are reluctant to omit cranial irradiation
from protocols for high-risk patients. When radiation dose was decreased from
2400cGy to 1800 cGy it reduced the neurotoxicity to an acceptable level without
decreased efficacy. Late effects on pituitary function and growth were also reported by
most endocrinologists involved in the follow-up of the cancer survivors [6],they agree
that cranial radiation dose lower than 16 Gy is associated withlower risk of
hypothyroidism development.
Design/Methods: It includes all patients diagnosed as ALL (high risk) in the Pediatric
Oncology department south Egypt Cancer Institute between the years 2000 and 2013.
All patients received Whole Brain Irradiation (WBI) as part of their treatment
protocol.We consider the patient as high risk ALL patients if:-age more than 10
years.-Total leukocyte count more than 50000-Slow early responder to the
induction-Extramedallary presentation of the diseases.The patients will divided to 2
groups: Group A: received 1800cGy whole brain irradiation as a part of treatment
prococol.Group B: received 1200cGy whole brain irradiation as a part of treatment
protocol.
Results: There was no difference in CNS relapse between the two groups (p=0.845). The
1800cGy group showeda significant abnormalities in hypothalamic pituitary axis eg
decreased growth hormone (p< 0.001). decreased thyroid hormones (p< 0.001).
Conclusion: Prophylactic whole brain irradiation if given for high risk ALL the
recommended dose is 1200cGy due to the lower long term endocrinal abnormalities
and no difference in the CNS relapse.
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ACTIVE VIDEO GAMING IMPROVES MOTOR AND PROCESS SKILLS IN
SURVIVORS OF CHILDHOOD BRAIN TUMORS
M. Sabel1,2, A. Sjölund1, J. Broeren3, D. Arvidsson4,5, J.M. Saury6, J. Gillenstrand6,
K. Blomgren1,2,3,7, I. Emanuelson2, B. Lannering1,2
1The Queen Silvia Children’s Hospital-Sahlgrenska University Hospital, Department of
Pediatric Hematology and Oncology, Gothenburg, Sweden; 2University of Gothenburg,
Inst of Clinical Sciences-Department of Pediatrics, Gothenburg, Sweden; 3University of
Gothenburg, Institute of Neuroscience and Physiology-Centre for Brain Repair and
Rehabilitation, Gothenburg, Sweden; 4Lund University, Department of Clinical
Sciences-Faculty of Medicine, Lund, Sweden; 5University of Southern Denmark, Institute
for Sports Sciences and Clinical Biomechanics, Odense, Denmark; 6The Queen Silvia
Children’s Hospital-Sahlgrenska University Hospital, Regional Habilitation Centre,
Gothenburg, Sweden; 7Karolinska Institute, Department of Women´s and Children´s
Health, Stockholm, Sweden
Background/Objectives: Physical activity can positively affect cognitive functions in
humans and neurogenesis in animal models. We hypothesized that active video gaming
(AVG) could: i) improve cognitive functions; ii) improve the execution of activities of
daily living; iii) improve physical functioning, in survivors of childhood brain tumors.
Design/Methods: Children 7-17 years old who completed treatment, including
radiotherapy, for a brain tumor 1-5 years earlier were randomized to either intervention
or waiting-list. After 10 weeks the groups crossed-over. A motion-controlled video
console (Nintendo Wii) was used during the intervention period, for a minimum of 30
minutes/day, 5 days/week. Weekly Internet based coaching sessions were held. Cognitive
tests, motor tests (BOT-2), as well as testing the execution of daily activities (ADL),
using the Assessment of Motor and Process Skills (AMPS) were done before and after
each period, by a blinded examiner. Test scores before and after the intervention were
compared. A parallel group comparison was performed as a sensitivity analysis.
Results: All 13 children (mean age 12.5 years) enrolled in the study (six boys and seven
girls) completed the program. A significant improvement was seen after the
intervention period compared to baseline, in Body Coordination (p= 0.020), and in the
motor (p= 0.012) and process (p=0.002) parts of AMPS. In the parallel group analysis
the improvement in the process part of AMPS remained statistically significant (p=
0.029), but the change in AMPS motor (p= 0.059) or Body Coordination (p= 0.28) was
not. No statistically significant change in the cognitive outcome was seen although there
were trends for improvement in sustained attention (p = 0.090) and selective attention
(p = 0.078).
Conclusion: AVG, used as an enjoyable home-based intervention for survivors of
childhood brain tumors, improved body coordination as well as motor and process
skills in ADL after a 10 week AVG period.
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LATE EFFECTS OF TREATMENT IN SURVIVORS OF CHILDHOOD
CANCERS : SINGLE CENTER EXPERIENCE
R. Seth1, S. Seth2, S. Sapra3
1All India Institute of Medical Sciences, New Delhi, India; 2All India Institute of
Medical Sciences, Cardiology, New Delhi, India; 3All India Institute of Medical Sciences,
Pediatrics, New Delhi, India
Background/Objectives:With refinements in diagnostics and advances in therapeutics
and supportive care the overall survival of childhood malignancy has increased. This is
however at the cost of increased morbidity in the form of various long/late effects of
cancer treatment. Comprehensive studies assessing the whole spectrum of late effects
and their impact on the social, health and professional life of these survivors are still
lacking from developing economies. We report data from a cohort of 300 childhood
cancer survivors being followed at our pediatric cancer survivor clinic.
Design/Methods: Retrospective evaluation of case records was done. Details of primary
diagnosis, treatment received were noted. Details of remission/relapse, growth and
Myocardial function were obtained. Pulmonary function assessment thyroid profile,
hearing and vision assessment was done where indicated. IQ assessment and psycho
social assessment was also done. Transfusion related hazards were assessed. Details of
second malignant neoplasm were noted and grades of disability recorded. Details of
social adjustment into home, school, society were recorded.
Results: Commonest cancers include Hodgkin lymphoma, acute lymphoblastic
leukemia and retinoblastoma. Eleven patients relapsed. Two second malignancies were
recorded .69 patients had minimal disability (growth impairment), 39 had moderate
disability (majority due to HBSAg positivity), 1 had grade 3 (mental retardation) and
one died of liver disease (grade 5). Intelligence was affected and behavioral
abnormalities identified. 25% patients had height less than 3rd centile. Hypothyroidism
was seen in 2. Azoospermia was seen in one. Only three patients (4%) were found to
have asymptomatic mild myocardial dysfunction.
Conclusion: Long term morbidity in childhood cancer survivors is an emerging concern:
the challenge being to improve survival while reducing severity of late effects. Our study
shows that late effects are of concern: Awareness towards the existence of late effects of
cancer therapy is required among parents, patients and health
professionals.
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OBSTRUCTIVE SLEEP APNEA IN SURVIVORS OF PEDIATRIC BRAIN
TUMOURS
M. Valencia1, K. Wang1, C. Samaan2
1McMaster University, Faculty of Health Sciences, Hamilton, Canada; 2McMaster
Children’s Hospital, Pediatrics, Hamilton, Canada
Background/Objectives: Obesity has become an increasingly prevalent condition in
children impacting 42 million children under the age of five today. A pediatric
population at great risk of obesity are survivors of pediatric brain tumours due to
post-treatment endocrine abnormalities. Obstructive sleep apnea (OSA) is a common
comorbidity of obesity and little is known about OSA in survivors of pediatric brain
tumours. The aim of this study was to assess the risk of OSA by evaluating sleep-related
breathing disorder (SRBD) symptoms in survivors of pediatric brain tumours (cases)
compared to non-cancer controls using Chervin’s Pediatric Sleep Questionnaire (PSQ).
Design/Methods: One hundred participants (37 cases and 63 controls) were recruited to
the Canadian Study of Determinants of Endometabolic Health in Children
(CanDECIDE) from a tertiary care centre in Hamilton, Ontario, Canada. Recruitment
was based on the following inclusion criteria: 5 years and older, male or female, history
of surviving a brain tumour or no history of brain tumour, no previous use of
immunosuppressant therapy or steroids, and 2 weeks without active infection.
Participants were assigned an SRBD score using Chervin’s PSQ scoring criteria.
Results: Twenty-seven percent of cases (n=10/37) and 25% of controls (n=16/63) were
identified as overweight or obese (BMI-centile85). Cases had a mean SRBD score of
0.128 (SD±0.131) compared to the mean SRBD score of controls 0.119 (SD±0.110)
(p=0.722). Linear regression correlated an increased BMI-centile to an increased
SRBD score however the results were statistically insignificant (p=0.790).
Conclusion: Numerous case reports have identified SRBD in survivors of pediatric
brain tumours. A cross-sectional case-control study has not been completed. OSA
interventions have been used as a treatment for obesity in the general population and
may be a possible obesity intervention for survivors of pediatric brain tumours. Further
research is needed to determine the risk of OSA in patients who have survived pediatric
brain tumours.
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WELLBEING OF CHILDHOOD BRAIN TUMOR SURVIVORS: WHAT CANWE
LEARN FROM THEIR AFTERCARE AND SCHOOL TRAJECTORIES AND
WHAT ARE THE PARENTS’ PERSPECTIVES?
S. Vanclooster1, S. Genin2, S. Hardonk3, L. Peremans1, J. Van der Werff Ten Bosch4,
J. Bilsen1, P. Paquier2, A. Jansen1,5
1Vrije Universiteit Brussel, Mental Health and Wellbeing Research Group - Faculty of
Medicine and Pharmacy, Brussels, Belgium; 2Hôpital Erasme - Université Libre de
Bruxelles, Service de Neuropédiatrie, Brussels, Belgium; 3Universiteit Hasselt, Discipline
Group Behaviour Communication & Linguistics, Hasselt, Belgium; 4Universitair
Ziekenhuis Brussel, Pediatric Oncology, Brussels, Belgium; 5Universitair Ziekenhuis
Brussel, Child Neurology, Brussels, Belgium
Background/Objectives: Children who survived a brain tumor are more prone to
neurocognitive difficulties and frequent absences at school, often compromising their
educational trajectory. A close monitoring by the school staff is crucial for timely
intervention in case of problems. Unfortunately, most teachers and counselors are not
aware of or informed about these vulnerabilities. Moreover, children are frequently
referred to a professional only when obvious deficits emerge. Contemporary research on
the aftercare and educational trajectories including parental and school perspectives, is
scarce. Recommendations on follow up aimed at the school staff, caregivers and
parents, are needed. We want to identify key events during the aftercare trajectory
exploring experiences, needs and expectations of these children and their parents. In
addition, we focus on the communication between the main care providers, family and
school environment.
Design/Methods: A longitudinal qualitative study is carried out among a group of
children, their parents, caregivers and key figures at school. We conduct semi-structured
interviews and focus groups during two years. Children that are included, have finalized
their treatment and returned to regular elementary school at the start of the study. Data
are analyzed according to the case study design from a phenomenological perspective.
Results: Our preliminary findings reveal that psychosocial difficulties and
neurocognitive sequelae have an impact on the child’s wellbeing and overall
development and are not monitored for in a systematic way, delaying implementation
of appropriate guidance and support. Parents are highly concerned about the
socioemotional functioning of their child. When confronted with poor academic
results, the communication between the key figures is not always sufficient or effective
and expectations, responsibilities and working methods seem to differ.
Conclusion: Drawing on the results, we hope to improve the wellbeing of children who
survived a brain tumor and their families by developing recommendations for the
school staff and care providers involved.
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LEFT VENTRICULARMASS AND AMBULATORY BLOOD PRESSURE –
IMPORTANT FOLLOW-UPMARKERS IN CHILDHOOD CANCER
SURVIVORS
A. Vatanen1, T.H. Ojala2, T. Sarkola2, M. Turanlahti2, T. Jahnukainen3,
U.M. Saarinen-Pihkala1, K. Jahnukainen1
1Helsinki University Hospital-Children’s Hospital-University of Helsinki, Division of
Hematology-Oncology and Stem Cell Transplantation, Helsinki, Finland; 2Helsinki
University Hospital-Children’s Hospital-University of Helsinki, Division of Cardiology,
Helsinki, Finland; 3Helsinki University Hospital-Children’s Hospital-University of
Helsinki, Division of Transplantation, Helsinki, Finland
Background/Objectives: The aim of this study was to investigate left ventricular mass
(LVM) and cardiac function - predictors of cardiovascular morbidity and mortality - in
young adult survivors of childhood cancer treated with intensive induction
chemotherapy regimens followed by myeloablative treatment with hematopoietic stem
cell support.
Design/Methods: Our national cross-sectional study cohort consisted of 19 adult (age
22.7±4.9 years, range 16-30) neuroblastoma (NBL) survivors and 20 age and sex
matched healthy controls. NBL survivors were transplanted during 1984-1999 at the
mean age of 2.5±1.0 years. Indexed LVM, left ventricular (LV) function and volumes
were assessed with Three-Dimensional echocardiography and Tissue Doppler
echocardiography. The cardiovascular risk assessment included history, body-mass
index, fasting plasma lipids, glucose, and 24h ambulatory blood pressure (BP).
Results: Survivor’s indexed LVM was increased compared with healthy controls (33.9
g/m2.7 vs. 28.1g/m2.7, p=0.038). In multiple linear regression analysis, the systolic BP
was positively associated with LVM in NBL survivors. Increased LVM in survivors was
associated with a decrease in both systolic and diastolic LV function. The end diastolic
LV volume was decreased in the irradiated patient group when compared with controls
suggesting myocardial fibrosis related restriction (41.1ml/m2 vs 48.5ml/m2, p=0.004).
Conclusion: LVM is increased in long-term childhood cancer survivors. The treatment
of BP might prevent adverse left ventricular remodeling in these patients.
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THE EFFECTIVE STERILISING DOSE OF RADIATION FOR THE HUMAN
OVARY
T. Kelsey1, H. Wallace2
1University of St Andrews, School of Computer Science, St Andrews, United Kingdom;
2Royal Hospital for Sick Children, Edinburgh, United Kingdom
Background/Objectives: To determine the dose in Gray of fractionated radiotherapy
that will reduce the fixed and non-renewing population of immature eggs in the human
ovary to below the threshold at which premature ovarian insufficiency (POI) ensues.
Design/Methods: Age at treatment, RT dose and age at occurrence of POI were
recorded from subjects (n = 6, median age at treatment 12.6 years, range 4.9 – 15.1
years) receiving Total Body Irradiation (TBI) as conditioning treatment for a stem cell
transplant. These data were analysed to derive a formula that gives the proportion of
immature eggs after a given dose. Solving this formula in conjunction with a model of
the decline of the non-growing follicle pool with age determines whether the dose is
sufficient to reduce the immature egg population to below 1,000 for 97.5% of the female
population at the age of treatment.
Results: The formula is log10 (NGF) = 2 – 0.141(dose), where NGF denotes the
percentage of non-growing follicles present at age at treatment and dose denotes the
radiation in Gy delivered to the ovary. Given that 97.5% of human ovaries contain
540,000 immature eggs at 5 years of age, 440,000 immature eggs at 10 years, and
330,000 immature eggs at 15 years, we report exemplar effective sterilising doses of 19.2
Gy at age 5, 18.6 Gy at age 10, and 17.8 Gy at age 15.
Conclusion:We show that if the dose of radiation to both ovaries is known, it is
possible to calculate the effective sterilising dose of radiation for the human ovary. It
therefore remains important for the radiation oncologist to calculate the dose received
by the ovary furthest away from the radiation field. Knowledge of the effective
sterilising dose provides important information for counselling females about their
future reproductive potential and the potential need for fertility preservation.
Posters: Liver Tumours
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PEDIATRIC HEPATOCELLULAR CARCINOMA: A 23-YEAR EXPERIENCE AT
A SINGLE INSTITUTION IN ARGENTINA
M.L. Cosentini1, P. Flores2, V. Ayarzabal2, A. Bosaleh3, M.T. De Dávila3,
W. Cacciavillano1, P. Zubizarreta1, A. Rose1, A. Rizzi4
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1Hospital de Pediatría J.P. Garrahan, Hematology an Oncology Department, Buenos
Aires, Argentina; 2Hospital de Pediatría J.P. Garrahan, Surgery Department, Buenos
Aires, Argentina; 3Hospital de Pediatría J.P. Garrahan, Pathology Department, Buenos
Aires, Argentina; 4Hospital de Pediatría J.P. Garrahan, Radiology Department, Buenos
Aires, Argentina
Background/Objectives: Hepatocellular carcinoma (HCC) in childhood is rare, less than
0.5 % of all pediatric malignancies. Is the second most common primary liver
malignancy of childhood after hepatoblastoma. Surgical resection remains the mainstay
of treatment. To report the 23-year experience of pediatric patients (pts) with HCC
treated at a single Institution in Argentina following the guidelines of SIOPEL- trials.
Design/Methods:We retrospectively analyzed 41 consecutive pts with diagnosis of HCC
admitted at our Institution from January 1990 to December 2013.
Results:M/F: 1.4:1.Nine pts (22 %) had underlying disease (UD): Autoimmune
Hepatitis type1 (2pts), Familiar Cholestasis (1 pt), Tyrosinemia (1 pt), Hepatitis chronic
(1 pt), Cryptogenic cirrhosis (1 pt), Tyrosinemia and Fanconi Syndrome (1 pt),
Glycogenosis Type 1 (1 pt), and Ataxia telangiectasia (1 pt). Median age at diagnosis:
121 months (19 -209), and 79 vs 148 months with or without UD.Most common
symptoms were abdominal mass: 54% and abdominal pain: 34%. Median onset of
symptoms: 2 months (1 - 32). Median serum AFP levels: 221.590ng/dL (14 - 1.226.040),
elevated in 68%. PRETEXT (pretreatment extent of disease): available in 38/41.
PRETEXT I: 16, II: 21, III: 31.5 and IV: 31.5%. Multifocal tumors: 51%. Vascular
involvement: 34%. Metastatic disease: 27% (all lung metastasis). Twenty four pts (58%)
underwent surgery, liver transplantation 10, and resection 14 pts. 55% received
quimioterapy before surgery. All patients who did not undergo surgery procedure died.
With a median follow up of 11 months (2.9-80.88), 5-year Overall Survival was 22 %,
for the whole group, and 45% vs 6%, for localized vs metastasic disease respectively
(p=0,0001).
Conclusion: HCC in children is associated with poor survival, mainly among metastatic
disease and unresectable liver tumors. In contrast to adults series, in only 20%
underlying diseases could be identified. Innovative therapeutic approaches are needed
to improve the outcome.
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RETROSPECTIVE STUDY ON PROGNOSIS OF CHILDREN
HEPATOBLASTOMA IN BEIJING TONGREN HOSPITAL FROM 2006 TO 2014
H. Dongsheng1, Y. Zhang2, W.L. Zhang2
1Beijing Tongren Hospital-Capital Medical University, Beijing, China; 2Beijing Tongren
Hospital-Capital Medical University, Pediatrics Department, Beijing, China
Background/Objectives: Hepatoblastoma (HB) is a rare malignant solid tumor, but is
the most commonly liver malignant tumor in children.study on clinical therapy and
prognosis of children hepatoblastoma with comprehensive treatment through analysis
the morbidity characters and isk factors.
Design/Methods: In this study, a total of 102 hepatoblastoma subjects were collected
from September, 2006 to June, 2014. Clinical record and follow-up information of these
subjects was also obtained to conduct the Kaplan-Meier survival analysis and log-rank
test.
Results: (1)In 102 cases, the median age of the subjects was 1.5 years. According to
clinical stage standard in CCG-POG: 4 cases of II stage, accord for 3.9%, 46 cases of
III stage, accord for 45.1%, 52 cases of IV stage, accord for 51.0% . pathological type:
63 cases of epithelial, accord for 69.24%, and 28 cases of mixed, accord for 30.76%
(2)In 102 cases, 52 cases were complete remission (CR), 51%, and 20 cases were partly
remission (PR), 19.6%, and 28 cases were dead, 27.4% after comprehensive treatment.
Follow up to January 2015, average follow up time were 27.54±19.95)months, 2-year
total survival rate was 76.54%, 3-year EFS was 60.5%. 81 cases of followed up time
were more than 12 months. In 81 cases, 5-year average survival time was 71.1 months,
and 95% credible interval was 61.15-80.9 months by analysis on kaplan-merine. 3
Event-free survival (EFS) of II stage were: 100%,100%,0, 3-year EFS of III stage were
100%,71.4%,62.5%,0%,100%,100%, and 3-year EFS of IV stage were
66.7%,25%,33.3%. 3 EFS of IV stage with metastasis was 51.2%, and 3-year EFS of
AFP less than <100ng/dl was 50%.
Conclusion: the distant organs metastasis, hepatic portal vein, central venous invasion
was still important prognostic factors. It should be noted as well as younger children
with early disease, AFP obvious increase in cases of early disease for reduce the relapse
rate.
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SUCESFUL TREATMENT OF UNDIFFERENTIATED SARCOMA OF THE
LIVERWITH SURGERY AND CHEMOTHERAPY
J.M. Eguiguren Leon1, P. Astudillo2, G. Sanchez3, C. Vicuña4, M. Eguiguren5,
E. Villanueva6
1Hospital Solca-Hospital Metropolitano, Pediatric Hematology-Oncology, Quito,
Ecuador; 2Hospital Metropolitano, Pediatric Surgery, Quito, Ecuador; 3Hospital Solca,
Hematology-Oncology, Quito, Ecuador; 4Solca Hospital, Pediatric Surgery, Quito,
Ecuador; 5St. Joseph’s Children´s Hospital, Pediatrics, Paterson, USA; 6Solca Hospital,
Pediatric Hematology-Oncology, Quito, Ecuador
Background/Objectives: Primary malignant hepatic tumors in children are rare,
accounting for less than 2% of childhood cancers. Undifferentiated sarcoma of the liver
(USL) constitutes the third most common after hepatoblastoma and hepatocellular
carcinoma. We review our cases and present their treatment.
Design/Methods: Patient 1: In May, 2000, an asymptomatic 6 years-old girl presented
with an abdominal mass. Ultrasound and CT scan disclosed a cystic hepatic tumor in
the left lobe. Transaminases were elevated, bilirubin and AFP were normal. The
diagnosis of Hydatid cyst was considered. A complete surgical resection was done and
the diagnosis of USL was rendered. She received chemotherapy. Patient 2 presented in
May 2012 at 9 years of age with progressive abdominal pain, malaise and fever. CT scan
disclosed a mixed solid/cystic hepatic tumor with evidence of necrosis. She underwent
total tumor resection and chemotherapy. Patient 3 is a 7 years–old boy with abdominal
pain, he had a history of mild trauma and the pain increased progressively. He
developed abdominal distention and underwent a partial resection of an hepatic tumor
and was refered to our care in June 2014. He is undergoing chemotherapy and is
scheduled for a second look surgery. All patients were treated with this chemotherapy
protocol: Three cycles of PIAV alternating with 2 cycles of VAIAPIAV: Cisplatin 90
mg/m2 day 3,24, Ifosfamide 3g/m2 day 1,2,22,23,43,44, Doxorubicine day 43,44 and
Vincristine 1.5 mg/m2 weekly VAIA: Vincristine 1.5 mg/m2 weeks 1 to 4 and 7,
Dactinomycin 0.5 mg/m2 daily for 3 days 1-3 and 43-45, Ifosfamide 3g/m2 days
1,2,22,23,43,44 and Doxorubicine 40 mg/m2 days 22 and 23.
Results: The patients are alive, two of them off therapy for 15 and 2 years.
Conclusion:With this aproach we have had good results in our patients. It is necesary to
implement an international trial in order to standardize the treatment of USL.
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PHOTODYNAMIC EFFECTS OF CURCUMIN ON PEDIATRIC
HEPATOBLASTOMA AND HEPATOCELLULAR CARCINOMA CELLS LINES
N. Bortel1, S. Armeanu1, E. Schmid1, S. Warmann1, J. Fuchs1, V. Ellerkamp1
1University Hospital Tuebingen, Pediatric Surgery and Pediatric Urology, Tuebingen,
Germany
Background/Objectives: Curcumin, the yellow dye derived from the roots of turmeric, is
a promising agent complementary oncology. The former low oral bioavailability of
curcumin was overcome by a micellar formulation with high concentrations of
curcumin e.g. in experimental pediatric hepatocellular carcinoma in vivo. The recent
study analyzed the photoactive properties of curcumin on hepatoma cell lines in vitro.
Design/Methods: Hepatoblastoma cell lines (HuH6, HepT1) and hepatocellular
carcinoma cell lines (HepG2, HC-AFW1) were treated with curcumin with increasing
concentrations, the cultures were either kept in the dark or exposed to blue light (480
nm). Analysis of cell viability was performed in MTT-tests. Cellular oxidative stress was
analyzed measuring the production of reactive oxygen species (ROS). Reduction of
cancer stem cells population (CSC) by cisplatin, by curcumin alone, or by curcumin
with PDT, was investigated with FACS analyses.
Results: In all cell lines IC50 were significantly lower after blue light exposure than after
curcumin alone (p < 0.001, two-way ANOVA). Blue light exposure resulted in
significant ROS production in all cell lines. Curcumin alone reduced HEK-6D6 positive
CSC not as effectively as cisplatin alone or as curcumin with PDT.
Conclusion: Considering the strong potential of reducing viability and the proportion
of cancer stem cells in hepatoma cells lines, curcumin may be developed as a potential
photodynamic agent as well as a chemotherapeutic agent in pediatric solid liver tumors.
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CISPLATIN ALONE IN THERAPY OF STANDARD-RISK HEPATOBLASTOMA:
FEASIBILITY OF SIOPEL-3 SR PROTOCOL IN RUSSIA
D. Kachanov1, A. Filin2, R. Moiseenko1, A. Usychkina1, V. Roschin3, G. Tereschenko4,
E. Feoktistova4, S. Talypov5, T. Shamanskaya1, G. Novichkova1, S. Varfolomeeva1
1Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
Immunology named after Dmitry Rogachev, Department of Clinical Oncology, Moscow,
Russia; 2Acad. B.V. Petrovsky Russian Surgery Research Center, Department of Liver
Transplantation, Moscow, Russia; 3Federal Scientific and Clinical Center of Pediatric
Hematology Oncology and Immunology named after Dmitry Rogachev, Department of
Pathology, Moscow, Russia; 4Federal Scientific and Clinical Center of Pediatric
Hematology Oncology and Immunology named after Dmitry Rogachev, Department of
Radiology, Moscow, Russia; 5Federal Scientific and Clinical Center of Pediatric
Hematology Oncology and Immunology named after Dmitry Rogachev, Department of
Surgery, Moscow, Russia
Background/Objectives: Hepatoblastoma is a most common primary liver malignancy
of childhood. Risk-adapted therapeutic approach resulted in significant
de-intensification of therapy in certain subgroup of patients. The purpose of this study
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was to analyze patients with hepatoblastoma treated according to SIOPEL protocols in
two centers in Russian Federation.
Design/Methods: Thirty two patients with malignant liver tumors were treated during
the period 01.2012 - 12.2014. Hepatoblastoma was diagnosed in 24 (75.0%) patients.
Initial work-up included chest computed tomography (CT), abdomen CT and magnetic
resonance imaging (MRI), alpha-fetoprotein (AFP) level. The pretreatment extent of
disease (PRETEXT) system was used for staging. SIOPEL criteria were used to stratify
patients to standard and high-risk group. Patients were treated according to SIOPEL
treatment strategy. Fifteen (62.5%) patients were stratified to standard-risk group. Two
patients received more than one drug and were excluded from the analyses.
Results: Thirteen (54.2%) patients received cisplatin monotherapy. Median age was 11.5
months (range 0.1-37.0). Seven (53.8%) patients were < 1 year. Male: female ratio was
0,44:1. Initial diagnosis was based on histology (11/13, 84.6%) or clinical data (2/13,
15.4%). Median AFP level was 349,160 (range 847-1,971,991). Distribution of patients
by PRETEXT stage was the following: I - 2 (15.4%), II - 10 (76.9%), III - 1 (7.7%).
Response was observed in 12/13 patients, in 1 (7.7%) case the therapy was switched to
high risk protocol. Surgery was done in all 12 patients after the 4th cycle and resulted in
R0 resection. 11/12 patients received 6 planned doses of cisplatin. In 1 patient two
postoperative doses of cisplatin were omitted because of postsurgical complications.
All patients are alive with no evidence of disease. Median time of follow-up was 14.5
months (range 3.8 – 28.5).
Conclusion: The introduction of PRETEXT system allowed reducing the therapy
intensity in 50% patients with hepatoblastoma while maintaining high efficiency of
therapy.
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HEPATOBLASTOMA; A SINGLE CENTRE EXPERIENCE FROM A
DEVELOPING COUNTRY
M. Khan1, A. Qazi1, A. Rao1, F. Hanif1, A. Syed1
1Shaukat Khanum Memorial Cancer Hospital Lahore, Surgical Oncology, Lahore,
Pakistan
Background/Objectives: Hepatoblastoma is the commonest liver malignancy in
children. Complete surgical resection is the main goal of treatment and a prerequisite
for cure. Early detection, thorough diagnostic assessment and modern imaging
modalities are helpful in achieving the goal of complete surgical resection. Management
becomes even more challenging in a developing country with limited resources, poor
framework of healthcare system and understanding of disease.
Design/Methods:Medical records of patients with hepatoblastoma treated between
2005 and 2015 were retrieved from the hospital data base and analysed retrospectively.
Diagnostic labs including serum alph fetoprotein level (AFP), radiological imaging,
tissue diagnosis technique, histology, staging details, treatment protocol and surgical
details were recorded. Finding of repeat CT recorded for the surgical planning. The
main outcome variable was survival. Results were analysed using Statistical Package for
Social Sciences (SPSS 17).
Results: A total of 17 patients were treated during this period. Majority of them were
males 13 (77%). More than 60% of the patients were less than 2 years at presentation.
All the patients received chemotherapy according to SIOPEL. Three patients had
metastatic disease at presentation and died while on chemotherapy while two were lost
to follow up (presumed dead). Those patients who underwent surgery (n=12) the
overall survival was 75% (n=8) after a mean follow up of 33 months. Out of the 4
observed mortalities, one developed lung metastasis, two had incomplete resection and
developed local recurrence while one died due to adjuvant chemotherapy related issues.
All those patients who are alive had a complete surgical resection. One patient had
significant disease involving couinaud’s segment 4-8 underwent associated portal vein
ligation with liver partition for staged hepatectomy (ALPPS). This patient had
complete resection of tumour and did not suffer liver insufficiency.
Conclusion: Long term overall survival is determined by complete surgical resection.
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IMPACT OF LIVER TRANSPLANTATION ON SURVIVAL OUTCOMES OF
HEPATOBLASTOMA
K.N. Koh1, J.K. Suh1, S.W. Lee1, S.H. Oh1, K.M. Kim1, J.M. Namgoong2, D.Y. Kim2,
H.J. Im1, J.J. Seo1
1Asan Medical Center-University of Ulsan College of Medicine, Pediatrics, Seoul, Korea;
2Asan Medical Center-University of Ulsan College of Medicine, Pediatric Surgery, Seoul,
Korea
Background/Objectives: Liver transplantation (LT) permits long-term survival of the
patients with unresectable hepatoblastoma, whose outcomes are extremely dismal
without LT. This study was to analyze the outcomes of hepatoblastoma, highlighting
on the impact of LT.
Design/Methods:We retrospectively analyzed the medical records of 64 children with
hepatoblastoma treated at Asan Medical Center between 1991 and 2014. LT program
for hepatoblastoma started at Asan Medical Center in 2007. Twenty-nine and 35
patients were treated before and after 2007, respectively.
Results: According to the PRETEXT staging system, 3 patients were PRETEXT I, 31
were II, 13 were III, and 17 were IV. Twenty-five patients had distant metastases at
diagnosis. Of 64 patients, 5 underwent primary tumor resection, and 59 patients
received preoperative chemotherapy, followed by tumor resection (including LT in 12
patients). The 5-year overall survival (OS) rate was 66.8%. PRETEX stage and
metastasis at diagnosis were significantly associated with OS (PRETEXT I vs. II vs. III
vs. IV: 100% vs. 79.7% vs. 55.9% vs. 43.9%, P = 0.004; no metastasis vs. metastasis:
79.6% vs. 47.1%, P = 0.026). The 5-year OS after 2007 was significantly better than that
before 2007 (80.7% vs. 55.2%, P = 0.045). The prognostic impact of PRETEXT stage
was observed only before 2007, and not after 2007 (PRETEXT I vs. II vs. III vs. IV:
100% vs. 73.3% vs. 50.0% vs. 14.3% before 2007, P = 0.008; 100% vs. 93.8% vs. 60.0%
vs. 67.5% after 2007, P = 0.379). Furthermore, impact of metastasis at diagnosis on
survival tended to be less prominent after 2007 (no metastasis vs. metastasis: 71.4% vs.
40.0%, P = 0.147 before 2007; 83.6% vs. 70.0%, P = 0.405 after 2007).
Conclusion: Our result demonstrated that LT could overcome previously known poor
prognostic factors of hepatoblastoma such as PRETEXT stage and metastasis.
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13 - YEARS EXPERIENCEWITH LIVER TUMOURSMANAGEMENT - SINGLE
CENTRE REPORT
M. Mikeskova1, A. Kolenova1, I. Beder2, Z. Pavlovicova3, J. Puskacova1
1Comenius University Faculty of Medicine, Department of Paediatric Hematology and
Oncology, Bratislava, Slovakia; 2Comenius University Faculty of Medicine, Department
of Paediatric Surgery, Bratislava, Slovakia; 3Comenius University Faculty of Medicine,
Department of Radiology, Bratislava, Slovakia
Background/Objectives: Liver tumors are very rare and constitute only 1-4% of all solid
tumors in children. Two-thirds of these tumors are malignant. The most common
primary malignant tumors are hepatoblastoma and hepatocellular carcinoma. The
main objective of this report is to present 13 years experience with diagnosis, treatment
and outcome in children with liver tumors at our Department of Pediatric Oncology in
Bratislava. The cornerstone of longterm survival remains complete surgical resection in
liver speciality center. Pre and postoperative chemotherapy increases resectability rate,
decreases the risk of microscopic residual disease as well as local relapse rate.
Design/Methods: In the retrospective study we analysed 16 patients with different types
of liver tumours, mainly hepatoblastoma (HB) and hepatocellular carcinoma (HCC).
The children were treated according the SIOPEL protocols, and after that in a case of
resectability, complete resection of the tumor, liver transplant included.
Results: In the group of the patients with HB (8) complete resection was possible in 6.
In 1 patient primary liver transplant (OLT) was indicated. 5 patients are alive with
follow up 60 - 142 months. 2 patients relapsed (1 after complete resection, 1 after
primary OLT). 1 patient died due to progression on the treatment and 2 patients died
due to relapse after primary resection. In the group of patients with HCC (5), complete
resection was possible in 4 cases, these patients are alive in complete remission with
follow up 44 - 129 months. 1 pt. relapsed after complete resection, curently is alive in
progression of disease, 1 pt. died (non resectable tumour).
Conclusion: In a case of complete resection the outcome was better and those patients
had the chance for cure. The past two decades has brought significant improvement in
managment and outcome for children diagnosed with liver tumors. These
improvements are the results of multidisciplinary approach and international trials.
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LIVER TUMOURS IN CHILDREN; RELATION OF HEPATOBLASTOMAWITH
LOW BIRTHWEIGHT AND INCIDENCE OF HEPATOCELLULAR
CARCINOMA EARLIER IN AGE?
M. Moschovi1, M. Nikolaou1, A. Zampogiannis1, K. Stefanaki2, E. Antoniou3
1University of Athens Medical School, 1st Pediatric Department Hematology/Oncology
Unit, Athens, Greece; 2Aghia Sofia Children’s Hospital, Pathology Department, Athens,
Greece; 3University of Athens Medical School, 2nd Propedieutic Surgical
Department-Laikon Hospital, Athens, Greece
Background/Objectives: The most common types of liver tumors in pediatric patients
are hepatoblastoma (HB, 80%) and hepatocellular carcinoma (HCC, 20%). The
relationship between perinatal characteristics and hepatoblastoma as well as the
outcome of liver tumors is the aim of our study.
Design/Methods: Eleven children with liver tumors who were diagnosed and treated in
our unit were enrolled in our study. The age at diagnosis ranged from 2 months to 5
years for HB(med:12 months) and 7-8 years for HC. Predisposing factors such as
hepatitis B,C, CMV, or metabolic disorders were tested. All patients treated according
to SIOPEL protocol (plus Nexavare, in HCC) and remain in follow up.
Results: 9 cases had HB (3 with stage IV), and 2 HCC. The birth weight of patients was
ranged from 1770gr-3850gr while 6 out of eleven children (66%) had birth weight lower
than 2900gr. The gestational age in 4 cases was also lower than 37 weeks. Predisposing
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factors were not observed in any of our cases with HCC. The a-FP level ranged from
714ng/ml to 418,846.00ng/ml in HB while from 10,520.00ng/dl to 60,500.00ng/ml in
HCC. All cases are in complete first remission. One patient with HCC had reactivation
of the disease. He had a second total resection of the tumour and received Nexavar. He
achieved second remission.
Conclusion: 1) There is an increased risk for hepatoblastoma among children with low
birth weight. 2) No predisposing factors were found in children with HCC. 3) Although
the HCC is usually diagnosed at the age of 10-14 years old, our cases were diagnosed in
the earlier childhood. 4) Surgical resection and the SIOPEL protocol give an excellent
outcome even in stage IV, without radiotherapy.
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LAPAROSCOPIC RESECTION OF LIVER TUMORS IN A CHILDREN
P. Czauderna1, M. Murawski2, M. Losin1
1Medical University of Gdansk, Pediatric Surgery and Urology, Gdansk, Poland;
2Medical University of Gdansk, Gdansk, Poland
Background/Objectives: Laparoscopy for the resection of liver tumours in children has
remained undeveloped in comparison to adults. Most of the indications for pediatric
laparoscopic hepatic surgery have been limited to diagnostic laparoscopy and
laparoscopic biopsy. Over the past ten years, however, laparoscopic liver resections for
pediatric hepatic diseases have been performed successfully, and many case reports have
been published.
Design/Methods: The authors report 4 cases of laparoscopic hepatic resection of benign
tumors in children.
Results: In 2 patients (11-month-old boy and 3-year-old girl) an anatomical resection
was performed (left lobectomy). In another 2 (12-year-boy and l6-year-old girl) a
nonanatomical resection was done. There were no complications and patients were
discharged on postoperative day 4, 5, 5 and 7 accordingly. The postoperative pathology
of the specimens confirmed their benign nature: 1 – haemangioendothelioma infantile,
1 – „nested stromal epithelial tumor”, 2 – focal nodular hyperplasia. The tumors
measured 2,2 cm, 3 cm, 6,5 cm and 5 cm in maximum diameter, accordingly.The
resection margins were disease-free in all cases.
Conclusion: This report demonstrates the feasibility of a laparoscopic hepatic resection
in children. On the other hand, laparoscopic liver resection is challenging and
teamwork and specific training are necessary.
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LIVING-RELATED TRANSPLANTATION OF A LIVER IN CHILDRENWITH
HEPATOBLASTOMA
G. Klymnyuk1, O. Kotenko2, M. Grigorian2, A. Ijovskyi1, O. Belokon1, M. Stezhka
Michael1, A. Popov2, A. Gusev2, A. Grinenko2, D. Fedorov2, A. Korshak2
1National Institut of Cancer, Pediatric oncology, Kyiv, Ukraine; 2National Institute of
Surgery and Transplantology, Pediatric, Kyiv, Ukraine
Background/Objectives:Malignant liver tumors make 1 – 2% of a number of all tumors
of the child age, with yearly incidence of 1,5 cases per million of children aged up to 15
years.
Design/Methods: At the posthoc analysis as of from 2008 to 2014 in Ukraine at the
stage of surgical treatment of hepatoblastomas in children 7 living-related
transplantations of a liver were performed, among them: orthotopic transplantation of
the lateral section of a liver from the live relative donor (mother) was executed to five
patients at the stage of surgical treatment, to one patient - hepatectomy, total
pancreatectomy, gastroduodenectomy, splenectomy, extended lymphadenectomy,
esophagojejunostomy, mesocaval shunting, orthotopic transplantation of the left lateral
section of the liver from the live relative donor (mother) with cava portal transposition,
and the transplantation concerning recurrence of hepatoblastoma after left-sided
expanded hepatectomy was executed to one patient. Average age of children to whom
the living-related transplantation of a liver was carried out made 2,7 years.
Chemotherapy according to the clinical protocol SIOPEL 3 was carried out to all
patients, group of high risk.
Results: The average time of the execution of the operation made 14,5 hours. In the
postoperative period biloma of the resective surface of the graft developed in 1 patient,
it was removed by way of ultrasound-controlled puncture. Complete remission of the
disease was recorded in all 7 patients to whom living-related transplantation of the liver
was executed. The five-year survival rate of patients with hepatoblastoma to whom
transplantation of the liver was executed makes 100%, the five-year survival of the graft
made 100%.
Conclusion: Executing the living-related transplantation of a liver in children with
hepatoblastoma of a liver is a difficult stage of multimodality therapy demanding
considerable material and technical support and it allows to achieve good remote results
statistically authentically.
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THE SIGNIFICANCE OF PIVKA-II TO HEPATOCELLULAR CARCINOMA
PROGNOSIS
S.A. Shamsdin1, M. Zahmatkeshan2, P. Badiee3, Z. Hashemzadeh4
1Gasteroenterohepatology Research Center-Shiraz University of Medical
Sciences-Shiraz-Iran-Professor Alborzi Clinical Microbiology Research Center-Shiraz
University of Medical Sciences-Shiraz-Iran, Gasteroenterohepatology Research Center,
Shiraz, Iran; 2Gasteroenterohepatology Research Center-Shiraz University of Medical
Sciences- Shiraz-Iran, Gasteroenterohepatology Research Center, Shiraz, Iran; 3Professor
Alborzi Clinical Microbiology Research Center-Shiraz University of Medical
Sciences-Shiraz-Iran, Professor Alborzi Clinical Microbiology Research Cente, Shiraz,
Iran; 4Professor Alborzi Clinical Microbiology Research Center-Shiraz University of
Medical Sciences-Shiraz- Iran, Professor Alborzi Clinical Microbiology Research Center,
Shiraz, Iran
Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of
mortality among patients with cirrhosis. Detection of HCC at early stage is critical for
good clinical outcome, as the prognosis of HCC patients is very poor.The present study
was designed to study the role of prothrombin induced by vitamin absent II (PIVKA-II)
in early diagnosis of liver cirrhosis, compared with alpha-fetoprotein (AFP).
Design/Methods: The patients consisted of 45 children with liver cirrhosis and 45
normal children. Female and male ratios in cirrhosis and controls were 24/21 and 26/19,
respectively, and the mean ages were 12.5 and 13 years. Complete clinicopathological
examination was carried out for each children to confirm diagnosis. The serum levels of
AFP and PIVKA-II were determined by the ELISA methods.
Results: The results revealed a significant increase of PIVKA-II and AFP levels in
cirrhosis group, compared to the controls. PIVKA-II showed a significantly higher
increase than AFP level in liver cirrhosis, compared with levels in normal group.
Conclusion: Therefore, PIVKA-II can serve as an important factor in screening high
risk children and early diagnosis.
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PATTERN OF CLINICO-RADIOLOGICAL CHARACTERISTICS AND
RELATED BIOCHEMICAL AND PATHOLOGICAL FEATURES OF
HEPATOBLASTOMA IN A DEVELOPING COUNTRY
F. Yasmin1, C.Y. Jamal2, A. Islam2, M.A. Karim2, A.A. Rahman2, M. Begum2, Z. Ara2,
L.R. Molla2, F. Begum2, R. Siddique2, B. Yeamin2, S.M.R. Rahman2
1BSMMU, Dhaka, Bangladesh; 2BSMMU, Pediatric Hematology and Oncology, Dhaka,
Bangladesh
Background/Objectives: The aim of this study was to describe the clinico-radiological
characteristics and related biochemical and pathological features of hepatoblastoma in
a developing country.
Design/Methods: A prospective observational study was conducted between March,
2010 to July, 20114 in a single tertiary care centre at BSMMU in Bangladesh. The
clinical features, radiological findings and biochemical and pathological changes of
hepatoblastoma were evaluated. Radiological evaluation was by CT scan and serum
alphafetoprotein was done as tumor marker for hepatoblastoma and histopathological
evaluation was done by light microscopy.
Results: During this study periods total 50 patients were diagnosed as hepatoblastoma.
The median age of diagnosis was 4 years, M:F ratio was 3:1. The median time of
diagnosis after onset of symptoms was 8 months (Range – 2 months to 18 months). Of
these patients 90% cases presented with abdominal mass , 95 % abdominal distension ,
30% abdominal pain , 50% anorexia, 20% vomiting , 20% fever , 5% jaundice and 3%
with diarrhoea .Serum alpha fetoprotein was raised in 95% of patients. PRETEXT
staging at diagnosis were 5% stage – I , 15% stage – II , 50% stage – III , 30% stage – IV
and 20% patient had extrahepatic involvement and 30% had pulmonary metastasis at
diagnosis .On histological examination 50% fetal type , 10% embryonal , 10% mixed
and 30% was anaplastic type.
Conclusion: As Bangladesh is a developing country and poverty is one of the major
problem, the diagnosis of childhood cancer is challenging. In case of childhood
hepatoblastoma there is delay in diagnosis, so highest proportion of patients had
advanced disease at diagnosis and has bad prognosis.
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STUDY ON THE CLINICAL DIAGNOSIS AND TREATMENT OF 52 CASES IV
STAGE HEPATOBLASTOMA IN CHILDREN
Y. Zhang1, W.L. Zhang2, D.S. Huang2
1Beijing Tongren Hospital-Capital Medical University, Beijing, China; 2Beijing Tongren
Hospital-Capital Medical University, Pediatrics Department, Beijing, China
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Background/Objectives: Hepatoblastoma (HB) is a most common malignant liver
tumor in children. The prognosis was very poor while having metastasis with some
diatant organs. Our objection was to study on the clinical experience and prognosis
through analysis the clinical data of IV stage HB.
Design/Methods: 52 cases of IV stage HB were collected and treated in our hospital
from September, 2006 to June, 2014. Study on the clinical efficacy and prognosis factors
by statistics analysis on the chemotherapy efficacy, the rate of tumor relapse, the clinical
remission rate after relapse and the treatment efficacy of different metastasis condition.
Results: In 52 cases, 16 cases were 0-12 months old (30.7%), and 24 cases were 13-36
months old (46.1), and 9 cases were 3-6 years old (17.3), and 3 cases were more than 6
years old (only 5.9%). 40 cases had distant poly organs metastasis, account for 76.9%,
and 12 cases had adjacent organs invaded, account for 23.1%. Followed up to 31rd,
January, 2015, average followed up time was 12.4 months (3-79 months), middle
followed up time was 13 months. 3 years free event survival (EFS) rate was
32.69%(17/52), and 3 years total survival rate was 61.53%,and mortality was 38.46%
(20/52).In 52 cases, 31 cases had relapse during and after treatment, account for
59.61%. 2 years EFS of 31 cases with surgery and chemotherapy was 22.58%, and 3 and
5 years total survival rate (OS) of that was 32.25% and 15%, and average survival time
was (45.23±4.72)months, 95% CI was 35.98-54.48 months.
Conclusion: The clinical efficacy and prognosis of IV stage HB was more poor than
other stage, but the clinical remission still could be improved by personalized
comprehensive treatment methods. Se, we should enhance the treatment confidence for
prolong survival time and improve clinical remission.
Posters: Lymphomas
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VITAMIN D RECEPTOR POLYMORPHISM OF PATIENTS PRESENTING
WITH HODGKIN LYMPHOMA
S. Akpinar Tekgunduz1, A.C. Oren1, C. Bozkurt1, S. Yesil1, H.G. Tanyildiz1,
S. Ceylaner2, S. Toprak1, O. Candir1, G. Sahin1
1Sami Ulus Obstetrics Gynaecology and Pediatrics Training and Research Hospital,
Department of Pediatric Haematology and Oncology, Ankara, Turkey; 2Intergen Genetic
Laboratory, Medical Genetics, Ankara, Turkey
Background/Objectives: It is well known that 1-25-OH vitamin D is inhibiting cell
proliferation, angiogenesis and cell migration, while inducing apoptosis and cell
differentiation. Many in vivo and in vitro studies on various cancer types indicated that
binding of 1,25-OH D vitamin to its receptor (vitamin D receptor-VDR) results
proapoptotic and anticancer effects. VDR polymorphism have been evaluated in
different types of malignancies including breast, prostate, pancreas, colon, bladder,
thyroid, skin cancers and glioma, neuroblastoma, leukemia, non-Hodgkin lymphoma.
In aforementioned tumor types, mostly Cdx2, Fox1, Bsm1, Apa1 and Taq1
polymorphisms of VDR have been studied. Higher frequencies of certain VDR
polymorphism in patients with cancer compared to healthy controls, suggest that these
polymorphisms may in fact play a role in development of cancer. According to our
knowledge no study evaluated VDR polymorphisms in patients with Hodgkin
lymphoma (HL).
Design/Methods:We compared HL patients with with healthy controls in terms of
VDR polymorphisms. The study included 95 patients with classic HL and 100 healthy
controls. In all participants Cdx2, Fox1, Bsm1, Apa1 and Taq1 polymorphisms of
VDR were evaluated.
Results:We did not observe any statistically significant difference in term of evaluated
VDR polymorphisms between patients with HL and controls. Our results indicate that
Cdx2, Fox1, Bsm1, Apa1 and Taq1 VDR polymorphisms did not seem to play an
important role in development of HL.
Conclusion:We did not observe any statistically significant difference in term of
evaluated VDR polymorphisms between patients with HL and controls. Our results
indicate that Cdx2, Fox1, Bsm1, Apa1 and Taq1 VDR polymorphisms did not seem to
play an important role in development of HL.
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HIGH DOSE CHEMOTHERAPY AND PERIPHERAL HAEMATOPOIETIC
STEM CELLS TRANSPLANTATION FOR YOUNG PATIENTS (AGE 20
YEARS) WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: SINGLE
CENTRE
M. Bayoumy1, J. Zekri1, M.M. Alam1, R. Dada1, M. Kelta1, E.M. Abdelghany1,
J.U. Rehman1, Z.A. Khan1
1King Faisal Specialist Hospital & Research Centre-J, Department of Oncology, Jeddah,
Saudi Arabia
Background/Objectives: The current standard therapy for relapsed/refractory Hodgkin
lymphoma (RR-HL) is salvage chemotherapy followed by high dose chemotherapy
(HDC) and autologous stem cell transplantation (ASCT). This standard is extrapolated
from the results of 2 randomized trials in the adult population. Reports from younger
patient population series can add valuable information. This study reports a single
centre experience.
Design/Methods: All patients aged 20 years with RR-HL and underwent HDC &
ASCT between years 2001 and 2013 were included. Data was collected retrospectively
by the investigators. Relevant imaging was reviewed and reported by an independent
radiologist.
Results: 28 patients were identified and reviewed. Median age was 18 (4-20) years. 15
were males and 13 were females. 23 (82%) patients underwent HDC & ASCT after
achieving radiological response to salvage chemotherapy. The rate of radiological
complete response (CR) to salvage chemotherapy was 10.7% and improved to 46.2%
within 3 months after ASCT. After median follow up of 35 months, 14 (50%) are still
alive with no evidence of relapse or progression. Median EFS was 24 months (95% CI:
9.3-38.7), 3 years EFS was 42% and median overall survival was not reached. CR after
HDC (P=0.01) and serum haemoglobin 10 g/dl (P=0.01) were associated with longer
EFS on univariate analysis. These 2 factors and Time to first relapse (TTR)  12
months were associated with longer EFS on multivariate analysis (P=0.009, 0.009 &
0.02 respectively). One hundred day transplant related mortality was 7%.
Conclusion: The value of HDC & ASCT for younger patients remains to be defined.
TTR and serum haemoglobin predict the outcome. Large scale international
collaboration should identify other predictive factors to better select patients for this
intensive approach.
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RETROSPECTIVE STUDY OF CHILDHOOD BURKITT LYMPHOMA IN
CENTER OF TUNISIA
N. Ammar1, H. Bhiri2, I. Chabchoub2, M.O. Bellmlih2, F. Ezzairi2, I. Belaid2,
M. Hochlef2, O. Gharbi2, L. Ben Fatma2, M. Mokni3, H. Zaghouani4, S. Ben Ahmed2
1Hopital Farhat Hached, Sousse, Tunisia; 2Hopital Farhat Hached, Medical Oncology,
Sousse, Tunisia; 3Hopital Farhat Hached, Pathology Department, Sousse, Tunisia;
4Hopital Farhat Hached, Radiology Department, Sousse, Tunisia
Background/Objectives: Burkitt lymphoma (BL) is a malignant tumor of B-cell
lymphocyte origin and is the most frequent non-Hodgkin lymphoma in children in
Tunisia. This study aimed to describe the epidemiological characteristics and survival
of children presenting with BL in the center of Tunisia.
Design/Methods: This retrospective study reviewed all pediatric cases of Burkitt
lymphoma confirmed by histology between 1994 and 2014. The patients were treated
with the LMB 89, LMB 96 and LMB 2001.
Results: A total of 39 patients with Burkitt lymphoma were analyzed. Their age ranged
from 2 to 16 years (mean of 6.5 years). The male to female ratio was3.3. According to
Ann Arbor Classification, 21 of them (54%) had III stage disease, 9 (23%) had IV stage
disease and the most common primary site was the abdomen (82%). The majority of
patients (87%) were treated with the LMB 89 protocol with three therapeutic arms A, B
and C respectively in 0%, 94% and 6% therapeutic group disease. All patients had grade
4 hematologic toxicity. Lysis syndrome was observed in two cases after the first cycle of
COP which indicated to re-challenge another cycle of COP. Four children (10.4%) died
(two after hematologic toxicity, one by his cancer and one par another cancer). Thirty
four patients (87%) achieved complete clinical remission and all of them were alive at
the last contact. The overall survival rate was 87%. No late sequel was noted.
Conclusion: Our findings confirm the favorable prognosis of children with Burkitt
lymphoma with multi agent chemotherapy. Outcome needs a further challenge for
decreasing intensity and duration of therapy especially in patients with central nervous
system involvement and medullary infiltration.
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A COLLABORATIVE PROTOCOL FOR NEWLY DIAGNOSED INDIAN
CHILDHOOD HODGKIN LYMPHOMA PATIENTS
A. Mahajan1, M. Kalra1, V. Dinand2, R. Arora3, S. Jain4, J. Chandra5
1Indraprastha Apollo Hospital, Pediatric Hematology Oncology, New Delhi, India; 2Sir
Ganga Ram Hospital, Pediatric Hematology Oncology, New Delhi, India; 3Max
Super-Speciality Hospital, Medical Oncology, New Delhi, India; 4Rajiv Gandhi Cancer
Institute, Pediatric Oncology, New Delhi, India; 5Kalawati Saran Children’s Hospital,
Pediatrics, New Delhi, India
Background/Objectives: Previous information on childhood Hodgkin lymphoma in
India has been restricted to a few single centres reports, mostly retrospective in design
with non-uniform approaches to stratification, chemotherapy and radiotherapy. The
Indian Childhood Hodgkin Lymphoma collaborative protocol (ICHL-1) is an initiative
to overcome these limitations.
Design/Methods: The study team developed a protocol which was scientifically sound,
locally acceptable and deliverable, stratified for risk, accounted for late effects, and
considered treatment cost and risk of abandonment. A systematic review of published
and grey literature of relevant studies from India was undertaken, along with a survey
of treatment practices at treating centres in India. The initial protocol was reviewed by
national experts in paediatric oncology, radiation oncology, pathology and nuclear
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medicine. The final draft was reviewed by international experts from resource-rich and
resource-limited settings. The primary aim was to develop a protocol to prospectively
collect data on staging, risk-stratification, management, outcomes and to form a
standardised therapeutic strategy with regards to chemotherapy, radiation and
late-effects monitoring.
Results: A prospective, observational protocol ICHL-1 was developed. It evaluates
ABVD chemotherapy, used in a risk-stratified fashion: early stage patients will receive 4
ABVD cycles, and advanced stage patients 6 cycles. Guidelines for consolidative
radiation therapy (involved-field radiotherapy reserved for bulky disease and
slow/non-responders) and follow-up are given. Till date 23 centres have joined the
protocol. The newly structured Indian Pediatric Oncology Group has been approached
to register ICHL-1 under their umbrella of studies. Ethics approval is ongoing in
individual centres and recruitment is expected to start in spring 2015.
Conclusion: A prospective, observational ABVD-based protocol for management of
Hodgkin lymphoma in Indian children has been successfully developed and found
acceptance. This is the first step in improving standards of care in managing this disease
in India, thus improving outcomes and stimulating research.
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THE ROLE OF ANTHRACYCLINES IN THE TREATMENT OF ENDEMIC
BURKITT LYMPHOMA
E. Molyneux1, E. Schwalbe2, G. Chagaluka3, K. Banda3, T. Israels4, S. Depani5,
K. Mittermayer-Vassallo3, K. Windebank6, J. Mvula1, J. Njiram’nadzi1, P. Carey7,
S. Bailey6
1College of Medicine, Paediatrics, Blantyre, Malawi; 2University of Northumbria,
Applied Science, Newcastle upon Tyne, United Kingdom; 3Queen Elizabeth Central
Hospital, Paediatrics, Blantyre, Malawi; 4VU Medical Centre, Paediatric Oncology,
Amsterdam, Netherlands; 5Royal Marsden Hospital, Paediatric Oncology, London,
United Kingdom; 6Newcastle University, Child Health, Newcastle upon Tyne, United
Kingdom; 7Royal Victoria Infirmary, Haematology, Newcastle upon Tyne, United
Kingdom
Background/Objectives: Endemic Burkitt lymphoma is the most common childhood
cancer in Malawi, one of the world’s poorest countries. At the Queen Elizabeth Central
Hospital in Blantyre approximately 100 children present annually with this disease.
Children are treated on a 28 day regime using cyclophosphamide, vincristine,
prednisolone and intrathecal methotrexate with an event free 1 year survival rate (EFS)
of 48%. Children presenting with stage 3 and 4 disease however had poor one year EFS
of 24% and 32% respectively. In an attempt to improve the outcome for higher stage
disease doxorubicin (60 mg/m2/dose) was added in week 2 and 4 of the regime.
Design/Methods: The event free and overall one year survival for 76 children treated for
Burkitt lymphoma on the updated protocol were analysed. In addition univariate
analysis of other clinical and co-morbidities were performed.
Results: The one year EFS of children presenting with stage 3 and stage 4 Burkitt
lymphoma were 53% and 55% respectively, compared with 24% and 32% in the
previous protocol which was identical except for the addition of doxorubicin at day 21
and 28. No significant increase in toxicity was seen with the addition of doxorubicin.
Univariate analysis demonstrated an improvement in EFS with decreasing total white
blood cell count prior to day 15 of chemotherapy (Hazard Ratio 1.24 (95% CI 1.08 –
1.42) p=0.003).
Conclusion: Anthracyclines play an important role in the treatment of children with
higher stage endemic Burkitt lymphoma. These results also suggest that in the
Malawian setting the benefit of increasing dose intensity for higher stage disease may
outweigh the risk of increased toxicity.
P-299
POST KIDNEY TRANSPLANT EBSTEIN-BARR VIRUS ASSOCIATED DIFFUSE
LARGE B CELL LYMPHOMA: A SUCCESS STORY
F.B. Cakir1, R. Tuna2, A. Dogan Demir2, F. Oktem3, B. Zulfikar4, R. Kebudi4
1Bezmialem Vakif University, Pediatric Hematology Oncology, Istanbul, Turkey;
2Bezmialem Vakif University, Pediatrics, Istanbul, Turkey; 3Bezmialem Vakif University,
Pediatric Nephrology, Istanbul, Turkey; 4Istanbul University Cerrahpasa University
Medical Faculty, Pediatric Hematology Oncology, Istanbul, Turkey
Background/Objectives: Posttransplant lymphoproliferative disorder (PTLD) is a
serious complication of organ transplantation that represents an uncontrolled
proliferation of lymphoid cells. Epstein-Barr (EBV) is closely involved in the
pathogenesis of PTLD. We present a patient, who developed Epstein-Barr virus
(EBV)-related PTLD in the abdomen after renal transplantation.
Design/Methods: A 10-year-old girl with chronic renal failure underwent a renal
transplantation. She was EBV-seronegative and under EBV prophylaxis. After one year
of posttransplantation, she had a pelvic mass in the periodic abdominal screening.
Results: Tru-cut biopsy of the lesion resulted in diffuse large B-cell lymphoma that was
compatible with PTLD. We stopped all immunosupressive agents other than
prednisolone. Rituximab was initiated before chemotherapy administration. Partial
response (60% regression) was achieved after four doses of Rituximab. Low dose
chemotherapy consisting of six courses of cyclophosphamide, vincristine and
prednisolone was applied with four more Rituximab doses. The mass totally resolved
and she is in full remission and under follow up for six months.
Conclusion: PTLD is one of the most important complications of organ
transplantation. Even with treatment, the mortality rate is high. Various treatment
approaches have been used. Rituximab and low dose chemotherapy deserves
mentioning in achieving succesful outcome.
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DIAGNOSIS,TREATMENT AND OUTCOME OF PATIENTS WITH BURKITT
LYMPHOMA IN AUCKLAND ,NEW ZEALAND FROM JANUARY 2000 TO
DECEMBER 2014
T. Oliver1, P. Morreau2, L. Teague3, R. Cockcroft3
1School of Medicine-University of Auckland, Auckland, New Zealand; 2Starship
Children’s Hospital, Department Paediatric Surgery and Urology, Auckland, New
Zealand; 3Starship Children’s Hospital, Starship Blood and Cancer Centre, Auckland,
New Zealand
Background/Objectives: To determine the effect of Rasburicase R© (Urate oxidase) in
prevention of tumour lysis syndrome (TLS) and the correlation with serum chemistry
parameters. To document surgical interventions and complications and outcome in
these patients.
Design/Methods: A retrospective chart review was performed on 29 patients.Data
collected included histology, molecular biology, serum chemistry levels, presenting site,
surgical interventions, treatment and outcome.
Results: There were 20 males & 9 females in this group, of European(15), NZMaori(7),
Samoan(2), Tongan(4), and Asian(3) descent. There were 13 Abdomen, 4 head and
neck, 1 stomach, 1 CNS with secondary kidney involvement, & 1 mediastinal site of
presentation. Only 4/29 had Burkitt Leukaemia. There were 7 lymph node biopsies
performed in the oropharyngeal region. There were 14 biopsies taken from solid
masses; 1 was a mediastinal mass and 13 were abdominal masses. In the majority of
patients, (22/29) bone marrow aspirates and trephines were utilised as
staging/diagnostic procedure. Surgical complications occurred in 7 of the patients. Four
were related to the line insertions and 3 patients had complications relating to surgery.
Biochemical data determined that 20/29patients were at risk of developing TLS and 15
received Rasburicase R© treatment. The 3 patients that did not receive Rasburicase R©
required multiple days’ worth of allopurinol treatment. No information was available
on 1 patient & another patient received no TLS preventative treatment.
Conclusion: The results showed that Rasburicase R© is effective in preventing the onset of
TLS. Allopurinol alone was not as effective at normalizing calcium levels after the 1st or
2nd cycle of Chemotherapy (COPADM1).Surgical complications were limited and no
death occurred during or following surgical interventions. Four patients (2 stage III and
2 stage IV patients) with refractory or recurrent disease passed away (EFS 9.5 months
median). The 25/29 remaining patients continue in 1st CR 10 – 180 months after
treatment (m= 60).
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HODGKINS DISEASE: A SURVEY OF CHILDREN AND ADOLESCENT
TREATED AT A SINGLE INSTITUTION
R. Deebajah1, M. Tawfeq2, F. Bazzeh2
1King Hussein Cancer Center, Amman, Jordan; 2King Hussein Cancer Center, Pediatric,
Amman, Jordan
Background/Objectives:We implemented a risk-adapted, gender-based approach to
treat children and adolescents with Hodgkin lymphoma (HL) in our center.
Design/Methods: Data of HL patients treated at King Hussein Cancer Center (KHCC)
between July2006 until January2015 was retrospectively analyzed. During the study
period, we adapted a risk stratification system according to stage, presence of B
symptoms and bulk of disease. Patients were stratified to Low Risk (LR) group, treated
with 4 cycles of ABVD; Intermediate Risk (IR) group, treated with 4 cycles of ABVD
followed by 2 cycles of COPP or COPDac according to gender; and High Risk (HR)
group, treated with intensive regimen that was adjusted according to response.
Radiotherapy was omitted in LR and IR patients demonstrating rapid early response
(RER).
Results:We identified 173 children (101 Males) in this study. Median age at diagnosis
was 12.7 years (range, 3.2 to 17.9). Stage distribution was as follows: stage I (10%),
stage II (46%), stage III (27%), and stage IV (17%). Fifty patients had bulky disease and
77 had B-symptoms. Patients were stratified LR (35%), IR (31%) and HR (34%) groups.
The 5- year EFS and OS were 92% ±2.5% and 99% ±0.7%, respectively. No patients
died of treatment toxicity and one patient developed secondary AML. The 5-year EFS
of patients in different risk groups were as follows: LR (90% ±4.3%);IR (93% ±3.9%)
and HR (92% ±4.9%) with no statistically significant difference (P=0.89). We couldn’t
identified prognostic factors using log-test.
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Conclusion: Hodgkin lymphoma patients treated at KHCC have excellent outcome
regardless of their risk group. Omission of radiotherapy is safe in LR and IR patients
with RER. Treatment intensification in HR patients was feasible and resulted in
excellent cure rates.
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INITIAL RESULTS OF A PROSPECTIVE PILOT STUDY EVALUATING
FEASIBILITY AND UTILITY OF ECG-GATED CT ANGIOGRAPHY FOR
CORONARY-SPARING RADIATION THERAPY PLANNING IN PEDIATRIC
HODGKIN LYMPHOMA
R. Funk1, M. Blanchard1, E. Williamson2, P. Young2, C. McCollough2, A. Tasson1,
S. Leng2, S. Childs1, N. Laack1
1Mayo Clinic, Radiation Oncology, Rochester, USA; 2Mayo Clinic, Diagnostic
Radiology, Rochester, USA
Background/Objectives: Cardiovascular morbidity and mortality is common among
survivors of mediastinal Hodgkin lymphoma (HL) treated with radiation therapy (RT).
Toxicity data suggests that mean heart doses of less than 15 Gy and 25 Gy are sufficient
to cause accelerated atherosclerosis and valvular disease, respectively. Dose to cardiac
substructures likely influence toxicity but most RT plans evaluate heart as a single
structure. ECG-gated CT angiography (E-CTA) could allow for accurate RT dose
calculation and possible dose reduction to critical heart structures.
Design/Methods: After providing informed consent, patients receiving RT for
mediastinal HL underwent E-CTA in breathhold in addition to conventional
breathhold imaging. E-CTA was used to identify cardiac vessels and valves, accounting
for position on both diastolic and systolic phases. Target and organ-at-risk (OAR)
structures (including heart) were contoured on conventional imaging. Two volumetric
intensity-modulated arc RT plans were generated for each patient. A conventional RT
(CRT) plan was generated by optimizing target and OAR dosimetry without heart
substructure constraints. A coronary-sparing RT (CSRT) plan was optimized with the
same target coverage normalization but with coronary and valve structure constraints
included. OAR D0.03cc (an estimate of maximum dose to a structure) and V15Gy
(volume of a structure receiving 15 Gy or more) were calculated.
Results: Four patients with HL underwent RT planning as above. Patient characteristics
include median age 15.7 (range 14.6-16.9), Stage IIA (n=2), IVA (n=1), or IVB (n=1)
HL with complete response (n=3) or partial response (n=1) after chemotherapy.
Average D0.03cc and V15Gy for CSRT vs CRT plans, respectively, were: left main (14.1
vs 17.8 Gy and 0.02 vs 0.66 cc), left anterior descending (13.7 vs 16.6 Gy and 0.01 and
1.20 cc), and aortic valve (18.6 vs 19.4 Gy and 2.7 vs 5.9 cc).
Conclusion: RT planning using E-CTA was feasible and decreased dose to cardiac
structures compared to conventional planning.
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CLINICAL OUTCOME OF CHILDRENWITH HODGKIN LYMPHOMA AFTER
CHEMOTHERAPY ALONE- THE RED CROSS CHILDREN’S HOSPITAL
EXPERIENCE
G. Chagaluka1
1University of Cape Town-Red Cross Children’s Hospital, Haematology and Oncology,
Cape Town, South Africa
Background/Objectives: To assess the efficacy of hybrid chemotherapy protocol for
Hodgkin lymphoma.
Design/Methods: The 35 accessible documents of patients treated for Hodgkin
lymphoma between 2005 and 2012 at Red Cross Children’s Hospital, were reviewed to
evaluate overall survival (OS), Event free survival (EFS) and cause of death. The
protocol used included chlorambucil, vinblastine, prednisolone, procarbazine
(ChlVbPP) alternating with adriamycin, bleomycin, vincristine, dacarbazine (ABVD).
Relapsed or refractory patients received six courses of etoposide, prednisolone,
ifosfamide and cisplatin (EPIC) with involved field radiotherapy (IFRT). Autologous
stem cell transplant (ASCT) was treatment of choice for patients who had poor
response to the first four courses of EPIC.
Results:Median age was 9.5 at diagnosis and 25 (71%) were male. Two (6%) patients
were HIV infected. The cervical region was the commonest site of primary disease and
14 (40%) had bulk disease. Seven (20%) had bone marrow involvement and Stage IV
disease was recorded in 11 (31%) patients. Twenty two (63%) had Nodular Sclerosing
histology. Thirty one were alive, including two lost to follow up in remission, including
two patients with Stage III disease who relapsed off treatment and were salvaged. One
Stage IV patient died soon after admission, and four Stage IV patients had refractory
disease, one of whom was salvaged with EPIC, ASCT and IFRT. OS and EFS were
87% and 79% respectively for the whole study group. OS for stage I, II and III was
100% declining to 59% in Stage IV (p=0.02). EFS was 100% for stage I and II, 68% for
stage III, 55% for stage IV (p=0.02).
Conclusion:Hybrid chemotherapy is associated with good outcome in stage I, II and III
Hodgkin disease. Refractory Stage IV disease remains a problem and earlier evaluation
with a view to adopting alternative strategies is warranted.
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USE OF F-18-FLUORO-2-DEOXY-D-GLUCOSE POSITRON EMISSION
TOMOGRAPHY / CT IN THEMANAGEMENT OF PAEDIATRIC
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE
P. Guerra-García1, S. Hirsch1, D. Levine2, M.M. Taj1
1The Royal Marsden Hospital, Paediatric Oncology, London, United Kingdom; 2The
Royal Marsden Hospital, Nuclear Medicine, London, United Kingdom
Background/Objectives: Post-transplant lymphoproliferative disease (PTLD) may arise
following transplantation secondary to immunosuppression.
F-18-Fluoro-2-deoxy-glucose positron emission tomography/Computed Tomography
(PET/CT) is an imaging modality useful in the staging and evaluation of treatment
response in adult and paediatric lymphoma. Our objective is to evaluate the use of
PET/CT in paediatric PTLD.
Design/Methods: Paediatric patients diagnosed with PTLD referred to our institution
between July 2002 and October 2014 (n=13) were reviewed retrospectively. Those who
had undergone PET/CT at diagnosis and/or follow-up were included.
Results: Seven patients were identified. Four were male, median age 6.3 years (range
1.8-14.5). Six patients were post-solid-organ transplant while one patient had non
transplant-related immunodeficiency. Monomorphic disease was present in 6, with
extranodal disease in 4. All except one were Epstein-Barr virus positive. Mean
follow-up was 43 months (range 8-99), although 2 patients were lost to follow-up.
Patients were treated with a combination of reduction in immunosuppression,
chemotherapy ± rituximab. Four patients had PET/CT at diagnosis. All lesions seen
with staging CT were identified. All seven patients had at least one PET/CT during
follow-up. Five still had FDG-avid lesions, in 3 cases confirmed with biopsy. In one
case, PET/CT showed increased uptake in areas that were unclear on CT alone.
However, in another case PET/CT did not identify additional central nervous system
involvement demonstrated on magnetic resonance imaging. Treatment was continued
for all five PET/CT-positive patients. Five patients had a negative PET/CT, including
two cases where CT alone showed persisting abnormalities of uncertain significance. In
all five patients treatment was stopped and they remain in remission.
Conclusion: In this small cohort PET/CT was found to be a valuable tool in staging and
assessing treatment response in PTLD. It was also helpful in clarifying equivocal
findings on other imaging modalities. Larger cohort studies would better define the
potential role of PET/CT in paediatric PTLD.
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CHILDHOOD HODGKIN LYMPHOMA INMOROCCO: AN
EPIDEMIOLOGICAL STUDY
H. Hami1, A. Arfaoui2, F. Habib3, A. Soulaymani1, A. Mokhtari1, A. Quyou1
1Laboratory of Genetics and Biometry, Faculty of Science-Ibn Tofail University, Kenitra,
Morocco; 2Department of Life Sciences, Royal Institute of Executive Education, Salé,
Morocco; 3Al Azhar Oncology Center, Rabat, Morocco
Background/Objectives: Hodgkin lymphoma (HL) is a rare malignancy in Northern
Africa, with an incidence of 1.4 per 100 000 in 2012. It is the 18th most common cancer
and the 18th leading cause of cancer-related death in both sexes, with an estimated 3
107 new cases of HL (1 758 men and 1 349 women) and 1 698 deaths from HL in 2012
(GLOBOCAN 2012). The aim of this study is to determine the frequency and the
epidemiological characteristics of pediatric Hodgkin lymphoma in Morocco.
Design/Methods: This is a descriptive retrospective analysis of pediatric Hodgkin
lymphoma cases, diagnosed and treated at Al Azhar Oncology Center in Rabat between
1994 and 2004.
Results: There were 18 children under the age of 15 years diagnosed with Hodgkin
lymphoma at Al Azhar Oncology Center, which was 40.9% of all new cases of pediatric
hematologic malignancies and 14.3% of all cancers in children collected during the
study period. More than one-half of the cases were boys, with a male-female ratio of
1.25. The average age at diagnosis was 10.7±3.5 years (range 5-14 years). More than
two-thirds of the cases were diagnosed in children aged 10-14 years (66.7%), while the
highest rates for boys were noted between 5 and 9 years and for girls between 10 and 14
years of age. Among the cases for whom the outcome was known, a 14-year-old girl
died during the study period.
Conclusion: Although rare, cancer in children has a substantial impact on public health
in Morocco. A national cancer registry will assist in better planning, resource allocation
and management including psychosocial support to improve the quality of life of
childhood cancer survivors and their families.
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A RURAL PAEDIATRIC CANCER SERVICE IN CAMEROON - A SUCCESSFUL
TWINNING PROJECT
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P. Hesseling1, F. Kouya2, E.E. Mbanga2, P. McCormick3, P.P. Wharin3, K.E. Edouard2,
P.P. Tih2, G. Mbab2, R.R. Bardin2, P. Achu4, L. Burns5, M. Kruger1
1Stellenbosch University, Paediatric and Child Health Department, Cape Town, South
Africa; 2Cameroon Bapist Convention Health Board, Bamenda, Cameroon; 3Beryl Thyer
Memorial Africa Trust BTMAT, Kettering, United Kingdom; 4Mezam Clinic, Bamenda,
Cameroon; 5World Child Cancer-WCC, Ondou, United Kingdom
Background/Objectives: A Burkitt lymphoma treatment program started at Banso
Baptist Hospital (BBH) in 2003. This was extended to Mbingo (MBH) and Mutengene
Baptist Hospitals (BHM), 400 km away. In 2007 treatment of Wilms Tumour (WT)
commenced, followed by SIOP recommended protocols for retinoblastoma and (RB)
and Kaposi sarcoma (KS), and ad hoc protocols for other cancers.The only available
children’s cancer service in Cameroon was at Chantal Biya Hospital in Yaounde.
Design/Methods: Start–up funding was by the Lisa Thaxter Trust, followed by BTMAT,
the NRF, Swiss Cancer League. In 2012 a twinning agreement was signed between the
CBCHB, BTMAT, Stellenbosch University and WCC. Each hospital has a dedicated
research nurse, supervising physician and registry office, using POND. Regular site
visits and expert advice are provided by PBH and PW.Guardians only pay a basic
admission fee. Hospitalisation, investigations, protocol approved drugs and supportive
care is free. Parents/patients are supported with food and public transport. Three rural
parent support groups provide advocacy and do farming projects (chickens, pigs,
maize). A palliative care outreach program commenced in 2013. The research nurses’
duties include counselling, performing basic investigations, chemotherapy
administration, POND registration, long term follow and advocacy. Members of staff
are trained locally and abroad. Each hospital has dedicated beds. Basic laboratory
services (including a resident pathologist), radiology, surgeons, internists and
ophthalmologists are available.
Results: Long term survival in ± 1000 BL patients is 50%. During 2014 our 111 new
patients included BL 55%, RB 19%, WT 9%, other malignancies 17%. New patients live
as far as 400 km distant, and in surrounding countries.Nurses acquired new skills to
provide the backbone of this service.
Conclusion: A South to South collaboration between an academic institution, local
health care providers, research foundations and NGO’s has resulted in an effective, low
cost children’s cancer service in rural Cameroon.
P-307
CAN USE OF PET SCAN REDUCE THE BURDEN OF TREATMENT FOR
CHILDRENWITH HODGKIN LYMPHOMA
G. Kapoor1, S. Jain2
1Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India; 2Rajiv Gandhi Cancer
Institute and Research Centre, Pediatric Hematology & Oncology, Delhi, India
Background/Objectives: Current treatment paradigms can cure most children with
Hodgkin lymphoma, even in the developing world. In India, ABVD remains the most
preferred chemotherapy regimen. This is due to its good tolerance despite its known
cardiac and pulmonary late effects. PET scans are expensive and have become available
only in recent years. This study was planned to evaluate if the additional cost of PET
scan can be justified by reduction in burden of therapy.
Design/Methods:Medical records of 148 children <18 yrs of age, treated between 1998
and 2013 were reviewed. In the pre PET scan era, most patients received six cycles of
ABVD with involved field radiotherapy being reserved for bulky or residual disease.
Burden of treatment was assessed by number of cycles of chemotherapy and use of
radiotherapy.
Results:Median age of the 140 evaluable patients was 9 years (range 2-18 years),
11(7.8%) were girls and mixed cellularity was the commonest histology 71(51%). B
symptoms, bulky disease and advanced stage was observed in 24(17%), 58(41%), and
79(56%) patients respectively. PET scans were available for 30/140 patients whose
demographic and disease characteristics were similar to the remaining cohort. Fewer
patients received radiotherapy in the PET subgroup, (4/30,13% versus 37/110,33%,
p0.02). They also received fewer (<6) chemotherapy cycles (10/30, 33% versus 16/110,
14%, p0.04). The 5 year overall and event free survival of the subset with and without
PET scan was 90% and 79% versus 91% and 86% (p,0.8) respectively and median follow
up was 60 months.
Conclusion: Trends of this small analysis suggest that better response assessment with
PET scans are likely to lead to reduction in burden of therapy while maintaining
excellent survival in pediatric Hodgkin lymphoma. This should encourage pediatric
oncologists in developing countries who often tend to over treat due to fear of
abandonment at relapse.
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CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF
PERIPHERAL T-CELL LYMPHOMA IN CHILDREN AND ADOLESCENTS
K.N. Koh1, D. Lee1, J.K. Suh1, S.W. Lee1, H.J. Im1, J.J. Seo1
1Asan Medical Center-University of Ulsan College of Medicine, Pediatrics, Seoul, Korea
Background/Objectives: Peripheral T-cell lymphoma (PTCL) is rare non-Hodgkin
lymphoma (NHL) which is usually associated with an inferior outcome to those of
B-cell lymphomas. Data in children with PTCL are particularly rare, and optimal
therapy has not been defined. This study was to analyze the clinical characteristics and
treatment outcomes of children with PTCL.
Design/Methods: In this study, we retrospectively investigated 19 cases of PTCL
diagnosed at the Asan Medical Center from 1995 to 2014. The clinical characteristics,
treatment results, and outcomes were reviewed. Those with isolated cutaneous T-cell
lymphoma and anaplastic large cell lymphoma were excluded from this analysis.
Results: According to the World Health Organization (WHO) PTCL classification, 10
patients had PTCL, not otherwise specified (PTCL-NOS), 7 had extranodal natural
killer/T-cell lymphoma, nasal type (ENKL), 1 had subcutaneous panniculitis-like T-cell
lymphoma and 1 had angioimmunoblastic T-cell lymphoma. Patients with PTCL-NOS
were treated with various multi-agent chemotherapeutic regimens designed for T-cell
acute lymphoblastic leukemia and NHL. Of 7 patients with ENKL, 4 received up-front
radiotherapy, followed by multi-agent chemotherapy. Two patients with relapsed
PTCL-NOS underwent allogeneic hematopoietic stem cell transplantation (HSCT) and
autologous HSCT, respectively, and 1 patient with relapsed ENKL underwent
autologous HSCT. Of the 19 patients, 7 (36.8%) died from disease progression, and
there was no treatment-related mortality. The 5-year overall and event-free survival
rates were 73.7% and 50.0% in all cases, 80.0% and 56.1% in PTCL-NOS, and, 71.4%
and 28.6% in ENKL, respectively.
Conclusion: Although children with PTCL experienced frequent relapse, many of them
could be rescued by salvage treatment, resulting in comparable overall survival
outcomes to other NHL. Multi-center trials are required to refine the prognostic factors
in PTCL and further confirm the outcome of PTCL in children.
P-309
TREATMENT RESULTS OF ANAPLASTIC LARGE CELL LYMPHOMA IN
CHILDREN AND ADOLESCENTS ACCORDING TO "MODIFIED ALCL-BFM
2003 PROTOCOL": SINGLE CENTER EXPERIENCE
A. Levashov1, T. Valiev1, E. Belyaeva1, A. Popa1, A. Kovrigina2, G. Mentkevich1
1Pediatric Hematology and Oncology Institute N.N.Blokhin Russian Cancer Research
Center, Hemoblastoses Chemotherapy, Moscow, Russia; 2National Reserch Center for
Hematology, Department of pathology, Moscow, Russia
Background/Objectives: The results of anaplastic large cell lymphoma (ALCL)
treatment in children and adolescents are not satisfactory in comparison with other
non-Hodgkin’s malignant high-grade lymphomas. According to the data of different
protocols (NHL-BFM 90, CCG5941, SFOP-LM 89/91, UKCCSG, ALCL99
vinblastine, POG APO 9315, AIEOP LNH - 92, AIEOP LNH 97) 5-year overall
survival and event-free survival are not more than 85 and 76%, respectively.
Design/Methods: From 2003 to 2014 years twenty children and adolescents with ALCL
were included in trial «Modified ALCL-BFM 2003». Male/female ratio was 1/1.
Median age - 11.3 years (range from 5 till 17). Stage I-II were revealed in 7 patients
(35%), stage III-IV – in 13 patients (65%), intermediate-risk group (K2) – in 8 patients
(40%), high-risk group (K3) – in 12 patients (60%). Patients without T-cell antigen
expressed ALCL samples received chemotherapy by B-NHL-BFM 95, while patients
with T-cell antigen expressed ALCL samples received chemotherapy by high-risk
courses ALL-IC-BFM 2002 including L-asparaginase. All patients received
maintenance therapy with vinblastine 6 mg/m2 once every 3 weeks during 6 months.
Results: ALK-positive variant ALCL was revealed in 19 out of 20 cases (95%), T-cell
antigen expression – in 12 out of 20 cases (60%), pSTAT3-positive variant ALCL – in 5
out of 7 cases (71%), t(2; 5)( р23; q35) – in 8 out of 9 cases (88%). We have got an
excellent results. Five-year overall survival and event-free survival were 100%, a median
follow-up was 63 months (range from 5 till 145).
Conclusion: «Modified ALCL-BFM 2003» protocol can be regarded as optimal
therapeutic approach in treatment children and adolescents with ALCL.
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PROGNOSTIC INFLUENCE OF C-MYC, BCL2, PSTAT3 EXPRESSION,
GCB/NON-GCB SUBTYPE ON TREATMENT RESULTS OF DIFFUSE LARGE B
CELL LYMPHOMA IN CHILDREN AND ADOLESCENTS
A. Levashov1, A. Kovrigina2, T. Valiev1, E. Belyaeva1, A. Popa1, G. Mentkevich1
1Pediatric Hematology and Oncology Institute N.N.Blokhin Russian Cancer Research
Center, Hemoblastoses Chemotherapy, Moscow, Russia; 2National Research Center for
Hematology, Department of Pathology, Moscow, Russia
Background/Objectives: At the present time results of some pediatric protocols
(FAB/LMB96 with and without rituximab (± R), B-NHL-BFM90/95, B-NHL-2004m)
were published but prognostic significance of markers, such as: non-GCB DLBCL
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subtype, C-MYC, pSTAT3, BCL2/C-MYC coexpression, C-MYC, BCL2/C-MYC gene
rearrangements in childhood DLBCL is unknown.
Design/Methods: From 2003 to 2014 thirty children and adolescents with DLBCL were
included in trial «B-NHL-BFM 95 ± R». Male/female ratio was 2/1. Median age - 9
years (range from 2 till 16). Stage I-II were revealed in 17 patients (56.7%), stage III-IV
– in 13 (43.3%), R1-R2-risk group – in 17 (56.7%), R3-R4-risk group – in 13 (43.3%).
GCB/non-GCB DLBCL subtypes were assessed by Hans, Tally and Visco-Young
immunohistochemical algorithms. Cutoff values of 40% for MYC, 70% for BCL2, 50%
for pSTAT3 were established.MYC gene rearrangement was assessed by FISH using
locus-specific IGH/MYC/CEP8 tricolor dual-fusion probes and locus-specificMYC
dual-color breakapart probes.
Results: GCB/non-GCB DLBCL subtypes were revealed in 10 and 11 out of 21 cases
(47.6 and 52.4%, Hans, Visco-Young), in 11 out of 21 cases (52.4 %, Tally). Ten (71.4%)
out of 14 DLBCL samples were positive for MYC, 7 (36.8%) out of 19 – for BCL2, 2
(18.2%) out of 9 – for BCL2/C-MYC coexpression, 1 (9.1%) out of 11 – for pSTAT3.
MYC gene rearrangement was revealed in 3 (21.4%) out of 14 patients. BCL2 gene
rearrangement was not revealed. Five-year overall survival (OS) and event-free survival
(EFS) were 90 ± 5%, a median follow-up was 57 months (range from 4 till 142). There
is not revealed any influence of investigated markers on OS and EFS.
Conclusion: Number of patients in this study is not enough to estimate authentic
prognostic significance of these markers but high-intensive B-NHL-BFM90/95 ± R
chemotherapy showed good therapeutic effect in our patients. This study will be
continued.
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PAEDIATRIC DOUBLE-HIT LEUKAEMIA: CASE REPORT AND LITERATURE
REVIEW
G. Macey1, J. Hayden1
1Alder Hey Children’s NHS Foundation Trust, Department of Oncology, Liverpool,
United Kingdom
Background/Objectives: Double-hit leukaemias (DHL) with complex abnormalities of
theMYC and BCL2 oncogenes are rare tumours in adult patients and have not been
previously reported in paediatric literature. Here, we present a child with double-hit
leukaemia with a literature review of this rare malignancy.
Design/Methods: A literature search was conducted in PubMed using the terms
“double-hit leukaemia” and “dual-hit leukaemia”, as well as MeSH terms “MYC” and
“BCL2”.
Results: A 7 year-old girl presented with facial and gum swelling, and difficulty walking.
Bone marrow aspirate identified a leukaemic infiltration, but no evidence of central
nervous system (CNS) disease on cerebrospinal fluid (CSF) analysis. Subsequent genetic
analysis showed concurrentMYC and BCL2 translocations; confirming DHL. The
patient was treated with standard chemotherapy for Burkitt/ B-cell leukaemia
according to Group C on the United Kingdom Children’s Cancer Leukaemia Group
(CCLG) guidelines. Chemotherapy resulted in complete disease remission at the
microscopic, cytogenetic and molecular levels. The patient presented 22 days after
completing chemotherapy with a left hemiparesis. An MRI scan identified an
intracranial mass. CSF analysis and bone marrow examination confirmed a combined
marrow and CNS relapse. The patient progressed and died 14 months after initial
diagnosis. In the literature, there are no reports of DHL in children. The combination
of MYC and BCL2 translocations results in uncontrolled proliferation of malignant
cells, and an aggressive clinical phenotype. Bone marrow, extranodal and CNS
involvement is common at presentation and relapse/progression. There is no consensus
on the management of these patients. Prognosis is poor with primary resistance to
chemotherapy or early relapse and median survival of 4.5-18.5 months.
Conclusion: Double-hit leukaemia withMYC and BCL2 translocations in childhood is
a rare entity, associated with a similarly dismal prognosis as reported in adults. Further
research and the development of a novel treatment strategy in this rare disease is
required.
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BURKITT LYMPHOMA PRESENTING AS ACUTE PANCREATITIS -
DIAGNOSTIC PROBLEMSWITH AN UNUSUAL ONSET
L. Maciejka-Kemblowska1, M. Kozlowska1, N. Irga-Jaworska1, M. Niedzwiecki1,
M. Szalewska1, E. Adamkiewicz-Drozynska1
1Medical University of Gdansk, Department of Pediatrics-Hematology and Oncology,
Gdansk, Poland
Background/Objectives: Burkitt lymphoma comprises 30% of non-endemic paediatric
lymphomas. Most patients are characterised by the presence of large abdominal masses,
frequently involving the ileocecal region of the bowel. Involvement of pancreas is a
rather rare manifestation of this neoplasm.
Design/Methods:We are concerned with a case of a 6-year-old boy who presented
pancreatitis and cholestasis. It took 16 days from the first symptoms for the neoplasm
to be diagnosed.
Results: First symptoms of the disease involved mild abdominal pain, icterus, and stool
discoloration. The boy also suffered from lower limbs pain which was initially
interpreted as reactive arthritis after upper respiratory tract infection. Laboratory tests
revealed parenchymal liver damage (ALT 545U/l, AST 129U/l) with signs of cholestasis
(total bilirubin 8,79 mg/dl, conjugated 8,06 mg/dl), and normal liver synthetic function
(albumin 35g/l, prothrombin index 100%). Infectious diseases of the liver were excluded
(HBV, HCV, EBV, HAV). Level of amylase in serum increased up to 245U/l, and in
urine up to 1920U/l. Initial sonography did not reveal any abnormalities. After 7 days
of symptoms onset sonography showed 3-cm lesion in pancreas, which initially was
interpreted as inflammatory lesion. However, 7 days later imaging of the abdomen
revealed significantly enlarged pancreas, 7mm expanded common bile duct, tumor mass
in pelvis 10×5cm, and a 20mm lesion in the right kidney. Pelvic mass penetrated and
filled the spinal canal. Moreover, infiltration of femur was found. On the basis of
histopathologic examination of the tumor, Burkitt lymphoma IV stage with CNS
involvement was diagnosed and chemotherapy according to B-NHL BFM04 was
introduced.
Conclusion: Localisation of Burkitt lymphoma in pancreas is rare and might be
mistaken for acute pancreatitis. Because of its very rapid growth rate, it requires prompt
diagnosis for initiation of proper treatment. Therefore it is essential to consider Burkitt
lymphoma when confronted with a paediatric presentation of any pancreatic mass.
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OUTCOME FROM BASIC PEDIATRIC CANCER RESEARCH IN RESOURCE
LIMITED COMMUNITIES MAKES A HUGE DIFFERENCE
J. Menang1, S. Njimogu2
1CALMEF Health Centre, Children’s Unit, South West Region, Cameroon; 2St. Louis
University of Medicine and Health Sciences, Administration, North West Region,
Cameroon
Background/Objectives: Burkitt lymphoma (BL); the most prevalent children cancers in
Cameroon, is lethal if not treated; but 50% curable with lone cyclophosphamide (CPD)
therapy or combination with methrotrexate. Applying June 2010 - June 2012
cross-sectional community study outcome improving treatment and supportive care.
Design/Methods: Previous survey outcome that was done using questionnaires based on
aspects of palliative care in relation to the cultural views and traditional beliefs of the
community with special attention on paediatric oncology needs has proven to be very
vital in service improvement where this care and support is provided to ascertain
palliative care needs and possible practical interventions.
Results: A huge gap exists between the western palliative care and support approach, to
this community because of their unique super attachment to their cultural views and
beliefs; some of which are not compatible with a typical modern approach. Death rates,
as much as 50% result from the late diagnosis, lack of health units, inaccessibility of
treatment products and more.
Conclusion: Poverty and unhealthy cultures noted as the main hurdle in that, high
percentage of children die at home either due to poverty, parents assumed child’s cancer
cause to superstition, child is taken to a basic health care clinic with no expert to timely
diagnose or any similar reason. The study outcome guided in new treatment, support
and advocacy guidelines. It is difficult to ’copy and paste’ a modern approach to
palliative care and support though it is evidently clear that modern treatment and
support approach remain superb even in this community.
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CHILDHOOD BURKITT LYMPHOMA IN GHANA: A RETROSPECTIVE
STUDY FROM THE PEDIATRIC ONCOLOGY UNIT OF KORLE BU
TEACHING HOSPITAL, ACCRA
U. Offor1, R. Akyea1, J. Neequaye2, L. Renner3, C. Segbefia3
1Korle Bu Teaching Hospital, Paediatric Oncology Unit, Accra, Ghana; 2School of
Dentistry and Medicine-College of Health Sciences-University of Ghana, Child Health,
Accra, Ghana; 3School of Dentistry and Medicine-College of Health Sciences-University
of Ghana, Paediatric Oncology Unit-Child Health, Accra, Ghana
Background/Objectives: Burkitt Lymphoma (BL) is the commonest childhood cancer in
sub-Saharan Africa, where the predominant variant is the endemic type, usually
presenting as a jaw tumor and historically highly chemo-sensitive to single agent
cyclophosphamide or relatively minimal dose combination chemotherapy. We analyzed
the clinical and demographic features of children with BL treated over a 6-year period
at the main tertiary referral hospital in Ghana; a low-middle income country.
Design/Methods: Retrospective review of all confirmed cases of BL at the pediatric
oncology unit, Korle Bu Teaching Hospital between January 1st 2007 and December
31st 2012.
Results: A total of 173 children with BL were diagnosed during the study period with a
mean age of 6.9 years (range = 2-12 years), and a male predominance (male to female
ratio: 1.5:1). The abdomen was commonest site of tumor presentation (46%), while the
jaw was the 2nd commonest tumor site (31%). A significant association was observed
between girls and abdominal tumors (p < 0.05) as well as between boys aged 0-4 years
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and facial tumors (p=0.03). Most children presented with advanced/disseminated
disease (stage 3, 47% and stage 4, 41%). All patients received at least 1 cycle of
chemotherapy with 61% achieving an objective tumor response ( 50% reduction in
tumor size). Forty-three children (25%) died during the course of treatment. Treatment
delays were seen in 85% of all patients, with financial constraint of the families being a
major contributor (75%). Treatment abandonment was observed as a first event in 94%
of patients and two-thirds of children in the study were eventually lost to follow up.
Conclusion:While the demographic characteristics observed in this study remain
consistent with endemic BL, the clinical features are suggestive of a changing pattern in
disease presentation. Delayed health-seeking practices and abandonment of therapy
remain major detriments to patient outcomes.
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DESCRIPTIVE EPIDEMIOLOGICAL STUDY OF CHILDHOOD CANCER IN
PERU PERIOD 1981-2014
G.G. Paredes1, A. Bustinza2
1Rebagiati Essalud Hospital and Ministry of Heath, Oncology and Hematology, Lima,
Peru; 2Rebagliati Essalud Hospital, Hematology, Lima, Peru Background/Objectives:
The epidemiological knowledge of childhood cancer is the main basis for planning health
policies at national level, the cancer a disease that demands a high economic and social
costs for the nation. Describe the epidemiology based on the National Register of the
Ministry of Health (MINSA) and Essalud Hospital.
Design/Methods: Data were obtained since 1981 to 2014 period; children 0 to 18 years ;
incidence rates, mortality rates were estimated, adjusted for age, gender and pathology
and analysis for overall survival period was performed.
Results: Health coverage national is 60% from MINSA and 30% Essalud for 8 millions
of children. Total accumulate 13,072 cases in thirty four years; 84% (11,049) MINSA
and 16% (2,023) Essalud, an incidence of 111 new cases / million children-year. Genre
masculine: 56.4% MINSA and 53.68% Essalud, students from 6 to 14 years (52.5%) in
both institutions.First pathology Leukemia 44% MINSA et 30.98% Essalud ,second
Brain tumors 8% MINSA and 19.42% Essalud, third retinoblastome MINSA 7.8% and
NHL 13.14% Essalud , fourth NHL (6.9%)MINSA and Essalud renal tumors (7.31%),
ranking fifth in both institutions bone tumors, 5.2% .Advance stages Ewing sarcoma
(41.3%), melanoma (33%) and Neuroblastoma (19.9%). Coast population 66.5%
Essalud and 52% MINSA. Mortality 36.3% MINSA and 28.53% in Essalud. The
burden of disease from cancer 48, 960 represent 8% of the global burden of disease.
Survival at 5 years 72- + 4.3.
Conclusion: The reported incidence rate is similar at Europe and America, the mortality
is higher in last stages and now the remission is 75 to 80% through prevention, early
diagnosis and multidisciplinary treatment of childhood cancer with full coverage.
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OUTCOME OF HODGKINS DISEASE IN CHILDRENWITH
CHEMOTHERAPY ALONE IN A RESOURCE LIMITED COUNTRY,
BANGLADESH
A.A. Rahman1, M.T. Ahammed2
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; 2Bangabandhu
Sheikh Mujib Medical University, Pediatric Haematology & Oncology, Dhaka,
Bangladesh
Background/Objectives: Background: Forty Eight children with Hodgkins disease (HD)
treated with chemotherapy alone were studied between January 2004 and December
2010 at the Paediatric Haematology & Oncology, department of Bangabandhu Sheikh
Mujib Medical University (BSMMU). Objective: To assess the outcome of treatment
of HD in all stages with combination chemotherapy alone.
Design/Methods: Study design: Prospective. Patients and methods: Forty eight children
with Hodgkins disease less than 16 years of age were treated at the Paediatric
Haematology & Oncology department of BSMMU with eight cycle of chemotherapy,
with of ABVD (Adriamycin/Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine)
regime on an outpatient basis over a period of 8 months. The following data were
analyzed: age, sex, stage of the disease, histopathological subtypes at diagnosis,
response to therapy, relapses, and early treatment suspension by the patient.
Results: The mean age was 10.3 years (range 3-16). There were 42 males and 6 females
giving a male: female ratio of 7: 1. Mixed cellularity is the commonest histologic
subtype observed in 20 of 48 (42%) patients. Forty two (88%) patients achieved
complete response, 5 (10%) had partial response and one patient did not respond at all.
Three patients (Stages IIA, IIA, IVB) were lost after 2, 6 and 20 months of follow-up.
Fifteen patients (31%) are known to be dead and the rest are alive and tumor free.
Conclusion: ABVD combination should be regarded at the present moment as the
simplest and most effective drug therapy for treating childhood Hodgkins disease.
P-317
OUTCOMEWITH CHEMOTHERAPY (ABVD) ALONE IN PEDIATRIC
HODGKIN’S DISEASE
G. Sezgin1, C. Acipayam1, I˙. Bayram1, A. Tanyeli1
1Cukurova University Medical School, Divivsion of Pediatric Oncology/BMT Unit,
Adana, Turkey
Background/Objectives: To assess the efficacy of chemotherapy alone, using six to eight
cycles of ABVD in all stages of childhood Hodgkin’s disease (HD).
Design/Methods: Between May 1993 and November 2011, charts of 39 Hodgkin disease
patients who received ABVD only were investigated and analyzed retrospectively for
remission and survival.
Results: There were 29 boys and10 girls with a median age of 9 years, 48.7% were less
than 10 years old. 46.1% had advanced stage disease (IIB–IV). B symptoms were
present in 35.9% of cases; bulky mediastinal mass in 3 cases (7.7%); spleen and bone
marrow involvement in 10 (25.6%) and seven cases (17.9%), respectively. Mixed
cellularity (MC) subtypewas found in 38.5%. Complete remission was achieved in 33
patients (84.6%), Six patients (15.3%) relapsed and three (7.6%) patients died on
therapy. The 5-year overall survival (OS) was 88% and disease free survival (DFS) was
80%.
Conclusion: Although our group of patients is small,chemotherapy alone with ABVD,
without additional radiotherapy, provides high rates of durable remission and effective
in childhood HD.
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LONG-TERM RESULTS OF THEMILAN CHEMOTHERAPY PROGRAM FOR
ADVANCED-STAGE BURKITT LYMPHOMA (BL) IN CHILDREN AND
ADOLESCENTS
E. Schiavello1, M. Massimino1, R. Luksch1, L. Bergamaschi1, V. Biassoni1,
M. Casanova1, S. Catania1, S. Chiaravalli1, P. Collini2, A. Ferrari1, C. Meazza1,
M. Podda1, N. Puma1, M. Terenziani1, F. Spreafico1
1Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology and Pediatric
Onco-Hematology, Milano, Italy; 2Fondazione IRCCS Istituto Nazionale dei Tumori,
Department of Pathology and Laboratory Medicine, Milano, Italy
Background/Objectives: The treatment strategy for advanced Burkitt lymphoma (BL)
relays on short-pulse dose-intensive i.v. chemotherapy and intrathecal chemotherapy.
Until 2014 we treated children with advanced-stage BL with a short chemotherapy
program, which was originally designed 25 years ago, remaining unchanged (J Clin
Oncol 2002;20:2783). We seek to monitor the continuing results of this long-lived
protocol.
Design/Methods: Between June 2001-September 2014, 40 additional children with
Murphy stage III (n=24) or IV (n=16) BL were enrolled into the Milan protocol. The
chemotherapy consisted of a 5-week induction based on weekly infusion of
vincristine/cyclophosphamide, doxorubicin, high-dose methotrexate (two courses),
etoposide, alternating intrathecal methotrexate or cytarabine, followed by a
consolidation with high-dose cytarabine/cisplatin.
Results: Patients’ characteristics: 36 were male; the median age was 7 years (range,
3-17); LDH upper normal limits in 32 cases; B symptoms in 16 children; CNS
involvement in 7 children, bone marrow involvement in 12 children (both in 4 cases).
The effective median duration of the whole program was 61 days (range, 45-81 days).
All the patients achieved a complete remission. One toxic death occurred
(cytarabine-related acute heart failure). Four patients relapsed at 3, 3, 5 and 10 months,
respectively, and all subsequently died of progressing lymphoma (two of them had
CNS/bone marrow disease at diagnosis). One further relapse occurred at 29 months,
and the patient achieved cure through repeating the same protocol. At a median
follow-up of 69 months, 4-year overall and disease free survival rates were 87% ±5%
and 86.5% ±6%, respectively. Relapse-free survival was not significantly different
between children classified as stage III (87%) or stage IV (86%).
Conclusion: Our data show that the Milan regimen applied for advanced BL is still
topical, despite originally designed over than 25 years ago, and not including rituximab.
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EVALUATION OF THYROID FUNCTIONS IN PEDIATRIC PATIENTS
TREATED FOR HODGKIN LYMPHOMA
D. Tugcu1, M. Eltan1, A. Ferhan1, G. Aydogan1, M. Demirkaya2, Z. Salcioglu1,
M. Gokce1, A. Akcay1, C. Bayram1, H. Sen1, A. Er3, H. Onal4, A. Irıbas5,
E. Darendeliler5
1Kanuni Sultan Suleyman Education and Research Hospital, Pediatric
Hematology-Oncology, Istanbul, Turkey; 2Uludag University-Uludag Medical School,
Pediatric Oncology, Bursa, Turkey; 3Kanuni Sultan Suleyman Education and Research
Hospital, Radiology, Istanbul, Turkey; 4Kanuni Sultan Suleyman Education and
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Research Hospital, Pediatric Endocrinology, Istanbul, Turkey; 5Istanbul
University-Oncology Institute, Radiation Oncology, Istanbul, Turkey
Background/Objectives:We aimed to evaluate late side effects of chemotherapy and
radiotherapy on thyroid functions treated for Hodgkin Lymhoma in childhood.
Design/Methods: Forty patients, followed and treated between 1994 and 2013, in
Pediatric Hematology-Oncology Unit were evaluated. Demographic features,
histopathologic type of tumor, stage, age at the time of radiotherapy, dose of radiation,
time period after radiotherapy, TSH, free T4, thyroglobulin, antithyroid
peroxydase,calcitonin,thyroid ultrasonography,occurence time of hypothyroidism and
nodules were recorded. Whenever a nodule was detected in thyroid ultrasonography,
scintigraphy was performed followed by a biopsy if indicated.
Results: All patients had radiotherapy and chemotherapy. Thirty four of them(85%)
male and six(15%) were female. Age at diagnosis was 9.45±4.082, dose of radiotherapy
was 21.48±4.48 Gy. In 72.5% of patients, the primary localization was head and neck.
Seven patients(17.5%) had B symptoms and 17 patients(42.5%) had stage III+IV.
Hypothyroidism was detected in twelve(30%) of forty patients (11 male, 1 female).
Thyroid hormone therapy was given to five patients due to clinical
hypothyroidism.None of the patients have hyperthyroidism and thyroid antibody
positivity. There isn’t any significant relationship according to age at the radiotherapy,
time after radiotherapy, radiotherapy doses, stage and hystopathologic type between
the patients with hypothyroidism and without hypothyroidism
(p=0.434,0.45,0.77,0.882,0.479 respectively). Thyroid nodules were detected in 5(3
male, 2 female)(12%) patients with ultrasonography. Biopsy was performed to 3 patients
according to result of USG, thyroglobuline and scintigraphy.
Results:Malignancy wasn’t observed none of them. There isn’t also any significant
relationship according to age, dose of radiotherapy, stage and hystopathologic type
(p=0.709,0.799,0.882,0.432). Time after radiotherapy was longer in patients with
nodules(p=0,049). Time of developing hypothyroidism(n=12) was 3.10±2.02 years and
nodule formation(n=5) was 8.90±7.10 years. Nodule formation time was significantly
longer than development of hypothyroidism (p=0,048).
Conclusion: Pediatric patients treated due to Hodgkin lymphoma have increased risk for
thyroid function abnormalities and long term follow-up was needed.
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IS QUALITY OF LIFE IS BETTER IN PATIENTS WHO RECEIVED
CHEMOTHERAPY AFTER SURGERY IN CASES OF INTESTINAL BRKUIT
LYMPHOMA?
V. Upadhyaya1, B. Kumar2
1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; 2Sanjay
Gandhi Postgraduate Institute of Medical Sciences, Pediatirc Surgery, Lucknow, India
Background/Objectives: Primary tumors of the gastrointestinal (GI) tract are rare in
children and represent less than 5% of all pediatric neoplasms. Non-Hodgkin’s
lymphoma (NHL) remains the most common malignancy of the GI tract in children.
The abdomen is the most frequent onset site of non-endemic Burkitt’s lymphoma.
Three variants have been described. We are presenting our experience with 5 cases of
Burkitt’s lymphoma in pediatric age group in reference to their age of presentation,
clinical manifestation and anatomical location and its management.
Design/Methods:We studied 5 pediatric cases of Burkitt’s lymphoma (BL) of GI tract
from Feb 2011 to March 2014. Following features were noted: extent of disease was
determined by history, physical examination, baseline complete hemogram, liver
function tests, lactate dehydrogenase (LDH) as a tumor bulk indicator, uric acid, serum
electrolytes, bone marrow biopsy, abdominal ultrasound and/or contrast-enhanced
computed tomography (CECT) scan of the abdomen. Quality of life in patients
received chemotherapy after surgery was compared with those who required surgery
during chemotherapy.
Results: In two cases presented with intususception which was resolved with
conservative management, and one case which presented with subacute intestinal
obstruction was managed initially with chemotherapy but required surgical intervention
in between. Where as in one case had presented with intususception with suspected leak
and one case which has featuresof subacute intestinal obstruction was initially treated
by resection followed by chemotherapy. The group of patient which are treated
surgically initially were tolrated chemotherapy better than other group.
Conclusion: Quality of life during chemotherapy is better in patients who received
chemotherapy after surgery than who initially treated with chemotherapy though a
detailed study is required for definitive conclusion.
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EARLY COMPLETE RESPONSE AS A FACTOR OF TREATMENT
REDUCTION IN ADVANCED STAGES PEDIATRIC BURKITT LYMPHOMA
A. Levashov1, A. Popa1, G. Mentkevich1
1Pediatric Oncology and Hematology Research Institute of N.N.Blokhin National Cancer
Center, Hemoblastoses Chemotherapy, Moscow, Russia
Background/Objectives: Progress in treatment of advanced stages Burkitt lymphoma
(BL) is associated with intensive chemotherapy, supportive care and rituximab use.
Current studies investigate clinical and/or biologic features for treatment reduction. By
literature data (C.Patte, 2007) it is possible to reduce treatment for early responding
intermediate risk patients with B-NHL. In our study we reduced treatment for high risk
BL pts.
Design/Methods: Forty one newly diagnosed BL pts with Murphy stage III-IV, 3-4
BFM risk groups were treated according to the r-B-NHL-BFM 95red protocol,
between January 2007 and February 2015. The median age was 8,3 years (range, 3-16),
male/female ratio – 4/1. Rituximab (375 mg/m2) was administrated on day 0 of block
AA and BB. Therapeutic effect was estimated.
Results: 7-year event-free survival (EFS) by r-B-NHL-BFM 95red protocol was
96,6+/-2,4%. Twenty pts (48,8%) achieved early complete response (CR) after 2 blocks
of chemotherapy. The following treatment consisted of blocks CC-AA-BB without
rituximab. Al the 20 (100%) pts with CR are in remission with follow up 78 months.
Twenty one (51,2%) pts did not get CR after 2 blocks of chemotherapy and continued
treatment by protocol without block number reduction (CC-AA-BB-CC). 7-year EFS
was 91,2+/-5,1%. Two (4,9%) pts died: one – of disease progression and another – of
Pseudomonas aeruginosa sepsis.
Conclusion: Our results suggest that early complete response may be an important
prognostic factor for treatment reduction in near 50% of advanced stages pediatric
Burkitt lymphoma. Our results revealed that early responded advanced stages BL pts
have the same excellent results with treatment reduction protocol (from 6 to 5 blocks).
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PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN CHILDHOOD
A. Varan1, I. Bajin1, A. Uner2, B. Aydin1, B. Yalcin1, N. Kurucu1, T. Kutluk1, C. Akyuz1
1Hacettepe University-Institute of Oncology, Department of Pediatric Oncology, Ankara,
Turkey; 2Hacettepe University-Faculty of Medicine, Department of Pathology, Ankara,
Turkey
Background/Objectives: To evaluate the clinical characteristics, treatment regimens, and
outcome of the patients with primary central nervous system lymphoma (CNS).
Design/Methods: Five patients diagnosed with primary CNS lymphoma between 1988
and 2014 were retrospectively evaluated. All patients were treated with chemotherapy
and radiotherapy. Chemotherapeutic regimens included LMB, LSA2-L2 and high dose
cytarabine and methotrexate.
Results: All of the patients were male. The median age was 10 years (5-14 years). Tumor
locations were frontal lobe (1), parietal and temporal lobe (2), thalamus (1),
leptomeningeal (1). All had B cell phenotype. LMB chemotherapy protocol was used in
3 patients, 1 patient was in LSA2-L2 protocol and 1 patient received high dose
cytarabine and methotrexate. Intratechal rituximab was used in two patients. All
patients received radiotherapy. Three patients treated with LMB protocol relapsed and
died while the other 2 patients were on disease-free follow-up.
Conclusion: Primary CNS lymphoma is very rare in childhood. Although high dose
cytarabine and methotrexate seems to be efficient in one patient and LSA2-L2 protocol
is effective in another, our series is small and further studies are needed.
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ROLE OF IL10 PROMOTER POLYMORPHISMS IN THE PATHOGENESIS OF
PEDIATRIC HODGKIN LYMPHOMA
L. Wittmund1, P. Chabay2, M. Cohen2, A. Ferrero3, M.V. Preciado2, E. De Matteo4,
M. Garcia Lombardi3
1Hospital De Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina; 2Hospital De Niños
Dr Ricardo Gutierrez, Molecular Biology, Buenos Aires, Argentina; 3Hospital De Niños
Dr Ricardo Gutierrez, Oncology, Buenos Aires, Argentina; 4Hospital De Niños Dr
Ricardo Gutierrez, Pathology, Buenos Aires, Argentina
Background/Objectives: IL10 is a cytokine involved in anti-inflammatory responses.
Three Single Nucleotide Polymorphisms (SNPs), -1082 (A/G), -819 (C/T) and -592
(C/A) in the gene promoter display differential susceptibility to Hodgkin Lymphoma
(HL) development, Epstein Barr Virus (EBV) susceptibility and treatment
response.Objective: Investigate the role of IL10 gene polymorphisms in HL
pathogenesis as well as EBV involvement in a population from Argentina.
Design/Methods: One hundred thirteen pediatric patients were studied: 64 HL and 49
reactive hiperplasias (RH) as controls. EBV infection was assessed by PCR and EBERs
in situ hybridization, while IL10 promoter polymorphisms SNPs -1082A/G and
-592A/C were genotyped by allele-specific (AS-) PCR. Based on the strong linkage
disequilibrium between SNPs -819 and -592, three crossing AS-PCRs were carried out,
to confirm the haplotypes ACC, ATA and GCC. Clinical outcome in 48 of the 64
patients with HL was analyzed.
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Results: Both SNP-1082 and SNP -592 did not display statistical significant differences
between HL and RH controls (p>0.05, χ2 test). Only the haplotype ACC was
statistically overrepresented in HL versus controls (p=0.011, χ2 test). EBV was
expressed in 65% HL and in 54% RH, and neither genotype distribution of SNPs -1082
and -592, nor IL10 haplotype showed a differential association with EBV+ and EBV-
HL and controls (p>0.05, 2 test). The carriers of the SNPs -592 A/C had lower event
free survival and global survival specifically in the HL group (EFS 62% vs 82% p=0,04/
GS 80% vs 100% p=0,026).
Conclusion: ACC haplotype was associated with increased susceptibility to HL. Even
though the G allele in -1082 and ATA haplotype were protective for EBV primary
infection, this decreased susceptibility was not observed in EBV-associated pediatric
HL. We found statistical significant association between the carriage of SNP -592A/C
and lower survival. Our study highlights the importance of analyzing IL10 promoter
polymorphisms as another prognostic factor.
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ATORVASTATIN REGULATING THE AUTOPHAGY OF LYMPHOMA RAJI
CELL VIA THE PI3K/AKT/MTOR PATHWAY
L. Miao1, T. Rong1, J. Yi1
1Wuhan Univ-Renmin Hospital, Department of Paediatrics, Wuhan, China
Background/Objectives: To investigate the effect of atorvastatin on the autophagy of
human lymphoma Raji cell line, and to explore the signaling pathway in this process.
Design/Methods: Raji cell line was divided into negative control group, atorvastatin
group, LY294002(a PI3K inhibitor) group, rapamycin(a mTOR inhibitor) group, and
they were co-cultured for 24h. The formations of autophagy were observed by acridine
orange staining.The expressions of autophagy protein LC3- II and Beclin-1 were
examined by Western blot. The expressions of phosphorylation of Akt and mTOR
were detected by RT-PCR and Western blot methods, respectively.
Results: Compared with the negative control group, atorvastatin inhibited the
autophagy of lymphoma Raji cell (t=3.972, P<0.05), and down-regulated the
expressions of LC3- II and Beclin-1(t=4.038, P<0.05;t=3.639, P<0.05). Compared
with atorvastatin group, LY294002 group increased the expressions of LC3- II and
Beclin-1(t=4.772, P<0.05; t=2.939,P<0.05); rapamycin group also up-regulated the
expressions of LC3- II and Beclin-1 (t=3.287, P<0.05; t= 4.316,P<0.05).Compared
with atorvastatin group, LY294002 group decreased the mRNA and protein expression
levels of p-Akt and
p-mTOR(t=4.578,P<0.05;t=3.767,P<0.05;t=4.565,P<0.05;t=3.633,P<0.05);
rapamycin group also reduced the mRNA and protein expression levels of p-Akt and
p-mTOR (t=2.916, P<0.05; t=3.815, P<0.05; t=2.995,P<0.05; t=4.079, P<0.05).
Conclusion: Atorvastatin can inhibit the autophagy of lymphoma Raji cell, the
mechanism might be related to the activation of PI3K/Akt/mTOR signaling pathway.
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THE EFFECT OF ATORVASTATIN REGULATING GLYCOLYSIS
METABOLISM PATHWAY ON LYMPHOMA CELL THROUGH TLR4/MYD88/
NF-KAPPA B PATHWAY
L. Miao1, T. Rong1, J. Yi1
1Wuhan Univ- Renmin Hospital, Department of Paediatrics, Wuhan, China
Background/Objectives: To investigate the effect of atorvastatin regulating the glycolysis
metabolism pathway on lymphoma cell line Raji, and explore the role of
TLR4/MyD88/ NF-kappa B signaling pathway in this process.
Design/Methods: Raji cells were incubated with different concentrations of atorvastatin
(0.1μmol/L, 1μmol/L, 10μmol/L), and Raji cells without any treatment were used as
control. The glycolytic rates of Raji were investigated by glucose consumption assay
when cells were cultured for 6, 12, 24 hours. The apoptosis was detected by flow
cytometry after cells incubated for 24 hours. The mRNA expression of HK2, PKM2
and HIF-1 was detected by RT- PCR technique. The protein expression of TLR4,
MyD88 and NF-kappa B was detected by Westernblot method.
Results: The results indicated that atorvastatin could inhibit the glycolytic activity on
Raji cell. When treated with 10 μ mol/L atorvastatin after 24 h, the effect of inhibition
to the glycolytic activity on Raji cell was most strikingly, the glycolytic rates reduced to
(37.92±1.06)% (t=3.975,P<0.05). In addition, atorvastatin could induce the apoptosis
of Raji cells. When treated with 10 μ mol/L atorvastatin, the apoptosis of Raji was
most notably, at a rate of(52.39±2.72)%,(t=3.992,P<0.05).There was basal mRNA
expression of HK2, PKM2 and HIF-1 gene in the control group. When treated with 10
μ mol/L atorvastatin, it showed that the mRNA expression of HK2, PKM2 and HIF-1
was down-regulated most obviously, at a decrease of (51.67±3.89)%,(63.29
±2.69)%,(45.95±4.02)% (t=3.798,P<0.05;t=4.428,P<0.05;t=3.956,P<0.05),
respectively. There was basal protein expression of TLR4, MyD88 and NF-kappa B
gene in the control group. When treated with 10 μ mol/L atorvastatin, it showed that
the protein expression of TLR4, MyD88 and NF-kappa B was decreased most visibly,
with a decline of (61.09 ±5.37)%,(65.47±3.73)%,(49.06
±4.62)%(t=4.615,P<0.05;t=3.773,P<0.05;t=3.292,P<0.05), respectively.
Conclusion:
Atorvastatin can inhibit the the glycolytic activity and induce the apoptosis on Raji cell,
and the mechanism may be associated with the TLR4/MyD88/ NF-kappa B signal
pathway.
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TREATMENT RESULTS OF PEDIATRIC HODGKIN LYMPHOMA:
EXPERIENCE OF SINGLE CENTER FROM DEVELOPING COUNTRY
Ü. Yildirim1, N. Sarı1, Y. Güney2, N. Kurucu3, I˙. Ergürhan I˙lhan1
1Ankara Oncology Hospital, Pediatric Hematology and Oncology, Ankara, Turkey;
2Ankara Oncology Hospital, Radiation Oncology, Ankara, Turkey; 3Hacettepe
University Medical Faculty, Pediatric Hematology and Oncology, Ankara, Turkey
Background/Objectives: The evaluation of clinical characteristics, treatment and follow
up results of patients with Hodgkin Lymphoma (HL) in a developing country.
Design/Methods: Clinical characteristics, treatment and follow up results of 105
children with newly diagnosed HL were analyzed retrospectively.
Results: There were 68 boys (65%) and 37 girls (35%) with a median age of 10.5 (3-17
years). Duration of symptoms was median 120 days (3-1095) and out of 105, 39
patients had B symptoms. The most common histological subtype was mixed cellularity
(52%). The percentage of patients with localized disease (stage l- ll) and advanced
disease (stage lll- lV) were 49 and 51, respectively. The first-line treatments of patients
were DAL-HD-90 (n=41), only COPP (n=31), ABVD (n=27), ABV-COPP (n=5)
protocols. Radiotherapy was administered to 88 (84%) patients. Eleven patients didn’t
receive radiotherapy because of advanced disease and five due to decision of different
consultant doctors. At a median follow-up of 51 months, the 5-year overall (OS) and
event-free (EFS) survival rates of whole group were 84% and 74%. There found a
statistically difference between the groups receiving radiotherapy and not (5-year EFS
78% vs. 45% p=0.01). Patients with stage III-lV disease had significantly lower OS rates
when compared to stage l-ll disease (5-year OS 77% vs. 91% p=0.03). Patients received
radiotherapy in the first-line treatment had significantly higher OS rates then patients
who didn’t receive radiotherapy (5-year OS 90% vs. 52% p=0.001). In multivariate
analysis only radiotherapy was found to be positively correlated with OS.
Conclusion: The treatment approaches applied in our department has successful results
in general, survival rates of patients with advanced disease and treated without
radiotherapy has been shown to be lower when compared to the patients with local
disease and treated with radiotherapy. That’s why we emphasize the necessity of
radiotherapy for the patients with HL.
Posters: Myeloid Leukemias, Myelodysplastic & Myeloproliferative Syndromes
P-327
CLINICAL PROFILE AND OUTCOME OF CHRONIC MYELOGENOUS
LEUKEMIA (CML) AMONG PEDIATRIC PATIENTS IN PHILIPPINE
GENERAL HOSPITAL (UP-PGH): A RETROSPECTIVE STUDY (2008-2013)
M.M. Pedro1, E. Melendres1, A.P. Alcasabas2, P. Fajardo1, M.Y. Lesaca-Medina1
1Philippine General Hospital, Pediatrics, Manila, Philippines; 2Philippine General
Hospital, Manila, Philippines
Background/Objectives: Chronic myeloid leukemia (CML) in childhood is rare
representing 2-3% of pediatric leukemias. At Philippine General Hospital, the country’s
national referral center, the survival rate for pediatric CML was 35% (2002-2005)
without tyrosine kinase inhibitor. Since then Imatinib was made locally available
through the Max Foundation Novartis Glivec International Patient Assistance Program
(GIPAP). We report the outcome of our patients.
Design/Methods:Medical records of pediatric CML patients diagnosed from January
2008-December 2013 were reviewed. Demographic data were collected and outcome
evaluated at study endpoint, November 2014.
Results: Thirty seven patients were diagnosed during the study period. Only 33 charts
were available for review. Ages ranged from 5-18 years (mean 12 ± 5). Splenomegaly
was present in 27 patients (82%). Philadelphia chromosome was documented by FISH
and karyotyping in 25 (76%) and 5 patients (15%), respectively. At diagnosis 24 (73%)
were in chronic phase, 6 (18%) accelerated and 3 (9%) blastic. Only 22 (67%) patients
received Imatinib due to financial constraints. Of these, 20 were chronic and 2 in
accelerated phase. At 3 months, 95% (n=20) achieved complete hematologic response
(CHR); no data (n=2). Twenty eight percent (28%; n=6) had complete cytogenetic
response at 12 months and 12 % (n=3) had major molecular response at 18 months. At
study endpoint, 18% (n=4) achieved complete molecular response but 23% (n=5) had
loss of CHR due to treatment abandonment and 14% (n=3) died of disease. Eleven
patients did not receive imatinib. Of these, 5 died of disease, 5 abandoned hydroxyurea
treatment, and 1 remained with CHR on hydroxyurea. The 6 year overall survival of all
patients (n=33) is 49%, and 73% for those on Imatinib (n=22).
Conclusion: Survival rate among our pediatric CML patients has improved with
imatinib availability. Better compliance and more financial support for disease
monitoring studies are needed to define treatment response.
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DIFFICULTY IN THE DIAGNOSIS OF SMALL ROUND BLUE CELL TUMORS
IN A LOW INCOME COUNTRY. A CLINICAL CASE
F. Arreguin1, S. Hernandez2, B. Almazan2, G. Frias2
1Centro Medico Nacional "20 de Noviembre" ISSSTE, Mexico City, Mexico; 2Centro
Medico Nacional "20 de Noviembre" ISSSTE, Pediatric Oncology, Mexico City, Mexico
Background/Objectives: Small round blue cell tumors (SRBCTs) are a group of
malignancies that occur in children. The differential diagnosis mainly include
rhabdomyosarcoma (RMS), Peripheral primitive neuroectodermal tumors (pPNETs),
leukemia, lymphoma, Neuroblastoma among others. Immunohistochemistry is one of
the most prevalent and convenient methods for pathological diagnosis; however,
differentiation between those tumors, in a low income country is still very challenging.
We present a clinical case of an 11-month-old male infant with a small round blue cell
tumor.
Design/Methods:We present a clinical case of an infant with SRBCTand a discussion
of the differential diagnosis of these tumors in the pediatric population, which
represent a challenge in low income countries.
Results: An 11 old month male was admitted to the Pediatric Oncology Service at
Centro Medico Nacional 20 de Noviembre ISSSTE in Mexico City, with a single small
bluish colored skin nodule in foot plant since he was 2 month old. An excisional biopsy
was made with diagnosis of Neuroblastoma. Our pathologists reviewed the biopsy and
concluded pNET. Image studies were performed with no primary tumor site. We started
chemotherapy according to Mexican National Protocol.After 5 cycles of
chemotherapy, a subcutaneous soft tissue lesion in left gluteous appeared with
hystophatologic diagnosis of pNET, bone marrow aspirate and biopsy were made with
final diagnosis of Acute Myeloid Leukemia.
Conclusion: The differential diagnosis of SRBCTs isn´t easy in low income countries,
where there is a lack of resources and investigation. The oncologists must perform a
complete clinical investigation, but it is clear that the diagnosis of SRBCTs should be
based on a comprehensive analysis involving morphology and immunoreactivity to a
panel of markers. We should also investigate the ocurrence of major chromosomal
translocations to validate the diagnosis. If we perform the accurate diagnosis, we can
treat cancer in a proper way.
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USE OF ANTIFUNGAL AGENTS IN PEDIATRICS WITH HEMATOLOGIC
DISORDERS
P. Badiee1, Z. Hashemzadeh2,4, S.A. Shamsdin3
1Shiraz University of Medical Sciences, Prof. Alborzi Clinical Microbiology Research
Center, Shiraz, Iran; 2Shiraz University of Medical Sciences, Shiraz, Iran, 3Shiraz
University of Medical Sciences, Gasterohepathology Research Center, Shiraz, Iran; 4Prof.
Alborzi Clinical Microbiology Research Center, Shiraz, Iran
Background/Objectives: Fungal infections are important causes of morbidity and
mortality in pediatric patients with hematologic disorders. Antifungal resistance
increases the cost of treatment and prolongs hospitalization, thus, leading to increasing
adverse drug reactions in humans.This article seeks to investigate the rational use of
antifungals in oncology wards, considering the radiological and mycological evidence.
Design/Methods: Besides the routine laboratory examination, blood cultures, molecular
assays for Aspergillus and Candida albicans on serum samples were done for all patients
by real time PCR. Clinical signs and symptoms and use of antifungal agents were
studied, according to the patients’ medical files.
Results: Among 44 febrile pediatric patients with hematologic disorders, 22 were males.
The back grounds of patients were acute lymphoblastic leukemia in 26 cases, acute
myelogenous leukemia in 9, non-Hodgkin lymphoma 3, Fanconi anemia 2 and
Histiocytosis in 1 case. The mean of white blood cell count and age were 4491 and 8
years. Radiologic signs of infections were positive in 27 patients, Candida albicans were
isolated from 3 (6.8%) blood cultures and sera samples were positive in 20 (45.5%)
patients with real time PCR, 9 Aspergillus and 11 Candida albicans. Antifungals were
started in 35 (79.5%) patients; amphotericin B in 23, Amphotericin and fluconazole in
4, Amphotericine with voriconazole in 2, amphotericin with itraconazole in 2 ,
itraconazole in 3 and fluconazole in 1 patient.
Conclusion:Unfortunately, the use of antifungal agents in pediatric oncology wards was
not according to documented evidence, as the study revealed. Given the similar clinical,
radiological features in microbial infections, mycological examination can help restrict
the irrational use of antifungals and thereby control the respective resistance and save
on the health costs. In doing so, further research based on clinical as well as
microbiological parameters of fungal infections are suggested.
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ABANDONMENT AND OUTCOME OF CHILDHOOD ACUTEMYELOID
LEUKEMIA IN A TERTIARY LEVEL HOSPITAL
M. Begum1, A. Islam2, C. Jamal2, A.A. Rahman2, A. Karim M.A2, Z. Ara2,
L.R. Molla2, F. Yasmin2, M. Akter2, M.T. Ahammed2
1BSMMU, Dhaka, Bangladesh; 2BSMMU, Pediatric Haematology and Oncology,
Dhaka, Bangladesh
Background/Objectives: Acute leukemias are the most common child hood malignancy,
of which acute myeloid leukemia (AML) are 15% to 20%. Abandonment is one of the
most important causes of treatment failure in AML in developing countries. Lost to
follow-up is also a big problem in low income countries. Many patients stop therapy
soon after diagnosis due to cost, distance and ignorance. Objective: To determine the
abandonment, outcome and treatment related mortality (TRM) and morbidity among
children with AML.
Design/Methods: This prospective observational study was conducted in the
Department of Pediatric hematology and Oncology, BSMMU, Dhaka for duration of
one year. Fifty (50) patients of AML visited to out patient department (OPD) of
Pediatric hematology and Oncology. Among them 11(22%) patients refuse treatment
from outdoor. Thirtynine 39 (78%) patients of AML were selected as per inclusion and
exclusion criteria. After proper evaluation and clinical examination of these patient,
CBC and Bone marrow examination was done for confirmation of diagnosis.
Results: A total of 39 patients were recruited in this study. Seventeen (43.6%) patients
were male and 22 (56.4%) were female. Mean ± SD of age was 7.80 ±4.42 and range
was 6 months to 15 years. Out of 39 patients, 18(46.1%) patients were abandoned,
15(38.4%) expire, relapse 2(5.2%) & alive 4(10.3%).
Conclusion: High abandonment (46.1%) and treatment related toxic death (38.4%) has
compromised the outcome of Acute myeloid leukemia. However AML can be treated
with better outcome if improved the supportive care, reduce toxic death, refusal or
abandonment.
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HIGH DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR REFRACTORY
ACUTE LEUKAEMIAS IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS
F. Carceller1, S. Hirsch1, K. Khabra2, L. Moreno1, T. Petterson3, M. Taj1, M. Ethell4,
M. Potter4, L. Marshall1, D. Lancaster1
1Royal Marsden Hospital, Paediatric Haemato-Oncology Unit, Surrey, United Kingdom;
2Royal Marsden Hospital, Statistics, Surrey, United Kingdom; 3Royal Marsden Hospital,
Paediatric Haemato-Oncology Unit / Haematopoietic Transplant Unit, Surrey, United
Kingdom; 4Royal Marsden Hospital, Haematology Department / Haematopoietic
Transplant Unit, Surrey, United Kingdom
Background/Objectives: Overall 30-40% of children with acute myeloid leukaemia
(AML) will experience relapse [Rubnitz 2007]. The 5-year overall survival (OS) for
children with relapsed AML is 23% [Sander 2010]. High dose etoposide and
cyclophosphamide (HD Etop/Cyclo) has achieved complete remission (CR) rates of
28–57% in adults with refractory/relapsed acute leukaemias [Brown 1990, Johny 2006,
Trifilio 2013]. We aimed to evaluate the efficacy/safety of HD Etop/Cyclo in children,
adolescents and young adults with refractory acute leukaemias treated at our
institution.
Design/Methods: Retrospective study of patients aged 1-24 years with AML, acute
lymphoblastic leukaemia (ALL) and/or biphenotypic leukaemia (BL) refractory to 1
line of chemotherapy, either at initial diagnosis or at relapse, between 2006-2014.
Efficacy was assessed as per IWG criteria and adverse events according to CTCAE
v4.03. Study endpoints were overall response (OR) after 1-2 cycles, event-free survival
(EFS) and OS.
Results: Nine patients were included (10 cycles): all males; median age (range) 13 years
(1–23); 6 AML, 2 ALL, 1 BL; refractory at diagnosis (n=3), following relapse (n=6).
OR was: 1 CR, 2 CR with incomplete platelet recovery and 1 partial response (44.4%,
95%CI 13.7–78.8). All patients had grade (G) 4 neutropenia and thrombocytopenia.
Other toxicities included (all G3): febrile neutropenia (n=8); mucositis (n=3); tumour
lysis syndrome (n=2); and lung infection (n=1). One non-responder and 3 responders
subsequently underwent allogeneic stem cell transplant. Median (95%CI) EFS for
responders: 10.2 months (6.7–n/a). Median (95%CI) OS for the whole cohort: 8.7
months (1.9–n/a). One non-responder and one responder remain disease-free 1 and 2.9
years after HD Etop/Cyclo, respectively.
Conclusion: These results are consistent with those reported in adults. It is feasible to
administer HD Etop/Cyclo in children with a toxicity profile similar to other regimes
used in the relapsed setting. Hence, we believe HD Cyclo/Etop would merit further
evaluation in prospective studies.
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COMPARISON OF IMMUNEMANIFESTATIONS BETWEEN REFRACTORY
CYTOPENIA OF CHILDHOOD AND APLASTIC ANEMIA IN CHILDREN: A
SINGLE-CENTER RETROSPECTIVE STUDY
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Y. Cheng1, J. Wu2, L. Zhang2
1The Affiliated People’s Hospital of Peking University, Peking, China; 2The Affiliated
People’s Hospital of Peking University, Department of Pediatrics, Peking, China
Background/Objectives: This retrospective single-center study assessed the incidence
and clinical features of immune manifestations of refractory cytopenia of childhood
(RCC) and childhood aplastic anemia (AA).
Design/Methods: From February 2008 to March 2013, 72 and 123 children with RCC
and AA, respectively, were evaluated.
Results: RCC was associated with autoimmune disease in 4 children, including 1 case
each with autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus
erythematosus, and anaphylactoid purpura. No children with AA were diagnosed with
autoimmune diseases. The incidence rate of autoimmune disease in childhood AA was
significantly lower than that children with RCC (P = 0.008, χ2 = 6.976). Immune
abnormalities were common in both RCC and AA; the most significant reductions were
in total lymphocyte count and the relative numbers of CD3−CD56+ subsets found in
RCC. Despite the many similar immunologic abnormalities in AA and RCC, the
incidence rate of autoimmune disease was significantly lower in childhood AA than
RCC. The relative numbers of natural killer cells were significantly lower in RCC
patients than AA patients.
Conclusion: The large overlap of analogous immunologic abnormalities indicates RCC
and childhood AA may share the same pathogenesis.
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CYTOGENETIC ABNORMALITIES IN CHILDHOOD ACUTEMYELOID
LEUKEMIA: A SERIES FROM TERTIARY CARE HOSPITAL OF NORTH INDIA
M. Chowdhry1, R. Makroo2, M. Kumar3, D. Rani3, Y. Thakur3, M. Singh3
1Indraprastha Apollo Hospital-Delhi, Delhi, India; 2Indraprastha Apollo Hospitals,
Molecular Biology & Transplant Immunology, New Delhi, India; 3Indraprastha Apollo
Hospital-Delhi, Molecular Biology & Transplant Immunology, Delhi, India
Background/Objectives: Karyotype is an independent indicator of prognosis in acute
myeloid leukemia (AML) that is widely applied to risk-adapted therapy. Because AML
is rare in children, the true prognostic significance of individual chromosomal
abnormalities in this age group remains unclear.
Design/Methods: The study was taken in the Department of Molecular Biology &
Transplant Immunology, Indraprastha Apollo Hospital, New Delhi, India for all
pediatric AML patients referred for cytogenetic analysis between 2011 and 2014.
Results: Between 2011 and 2014, 26 children with AML were referred for cytogenetic
analysis. Cytogenetic analyses was successful in all 26 cases (100%), and clonal
chromosomal abnormalities were detected in 18(69.2%).The most common aberration
was t(8;21)(q22;q22) (n=7, 38.8%) which was present in isolation (n=3, 42.8%) as well
as a part of a complex karyotype (n=4, 57.2%). The complex karyotype involved loss of
sex chromosome in 3 cases and trisomy 21 in 1 case besides the common t(8;21) in these
cases. Since we regularly perform FISH analysis for all cases of AML, we were able to
diagnose a case of cryptic AML-ETO which was missed in the conventional karyotype
technique. 2(11.11%) cases each of Trisomy 21 and Trisomy 8 were observed. Complex
karyotypes were observed in 6 cases (33.3%). A single (5.5%) case of Trisomy 6 was
seen. High hyperdiploidy (96, XXY) was observed in 1 (5.5%) case. Other chromosomal
abnormalities observed in isolation were 1 case of loss of sex chromosome
andisochromosome 9 each.Loss of sex chromosome was present in 3 cases (37.5%).
Conclusion: Since the spectrum of chromosomal changes and their risk association
seem to differ between children and adults with AML, it is imperative to perform
cytogenetic analysis for all pediatric AML cases. FISH should be perform for rapid
testing and wherever subtle duplications/deletions or translocations are anticipated.
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DIFFERENTIAL EXPRESSION OF NK CELL LIGANDS ON T, B AND
MYELOID ACUTE CHILDHOOD LEUKEMIA
J. Fuster1, M.V. Martínez-Sánchez2, J.F. Pascual-Gázquez3, L. Gimeno-Arias2,
A.M. Galera-Miñarro3, M. Bermúdez-Cortés3, M. Blanquer4, T. Escámez-Martínez5,
A. García-Alonso2, J.M. Moraleda4, A. Minguela-Puras3
1Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; 2Hospital Clínico
Universitario Virgen de la Arrixaca, Immunology, Murcia, Spain; 3Hospital Clínico
Universitario Virgen de la Arrixaca, Pediatrics, Murcia, Spain; 4Hospital Clínico
Universitario Virgen de la Arrixaca, Hemathology, Murcia, Spain; 5Hospital Clínico
Universitario Virgen de la Arrixaca, Biobank, Murcia, Spain
Background/Objectives: NK cell function is finely tuned by inhibitory (iRec) and
activating (aRec) receptors. Consistent with the “missing self” hypothesis, NK cells
sensing the loss of self-HLA-class-I (HLA-I) through inhibitory killer cell
immunoglobulin-like receptors (KIR) can eliminate tumor cells. NK cell function also
depends on signals delivered through interaction of aRecs with their ligands. aRec such
as NKG2D recognizes the stress-inducible MICA/B14 and ULBPs proteins, whereas
DNAM-1 (CD226) specifically recognizes poliovirus receptor (CD155) and Nectin-2
(CD112).
Design/Methods: The expression of ligands for iKIR (HLA-I and HLA-C) and aRec
(CD112, CD155, ULBP1 and MICA/B) was evaluated in 36 acute childhood leukemia
at diagnosis (24 B-ALL, 6 T-ALL and 6 AML) using FACSCanto flow-cytometer on
bone marrow tumor cells and on residual lymphocytes as a control for normal/basal
expression. HLA-I and HLA-C expression was normalized as ratio (%) of mean
fluorescence intensity (IMF) on tumor cells / IMF on control cells.
Results: The expression of ligands for iKIR was significantly lost in T-ALL (40% and
26%, respectively for HLA-I and HLA-C) but maintained for HLA-I or slightly
decreased for HLA-C in B-ALL (123.6% and 73%) and AML (109% and 67.5%)
compared to normal lymphocytes (p<0.01, T-ALL vs B-ALL or AML). In contrast,
the expression aRec ligand was significantly (p<0.05) lower in T-ALL blasts (MFI: 159,
163, 125 and 27), than in B-ALL (IMF: 1643, 129, 188 and 45) or AML (IMF: 3902,
1013, 494 and 63) for CD112, CD155, ULBP1 and MICA, respectively.
Conclusion: The differential expression of ligands for NK cells inhibitory and activating
receptors between B-ALL, T-ALL and AML acute childhood tumour cells, could
potentially condition NK cell antitumor response on these types of tumours.
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PAEDIATRIC CHRONIC MYELOID LEUKAEMIA: A SINGLE UNIT
EXPERIENCE IN KWA-ZULU NATAL, SOUTH AFRICA
Y. Goga1, R. Thejpal1, N. Moonsamy1, K. Moodley1, B. Neethling1
1University of Kwa-Zulu Natal, Paediatrics and Child Health, Durban, South Africa
Background/Objectives: To describe patient characteristics, treatment response and
survival of patients with Chronic Myeloid Leukaemia, at a single centre from 2003 –
2015.
Design/Methods: A retrospective chart review of patients with Chronic Myeloid
Leukaemia diagnosed between January 2003 and March 2015.
Results: Nine patients were diagnosed with CML. There was a male predominance,
M:F= 7:2 All 9 patients were Black. Eight patients presented with chronic phase
disease, and one patient presented with blastic crisis. White cell counts ranged from 53–
423, with a median of 330. Hydroxyurea, busulphan and mercaptopurine were used in
8/9 patients to control the white cell count at the outset. One patient was treated with
interferon, and 7/9 were treated with Imatinib which made available via a donor
programme. Four patients (4/8) with chronic phase disease progressed to accelerated
phase. Of these, one was resistant to imatinib, and dasatinib was not available at the
time. The second patient was salvaged with 2nd and 3rd line tyrosine –kinase inhibitors
(TKI) and reverted to chronic phase. Three of the 4 patients with accelerated phase
disease progressed to blast phase, and 2/4 had CNS disease. All 4 blastic phase patients
demised. There was poor compliance in all 4 patients who progressed to accelerated
phase. Difficult social circumstances and fatigue were the main causes of
non-compliance. Compliance has been excellent in the subsequent 3 patients. 4/9
patients are still alive (survival of 5.6-9yrs) on TKI’s. Three are on Imatininb and 1 is on
Dasatininb.
Conclusion: Chronic Myeloid Leukaemia is a rare paediatric malignancy. Access to
TKI’s via donor programmes has improved survival of patients, and are critical
especially in countries where stem cell transplantation is limited. Good compliance is
pivotal to prevent progression to accelerated and blast phase. RT-PCR is more readily
available, and treatment algorithims are now well defined, resulting in better survival.
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INFECTION TRENDS AND ANTIBIOTIC PROPHYLAXIS AMONG CHILDREN
PRESENTINGWITH ACUTEMYELOID LUKEMIA: A RETROSPECTIVE
STUDY FROM PAKISTANI POPULATION
T. Hussain1, U. Allen2
1Islamabad, Pakistan; 2Tongji Medical College, Oncology Department, Wuhan, China
Background/Objectives: Acute myeloid leukemia (AML) diagnosed among pediatric age
group carries a great risk of immunosuppression and superimposed infections. Patients
with this disease usually die of the related complications rather than the disease itself.
The basic aim of this study was to rule out the beneficial role of prophylactic
generalized antibiotic regimen for such patients thus to enhance the quality of life and
decrease morbidity.
Design/Methods: This retrospective study was conducted at the oncology department of
Rawalpindi Medical College allied teaching hospital. Data was collected for a period of
4 years Pediatric patients (aged 1-12 years) consecutively diagnosed with AML and
treated from Jan 2011 through Dec 2014. Patients were treated on the International
treatment guidelines per hospital policy protocol Data were extracted from hard copy
or electronic chart review.
Results: A total of 11 cases were studied in detail. Staphylococcus is the major bug
found among infective cases. Of the total 24 chemotherapy phases among 11 patients,
each phase reported, preventive antibiotics were initiated when the daily absolute
neutrophil count was falling <1000 cells/mcl and before the onset of fever. 5 episodes of
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bacteremia were documented with predominantly coagulase-negative staphylococci and
viridans group streptococci. 4 confirmed infection-related death occurred, primarily
because of the respiratory tract infection leading to respiratory failure.
Conclusion: Antibiotic coverage should be organism specific and the commonest
organism found to be was Staph group. Respiratory tract infection, neutropenia and
onset of fever should be set as the starting point for bug specific antibiotic.
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LEUKEMIAS WITH ISOLATED EXTRAMEDULLARY RELAPSE AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
WITHOUT UNFAVORABLE CYTOGENETICS
U. Kocak1, Z. Kaya1, I˙. Altan1, M. Isık1, A.E. Sal1, F. Tekkesin1, I. Yenicesu1, T. Gursel1
1Gazi University School of Medicine, Pediatric Hematology and Oncology, Ankara,
Turkey
Background/Objectives: Extramedullary relapse (EMR) following allo-HSCT is a major
contributor to mortality. Post-HSCT outcome continue to be challenging.
Design/Methods: Of the 38 leukemia patients receiving allo-HSCT from a matched
sibling donor (MSD), 13 relapsed, five of whom (2 ALL, 3 AML) (38.5 %) had isolated
EMR.
Results: All EMRs occurred median 6 months posttransplant. All 5 patients received
myeloablative conditioning (4 TBI based, 1 busulfan based) and had 100 % chimerism
when EMR occurred. Case 1, relapsed biphenotypic leukemia with pleural effusion at
diagnosis. She experienced grade II/IV aGVHD. One year posttransplant she relapsed
with pleural infiltrates. After two cycles of chemotherapy she died of sepsis. Case 2,
resistant t(8;21) positive AML. Six months posttransplant she had a 10×5 cm mass in
the upper right quadrant while suffering from extensive skin cGVHD. She received
chemo/radiotherapy that lead to disappearence of the mass. She died of sepsis 17
months after EMR. Case 3, resistant AML while receiving donor lymphocyte infusions
(DLIs) at six months posttransplant a mass in the leg appeared. He continued to receive
DLIs and although the mass disappeared he developed grade III/IV hepatic GVHD
and died because of progressive disease at 8 months of EMR. Case 4, resistant AML
had paravertebral and hepatic masses nine months posttransplant while suffering from
grade III/IV intestinal GVHD. He received chemotherapy and died of sepsis one month
later. Case 5, resistant T-ALL and pericardial effusion at diagnosis, Six months
posttransplant a 6×1 cm mass in the thorax appeared. She received
chemo/radiotherapy and is still alive on ALL maintenance therapy.
Conclusion: EMR, which could escape from the immunotherapeutic effect of allo-SCT
is a significant factor in the transplantation mortality. Neither myeloablative
conditioning nor GVHD could have protected against EMR probably due to resistant
nature of our leukemias. Best treatment of EMRs after transplantation is still not
known.
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UNMANIPULATED HAPLOIDENTICAL FAMILY DONOR
TRANSPLANTATION FOR THE TREATMENT OF CHILDREN AND
ADOLESCENTS WITH HEMATOLOGIC MALIGNANCIES: A SINGLE
INSTITUTION KOREAN STUDY
J.W. Lee1, S.K. Kim1, P.S. Jang1, N.G. Chung1, D.C. Jeong1, B. Cho1, H.K. Kim1
1The Catholic University of Korea, Pediatrics, Seoul, Korea
Background/Objectives: Haploidentical family donor (HFD) hematopoietic cell
transplantation (HCT) is an important treatment modality for patients with
hematologic malignancies who require allogeneic transplant, but lack an HLA-matched
donor. Here, we report our experience in treating pediatric patients with high risk
hematologic malignancy with unmanipulated HFD transplant.
Design/Methods: Thirty-nine patients (13 female (33%)) received unmanipulated HFD
transplant from August 2010 to July 2014 at a median age of 5.6 years (range: 0.7 –
17.4). Patient diagnoses were as follows: AML 26, JMML 8, ALL 3, mixed phenotype
acute leukemia 1, dendritic cell sarcoma 1. Maternal donors were utilized for 34 (87%)
of the patients. All patients received G-CSF mobilized peripheral blood stem cells.
Conditioning regimen was as follows: busulfan-based 32, TBI-based 1, TBI and
busulfan-based 6. Rabbit ATG was given for 4 days prior to transplant at a total dose
of 5 – 10 mg/kg. GVHD prophylaxis consisted of cyclosporine and mini-dose
methotrexate.
Results:Median cell dose infused was as follows: TNC 32.5 x108/kg, MNC 20.8
x108/kg, CD34+ 7.9 x106/kg, CD3+ 90.3 x107/kg. Cumulative incidence of grades II-IV
and grades III-IV acute GVHD was 82.1±6.4% (32/39) and 25.6±7.1% (10/39)
respectively. Cumulative incidence of overall chronic GVHD and extensive chronic
GVHD was 47.2±8.3% (18/39) and 31.1±7.6% (12/39) respectively. Rate of relapse and
transplant-related mortality (TRM) was 31.2±7,6% (13/39) and 10.8±5.2% (4/39)
respectively. Event-free survival (EFS) of the cohort was 58.0±8.1% (22/39). None of
the factors studied, including donor gender and degree of HLA mismatch, had a
significant impact on EFS.
Conclusion: Unmanipulated HFD transplant done with rabbit ATG-based in vivo T cell
depletion only is a feasible option for children and adolescents with high risk
hematologic malignancy who require allogeneic HCT for cure. Although TRM
remained low, further measures are necessary to decrease rates of acute and chronic
GVHD.
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REMISSION INDUCTION IN MIXED LINEAGE T/MYELOID LEUKEMIA
WITH CLOFARABINE IN PATIENTS WHO FAIL ALL-TYPE THERAPY
FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION
S. Minkowitz1, J. Davis2, B. Wistinghausen2, B. Petersen3
1Icahn School of Medicine at Mount Sinai, New York City, USA; 2Icahn School of
Medicine at Mount Sinai, Pediatric Hematology Oncology, New York City, USA; 3Icahn
School of Medicine at Mount Sinai, Pathology, New York City, USA
Background/Objectives:Mixed phenotype leukemias are a rare subset of leukemias with
a majority of B/Myeloid phenotype. There is no standard of care but some evidence
that they are more responsive to acute lymphoblastic leukemia (ALL) type therapy. We
report three cases of T/Myeloid mixed lineage leukemia. One patient achieved complete
remission (CR) with ALL type therapy. In the two other, early initiation of clofarabine
after failure of ALL type therapy led to remission. All three patients underwent
successful hematopoietic stem cell transplantation (HSCT). We conclude T/Myeloid
leukemia may be more common than previously reported and clofarabine may aid in
achieving early remission allowing HSCT.
Design/Methods: A 15 year old female, a 5 year old male and a 18 year old male were
diagnosed with acute T-myeloid leukemia between 2009 and 2014 by
immunophenotyping of bone marrow aspirates using flow cytometry: Patient 1: CD3+,
MPO partial+, CD34 partial+, CD117+, Tdt dim+. Patient 2: CD3+ and CD14+,
CD64+, CD34 partial+. Patient 3: CD3+ and MPO+, CD4 partial dim+, CD117
partial dim+. All patients received ALL type induction chemotherapy.
Results: Only patient 1 achieved CR. Patient 2 and 3 required retrieval therapy but only
achieved remission with negative minimal residual disease (MRD) after addition of
clofarabine. All three underwent HSCT without relapse. The third patient died 190 days
after HSCT due to transplant related complications.
Conclusion:We report three cases of acute T-myeloid leukemia that achieved MRD
negativity prior to HSCT which has been associated with improved prognosis in ALL.
Based on our and others experience ALL type induction regimen is reasonable. Instead
of switching to acute myeloid leukemia type therapy, early initiation of clofarabine may
be indicated to improve prognosis of HSCT if negative MRD is not achieved at the end
of induction.
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EPIGENETIC THERAPY FOR TREATMENT PEDIATRIC ACUTEMYELOID
LEUKEMIA
V. Nemirovchenko1, A. Popa1, G. Mentkevich2
1Pediatric Oncology and Hematology Institute-Federal State Budgetary Institution
«N.N.Blokhin Russian Cancer Research Center», Hematology, Moscow, Russia;
2Pediatric Oncology and Hematology Institute-Federal State Budgetary Institution
«N.N.Blokhin Russian Cancer Research Center», Bone Marrow Transplantation,
Moscow, Russia
Background/Objectives: Acute Myeloid Leukemia (AML) is a highly heterogeneous and
poor prognosis disease with few available therapeutic options. The goal of our clinical
trials was to increase survival of children with AML by using chemotherapy along
Epigenetic drugs.
Design/Methods: Eight Russian Oncology Hospitals participated in our clinical trials.
Chemotherapy was used in treated after AML-2002 protocol. Epigenetic drugs were
added to chemo after AML-2007 protocol. There were 51 children after AML-2002
protocol. There were 70 children after AML-2007 protocol. Epigenetic drugs (valproic
acid and all-trans-retinoic acid) were added to the maintenance therapy after
AML-2007 protocol for Standard risk group. We used high-doses of chemo and
autologous stem cell transplantation for treatment the patients in Intermediate risk
group after AML-2002 protocol. AML-2002 protocol for High risk group consisted of
alternate courses of chemo. The patients got epigenetic drugs from the first day of the
treatment after AML-2007 protocol for Intermediate and High risk groups.
Results: The upwards going trend was seen in the increase of Disease-Free Survival
(DFS), Event-Free (EFS) and Overall Survival (OS) after AML-2007 protocol:
55,3±6,7% vs 43,6±7,2% AML-2002 (p=0,11); 49,5±6,4% vs 39,2±6,8% AML-2002
(p=0,1); 53,5±6,3 vs 45,9±7,1% AML-2002 (p=0,3). The upwards going trend was
seen in the increase of DFS and OS after AML-2007 protocol in all risk groups. We
managed to increase OS accurately after AML-2007 vs AML-2002 protocol in High
risk group (50,2 ±9,0% vs 30,8 ±12,8%, p=0,05). The survival values grew up more and
accurately in children under one year old after AML-2007: DFS=83,3 ±10,8% vs 25,0
±21,7% AML-2002 (p=0,04); OS=84,6 ±10,0% vs 25,0 ±21,7% AML-2002 (p=0,01).
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Conclusion: Thanks to putting on epigenetic drugs the upwards going trend was seen in
the increase of survival in children with AML.
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LEUKEMIA PREDISPOSITION: A REPORT OF CHILDHOOD ACUTE
MYELOID LEUKEMIA ATMAHAK’S PEDIATRIC CANCER TREATMENT
AND RESEARCH CENTER
A. Mehrvar1, M. Tashvighi1, M. Faranoush1, D. Reinhardt2, N. Niktoreh Mofrad3,
A.A. Hedayati Asl1, M. Alebouyeh1
1Mahak - The Society To Support Children Suffering From Cancer, Department of
Oncology, Tehran, Iran; 2University Children Hospital of Essen, Pediatrics III, Essen,
Germany; 3Mahak - The Society To Support Children Suffering From Cancer, Research
Department, Tehran, Iran
Background/Objectives: This study reports the epidemiology, characteristics, and
outcome of pediatric Acute Myeloid Leukemia (AML) at Mahak’s Pediatric Cancer
Treatment and Research Center, diagnosed between 2007 and 2012.
Design/Methods: Retrospectively, 42 children meeting the inclusion criteria were
enrolled in this study. Patients were treated according to the AML-BFM 83 protocol
and have undergone prophylactic CNS radiotherapy after reaching a minimum age of 2
years.
Results: In 20 children (47%) a family history of malignant tumors has been reported,
in 9 children (21%) occurrence of leukemia had been known. Both were associated with
the risk of relapse (family history of cancer in relapse: n=11; 61%, P=0.136; leukemia:
n=7; 39%; P=0.016). Treatment related mortality was 19% and associated with
underweight patients (n=5; 62.5%; P=0.158). Following the 1st induction, 83.5% of the
children (n=35) achieved complete remission, increasing to 95% (n=40) after the 2nd
treatment element. The event-free and overall survivals were 36% (SE=3.5) and 44%
(SE=3.4), respectively. The median time of event-free and overall survival were 18 ± 3.4
and 26 ± 6.8 months, respectively. Eighteen patients (42.9%) experienced relapse.
Relapse rate was significantly associated with bone pain as the first clinical
manifestation (P=0.012).
Conclusion: This study shows a relation of positive family history and relapse rate and
warrants further studies on this subject. Improvements of diagnostics (founding a
central lab), better risk stratification and supportive care, shifting to a feasible new
protocol, improvement of human stem cell transplantation are crucial steps towards
better outcome of pediatric AML in Iran.
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HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN
REPUBLIC OF KAZAHSTAN
K. Omarova1, A. Tulebayeva2, L. Manzhuova3, G. Bulabayeva1, G. Abdilova1
1Scientific Centre of Pediatrics and Children Surgery, Oncohematology, Almaty,
Kazakhstan; 2Scientific Centre of Pediatrics and Children Surgery, Haematopoietic Stem
Cell Transplantation, Almaty, Kazakhstan; 3Scientific Centre of Pediatrics and Children
Surgery, Oncohemotology, Almaty, Kazakhstan
Background/Objectives: Pediatric haematopoietic stem cell transplantation (HSCT)
department was opened in May, 2012 in Scientific Centre for Pediatrics and Children
Surgery in Almaty.
Design/Methods: 5 allo-HSCT of the bone marrow stem cells from matched sibling
donors (MSD) were performed in our unit for children with ALL, AML, JMML and
SAA recently. First allo-HSCT was done in 14 yo boy with very SAA who was failed
primarily immunosuppressive therapy. Conditioning regimen consisted of fludarabine,
cyclophosphamide and rabbit ATG with cyclosporine A (CsA) and mycophenolate
mofetil for GvHD prophylaxis. Due to poor graft function he underwent
retransplantation with the same donor outside the country. Two HSCT were performed
in patients with AML, CR2, who had history of hepatitis C. Conditioning regimen
included: TreoCyMel, GvHD prophylaxis tacrolimus + methotrexate. PCR showed
donor chimerism of 100% since 2 years with continuous hematological remission in first
patient and chimerism of 100% since day+90 in second patient with AML. 2.8 yo girl
with JMML underwent HSCT after TreoCyMel, GvHD prophylaxis with CsA.
Engraftment was detected at day+24, PCR chimerism showed 100% donor cells at 1,6
years. 2.6yo girl underwent HSCT for ALL; t(4;11) after early bone marrow relapse in
CR2. Conditioning regimen: TreoCyMel, GvHD prophylaxis with CsA. Engraftment
was detected at day+22. PCR chimerism showed 97% donor cells on day+120.
Results: Despite our limited experience of HSCT, none of our patients suffered from
early transplant mortality. Only one suffered from acute GvHD grade II (on day +24)
and was treated with steroids. In one case, a patient with ALL at 120 days after allo held
ascertained disease relapse. All other are alive early after HSCT (4-24 months).
Conclusion: Using of transplantation HSCT can improve the outcome of most children
with different malignant and non-malignant disorders in our country.
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TET2 ALTERATIONS IN TAIWANESE CHILDHOOD ACUTEMYELOID
LEUKEMIA
M.J. Li1,2, D.T. Lin3,4, F.J. Tsai2,5, C.H. Tsai2,5, C.T. Peng2,5
1National Taiwan University Hospital Hsin-Chu Branch, Pediatrics, Hsinchu, Taiwan;
2China Medical University, Children’s Hospital, Taichung, Taiwan; 3National Taiwan
University Hospital, Laboratory Medicine and Pediatrics, Taipei, Taiwan; 4National
Taiwan University, College of Medicine, Taipei, Taiwan; 5Asia University, Biotechnology,
Taichung, Taiwan
Background/Objectives:Mutations in the tet oncogene family member 2 gene (TET2)
are frequently found in adult acute myeloid leukemia (AML) patients and had some
prognosis effect. However, reports of TET2 mutation in children are limited. We assess
the prevalence of TET2 mutations in Taiwanese childhood AML and attempt to
analyze the prognosis effect.
Design/Methods: Sixty-nine consecutive AML children from 1997 to 2010 were
enrolled. TET2 analysis was performed by direct sequencing and assumed as mutation
according to public database, literature documents and bioinformatics tools evaluation.
Clinical characters and overall survival (OS) were compared between patients with and
without TET2 alterations.
Results: Only intronic and missense mutations were identified and there was no
nonsense or frameshift mutation. Two putative disease-causing missense mutations
(S609C and A1865G) were identified in 1 patients and we estimated the prevalence of
TET2 mutation in our patients was 1.4% The most common polymorphism was I1762V
(45%), followed by V218M (12%), P29R (6%) and F868L (6%). Patients with
polymorphism I1762V tended to have better survival rate then patients without I1762V
(48.4% vs 25.7%, p = 0.049) thought the OS was no different by the Kaplan–Meier
method (p = 0.104).
Conclusion: The prevalence of TET2 mutations in childhood AML patients was lower
and the mutations were less complex than in adult AML. The prognosis effect of TET2
mutation needs further investigations to confirm the role in childhood AML.
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COMPLETE CLINICAL, HEMATOLOGICAL, CYTOGENETIC AND
MOLECULAR TRANSCRIPT PROFILE AND OUTCOME ANALYSIS OF
PEDIATRIC AND ADOLESCENT CHRONIC MYELOID LEUKEMIA CASES
B. Prateek1, D. Bansal2, A. Trehan3, P. Malhotra4
1PGIMER, Chandigarh, India; 2PGIMER, Pediatric Hemato-Oncology Unit,
Chandigarh, India; 3PGIMER, Pediatric Hematology-Oncology Unit, Chandigarh,
India; 4PGIMER, Internal Medicine, Chandigarh, India
Background/Objectives: CML comprises 3% of all pediatric leukemias, with an annual
incidence of 1 per million children and adolescents < 20 years of age.
Design/Methods: A total of 20 pediatric and adolescent CML cases (0-18 years)
prospectively diagnosed on cytogenetic and RT-PCR analysis over four years
(2010-2014) were enrolled.
Results: 7/20 (35%) were pediatric (0-12 yrs) and 13/20 (65%) adolescent (12-18 yrs)
cases. Male: Female ratio was 1:1. All (100%) presented with massive splenomegaly.
19/20 (95%) were in chronic phase, and one (5%) presented in blast crisis. All had high
TLC at diagnosis, with 7/20 (35%) having a WBC count more than 200 × 109/L. 13/20
(65%) had normal platelet counts, 6/20 (30%) high (>500 × 109/L) and one case (5%)
had a low platelet count. High absolute basophil count (> 0.5 × 109/L) was seen in
19/20 (95%) cases. 15/20 (75%) cases had a low LAP score. Ph positivity on cytogenetic
analysis was noted in 16/20 (80%) cases. No case had any other numerical or structural
genetic change. All cases (100%) were positive for BCR-ABL transcript (p210 type) by
RT-PCR analysis. 12/20 (60%) had a b2a2 type of p210 transcript while 8/20 (40%) had
a b3a2 transcript. 18/20 (90%) cases received imatinib (200 mg-OD), 2/20 (10%)
developed relapse, while 1/20 (5%) died and 1/20 (5%) did not respond to treatment.
The event free survival was 78% at a median follow up of 30 months while the overall
survival in responders was 85% at 30 months.
Conclusion: Pediatric CML though rare, needs to be considered in cases with high TLC
and high absolute basophil count. BCR-ABL studies are necessary for a confirmed
diagnosis. The overall outcome with imatinib treatment was very good as 85% of them
were in remission at 30 months of follow up.
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TREATMENT OF ACUTEMYELOID LEUKEMIA IN DOWN AND NON DOWN
SYNDROME CHILDREN. SEVENTEEN YEARS EXPERIENCE AT A TERTIARY
CARE INSTITUTION
M. Saleh1, S. Al-Sweedan1, K. Alkayed1, R. Jafri2, A. Al-Ahmari1, I. Ghemlas1,
K. Siddiqui2, H. El-Solh1, N. Farhan1, A. Khairy1
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Riyadh, Kingdom of Saudi Arabia; 2King Faisal Specialist Hospital and Research Centre,
CDU-Pediatric Hematology / Oncology, Riyadh, Kingdom of Saudi Arabia
Background/Objectives: Patients of Down syndrome (DS) with Acute Myeloid
Leukemia (AML) have an overall good outcome compare to Non DS.
Design/Methods:Medical records of 27 DS AML patients who received chemotherapy
between 1998 and 2013 were reviewed. Their outcome was compared to the 134 Non
DS AML patients treated during the same time period.
Results: In the DS group 20 patients were males (74%). Median age at diagnosis was 24
months (range 1.32-153.24). Four patients were below the age of 12 months (14.81%). 7
were FAB M7. Mean WBC count was 32.73(range 1.80-219.96). Two patients were
CNS positive. 22(81.48%) were in remission at the end of induction .Seven (25.9%)
patients relapsed with a median relapse free time of 3.96 months (range1.8-16.08).
Seven patients (25.9%) died (PD in 6 and Infection in 1).23 patients (85.1%) develop
different chemotherapy related toxicities. Amongst the Non-DS AML, 74 (55.22%)
patients were males. Median age at diagnosis was 74.16 months (range 3.36-165.96).17
patients (12.68%) were below the age of 12 months.15 had M7 and 21 had M5. Mean
WBC count was 45.23(range1-539). Nineteen patients were CNS positive. 42 patients
(31.34%) relapsed with a median relapse free time of 9.24 months (range0.96-39.36). 62
patients (46.26%) died (PD in 46 and infections in 16).123 patients (91.79%) develop
different chemotherapy related toxicities .The OS of DS AML group was 71.4%
compare to Non DS AML group of 43% and EFS of the DS AML group was 65.8%
compare to Non DS AML group of 40.2%.
Conclusion: Our results show a favorable outcome in DS AML group compare to Non
DS AML group treated at our institute.
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ACUTE MYELOID LEUKEMIA - M7 IN DOWN SYNDROME; DOSE IT MAKE
A DIFFERENCE?
M. Saleh1, S. Al-Sweedan1, K. Alkayed1, R. Jafri2, A. Al-Ahmari1, I. Ghemlas1,
K. Siddiqui2, H. El-Solh1, S. Markiz1, N. Farhan1, A. Khairy1
1King Faisal Specialist Hospital & Research Center, Pediatric Hematology / Oncology,
Riyadh, Kingdom of Saudi Arabia; 2King Faisal Specialist Hospital & Research Center,
CDU-Pediatric Hematology / Oncology, Riyadh, Kingdom of Saudi Arabia
Background/Objectives: AML-M7 is a rare form of childhood leukemia which is
characterized by a poor response to therapy compared to patients with AML-M7 in
children with Down syndrome (DS).
Design/Methods:We compared 7 DS AML- M7 with 15 Non DS AML-M7 patients
treated at KFSHRC, Riyadh, Saudi Arabia between 1987 and 2013. Data were
analyzed for clinical characteristics of the patients and their outcome.
Results: The 2 groups received institutional AML protocol. In the DS group 6 patients
were males (85.7 %). Median age at diagnosis was 20.52 months (range 7.93-27.51).
Two patients were below the age of 12 months (28.57%). Mean WBC count was
25.03(range 3-138). All patients were CNS negative. 6 patients (85.7%) were in
remission at the end of induction .No relapses. One patient (14.28%) died due to
progressive disease. Six patients (85.7%) had infectious toxicities during the induction (
BI 5,FI 3,F/N 5) and 2 patients(28.57%) in post induction phase( BI 1,FI 1,F/N 1) .
Amongst the Non-DS AML, 10 patients (66.6%) were males. Median age at diagnosis
was 15.31 months (range 3.34-84.72). Seven patients (46.6%) were less then 12 months.
Mean WBC was 14.60(range5-32). All were CNS negative. Ten patients (66.6%)
achieved remission at the end of induction. 3 patients (20%) relapsed with a median
relapse free time of 2 months (range1.18-2.72). 6 patients (40%) died (PD in 3 and
infections in 3). 9 patients (60%) develop infectious toxicities during induction (BI 3, FI
3, F/N 8) and 8 patients(53.3%) in the post induction phase(BI 5, FI 2,F/N 5) . The OS
in Non-DS group was 57% compared to 85.7% in DS group (p=0.484) and EFS was
58.3% compared to DS AML group of 85.7 %.( p=0.014).
Conclusion: Our results support a favorable outcome of DS AMLM7 group compare
to Non DS AMLM7 group.
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REDUCED INTENSITY CONDITIONING TRANSPLANTS WITH POST
TRANSPLANTATION CYCLOPHOSPHAMIDE FOR RELAPSED LEUKEMIA -
A BELIEVABLE OPTION IN THE DEVELOPINGWORLD!
N. Rastogi1, S. Katewa1, S. Nivargi1, S. Kohli1, Y.R. Chopra1, S.P. Yadav1
1Fortis Memorial Research Institute, Department of Pediatric Hematology-Oncology &
BMT, Gurgaon, India
Background/Objectives: High non-relapse mortality (NRM) of myeloablative
hematopoietic stem cell transplant (HSCT) in leukemia patients with comorbidities, has
led to increased interest in Reduced intensity conditioning transplants(RIC).
Post-transplant cyclophosphamide (PtCY) with RIC is a new strategy which decreases
graft versus host disease (GvHD) without compromising graft versus leukemia (GvL)
effect. We report here the feasibility and outcome of these RIC transplants in a
developing world setting.
Design/Methods: Five children with relapsed leukemia and co-morbidities (Intracranial
bleed-1, Invasive fungal infection-2, hepatitis C-1, poor general condition-1) from
Dec2013 to Dec2014 underwent PtCY RIC HSCT. The clinical records and
investigation sheets were analyzed retrospectively. Patient’s follow-up ranged from
Day+83 to Day+305.
Results:Mean age was 11.4 year (6-19 years). All had relapsed leukemia (Acute myeloid
leukemia-1, chronic myeloid leukemia-1, acute lymphoblastic leukemia-3) and all
except one were in complete remission (CR). Conditioning was Fludarabine
(160 mg/m2), Cyclophosphamide (29 mg/kg), ATG (4.5 mg/kg), Thiotepa (8 mg/kg)
and TBI (2Gy). Three patients had matched sibling peripheral blood stem cell (PBSC)
graft, one had haploidentical PBSC and one had double cord blood (DCB) graft. Mean
CD34+ cell dose was 6.6×106/kg for patients with PBSC graft and 2.1×105/kg for DCB
graft. PtCY was given on Day+3 and Day+4 at dose of 50 mg/kg/day. All patients
engrafted. Mean neutrophil engraftment was on 18.6 day. Chimerism studies showed
fully donor in 4 and mixed chimerism in 1. Child with mixed chimerism was treated
successfully with donor lymphocyte infusion, GVHD grade3 was seen in 1 and grade2
in 2 patients. There were two deaths. The patient with DCB transplants died on D+83
due to BK virus and cytomegalovirus infection with GVHD and second patient
relapsed post-transplant and died during re-induction on Day+88. Day-100 mortality
was 40% and overall survival was 60%.
Conclusion: In relapsed leukemia patients with co-morbidities, RIC HSCT with PtCY
constitutes a feasible and effective option.
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DIFFERENTMODES TO INACTIVATE THE SECOND ALLELE OF TP53 IN
THREE INDEPENDENTMALIGNANCIES IN A YOUNG FEMALE PATIENT
WITH LI-FRAUMENI SYNDROME
B. Schlegelberger1, H. Kreipe2, U. Lehmann2, D. Steinemann1, T. Ripperger1,
G. Göhring1, K. Thomay1, A. Rump3, N. Di Donato3, M. Suttorp4
1Hannover Medical School, Institute of Human Genetics, Hannover, Germany;
2Hannover Medical School, Institute of Pathology, Hannover, Germany; 3TU Dresden,
Institute for Clinical Genetics-Medical Faculty Carl Gustav Carus, Dresden, Germany;
4University Hospital Dresden, Department of Pediatric Hematology and Oncology,
Dresden, Germany
Background/Objectives: Li-Fraumeni syndrome, a cancer predisposing syndrome,
caused by germline mutations in TP53, is associated with the development of various
tumors at a young age.
Design/Methods: Here we investigated the inactivation of the second allele of TP53 by
sequencing, TOPO TA cloning, karyotyping and FISH, in three different malignancies
that developed in a female child with Li-Fraumeni syndrome: a choroid plexus
carcinoma at the age of 4 months, a secondary acute myeloid leukemia (AML) by the
age of 4 years, and a Wilms tumor at the age of 5 years.
Results: The de novo heterozygous TP53 germline mutation c.818G>A; p.Arg273His
(rs28934576) located within the DNA binding domain of TP53 is a first and important
step towards tumorigenesis. Investigating the TP53 mutation status in all three tumor
tissues, we show that 1) in the choroid plexus carcinoma, the known germline mutation
was detected in a homozygous state as a result of loss of the wild-type allele and a
duplication of the mutant allele due to copy-number neutral LOH/uniparental disomy,
2) in the secondary AML, a complex karyotype indicating an increased genomic
instability led to the loss of TP53 - most probably the wild-type allele - due to a deletion
of 17p, and 3) in the Wilms tumor, the somatically acquired mutation c.814G>A was
identified leading to compound heterozygosity.
Conclusion: The findings show that the complete inactivation of TP53 either by loss of
the wild-type allele or by compound heterozygous mutations is the decisive step towards
tumorigenesis in this young patient with Li-Fraumeni syndrome.
P-349
CO-EXPRESSION OFMULTIPLE ABC-TRANSPORTERS IS STRONGLY
ASSOCIATEDWITH TREATMENT RESPONSE IN CHILDHOOD ACUTE
MYELOID LEUKEMIA
D. Steinbach1, S. Bartholomae1, B. Gruhn2, K.M. Debatin1, M.Z. Martin
Zimmermann3, C. Ursula3, D. Reinhardt4
1University Medical Center, Pediatrics, Ulm, Germany; 2University of Jena, Pediatrics,
Jena, Germany; 3Hannover Medical School, Pediatrics, Hannover, Germany; 4University
of Essen, Pediatrics, Essen, Germany
Background/Objectives: To analyze whether expression of ABC-transporters is
associated with remission rate and long term outcome in a prospective clinical study of
childhood acute myeloid leukemia (AML).
Design/Methods: The expression of four ABC-transporter genes (ABCA3 encoding
drug transporter ABCA3, ABCB1 encoding multidrug resistance protein 1, ABCC3
encoding multidrug resistance-associated protein 3 and ABCG2 encoding breast cancer
Pediatr Blood Cancer DOI 10.1002/pbc
SIOP ABSTRACTS S325
resistance protein) was measured by TaqMan real time PCR in pretreatment samples
from 112 children with AML. Patients were treated according to multicenter study
AML-BFM 2004.
Results: ABCC3 (p=0.009) and ABCG2 (p=0.03) were associated with a lower chance
to achieve remission after the first course of chemotherapy. ABCC3 was associated with
lower relapse free survival (p=0.02). ABCG2 was expressed at higher levels in subtypes
of AML with favorable outcome but within standard and high risk patients it was
associated with poor outcome (p=0.02). A strong association was observed between the
number of overexpressed ABC-transporters and the chance to achieve remission
(p=0.01) or the chance of relapse free survival (p<0.001).
Conclusion:Modern and intensive treatment regimens do not readily overcome drug
resistance caused by ABC-transporters. Inhibition of ABC-transporters could be
particularly useful in patients who express multiple of these genes.
P-350
ISOLATED CENTRAL NERVOUS SYSTEM RELAPSES OF CHRONIC
MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION SUCCESSFULLY TREATEDWITH CRANIOSPINAL
RADIATION, A CASE REPORT
P. Techavichit1, C. Kanhatai1, S. Lauhasurayotin1, K. Suppipat1, D. Sosothikul1
1Chulalongkorn University, Pediatrics, Bangkok, Thailand
Background/Objectives:Hematopoitic stem cell transplantation (HSCT) was considered
as one of the curative treatment for chronic myeloid leukemia (CML), a rare
hematologic malignancy among pediatric population. Isolated extramedullary relapse
in central nervous system (CNS) of CML in pediatric patient after HSCT have never
been reported.
Design/Methods: A 5–year old Thai boy presented in 2008 with fever, marked
splenomagaly was diagnosed with chronic phase CML in our institute.
Results: His initial blood counts showed anemia with hyperleukocytosis while CSF
cytology was negative. A bone marrow (BM) karyotype showed, 46,XY,t(9,22) and BM
pathology was compatible with CML in chronic phase. He was treated with
hydroxyurea follow by Imatinib. Repeated BMA and cytogenetic revealed normal study
three months after treatment. Eleven months later, he developed an episode of myeloid
blast crisis. He received induction of remission chemotherapy according to ThaiPOG
protocol for AML which consist of intravenous idarubicin, cytosine arabinoside with
concurrent intrathecal metrotrexate, cytosine arabinoside and hydrocotisone.
Subsequently, he achieved remission and underwent HSCT from matched related
donor. He received busulfan plus cyclophosphamide as a conditioning regimen. Twelve
months after transplantation, he developed ataxia. MRI of the brain and spine revealed
an infiltrative lesion sized 4×3×2 cm. involving superior cerebellar vermis with
leptomeningeal enhancement along conus medullaris. BM examination revealed
remission. A biopsy of a cerebellar tumor showed the infiltration leukemic cells with
mixed phenotype of B lymphoblastic and myeloid. IHe received whole brain (3,060
cGy) and spinal (3,170 cGy) radiation. Currently, he is in remission 4 years after the
relapse.
Conclusion: Risk factors of isolated CNS relapse in this patient include conditioning
regimen without total body irradiation and poor CNS penetration of imatinib. Given
its rarity, treatment for this entity is not yet well defined. In summary we report our
treatment experience in pediatric patient with isolated CNS relapse CML following
HSCT.
P-351
ACUTEMYELOID LEUKAEMIA (AML) TREATED ON THE RED CROSS WAR
MEMORIAL CHILDREN’S HOSPITAL (RCWMCH) TREATMENT PROTOCOL
RX 2071 (ADAPTED FROMMRC-AML15)
K. Thomas1, A. Davidson2, M. Hendricks2, A. Van Eyssen2
1Frere Hospital, East London, South Africa; 2Red Cross War Memorial Children’s
Hospital, Paediatric Oncology, Cape Town, South Africa
Background/Objectives: Due to the poor outcomes achieved in Acute Myeloid
Leukaemia (AML) treatment, the Red Cross War Memorial Children’s Hospital
(RCWMCH) Oncology service changed from a protocol based on BFM-87 to one
based on MRC-AML15.This study was to assess the outcomes and treatment – related
toxicity among children treated with RCWMCH protocol Rx 2071.
Design/Methods: This was a retrospective review of AML patients treated with RX2071
between 2007 and 2012 at RCWMCH. Patients with Acute Promyelocytic Leukaemia
(APL) and trisomy 21 were excluded. Patients with APL are treated with All Trans
Retinoic acid (ATRA), and since 2009 their protocol also includes 6- Mercaptopurine
and Methotrexate in the maintenance phase. Risk was assigned by cytogenetics. Good
risk patients were those with translocations t(8; 21) and inv(16). Poor/standard risk
included all other cytogenetics according to MRC-AML15.Data pertaining to toxicity
was obtained and captured from patient folders.
Results: Thirty five children were treated on Rx 2071. Males comprised 51.43% (18/35)
and females 48.57% (17/35). Ages ranged from 0.33 to 12.51 years with the median age
being 5.68 years. Off-treatment follow up ranged from 1 year 7 months to 6 years 8
months. Fifteen patients had favourable cytogenetics, 14 with t (8; 21) and 1 with
inv(16). Event free survival (EFS) for the good risk group was 86.7%.Twenty patients
presented with standard/poor risk cytogenetics: four did not achieve remission and
were deemed poor risk while 16 were standard risk. EFS in this group was 39.7%.
Patients had a median of 4 neutropaenic fevers, and required a median of 8 packed cell
transfusions and 11 platelet transfusions. There were 38 positive blood cultures, one
patient needed inotropic support and there were no toxicity-related deaths.
Conclusion: Results are superior to those achieved with the previous regime, and the
toxicity is not excessive.
P-352
OUTCOME OF HIGH HYPERDIPLOIDY IN INDIAN CHILDRENWITH
ACUTE LYMPHOBLASTIC LEUKEMIA
S. Vasanna1, N. Radhakrishnan2, V. Dinand2, P. Saviour3, M. Lall4, A. Sachdeva5
1Sir Ganga Ram Hospital, Pediatric Hemato Oncology - Institute of Child Health, Delhi,
India; 2Sir Ganga Ram Hospital, Pediatric Hematology Oncology Unit-Institute of Child
Health, Delhi, India; 3Sir Ganga Ram Hospital, Centre of Medical Genetics, New Delhi,
India; 4Sir Ganga Ram Hospital, Center of Medical Genetics, New Delhi, India; 5Sir
Ganga Ram Hospital, Department of Pediatric Hemato Oncology, New Delhi, India
Background/Objectives: High hyperdiploid ALL (hHALL) (51- 65 chromosomes per
cell) is a good risk subgroup that accounts for 25 – 30% cases of Pre B ALL.
Design/Methods:We analyzed the clinical presentation and outcome of children with
hHALL diagnosed at our center between 1995-2013.
Results: Two hundred and eleven children diagnosed pre B ALL with evaluable
cytogenetic and follow up data were included in this study. 58 patients (27%) had
hHALL.Those who had t(9:22) along with hHALL were excluded from the analysis.
Median age at diagnosis was 4 years. High WBC count (>20,000 cells/mL) was
observed in 19% hHALL and 25% of non-hHALL. There was no difference in median
age or sex ratio between both groups. Median duration of follow up was 4 years. 3
children with hHALL relapsed (5.7%) compared to 13 in the other group. Chromosome
21 was most commonly affected (60%) followed by 17, 6, 10, 14, 4, 5 and X. Triple
trisomy (+4, +10, +17) was observed in 4 patients.Six patients had additional
structural abnormalities. Three children with hHALL relapsed (5.7%) compared to
13(8.1%) in the non-hHALL group. One had isolated CNS and 2 had combined
relapses. No significant difference was noted regarding the site of relapse between the
two groups. Early relapses (< 18 months) were more common in non-hHALL cases
(75%). Six out of 58 hHALL patients had additional cytogenetic abnormalities and had
poor outcome compared to those without. There was no significant difference in EFS
(hHDALL 68.2 ± 8.8% vs. non hHALL 74.3 ± 4.4 %) and OS (78.3 ± 6% vs 79.8 ±
3.9%) between the two groups.
Conclusion: The prevalence of hHALL and chromosome 21 involvement was similar to
previously published literature. Pattern of relapse seems to be different in hHALL
although not statistically significant.Additional structural abnormalities reduce the
prognostic benefit of hHALL.
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EMERGING ROLE OFMICRORNA-106B25 CLUSTER IN RELAPSED
MLL-REARRANGED PEDIATRIC AML
L. Verboon1, J. Katsman-Kuipers1, A. Obulkasim1, J. de Rooij1, E. Sonneveld2,
A. Baruchel3, J. Trka4, D. Reinhardt5, R. Pieters6, J. Cloos7, G. Kaspers7, M. Fornerod1,
J.H. Klusmann8, C.M. Zwaan1, M. van den Heuvel - Eibrink6
1Erasmus MC University Medical Center, Pediatric Oncology, Rotterdam, Netherlands;
2Dutch Childhood Oncology Group DCOG, Central Laboratory, The Hague,
Netherlands; 3Hopital Saint-Louis, Hematology, Paris, France; 42nd Medical
School-Charles University, Pediatric Hematology/Oncology, Prague, Czech Republic;
5Children University Hospital, Pediatric Hematology/Oncology, Essen, Germany;
6Princess Máxima Center, Pediatric Oncology, Utrecht, Netherlands; 7VU University
Medical Centre, Paediatric Oncology/Haematology, Amsterdam, Netherlands;
8Hannover Medical School, Pediatric Hematology/Oncology, Hannover, Germany
Background/Objectives:Mixed lineage leukemia (MLL) rearrangements represent about
15-20% of pediatric acute myeloid leukemia (AML) cases. Survival rates have increased
over the past decades, still, approximately 30-40% will relapse during or after therapy.
The role of microRNAs (miRNAs) in leukemogenesis of MLL-rearranged AML,
especially towards the development of relapse, is unknown.
Design/Methods: To determine whether specific miRNAs are involved in relapse
development, we performed miRNA profiling, using TaqMan Low Density Array
(TLDA) in 6 paired initial diagnosis–relapse pediatric AML samples with
MLL-rearrangements. An independent set of 8 paired initial diagnosis-relapse cases
was used to confirm the identified miRNAs using single stemloop RT-qPCR.
Expression of predicted targets of differentially expressed miRNAs were determined
with RT-qPCR (n=14) and Western blot (n=3) in paired samples. Samples were based
on material availability.
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Results: Fifty-three miRNAs were significantly differentially expressed (FDR <0.1) in
the 6 paired cases. miR-106b, miR-93 and miR-25 (miR-106b25 cluster), located as a
cluster in intron 13 of MCM7, were overexpressed in relapse patient samples, as well as
in 8 additional paired samples (n=14, p<0.05). E2F1, a transcription factor, acts a as
an upstream regulator of MCM7.MCM7 and E2F1 expression based on RT-qPCR
was significantly higher expressed in relapse samples compared to initial (n=14,
p=0.008 and p=0.006, respectively). On protein level, a decrease of two targets of the
miR-106b25 cluster, p21WAF1/CIP1 and BIM protein was found at relapse in 2/3 paired
samples, although no difference in mRNA expression was found.
Conclusion: p21WAF1/CIP1 and BIM are important proteins for the cell cycles and
apoptosis, respectively. Overexpression of miR-106b-25 cluster and decreased of
p21WAF1/CIP1 and BIM protein at relapse may play an important role in relapse pediatric
AML withMLL-rearrangements. Further research is warranted to identify the role of
this cluster for clinical resistance and as treatment target.
Posters: Neuroblastoma
P-354
I131 META-IODOBENZYLGUANIDINE THERAPY IN CHILDRENWITH
ADVANCE NEUROBLASTOMA. THE EXPERIENCE OF A HOSPITAL
R. Adan1, R. Rubio1, J. Udaondo1, O. Lopez-Macias2, A. Echebarria1,
R. Lopez-Almaraz1, M. Garcia-Ariza1, J. Genolla3, T. Rodriguez-Inchausti3,
I. Astigarraga1
1Hospital de Cruces, Pediatric Oncology, Barakaldo-Bizkaia, Spain; 2Hospital de Cruces,
Pediatric, Barakaldo-Bizkaia, Spain; 3Hospital de Cruces, Nuclear Medicine,
Barakaldo-Bizkaia, Spain
Background/Objectives: Survival rate of advance neuroblastoma is low therefore,
improved therapeutic strategies are necessary. I 131 meta-iodobenzylguanidine (MIBG)
has been used as treatment for advance or relapse neuroblastomas in an attempt to
improve prognosis. This study describes our experience with MIBG.
Design/Methods: Retrospective study of patients diagnosed with neuroblastoma,
younger than 21 years, treated with MIBG in our hospital. We collected data about age,
stage of disease at diagnosis, previous treatment, disease at the time of MIBG therapy,
toxicity and follow up.
Results: Ten patients received MIBG therapy. Two of them had N-myc amplification.
Stages at diagnosis were: one patient stage II, other stage III and eight stage IV. Three
of those 10 patients received a second dose of MIBG, thus a total of 13 treatments were
considered: eight received treatment at first relapse/progression; two at second and the
three remaining at third relapse/progression. Adverse events were: one acute thyroiditis,
four oral mucositis (none of them required parenteral nutrition), neutropenia grade 4 in
7 patients (with no severe infections), all patients had grade 4 thrombocytopenia
(without hemorrhagic complications), one patient had grade 4 anemia, six grade 3, and
three patients grade 2. Eight out of 10 died from the disease: one of them at 90 and 3
months after the first and second doses of MIBG; another at 43 and 8 months after the
administration of treatment; a third one at 14 and 7 months after the respective doses;
and the remaining five patients died within 30, 22, 6, 5 and 5 months of therapy; one
patient is in complete remission and other alive with disease progression at the time of
the study.
Conclusion: Treatment with MIBG has benefits in neuroblastomas in
relapse/progression improving survival rates without severe toxicity.
P-355
DETERMINATION OF THE EXPRESSION OF ALK PROTEIN IN
NEUROBLASTIC TUMORS (NT) IN CHILDHOOD. ASSOCIATIONWITH
PROGNOSIS DETERMINANTS
S. Alderete1, F. Gonzalez1, S. Estevez1, M. Cores1, G. Puppa1, M. Urbieta1, E. De
Matteo1, M. Garcia Lombardi1
1R. Gutierrez Children Hospital, Buenos Aires, CABA, Argentina
Background/Objectives: Recently, changes in the ALK gen (mutation, amplification,
translocation) have been implied in the oncogenic pathways of neuroblastic tumors
(NT), through the inhibition of apoptotic mechanisms, with the consequent adverse
outcomes. The over-expression of ALK (ALK+) is, for some authors, an independent
adverse prognostic determinant. To systematize the study of ALK status in NT, would
allow the identification of those cases that might evolve in adverse ways and to modify
the treatment. The use of Crizotinib would be a therapeutic target for these patients. To
determine the expression of ALK protein by inmunohistochemistry in NT and
associate it with other known prognosis determinants.
Design/Methods: Clinical charts and histopathological reports were evaluated in 23
patients with primary NT, diagnosed between January 2007 and December 2014. The
International Classification for NT was used. The variables evaluated in patients with
ALK + were: age, gender, stage, histology and NMYC amplification. Overall Survival
(OS) and Event Free Survival (EFS) were analyzed with the Kaplan Meier Estimator.
Results: Twenty three patients were evaluated, male 13 (54%). Median age 29 months
(range 1-130). Five patients had ALK +; 3 of them were Stage IV with N-MYC
non-amplified, histological type was 1 patient differentiating, 1 patient
ganglioneuroblastoma intermixed and 1 poorly differentiated, all of them with adverse
results and death. The remaining 2 patients were Stage 1, with non evaluated N-MYC
with histological subtype undifferentiated (1 patient) and 1 differentiating, both in
complete remission today. Median follow-up 30 months (range 0.3-85). EFS and OS 40
%.
Conclusion: Although the small sample, three of the relapsed patients presented
non-amplified NMYC and ALK+, these might indicate ALK as an adverse prognostic
factor in these patients. It would be useful to evaluate the efficacy of Crizotinib as a
therapeutic target in these patients.
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NEUROBLASTOMA IN SAUDI ARABIA: SINGLE CENTRE EXPERIENCE
Z. Alnaqib1, M. Rayis2, A. Ahmad3, A. Alanazi2, M. Alaharbi2, F. Almanjomi2,
T. Wani4, W. Ballourah2, O. Mosleh2, Z. Ullah2
1King Fahd Medical City, Riyadh, Saudi Arabia; 2King Fahd Medical City, Pediatric
Hematology Oncology, Riyadh, Saudi Arabia; 3King Fahd Medical City, Laboratory
Department, Riyadh, Saudi Arabia; 4King Fahd Medical City, Clinical Research, Riyadh,
Saudi Arabia
Background/Objectives: Neuroblastoma is the most common extracranial solid tumour
in childhood. While the survival has improved in the last few decades, children with
high-risk neuroblastoma still have very poor outcomes despite aggressive treatment,
with significant Short- and long-term complications. We aimed to assess the trends of
overall survival (OS) and event free survival (EFS) of patients with neuroblastoma
treated at King Fahad Medical City (KFMC)nd to correlate the survival data with the
clinical, pathological and biological features of the tumors.
Design/Methods: Retrospective observational study of all patients, with diagnosis of
neuroblastoma, who attended on KFMC and treated on Children Oncology Group
based protocol, period July 2006 to June 2014.
Results: Eight years neuroblastoma data was available for the 42 patients of which
22(52.5%) were male and 20(47.6%) were females. Age at diagnosis was in between 0
and 91 months with mean and median 26.3± 3.7 and 18.5 months respectively. Sixteen
(38.1%) patients were under one year and 26(61.9%) above 1 year of age. The OS and
EFS rates were 71.5% and 66.5% respectively. Patients under one year of age did better
with OS and EFS 82% and 75% respectively, p<0.05 , whereas were 62% and 59%
respectively, p<0.05 on patients older than one year of age. OS and EFS at the end of
interval in Low Risk group was 100.0%, Intermediate Risk group was 100.0% and High
Risk group was 55% and 48.0% respectively. The difference was significant (p < 0.05).
Conclusion: Our results are very encouraging and comparable with the known
published of other international cohorts, with an excellent outcome for stage 1, 2,3&4s.
The prognosis for advanced (Stage 4) remains rather poor. A collaborative Saudi-wide
effort, with an emphasis on research in detecting biologic characteristics of aggressive
disease and tailoring therapy, is needed.
P-357
BUSULFAN/MELPHALAN CONDITIONING REGIMEN FOR AUTOLOGOUS
TRANSPLANTATION IN HIGH-RISK NEUROBLASTOMA: EARLY TOXICITY
AND OUTCOME REPORT FROM A SINGLE INSTITUTION
F. Alshehri1, M. Bayoumy1, M. Alam1, I. Abosoudah1
1King Faisal Specialist Hospital and Research Center-Jeddah, Oncology, Jeddah,
Kingdom of Saudi Arabia
Background/Objectives: Neuroblastoma is the most common extracranial solid tumor,
accounts 8% of childhood cancer. Busulfan/Melphalan (BuMel) conditioning regimen
is recommended by SIOPEN in treatment of high-risk neuroblastoma (HRNB). BuMel
toxicity outcome data is lacking following COG induction. The aim of this study is to
determine the toxicity of BuMel conditioning regimen in pediatric patients with HRNB
at King Faisal Specialist Hospital and Research Center-Jeddah.
Design/Methods: Retrospective chart review was done and clinical, laboratory and
outcome data of 19 pediatric patients with HRNB admitted between May 2011 and
Oct. 2014 were analyzed.
Results: Out of 19 patients 13 (68.4%) were males. The mean age at diagnosis was 3.6
(+/-2.5) years. Seven (36.8%) patients were treated with CCG 3891 protocol while 12
(63.2%) patients with COG A3973 protocol. Mucositis 15 (78%) was the most common
toxicity observed followed by bleeding 14 (74%) (10/14 had GIT bleeding), Sinusoidal
obstruction syndrome (SOS) in 8 (42%) out them 6 had moderate SOS, fungal infection
7 (37%), bacterial infection 6 (31.5%), CMV reactivation 3 (16%) and hemorrhagic
cystitis 1 (5%). None of them developed idiopathic Pneumonia Syndrome. The median
ANC and platelet recovery was 17 (range: 12-48) days and 80 (range: 14-510) days
respectively. Transplant related mortality at day +100 is 5% and overall relapsed rate is
37% with mean time of relapse 4.7 months. Event free survival is 63% and overall
survival is 58% with mean duration of follow up 8.2 months.
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Conclusion: Our study showed potential benefit of BuMel as a conditioning in HRNB
treatment. However, we observe high incidence of SOS and delayed platelet recovery.
Further large scale multi-center long term follow up study will be needed.
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OUTCOME OF CHILDRENWITH HIGH RISK NEUROBLASTOMA TREATED
IN NORTHERN EGYPT
H. Alsheikh1, N. Mashali2, H. Badawy3, A. Abd-Elkarem4, S. Fadel1
1Faculty of Medicine, Pediatric Oncology Unit, Alexandria, Egypt; 2Faculty of
Medicine, Pathology, Alexandria, Egypt; 3Faculty of Medicine, Urology, Alexandria,
Egypt; 4Faculty of Medicine, Diagnostic and intervention Radiology, Alexandria, Egypt
Background/Objectives: The long-term survival probability for children with high-risk
disease historically was less than 15%. Better results have been achieved using an
aggressive multimodality approach. Despite aggressive multimodality therapy, current
survival rates remain unacceptably low. Limited resources form a barrier to apply
different treatment modalities and manage treatment related toxicities.
Design/Methods: A retrospective review of the clinical records of all patients younger
than the age of 18 years diagnosed with high risk Neuroblastoma and treated at
Alexandria University Hospital Pediatric Oncology unit according to
HRNBL1/SIOPEN protocol, over a period of 4 years (2010– 2014).The primary
outcome was Overall survival and a secondary outcome progression free survival rates
were calculated.
Results: Out of 104 patients confirmed as Neuroblastoma, 58 patients (56%) stratified
as high risk. The age at presentation varied between 9 to 72 months with a median of 37
months .There were 29 males (50%) and 29 females (50%).Primary site was Adrenals in
43 patients (75%), abdominal retroperitoneal in 13 patients (22%),Thorasic
paravertebral in 2 patients (3%). Stage M was the most common in 56 patients
(97%).NMYC amplification was done in 6 patients and was amplified in 3 patients
(50%). surgery was incomplete in 26 patients (62%), Complete or minimal residual in 13
patients (31%) and was avoided due to major risk in 3 patients (7%). There were 33
patients candidate for Autologus Bone marrow transplantation, only 20 of them (60%)
were transplanted and 13 patients relapsed before BMT, with a mean time delay to the
BMT was 5.3 months. Median follows up was 17 months. The 2-year PFS and OS were
29% and 34% respectively.
Conclusion: The outcome in our setting is better than reported outcomes without BMT
but worse than reported outcomes with BMT, this could be attributed to the delay
between end of induction therapy and the BMT.
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OUTCOME OF CHILDRENWITH NON HIGH RISK NEUROBLASTOMA
TREATED IN NORTHERN EGYPT
H. Alsheikh1, N. Mashali2, H. Badawy3, A. Abd-Elkarem4, S. Fadel1
1Faculty of Medicine, Pediatric Oncology Unit, Alexandria, Egypt; 2Faculty of
Medicine, Pathology Department, Alexandria, Egypt; 3Faculty of Medicine, Urology
Department, Alexandria, Egypt; 4Faculty of Medicine, Diagnostic and Interventional
Radiology, Alexandria, Egypt
Background/Objectives: Neuroblastoma is a disease exhibiting extreme heterogeneity
varying in location, histopathologic appearance, and biologic characteristics.
Multimodality therapy including chemotherapy and/or surgery are the mainstay for
therapy in very low, low and intermediate risk Neuroblastoma or even observation in
some patients with stage MS Neuroblastoma. Recent focus has been to reduce therapy
for low and intermediate risk Neuroblastoma while maintaining survival rates at
90%.Limited resources can be challenging in diagnosis, risk stratification and treatment.
Design/Methods: A retrospective review was made of the clinical records of all patients
younger than the age of 18 years diagnosed with very low, low and intermediate risk
Neuroblastoma and treated at Alexandria University Hospital Pediatric Oncology unit
according to SIOP Europe Neuroblastoma (SIOPEN) study protocol, over a period of
4 years (2010 – 2014).The primary outcome examined was Overall survival and a
secondary outcome progression free survival rates were calculated.
Results: Out of 104 patients histologically confirmed as Neuroblastoma, 46 patients
(44%) stratified as very low, low and intermediate risk. The age at presentation varied
between 1 week to 120 months with a median of 9 months .There were 30 males (65%)
and 6 females (35%).Primary site was Adrenals in 26 patients (56%), abdominal
retroperitoneal in 8 patients (17%) ,Dumbell tumour in 6 patients (13%) and others in 6
patients (14%). Stage was L2, MS, L1 & M (54%,26%, 18% & 2%) respectively .NMYC
amplification was done in 12 patients (26%).surgery was incomplete in 15 patients
(48%) Complete in 14 patients (45%).Median follow up was17 months. The 2-year PFS
and OS were 77% and 82% respectively.
Conclusion: Our results in a limited resource country, is close to published data, when
multimodal treatment was applied.this reflects the non demanding nature of the
treatment of low/intermediate risk Neuroblastoma.
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RESPONSE TO RE-VACCINATION IN CHILDREN AFTER TREATMENT FOR
SOLID TUMORS
S. Anak1, E. Erdem Ozcan1, A. Kilic2, M. Onel3, A. Ozguven1, A. Unuvar1,
Z. Karakas1, G. Ozturk1, A. Agacfidan3, O. Devecioglu1, L. Agaoglu1
1Istanbul University Istanbul Medical Faculty, Department of Pediatric Hematology
Oncology, Istanbul, Turkey; 2Istanbul University Istanbul Medical Faculty, Department
of General Pediatrics, Istanbul, Turkey; 3Istanbul University Istanbul Medical Faculty,
Department of Microbiology, Istanbul, Turkey
Background/Objectives: The aim of this study was to examine effectiveness of
re-vaccination in pediatric patients with solid tumors at least 6 months after the
cessation of the of treatment.
Design/Methods: The study was performed prospectively in 35 patients with solid
tumors. Diphtheria, tetanus, acellular pertussis, hepatitis B, hepatitis A,
measles-mumps-rubella (MMR) and varicella vaccines were applied to patients.
Results: In patients with various solid tumors, 80% of patients had complete protection
against diphtheria and 88,5% against tetanus before vaccination, but only 28,6%
against hepatitis A. All seronegative patients achieved protective antibody levels after
one dose against diphtheria, tetanus and hepatitis A. Before vaccination, 54.3% of
patients were protected against pertussis and 66,7% against hepatitis B. For pertussis,
60% of patients achieved protective antibody levels after one dose, but 64,2 % for
Hepatitis B. Before vaccination, 34.4% of patients were seropositive against measles.
After one dose, 73.3% of seronegative patients achieved protection. Before vaccination,
78.1% and 71,9 % of patients were seropositive against rubella and mumps respectively,
all seronegative patients achieved full protection against rubella and mumps after one
dose. Fifty-nine point four percent of patients were seropositive against varicella before
vaccination. 87,5 % became seropositive after one extra dose.
Conclusion: In our study, patients had very good antibody response against diphtheria,
tetanus, hepatitis A, rubella and mumps vaccines at least 6 months after the cessation
of therapy. Performing one booster dose of these vaccines appeared to be sufficient for
all groups. Protection after pertusis, hepatitis B, measleses and varicella zoster vaccines
were in moderate levels. The patients showed different antibody responses to vaccines,
depending on age, the time passed after the cessation of treatment and their primary
vaccination status. Antibody levels should be followed to evaluate the response
obtained. A booster should be considered when there is a decrease or loss in antibody
levels.
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VENETOCLAX IS A PROMISING DRUG FOR THE FUTURE PERSONALIZED
TREATMENT OF NEUROBLASTOMA PATIENTS WITH HIGH BCL-2
EXPRESSION
L. Bate-Eya1, I. Van der Ploeg1, I. den Hartog1, L. Schild1, J. Koster1, R. Versteeg1,
H. Caron1, J. Molenaar1, E. Dolman1
1Academic Medical Center University of Amsterdam, Oncogenomics, Amsterdam,
Netherlands Background/Objectives: The anti-apoptotic B cell lymphoma proteins are
highly expressed in numerous cancer types and have been shown to play an oncogenic role.
BCL-2 is highly expressed in neuroblastoma tumours. Previous studies showed that BCL-2
knockdown with shRNA or inhibition with small molecule inhibitor navitoclax induced a
strong apoptotic response in neuroblastoma cells expressing high BCL-2 levels.
Additionally, navitoclax delayed the onset of neuroblastoma tumour formation in vivo.
Unfortunately, navitoclax causes dose-limiting thrombocytopenia in patients due to
inhibition of BCL-XL. We therefore studied in vitro and in vivo responses of
neuroblastoma cells treated with the new and more specific BCL-2 inhibitor venetoclax.
Design/Methods:We used in silico analysis of the BCL-2 family members mRNA levels,
protein expression and the BIM/BCL-2 complex levels of neuroblastoma lines (n=24)
as selection biomarkers for sensitivity to venetoclax. Immunoprecipitation of BIM
displaced from BCL-2 in vitro and in vivo served as an efficacy biomarker for sensitivity
to venetoclax. In vivo experiments were performed in NMRI nu/nu mice with
subcutaneous KCNR xenografts.
Results:We show that venetoclax induces strong apoptotic responses in cell lines with
high BCL-2 expression levels, indicated by dose-dependent cytochrome c release from
the mitochondria into the cytoplasm and PARP cleavage. The in vitro efficacy of the
compound was ascertained by BIM displacement from BCL-2. Combining venetoclax
with cytostatics used in neuroblastoma treatment showed synergistic responses.
Venetoclax significantly inhibited the growth of high BCL-2 expressing neuroblastoma
xenografts in mice. Despite complete displacement of BIM from BCL-2 and increased
cleaved caspase 3 levels, complete tumour regression was not observed.
Conclusion: Taken together, our findings suggest that BCL-2 inhibition with venetoclax
strongly induces cell death in neuroblastoma cells expressing high BCL-2 levels.
However, resistance to the compound does occur, indicating the necessity of
combination treatment with other targeted inhibitors and cytostatics to overcome
neuroblastoma resistance to venetoclax.
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COMPARISON OF THE SIOPEN ANDMODIFIED CURIE SCORING AND
CORRELATIONWITH THE PROGRESSION FREE SURVIVAL IN STAGE IV
NEUROBLASTOMAS:SINGLE INSTITUTIONAL EXPERIENCE
C. Bongulwar1
1Tata Memorial Hospital, Mumbai, India
Background/Objectives: Semi-quantitative studies using MIBG scoring have been
devised that are easy to use with short training time, reliable and reproducible,
facilitates comparison between results obtained by different investigators and centres
,readily adapted to multi-center use and have been validated for this purpose. Initial
evolved scoring system included the French group Curie scoring by Curie Institute in
France and the recently evolved SIOPEN scoring .The aim of the present study is to
comparison between the Modified Curie and the SIOPEN scoring in Indian patient
population in terms of inter-score and inter-observer reliability and correlate with the
progression free survival.
Design/Methods: Data of 92 MIBG scans of 60 patients was retrospectively analyzed in
patients diagnosed or suspected to have stage IV high risk neuroblastomas at initial
staging, post induction, follow up and suspected recurrence (known MIBG avid
disease).These scores were assessed for interscore and inter observer variability using
the Spearman’s coefficient of variation .Absolute and relative scores (post therapy
scores divided by the pre therapy scores were obtained). Correlation with the
progression free survival using Kaplan Meier survival analysis was done.
Results: Scoring results were highly correlated between both methods, and inter
observer reliability was excellent at both initial staging and at post induction. A Curie
score </= 2 and a SIOPEN score </= 4 (best cut off) at post induction were correlated
to significantly better progression free survival.Patients with lower initial scores were
more likely to reach complete remission at the end of induction. Achieving a lowMIBG
score is more important than achieving a specified reduction in the MIBG scores.
Conclusion: The modified Curie score and SIOPEN score have an excellent inter
observer reliability with an excellent inter-score comparison. Both the scoring systems
at post induction correlates with event free survival.
P-363
BORTEZOMIB BASED CHEMOTHERAPY IN RELAPSED NEUROBLASTOMA
AS A BRIDGE TOMIBG THERAPYWITH STEM CELL TRANSPLANT
Y.R. Chopra1, S. Katewa1, S. Nivargi1, S. Kohli1, N. Rastogi1, S.P. Yadav1
1Fortis Memorial Research Institute, Pediatric Hematology Oncology and Bone Marrow
Transplant Unit, Gurgaon, India
Background/Objectives: Bortezomib is a proteasome inhibitor and inhibits cell growth
and angiogenesis in neuroblastoma cells. The aim of the study was to evaluate safety
and efficacy of Bortezomib based chemotherapy for relapsed neuroblastoma as a bridge
to MIBG therapy and autologous stem cell transplant (SCT).
Design/Methods: All children with relapsed neuroblastoma were treated with at least 2
courses of chemotherapy Bortezomib 1 mg/mt2 day1, 4, 8, 11, Cyclophosphamide 440
mg/ mt2 day1-5, Etoposide 100 mg/ m2 day1-5 and All-Trans Retinoic acid (ATRA) 25
mg/ mt2 day1-28 after taking informed consent of the parents. Data regarding side
effects (NCI Grading) was collected prospectively and response was assessed after 2
courses by PET-CT scan and bone marrow (BM) examination.
Results: Three children who had relapsed after autologous SCT (male-2, female-1) were
given a total of six courses. Median age was 4.5 years. Sites of relapse were
abdominal-3, BM-3, Bone-1 and Brain-1. Mean duration of hospital stay was 7.3
days/cycle. Grade-3 oral mucositis and thrombocytopenia was noted in all. Grade-3
neutropenia seen in each cycle. Sepsis workup negative in 2 children (4 cycles). One
child (cycle 2) developed invasive aspergillosis; one had Grade -1 neurotoxicity in the
form of self-limiting hallucinations with normal MRI Brain. PET-CT post 2 cycles
could be done only in 2 as third child moved to another centre showed no to markedly
decreased FGD avidity in the lesions. BM was negative for tumor cells in both these
cases. They both successfully underwent MIBG therapy combined with myeloablative
chemotherapy followed by autologous SCT in one and haploidentical SCT in other.
Conclusion: Bortezomib based chemotherapy can be safely used to treat relapsed
neuroblastoma with acceptable side effects. Its efficacy seems to be good as a bridge to
MIBG and SCT but it needs to be confirmed in a setting of multi-centric clinical trial.
P-364
CONGENITAL NEUROBLASTOMA PRESENTINGWITH SYMPTOMATIC
EPIDURAL COMPRESSION AT BIRTH
B. De Bernardi1, S. Sorrentino1, A.R. Gigliotti2, M.A. De Ioris3, M. Podda4,
M. Cellini5, C. Gandolfo6
1G.Gaslini Institute, Haematology-Oncology, Genoa, Italy; 2G.Gaslini Institute,
Epidemiology-Biostatistics and Committees Unit, Genoa, Italy; 3Bambino Gesù
Children’s Hospital, Haematology-Oncology, Roma, Italy; 4Istituto Nazionale Tumori,
Paediatric Oncology, Milano, Italy; 5University of Modena and Reggio Emilia,
Haematology-Oncology Unit-Department of Paediatrics, Modena, Italy; 6G.Gaslini
Institute, Paediatric Interventional Radiology and Neuroradiology Unit, Genoa, Italy
Background/Objectives: Seven-10% of neuroblastoma present with symptoms of
epidural compression (SEC). The optimal treatment of this condition is undefined.
More than a half these patients develop permanent sequelae. Occasionally, SEC are
discovered at birth. The related literature is limited to few cases with short follow-up.
None of the survivors recovered neurologically, with the exception of the two described
most recently, delivered prematurely. The three cases described herewith were followed
for a minimum of 5 years.
Design/Methods: Of 1,436 patients aged 0-18 years diagnosed with neuroblastoma
between 2000-2011 enrolled in the Italian Neuroblastoma Registry, 75 (5.2%) presented
with SEC, and 3 (0.28%) had SEC at birth.
Results: The three patients were born at term of pregnancy. Third trimester ultrasound
was performed in all and was read normal. Details on clinical presentation, therapy,
neurologic response and sequelae are summarized as follows. Case 1/F/ 2008; Gestation
weeks 40; Symptoms of SEC: limbs hypotonia and poor motility; Therapy: 2
CARBO/VP, 2 CADO, steroid Neurologic response: improved; FU mos 168;
Sequelae:neurologic bladder, paraparesis, walking with casting, scoliosis. ; Case 2/F/
2008; Gestation weeks 39; Symptoms of SEC: limbs hypotonia, no spontaneous
movement and reflexes; Therapy: 2 CARBO/VP, steroid; Neurologic response:
improved; FU mos: 81; Sequelae:neurologic bladder, walking with casting,
constipation. Case 3/M/ 2011; Gestation weeks 38; Symptoms of SEC; limbs hypotonia
and gluteal muscles hypotrophy; Therapy:4 CARBO/VP, 2 CADO, steroid;
Neurological response: improved; FU mos: 77; Sequelae:neurologic bladder, leg
hypotrophy, right equinus-varous foot.
Conclusion: These three cases confirm that newborns with neuroblastoma and SEC are
destined to develop permanent sequelae. However, two cases described on 2008, who
were delivered prematurely following ultrasonic detection of an intracavitary paraspinal
tumour, survive free of sequelae. Routine third trimester ultrasound should take into
greater account the possibility of detecting paravertebral tumours. Following
foetal-MR scan the interdisciplinary team should discuss the possibility of anticipating
patient’s delivery.
P-365
ITCC BIOLOGY: PRE-CLINICAL TARGETED DRUG DEVELOPMENT FOR
HIGH-RISK PEDIATRIC CANCERS
E. Dolman1, H. Caron2, M. den Boer3, A. Verschuur2, J. Koster1, J. Molenaar1
1Academic Medical Center University of Amsterdam, Oncogenomics, Amsterdam,
Netherlands; 2Academic Medical Center University of Amsterdam, Pediatric Oncology,
Amsterdam, Netherlands; 3Erasmus MC, Pediatric Oncology and Hematology,
Rotterdam, Netherlands
Background/Objectives: The European consortium Innovative Therapies for Children
with Cancer (ITCC) has been created in 2003 and aims to develop novel therapies for
pediatric cancers. Within the consortium, ITCC Biology endeavours to supply the
biological rationale for targeted drug trials in children with cancer. Therefore, a stepwise
pipeline for the pre-clinical testing of targeted drugs across high-risk pediatric cancer
types has been set-up, from drug selection to in vivo evaluation. Currently, ITCC
Biology focusses on opportunities for further expansion and development of the
pre-clinical drug development pipeline.
Design/Methods: The bioinformatics platform R2 (http://r2.amc.nl) will be expanded
with genomics data for (not yet covered) pediatric cancer types and gene signatures that
can predict the activation status of actionable signaling pathways. To quickly analyze
protein expression levels of drug targets in large series of primary tumour samples, a
new tissue-microarray facility is being developed. In addition, a robotic platform
allowing high-throughput drug testing across multiple cell lines is being set-up.
Results: Targeted inhibitors venetoclax, cobimetinib, binimetinib, selumetinib,
trametinib, alectinib, crizotinib, LDK378, ribociclib, RG7388, TH588 and AT7519 have
been selected for the first cytotoxicity screen in a panel of 33 cell lines representing 6
types of pediatric cancer. The bioinformatics platform R2 has been expanded with
mRNA profiling data for primary Ewing sarcoma and osteosarcoma and gene
signatures predicting the activity of the PI3K-mTOR and RAS-MAPK pathways.
Preliminary tests to study manual versus robotic drug screening showed similar results
with both techniques. Currently, the optimal seeding densities and growth rates for all
cell lines are being determined. The first screen will be performed within the next 6
months.
Conclusion: Proposed improvements in pre-clinical drug testing should eventually lead
to more drugs entering clinical trials for pediatric cancer treatment and the faster
discovery if drugs might be useful for more than one cancer type.
P-366
INHIBITION OF RHO-ASSOCIATED KINASE 2 INHIBITS MALIGNANT
PROGRESSION IN NEUROBLASTOMA BY INDUCING DIFFERENTIATION
ANDMYCN DEGRADATION
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C. Dyberg1, D. Forsberg2, S. Fransson3, J. Lännerholm-Palm2, B. Sveinbjornsson4,
T. Martinsson3, P. Kogner2, J.I. Johnsen2, M. Wickstrom2
1Karolinska University Hospital, Stockholm, Sweden; 2Karolinska University Hospital,
Women and Children Health, Stockholm, Sweden; 3University of Gotenburg, Medical and
Clinical Genetics, Gotenburg, Sweden; 4University of Tromso, Immunology, Tromso,
Norway
Background/Objectives: The non-canonical Wnt/planar cell polarity (PCP) pathway
regulates cytoskeletal organization, migration and neuritogenesis. Signaling is
characterized by activation of the GTPases Rho and Rac, and the downstream
Rho-associated protein kinases (ROCKs). Neuroblastoma is a malignant embryonal
tumor of the sympathetic nervous systems, often with poor prognosis. The need for
novel therapeutic approaches is great. Genetic analyses have revealed mutations and
aberrations in the regulators Rho/Rac in neuroblastoma. The aim of this study was to
characterize the Wnt/PCP signaling and the effects of ROCK inhibition in
neuroblastoma.
Design/Methods: Cytotoxic activity of ROCK inhibitors was studied in cell viability
assays. Morphology and invasion were studied with microscopy. The molecular
mechanisms were characterized using cell- and molecular biology techniques. In vivo
studies in mice were carried out to validate the therapeutic effects and toxicity.
Results: Several mediators in the pathway were differentially expressed in cell lines and
patient samples. Using compounds blocking ROCK1 and ROCK2 activity revealed that
the ROCK2 inhibitor HA-1077 effectively repressed proliferation and reduced cell
viability in neuroblastoma. Additionally, HA-1077 inhibited migration and induced
differentiation through initiating neural outgrowth. Furthermore, HA-1077 reduced the
growth of established neuroblastoma xenografts in nude mice.
Conclusion: These results suggest that non-canonical Wnt signaling in general and
ROCK in particular is a promising new therapeutic target for high-risk neuroblastoma.
P-367
EXOSOMES FROMMYCN-AMPLIFIED NEUROBLASTOMA CONTAIN
ONCOGENIC MICRORNAS
T. Flægstad1, B.H. Haug1, Ø. Hald1, P. Utnes1, C. Løkke1, C. Einvik1
1Institute of Clinical Medicine, Pediatrics, Tromsø, Norway
Background/Objectives: The MYCN oncogene is frequently amplified in neuroblastoma
and is associated with aggressive disease and treatment failure. MYCN induces
expression of different miRNAs, which are posttranscriptional regulators of gene
expression with established roles in neuroblastoma development.
Design/Methods:We have isolated and characterized exosomes from MYCN amplified
cell lines, and here demonstrate their ability to be taken up by other cells.
Results: In this study, we show that MYCN -amplified cell lines not only express
miRNAs with functions inside the cell, but also secrete populations of miRNAs inside
small vesicular structures called exosomes, with the ability to shuttle to other cells. By
profiling the miRNA expression, we demonstrate high expression of a group of
established oncomirs in exosomes from two MYCN- amplified cell lines. Despite the
fact that other studies have demonstrated the ability of exosomal miRNAs to regulate
their targets in recipient cells, we did not observe this with exosomes from MYCN
-amplified cells. However, exosomes were able to induce in vitro angiogenic tube
formation, suggesting that they can have tumorigenic properties.
Conclusion: These new findings reveal a potential new way for MYCN -amplified
neuroblastoma cells to interact with their environment.
P-368
MICRORNAS AND CHEMORESISTANCE IN NEUROBLASTIOMA
T. Flægstad1, S. Roth1, S. Bhavsar1, C. Løkke1, P. Utnes1, C. Einvik1
1Institute of Clinical Medicine, Pediatrics, Tromsø, Norway
Background/Objectives: Neuroblastoma represents the most frequently diagnosed solid
tumor in infants. Chemoresistance is a major obstacle in treating high risk
neuroblastoma. Several studies indicate that deviant expression of certain miRNAs
correlate with poor clinical outcome in neuroblastoma. However, the role of miRNAs
in neuroblastoma cell resistance to chemotherapeutic drugs is poorly understood. The
understanding of biological and molecular aspects of miRNA-mediated drug
resistance in neuroblastoma may provide exciting opportunities for therapy of
aggressive neuroblastoma. The aim of this study is to determine potential miRNAs that
could be linked to chemoresistance in neuroblastoma.
Design/Methods: To investigate the role of miRNAs for drug resistance in
neuroblastoma, ten neuroblastoma cell lines were used. These cell lines consisted of five
isogenic pairs isolated from the same patient before treatment and after relapse.
Results: A miRNA cDNA library was been generated from all neuroblastoma cell lines
used in this study. To identify differentially expressed miRNAs between cell lines
deriving from patients before and after chemotherapy, a deep sequencing analysis
(SOLiD sequencing) was performed using the miRNA cDNA library. To analyze
miRNA expression data in the context of known biological functions, “Ingenuity
Pathway Analysis” (IPA) was used.
Conclusion: Differential expression of miRNAs upon chemotherapy in neuroblastoma
cell lines is predicted to alter biological functions associated with drug resistance.
Manipulation of one or more of these miRNAs could be a potential new therapeutic
approach to overcome neuroblastoma chemoresistance.
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EXPERIENCE WITH HIGH RISK NEUROBLASTOMA IN JORDAN
H. Halalsheh1, T. Ismael1, K. Ghandour2, A. Almousa3, R. Deebajah1, N. Alshawabkeh4,
I. Sultan5
1King Hussein Cancer Center, Pediatric, Amman, Jordan; 2King Hussein Cancer Center,
Surgery, Amman, Jordan; 3King Hussein Cancer Center, Radiation Oncology, Amman,
Jordan; 4King Hussein Cancer Center, Nursing, Amman, Jordan; 5King Hussein Cancer
Center, Pedatric, Amman, Jordan
Background/Objectives: High risk neuroblastoma (HRNB) carries poor prognosis
despite multimodal treatment. The management of HRNB in developing countries is
controversial.
Design/Methods:We conducted a retrospective analysis of children (<18 years) with
HRNB who presented from July2006 until December2014. Patients’ characteristics,
treatment modalities and outcome were analyzed. All cases were discussed in
multidisciplinary clinic that included pediatric oncologists, radiologists, pediatric
surgeons and radiation oncologists.
Results:We identified 61 patients (31 males) who presented with HRNB to our center.
The median age at diagnosis was 3.1 years (range 0.3 to 11). Four patients had stage III
disease, 4 stage IVs, and 53 stage IV. MYCN was amplified in 45% of tested patients (23
of 51). Forty two patients underwent High dose chemotherapy with stem cell rescue
(HDC/SCR). The 5-year EFS and OS were 27%±7.1% and 34%±7.5%, respectively.
The following factors were significantly associated with better survival: HDC/SCR
(P=0.0094) and diagnosis year after 2010 (P=0.037). In a separate analysis of patients
who had BMT, patients diagnosed after 2010 had a better outcome although not
statistically significant (48%±16% vs. 24%±10%, P=0.18). Of note, doses used for
HDC/SCR were increased after 2010.
Conclusion: There is improvement over time in the outcome of patients with HRNB;
this can be attributed to multidisciplinary care and improvement in supportive care as
well as optimization of chemotherapeutic doses used.
P-370
CLINICAL AND BIOLOGICAL FEATURES OF POOR RESPONDERS TO
INITIAL TREATMENT DEFINED BY SEMI-QUANTITATIVE MIBG SCORING
IN METASTATIC NEUROBLASTOMAS
T. Hishiki1, H. Yasuyuki1, Y. Katsumi1, S. Komatsu1, Y. Okimoto2, H. Kakuda2,
Y. Taneyama2, K. Furudate2, T. Saito3, T. Keita3, T. Mitsunaga3, M. Nakata3,
H. Ochiai4, M. Hino4, K. Ando4, Y. Hideo3, J. Iwai1
1Chiba Children’s Hospital, Pediatric Surgery, Chiba, Japan; 2Chiba Children’s Hospital,
Hematology and Oncology, Chiba, Japan; 3Chiba University Graduate School of
Medicine, Pediatric Surgery, Chiba, Japan; 4Chiba University Graduate School of
Medicine, Pediatrics, Chiba, Japan
Background/Objectives: 123I-mIBG scintigraphy has proven its clinical value for staging
and response evaluation of patients with neuroblastoma (NB). Any residual
mIBG-positive metastases after 4 cycles of chemotherapy indicate an extremely poor
prognosis, and early prediction of poor response is warranted. We performed a
retrospective institutional review of stage 4 NBs to investigate the correlation between
post-treatment mIBG scores and clinical / biological features at diagnosis.
Design/Methods: Nineteen stage 4 NB patients treated in two regional pediatric
oncology centers from 2005 to 2014 were included. Extent of metastatic disease was
evaluated at diagnosis and after 4 cycles of induction chemotherapy using the
established semi-quantitative mIBG scoring method (SIOPEN score). Patient were
treated with induction chemotherapy consisting of vincristine, cyclophosphamide,
cisplatin and pirarubicin, following the group study protocols in which each patient had
been enrolled.
Results: The median of SIOPEN score at diagnosis was 36. After 4 cycles of induction
chemotherapy, 5 had at least one SIOPEN score (positive group) and 14 had a score of
zero (negative group). The positive group consisted of older patients compared to the
negative group, with 3 out of 5 cases over 8 years of age in the positive group
(P=0.0160). There were no differences in pretreatment tumor markers. Initial SIOPEN
score did not differ between the two groups (P=0.211). Out of 8MYCN amplified
cases, 7 were in the negative group, whereas only one was in the positive group,
although theMYCN status was not statistically different between the two groups
(P=0.153). DNA index did not correlate to SIOPEN score.
Conclusion: Older patients showed poor response to initial chemotherapy. In the
majority of the younger cases, despite the high scores observed at diagnosis, the scores
Pediatr Blood Cancer DOI 10.1002/pbc
S330 SIOP ABSTRACTS
sharply decreased to zero after induction chemotherapy. A prospective study with a
larger cohort is needed to verify our results.
P-371
NON-INVASIVE DETECTION OFMYCN AMPLIFICATION IN PLASMA
CELL-FREE DNA DIGITAL PCR IN NEUROBLASTOMA
K. Masato1, E. Hiyama1, K. Sho1, U. Yuka1, O. Yoshiyuki1, H. Shoko2, I. Fumiko2,
O. Emi2, F. Ikuko2
1Hiroshima University Hospital, Pediatric Surgery, Hiroshima, Japan; 2Hiroshima
University, Natural Science Center for Basic Research and Development, Hiroshima,
Japan
Background/Objectives: Amplification of neuroblastoma derived (avian) v-myc
myelocytomatosis viral related oncogene (MYCN) is an important risk-stratified
indicator in neuroblastoma. In noninvasive measurement of MYCN amplification using
plasma cell-free DNA, we have used quantitative real-time PCR (qPCR). In this study,
we used Digital PCR (dPCR), which is a highly accurate method of determining DNA
concentration, for detectingMYCN amplification in stored blood plasma samples.
Design/Methods:We used 10 ng of plasma-derived DNA for qPCR and 2-4 ng DNA
for highly sensitive droplet dPCR to determineMYCN copy numbers in 10 healthy
volunteers and 47 neuroblastoma cases. The copy number was calculated as the ratio of
copies of MYCN to those of a reference gene(NAGK2.
Results: In 27 neuroblastoma cases with non-amplified tumors,MYCN copy numbers
of MYCN were was 1.05 ±0.27 and 1.06 ±0.13 in both qPCR and dPCR, respectively.
In 20 cases with amplified tumors, calculated copy numbersMYCN were 12.0-110.9
and 13.6- 194.0 copies, respectively. The correlation coefficients betweenMYCN copy
numbers in tumor tissue and in blood plasma using qPCR and dPCR were
approximately 0.9 and 0.94, respectively.
Conclusion:We can detectMYCN amplification of neuroblastoma tissue noninvasively
and quantitatively by measuring theMYCN copy number in the plasma DNA digital
PCR. This dPCR system is more accurate method using smaller amount plasma-free
DNA than qPCR. Determination of MYCN copy number in plasma DNA digital PCR
may be useful when evaluating risk-stratified indicator in neuroblastoma before surgery.
P-372
RESULTS OF TREATMENT OF PATIENTS WITH NEUROBLASTOMA STAGE
3 HIGH-RISK GROUPS
A. Hizhnikov1, K. Anatoly1, K. Polad1, R. Michael1, R. Marina1, K. Olga1, R. Diana1
1N. N. Blokhin Cancer Research Center, Thoracoabdominal Department of the Institute
of Pediatric Oncology, Moscow, Russia
Background/Objectives: At the moment, the survival of patients with stage III
neuroblastoma high risk does not exceed 50%. Current approaches to the treatment of
patients in this group may improve survival of these patients and 65%.
Design/Methods: From 2013 to the present time in the Institute of Pediatric Oncology
examined and treated with 4 children with neuroblastoma stage III high-risk groups
aged 1 to 3 years. Three of the children had a tumor of the adrenal gland, one - in the
retroperitoneal space. Three of the children had metastases in retroperitoneal lymph
nodes. All patients on the first biopsy of the tumor was performed. In one case - the
tumor was removed radically. Were carried out histological and molecular genetic
studies to determine gene amplification MYCN, deletion 11q23 and 1p36. After due
diligence and risk assessment for all patients was conducted treatment program that
includes an inductive combination chemotherapy, surgery, high-dose chemotherapy
with ASCT, radiation therapy, and biotherapy 13-cis-retinoic acid.
Results: At the moment, 3 out of 4 children have completed treatment and are in
dynamic observation with no signs of recurrence of the disease, with follow-up of 12 to
18 months. One of the children currently receiving special treatment, his condition is
clinical remission.
Conclusion: Conducting comprehensive treatment that includes intensive inductive
chemotherapy, high-dose chemotherapy with ASCT, radiation therapy, and biotherapy
in patients with neuroblastoma stage III high-risk groups can improve survival in this
group of patients up to 65-70%.
P-373
ARE NEUROLOGIC DISORDERS CAUSED BY THE TUMOR ITSELF OR BY
SURGICAL INTERVENTIONS IN PATIENTS WITH NEUROBLASTOMAS/
GANGLIONEUROMAS OF THE SMALL PELVIS?
J. Hubertus1, A. Pohl2, D. von Schweinitz2
1Dr. von Haunersches Kinderspital, München, Germany; 2Dr. von Haunersches
Kinderspital, Pediatric surgery, Munich, Germany
Background/Objectives: Neuroblastomas (NB)/ Ganglioneuromas (GN) localized in the
small pelvis are a rare entity and account for less than 5% of all NB/ GN. In some cases,
neurologic disorders, like bladder or rectal dysfunctions, are one of the first clinical
signs. Notwithstanding, neurogenic bladder or rectum is a known complication after
NB/ GN resections in the small pelvis. Aim of this analysis was to review our patients in
regard to neurologic outcome after NB/ GN resection in that region.
Design/Methods:Medical charts were reviewed of patients with NB/ GN of the small
pelvis, who were operated in our institution between 2004 and 2014. All patients were
treated according to the NB2004 trial protocol of the GPOH. Cystomanometry was
performed in addition to the standard preoperative diagnostic work-up and in cases of
postoperative symptoms of neurogenic bladder.
Results: 9 out of 209 patients (m:f 1:1.5) had tumor resection due to NB/ GN of the
small pelvis. Tumors were located between L4 to S5. Complete or near total resection
was feasible in 6 cases. Histology revealed NB in 2 cases, only. Others were GN. All
were negative for MYCN amplification. Neurologic disorders were seen in 4 patients (3
neurogenic bladder, 1 cauda equine syndrome, 1 injury of ischiadic nerve). 3 of these
patients had tumor extension to spinal canal.
Conclusion:While oncological outcome of NB/ GN of the small pelvis is superior
compared to other locations, these patients are at risk to develop neurologic
deficiencies. Apart from surgical trauma of nerval structures, tumor extension to the
spinal canal might be negative predictive factor for the development of neurogenic
disorders. Therefore, the impact of surgery resp. tumor extension to the spinal canal
should be analyzed for more cases to adapt the surgical strategy for these patients.
P-374
ANALYSIS OF SETUP ERROR IN RADIOTHERAPY OF PEDIATRIC
NEUROBLASTOMAWITH CONE BEAM CT
M. Jiang1
1Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,
Shanghai, China
Background/Objectives: To evaluate the setup error for pediatric patients with neuro-
blastoma using cone beam CT imaging (CBCT) and discuss margin between CTV and
PTV. It can be a reference for treatment plan design.
Design/Methods: Ten neuroblastoma patients were selected between October 2012 and
May 2013 underwent daily pretreatment localization CBCT and post-treatment CBCT.
Localization was based on CBCT to treatment planning CT registration, setup errors in
the medial-lateral (ML), superior-inferior (SI) and anterior-posterior (AP) directions
were obtained. Interfraction and intrafraction positioning errors were calculated based
on weekly and daily images.
Results: A lateral, longitudinal and vertical setup error of 5.3 mm, 5.7 mm and 5.2 mm
is required with weekly CBCT. When daily CBCT was incorporated, the setup error was
reduced to 2.1mm, 1.7 mm and 1.4 mm.
Conclusion: Daily localization based on CBCT can reduce the required setup error for
neuroblastoma patients and reduce margin between CTV and PTV, thereby reducing
normal tissue exposure for the patients. This is particularly important to pediatric
patients. The internal margin needs further investigation for margin between CTV and
PTV.
P-375
TREATMENT OF LOW-RISK NEUROBLASTOMA: SINGLE CENTER
EXPERIENCE IN RUSSIA
D. Kachanov1, T. Shamnaskaya1, E. Andreev2, G. Muftakhova1, G. Tereshenko3,
D. Konovalov4, Y. Likar5, Y. Olshanskaya6, E. Osipova7, S. Varfolomeeva1
1Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
Immunology named after Dmitry Rogachev, Department of Clinical Oncology, Moscow,
Russia; 2Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
Immunology named after Dmitry Rogachev, Department of Surgery, Moscow, Russia;
3Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
Immunology named after Dmitry Rogachev, Department of Radiology, Moscow, Russia;
4Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
Immunology named after Dmitry Rogachev, Department of Pathology, Moscow, Russia;
5Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
Immunology named after Dmitry Rogachev, Department of Nuclear Medicine, Moscow,
Russia; 6Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
Immunology named after Dmitry Rogachev, Laboratory of Cytogenetics, Moscow,
Russia; 7Federal Scientific and Clinical Center of Pediatric Hematology Oncology and
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Immunology named after Dmitry Rogachev, Laboratory of Physiology and Pathology of
Stem Cells, Moscow, Russia
Background/Objectives: Patients with low-risk neuroblastoma represent up to 40% of all
patients. Surgery is the main method of therapy and reducing proportion of patients
requiring chemotherapy is a priority. The purpose of this study was to analyze
treatment outcomes in a group of patients with low-risk neuroblastoma treated in a
single oncological center in Russia.
Design/Methods: During the period 01.2012-12.2014 243 patients with neuroblastoma
were observed and treated. International neuroblastoma staging system criteria were
used for staging and response evaluation. Patients were allocated to the risk groups
based of the criteria of German neuroblastoma study group and treated according to
NB2004 protocol.
Results: Low-risk group included 132 (54.3%) patients. Median age was 5.5 months
(range 0.5-103.3). M:F ratio was 1.1:1. The distribution by the site of the primary
tumor: adrenal gland - 65 (49.2%), retroperitoneum – 31 (23.5%), mediastinum – 30
(22.7%), other – 6 (4.6%). Stage distribution: stage 1 – 55 (41.7%), stage 2 – 38 (28.8%),
stage 3 – 11 (8.3%), stage 4S – 28 (21.2%). Initial therapeutic modalities included
observation - 4 (3.0%), surgery - 99 (75.0%), chemotherapy and other modalities - 29
(22.0%). Disease progression was observed in 14 (10.6%) and relapses in 8 (6.0%).
Median follow-up was 15.7 months (range 0.5-35.1). Outcomes: 127 (96.2%) patients
are alive, 5 (3.8%) died. 2-year overall survival was 0.96±0.017, 2-year event-free
survival (EFS) 0.77±0.03. 2-year EFS by stage: stage 1 – 0.83, stage 2 - 0.82, stage 3 –
0.41, stage 4S – 0.69. Cause of death included tumor progression in 2/5 and
treatment-related death in 3/5. All deaths were registered during the first three months
from diagnosis.
Conclusion: In our study the majority of patients with low-risk NB patients had
localized stage 1-2 tumors and treatment was limited only by surgery. Chemotherapy
required for patients with the presence of life-threatening symptoms.
P-376
PROGNOSTIC SIGNIFICANCE OF miRNAs EXPRESSION INVOLVED IN THE
EPIGENETIC REGULATION OF P53/MDM2 PATHWAY IN CHILDHOOD
NEUROBLASTOMA
N. Khranovska1, G. Klymniuk2, N. Svergun1, M. Inomistova1, O. Skachkova1,
O. Gorbach1, E. Shaida2, S. Pavlyk2
1National Cancer Institute MPH of Ukraine, Experimental Oncology Department, Kiev,
Ukraine; 2National Cancer Institute MPH of Ukraine, Research Department of Pediatric
Oncology, Kiev, Ukraine
Background/Objectives:Much of the difficulty in devising effective therapies lies in the
biologic and clinical heterogeneity of neuroblastoma, which can be attributed largely to
the interaction of multiple genetic and epigenetic factors. ; The aim of our study was to
investigate prognostic significance of miRNAs expression involved in the epigenetic
regulation of p53/MDM2 pathway in childhood neuroblastoma.
Design/Methods: The case group comprised 80 patients with histologically confirmed
neuroblastoma (median age: 39.6 months; range: 1.5–204 months; I-II stages: 12; III
stage: 26; IV stage: 42; MYCN-amplified tumors (MNA): 27%). Patients were treated
according to a risk groups under the international standard protocols. MYCN gene
amplification, MDM2 and miR-34-family, miR-885-5p, miR-380-5p gene expression
level were detected in tumors by FISH and TaqMan real time RT-PCR methods.
Results: Tumors were categorized into groups according to high or low miRs expression
levels based on cutoff point - optimal criterion, that was determined by ROC analysis.
It has been found that downregulation of miR34-family associated with significant
reduction of 3-year overall survival (OS) in patients with MDM2 overexpression
regardless MNA. In not-MNA neuroblastomas with low MDM2 expression 3-year OS
was on 44 % lower in downregulated miR-34a cases compared to miR-34a high
expressed neuroblastomas which excludes their impact in p53 regulation. It has been
found that high levels of miR-380-5p expression are correlated with a significant
decrease in OS. The 4-year OS rate for patients with high miR-380-5p expression was
80% compared to 21% for low miR-380-5p expression (p<0,001). The 5-year event free
survival (EFS) rate for patients with high miR-885-5p expression was 53% compared to
12% for low expression (p<0,04). No effect of miR-885-5p expression on OS rate for
neuroblastoma patients has been revealed.
Conclusion: Our results suggest the possibility of using the level of miR-34-family,
miR-885-5p, miR-380-5p expression in neuroblastoma as prognostic and risk group
stratification markers.
P-377
THE COX/MPGES-1/PGE2 PATHWAY DEPICTS AN INFLAMMATORY
DEPENDENT HIGH-RISK NEUROBLASTOMA SUBSET AVAILABLE FOR
NOVEL SPECIFIC ANTI-INFLAMMATORY TREATMENT
A. Kock1, K. Larsson2, J. Raouf2, M. Korotkova2, J.I. Johnsen1, P.J. Jakobsson2,
P. Kogner1
1Karolinska Institutet, Children’s and Women’s Health, Stockholm, Sweden; 2Karolinska
Institutet, Medicine, Stockholm, Sweden
Background/Objectives: High-risk neuroblastoma often have poor prognosis. Older
children with 11-q deleted tumors show resistance to induction chemotherapy, late
relapses and poor outcome despite intensified treatment. Although adult cancers show
an inflammatory microenvironment knowledge is limited on potential significance of
inflammation in childhood malignancies.
Design/Methods: Human tumors were analysed for expression of pro-inflammatory
lipid mediators. Xenografts in nude mice and spontaneous tumors in transgenic mice
were treated with specific inhibitors of the COX/mPGES-1/PGE2 inflammatory
pathway.
Results: High-risk neuroblastomas showed high expression of enzymes involved in the
production of pro- inflammatory lipid mediators including microsomal prostaglandin E
synthase-1 (mPGES-1) the major enzyme converting prostaglandin H2 (PGH2) to
prostaglandin E2 (PGE2) and lack of expression of the PGE2 metabolizing enzyme
15-hydroxyprostaglandin dehydrogenase (15-PGDH) resulting in high PGE2
concentrations. High mPGES-1 and low 15-PGDH corresponded to poor survival. 11-q
deleted tumors showed significantly higher PGE2 than other subsets. Neuroblastoma
microenvironment showed abundant occurrence of immunosuppressive CD163+
M2-polarized macrophages and CD11b+ myeloid-derived suppressor cells. mPGES-1
expressing cells were indicated cancer associated fibroblasts (CAFs) expressing
vimentin, fibroblast activation protein (FAP), alpha smooth muscle actin (αSMA), and
platelet-derived growth factor receptor beta (PDGFRβ). Specific PGE2 targeting by
Cox-inhibiting celecoxib or a novel specific mPGES-1 inhibitor significantly delayed
tumor growth in vivo. Tumor weights were reduced at sacrifice both in transgenic
TH-MYCN mice and nude mice with11-q deleted xenografts compared to untreated
control animals. Treated tumors showed significant decrease of M2-polarized
macrophages and reduced angiogenesis.
Conclusion:We found that high prostaglandin E2 production and expression of
microsomal prostaglandin E synthase-1 (mPGES-1) is coupled to high-risk
neuroblastoma tumors with 11q-deletions. Infiltrating cancer-associated fibroblasts
contribute to neuroblastoma inflammation microenvironment. The inflammatory
COX/mPGES-1/PGE2 pathway plays a crucial role in cancer-related inflammation
providing specific therapeutic targets. Anti-inflammatory drugs combined with current
treatment should be considered for novel high-risk neuroblastoma therapy.
P-378
ARSENIC TRIOXIDE POTENTIATES THE CYTOTOXICITY OF
CHEMOTHERAPEUTIC AGENTS AGAINST HUMAN SK-N-SH
NEUROBLASTOMA CELL LINE
Y. Li1, K. Qi1, X.L. Xiong1, C. Zhang1, K. Huang1, J. Fang1, H. Guo1, W. Weng1
1Sun Yat-Sen Memorial Hospital-Sun Yat-Sen University, Pediatric
Hematology/Oncology, Guangzhou, China
Background/Objectives: The aim of this study was to investigate whether arsenic
trioxide combined with mitosis-phase-specific antineoplastic agent or non
mitosis-phase-specific antineoplastic agent has synergistic effects of cytotoxicity in
human SK-N-SH neuroblastoma(NB) cell line.
Design/Methods: At first, we investigated the exposure time that arsenic trioxide could
arrest NB cell cycle in G2/M phase with the highest proportion by flow cytometry, then
we monitored the ability of arsenic trioxide combined with four various
chemotherapeutic agents including vinorelbine, docetaxel, etoposide and cisplatin to
induce NB cells apoptosis. There were two different ways that arsenic trioxide combined
with one of the four drugs, NB cells were either incubated with another drug
simultaneously, or firstly incubated with arsenic trioxide and then with another drug
when cell cycle was arrested in G2/M phase with the highest proportion.
Results: Our results showed that arsenic trioxide induced NB cells apoptosis in a time-
and dose-dependent manner, and arsenic trioxide arrested NB cell cycle in G2/M phase
with the highest proportion after 48 hours incubation. Arsenic trioxide potentiated the
apoptotic rate of NB cells induced by chemotherapeutic drugs. We further determined
that the combination of 48 hours of arsenic trioxide followed by the addition of
mitosis-phase-specific antineoplastic agent (vinorelbine, docetaxel) caused a synergistic
increase in cytotoxicity of NB cells, while less effective caused by arsenic trioxide
combined with non mitosis-phase-specific antineoplastic agent (etoposide, cisplatin).
Conclusion: Our in vitro study shows that co-application of arsenic trioxide with
mitosis-phase-specific antineoplastic agent (vinorelbine, docetaxel) may potentiate the
curative effects against NB. Arsenic trioxide shows a very good prospect in NB
treatment.
P-379
LOW DOSE OF ARSENIC TRIOXIDE INHIBITS MULTIDRUG
RESISTANT-RELATED P-GLYCOPROTEIN EXPRESSION IN HUMAN
NEUROBLASTOMA CELL LINE
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Y. Li1, L. Liu2
1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Department of Pediatric
Hematology/Oncology, Guangzhou, China; 2Guangdong Medical College Affiliated
Hospital, Pediatric, Zhanjiang, China
Background/Objectives: The present study aimed to investigate arsenic trioxide (As2O3),
cisplatin (DDP) and etoposide(Vp16) on the anticancer effects and P-gp expression in
NB SK-N-SH cells.
Design/Methods: The potential influence of As2O3, DDP and Vp16 on cytotoxicity in
SK-N-SH cells was assessed by Flow cytometry with Annexin V-PI staining and drugs
IC50 were established. Moreover, chemotherapeutic agents-mediated the changes of
cellular expression levels of resistant-related P-gp were analyzed using Western-blotting.
Results: (1) Data showed that As2O3 had a dose- and time-dependent toxic effect on
SK-N-SH cells via induction of apoptosis in manner. Furthermore, As2O3, DDP and
Vp16 were observed with their IC50s on SK-N-SH cells being 3umol/L, 8ug/ml and
100ug/ml respectively. (2)As2O3 in SK-N-SH cells led to enhanced accumulation of cell
populations in G2/M phase with increasing the exposure time. In contrast, we observed
that SK-N-SH cells populations arrested in S phase by DDP and Vp16. (3) Following
pretreatment of SK-N-SH cells with As2O3, the expression of P-gp was not increased.
The expression of P-gp down-regulation was noted following pretreatment of
SK-N-SH cells with As2O3, and these changes were statistically significant with As2O3
in the concentration of 2umol/L and 3umol/L(P<0.05). 3umol/L As2O3 for 72h
induced significantly decreased the expression of P-gp than 2umol/L As2O3 for 72h in
SK-N-SH cells(P<0.05). However, the expressions of P-gp were up-regulated in
SK-N-SH cells by DDP and VP16 on different concentration.
Conclusion: In summary, SK-N-SH cells were responsive to drugs-induced apoptosis in
a dose- and time-dependent manner. These findings showed that low dose As2O3
reduces the P-gp expression in human NB cell line. Taken together, these results
indicated that the effect of As2O3 on reducing the expression of P-gp may make the
drug as an excellent candidate in chemotherapy regimens for MDR NB.
P-381
RACK1 GENE SILENCING INDUCES APOPTOSIS IN MYCN GENE
AMPLIFIED NEUROBLASTOMA CELL LINES
F. Lu1
1Xinhua Hospital, Shanghai, China
Background/Objectives: To evaluate the role of Receptors for Activated C- Kinases
(RACK1) in the apoptosis of Neuroblastoma (NB).
Design/Methods: Expression of RACK1 was evaluated by immunofluorescence in
MYCN gene amplified NB cell lines, SK-N-BE (2) and IMR32. RACK1 gene was
silenced by RNA interference (RNAi). Then cell apoptosis and expressions of pro- and
anti- apoptotic Bcl-2 members and caspases were detected by flow cytometry and
western blotting respectively.
Results: RACK1 expressed in SK-N-BE(2). RACK1 gene silencing significantly
increased the apoptosis ratio of SK-N-BE(2), and increased the cleavage of Caspase-3,
-7, -9, but not -8. RACK1 RNAi decreased the expressions of Bcl-2, Bcl-xl and Mcl-1,
while increased the expression of Bim.
Conclusion: RACK1 gene silencing induced NB cell apoptosis via activating intrinsic
pathway and repressing anti-apoptotic Bcl-2 family members.
P-382
THE PPM1D ENCODED PHOSPHATASEWIP1 IS A NOVEL ONCOGENE AND
POTENTIAL THERAPEUTIC TARGET IN NEUROBLASTOMA AND
MEDULLOBLASTOMA
J. Milosevic1, D. Treis1, M. Malin1, S. Fransson2, B. Sveinbjörnsson3, N. Eissler1,
N. Baryawno1, K. Tanino4, G. Selivanova5, K. Sakaguchi4, T. Martinsson2, J.I. Johnsen1,
P. Kogner1
1Karolinska Institutet, Women´s and Children´s Health, Stockholm, Sweden; 2Institute of
Biomedicine-University of Gothenburg, Department of Clinical Genetics, Gothenburg,
Sweden; 3University of Tromsö, Division of Immunology-IMB, Tromsö, Norway;
4Faculty of Science-Hokkaido University, Laboratory of Biological
Chemistry-Department of Chemistry, Sapporo, Japan; 5Karolinska Institutet,
Department of Microbiology-Tumor and Cell Biology, Stockholm, Sweden
Background/Objectives: The most common cytogenetic lesions in the embryonal neural
tumors medulloblastoma (MB) and neuroblastoma (NB) affect chromosome 17, with
17q+ or isochromosome 17q, in approximately one-third of MB with these aberrations
being a significant indicator of poor clinical outcome. Similarly, in NB gain of 17q is
the most powerful genetic predictor of adverse clinical outcome. 17q+ correlates with
poor survival in our population-based material where we found aberrations of
chromosome 17 in 85% of primary neuroblastomas, specifically, gain of PPM1D/Wip1
at 17q23. Wip1 is a serine/threonine phosphatase encoded by the gene PPM1D,
described as a gatekeeper in the Mdm2-p53 regulatory loop involved in genetic stability,
inflammation and a potential oncogene contributing to carcinogenesis.
Design/Methods: Comparative genomic hybridization (CGH) was used to examine
PPM1D/Wip1 in neuroblastoma and medulloblastoma tumors and cell lines. Wip1
knockdown SK-N-BE(2) cells were generated by shRNA transfections and tested in
vivo in tumor xenografts. Pharmacological inhibition with the p53-mdm2 modulating
inhibitors RITA, Nutlin-3 and a new PPM1D/Wip1 inhibitor, was used to evaluate the
function of PPM1D/Wip1 in preclinical models.
Results: CGH-array analysis detected PPM1D/Wip1 extra copies in all tumors and cell
lines containing 17q-gain. Tumor neuroblastoma xenograft development was
significantly delayed showing median tumor development (0.10 mL) to be more than
doubled (median 15 days, vs. 33 days, p<0.001) after Wip1 downregulation compared
to scrambled controls. A novel Wip1 inhibitor was highly potent in cytotoxic/cytostatic
effect in a variety of neuroblastoma and medulloblastoma cell lines. Furthermore, this
Wip1 inhibitor significantly inhibited growth of established human neuroblastoma- and
medulloblastoma tumors in nude mice after treatment (P<0.01).
Conclusion: Our results show that PPM1D/Wip1 is oncogenic in neuroblastoma and
medulloblastoma development and provides a novel therapeutic target in these two
childhood cancers of the nervous system. More studies investigating the effects of
PPM1D/Wip1 inhibition are needed to evaluate its clinical significance.
P-383
CLINICAL BEHAVIOR, AND EPIDEMIOLOGICAL, DEMOGRAPHIC AND
THERAPEUTIC ASPECTS OF THE DESMOID TUMOR IN CHILDREN OF
CALI–COLOMBIA
L.J. Moreno1, J.M. Satizabal2, C.A. Portilla1
1Universidad del Valle, Pediactrics, Cali, Colombia; 2Universidad del Valle, Basics
Science, Cali, Colombia
Background/Objectives: Desmoid-Tumors(DT) or
Aggressive-Fibromatosis-Juvenile(AFJ) are tumors with low grade of malignancy, low
potential to produce soft-tissue metastases, and high rate of recurrence.Prevalence is
unknown with a very low incidence. The etiopathogenic mechanism is unknown,
literature register that may be multifactorial involving genetic, hormonal, surgical and
trauma factors. The clinical presentation is non-specific and there are not enough
reports. Describe the clinical behavior, demographic, epidemiological and therapeutic
variables of Children with DT in Cali, Colombia-South America.
Design/Methods: A retrospective descriptive cross-sectional study of pediatric patients
with histopathological diagnosis of DT/AFJ deposited in the clinical database from the
Department of Pathology at Hospital Universitario del Valle between the period of
January 2000-May 2014.Among the factors that describe the behavior of the disease
were taken into account: median age at diagnosis, ethnicity, sex, location of the lesion,
(total resection of the lesion -partial), treatment outcome after surgical technique.
Surgical and traumatic personal history and family history of cancer was also
considered.
Results: Sample from universe of this study consists in 4 patients diagnosed during this
period of time: three Africancolombian children and one Caucasian showed a
diagnosis median age of 3.25 years, ratio female-masculine: 3:1, location: 1extremities,
2head and neck, one buttock. Three patients had complete resection of the tumor with
negative margin, one patient relapse after radiotherapy received, none received
cytostatic treatment, hormonal or chemotherapy; 3 patients had relapses and required
surgery again, none was amputated. None had a history of traumatic significance. One
patient had a family history of brain cancer and cancer unspecified. None reported
associated metastases.
Conclusion: From our screening the most important risk factors for poor control are:
early age of onset, size, recurrence, surgical margin requirement radio-chemotherapy.
Finally, since there are tumors of low incidence, prospective multicenter studies are
needed to clarify epidemiological behavior.
P-384
EFFICIENT ADAPTIVE RANDOMISED TRIAL DESIGN IN
NEUROBLASTOMA: THE BEACON-NEUROBLASTOMA TRIAL
V. Moroz1, A. Pearson2, L. Moreno2, P. Kearns1, K. Wheatley1
1University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham,
United Kingdom; 2The Royal Marsden NHS Foundation Trust and Institute of Cancer
Research, Paediatric Oncology Drug Development, Surrey, United Kingdom
Background/Objectives: Running clinical trials in relapsed neuroblastoma is challenging
due to its rarity. There remains uncertainty as to the best treatment for children with
relapsed/refractory neuroblastoma and randomised trials will be essential to evaluate
new treatments reliably. There have been many single arm, but few randomised, phase
II trials in this patient group. This lack of reliable evidence risks the introduction of
ineffective new agents into standard clinical practice.
Design/Methods: Adaptive trials using novel methodology, such as multi-arm
multi-stage (MAMS), can increase the efficiency of trials, enabling more agents to be
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evaluated more quickly, without gaps between studies. The evolution of the
BEACON-Neuroblastoma trial in relapsed/refractory neuroblastoma is described here.
Results: BEACON-Neuroblastoma started as 2×2 factorial trial investigating the role
of two agents added to a backbone of temozolomide as chemotherapy for
relapsed/refractory neuroblastoma: 1) bevacizumab (Jung design); 2) irinotecan
(likelihood-based Bayesian design). The phase II trial to obtain initial evidence of
activity (response) will become a Phase III trial to evaluate efficacy (event-free survival)
in agents/regimens that meet the Phase II success criteria. As result of recently
published promising results on the combination of topotecan and temozolomide
(TOTEM), BEACON-Neuroblastoma was amended to a 3×2 factorial design to
evaluate this combination in addition to the two existing questions. The recruitment
target was initially 120 patients (60 for each comparison); the amendment will increase
the sample size to 160 patients (60 for each comparison) and duration of the study from
two to four years. The successor to BEACON-Neuroblastoma will expand on this
approach and become an ongoing MAMS trial.
Conclusion: The adaptive design of BEACON-Neuroblastoma and its successor will
allow multiple agents to be evaluated quickly and efficiently, with ineffective ones being
dropped and new ones brought in as they become available, in a rolling programme of
research.
P-385
INTRAABDOMINALMALIGNMASSES: EXPERIENCE OF 406 CASES IN 24
YEARS TREATED IN A SINGLE CENTRE
A. Okur1, C. Karadeniz2, F.G. Pınarlı2, E. Sal2, A. Og˘uz2
1Gazi University, Ankara, Turkey; 2Gazi University, Pediatric Oncology, Ankara, Turkey
Background/Objectives: The diagnosis, treatment and follow up of intraabdominal
tumors have a special importance among all pediatric malignancies. In this study, we
aimed to evaluate the demographic, clinical and pathological properties of
intraabdominal tumors followed by our department.
Design/Methods: Intraabdominal malign tumors account for 31.7% of all pediatric
malignancies followed by our department. Medical records of 406 children with
intraabdominal malign tumor diagnosed in the Department of Pediatric Oncology,
Gazi University Medical Faculty during 1991-2015 were reviewed.
Results: The mean age at diagnosis was 5.4 ± 4.6 years (10 days-17 years). The mean
duration of symptoms until the diagnosis was 25.4 ± 24.3 days (1-200 days). In 43% of
the patients, the masses were noticed by parents. The most common symptoms were
abdominal mass (47.7%), abdominal pain (34.2%), constipation (16%), fever (19%) and
hematuria (%3.9). The tumor was most commonly located in the upper right quadrant
(27%) followed by pelvis (21.1%), widespread abdominal (15.5%) and upper left
quadrant (18.9%). The first five tumor types causing intraabdominal mass were
neuroblastoma (20.9%), non-Hodgkin lymphoma (18.2%). Wilms tumor (17.4%), germ
cell tumors (16.7%) and hepatoblastoma (4.4%). The most common tumors under 12
months of age were neuroblastoma (31.1%) and germ cell tumor (25.2%) and was non-
Hodgkin lymphoma (29.7%) above 5 years of age. There were spinal cord compression
symptoms in 7.1%, bone marrow infiltration in 12% and tumor lysis syndrome in 8.3%
of the patients at the time of diagnosis.
Conclusion: In our series, the most common abdominal malignant tumor was
determined as neuroblastoma in infants and non-Hodgkin lymphoma above 5 years of
age, as consistent with the literatüre.
P-386
TANDEM PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AS
TREATMENT OF NEUROBLASTOMA IN CHILDREN
S. Pavlyk1, G. Klymnyuk1, E. Shayda1, O. Bilokon1, O. Ijovsky1, N. Khranovska2,
O. Skachkova2, N. Svergun2
1National Cancer Institute, Pediatric Oncology, Kyiv, Ukraine; 2National Cancer
Institute, Experimental Oncology, Kyiv, Ukraine
Background/Objectives: Currently investigate the feasibility of using tandem high-dose
chemotherapy in the treatment of many malignant solid tumors: medulloblastoma,
germ cell tumor, soft tissue sarcomas and high-risk neuroblastoma. Nevertheless
effectiveness convincing results haven’t been obtained.
Design/Methods: From 2012 to 2015 year in the Department of Pediatric Oncology at
the National Cancer Institute have been carried out 15 tandem transplantations (TT) in
children with high-risk of neuroblastoma. Patient’s age was 1-14 years. 10 pts. with
primary neuroblastoma got TT after chemotherapy on HR-NBL-1/ESIOP protocol, 5
pts. as a consolidation of relapse second-line therapy. The first part of tandem
transplantation was BuMel in all patients. Twelve patients had topotecan-based
regimens as the second part of tandem transplantation and three patients had CEM
regimen. A time interval between parts of tandem was 1-3 months. For autologous
transplantation have been used only peripheral stem cells. All patients received 13-cis
retinoic acid after of conventional treatment.
Results: All patients successfully completed high-dose chemotherapy. There were
neutropenia and thrombocytopenia 4th rate, oral mucositis with different degrees of
severity in all patients. WBC count recovered more then 500/μL after first cycle on
+10-15 day, PLT count recovered on +13-28 day. In 2 patient was observed
neurotoxicity like short clonic and tonic seizures after second cycle. WBC count
recovered more then 500/μL after second cycle on +9-14 day, PLT count recovered on
+10-22 day. Currently, 7 of 15 patients are in CR, 3 patients had early relapse and
continue treatment, 5 died of PD. The follow-up period after accomplishment of TT is
2-26 months.
Conclusion: Application of TT in children with high-risk neuroblastoma resulted to
three-year disease-free survival rate of about 46.4% and the overall four-year survival
rate to 66,3%. With no possibility of mIBG therapy and antibody therapy, the use of
tandem transplantation provides an opportunity to improve outcomes.
P-387
LYMPHATIC LEAKAGE (LL) AFTER RESECTION OF NEUROBLASTOMA
A. Pohl1, T. Komm1, D. Seitz1, M. Jakob1, D. Von Schweinitz1
1Dr von Hauner Childrens´Hospital-LMUMunich, Department of Pediatric Surgery,
Munich, Germany
Background/Objectives: Lymphangiogenesis and lymphangiogenic vessel remodeling is
known to play an important role in cancer progression. Little is known about the
impact of lymphangionesis in neuroblastoma. From a surgical point of view, lymphatic
fistula is a potential complication after neuroblastoma surgery. Aim of this study was
the evaluation of frequency and impact of lymphatic leakage in a center for
neuroblastoma surgery.
Design/Methods: Between 2003 and 2014, 210 patients (pts) were resected for
neuroblastoma in our department for neuroblastoma. Out of these, 200 patients were
eligible for this study. Patient charts were reviewed for INSS stage, surgical radicality,
duration of abdominal or thoracic drainage and maximum amount of fluid drained per
24 h.
Results: Out of 200 patients, 73 patients (37%) had a duration of drainage of 7 or more
days. Maximum amount of drainage was 4 liters per day; longest duration of
intraabdominal drainage was 91 days. In case of chylous fistula, all patients were treated
with a conservative approach. Duration of drainage was significantly associated with
surgical radicality (p=0.000). Furthermore, the duration of drainage was significantly
associated with the maximum amount of fluid drained per 24 h (p=0.000). Lymphatic
fistula was significantly associated with INSS stage (p=0.000). Overall Survival (OS)
demonstrated a better OS for patients without LL (87% alive) than pts with LL (72%
alive). OS was significantly associated with the maximum amount of fluid drained per
24 hrs (p=0.009), but not with duration of drainage.
Conclusion: LL is a frequent complication after neuroblastoma surgery and in some
cases with substantial loss of fluids and proteins. It can be treated in nearly all cases
conservatively. One major problem is the delay of further chemotherapy and radiation
which however does not seem to have a great impact on the prognosis.
P-388
MIBG (METAIODOBENZYLGUANIDINE) CROSSES BLOOD BRAIN BARRIER
ADEQUATELY? REALITY OR ILLUSION
N. Rastogi1, S. Katewa1, Y.R. Chopra1, S. Nivargi1, S. Kohli1, S.P. Yadav1
1Fortis Memorial Research Institute, Department of Pediatric Hematology-Oncology &
BMT, Gurgaon, India
Background/Objectives: Even after high dose chemotherapy, the overall survival of
Relapsed Stage 4 Neuroblastoma patients remain inconsequential. MIBG
(Metaiodobenzylguanidine) appears to be a suitable option but its penetrability across
Blood brain barrier (BBB) is largely unknown. We describe a case with CNS changes
after MIBG therapy.
Design/Methods: A patient with Relapse Neuroblastoma underwent MIBG with
Autosomal stem cell transplantion (AutoSCT) in a tertiary hospital. The clinical
records were retrospectively analyzed.
Results:A 5 year old boy Stage 4 Neuroblastoma (Poorly differentiated) with abdominal
mass with bilateral pelvic bone involvement and received 6 cycles of chemotherapy
followed by AutoSCT. Then received 20G radiation followed by Cis-retinoic cycles.
After 4th cycle, patient developed bone pains and MRI showed increase in abdominal
tumor size along with Bone marrow metastasis. He developed seizures. PET-CT showed
6.1×7.4×9 cm mass in retro peritoneum with multiple lymph nodes with bilateral brain
metastases. He received 3 cycles of Cyclophosphamide, Etoposide, Vincristine and
Bortezomib. Stem cells collected after two cycles. Surgical resection not possible so
biopsy taken which showed Ganglioneuroblastoma. He underwent MIBG with
AutoSCT. MIBG was given @ 12mCi/kg BW on Day-21, complicated by hypertension
within 24 hrs. After four days of MIBG, seizures reoccurred and CT showed cerebral
edema, hemorrhage surrounding the metastatic lesion and necrosis within the lesion. He
received Melphalan (140 mg/m2), Carboplatin (1500 mg/m2) and Etoposide (1200 mg/
m2) from Day-7. Dose of stem cells 10.6 × 106/kg. Day+12 Neutrophil engrafted. On
Day+17 repeat PET-CT revealed marginal reduction in size of retroperitoneal mass
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with no FDG avidity and calcification.Follow-up CT head revealed absence of edema
with tumour necrosis. One month post-transplant, patient is fine.
Conclusion: Necrosis within brain lesions with perilesional edema and hemorrhage
suggest that MIBG has brain penetration and can cross BBB. Thus, MIBG with
AutoSCT can also be used for relapse and refractory CNS Neuroblastoma.
P-389
CURETTAGE FOR FOCAL HIGH-RISK SKELETAL NEUROBLASTOMA
RESISTANT TO CHEMOTHERAPY AND RADIOTHERAPY
Z. Salman1, B.H. Kushner1, N.K.V. Cheung1, E. Basu1, S. Roberts1, S. Wolden2,
J. Mora3, S. Modak1
1Memorial Sloan Kettering Cancer Center, Pediatrics, New York, USA; 2Memorial
Sloan Kettering Cancer Center, Radiation Oncology, New York, USA; 3Hospital Sant
Joan de Déu, Department of Pediatric Hematology and Oncology, Barcelona, Spain
Background/Objectives: High-risk neuroblastoma (HR-NB) refractory to, or relapsed
after, high-dose induction chemotherapy is considered incurable, even when focal. Our
initial strategy to eradicate this resistant disease is local radiotherapy followed by
anti-GD2 immunotherapy. In a subgroup of patients with focal skeletal NB refractory
to radiotherapy, surgical curettage was performed. We now report on their outcome.
Design/Methods: After obtaining IRB waiver, we retrospectively reviewed the records of
patients with metastatic HR-NB who underwent surgical curettage between 2007 and
2011 of a single chemoradiotherapy-resistant skeletal site.
Results: Six patients (age 1.5 - 8.5 years at diagnosis, 2 - 11.5 years at curettage)
underwent surgical curettage of their single site of persistent skeletal NB. Three patients
each had refractory and relapsed NB, respectively. Sites of disease were humerus (n=2
patients) and tibia (n=4), documented by MIBG and MRI. All 6 patients had received
intensive induction chemotherapy and second-line chemotherapy, and 5/6 had received
radiotherapy (2100-3600cGy) to the site of persistent disease. Curettage was not
associated with any surgical complications. Active NB was detected histologically in all
samples. Post-operatively, MIBG scan normalized in all patients. Post-curettage therapy
included radiotherapy, 3000-3600cGy (n=6), chemotherapy (n=4), and
immunotherapy with anti-GD2 antibody 3F8+GM-CSF (n=6). Three patients
subsequently relapsed: only 1 at the site of curettage. Median 5-year progression-free
survival was 50±20% post-curettage. Two of 3 patients achieved a further remission
and continue to remain disease-free 56+ and 87+ months post-curettage; one died of
progressive multifocal disease. Five-year overall survival for the 6 patients was 83±15%.
Conclusion: Surgical curettage as part of a multi-modality strategy represents safe,
effective local therapy for focal skeletal HR-NB resistant to chemoradiotherapy. This
experience suggests that, with current treatment modalities such as anti-GD2
immunotherapy, focally chemoradioresistant HR-NB is not necessarily a harbinger of
widespread disseminated disease, potentially changing the therapeutic paradigm for this
group of patients.
P-390
CAN FDG PET/CT BE A SURROGATEMARKER FORMYCN EXPRESSION IN
NEUROBLASTOMA
S. Shah1, A. Agarwal1, N. Purandare1, A. Singh1, M. Ramadwar2, S. Desai3,
S. Kembhavi4, S. Qureshi5, T. Vora6, G. Chinnaswamy6, M. Prasad6, V. Rangarajan1
1TATA Memorial Hospital, Department of Nuclear Medicine and Molecular Imaging,
Mumbai, India; 2TATA Memorial Hospital, Department of Histopathology, Mumbai,
India; 3TATAMemorial Hospital, Deaprtment of Molecular Pathology, Mumbai, India;
4TATAMemorial Hospital, Department of Radiology, Mumbai, India; 5TATAMemorial
Hospital, Department of Surgical Oncology, Mumbai, India; 6TATA Memorial Hospital,
Department of Medical Oncology, Mumbai, India
Background/Objectives: N mYC amplification is one of the factor utilized for risk
stratification of neuroblastomas. This molecular profiling takes a few days and hence
the possibility of predicting the expression through surrogate marker could help early
management decisions. To evaluate the possibility of Flurodeoxy glucose positron
emission tomography/computed tomography (FDG PET/CT) uptake using the
semiquantitative maximum standard uptake value (SUV max) as a surrogate marker for
MYCN expression in neuroblastoma.
Design/Methods:Method: Retrospective analysis of 22 patients of neuroblastoma (13
male & 9 female; 12 patients > 18 month age) who were a part of hospital protocol was
done to correlate SUV max of the primary tumor on a baseline FDG PET/CT study
with MYCN expression. The SUV max of the primary tumor was noted and compared
with the MYCN amplification done using PCR or FISH on biopsy sample. These 2
parameters were analysed using the Mann Whitney U test. Cut off value for SUV to
predict expression of MYCN dentified using the ROC curve method.
Results: The SUV max range for 21 patients was 2.4 -30.1 (mean :7); 1 patient showed
no FDG uptake. MYCN was expressed in 7 patients whose SUV ranged 5.8 -30.1
(median 9) while those with no MYCN expression the range was 2.7 -10.6 (median 3.6)
Statistical analysis using Mann Whitney test revealed a higher SUV paramenter
correlating with a MYCN expression. The SUV Cut off for a positive MYCN was
calculated to be 6.9 with a specificity of 80% and sensitivity of 75%.
Conclusion: The pilot study shows a correlation of SUV and MYCN. Patients
expressing MYCN tend to show a higher SUV level. The small sample size derived a
SUV cut off of 9 to predict MYCN expression this however needs further validation
with a prospective large population.
P-391
13-CIS RETINOIC ACID INDUCES DIFFERENTIATION OF THREE TYPES OF
HUMAN NEUROBLASTOMA CELL LINES IN VITRO
J. Shao1, H. Jiang2
1Shanghai Children’s Hospital, Shanghai, China; 2Shanghai Children’s Hospital,
Hematology/Oncology, Shanghai, China
Background/Objectives: To investigate the effects of 13-cis retinoic acid (13-cis RA) in
inducing differentiation of three types of human NB cells in vitro.
Design/Methods: The status of N-MYC gene amplification of cultured SH-SY5Y,
SK-N-SH and SK-N-BE2 cells was detected by fluorescence in situ hybridization
(FISH). After treatment with different concentrations of 13-cis RA, morphological
changes were observed by phase-contrast microscope, and neuron-specific enolase
(NSE) concentrations were determined by ELISA. The cell viability was measured
through cell counting kit-8(CCK-8) assay, and the cell apoptosis was assayed with flow
cytometry (FCM).
Results: The morphological changes characteristic of differentiation were observed in
all 3 types of NB cells after 13-cis RA treatment. N-MYC amplification was detected in
SK-N-BE2 cells even after 13-cis RA treatment, while the other two cell lines were
amplification-null. After different concentrations of 13-cis RA treatment, NSE
concentration increased with prolonged time, especially for SK-N-BE2
cell(F=27,P<0.0001).13-cis RA stimulated cell proliferation within 48 hours of
treatment, and then inhibited cell growth. FCM indicated that the degree of apoptosis
in SH-SY5Y cell were significantly higher after 13-cis RA treatment of 10μM
concentration for continuous 96h(F=16.21,P=0.011) and 120h (F=16.04,P=0.016)as
compared to the control group. Cell apoptosis of SK-N-SH cell after 13-cis RA
treatment of 1μM and 10μM concentration for 48h, while SK-N-BE2 cell with
different concentrations of 13-cis RA for 120h were significantly higher than that of the
control groups.
Conclusion: The present study showed that 13-cis RA could induce differentiation of
human NB cells in vitro. It induces cell proliferation within 48 hours of 13-cis RA, and
thereafter suppresses cell growth. No improvement of N-MYC amplification cells with
the detection of DNA level after 13-cis RA treatment, which suggests that combination
treatment is possibly needed.
P-392
THE PD-L1 EXPRESSION INCREASES AFTER CONSECUTIVE
MULTIMODAL THERAPIES IN NEUROBLASTOMA
S. Uehara1, K. Nakahata2, M. Kawatsu2, M. Zenitani2, T. Miyamura3, Y. Hashii3,
H. Okuyama2
1Osaka University Hospital, Suita, Japan; 2Osaka University Hospital, Pediatric
Surgery, Suita, Japan; 3Osaka University Hospital, Pediatrics, Suita, Japan
Background/Objectives: Programmed death 1 (PD-1) protein, a T-cell co-inhibitory
receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells
to evade the host’s immune system. We investigated the expression of PD-L1 on
neuroblastoma cells by immunohistochemistry.
Design/Methods: Forty-one NB patients diagnosed and treated between 1993 and 2014
were included in this study. Ten patients underwent a primary operation (PO). Of the
remaining 31 patients, 6 patients received biopsy alone, while 25 patients underwent a
delayed primary operation (DO) after chemotherapy. The PD-L1 protein expression
was detected by immunohistochemistry of formalin-fixed paraffin-embedded specimens
using an anti-human PD-L1 monoclonal antibody (5H1). PD-L1 tumor positivity was
defined as 5% tumor cell membrane staining. Statistical analyses were performed
using Fisher’s exact test.
Results: Four out of 10 neuroblastoma sections collected with PO were positive for
PD-L1. Only one of 31 biopsy specimen was positive for PD-L1, thus demonstrating
that PD-L1 was positive in only 5 out of 41 specimens obtained before chemotherapy.
However, 14 out of 25 specimens obtained from DO were positive for PD-L1 (p<0.01;
biopsy specimen vs DO specimens). Of these 14 PD-L1 positive specimens obtained
from DO, relapse occurred in 7, while no relapse was observed in 7 patients. In contrast,
recurrence occurred in 4 patients according to the findings of 11 PD-L1 negative
specimens. No statistical correlation between the PD-L1 expression and the incidence
of relapse was thus observed (n.s.).
Conclusion: Our results indicate that most primary neuroblastomas do not express
PD-L1, and its expression was found to increase after chemotherapy. Although the
expression of PD-L1 does not correlate with recurrence, PD-L1 may nevertheless be
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associated with the survival of tumor cells, and therefore still be a potential target for
the treatment of neuroblastoma after multimodal therapy.
P-393
A TREATMENT OPTION OF CONGENITAL NEUROBLASTOMAWITH
EXTENSIVE HEPATIC METASTASIS: TRANSARTERIAL INFUSION
CHEMOTHERAPY
J. Wang1, J. Cai1, M. He1, J. Mao1, M. Li1, Q. Shu1
1Children’s Hospital-Zhejiang University School of Medicine, Surgical Oncology
Department, Hangzhou, China
Background/Objectives: Due to the possibility of spontaneous regression, Stage IVs
neuroblastoma generally confers a good prognosis. However, neuroblastoma with
extensive hepatic metastasis is frequently life-threating because of its massive
hepatomegaly and thoracoabdominal compression. The authors report 6 cases of
congenital neuroblastoma with extensive hepatic metastasis and introduce our
experience in controlling this lession.
Design/Methods: Between September, 2013 and August, 2014, six cases of congenital
neuroblastoma with extensive hepatic metastasis were admitted to our institution. Six
patients aged from 2 weeks to 13 weeks at time of diagnosed. 1 case refused
chemotherapy. 5 cases received chemotherapy and 2 of them accepted transarterial
infusion chemotherapy (TAIC) later on.
Results: The case refused chemotherapy died from thoracoabdominal compression and
renal failure at the age of 14 weeks. In the 5 cases underwent systematic chemotherapy,
4 cases still suffered from gradually increased abdominal distension. 2 cases died at the
age of 15 weeks and17 weeks respectively. Other 2 cases accepted TAIC 3 weeks after
systematic chemotherapy. Hepatomegaly was relieved in both cases after TAIC therapy.
1case survived by systematic chemotherapy only.
Conclusion: Extensive hepatic metastasis in congenital neuroblastoma is a life-threating
sign. TAIC is a considerable treatment option in cases despite systematic chemotherapy.
P-394
HIF-1A COULD PROMOTE THE PROLIFERATION ANDMIGRATION
ACTIVITY OF NEUROBLASTOMA CELL LINE SK-N-SH
W. Tang1, K. Dong1, X. Cui1, S. Zheng1
1Children’ Hospital of Fudan University, the Department of Pediatrical Surgery,
Shanghai, China
Background/Objectives: HIF-1a plays a significant role in some tumors’ process. The
purpose of our study is to investigate the influence on the growth and development of
neuroblastoma that HIF-1a has.
Design/Methods: The neuroblastoma cell line SK-N-SH was cultured and treated with
100uM Cocl2 for making hypoxic microenvirenment. There were two groups (control
group and Cocl2 group) and three time points(0h,12h and 24h). CCK8 Kit, cell scratch
test was used for testing the cell proliferation and migration activity, respectively.
Real-Time PCR and Western Blot were used for measuring the content of HIF-1a
mRNA and HIF-1a protein, respectively.
Results: During 0 to 12 hours, the proliferation activity and migration activity of
SK-N-SH in Cocl2 group were both stronger than that in control group. The difference
value of OD value(`x±s) in control and Cocl2 group was 0.251±0.113 and
0.646±0.207, respectively(P<0.05) .The difference value of wound width in control and
Cocl2 group was 50.367±9.085 and 108.87±7.86, respectively(P<0.01). While during
12 to 24 hours, the proliferation activity of SK-N-SH was weaker than that in control
group, and there was no significant difference about the migration activity of SK-N-SH
between control and Cocl2 group.The difference value of OD value(`x±s) in control
and Cocl2 group was 1.361±0.15 and 0.367±0.084, respectively(P<0.01) .The
difference value of wound width in control and Cocl2 group was 30.29±13.67 and
20.45±11.991, respectively(P>0.05). HIF-1a mRNA and HIF-1a protein increased in
12 hours(P<0.01), while HIF-1a mRNA increased in 24 hours(P<0.01), and HIF-1a
protein had no obvious increasing during 12 to 24 hours(P>0.05).
Conclusion: Hypoxia probably promotes the malignancy activities of neuroblastoma.
And HIF-1a might be the most important factor in hypoxic microenvironment that
promotes the malignance of neuroblastoma cells.
Posters: New Drugs/Experimental Therapeutics
P-395
SUCCESSFULMANAGEMENT OF CHEMOTHERAPY INDUCED
HYPERTRIGLYCERIDEMIA IN ACUTE LEUKEMIA WITH OMEGA 3 FATTY
ACID
S. Agarwal1
1Sir Ganga Ram Hospital, Delhi, India
Background/Objectives: To study the effect of presecribing omega 3 Fatty acids for
treatment of hypertriglyceridemia in ALL instead of invasive procedures like
plasmapheresis and demonstrating its efficacy.
Design/Methods: Two Patients who developed severe hypertriglyceridemia while on
chemotherapy for ALL were prescribed Omega 3 Fatty Acids. Triglyceride and
Cholesterol levels were monitored sequentially on days 2,4, 6 and 10 along with clinical
assessment for development of complications due to hypertriglceridemia.
Results: A 15-year-old male child who was a case of T cell ALL on reinduction
chemotherapy as per BFM 95 protocol, presented with symtoms of neuropathy and
myopathy. His seum sample was lipemic. His S.Triglyceride levels were >4870 mg/dl
and cholesterol level was 655 mg/dl. He was started on Omega-3 capsules (300 mg)
thrice a day. Triglyceride levels dropped to 1,980 mg/dl, 1120 mg/dl ,540 mg/dl,
326 mg/dl and 250 mg/dl on days 2,4,6,10 and 12 respectively. His cholestrol levels
decreased from 380 mg/dl to <150 mg/dl within 10 days. The patient recovered
clinically and his neurological as well as laboratory parameters remained stable. A 4
year old patient, who was a case of B cell ALL was being treated on BFM95 Protocol
developed hypertriglyceridemia which was detected during routine sampling while on
induction chemotherapy. His Triglyceride levels were equal to 2489 mg/dl. He was
started on omega 3 fatty acids. His triglyceride level decreased to 1500 mg/dl, 840 mg/dl
and 437 mg/dl and 250 mg/dl on days 2,4,6 and 10 following starting of therapy. We
were able to avoid plasmapheresis in both these patients and successfully treat them
conservatively.
Conclusion: Severe hypertriglyceridemia may be conservatively managed with omega 3
fatty acids as an adjunct to diet. Plasmapheresis may be reserved for symptomatic
patients with very high triglyceride levels not responding to conservative therapy. The
availability of omega-3 fatty acids, has demonstrated efficacy, safety and is valuable for
the medical management of hypertriglyceridemia in ALL patients.
P-396
THE “TRIALGAP”: REDUCED ACCESS TO CANCER TRIALS FOR CHILDREN
AND YOUNG PEOPLE IN SCOTLAND
A. Edgar1, S. Ritchie2, E. Jesudason3
1Royal Hospital for Sick Children, Edinburgh, United Kingdom; 2National Managed
Service Network, Children & Young People with Cancer, Dundee, United Kingdom; 3NHS
Lothian, Medicine, Edinburgh, United Kingdom
Background/Objectives: The Scottish Government recommends that all children and
TYA (teenage and young adults aged 16-24 years) with cancer should be able to
participate in clinical trials due to reported benefits in survival and patient experience.
We sought to determine how Scottish children and TYA fared in this regard compared
to peers in the rest of the UK.
Design/Methods: Information on available clinical trials by cancer diagnosis was
collected from: NCRI Portfolio Maps; the UK Clinical Research Network Database
Portfolio; Edge Database (regional directory of clinical trials); hospital data managers.
Results: Trials (UK vs Scotland): The UKCRN site designates 22 UK cancer trials that
are only for “TYA Cancer” and 39 trials as “paediatric”. Respectively, only 11 and 19 of
these designated trials are available in Scotland. Further, we found 712 studies that
could recruit TYA, of which only 215 are available in Scotland.Treatment in Scotland
(TYA vs paediatric): Treatment of children with cancer (aged 0-15 years) is
concentrated in 3 centres while TYA may be treated in one of 19 centres (2 TYA units,
17 adult hospitals).
Conclusion: Children and TYA in Scotland have reduced access to trials of cancer
therapy compared to the UK as a whole. This “trial gap” is exacerbated by incomplete
listing of available trials and, for TYA, by their dispersion amongst numerous treatment
centres.
P-397
MYOSTATIN AS AMARKER FOR SHOWING DOXORUBICIN INDUCED
CARDIAC DAMAGE
V. Kesik1, T. Honca2, M. Gulgun3, B. Uysal4, Y.G. Kurt2, T. Cayci2, O. Babacan5,
E. Gocgeldi6, N. Korkmazer7
1Gulhane Military Medical Academy, Department of Pediatric Oncology, Ankara,
Turkey; 2Gulhane Military Medical Academy, Department of Biochemistry, Ankara,
Turkey; 3Gulhane Military Medical Academy, Department of Pediatric Cardiology,
Ankara, Turkey; 4Gulhane Military Medical Academy, Department of Physiology,
Ankara, Turkey; 5Gulhane Military Medical Academy, Department of Pediatric
Hematology, Ankara, Turkey; 6Gulhane Military Medical Academy, Department of
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Background/Objectives: Doxorubicin (DXR) is an effective chemotherapeutic agent but
causes severe cardiac failure over known doses. Thus, early detection and prevention of
cardiac damage is important. Various markers have been tested for early detection of
cardiac damage. Myostatin is a protein produced in skeletal muscle cells inhibits muscle
differentiation and growth during myogenesis. We evaluated the role of myostatin as a
marker for showing DXR induced cardiac damage and compared with well known
cardiac markers like NT-proBNP, hs-TnT and CK in a rat model of chronic DXR
cardiotoxicity.
Design/Methods: The study was performed with 32 male rats and divided into four
groups. Group 1 received one month, group 2 two month, group 3 tree months of
adriamycin therapy and group 4 served as control.
Results: There was no statistically significant difference between study groups and the
control group in terms of CK, AST, LDH, MDA, SOD, GSH-Px and IL-1 levels.
Myostatin levels were significantly increased in Group 3 in comparison to the control,
and there was no difference between Group 1, 2 and 3. Myostatin levels in Group 1 and
2 were not significantly higher than the levels in the control group. High sensitive
troponin levels were significantly increased in Group 2 and 3, compared to those in the
control group (no change in Group 1), and there was no statistical significance between
Group 1, 2 and 3 regarding the myostatin levels. The proBNP level was higher in Group
3 than it was in the control group, and there was no statistical significance between
group 1, 2 and 3 regarding the proBNP levels. There was a 9.56, 3.00, and 2.30 fold
increase in the first month of ADR administration on NT-proBNP, hs-TnT and
myostatin levels, respectively.
Conclusion:Myostatin, NT-proBNP, and hs-TnT but not CK rose significantly during
DXR treatment.
P-398
PEDIATRIC AND ADULT SUBGROUP RESULTS FROM AN ONGOING
DEFIBROTIDE EXPANDED ACCESS PROGRAM IN THE US FOR PATIENTS
WITH HEPATIC VENO-OCCLUSIVE DISEASE
P. Richardson1, A. Smith2, B. Triplett3, N. Kernan4, S. Grupp5, J. Antin6, L. Lehmann7,
M. Miloslavsky8, R. Hume8, A. Hannah8, B. Nejadnik8, R. Soiffer6
1Harvard Medical School, Jerome Lipper Multiple Myeloma Center-Division of
Hematologic Malignancy-Department of Medical Oncology-Dana-Farber Cancer
Institute, Boston, MA, USA; 2University of Minnesota, Division of Pediatric Blood and
Marrow Transplantation, Minneapolis, MN, USA; 3St. Jude Children’s Research
Hospital, Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA;
4Memorial Sloan-Kettering Cancer Center, Pediatric BMT Service, New York, NY,
USA; 5The Children’s Hospital of Philadelphia, Pediatric Oncology, Philadelphia, PA,
USA; 6Dana-Farber Cancer Institute, Stem Cell/Bone Marrow Transplantation
Program-Division of Hematologic Malignancy-Department of Medical Oncology,
Boston, MA, USA; 7Harvard Medical School, Center for Stem Cell
Transplantation-Division of Hematologic Malignancy- Department of Medical
Oncology- Dana-Farber Cancer Institute, Boston, MA, USA; 8Jazz Pharmaceuticals-
Inc., Clinical, Palo Alto, CA, USA
Background/Objectives: Hepatic veno-occlusive disease (VOD), or sinusoidal
obstruction syndrome, is an unpredictable, life-threatening complication of
hematopoietic stem cell transplantation (HSCT). Severe VOD (sVOD) is associated
with >80% mortality; it is characterized clinically by multi-organ failure (MOF). In the
European Union, defibrotide is approved for treatment of sVOD in HSCT. In the
United States, defibrotide is available through an ongoing, expanded-access,
protocol-directed treatment IND (T-IND) study. T-IND day+100 survival post
HSCT/chemotherapy was analyzed for pediatric/adult subgroups.
Design/Methods: Patients received defibrotide 25 mg/kg/day, 21 days recommended.
Eligibility: Originally, sVOD with MOF (renal/pulmonary) by Baltimore criteria post
HSCT; amended to include patients post HSCT/chemotherapy with non-sVOD
(without MOF), VOD per modified Seattle criteria, or biopsy-proven VOD.
Results: Of 641 patients enrolled through 2013 receiving 1 dose (median treatment
duration, 21 days), 636 had age data: 58% were pediatric (aged <16y) and 42% adult
(>16y). Among pediatric and adult patients post HSCT, day+100 survival was 58%
(163/283) and 45% (109/243), respectively. sVOD occurred in 55% of children and 50%
of adults. Among sVOD and non-sVOD post-HSCT subgroups, respectively, pediatric
survival was 50% (79/157) and 67% (84/126); adult survival was 38% (46/122) and 52%
(63/121). For pediatric and adult patients post chemotherapy, survival was 83% (39/47)
and 60% (9/15), respectively; sVOD subgroup rates were 77% (20/26) and 67% (4/6).
Adverse events (AEs) occurred in 61% (227/372) of children and 76% (200/264) of
adults, with treatment-related AEs in 19% and 24%, respectively. Serious AEs occurred
in 45% of children (most common non-VOD/non-MOF: pulmonary hemorrhage [8%])
and 53% of adults (most common non-VOD/non-MOF: hypotension [5%]).
Conclusion: Defibrotide was generally well tolerated, with manageable toxicity. The
higher survival rates in the non-sVOD subsets indicate further study is warranted to
determine the impact of treatment earlier in the course of VOD. T-IND enrollment
continues. Support: Jazz Pharmaceuticals.
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MOBILISATION OF HAEMATOPOIETIC STEM CELLS IN PAEDIATRIC
PATIENTS, PRIOR TO AUTOLOGOUS TRANSPLANTATION FOLLOWING
ADMINISTRATION OF PLERIXAFOR AND G-CSF
H. Pearson1, P. Bhumik2, S. Zacharoulis3,4
1The Royal Marsden NHS Foundation Trust, Nursing, Surrey, United Kingdom; 2The
Harley Street Clinic, Pharmacy, London, United Kingdom; 3The Harley Street Clinic,
Medical, London, United Kingdom; 4The Royal Marsden NHS Foundation Trust,
Medical, Surrey, United Kingdom
Background/Objectives: Plerixafor is a selective reversible antagonist of CXCR4,
capable of interfering with CXCR4 interaction with Stromal cell-derived factor 1 alpha
(SDF-1). Therefore when used in combination with granulocyte-colony stimulating
factor (G-CSF) it is capable of amplifying the effects of G-CSF in mobilizing
haematopoietic stem cells. In this we retrospectively review our single centre experience
with Plerixafor and G-CSF to mobilize stem cells in five extremely heavy pre-treated
oncology patients, as a primary method of mobilization.
Design/Methods: All patients started G-CSF at 10microgram/kg 4 days prior to the first
administration of plerixafor. Plerixafor was administered at 0.24 mg/kg on the first day
of apheresis and administered on subsequent days if further stem cell harvesting was
required.
Results: Patient 1 mobilized on day 1 alone and achieved 10.7×106/kg; Patient 2 and 3
continued to have rising CD34 levels demonstrated over the 3 days of apheresis and
with an incremental number achieved each day, although the measured CD34 level
pre-harvest showed a drop for Patient 3. Patient 4 and 5 mobilized extremely well on
day 1 alone and yielded the CD34 positive stem cell dose required. During apheresis
patient 2 developed signs and symptoms of hypocalcaemia but this corrected with oral
calcium correction, whilst patient 3 during harvest required phosphate and potassium
correction.
Conclusion: Plexiaflor in combination with G-CSF has shown encouraging results in
this small selection of patients who were heavily pre-treated prior to undertaking the
stem cell mobilisation regimen. Although this is a small cohort of patients the data
obtained provides a foundation for future research within a larger patient group.
P-400
REVIEW OF PRESCRIBEDMEDICATION AND CLOSE COOPERATION
WITH PHARMACIST LEADS TO REDUCTION OFMEDICATION ERRORS IN
A PAEDIATRIC ONCOLOGY DEPARTMENT
V. Spager1, R. Pernille1, M. Madsen1, P. Megaard1, R. Mathiasen1
1Rigshospitalet-Copenhagen University Hospital, Department of Pediatric
Hematology/Oncology, Copenhagen, Denmark
Background/Objectives: Approximately 100 children between 0-15 years are diagnosed
with cancer each year and treated at Rigshospitalet, Copenhagen. A review of
medication errors at the department showed that medication errors were primarily
related to errors of prescription and were discovered at dispensation step by nurses or
administration by parents. In order to optimize patient safety, the department and
pharmacy initiated a project of pharmacist review of medication.
Design/Methods: The purposes of the project were a) to ensure that prescription errors
were discovered and corrected before dispensation and administration and to correct
eventual errors, through dialogue with the prescribing physicians, b) to ensure best
practice of drugs prescribed and c) to ensure the most effective and appropriate use of
medicines.Two pharmacists reviewed medicine prescribed for admitted children every
weekday from 10-12 am. Review of medication was prioritized as follows: 1. Children
with complex treatment or unstable disease. 2. Recently admitted children. 3. Children
who had been transferred from other departments within the same day. In case of
inappropriate prescription the pharmacists contacted the responsible physician in order
to change prescription if relevant. All reviews were recorded in a central database by
date, age of child, any deviance from best practice and if intervention was accepted by
physician.
Results:Within the period from March1st. 2014 to February 28th 2015, 3253
prescriptions were reviewed. In 51.2% (N=1585) there was no deviation from best
practice. In 12,2% (N=396) errors of prescribed dose or incorrect duration of treatment
were found. Of these, 95.0% (N=375) were accepted by the physician. The remaining
36.6% of findings concerned side effects, dispensing intervals, formulation of drug and
interacting drugs.
Conclusion: Review of prescribed medication in a paediatric oncology department and
collaboration between pharmacists and prescribing doctors improves quality of
medication and reduces adverse events.
P-401
EFFECTIVENESS OF ANKAFERD BLOOD STOPPER IN PROPHYLAXIS AND
TREATMENT OF ORALMUCOSITIS SEEN IN CHILDHOOD CANCERS AND
CORRELATIONWITH PLASMA CITRULLINE LEVELS
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T. Patiroglu1, N. Sahin2, E. Unal1, M. Kendirci3, M.A. Ozdemir1, M. Karakukcu1
1Erciyes University School of Medicine, Department of Pediatric Hematology and
Oncology, Kayseri, Turkey; 2Erciyes University School of Medicine, Department of
Peditrics, Kayseri, Turkey; 3Erciyes University School of Medicine, Department of
Pediatric Metabolism, Kayseri, Turkey
Background/Objectives: Oral mucositis is observed in 52-80% of the children receiving
cancer therapy. Ankaferd Blood Stopper (ABS) is an herbal product that is used as a
hemostatic agent. In previous studies, it was shown that ABS has anti-microbial,
anti-inflammatory effects as well as positive effects on healing of tissue injury. This
study aimed to investigate effectiveness of ABS in prophylaxis and treatment of oral
mucositis.
Design/Methods: This was a randomized, controlled and open study which included 27
patients aged 4-17 years receiving chemotherapy regimens with strong mucotoxic effect.
The patients were asked to perform standard oral care (SOC) upon first day of
chemotherapy for 10 days and oral mucosa was assessed daily upon completion of
chemotherapy based on World Health Organization scale for oral mucositis. Same
patients receiving same chemotherapeutic agents in the second course of chemotherapy
were asked to gurgle by using ABS four times daily in addition to SOC. Mucosa ratings
were performed before second chemotherapy course and at the period where mucositis
became most intensive, and blood samples were drawn to measure citrulline levels again.
Results: Stages of oral mucositis were found lower in the second chemotherapy course
given SOC plus ABS when compared to first chemotherapy course given SOC alone
(p=0.007). Mean plasma citrulline level obtained before and after chemotherapy
decreased from 44.08 to 23.99 nmol/mL in chemotherapy course given SOC alone
(p<0.001) while it decreased from 38.67 to 26.78 nmol/mL. When extent of decrease in
plasma citrulline level was assessed, it was greater in courses given SOC alone
compared to those given SOC plus ABS (p=0.009).
Conclusion: Based on our results, ABS exhibited beneficial effects in the prophylaxis
and treatment of oral mucositis. However, multi-center experiences and further studies
with larger sample size are needed for introduction of ABS into primary oral care and
treatment protocols of oral mucositis.
P-402
LIPOPLATIN; A NEW LIPOSOMAL AGENT, IN THE TREATMENT OF
RELAPSED ORMETASTATIC CHILDHOOD SOLID TUMORS : TOXICITY
AND CLINICAL OBSERVATIONS OF EFFECTIVENESS
N. Tacyildiz1, H. Dincaslan1, G. Yavuz1, E. Unal1, E. Pekpak1, B. Adaklı Aksoy1,
Z. Gordu1, F. Asarcikli1
1Ankara Üniversity Faculty of Medicine, Pediatric Oncology, Ankara, Turkey
Background/Objectives: Liposomal cisplatin (Lipoplatin) is a new cisplatin formulation
and has been investigated in a small number of adult cancer studies to Compare with
cisplatin for effectiveness and toxicity. There is no childhood studies.
Design/Methods: we aimed to investigate renal toxicity, myelotoxicity, other side effects
and effectiveness of lipoplatin in highly pretreated relapsed or metastatic solid
childhood tumors. Patients (were enrolled to study after july 2014) ages were between 4
to 7 years old (2 boys, 3 girls) with relapsed, metastatic solid tumors 2
rhabdomyosarcoma, 2 neuroblastoma; relapsed after high dose therapy followed by
autologous peripheral stem cell transplantation, 1 condrosarcoma). Patients have been
received Lipoplatin (125-175 mg /m2) and Paclitaxel (125-175 mg/m2, before Lipoplatin
administration) every other week between 2 to 5 cycles, total 15 cycles. Renal function
tests, blood counts, vomiting side effects, and other possible side effects have been
recorded before and after each cycle besides imaging studies to asses clinical
effectiveness.
Results: Creatin level range before treatment were 0.25 - 0.92 mg/ dl (median: 48) while
it was between 0.38 - 0.82 mg/dl (median: 0.49) after Lipoplatin-Paclitaxel treatment.
There was no renal failure or any other important side effects to restrict chemotherapy
schedule. Only mild, Grade 1-2 myelosupression and grade 1 vomiting have been
observed. Although, it is early to evaluate effectiveness of the treatment, it was possible
to receive stable disease for 2-8 months in that advanced disease patients with better
quality of life.
Conclusion: According to preliminary results of our study; Lipoplatin is effective and
well tolerated by children with relapsed and metastatic cancer with no grade 3/4
nephrotoxicity, myelospression or neuropathy. It may even serve as an option as first
line therapy for advanced stage, metastatic childhood solid tumors to prevent any renal
or neurological side effects before they observed.
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PHARMACOTHERAPEUTIC COUNSELING BY A CLINICAL PHARMACIST
ON A PEDIATRIC HEMATOLOGY AND ONCOLOGY UNIT
B. Deleenheer1, I. Ceuterick1, N. Moerman1, S. Jacobs2, A. Uyttebroeck2, K. Cosaert1
1University Hospitals Leuven, Pharmacy Department, Leuven, Belgium; 2University
Hospitals Leuven, Pediatric Hematology and Oncology, Leuven, Belgium
Background/Objectives: Pharmacotherapy in pediatric hematology and oncology
(PHO) patients is complex. To improve the quality of treatment and care, a team of 4
clinical pharmacists is involved in the PHO unit of the University Hospitals Leuven. To
guarantee optimal continuity, standardization of the interviews is essential.
Design/Methods:Different types of interview are defined: first discharge interview, basic
discharge interview, start-up of corticosteroids, start-up of an oral chemotherapeutic,
maintenance therapy, tapering of corticosteroids. After each interview, the pharmacist
registers patient and type of interview.
Results: From February 2014 until January 2015, 205 patients (0-18 years) were
followed: 64 new diagnoses, 141 patients already on treatment. A total of 914 interviews
were performed. The greatest attention is paid to the basic discharge interviews (n=612,
67%), followed by start-up of corticosteroids (n=73, 8%) and first discharge interviews
(n=65, 7%). Most of the interviews (74%) are done during hospitalization. Only 26% of
the interviews are performed at day-clinic.
Conclusion: Given the great amount of interviews, a fulltime presence of a clinical
pharmacist on a PHO unit is needed. As 74% of all the interviews are discharge
interviews, and performed by a team of 4 pharmacists, a structured approach of these
interviews is needed to guarantee content quality. In the near future a qualitative survey
will be carried out at the physicians, nurses and patients and their families to evaluate
the content of the interviews.This project is funded by the NationalCancerPlan and
Kinderkankerfonds Leuven.
Posters: Nursing
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EVERYONE HAS A ROLE IN INFLUENCING AND SHAPING BEST CARE
PRACTICE IN PAEDIATRIC CANCER CARE: THE JOURNEY FROM
CLINICAL SUPPORTWORKER TOWARDMANAGER
T. Aston1
1Birmingham Children’s Hospital NHS FT, Birmingham, United Kingdom
Background/Objectives: Every member of the paediatric oncology nursing team play a
vital role in delivering the best care to patients within paediatric oncology. From the
role of clinical support worker, to staff nurse, through to senior sister. At every level of
competence nursing staff can impact, influence and shape the practice that is delivered
to patients and their families. The model of the service in which that is delivered is
paramount.
Design/Methods: The role of the clinical support worker has undergone many changes
throughout time from a clinical role to a non-clinical role and back again. With the
current challenging climate of less qualified nurses available to employ, the role of the
clinical support worker has needed to be developed and adapted further to underpin
and support the role of the qualified paediatric oncology nurse. Through personal
experience of a career starting as a clinical support worker, progressing to a ward
manager the author has great insight and understanding of what the role of clinical
support worker within paediatric oncology should entail.
Results: Increasing the number of clinical support workers that are employed and that
undertake a trust wide education and development programme will aim to support
recruitment and retention of clinical support workers and nursing staff too. Shaping
and tailoring a further training and education programme within paediatric oncology
for clinical support workers will endeavour to compliment this further.
Conclusion: The clinical support worker role plays an essential part in the delivery of
care. They assist nursing staff with their clinical duties and also can support patients
and parents through their journey. In an ever changing culture of fewer nurses coming
through the nurse training programmes the role of the clinical support worker in
paediatric oncology is as pivotal as ever in delivering, influencing and shaping best care
within paediatric oncology.
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IMPLEMENTATION OF A NUTRITION THERAPY PROTOCOL IMPACTS IN
THE USE OF PARENTERAL NUTRITION IN PAEDIATRIC ONCOLOGY
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
G. Bouchabki1, K. Viani1, B. Stachissini Manzoli1, M. Neto Rafael1, V. Oliveira1
1Instituto de Tratamento do Câncer Infantil-Hospital das Clínicas-University of Sao
Paulo’s Medical School, Nutrition Department, Sao Paulo, Brazil
Background/Objectives: The Hematopoietic Stem Cell Transplantation (HSCT)
represents increased nutritional risk to paediatric oncology patients. Parenteral
Nutrition (PN) is often used for patients undergoing HSCT, which could represent
increased risk of line infections, hyperglycemia, hypertriglyceridemia and cholestasis,
apart from higher cost. The use of Nutrition protocols is essential to standardise
nutritional care and follow up, especially in complex procedures such as HSCT. The aim
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of this study was to investigate whether the implementation of a Nutrition therapy
protocol reduced the use of PN in paediatric oncology patients undergoing HSCT at a
tertiary Paediatric Oncology hospital in Sao Paulo, Brazil.
Design/Methods: A retrospective study was conducted by chart review on the use and
duration of PN in children and adolescents with cancer, from conditioning to 60 days
after HSCT. Transplants from January 2012 to January 2015 were analysed. The data
was divided in before and after the implementation of a Nutrition therapy protocol
(January/2014) and the percentage of patients who received PN in both groups was
compared. The protocol indicates the use of nasogastric tube feeding for patients
undergoing HSCT. The chi-square test was used to verify the statistical significance of
the difference between the frequencies.
Results: Data of 26 patients were analysed, 14 before (42.9% female; mean age 10.9
years) and 12 after (50% female; mean age 10.1 years) the implementation of the
protocol. The frequency of use of PN dropped from 71.4% to 8.3% (p < 0.05) and the
duration from 12.6 to 0.8 days/patient.
Conclusion: The implementation of a Nutrition therapy protocol decreased the use of
PN in this group of patients.
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THE EFFECT OF FAMILY LIFE AND CHILDREN RAISING ATTITUDES TO
PAIN PERCEPTION OF CANCEROUS CHILDREN
G. Boyraz1
1Marmara Üniversity, School of nursing, I˙stanbul, Turkey
Background/Objectives: This study was performed to determine the effect of parents’
children raising attitudes in cancerous children pain perception with definitive and
comparative methods.
Design/Methods: One hundred and twenty children and their parents’ were taken as
trial group in compliance with study criteria between the dates during the study was
performed. The data were collected using child and parent data collect forms and
PARI-Parental Attitude Research Instrument. In evaluation of the data, for statistical
analyses SPSS Windows 10.0 sorftware used. For evaluation of study data, Kruskal
Wallis test and Mann Whitney U test were used for comparing quantitative data in
addition to identifying statistical methods, Chi-square test were used in comparing
quantifiable data.Pearson Correlation Analysis were used for determining relations
between parameters.The results were evaluated within a confidence interval of 95% an
at a significance level of p<0.05).
Results: At the end of the study; mother’s child raising attitudes didn’t affect children
pain perception level was found. There were a negative relation between the
mothers’expression of children in Facial Pain Scale( 22.4% level in negative
direction,p<0.05) and VAS scores ( 24.4% level in negative direction,p<0.01).The result
of this research showed that child raising attitudes didn’t affect the pain perception of
the children but effect the expression and expression manners of pain. While democratic
behavior and equality respect bottom dimension points of mothers children who
express pain are higher than mothers of children who don’t express pain( p<0.05).Also,
emotional expressions of pain in children, whose mothers have high points from
constraint and discipline bottom dimension, are significantly lower than children who
express their pain behaviourally (p=0.023, p<0.05) and physically (p=0.008,p<0.01).
Conclusion: In concslusion, parents’ children raising attitudes affected the children’s
pain expression and behaviours. Considering these effects, it is thought that the efficient
analgesia chance of cancerous children will be raising with holistic nurse approach
made by evaluating.
P-407
NURSING CHALLENGES CARING FOR PRE-ADOLESCENT ONCOLOGY
PATIENTS WITH ORTHOPAEDIC COMPLICATIONS
Z. Brown1, C. Jefthas2, N. Somagaca3, N. Twala1, B. Mjikeliso1
1Red Cross War Memorial Children’s Hospital, Ward G1, Cape Town, South Africa;
2Red Cross War Memorial Children’s Hospital, G1, Cape Town, South Africa; 3Red
Cross War Memorial Children’s Hospital, Ward G1, Cape Town, South Africa
Background/Objectives: To overcome the nursing challenges of pre-adolescent oncology
patients nursed in traction due to pathological fractures.
Design/Methods: Data collected retrospectively from folder review from one patient.
Another patient currently observed in hospital, while in traction. Qualitative study
regarding two patients with pathological fractures.
Results: One patient currently receiving physiotherapy to improve mobility. The second
patient is still in traction while receiving chemotherapy with view of limb salvage.
Conclusion: Patients at risk of pathological fractures and those who have sustained
pathological fractures, can still have an equally good quality of life especially during the
challenging period of immobility.
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RESILIENCE ANDMENTAL HEALTH IN PARENTS OF CHILDREN
SURVIVING ACUTE LYMPHOBLASTIC LEUKEMIA
M.E.B. Eilertsen1, T. Reinfjell2, T.T. Le3, T. Diseth4, O. Hjemdal2
1University College Sør-Trøndelag, Faculty of Nursing, Trondheim, Norway; 2Faculty of
Social Sciences and Technology Management-Norwegian University of Science and
Technology Sør-Trøndelag, Department of Psychology, Trondheim, Norway; 3Faculty of
Social Sciences and Technology Management-Norwegian University of Science and
Technology Sør-Trøndelag, Department of Social Work and Health Science, Trondheim,
Norway; 4Oslo University Hospital- Section of Child and Adolescent Psychiatry,
Department of Paediatrics, Oslo, Norway
Background/Objectives: Cancer in children is a tremendous stressor that requires
parents to adapt to new challenges related to the child`s illness. Research has mainly
focused on psychopathology, and rarely on a resource-oriented perspective, such as
resilience. The objective of this study is to assess resilience factors among both mothers
and fathers of children surviving acute lymphoblastic leukemia (ALL) compared to
parents of healthy children. In addition, to explore the association between parental
resilience and mental health.
Design/Methods: This cross-sectional study consisted of parents (n=55) of 40 children
in remission from ALL between 8 to 15 years of age, compared to parents of healthy
children (n=63). Children were recruited from the Norwegian Radium Hospital, Oslo
and St. Olavs University Hospital, Trondheim, Norway. The Resilience Scale for Adults
(RSA) assessed parental resilience and the General Health Questionnaire (GHQ-30)
assessed parents’ mental health.
Results: Significant lower scores were found for the RSA total scores for both mothers
and fathers compared to healthy controlgroup. No significant differences were found for
mental health. The resilience factors: Perception of Self, Planned Future and Family
Cohesion were significant predictors for mental health in mothers of children surviving
ALL, and Social Competence was a predictor for fathers.
Conclusion: Resilience factors associated with parents’ mental health may be of
protective value, and should therefore be considered in a clinical setting.
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CONFIRMATORY FACTOR ANALYSIS OF THE FATIGUE
SCALE-ADOLESCENT
H. Ka Yan1, H.C.W. Li2
1The University of Hong Kong, N.A., Hong Kong-China; 2The University of Hong Kong,
School of Nursing, Hong Kong, Hong Kong-China
Background/Objectives: Fatigue is one of the most common symptoms reported by
adolescents who have survived cancer. Numerous studies have indicated that it can
exacerbate other late effects of cancer treatment and limit the survivors’ capacity to
perform daily activity, consequently affecting their quality of life (QoL). It is therefore
vital for healthcare professionals to develop interventions that can help reduce fatigue.
First, however, the availability of a reliable and valid instrument accurately assessing
fatigue is crucial before any intervention can be planned and evaluated. This study
aimed to examine the psychometric properties of the Chinese version of the Fatigue
Scale for Adolescents (FS-A) and assess its factorial structure by confirmatory factor
analysis (CFA).
Design/Methods: A cross-sectional study design was employed in an outpatient clinic. A
convenience sample of two hundred adolescents who have survived cancer were invited
to participate. The internal consistency, test-retest reliability, content validity and
construct validity of the Chinese version of the FS-A were assessed.
Results: The Cronbach’s alpha coefficient and intra-class correlation coefficient were
0.89 and 0.85 respectively. The content validity index was 0.92. There was a strong
positive correlation (r = –0.58) on the scores between adolescents’ fatigue and
depressiveness, but a strong negative correlation (r = 0.53) on scores between
adolescents’ fatigue and QoL. The mean score of fatigue of the survivors was found to
be significantly lower than that of children receiving cancer treatment, but significantly
higher than that of their healthy counterparts. The result of CFA showed that a
four-factor model was adequately fit the data obtained by the Chinese version of the
FS-A, indicating that the factorial structure is the same as its original version.
Conclusion: The result provides further evidence to support that the Chinese version of
the FS-A is a reliable and valid instrument assessing fatigue among adolescents who
have survived cancer.
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ADJUSTMENT AND COPING IN PARENTS OF CHILDRENWITH CANCER
E. Kiziler1, D. Yildiz1, F. Arslan2, B.E. Fidanci1, D. Suluhan1
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1Gülhane Military Medical Academy, School of Nursing, Ankara, Turkey; 2Yeditepe
University, Faculty of Health Sciences-Nursing Department, Istanbul, Turkey
Background/Objectives: The diagnosis and treatment of cancer is very stressful event for
children and other family members, as well as causing physical, social, emotional and
economic difficulties. It requires using of appropriate coping strategies to ensure
adherence to treatment and to be protected from the psychopathological effects of
diagnosis and long term treatment of cancer. Research has been conducted to
investigate the coping in parents of cancer patients.
Design/Methods: The study was performed in Clinics of Pediatric Oncology and
Hematology with participating of 187 parents of children with cancer. In collecting the
data, an information form, which was developed by researchers and “Ways of coping
inventory” were used. The frequency distribution, arrhythmetic average and standard
deviation of the data was obtained. In analyzing the data, Student’s t test, one- way
ANOVA, Bonferroni and Tukey advanced level test, Pearson correlation test and
Chisquare test were used.
Results: The majority of the parents were shocked when they first heard the diagnosis
and felt the fear of the loss of the child. Parents use spiritual beliefs, compare their
situation with others and need health care practitioners’ to cope with their problems.
It’s shown that the factors effected the coping in parents are; the age of children,
negative relations with other family members, the way to get the medical therapy,
education level of the parents and the effect of cancer on family budget. It’s found that
when the income level decreases, the approaches of seeking support, helplessness and
submissive are increasing.
Conclusion: According to these results, it’s evaluated that providing social support by
health care team and being informed about their child’s illness and treatment options
can help parents to cope with anxiety in childhood cancers. Planning the health care
programme will also eliminate the negative attitudes and social support systems will be
developed.;
P-410
NURSING INTERVENTION FOR FATIGUE IN CHILDRENWITH CANCER
LITERATURE REVIEW
K. Kobayashi1, K. Maeda2
1St. Luke’s International University, Chuo-ku, Japan; 2St. Luke’s International Hospital,
Pediatric, Tokyo, Japan
Background/Objectives: Purpose: Cancer-related fatigue (CRF) is one of the most
frequent symptoms experienced by children with cancer, and several previous studies
reported that fatigue is considered as the most distressing symptom that is related to
cancer treatment by children and adolescents patients with cancer. There are some
guidelines regarding pharmacological interventions in CRF, however, nursing
intervention is still under investigation. Therefore, the aim of this study is to review
nonpharmacological intervention and obtain clues to the implementation of nursing
intervention that will improve QoL of children with cancer.
Design/Methods:Methods: We searched literature by PubMed by the key words
“intervention” “cancer” “children” and “fatigue”.
Results: Thirty-one studies were found through the search. We excluded 17 studies
which were review articles or investigated survivors fatigue. We examined rest 14
studies. Of 14 studies, 3 were study protocol and these studies aimed to present
rationale and design of the clinical research program or evaluated the efficacy of the
programs for fatigue in pediatric cancer patients. 2 studies were developed self-reported
scales for fatigue in children or adolescents, and 5 were descriptive studies (e.g.
frequency of fatigue between children and adolescents was compared). Other 4 studies
were randomized prospective intervention studies or case control studies. The aims of
randomized prospective intervention studies and care control studies were to examine
feasibility and efficacy of the interventions, and a home-based aerobic exercise, a
bicycle-type exercise, and a complementary energy therapy were examined its efficacies.
Conclusion: A few interventions to examined to relieve and decrease fatigue in children
with caner, and all of the examined interventions were exercises. Further investigations
are necessary to establish the standard nursing intervention for fatigue in children with
cancer.
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THE IMPACT OF CANCER AND ITS TREATMENT ON PHYSICAL ACTIVITY
LEVELS AND QUALITY OF LIFE AMONG YOUNG HONG KONG CHINESE
CANCER PATIENTS
K.W.K. Lam1, H.C.W. Li2
1The University of Hong Kong, Hong Kong, Hong Kong-China; 2The University of Hong
Kong, School of Nursing, Hong Kong, Hong Kong-China
Background/Objectives: Despite the evidence that regular physical activity can have
beneficial effects on the physical and psychological well-being of cancer patients, a
review of the literature reveals that a majority of young cancer patients fail to attain the
same levels of physical activity that they had before contracting the disease. This study
is to examine the impact of cancer and its treatment on the physical activity levels and
quality of life of young Hong Kong Chinese cancer patients.
Design/Methods: A cross-sectional study was conducted, with 76 young cancer patients
admitted for treatment to a pediatric oncology unit, and another similar age group of
148 healthy counterparts from the two integrated child and youth service centers were
invited to join the study.
Results: The study found that the current physical activity levels of young cancer
patients were markedly reduced when compared with their pre-morbid situation.
Moreover, they were significantly less active in performing physical exercise, and
reported lower levels of self-efficacy and quality of life than their healthy counterparts.
The results of the hierarchical multiple regression analysis showed that physical activity
is an important indicator of quality of life among young cancer patients.
Conclusion: The results provide further evidence that cancer and its treatment have
negative effects on physical and psychological well-being and quality of life among
young cancer patients. There is an imperative need for healthcare professionals to
promote the adoption of regular physical activity among such patients, even during the
treatment itself.
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VALIDATION OF ‘THE RAINBOW PAIN SCALE’
P. Mahon1, L. Holsti1, C. Strahlendorf2, L. Turnham3, D. Giaschi4, H. Siden2
1University of British Columbia, Occupational Science, Vancouver, Canada; 2University
of British Columbia/BCCH, Pediatrics, Vancouver, Canada; 3BC Childrens Hospital,
Oncology/Haematology, Vancouver, Canada; 4University of British Columbia,
Ophthalmology, Vancouver, Canada
Background/Objectives: Self-report, when available, is considered the primary way to
assess the intensity and other aspects of pain in children. However, self-report scales are
often too complex cognitively for preschool-aged children (2-4 years). The Rainbow
Pain Scale (RPS) was developed to provide individualized self-reported pain ratings for
preschool-aged children. The psychometric properties of this scale have yet to be
evaluated. To ensure validity, our first step was to compare RPS scores to a
well-validated scale in older children who were able to self-report their pain. Assess the
concurrent validity of the RPS in children aged 5 to 10 years as proof of principle.
Design/Methods:We compared ratings of 49 children’s pain using the RPS with those
on the Faces Pain Scale –Revised (FPS-R). Participants suffering from pain related to
cancer were recruited to complete both scales at 3 time points, during both inpatient
and out-patient clinic visits. Pearson’s r and Cohen’s kappa were used to evaluate the
level of association between the scales.
Results: The association between RFC and The FPS-R was greater than 0.7 at all three
visits; r = 0.96 between the scales at the first clinic visit, 0.97 at the second visit and 0.93
at the third visit. Cohen’s kappa between scales was 1.0 at the first clinic visit, 0.95 at the
second visit and 0.87 at the third visit.
Conclusion: The RPS shows excellent concurrent validity with the FPS-R in
school-aged children. The next step will be to examine the psychometric properties of
the RPS in pre-school aged children. We are currently recruiting 100 children from the
oncology population age 30 months to 59 months. Convergent validity is being assessed
by evaluating the agreement between the RPS and their parents’ assessment of their
pain on the FPS-R using a Bland and Altman plot.
P-413
RETROSPECTIVE ANALYSIS OF REPORTED DRUG ERRORS IN A
PEDIATRIC HEMATO-ONCOLOGYWARD
A. Mannaerts1, S. Van Lancker1, A. Maes1, T. Bauters1, J. De Porre1, G. Laureys1
1Ghent University Hospital, Pediatric Hemato-Oncology, Gent, Belgium
Background/Objectives:Working on a Pediatric Hemato-Oncology ward (PHO)
involves complex medication regimens. Clear procedures with regard to prescribing and
administering medications are important. The hospital uses a reporting system to
register (near) incidents and to define corrective and preventive actions, without
penalizing consequences for the reporter/culprit.
Design/Methods:We retrospectively analyzed the drug errors reported over a period of
4,5 years (September 2010 - February 2015) and studied the difference in drug errors
reported before and after the introduction of an electronic medication program (EMP)
in October 2014. Incidents are classified according to the point of time in the
medication process. Main stages are: prescription, preparation/distribution and
administration of medication.
Results: Before the introduction of EMP the mean number of incidents reported was
2.4/month. Drug errors that occurred during prescription (17%, 20/117) were mostly
related to prescribing a wrong dose, concentration or frequency.Most drug errors (69%,
81/117) occurred during the administration to the patient and concerned wrong
dose/concentration or frequency (30%, 24/81), wrong drug (15%, 12/81) or an omitted
dose (25%, 20/81). There was a decrease in the reporting of errors after the introduction
of EMP (0.8/month), 75 % of them were errors in the administration to the patient and
none during the prescription.
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Conclusion: The most frequent reason for drug errors at the PHO-ward is wrong
prescription, and more frequently, wrong administration to the patient. During and
after the implementation of EMP many ‘growing pains’ were observed and there was a
decrease in reported errors. We suppose a strong underreporting, probably due to lack
of time, as the EMP is more time consuming for prescribers and administrators of
medication. It remains important, even during changing processes, that all incidents are
reported especially to optimize the use of EMP. In this respect it is extremely important
to encourage nurses and physicians to report each incident.
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EXPERIENCES OF PARENTS OF CHILDRENWITH CANCER STAYING AT A
MOTHERS’ HOSTEL AT THE KORLE BU TEACHING HOSPITAL, ACCRA,
GHANA
M. Mensah1, E. Bosumprah1
1Korle Bu Teaching Hospital, Department of Child Health, Accra, Ghana
Background/Objectives: The majority of children receiving treatment for cancer at
Korle Bu Hospital are referred from outside Accra. With their parents, they are
accommodated at a hospital hostel. This study seeks to explore the experiences of
parents of children with cancer in Ghana staying at the Mothers’ Hostel.
Design/Methods: A qualitative study was undertaken with parents of children with
cancer staying at the Mothers’ Hostel of the Korle Bu Hospital. Using open-ended
questions, their experiences were explored.
Results: Twenty parents were interviewed. Most (80%) of parents were between 20 – 40
years of age with the same percentage being females. Eighty percent had other children,
80% had stayed at the hostel for more than four months. Thirty percent had not had
any visitors since coming to Accra. Sixty percent had difficulty feeding themselves as
one stated “I have to go hungry to be able to feed my child”. Sixty-two percent of them
relied on grandparents and relatives other than spouses to take care of their other
children. Only 30% felt comfortable, the rest complained of a lack of privacy and
congestion. Of concern was the fact that 80% expressed feelings of wanting to abandon
treatment due to financial difficulties. One person stated “I pray God will have mercy on
me and cure my child’s disease”. Other concerns expressed were worries about the
children left at home and their work. Surprisingly, only 30% felt their marriages had
been affected. Emotional stress was expressed by 70% of them. There was an expression
of “I feel helpless and dejected”.
Conclusion: Despite free accommodation being provided for parents and children with
cancer for the duration of treatment, they still face major psychosocial challenges and
potential treatment abandonment. Paediatric oncology staff in developing countries
should be aware of this and strategies put in place to address this.
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FOOTSTEPS AND CHALLENGES OF PAEDIATRIC ONCOLOGY NURSING
CARE THROUGH ILLNESS AND BEYOND: A UNIT EXPERIENCE
S.G. Mngomezulu1
1South Africa
Background/Objectives: Paediatric cancer nursing in South Africa is enormously
challenging as it compromises of medical, physical, psychological, cultural and social
problems and issues. These need a nurse who is highly motivated with an inherent drive
to move towards self actualization and creative thinking by pursuing knowledge and to
give to the oncology community. South Africa is still considered as a developing
country where skills and resources are still out of reach. To highlight how challenges,
lack of skills and setbacks can lead to de-motivation or perseverance.To promote the
culture of caring, commitment and flexibility for those directly or indirectly involved
oncology care. To encourage peers to acquire skills, knowledge, do research and case
management in spite of all these challenges.
Design/Methods: A prospective observational and cross sectional survey of from
2001-2014: Staff quota on: experience, training/development opportunities and needs,
staff retainment and resignations; Analysis thereof is: expert vs. novice is 1:8, carrier
opportunities is 1:15, employment vs. resignations is 2:4Client turnover/satisfaction:
400 – 600 a year, survival 70%- 80%Records on disease profile and research: Cancer
mutations and presentation are diverse. Media analysis: ‘The Star‘newspaper, out of
458,933 deaths in the country in 2013, 8.3% were caused by neoplasm and ‘The Star’
3/12/2014, pg4.
Results: Limited skills development: 57%, resignations/transfers/ retirements 45%: and
patient turn over 75%.
Conclusion: An oncology nurse serves many roles depending on her experience, insight
and education on how to handle changes and challenges facing her profession, client
and family.The philosophy of caring demands professional growth and development,
but with the ongoing challenge of human and material shortages, care will always be
compromised.
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BEABOOK: PATIENT-ORIENTED EDUCATIONAL BOOKLET
M. Simone1, E. Sassi2, L. Panzoldo3, F. Santos3
1Instituto Beaba, Directory, Sao Paulo, Brazil; 2Instituto Beaba, Creative, São Paulo,
Brazil; 3Instituto Beaba, Medical, São Paulo, Brazil
Background/Objectives: The child with cancer feels the need to know what is going on,
even when the family tries to hide the diagnosis. To inform the child about the disease
increases their cooperation and reduces passivity, also increasing their control over the
situation. But the majority of the available information isn’t adequate for this. It’s
necessary to establish patterns able to homogenize the meaning of words, phrases and
symbols, contributing to minimize the barriers of understanding, providing an efficient
and reliable means for the information exchange. For this purpose, we based ourselves
on Information Architecture, which consists of design of shared information
environments, seeking to ensure comfort first and secondly technology, and Information
Design, which equates the syntactic, semantic and pragmatic aspects for the audience.
Design/Methods: To compile all necessary and relevant information for patients and
their families, The Beabook was born, an educational booklet consisting of oncologic
words and terms. The method used to develop the material includes categorization,
labeling, taxonomy, perspective, knowledge management and lexivisual interface. For
each stage of the production process - creation, production, validation and approval -
the target audience had an effective participation.
Results: The Beabook is being implemented and it’s in the process of collecting data of
theoretical approaches. Qualitative analysis of the product has been above expectations
and has opened the way for patients and families contribution.
Conclusion: To provide good quality information isn’t enough. It’s necessary that it will
be available and appropriate to the target audience, which has reflective thinking about
knowledge and skills related to the subject of investigation, or the consequences will be
contrary to the proposed objectives. The crisis of contemporary society reflects the
difficulty of transforming data into information and this into knowledge. It’s necessary
to consider Architecture and Design Information disciplines, in addition to effective
consumer participation in the creative and production process.
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DEVELOPMENT OF POST ANAESTHESIA RECOVERY SKILLS,
KNOWLEDGE AND COMPETENCE, FOR PAEDIATRIC ONCOLODY NURSES
WORKINGWITHIN A DAY CARE UNIT IN A PRIMARY TREATMENT
CENTRE (PTC)
A. Nordoff1
1Croydon, United Kingdom
Background/Objectives: Numbers of children and young people (CYP) with an
oncology diagnosis receiving anaesthesia for lumbar punctures (LP), intrathecal agents
and bone marrow aspirates (BMA) are increasing due to the implementation of the
UKALL 2013 protocol. However, the number of nurses within the day-care (DC)
setting competent to recover CYP post anaesthesia does not represent the increasing
patient numbers. A standardised development pathway and competency document to
support the training of paediatric recovery nurses within the DC setting of PTC is
required.
Design/Methods:Data was collated from other PTC’s and organisations/associations on
competency documents and pathway available for recovery nurse development within
the oncology DC setting. This included exploration of external courses/simulation days
available for recovery nurses.
Results: It was established that no national or local competencies or role development
pathways specifically for paediatric oncology recovery nurses within a DC setting were
available. External courses/simulation days were found to be costly and not meeting the
requirements of the role within DC.
Conclusion:With support from the anaesthetic team, a competency document was
produced and ratified by the Trust. The document confirms key skills and knowledge
required for the recovery of CYP within the oncology DC setting. It is to be completed
alongside annual compliance in the completion of Paediatric Intermediate Life Support
and study days on stabilisation of the deteriorating child. This is all achieved at a local
level saving time, finances and meeting operational demands. The continuing role
development of the oncology DC nurse was shown to aid job satisfaction by the
increased opportunities and varied role, resulting in greater nurse retention.
Development of this innovative document has also ensured patients and their families
receive a personalised holistic oncology journey, with care provided within one clinical
unit by multi-skilled nurses who know the specific needs and care requirements for the
CYP.
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HEALTH BEHAVIORS OF CHILDHOOD CANCER SURVIVORS (CCSS) IN
YOUNG ADULTS
Pediatr Blood Cancer DOI 10.1002/pbc
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J. Ogawa1, N. Ito1, F. Inoue2, E. Suzuki1, C. Kawakami3
1Shukutoku University, School of Nursing and Nutrition, Chiba, Japan; 2Nonprofit
Organization of Mille-Feuille Childhood Cancer Frontiers, the Board of Directors, Chiba,
Japan; 3Toho University, School of Nursing, Tokyo, Japan
Background/Objectives: This study aimed to find health behaviors of CCSs in Young
Adults.
Design/Methods: Participants are survivors aged 18-39 years, 5 years after completion
of cancer treatment. The original questionnaire was mailed to survivors.
Results: The participants (n=37:M13/F24, mean age 26.6) are survivors of leukemia
(n=28, 75.7%), malignant lymphoma (n=4, 10.9%), and solid tumor (n=3, 8.1%)
included 10 hematopoietic stem cell transplantation.LTFU:28(75.7%) have been seeing
doctors on a regular basis. The frequency is ; once a year (12),once a few months - 6
months(12),every month (4). 20 CCSs (54.1%) visit the clinic for late effects from cancer
treatment.Current state: full time worker(20), part time worker(6), student(3),
self-employed(4), unemployed (1) and going community workshop(1). 21(56.8%)
survivors lead a well-regulated life style on weekdays and have lunch and dinner every
day but 9 (24.3%) are on no breakfast or almost every day no breakfast. Drinking: 26 are
habitual and 11 are not habitual, Smoking: 29 are nonsmokers, 5 are current smokers
and 3 are ex-smokers. Exercise: 23(62.4%) with no regular physical activities.Mean Body
Mass Index (BMI) for men is 22.4 and for female is 20.9 which are slightly lower than
healthy people.16 have no experience to go on a diet, 15 have, and 6 are on a diet.More
than 80 % survivors interested in “health”, “things which regulate life rhythm”,
“exercise” and “meal and ingredients”.But there were several CCSs who answered "No
time”. And 8 including 2 with BMT experience don’t pay attention to effect of sunlight.
Conclusion: About half of CCSs have been seeing doctors or such as late effects. The
physique tends to be thin but health behaviors are generally good. It is significant to let
CCSs who don’t exercise regularly understand the importance of physical activities.
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PARENTAL UNCERTAINTY AND HEALTH-RELATED QUALITY OF LIFE
[HRQOL] IN CHILDRENWITH CANCER
I. Ogunlade1
1Boston Children’s Hospital, Hematology/Oncology, Boston, USA
Background/Objectives: Research suggests that parents of children with cancer are
prone to feelings of anxiety and depression because they are uncertain if their children
will live or if the treatment will work. Due to this vulnerability, they may perceive that
their child is experiencing poor HRQOL, which in turn could affect the child’s
treatment outcomes. The Roy Adaptation Model and Mishel’s Uncertainty in Illness
Theory are the guiding theoretical framework for this study.
Design/Methods: This study will utilize a longitudinal, exploratory design.
One-hundred newly diagnosed children with cancer ages 2 to 17 years receiving care at
Boston Children’s Hospital will be recruited. The aims are to: 1) Describe the child’s
HRQOL at time of diagnosis, 2 months and 6 months after diagnosis; 2) Describe the
relationship between parental uncertainty and HRQOL in children with cancer, and if
this relationship changes over time; 3) Determine the degree of concordance between
child self-report and parental proxy report of HRQOL; and 4) Determine if perceived
social support, trait anxiety and depression function as moderators between parental
uncertainty and HRQOL in children with cancer. Parents will complete the Beck
Depression Inventory, the Multidimensional Scale of Perceived Social Support, and the
State-Trait Anxiety Inventory for Adults at baseline. Children and parents will
complete the Pediatric Quality of Life Inventory 3.0 Cancer Module Scale and the
parents will complete the Parents’ Perception of Uncertainty in Illness Scale within the
first two weeks of diagnosis, 2 months, and 6 months after diagnosis.
Results: The study is ongoing. However, baseline assessment data will be presented.
Conclusion: Once the relationship between parental uncertainty and children’s HRQOL
is understood, interventions can be developed to help these families with the long-term
goal of improving the children’s HRQOL.
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YOU’VE ONLY GOT ONE CHANCE TO GET IT RIGHT” CHILDREN’S
CANCER NURSES’ EXPERIENCES OF PROVIDING PALLIATIVE CARE IN
THE ACUTE HOSPITAL SETTING
H. Pearson1
1Surrey, United Kingdom
Background/Objectives: Palliative care for children with cancer is rarely hospital centred
and predominately care is provided in the community or hospice setting. Vast research
has looked at the experiences of children’s nurses providing palliative care within the
child’s home environment or the hospice. This research has suggested that nurses need
adequate support to avoid stress and burnout. Parental views focus on the nurses
attributes as opposed to the clinical skills which are required. This research study
wanted to ascertain whether specific educational preparation or support is needed to
prepare children’s cancer nurses in providing palliative care in the acute hospital setting.
Design/Methods: The research study used a qualitative approach with semi-structured
in depth interviews across three primary treatment centres within the United Kingdom
that provide cancer care to children.Data was collected and analysed using a
phenomenological approach. Data was collected between October 2011 and February
2012. Interviews took place in the participants preferred location and lasted between
forty five and sixty minutes. Data was analysed using the Strauss and Corbin method.
Results: Five themes emerged which were ‘lack of a plan’, ‘managing the symptoms’,
‘family’ and ‘experience’. Categories within these themes were devised from participant
narratives.
Conclusion: The findings of this research study suggest nurses need specific palliative
care education not only at pre-registration level but also continuing professional
development.
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THE IMPLEMENTATION OF CENTRAL LINE MAINTENANCE CARE
BUNDLE IN REDUCING CATHETER RELATED BLOOD STREAM
INFECTION (CRBSI) IN THE PAEDIATRIC ONCOLOGY SETTING OF A
TERTIARY HOSPITAL
N.A. Pham1, S.T. Wong2, W.L.C. Quek3
1KK Women’s & Children’s Hospital, Singapore, Singapore; 2KK Women’s & Children’s
Hospital, Division of Nursing, Singapore, Singapore; 3KK Women’s & Children’s
Hospital, Ward 76, Singapore, Singapore
Background/Objectives: The study aims to evaluate the effectiveness of a central line
maintenance care bundle in reducing the rate of CRBSI in the paediatric oncology
setting.
Design/Methods: A prospective, descriptive, quantitative study was carried out to
monitor the rate of CRBSI for port a-cath and Hickman line before and after the
implementation of a central line maintenance care bundle. The components of central
line maintenance care bundle were derived from the recommendation by
Communicable Disease Centre (USA) which includes hand hygiene, maximal barrier
precaution upon line insertion, Chlorhexidine skin antisepsis, training and education.
With multidisciplinary approach, interventions were put in place to improve
compliance with each component. Hand hygiene audit was done to ensure 100%
compliance. All patients undergoing central line insertion were to have Chlorhexidine
shower twice prior operation. Chlorhexidine usage for central line related procedures
was revised, emphasizing on duration of cleansing and drying. Central line training
were organized 3 monthly for both nursing and medical personel. A total of 57 nurses
and 54 doctors were trained from Jan 2013 till Jun 2014. Both regular (6 monthly) and
ad hoc audits were carried out to ensure compliance. CRBSI rate and epidemiological
data were collected 12 months before and 18 months after the implementation of the
bundle in January 2013.
Results: Results showed substantial decrease in the rate of CRBSI per 1000 catheter
days for both port-a-cath and Hickman line which are lower than the international
benchmark set at 1.45 per 1000 catheter days for port a-cath and 4.65 per 1000 catheter
days for Hickman line.
Conclusion: The implemented central line maintenance care bundle is effective in
reducing the rate of CRBSI in paediatric oncology. Continued vigilant monitoring and
strict compliance to standard practices are essential to further minimise and prevent
CRBSI.
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CHILDREN AND ADOLESCENT EXPERIENCE OF HAVING A SIBLINGWITH
A LIFE THREATENING DISEASE - AN EXAM ASSIGNMENT FROM A
NATIONAL PEDIATRIC ONCOLOGY EDUCATION IN SWEDEN
C. Rinaldo1, M. Pusa1, M. Allsten2, A.C. Månsson3
1Karolinska University Hospital, Pediatric Oncology and Coagulation, Stockholm,
Sweden; 2Kristianstad Central Hospital, Pediatrics, Kristianstad, Sweden; 3Ryhov
University Hospital-Jönköping, Pediatrics, Jönköping, Sweden
Background/Objectives: Since 2005 there is a 2 years, part time, national pediatric
oncology education in Sweden for registered nurses at Karolinska Institute, founded by
the Swedish Childhood Cancer Foundation. All participants were supposed to do an
examination assignment preferably based on their clinical experiences and needs. In this
particular assignment we focused on siblings as we have noticed that the entire family is
affected when a child suffers from a life-threatening illness. The aim of this exam was
therefore to explore siblings’ experiences of having a brother or sister with a life
threatening disease.
Design/Methods: A literature review was conducted of eight articles focusing on siblings
in the age of 5-30 years, with a brother or sister with a life threatening disease.
Results: The siblings expressed anxiety regarding if, when and how their ill brother or
sister should die. They felt anxiety about their parents’ wellbeing, but also regarding
themselves if they would become ill as well. They described that family life and routines
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were changed, the parents were absent and the siblings took much greater responsibility
at home. At the same time they described the family got a better cohesion. The siblings
had difficulty in school with concentration and homework. They wanted to participate
in the care of the brother/sister and needed better medical information from diagnosis
and onward. The siblings also expressed that they needed own support from extended
family members, friends as well as other adults.
Conclusion: The pediatric oncology nurses have a key role in including siblings in the
care and provide age-appropriate information from diagnosis and onward. It was a
valuable exam assignment for clinical nurses in order to increase knowledge about
clinical related problems, such as - in this case - siblings’ experiences, search for
literature, compile the new knowledge and use it in practice.
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BALANCING ADVOCACY AND PATERNALISM; RESEARCH NURSES’
EXPERIENCES OF WORKINGWITH FAMILIES WITHIN THE PEDIATRIC
ONCOLOGY CARE
A. Schroder Hakansson1
1Lysekil, Sweden
Background/Objectives: Pediatric oncology care is a research intense environment where
most of the families participate in several research studies. By law, it is required that the
family gives their informed consent prior to participation. This often means that the
informed consent is obtained in close connection to the disclosure of the diagnosis. It is
within this complex situation that the research nurse carries out her work.
Design/Methods: Aim: To describe the research nurse’s experience of working with
families who have been asked to participate in clinical trials at the pediatric oncology
ward.Method: This qualitative study used a Grounded Theory (GT) method. Six
research nurses and two consultant nurses were interviewed via internet based
Communication.
Results: In the research integrated care environment, the nurses’ main concern was that
the family should have the opportunity to participate in studies that the nurses believed
would be beneficial for the child and the family. When obtaining the informed consent,
the nurses balanced advocacy and paternalism. The nurses used a number of strategies
in order to make sure that the informed consent was obtained. These included:
adapting the information, gently introducing the research and selling the research.
Conclusion: If there are language barriers or psychological barriers that impact the
family’s ability to give their informed consent, then there is an immediate risk that the
nurse will give more weight to paternalism when balancing between it and advocacy.
Furthermore, there are problems in meeting the child’s right to be able to give their
consent to participate in research studies.
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PEDIATRIC ONCOLOGY NURSING RELATED KNOWLEDGE ASSESSMENT
FOR NURSES OF 17 HOSPITALS IN CHINA
N. Shen1
1Shanghai Children’s Medical Center, Shanghai, China
Background/Objectives: The objective was to know pediatric oncology nursing related
knowledge level of nurses caring for children with cancer in China.
Design/Methods: Five hundred and thirty two nurses caring for children with cancer
from 17 nationwide hospitals were sampled conveniently and investigated by multiple
choice questionnaires on pediatric oncology nursing related knowledge (142 scores)
including 5 domains of disease (34 scores), treatment (36 scores), symptom
management (33 scores), critical care (18 scores) and technique (21 scores). Variances
were analyzed on hospital, hospital-related region, age, education degree, clinical ladder,
working duration, specialty, specialty working duration and post.
Results:Mean score knowledge was 62.95±12.05, showing significant difference among
variances (hospital: F=13.18, P=0.00; region: F=6.81, P=0.00; age: F=6.96, P=0.00;
education degree: F=16.30, P=0.00; clinical ladder: F=11.22, P=0.00; working
duration: F=5.57, P=0.00; specialty: F=15.50, P=0.00; specialty working duration:
F=6.23, P=0.00; post: F=3.07, P=0.01). Among 5 regions of China, the lowest score
(59.19±10.82) existed in the midland. The score of nurses with diploma (58.83±11.65),
or working in general hematology unit (52.25±8.14), or working as basic primary nurse
(62.63±12.18) ranked the lowest level as predicted, meanwhile, nurses with 45 years
working experience or 45 years specialty working experience showed the lowest score
unexpectedly (59.64±13.36; 59.83±13.04). Five domains among education degrees or
specialties, four domains, except technique, among ages, (specialty) working durations
or clinical ladders, and the domains of treatment and critical care among posts
demonstrated significant difference (P<0.05).
Conclusion: Nurses caring for children with cancer in the hospitals of China did not
have enough specialty-related knowledge which would influence the clinical competence
and quality of care. Related knowledge level displayed significant difference among
regions, hospitals or specialties, which hinted the necessity of homogeneous education.
Nurses among demographic characteristics or working experiences also demonstrated
significant difference on knowledge, which indicated the requirement of targeted
education.
P-425
EVIDENCE BASED PRACTICE MEETING FOR NURSES IN A NEW
PEDIATRIC ONCOLOGY CENTER
I. Sieswerda1
1Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands
Background/Objectives: The Princess Maxima Center (PMC) for pediatric Oncology
(Utrecht, the Netherlands) has opened in October 2014. In the near future, when the
care for all pediatric oncology patients in the Netherlands is centralized in the PMC, it
will become the largest center of Europe.In this centralization process, nursing staff
from all academic hospitals (7) merged into a new, motivated team. The team was
challenged by a large variety of care, such as how to withdraw blood from a central line
and how to flush it afterwards. This variety is caused by different experience and
approach from the academic hospitals. We aim to harmonize the protocols and to work
uniform.Therefore, the purpose of this project is to (1) define important differences in
care, (2) reinforce conformity and (3) to develop evidence-based protocols for highly
variable practices.
Design/Methods:Weekly evidence-based practice (EBP) meetings will be held. Two
nurses with EBP experience and training will chair this meeting, supported by
experienced clinical researchers. Based on structured discussions, the nursing team will
define important differences in care. Thereafter, uncertainties will be prioritized and
Patient-Intervention-Comparison-Outcome (PICO) will be made. For each PICO, one
nurse will subsequently review all available evidence and prepare a Critically Appraised
Topic (CAT). Depending on the results of the CAT, this will lead to new evidence-based
care protocols.
Results: Since January 2015 we defined a large variety in care in our EBP meeting.
Further results will be presented at the conference: Examples of remarkable differences
in care between the 7 academic hospitalsThe priority PICO’s of the EBP
meetingsExamples of changes in care.
Conclusion: This project will show a way to solve differences in care protocols in a new,
large pediatric oncology center. This will improve conformity and ensure high quality
and up-to-date protocols.
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SIOP PODC NURSINGWORKING GROUP BASELINE STANDARDS
ASSESSMENT IN BOTSWANA
M. Raletshegwana1, P. Semetsa1, A. Slone2, J. Hesselgrave3, D. Kollar2, P. Mehta2,
J. Slone2
1Princess Marina Hosptial, Paediatrics, Gaborone, Botswana; 2Texas Children’s Cancer
and Hematology Centers-Baylor College of Medicine, Pediatric Hematology-Oncology,
Houston, USA; 3Texas Children’s Cancer and Hematology Centers, Pediatric
Hematology-Oncology, Houston, USA
Background/Objectives: The overall survival rate of children with cancer is 80% in high
income countries but often less than 25% in low and middle income countries (LMICs)
where 80% of children live. Quality nursing care is essential in paediatric cancer care.
The International Society of Paediatric Oncology (SIOP) Paediatric Oncology in
Developing Countries (PODC) Nursing Working Group developed six baseline
standards for paediatric oncology nursing in LMICs.
Design/Methods: Nursing practices of the Paediatric Oncology Ward (POW) of
Princess Marina Hospital (PMH) were analyzed by PMH paediatric nurses and
compared to the SIOP-PODC standards. PMH is the only hospital in Botswana
managing children with cancer. A score of 0-2 (0 - does not meet at all, 1 -occasionally
meets, 2 - meets on a regular basis) was applied to each standard.
Results: The POW of PMH did not meet any of the six standards on a regular basis
(score of 2). There is neither orientation for POW nurses nor nursing policies and
procedures located on the POW (score of 0). The POW occasionally met the
nurse:patient ratio of 1:5; although these nurses were not always oncology trained
(score of 1). Some continuing education was available but not 10 hours annually as
prescribed by the standard (score of 1). Nurses are included as part of the
multidisciplinary team; however, there are no dedicated paediatric oncology nurses
(score of 1). Although some improvements have been made including hand sanitation,
environmental ward deficiencies remain including limited personal protective
equipment and isolation facilities (score of 1).
Conclusion: Based on the SIOP-PODC criteria, PMH does not currently meet the
standards for paediatric oncology nursing. The availability of oncology training
curricula, a dedicated paediatric oncology unit, mentorship through a twinning
partnership and paediatric-trained nurses will make reaching these standards a reality.
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PAEDIATRIC NURSES` PAIN ASSESSMENT ANDMANAGEMENT SURVEY IN
BOTSWANA
P. Semetsa1, M. Raletshegwana1, A. Slone2, J. Hesselgrave3, D. Kollar2, P. Mehta2,
J. Slone2
1Princess Marina Hospital, Paediatrics, Gaborone, Botswana; 2Texas Children’s Cancer
and Hematology Centers-Baylor College of Medicine, Pediatric Hematology-Oncology,
Houston, USA; 3Texas Children’s Cancer and Hematology Centers, Pediatric
Hematology-Oncology, Houston, USA
Background/Objectives: Pain in children can be debilitating. Princess Marina Hospital
(PMH) in Gaborone, Botswana is the site of the country’s only paediatric
haematology-oncology program. A survey of nurses in the paediatric medical and
surgical wards of PMH was administered to assess general knowledge of paediatric
pain management and familiarity with the 2011 Ministry of Health (MOH) paediatric
pain policy.
Design/Methods: Paediatric nurses were given a ten question survey on paediatric pain
management and five self-assessment queries assessing nurses’ confidence managing
paediatric pain. One question assessed awareness of the MOH policy.
Results: The survey was completed by 84% (32/38) of paediatric nurses of which 60.7%
were female, 75% were Diploma graduates, 21.9% had a Bachelor’s Degree and 3.1%
had other training. General nursing experience <10 years was reported by 62.5% while
37.5% had > 10 years’ experience. A minority (41.9%) of the nurses reported awareness
of the MOH paediatric pain policy. Years of experience impacted knowledge of the
policy: 0% of nurses with 10-15 years’ experience were aware of the policy compared to
42.9% with 0-5 years, 80% with 6-9 years and 60% with >15 years (p=0.03). Pain
management knowledge gaps included understanding opioid routes of administration
(70% answered incorrectly), childrens’ ability to report pain (62.5% incorrect) and
opioid oral:intravenous conversion (75% incorrect). There were no knowledge
differences based on gender, education level or years of experience. With regard to their
confidence in appropriately assessing pain in children, 81.8% of males responded
“agree” or “strongly agree” (4-5 on a 1-5 scale) compared to 23.5% for females (p=
<0.01).
Conclusion: Based on the survey results, knowledge gaps exist for paediatric nurses
regarding the assessment and management of pain in children as well as awareness of
the paediatric pain policy. Interventions including mentoring and in-service training
will be instituted to narrow this knowledge gap.
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NATIONAL PAEDIATRIC CANCER RECOGNITION TRAINING PROGRAM IN
BOTSWANA
J. Slone1, E. Ishigami2, P. Mehta1
1Texas Children’s Cancer and Hematology Centers-Baylor College of Medicine, Pediatric
Hematology-Oncology, Houston, USA; 2Texas Children’s Cancer and Hematology
Centers, Pediatric Hematology-Oncology, Houston, USA
Background/Objectives: The majority of the world’s children who develop cancer live in
low and middle income countries (LMIC), and most do not have access to diagnosis
and treatment of cancer. Thus, while survival of paediatric cancer in high income
countries is 80%, survival is often <25% in LMICs. One major barrier to survival is
delayed recognition of cancer leading to death before diagnosis or presentation with
advanced disease. To improve timely diagnosis of paediatric cancer in Botswana, we
conducted a national training of health care workers (HCW) on the recognition of
common signs of paediatric cancer.
Design/Methods: A paediatric haematologist-oncologist based at Princess Marina
Hospital (PMH), the only hospital treating childhood cancer in Botswana, visited
twelve hospitals throughout Botswana. All HCW attending these sessions were
instructed on common presenting signs of childhood cancers and the referral process to
PMH.
Results: At twelve hospitals throughout Botswana, 297 HCW [137 nurses (46.1%), 102
physicians (34.3%), 58 others/not identified (19.5%)] attended the training. Of the 297
attendees, 222 (74.7%) completed a pre-test, post-test, self-assessment and evaluation.
Formal paediatric oncology training (clinical rotation/workshop) was indicated by 7.8%
of HCW and 26.7% had paediatric oncology exposure (clinical
experience/lectures/readings) during their training program. Awareness of the global
burden of pediatric cancers increased by 55% and knowledge of survival rates by
128.3%. Acquaintance with the pediatric oncology referral process in Botswana
increased by 133.3%. Respondents found the training helpful (96.6% responded 4-5 on
1-5 scale) with 89.6% saying it would change their practice.
Conclusion:Missed or delayed diagnosis of paediatric cancer negatively impacts
survival. The majority of HCW in Botswana indicated they received no training in
paediatric oncology. We demonstrated that a brief training session improves health care
workers’ knowledge of paediatric cancer and understanding of how to refer children
with suspected cancer to sub-specialty care.
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HUMAN FACTORS TEAM-TRAINING LEADS TO IMPROVED PATIENT
OUTCOMES AT THE BEDSIDE FOR THE PAEDIATRIC ONCOLOGY CHILD
B. Smith1, T. Wood2
1Starship Children’s Hospital, Auckland, New Zealand; 2Starship Children’s Hospital,
Starship Simulation Department, Auckland, New Zealand
Background/Objectives:Much has been published about the positive effects of
team-training simulation in the healthcare setting. When healthcare teams
communicate efficiently we can expect improved team processes leading to better
patient outcomes and decreased adverse events. At the SIOP 2011 conference held in
Auckland delegates where given the opportunity to take part in a trial human factors
team-training simulation session designed specifically for the paediatric oncology
environment. Interest amongst delegates was high with the majority stating that they
increasingly wanted active learning opportunities at the bedside.
Design/Methods: The findings from the trial session run at the SIOP conference lead us
to develop a permanent paediatric oncology programme. Building on the foundations
already laid by the Starship Simulation Team we were able to take what had worked in
other areas of the hospital and tailor it to our specific needs. In taking in-situ human
factors team-training to the bedside it allowed us to meld together a combination of
different learning styles that enabled us to demonstrate improved patient management
at the bedside.
Results: By applying the principles of crisis resource management it has been noted that
responses to and management of the deteriorating child have improved greatly. By
standardising our teaching model we have been able to create a standard approach to
care. There is now also evidence of improved communication within our team, leading
to quicker identification and management of the deteriorating child.
Conclusion:Within one year we have built an in-situ human factors simulation
programme for the paediatric oncology environment. Where previously there was
uncertainty and fear around simulation there is now a willingness to embrace not only
in-situ simulation but a variety of different education techniques.
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TRANSITIONS THROUGH SURVIVORSHIP: MODEL OF CARE AFTER
CHILDHOOD CANCER TREATMENT
L. Soanes1, E. Potter2, S. Nussey2, J. Passmore2
1The Royal Marsden NHS Foundation Trust, London, United Kingdom; 2The Royal
Marsden NHS Foundation Trust, Oak Centre for Children & Young People, Sutton,
United Kingdom
Background/Objectives: The issue of transition is a central theme and repeated
experience in survivorship following childhood cancer treatment. In many cases this
involves transition from active treatment to surveillance, to long term follow
up/supported self management as well as transition across paediatric, teenage and adult
services. The final transition differs from other childhood diseases, as cancer itself is no
longer a problem. However, the potential complexity of outcome can create dependence
on the paediatric oncology setting and may delay the transition process to late
adolescence or early adulthood. Staff working in a single paediatric oncology centre in
the UK reflected that these multiple transitions, dependence and meeting the ongoing
needs as adulthood progressed could be smoother, more proactive and user focused.
Design/Methods: Building on previous work undertaken in national survivorship
programme a revised model of care was designed and implemented. This programme:
Educates children on their cancer diagnosis, potential and actual consequences of
treatment; Encourages and supports incremental participation in self management;
Prepares for transition to the teenage survivorship clinic; Increases teenager’s autonomy
in their care and holistic needs through ownership of their treatment summary, care
plan and holistic needs; Prepares teenagers for discharge to supported self-management
in the community or; Transition to an adult survivorship clinic at a new centre with
expertise in sub specialities required for adulthood.
Results: This programme has allowed a more cohesive, planned and user focused model
of care. A model that allows survivorship to reflect the bi-psychosocial model of
development of childhood, adolescence and adulthood. Staff work with those who use
the service on an individual pathway of care and have collaborated with colleagues
across services and providers to allow managed transition to adulthood.
Conclusion: This poster describes the ethos, design, challenges, collaboration and
implementation to develop a survivorship programme creatively and within finite
resources.
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DEVELOPING A NURSE-LED CLINIC FOR PATIENTS WITH ACUTE
LYMPHOBLASTIC LEUKAEMIA DURINGMAINTENANCE THERAPY
S. Spencer1
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1Birmignham Children’s Hospital NHS Foundation Trust, Birmingham, United Kingdom
Background/Objectives: Children on maintenance therapy attend clinic once a month
for review and administration of bolus vincristine (VCR). The child is reviewed by the
Consultant, Leukaemia Advanced Nurse Practitioner (ANP) or a Specialist Registrar.
A clinic nurse then inserts a cannula and administers the vincristine which is checked by
a second nurse. Both of these steps can incur a long period of waiting for the patient
and family during a busy treatment clinic. A nurse-led clinic has been set up to improve
the patient pathway and to ease the congestion in consultant-led clinics.
Design/Methods: Following initial written consultant referral, children are booked into
a 30 minute appointment every 4 weeks. The child is reviewed by the ANP and the VCR
given immediately after the consultation, with the ANP acting as the second checker to
the cannulating nurse. Children eligible for the clinic receive 100% doses of VCR and
dexamethasone. Those patients with significant toxicity or who are not receiving 100%
doses remain in the consultant-led clinic. During the clinic’s first 10 weeks families were
offered the opportunity to complete the hospital friends and family survey and data was
collected to ascertain the length of time each patient spent in clinic. This was also
collected from patients attending the consultant-led clinics to enable data comparison.
Results:With 51 clinic attendances the average time spent in the nurse-led clinic was 50
minutes compared to 2 hours and 20 minutes in the consultant-led clinic. Patients were
seen on average within 10 minutes of their appointment time compared to 50 minutes in
the consultant clinics.100% of parents who completed the hospital friends and family
survey said that they are extremely likely to recommend the service to others.
Conclusion: The data collected demonstrates that the nurse-led clinic provides a more
time efficient service without compromising patient and family satisfaction.
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SURVEY OF PEDIATRIC ONCOLOGY NURSING EDUCATION IN SIXTEEN
COUNTRIES
C. Sullivan1, B. Mandrell2, S. Day3
1St. Jude Children’s Research Hospital, International Outreach Program, Memphis,
USA; 2St. Jude Children’s Research Hospital, Division of Nursing Research, Memphis,
USA; 3St. Jude Children’s Research Hospital, Department of Nursing Education,
Memphis, USA
Background/Objectives: In response to the lack of specialized pediatric oncology
nursing education and training at St. Jude Children’s Research Hospital international
partner sites, the Latin American Center for Pediatric Oncology Nursing Education
was founded in 2007. The center provides culturally sensitive and language appropriate
training and ongoing mentoring of pediatric oncology nurse educators, a role pioneered
in Latin America through this program.
Design/Methods: In efforts to assess nurse educator roles and programs at International
Outreach Program partner sites, including those outside of Latin America, the
International Outreach Nursing Program conducted an audit through a web-based
survey. The survey assessed orientation program and continuing education content; the
nurse educator role, responsibilities, and satisfaction, and nurse patient ratios.
Thirty-two nurse educators and/or administrators from twenty-five hospitals in
nineteen countries were invited to participate in the survey.
Results: Responses were received from twenty nurses representing sixteen countries, six
from lower-middle income countries, thirteen from upper-middle income countries, and
one from a high income country. Of those, fourteen reported having a pediatric
oncology nursing orientation program in addition to a hospital-based orientation
program. For this survey, orientation was defined as two weeks of pediatric oncology
education in addition to hospital orientation. Of the fourteen, two met the criteria;
however, supportive documentation was not provided. Eleven out of twenty reported
having a full-time pediatric oncology nurse educator. Part-time educator positions
involved staffing or supervisory responsibilities and a limited amount of time for
nursing education. The average nurse-to-patient ratio was 1:6, ranging from 1:3-16,
with nine hospitals’ nurse patient ration 1:6.
Conclusion: Pediatric oncology nurses in low, middle, and upper-middle income
countries continue to have less than optimal support and education. This is a major
impediment and contributes to the disparity in survival rates between high and low
income countries.
Acknowledgements: Thank you to the American Lebanese Syrian Associated Charities
(ALSAC).
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COMMUNITY OUTREACH: EDUCATING THEWELL CHILD AND EASING
TRANSITION AFTER TREATMENT FOR THE ONCOLOGY PATIENT
K. Temple1
1Boston Children’s Hospital, Boston, USA
Background/Objectives: Community outreach is the responsibility of oncology nurses
worldwide. Cancer prevention for lung, skin and cervical cancers must begin at a young
age. Research shows a link between sunburns in youth and an increased risk of skin
cancer; the known cause in 95% of cervical cancer is Human Papilloma Virus; one-third
of young smokers will die prematurely from a smoking-related disease.
Design/Methods: Recognizing that the complex care of the pediatric oncology patient
does not cease upon discharge the Dana-Farber/ Boston Children’s Cancer and Blood
Disorders Center created the Pediatric Oncology Community Outreach Program. This
hospital-based program consists of a home visit to facilitate the coordination of care
between the hospital, home and community for a newly diagnosed patient. The goal of
the visit is to reinforce and review discharge instructions, medication reconciliation and
plan of care with community agencies. The Pediatric Community Cancer Prevention
Initiative uses a mobile health van delivers an evidenced-based prevention curriculum
to schools, health fairs, and beaches. This program is based on the assessment of
children’s literacy, learning styles, knowledgebase and cultural concerns.
Results: Ongoing monitoring of this program has revealed that 57 percent of patients
required an intervention in the transition from hospital to home by the pediatric
oncology nurse. The most common interventions include medication management;
central line care and issues related to home care supplies. The Pediatric Community
Cancer Prevention Initiative educates approximately 500 children and families each
year in the community. Using validated tools to measure effectiveness, the Harvard
School of Public Health will study the impact of this program on behavior, prevention
and outcomes.
Conclusion: Community outreach programs are aimed at teaching well children healthy
behaviors and cancer prevention strategies. Equally as important are nurse designed
community outreach programs that target patient education needs when transitioning
from hospital to home.
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IMPACT OF THE IMPLEMENTATION OF A NUTRITION THERAPY
PROTOCOL ON UNDERNUTRITION IN CHILDREN AND ADOLESCENTS
WITH CANCER
K. Viani1, G. Bouchabki1, B. Stachissini Manzoli1, M. Neto Rafael1, V. Oliveira1
1Instituto de Tratamento do Câncer Infantil-Hospital das Clínicas-University of Sao
Paulo’s Medical School, Nutrition Department, Sao Paulo, Brazil
Background/Objectives: Despite advances in Paediatric Oncology, undernutrition is still
a major concern among these patients all around the world. However, Nutrition
therapy is often neglected, regardless of studies demonstrating that undernutrition is
strongly associated with poorer outcomes and remediation of poor nutritional status
results in survival comparable to that of children with optimal nutritional status. The
use of Nutrition protocols is essential to standardise nutritional care and follow up. The
aim of this study was to investigate whether the implementation of a Nutrition therapy
protocol at a tertiary Paediatric Oncology hospital in Sao Paulo, Brazil had an impact
on undernutrition.
Design/Methods: A database containing nutritional assessments of children and
adolescents with cancer from April/2007 to December/2014 was analysed. The data was
divided in before and after the implementation of a Nutrition therapy protocol
(January/2012) and the percentage of patients classified as undernourished by mid
upper arm circumference (below 5th percentile according to Frisancho, 1999) was
compared. The chi-square test was used to verify the statistical significance of the
difference between the frequencies.
Results: A total of 4502 nutritional assessments of oncologic patients from 1 to 18.9
years were analysed, 1588 before (42.6% female; mean age 8.9 years) and 2914 after
(42.7% female; mean age 9.7 years) the implementation of the protocol. The frequency
of undernourished patients dropped from 34.6% to 26.9% (p < 0.05).
Conclusion: The implementation of a Nutrition therapy protocol decreased the
frequency of undernutrition in this group of paediatric oncology patients, as measured
by MUAC.
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THE DIETARY RESTRICTIONS AT HOME BETWEEN CYCLES OF
CHEMOTHERAPY
A. Wakasa1, K. Yamaguchi2
1Nagano Children’s Hospital, Department of Nursing, Azumino, Japan; 2Aichi
Prefectural University, School of Nursing, Nagoya, Japan
Background/Objectives: During the period patients experience chemotherapy induced
myelosuppression, dietary restrictions are used to prevent infection. However
experience shows the details of dietary restrictions vary widely between establishments.
This study aims to determine how widely dietary restriction criteria, including the
commencement and cessation of dietary restrictions and the specific foods restricted,
vary with each institution. The results showed that for patients at home between cycles
of chemotherapy, some establishments instated similar restrictions to neutropenia
patients while others had no restrictions at all. The objective of this study was to
determine what foods were restricted at home between cycles of chemotherapy.
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Design/Methods:Mailed survey. The anonymous questionnaire was sent to one nurse
working at each of the institutions registered with JPLSG (145 institutions). The study
period was between February and March 2013.
Results: Thirty-seven (25.5%) nursing administrators agreed to participate in the survey.
Twenty-eight surveys were returned (collection rate 75.7%). Of the institutions that
responded, 11(39.3%) wrote about dietary restrictions during that time. Two (18.2%)
establishments had no dietary restrictions. Two institutions used the same restrictions
as for a period of neutropenia, and seven establishments used laxer dietary restrictions
than for neutropenia. The most commonly restricted foods were raw meat and raw
seafood (nine institutions each; 81.8%) and raw eggs (seven; 63.6). Followed by natto,
honey, natural cheese and raw cream (three; 27.3%), then Japanese pickles, fresh
vegetables and fruits, unroasted nuts and sushi (two; 18.2%).
Conclusion: During at home periods between chemotherapy treatments there are
institutions implementing dietary restrictions and others that don’t. Among institutions
implementing dietary restrictions there was a wide range of restrictions from those
implementing the same restrictions as for neutropenia and others limiting nothing but
raw fish, meat and eggs.
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IMPLEMENTATION OF A NURSE-LED CLINIC FOR CHILDRENWITH A
BRAIN TUMOR ON THE PEDIATRIC HEMATOLOGYWARD : FIRST
INSIGHTS
E. Willems1, V. Van de Velde1, A. Mannaerts1, J. De Porre1, G. Laureys1, L. Willems1
1University Hospital Ghent, Pediatric Hemato-Oncology and Stem Cell Transplantation,
Ghent, Belgium
Background/Objectives: In 2013 a nurse-led clinic for patients with solid tumors was
introduced on our ward. Initially we focused on children diagnosed with brain tumors.
They often receive a combination of surgery, chemotherapy and/or radiotherapy.
Inevitably, they have contact with a wide range of professionals. Our goal is to improve
patient care by introducing a nurse as case manager during this complex pathway.In the
nurse-led clinic, the consultations take place on well described time points as well as on
demand of the patient and his parents. These consultations are free of charge.
Design/Methods:We analyzed 6 months records from the newly established solid tumor
clinic. We compared expected number of visits based on the time points with the reality
and looked at reasons for consultation.
Results: Thirty patients were diagnosed with and/or treated for a brain tumor and
included in this study. 230 consultations took place. The average number of visits for
each patient was 7. During these visits different topics were discussed (n=588):
information about treatment itself (n=100), follow up (n=115), and this often in
combination with emotional support for patients and their parents (n=235), are most
common discussed items. Considering the key-time points (at diagnosis, before surgery,
before start chemotherapy, at the end of treatment,.. ), we expected 114 visits. The
patients or their parents asked for 116 extra visits while hospitalized, by e-mail or by
telephone.
Conclusion: Despite the short period of implementation, we experienced that patients
and their parents find their way to the nurse-led clinic, not only at key-time points. The
nursing consultant is accessible when needed to provide more information .Our main
goals for the future are to inform all health care providers involved in the care for these
children about the nurse-led clinic and to anchor it in a clinical pathway for children
with a brain tumor.
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TO ASSESS THE LEVEL OF SATISFACTION AMONG PARENTS OF
CHILDRENWITH CANCER REGARDING NURSING CARE IN TMH
R. Yadav1
1TATAMemorial Hospital, Mumbai, India
Background/Objectives: Patient satisfaction has become an important indicator to
measure the quality of care rendered to the patients while in hospital. Patient
satisfaction surveys can help identify ways of improving nursing and health care
services. The pilot study was planned to assess the parent satisfaction with nursing care
in selected hospital. To identify level of parent satisfaction in various aspects of nursing
care and thereby improve the quality of care and approach. Set Up: Pediatric Ward of
TMH.
Design/Methods: Design: Descriptive Exploratory study. Methodology & Data
Collection: The study tool was a questionnaire which had four aspects of nursing care:
communication, physical, psychological and socio-economical and assessment biographic
data of the parents.
Results: The overall rating scale was 4.6 on an average (on a Likert scale of 1-5 where 1
was poor rating and 5-excellent). The mean score was 93.1. Highest scores (109) was for
infection control practices communicated well and timely reinforcement given. Lowest
scores (79) was given for explanation during orientation phase and diagnosis,
physiology of disease, treatment and prognosis of the child. There was a trend seen
with the patients admitted first time were more satisfied than those admitted more than
once. The nurse scored 3.7 mean score (out of 5) for reference given to social help given
by hospital and various NGOs.
Conclusion: Nurses are pivotal in communicating and counseling about all aspects of
nursing care. Hence this could help to reduce the fear, anxiety and uncertainty among
parents and children.
Posters: Psychosocial (PPO)
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TO ASSESS THE CONTINUED IMPACT OF HOLISTIC CARE PROVIDED AT
ST. JUDE INDIA CHILDCARE CENTRES (SJICCC) TO PEDIATRIC CANCER
PATIENTS, THEIR FAMILIES AND COMMUNITIES
T. Bilgrami1, M. Marathe2, P. Kurkure3, U. Banerji4, M. Parathasarthy1
1St.Jude ChildCare Centres, Development, Mumbai, India; 2St.Jude ChildCare Centres,
Counselling, Mumbai, India; 3Tata Memoristal Hospital, Paediatric Oncology, Mumbai,
India; 4St.Jude ChildCare Centres, Management, Mumbai, India
Background/Objectives: SJICCC has provided a ’home away from home’, for 5087
children since 2006. An earlier study undertaken with ALL patients from Tata
Memorial Hospital and presented at SIOP 2012 in Auckland showed that the holistic
care provided to these children did favorably impact both morbidity and mortality. The
purpose of this study is to understand the impact St Jude’s has had on the quality of life
of patient-families and communities when they return home after treatment. To use
these findings to further support the families, as well as improve our model.
Design/Methods: A pilot study was conducted with 30 families at the centre to establish
the parameters of the study. A random selection of 37 families who have returned home
and who agreed to participate in the study and home visits were interviewed. Their
homes were photographed and a checklist of items observed was maintained. Before
returning home 24 families were counselled how to handle the readjustment. Three of
the older children also participated voluntarily. All were contacted to follow up and
their feedback is recorded.
Results: There is an observed change for the better for the entire family when the daily,
routine, cleanliness of the home and eating habits improve. More than 70% of the
families have managed to keep their homes clean. Children learn these good habits and
pass them on to others. Thirteen(or 34.21%) of the families have relocated for better
homes and schools. The 24 families counselled prior to returning home found the
sessions valuable. They appreciated the ongoing support. All found the information
regarding water purification, maintaining harmonious relations with family members
and responding to medical emergencies particularly useful.
Conclusion: The study shows the impact of holistic care has been long lasting and has a
ripple effect on the extended families and communities.
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DEVELOPMENT OF A CHILD EXPERIENCEMEASURE FOR CHILDREN
WITH CANCER
K. Bravery1, A. Cabrera2, V. Harding3, A. Martins4, N. Oldreive1, D. Smithson3,
P. Snowdon1, R. Sweet5, F. Gibson6
1Great Ormond Street Hospital, Haematology/Oncology, London, United Kingdom; 2St
Mary’s Hospital, Paediatric Oncology, London, United Kingdom; 3University College
London, UCL Health Creatives, London, United Kingdom; 4London South Bank
University, Faculty of Health and Social Care, London, United Kingdom; 5Great Ormond
Street Hospital, Psychosocial and Family Services, London, United Kingdom; 6Great
Ormond Street Hospital & London South Bank University, Children and Young Peoples
Cancer Care, London, United Kingdom
Background/Objectives: Little is known about young children’s views of hospital care
and whether services meet their needs. Most measures are aimed at children older than
seven years and rely on parents as proxies for the younger age group. There is a lack of
validated measures for children with cancer. A multi-professional working group
undertook to develop a measure for children with cancer, ages four to twelve to report
their experience of being in hospital.
Design/Methods: The group employed a rigorous development process drawing on the
principles of service evaluation. A literature review was first undertaken to identify the
domains and questions around which the measure would be structured. A creative
process between the group and an artist followed to identify the format and images for
the measure. Input from other professionals, stakeholders and parents in the
development of the measure were obtained by means of an expert advisory forum. The
measure was then shared with children with cancer and their families at a one-day
interactive workshop, including design and testing activities. Feedback was utilised to
revise the measure and inform development of a digital version.
Results: The key domains identified from the review were: overall experience; physical
environment; social environment; interactions; treatment and procedures, and feelings.
The measure consists of a series of cards with positive/negative images on opposite
sides that explore each domain. A list of questions accompanies each image, and acts as
an additional prompt.
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Conclusion: A collaborative approach involving children, families, professionals,
stakeholders and an artist enabled the working group to develop a measure designed
specifically for children with cancer. The measure builds on existing knowledge and
highlights the importance of consulting with children in the creation and early testing
of a prototype. The development process will be presented followed by a demonstration
of the digital version.
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THE DEVELOPMENT AND IMPLEMENTATION OF A HOLISTIC NEEDS
ASSESSMENT TOOL FOR CHILDRENWITH CANCER AND THEIR FAMILIES
K. Bravery1, R. Sweet1, Z. Berger1
1Great Ormond Street Hospital, Haematology / Oncology, London, United Kingdom
Background/Objectives: Cancer in childhood has social, practical and emotional
consequences in addition to the effects on the child’s physical health. In the UK,
national guidelines state that keyworkers (who are usually Specialist Nurses) need to
assess and document these needs, and address them through multi-disciplinary working
and signposting. Patients’ key concerns can be assessed through a Holistic Needs
Assessment (HNA). To date, the HNA tools in the cancer literature are adult-focused
and tailored to individuals. There is a need to design a child-focused tool that
recognises that the wellbeing of the child with cancer is dependent on his or her whole
family being supported. A pilot project is being undertaken at Great Ormond Street
Hospital to address this gap.
Design/Methods: A Holistic Needs Assessment tool that is suitable for children and
families was developed. Specialist cancer nurses were given a tailor-made 2-day training
course to introduce them to the tool, enhance their communication skills, and practice
using the tool in semi-structured interviews with actors. They then piloted the use of
the tool with recently diagnosed children and their families.
Results: The effectiveness of the HNA tool will be assessed by evaluating families’ and
nurses’ and feedback about Holistic Needs Assessments, as well as an analysis of the
time this takes for nurses. Specific case examples will be shared. The question of how
this work complements the work of the wider multi-disciplinary team, including social
workers and psychologists, will also be addressed.
Conclusion: Training specialist nurses to carry out Holistic Needs Assessments can
equip the service to better identify and meet the emotional and social needs of children
with cancer and their families. Some of the challenges in the process of developing and
introducing a new tool for use by specialist nurses will be discussed.
P-441
BEHAVIORAL CHANGES IN CHILDRENWITH ACUTE LYMPHOBLASTIC
LEUKEMIA TREATEDWITH BFM-95 PROTOCOL
S. Chidambaram1, V. Elangovan1, R. Venkatraman2, R. Rejiv2
1Cancer Institute WIA, Psycho-Oncology, Chennai, India; 2Cancer Institute WIA,
Medical Oncology, Chennai, India
Background/Objectives: CNS prophylactic treatment has reduced the risk of CNS
relapse and thereby resulted in a remarkable increase in survival rates. However,
improved survival rates have not been achieved without neuropsychological sequelae.
Therefore, this study aimed to examine the impact BFM-95 protocol on behavioral
problems of children diagnosed with ALL.
Design/Methods: All children (n=25) diagnosed with ALL who received CRT and
HD-MTX as part of their treatment protocol were included. Child Behaviour Check
list for ages 6-18 was used to assessing the behavioural problems (anxious/depressed,
withdrawn/depressed, social, somatic complaints, attention, thought, rule breaking).
Five assessments were done during induction, end of re-induction, end of re-induction
II, commencement of maintenance, and end of maintenance. ALL children were
compared to a group of healthy children (n=55). Baseline and post assessment
completed for healthy children while baseline and post assessment were done for ALL
children. Parents completed the behaviour check list questionnaire across those five
phases.
Results: Behavioral problems of somatic complaints, rule breaking, and aggressive
behavior differed significantly among five assessments. When comparing the first,
second, third and fourth assessment mean scores, ALL children’s scores decreased on
somatic complaints and aggressive behaviour by the fifth assessment after the
completion of the CNS prophylactic treatment.There was no significant difference
between treated ALL and healthy children with respect to behavioral problems on
anxiety/depressed, withdrawn/ depressed and aggressive behavior in the baseline
assessment. Although, there was a significant difference observed between treated ALL
children and healthy children on anxious/depressed, withdrawn/depressed social
problems, thought problems, attention problems and aggressive behavior at the post
assessment.
Conclusion: Behavioural problems of somatic complaints, aggressive behaviour and
rule-breaking behaviour were of more concern after diagnosis and during the intensive
phase of treatment. It was found to gradually reduce to the baseline scores and normal
behaviour was evident after completion of the treatment.
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IN WHATEVER LANGUAGE ‘CANCER’ IS UNDERSTOOD: EXPERIENCES OF
LIMITED ENGLISH PROFICIENT HISPANIC FAMILIES RECEIVING CARE
FOR PEDIATRIC CANCER
T. Flatt1, A. Ramphal2, J. Zauche2, K. Stegenga2
1Children’s Mercy Hospital, Kansas City, USA; 2Children’s Mercy Hospital, Pediatric
Hematology/Oncology, Kansas City, USA
Background/Objectives: The diagnosis of cancer in a child is always stressful but more
so for families who do not speak the native language of the country where they are
receiving care. The objective of this study was to explore the perspectives of Hispanic
families with limited English proficiency receiving care for their child’s cancer. The aim
of the study was program development that would best meet the needs of these families.
Design/Methods: Parents were recruited at a tertiary care pediatric care institution in
the Midwest to participate in a qualitative focus group conducted in Spanish. A total of
10 parents from 6 families participated. The focus group was digitally recorded,
transcribed verbatim in Spanish, translated to English, double checked for accuracy by
a certified bi-lingual translator, and then analyzed for themes pertinent to the
experience of families.
Results: Three main themes emerged from the focus groups: 1) Interpreter errors and
miscommunication and the burden of siblings or the patient interpreting for family; 2)
Language is the key to building relationships and trust through the cancer experience;
3) the sharing of socio-cultural experiences is cornerstones to provider-patient trust.
Conclusion: This study demonstrated the importance of access to bilingual providers
who can speak directly to patients of any language to avoid challenges with
interpretation, form direct and meaningful relationships, and provide socio-culturally
competent care. We now have a Spanish-speaking clinic with a dedicated bilingual
provider for oncology care. It is important to identify bilingual providers who can
provide equal care to families with limited English proficiency regardless of their
primary language, particularly when they are dealing with a long-term, life-threatening
illness.
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COMPLEMENTARY AND ALTERNATIVE (CAM) PRACTICES, TRADITIONAL
HEALING (TH) PRACTICES, AND CULTURAL COMPETENCY IN PEDIATRIC
ONCOLOGY IN HAWAII
A. Ghiasuddin1, J. Wong2, A. Siu3
1University of Hawaii-John A. Burns School of Medicine, Honolulu, USA; 2KMCWC,
Child LIfe, Honolulu, USA; 3HPH, HPH Research Institute, Honolulu, USA
Background/Objectives: Hawai’i is an ethnically diverse island state with a high rate of
both Traditional Healing (TH) and Complementary and Alternative Medicine (CAM)
use. The aim of this study is to assess the rates of use of TH and CAM within the
pediatric oncology population, as well as glean any insights into delivering culturally
competent care to these families.
Design/Methods: A 9 item anonymous survey is being distributed to every pediatric
oncology patient in the inpatient and outpatient setting at Kapi’olani Medical Center
for Women and Children for a 3 month period starting March 2015, hoping to capture
all children in active treatment (estimated 25-30 patients) as well as long term follow
ups (between 60-90 patients). The survey inquires about patient and family ethnicity,
traditional healing practices used in the home and hospital, and CAM practices used in
the home and hospital. It also inquires about their perception of culturally competent
care received in the medical center.
Results: Results from the survey will provide data on a more refined ethnic breakdown
of the patient population, what percentage of each ethnicity uses TH/CAM, and what
types of TH/CAM are being utilized. Free form comments regarding culturally
competent care will also be included and analyzed for any common themes.
Conclusion: Results from the survey will be analyzed reported prior to SIOP meeting,
adding to the body of knowledge on the rates of use of TH and CAM in the pediatric
oncology population in Hawaii, an ethnically diverse island state. This knowledge could
be used to improve the delivery of culturally competent care to this patient population.
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ASSESSMENT OF SLEEP IN PEDIATRIC PATIENTS WITH CANCER
D. Ince1, B. Demirag1, T. Karapinar1, Y. Oymak1, Y. Ay1, A. Kaygusuz1, E. Toret1,
C. Vergin1
1Dr Behcet Uz Children Hospital, Pediatric Hematology Oncology Clinic, Izmir, Turkey
Background/Objectives: The aim of this study was to characterize sleep disorders of
children with cancer.
Design/Methods: Participants included children (5 – 12 years old). There were 135
children with cancer and 190 healthy controls eligible for evaluation. The patient group
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consisted of 104 (77%) children with lymphoproliferative cancer (acute lymphoblastic
leukemia (ALL) n: 76, lymphoma n:28), and 31 (23%) with diagnosis of solid tumor.
Oncologic treatment was completed in 100 patients with cancer (Group1: survivors),
treatment is continuing in 35 patients (Group2). Healthy children matched for age, sex,
economic status, parental education and family structure constituted the control group
(Group3). Sleep was evaluated by using the validated Turkish version of the Children’s
Sleep Habits Questionnaire (CSHQ). Clinical characteristics and the treatment details
of the patients were recorded from medical records. No significant differences was
found between parents of patients and controls with respect to age, gender and
educational level.
Results: Sleep problems were detected in half of our patients with cancer. There were no
statistically significant differences in total sleep score and subscale scores between
patients and healthy controls. No significant differences for average bedtime, length of
wakings and total sleep duration existed between the groups. Solely the waketime was
found significantly different between patients and controls. We couldn’t demonstrate
significant difference in sleep scores and sleep characteristics of patients who did or did
not receive intratechal chemotheraphy, HD methotrexate, HD cytarabine, craniospinal
radiotherapy.
Conclusion: Although our results indicated that neither childhood cancer survivors nor
patients with cancer during treatment period had no more sleep problems than their
healthy peers, sleep problems were not uncommon in whole study group. Sleep
problems were identified in about half of of children with cancer and also healthy
controls. This study underlines the need to screen, assess and manage sleep problems in
children with diagnosis of cancer.
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EVALUATION OF HEALTH RELATED QUALITY OF LIFE IN CHILDREN
WITH CANCER AND IN THEIR MOTHERS
D. Ince1, A. Kaygusuz1, B. Demirag1, Y. Oymak1, Y. Yaman1, G. Ozek1, B. Tatli
Gunes1, C. Vergin1
1Dr Behcet Uz Children Hospital, Pediatric Hematology Oncology Clinic, Izmir, Turkey
Background/Objectives: To evaluate quality of life of children with cancer both child’s
and mother’s perspectives. Also to evaluate quality of life of their mothers.
Design/Methods: Children who diagnosed with cancer and has been treated at least 6
months in our center and their mothers are included to study. Quality of life (QoL) is
evaluated by quality of life questionnaire (KINDLR©). Quality of life of mothers was
evaluated by WHO Quality of Life -BREF scale (WHOQOL-BREF). Ethical committe
approval was taken.
Results: The median age of patients was 9 years, and M/F ratio was 0.65. The mean age
of mothers was 34 years. The total QoL score and chronic disease QoL score of
patients were 71 and 55, respectively. The total QoL score and chronic disease QoL
score of patients with the mother perspective were 69, and 53, respectively. The QoL
scores of patients with both the patient and the parent perspective was found
correlated. The maximum and minmum scores of patients were in family well-being
subscale (79), and in physical well-being subscale (63), respectively. There was no gender
difference in total scores of QoL. The QoL scores of mothers were 14.11±2,9 in
physical field, 11,55±3,4 in physicological field, 13,69±3,4 in social field, and 11,9±2,6
in environmental field. The self esteem scores of patients and environmental field scores
of mothers was found correlated.
Conclusion: Children with cancer show lower QoL scores compared to the general
population that published in the literature. In patients especially chronic disease QoL
scores, and in mothers QoL scores of physicological and environmental fields were
effected. It has been thought that environmental factors including economic status,
financial resources, physical security and reachability of health care, effect the self
esteem of children with cancer. Further studies are needed in this field.
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THEYWANT THE TRUTHWHILE STILL BEING ALLOWED TO HOPE – AN
INTERVIEW STUDYWITH SEVERELY ILL CHILDREN ON RECEIVING BAD
NEWS
L. Jalmsell1, M. Lövgren2, M. Hansson3, U. Kreicbergs4, B.M. Frost5, J.I. Henter2
1Uppsala University, Centre for Research Ethics & Bioethics, Uppsala, Sweden;
2Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm,
Sweden; 3Uppsala University, Centre for Reserch Ethics & Bioethics, Uppsala, Sweden;
4Ersta Sköndal University College, Palliative Research Centre, Stockholm, Sweden;
5Uppsala University, Department of Pediatrics, Uppsala, Sweden
Background/Objectives: It remains a great challenge when and how to inform a severely
ill child about Bad News, e.g. that no more treatment is available and the disease will
lead to death. Studies focusing on the child’s own perspective on how they wish to
receive Bad News are few. In the present study we interviewed children with
malignancies regarding their own preferences on how they wish to receive Bad News.
Design/Methods:We conducted individual interviews with ten children, aged between 7
and 17 years, under treatment for a malignancy at a single pediatric oncology unit in
central Sweden. Interviews were audiotaped and analyzed with qualitative methodology
using systematic text condensation.
Results: The children expressed that they wanted truthful information, and they did not
want to be excluded from Bad News regarding their own illness. However, even though
they expressed a wish for truthful information they also wanted Bad News to be given
in as positive wordings as possible, allowing them to keep hope. In addition, the
children wanted to receive Bad News at the same time as their parents and in words
they could understand.
Conclusion: All children in our study expressed a strong wish to receive truthful
information even in the case of Bad News. Importantly, they wished Bad News to be
delivered in a sensitive way allowing for a glimpse of hope to remain. Our findings may
assist physicians struggling with how to inform severely ill children about a poor
prognosis.
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ACCESS TO CARE AND PSYCHOLOGICAL WELL-BEING IN PEDIATRIC
ONCOLOGY
C. Karlson1, P. Graves2
1University of Mississippi Medical Center, Jackson, USA; 2University of Mississippi
Medical Center, Pediatrics, Jackson, USA
Background/Objectives: Research indicates that demographic and community factors
such as patient age at diagnosis, number of local primary care providers, and
community socioeconomic status may be related to patient access to specialized
oncology care and patient medical outcomes. These variables have yet to be examined
as they relate to psychological outcomes. The aim of this study was to examine
demographic, family, and community factors as they relate to access to care and
psychological well-being in children with cancer and their caregiver.
Design/Methods: Participants were 223 caregivers (89% mothers; 54% married) of
children diagnosed with cancer (M = 11.1 years; 44% female; 47% White, 48% African
American;Med time since diagnosis = 2.2 years). 30.1% children were diagnosed with
ALL/AML, 26.9% brain tumor, 14.3% solid tumor, and 28.7% another type of cancer.
Caregivers completed demographic information and the Family Symptom Inventory, a
measure of child and caregiver depression/anxiety symptoms. State records provided
local number of pediatricians and median community income. Distance from the single
specialty pediatric oncology center was calculated using GoogleMaps. Analyses were
conducted in SPSS 22.0.
Results: Child demographic variables (age at diagnosis, gender, ethnicity) were not
independently related to child or caregiver depression/anxiety (p’s > 0.05). Number of
local pediatricians, median community income, and distance from specialty oncology
care were also not related to child or caregiver depression/anxiety (p’s > 0.05). However,
caregiver financial difficulty was associated with both child (t =2.41, p = 0.02) and
caregiver (t =4.40, p < 0.01) depression/anxiety symptoms. More African American
caregivers reported financial difficulty than White caregivers (χ2 = 5.5, p = 0.02).
Conclusion: Access to local medical care and specialty oncology care were not
associated with psychological outcomes in this pediatric oncology sample. However,
psychological health disparities appear to exist for African American families due to
more frequent financial difficulties.
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FIRST SUMMER SCHOOL FOR CHILDRENWITH CANCER IN ISTANBUL
I. Kebudi1, R. Kebudi2
1Hisar Schools - accepted to Columbia University-NY, Senior in High School, Istanbul,
Turkey; 2Istanbul University-Cerrahpasa Medical Faculty and Oncology Institute and
President of Childhood Love and Support Society, Pediatric Hematology-Oncology,
Istanbul, Turkey
Background/Objectives: Summer school / camp programs are wonderful experience for
kids with cancer and their families. Although these programs are available in USA and
West Europe, they are not common in developing countries.
Design/Methods: "The summer school for kids with cancer and their families" project,
the first of its kind in Istanbul, Turkey, was planned and coordinated by Izzet Kebudi, a
senior in high school who had previous training/experience of a summer school
program for children in a limited-resource area in Turkey. The summer school was free
of charge. Volunteers of the Childhood Cancer Love and Support Society (COKSEV)
supported the project. A short survey at the end of the summer school was done to get
feed back for promoting the project for coming years.
Results: 40 children with cancer, their siblings and parents joined the program. Half
were coming from other cities or neighboring countries. Most families had poor
socioeconomic resources. The major theme was "To learn about our environment". A
one-week program was done, continued with once weekly tours during the summer.
Each day education in English for beginners, painting/music, outdoor excursions in
Istanbul were done. These included, historical tour of Istanbul, Miniaturk (an openair
museum), a Bosphorus boat tour, Classic Car Museum, Aquarium, Turkish Airlines
Flight Simulation School, Helicopter Ride over Istanbul. Every day breakfast and a full
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lunch was served to all children and families. The kids and families were very happy to
join such a program and expressed their wish to join further programs.
Conclusion: The Summer School Project was very succesful and gave the patients,
siblings and parents a chance to be together, have fun and to open up. They expressed
that during the psychological burden of cancer, it may them better cope with cancer
and their treatment process.
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SECONDARY TRAUMA FACED BY HEALTH PROFESSIONALS PROVIDING
END OF LIFE CARE TO CHILDRENWITH CANCER
E. Khan Ghazi1
1Children Cancer Unit-Indus Hospital, Psychosocial Oncology, Karachi, Pakistan
Background/Objectives:Health professionals who deal with end of life care, have the job
of breaking bad news and taking the patient through the treatment process with a child
with cancer also undergo secondary trauma which affects their quality of life.
Design/Methods: Twenty-four health professionals were interviewed using a semi
structured questionnaire and these included mental health professionals, nurses and
doctors who were working with children with cancer in Children Cancer Unit, Indus
Hospital.
Results: Qualitative analysis of data gathered from interviews revealed themes such as
feelings of helplessness, repression of their emotions and an aversion to noise and
crowds. Some turned to family and friends for comfort and reassurance. Quality of life
and emotional well being were factors that were adversely affected as health
professionals carried the aftermath of the effect of end of life care into their personal
lives and interpersonal relationships.
Conclusion: Health professionals’ need for venting and training in stress reduction and
self awareness activities are possible ways so as to help them in overcoming secondary
trauma.
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DEPRESSIVE TRENDS IN CHILDREN AND ADOLESCENTS SUFFERING
FROM BETA-THALASSEMIA
S. Khanum1, S. Barerah1, Q. Asim2
1Afzaal Memorial Thalassemia Foundation, Psychology, Karachi, Pakistan; 2Afzaal
Memorial Thalassemia Foundation, Heamoglobinopathy, Karachi, Pakistan
Background/Objectives: Thalassemia is a chronic disease affecting 10,000 people in 60
countries (Alavi.A 2007). Many studies show that prolonged medical conditions cause
depression (Patten, 1999; Gagnon & Patten, 2002; Katon.2003, Patten, 2005). Due to
the invasive procedures and suffering, Beta-Thalassemia cause great psychological
distress to both children and their caregivers (Klein, 1998). Study shows 14-24%
prevalence of psychiatric problems in Thalassemic patients (Hoseini SH et al, 2007).Our
current study aims to determine the risk factors and frequency of depressive trends in
children and adolescents suffering from Beta-Thalassemia.
Design/Methods: Sample consisted of 195 registered patients of A.M.T.F (Female=95
and Male=100). Based on age range the sample was divided into two groups, Group A
= children (4-9 years) and Group B = adolescent (10-16 years). Detailed interview with
a self-made screening measure was administered on parents to find out the level of
depression in patients.
Results: Chi-square and t-test was applied in order to analyze the data. Results show
high prevalence of depression, depression n= 131(66.83%), no depression
n=65(33.16%). Analyses reflect that age influences the level of depression Adolescent
(71.05%) and Children (64.16%). Analysis also shows difference in level of depression
between both genders. (t=2.975, p <.05).
Conclusion: There is a high possibility of developing depressive trend in children
affected with Beta Thalassemia; especially females. Therefore, there is a dire need of
psychological screening and appropriate treatment in order to improve physical; as well
as mental health.
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QUALITY OF LIFE AND ADAPTIVE BEHAVIOR OF CHILDHOOD BRAIN
TUMORS SURVIVORS - COMPARATIVE ANALYSIS, PRACTICAL
APPLICATIONS
J. Korzeniewska1, B. Dembowska-Baginska1, M. Perek-Polnik1
1The Children’s Memorial Health Institute, Pediatric Oncology, Warsaw, Poland
Background/Objectives: Difficulties with operationalization of the quality of life (QoL)
concept, the reliability measurement problem, and discrepancies between the health
related QoL and personal satisfaction from life, tend to look for new approach to late
effects of childhood brain tumors. The new way seems to be assessment of adaptive
behavior defined as the performance (not only ability) of daily activities required for
personal and social sufficiency, and measured by Vineland-II.
Design/Methods: Psychological repeated testing and long-term observation was
performed in 350 childhood brain tumor survivors (various types and localizations of
tumor) to determine psychosocial late effects and QoL. Age at psychological diagnosis
ranged from 6 to 26 years. The patients were examined using battery of
neuropsychological methods and psychological interview. Analysis of medical history
was also performed. From this group randomly selected 30 patients to assessment by
the Vineland Adaptive Behavior Scales – expanded form (Vineland-II).
Results: In our sample patients present low scores in the all domains: communication,
daily living skills, socialization, motor skills, with significantly low level of social
contacts. Typical problems in this area: difficulties in appropriate expression of
emotions, inadequate mimic and body language, problems with establish and maintain
peers relationships, low tolerance of frustration, trouble with postpone of gratifications.
An interesting problem emerging from research and requires a deeper exploration are
the differences between the declarations of the patients or their parents expressed
during the psychological interview and the real level of adaptive behavior.
Conclusion: The results of our study suggest that adaptive behavior concept well
describes and explains the problems of this group of patients. Vineland-II is a useful
and reliable tool to assess psychosocial late effects survivors of cancer as a group as well
as a method to individual assessment. It also allows prepare an individual psychological
interventions and rehabilitative program for particular patient.
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COMPARISON OF BODILY MEMORY IN TWO GROUPS OF PEDIATRIC
CANCER SURVIVORS DIFFERING IN AGE OF DISEASE ONSET
E. Krivoy1, M. Peretz1, S. Makhoul1, S. Kreitler2, M.W. Ben Arush1,3
1Ruth Rappaport Children Hospital, Pediatric HematoOncology, Haifa, Israel; 2Tel Aviv
University, School of Psychological Sciences, Tel Aviv, Israel; 3B. Rappaport Faculty of
Medicine-Technion, Faculty of Medicine, Haifa, Israel
Background/Objectives: Studies of pediatric cancer survivors show that most have an
impressive ability to cope with their cancer experience and adequate psychosocial
adjustment in their life subsequently. It is also known that there are early childhood
memories that are manifested as bodily memory, which may store impressions not
available consciously.To compare bodily memories in two groups of pediatric cancer
survivors differing in age of disease onset.
Design/Methods: The participants were 50 young adult cancer survivors, 16 to 24 years
old, divided into two study groups, in line with the age of disease onset: (a) 0-3 years
and (b) 8-11 years. The number of subjects was 24 (16 men, 8 women) in group (a) and
26 (17 men, 9 women) in group (b). The clinical diagnoses were: solid tumors, 17;
lymphoma-leukemia, 24; brain tumors, 9. After receiving the IRB permit (RMC
540-14) the subjects were contacted by one of the investigators who conducted with
each individually a telephone interview according to a prearranged list of questions,
with predetermined response options, referring to four themes: Behavioral indices;
Bodily sensations; Organ sensitivity; and Nightmares.
Results:When all questions were considered together, a significant difference was found
(chi-square, P=0.001) between the two groups. The "behavioral indices" questions did
not differ significantly between the two groups, while "bodily sensation" (P=0.002),
"organ sensitivity" (P=0.02) and "nightmares" (P=0.04) demonstrated a significant
difference in terms of chi-square between the two groups, whereby the first group
scored higher than the second.
Conclusion: The results demonstrated that the group with earlier disease onset (0-3 yrs)
has more bodily memories than the group with later disease onset. The explanation
could be either that earlier disease onset is related to stronger emotional impact or that
cognitive elaboration and language development that promote coping and acceptance is
less develop during the early ages.
P-453
COMPARING “FREQUENCY” AND “INTENSITY” BASED PERCEIVED
COGNITIVE FUNCTION REPORTED BY PARENTS AND CHILDREN
J.S. Lai1, J. Beaumont2
1Northwestern University, Chicago, USA; 2Northwestern University, Medical Social
Sciences, Chicago, USA
Background/Objectives: Cognitive dysfunction is a common concern for children with
brain tumors and those who received neuro-toxic treatment. Child- and
parent-perceived cognitive function (PCF) could be used for repeated assessment given
their ease of administration, low cost and relevance to patients’ daily lives. The purpose
of this analysis was to evaluate whether agreement between parent- and child-reported
PCF was associated with rating scale type (frequency vs intensity) and whether the level
of agreement differed between children with versus without cancer.
Design/Methods: Data from 1,409 children (mean age=12 yrs) drawn from the US
general population and their parents and 515 children with cancer (53% brain tumor;
mean age=14 yrs) were analyzed. For cancer sample, 34% received radiation therapy,
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72% chemotherapy, 71% surgery and mean years since last treatment = 3.3. All
completed two versions of a newly developed pediatric perceived cognitive function
short-form (pedsPCF-SF). Both had the same 13 item stems but with different rating
scales: 1) “frequency” (from “none of the time” to “all of the time” and 2) “intensity”
(from “not at all” to “very much”). Weighted Kappa was used to evaluate agreement at
individual item level between parent- and child-reported pedsPCF-SF. Intra-class
correlation (ICC) was used to evaluate agreement at the scale level.
Results: For cancer sample, weighted kappas between children and parents were
0.27-0.39 for both intensity and frequency. For general population, weighted kappas
were 0.53-0.67 and 0.64-0.70 for intensity and frequency, respectively. At the scale level,
higher agreement was found on general population sample (ICC=0.77 and 0.81 for
intensity and frequency, respectively) than cancer sample (ICC=0.46 and 0.38,
respectively).
Conclusion: This study showed higher agreement between children and their parents
without cancer compared to those with cancer. Results from this study can be applied
to improving assessment in future cancer studies.
P-454
RESILIENCE IN PARENTS OF A CHILDWITH CANCER
T. Vercruysse1, S. Prikken1, M. Haers1, K. Vandenabeele1, V. Labarque1, S. Jacobs1,
J. Lemiere1
1UZLeuven, Pediatric Hemato-Oncology, Leuven, Belgium
Background/Objectives: Due to improved survival rates in pediatric oncology more
attention is given to psychosocial factors. There is growing evidence that resilience is
one of these important factors. Resilience implies an ability to withstand stress, but the
literature is confounded by a lack of a consensus definition. There are several different
conceptualizations: 1) preexisting trait that allows persons to thrive in the face of
adversity, 2) dynamic process of positive adaptation and 3) a final outcome. The aim of
the present study is to investigate resilience over time in parents of a child with cancer.
Design/Methods: Between June 2010 and December 2012 all parents (n=334) of a child
with a new diagnosis of cancer were invited to participate. Eventually, 64 parent couples
gave consent to participate. The resilience-Scale-NL was assessed four times: at
diagnosis (n=64), 6 months (n=38), 1 year (n=28) and 2 year (n=14) after diagnosis.
The total score of the mother and father was compared at each time point with age and
gender norms.
Results: No significant differences were found on any time point for the resilience score
of couples compared with the average norm scores. However, a significant difference
was found after diagnosis for the total group of participants, but the score was still
within normal limits (t-score 47.87). 20-22% of the parents obtained a clinical deviant
score (t-score <40) at all time points.
Conclusion: Our longitudinal study demonstrated that in the majority of parents
resilience was not negatively affected by the diagnosis of cancer and treatment of their
child. However, more than 20% of the parents obtained a clinical deviant score.
Additional, our study provided some preliminary evidence of the stability of resilience.
More research is needed to investigate the group of parents with low resilience scores, in
order to find strategies to support better this potential vulnerable group.
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BEREAVED SIBLINGS’ ADVICE TO HEALTH CARE PROFESSIONALS
WORKINGWITH CHILDRENWITH CANCER AND THEIR
FAMILIES
M. Lövgren1,2, T. Bylund Grenklo1,3, L. Jalmsell4, A. Eilegård Wallin2,
U. Kreicbergs1,5
1Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm,
Sweden; 2Dalarna University, School of Education-Health and Society, Falun, Sweden;
3Linnaeus University, Department of Health and Caring Sciences, Växjö, Sweden;
4Uppsala University, Centre for Research Ethics & Bioethics, Uppsala, Sweden; 5Ersta
Sköndal University College, Palliative Research Centre, Stockholm, Sweden
Background/Objectives: Even if healthy siblings go through several challenges
throughout the cancer-trajectory they often stand outside the spotlight of attention.
Therefore, this study explored siblings’ advice to health care professionals (HCPs)
working with children with cancer and their families.
Design/Methods: In this nationwide study, performed in Sweden 2009, 174/240 bereaved
siblings (73%) participated, and 108 answered an open-ended question about what
advice they would like to give to HCPs working with children with cancer and their
families. Data were analyzed with content analysis.
Results:Most of all siblings’ advice was related to support. They wished to be included,
either to get support themselves or because they wanted to be involved in the
brother’s/sister’s care; they wanted better medical information, to be more practically
involved and suggested that HCPs should give parents guidance on how to involve
siblings. Other advice was related to the ill child’s care, e.g. listen to how the ill child
wanted to be cared for, or siblings wish for HCPs to mediate hope, but also realism.
Conclusion: Siblings’ advice focused on inclusion from diagnosis until bereavement in
order to facilitate siblings’ psychosocial needs not only in the health care setting but
also within the family.
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COPING STRATEGIES FOR GRIEF AMONG SIBLINGS WHO HAVE LOST A
BROTHER OR SISTER TO CANCER
M. Lövgren1,2, J. Sveen3, M.E. Bradley Eilertsen1,4, A. Eilegård Wallin2, U. Kreicbergs1,3
1Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm,
Sweden; 2Dalarna University, School of Education-Health and Society, Falun, Sweden;
3Ersta Sköndal University College, Palliative Research Centre, Stockholm, Sweden;
4Sør-Trøndelag University College, Faculty of Nursing, Trondheim, Norway
Background/Objectives: Cancer-bereaved siblings report several distressing problems
such as sleeping difficulties and unresolved grief years after the loss. The aim of this
study was to identify coping-strategies for grief among cancer-bereaved siblings.
Design/Methods: This study was based on an open-ended question from a nationwide
survey, conducted 2009 in Sweden, among cancer-bereaved siblings who have lost a
brother/sister during 2000-2007 (N=174, response-rate 73%). The open-ended question
“What has helped you in your grief after the death of your brother or sister?” was
analyzed with content analysis.
Results:Many of the siblings’ strategies were either related to different ways of
distracting themselves from distressing thoughts/feelings in relation to grieving or to
think of, feel and express their grief in different ways. Strategies for distraction were
related to keep themselves busy with work and hobbies, and to return to everyday
routines. To think of, feel and express themselves in relation to the grieving included e.g.
talking to others, crying, and writing, but also talking to their dead brother/sister. The
siblings also evoked positive memories (the good times together), and negative
memories, e.g. their brother’s/sisters’ suffering. To think/feel and express thoughts and
feelings in relation to the grieving versus distracting themselves from distressing
feelings/thoughts did not always compete; some individuals reported strategies related
to both these aspects. Family, friends and pets often assisted the sibling to express their
feelings/thoughts but also distraction. Other strategies were associated with religious
beliefs, e.g. that siblings will meet again. Waiting for time to pass was also mentioned as
a strategy; since some siblings were convinced that time would heal some of their grief.
Conclusion: Siblings reported a wide range of different strategies to cope with their
grief. Most coping-strategies found are accessible and may be valuable for health care
professionals in order to support future bereaved siblings.
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CANKIDS CHILD LIFE PROJECT INDIA: A CHILD LIFE MODEL FOR A
RESOURCE LIMITED SETTING
H. Anis1
1CanKids… Kidscan, Pediatric Psycho-Oncology, New Delhi, India
Background/Objectives: The cancer diagnosis is an immediate crisis for the family and
psychological support is a vital component of treatment. Child life is a field dedicated
to providing psychosocial support to children and families facing difficult
circumstances in the healthcare setting. Although child life is a new concept within the
Indian healthcare setting, the Pediatric Psycho-Oncology program uses child life
principals and philosophies. We value the rights of the child to play and have a
stimulating, enriching, safe and clean healthcare environment to promote optimal
development. The CanKids Child Life Project objective is to improve the quality of life
for children with cancer in India.
Design/Methods: CanKids has initiated a Child Life Project, which serves as a low cost
model for other cancer institutions and organizations. This initiative outlines
advocating and implementing the “Child Friendly Ward Project” and child life
interventions to make the hospital environment the best possible place for children. We
start by educating and sensitizing the hospitals of the importance of psychosocial care
of and then partnering with them.
Results: The implementation of the Child Life Project across India provides optimum
healthcare experiences for children and families facing cancer. This project brings in
breakfast game tables, art display boards, shoe racks, toy and book libraries in addition
to implementing child life interventions. These resources promote health, psychological
well-being and encourage continuation of proper development throughout the
healthcare process.
Conclusion: Our goal is to spread awareness about the child’s right to have a safe
stimulating environment and partner with hospitals to effectuate child friendly wards,
individual counseling, group counseling, and play therapy. In implementing this project,
the amount of stress experienced by children and families facing cancer is reduced and
healthcare providers are empowered to be more effective when working with the child
and family.
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TREATMENT-RELATED LOCUS OF CONTROL AND LIKELY
CORRELATIONS WITH COPING IN CHILDREN SUFFERING FROM ALL: A
MULTICENTRIC STUDY
G. Perricone1, C. Polizzi1, V. Fontana1, S. Burgio1, C. Taormina2, F. Nichelli3,
P. D’Angelo2, M. Jankovic3
1University of Palermo, Department of Psychological and Educational Sciences, Palermo,
Italy; 2Hospital A.R.N.A.S. “Civico-Di Cristina Benfratelli”, Onco-Hematology Unit,
Palermo, Italy; 3Hospital “San Gerardo”, Pediatric Hematology Unit, Monza, Italy
Background/Objectives: The study examines the variable of locus of control - either
external or internal - in children with ALL at treatment phase, because, despite its
significance in the psychosocial adjustment process as an evolutional resource, it has
been rarely investigated. When facing the critical events, children’s own sense of
self-efficacy can guide them towards active behaviour - monitoring coping - or towards
passive one, such as avoiding responsibility - blunting coping. The possible relationship
between attribution styles and coping has been investigated.
Design/Methods: Participants: an experimental group of 40 children with ALL at
treatment regimen phase (average age=10.8, SD=2.5), recruited from two Italian
Oncology and Haematology centres (Monza; Palermo); a control group of 30 healthy
children.Tools: Locus of Control Scale for Children (Nowicki Strickland, 1973); Child
Behavioral Style Scale (Miller, 1987).A multivariate analysis of variance was calculated
to compare the scores obtained by each group. The paired t-test was utilized to
compare the mean of the scores of the scales of locus and those of coping. Pearson’s r
coefficient was calculated to measure the correlation between locus and coping.
Results: The internal locus of control score obtained by the experimental group is
higher than the score of the external locus (t=11.7; df=39; p<.001), and it is much
higher in the control group (F(2,69)=5.53; p<.05). The experimental group also shows a
statistically significant correlation between external locus and monitoring coping
(r=400; p<.05), in spite of the fact that the monitoring is the prevailing coping style
adopted by both groups (t=3.09; df=39; p<.005).
Conclusion: The predominance of internal locus of control coupled with the
monitoring coping is a resource for children with ALL useful to consciously cope the
treatment phase. The correlation between external locus and monitoring coping
displays children’s preference to react actively.
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MENTAL AND PHYSICAL OF CO-ORDINATES OF OPPOSITIONAL
DEFIANCE DISORDER IN BETA-THALASSEMIC ADOLESCENTS &
PRE-ADOLESCENTS
A. Qidwai1, B. Siddiqui2, S. Khanum2
1Afzaal Memorial Thalassemia, Heamoglobinopathy, Karachi, Pakistan; 2Afzaal
Memorial Thalassemia Foundation, Psychology, Karachi, Pakistan
Background/Objectives: Thalassemia continues to be the most common form of
Hemolytic anemia (Dubey, Parakh, & Dublish, 2008), which is 5.3% prevalent in
Pakistani Population (Ahmed, 1998). It results in poor physical and mental health
among patients (Azarkeivan et. al., 2009). Moreover it causes substantial disturbances
in every aspect of life and well-being.Since depression & anxiety continue to be the
major ailments associated with thalassemia (Mednick et al., 2010, Kiskek, Krim,
Turhan&Turan., 2013) not much attention has been given to the behavioral deficits
co-morbid with Thalassemia .Beratis (1993) found high frequency of Oppositional
defiance disorder in thalassemic children along with high ferritin rates in them. Our
study brings into light prevalence of these behavioral abnormalities in Thalassemic
children and associative medical factors that constitute the diagnosis of ODD.
Design/Methods: Our study population comprised of 197 registered Beta-Thalasemic
patients of A.M.T.F, the gender ratio composed of (Females= 95, Males= 100).
Sample was classified into 2 age based groups (Group 1: Preadolescent 4-9 years;
Group 2: Adolescent 10-16 years). Sample was screened through a self-structured
questionnaire measuring the level of ODD, along with a detailed clinical interview.
Results: Data was analyzed through non parametric test, chi-square and independent
sample t-test. Result values indicate high incidence of oppositional defiance disorder in
Thalassemic children ODD: n=141 (71.93%). Analysis also reflect that age impacts the
level of ODD in children (Group 1: Preadolescent=70%& Group 2: Adolescent =
75%).However no significant gender difference was observed (t= 1.15, p > 0.05).
Conclusion: Beta-Thalassemia inadvertently causes many emotional and behavioral
disturbances, the impact of which is detrimental to the physical health of child.The
multidimensional treatment approach employed at Afzaal Memorial Thalassemia
Foundation, makes it possible to identify psychological issues comorbid with
Thalassemia[. Psychological Screening and diagnostic procedures utilized at A.M.T.F
appear to be a valid tool to enhance compliance of transfusion dependent child towards
treatment.
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THE STIGMA OF CANCER IN DEVELOPING COUNTRIES
S. Ramachandrakurup1, R. Uppuluri2, H. Doss3, R. Raj3
1Apollo Speciality Hospital, Chennai, India; 2Apollo Speciality Hospital, Paediatric
Haemato Oncology, Chennai, India; 3Apollo Speciality Hospital, Paediaterc
Haematology Oncology, Chennai, India
Background/Objectives: The diagnosis of cancer is seldom disclosed to children or
discussed with them in developing countries after completion of chemotherapy. We
present data on the extent and patterns of social stigma associated with the diagnosis of
childhood cancer in middle income families in India after completion of therapy.
Design/Methods: This a retrospective oral questionnaire done on parents of children
treated in India over a ten year period between 2002 and 2012. The children who were
less than 7 years old during therapy and were in remission over 3 years were chosen as
our study population. The parents were questioned on 3 parameters – discussion of the
treatment of cancer with the child, attitude towards follow up care and fear regarding
long term side effects of the treatment.
Results: A total of 59 parents were interviewed for the study. The diagnosis was
Leukaemia in 37 children, Hodgkins lymphoma in 5 and NHL in 10 children. Only two
parents had discussed the diagnosis of cancer with their child (3.4%). Follow up was
not offered for fear of sensitive questions from the children in 83% of children and only
10 children have been coming for regular annual follow up since discharge. All parents -
100% expressed fears about delayed side effects from the chemotherapy especially on
pubertal growth and fertility but did not wish to discuss this issue with the child.
Separate appointments were made to perform a chart review in 12% patients by the
parents to address this issue of late side effects.
Conclusion: The social stigma of cancer chemotherapy in our society has resulted in a
huge loss of data on the psychosocial aspects of cancer and its impact on the family.
More COPE programs – creating opportunities for parent empowerment are required
to overcome these barriers and help support these families long term.
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DEVELOPMENT OF A NOVELWEB-BASED RESOURCE TOOL FOR
PATIENTS & FAMILES OF CHILDRENWITH LIVER TUMORS : THE SIOPEL
PATIENT / FAMILY FORUM
A. Rangaswami1, A. O’Neill2, E. Rinaldi3, D. Saraceno3, A. Kienesberger4,
P. Czauderna5
1Stanford University, Palo Alto, USA; 2Dana Farber Cancer Istitute-Harvard University,
Pediatrics, Boston, USA; 3Cineca, Information Technology, Bologna, Italy;
4Österreichische Kinder-Krebs-Hilfe, Communications, Vienna, Austria; 5Surgery,
Gdansk, Poland
Background/Objectives: Hepatoblastoma and hepatocellular carcinomas are the most
common primary malignant liver neoplasms in pediatric patients under the age of 18
years. Due to the rarity of these tumors, when confronted with these diagnoses,
patients, survivors, and their families, are challenged in identifying support networks
that permit them to share information and experiences. In an effort to facilitate
communication, clinicians, survivors, and parents have cooperated to develop a novel
web-based virtual support network.
Design/Methods: Funded by a grant from ENCCA (the European Network for Cancer
Research in Children and Adolescents), hysician representatives from SIOPEL, in
collaboration with pediatric liver tumor survivors and their parents, developed a
web-based service, the Patient/Family Forum. Membership requires registration with a
secure username and password. Once registered, clients may utilize this forum to share
their experiences, solicit advice, and benefit from the experiences of others. This secure
web-based platform is hosted by the Italian Supercomputing facility, Cineca. The
interface language may be customized by clients to their own and exchanges between
users may take the form of public group or private messaging. The forum is supervised
by two moderators (one pediatric liver cancer survivor and one parent). Questions
regarding medical concerns such as diagnosis, prognosis, and treatment, are referred by
the forum moderators to recognized experts in the field for coordinated review and
response.
Results: This Patients/Family forum was developed and launched in July, 2014.
Conclusion: Such a forum serves as a potential model for the development and
cultivation of international support communities for patients, parents, and survivors of
other rare paediatric rare malignancies. The research leading to these results. This effort
has received funding from the European Union’s Seventh Framework Programme
(FP7/2007-2013) under the project ENCCA, grant agreement n° 261474The authors
have no financial interests to declare.
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PREVALENCE OF SYMPTOMATIC ANXIETY IN PRE-ADOLESCENT AND
ADOLESCENTS SUFFERING FROM BETA-THALASSEMIA: A
LONGITUDINAL STUDY
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B. Siddiqui1, K. Sanober1, Q. Asim2
1Afzaal Memorial Thalassemia Foundation, Clinical Psychology, Karachi, Pakistan;
2Afzaal Memorial Thalassemia Foundation, Heamoglobinopathy, Karachi, Pakistan
Background/Objectives: Thalassemia is a lifelong condition-requiring adherence to a
cumbersome medical procedure. The course of disorder affects not only the physical
condition of the child but also impedes his/her mental health. (Mednick, 2010). Anxiety
disorders are considered to be the most common type of psychopathologies affecting
Child and adolescent with a ratio of about 10-20 %. (Bersntein GA et al., 1996, Moreno
MA et al., 2010). Many researches have been conducted in the western society to
investigate the prevalence of anxiety in Beta-Thalassemia patients. However there is a
dearth of research data in Pakistan calculating this risk factor. This research paper
brings into light the prevalence and incidence of symptomatic anxiety in pre-adolescent
and adolescents suffering from Transfusion dependant Beta-Thalassemia.
Design/Methods: The sample population comprised of 196 beta-thalassemia patients,
registered in Afzaal Memorial Thalassemia Foundation. The inclusion criteria
encompassed an age range of 4-16 years, whereby 2 categories (i) pre-adolescent (age
range 4-9 years) and (ii) adolescent (age range 10-16 years) were made. A self-made
screening questionnaire was administered on the caregivers along with in depth history
and clinical observation of child during psychotherapy sessions.
Results: The result findings indicate high incidence of anxiety in children suffering from
Beta-Thalassemia. Chi-square values show Anxiety: n=128(65.30%). It was found that
Anxiety was significantly higher in pre-adolescent (65%) as compared to adolescent
(60%).There was no significant difference in level of anxiety among both genders
(t=1.74,p>0.05).
Conclusion: The study indicated that children suffering from Beta-Thalassemia are at a
higher risk for developing anxiety disorders. There is a strong need of adjunct
psychotherapeutic sessions with medical treatment to alleviate their quality of life and
mental health.
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PHYSICIANS AND NURSES BURN OUT IN PEDIATRIC ONCOLOGY
DEPARTMENTS IN ISRAEL
S. Tamir1, O. Mordechai1, N. Tuma1, H. Izraeli1, R. Ofir1, M. Ben-Arush1
1Rambam Health Care Campus, Pediatric Oncology, Haifa, Israel
Background/Objectives: Burn out is a term used to explain the decrease job
performance and commitment as well as the stress and dissatisfaction of health
workers. There are three characteristics of burn out - depersonalization, low personal
accomplishment and emotional exhaustion. The health care experiences psychological
and physical stress increasing along the years and negatively affecting the quality of life
and the quality of care of the medical teams.
Design/Methods:We used a questionnaire consisting of three components:
Demographic variables, Burnout Questionnaire –MBI and Coping Strategies
Questionnaire –COPE.The questionnaire posted to all the physicians members of the
Israel Society of Pediatric Hematology Oncology and to the nursing staff of the main
pediatric Hematology Oncology departments in Israel.
Results: 119 subjects filled the questionnaire, 41 medical staff and 78 nursing staff.
Regarding the question: “Do you feel burnt out”, on a scale from 0-6 (6- more burnt
out), the nursing team answered on average 3.6±1.6 as opposed to the medical team 2.3
±1.6 (p=0.003) as this single question correlate with the statistical analysis of the
sub-questionnaires that demonstrated differences between the groups in emotional
fatigue, depersonalization and emotion focused coping and the nurses reported on
higher burn out feelings. A significant correlation was found between the nursing staff’s
age groups and their emotional fatigue- the higher the average age, the higher the
feeling of emotional fatigue (p=0.03).
Conclusion: In this study, we found that there are differences between the nursing team
and the medical teams both in the level of burnout as well as in the level of coping.
These findings consider the basic differences between the nurses and the physicians and
can be explained especially by the support received outside of the workplace.
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TO HEAL A STUDENT, NOT JUST HIS DISEASE
S. Yáñez1, M. Fierros1, C. Bengoechea2, B. López-Ibor2
1Hospital Universitario HMMontepríncipe, Hospital School, Boadilla del Monte, Spain;
2Hospital Universitario HMMontepríncipe, Paediatric Hematology/Oncology Unit,
Boadilla del Monte, Spain
Background/Objectives: The importance of hospital schools has been rising during the
last decades. They have gained a lot of influence in the lives of children and teenagers
under treatment for different diseases. Those in paediatric hematology/oncology units
are not an exception. Though the hospital schools are nowadays capable of synchronize
their work with the patients regular schools, the purpose of this project is to present
and describe a case report which underlines de role of the hospital schools as
themselves, as a teaching tool which is useful in the goal of educating its students in a
global and comprehensive way.
Design/Methods: It presents the case of a 16 years old boy who was merely a patient
(with a localized osteosarcoma that required preoperative and post-operative
chemotherapy, high complexity surgery and inmunotherapy) without any kind of
learning activity. Its approach is necessarily cross-disciplinary, but the present report
has an educational perspective and it stresses the function, possibilities, advantages and
disadvantages of hospital schools within paediatric oncology units and their
coordination with the rest of the staff. It does it by putting the patient in the middle of
its scope, trough a humanist vision that emphasizes the real meaning of education. Its
methodology is qualitative.
Results: The patient had finished the obligatory educational stage and wasn’t enrolled in
any school. He was apathetic and he had had a negative experience in a former hospital
schoo. Through the Montepríncipe Hospital School in the Paediatric
Hematology/Oncology Unit (HMMontepríncipe Hospital) became a curious and
motivated student.
Conclusion: Though it does not have a single conclusion, this project concludes that
hospital schools are not just a way of linking the patients with their regular schools, but
a powerful tool to help healing process, since cancer has both physical and psychic
effects and consequences.
Posters: Radiation Oncology (PROS)
P-465
18-FDG PET-MRI IN PEDIATRIC ONCOLOGY. A NEW DIAGNOSTIC AND
TREATMENT PLANNING TOOL
B. Herrero1, I. Martinez1, L. Garcia-Cañamaque2, M. Villa1, A. Ramos3, E. De Luis3,
A. Lancharro4, E. Martinez5, R. Alonso6, B. Lopez-Ibor1
1HM Hospitales, Pediatric Hematology and Oncology Unit, Madrid, Spain; 2HM
Hospitales, Nuclear Medicine, Madrid, Spain; 3HMHospitales, Neuroradiology, Madrid,
Spain; 4HM Hospitales, Pediatric Radiology, Madrid, Spain; 5Universidad San Pablo
CEU, Madrid, Spain; 6HM Hospitales, Radiation Therapy, Madrid, Spain
Background/Objectives: It is shown that PET-CT with 18-FDG, has a high sensitivity
and specificity in studies of whole body in evaluating pediatric malignancies. However
the of exposure to ionizing radiation, has led us to search new diagnostic tools such as
PET-MRI. PET-MRI is a very novel technique worldwide, and is part of the so-called
integrated image studies in which a single test is used to improve not only the diagnosis
of the patient’s illness and its treatment effect, but to improve the cost-effectiveness.
Design/Methods: A descriptive analysis of the technical characteristics and pathologies
of the studies is conducted. Nine pediatric studies have been done from November 2014
to March 2015. Our equipment is a Siemens Biograph MMR formed by the PET and
3T MRI with simultaneous acquisition of both techniques. 6MBq are injected 18-FDG
in studies of full body and a fixed dose of 111 MBq in brain studies. We have used
different protocols depending on the pathology of the patient. In all the studies we
acquired specific sequences of post-contrast MRI with gadolinium.
Results: A total of 9 patients were studied. Indications for PET-MRI were: radiation
therapy planning (2 DIPG,1 relapsed STS, 1 anaplastic ependimoma and 1
disseminated pinealoblastoma), end of treatment evaluation (1 hodgkin disease) and
re-staging ( 1 relapsed medulloblastoma and 1 relapsed neuroblastoma).
Conclusion: The 18-FDG PET-MRI is a technique of integrated images, with high
sensitivity and specificity in the diagnosis of pediatric tumors, and a significant decrease
in the rate of exposure to ionizing radiation in children compared to other diagnostic
techniques.
P-466
RAPID-LEARINING SYSTEM FOR PAEDIATRIC RADIOTHERAPY -
IMPLEMANTATION OF A NATIONWIDEWEB-BASED QUALITY
ASSURENCE PLATFORM AND REGISTER IN PAEDIATRIC RADIATION
ONCOLOGY IN AUSTRIA
C. Lütgendorf-Caucig1, S. Sibinovic1, K. Dieckmann1
1Medical University of Vienna, Radiation Oncology, Vienna, Austria
Background/Objectives: In Austria each year only a small amount of children receive
radiation at five different centres. Due to the limited amount of cases and the
inhomogeneous group of tumours an expert level is difficult to achieve. Up to now the
collaboration among these centres is based on communication via telephone, e-mail and
postal services. Objective is the development of a centralized web-based platform to
evaluate the standard of nationwide pediatric radiotherapy and subsequently build up a
nationwide register.
Design/Methods: All children receiving radiotherapy will be registered before start of
treatment at the web-based quality assurance platform. The patients´ histories, all
relevant diagnostic reports and radiological images will be uploaded and
pseudonymized. Thereafter the patient cases will be discussed among the pediatric
radiation oncologist group. The defined target volume and treatment plan will be
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evaluated with respect to dose distribution to the tumour and organs at risk.The
implementation will roll out in four stages to simplify and unify the actual process of
data aggregation and data representation, to grantee an easy data access for all
collaborating centres.Stage 1: First use of digital DICOM-archive Stage 2: Enabling a
secure digital data transfer and data access to the archive via stand-alone client
softwareStage 3: The stand-alone client software is replaced by a web-based online
viewerStage 4: Completing the fully accessible web application by adding upload
features and automatized processes. Apart from the web front end, which allows the
user to interact and to exchange data, another crucial part of the platform is the back
end that is responsible for data management and data archiving of medical multimedia
data.
Results: The first results will be presented at the congress.
Conclusion: A national quality assurance platform and register of pediatric radiation
oncology will be built up for further research and advanced training.
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IMPLEMENTATION OF PROTON THERAPY FOR PEDIATRIC TUMORS AT
THE NEW PROTON FACILITY IN TRENTO
B. Rombi1, S. Vennarini2, L. Meneghello3, C. Bonazza3, A. Di Palma3, M. Amichetti2
1Trento, Italy; 2Center of Proton Therapy, S. Chiara Hospital, Trento, Italy; 3Paediatric
Department, S. Chiara Hospital, Trento, Italy
Background/Objectives: Although both photon and proton radiation techniques permit
similar target volume coverage, the physical properties of protons allow a better sparing
of normal tissues with the consequent reduction of acute and late toxicities.
Design/Methods: The Trento facility is equipped with active beam delivery based on
spot scanning. A cyclotron provides beams of variable energy (70-226 MeV at
isocentre) and spot size (σ 3-7mm in air at isocentre). Each treatment room is equipped
with a gantry which allows 360° rotation of the beam line, 6 degrees of freedom robotic
treatment table, two orthogonal X-ray devices, a CT on-rails in one room and a
cone-beam CT in the other. Two horizontal beam lines are placed in a third room. The
center is equipped also with a dedicated CT and 1.5T MRI and an anesthesia area. In
October 2014 the facility started clinical activity on adult patients; the plan is to accept
pediatric patients around six months later.
Results:We evaluated 25 pediatric cases (21 national and 4 international) referred by
physicians, parents and family members. The mean age was 9 year (range, 1-20) and the
histology was: rhabdomyosarcoma (2), high-risk medulloblastoma (4), diffuse intrinsic
pons glioma (2), meningioma (2), primitive neuroectodermal tumor (3), choroid plexus
carcinoma (1), Ewing sarcoma (2), low-grade glioma (3), chordoma (1), atypical
teratoid rhabdoid tumor (1), pituitary germinoma (2), osteosarcoma (1), malignant
schwannoma (1). Nineteen patients were evaluated eligible to receive proton radiation
although the radiation timing was not always correctly set. Six patients were declined
due to metastatic progression of disease or because already treated with high doses of
radiation.
Conclusion: At Trento Proton Center, we expect to treat in a very near future pediatric
patients and to contribute to the limited but growing body of literature demonstrating
effectiveness and safety of protons for pediatric tumors.
Posters: Rare Tumours
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RUPTURED SOLID PSEUDOPAPILLARY NEOPLASM OF PANCREAS (SPT)
MANAGED BY CHEMOTHERAPY AND LIMITED SURGERY
S. Agarwal1
1Sir Ganga Ram Hospital, Delhi, India
Background/Objectives: To report a case of SPT of pancreas highlighting that
chemotherapy may be used as an adjunct to surgery in management of such tumors to
avoid morbid surgical resection.
Design/Methods:We report here, a case of SPT managed successfully using low dose
chemotherapy followed by limited surgery.
Results: An 11 yr old female presented with severe abdominal pain, bilious projectile
vomiting and signs of shock. A firm abdominal mass was palpable in the epigastric
region. USG abdomen revealed a large heterogeneous mass in lesser sac. CECT showed
a large ruptured necrotic hemorrhagic mass in relation to the body and tail of pancreas.
An exploratory laparotomy was planned and major debulking of ruptured pancreatic
tumor was done. Biopsy was s/o a Solid pseudopapillary neoplasm of pancreas Tumor
cells stained positive for Synaptophysin, CD 10 and beta catenin and negative for
chromogranin. However she developed recurrence of symptoms after 2 months. CECT
abdomen showed evidence of large mass in relation to the tail of pancreas s/o residual
tumor. It was opined that a surgical resection at this point of time would mean
complete pancreatectomy, splenectomy, bowel resection and a temporary colostomy. In
consultation with the gastrosurgical team it was decided to give her 4 Cycles of VAC
chemotherapy and reassess for surgery later. She showed some decrease in the size of
the mass .It was then planned to take her for surgery. Only a distal pancreatectomy with
splenectomy was done. The resected margin was free of tumor and all 12 regional
lymph nodes were tumor free. Three months after the surgery she is asymptomatic and
has no evidence of recurrence.
Conclusion: SPT of Pancreas is a rare tumor with a little literature on management
guidelines. We successfully combined chemotherapy with surgery in this young girl to
avoid morbid surgical outcome.
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MEDIASTINAL CYSTIC TERATOMAWITH RIGHT SIDED EXTRA RENAL
WILMS TUMOR-A RARE CASE REPORT
M. Akm1, M.K. Ahsan2, S. Islam3
1Dhaka Medical College Hospital, Dhaka, Bangladesh; 2Dhaka Medical College
Hospital, Thoracic Surgery, Dhaka, Bangladesh; 3Dhaka Medical College Hospital,
Paediatric Surgery, Dhaka, Bangladesh
Background/Objectives:Wilms’ tumour is one of the most common tumours of
childhood, majority of these tumours arise from the kidney .Very few cases, only about
100 documented cases of Extrarenal Wilms’ tumour had reported. Mediastinal
teratoma also seen in children but association of these two is rare. We failed to find any
case report. So we decided to report it.
Design/Methods: A 26 months old boy presented with fever, chest pain, respiratory
distress & abdominal distention for 8 months. His respiratory distress was not relieved
by medication. He used to scream with pain. He had anorexia & weight loss. With these
complains, in last 8 months, he got admitted 9 times in 6 different hospitals and
investigated with CXR 16 times, USG of abdomen 4 times, CT Scan of Chest two times
and undergone minor chest surgery 5 times and major surgery once (mini thoracotomy
& open drainage). On examination he was irritable, ill-looking, dyspnoeic, mildly
anaemic & no lymphadenopathy was found.Respiratory system examination suggestive
of left sided pleural effusion with scar marks & a sinus with purulent discharge on left
side. Right kidney was palpable, ballotable & non-tender.
Results: Several investigation like x-ray chest revealed trachea shifted to rt side and left
lung totally opaque and comment was left sided pleural effusion. CT scan report was in
favour of left sided renal mass and metastatic lesion at left lung. Thoracotomy was
done and found cystic teratoma, confirmed by histology. Laparotomy was done to
remove the mass.The mass was free from kidney. Histology report in favour of extra
renal wilms tumour. Pathology slide was reviewed and expert panel board confirmed
the case of extra renal wilms tumor.
Conclusion:With meticulous history, clinical examination, proper investigation and
appropriate surgical approach may identify the rare cases.
P-470
MANDIBULAR DESMOID FIBROMATOSIS: BALANCING AGGRESSION OF
CARE FOR A BENIGN DISEASE
M. Arnold1, C. De Vos2, A. Van Zyl3, P. Schubert4, A. Zühlke5, J. Morkel6, D. Sidler2
1Stellenbosch University, Cape Town, South Africa; 2Stellenbosch University, Paediatric
Surgery, Cape Town, South Africa; 3Stellenbosch University, Paediatric Oncology, Cape
Town, South Africa; 4Stellenbosch University, Anatomical Pathology, Cape Town, South
Africa; 5Stellenbosch University, Plastic Reconstructive Surgery, Cape Town, South
Africa; 6University of the Western Cape, Maxillo-facial and Oral Surgery, Cape Town,
South Africa
Background/Objectives: Desmoid fibromatosis is a rare benign tumour which grows
rapidly and destroys local tissue. Mandibular predilection may cause impingement on
the airway and surrounding neurovascular structures. A high risk of recurrence needs
to be weighed against the risks of mutilating surgery and chemotherapy for a tumour
which does not metastasize, but its rarity precludes a strong evidence-base for care.
Design/Methods:We retrospectively reviewed our management and outcome of cases of
mandibular desmoid fibromatosis presenting over 5 years at Tygerberg Academic
Hospital, Cape Town.
Results: Three patients presented with unilateral mandibular swellings of 2 months’
median duration at a median age of 29 months. Mean tumour volume on magnetic
resonance imaging (MRI) was 129cm3. No syndromic features or significant family
history was found. Core needle biopsy confirmed diagnosis in each case. Patient A (a 41
month-old male with 67cm3 left-sided lesion) had a primary excision with
hemi-mandibulectomy and concurrent osteomyocutaneous free fibular flap repair, with
clear resection margins. Patient B (a 29 month-old female with 211cm3 left-sided lesion
and nocturnal stridor from airway compression) had the same procedure performed
after two courses of vincristine, adriamycin and cyclophosphamide (VAC).
Neoadjuvant chemotherapy achieved 17% tumour volume reduction, but microscopic
excision margins were positive. Patient C (a 16 month-old malewith 107cm3 right-sided
lesion with parotid involvement, airway compression radiologically, facial nerve palsy
and previous exomphalos repair) had tumour progression on VAC chemotherapy.
Gross tumour debulking was followed by 8 cycles of methotrexate with vinblastine and
a 1.8cm3 residual lesion on subsequent MRI did not progress. All patients had good
functional outcome at 46 months average follow-up (range 30-55).
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Conclusion: Individualized management that aims to control local disease but preserves
function and cosmesis requires a multidisciplinary team in aggressive fibromatosis of
the jaw not amenable to simple wide local resection. Long-term multicentre cohorts
should clarify care choices.
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MALIGNANT TRITON TUMOR AND NEUROFIBROMATOSIS. A RARE CASE
REPORT AND LITERATURE REVIEW
F. Arreguin1, S. Hernandez2, S.J. Sandoval2
1Centro Medico Nacional "20 de Noviembre" ISSSTE, Mexico City, Mexico; 2Centro
Medico Nacional "20 de Noviembre" ISSSTE, Felix Cuevas 540 Col. del Valle, Mexico
City, Mexico
Background/Objectives:Malignant peripheral nerve sheath tumors (MPNST) constitute
a rare variety of soft tissue sarcomas. Malignant triton tumor (MTT), a very rare,
highly aggressive soft tissue tumor, is a subgroup of MPNST coexisting with malignant
rhabdomyoblasts. Only case reports and small seriers of patients have been published.
Design/Methods:We present a case report of a 6 year old boy with NF-1 and MTT. A
review of the literature was done.
Results:We report a sporadic case of MTT in a 6 year old boy. We present the clinical
course, pathological findings and image findings. Immunohistochemistry confirmed the
neurogenic origin with S-100 expression and the rhabdomyoblastic differentiation with
desmin and vimentin positivity. Parcial surgical excision was done and preoperative
chemotherapy was given.
Conclusion:MTT are a rare form of peripheral nerve sheath tumors that follows a
particularly aggressive course. Given its rarity, only case reports and small series of
patients have been published. Early diagnosis and referral to multidisciplinary team are
important in ensuring the best diagnosis and optimal therapy in this young age.
Complete surgical resection and adjuvant radiotherapy should be the cornerstones of
treatment for MTT, but preoperative chemotherapy can be given.
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CLINICAL FEATURES AND TREATMENT RESULTS OF PATIENTS WITH
HEMANGIOMA
E. Atas1, V. Kesik1, O. Koc2, H. Atas3
1Gülhane Military Medical Academy, Pediatric Oncology, Ankara, Turkey; 2Gülhane
Military Medical Academy, Pediatrics, Ankara, Turkey; 3Diskapi Yildrim Beyazit
Training Hospital, Dermatology, Ankara, Turkey
Background/Objectives: Hemangioma is a disease with high incidence of spontaneous
recovery. It is not usually evident at birth. But, rapid growth after birth, stabilization of
lesion between 1 and 2 years of age and involution after 2 years of age are some clinical
features of hemangioma. Vascular malformations in the opposite situation should be
considered. Hemangioma is the most common benign vascular tumors of childhood.
Design/Methods: Forty-nine patients with hemangioma who admitted between 2001-
2015 were evaluated retrospectively.
Results: The median age of onset and age at admission were 0 (0-156, mean 8.4) and 7
(0.25-192, with a mean of 19.9) months. The localization of lesions were 57.2% (n = 28)
on head region, 16.3% (n = 8) on trunk, 16.3% (n=8) on limb, and 10.2% (n = 5) on
neck region. 17 patients (34.7%) were treated with propranolol alone in 12 (24.5%)
patients, steroid alone in 2 (4.1%) patients, prednisone and propranolol in 2 (4.1%)
patients, propranolol and surgery 1 (2%) patients were used. Regression was observed
81.6% of patients (n = 40). The number of hemangioma (>1) (p = 0.026, HR = 9.5,
95% CI 1.3-69.2) and treatment except observation (p = 0.008, HR = 10.5, 95% CI
1.8-59.1) were found significant in the univariate analysis, and treatment except
observation was found effective on clinical response (p = 0.014, HR = 9.8, 95% CI
1.5-90.9).
Conclusion: Despite very small at birth, hemangioma can grow rapidly in the first year
of life. Treatment indications are ulceration, infection, bleeding, and some special
location such as laryngeal, tongue, eyelid, ear canal. Treatment options include
observation (90%) and treatment modalities such as steroid, propranolol, interferon,
chemotherapy, interventional radiological lesion embolization, surgical resection and
laser which are applied to prevent organ dysfunction. Number of hemangioma and
underwent to treatment except observation are significant on treatment response.
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EUROPEAN SURVEY ON THE EXISTENCE AND ACTIVITY OF
COOPERATIVE GROUPS DEDICATED TO CHILDREN AND ADOLESCENTS
WITH VERY RARE TUMORS. AN EXPO-R-NET/EXPERT INITIATIVE
G. Bisogno1, S. Sorbara1, D. Schneider2, A. Ferrari3, G. Petrarulo4, D. Orbach5,
I. Brecht6, B. Eva7, Y. Reguerre8, J. Godzinski9, T. Stachowicz-Stencel10,
G. Cecchetto11, R. Ladenstein12
1University of Padua, Department of Woman’s and Child’s Health, Padova, Italy;
2Klinikum Dortmund, Pediatric Oncology Division, Dortmund, Germany; 3Istituto
Nazionale Tumori, Pediatric Oncology Unit, Milano, Italy; 4SIOP Europe, Office,
Brussels, Belgium; 5Institute Curie, Pediatric Oncology Unit, Paris, France; 6Kinder-und
Jugendklinik Universitätsklinikum Erlangen, Ambulanz der Pädiatrischen Onkologie und
Hämatologie, Erlangen, Germany; 7Medical University, 1Department of Pediatrics,
Gdansk, Poland; 8CHU de Saint Denis, Service d’Oncologie et d’Hématologie
Pédiatrique, La Reunion, France; 9Marciniak Hospital, Department of Paediatric
Surgery, Wroclaw, Poland; 10Medical University of Gdansk, Department of
Pediatrics-Hematology-Oncology and Endocrinology, Gdansk, Poland; 11University of
Padova, Division of Pediatric Surgery, Padova, Italy; 12St. Anna Kinderkrebsforschung,
Children’s Cancer Research Institute, Wien, Austria
Background/Objectives: Very rare tumors (VRT) in children are an orphan disease in
terms of lack of clinical and biological knowledge, dedicated studies, economic interest.
VRT are heterogeneous: some are characteristic of childhood (pneumoblastoma,
pancreatoblastoma,…), others are frequent in adults but rare in children (carcinomas,
melanoma,…), where they show distinct characteristics. For this reason, VRT have
been included in EXPO-r-NeT, a EU funded project that aims to reduce inequalities in
childhood cancer survival and healthcare capabilities in different member states. A
major objective is to improve access to high quality care for children with VRT that
may require specialized resources or expertise not available in every center.
Design/Methods: The chairs of each European pediatric oncology society and, where
existing, the coordinator of the national VRT cooperative group have been invited to
respond to an online survey.
Results: 36 countries (including Turkey and Israel) responded: a VRT cooperative group
exists in Italy, Germany/Austria, Poland, France, Spain, the Netherlands. A registry is
active in the UK/Ireland and Hungary. In 2015, VRT groups have been formed in
Croatia and Israel. Thus, structured activities dedicated to children with VRT exist in
only 30% of European countries. This translates in a “coverage” of approximately 60%
of the European population. The absence of activity was justified by low clinical and
scientific priority and/or lack of trained staff. “Small” countries declared that the
limited number of children with VRT does not justify dedicated resources.
Conclusion: in many European countries, VRT management is not at the same level of
other more frequent pediatric cancers. The establishment of an international network,
based on the EXPeRT experience, would be important to establish standards of care,
allow consultation, facilitate access to expert centers. ExPO-r-Net project is funded by
The European Union in the framework of the Health Programme (2008-2013), grant
201312 07.
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MALIGNANT PANCREATIC TUMORS IN CHILDREN: EXPERIENCE IN
INSTITUTO NACIONAL DE PEDIATRIA IN 9 YEARS
V. Carrasquel Valecillos1, J.M. Palacios Acosta1, F.A. Medina Vega2, E. Vidales Nieto2,
D. Hernandez Arrazola1
1Instituto Nacional de Pediatria, Pediatric Oncology Surgery, Mexico City, Mexico;
2Instituto Nacional de Pediatria, Pediatric Surgery, Mexico City, Mexico
Background/Objectives: The Pancreatic tumors are very rare in pediatric age. It is occur
in 1 per 18000 cases during childhood and it’s the cause of 0.2% of the pediatric cancer
death worldwide. This issue, leading to apply the same approach performed in Adults
patients. The aim of this study is relate our experience in management of the malignant
pancreatic tumor in children in our institution during the period between 2006-2015.
Design/Methods:We developed an ambispective study when we observed the cardinal
symptom, the diagnostic method, the surgical technique used, the pathology results and
the evolutions of each case.
Results:We treated nine cases with pancreatic tumors in age between 0-17 years. The
cardinal symptom was abdominal pain in seven patients, follow by vomits in five
patients and abdominal distension by mass in three. The average age was 7.5 years with
a range between 2-12 years. The pathology evaluation report four Solid Pseudopapillary
tumor (SPPT), two pancreatoblastoma, one Teratoma, one Pnet and one Islets Cells
Carcinoma + Pheochromocytoma. Location of the lesion was head in 5 cases. We take
to the OR all the cases and performed Whipple procedure in 5 cases and distal
Pancreatectomy in four, (one of these cases was a distal pancreatectomy +
Splenectomy). Complications occur in 5 cases (one bleeding, one pancreatic fistulae+
intrabdominal abscess, one intrabdominal abscess, one pancreatic insufficiency, one
progression of the disease).
Conclusion:We establish a method to approach to malignant pancreatic tumors in our
institution. Otherwise, we suggest a worldwide multicentric study to define a standard
approach method.
P-475
NASOPHARYNGEAL CARCINOMA IN CHILDREN AND ADOLESCENT;
EXPERIENCE OF EGE UNIVERSITY FROM TURKEY
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N. Çetingül1, A. S¸ahin2, H. Öniz3, B. Demirag˘4, S. Kamer5, M. Kantar2, S. Aksoylar2,
S. Kansoy2, S. Gözmen2, A. Veral6, H. Alper7, Y. Anacak5
1Ege University Faculty of Nursing, Izmir, Turkey; 2Ege University-Faculty of Medicine,
Pediatric Hematology-Oncology, I˙zmir, Turkey; 3Tepecik State Hospital, Pediatric
Oncology, I˙zmir, Turkey; 4Dr. Behçet Uz Children Hospital, Pediatric
Hematology-Oncology, I˙zmir, Turkey; 5Ege University-Faculty of Medicine, Radiation
Oncology, I˙zmir, Turkey; 6Ege University-Faculty of Medicine, Pathology, I˙zmir, Turkey;
7Ege University-Faculty of Medicine, Pediatric Radiology, I˙zmir, Turkey
Background/Objectives: The incidence of nasopharyngeal carcinomas (NPCs) among
children and adolescents varies widely among different regions and races. The aim of
our retrospective study was to evaluate the clinical features, histophathology, treatment
results, and late toxicities of patients with NPCs.
Design/Methods: Between 1988 and 2014, 31 patients younger than 20 years old were
treated and followed up in Ege University, Department of Pediatric Oncology and 2
other state hospitals in I˙zmir.
Results: The mean age of 31 patients was 13 (8-17,5) years. Male to female ratio was
1.6/1. Neck mass (cervical lymphadenomegaly) (67.7%), headache (16.1 %), hearing
loss and nasal obstruction (12,9%) were the most common complaints. Twenty–five
(80,6%) patients had undifferentiated carcinoma (type III), 6 (%13,4) patients had other
non-keratinizing carcinoma histopathologically. There were 29 (93.5 %) patients in
stage III (locally advanced disease) and in stage IV. EBV serology/ DNA was
investigated in 16 patients and was found positive. Before RT, German POG protocol
(Cisplatin, 5- FU and MTX) was applied. However, 5 (48.4%) patients did not receive
MTX. All patients received local radiotherapy (60 Gy). After that they received IFN –
beta for 6 months. Follow- up mean time was 6, 5 years (1.- 14.9 years). Three patients
relapsed in mean time 7.8 monhts. In all patients 7- year relapse free survival (RFS) rate
was 87.1%, and overall survival (OS) rate was 92.9 %. Late toxisities seen in patients
were neck fibrosis (51.6%), hypothyroidism (35.4%) and hearing loss (12.9%).
Conclusion:Most children and adolescent patients with NPC are local –regional
advanced diseases at first diagnosis and the outcomes are generally better than adults.
But late toxisities due to RT are significantly high. Also, response-adapted RT is worth
for further evaluation to minimize late toxicities.
P-476
CONGENITAL GIANTMELANOMA - A PARTICULAR BIOLOGICAL ENTITY
C.F. Classen1
1Rostock, Germany
Background/Objectives:Melanomas in infants are a rare and heterogeneous disease.
Initial presentation, clinical course, genetic background and prognosis may be different
than in older chrildren or adults.
Design/Methods:We report on a female infant, born after uneventful pregnancy that
presented with a large subcutaneous tumor at the occiput, about 5 cm in lenth, and 1.4
cm thick. Primarily, an excision biopsy was performed.
Results: Histopathology revealed the diagnosis of a malignant melanoma of epitheloid
type, with tumor-infiltrated margins. Two subsequent resections were performed, finally
leading to tumor-free margins. Genetic analysis of the tumor performed by CGH
revealed an unspecific aberration on chr. 1 and a copy number loss on chr. 17 that is not
typically seen in adult melanomas. Staging showed no lymph node enlargement or signs
of metastasis; however, no sentinal node biopsy was done. The mother was free of
melanoma, thus excluding diaplacentar transmission, and there was no family history
of malignancy or syndromous disorders. In the infant, no further therapy was
performed. The child is now 4 years old with normal development and no sign of
relapse.
Conclusion:We conclude that even large melanomas in small infants may have a good
prognosis with surgical therapy alone. The genetic basis of melanomas may be different
in infants as compared to older children or adult patients.
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NASOPHARYNGEAL CARCINOMA IN CHILDREN AND ADOLESCENTS: A
SINGLE INSTITUTION EXPERIENCE OF 64 PATIENTS
M. El Kababri1, K. Mouden2, A. Kili1, H. El Kacemi2, L. Hessissen1, M. El Khorassani1,
N. Benjaafar2, M. Khattab1
1Ibn Sina University Hospital, Hemato-Oncology Pediatric Center, Rabat, Morocco;
2National Institute of Oncology-Rabat-Morroco, Department of Oncology Radiotherapy,
Rabat, Morocco
Background/Objectives: The aim of our study is to investigate the epidemiological,
clinical, radiological, therapeutic particularities of the nasopharyngeal carcinoma
(NPC) in children, and to determine prognostic factors correlated with outcome and
features of a series of 64 cases collected in the Pediatric Hematology Oncology Center
of Rabat.
Design/Methods: A total of 64 newly diagnosed NPC patients younger than 21 year old
in the Pediatric Hematology and Oncology Center of Rabat, from 2001 to 2010 were
retrospectively analyzed. Overall survival (OS) rate estimates and Kaplan–Meier
survival curves were calculated.
Results:Most patients were male (77%). Median age was 12 years. The main presenting
symptoms were neck mass (83%), tinnitus/hearing loss (61%), bloody nasal discharge
(50%), headache (53%), and nasal obstruction (36%). Stage I, II, III, IVA, IVB and IVC
patients accounted for 0%, 1%, 42%, 25%, 28%, 1% and 3%, respectively. All patients
were treated by neoadjuvant chemotherapy either. The complete response rate to
chemotherapy was 78%. All patients were treated by radiotherapy: 70 Gy to primary
tumors, 50 Gy to cervical lymph nodes and 70 Gy to lymphadenopathy. Locoregional
relapses were observed in 5 patients, with a median delay of 45 months from the end of
treatment (14-82 months). Local control was 92%. The 2-, 5- and 10- year overall
survival (OS) rates were 90%, 84% and 76%, respectively. Relapse-free survival (RFS)
was 94%, 84% at 5 and 10 years respectively. The main long-term complications of
therapy were trismus (59%), hearing loss (52%), xerostomia (50%) and neck fibrosis
(37%).
Conclusion: The majority of patients were diagnosed at the advanced stage. Children
and adolescents with NPC had excellent survival except metastatic disease. The TNM
stage was the most relevant prognostic factor.
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A RARE CASE OF CRIBRIFORM FLORID HYPERPLASIA IN MALE PATIENT
WITH BILATERAL GYNECOMASTIA: A MIMICKER OF FEMLAE
CRIBRIFORM IN SITU CARCINOMA?
R.S.S. Medeiros1, P.L.B.J. Meirelles1, S. Epelman1
1Santa Marcelina Hospital, Pediatric Oncology Department, Sao Paulo, Brazil
Background/Objectives: Bilateral gynecomastia is an uncommon condition that affects
male patients at puberty. Most of these cases are related to obesity and precocious
puberty which gynecomastia reverts only with clinical therapy or observation. Surgical
mastectomy is only indicated for aesthetic purpose or when malignancy is suspected by
radiologic findings. Bilateral breast in situ carcinoma is extremely rare in patients with
bilateral gynecomastia and few reports were recovered from scientific publications.
Design/Methods:We present a case of bilateral gynecomastia without previous diseases
or endocrinology abnormalities but treated obesity.
Results: A 16-years-old male patient was treated with surgical bilateral mastectomy
because of progressive bilateral breast augmentation since 6 years old and diagnosed as
bilateral cribriform low grade in situ carcinoma. He was admitted for second opinion
and additional adjuvant therapy. No remarkable clinical, androgenic and female
hormones as well as whole body computadorized tomography alterations were
detected. After pathological and immunohistochemistry evaluation, the final diagnosis
was bilateral florid cribriform ductal hyperplasia.
Conclusion: Despite bilateral in situ carcinoma in gynecomastia is uncommon; this
condition is far more commonly reported in literature than our case of cribriform florid
hyperplasia which there was only one case reported in literature. This reality imposes an
additional challenge for the diagnosis due to lack of histopathological criteria or solely
based on experience in female breast diseases. However, the bilaterallity, cribriform
pattern and cytokeratin 5/6 expression in young male patient favors benign condition
with favorable outcome.
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UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA IN CHILDREN: A
RETROSPECTIVE STUDY IN THE CENTER OF TUNISIA
B. Hanen1, N. Ammar2, I. Chabchoub2, O. Mammou Bellamlih2, F. Ezzairi2, I. Belaid2,
M. Hochlef2, O. Gharbi2, L. Ben Fatma2, N. Bouzid3, N. Bouaouina3, M. Abdelkafi4,
M. Mokni5, S. Ben Ahmed2
1Sousse, Tunisia; 2Farhat Hached Hospital, Medical Oncology, Sousse, Tunisia; 3Farhat
Hached Hospital, Radiotherapy, Sousse, Tunisia; 4Farhat Hached Hospital, ORL
Department, Sousse, Tunisia; 5Farhat Hached Hospital, Pathology Department, Sousse,
Tunisia
Background/Objectives: Nasopharyngeal carcinoma (NPC) occurs very rarely in
childhood. Children and adolescents are more likely to have advanced disease with
particularly lymph nodes metastasis but they have a significantly better chance of
survival. The risk of long-term treatment-related toxicity also may be a more important
issue in younger individuals.
Design/Methods: This is a retrospective study of 17 pediatric patients who were
diagnosed with undifferentiated nasopharyngeal carcinoma and treated at Farhat
Hached hospital from 1994 to 2013.
Results: The mean age at diagnosis was 13 years (10-17 years). The male to female ratio
was 1.4. The most common presenting symptom was neck swelling (82%). The mean
duration of symptoms before diagnosis was 3 months (1-9 months). Eight patients had
stage III disease (47%), 9 patients had stage IV disease (53%). All patients were treated
by chemotherapy (88% received neo adjuvant chemotherapy containing cisplatin, 12%
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palliative chemotherapy). Eighty two% of the patients were treated by radiotherapy at a
median dose of 67G (range from44Gy to 128Gy). The complete response rate was 53%.
On follow-up, 11 patients (64.7%) were still alive at last clinical contact. Five patients
(33%) developed distant metastasis; 4 were lost to follow-up and 02 died (12%). The
median overall survival was 40 months. The main long-term complications of therapy
were neck fibrosis (23.5%), xerostomia (100%) and growth retardation (23.5%).
Conclusion: The outcome of children with undifferentiated carcinoma improved over
the past 4 decades with the use of cisplatin-based chemotherapy and higher RT doses.
However, many survivors had long-term treatment-related morbidities.
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SUCCESSFUL LONG-TERM USE OF SORAFENIB IN PROGRESSIVE
PULMONARYMETASTASES IN PEDIATRIC PAPILLARY THYROID
CARCINOMA
S. Heine1, N. Graf1, T. Rohrer2, P. Fries3
1Saarland University Medical Center, Department of Pediatric Haematology and
Oncology, Homburg, Germany; 2Saarland University Medical Center, Department of
Pediatric Endocrinology, Homburg, Germany; 3Saarland University Medical Center,
Department of Diagnostic and Interventional Radiology, Homburg, Germany
Background/Objectives: Sorafenib has been studied in adult patients with advanced
thyroid cancer and prolonged their progressive-free survival. Reports on the use of this
substance in the pediatric population are scarce.Our objective is to present a young girl
with progressive metastases due to RAI-resistant PTC who achieved stable disease with
few side-effects with long-term use (4 years so far) of Sorafenib in adult dose.
Design/Methods: A twelve year old girl had been diagnosed with PTC 6 years
previously (TNM 2002) pT3N1bpM1 (pul). She underwent thyreoidectomy, neck
dissection, and eight courses of radioactive iodine, the final three courses after
retinoids. But pulmonary metastases progressed, thyreoglobulin increased and signs of
pulmonary insufficiency developed. Off-label use of Sorafenib was initiated in 5/2011,
200 mg once daily and step-wise increased to twice 400 mg after 6 months. Hematologic
side-effects were minimal, also cutaneous side-effects were mild (grade 1 hand / foot
syndrome). Due to cramping, diarrhea and weight loss, therapy was decreased to once
daily 400 mg after a year and increased again to the full dose after 5 months. Thereafter
minor reductions of the dose were necessary for a further few months, but for two years
now the patient has tolerated the full dose of 2 * 400 mg with hardly any side-effects.
Thyrotropin-suppressive therapy, calcium and calcitriol therapy were continued as
before.
Results: One month after initiation of Sorafenib the extensive pulmonary metastases
showed a mild reduction, thereafter we observed stable disease with MRI / CT.
Thyreoglobulin levels and thyreoglobulin antibodies have remained elevated without
significant decrease due to fluctuating values (thyreoglobulin 200 ng/ml - 75 ng/ml).
Conclusion: In a case of pediatric PTC with progressive pulmonary metastases and no
further RAI option Sorafenib con help to stabilize the disease with the adult dosage of
2 * 400 mg without severe side-effects.
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CASE REPORT: PERIVASCULAR EPITELIOID TUMOR UTERUS OF
CHILDREN 5 YEAR OLD
A. Hizhnikov1, O. Romantsova1, A. Kazantsev1, P. Kerimov1, O. Kapkova1,
D. Rybakova1, M. Rubansky1, M. Rubanskaya1
1Russian Cancer Research Center named Blokhin, Institute of Pediatric Oncology and
Hematology, Moscow, Russia
Background/Objectives: Perivascular epitelioid tumor (PEComa), a recently defined
tumor, is a very rare disease. These tumors have primitive mesenchymal tissue origin. It
is characterized by the presence of a peculiar population of myomelanotic
marker-positive perivascular epithelioid cells. They don’t have a specific visualization of
radiological diagnosis. Diagnosis is possible after the immunohistochemical analisis.
Tumor is commonly detected in the uterus. Tumor classified into the structure of a
typical pitch benign and malignant. The differential diagnosis is carried out with
epithelioid leiomyoma and leiomyosarcoma and endometrial stromal sarcoma with. All
the world maximum observation 161 cases of malignant uterus PEComas, 6 cases
described in children. Extremely unfavorable prognosis, with a median survival of less
that 2 years. Only surgical treatment for common cases possible to use radiotherapy,
whose don’t have been proven. No sensitivity to chemotherapy.
Design/Methods: From 2000 to the present in Federal State Scientific Institution
"Russian Cancer Research Center named. Blokhin " were 2 women with this diagnosis.
They received surgical treatment. On December in 2014, а 5-year-old girl with
abdominal pain and vaginal spotting was diagnosis with PEComa of the uterus with
metastasis in iliac lymphatic node. The girl underwent surgical treatment –
hysterectomy with appendages right to pre-embolization of vessels.
Results: After this treatment, there was no evidence of recurrence or further metastasis.
Conducted dynamic monitoring.
Conclusion: Surgery is the only effective treatment for perivascular epitelioid tumor.
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PROPRANOLOL AS A FIRST-LINE TREATMENT OF HEMANGIOMA:
SINGLE CENTER EXPERIENCE
D. Ince1, B. Demirag2, E. Toret2, Y. Oymak2, Y. Yaman2, G. Ozek2, T. Mese1,
C. Vergin2
1Dr Behcet Uz Children Hospital, Izmir, Turkey; 2Dr Behcet Uz Children Hospital,
Pediatric Hematology Oncology Clinic, Izmir, Turkey
Background/Objectives: Infantile hemangiomas (IHs) are the most common benign
vascular tumors in infancy. Spontaneous regression is expected in majority of IHs, so
watchful waiting is the best management. Currently propranolol has taken the place of
corticosteroids for the treatment of risky IHs. Herein we aimed to analyze our patients
with IHs treated with propranolol.
Design/Methods: There were 180 patients with diagnosis of IH, treatment was indicated
in 10.8% (n:19) of them, and these 19 patients received propranolol as a first-line
treatment between January 2012 - June 2014. Medical records of these 19 patients were
analized retrospectively. Clinical characteristics, physical examination findings,
treatment indications, treatment details, responses and side effects of propranolol were
analized retrospectively.
Results: The median age at diagnosis was 4.5months (1–15), and F/M ratio was 5.33.
The most common hemangioma localization was skin and head-neck region in 63% of
patients. Treatment indications were local complications (haemorrhage, ulceration,
infection) (42%), life threating organ dysfunction (37.6%) and relative indications
(26.3%). The median follow-up period was 19.5months (3-41). Pallor and partially
regression in hemangiomas were observed between the fourth and sixth weeks in all
patients. Complete remission occured in 13 patients, treatment is going on with partial
remission in remaining 6 cases. There was no observed side effects of propranolol.
Conclusion: Propranolol is a well-tolerated, efficacious, and safe drug for treatment of
IHs. It can be initiated and administered in the outpatient setting. Treatment
indications of IHs may become more flexible taking into account of the safety profile
of propranolol.
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A TERTIARY HOSPITAL EXPERIENCE OF CHEST WALL LESIONS IN
CHILDREN
S. Kabir1, H. Thakkar2, K. Lakhoo1, K. Wheeler3, S. Wilson3
1John Radcliffe Hospital, Paediatric Surgery Department, Oxford, United Kingdom;
2John Radcliffe Hospital, Paediatric Surgical Department, Oxford, United Kingdom;
3John Radcliffe Hospital, Department of Paediatric Oncology, Oxford, United Kingdom
Background/Objectives: Primary chest wall tumours originate from different
constructions of thoracic wall such as soft tissues, the bony thorax, or extra-pleural
region. These tumours are rare and the management of these lesions is challenging and
often controversial. We report our multidisciplinary experience in the management of
primary chest wall tumours.
Design/Methods: All patients, 16 years and under, who received treatment for chest wall
lesions were evaluated. The study period extended over 15 years from 2000-2014. Data
was obtained for demography, presentation, management, surgical technique and
outcomes.
Results: Primary chest wall tumours were noted in ten patients. There were seven female
and three male patients. The most common presentation was a mass. The pathology
included rhabdomyosarcoma, osteochondroma, lipoblastoma and ewing’s tumour. In
only three patients (30%) was the lesion benign. The most common site of distant
metastasis was lung (40%).Treatment included surgery alone (40%) and surgery with
neo-adjuvant/adjuvant treatment (60%). Reconstructive surgery was undertaken in two
patients. The postoperative recovery was mostly uneventful. One patient had a small
pneumothorax and two patients had muscle paresis, all of which were successfully
treated conservatively. The median hospital stay was 4 days (range 3-7). Disease free
survival was noted in eight patients (80%) to date. Two patients were not amenable to
curative surgery as they presented at a late stage with locally advanced disease and were
given palliative treatment leading to a mortality of 20%.
Conclusion: Chest wall tumours are rare and majority are amenable to surgical
resection. The morbidity associated with surgical resection is low. Delayed presentation
has a significant impact on the outcome.
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SIROLIMUS IN THE TREATMENT OF CHILDRENWITH DIFFERENT
COMPLICATED VASCULAR ANOMALIES
H. Lackner1, W. Schwinger1, M. Benesch1, P. Sovinz1, M. Seidel1, D. Sperl1, S. Lanz1,
E. Haxhija2, F. Reiterer1, E. Sorantin3, C. Urban1
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1Medical University of Graz, Department of Pediatrics and Adolescent Medicine, Graz,
Austria; 2Medical University of Graz, Department of Pediatric and Adolescent Surgery,
Graz, Austria; 3Medical University of Graz, Department of Radiology, Graz, Austria
Background/Objectives: Vascular anomalies comprise a heterogeneous group of
disorders that are categorized as vascular tumors (e.g. hemangiomas or
hemangioendotheliomas) or vascular malformations. Treatment options include
interventions such as resection, embolization, laser therapy and sclerotherapy or
medical treatment such as propranolol, steroids, interferon and cytostatic
chemotherapy. Mammalian target of rapamycin (mTOR) seems to play a key role in the
signal pathway of angiogenesis and subsequently in the development of various
vascular anomalies. The successful use of the mTOR inhibitor sirolimus has been
reported recently in children with lymphatic malformations and Kaposiform
hemangioendotheliomas.
Design/Methods: Six patients (4 males, 2 females) with different vascular anomalies
(Kaposiform hemangioendothelioma n=2, combined lymphatico-venous malformation
n=2, diffuse microcystic lymphatic malformation with pleural effusions n=1, and
orbital lymphatic malformation n=1 were treated with sirolimus in a dose of 0.1
mg/kg/day perorally. Diagnosis was established at birth in 4/6 children and at the age of
10 or 13 months, respectively. Three of the children initially had a Kasabach-Merrit
phenomenon (KMP).
Results:Median duration of treatment with sirolimus was 10 months (range 3 to 53
months), 2 children are still treated. Three children achieved complete remission, KMP
resolved within 2 months in all patients. Partial remission was seen in 3 children, in one
of them complete surgical resection of an orbital lymphatic malformation was
successfully performed after a 6- month pretreatment with sirolimus. Treatment with
sirolimus was tolerated well, only mild reversible leukopenia was observed.
Conclusion: Sirolimus proved to be effective in 6 children with complicated lymphatic or
lymphatico-venous malformations as well as in children with Kaposiform
hemangioendothelioma and KMP. Treatment was tolerated well with acceptable side
effects. More clinical data are needed to evaluate the optimum length of treatmen t and
possible long-term side effects.
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HEMAGIOPERICYTOMA AN UNUSUAL PRESENTATION AS NECKMASS IN
A NEW BORN CHILD CAUSING RESPIRATORY DISTRESS
R. Nerli1, A. Patil2, R. Nerli2
1Belgaum, India; 2KLE’S Dr. Prabhakar Kore Hospital-Belgaum-Karnataka,
Department of Urology, Belgaum, India
Background/Objectives: Cervical neoplasm in the child giving rise to obstectric
emergency is a rare entity. More commonly cervical teretoma nasopharyngeal tertomas,
dermoids the congenital goitres and cystic hygroma are the diagnosis. We operated a
new born child with neck swelling presenting with respiratory distress.
Histopathological diagnosis of the swelling was hemangiopericytoma. This is a very
rare entity.
Design/Methods: Primigravida was referred to our obstectric department with fetal
distress at full term. Caesarean section was done to deliver a male infant. The new born
showed signs of severe respiratory distress with neck swelling. He was incubated and
resuscitated, CT scan showed a large homogenous mass compressing the trachea and
oesophagus. Chest X-ray showed pulmonary edema. All other parameters were within
normal range. On exploration a well defined homogenous mass was completely excised.
Post operative recovery was uneven full. HPR showed haemangiopericytoma. The child
is on regular follow up.
Results: Respiratory insufficiency in immediate new born is an emergency requiring
multidisciplinary action prompt intervention by the neonatologist is life saving. In our
patient C-section immediate incubation correction of acidosis and fluid resuscitation
gave the infant the fighting chance. Hemangiopericytoma is very rare and often
multicentric vascular tumour most commonly found at retrophyranx, distal index finger
and buttocks. In all around 224 cases have been discussed in literature. It is believed to
be potentially malignant though the growth rate is slow. The recurrence is 80% when
involving central nervous system as compared to 41% to other organ systems. Surgical
excision is the treatment of choice with radiotherapy showing promise.
Conclusion: This case is unusual because of site and presentation of the disease.
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ANGIOMATOID FIBROUS HISTIOCYTOMA: A CASE OF LOCAL
RECURRENCE ANDMETASTASES THAT RESPONDED TO
CHEMOTHERAPY
S. Ogden1, S. Harave2, B. Brennan3, L. Jeys4, J. McPartland5, B. Pizer1
1Alder Hey Children’s Hospital, Oncology, Liverpool, United Kingdom; 2Alder Hey
Children’s Hospital, Radiology, Liverpool, United Kingdom; 3Royal Manchester
Children’s Hospital, Oncology, Manchester, United Kingdom; 4Royal Orthopaedic
Hospital Birmingham, Orthopaedic Oncology, Birmingham, United Kingdom; 5Alder Hey
Children’s Hopital, Pathology, Liverpool, United Kingdom
Background/Objectives: Angiomatoid Fibrous Histiocytosis (AFH) is a rare soft tissue
tumour of intermediate malignant potential that most commonly occurs in the dermis
or subcutaneous tissues in children and young adults. AFH is usually successfully
treated with wide local excision. Local recurrence is unusual (10 % cases) and very
rarely (<2%) distant metastases can occur. There is only one previous report of
response to chemotherapy. We report a child with AFH who relapsed both locally and
with lymph node metastases who showed a good response to chemotherapy.
Design/Methods: A 3-year-old boy presented with a painless firm lump within the flexor
surface of the right forearm, MRI scanning demonstrating a 1.9×1.5×1.5cm
subcutaneous mass. Complete surgical excision was performed with a histological
diagnosis of AFH, positive for EWS-CREB1 fusion gene.
Results: 18 months later, he developed a right axillary lymph node mass. Axillary
clearance was performed with nodes showing AFH metastases. MRI demonstrated four
lymph nodes in the upper arm and two nodes at the elbow. Within the forearm there
were signs of local recurrence with two masses with a maximal diameter of 12 and 15
mm respectively.Surgery was felt to carry a high risk of morbidity. He was thus treated
with chemotherapy, receiving six cycles of ifosfamide and Doxorubicin according to the
EpSSG non-RMS Study. MRI following four cycles of chemotherapy showed a clear
response of the two areas of local recurrence and also of all of the affected nodes. An
MRI after six courses showed further response. He received three additional courses of
single agent ifosfamide and will now be observed closely with frequent scans.
Conclusion: This case confirms that children with AFH may rarely develop lymph node
metastases. Furthermore, we report that metastatic AFH may respond to
chemotherapy, and this modality should be considered in the treatment of metastatic or
unresectable cases.
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CARDIOPULMONARY BYPASS SURGERY OF COMPLICATED GIANT
TUMORS OF THE ABDOMEN AND RETROPERITONEUM IN CHILDHOOD
I. Shchepotin1, I. Yemets2, G. Klymnyuk3, A. Lukashenko1, O. Ijovskyi3, M. Stezhka3,
E. Protsenko2
1National Institut of Cancer, Abdominal Oncological Surgery, Kyiv, Ukraine; 2The
Scientific-Practical Children’s Cardiac Center, Government Institution, Kyiv, Ukraine;
3National Institut of Cancer, Pediatric oncology, Kyiv, Ukraine
Background/Objectives: Surgical treatment is one of the main stages of the combined
treatment in children with solid tumors that directly prognosis the good long-term
results.
Design/Methods:Were made 8 of surgical interventions for children with solid tumors
with the use of cardiopulmonary bypass. The selection of patients for surgery with the
use heart-lung machine was performed on the inclusion criteria: the presence of a
complicated giant tumors of the abdomen and retroperitoneum with a high risk of fatal
bleeding; a thrombus in the inferior vena cava and/or right atrium; the presence of
concomitant heart disease requiring surgical correction.
Results: Radical nephrectomy was performed four patients with nephroblastoma in
conditions of artificial circulation: in one of them simultaneous operation is performed
with the removal of tumor thrombus fixed right atrium and another one - with the
removal of floating thrombus of the inferior vena cava and right atrium, in another
patient due to tumor invasion into the splenic artery and vein was performed radical
nephrectomy with splenectomy. One patient was performed with left lateral segment
liver resection with a complex two-stage correction of complex congenital heart defect;
one patient with malignant paraganglioma performed a left adrenalectomy with
simultaneous operation for removal of tumor thrombus of the inferior vena cava and
right atrium and one patient underwent removal of a giant malignant neurosarcoma in
the retroperitoneal space and pelvis. Long-term results of treatment: 3 patients have
died due to disease progression, 2 of them patients with Wilms tumor, other one patient
with a malignant paraganglioma.
Conclusion: The use of cardiopulmonary bypass surgery complications giant solid
tumors in children allows to perform most difficult surgical procedures with which were
considered earlier, unresectable tumors achieving good long-term result of the
combination treatment.
P-488
PEDIATRIC GASTRIC CANCER PRESENTINGWITHMASSIVE ASCITES
C.H. Lin1, W.C. Lin2,3, I.H. Lai1, S.F. Wu1, K.H. Wu1, F.J. Tsai1,4, C.H. Tsai1,4,
C.T. Peng1,4, A.C. Chen1
1China Medical University, Children’s Hospital, Taichung, Taiwan; 2China Medical
University Hospital, Radiology, Taichung, Taiwan; 3China Medical University, College of
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Medicine-School of Medicine, Taichung, Taiwan; 4Asia University, Biotechnology,
Taichung, Taiwan
Background/Objectives: Gastric adenocarcinoma is rare cancer case in children, so a
few cases had been reported with the complete clinical procedure in Taiwan.
Design/Methods: In this case, a16-year-old boy felt abdominal fullness with a poor
appetite for 7 days. We used the Sonography, Computed tomography (CT) imaging to
discover the gastric mucosa thickness with omentum caking and diagnosed his gastric
adenocarcinoma by endoscopic biopsy.
Results: Gastric adenocarcinoma was proven on a 16 yr young boy and the finding is
rare in the pediatric population.
Conclusion: Even the incidence of gastric adenocarcinoma is very rare in pediatric
patients. Based on the change of modern diet habits, we should pay more attention
focus on the possibility on gastric cancer when a child presents the symptoms of
distended abdomen and massive ascites.
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DESMOID TUMORS IN CHILDREN
I.Z. Reiman1, A. Tarasik2
1National Research Center for Pediatric Oncology-Hematology and Immunology, Minsk,
Belarus; 2National Research Center for Pediatric Oncology-Hematology and
Immunology, Surgery Department, Minsk, Belarus
Background/Objectives: Desmoid tumors (DT) are locally aggressive tumors with no
known potential for metastasis. However, tumor invasion into vital structures can result
in substantial morbidity and may be even fatal. DT are account for about 0.03 percent
of all neoplasms and less than 3 percent of all soft tissue tumors. Clinical behavior and
recommended treatments are often dictated by anatomic site.
Design/Methods: Long-term results of treatment in Pediatric DT patients (pt) were
evaluated in the Republic of Belarus from 1996 to 2013. A total of 40 children (boys-23,
girls-17) with median age of 7,7 years (range 1-16) were treated and 39 of them
underwent tumor excision and 1 -tumor biopsy. Tumor sites were: pelvic area- in 18 pt,
lower extremity (ex)-8, upper ex-2, abdomen-5, head & neck-3 and others-4.
Radiotherapy was given in 14 patients including 6, who received radiotherapy with local
electromagnetic hyperthermia. Chemotherapy (usually vinblastin+metotrexate) was
administrated in 10 cases, 6 of them additionally received tamoxifen. Tamoxifen
without chemotherapy was given in 4 patients as well.
Results: In 14 pts tumor relapsed, particularly in 5 pts two and more times during 12
months after wide excision. Conservative treatment curried out in 10 pts with non
operable relapsed tumors. PR registered in 1 pt, SD- 8 and PD-1 with Gardner
syndrome who died. 39 pts are alive. Ten years overall and relapse-free survival rate
were 94 % and 49% respectively (follow up 74 months).
Conclusion: Our results based on considerable number of patients suggest that radical
surgical excision is the method of choice in the treatment of DT patients. Additional
chemo, radio as well as hormone therapy could be used in locally advanced and
recurrent forms of disease.
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A CASE REPORT: ANGIOMATOID FIBROUS HISTIOCYTOMA IN A
5-YEAR-OLD GIRL AND REVIEW OF THE LITERATURE
J. Reyes-Kattar1, R. Duran2, E. Ross3, S. Romero4, M.C. Gómez1, Y. Millán1,
A. Pereira1
1Hospital de Niños JM de Los Ríos, Servicio de Oncología Pediátrica, Caracas,
Venezuela; 2Centro Médico Docente La Trinidad, Servicio de Tumores Óseos, Caracas,
Venezuela; 3Hospital de Niños JM de Los Ríos, Servicio de Anatomía Patológica,
Caracas, Venezuela; 4Centro Médico Docente La Trinidad, Anatomía Patológica,
Caracas, Venezuela
Background/Objectives: Angiomatoid fibrous histiocytoma (AFH) is a rare disease that
is often misdiagnosed initially, accounting for approximately 0.3% of all soft tissue
tumors. Although predominantly occurring in children and and young adults, the age
distribution is wide. There is a slight female predilection. The tumor usually presents as
a slowly growing mass within the deep dermis and subcutis, although deep-seated
lesions have been described. It most often arises within the extremities but can also
occur on the trunk or neck. Surgery remains the mainstay of management, and can
effectively control local recurrences and metastases. Herein we describe a case report of
a 5-year-old girl whose presentation was concerning for lypoma. Subsequently we
review of the relevant literature.
Design/Methods: An 5 year-old girl presented with a painless mass in her right arm for
2 months without constitutional symptoms. Physical exam demonstrated a mobile,
nontender, palpable mass along the lateral aspect of the right arm without erythema or
soft tissue swelling. The patient underwent en bloc surgical excision, whose biopsy
reported AFH. The patient had local recurrence 9 months after the operation. Tumor
excision biopsy (wide resection) was performed which reported AFH with disease-free
margins. Two months after the operation presents new local relapse, so we decided to
meet Radiotherapy (currently serving treatment).
Results: AFH is a rare soft tissue tumor most commonly occurring in children,
adolescents, and young adults. Surgery alone with a wide local excision can be utilized
to establish local control; however, in cases where a marginal excision is planned,
radiation therapy should be utilized to maximize control.
Conclusion: AFH is a rare disease that is often misdiagnosed initially. The diagnosis of
AFH is made based on histopathology and immunohistology Radiotherapy may be
utilized when wide excision margins are not feasible. AFH does have low potential for
metastasis.
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GESTATIONAL TROPHOBLASTIC NEOPLASIA WITH RESIDUAL LUNG
MASSES AFTER CHEMOTHERAPY
B. Rowe1
1Alberton, South Africa
Background/Objectives: Clinical Details.
Design/Methods: A sixteen year old girl presented with cough, abdominal pain and
vaginal bleeding. She had a spontaneous abortion 3 months before. Examination was
significant for pallor and abdominal masses. Blood investigations revealed a
haemoglobin of 4g/dl and a B-HCG of 424 846 IU/L. An abdominal ultrasound
showed a bulky uterus with no foetus and a large left adnexal mass. Chest X-ray showed
cannon-ball lesions. Splenic lesions were seen on CT-scan. A diagnosis of Gestational
trophoblastic neoplasia, high risk, was made – FIGO stage IV, prognostic score 8. She
developed uncontrolled vaginal bleeding which necessitated surgery. A fungating mass
was found, extending through the myometrium into the left adnexa. The tumour was
confirmed as a gestational choriocarcinoma. She was treated with chemotherapy until
the BHCG normalised and for 6 weeks thereafter. Post-treatment CT scan was
significant for residual lung masses. She was in marker remission with a BHCG of 1.
She was followed up clinically without removal of the lung masses. Four months post
treatment she remains in marker remission and the lung lesions are unchanged in size.
Results: Discussion.
Conclusion: Gestational trophoblastic disease (GTD) refers to a range of
pregnancy-related disorders with abnormal trophoblast proliferations. Benign GTD’s
include complete and partial hydatidiform moles and malignant GTD’s include invasive
moles, choriocarcinoma and placental site trophoblastic tumour. The diagnosis of
GTD is made on combined clinical and radiological findings in the setting of a rising or
plateauing level of BHCG post pregnancy as biopsy is deemed too dangerous owing to
the vascularity of the tumours. The FIGO prognostic scoring system separates low risk
patients (0-6) from high-risk patients (7). High risk patients, including all
choriocarcinomas, are treated with multiagent chemotherapy. Five-year OS vary
between 75-90%. Residual masses post-treatment in patients with marker remission
likely represent non-viable tissue and should not be removed.
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PLEOMORPHIC LIPOMA NECK IN A 10 MONTH OLD CHILD : A RARE
CLINICAL ENTITY
R. Samujh1, N. Peters2, A. Chhabra2, A. Das3, P. Uthamalingam4
1Chandigarh, India; 2Pgimer Chandigarh, Pediatric Surgery, Chandigarh, India; 3Pgimer
Chandigarh, Pathology, Chandigarh, India; 4Pgimer Chandigarh, Pathology,
Chandigarhin, India
Background/Objectives: Neck masses are not uncommon in children and commonly
include congenital lesions and their complications. Other masses include
lymphadenopathy, vascular, inflammatory, infectious and malignant lesions. Lipomas
are rare in children. We report the first case of Pleomorphic Lipoma in the paediatric
population in world literature.
Design/Methods: Ten month old male child presented with a lump on the right side of
the neck noticed for 3 -4 days. No constitutional symptoms were present. On
examination a 5×4 cm lump noted in the right lower cervical region which was non
tender, firm in consistency, slight mobile in lateral directions and the overlying skin was
normal. Contrast Enhanced Computed Tomography (CECT) neck showed a well
defined heterogeneously enhancing mass measuring 4.3×4.5×2.7cm (CC x AP x TR) in
the right posterior triangle of the neck with few hypodense areas within it. Fine needle
aspiration cytology was inconclusive.
Results: Complete excision of mass under general anaesthesia was done.
Histopathology showed lipomatous tumor with spindle cells. The higher magnification
showed multinucleated floret cells and bizarre cells. The tumor cells were positive for
CD 34 immunohistochemically. At one year follow up the patient is doing well with no
recurrence.
Conclusion: Pleomorphic lipoma is a disease of older men not previously reported in
children. The treatment includes complete excision of the mass with regular follow up.
It may be considered as a differential in large insidious neck masses.
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STEPS TOWARDS AN EUROPEAN VIRTUAL TUMOR BOARD FOR VERY
RARE TUMORS— REPORT FROM THE EUROPEAN COOPERATIVE STUDY
GROUP ON PEDIATRIC RARE TUMORS AND EXPO-R-NET PROJECT
D.T. Schneider1, A. Ferrari2, E. Bien3, I.B. Brecht4, B. Brennan5, G. Cecchetto6,
J. Godzinski7, F. Hippert1, T. Stachowicz-Stencel3, D. Orbach8, Y. Reguerre9,
R. Ladenstein10, G. Bisogno11
1Klinikum Dortmund, Clinic of Pediatrics, Dortmund, Germany; 2Istituto Nazionale
Tumori, Pediatric Oncology Unit, Milano, Italy; 3Medical University of Gdansk,
Department of Pediatrics-Hematology-Oncology and Endocrinology, Gdansk, Poland;
4University of Erlangen, Clinic of Pediatric Oncology and Hematology, Erlangen,
Germany; 5Royal Manchester Childrens Hospital, Department of Paediatric Oncology
and Haematology, Manchester, United Kingdom; 6University of Padova, Pediatric
Surgery, Padova, Italy; 7Wroclaw Medical University, Wroclaw, Poland; 8Institut Curie,
Department of Paediatric Oncology, Paris, France; 9CHU Saint Denis de La Réunion,
Pediatric Oncology, Reunion, France; 10St. Anna Spital, Children Cancer Research
Institute, Vienna, Austria; 11University of Padova, Pediatric Oncology and Hematology,
Padova, Italy
Background/Objectives: EXPO-r-NeT is an international EU-funded project. Among
other activities, EXPO-r-NeT aims to improve access to qualified care for children with
very rare tumors (VRT) by intensified networking between pediatric oncology centers
and national study groups. Based on the activities of the recently founded EXPeRT, a
tumor board structure shall be developed. Here, we report on the national and
international consultation activities of EXPeRT and its national partners.
Design/Methods: The EXPeRT group has developed a structure for consultation
activities. International consultations regarding particularly rare or complicated cases
are centrally coordinated (expert-advice@klinikumdo.de), using a specific consultation
request form. Between October 2014 and February 2015, the national coordinators
reported all national and international consultations to EXPeRT.
Results: In this 5-month period, the national VRT boards and the EXPeRT board
responded to 143 consultation requests. 48 requests were international, either within the
EU (n=24) or from pediatric oncologists outside of the EU (n=24). Between the
national groups, the panel of diagnoses varied according to the scientific focus of the
group, with a high proportion of very rare sarcomas in France or Italy, and
non-germ-cell gonadal tumors in Germany. 24 patients have been discussed within the
complete EXPeRT panel and/or with associated experts for specific entities.
Conclusion: There is a continuous demand of consultation regarding pediatric VRTs.
With the increasing visibility of the EXPeRT group, increasingly more requests from
EU and non-EU states are seen. Approximately, 80% of consultation requests can be
solved at the national level. For particularly rare and difficult cases, an IT-based
consultation platform is currently established, which will allow a thorough discussion
of the patients. In addition, recommendations for diagnosis and treatment are currently
consented to assist pediatric oncologists in clinical management. ExPO-r-Net is funded
by the European Union in the framework of the Health Programme (2008-2013), grant
201312 07.
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THYMUS TUMORS IN CHILDREN: A REPORT FROM THE EUROPEAN
COOPERATIVE STUDY GROUP FOR PEDIATRIC RARE TUMORS (EXPeRT)
T. Stachowicz-Stencel1, D. Orbach2, I. Brecht3, D. Schneider4, E. Bien5,
A. Synakiewicz6, R. Julien7, A. Ferrari8, G. Cecchetto9, G. Bisogno10
1Medical University of Gdansk, Gdansk, Poland; 2Institut Curie-Paris-France,
Department of Pediatrics Adolescent Young Adults, Paris, France; 3University Children’s
Hospital Erlangen-Germany, Pediatric Hematology and Oncology, Erlangen, Germany;
4Municipal Hospital Dortmund- Germany, Clinic of Pediatrics, Dortmund, Germany;
5Medical University- Gdansk-Poland, Department of Pediatrics-Hematology and
Oncology, Gdansk, Poland; 6Medical University of Gdansk-Poland, Department of
Pediatrics-Hematology and Oncology, Gdansk, Poland; 7University of Caen
Hospital-France, Department of Pediatric Surgery, Caen, France; 8Fondazione IRCCS
Istituto Nazionale Tumori- Milano- Italy, Pediatric Oncology Unit, Milano, Italy;
9Padova University Hospital-Padova-Italy, Pediatric Surgery Unit-Department of
Woman’s and Child’s Health, Padova, Italy; 10Division of Hematology-Oncology,
Department of Woman’s and Child’s Health-University Hospital of Padova-Italy, Padova,
Italy
Background/Objectives: Background: Thymomas and thymic carcinomas are extremely
rare in children in which no therapeutic guidelines has been established.
Design/Methods:Methods: Retrospective analysis of clinical data and therapeutic
characteristics of pediatric patients till 18 year with thymus tumors treated in years
2000-2012 and registered in the EXPeRT database of the cooperating national rare
pediatric tumors working groups from France, Italy, Germany, and Poland.
Results: Sixteen children with thymoma (median age 11 y) and 20 patients with thymic
carcinoma (median age 14 y) were included into study. At diagnosis R0- in 11 patients
with thymoma and one with thymic carcinoma; R1- in 3 cases and R2- in 4 patients.
Chemotherapy was administered to 22 children (17-neoadjuvant chemotherapy). Eight
patients with thymic carcinoma received additional radiotherapy. 17 patients died (15-
thymic carcinoma, 2 -thymoma). Five-year OS for patients with thymic carcinoma is
21.0±10.0%.
Conclusion: Thymoma is the tumor with good prognosis but thymic carcinoma has very
poor prognosis independent of multimodal management. Multidisciplinary,
multicenter approach and collaboration with adults’ physician are necessary in order to
propose homogenous guidelines.
P-495
MALIGNANTMELANOMA IN CHILDREN: ETIOLOGY, TREATMENT, AND
PROGNOSIS
A. Varan1, O. Gokoz2, F. Ozgur3, B. Aydin1, B. Yalcin1, N. Kurucu1, T. Kutluk1,
C. Akyuz1
1Hacettepe University-Institute of Oncology, Pediatric Oncology, Ankara, Turkey;
2Hacettepe University-Faculty of Medicine, Pathology, Ankara, Turkey; 3Hacettepe
University-Faculty of Medicine, Plastic and Reconstructive Surgery, Ankara, Turkey
Background/Objectives: To evaluate the etiology, treatment and prognosis of the
malignant melanoma in children.
Design/Methods: Twentyone patients who had been diagnosed with malignant
melanoma between 1972 and 2015 were retrospectively analyzed. Age range was 0.5-14
years (median: 8), male/female ratio was 13/8. Staging was done according to AJCC.
High dose interferon, or CDDP based regimens have been used.
Results:We could define the etiologic factors in only 5 (23.8%) patients. In three
patients malignant melanoma occurred within the area of Giant hairy cell nevus, one
melanoma patient previously had bone marrow transplantation due to Gricelli
syndrome, one patient also had Xeroderma pigmentosum.Tumors were located in head
and neck (7), trunk (5), ocular (2), upper extremity (2), lower extremity (2), and
intracranial (1). Tumor location was not detected in two patients. Stage distributions
were 0 (1), I (1), II (5), III (6), and IV (6). The stage was not defined in two patients. Six
patients did not require treatment due to low stages. High dose interferon was given to 9
patients. Three patients were treated with cisplatin based protocols, and three with
other chemotherapeutic regimens. Five patients died with disease progression. Overall
survival was 75%, whereas event-free survival rate was 70%. Prognostic factors on
survival were treatment with interferon (p=0.001) and metastatic disease (p=0.01).
Conclusion:Malignant melanoma is rare tumor in childhood period. Metastasis is the
worst prognostic factor. Melanoma patients were treated successfully with high dose
interferon in our series.
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CARCINOID TUMORS IN CHILDREN: HACETTEPE EXPERIENCE
B. Yalcin1, T. Kutluk1, I˙. Karnak2, D. Orhan3, H. Susam Sen1, M. Haliloglu4, B. Aydin1,
A. Varan1, M. Buyukpamukcu1
1Hacettepe University Faculty of Medicine, Pediatric Oncology, Ankara, Turkey;
2Hacettepe University Faculty of Medicine, Pediatric Surgery, Ankara, Turkey;
3Hacettepe University Faculty of Medicine, Pediatric Pathology, Ankara, Turkey;
4Hacettepe University Faculty of Medicine, Radiology, Ankara, Turkey
Background/Objectives: Carcinoid tumors (CT) are rare in children. We aimed to review
our institutional experience to document their distribution, clinical presentation,
treatment and follow-up data.
Design/Methods: Among 10000 children with cancer diagnosed between 1972-2014, we
identified 20 CT cases (0.2%). Data regarding age and sex, initial symptoms, physical
examination findings, radiologic and other laboratory data, surgeries, treatment
approaches and outcomes were noted.
Results:Median age of 20 children was 13.5 years (7-16; male/female: 8/12). Primary
tumors were located in appendix in 16 cases, in main bronchi (n=2), in left lower lung
(n=1), in ileum (n=1). All 16 cases with appendiceal CT presented with abdominal
pain, 4 had fever, 3 had vomiting; preoperative diagnoses were acute appendicitis in 15
and ovarian mass in 1. Histopathological examination of surgical specimens revealed
invasion of submucosa in 7, tunica muscularis in 7, serosa in 6 cases; median tumor size
was 0.8 cm (0.2-2 cm). Fourteen cases had no evidence of recurrence at a median
follow-up of 8 years, 2 cases were lost to follow-up. A 7-year-old boy had a CT of the
ileum with abdominal dissemination, ileocolectomy was performed, but he died with
progressive disease despite chemotherapy. Two cases with CT of main bronchi were
admitted due to cough, hemoptizis, fever and pneumonia, both tumors were resected.
The boy who had a positive lymph node received chemotherapy, both cases are
disease-free for 13 and 14 years. The adolescent boy with a pulmonary CT and Cushing
syndrome findings underwent tumor resection. None of the cases had carcinoid
syndrome symptoms.
Conclusion: No clinical or laboratory findings suggestive of CT were evident in children
with appendiceal CTs pre- or postoperatively; none necessitated further intervention or
treatment. Localized CTs in children were mostly curative with surgical resection.
Pediatr Blood Cancer DOI 10.1002/pbc
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Prognosis is poor for patients with metastatic disease, who might need novel therapeutic
strategies.
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USEFULNESS OF LONG TERM FOLLOW-UP FOR THE CHILDHOOD
CANCER SURVIVOR - A CASE OF PEDIATRIC THYROID CARCINOMA
FOLLOWING THE TREATMENT OF NEUROBLASTOMA
M. Yasui1, M. Sato1, K. Higuchi1, A. Mayumi1, M. Shimizu1, A. Sawada1, Y. Etani2,
M. Nakacho2, M. Inoue2
1Osaka Medical Center and Research Institute for Maternal and Child Health,
Hematology/Oncology, Izumi, Japan; 2Osaka Medical Center and Research Institute for
Maternal and Child Health, Pediatric Gastroenterology-Nutrition and Endocrinology,
Izumi, Japan
Background/Objectives: Neuroblastoma(NBL) is one of the most frequent solid tumor
and mass screening had used to be performed at six months in Japanese children.
Recently, lomg term follow-up(LTFU) is very important for heavily treated childhood
cancer survivor(CCS) because of late complications such as endocrine disorder,
metabolic disease, second cancer and so on.
Design/Methods:We present a case of pediatric thyroid carcinoma diagnosed 12 years
after the treatment for infantile NBL.
Results: The patient is a 12-year-old girl with a history of infantile NBL with Horner’s
syndrome diagnosed in 6 months of age. She had no family history of thyroid disorders
and underwent chemotherapy, surgical resection and autologous bone marrow
transplant (aBMT) with high dose chemotherapy at 10 months of age. After aBMT, she
achieved VGPR because of residual tumor with no signs of tumor marker elevation.
LTFU was started in January 2012 between two departments of Pediatrics. Two years
later at 12 years of age, a large mass was noted in the left thyroid. Since other laboratory
findings were within normal, she underwent thyroid tumor resection. Pathological
diagnosis revealed papillary carcinoma of thyroid with metastatic lymph node. After
the operation, she is receiving l-thyroxin for hypothyroidism and is well doing.
Conclusion: There are no adequate studies to draw conclusions about treatment for
children with thyroid cancer. We emphasize the importance of LTFU in cooperation
with at least the two specialized department in CCS.
Posters: Renal Tumours
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PROFILE AND OUTCOME OFWILMS’ TUMOR PATIENTS AT THE
UNIVERSITY OF THE PHILIPPINES-PHILIPPINE GENERAL HOSPITAL
(UP-PGH): A RETROSPECTIVE STUDY (2008 - 2014)
J. Estanislao1, J.P. Caneba1, J. Castro2, E. Saguil2, M.J. Avila3, A.P. Alcasabas1
1Philippine General Hospital, Pediatrics, Manila, Philippines; 2Philippine General
Hospital, Surgery, Manila, Philippines; 3Philippine General Hospital, Pathology, Manila,
Philippines
Background/Objectives:Wilms’ tumor (WT) is highly curable with appropriate
multimodality treatment. At Philippine General Hospital, the country’s national
referral center, radiation, surgery and chemotherapy are available but survival rates for
solid tumors remain low. We reviewed our WT experience and outcomes.
Design/Methods:Medical records of newly-diagnosed patients with WT from January
2008 to December 2014 were reviewed. Treatment outcome was determined at study
endpoint, February 2015.
Results: Thirty-nine children with WT were seen, ages 0.3-9 years (mean 3.1). M:F ratio
1.05:1. All were unilateral. Twenty-four (61.5%) treated with NWTS V and upfront
nephrectomy. Five had lymph node sampling (LNS) and 2 tumor spillage. Post-surgical
staging: stage I (n=2), stage II (n=1), stage III (n=2), stage IV (n=1) and no LNS
(n=18). Pathology: favorable (n=14), unfavorable (n=1), unspecified (n=8) and
blastemal (n=1). Four (16.7%) received radiation. Fifteen patients (38.5%) underwent
neo-adjuvant chemotherapy due to unresectable tumor (n=8) and as per SIOP regimen
(n=7), adopted in March 2014. Thirteen (86.7%) had nephrectomy after 5-22 weeks of
chemotherapy (mean 9.9), 1 abandoned and 1 unresectable. Six had LNS and 1 tumor
spillage. Post-surgical staging: stage I (n=2), stage II (n=0), stage III (n=6), stage IV
(n=4) and no LNS (n=2). Pathology: favorable (n=3), unspecified (n=3), necrosis
(n=3), blastemal (n=4) and mixed type (n=1). Five (38%) received radiation. At study
endpoint, 20 (51.3%) completed treatment: 13 in remission, 6 lost to follow-up and 1
relapsed. Eight (20.5%) abandoned treatment. Eight (20.5%) died due to disease (n=7)
and toxic death (n=1). Two (5.1%) have progressive disease. One (2.6%) on-going
treatment. The overall survival (OS) rate at 63 months is 71.4% and 54.7% with
abandonment as an event.
Conclusion: Abandonment of treatment, incomplete staging and therapy contribute to
poor WT outcome. Knowledge of the treatment protocol and close coordination
between subspecialties will help improve survival.
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HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN SOUTH AFRICAN
CHILDREN TREATED FORWILMS TUMOUR: PREVALENCE, RISK
FACTORS AND OUTCOMES
A. Andrade1, R. Wainwright2, G. Naidu2
1Red Cross War Memorial Children’s Hospital, Haematology/Oncology, Cape Town,
South Africa; 2Chris Hani Baragwanath Hospital, Haematology/Oncology,
Johannesburg, South Africa
Background/Objectives:Wilms Tumour (WT) is one of the commonest tumours in
children. Hepatic Sinusoidal Obstruction Syndrome (HSOS) is a documented
complication following treatment of WT but the role of malnutrition in the
development of HSOS has not been studied. Malnutrition reduces tolerance to
chemotherapy and increases the risk for toxicity. This study aims to determine the
prevalence, predisposing factors and outcomes of HSOS in children with WT.
Design/Methods: Descriptive retrospective analysis of medical records of children
treated for WT, who developed HSOS, at the Paediatric Haematology/Oncology Unit,
Chris Hani Baragwanath Hospital.
Results: Eighty two patients were evaluated. Utilising the MacDonald’s criteria, 19
patients (23%) had 21 episodes of proven HSOS and 13 episodes of suspected HSOS.
Irradiation (OR 0.5; 95% C.I. 0.25- 1.98; P= 0.5) and a right-sided WT (OR 0.65; 95%
C.I. 0.21- 1.9; P= 0.73) predicted the development of HSOS but were not statistically
significant. Serum albumin levels were lower in the affected group (P = 0.02), but these
patients were not more malnourished according to Z-scores. Apart from 2 deaths,
outcomes were good, with all other patients showing full resolution of symptoms.
Conclusion: A higher prevalence of HSOS was shown than previously reported.
Traditional risk factors showed a trend towards significance. Low serum albumin levels
may reflect a child’s overall nutritional status, however as an acute phase reactant its use
as a biochemical marker of malnutrition may have limitations. Further study of the role
of nutrition is warranted.
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EXPRESSION OF PODOPLANIN IN PAEDIATRIC RENAL TUMOURS
S. Barman1, U.R. Singh1, K. Mishra1
1University College of Medical Sciences and Guru Teg Bahadur Hospital, Pathology,
New Delhi, India
Background/Objectives: High stage renal tumours have a worse prognosis as compared
to stage I and II tumours, the prognosis being best in stage I. There are studies on
lymphatic spread in adults with renal renal cell carcinoma. However metastasis by
lymphatics in Wilms tumour and other renal tumours in children has not been
adequately studied. In this study we analyzed the lymphatic distribution in these
tumours by immunostaining for lymphatic marker D2-40.
Design/Methods: A cross-sectional, observational study was conducted in the
department of pathology in a general hospital of east Delhi, India.
Immunohistochemistry with D2-40 antibody was performed and lymphatic density was
counted (in twenty two cases of paediatric renal tumours) within the tumour, in the
renal capsule and sinus area. This was correlated with stage and type of the tumour.
The findings were compared to twenty two cases of adult renal tumours.
Results: Using the Mann-Whitney U test significant difference was observed in
peritumoural lymphatic density in the capsule (p value=0.009) and sinus (p
value=0.024) of kidneys with tumors in adults and children, the values being
significantly higher in the adult patients. Spearman’s rho for correlation between
increasing age and intratumoural lymphatic density was significant (p value=0.042).
Conclusion: The higher peritumoural lymphatic density in adult tumours may either be
due to increase in number of lymphatics with age or indicate increased secretion of
lymphangiogenic cytokines by adult tumours (renal cell carcinoma) as compared to
paediatric renal tumours. The increase in intratumoural lymphatic density with age also
reflects on the increased potential for metastasis in older children as reported in
literature. However these findings are preliminary and need confirmation on a larger
sample.
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MALIGNANT RENAL TUMOURS IN SINGLE INSTITUTION,
SINMALIGNANT RENAL TUMOURS IN SINGLE INSTITUTION,
SINGAPOREGAPORE
K.T. D1, S.Y. Soh1, A.M. Tan1, H.Y.J. Chua2, Q.C.F. Chin3, Y.H.J. Teh3, M.Y. Chan1
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Singapore, Singapore
Background/Objectives: Renal tumours represent 7% of childhood malignancies. This
study retrospectively reviewed clinical profile and outcome of patients with malignant
renal tumour in KKWomen’s and Children’s hospital (KKH), Singapore.
Design/Methods: The study was approved by Singhealth Centralized Institutional
Review Board. We included all patients with malignant renal tumours seen at KKH
from 1997 to 2012 (16 years).
Results:We identified a total of 29 patients. There were 15 females and 14 males with
median age at diagnosis of 3.5 years (range 0.25 to 11 years). 22 patients (75%)
presented with abdominal mass either isolated or along with fever, poor feeding,
vomiting, abdominal pain, haematuria or hypertension. Four presented with painless
gross haematuria only. Two patients had tumour diagnosed on screening - one had
underlying aniridia; the other had hemihypertrophy with umbilical hernia. One child
was diagnosed incidentally during workup for diabetic ketoacidosis and fever. The
histological diagnoses included: Wilms tumour (21/29, 72.4%), malignant rhabdoid
tumour (4/29, 14%), clear cell sarcoma (3/29, 10.3%) and renal cell carcinoma (1/29,
3%). The staging according to NWTS were: 7 (24%) stage I, 8 (28%) stage II, 9 (31%)
stage III and 5 (17%) stage IV. All patients received treatment according to NWTSG
protocol except one who was treated with SIOP protocol. Median follow up time was
4.7 years. There were two deaths in this series – both had stage IV malignant rhabdoid
tumour. One patient with stage III clear cell sarcoma developed disease recurrence. The
remaining patients were alive and recurrence-free.
Conclusion: Although the numbers were small, our series demonstrated excellent
disease-free outcomes for paediatric renal tumours, especially Wilms tumour.
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SIRT1 PROTEIN EXPRESSION IN WILMS TUMOR
N.J. dos Reis Farinha1, S. Monteiro Reis1, C. Bartosch2, M. Afonso2, P. Dias2,
H. Barroca3, R. Henrique2, C. Jerónimo1
1Portuguese Oncology Institute-Porto, Cancer Biology and Epigenetics Group-Research
Center, Porto, Portugal; 2Portuguese Oncology Institute-Porto, Department of Pathology,
Porto, Portugal; 3São João Hospital Center, Department of Pathology, Porto, Portugal
Background/Objectives: Histone deacetylase Sirtuin 1 (SIRT1) is involved in
tumorigenesis and may function either as a tumor promoter or suppressor.The
objective of this study was to characterize SIRT1 expression in Wilms tumor (WT) and
to determine whether its three components display different expression patterns.
Design/Methods: Histological slides of 58 patients with WT diagnosed between 1998
and 2012 enabled the selection of areas of blastema (n=42), epithelium (n=9) and
mesenchyme (n=40). Additionally, non-neoplastic renal parenchyma adjacent to WT
(n=23), fetal kidney (n=11), renal dysplasia (n=6) and renal non-WTs (n=16) served as
controls. SIRT1 nuclear expression was evaluated by immunohistochemistry and
quantified using image analysis (GenASIs Go-Path, ASI). Five random images of
selected areas in each slide were evaluated to determine H-score. Non-parametric tests
were used for statistical analyses.
Results:WT patients included one adult and 57 children [median age: 48 months
(range: 6 months–10 years)]. Median SIRT1 expression was higher in WT [H-score: 153
(range 0.9-295.5)], than in benign tumors [1.95 (1.4-2.1)], fetal kidney [24.1 (0.5-128.2)],
adjacent renal parenchyma [39.2 (1.9–79.7)] and dysplasia [19.8 (9.8-44.9)] (p<0,001).
Among WT components, blastema displayed the highest H-score [269.5 (range:
42.5-294.4)] compared to epithelium [196.6 (137.5-296.1)], although not reaching
statistical significance (p=0.061). Mesenchyme showed significantly lower expression
than blastema or epithelium [46.6 (6.1-190.6)] (p<0.001), and the same trend was
observed for malignant non-WTs [114.1 (3.4–280,2)].
Conclusion: SIRT1 is overexpressed in WT, mostly in blastema and epithelium, and in
other malignant renal tumors. It may serve as WT biomarker as well as a promising
therapeutic target.
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WILMS TUMOUR: EXPERIENCE AT A TERTIARY CENTER IN A RESOURCE
LIMITED SETTING
G.K. Eke1, S. Ujuambi2
1Port Harcourt, Nigeria; 2University of Port Harcourt Teaching Hospital-Nigeria,
Paediatrics, Port Harcourt, Nigeria
Background/Objectives:Wilms tumour (WT) is the commonest primary malignant renal
tumour of childhood. Enormous progress has been made in its treatment, resulting in
an outcome exceeding 85% in high income countries. It is however a difficult cancer to
treat in developing countries with much lower survival rates. To review the clinical
profile and outcome of treatment of children with WT at the University of Port
Harcourt Teaching Hospital (UPTH), Nigeria.
Design/Methods: All patients with WT admitted into the Paediatric Oncology unit of
the UPTH from January 2011 to December 2014 were reviewed. Their clinical profile,
management and outcome were analyzed using SPSS version 20.0.
Results: Out of 105 children with various childhood malignancies, 31(29.5%) had WT:
17 males (54.8%), 14 females (45.2%). All children presented with abdominal mass, 6
(19.4%) had hypertension. All had an abdominal ultrasound, 9(29%) had abdominal
CT scan while only 11(35.5%) had histological diagnosis. Twenty-six children (83.8%)
had metastatic disease at diagnosis and 4(13%) had bilateral disease. Sixteen (51.6%)
received native treatment prior to presentation, 19(61.2%) had chemotherapy, 12(38.7%)
had surgery and 3(9.6%) radiotherapy. Twelve patients (38.7%) defaulted with or
without commencement of treatment while mortality was recorded in 8(25.8%) cases.
Conclusion:Most children with WT had advanced disease at presentation. Default and
mortality rates are high in our environment. Introduction of palliative care from
diagnosis as an integral part of management, and free treatment of childhood
malignancies are advocated to reduce default rate and improve outcome.
P-504
RESULTS OF PATIENTS CONWILMS TUMOR STAGE 1 (WTS1) TREATED IN
A PEDIATRIC ONCOLOGY CENTER
F. Gonzales1, M.S. Alderete1, M. Urbieta1, M. Cores1, G. Puppa1, M. Garcia Lombardi1
1Hospital de Niños R Gutierrez, Oncology, Buenos Aires, Argentina
Background/Objectives: Renal tumors represent 5 % of all malignant tumors in
children. Among those, 92 % are WT. Stage is one of the most important prognostic
factor. According to the International Society of Pediatric Oncology (SIOP), WTS1
Overall Survival (OS) at 4 years is around 98 % and the Event Free Survival (EFS)
reaches 92 %. The purpose is describe patients with WTS1 treated with SIOP protocols
at the Hospital de Niños “Ricardo Gutierrez” (HNRG). To analyze the OS and the EFS
of these patients.
Design/Methods: Clinical charts of patients diagnosed with WTS1 were retrospectively
analyzed between January 1990 and May 2013. The variables evaluated were age, sex,
risk according to SIOP Protocols, histological type and treatment received. Kaplan
Meier Estimator was used for the survival analysis.
Results: Thirty four patients with WTS1 were included. Male 20 (56 %). Median age 37
months (range 7-146 months). Right kidney 20 (56%). High risk (HR) 3 patients,
intermediate risk (IR) 28 patients, low risk (LR) 4. Median follow-up 63 months (range
1 to 163 months). Three patients relapsed: 1 locally and 2 at distance; 2 patients IR
(focal anaplasia and mixed type), 1 patient HR (blastemal type); 1 deceased due to
disease progression, 2 alive (1 complete remission and 1 in treatment). The 5-year OS
was 98 % and the EFS was 91,4 %.
Conclusion: The OS and EFS of these patients was similar to the findings reported by
international literature. However, the sample size is not statistically significant to define
other adverse prognostic factors for relapse.
P-505
EMERGENCY SURGERY IN CHILDRENWITH NEPHROBLASTOMA
A. Hizhnikov1, R. Michael1, K. Anatoly1, K. Polad1, R. Marina1, R. Diana1
1N. N. Blokhin Cancer Research Center, Thoracoabdominal Department of the Institute
of Pediatric Oncology, Moscow, Russia
Background/Objectives: Nephroblastoma - one of the most common solid tumor of
childhood (6-7%). Sometimes patients come to the hospital for urgent surgical
indications, and it is necessary to perform emergency surgery on the first stage of
treatment.
Design/Methods: From 2006 through 2012, at the Institute of Pediatric Oncology were
treated 156 children with monolateral nephroblastoma. According to the plan are made
surgery in 141 (90.4%) patients. Emergency surgery was performed in 15 (9.6%)
patients. The reason for emergency surgery in 11 cases was bleeding (hematuria), do not
respond to conservative treatment, and in 4 cases - suspected rupture of the tumor,
which was confirmed in only one case. In this group all patients underwent
nephrectomy, retroperitoneal lymph node biopsy. For all children, the diagnosis is
confirmed morphologically. There were no deaths and threatening surgical
complications. Postoperatively, patients were treated with chemotherapy and, if
indicated, radiation therapy, according to the accepted protocol.
Results: 14 children are alive more than two years after the end of special treatment.
One child subsequently died of tumor progression of the disease.
Conclusion: Implementation of adequate surgical intervention in emergency and urgent
situations in children with nephroblastoma, except in cases of tumor rupture, does not
lead to a deterioration in survival in this group of children.
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RARE PEDIATRIC MALIGNANT TUMORS: SINGLE CENTER EXPERIENCE
Z. Karakas1, A. Selime1, S. Karaman1, E. Uysalol1, A. Demirel1, A. Unuvar1,
O. Devecioglu1, S. Anak2, D. Oner3, B. Bilge3
1Istanbul University-Istanbul Medical Faculty, Pediatric Hematology-Oncology, Istanbul,
Turkey; 2Medipol University-Medical Faculty, Pediatric Hematology-Oncology, Istanbul,
Turkey; 3Istanbul University-Istanbul Medical Faculty, Pathology, Istanbul, Turkey
Background/Objectives: Knowledge of the clinical presentation, management, and
long-term outcome of rare pediatric tumors has been based on limited single institution
data or studies on adults. Aim of this presentation is to share our experience about rare
childhood malignancy from Istanbul University, Istanbul Medical Faculty, Division of
Pediatric Hematology/Oncology.
Design/Methods:We retrospectively evaluated records of 13 patients with rare
malignant tumors in terms of presentation and outcome.
Results:We have 13 patients; each of whom was diagnosed with rare tumors namely
sialoblastoma, intracardiac sarcoma, infantile choriocarcinoma, renal
rabdomyosarcoma, breast rabdomyosarcoma, thyroid papillar carcinoma, granulocytic
sarcoma of the bladder, signed ring cell carcinoma of the stomach and angiosarcoma
except peripheral T cell lymphoma diagnosed in 2 patients and Li- Fraumeni syndome
in 2 relative patients. The median age of the patients was 6 years (3 day-16 years), Six of
them were male. Five of them were adolescent. Symptoms and signs of the diseases
were very heterogeneous and nonspesific: Symptoms of our patients were mass(10),
lympadenopathy(4), fever(4), chest pain and palpitation (2), hematuria (2), pericardial,
pleural effusion and ascites(2), headache, convulsion, vomiting(1), DIC (1), back
pain(2), pathologic fractures(1). Two patients had a family history with cancer and
R337P mutation (member of p53 gene family). Pathologic diagnosis was very difficult
and need further stain and consultation. The mean time between onset of symptoms
and diagnosis was 2 months(15 days-4 monhs). Eleven patients admitted to hospital
with advanced stage. Six patients succumbed to death. Four patients alive without
disease. Three patients are under treatment.
Conclusion: Due to the broad heterogenity of tumor types and encompassing rare
pediatric malign tumors, the limited resources of the different groups, registries and
clinics has resulted in disparity within the clinical and molecular genetic study of rare
childhood cancer. These problems might be solved by establishing large international
cooperative groups.
P-507
OUTCOME OFWILMS TUMOR IN CHILDREN: SINGLE CENTER
EXPERIENCE
O. Kashari1, M. Alam1, F. Yassin1, H. Al-Trabolsi1, M. Bayoumy1, I. Abosoudah1
1King Faisal Specialist Hospital &Research Centre-Jeddah, Oncology, Jeddah, Kingdom
of Saudi Arabia
Background/Objectives:Wilms tumor (WT) is the most common renal malignancy and
accounts for 6-7% of all childhood cancers. Advanced stages associated with worse
prognosis. Regional outcome data is secarse. The aim of this study is to determine the
demographic and outcome of WT patients in King Faisal Specialist Hospital-Jeddah.
Design/Methods: A retrospective chart review was performed. Laboratory and clinical
outcome data for a total of 27 patients with WT diagnosed between 2000 and 2013 were
analyzed.
Results: Out of 27 patients 16(59%) were females. The mean age at time of diagnosis
was 3.4(+/-3) years. Abdominal mass was the most common presentation (n=15, 56%)
followed by hypertension (n=8, 30%). Distribution of the cases according to staging I,
II, III, IV and V is 22%, 15%, 26%, 22%) and 15% respectively. Seven (26%) patients
had lung metastasis at presentation. Majority of cases had a favorable histology
25(93%). The median time between symptoms and diagnosis was 28(Range: 11-270)
days. All patients treated with National Wilms Tumor chemotherapy trial-4 except one.
Twenty six (96%) patients got surgical resection, 22 of them had complete and 4 had
partial resection. Thirteen patients (48%) received radiation. Relapse was observed in
10(37%), 2 are due to treatment abandonment. All relapse cases were salvaged with
chemotherapy. However, 3 of them were expired (11%). The median time of relapse was
5 months. Three patients had lung relapse and 3 had both lung and pelvis relapse. Event
free survival (EFS) was 63% and overall survival (OS) was 89% with median follow-up
period of 37(Range: 8-78) months.
Conclusion:We observed increased number of relapses in comparison to the published
international data. This could be due to delay of starting treatment and/or
abandonment treatment. Therefore, regional multicenter study is needed to better
understand the epidemiology and outcome of Wilms tumor.
P-508
CHARACTERIZATION OF CYCLIN D1 IMMUNOREACTIVITY AND
IDENTIFICATION OF NOVEL TRANSLOCATIONS IN CLEAR CELL
SARCOMA OF THE KIDNEY
S.J. Aw1, C.H. Kuick2, M.H. Yong2, D.W.Q. Lian2, S. Wang3, A.H.L. Loh4,
S.A.C. Ling2, G.L. Peh2, S.Y. Soh5, A.H.P. Loh6, P.H. Tan4, K.T.E. Chang2
1National University of Singapore, Yong Loo Lin School of Medicine, Singapore,
Singapore; 2KK Women’s and Children’s Hospital, Department of Pathology and
Laboratory Medicine, Singapore, Singapore; 3National University Hospital, Department
of Pathology, Singapore, Singapore; 4Singapore General Hospital, Department of
Pathology, Singapore, Singapore; 5KK Women’s and Children’s Hospital, Department of
Paediatric Subspecialties Haematology/Oncology Service, Singapore, Singapore; 6KK
Women’s and Children’s Hospital, Singapore, Singapore
Background/Objectives: Pathological diagnosis of clear cell sarcoma of the kidney
(CCSK) is challenging because it resembles blastemal Wilms tumour (WT) and other
paediatric sarcomas, but lacks a distinctive immunophenotype. Recently, subsets of
CCSK have been found to have the YWHAE-FAM22 translocation t(10;17)(q22;p13).
This also occurs in high-grade endometrial sarcoma in which it is associated with cyclin
D1 overexpression. We sought to determine YWHAE-FAM22 translocation status and
cyclin D1 immunoreactivity in a series of CCSKs.
Design/Methods: Immunohistochemical staining staining for Cyclin D1 was performed
on 8 CCSKs from 7 patients, and compared with a custom tissue microarray of other
renal tumors. YWHAE-FAM22 fusion status was determined by RT-PCR.
Conventional cytogenetics and fluorescence in-situ hybridization (FISH) were
performed to characterize karyotypes and novel translocations that were identified.
Results: No CCSK in our series had the YWHAE-FAM22 fusion transcript. However,
novel karyotypes were identified in 2 cases – t(2;13)(q13;q22) and t(3:17)(q29;p11.2).
FISH utilizing break-apart probes flanking the break-points showed a break-apart
signal in tumor specimens but not non-neoplastic kidney sections. Seven of seven
CCSK (100%) showed diffuse and strong nuclear cyclin D1 staining, excluding one case
with poor tissue section antigenicity. In comparison, 3 of 3 congenital mesoblastic
nephromas (100%), and 18 of 29 (62%) neuroblastomas showed diffuse and strong
positive staining. Six rhabdoid tumors and 1 metanephric adenoma showed patchy and
weak staining. Among WTs, stromal and blastemal components were negative, and
epithelial components showed 2+ to 3+ staining in 50-75% cells forming
morphologically distinctive epithelial structures.
Conclusion: CCSK shows strong and diffuse nuclear cyclin D1 immunoreactivity which
helped to distinguish CCSK from blastemal WT, metanephric adenoma and rhabdoid
tumours, but not from neuroblastomas and mesoblastic nephromas. Unlike in
endometrial stromal sarcomas, Cyclin D1 overexpression in CCSK is not consistently
associated with YWHAE-FAM22 translocation. In addition we describe novel somatic
translocations t(2;13)(q13;q22) and t(3:17)(q29;p11.2) in two cases.
P-509
PREOPERATIVE RISK FACTORS IDENTIFIED FOR INTRAOPERATIVE
EXTENSIVE HEMORRHAGE OFWILMS TUMOR
F. Lu1
1Xinhua Hospital, Shanghai, China
Background/Objectives: The role of surgery in the therapy of Wilms tumor is
paramount while extensive Intraoperative hemorrhage is a severe complication. Here
we present our data on the treatment of Wilm’s tumor with an emphasis on finding
preoperative risk factors associated with extensive hemorrhage during nephrectomy.
Design/Methods:We retrospectively reviewed all patients diagnosed with Wilms tumor
and had undergone radical nephrectomy between January 2005 and January 2013 at
Shanghai Xinhua Hospital. Patient characteristics noted include age at surgery, gender,
body weight, tumor laterality, tumor histology and administration of preoperative
chemotherapy. Preoperative CT parameters recorded include tumor dimensions, and
displacement of great vessels. A radiologist will calculate tumor volume and assigning a
tumor stage. All of the nephrectomy was performed by five experienced surgeons.
Results: There were 80 patients diagnosed with Wilms tumor (57 males, 23 females)
included in this study. There were 38 cases of left side tumor and 43 cases of right side
tumor;48 cases classified as stage I \ II tumors and 32 cases classified as stage III \ IV
tumors; 10 cases accompanied by great vessel displacement; 19 cases underwent
preoperative chemotherapy. Comparison of patients with and without intraoperative
extensive hemorrhage (defined as ATLS Class III and IV blood loss) demonstrated no
significant differences in age, sex, body weight, tumor laterality, and tumor stage.
Significant differences existed on the rate of great vessel displacement, the rate of
preoperative chemotherapy and tumor volume (P <0.05). Patients with tumors greater
than 600 cm3 had an increased risk of extensive hemorrhage compared with those less
than 600 cm3.
Conclusion: Patient with wilms tumor volume greater than 600 cm3 and great vessel
displacement is prone to suffer extensive hemorrhage during nephrectomy and should
be handled carefully.
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WILMS TUMOR INCIDENCE IN THE KYRGYZ REPUBLIC
E. Makimbetov1, S. Stambekov2
Pediatr Blood Cancer DOI 10.1002/pbc
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1Kyrgyz-Russian Slavonic University, Bishkek, Kyrgyz Republic; 2National cancer center,
pediatric oncology department, Bishkek, Kyrgyz Republic
Background/Objectives: To study age-specific, regional and ethnic childhood Wilms
tumor incidence in the Kyrgyz Republic.
Design/Methods: Calculated the incidence rate of childhood solid tumor of kidney
between 1989 and 2013. Collected a histological and cytological dates, and deaths
certificates. Estimated population relative risk (RR) for the Wilms tumor in children at
the urban and rural areas, and ethnic groups. Counted crude, age-standardized rates
(ASR) per 1 000 000.
Results: There were registered 1009 with a new diagnoses of cancer in children.Total
annual childhood cancer incidence was 71.8 per 1 million. The most frequent diagnostic
groups were leukaemia’s (31.5%, ASR 21.7) and lymphomas (17.4%, ASR 10.4). Wilms
tumor was on the 2nd place among solid tumours (7.1%) with ASR 5.1 (124 cases, 72
boys and 52 girls). Male/ female proportion was 1.44. Wilms tumor incidence was
significantly higher at the South regions (Osh, Galalabat, Batken) with ASR 7.2
compare with North (Bishkek, Chui, Issyk-Kul, Naryn) areas (4.3). High incidence of
Wilms tumor was registered in the rural (RR=1.2, 95% CI 3.0, 7.7) compared with
urban regions. High incidence rate of Wilms tumors was registered in the Uzbeks ethnic
group (6.1), compare with native Kyrgyzs (3.9) or Russians (4.4).
Conclusion: Childhood Wilms tumor incidence in the Kyrgyz Republic is low and
similar to those reported from some Asian developing countries. Our findings suggest
an ongoing need for population-based surveillance and etiologic research.
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THE EFFICACY OF THERAPY BY IFOSFAMIDE, CARBOPLATIN AND
ETOPOSIDE IN CHILDRENWITH RECURRENTWILMS’ TUMOR IN A
SINGLE CENTER HOSPITAL STUDY
M. Tashvighi1, A. Mehrvar2, V. Fallah Azad3, A.A. Hedayati Asl4, M. Faranoush5,
F. Gharehdaghi6, N. Mehrvar7, M. Alebouyeh4
1MAHAK’s Pediatric Cancer Treatment and Research Center-Islamic Azad University,
Oncology, Tehran, Iran; 2MAHAK’s Pediatric Cancer Treatment and Research
Center-Army Medical Science University, Oncology, Tehran, Iran; 3MAHAK’s Pediatric
Cancer Treatment and Research Center, General Laboratory, Tehran, Iran; 4MAHAK’s
Pediatric Cancer Treatment and Research Center, Oncology, Tehran, Iran; 5MAHAK’s
Pediatric Cancer Treatment and Research Center-Iran Medical Science University,
Oncology, Tehran, Iran; 6MAHAK’s Pediatric Cancer Treatment and Research Center,
Research, Tehran, Iran; 7MAHAK’s Pediatric Cancer Treatment and Research
Center-Cancer Research Center of Shahid Beheshty Medical Science University,
Research, Tehran, Iran
Background/Objectives: Different researches reported that hematopoietic stem cell
transplantation following high dose chemotherapy will improve the survival rate in
patients with recurrent wilms’ tumor. In this study the question is about the rate of
efficacy of using Ifosfamide, Carboplatin and Etoposide with more courses in
mentioned patients without bone marrow transplantation.
Design/Methods: Children less than 15 years old with recurrent wilms tumor during
May 2007 to April 2013 implied in this study. The chemotherapy regiment was
according to NWTS-5R. The hematopoietic recovery after each cycle and tumor size
following four cycles of ICE was evaluated. Finally the data analyzed by SPSS software
version 22 and compared with different literature reviews about stem cell
transplantation’s results.
Results: Seven cases enrolled that 57.1% (n=4) had initial stage II and 85.7% (n=6) had
Favorable histology. The median time from diagnosis to relapse was 19 months. The
sites of relapse were pulmonary (n=5, 71.4%) and renal (n=2, 28.6%). The median
number of days for hematopoietic recovery with G-CSF rescue was 22 days following
the ICE cycles. After four cycles of chemotherapy 85.7% of patients showed complete
and partial response rate. Five-year survival rate was 68.6% and the median time of
disease free survival was 19 months following the end of chemotherapy.
Conclusion: Chemotherapy with more number of ICE cycles in mentioned patients can
improve the response rate and overall survival with low toxicity. The suggestion of
authors is administration of ICE cycle with more courses whereas there aren’t suitable
criteria for bone marrow transplantation of the patient.
P-512
NEPHRON-SPARING SURGERY FOR NEPHROBLASTOMA IN CHILDREN
AND ITS IMPACT ON SURVIVAL
O. Bilokon1, E. Stakhovsky2, G. Klymnyuk1, V. Voilenko3, O. Izhovskiy1
1National Institut of Cancer, Pediatric Oncology, Kyiv, Ukraine; 2National Institut of
Cancer, Oncourogy, Kyiv, Ukraine; 3National Institut of Cancer, Oncourology, Kyiv,
Ukraine
Background/Objectives: Today, in pediatric oncology there are two groups of
researchers who have exactly the opposite point of view on the use of this type of
intervention. One group of researchers believes that nephron-sparing surgery can be
applied for the treatment of children with nephroblastoma, the second group is of the
opinion that this type of intervention should only be used for bilateral nephroblastoma.
The aim of our study was to summarize the experience gained in the pediatric oncology
unit of the National Cancer Institute.
Design/Methods:We retrospectively reviewed the database for the time period of
2007-2014. The study involved the Wilms’ tumor patients under 18. We evaluated
clinical-radiological data.
Results: During 2007–2014, 186 children with nephroblastoma received in-patient care
in the pediatric oncology unit. 33 of these underwent nephron-sparing surgery, that
makes 17.7% of the cases. 13 children were treated for bilateral nephroblastoma, in 20
cases there was a unilateral nephroblastoma. In patients with unilateral
nephroblastoma distribution by stages of disease was as follows: 2 children were
operated with st. I (10%), 13 children with st. II (65%), 4 with st. III (20%), 1 with st. IV
(5%). At the present moment all children who were under observation after
nephron-sparing surgery are alive.
Conclusion: Children with Wilms’ tumor quite rarely undergo nephron-sparing surgery.
This type of operation was previously used exclusively with bilateral tumors, but
recently there appeared a tendency to expand the indications for nephron-sparing
surgery. The study showed no difference in survival in children after nephron-sparing
surgery and children who have undergone radical nephrectomy. Taking into
cosideration a number of studies that have shown a high risk of chronic renal failure in
patients with one kidney after nephrectomy, the use of nephron-sparing surgery is of
higher priority.
P-513
DOES PROLONGED PRE-OPERATIVE CHEMOTHERAPY AFFECT
RESECTABILITY AND SURVIVAL OFWILMS TUMOR?
S. Raza1, F. Zoona Q2, K. Muhammad S1, N. Muhammad Umer3, Q. Abid Q2
1Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore, Pakistan;
2Shaukat Khanum Memorial Cancer Hospital & Research Center, Surgical Oncology,
Lahore, Pakistan; 3Shaukat Khanum Memorial Cancer Hospital & Research Center,
Radiology, Lahore, Pakistan
Background/Objectives: To determine effects of prolonged chemotherapy on
resectability of Wilms Tumor. Survival of patients with Wilms tumor has improved
significantly owing to development and adherence to comprehensive treatment
protocols for the diagnosis, chemotherapy, surgery and radiation in addition to public
awareness. Poor healthcare infrastructure, inconsistent referrals, and varied skill level of
physicians hinder in following a regimented treatment protocol in developing countries.
Design/Methods: A retrospective study of patients with Wilms tumor (WT) was
conducted in a cancer hospital in Pakistan. Patients undergoing > 4 cycles of
preoperative chemotherapy were included in the study. Patients following SIOP
protocol (4 cycles of preoperative chemotherapy), having surgery outside and bilateral
tumours were excluded. Three groups were identified. Group I patients received
pre-operative chemotherapy followed by surgery. Group II includes patient where
tumour remained inoperable after prolonged chemotherapy. Group III patients
presented with a recurrence to our hospital that had upfront surgery elsewhere.
Results: A total of 25 patients with WT were studied. Eleven patients in Group I had 11
patients who underwent surgery after mean 16.4 (range 6 -34) weeks of chemotherapy.
Five patients in Group II had inoperable tumors after 19.4 (16 -34) weeks of
chemotherapy. Six of 9 patients in group III remained inoperable after 25 (6-42) weeks
of chemotherapy, while 3 patients underwent excision of recurrence after 8 cycles of
chemotherapy. Treatment response was observed in 11 (68.7%) patients of groups I and
II.Neither the resectability improved with prolonged chemotherapy nor size reduction
observed in group III patients.
Conclusion: Our review suggests that prolonged pre-operative chemotherapy does not
improve resectability of Wilms tumors.
P-514
PARTIAL NEPHRECTOMY VERSUS TUMOR ENCULATION FORWILMS
TUMORS CRITERIA AND OUTCOME: PROSPECTIVE SOUTH EGYPT
CANCER INSTITUTE STUDY
M.A. Salem1, A. Ali2, M. Hamedy3, H. Abdelrazik2
1South Egypt Cancer Institute, Surgical Oncology, Assiut, Egypt; 2South Egypt Cancer
Institute, Pediatric Oncology, Assiut, Egypt; 3South Egypt Cancer Institute, Diagnostic
Radiology, Assiut, Egypt
Background/Objectives: Approximately 5 - 10% of children with Wilms tumor present
with bilateral disease. The treatment challenge is to achieve a high cure rate while
maintaining adequate long-term renal function. In unilateral Wilms’ tumor (WT),
nephrectomy is the standard surgical approach, whereas partial nephrectomy (PN) is
controversially discussed.
Design/Methods:We prospectively evaluated the feasibility of nephron sparing surgery
(NSS) in children with unilateral (WT) and bilateral (WT). All patients’ receive
preoperative chemotherapy for 6 weeks and postoperative chemotherapy. From 2006 to
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2014, 9 patients with bilateral (WT) and 6 patients with unilateral (WT) underwent
nephron sparing surgery.
Results: Nine patients with synchronous, bilateral (WT) were identified, including 4
patients who underwent successful bilateral tumor enculation procedures. Three
patients who underwent successful bilateral (PN) and 2 patient underwent tumor
enculation on one side and nephrectomy on the other side where the tumor destroys
whole normal renal tissue. Six patients with polar unilateral (WT) were identified and
candidate for (PN). Four patients underwent successful (PN). Two patient develops
postoperative hematoma and positive margin in postoperative pathology underwent
radical nephrectomy. Postoperative complications included postoperative hematoma in
2 patients, wound infection in 2 patients, microscopic residual in 2 patients. Long-term
complications included local tumor recurrence in one patient, incision hernia in one
patient, Distant relapse in lung in one patient who saved by lung metastatectomy. The
overall survival rate was 87% (mean follow-up, 4 years); both patients who died had
unfavorable histology.
Conclusion: (PN) eliminate the need for, nephrectomy in polar stage I unilateral or
bilateral (WT) however enucleative surgery is a reasonable option and oncologycally
safe in bilateral multi-centric or central (WT) after receiving preoperative chemotherapy.
P-515
LONG-TERMOUTCOME OF THE REMNANT KIDNEY IN PATIENTS AFTER
NEPHRECTOMY FORWILMS TUMOR
R. Semo Oz1, S. Ash2, M. Davidivits1
1Schneider Children’s Medical Center of Israel, Institute of Nephrology, Petah Tikva,
Israel; 2Schneider Children’s Medical Center of Israel, Pediatric Hematology-Oncology
Center, Petah Tikva, Israel
Background/Objectives:Wilms tumor (WT) is the second most common abdominal
tumor in childhood, with survival rates of 80-95%. Many attempts have been made to
assess and reduce the potential long-term complications, including renal dysfunction.
The present study sought to evaluate the function and growth rate of the remnant
kidney in children after nephrectomy for unilateral WT and to identify risk factors for
renal injury.
Design/Methods: Data were retrospectively collected on all patients treated by radical
nephrectomy for unilateral "WT" in 1995-2014 at Schneider Children’s Medical Center
of Israel. Glomerular filtration rate (GFR) was calculated according to the Schwartz
formula. Hypertension was defined as systolic blood pressure above the 95th percentile
for age, sex, and height. Length of the remnant kidney was expressed in standard
deviations (SD) from average for age and size.
Results: Sixty-four children met the inclusion criteria. Median age at presentation was
3.5 years (0.5-14). At presentation, mean GFR was 100ml/min/1.73m2; 22% of patients
had a GFR less than 80ml/min/1.73m2 and 74% had hypertension. At the last visit
mean GFR was 103ml/min/1.73m2; 18% of children had a GFR less than
80ml/min/1.73m2, and 25% had hypertension. Albuminuria was found in 22%. There
was no correlation of chemotherapy type with decreased GFR or increased blood
pressure. Radiotherapy was a significant risk factor for protein secretion (p=0.02).
Renal length increased significantly, from 0.9SD at presentation to 2.9SD at the last
visit (R<0.01). The maximal growth rate was observed during the first
post-nephrectomy year.
Conclusion: Although the overall prognosis of children after nephrectomy for WT is
guarded, the present cohort had a 20% rate of impaired renal function in the long term.
Radiotherapy increased the risk of proteinuria. Close follow-up of this patient
population is necessary to monitor the effect of hyperfiltration on the remnant kidney
and determine the need for treatment.
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MANAGEMENT AND OUTCOMES OF NEWLY DIAGNOSEDWILMS’ TUMOR
AT TWO LARGE CENTERS IN EGYPT
M. El-Ayadi1, W. Zekri1, E. Ebeid2, A. Yones3, M. Saad Zaghloul4, N. El Kinaai5,
A. Refaat6, R. Soliman7
1National Cancer Institute-Children’s Cancer Hospital Egypt, Pediatric Oncology, Cairo,
Egypt; 2National Cancer Institute, Pediatric Oncology, Cairo, Egypt; 3Children’s Cancer
Hospital Egypt, Surgical Oncology, Cairo, Egypt; 4Children’s Cancer Hospital Egypt,
Radiotherapy, Cairo, Egypt; 5Children’s Cancer Hospital Egypt, Surgical Pathology,
Cairo, Egypt; 6Children’s Cancer Hospital Egypt, Radiology, Cairo, Egypt; 7Children’s
Cancer Hospital Egypt, Research, Cairo, Egypt
Background/Objectives: A huge progress has been made since the early 1970s in the
treatment of Wilms’ tumor (WT), resulting in a survival outcome of more than 85%.
Our study aimed at evaluating the demographics, disease characteristics and treatment
outcomes for unilateral WT patients at the National Cancer Institute and Children
Cancer Hospital-Egypt.
Design/Methods: A prospective cohort study included newly diagnosed pediatric
patients with nephroblastoma between January 2010 and December 2011. Patients were
treated according to an institutional protocol based on current COG protocol and were
followed till December 2013.
Results: One-thirty five patients were included in the study. 72 were males (53.3%),
mean age was 3.5 years. 35 patients (25.9%) were initially metastatic. Post surgery, 49
patients (36.3%) had stage III tumor, 40 patients (29.6%) had stage I and 11 patients
(8.1%) were stage II. Anaplasia was seen in 15 patients (11.1%). The median follow-up
was 29.3 months (0.3 - 46.6 months). 3-year OS and EFS in favorable histology patients
were 83.4% and 64.2% respectively. Early tumor stages (I/II) were associated with
significantly improved EFS and OS compared to stage III and stage IV (3-Y EFS 83.3%
vs. 63.8% vs. 18.2%, (p-value<0.001) and 3-Y OS: 95.7% vs.94.7% vs. 66% respectively,
p-value<0.001). Initial tumor extension into IVC was associated with inferior EFS
compared to other stage III local FH-WT (36.5% vs. 63.3% respectively, p-value =
0.049). Blastemal predominance after chemotherapy had no statistically significant
impact on prognosis, although a trend towards inferior outcomes was noticed (3-Y EFS
20% vs. 56.3%, p-value=0.253). Median time to start radiotherapy was 27 days which
didn’t reflect on outcome.
Conclusion: Outcome for early stage WT was comparable to international results, while
metastatic WT had a significantly worse outcome. FH-WT with IVC thrombus has to
be treated aggressively for a better outcome. Radiotherapy delay might not affect local
recurrence in WT.
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TREATMENT AND OUTCOMES OF ANAPLASTIC WILMS’ TUMORS IN
EGYPT
W. Zekri1, A. Alfaar2, D. Yehia2, A. Labib2, M.S. Zaghloul3, H. Taha4, N. El Kinaee4,
A. Refaat5, M. Elshafie6, A. Younis6
1Children’s Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; 2Children’s Cancer
Hospital Egypt, Research, Cairo, Egypt; 3Children’s Cancer Hospital Egypt,
Radiotherapy, Cairo, Egypt; 4Children’s Cancer Hospital Egypt, Surgical Pathology,
Cairo, Egypt; 5Children’s Cancer Hospital Egypt, Radiology, Cairo, Egypt; 6Children’s
Cancer Hospital Egypt, Surgical Oncology, Cairo, Egypt
Background/Objectives:Wilms tumor (WT) is the most common renal tumor of
childhood. Unfavorable Anaplastic WT histology accounts for 5-10% among wilms’
tumor. It is considered to be resistant to the regular treatment and carries worse
prognosis. Previous National Wilms Tumor Study group studies had hypothesized that
anaplasia is not an indicator of aggressiveness of tumor, but only indicates its resistance
to chemotherapy. Our aim is to show demographic data for the patients with anaplastic
subtype, clinical presentation, and staging in relation to outcome.
Design/Methods:We included all cases diagnosed as anaplastic WT in the period
between August 2007-January 2012, at Children’s Cancer Hospital- Egypt. We
aggregated clinical data on different treatment modalities, demographics, radiological
and pathological finding and final outcome. Follow up was continued till July 2013-
average period of 12 months.
Results: Twenty-three cases were diagnosed as anaplastic WT in the defined time
interval, accounts for 7% of all WT in our institution with 1.8% (focal) and 5.2%
(diffuse) subtypes. Median age of 39 months, range from 13-98 months. Abdominal
swelling was the most common presentation. Stages I, II, III and IV represented 5
(21.7%), 2 (8.7%), 9 (39.1%) and 7 (30.4%) respectively. Patients were treated according
to different protocols. Out of 23 cases, 7 patients died (30.4%), while 16 (69.5%) patients
are alive. By comparing the overall survival of anaplastic WT with other pediatric renal
malignancies, it showed a poor overall survival (OS) of 43%. Most of the cases are stage
III (39%) and IV (30%) of cases, OS between different stages is (P = 0.019). Stage I had
recurrence (40% recurrence rate) and recurrence rate for all stages was 26%.
Conclusion: There is a statistical significant difference of OS between different stages
and the higher than expected recurrence and death rates was present in stage I.
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OUTCOMES OF ADOLESCENTWILMS’ TUMOR: EXPERIENCE OF A
SINGLE CENTER IN EGYPT
W. Zekri1, A. Ibrahim2, D. Yehia2, R. Soliman2, M.S. Zaghloul3, H. Taha4, N. El
Kinaee4, A. Refaat5, H. El Zomor1, M. Elshafie1, A. Younis6
1Children’s Cancer Hospital Egypt, Pediatric Oncology, Cairo, Egypt; 2Children’s Cancer
Hospital Egypt, Research, Cairo, Egypt; 3Children’s Cancer Hospital Egypt,
Radiotherapy, Cairo, Egypt; 4Children’s Cancer Hospital Egypt, Surgical Pathology,
Cairo, Egypt; 5Children’s Cancer Hospital Egypt, Radiology, Cairo, Egypt; 6Children’s
Cancer Hospital Egypt, Surgical Oncology, Cairo, Egypt
Background/Objectives:Wilms’ tumor (WT) is the most common abdominal
malignancy in childhood, while its incidence in adults is extremely rare, it represents
0.5% of all renal tumors and 3% of wilms’ tumor are reported in adults. Society of
Pediatric Oncology (SIOP) 93-01 study, reported a total number of 30 adult patients
over 7 years, with a good survival of 4-years overall survival of 83% our aim is to report
the outcome of adults patients.
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Design/Methods:We included all cases diagnosed as adults wilms’ tumor (10 years
old) between period July 2007 and December 2014 at Children’s Cancer Hospital
57357-Egypt. Clinical presentation; demographics, radiological and pathological
finding and prognosis is reported.
Results: Out of 447 cases, 12 cases are adult wilms’ tumor; it represents 2.7% of all
wilms’. Patients ranged from 10 to 14.5 years (Mean; 11.78, and Median 10.77 years),
there is equal distribution in gender females (n=7) and males (n=5). Most of the
patients had a left renal masses (n=8), while the right kidney had lower frequency
(n=4), there were no bilateral cases reported, Stages were II, III and IV as following 3, 3
and 6 respectively. Upfront nephrectomy was done whenever possible and all cases
continued a postoperative chemotherapy. The pathological finding were favorable
histology (n=11) as following Mixed subtype (n=5), Blastemal subtype (n= 3),
Epithelial subtype (n= 3), and a case of diffuse anaplastic histology. The patients’ final
outcome; alive and in complete remission (n=7), relapsed (n=3) who didn’t reach a
second remission, stationary case (n=1) and patient died post relapse (n=1).
Conclusion: Adolescent wilms’ tumor is a rare entity; most of the cases are with
favorable histology but it constitutes a poor prognosis, requiring more aggressive lines
of treatment or new modalities for achieving better outcomes, larger number are needed
for better reporting about survival outcome.
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ATYPICAL PAEDIATRIC RENAL TUMOURS - OUR EXPERIENCE
H. Thakkar1, K. Platt2, S. Wilson3, K. Wheeler3, K. Lakhoo1
1John Radcliffe Hospital-Oxford University Hospitals NHS Trust, Department of
Paediatric Surgery, Oxford, United Kingdom; 2John Radcliffe Hospital-Oxford University
Hospitals NHS Trust, Department of Paediatric Radiology, Oxford, United Kingdom;
3John Radcliffe Hospital-Oxford University Hospitals NHS Trust, Department of
Paediatric Haematology/Oncology, Oxford, United Kingdom
Background/Objectives: Paediatric renal tumours are rare in childhood accounting for
less than 5% of all paediatric malignancies. We present a case series of our recent
experience with such tumours that have demonstrated atypical behaviour.
Design/Methods: All patients presenting with atypical features of renal malignancy in
the last five years were identified from hospital patient records and multidisciplinary
documentation. Patient demographics, clinical symptoms, radiological findings and
outcomes were recorded and analysed.
Results: Ten patients were identified with a median age at presentation of 4 years (1-13
years). Two patients presented with extensive hepatic involvement. One of these
patients had a history of multiple systemic haemangiomata posing a diagnostic
challenge requiring an additional liver biopsy and localised liver resection. One patient
presented with atypical features of a tri-lobulated Wilm’s tumour appearing to be
separated by vessels on cross-sectional imaging. Two younger patients presented with
bilateral pathology. The first patient was found to have stage V disease requiring
nephron-sparing surgery on screening for suspected Beckwith-Wiedemann syndrome.
The second patient presented with sepsis and abdominal pain following blunt trauma.
Cross-sectional imaging revealed renal rupture and contralateral pyonephrosis
associated with a pelvi-ureteric junction obstruction. Follow-up imaging showed a mass
on the traumatic side confirmed to be a Wilm’s tumour. A unilateral nephrectomy and
contralateral pyeloplasty was performed. Three patients presented with extensive local
disease. The first had involvement of the collecting system and bladder presenting with
haematuria and difficulty voiding. Two older patients presented with inferior vena cava
involvement. The presumed diagnosis of these was a Wilm’s tumour; however biopsy
results confirmed a primitive neuroectodermal tumour in both cases.
Conclusion: Paediatric renal tumours can present with several distinct clinical
morphologies. We re-emphasise the importance of an individualised multi-disciplinary
team approach in the management of such unusual cases.
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EVALUATION OF THE EFFICACY AND SAFETY OF DEFIBROTIDE
TREATMENT IN VENO-OCCLUSIVE DISEASE DUE TO ACTINOMYCIN-D
S. Yesil1, G. Tanyildiz1, G. Sahin1, S. Toprak1, M. Tanyildiz2, S. Tekgunduz1,
M. Candir1, C. Bozkurt1
1Dr. Sami Ulus Pediatric Research and Training Hospital, Pediatric Hematology and
Oncology, Ankara, Turkey; 2Hacettepe University Medicine Faculty, Pediatric Intensive
Care Unit, Ankara, Turkey
Background/Objectives: Veno-occlusive disease (VOD) is a potentially life- threatening
complication of actinomycin-D. The clinical signs of the disease are hepatomegaly,
sudden weight gain with or without ascites and jaundice. We evaluated the efficacy and
safety of defibrotide in patients who developed VOD while receiving Actinomycin-D
containing chemotherapy for Wilms tumor.
Design/Methods: Two patients (Patient 1: One year-old male, Patient 2: Three years-old
male) were admitted in our unit with the complaint of abdominal mass. Ultrasound and
computed tomography of the abdomen identified solid mass in the right kidney of the
both patients. Right radical nephroureterectomy was performed and histology revealed
Wilms tumor. Postoperative radiotherapy was given and chemotherapy regimens were
planned for stage III Wilms Tumor in both of the patients. Abdominal distension
occurred and clinical condition of two patients progressively worsened after
Actinomycin-D therapy. The patients gained weight and the abdominal ultrasound scan
confirmed enlargement of liver and spleen with ascites. Doppler ultrasound revealed
reverse hepatic and portal venous flows. Blood tests showed severe thrombocytopenia
and very high levels of hepatic enzymes. The coagulation parameters were also
abnormal. The patients were treated with life support treatment in intensive care unit.
Defibrotide treatment was started with a dose of 20 mg/kg/day in 4 divided doses.
Results: The clinics and laboratory of the patients were improved rapidly after
defibrotide. Hepatic and portal venous flows were also recorded normal one week after
defibrotide treatment. Defibrotide treatment was maintained for 14 days in both of the
patients. These patients completed the chemotherapy protocol without any problem.
Conclusion: Defibrotide, an antithrombotic, anti-ischemic, anti-inflammatory, and
thrombolytic single-stranded polydeoxyribonucleotide with fibrinolytic properties is a
safe, well tolerated, and efficacious therapy in VOD.
Posters: Retinoblastoma
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CHALLENGES IN TREATING BILATERAL RETINOBLASTOMA IN
DEVELOPING COUNTRIES: CHILDREN’S HOSPITAL LAHORE PAKISTAN
EXPERIENCE
A. Ahmad1, F. S.Khan1, N. Asghar1
1The Children’s Hospital Lahore Pakistan, Haematology/Oncology, Lahore, Pakistan
Background/Objectives: The Children’s Hospital Lahore Pakistan is a tertiary center
receiving over 600 new cancer patients per year from all over the country. The purpose
of this study was to analyze management and outcome of children with bilateral
Retinoblastoma and to discuss the role of Neoadjuvant chemotherapy in developing
countries.
Design/Methods: Retrospective review of 36 patients enrolled between January 2014 to
January 2015 was done. Data regarding their age, sex, stage, laterality, treatment,
outcome and impact of Neoadjuvant chemotherapy was analyzed.
Results: Total 36 patients with age ranging from< 1 to 7 years (93% <5 yrs) were
included. M: F Ratio was 1:1.4. 16/36 (45%) presented with bilateral Retinoblastoma
and 12/16 (75%) with optic nerve involvement and 23/36(64%) for whole
group.17/36(47%) defaulter treatment and 18/36 (50%) refused Enucleation at diagnosis.
Only 2/16(13%) had bilateral Enucleation and 9/16(56%) unilateral Enucleation with
laser therapy in 5/16(32%). Enucleation was done in 25/36(70%). Total 14/36 (39%) have
completed treatment, 7/36 (19%) are on treatment, 10/36 (28%) left against medical
advice (LAMA) and 4/36 (11%) expired due to metastatic and progressive disease and
sepsis. one patient (3%) relapsed. In the Bilateral group 8/16(50%) have completed Rx,
3/16 (19%) on Rx, 4/16(25%) got LAMA and one patient (6%) expired just post RX
due to sepsis. When compared with the previous study presented in SIOP 2014
mortality decreased from 18 to 11% for whole group and 1/16 (6%) for BL RB and
defaulter trend decreased from 66% to 47% (17/36) and Neoadjuvant chemotherapy
used in 58% cases as compared to 54%.The number of bilateral RB was increased to
45%as compared to 10/56(18%) the number of LAMA increased from 13% to 28%.
Conclusion:Mortality of 11% can further be reduced by early diagnosis, treatment,
improved ICU care, efficient Multidisciplinary team management. The Neoadjuvant
group needs extensive social support to decrease LAMA rate(60%).
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SIRTUIN1 EXPRESSION AND CORRELATIONWITH HISTOPATHOLOGICAL
FEATURES IN RETINOBLASTOMA
A. Batra1, S. Kashyap2, L. Singh2, S. Bakhshi1
1All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; 2All India
Institute of Medical Sciences, Ocular Pathology, New Delhi, India
Background/Objectives: Sirtuin1 (Sirt1) has been implicated for a dual role as a tumor
promoter as well as tumor suppressor. One of the several mechanisms is deacetylation
of retinoblastoma protein and thereby inhibiting its tumor suppressor function. Data
on Sirt1 expression in retinoblastoma do not exist.
Design/Methods:We assessed expression of Sirt1 in sections of archived tissue blocks
of enucleated and exenterated specimens of patients with retinoblastoma by
immunohistochemistry. Nuclear staining was considered positive. For analysis, grade 3
stained specimens were compared with the rest. The histopathological features were
reviewed and correlated with expression of Sirt1. The clinical and survival data were
obtained from database. Effect of Sirt1 expression on survival was analyzed.
Results: Out of 100 retrieved blocks, 6 did not contain any viable tissue. Retrospective
data of the 94 patients revealed that median age at presentation was 36 months with
male: female ratio of 1.9:1. Fifty-one percent of patients had International
Retinoblastoma Staging System (IRSS) stage 1 disease. Of the 94 sections, 89 (95%)
expressed Sirt1. Forty-eight percent (45/94) specimens showed grade 3 staining (>75%
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of cells) and intensity was 3+ in 53% (50/94). No association was noted with degree of
Sirt1 expression and any histopathological features of retinoblastoma specimens. Also,
degree of Sirt1 expression did not affect the overall survival (OS) and progression free
survival (PFS) in the entire group (5-year OS: 93% vs 86%, p= 0.23; 5-year PFS: 89% vs
88%, p= 0.85) as well as in the sub-group of patients with extraocular and metastatic
retinoblastoma (5-year OS: 94% vs 83%, p= 0.33; 5-year PFS: 87% vs 81%, p= 0.66).
Conclusion: Sirt1 was expressed in most of the retinoblastoma samples. However,
degree of Sirt1 expression was not associated with any high-risk histopathological
feature or survival. The near uniform expression of Sirt1 in retinoblastoma specimens
may suggest a pathophysiological and therapeutic role.
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CYTOPLASMIC EXPRESSION OF FOXO3A IN RETINOBLASTOMA
PREDICTS HIGH RISK HISTOPATHOLOGICAL FEATURES
A. Batra1, S. Kashyap2, L. Singh2, S. Bakhshi1
1All India Institute of Medical Sciences, Medical Oncology, New Delhi, India; 2All India
Institute of Medical Sciences, Ocular Pathology, New Delhi, India
Background/Objectives: Forkhead box (FOX) transcription factors serve critical cellular
functions including apoptosis and cell cycle regulation. The downstream mechanisms
of cell cycle regulation involve preservation of retinoblastoma protein function, acting
as tumor suppressor. Its deactivation by phosphorylation and trans-location from
nucleus to cytoplasm leads to cell proliferation. Cytoplasmic expression of FOXO3a
has been reported to be associated with higher stage and inferior survival rates in breast
and prostate cancers. No study has been reported on expression of FOXO3a in
retinoblastoma.
Design/Methods:We assessed the expression of FOXO3a in sections of archived tissue
blocks of enucleated and exenterated specimens of retinoblastoma by
immunohistochemistry. Cytoplasmic staining was considered positive. The
histopathological features were reviewed and correlated with its expression. Clinical and
survival data were obtained from the database. Effect of FOXO3a expression on
survival was analyzed.
Results: Six of 100 retrieved blocks did not contain any viable tissue. Retrospective data
of these 94 patients revealed that median age at presentation was 36 months with male:
female ratio of 1.9:1. Fifty-one percent of patients had International Retinoblastoma
Staging System (IRSS) stage 1 disease. Of the 94 sections, 68 (72%) were positive for
cytoplasmic expression. Choroidal invasion was associated with cytoplasmic FOXO3a
(59% vs 35%, p=0.04). A trend was also noted in optic nerve resected margin
involvement (12% vs 0, p=0.07). However, the overall survival and progression free
survival were not affected by FOXO3a expression in the entire group as well as in the
sub-group of patients with extraocular and metastatic retinoblastoma.
Conclusion: Cytoplasmic expression of FOXO3a was frequently found in
retinoblastoma specimens. Despite the association of cytoplasmic FOXO3a expression
with high risk histopathological features, no effect on survival was noted. Activation by
relocation of FOXO3a to nucleus may activate non-mutated retinoblastoma and can be
a potential target of treatment in patients with retinoblastoma.
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LOSS OF SPERM DNA INTEGRITY AND CHILDHOOD CANCER
S. Bisht1, S.B. Kumar1, S. Gautam1, B. Chawla2, R. Dada1
1All India Institute of Medical Sciences, Anatomy, New Delhi, India; 2All India Institute
of Medical Sciences, Ophthalmology, New Delhi, India
Background/Objectives: Sperm chromatin integrity is essential in fertilization, proper
embryonic development and birth of healthy offspring. Sperm is highly vulnerable to
oxidative damage to both nuclear and mitochondrial DNA due to minimal cytosolic
anti-oxidants. B-cell Acute Lymphoblastic Leukaemia (B-ALL) and Retinoblastoma
(RB) are the most common childhood malignancies but the causative factors are not
known. This study was planned to analyze the sperm DNA quality as a possible
etiological factor for childhood cancers (B-ALL & RB).
Design/Methods: A total of 75 fathers of children with non-familial RB (n=55), B-ALL
(n=20) and 75 fathers of healthy children were recruited for the study. Semen samples
were collected and normal semen parameters were analyzed. Markers for Sperm DNA
damage such as DNA fragmentation index (DFI) were measured by Sperm Chromatin
Structure Assay, 8-hydroxy-2’-deoxyguanosine (8-OHdG) by ELISA and Reactive
Oxygen Species (ROS) by Chemiluminiscence assay.
Results: In the fathers of RB, the seminal mean ROS levels were significantly higher
(36.086±1.83 vs 20.51±2.71 RLU/s/million; p<0.05) than in controls but the difference
was not significant between the fathers of B-ALL and controls (p>0.05). In the fathers
of RB, there was a significant increase in mean DFI levels (31.50±6.67 vs 21.9±9.4;
p<0.001) but there was no significant difference in DFI levels (26.33±8.36 vs
21.9±9.4;p>0.05) between the fathers of B-ALL and controls. In the fathers of RB, the
8-OHdG levels (66.02±2.91 vs 23.10±2.71 pg/ml) were significantly higher (p<0.05)
but in fathers of B-ALL, the difference in 8-OHdG levels (38.51±3.28 vs 23.10±2.71
pg/mL; p>0.05) were not significant as compare to controls.
Conclusion: Increased seminal oxidative stress and sperm DNA damage may be the
etiological factors for the development of childhood cancers. Paternal age, smoking,
pesticide exposure and alcohol intake are the known inducers of oxidative stress, a
major factor causing genome hypermutability & DNA damage which may ultimately
cause morbidity & childhood cancer.
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OUTCOMES ANALYSIS OF DIFFERENT ONCOLOGY PEDIATRIC
TREATMENT IN ADVANCED STAGE RETINOBLASTOMA IN QUITO
ECUADOR
A. Borja1, J.D. Naranjo1, M.J. Pesantez1, D. Franco2
1Hospital Axxis, Pediatric Oncology, Quito, Ecuador; 2Hospital Metropolitano,
Anatopathology, Quito, Ecuador
Background/Objectives: Evaluate different oncology treatment pathways in Stage IV
Retinoblastoma including intra-arterial chemotherapy. Retinoblastoma is the most
common primary intraocular malignant neoplasia. It represent the 4% of malignant
tumors in the principal Pediatric BO Hospital in Quito Ecuador. This neoplasia
variants presentation including laterality, focal, genetic etiology and stage. In Ecuador
diagnosis may be delayed by clinical manifestation, unknown of pathology in pediatric
services, absences of screening protocols. With early diagnosis, 5 year survival and
visual preservation is 97% (USA), in Ecuador survival is 70%, otherwise the disease is
fatal without treatment. Chemotherapy, radiotherapy, local laser, surgery and new
chemotherapy intra-arterial are the protocols used.
Design/Methods: Prospective, descriptive, open.Stadistical database recollected in
Pathology Service obtained Retinoblastoma cases and observational evolution of
treatment during 8 years.
Results: Forty two patients were diagnosed with histopathology in a Pediatric Hospital
between 1994 - 2012, 58% women and 42% men, ages included 1 month to 14 years, age
groups were from 1 - 5 years 31.4%, 0 - 1 year 17.3%, 5 - 8 years 17%, 8 - 12 years 17,3%,
>12 years 17%. The majority of cases were stage IV representing 38% of cases, followed
by stage II 32%. Due conditions of ecuadorian population secondary an low income
country, all patients were enucleated, concomitant treatment included chemotherapy in
all patients, completed radiotherapy 70%, laser thermotherapy 30% and intra-arterial
chemotherapy, first time reported in Ecuador, 1 patient. At the moment this patient
presents relapse and enuclation was done. The free survival of the study was 71%.
Conclusion: Almost all patient come in advanced stages of disease, and absence of
protocols for different treatment stages limits successful results, new perspectives are
being implemented in Ecuador without seeing a favorable outcome, due to the
limitation of cases and sources. We recommend a Retinoblastoma national neonatal
screening.
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TWO CASES OF SYSTEMIC TROMBOSIS AS A COMPLICATION OF
INTRAARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA
T. Celkan1, N. Ozdemir1, O. Kizilkilic2, A. Sarici3
1Istanbul UNiversity-Cerrahpasa Medical Faculty, Pediatric Hematology-Oncology,
Istanbul, Turkey; 2Istanbul UNiversity-Cerrahpasa Medical Faculty, Pediatric Radiology,
Istanbul, Turkey; 3Istanbul UNiversity-Cerrahpasa Medical Faculty, Ophthalmology,
Istanbul, Turkey
Background/Objectives:We describe 2 retinoblastoma children with thrombotic events
triggered by intra arterial melphalan(IAC) therapy.
Design/Methods: The first patient whom presented due to cerebrovascular events was
most likely attributable to local toxicity of the chemotherapy with peripheral
embolization. The second case‘s thrombosis involving the extremity is associated with
the catheter and resolved very early after antiaggregan and anticoagulant medication.
Results: Our second case demonstrates the more common presentation while the first
case, the more severe one, a transient ischemic attack manifested by confusion and
vomiting resulting with perminent right side hemiplegia.
Conclusion: During intraartrial melphalan treatment ophthalmologist must be aware of
more serious complications and give information to parents. Either ophthalmologist or
oncologist learn the history of the family for clinical thrombosis and if necessary tests
for thrombofilia might be done prior IAC.
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IMMUNOHISTOCHEMISTRY OF NOXA PROTEIN IN PRIMARY
RETINOBLASTOMA TUMORS
F. Chauhan1, L. Singh1, N. Pushker2, S. Sen1, M. Singh1, S. Kashyap1
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1All India Institute of Medical Sciences, Ocular Pathology, Delhi, India; 2All India
Institute of Medical Sciences, Ophthalmology, Delhi, India
Background/Objectives: Diagnostic immunohistochemistry (IHC) is widely used to
evaluate various intraocular malignancies. The most common primary intraocular
tumor in children is retinoblastoma. NOXA is the bcl-2 family protein and represents a
mediator of p53-dependent apoptosis. Therefore, the aim of our study is to evaluate the
immunohistochemical expression of NOXA protein in retinoblastoma.
Design/Methods: Prospective analyses of 19 primary retinoblastoma over a period of
one year were included. Expression of NOXA protein was analyzed by
immunohistochemistry (IHC) in formalin fixed paraffin embedded sections and
correlated with clinical and histopathological high risk factors (HRFs).
Results: There was a slight male preponderance (58%) & 5/19 (26.3%) were bilateral in
our study. Out of 19 cases, 14 were found to be poorly differentiated retinoblastoma
(PDRB). Massive choroidal invasion was the most frequently observed
histopathological high risk factor. Expression of NOXA was seen in 10/19 (52.63%)
retinoblastoma cases. Expression of NOXA protein was statistically significant with
various histopathological high risk factors.
Conclusion: Immunohistochemistry is being used increasingly in the prognostic
assessment of tumors. IHC revealed NOXA as a poor prognostic marker in
retinoblastoma. This provides important prognostic information that can guide clinical
management and researchers to find molecular target in intraocular tumors.
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CLINICAL PROFILE, RISK FACTORS AND OUTCOME OF ORBITAL
RETINOBLASTOMA AT A TERTIARY CARE REFERRAL CENTRE IN INDIA
B. Chawla1, F. Hasan2, R. Seth3, S. Pathy4
1All India Institute of Medical Sciences, New Delhi, India; 2All India Institute of
Medical Sciences, RP Centre, New Delhi, India; 3All India Institute of Medical Sciences,
Pediatrics, New Delhi, India; 4All India Institute of Medical Sciences, Radiation
Oncology, New Delhi, India
Background/Objectives: Management of orbital retinoblastoma (RB) remains a challenge
in developing countries. The purpose is to study the clinical profile and outcome of orbital
RB in Indian children and to analyse risk factors for metastatic disease.
Design/Methods: Medical records of children who presented to the RB clinic of our
tertiary care referral centre between 2011-13 and were diagnosed as RB with orbital
invasion were retrospectively reviewed. Treatment consisted of a multimodal protocol that
included neo-adjuvant chemotherapy, enucleation, orbital radiotherapy and adjuvant
chemotherapy. Those children who had CNS disease at presentation were treated either
with multi-modal therapy or were advised palliative care.
Results: Orbital Retinoblastoma accounted for 29% (77/265) of all cases diagnosed with
RB during the study period. Of the 77 cases with orbital spread at presentation, CNS
metastasis was noted in 17 (22%) cases. Risk factors for metastatic disease at
presentation included bilateral disease (p=0.03) and a longer lag period (p=0.04).
Other factors such as age (p=0.74) and gender (p=0.633) had no significant association
with metastasis. The follow up period ranged from 12-36 months. Survival rate at last
follow-up was 75.4% for non-metastatic cases and 18% for metastatic cases (p=0.0001).
Conclusion: Orbital RB accounted for a high proportion of RB cases in our series,
underlining the need for awareness campaigns to facilitate early detection. Bilateral
disease and delay in seeking healthcare are significant risk factors for metastatic disease.
Although locally invasive non-metastatic orbital RB can be managed with multi-modal
protocol, CNS metastasis is associated with a poor prognosis for survival.
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A REVIEW OF DIAGNOSIS AND TREATMENT OF RETINOBLASTOMA IN
AUCKLAND , NEW ZEALAND FROM JANUARY 2000 TO DECEMBER 2014
R. Cockcroft1, E. No2, B. Smith3, Y. Ng4
1Starship Children’s Hospital, Auckland, New Zealand; 2University of Auckland,
University of Auckland School of Medicine MB ChB4, Auckland, New Zealand;
3Starship Children’s Hospital, Starship Blood and Cancer Centre, Auckland, New
Zealand; 4Auckland City Hospital, Department of Ophthalmology-Greenlane Clinical
Centre, Auckland, New Zealand
Background/Objectives: Sixty Nine cases of Retinoblastoma (RBL) were identified in
New Zealand. This study investigates the epidemiology of RBL, specifically in the
North Island.
Design/Methods: This is a retrospective chart review (patient demography, staging,
treatment and outcome) of 53 patients with RBL who were seen in Auckland only.
Results: Of 36 unilateral RBL patients, there were 19 European, 7 Maori, 3 Cook Island
Maori, 6 Pacific Islanders and 1of Asian descent. Fourteen patients had High Risk
Histology in enucleated specimens and received 3 drug adjuvant chemotherapy. The OS
of this group is 100% at 4-136 months after treatment. They all have good vision in the
remaining eye. No severe late effects have been documented yet.Thirteen of 14 patients
presenting with bilateral disease (7 European, 5 Maori,1 Pacific Island, and 1 Asian)
received local therapy to the remaining eye and concomitant chemotherapy. All have
survived. Only 1 patient received local Radiotherapy, relapsed locally and was salvaged
with High dose chemotherapy & ABMT and is alive 9 years later. One patient needed
the 2nd eye enucleated and is free of disease 9 years later.One patient had both eyes
salvagedOne European patient that presented with trilateral disease and is alive at 13
years from treatment. Two patients who presented with metastatic disease did not
survive.83% of unilateral RBL cases presented with a group E eye according to the
International Intraocular Retinoblastoma Classification (IIRC).These were enucleated
soon after diagnosis. All group D eyes and 2 group C eyes were also initially enucleated.
Conclusion: Despite the majority of our patients being diagnosed with advanced group
eyes, the superb treatment of a well defined and organized multi disciplinary team has
resulted in 100% OS for patients with unilateral, bilateral and trilateral disease.
Metastatic disease (Stage 4a& 4b) at diagnosis is still incurable in our unit.
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A RETINOBLASTOMA PROGRAM IMPROVES OUTCOMES AND ACCESS TO
CARE FOR PATIENTS IN RESOURCE LIMITED SETTINGS
M.C. Dolendo1, C.L. Diez1, K. Caranto1, A.P. Alcasabas2, C. Lam3, M. Wilson4,
C. Rodriguez-Galindo5, G. Sundar6, T.C. Quah7
1Southern Philippines Medical Center, Section of Oncology-Department of Pediatrics,
Davao City, Philippines; 2Philippine General Hospital, Section of
Hematology/Oncology-Department of Pediatrics, Manila, Philippines; 3St Jude
Children’s Research Hospital, Department of Hematology/Oncology and International
Outreach Program, Memphis, USA; 4St Jude Children’s Research Hospital, Department
of Surgery-Division of Ophthalmology and Pathology, Memphis, USA; 5Dana Farber
Cancer Institute, Department of Pediatric Oncology, Boston, USA; 6National University
Hospital, Department of Ophthalmology, Singapore, Singapore; 7National University
Hospital, Section of Pediatric Hematology/Oncology-Khoo Teck Puat Children’s
Medical Institute, Singapore, Singapore
Background/Objectives: Clinical outcomes for patients with retinoblastoma are excellent
with early detection and multidisciplinary management. Implementing a RB program
addresses multiple aspects of clinical care that impacts overall outcomes. However,
resource limited settings particularly public hospitals are challenged by lack of
specialists, infrastructure, referral systems and support for treatment. Designing an
appropriate RB program in this context is crucial.
Design/Methods: An RB program encompassing early detection campaigns, referral
pathway and treatment center, mentoring, RB registry and measuring designated
outcomes was implemented in a public tertiary hospital in Davao City, Mindanao,
Philippines. Data was collected for patients diagnosed with RB from June 2011 to
December 2014. The clinical profile and outcome measures of extra ocular disease
percentage, survival and abandonment were documented and analyzed using descriptive
statistics.
Results: Fifty-four patients were included in the study. Majority of the patients were
male (n=30; 56%), aged 1-5 yrs old (n=49; 91%), unilateral RB (n=37; 69%), and
non-Davao residents (n=44; 81%). Leukocoria (n=19; 35%) and proptosis (n=17; 31%)
were the most common presenting complaints. Sixty-three percent of patients have
advanced disease at presentation (IRSS Stage 3, n=11; 20%; Stage 4, n=23; 43%).
There was a three-fold rise in the average number of patients seen per year compared to
baseline (n=4, 2005-2010; n-12, 2011-2014) and marked increase in Stage 1 patients in
recent 2 years. Overall survival was 35% (n=19) with 19% (n=10) abandonment and 2%
(n=1) lost to follow up.
Conclusion: A retinoblastoma program addressing concerns in limited resource settings
improves access to care and outcomes for patients.
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MANAGEMENT OF RETINOBLASTOMA IN ALGERIA
G. Fatiha1
1Pierre and Marie Curie Center, Algerie, Algeria
Background/Objectives: Retinoblastoma (RB) is the most common ocular eye tumor in
children, with an incidence of 1/15 000 births. Management of patients with
retinoblastoma must take into account the various aspects of the disease. The aim of
this study is to determine the treatment pattern and outcome of retinoblastoma to raise
a reflection on a management policy of retinoblastoma in Algeria.
Design/Methods: This study is a retrospective review of children presenting to a
Pediatric oncology unit, Pierre & Marie Curie Center, with a retinoblastoma between
2009 and 2013, tailored treatment strategies were used, including combinations of
enucleation, chemotherapy, and radiotherapy, conservatives treatments are made
abroad.Tumor control rates and outcomes are reviewed.
Results: 89 children with retinoblastoma were enrolled, 28 bilateral cases (31%) and 61
unilateral (69%), Among the 61 with unilateral involvement, enucleation was performed
for a majority (90%). 11 of these patients had neoadjuvant chemotherapy for
extraocular or optic nerf extension. Furthermore, in 28 patients with bilateral
involvement, 20 (71%) eyes were enucleated and 3 patients were enucleated both eyes
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after conservative treatment failure. Overall survival was 94% and relapse free survival
92%.
Conclusion: pediatric oncology team has acquired a certain technicality in the treatment
of retinoblastoma, however, it is made difficult because of the unavailability of
conservative treatment in Algeria, the implementation of these means will allow to
facilitate the management and improve outcomes.
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SECONDMALIGNANT TUMORS:THE SWORD OF DAMOCLES OVER
SURVIVORS OF RETINOBLASTOMA
A. Fernandez-Teijeiro1, N. Conde1, D. García1, V. Granados1, J. Ibañez2, M. Martínez
de Sancha3, M. Gessa4, F. Espejo5
1Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Pediatric Oncology
Program. National Reference Unit for Retinoblastoma, Sevilla, Spain; 2Hospitales
Universitarios Virgen Macarena y Virgen del Rocío, Pathology Department, Sevilla,
Spain; 3Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Radiology
Department, Sevilla, Spain; 4Hospitales Universitarios Virgen Macarena y Virgen del
Rocío, Ophtamology Department, Sevilla, Spain; 5Hospitales Universitarios Virgen
Macarena y Virgen del Rocío, Ophtalmology Department, National Reference Unit for
Retinoblastoma, Sevilla, Spain
Background/Objectives: Although retinoblastoma(RB) is the most curable pediatric
malignant tumor,long-term survivors,specially hereditary cases,have an well-known
increased risk of developping second malignant tumors(SMT).We review the patients(p)
diagnosed with SMT within our National Reference Unit for Retinoblastoma.
Design/Methods: Review of clinical records of 91p:67 new diagnosis,24p referred from
other hospitals:12p for follow-up,5p for treatment,4 parents with RB,3p for genetic
study.Descriptive analysis.
Results: Unilateral 48(53%),bilateral 42(46%),trilateral 1(1%).Median age at diagnosis
12 months(m)(range 1m-5years(yr).Confirmed hereditary cases 43(5
unilateral).Follow-up:median 73m(range 4m-56yr),31p>10yr.External RT:12p,
brachytherapy 16p.SMT in four females diagnosed and treated for hereditary bilateral
RB during the first year of life.Mean age at diagnosis of SMT:21,7 yr(range 13-28yr).
Patient 1: Diagnosed at age 1m:bilateral enucleation.At age 28 year old basal cell
carcinoma on left foot was diagnosed.Alive 5yr after complete excision. Patient
2:Diagnosed at age 2m:right eye enucleation,cryotherapy and external radiotherapy on
left eye.At age 27 year old right nasal leyomiosarcoma was diagnosed:progression after
polychemotherapy and exitus 27m after SMT diagnosis. Patient 3: Diagnosed at age
4m:VEC chemotherapy(vincristine,carboplatine and etoposide) x6 and bilateral
external radiotherapy(RT).At age 13 year old,left nasal leyomiosarcoma was
diagnosed.Treatment according to EpSSG-2005 strategy:ifosfamide and adryamicine
x5,left orbit exenteration with complete resection,external RT(60Gy) and ifosfamide
x2.Alive after 12m of follow-up with good quality of life. Patient 4: Diagnosed at age
6m:polychemotherapy (vincristine,cisplatin,etoposide,adryamicine and
cyclophosphamide),cryotherapy on right eye and external RT(40Gy) on left eye.At age
22 month old she presented right eye recurrence:VEC x6+ brachytherapy.In
December-14,at age 19 year old left naso-orbital undifferentiated sarcoma was
diagnosed:good clinical response after 3 cycles of
IVADO(vincristine,doxorubicine,ifosfamide,D-actynomycine).After imaging evaluation
local treatment with radical surgery and/or radiotherapy will be planned apart from
maintenance chemotherapy.
Conclusion: SMT are the sword of Damocles over long-term survivors of hereditary
RB.Germline RB1 gene mutation,external RT and alkilating agents are the main risk
factors.The role of brachytherapy is not defined yet.Individualized follow-up strategies
and guide recommendations for current and future treatment protocols must be
stablished.
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FAMILIAL RETINOBLASTOMA; SINGLE EXPERIENCE OF A TERTIARY
CANCER CENTER IN JORDAN
I. Nawaiseh1
1King Hussein Cancer Center, Head President of Opthalmology Oncology Department,
Amman, Jordan
Background/Objectives: Familial retinoblastoma Aseel Ghanem,MD, Ibrahim
Al-Nawaiseh, MD, Yacoub A. Yousef, MD, Department of Surgery/ Opthalmology, King
Hussein Cancer Center, Amman, Jordan. Objective: To evaluate the difference in
outcome of management of retinoblastoma between the proband (first affected patient
in the family) and the other affected patients in the same family.
Design/Methods: Fourty two patients with familial Retinoblastoma. Retrospective
Review of the medical records and Ret-Cam images between 2003-2015.
Results: Out of 200 Retinoblastoma patients in our registree, 42 (21%) patients were
familial; 17 were probands and 25 were second or third affected family members. There
was 62 affected eyes; 23 eyes for probands and 39 eyes for the other affected family
members.In proband, all patients (100%) had at least one eye enucleated, 15(52%) of
the affected eyes were enucleated, and 9(31%) of the affected eyes were radiated. In the
other hand, in the other affected family members, only 20% had one eye enucleated, 4
(20%) of the affected eyes were enucleated and no single patient received radiation. The
Eye salvage rate was significantly higher in the other affected family members than the
probands in this series (p=0.0206).All patients who were diagnosed by screening
(before having signs or symptoms) had both eyes salvaged with excellent visual outcome
and without need for radiation or even chemotherapy.At the last day of follow up, 1
(7%) of the probands was dead due to metastasis, and 1 (7%) had second malignancy
(osteosacrcoma in the field of radiation), while no single case in the other family
members had metastasis or was dead.
Conclusion: Awareness of families of the possibility of retinoblastoma (by having one
person in the family affected with this diseases), and adequate screening (even in
absence of genetic testing) showed significantly higher rate of eye salvage in patients
with familial retinoblastoma.
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COMBINED SYSTEMIC CHEMOTHERAPY AND INTRA-ARTERIAL
CHEMOTHERAPY AS PRIMARY CURATIVE TREATMENT OF
RETINOBLASTOMA
S.M. Hahn1, H.S. Kim1, J.W. Han1, D.J. Kim2, S.C. Lee3, C.J. Lyu1
1Severance Hospital, Pediatric Hematology & Oncology, Seoul, Korea; 2Severance
Hospital, Radiology, Seoul, Korea; 3Severance Hospital, Ophthalmology, Seoul, Korea
Background/Objectives: The treatment of retinoblastoma is consistantly evolving,
current goal of the treatment is not only survival but also saving the eye, saving the
vision and minimizing complications following therapy. From early 2000s, Intra-arterial
chemotherapy (IAC) has been introduced in the similar context. Our center started IAC
in 2010 and have experienced 100 times of IAC treatment.
Design/Methods: From January 2001 and December 2014, among 23 retinoblastoma
patients treated with IAC in our center, 11 patients (13 eyes, 2 bilateral) who had IAC
for primary curative aim were evaluated. Each patient received both systemic
chemotherapy and IAC. For IAC, femoral arterial puncture is done and microcatheter
is positioned into the ophthalmic artery during 30 minutes of melphalan infusion.
Results:Median age of total 11 patients was 18.8 months at diagnosis (range, 4.0 to
34.1 months). The Interntational Classificaion of Retinoblastoma (ICRB) sorted the
eyes as group B (n = 1), stage C (n = 2), group D (n = 4), or group E (n = 6). Only two
eyes initially received IAC and then systemic chemotherapy proceeded. Most eyes had
systemic chemotherapy first for one to five cycles. Three to five times for each patient,
total 50 times of IAC have been performed to 13 eyes. Except for the eyes of one patient
who received IAC abroad, other eyes alternatively repeated IAC and systemic
chemotherapy. Focal therapies such as thermotherapy, laser photocoagulation,
cryotherapy and intravitreal chemotherapy injection were treated to 11 among 13 eyes
(84.6%). There was no death during follow up duration of 29.6 month (median, 6.3 to
55.7 months). Overall eye salvage rate is 72.2 ± 13.8 %. Three of thirteen eyes (23.1%)
were enucleated.
Conclusion: Primary IAC for the retinoblastoma patients was tolerable and effective.
Alternate systemic chemotherapy and IAC was a promising option for advanced
retinoblastoma.
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EVALUATION OF AN INTERACTIVE RETINOBLASTOMA GENETICS
WORKSHOP FOR CLINICIANS IN KENYA
J. Hill1, S.Y. Lee2, L. Njambi3, T. Corson4,5,6, H. Dimaras7,8,9
1The Hospital for Sick Children, Toronto, Canada; 2University of Toronto, Laboratory
Medicine and Pathobiology Program, Toronto, Canada; 3University of Nairobi,
Ophthalmology, Nairobi, Kenya; 4Indiana University, Ophthalmology, Indianapolis,
USA; 5Indiana University, Pharmacology and Toxicology, Indianapolis, USA; 6Indiana
University, Biochemistry and Molecular Biology, Indianapolis, USA; 7University of
Toronto, Ophthamology and Vision Sciences, Toronto, Canada; 8University of Nairobi,
Human Pathology, Nairobi, Kenya; 9The Hospital for Sick Children, Ophthalmology and
Vision Sciences, Toronto, Canada
Background/Objectives: Genetic testing is integral to care for inherited disorders in
high-income countries, while low- and middle-income countries like Kenya have limited
genetic testing and counselling services. Genetic testing will likely become widespread in
Kenya within the next decade, yet there has not been a concomitant increase in genetic
counselling resources. To address this gap, we designed an interactive workshop for
clinicians in Kenya focused on the genetics of the childhood eye cancer retinoblastoma.
The objectives were to increase retinoblastoma genetics knowledge, build genetic
counselling skills and increase confidence in those skills.
Design/Methods: The workshop was conducted at the 2013 Kenyan National
Retinoblastoma Strategy meeting. It included a retinoblastoma genetics presentation,
small group discussion of case studies and genetic counselling role-play. Knowledge was
assessed by standardized test, and genetic counselling skills and confidence were
self-reported by questionnaire.
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Results: Knowledge increased significantly post-workshop, driven by increased
knowledge of retinoblastoma causative genetics. One-year post-workshop, participant
knowledge had returned to baseline, indicating that knowledge retention requires more
frequent reinforcement. Participants reported feeling more confident discussing genetics
with patients, and had integrated more genetic counselling into patient interactions.
Conclusion: A comprehensive retinoblastoma genetics workshop can increase the
knowledge and skills necessary for effective retinoblastoma genetic counselling.
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EXPRESSION OF NADPH OXIDASE AS A REACTIVE OXYGEN SPECIES
MARKER IN RETINOBLASTOMA
S. Kashyap1, L. Singh1, N. Pushker2, S. Sen1, M. Singh1, F. Chauhan1, A. Sharma3
1All India Institute of Medical Sciences, Ocular Pathology, Delhi, India; 2All India
Institute of Medical Sciences, Ophthalmology, Delhi, India; 3All India Institute of
Medical Sciences, Ocular Microbiology, Delhi, India
Background/Objectives: Reactive Oxygen Species (ROS) have been shown to enhance
proliferation of cancer cells. NADPH Oxidases (NOX4) are major intracellular source
of reactive oxygen species and elevated ROS levels are often found associated with
cancer, apoptosis resistance, tumor cell invasion etc. Under oxidative stress conditions,
excessive ROS can damage cellular proteins, lipids and DNA, leading to fatal
lesions/mutations in cell that contribute to carcinogenesis. Therefore, the purpose of
this study is to examine the expression of NOX4 protein in human retinoblastoma.
Design/Methods: Immunohistochemical (IHC) expression of NOX4 protein was
analyzed in 72 prospective cases of primary enucleated retinoblastoma specimens and
then validated by western blotting. Cytoplasmic staining was considered as positive and
graded as weak/negative, moderate and strong. Expression of this protein was
correlated with clinical parameters, tumor differentiation, and various histopathological
high risk factors (HRFs).
Results: The tumor was poorly differentiated in 75% with extensive necrosis in 61.66%
cases. Calcification was found in 28.33% cases. Massive choroidal invasion was the most
frequently observed histopathological high risk factor in 33.3% cases. In addition, optic
nerve cut end and retrolaminar invasion was seen in 28.3% cases, iris & ciliary body in
15% whereas scleral invasion was found in 11.66%. One or more than one HRFs were
identified in 28/72 cases. NOX4 protein was expressed in 71.6% primary retinoblastoma
cases by immunohistochemistry. NOX4 was statistically significant with massive
choroidal invasion and poor differentiation.
Conclusion: This is the first study to show the expression of NOX4 protein in
retinoblastoma tumor. Our results revealed that NOX4 was highly expressed in human
retinoblastoma. Therefore, retinoblastoma tumor may exhibit greater ROS stress than
normal cells. Investigating NOX4 might be helpful for developing therapy with
combination of ROS-eliminating strategies in the management of retinoblastoma
patients.
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DELAYED DIAGNOSIS, THE CRITICAL LANDMARK RISK FACTOR IN
MANAGEMENT OF RETINOBLASTOMA
A. Mehrvar1, M. Faranoush2, A.A. Hedayati Asl3, M. Tashvighi4, N. Mehrvar5,
F. Gharehdaghi6
1MAHAK’s Pediatric Cancer Treatment and Research Center-Army Medical Science
University, Oncology, Tehran, Iran; 2MAHAK’s Pediatric Cancer Treatment and
Research Center-Iran Medical Science University, Oncology, Tehran, Iran; 3MAHAK’s
Pediatric Cancer Treatment and Research Center, Oncology, Tehran, Iran; 4MAHAK’s
Pediatric Cancer Treatment and Research Center-Islamic Azad University, Oncology,
Tehran, Iran; 5MAHAK’s Pediatric Cancer Treatment and Research Center-Cancer
Research Center of Shahid Beheshty Medical Science University, Research, Tehran, Iran;
6MAHAK’s Pediatric Cancer Treatment and Research Center, Research, Tehran, Iran
Background/Objectives: One of the clinical landmark risk factors in managing
retinoblastoma is early diagnosis for increasing the survival of these patients. The main
idea of this study was to recognise delayed diagnosis in children with retinoblastoma to
assess the degree and cause of delays from presenting symptoms to starting treatment
of retinoblastoma.
Design/Methods: A retrospective review of all children with proven retinoblastoma,
who presented to MAHAK hospital in Tehran, Iran from April 2007 to Dec 2011, was
performed. Data was analysed by SPSS version 19 with Chi-square test.
Results: There were 157 (91 boys) children eligible for study. The mean age was
1.21±0.11 years with the mean interval of the delayed diagnosis 3.4±0.53 months.
Classification of D group in both unilateral (93 patients) and bilatera tumors was the
largest category. The significant relation (P-value=o.o5) delay diagnosis time and tumor
grouping was evident. The most frequent symptoms were leukocoria and strabismus
respectively. Age was significantly lower in the subgroup of bilateral tumor than
unilateral retinoblastomas (0.6±0.12 years versus 1.6±0.15 years). There was late
diagnosis in subgroup of extraocular retinoblastoma than intraocular (8.7±2.9 months
versus 2.9±0.52 months).
Conclusion: The suggestion of authors is early referring to ophthalmologists and
pediatric oncologists, educational programs around signs and symptoms such as
leukocoria, strabismus and inflammatory abnormalities through national media. In
conclusion, early diagnosis of retinoblastoma can be the critical landmark risk factor in
managing those patients because the delay in the diagnosis account for highly advanced
clinical and poor prognosis of the therapy.
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EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND KI-67
PROTEIN IN CHEMOREDUCTION FAILED RETINOBLASTOMA
N. Pushker1, L. Vekaria1, L. Singh2, S. Kashyap2, S. Bakhshi3
1All India Institute of Medical Sciences, Ophthalmology, New Delhi, India; 2All India
Institute of Medical Sciences, Ocular Pathology, New Delhi, India; 3All India Institute of
Medical Sciences, Medical Oncology, New Delhi, India
Background/Objectives: To study the immunohistochemical expression of vascular
endothelial growth factor (VEGF) and Ki-67 protein and to determine its association
with clinico-histopathological features in enucleated eyes of chemoreduction failed
retinoblastoma (Rb).
Design/Methods: This was a prospective cum retrospective study conducted after
obtaining ethical clearance. According to International Classification of Intraocular
Retinoblastoma, patients with group C and group D Rb underwent enucleation
because of chemoreduction failure were included in our study.
Clinico-histopathological features along with expression of VEGF and Ki-67 by
immunohistochemistry were correlated.
Results: Total of 53 eyes was included. 14 eyes had group C and 39 had group D Rb. All
patients underwent chemoreduction with focal treatment. 18 eyes (18 patients) failed
chemoreduction, out of which 15 eyes were enucleated. Failure rates were 14% in group
C and 41% in group D Rb. Histopathology showed viable tumor cells in all enucleated
specimens. High risk features were found in 67% cases. There was significant
association of poorly differentiated tumor with high risk features. Positive expression of
VEGF was found in 47% eyes and Ki-67 in 93% eyes. No statistical association was
found of VEGF and Ki-67 protein expression with clinico-histopathological features.
Conclusion: Failure rates of chemoreduction was 14% in group C and 41% in group D
retinoblastoma. Presence of viable tumor, high risk features, and Ki-67 expression were
found in most of the enucleated retinoblastoma specimens suggesting their possible role
in chemoreduction failure.
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RETINOBLASTOMA: CHANGING PARADIGM IN INDIA - EXPERIENCE
FROM A TERTIARY CARE CENTRE
R. Seth1, M. Vinay2, G. Pai2, A. Singh2, B. Chawla3
1All India Institute of Medical Sciences, New Delhi, India; 2All India Institute of
Medical Sciences, Pediatrics, New Delhi, India; 3All India Institute of Medical Sciences,
Ophthalmology, New Delhi, India
Background/Objectives: Retinoblastoma (RB) is the most common intraocular
malignancy in childhood. When treated early and appropriately, especially in
intraocular RB, it has a high survival rate with lesser morbidities. The developing
countries share larger burden of disease with lesser survival rate. This study aims to
throw light on the changing paradigm in clinical and epidemiologic factors of
retinoblastoma.
Design/Methods: This is a retrospective descriptive study of children with
retinoblastoma followed up in the Pediatric Oncology Clinic at our Centre from a
period of August 2011-2014. Clinical and epidemiological profile of these children are
described.
Results: A total of two eighty six (38%) outof 752 patients enrolled in to the pediatric
oncology clinic over a period of 3 years from August 2011-2014 were diagnosed with
retinoblastoma. There was a male predilection (M: F = 1.6:1). One third (33%) of these
children had extra ocular extension. Forty five percent (n=130) of the total burden had
bilateral disease. Fifty eight percent of intraocular tumors were bilateral against 20%
advanced disease being bilateral. Overall 207/286 children were on follow up and have
either completed or receiving treatment. 35(12%) children were loss to follow up. Thirty
six children (12%) had either progressive disease or have expired.
Conclusion: The data reveals a sharp contrast in the clinical and demographic profile of
Retinoblastoma when compared to that of developed countries. Retinoblastoma is
major contributor (38 %) of pediatric oncology cases at our Centre, compared to 4% of
total cases in developed countries. Advanced disease contributed to 33%, in contrast to
5% in developed countries. We observed a very low loss to follow up (only 12%) of cases
owing to the efficient tracking system. High incidence and burden of the disease makes
early screening and timely referral imperative for better outcomes in management of
retinoblastoma.
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PROGNOSTIC SIGNIFICANCE OF HIGHMOBILITY GROUP PROTEIN IN
PRIMARY RETINOBLASTOMA
M.K. Singh1, L. Singh2, N. Pushker3, S. Sen2, F. Chauhan2, A. Sharma4, S. Kashyap2
1All India Institute of Medical Sciences, Delhi, India; 2All India Institute of Medical
Sciences, Ocular Pathology, Delhi, India; 3All India Institute of Medical Sciences,
Ophthalmology, Delhi, India; 4All India Institute of Medical Sciences, Ocular
Microbiology, Delhi, India
Background/Objectives: High mobility group proteins are the members of non histone
nuclear factors associated with cell proliferation, differentiation and neoplastic
transformation. High mobility group (HMG) proteins are a newly recognized protein
regulating cancer cell tumorigenesis, expansion and invasion. Patients who have
histopathological high risk factors (HRFs) are more prone to metastasis and
recurrence. However, the role of HMG protein is still unclear in retinoblastoma.
Design/Methods: Prospective analysis of 60 primary enucleated retinoblastoma cases
over a period of one year. Expression of HMGA1 was analyzed by
Immunohistochemistry (IHC) in formalin fixed retinoblastoma specimens and their
results were confirmed by western blotting. Expression of HMGA1 protein was finally
correlated with clinical and histopathological parameters.
Results: A total of 60 eyes were taken of which 12(17.39%) eyes had bilateral
involvement. Ages ranged from 7months to 8years. 45 (75%) cases were reported as
poorly differentiated tumors. Histopathologically, 12(20%) had massive choroid
invasion, 16(23.33%) had optic nerve invasion, 6 cases each had sclera and ciliary body
invasion. Strong expressions of HMGA1 were seen in 55.07% cases. Western Blotting
was performed to confirm the immunohistochemistry results. Expression of HMGA1
was statistically significant with poor differentiation (p=0.0440), and with HRF
(p=0.0166).
Conclusion: Overexpression of HMGA1 is seen more frequently in poorly differentiated
tumors and those with, histopathological high risk factors. HMGA1 could serve as a
poor prognostic marker in retinoblastoma. Better understanding of the molecular
mechanisms underlying HMGA1 function could yield novel therapeutic approaches to
anti-cancer strategies.
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ADVANCED PRESENTATION AND ABANDONMENT : CHALLENGES IN THE
MANAGEMENT OF RETINOBLASTOMA IN LOW / MIDDLE INCOME
COUNTRIES (LMICS)
S. Tandon1, M. Prasad2, S. Quereshi3, N. Shetye2, S. Kembhavi4, M. Ramadwar5,
S. Laskar6, N. Khanna6, T. Vora2, P. Kurkure2, S. Banavali2, G. Chinnaswamy2
1Tata Memorial Centre, Mumbai, India; 2Tata Memorial Centre, Paediatric Oncology,
Mumbai, India; 3Tata Memorial Centre, Pediatric Surgery, Mumbai, India; 4Tata
Memorial Centre, Radiodiagnosis, Mumbai, India; 5Tata Memorial Centre, Pathology,
Mumbai, India; 6Tata Memorial Centre, Radiation Oncology, Mumbai, India
Background/Objectives: The profile of Retinoblastoma(RB) in LMICs differs greatly
from that in more affluent settings.This study evaluated the clinical/epidemiological
profile and outcome of RB at a paediatric oncology centre in India.
Design/Methods: Retrospective study of all children diagnosed with retinoblastoma
between January2009 and December2014. Patients with extraocular/optic nerve
involvement were staged using lumbar puncture and bone marrow examination.
Patients with advanced intraocular disease and/or no useful vision underwent upfront
enucleation.They received 6 cycles of systemic chemotherapy
(carboplatin,etoposide,vincristine,cyclophosphamide) in case of high-risk
post-operative histopathology.Patients with early stage disease were considered for focal
therapies +/- systemic chemoreduction.Extraocular disease warranted 12 cycles of
chemotherapy and local radiotherapy.Since 2013,intra-arterial
chemotherapy(IACT)has been used at our centre.
Results: In 188 patients(male:female-1.2:1),median age at presentation was
2years(unilateral 2.5years;bilateral2 years).Unilateral and bilateral disease were 71.2%
and 28.7%.Median duration of symptoms was 2.35 months (range15days – 2years),with
leucocoria (83%) being the commonest presentation. Over two-thirds(68.6%)had group
E disease.28%patients had advanced stage(IRSS stage III+ stage IV)at
presentation,with extraorbital disease in 12%.Two-year EFS and OS of the entire
cohort were 79.4% and 80.5 %. By stage,2-year EFS and OS were : stage1(EFS-96.7%
,OS-96.5%), stage2(EFS -88%,OS-91.4%),stage3(EFS-53.3%,OS-67.1%),and
stage4(EFS-15%,OS-12 %).Survival outcomes were poorer when massive choroidal
involvement was noted on histopathology of enucleated specimen(p<0.01) .Of the 16
patients who received IACT,enucleation could be avoided in 10. Abandonment of
treatment in the entire cohort was 15%.However, with increased use of ocular salvage
strategies like IACT, and improvement in social/financial support abandonment rates
dropped from 26% in 2010 to 2.6% in 2013 and 2014.
Conclusion: The outcomes in our patient population are lower than described in
Western literature due to delayed presentation, and a higher proportion of advanced
stage disease.Improvement in social and financial support systems, and newer
modalities of ocular salvage have helped decrease abandonment, and improve outcomes
of RB in LMICs.
Posters: Soft Tissue Sarcomas
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GENITOURINARY RHABDOMYOSARCOMA OUR EXPERIENCE USING
MULTIMODAL THERAPY
D. Boddu1, R. John2, N. Choudhary2, L.G. Mathew2
1Vellore, India; 2Christian Medical College-Vellore, Department of Pediatric
Hemato-Oncology, Vellore, India
Background/Objectives: To study the clinical profile and outcome of children with
genitourinary Rhabdomyosarcoma (RMS).
Design/Methods: Retrospective review of children treated for Genitourinary RMS at
Christian Medical College, Vellore, India from Jan, 2004 – Jan, 2015.
Results: Sixteen children (11 boys, 5 girls) aged 1.5 - 14 years were included. Primary
site of tumour was bladder/prostate (BP RMS) in 8 and non bladder/prostate (NBP
RMS) in 8. NBP sites were vagina in 3 and one each from the following areas; testis,
para-testicular, urethra, para-vesical and scrotum. 11 had embryonal, 4 had botryoidal
and 1 had alveolar RMS. Tumour size was >5cm in 75%. Multimodal treatment
including chemotherapy (CT) [IVA/VAC], Surgery (Conservative/ Radical) and
Radiotherapy (RT) (1440 Gy -5040 Gy) was used depending on clinical stage and
operability. Among those with BP RMS, two are currently on treatment; two had
disease progression and four achieved CR (complete remission) of which one relapsed.
Among three in CR, one had radical surgery, RT and CT; one had radical surgery and
CT; and one had CT and RT. Children who had radical surgery required lifelong clean
intermittent catheterization.Among those with NBP RMS, 6 achieved CR and 2 had
progressive disease. Two children achieved CR with CT and R0 resection; one child
with para-vesical RMS with intra-abdominal metastasis achieved CR with R2 surgery
and individualised CT. Three children with vaginal RMS relapsed with CT alone.
Conclusion:Majority of children presented with tumours larger than 5cm at diagnosis.
All 3 girls with vaginal RMS relapsed. Children who had multimodal therapy had
better outcome.
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CORRELATON OF E-CADHERIN AND β-CATENIN mRNA AND PROTEIN
LEVELS IN EWING SARCOMA AND PRIMITIVE PERIPHERAL
NEUROECTODERMAL TUMORS
A. Bonevski1, M. Mišic´2, J. Stepan3, G. Jakovljevic´3, S. Seiwerth2
1Children’s Hospital Zagreb, Zagreb, Croatia; 2Medical School University of Zagreb,
Pathology, Zagreb, Croatia; 3Children’s Hospital Zagreb, Oncology and hematology,
Zagreb, Croatia
Background/Objectives: Ewing sarcoma (ES) and primitive neuroectodermal tumors
(pPNET) are part of Ewing sarcoma family of tumors with very aggressive biology.
The lack of differentiation has led to difficulties in understanding tumors histogenesis.
It was shown that EWS and pPNET could express cytokeratins, suggesting the partial
epithelial differentiation indicative of intercellular junctions, including the tight cell-cell
junctions.
Design/Methods:We analyzed 12 specimens of primary tumor tissue of patients with
EWS and pPNET. The specimens were obtained by diagnostic biopsy fixed in 4%
buffered formalin and embedded in paraffin. For E-cadherin and β-catenin expression
analysis we used: RT-PCR and immunohistochemistry (IHC) method with specific
antibodies. IHC included the analysis of pan-cytokeratin (AE1/AE3), epithelial marker.
All the specimens were previously analyzed by standard histopathology methods,
including the IHC positive expression of membrane glycoprotein CD99 and RT-PCR
analysis of specific translocation t(11;22)(q12;24) EWSR1/FLI1, which provided the
definitive diagnosis.
Results: IHC: 3 specimens had low positivity of pan-cytokeratin – in individual cells or
small clusters. 11 specimens were positive for membrane β-catenin, and 2 were positive
for membrane E-cadherin. One specimen showed nuclear staining for all 3 markers in
individual cells. RT-PCR: 11 specimens were positive for β-catenin and 2 for
E-cadherin.
Conclusion: IHC and RT-PCR methods were used to determine and compare the
results of E-cadherin and β-catenin expression in EWS tumor specimens and there was
a strong correlation between this two methods. Expression of β-catenin by RT-PCR
and mainly non-expression of E-cadherin are in accordance to existence of cell-cell
adhesive receptors. Partial epithelial differentiation was determined by positive
expression of pan-cytokeratin obtained by IHC in 25% of primary tumor specimens.
Further studies could clarify possible significance of these findings.
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OUR SURGICAL EXPERIENCEWITH RHABDOMYOSARCOMA IN
CHILDREN
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1Cukurova University, Adana, Turkey; 2Cukurova University, Pediatric Surgery, Adana,
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University, Radiology, Adana, Turkey; 5Cukurova University, Pathology, Adana, Turkey
Background/Objectives: Rhabdomyosarcoma is the most common soft tissue sarcoma
in children. Surgical method is important for diagnosis, staging, treatment and long
term follow-up. We aimed to evaluate the results of rhabdomyosarcoma patients whom
we operated.
Design/Methods: Between 2008-2015 the records of rhabdomyosarcoma patients were
retrospectively reviewed. Gender, initial complaints, age at surgery, size and site of the
tumor, histological subtype, metastasis, surgery, chemotherapy, radiotherapy and
survey of the patients were evaluated.
Results: The median age of 8 patients was 30.6 months (16-60 months). All of the
patients were male. Initial complaints were abdominal distension, inability to urinate,
constipation, swelling on the pelvis, mass on the perineum noticed after falling,
subdiaphragmatic mass detected by tests after falling from bike. One patient also had
itching and jaundice. Tumor size was 5-9cm for 6 patients and  10cm for 2 patients.
Four patients had pelvic tumor. The origin was prostatic urethra in 3 patients and pelvic
floor muscles in 1 patient. Others were located in perineal region, iliac region, portal
hilus and subdiaphragmatic area. Seven patients underwent tumor excision and two of
them also underwent cystectomy. Tumor and liver biopsy were performed in 1 patient.
Pathological results were embryonal rhabdomyosarcoma for 8 patients. Thoracal
rhabdomyosarcoma was detected in the postoperative second year in the patient with
perineal tumor and it was resected. All patients had chemotherapy and 7 patients had
radiotherapy according to IRSG (International Rhabdomyosarcoma Study group) IV
treatment guidelines. Median survival time was 29.1 months (13-49 months). Two
patients died 13 and 29 months after the surgery.
Conclusion: Surgery of rhabdomyosarcoma is a controversial subject. As the survival
times increased the quality of future lives of the patients gained importance. As a result
multidisiplinary treatment of rhabdomyosarcoma patients is important.
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Background/Objectives: To evaluate the outcomes of children with biopsy proven
rhabdomyosarcoma through a period of protocol transition from 1990 - 2010.
Design/Methods: All data was collected retrospectively by folder review. All patients
included in the study were diagnosed between 1 January 1990 and 31 December 2010.
Results: One hundred and fifteen patients with rhabdomyosarcoma appeared on our
institutional registry between 1990 and 2010. Forty patients were excluded. Of the
remaining 75 patients, 34 were female and 41 male. Thirty seven patients had embryonal
histology and 18 were alveolar. Patients by stage and group were: Stage 1 (20); Stage 2
(5); Stage 3 (37) and 13 stage 4. Primary disease sites included 17 para-meningeal
tumours, 15 head and neck (non-orbital / non-para-meningeal), 11 pelvic (non-bladder,
non-prostate), 9 extremity, 6 bladder, 6 vagina, 5 abdominal, 5 orbital and 1 in which no
primary was found. By protocol division, 28 patients were treated on the current
protocols introduced after 2005, 5 were treated with new protocols introduced in 2003
and 42 on protocols used prior to 2003. With respect to treatment toxicity the main
complication was febrile neutropaenia. Twenty eight patients relapsed and only 2
patients were salvaged. Two patients died of infection during chemotherapy, 2 died of
refractory / progressive disease, 1 was lost to follow up and 4 died of late secondary
malignancies. Thirty eight patients are alive and disease free (5 year OS 61%: stage 1-
80%; Stage 2- 80%; Stage 3- 51%; Stage 4- 42%).
Conclusion: The unit treats proportionally larger numbers of patients with
rhabdomyosarcomas with adverse anatomical primaries. Toxicity has been acceptable
with very few deaths from infection (2/75). The salvage rate post relapse was dismal
(2/28). There is a trend to suggest that protocol revision has impacted positively on
survival (OS: pre-2003: 54.1%; 2003-2005: 59.4%; post 2005: 64.2%).
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Background/Objectives: Rhabdomyosarcoma(RMS) is the most common soft tissue
sarcoma in children.The most common site of metastasis is the lung. Breast metastases
are rare.
Design/Methods: All cases with breast metastasis within a cohort of 200 RMS patients
followed in the Istanbul University, Oncology Institute during 1990-2014 are assessed.
Results: There were three adolescent girls with breast metastasis. Two had breast
metastases at diagnosis, one during follow-up. All had alveolar histology. Case1: A
thirteen-year old girl was diagnosed with rhabdomyosarcoma of the lower extremity
with regional lymph node metastases. She received treatment for a year with complete
response. Five months after terminating treatment, a mass was detected in her left
breast. Tru-cut biopsy revealed rhabdomyosarcoma. Despite chemotherapy, the breast
mass progressed and new metastatis were detected in bone and abdomen. She
underwent radical mastectomy and further chemotherapy. She is alive for 15 months
after breast metastasis. There is no recurrence in the breast, axillary region and primary
site; but progression at other sites. Case2: A thirteen-year old girl was diagnosed with
rhabdomyosarcoma in the sphenoid sinus. There were metastases in breasts, ovaries,
pancreas, bones at diagnosis. Tru-cut biopsy from the breast mass revealed RMS. There
was significant regression in the primary site and complete response in all metastatic
sites after four courses of chemotherapy. Radiotherapy was given to the primary site.
Leptomeningeal metastasis developed after one year from diagnosis.The patient was
died with progressive disease sixteen months after diagnosis. Case3: A fourteen-year old
girl was diagnosed with RMS at the perineal region. There were bilateral breast and
bone metastases at diagnosis. She was treated with IRS-3 protocol. She died from
progressive disease in the first year.
Conclusion: The prognosis is poor in breast metastasis of RMS. Mastectomy may be an
option for chemotherapy-resistant cases. Breast metastasis should be considered when
evaluating adolescent girls diagnosed with RMS.
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Background/Objectives: Second malignant neoplasms (SMN) are serious late events in
childhood cancer survivors (CCS). Late endocrinological toxicities are also common
and lead to a frequent use of growth hormone (GH) in this population.
Design/Methods: A 13 month-old female was diagnosed with MYCN stage IV
neuroblastoma. She was successfully treated with etoposide based courses, surgery and
high dose chemotherapy with stem cell rescue. Twelve years later, the patient was
started on substitutive recombinant GH therapy due to a progressive growth delay.
Injections were performed in both thighs with a maximum dosage of 0,35 mg per kg
per week. While on treatment the patient presented a mass of the left thigh on one of
the injection site. Imaging was consistent with a hematoma. However, the mass had to
be surgically removed secondary to acute pain caused by a local progression. Pathology
revealed a Ewing-like ESWR1 negative CD99+ CIC-DUX4 sarcoma with lymph node
involvement. Despite chemotherapy, a second surgical resection and radiotherapy the
patient died from local and metastasis progression.
Results: SMN are not uncommon in CCS. The role of radiatiotherapy is widely
recognized, chemotherapies such as anthracyclines and particularly at high doses have
been shown to be independent risk factors for SMN. GH has an intrinsic proliferative
effect but has not been correlated with SMN in CCS. Upon subcutaneous injection a
substantial part of GH is locally degraded with on-site activity. Thus previous
chemotherapies could constitute a first hit and added with local GH effect have led to
the development of this SMN.
Conclusion: Both previous anti neoplastic therapies and GH injections contributed to
the development of this injection site CIC-DUX4 sarcoma.
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Background/Objectives: Sirtuins are histone de-acetylases that were first discovered in
yeast. There are seven sirtuins in mammals, they share the same catalytic domain but
with different enzymatic activity, cellular localization and various substrates.
Sirtuin-a(SIRT1) is the most studied mammalian Sirtuins.
Design/Methods: In our project, we ran IP to test protein interactions of SIRT1 and its
different substrates. Then several Sirtuin inhibitors were used with different
concentration to break down those interactions. After treatment, an antibody-based
probe-ligase-amplification method was used to detect these interactions.
Results:We have found that in Rhabdomyosarcoma and synovial sarcoma, SIRT1 has
interaction with histones and some non-histone chromatin proteins such as SSX, TLE1,
H3, H3K9, etc. Interactions were also observed in cytoplasmic lysis. These interactions
can be inhibited by Sirtuin inhibitors, like tenovin-6 and entinostat at 4uM and 10nM.
Conclusion: Therefore, we believe that our findings may help understanding the
mechanism of how Sirtuin inhibitors work.
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Background/Objectives: Epithelioid sarcoma (ES) is an uncommon subtype of soft
tissue sarcoma that occurs at a median age of 23-40 years at diagnosis. Malignancy in
pregnancy is also regarded as an infrequent phenomenon, with an occurrence estimated
at about one per 1,000 births.
Design/Methods: Case of a 17 year old gravid female diagnosed with ES metastatic to
the placenta.
Results: Seventeen year old G1P0 female presented at 31 weeks gestation with an
ulcerated wound involving her right fifth digit. Lesion initially appeared as a small wart
at age 10 but started ulcerating over the past year. Two months prior to evaluation, she
developed large masses over her right chest wall and axilla. Biopsy confirmed ES, and
staging revealed widely metastatic disease. Given the significant morbidity with high
dose ifosfamide and doxorubicin therapy in a gravid patient with minimal curative
benefit, decision was made to defer therapy until after the delivery of the infant. She
was induced at 34 weeks gestation and therapy initiated; the patient clinically
deteriorated shortly after and died. Placental pathology demonstrated intervillous
invasion of ES.As most cases of infant disease occurred within the first 12 months,
decision was made for whole body surveillance MRI every 3 months for the first year of
life. At 10 months of age, the infant remains free of disease.
Conclusion: There are no guidelines concerning appropriate surveillance of infants born
to mothers with sarcoma and placental metastases. Reports of fetal spread propose that
intervillous invasions may place infants at considerable risk for disease. This is the first
reported case of epithilioid sarcomatous placental invasion in a pediatric patient. With
many non-teratogenic chemotherapeutic agents available, the option of therapy should
be offered to a pregnant patient to possibly decrease the risk of metastatic spread to the
placenta and, therefore, decrease the risk of disease in the infant.
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Background/Objectives:We reported clinical features and treatment results of children
diagnosed with rhabdomyosarcoma (RMS) in our institution.
Design/Methods:Medical records of patients with RMS whose treatment and follow up
had been carried out in our institution between 1988 and 2015 were analyzed
retrospectively.
Results: There were 44 patients with a median age of 72 (13-204) months.The primary
tumor site was head and neck in 66%; genito-urinary in 18%; gluteal in 12%; paraspinal
in 2% and intraabdominal in 2% patient. Biopsy was performed 64% and primary
surgery 36% patient at diagnosis.The tumor histology was embryonal in 91% and
alveolar in 9% cases. Clinical group (CG) distribution of patients: CG 1: 4 (9%), CG 2:
3 (7%), CG 3: 34 (77%), CG 4:3 (7%). Primary surgery was resulted with total resection
in only 3 patients.“The Intergroup Rhabdomyosarcoma Study – IRS” -based treatment
regimens were used in 37 patients, COG ARST0431 protocol was used for other 7
patients.Thirty-six patients received conventional radiotherapy to the primary tumor
site, two patients to metastatic sites.Delayed surgery was performed in six patients and
complete resection was achieved in three of them.The median follow up time was 50
months (range 2 – 162), EFS was 58% at 5 and 10-years; overall survival was 66% at 5
and 10-years. Relapse/progression was developed in 9 head and neck, 4 genitourinary,
one intraabdominal and one gluteal RMS. Therapy related death was not seen.; median
relapse/progression time was 18 months (range: 20 days – 32 months). Nine relapsed
patients died from progressive disease; one patient with Li-Fraumeni syndrome died at
10th month of treatment.
Conclusion: Half of our patients had advanced stage disease, and 84% of patients was
in clinical group 3-4. Treatment response had been affected by tumor site. Local control
was problem particularly in parameningeal and genitourinary RMS. Survival rates are
acceptable.
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Background/Objectives: Inflammatory myofibroblastic tumour (IMT) commonly affects
children and young adults. Histologically, they display a variety of patterns and hence
overlap with other lesions of myofibroblastic origin. Approximately 50% of IMTs show
Alk1 rearrangement. Alk positivity is a promising predictive marker for treatment
response to crizotinib. We aim to review the histology of IMTs affecting paediatric
patients along with discussion on differential diagnoses and ALK positivity.
Design/Methods: A total of 46 patients below age of 15 years diagnosed with IMT at
various sites are included. Review of clinical details, imaging findings, histopathology
and immunohistochemistry was done. Differential diagnoses were considered and
discussed.
Results: Age range of patients was from 3 months to 15 years. M: F ratio was2:1.
Various sites were involved (head neck region: 12, GI tract : 12, lung and mediastinum:
9, bladder: 4, pelvis:3, others:6). Surgical resection was performed on 14 patients.
Histologically, myxoid / vascular pattern was the commonest. Small biopsy precluded a
definitive diagnosis of IMT in 5 patients. Three IMTs with spindle cell morphology
were difficult to differentiate from low grade myofibrosarcoma while two IMTs with
fibrous morphology were indistinguishable from fibromatosis. ALk positivity was seen
in 30% of tumours. One of the pancreatic lesions resembled IgG4 associated disease.
Conclusion: Our series demonstrates that IMTs affect a wide range of anatomical sites
in children. Histologically, typical myxoid/ vascular pattern aided diagnosis in most
patients. However, in spindle cell type of IMT, low grade myofibrosarcoma needed to
be excluded. Lack of atypical mitoses and absence of cellular atypia were deciding
features. Similarly, IMT with fibrous pattern resembled fibromatoses. Thus we
acknowledge a histologic overlap of IMT with other myofibroblastic tumours which
can impact clinical behaviour and treatment decisions. The incidence of Alk positivity
was 30% in our series which is lower than reported in literature.
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Background/Objectives: Annually, there are over 163,000 children diagnosed with
cancer worldwide. Infection with human immunodeficiency virus (HIV) increases the
risk of many cancers. Kaposi sarcoma (KS) is a common HIV-associated malignancy
and is more common where human herpes virus 8 is endemic, such as in equatorial
sub-Saharan Africa (SSA). The majority of children with HIV reside in SSA. The
overall incidence of KS among children in SSA is unknown due to few national cancer
registries, under-reporting, and limited diagnostic capabilities. This review compiles
available incidence data on KS among children in SSA and maps geographical burden
of disease.
Design/Methods: PubMed and Google Scholar were searched for all available studies
and registries documenting incidence of KS among children in SSA using key words
“pediatric”, “Kaposi sarcoma” and the respective country name. Studies that did not
report pediatric-specific data were excluded.
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Results: Sixty-four studies and two registries were evaluated from 48 countries in SSA.
Six case-control studies and one registry were included. Incidence data were extracted
and visually mapped. All included studies came from Eastern and Southeastern Africa
with a notable absence of data from Swaziland, which has the world’s highest HIV
prevalence. After indirect adjustment for pediatric population, the incidence of KS
among children ranged from 0.09 per 100,000 person-years in the equatorial nation of
Kenya to 160 per 100,000 person-years in the neighboring equatorial country Uganda.
Conclusion: There is a dearth of epidemiological information on KS among children in
SSA. Contrary to adult studies, which report the incidence of KS being highest in
equatorial SSA, this review suggests that living in equatorial SSA may not increase the
risk of KS among children. Larger national and regional studies are needed to
determine overall burden of disease for KS among children in SSA and to further
elucidate the association between geographic location and KS.
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Background/Objectives: Rhabdomyosarcomas are the most common soft tissue tumour
in children and account for 5-8% of childhood cancers , and 19% of all paediatric soft
tissue sarcomas. Overall 65% of all rhabdomyosarcomas are diagnosed in patients
under 10 years old. There is a slight male predilection (M:F 1.67:1 7) with Caucasian
children are affected more often than other races.
Design/Methods: Rhabdomyosarcoma usually manifests as an expanding mass;
symptoms, however, depend on the location of the tumour. 40% of the tumours occur
in head and neck region, including the orbits. Outcome of rhabdomyosarcomas varies
with the location of the primary site. The natural history, pattern of metastatic spread,
treatment, and prognosis of childhood rhabdomyosarcoma vary with the anatomic site
of the lesion. The orbit,head and neck (parameningeal) and genitor urinary (non
bladder/prostate) tumours represent the most prognistically favoured tumours. Factors
important with regard to prognosis includes large tumours (>5cm in size), invasive
tumours and locoregional lymph nodes. These prognostications can be determined at
CT scan and MRI.We present characteristic radiological features of paediatric
rhabdomyosarcomas in different locations, with their prognostic features.
Results: Radiology plays an important role in initial diagnosis, prognostication, staging
and monitoring response assessment of rhabdomyosarcomas in children.We intend to
present characteristic radiological features of paediatric rhabdomyosarcomas in
different locations, with their prognostic features.
Conclusion: Rhabdomyosarcomas are the most common soft tissue tumour in children.
Pediatric Oncologists should be aware of the various radiological features, which are
significant in prognostication and response assessment of these tumours in children.
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Background/Objectives: The aim of the study was to analyze clinical data and therapy
Results: in a cohort of patients with malignant rhabdoid tumor (MRT) of the liver
treated in federal cancer center in Russian Federation.
Design/Methods: Sixteen patients with extracranial MRT were treated during the period
of 02.2012-01.2015. Four (25%) patients with MRT of the liver were included in this
analysis. We analyzed age at diagnosis, alpha-fetoprotein level, stage of the disease
(according to Intergroup Rhabdomyosarcoma Study criteria), presence of initial tumor
rupture and therapy response. All diagnosis were established by histopathologic
examination and confirmed by lack of nuclear expression of INI1. Patients were treated
according to European Rhabdoid Tumor Registry recommendations.
Results: Diagnosis was verified on the 1st year of life in all 4 (100%) cases. Median age
was 6.75 months (range 1-11 months). M:F ratio was 4:0. There was no elevation of
alpha-fetoprotein level at diagnosis. Only 1 (25%) patient had localized disease, 3 (75%)
patients had distant metastases. Localization of metastases included lungs; lungs and
the opposite lobe of the liver; lungs, left adrenal gland and peritoneal metastases. Two
(50%) patients had initial tumor rupture. All patients had IRS IV (1 patient with
localized disease due to tumor rupture). Surgery was done in 2 patients (50%): delayed
R0 resection (1), initial R1 resection and secondary R0 resection (1). 2 (50%) patients
had unresectable tumors. Median number of chemotherapy cycles was 5.5 (range 4-9
cycles). Outcome: 1 (25%) patient - alive with no evidence of disease for 24 months; 3
(75%) – died due to early progression.
Conclusion: Our data confirmed unfavorable prognosis due to advanced stage of the
disease and poor response to therapy. However intensified dose-compressed
chemotherapy and aggressive surgical resection could be potentially curative in subset
of patients.
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Background/Objectives: Osteosarcoma is the most common primary bone tumor of
childhood. To improve on historically sub-optimal results, a dedicated musculoskeletal
unit established in 2009 and a new protocol initiated. To study demographic profile,
treatment related toxicities, outcome and survival of patients with osteosarcoma treated
with Cisplatin-Adriamycin-Methotrexate (100 mg/m2-75 mg/m2-12g/m2)
chemotherapy as in EURAMOS-1.
Design/Methods:Medical records of 47 children  18yrs, treated during 2009-2013
were reviewed. Toxicities were assessed using CTCAE ver 4.01, and survival by Kaplan
Meier method.
Results: Pretreatment demographic and disease characteristics included median age 15
yrs (5 – 18 yrs), with 68% males (32/47), BMI<-2 (Z score) in 14/47 patients; primary
extremity tumor in 96% (45/47), large tumors(>8cm) in 87% and non-metastatic
disease in 75% (35/47) patients. Limb salvage surgery was possible in 36 patients while 3
underwent amputation. The most common surgical complication was wound infection
(5).HUVOS grade III and IV necrosis occurred in 62% (24/39) cases. Clinically
significant toxicities observed with Cisplatin-Adriamycin (190 cycles) and methotrexate
(432 cycles) included mucositis grade III/IV in 6%(11/190), 5%(24/432) cycles, febrile
neutropenia in 20%(38/190), 1%(5/432) cycles, hospitalizations for supportive care in
22%(43/190), 8%(34/432) cycles respectively. Each patient required an average of two
hospitalizations for toxicity and delay in next cycle of chemotherapy was observed in 2
cycles per patient. At the end of treatment 35/47 patients remained in remission, 4
progressed, 6 abandoned therapy and there were two therapy related deaths. Event free
survival (EFS) was 53%, there were 9 relapses, and none were salvaged. Favorable
prognostic factors for EFS were absence of metastasis (62%, 25%, p0.005) and >90%
necrosis (78%, 27%, p0.01); median follow up for survivors was 33 months.
Conclusion: This EURAMOS-1 based protocol was feasible in our setting with modest
survivals and limb-salvage in most patients. Febrile neutropenia was the commonest
toxicity requiring hospitalization. Abandonment reduction strategy is needed.
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Background/Objectives: The purpose of the study is to summarize the clinical
characters of the non-rhabdomyosarcoma soft tissue sarcomas.
Design/Methods:We performed a retrospective analysis of all the data of
non-rhabdomyosarcoma soft tissue sarcomas in our hospital in 2003-2014. We
followed-up all the patients by telephone or letter to obtain their condition
post-operation.
Results: There were 55 cases in total. 1. There were 8 pathological types: synovical
sarcoma, fibrosarcoma, PNET, hyalocyte sarcoma, acinous soft tissue sarcoma,
embryonal sarcoma, malignant small cell sarcoma and extraosseous Ewing’s sarcoma.
The case load of these 8 pathological types were 14(25.45%), 15(27.27%), 10(18.18%),
5(9.09%), 4(7.27%), 3(5.46%), 3(5.46%) and 1(1.82%), respectively. 2. There was a
difference about tumor location among the eight sarcomas. (P<0.01) 3. There was no
difference about the therapeutic protocols. (P>0.05) Radical operation and radical
operation plus chemotherapy were the popular therapeutic protocols. 4.There was a
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difference about the use of chemotherapy(P<0.01).The utilization of chemotherapy in
PNET, malignant small cell sarcoma, acinous soft tissue sarcoma and embryonal
sarcoma were 100%, while the utilization of chemotherapy were 42.7% in other four
sarcomas. 5. The survival rate was 49.09%, the loss to follow-up rate was 12.73% and
the mortality rate was 38.18%. The two-year survival rate was 50.91% and five-year
survival rate was 18.18%.
Conclusion: There were several types in soft tissue sarcomas, and they needed to be
diagnosed by pathological examination. The non-rhabdomyosarcoma soft tissue
sarcoma should be performed radical operation or radical operation plus chemotherapy.
Posters: Supportive Care/Palliative Care
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Background/Objectives: A qualitative study was conducted to investigate the impact of
Soft Touch Therapy in Palliative and End of Life care, among children with cancer. It
was observed that most of the children in palliative and end of life care reported
persistent pain with increased heart rate, anxiety, aggression, irritation and distress.
Design/Methods: After a review of the literature, soft touch therapy was provided
randomly for those children who had irritated, aggressive, anxious and distressed
behavior. For this purpose, a sample of *N=480 was selected from Children Cancer
Unit, The Indus Hospital, Karachi. A qualitative change in behavior was observed, in
terms of reduced pain, anxiety, irritation and aggression, while heart rate returned to
normal slightly. The study lasted for two years, all through which necessary precautions
had been kept in mind.
Results: The results show a great impact of soft touch therapy for pain management
and other psycho-social factors, in children with cancer.
Conclusion: Soft touch therapy has the potential to improve the quality of life as well as
the well-being of children in palliative and end of life care.*Number of Patients.
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THE DEVELOPMENT OF SUPPORTIVE CARE GUIDELINES TO ENHANCE
OUTCOMES OF CHILDRENWITH CANCER IN THE CARIBBEAN
E. Adler1, A. Koo2, O. Abla3, U. Allen4, C. Bodkyn5, L.L. Dupuis6,7, H.A. Hume8,9,
W. Lau10, S. Read1,4, C. Sin Quee11,12, S. Weitzman1,3, V. Blanchette1,3
1The Hospital for Sick Children, Centre for Global Child Health, Toronto, Canada; 2The
Hospital for Sick Children, Department of Pharmacy-Division of
Haematology/Oncology, Toronto, Canada; 3The Hospital for Sick Children, Department
of Paediatrics-University of Toronto and Division of Haematology/Oncology, Toronto,
Canada; 4The Hospital for Sick Children, Department of Paediatrics-University of
Toronto and Division of Infectious Diseases, Toronto, Canada; 5University of the West
Indies- St. Augustine Campus, Department of Clinical Medical Sciences- Faculty of
Medical Sciences, Port of Spain, Trinidad and Tobago; 6The Hospital for Sick Children,
Department of Pharmacy-University of Toronto and Division of Haematology/Oncology,
Toronto, Canada; 7Peter Gilgan Centre For Research and Learning PGCRL, Child
Health Evaluative Sciences, Toronto, Canada; 8University of Montreal, Depratment of
Pediatrics, Montreal, Canada; 9CHU Ste-Justine, Division of Hematology/Oncology,
Montreal, Canada; 10The Hospital for Sick Children, Paediatric Laboratory Medicine,
Toronto, Canada; 11Princess Margaret Hospital, Paediatrics, Nassau, The Bahamas;
12University of the West Indies, SCMR, Nassau, The Bahamas
Background/Objectives: Non-communicable diseases such as cancer are emerging as an
increasingly significant cause of childhood mortality. In high-income countries (HIC),
childhood cancer survival is more than 80%, compared to 10-30% in low and middle
income countries (LMIC). Established paediatric cancer centres in HIC like the
Hospital for Sick Children (SickKids), Toronto, Canada are well positioned to share
clinical expertise with counterparts in resource-constrained countries. Launched in
March 2013, the SickKids-Caribbean Initiative (SCI) aims to enhance care for children
with cancer and blood disorders in 6 Caribbean countries: The Bahamas, Barbados,
Jamaica, St. Lucia, St. Vincent and the Grenadines and Trinidad and Tobago. In order
to prevent deaths due to complications of treatment interventions, intense protocol
regimens must be matched with appropriate supportive care.
Design/Methods: In consultation with Caribbean clinicians, 5 priority areas in
supportive care were identified: Febrile Neutropenia; Chemotherapy-induced nausea
and vomiting; Hyperleukocytosis; Tumour Lysis Syndrome; and Transfusion Medicine.
Specialists developed a survey for each respective area, which were then circulated to
Caribbean clinicians. Existing international and SickKids clinical practice guidelines
were used as a reference to draft documents integrating survey feedback about current
practice and available resources.
Results: At an upcoming workshop, SCI representatives will review each of the 5
documents, with consideration paid to local institutional implementation and
adherence. These will then be further adapted for institutional use in each country, and
a clinical delegate from each institution will be responsible for developing an
implementation plan for their clinical setting and finalizing the documents for local use.
Conclusion: Appropriate strategies need to be developed for the Caribbean clinical and
social setting, as resource-constraints create challenges for disease management and
supportive care. Through standardizing supportive care practices based on the best
available evidence, SCI hopes to contribute to increasing survival in the Caribbean.
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PALLIATIVE CARE NEEDS OF FAMILIES OF CHILDRENWHO DIE FROM
CANCER: A GHANAIAN STUDY
C.A. Adu1, A. Sarpong-Oduro2
1Korle Bu Teaching Hospital, Accra, Ghana; 2Korle Bu Teaching Hospital, Department
of Child Health, Accra, Ghana
Background/Objectives: In developing countries, a high percentage of children with
cancer present at an advanced stage. Often treatment for curative intent is not feasible
in such cases and the children are given palliative care. Ensuring palliative care is
effective and addresses the needs of the children and their families is important. The
objective of this study was to obtain feedback from parents of children who had died
from cancer to get to know their experiences and their needs. This would inform
improvements to the palliative care service.
Design/Methods: This qualitative study was undertaken at the Paediatric Oncology Unit
in Accra, Ghana. A questionnaire with open-ended questions, was administered to a
sample of parents whose children received palliative care and had died from cancer in
2014. Informed consent was obtained.
Results: Ten families were approached and six agreed to be interviewed. Parents were of
the opinion that cancer could not be cured. They all understood that palliative care was
to make the child relieve symptoms “until their peaceful death”. Of note is that
although almost all the children had received morphine for pain relief, half of them
stated it was inadequate. They all had an input into their child’s care. Although parents
felt the relationship with professionals was good, two were dissatisfied as “professionals
hardly understand us”. Of the three families that encountered the clinical psychologist,
two were not impressed, in quotes “he forgot every patient is unique”. Improvements
suggested included “individualized care”, privacy and more spiritual input.
Conclusion: Palliative care should form an important component of Paediatric
Oncology training for health workers in developing countries so that there will be
effective symptom control and they will be responsive to the individual needs of
children and families.
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THE INCIDENCE OF NEUTROPENIC FEVER THE FIRST 6 MONTHS OF
ANTI-CANCER THERAPY IN A SWEDISH COHORT OF CHILDREN AGED
7-16 YEARS
M. af Sandeberg1, E. Johansson†2, L. Wettergren3, O. Björk1, A. Nilsson4
1Karolinska Institutet, Childhood Cancer Research Unit-Department of Women’s and
Children’s Health, Stockholm, Sweden; 2Karolinska Institutet, Department of Medicine,
Stockholm, Sweden; 3Karolinska Institutet, Division of Nursing- Department of
Neurobiology-Care Sciences and Society, Stockholm, Sweden; 4Karolinska Institutet,
Clinical pediatrics- Department of Women’s and Children’s Health, Stockholm, Sweden
Background/Objectives: Children treated for cancer are at risk of significant
complications and even death during neutropenic fever (FN) episodes. There is a
knowledge-gap of factors predicting risk of severe infections, which leads to great
variation in clinical practice in the management of FN. In this nation-wide study we
investigated the incidence of antimicrobial treatments among children aged 7-16 years
during the first six months after start of cancer treatment.
Design/Methods: From January 2004 -May 2006, children newly diagnosed with cancer
and starting therapy (n=145) were invited to participate and 101 accepted (70%).
Disease and treatment related data were collected from the participant’s medical
records; including information on FN and laboratory data as well as demographic data.
An episode of infection was defined as the individual period of time use of oral or
intravenous antimicrobial treatment in association of symptoms of infection.
Results: 230 episodes of antimicrobial treatments were identified in 80 of the 101
children (79%) during the first six months of cancer treatment. Each child was in
median prescribed two (range 0-7) antimicrobial treatments. Microbial cultures were
obtained in 89 % (n=204) of the episodes. Children diagnosed with sarcoma were more
often receiving antimicrobial treatment whereas children diagnosed with central nervous
system (CNS) tumours and Hodgkin lymphoma more seldom received antimicrobial
treatment. Children diagnosed with acute lymphoblastic leukaemia and CNS tumours
were to a larger extent undergoing 1-2 episodes whereas children sarcoma and acute
myeloid leukaemia were to a larger extent undergoing >2 episodes. We will also provide
data on positive blood cultures and the presence of anti-microbial resistance.
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Conclusion: The majority of the children received antimicrobial treatment during the
first six month of treatment for cancer. Children with sarcoma were identified as a
“high-risk” group for FN together with AML patients.
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EVALUATION OF DO NOT RESUSCITATE (DNR) ORDERS AT A SINGLE
CENTER IN JORDAN
A. Al- Nassan1, S. Awadi1, A. Hmood1, I. Sultan2
1King Hussien Cancer Center, Pediatric, Amman, Jordan; 2King Hussien Cancer Center,
Department, Amman, Jordan
Background/Objectives: : Do not resuscitate orders (DNR) are crucial in planning
end-of-life care. Successful discussion of these orders depend on family background,
care giver’s perceptions and patients conditions.
Design/Methods:We retrospectively analyzed charts of patients who had DNR orders
placed between January 2006 and December 2011. We analyzed demographics, DNR
order documentation, and timing of DNR orders in relation to diagnosis and death.
Results:We evaluated the charts of 76 patients (44 males). The median age at diagnosis
was 5 years (range, 0 to 16.7). DNR orders were obtained from first attempt in 55
patients (76%). The majority of orders were obtained by primary oncologist (92%),
while the rest were placed by palliative care team and intensive care consultants. Orders
were placed in the outpatient clinic (48%), in-patient unit (41%) or intensive care unit
(11%). The median duration from DNR order placement to death was 2.1 month
(range, 0 to 25) and was significantly longer for patients with solid tumors (3.4 months)
in comparison to CNS tumors (1.6 months) and Leukemia/Lymphoma patients (0.4
months); p=0.022.
Conclusion: Our study showed no clear obstacles in placing DNR orders among our
patients. We believe that better analysis requires better documentation of the process
including all unsuccessful attempts to place the order. Patients with leukemia/lymphoma
in our center should have end-of-life planning done at an earlier stage.
P-562
CYTOMEGALOVIRUS INFECTION IN CHILDREN AFTER BONEMARROW
TRANSPLANTATION: RISK FACTORS, CLINICAL ASPECTS AND
OUTCOMES
M.M. Alam1, M. Bayoumy1, B. AL-enezi1, A. Areej1, I. Abosoudah1
1King Faisal Specialist Hospital & Research Centre-J, Department of Oncology, Jeddah,
Saudi Arabia
Background/Objectives: CMV infection remains the most common and potentially
severe viral complication in patients given HSCT.
Design/Methods: This study was a retrospective analysis of clinical, laboratory and
outcome data of all pediatric patients underwent BMT, at KFSH&RC-J, from July
2005 to June 2014 to identify the risk factors associated with the development of CMV
in post BMT patients and their outcomes. A p-value of < 0.05 was considered
statistically significant.
Results: 95 pediatric patients were admitted for BMT. The mean age was 6.5 ± 4 years.
Out of males were 63 (66.3%) and females were 32 (33.7%). Majority of patients have
hematological malignancy (n=31; 32.6%); out of them ALL (n=9), AML (n=15),
lymphoma (n=7), followed by beta-thalassemia (n=13), sickel cell anemia (n=8),
aplastic anemia (n=6), fanconi anemia (n=3), solid tumors (n=19, 20%) including
neuroblastoma (n=16) and medulloblastoma (n=3) and HLH (n=5; 5.3%) and others
miscellaneous disorders (n=11, 11.6%). Allogeneic transplant (n=71; 74.5%) and
remaining were autologous transplant (n=24; 25.7%).CMV reactivation was observed
in 29 patients (29/95; 30.5%) within 100 day of post BMT. Out of them majority were
asymptomatic (n=21; 77.8) and remaining (n=9 ; 22.2%) had clinical
manifestation/organ involvement (Liver, Skin, GIT and CNS).Age < 5 year (p= 0.043),
AML (p=0.019), positive pre-transplant CMV status (p=0.007), conditioning regimen
containing ATG (p < 0.041), allogeneic BMT (p < 0.027) lymphopenia < 300/mm3
(p=0.049) were identified as risk factors for CMV reactivation. 36 (37.9%) patients
developed GVHD and overall 27 (28.4%) patients were expired. Both outcome variables
were statistically significant GVHD (OR: 5.4; 95% CI: 2.42-12.18) and mortality rate
(OR: 8.1; 95% CI: 2.51-25.61) in patients with CMV reactivation.
Conclusion: Young age, AML, positive pre-transplant CMV status, ATG containing
conditioning regimen, allogeneic BMT and lymphopenia were identifiable factors
associated with development CMV reactivation in post BMT pediatric patients.
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USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN
PEDIATRIC CANCER PATIENTS: SNAPSHOT OF DATA FROM RIYADH,
SAUDI ARABIA
A. AlKofide1, H. AlKofide2, L. Alnaim3, S. Almazrou3, M. Barria1, M. Anas1, S. Jafri1,
K. Siddiqui1
1King Faisal Specialist Hospital & Research Center, Pediatric Hematology Oncology,
Riyadh, Saudi Arabia; 2King Saud University Hospital, Clinical Pharmacy, Riyadh,
Saudi Arabia; 3King Saud University, Clinical Pharmacy, Riyadh, Saudi Arabia
Background/Objectives: Despite the use of CAM globally there is no authorized body
governing its use in a heavily cultured population such as Saudi Arabia.The objectives
was to define prevalence and patterns of use of CAM by pediatric cancer patients at
King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia.
Design/Methods: A cross sectional study was conducted by interviewing parents of
children with cancer at a single institute from 2013-2014.
Results: A total of 228 parents were interviewed. Median age of parents was 37 years
(17-66), and 82.8% had post primary or more education. Out of the 228 interviewed
parents, 224 (98%) said they have used some form of CAM either in the past or current
treatment of their child. Herbs were used by 23% (55/224), dietary supplements by 46%
(103/224), and a combination of both by 98% (220/224). Among herbal remedies, the
most common type used was olive oil (60%), followed by black seeds [Nigella sativa
seeds] (41%), garlic (16%), and kurkum (9%). The dietary supplements that were
utilized included honey (48%), camel’s milk (11%), and Royal Jelly [queen bee’s honey]
(4%). In regards to alternative treatments, 95%, recited verses from Al-Quran, 82% used
holy water from the ZamZam Spring in Makkah Al-Mukaramah, followed by 9% who
reported using perfumed oils. In this sample, 53% of parents used CAM occasionally
for their child, and around 40% used it on daily basis. Overall, 61% of parents were
satisfied by the use of CAM; however nearly 60% used them without the knowledge of
the treating oncologist.
Conclusion: The high incidence of use of CAM among our pediatric cancer patients
warrants establishing a regional module for integrating CAM with cancer therapy and
underlines the importance of health care professionals asking routinely about the use of
CAM in this population.
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ASSESSMENT OF GRIEF AMONG HEALTH CARE PROVIDERS AT A
TERTIARY HOSPITAL IN THE PHILIPPINES AFTER A DEATH OF A
PATIENTWITH CHILDHOOD CANCER
D. Coniconde-Arca1, E. Melendres1, A. Goleta-Dy1, C. Leynes2, A.P. Alcasabas1,
P. Fajardo1, Y. Medina1
1University of the Philippines - Philippine General Hospital, Pediatric
Hematology-Oncology, Manila, Philippines; 2University of the Philippines - Philippine
General Hospital, Psychiatry, Manila, Philippines
Background/Objectives: Death is inevitable and people handle death differently. This
study aims to evaluate the intensity of grief experienced by the health care providers
(HPs) after the death of a pediatric cancer patient.
Design/Methods: A prospective cross-sectional descriptive study was done to measure
the intensity of grief among HPs who experienced bereavement from a death of a
pediatric patient with cancer using the Texas Revised Inventory of Grief (TRIG).
Results: A total of 105 respondents participated in the study (80% response rate) which
included medical interns (14%), nurses (28%), pediatric residents (30%), fellows (19%),
consultants (7%) and “others” (2%). Pediatric residents showed a more intense level of
past grief (p=0.0238) and present grief (p=0.0141) compared to the rest of the
respondents. Consultants scored the lowest percentile TRIG scores pertaining to
absence of grief, followed by 51.7% of nurses. Those belonging to the age group of
41-50 years old showed significant intensity of grief for the past and present grief
(p=0.0303 and p=0.0137, respectively). Only a small number of the study participants
(3%) had palliative training and only about half of the respondents (53%) sought some
emotional support after experiencing bereavement. There is no statistical difference in
the level of grief among male and female respondents.
Conclusion: Children with cancer are an endearing special group of patients, such that
when a child with cancer dies, an indelible mark is left behind especially among those
who took care of them. Everyday encounter with these patients endears them to their
HPs. For this reason alone, grief is experienced by the HPs most especially when their
patient dies. Experiencing grief can be a long process to endure; hence emotional and
psychological support is important because when grief is ignored or suppressed, it may
become a source of stress and even dysfunction.
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HIGHMORTALITY FROM CARBAPENEM RESISTANT GRAM NEGATIVE
SEPTICEMIA IN THE NEUTROPENIC CHILD IS A SIGNIFICANT
CHALLENGE IN INDIA
R. Arora1, B. Tarai2
1Max Super-Speciality Hospital, Medical Oncology, New Delhi, India; 2Max
Super-Speciality Hospital, Microbiology, New Delhi, India
Background/Objectives:Morbidity and mortality from gram negative septicemia (GNS)
in children with cancer is well recognized. Increasingly multidrug resistant infections,
including carbapenem resistant, are being reported. Our objective was to identify the
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prevalence, resistance patterns and outcomes of GNS in children with cancer at our
centre.
Design/Methods:We retrospectively analysed data of all newly diagnosed and treated
pediatric (0-18 years) cancer patients in 2 centres in New Delhi who had positive gram
negative bacterial growths in their blood cultures in the year 2014. Bacterial resistance
to various antimicrobial agents was determined. Outcome after septicemia was
documented.
Results: 256 blood cultures were done on 129 children (median 1 blood culture/child,
range 0-16 blood cultures/child). Of these 45(17.6%) were positive with 27(60%) gram
negative bacteria (Escherichia coli 8, Klebsiella pneumoniae 8, Pseudomonas aeruginosa
6, Enterobacter cloacae 3, Acinetobacter baumanni 2), 15(33.3%) gram positive bacteria
and 3(6.7%) fungal. Resistance to piperacillin/tazobactam, amikacin and meropenem
were seen in 68%, 51.8% and 63% of the gram negative bacterial isolates respectively
with resistance to all three in 48.1% of isolates. There were no deaths with gram positive
bacterial or fungal septicemia, but 5 deaths in the 14 children with 27 episodes of GNS
giving mortality rates of 35.7% per GNS child and 18.5% per GNS episode respectively.
Factors associated with GNS mortality were disease group (leukemia/NHL/transplant
27.8% vs solid tumours 0%, p=0.13), neutrophil count (ANC<0.5 45.4% vs ANC>0.5
0%, p=0.006) and carbapenem resistance (resistant 29.4% vs sensitive 0%, p=0.12). 5
out of 6 (83.3%) children with carbapenem resistant GNS who were also neutropenic
died. There were no deaths in children with GNS who either had carbapenem sensitive
growths or were not neutropenic.
Conclusion: Septicemia in children with cancer is characterized by GNS which are often
multidrug resistant (including carbapenem resistant) and carry a high mortality when
accompanied by neutropenia.
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DEVELOPING IMMUNIZATION SOLUTIONS FOR CHILDRENWITH
CANCER IN INDIA: A QUALITY IMPROVEMENT INITIATIVE
R. Arora1,2, P. Mandal3, N. Moulik4, S. Prabha2, P. Bagai2, J. Chandra3
1Max Super-Speciality Hospital, Medical Oncology, New Delhi, India; 2Cankids,
Quality Care Research and Impact, New Delhi, India; 3Kalawati Saran Children’s
Hospital, Pediatrics, New Delhi, India; 4Saroj Gupta Cancer Centre & Research Institute,
Pediatric Hematology Oncology, Kolkata, India
Background/Objectives: Children with cancer need special considerations regarding
their (and their siblings/parents) immunization during and after their cancer treatment.
Several guidelines are available in the resource rich countries, but these are not
completely applicable in the Indian context. We aim to address this gap by developing
guidelines and advocating for their implementation.
Design/Methods: Firstly, a survey was conducted among clinicians treating children
with cancer in India to understand current practices. Secondly, existing guidelines were
gathered from across the world. Simultaneously, the Indian Academy of Paediatrics
Committee on Immunization (IAPCOI) was contacted for their recommendations. All
this information was collated and gaps or contradictions identified.
Results: The survey of 37 institutes from 21 centres in India identified areas of
homogeneity (eg. contraindicated vaccines, time gap between end of therapy and re
immunization) and areas of heterogeneity (varicella exposure prophylaxis, influenza
vaccinations). Based on this, draft guidelines were developed and then disseminated to
the members of the North India Paediatric Oncology for feedback. The guidelines are
now finalised and include recommendations for the index child, siblings and parents,
both during and after end of treatment and take into account the index child’s age and
previous immunisation status.
Conclusion: Guidelines for immunisation of children with cancer (and their
siblings/parents) have been developed and tailored to the Indian context. Efforts are
now ongoing to adopt and disseminate these recommendations and to advocate for
their implementation.
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INTERVENTIONS OTHER THAN ANTICOAGULANTS AND SYSTEMIC
ANTIBIOTICS FOR PREVENTION OF CENTRAL VENOUS
CATHETER-RELATED INFECTIONS IN CHILDRENWITH CANCER - A
COCHRANE SYSTEMATIC REVIEW
K. Cooper1, R. Arora2, T. Eden3, B. Pizer1
1Alder Hey Children’s Hospital, Paediatric Oncology, Liverpool, United Kingdom; 2Max
Super-Speciality Hospital, medical oncology, New Delhi, India; 3University of
Manchester, Academic Unit of Paediatric and Adolescent Oncology, Manchester, United
Kingdom
Background/Objectives: Use of central venous catheters (CVC) in treatment of children
with cancer is associated with infective complications. This systematic review aimed to
find which interventions, if any, are effective in preventing CVC-related infections in
children with cancer. Antibiotics and anticoagulants were excluded as they have been
examined in other Cochrane reviews.
Design/Methods: A systematic search of electronic databases (CENTRAL, MEDLINE,
EMBASE and CINAHL(R) from inception till Oct 2014) was done. We also searched
reference lists of relevant articles and international conference proceedings. Procedures
for study selection, data extraction and quality assessment were specified a priori. The
primary outcome was catheter-related blood stream infection (CRBSI) and secondary
outcomes were catheter associated infection (CAI), exit infection, tunnel infection,
pocket infection and premature removal of the catheter.
Results: The search strategy yielded 922 articles. Seven trials involving five different
interventions were included. Two trials (n=680) compared flushing CVC with urokinase
(with or without heparin) versus heparin alone. There was non-significantly decreased
CAI (Rate Ratio 0.72, 95%Cl 0.12-4.41) in the urokinase arm. Two trials (n=183)
compared flushing CVC with taurolidine versus heparin alone. There was
non-significantly decreased CAI (Rate Ratio 0.54, 95%CI 0.06-5.25) in the taurolidine
arm. One trial reported a statistically significant reduction in CRBSI in the taurolidine
group. One trial (n=307) compared ethanol lock with heparin locks and showed a
statistically significant reduction in CAI in ethanol lock group. One trial (n=113)
compared frequency of catheter dressing change every 15 days versus every 4 days and
found no difference in premature catheter removals. One trial (n=83) found no
difference in premature catheter removals when insertion site was internal jugular or
subclavian vein.
Conclusion: A lack of adequate studies reporting standard outcomes from making any
definitive conclusions about the effectiveness of individual interventions for prevention
of CVC-related infection in children with cancer.
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THE DEVELOPMENT OF CORE DATA SETS AND OUTCOMES - IMPROVING
THE QUALITY OF PAEDIATRIC PALLIATIVE CARE RESEARCH IN
CHILDRENWITH CANCER
C. Barton1, K. Richardson1, L. Brook2
1Alder Hey Children’s Hospital, Paediatric Oncology, Liverpool, United Kingdom; 2Alder
Hey Children’s Hospital, Paediatric Palliative Care, Liverpool, United Kingdom
Background/Objectives: Palliative care research in children with cancer is complicated
by small, heterogeneous sample populations. Meta-analysis allows combining and
contrasting of results from multiple studies to identify concordance/disagreement,
requiring consistency in research design, outcome definition and data reporting. We
analysed these elements of research studies exploring the measurement of health related
quality of life in children dying from cancer.
Design/Methods:MEDLINE, EMBASE, CINAHL and PsychINFO were searched
using a Child Health Filter and defined search (+/-Thesaurus/MESH terms). The
Cochrane Database of Systematic Reviews was screened. 7601 citations were identified.
Using predefined inclusion criteria, 810 were included for subsequent review against
clear exclusion criteria. After final rejection of ’maybes’ and duplicates, 22 were
included for data extraction.
Results: Research was predominantly cross-sectional - only 5 studies describing
longitudinal assessment of outcomes. 11/14 interview based studies conducted a single
interview. Definition of the palliative phase and the timing of cross sectional analysis
was inconsistent. Most studies were single centre. Variation was noted in the statistical
parameters used to report demographic/sample data, age ranges, and stage of life where
age was reported (e.g. death vs diagnosis). Data on children dying from cancer could
often not be extracted from children with other conditions or stages of
cancer.Reporting, grouping and subanalysis of diagnoses was inconsistent - no studies
used diagnostic codes (e.g ICD-10).
Conclusion: Paediatric palliative care research opportunities are scarce and precious.
Consistency in study design and result reporting is therefore imperative to facilitate
meta-analysis, and the reproducibility and generalisability of findings. There is need for
a clearly defined core data set and reporting standards to be included in future research,
with consensus on the definition of outcomes used and palliative care terminology.
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RESEARCH GOVERNANCE AND STUDY DESIGN IN PALLIATIVE CARE
RESEARCH IN CHILDRENWITH CANCER
C. Barton1, K. Richardson1, L. Brook2
1Alder Hey Children’s Hospital, Paediatric Oncology/Palliative Care, Liverpool, United
Kingdom; 2Alder Hey Children’s Hospital, Palliative Care, Liverpool, United Kingdom
Background/Objectives: Asking children dying from cancer, and their families, to engage
in palliative care research is sensitive and challenging. However, published research has
demonstrated that high quality studies are possible, ethical and acceptable, and can
inform future research design and conduct to improve the quality and benefit derived.
Design/Methods:MEDLINE, EMBASE, CINAHL and PsychINFO were searched
using a Child Health Filter and defined search (+/-Thesaurus/MESH terms). The
Cochrane Database of Systematic Reviews was screened. 7601 citations were identified.
Using predefined inclusion criteria, 810 were included for subsequent review against
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clear exclusion criteria. After final rejection of ´maybes´ and duplicates, 22 were
included for data extraction.
Results: 10 of 22 studies described difficulty generalising research findings, citing causes
including single centre research, low response/recruitment rates and poorly validated
instruments/tools. Other limitations cited included small heterogenous populations,
lack of standardised diagnostic/symptom classification/coding/definition, researcher
bias, retrospective study/recall bias, and a lack of longitudinal research. One third of
studies contained no consideration of research limitations.Good practice included
active determination of children’s ability/appropriateness to participate (e.g. sickness,
young age, recent diagnosis), indentification of parental distress and need for
psychological support, children’s ability to assent/consent for themselves, impact of
research on daily life (e.g. long distance), stipulating minimum time since bereavement,
and ensuring support/follow-up post-research.
Conclusion: Palliative care research in children with cancer is sensitive and challenging,
especially in the transition from curative to supportive care. There is a need therefore for
excellence and transparency in both study design and conduct, high quality monitoring
and safeguarding of research participant welfare, and to learn from previous research.
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SYMPTOMS AT THE END OF LIFE IN CHILDREN DYING FROM CANCER
C. Barton1, K. Cooper1, S. Ogden1, L. Brook2
1Alder Hey Children’s Hospital, Paediatric Oncology, Liverpool, United Kingdom; 2Alder
Hey Children’s Hospital, Palliative Care, Liverpool, United Kingdom
Background/Objectives: The aim of this study was to identify published literature and
research on symptoms and problems experienced by children with cancer during the
palliative phase of their life, identify problems with symptom management and
determine how trends in reporting could inform future research and studies.
Design/Methods:MEDLINE, EMBASE, CINAHL and PsychINFO were searched
using a Child Health Filter and defined search (+/-Thesaurus/MESH terms). The
Cochrane Database of Systematic Reviews was screened. 7601 citations were identified.
Using predefined inclusion criteria, 810 were included for subsequent review against
clear exclusion criteria. After final rejection of ´maybes´ and duplicates, 22 were
included for data extraction.
Results: Pain (15/22 studies), fatigue (10/22), gastrointestinal (7/22) and respiratory
(7/22) symptoms, were the most prevalent symptoms cited. Symptoms were generally
reported in the context of ’all participants’, and not considered in the context of
different age groups or developmental stages. Only some studies considered symptom
prevalence and intractability with regard to other subcategories, such as diagnosis (e.g
brain tumours) or time since entering palliation. In terms of statistical analysis there is
marked inconsistency in reporting parameters such as age groups, disease classification,
sex, treatment received, and length of palliation. Of concern is the low percentage of
TYA data reported and extractable from the identified literature (3/18 studies with
adolescents).
Conclusion: Despite effective analgesia and clinical experience in its management, pain
remains the most prevalent symptom at the end-of-life in children with cancer. Given
small patient numbers and acknowledged problems treating and managing teenagers
and young adults (TYA), TYA data is not extractable from the majority of published
results and findings. There is a need for consistency in the presentation and statistical
treatment of published research findings, and availability of subcategory data.
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DETERMINANTS AND CHARACTERISTICS OF PARENTAL INVOLVEMENT
IN QUALITY OF LIFE STUDIES IN CHILDREN IN THE PALLIATIVE PHASE
OF CANCER
C. Barton1, K. Cooper2, S. Ogden2, B. Lynda3
1Alder Hey Children’s Hospital, Paediatric Oncology/Palliative Care, Liverpool, United
Kingdom; 2Alder Hey Children’s Hospital, Paediatric Oncology, Liverpool, United
Kingdom; 3Alder Hey Children’s Hospital, Palliative Care, Liverpool, United Kingdom
Background/Objectives: Approximately 260 children with cancer die from their disease
each year in the UK. Despite children as young as 5 being able to self-report, both
retrospective and prospective paediatric palliative care research remains patients
dependent on parent and carer proxy reporting. As part of a larger systematic review
the characteristics and determinants of parental involvement in clinical research was
explored.
Design/Methods: Clearly defined search terms and a Child Health Filter were used to
search MEDLINE, EMBASE, CINAHL and PsychINFO. All search terms where
matched to the Thesaurus/MESH Terms of each database where relevant. The
Cochrane Database of Systematic Reviews was searched, with a manual search of
known studies and research for relevant texts. 7601 citations were identified. Using
predefined criteria, 810 were identified for initial inclusion and review against a set of
clear exclusion criteria. After removal of duplicates and discussion of ‘maybes’, 22
citations were included for review and data extraction.
Results: Parental recruitment was around 69% of those eligible. 31% of parents were
fathers and 61% were mothers. The reasons cited for increased maternal involvement
studies was that mothers were the primary caregivers, that fathers were primary
providers (financial), that fathers found it more difficult to participate in both
retrospective and prospective studies and paternal mental health. Reasons for
involvement in studies included a desire to contribute to the care of others, hope,
lengthening time with their child, and that participation in research improved the
frequency and quality of communication whilst receiving palliative care.
Conclusion: Parental recruitment in palliative research in children with cancer is
motivated and affected by multiple factors. These factors, for both prospective and
retrospective studies are a potential source of bias in considering the health and quality
of life needs of children dying from cancer and need further dissemination to improve
the quality of future research.
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HOSPITAL VOLUNTARY INCIDENT-REPORTING SYSTEM: A 4-YEAR
SURVEY ON DRUG-RELATED PROBLEMS IN PEDIATRIC ONCOLOGY
T. Bauters1, A. Maes1, J. De Porre1, C. Dhooge1, G. Laureys1
1Ghent University Hospital, Pediatric Hemato-Oncology and Stem Cell Transplantation,
Ghent, Belgium
Background/Objectives: Hospital and healthcare providers strive to deliver the safest
care possible. However, drug-related problems are commonly reported. In 2011, a
hospital incident-reporting system was implemented as part of the Quality Assurance
system to improve patient safety and quality of care. Each incident is discussed by a
multidisciplinary team of experts and preventive or corrective actions are defined and
elaborated.
Design/Methods: A 4-year retrospective analysis of drug-related incidents as collected
from the incident-reporting system was performed in a pediatric hemato-oncology
ward. Incidents were further subclassified. All drugs involved were categorized
according to the Anatomical Therapeutic Chemical (ATC) classification system of the
WHO, which enabled to identify these classes of drugs that were most frequently
involved.
Results: A total of 125 out of 196 (63.7%) (nearly) reported incidents involved drugs.
For 94 out them (75.2%), the ATC level could be retrieved or defined. Class L
(antineoplastic and immunomodulating agents) was most commonly involved and
represented 53.2% (n= 50) of drug-related incidents. This was followed by classes B
(blood and blood forming organs, more especially perfusion solutions) (16.0%, n=15), J
(anti-infectives for systemic use) (12.7%, n= 12), N (nervous system) (6.4%, n= 6), A
(alimentary tract and metabolism) (5.3%, n=5), H (systemic hormonal preparations)
(3.2%, n=3) and V (various drugs) (3.2%, n=3).
Conclusion: Drugs were very frequently involved in the incident reporting system and
mainly included antineoplastic and immunomodulating agents. This might reflect the
profile and complexity of a pediatric oncology ward. Preventive actions include
optimization of an electronic medication/chemotherapy prescription/administration
program (especially for antineoplastic/immunomodulating agents and perfusion
solutions), as well as introduction of new or revision of existing guidelines for
supportive care agents (anti-infectives, pain medication, chemotherapy induced nausea
and vomiting). Finally, it must be mentioned that an underreporting of incidents is
suspected.
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THE REASONWHY THE RAPID RESPONSE TEAMWAS CALLED FOR THE
ONCOHEMATOLOGIC PATIENTS IN A BRAZILIAN GENERAL HOSPITAL
G. Bomfim1, S. Brandi1, E. Santos1, M. Jaures2
1Hospital Israelita Albert Einstein, Pediatria, São Paulo, Brazil; 2Hospital Israelita
Albert Einstein, Inpatients, São Paulo, Brazil
Background/Objectives: In THE REPORT TO ERR IS HUMAN, the Institute of
Medicine concluded that many deaths occur in hospitals in the United States as result
of errors. One initiative promoted by the Institute for Healthcare Improvement,
recommended strategies to decrease the number of preventable inpatient deaths; one of
the recommended strategies was the implementation of a rapid response team (RRT),
also known as a medical response team who are available 24 hours per day, for
evaluation of patients not in the ICU who develop signs or symptoms of clinical
deterioration. Pediatric inpatients manifest deterioration for several hours before
cardiopulmonary arrest so RRTs have the potential to be an effective intervention in
pediatric inpatients. Objective: Analyze the reason why the RTT was called to attend
pediatric oncohematologic patients during 2014.
Design/Methods: A retrospective analysis of the pediatric oncohematologic inpatients
attended by the RTT in 2014.
Results: There were 64 callings for the pediatric RTT in our institution, 25% were for
oncohematologic patients. The base diagnostics were febrile neutropenia,
neuroblastoma, bone marrow transplantation and ALL; the causes for the RTT callings
were: fall (25%), convulsion (6%), sepsis (19%), respiratory failure (13%) and others
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(37%). All the patients were evaluated for the ICU pediatrician, that took conduct and
after revaluation sent or not the patient for the ICU. Only one patient was sent to the
ICU, all the others remained in their units under the staff care.
Conclusion: The RTT may have caused a significant reduction in the number of
cardiorespiratory arrests in oncohematological pediatric patients because all of them
who presented any symptom of deterioration were evaluated and taken care by the
team, independent of the cause of the calling. None of the evaluated patients developed
cardiac arrest.
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UNCOMMON FEATURES OF NEUROBLASTOMA IN CHILDREN: A REPORT
FROM A SINGLE INSTITUTION IN ALGERIA
N. Bouterfas1, A. Mohand-oussaid2, S. Chabni3, A. Khati3, A. Khati2, S. Tari2,
M.E. Khiari2, H. Boukhelal2, N. Benhalla2
1Algiers, Algeria; 2CHU Beni Messous, Pediatrics, Algiers, Algeria; 3CHU Beni
Messous, Radiology, Algiers, Algeria
Background/Objectives: Neuroblastoma is the most common extra cranial solid tumor
in childhood. It’s a tumor characterized by a large spectrum of clinical and biological
heterogeneity. However, if classical manifestations are well known, neuroblastoma
continues presenting with atypical and exceptional symptoms that makes it a real
enigmatic disease. A series of one hundred sixty seven patients with neuroblastoma is
reviewed to report on atypical clinical characteristics at initial diagnosis or within
evolution, and to analyze treatment features.
Design/Methods:We performed a retrospective study from 2005 to 2014, in a Pediatric
Oncology Unit of CHU de Beni Messous. One hundred sixty seven patients with
neuroblastoma were registered. They were evaluated by biochemical and imaging
investigations, classified and treated according to the conventional protocol regimens.
Results: There were four patients presenting with paraneoplastic neurological
symptoms including opsoclonus-myoclonus ataxia syndrome OMA, bulbar syndrome,
and polyradiculoneuritis .Two patients had a cardiomyopathy, and three patients
developed central nervous metastasis. We observed two cases with multifocal
neuroblastoma .Two children exhibited a secondary acute leukemia at the end of
treatment.Survival rates were poor in patients with central nervous system involvement
and secondary acute leukemia, except those with OMA and cardiomyopathy.
Conclusion: Patients with paraneoplastic symptoms exhibited a delay in diagnosis; while
metastasis to the central nervous system, and secondary leukemia were associated with
poor prognosis.
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FEASIBILITY AND BENEFITS OF HYPNOSIS IN A PEDIATRIC CANCER
CENTER
C. Chantrain1, I. Nyssen1, J. Marini1, N. Francotte1, S. Schifflers1, L. Tomme1,
P. Philippet1
1SUHOPL- Clinique de l’Espérance- Liège, Pediatric Hematology Oncology, Montegnee,
Belgium
Background/Objectives: Hypnosis is an efficient method to reduce pain and anxiety
induced by invasive medical procedures and by diseases such as cancer. While they are
easier to hypnotize than adults, children behave differently under hypnosis. They are
less limited by cognitive stereotypes and have a more permeable boundary between
imagination and reality. However, during procedures, children often fidget, appear
restless and require sustained and animated hypnotic suggestions. We performed an
observational study to determine the feasibility and the benefits of hypnosis in a
pediatric cancer center.
Design/Methods: Two psychologists and one pediatric oncologist of the center were
trained to hypnosis with a particular focus on pediatrics. Hypnotic techniques were
proposed to the children and their families as alternative or complementary approaches
for pain and/or anxiety management related to disease, treatment or invasive medical
procedures. Patients younger than 3 years or with vulnerable psychological profile
(autism, psychosis) were excluded.
Results: From February 2014 to February 2015, 66 sessions of hypnosis were achieved
in 22 pediatric patients (age 4 to 17 years) treated for cancer and hematological diseases.
The most common indications were lumbar punctures (23 in 8 patients), pain
management (19 in 3 patients), anxiety management (11 in 9 patients), placement of
venous catheter (6 in 3 patients), placement of nasogastric tube (2 in 2 patients). For
some invasive procedures (30/66), hypnosis was associated to analgesics and a mixture
of nitrogen monoxide and oxygen (MEOPA). Hypnosis did not increase the duration or
the cost of the procedures. Patients reported it as a positive experience and preferred it
to MEOPA alone or sedation with propofol for the following procedures.
Conclusion: Hypnosis is an inexpensive and not time-consuming method that can be
easily implemented in a pediatric cancer center to improve the wellness of patients and
their families.
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MICROBIOLOGICALLY-DOCUMENTED INFECTIONS AMONG CHILDREN
WITH FEBRILE NEUTROPENIA IN A PEDIATRIC-ONCOLOGY UNIT IN
NORTH INDIA
A. Das1, A. Trehan1, D. Bansal1
1Postgraduate Institute of Medical Education and Research PGIMER, Pediatric
Hematology-Oncology Unit-Department of Pediatrics, Chandigarh, India
Background/Objectives: Bacterial (15-25%) and fungal (2.6-5%) infections contribute to
morbidity and mortality in children with cancer. This study analysed the spectrum of
microbiologically-documented infections (MDI) and attempted to identify the
risk-factors.
Design/Methods: Children with febrile neutropenia (FN) were prospectively evaluated
over 1-year. Culture-positive bacterial infections were included. Invasive fungal
infections (IFI) were classified as ‘proven’, ‘probable’ and ‘possible’ using
EORTC/MSG (2008) criteria. Risk-factors for MDI were analysed.
Results:MDI was documented in 82/414 (19.8%); 59 (14.2%) had isolated bacterial
infection (IBI), and 16 (4.3%) had IFI. Eight (9.7%) had polymicrobial sepsis. Sites:
blood (92.5%), urine (3%), pus (3%) and stool (1.5%). Commonest bacterial isolates E.
coli (17.9%), S. aureus (13.4%) and K. pneumoniae (10.4%). Drug-resistance
demonstrated: MRSA (22%), ESBL and carbapenem-resistance (50% and 17% of
Gram-negative isolates). All patients with IFI had underlying haematological
malignancies (81.2% ALL, 18.7% AML). IFI were ‘proven’ in 37.5%, ‘probable’ in
37.5%, and ‘possible’ in 31.2%. Fungi isolated: Mucor (2), Aspergillus (5), Candida (2)
and Pseudallescheria (1). Twenty-six-percent (109/414) developed complications:
metabolic (15.4%), fluid-refractory shock (12%), respiratory failure (12%), ICU
admissions (6.7%), neutropenic enterocolitis (5.3%), acute kidney injury (4.5%) and
encephalopathy (3.9%). Mortality rate was 10.3% (43/414); 21% due to IFI, and 39.5%
to IBI. MDI were associated with complications (OR 4.44; 95% CI 2.6-7.4) and death
(OR 8.6; 95% CI 4.3-16.8) (p< 0.001). IFI resulted in 50% mortality. Chemotherapy
interval 7 days (OR 3.6; 95% CI 1.6-7.6), a clinical focus of infection (OR 1.9; 95% CI
1.1-3.4), and platelet count <20000/μL (OR 2.1; 95% CI 1.0-4.5) at admission were
predictive of MDI in multivariate analysis.
Conclusion:MDI in children with malignancies result in complications and mortality.
Drug resistance is a concern needing antibiotic stewardship. Developing a risk score for
identification of high risk febrile neutropenia children at admission might improve
outcomes.
P-577
PAEDIATRIC PALLIATIVE CAREMODEL IN A DEVELOPING COUNTRY;
EXPERIENCE AT THE CHILDREN HOSPITAL, LAHORE
M. Faizan1, S. Anwar1, A. Shabbir Ali2, M. Taj3
1Children Hospital, Haematology/Oncology, Lahore, Pakistan; 2Lahore General
Hospital, Paediatrics, Lahore, Pakistan; 3Royal Marsden Hospital,
Haematology/Oncology, London, United Kingdom
Background/Objectives: Palliative care is an emerging discipline worldwide. Palliative
care unit was established at Childrens hospital, Lahore in 2009 with guidance from Dr
Aziza Shad. A four bedded room is allocated for supervised by a dedicated team of
doctor, psychologist, pediatric nurse and social workers. Aim of this study is to evaluate
demographics and services provided to the paediatric palliative care patients at the
Children hospital, Lahore.
Design/Methods: A retrospective review done of patients admitted in the paediatric
palliative care ward from Jan 2009 till Dec 2014. Medical records were reviewed, data
analyzed regarding patient number, diagnosis, indication for palliative care, outcome
and psychological support provided.
Results: Palliative care services provided to 541 patients. Median age 6 years(3-14
years). M:F 1.5:1. Newly registered patients 49(64%), 92(36%) repeat admissions. Acute
Myeloid leukemia 167(31%), relapsed acute lymphoblastic leukemia120 (22%)
,neuroblastoma 29(5%) . One hundred and forty one (26%) patients expired,
83(16%)lost follow up, 314(58%) still on follow up. Morphine used for pain
management in syrup/ injectable form. Psychological support was provided to all of
them. Currently our palliative care program is hospital based. There are future plan to
extend palliative care at home, provide oral morphine for extended period.
Conclusion: Palliative care is essential right of child when curative treatment is not an
option. Good supportive/palliative care should be available throughout the
journey.Aim of such treatment is to make patient is pain free throughout treatment and
any respiratory distress and anxiety at end of life is managed with appropriate
psychological support and anxiolytics/sedatives. In Pakistan, access and use of
morphine is limited and there are no algorithms for proper end of life care.Palliative
care should be recognized as an essential component of health care and both health
care professionals and the general public need education about palliative care.
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PAEDIATRIC ONCOLOGISTS IN JOHANNESBURGMAKE APPROPRIATE
REFERRALS TO THE PAEDIATRIC INTENSIVE CARE UNIT (PICU) TO
ENSURE APPROPRIATE ALLOCATION OF SCARCE
RESOURCES
N. van Staden1, J. Geel2, J. Poole1, D. Ballot1
1Faculty of Health Sciences-University of the Witwatersrand, Paediatrics and Child
Health, Johannesburg, South Africa; 2Orchards-Johannesburg, South Africa
Background/Objectives: The decision to admit a child to a state-funded PICU is based
on the probability of immediate and long term survival, in the context of severe
resource constraints. The aim of this study was to determine whether referrals by
paediatric oncologists to PICU were appropriate and to challenge the perception that all
oncology patients have poor prognoses and should thus be refused admission to PICU.
Design/Methods: A retrospective descriptive audit of all PICU admissions over a
12-year period was performed. Indications for admission, underlying oncology
diagnoses, survival rates and causes of death were analysed.
Results: One hundred and seven patients were admitted 120 times. The average duration
of stay in ICU was 3.5 days (range 1 to 76 days). Underlying diagnoses were central
nervous system tumours (48.7%), solid tumours (34.7%), haematolymphoid
malignancies (9.9%) and other tumours. Indications for admission included
post-operative care (107), neutropaenic sepsis (10) and other (4). The mortality rate of
the oncology patients was 15.8%, compared to an overall mortality rate for PICU
patients of 13.8%. Six of the 10 patients admitted for neutropaenic sepsis died. Of the
107 admissions for post-operative care, 11 patients died from treatment complications.
The five year survival rate for oncology patients discharged from PICU was 62%. Most
deaths occurred as a result of surgical complications (31.6%) and neutropaenic sepsis
(31.6%).
Conclusion: In this setting, oncology patients admitted to PICU have a relatively low
mortality rate, implying that selection criteria for PICU admission are sufficiently
stringent. As there is no validated scoring system for admission of oncology patients,
the decision to admit a patient to PICU should be based on the overall projected
prognosis of the oncological condition. Paediatric oncologists should refer patients
with an expected good prognosis, and refer only those patients with neutropaenic sepsis
who do not have multi-organ failure.
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SELF-ESTIMATION OF PHYSICAL ACTIVITIES DURING CANCER
TREATMENT - A COMPARISON OF SUBJECTIVE AND OBJECTIVE DATA
ASSESSMENT
M. Götte1, S. Kesting1, J. Boos1, C. Seidel2, D. Rosenbaum2
1University Children’s Hospital Münster, Department of Pediatric Hematology and
Oncology, Münster, Germany; 2University Hospital of Münster, Movement Analysis
Lab-Institute of Experimental Musculoskeletal Medicine, Münster, Germany
Background/Objectives: Due to a lack of exercise recommendations in pediatric
oncology, exercise adherence should be supervised with the help of parameters
describing the subjective exertion. Therefore, it is essential that children and adolescents
are capable of reflecting their own patterns of physical activities with respect to the
amount and intensity. The present study investigated how reliable children with cancer
are able to self-estimate their physical activities during acute treatment.
Design/Methods: In the course of a previous study on physical activities (Götte et al.
2014), a sub-group (n=29) was evaluated with the objective assessment tool
StepWatchTM Activity Monitor (SAM) in addition to the self-reporting with a
questionnaire. The results of the two instruments were compared with regard to ‘daily
minutes of walking’ and ‘amount of moderate-to-vigorous physical activities’ (mvpa).
For the SAM measurements, walking was defined as an intensity of >20 and moderate
activity as >50 gait cycles per minute.
Results: The patients were 13.8±2.8 years of age and 3.4±2.0 months after initial
diagnosis of various tumor entities (45% leukemia, 31% bone tumors, 24% others). The
Bland-Altman plots indicated an average under-estimation of the questionnaire by 3.4
min., with the limits of agreement ranging from -104.2 to 97.3 min., i.e. a fairly
symmetrical under- and over-estimation. The mvpa deviated by -3.1 minutes (limits of
agreement -132.5 to 126.2 min.). The comparison for the days with at least 60 min. of
mvpa showed a marked difference with 3.1±2.6 self-reported days versus only 0.1±0.4
measured days.
Conclusion: The results of this pilot work indicate that patients may not reliably
self-estimate their physical activities. Therefore, exercise therapy should also incorporate
counseling of self-competence with respect to perception of physical activities. A
possible solution would be a self-supervision of activities with commercial activity
trackers (e.g. fitbit) which is an approach we are just evaluating in our institution.
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NETWORK ACTIVEONCOKIDS TO ENHANCE EXERCISE PROMOTION FOR
PEDIATRIC PATIENTS WITH CANCER IN GERMANY
M. Götte1, S. Kesting1, F.T. Baumann2, J. Wiskemann3, M. Wulftange4, K. Eckert5,
D. Rosenbaum6, J. Boos1
1University Children’s Hospital Münster, Department of Pediatric Hematology and
Oncology, Münster, Germany; 2German Sport University Cologne, Department of
Molecular and Cellular Sport Medicine, Cologne, Germany; 3National Center for Tumor
Diseases NCT Heidelberg and University Clinic Heidelberg, Division of Medical
Oncology, Heidelberg, Germany; 4University Hospital of Leipzig, Department of
Pediatric Oncology-Hematology and Hemostaseology, Leipzig, Germany; 5University of
Leipzig, Faculty of Sport Science-Institute of Exercise and Public Health, Leipzig,
Germany; 6University Hospital of Münster, Movement Analysis Lab-Institute of
Experimental Musculoskeletal Medicine, Münster, Germany
Background/Objectives: Feasibility of physical activities and exercise in pediatric
oncology during and after treatment has been proven and evidence for positive effects is
increasing [Baumann et al. 2013; Braam et al. 2013]. However, exercise promotion
programs are not yet generally established and are currently offered only in selected
hospitals. Therefore, a nationwide network called ActiveOncoKids was founded to link
and extend existing programs offering exercise for pediatric patients with cancer as well
as to establish sustainable funding possibilities.
Design/Methods: The network was established in 2012 and comprises sports scientists,
physiotherapists, medical doctors and psychologists. Network meetings are organized
every two years for all network members and twice a year within a smaller steering
group to discuss current progress, problems, and potential scientific collaborations.
Results: Since the establishment we were able to successfully support additional
hospitals and sports clubs in implementing exercise programs for pediatric patients with
cancer, to compose multi-centric research applications, to cooperate with health
insurance companies and to gain the confidence of medical professionals. Although we
progressed well so that about 20% of Clinics of Pediatric Oncology are now offering
exercise programs for children and adolescents with cancer (starting with 9% in 2012),
sustainability could not be achieved yet and most projects are not financially secured.
Conclusion: As a next step we plan to evaluate training programs and adjust methods of
assessments to scientifically evaluate the efficiency of exercise in large multi-centric
studies and draft risks, contraindications as well as entity-specific aspects of training
control. Furthermore, transnational collaborations are required to exchange local
experience and carry out joint scientific studies and working groups.
P-581
SIMULATION AND TRAINING OF SKILLS FOR NURSES AND DOCTORS IN
PEDIATRIC ONCOLOGY
L. Grigull1, P. Tiroke1, B. Rodewald1
1Hannover Medical School, Pediatric Oncology and Hematology, Hannover, Germany
Background/Objectives: In emergency medicine, simulation and training programs are
well established. A specific program for skills training and simulation in pediatric
oncology is lacking. Therefore, we developed a three-step training and simulation
program for staff members in pediatric oncology.
Design/Methods: First, an analysis of needs was performed via a questionnaire-based
survey. Empathy, communication skills as well as practical skills (performing a lumbar
puncture, bone marrow aspiration) and knowledge-based topics (side-effects of
chemotherapy, complication management, and transfusion medicine) were identified as
hot topics. According to these needs, a concept composed of three modules was set up.
Results: In the first module, staff members learn ‘basic principles” of pediatric
oncology. Using commercially available models, lumbar puncture and central venous
line management could be trained. A model for simulation of bone marrow puncture
was not yet available and therefore newly developed. Besides, communication was
trained and challenged in hands-on exercises. One focus was set on the diversity of
pedagogical methods to enhance the learning success. The second module contains
more problem-orientated tasks. The participants receive challenges which have to be
resolved in small teams (management of given complications, e.g. tumor-lysis
syndrome). The third module focusses basically on team-based tasks. The quests are
complex and feed-back is spotlighted. After completion of the course, the participants
felt more self-confident in their job and this effect was sustainable.
Conclusion: Staff members in pediatric oncology have manifold challenges to master.
High quality performance needs knowledge, empathy, and practical as well as
communication skills. To train and develop these skills a multidisciplinary program for
employees in pediatric oncology was established resulting in amelioration of workplace
satisfaction. Acknowledgements: This project receives funding of “Verein fuer
krebskranke Kinder Hannover e.V.”; the bone marrow model was developed by Marc
Dilly and John Rosenthal (Clinical Skills Lab, University Of Veterinary Medicine
Hannover).
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THEATER AND PEDIATRIC PALLIATIVE CARE: THE CURTAIN OPENS. HIS
SOCIAL VALUE AND THERAPEUTIC POTENTIAL
M. Guibelalde1, M. Mambie2, R. Fullana3, A. Tavera3
1Son Espases, Pediatric, Palma, Spain; 2Casa del Mar CS, Pediatric, Palma, Spain; 3Son
Espases, Pediatric Palliative care, Palma, Spain
Background/Objectives: In our background as pediatricians and pediatric oncologists
there is a lack of spaces related to other disciplines such as theater. It is not often that
we have the chance of performing arts activities that promote and help staff from other
professional perspectivesObjectives:Spread the project that has been performed in our
pediatric hospital of the play written by the Indian Nobel Prize winner R.Tagore, The
Post Office, adapted and performed exclusively by health personnelShow the video
trailer of the work doneServe as an example for the continuity and dissemination of
such initiatives within the pediatric oncology community.
Design/Methods:MaterialAdaptation made from the original work of R. Tagore, The
Post OfficePerformed using a cast of pediatricians (attending doctors and residents),
assistants, nurses and pediatricians and four of their daughters.Directed by a
pediatrician trained in theaterThere have been 3 performances in local theaters with
more than 700 tickets sold Produced for the benefit of the Association for Pediatric
Palliative Care ChildrenMethodPreparation for the play has been the driving element
for teamworkThey have worked on the scenery and stage aspects (stage presentation,
speech, memory, emotional aspect of death and lost).
Results: The aspects that have been worked on have been very helpful in acquiring skills
that can help us to improve other aspects needed as professionals working with patients,
families in difficult situations such as a child in palliative care.There have also been
social and profitable results with a significant economic contribution to our association
dedicated to Children in Palliative Care.
Conclusion: The generous and unique effort of multidisciplinary collaboration among
people doing creative projects reciprocally enriches our personal skills and teamwork.
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PREDICTIVE VALUE OF SERUM PROCALCITONIN IN FEVER IN PEDIATRIC
ONCOLOGY PATIENTS: EXPERIENCE FROM INDIA
V. Gunasekaran1, N. Radhakrishnan2, V. Dinand3, A. Sachdeva4
1Sir Gangaram Hospital, New Delhi, India; 2Sir Gangaram Hospital, Pediatric
Hemato-Oncology, New Delhi, India; 3Sir Gangaram Hospital, Research, New Delhi,
India; 4Sir Gangaram Hospital, Pediatric Hematology-Oncology, New Delhi, India
Background/Objectives: There is paucity of data on the role of inflammatory
biomarkers in management of fever in immunosuppressed. Procalcitonin (PCT) has
been observed to have better discriminatory ability for serious infections. Objective: To
evaluate the role of PCT as a predictor for microbiologically documented infections
(MDI) in pediatric oncology patients.
Design/Methods: Pediatric oncology and transplant patients (on chemotherapy or
having neutropenia) with fever were enrolled (2007-2015). Correlation of PCT with
MDI was made. PCT was not used to guide therapy decisions.
Results: Data from 1023 episodes of fever were available for evaluation. 590 (57.6%)
episodes were classified as febrile neutropenia [Absolute Neutrophil Count <1000/μL].
225 (22%) episodes had MDI. PCT level at admission ranged from 0.05 to 560 ng/ml
(0.5ng/ml in 43.8%). Gram positive, gram negative, fungal, viral, mycobacterial and
parasitic infections constituted 53(23.5%), 89(39.5%), 51(22.6%), 30(13.3%), 1(0.4%)
and 1(0.4%) cases respectively. The sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of PCT (0.5 ng/ml) for MDI were 56.35%,
59.02%, 19.26% and 85.04% respectively, while those for bacterial infections alone were
53.8%, 57.98%, 15.96% and 89.43% respectively. These values, when evaluated for
fungal infections alone were 48.89%, 57.31%, 5.14% and 95.95% respectively. These
values, when evaluated for blood stream infections alone (bacteremia or fungemia) were
60.75%, 58.47%, 14.65% and 92.72% respectively. In febrile neutropenia episodes,
sensitivity, specificity, PPV and NPV for MDI were 52.78%, 60.58%, 23.08% and
85.13% respectively, while those for bacterial infections in febrile neutropenia were
50.7%, 59.54%, 14.17% and 90.17% respectively. At a PCT 1.0 ng/ml, specificity and
PPV for MDI improved to 76.96% and 30.8% respectively.
Conclusion: Procalcitonin level at the onset of fever in immunosuppressed patients is
not a sensitive biomarker for microbial infection (sensitivity of 50-60%) and cannot be
individually used for decision-making in management. However, it has good NPV
(85–93%) for microbial infections.
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SPECTRUMOFMICROBIOLOGICAL INFECTIONS IN PEDIATRIC
ONCOLOGY PATIENTS: EXPERIENCE FROM A TERITARY CARE CENTRE
IN NORTH INDIA
V. Gunasekaran1, N. Radhakrishnan2, S. Joy2, A. Sachdeva2
1Sir Gangaram Hospital, New Delhi, India; 2Sir Gangaram Hospital, Pediatric
Hematology-Oncology, New Delhi, India
Background/Objectives: In developing countries, infections pose the major challenge in
curing pediatric malignancies. Data on spectrum of infections in pediatric oncology
from developing countries is sparse. To analyze the spectrum of microbiological
infections in pediatric oncology patients diagnosed at our center.
Design/Methods:Microbiological data of pediatric oncology patients evaluated for
fever from 2007 to 2015 were analyzed.
Results: There were 1023 episodes of fever evaluated. Of these, 225 (22%) had
microbiologically documented infections. Since 2012, >90% patients had central venous
access devices. Gram positive, gram negative, fungal, viral, mycobacterial and parasitic
infections constituted 53 (23.5%), 89 (39.5%), 51 (22.6%), 30 (13.3%), 1 (0.4%) and 1
(0.4%) cases respectively. Among 53 gram positive infections, organisms included
Staphylococcus aureus(11.3%), Coagulase negative staphylococcus(65.7%),
Enterococcus fecium(13.2%), Enterococcus fecalis(3.7%) and Streptococcus
pneumoniae(1.8%). Among 89 gram negative infections, organisms included Klebsiella
pneumoniae (29.2%), Escherichia coli (16.8%), Pseudomonas aeruginosa (15.7%),
Acinetobacter species (8.9%) and Stenotrophomonas maltophilia (5.6%). Pseudomonas
putida, Pseudomonas stutzeri and Proteus mirabilis were identified in 2 cases each.
Salmonella typhi, Salmonella typhimurium, Nocardia, Chryseobacterium and
Elizabethkingia meningoseptica were isolated in one each. Among fungal infections,
invasive aspergillosis was diagnosed on the basis of galactomannan assay (in 34 cases).
Fungus was isolated from body fluids in 17 cases. These included Candida albicans(5),
Candida tropicalis(3), Candida parapsilosis(3), Candida glabrata(1), Candida
haemulonii(1), Candida pelliculosa(1) and Trichosporon asahii(2). Documented viral
infections included Cytomegalovirus, Dengue, Epstein-Barr virus and Herpes simplex
virus, which were found in 19, 5, 4 and 1 cases respectively. One child was found to have
cysts of Cryptosporidium parvum in stool examination. With advancing years, there is
no significant difference in the detection rate of microbial infections.
Conclusion: Gram negative bacteria are still the major isolate at our center. Gram
positive isolates have shown reduction over the years probably as a result of better
nursing care of central lines.
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PAIN MANAGEMENT IN MOROCCO: REPORT FROM THEMOROCCAN
SOCIETY OF PEDIATRIC HEMATOLOGY AND ONCOLOGY
L. Hessissen1, K. Nissrine2, M. Loubna3, B. Sarra4, E. Jamila5, K. Amina1, E. Khadija6,
C. Siham2, A. Mounia7, M. Abdellah2, H. Jamila6, Q. Asma2, K. Mohamed1,
H. Mhamed5
1Ibn Sina University Hospital - University Mohamed V, Hemato-Oncology Pediatric
Center, Rabat, Morocco; 220 Aout 1935 hospital, Pediatric Hematology and Oncology
Unit, Casablanca, Morocco; 3Ibn Sina University Hospital - University Mohamed V,
Rabat, Morocco; 4Hassan II University Hospital, Pediatric Hematology and Oncology
Unit, Fès, Morocco; 5Mohamed VI University Hospital, Pediatric Hematology and
Oncology Unit, Marrakech, Morocco; 6Abderrahim El Harouchi Hospital, Pediatric
Oncology and Hematology Unit, Casablanca, Morocco; 7Abderrahim El Harouchi
Hospital, Pediatric Surgery Department, Casablanca, Morocco
Background/Objectives: To improve the quality of pain management in Moroccan
pediatric oncology, a first program was developed in 2005 through the My Child
Matters (MCM) initiative. To consolidate the achievements and to roll out the program
to other PO units, a new project has been initiated on 2014 by The Moroccan Society of
Pediatric Hematology/Oncology with the support of the Lalla Salma Foundation
Prevention and Treatment of Cancer.
Design/Methods: To assess the current situation of pain management in Moroccan
pediatric oncology a parent/patient and healthcare providers surveys were conducted.
Results: Eighty one caregivers were assessed. Seventy nine (90%) of them were using
morphine, 17 (20%) have protocols and policies of pain management, 13 (17%)
documented pain management in chart, 71 (88%) were poorly satisfied of pain
management in their unit and all of them requested training.The second survey covered
156 children with cancer from the five Moroccan pediatric oncology units. Among them
150 suffered from pain (96%), 85 related to the disease, 46 related to procedure and
treatment and 19 related to both. Pain was severe in 82 cases (55%) and the majority
reported to doctors about pain. Procedural pain was mainly related to lumbar puncture
and bone marrow aspirate. Sixty seven patients (48%) received medication to prevent
procedural pain. Majority of patient/ parents reported an impact on their emotional,
physical and social functioning. Majority of parents requested information and
communication about pain management.
Conclusion: The MCM program allowed us to develop educational materiel and to
overcome our reluctance to prescribe morphine. The ongoing project includes
continuous education, training, policies and procedure development. We will reconduct
the same surveys after the full implementation of the program to assess its impact.
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IN VITRO INDUCTION OF SPERMATOGENESIS FROM TESTES OF
CYCLOPHOSPHAMIDE-TREATED SEXUALLY IMMATUREMICE
J. Kapelushnik1, M. Huleihel2, M. Ben Harush3, E. Lunenfeld2
1Ben Gurion University of The Negev, Beer-Sheva, Israel; 2Ben Gurion University of The
Negev, OBS/GY, Beer-Sheva, Israel; 3Ben Gurion University of The Negev, Pediatrics
Oncology, Beer-Sheva, Israel
Background/Objectives: Spermatogonial stem cells (SSCs) proliferate and differentiate
to all types of premeiotic, meiotic and postmeiotic cells. Cyclophosphamide (CP)
belongs to the group of alkylating agents’ drugs. It has a gonado toxic effect and may
cause azoospermia. To evaluate the possibility of induction spermatogenesis in vitro
from testes of CP-treated sexually immature compared to mature mice.
Design/Methods: 7 days-old (immature) and 8 weeks-old (mature) ICR mice were
divided into two groups: CP group (CP) and control group (CT). Immature mice were
injected intraperitoneally (i.p) with 100 mg/kg CP once a week during 3 weeks, while the
mature mice were injected every week with 200 mg/kg for 6 weeks. Mice of the CT
group were injected with saline. Mice were sacrificed every week after the last injection
(ALI) for 4-7 weeks. Testicular cells were isolated from 0.5- 3 weeks ALI. Cells were
cultured in three-dimension (3D) cultures in the presence or absence of purified Sertoli
cells (SCs) from immature normal mice. The presence of premeiotic, meiotic and
postmeiotic cells were examined before and after 4 weeks culture, by
immunofluorescence staining using specific antibody for each marker.
Results: CP treatment significantly reduced testicular and body weight during the 4
weeks ALI in the immmature mice while during 6 weeks of the matue. A significant
damage of STs was detected in the testes of CP groups compared to CT; this was in
parallel to the testis weight. An increase/induction in the percentage of some premeiotic
(PLZF, a-6-integrin, GFR-a, OCT4) meiotic (BOULE, LDH) and postmeiotic
(PROTAMINE, ACROSIN) positive cells was examined in 3D cultures that contained
SCs compared to cultures without SCs. This increase was not observed in cultures from
mature mice.
Conclusion: Our results show for the first time the possibility of spermatogenesis
induction in vitro from CP-treated immature mice.
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SUCCESSFUL OUTCOME OFMUCORMYCOSIS WITH ANTIFUNGAL
TREATMENT AND SURGERY IN A CHILDWITH ACUTE LEUKEMIA
R. Kebudi1, G. Hafız2, Z. Erturan3
1Istanbul University-Cerrahpasa Medical Faculty-Oncology Institute-and American
Hopital, Pediatric Hematology-Oncology, Istanbul, Turkey; 2VKV American Hospital,
Otolaryngology, Istanbul, Turkey; 3Istanbul University-Istanbul Medical Faculty,
Microbiology, Istanbul, Turkey
Background/Objectives:Mucormycosis is a fungal infection with a high morbidity and
mortality in children with hematologic malignancies. We present a pediatric case treated
successfully with antifungal agents and surgery and further continued with oral
posaconasole during maintenance chemotherapy.
Design/Methods: Retrospective assessment of a case.
Results: An 8 year old boy was treated for precursor B cell ALL with BFM-ALL
protocol. At the end of the first phase of delayed intensification (protocol II), he was
hospitalised with febrile neutropenia. Cefepime iv was initiated after obtaining cultures.
At 48 hours, fever continued and the patient began to complain of mild pain in the left
orbita. There was no pathology in the examination by the ophtalmologist and
otolaryngologist. An MRI revealed orbital cellulitis and sphenoid sinus infection.
Voriconasole iv was initiated, after a day, periorbital swelling was observed, iv
amphotericin B was added since we could not rule out a mucormycosis infection. After
5 days, fever continued and in MRI signs of progressive infection and periorbital abcess
formation was observed. Surgical drainage, curettage and an absorbable gelatin sponge
containing liposomal amphotericin B was inserted locally. Fever subsided in 24 hours.
Chemotherapy was initiated again. No pathogen was detected in cultures.
Mucormycosis was diagnosed by pathology. Liposomal amphotericin was continued
during delayed intensificaton and the first month of ALL maintenance treatment. Then
antifungal treatment was continued with oral posaconazole as ambulatory treatment
for a total of 6 months of antifungal treatment. The patient has remained in remission
for ALL and free of fungal infection.
Conclusion:Mucormycosis is a fungal infection with a high morbidity and mortality in
children with hematologic malignancies. Suspecting a fungal infection, timely diagnosis
and appropriate agressive treatment including antifungal treatment and surgery are key
component for a successful outcome.
P-588
ANTIMICROBIAL TREATMENT, AGRESSIVE SUPPORTIVE TREATMENT
(INTENSIVE CARE UNIT-ICU, EXTRACORPOREAL MEMBRANOUS
OXYGENATION -ECMO, GRANULOCYTE TRANSFUSIONS) MAY SAVE LIFE
IN SEPTIC SHOCK IN PEDIATRIC ALL
R. Kebudi1, M. Bahar2, B. Oflaz Sozmen3, I˙. Hacı2, A. Ekinci2, D. Egeli2, O. Eren2,
Y. Inel2, T. Paker4, Y. Bayrak5, O. Ergonul6, A. Dindar7
1Istanbul University-Cerrahpasa Medical Faculty-Oncology Institute-and VKV American
Hospital, Pediatric Hematology Oncology, Istanbul, Turkey; 2VKV American Hospital,
I˙ntensive Care Unit, Istanbul, Turkey; 3Koc University School of Medicine, Pediatric
Hematology Oncology, Istanbul, Turkey; 4VKV American Hospital, Cardiovascular
Surgery, Istanbul, Turkey; 5VKV American Hospital, Thoracic Surgery, Istanbul, Turkey;
6VKV American Hospital, Infectious Disease, Istanbul, Turkey; 7VKV American
Hospital, Pediatric Cardiology, Istanbul, Turkey
Background/Objectives: Systemic fungal infections and tiphilitis are complications with
high mortality rates during leukemia therapy. Early identification of infection,
antimicrobial therapy and aggressive intensive care support decreases mortality.
Design/Methods: Case report.
Results: A seven-year-old boy with acute lymphoblastic leukemia developed
neutropenic fever after completion of remission induction chemotherapy . Empiric
antibiotics were started after obtaining cultures. Fever subsided, but recurred.
Liposomal amphotericin B was added. Clinical status deteriorated within hours and he
was transferred to ICU. Acute respiratory distress syndrome (ARDS) developed, was
intubated. Candida tropicalis grew in blood culture. Stool was positive for Clostridium
difficile. Metronidazole, caspofungin and linezolid were added. Despite aggressive
supportive care, he continued to detoriorate. Granulocyte transfusions were given 11
times. Hemofiltration for fluid overload was done, chest tubes were placed for
pneumothorax. He was put on ECMO- extracorporeal membranous oxygenation for 55
days due to severe ARDS . Candida parapsilosis grew on blood culture during ECMO.
Micafungin was added. He was kept on micafungin prophylaxis after the completion of
his antifungal therapy. He had CMV reactivation and hemophagocytic syndrome,
responded to IVIG and gancyclovir. Acinetobacter baumanii was identified in his
tracheal aspirate which responded to meropenem. He had a respiratory detorioration
on the 95th day of his ICU stay, was diagnosed with pulmonary hypertension and
treated with iloprost and sildenafil. He was weaned off the mechanical ventilator as his
lung parenchyma restored. He was off of the ventilator to oxygen support via nasal
cannula on the 145. day, was transferred to hematology ward after 147 days in ICU.
Bone marrow evaluation showed morphologic and cytogenetic remission for
preB-ALL. He continues on his modified chemotherapy.
Conclusion: Systemic fungal infections and tiphilitis continue to be life threatening in
immunocompromised hosts. Aggressive intensive care support, granulocyte infusions
and ECMO can decrease mortality and morbidity.
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INFECTIONS WITH RESPIRATORY VIRUSES IN CHILDRENWITH CANCER
IN ISTANBUL AT THE LAST YEAR
S. Buyukkapu Bay1, R. Kebudi2, B. Oflaz Sozmen3, O. Gorgun4, B. Koc4, B. Zulfikar4,
S. Badur5
1Istanbul University-Oncology Institute, Pediatric Hematology Oncology, Istanbul,
Turkey; 2Istanbul University-Cerrahpasa Medical Faculty and Oncology Institute and
American Hospital, Pediatric Hematology Oncology, Istanbul, Turkey; 3Koc University,
Pediatric Hematology Oncology, Istanbul, Turkey; 4Istanbul University-Cerrahpasa
Medical Faculty and Oncology Institute, Pediatric Hematology Oncology, Istanbul,
Turkey; 5Istanbul University-Medical Faculty, Pediatric Hematology Oncology, Istanbul,
Turkey
Background/Objectives: Respiratory virus (RV) infection can cause significant
morbidity and mortality in pediatric cancer patients. The aim of this study is to identify
the RV infections in children with cancer presenting with signs and symptoms of
respiratory tract infection.
Design/Methods: During January 1st 2014- January 1st 2015, all children with cancer
presenting with signs and symptoms of respiratory tract infection were assessed for RV
infection. Specimens were collected by nasal swabbing. Samples were assessed with
algorithms and molecular techniques (rRT-PCR) suggested by CDC and WHO in the
reference Virology laboratory, of Istanbul University.
Results: Samples of 74 respiratory tract infection episodes of 51 children with cancer
were evaluated with simultaneous detection of 20 respiratory viruses. A respiratory viral
pathogen was obtained in 43 (58%) of the analyzed samples.Rhinovirus (n=11, 25%)
and concomitant detection of two viruses (18%) were the most frequently isolated
pathogens. Other viruses were Coronavirus (13.9%), Respiratory Syncytial Virus
(13.9%), Metapneumovirus (4.6%), Bocavirus (2.3%), Parainfluenza (9.3%), influenza A
(H3N2) (9.3%). Four (9.3%) had severe pneumonia (One Rhinovirus + Coronavirus,
others Rhinovirus, Metapneumovirus, Respiratory Syncytial Virus) and 11 (25.5%) had
mild lower respiratory tract infections. Patients with febrile neutropenic episodes and
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pneumonia were hospitalized and broad spectrum antibiotics were administered. The
other non-neutropenic and mild respiratory tract infections were treated with
supportive approach as outpatient. Patients with influenza were treated with
oseltamivir. There were no deaths due to respiratory tract infectons in our series.
Conclusion: Viruses are a major cause of respiratory tract infections in children with
cancer. Oseltamivir is effective in treatment of influenza in children with cancer. Since
there are no effective antiviral agents for some respiratory viruses, infection control and
early diagnosis are important to prevent spreading of infection. In most cases,
hospitalization and supportive care is needed to reduce morbidity and avoid mortality.
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STATUS OF PARTICIPATION IN PHYSICAL EDUCATION AT SCHOOL
AFTER TREATMENT FOR PEDIATRIC CANCER
S. Kesting1, M. Götte1, D. Rosenbaum2, J. Boos1
1University Hospital of Muenster, Pediatric Hematology and Oncology, Muenster,
Germany; 2University Hospital of Muenster, Institute for Experimental Musculoskeletal
Medicine, Muenster, Germany
Background/Objectives: Physical education (PE) at school aims at promoting the
children’s physical and psychosocial abilities and contributes to the development of a
long-term active lifestyle. In Germany, pediatric patients with cancer are often not
attending school and therefore cannot participate in PE during acute treatment.
Undergoing cancer therapy, the children’s physical activity levels are reduced
dramatically (Winter et al. 2009) and physical limitations persist throughout adulthood
(Ness et al. 2009). The primary objective was to analyze the status of participation in
PE, because it has not yet been sufficiently examined whether pediatric patients return
to PE following cancer treatment. Secondly, barriers which handicap reintegration
should be identified.
Design/Methods: Data was collected using a standardized questionnaire of the
KiGGS-study (German Health Interviews and Examination Survey for Children and
Adolescents) supplemented by questions related to PE and reasons against
participation. Using this instrument enables comparison with age- and gender-related
reference values of healthy children.
Results: Patients with cancer (n=114; m=61%) 13.5±4.0 years of age and 10.6±9.6
months post-treatment attending school since at least two months were included
(leukemia/lymphoma 46%, bone tumor 25%, brain tumor 16%, other solid tumor 14%).
Although 72% of the patients desired participation in PE, 38% were not participating
to full extent, whereof 17% reported no participation at all and 21% mentioned partly
participation. Most problems became obvious in patients treated for bone tumors (68%
partly/non-participation). Identified barriers included: personal (physical/psychosocial),
social (parents/classmates) and structural reasons (teacher/curriculum).
Conclusion: Contrary to the patients’ motivation, a high percentage is not participating
in PE at school within two years post-treatment. Initial attempts of a reintegration
program at our department and detailed examination of barriers showed that these can
be successfully conquered by communication, professional advice and support for
patients, teachers and parents.
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ENHANCEMENT OF PHYSICAL ACTIVITY LEVELS IN PEDIATRIC
PATIENTS WITH CANCER DURING ACUTE CANCER TREATMENT:
DEVELOPMENT OF A TWO-PART EXERCISE MODEL
S. Kesting1, M. Götte1, D. Rosenbaum2, J. Boos1
1University Hospital of Muenster, Pediatric Hematology and Oncology, Muenster,
Germany; 2University Hospital of Muenster, Institute for Experimental Musculoskeletal
Medicine, Muenster, Germany
Background/Objectives: Reduced physical activity levels (Winter et al. 2009) in children
with cancer additionally increase the cancer-related burden and presumably lead to
further persisting problems like reduced motor performance during (Götte et al. 2015)
and after treatment (Kesting et al. 2015). Furthermore, patients ask for supervised
training sessions and individual support to be motivated (Götte et al. 2014). The
objective was the implementation of a training program for pediatric patients during
cancer treatment.
Design/Methods: During the last six years a supervised and individually-tailored
training program is offered for children aged 4-21 years during treatment with various
entities and different physical limitations at our local department. Contents are adapted
to sports history, personal goals, medical condition and age-related physical education
topics. Intensity varies from low, moderate to high loadings, depending on the patients´
condition.
Results: The training program could be feasibly implemented at the local stationary and
ambulant pediatric cancer ward. Patients show high acceptance, but frequent presence
of physical complaints also underline the need of a broad range of exercise methods
that allow a minimum program even under poor general condition. Futhermore, no
exercise promotion was offered during home stays.
Conclusion: This program provides individual and safe enhancement of physical activity
at the cancer ward. To expand exercise promotion and include home stays during
treatment as well, we are currently evaluating a two-part model consisting of 1) a
supervised exercise intervention during in-patient stays and 2) a personal training
schedule comprising of individual goals and exercises for home stays. Activity trackers
(fitbit) provide feedback about daily steps during home stays and regular
communication (mail, phone, face-to-face) ensures support and safety. This special
offer could be a feasible alternative to cancer sports groups which are difficlut to realize
for pediatric patients with cancer due to limited incidence and large catchment areas.
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MINDFULNESS AND EFFECTIVE OBSERVATIONAL SKILLS: IMPROVED
QUALITY OF CARE FOR PEDIATRIC PATIENTS WITH CANCER
E. Khan Ghazi1, A. Abbas1, R. Waheed1
1Children Cancer Unit- Indus Hospital, Psychosocial Oncology, Karachi, Pakistan
Background/Objectives: Children Cancer Unit in Indus Hospital caters to the
underprivileged hence people from all over Pakistan and Afghanistan, come to the
hospital for treatment. Ensuring that each child receives the quality of care he or she
deserves is a struggle which health professionals face. Accuracy and objectivity are
essential components of patient care, and specifically where pediatric patients are
concerned who may not be able to verbalize their physical or psychological discomfort
or distress as well as adults, hence it becomes imperative that nurse technicians are able
to identify sources of distress or discomfort in pediatric patients with cancer.
Design/Methods: A pilot study was carried out on 12 students who were enrolled in the
nurse technician program in the Children Cancer Unit (CCU), Indus Hospital.
Results: The nurse technicians were then tested in observational skills in wards in
Children Cancer Unit then taught mindfulness skills, after the training they were tested
again in their observational skills with pediatric patients with cancer. A qualitative
analysis of the data revealed that their observational skills had improved remarkably
post intervention and the students were able to accurately gauge signs of physical and
psychological distress or discomfort in pediatric patients.
Conclusion: Inaccurate or biased reporting can be a major hurdle in pediatric care,
making health professionals overlook symptoms that may be life threatening because
effective observation skills are missing. The quality of care for pediatric patients is
already compromised because most of the time they are not able to voice accurately
their concerns and symptoms which may be causing them distress.The data yielded the
result that mindfulness skills can be used effectively to gather objective and accurate
information regarding patients, thus improving quality of care.
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REIKI USED IN ALLEVIATION OF PHYSICAL AND PSYCHOLOGICAL
DISTRESS IN END OF LIFE CARE IN CHILDRENWITH CANCER
E. Khan Ghazi1
1Children Cancer Unit-Indus Hospital, Psychosocial Oncology, Karachi, Pakistan
Background/Objectives: Children suffering from cancer are in excruciating pain
especially when they are in the end of life care phase. In order to improve the quality of
life in the end of life stage it becomes a priority to reduce physical and psychological
distress. Reiki, a complementary alternative energy therapy is used for alleviation of
stress, anxiety, increasing relaxation and improvement of the overall quality of life in
children with cancer while reducing physical and psychological distress.
Design/Methods: Hundred sessions of Reiki were carried out over a period of two years
on children with cancer who were on end of life care in Children Cancer Unit, Indus
Hospital.
Results: Out of the 100 sessions, 80% of the sessions resulted in reduction of physical
and psychological distress in patients. Sometimes the children would call the laying of
hands over affected areas as ‘magic’. Reiki helped alleviate their suffering and gave them
respite from the constant excruciating pain that they suffered.
Conclusion: Reiki needs to be a part of end of life care for children suffering from
cancer, as this not only provides relief from physical distress but also reduces the
psychological distress associated with impending death and progressive disease.
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COLD PACK APPLICATION FOR ALLEVIATION OF PHYSICAL
DISCOMFORT IN CHILDRENWITH CANCER AND REDUCTION OF
PSYCHOLOGICAL DISTRESS
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Background/Objectives: Since Children Cancer Unit (CCU), Indus Hospital is a
philanthropic organization catering to the poor and offering cancer treatment free of
cost, medicines are still given through cannulization rather than the central line, which
results in physical discomfort and psychological distress in children with cancer.
Design/Methods: After interviewing nurses, doctors and patients it was found that the
medicines causing the most physical discomfort and resulting psychological distress,
during administration were Vincristine, Levofloxacin, Vancomycine and Potassium
Chloride. In a clinical trial of 100 children in the hospital, cold pack application was
used on areas of physical discomfort closest to the cannula, while the child was being
administered medication.
Results: It was observed that ice pack application while the medicines were being
administered via cannula, caused significant reduction in physical discomfort. The
ensuing psychological distress of child and caregiver was alleviated, thus increasing
treatment compliance.
Conclusion: Children with cancer already have to deal with many adverse effects of the
disease as well the side effects of the medication they are taking for treatment be it
chemotherapy or radiation. Non pharmacological means need to be utilized more often
for the alleviation of physical discomfort in children with cancer so as to prevent toxic
overload. And ice packs are a price friendly and effective means of reducing discomfort
and psychological distress, when it occurs.
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IMMUNIZATION PRACTICES IN CHILDRENWITH CANCER: A GLOBAL
SURVEY CONDUCTED BY SIOP PODC SUPPORTIVE CAREWORKING
GROUP
M.S. Khan1, R. Kebudi2, P. Angelini3, R.S. Arora4
1Tawam Hospital-Alain-Abu Dhabi-United Arab Emirates, Pediatric
Haematology/Oncology, Alain-Abu Dhabi, Pakistan; 2Istanbul University-Cerrahpasa
Medical Faculty & Istanbul University, Pediatric Oncologist, Istanbul, Turkey; 3Geneva
University Hospital, Paediatric Haematology/Oncology Division, Geneva, Switzerland;
4Max Super Speciality Hospital, Pediatric Oncology Department, New Delhi, India
Background/Objectives: Immunization of children is a cornerstone in public health
interventions designed to address vaccine-preventable diseases (VPD). This process is
interrupted in the children who develop cancer because of multiple factors. This survey
was conducted by SIOP PODC Supportive Care Working Group to assess the
prevailing immunization practices for pediatric oncology patients.
Design/Methods: A questionnaire was designed in “PDF form” format and sent to
members of working group through emails. Questions included information about
availability of vaccines for cancer patients, counselling about VPD for the patients and
close relatives, vaccination guidelines for cancer patients and routine prescription of
vaccines during and after cancer therapy.
Results: Of 36 respondents from 23 countries, 20 belonged to lower and lower middle
income countries (LIC/LMIC), whereas 16 from upper and higher middle income
countries (UMIC/HIC). Half of the physicians had more than 10 years experience of
treating childhood cancers. The commonest free of cost vaccines included hepatitis-B,
haemophilus influenzae type B, pneumococcal and MMR vaccines. In LIC/LMIC
(n=20), no free vaccines were available in 35% centres. Prevalence of routine
counselling of caregivers about VPD in UMIC/HIC and LIC/LMIC was almost the
same (60% vs. 62%). Testing of titres for one or more vaccines was noted in 70% centres
of UMIC/HIC, in contrast to only 15% in LIC/LMIC. Annual influenza vaccine was
routinely prescribed in 75% patients and 88% of their close relatives in UMIC/HIC,
whereas it was provided to 15% and 20% respectively in LIC/LMIC. Seventy percent
centres in UMIC/HIC were following some vaccination guidelines, in contrast to 35%
in LIC/LMIC. Designed vaccination card was available in only 25% and 20% centres
respectively.
Conclusion:Unavailability of vaccines for pediatric oncology patients in LIC/LMIC is a
serious concern. There is a need to develop consensus vaccination guidelines during and
after cancer treatment based on their availability in different settings.
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PHYSICAL STRENGTH OF CHILDRENWITH CANCER
K. Kobayashi1, M. Inaki2, K. Tanigawa2
1St. Luke’s International University, Chuo-ku, Japan; 2Seinan Jyo Gakuin University,
Health and Welfare, Fukuoka, Japan
Background/Objectives: Treatment for children with cancer affects on children’s
strength, but the magnitude of the decreased strength and how it affects children’s daily
life are not revealed in Japan. The objectives of this research were to measure children’
physical fitness and identify difficulties in daily life from parents’ perspectives.
Design/Methods: The participants were children with cancer and their parents. Of 88
participants, 5 were in-patients, 35 were outpatients, and 48 had completed treatment.
We measured height, weight, muscular strength, instantaneous force, flexibility,
balancedness. Also, Parents were asked the degree of the strength of their children and
how the strength affected their daily life.
Results: The z cores of all scores were calculated based on standardized norm score in
Japan. Compared with norm, more than 30% children with cancer were in -2SD of
norm score in muscular strength during in-patient and outpatient. When compared the
scores between on and off treatment, muscular strength and instantaneous force of
on-treatment were significantly lower than that of off-treatment. Children who treated
by stem cell transplant (SCT) showed significantly lower height (p < .001), weight (p <
.001), muscular strength (p = .006), and instantaneous force (p = .021) than those of
children who did not have SCT. Regarding parents’ perspectives, 13% perceived their
children’s strength were the same compared with strength before they were diagnosed,
and 87% perceived that their children’s strength were decreased compared with before
they were diagnosed. Difficulties in daily life were seen in walking, fatigue, going up and
down the stairs, feeling an inferiority complex, and physical training in school.
Conclusion: The muscular strength is the most affected, and children who had SCT
might have severe strength problems. There are various difficulties; physically,
emotionally, socially, school, and it is important to give exercise programs to children
with cancer.
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PREDICTING THE RISK OF ADVERSE EVENTS IN CHILDRENWITH
FEBRILE NEUTROPENIA - VALIDATION OF A CLINICAL RISK
ASSESSMENT TOOL
M. Kruger1, L.L. Green1, A. van Zyl1
1Stellenbosch University, Paediatrics and Child Health, Cape Town, South Africa
Background/Objectives: To validate an existing clinical risk assessment tool to predict
adverse events (AE’s) in children with cancer and febrile neutropenia.1
Design/Methods: All patients less than 15 years of age, with confirmed malignancies
receiving chemotherapy, who presented with fever (axillary temperature >38°C twice in
24 hours or once >38.5°C) and neutropenia (neutrophil count <500cells/mm3) were
enrolled. A risk prediction score1 was calculated for each patient and AE’s were
documented until antibiotics had been stopped and neutropenia resolved. Risk
prediction score included: Hb  9 g/dl, WCC < 0.3 g/L, platelet count <50 g/L,
chemotherapy more intensive than ALL maintenance therapy. Adverse events were
defined as serious medical complications (SMC), microbiologically defined infection
(MDI), and radiologically confirmed pneumonia (RCP).
Results: There were 48 febrile neutropenia episodes in 29 patients of whom 48% had
haematological malignancies, 48% solid tumours and 4% CNS tumours (01 January
2014 - 28 February 2015). The male to female ratio was 1:1.6 with a mean age of 69
months (median age 54 months). Adverse events occurred in 11/29 patients with a low
risk (score <9) (10 MDIs and 1 SMC including 1 death) and 15/19 (11 MDIs, 3 SMCs,
2 RDPs) with a high risk score (score >9). Based on these interim results the risk
prediction model has a sensitivity of 57% and specificity of 73%. The study is ongoing
and final sensitivity and specificity is still to be determined.
Conclusion: Based on the interim analysis the risk prediction model does not achieve
the targeted sensitivity of more than 90%. Reference: Ammann RA, Bodmer N, Hirt A,
et al: Predicting adverse events in children with fever and chemotherapy-induced
neutropenia: The prospective multicenter SPOG 2003 FN study. J Clin Oncology
28:2008-2014, 2010.
P-598
PHYSICIAN PERSPECTIVES ON HOSPITAL DETENTION: THE
UNEXPLORED PATH
K. Kulkarni1, A. Patenaude2, C. Lam3, C. Salavveria4, S. Mostert5, F. Njuguna6
1IWK Health Centre and Dalhousie University, Halifax, Canada; 2Dana-Farber Cancer
Institute, Center for Cancer Genetics and Prevention Director of Psychology Research
and Clinical Services, Boston, USA; 3St. Jude Children’s Research Hospital,
International Outreach Program & Oncology, Memphis, USA; 4Hospital Nacional de
Niños Benjamin, Oncology, San Salvador, El Salvador; 5VU University Medical Center,
Pediatric Oncology-Hematology, Amsterdam, Netherlands; 6Moi University, Department
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Background/Objectives: Hospital detention (HoD) can be defined as practices whereby
patients are denied release after medical discharge due to families’ inability to pay
hospital bills. Only recently HoD is being recognized as a global phenomenon with little
existing data. Moreover, the perspectives and roles of physicians in relation to HoD are
unclear.
Design/Methods:We conducted exploratory analyses to define existing data and gaps to
generate ideas for future research on the perspectives of physicians in relation to HoD.
Results: On pilot, anonymized inquiry with over 100 physicians several distinct
categories of response emerged. Many reported no knowledge of HoD in their
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hospitals. Hearing about it appalled many. Some thought that the issue was very
complex and just asking physicians about their role was incorrect and not helpful. Few
were involved in hospital administration and thought it inappropriate to conclude that
HoD was totally incorrect, since hospitals need to receive payments to continue
functioning. It surfaced that in some cases and hospitals, HoD may not be obvious.
Hospitals may sign a contract with patients to ensure that patients are legally bound to
pay hospital fees for therapy. If they fail, hospitals may use pressure tactics or partially
waive fees. Overall, HoD may be grossly underrecognized and underreported. Based on
these analyses, areas of future focus for research include: 1) perception surveys with
standardized HoD definitions; 2) acknowledging complexity of HoD within health
systems such that accountability and transparency may be promoted without blame; 3)
working with field-based team members engaged in human rights, health law and
policy, governance, and ethics.
Conclusion: The present report highlights the need of exploring perspectives and roles
of physicians on HoD practices across settings where different policies may be in place.
Being an integral part of health care delivery system, physicians could play a pivotal
role in stopping hospital detention.
P-599
IMPACT OF DAY CARE CENTER IN IMPROVING QUALITY OF LIFE OF
PPEDIATRIC CANCER PATIENTS BY PROVIDING PALLIATIVE CARE
SERVICES NEAR TERTIARY HOSPITALS IN NEW DELHI
A. Kumar1
1CanKids…KidsCan, New Delhi, India
Background/Objectives:One of the most rapidly growing aspect of palliative care service
is the need of day care but enough research is not available to prove it.Thus this study
was conducted with an aim to assess the impact of a day care center in improving the
quality of life (QOL) of pediatric cancer patients by providing palliative care services
with a multi-disciplinary team approach near tertiary care hospitals in New Delhi.
Design/Methods: A prospective comparative study was conducted to evaluate the
effectiveness of palliative care services in the inpatient department of the day care
transition home of Cankids a non-governmental organization. Day care patients were
compared with a comparison group who were not provided with any type of palliative
care services. In order to examine the effectiveness of day care over time,
semi-structured interviews were carried out at entry to study or day care, at 0-1 week,
6-8 week and 12-13 week respectively. The interview schedule included palliative care
outcome scale (POS) as a measure of health related QOL in the form of a questionnaire.
Results: Fifty patients randomly selected (80% males, median age-10 years, 75% not
residents of New Delhi) over a 12 week period admitted to the day care center for any
palliative care service were recruited in the study. The comparison group also consisted
of 50 patients (80% males, median age-10 years, 75-80% not residents of New Delhi)
requiring palliative care support but were not receiving any and were only receiving
standard treatment of cancer at the tertiary center. The difference was statistically
significant (p=0.03) when the QOL of study group receiving palliative care services at
day care center were compared with the comparison group.
Conclusion: This study demonstrates that patients who were offered palliative care
services at a day care had a better QOL.
P-600
REHABILITATION OF CHILDHOOD CANCER PATIENTS- COLLABORATIVE
EFFORTS OF SRCC -CENTRE FOR CHILD DEVELOPMENT (CCD) WITH
TATAMEMORIAL HOSPITAL(TMH), AND UGAM-CHILDHOOD CANCER
SURVIVORS SUPPORT GROUP
P. Kurkure1, R. Jalali2, S. Goswami3, M. Prasad4, S. Jha5, A. Garware6
1TATAMemorial Hospital-Indian Cancer Society, Pediatric Oncology-Ugam, Mumbai,
India; 2Tata Memorial Hospital, Neuro-Oncology Disease Management Group, Mumbai,
India; 3Tata Memorial Hospital, Psycho-Oncology, Mumbai, India; 4Tata Memorial
Hospital, Pediatric Oncology, Mumbai, India; 5Indian Cancer Society, Ugam, Mumbai,
India; 6SRCC-Centre for Child Development, Rehabilitation, Mumbai, India
Background/Objectives: To rehabilitate young cancer patients whose psychological and
locomotor functions are affected due to treatment by providing therapy sessions in
collaboration with SRCC- CCD rehabilitation centre.
Design/Methods: TMH along with Ugam collaborated with SRCC-CCD, multi
specialty rehabilitation/therapy centre in Mumbai to offer therapy for young cancer
patients who have disturbance of their psychological and locomotor functions. An
executive administrator who is Ugam member is in charge of facilitating collaboration.
The centre conducts physiotherapy, occupational therapy, speech therapy and
educational therapy sessions to evaluate the patients. Patients are given ratings (Good,
Fair, Poor) based on the aforesaid evaluation. A monthly report is sent to the hospital
giving details of the assessment and the recommendation for follow up. The patient
may or may not be advised follow up after giving due consideration to his/her sensory,
ADL, psychological, psychosocial and locomotor functions during the evaluation.
These evaluations are done free of cost by SRCC-CCD.
Results: A total of 26 patients, median age 8Years(Range 2-15) are beneficiaries.20/26
(77%) are Brain tumor & 6/26(23%) are non Brain tumor patients; 12 reside in Mumbai
& 14 are from outside Mumbai. Parental feedback regarding these sessions have been
good in 80.8% and fair in 19.2%. Patients have shown overall improvement in their day
to day activities after these therapy sessions.
Conclusion: SRCC-CCD has taken exceptional steps for rehabilitation of active cancer
patients. These sessions have not only been a boon to the patients and their parents but
also to the doctors as they are able to rehabilitate the patients successfully.
Implementing such rehabilitation sessions have been imperative for the long term
physical and mental development of patients. It is expected that several cancer patients
will get benefited by such an activity.
P-601
IMPACT OF SUSTAINABLE FINANCIAL SUPPORT THROUGH INDIAN
CANCER SOCIETY(ICS)-CANCER CURE FUND (CCF) FOR TREATMENT OF
CHILDHOOD CANCERS AT TATAMEMORIAL HOSPITAL(TMH)-MODEL
FOR DEVELOPING COUNTRY
P. Kurkure1, T. Vora1, B. Arora1, S. Banavali1, G. Raverkar2, S. Agarwal2, P. Parikh2,
U. Thorat2, A. Kurkure2, N. Kaviratne2
1TATA Memorial Hospital, pediatric Oncology, Mumbai, India; 2Indian Cancer Society,
Cancer Cure Fund, Mumbai, India
Background/Objectives:With the non-availabilty of state sponsored or insurance based
health care model in developing countries, many children with cancers do not get
treatment due to lack of finances. Having evolved an incentive based financial model to
address this serious issue we show way forward for sustainable solution for cancer care.
Design/Methods: In 2011 HDFC AMC in joint initiative with ICS launched mutual
fund scheme to provide financial assistance to needy cancer patients for treatment by
tapping investors who would be willing to donate whole or part of dividend for the
ICS- CCFSeven hospitals across India were empanelled by ICS for this project & TMH
is one of them.A Due Diligence Team and the Governing Advisory Council of the
ICS-CCF fund were established to duly scrutinize the applications from the empanelled
hospitals for sanction and disbursement of funds.
Results: ICS has implemented CCF at a Pan India level covering patients from 20 states
and has granted financial assistance for cancer treatment of over Rs. 25 crores to 1200
patients till date.141 children(Age 0-15 years) have benefited from innovative venture
from Oct2011 to July 2014 at TMH. A total of INR 3,95,55,000 have been sanctioned
for them. 53/141(38%)were ALL, 32(23%)PNET, 30 (21%)
Lymphoma,12(9%)AML,9(6%) OGS,3(2%)APML and 2(1.%)Others. 39/141 (28%)
have completed treatment. 78/141 (56%) are on treatment and 18/141 (13%) have
expired. 6/141 (4%) were lost to follow up. 6/18 deaths were due to toxicity and 12/18
were due to disease progression.
Conclusion:Without the help of ICS-CCF most of these 141 patients could not have
afforded treatment &succumbed to disease. At median follow up of 16 months 117/141
(83%) are alive with controlled disease. As ICS-CCF supports the entire treatment cost,
parents don’t have to apply to multiple agencies for funding. It becomes a one-stop
process with assured funds leading to reduced treatment abandonment.
P-602
OVERCOMING BARRIERS TO IMPROVING THE TIME TO ANTIBIOTICS IN
THE FEBRILE PEDIATRIC ONCOLOGY PATIENT IN THE OUTPATIENT
SETTING
M. Beauchemin1, R. Zylber1, K. Yarnell2, T. Coffey2, F.M. Sonnett3, P. Dayan3,
J. Babineau3, A. Lee1
1Columbia University Medical Center, Pediatric Oncology, New York, USA; 2New York
Presbyterian-Columbia, Pediatric Oncology, New York, USA; 3Columbia University
Medical Center, Pediatric Emergency Medicine, New York, USA
Background/Objectives: Fever is a common complaint in children with cancer in
outpatient oncology clinics and emergency departments (EDs) and is a potentially
life-threatening complication requiring immediate identification and management with
a broad-spectrum antibiotic. We conducted a quality improvement project to decrease
the time to antibiotics (triage to administration) to 60 minutes or less in febrile
oncology patients with a central venous catheter (CVC) and undergoing treatment.
Design/Methods:We utilized the Model for Improvement methodology and collected
baseline data over 6 months. Discussions then occurred with relevant stakeholders
(including ED and oncology providers [MDs, NPs, RNs]) to identify barriers to
achieving the goal of 60 minutes for antibiotic administration. We subsequently
developed interventions and conducted PDSA (Plan, Do, Study, Act) cycles targeted at
these barriers over 12 months. Statistical process control charts were used prospectively
to analyze data.
Results: Identified barriers included lack of staff and parental education about the
importance of timely administration of antibiotics, ED and clinic staff discomfort in
administering antibiotic prior to knowing the child’s neutrophil count, and difficulty of
ED nurses in accessing and troubleshooting CVCs (particularly mediports). The
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following intervention bundle was developed: a) Staff education on guidelines in
managing a febrile oncology patient; b) Provider education in estimating a patient’s
neutrophil count; c) Distribution of parental/patient CVC cards; d) ED nurse education
to enhance CVC access skills. Median time to antibiotics decreased from 81 to 55
minutes. The overall percent of patients receiving antibiotics in under 60 minutes
increased from 36% to 53%.
Conclusion: In discussion with providers caring for febrile pediatric oncology patients,
we identified barriers and targeted them to decrease the time to antibiotics over 12
months. While some of these barriers may be institution specific, others may be global
barriers that may help to create febrile pediatric oncology patient management
guidelines.
P-603
DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR SUPPORTIVE
CARE IN CHILDHOOD CANCER IN THE NETHERLANDS - CURRENT
VARIATIONS IN SUPPORTIVE CARE PRACTICE
E.A.H. Loeffen1, R.L. Mulder2, A. Font-Gonzalez2, M.D. van de Wetering2,
L.C.M. Kremer2, W.J.E. Tissing1
1Beatrix Children’s Hospital-University Medical Center Groningen-University of
Groningen, Department of Pediatric Oncology/Hematology, Groningen, Netherlands;
2Emma Children’s Hospital-Academic Medical Center, Department of Pediatric
Oncology, Amsterdam, Netherlands
Background/Objectives: Because of intensive treatment strategies in children with
cancer, supportive care plays an increasingly important role. Unfortunately, few
evidence-based guidelines are available in this area, which might contribute to
suboptimal and conflicting supportive care in children with cancer. In this study our
objective was to explore current practice variations in supportive care in children with
cancer in The Netherlands.
Design/Methods:We conducted an in-depth review of local guidelines and protocols
among all 6 Dutch pediatric cancer centers. The compiled list comprised important
supportive care topics and was verified by a pediatric oncologist from each center to
assess correspondence with daily supportive care practice in their hospital.
Subsequently, we evaluated if the clinical practice in the 6 pediatric oncology centers
was concordant (same in 5 out of 6 centers), partly concordant (almost the same in
5 out of 6 centers) or discordant (same in <5 centers).
Results: The questionnaire comprised 67 questions regarding 14 supportive care topics.
We found concordance in 11 of 67 items (16.4%), partial concordance in 6 of 67 items
(9.0%) and discordance in 50 of 67 items (74.6%). We explored conformity with three
current evidence-based guidelines, which varied but was generally low.
Conclusion: In the Netherlands, major variations exist in daily practice of supportive
care for childhood cancer patients. The development and integration of clinical practice
guidelines in daily practice has the potential to greatly contribute to uniform
evidence-based practice, and thereby contribute to better outcomes of childhood cancer
patients. Development and implementation of these guidelines is the next step in our
project.
P-604
EFFICACY AND TOLERANCE OF LIDOCAINE 5% PATCHES IN
NEUROPATHIC PAIN AND VASO-OCCLUSIVE SICKLE-CELL CRISES PAIN
IN CHILDREN: A PROSPECTIVE MULTI-CENTER CLINICAL STUDY
V. Rousseau1, C. Arriuberge2, S. Chabaud3, V. Launay4, S. Thouvenin5, B. Tourniaire2,
M. Morelle3, P. Marec-Bérard1
1IHOP, Pediatric, Lyon, France; 2Trousseau Hospital, Pediatric Anesthesia, Paris,
France; 3Centre Leon Bérard, Biostatistic, Lyon, France; 4Hopital Femme Mere Enfant,
Pediatric Intensive Care Unit, Lyon, France; 5Saint Etienne Hospital, Pediatric
Oncology, Saint Etienne, France
Background/Objectives:Neuropathic pain and pain related to bone vaso-occlusive crises
in children are often treated with pain killers responsible for many side effects.
Lidocaine patches are recommended for treatment of neuropathic pain in adults but is
not evaluated in children.The purpose of this study was to evaluate the safety and
efficacy of Lidocaine patches5% in the pediatric population.
Design/Methods: Trial design: phase II, prospective, open, non-randomized and
multi-center study. Patients, 6 to 21 years-old, suffering from neuropathic pain or
superficial bone vaso-occlusive crises were proposed to participate. The rate of success
was defined by the rate of patients who, during at least 2 out of 3 consecutive days,
show a decrease of 2 points or more on the Visual Analogue pain Scale (VAS) between
Lidocaine 5% patch application and a measurement made after 12 hours. Using a
one-stage Fleming design, 39 patients had to be enrolled and a minimum of 29 successes
(74 %) was necessary to conclude that the treatment was effective. Tolerance was
determined by the rate of patients with adverse reactions according to the criteria of
the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.
Results: Forty patients were enrolled in the study and 39 were analysed. On Day 1, VAS
scores were significantly reduced by at least two points in 58.97% of the patients. 48.6%
of patients had a decrease of at least two points on the VAS on 2 consecutive days. Only
7.7% of the patients experienced grade 1 or 2 toxicities.
Conclusion: The use of Lidocaine5% patches allows reducing intensity of pain in half
of our population study. However we can’t conclude to an efficacy using the statistical
design beforehand established. Nevertheless, considering the good tolerance, we can
state that it is safe and could be integrated in the therapeutic arsenal available in
pediatrics pain management.
P-605
EFFICACY AND SAFETY OF LOW DOSE KETAMINE AS ADJUVANT
TREATMENT FOR REFRACTORY PAIN IN CHILDRENWITH CANCER: A
PROSPECTIVE OBSERVATIONNAL STUDY
M. Courade1, A. Bertrand2, L. Guerrini-Rousseau3, A. Pagnier4, D. Levy5, C. Lervat6,
N. Cojean7, A. Ribrault8, S. Dugue9, S. Thouvenin10, C. Piguet11, C. Schmitt12,
P. Marec-Bérard13
1CHU Grenoble, Oncologie Pédiatrique, Grenoble, France; 2Centre Léon Berard, Institut
d’Hématologie et Oncologie Pédiatrique, Lyon, France; 3Gustave Roussy, Oncologie
Pédiatrique, Paris, France; 4CHU de Grenoble, Oncologie Pédiatrique, Grenoble, France;
5Institut Curie, Oncologie Pédiatrique, Paris, France; 6Centre Oscar Lambret, Oncologie
Pédiatrique, Lille, France; 7CHU de Strasbourg, Oncologie Pédiatrique, Strabourg,
France; 8Hôpital Lapeyronie, Analgésie et soins Palliatifs Pédiatrique, Montpellier,
France; 9Robert Debré, Oncologie Pédiatrique, Paris, France; 10CHU de Saint Etienne,
Oncologie Pédiatrique, Saint Etienne, France; 11CHU de Limoges, Oncologie
Pédiatrique, Limoges, France; 12CHU de Nancy, Hématologie Oncologie et Centre de la
Douleur Pédiatrique, Nancy, France; 13France
Background/Objectives: Pain control is a challenge in children with cancer.
Consequences of disease progression, central sensitization and painkillers side effects
like opioids induced hyperalgesia can lead to intractable pain despite well conducted
treatments. Ketamine, a N Methyl D Aspartate receptor antagonist, has shown to be
efficient in relieving cancer pain in adult population. Literature regarding children is
scarce.
Design/Methods: This prospective multicentric observational study (approved by
French regulatories CCTRIS and CNIL) aims to assess efficacy, safety and
opioid-sparing effect of low doses of ketamine added to opioid analgesics to improve
refractory cancer pain in children.
Results: Thirty-eight patients (median age 15y.) from 10 French pediatric oncology
centers were registered during a 11 months period. All received Ketamine either
intravenously (37) or orally (1) as adjuvant treatment for refractory pain. The mean
pain score for the overall population has significantly decrease from Day 1 (Mean VAS
= 6.7 (2.8)) to Day 3 (Mean VAS = 4.3 (3.2)) (p < 0.001). VAS scores were reduced by
at least two points in 19 (56%) patients 48h after initiation of ketamine. Nine patients
experienced poor tolerance (at least 2 side effects), all with infusion rates lower than 0,05
mg/kg/h. None had limiting toxicities. Concomitant prescription of benzodiazepine has
not shown efficiency in controlling side effects. Opioid-sparing effect was highlighted in
four patients. 54% of the prescribers and 47% of the patients found ketamine addition
“very helpful” even when they did not experienced improvement of pain scores.
Conclusion: The adjunction of low doses of ketamine to opioids analgesics in children
suffering from refractory cancer pain allowed reducing intensity of pain in half of our
population study. However we can’t conclude to an efficacy using the statistical design
beforehand established. Nevertheless, Ketamine may be an interesting and safe option
for improving treatment of refractory pain in children with cancer.
P-606
TRADITIONAL AND COMPLEMENTARYMEDICINE STRATEGIES IN
PAEDIATRIC ONCOLOGY: GLOBAL PATTERNS OF USE
C. Diorio1, C.G. Lam2, E.J. Ladas3, F. Njuguna4, S. Marjerrison1,5
1McMaster University, Pediatrics, Hamilton, Canada; 2St. Jude Children’s Research
Hospital, Oncology, Memphis, USA; 3Columbia University Medical Center, Nutrition,
New York, USA; 4Moi University, Pediatrics, Eldoret, Kenya; 5McMaster Children’s
Hospital, Pediatric Hematology/Oncology, Hamilton, Canada
Background/Objectives: Traditional and Complementary Medicine (T&CM) strategies
are frequently sought by paediatric patients with cancer. Patterns of use vary widely
across different countries. The current review aimed to characterize the rates, types and
reasons for use of T&CM in paediatric oncology, stratified by reporting country
income level per World Bank.
Design/Methods: A systematic review of the literature was performed searching
MEDLINE, EMBASE, Global Health, CINAHL, PsycINFO, AMED, Cochrane
Database and Proceedings First from the date of inception for each database to
February 7, 2015. Inclusion criteria comprised children <18 years old representing at
least 10% of the participants, who were on active treatment for cancer, with any T&CM
use. Exclusion criteria included failure to include at least one of the core outcomes
(rate, type or reason for use). All primary study types were included, without language
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exclusion. Article screening and data extraction were independently conducted by two
reviewers with discrepancies resolved by consensus.
Results: 4088 abstracts were retrieved, with 3062 abstracts screened after duplicates
removed. 310 qualified for full-text review. 66 articles from 31 countries reported
relevant data; 1 from a low-income country (LIC), 6 from lower-middle-income
countries (LMIC), 15 from upper-middle-income countries (UMIC) and 44 from
high-income countries (HIC). Reported rates of T&CM use among pediatric oncology
patients varied between 59-90% (median 68%) in LIC/LMIC as compared to 6-100%
(median 42.7%) in HIC. Publications spanned 1977 to 2014, and reported rates of
T&CM use appeared to increase over time. Provision of care from Traditional Healers
was reported more frequently in LIC and LMIC than in HIC. Abandonment of
conventional cancer care, and delays in diagnosis were associated with T&CM use in
some settings.
Conclusion: T&CM strategies are used commonly by paediatric oncology patients
worldwide. Integration of T&CM practices into paediatric oncology programs may
offer an opportunity to improve treatment adherence and outcomes.
P-607
INFECTION-RELATEDMORTALITY IN CHILDRENWITH CANCER: A
10-YEAR STUDY
T.A. Martins1, F. Durão2, P. Costa Reis2, M.J. Ribeiro3, A. Neto3, A. Teixeira3,
X. Duarte3, G. Caldas3, C. Mendes3, C. Constantino3, S. Nunes3, A. Lacerda3,
F. Pereira3
1Hospital Garcia de Orta- EPE, Serviço de Pediatria, Almada, Portugal; 2Hospital de
Santa Maria- Centro Hospitalar Lisboa Norte- EPE, Serviço de Pediatria, Lisboa,
Portugal; 3Instituto Português de Oncologia de Lisboa Francisco Gentil- EPE,
Departamento de Oncologia da Criança e Adolescência, Lisboa, Portugal
Background/Objectives:Many children with cancer die from infection. Nevertheless, the
clinical characteristics of infection-related mortality are still poorly understood, yet
their understanding may help improve survival. We aimed to analyze infection-related
deaths in a Pediatric Oncology Unit (POU).
Design/Methods: Retrospective review of epidemiological and clinical data of children
who died between Jan’05-Dec’14 in a POU admitting circa 160 children annually, up to
age 16y.
Results: In this 10y period infection caused the death of 29 patients, accounting for 9%
of all deaths (N=317) and 60% of the toxic deaths (29/48). Most children were girls
(20/29). Eighteen children had hematologic malignancies (15 leukemias, 3 lymphomas),
7 had solid tumors and 4 had central nervous system tumors. Most (25/29) were being
exposed to intensive treatment protocols (levels 3/4 of the Intensity of Treatment Rating
Scale 2.0). Median age of death was 10.2y (IQR 4.4-14.3y). Median time from
diagnosis to death was 6m (IQR 2m-1.9y). Nineteen patients met criteria for septic
shock, of which 16 were neutropenic (10 leukemias, 2 lymphomas, 3 solid tumors and 1
medulloblastoma). The most common primary site of infection was the respiratory
tract (10/29), followed by gastrointestinal (3/29) and skin (1/29); in 15 patients, the
primary site of infection was not evident. A pathogen was identified in 16 children - 12
bacterial agents (7 Gram-), 4 fungal agents and 2 viruses. Three patients had
co-infections (two Gram- & fungus, one Gram- & Gram+ bacteria). Fifteen patients
died in intensive care units, 9 in the POU ward and 5 in the local hospital’s ward.
Conclusion: Infections are a major cause of toxic death in children with cancer. To
improve their overall survival, especially of those submitted to agressive treatments, new
strategies for infection prevention and treatment should be developed, as well as
education tools for professionals and families.
P-608
THE ROLE OF BASIC ORAL CARE AND THE NEED OF EVIDENCE
BASED-GUIDELINES FORMUCOSITIS MANAGEMENT IN
ONCOHEMATOLOGICAL PAEDIATRIC PATIENTS
C. Mata1, J. Huerta2, M. Barrios2, V. Gomez3, E. Martinez3, A. Alberto3
1Gregorio Marañon University Hospital, Pediatric Oncohematology, Madrid, Spain;
2Gregorio Marañón Hospital, Pediatric Oncohematology, Madrid, Spain; 3Complutense
University, Odontoestomatology, Madrid, Spain
Background/Objectives:Mucositis is a term that describes the inflammatory response of
any mucosal surface in the body in response to the cytotoxic effects of oncologic
treatment. Oral mucositis is the one that has received more attention, due to its high
incidence and impact on patient’s quality of life, and there is not a uniform standard
management. The aim of this small study is to describe some aspects related with dental
health and oral care in an aleatorial sample of pediatric oncohematologic patients.
Design/Methods: A sample of 36 aleatorized patients from "Gregorio Marañón"
Hospital-Oncohematology Paediatric Department were analyzed by three
odontoestomatologist, in order to describe different parameters in the oral health
status, dental care and prevention of oral mucositis.
Results: In this small study we observed that 67% of the patients had never received
prior dental boarding. Sweet and cold foods were the prefered by the 36% of them,
followed by cold salty ones. This enhances the fact that cryotherapy is effective as pain
treatment in mucositis. Only 56% of them had an acceptable oral hygiene at the time of
evaluation. Among all the patients evaluated (inpatients and outpatients) 17(47%) had
mucositis. All the patients were not brushing their teeth during the treatment.
According to the results of our study, patients who received hygiene tips, presented
higher degree of mucositis values ( probably related with a highest risk of having
mucositis, because of a longer neutropenia/drugs/ radiotherapy/type of cancer…) 72,22
% of the patients did not receive treatment for mucositis but 11,11% reported that
chlorhexidine was the best option for its healing.
Conclusion: There is a need to unify criteria and to develop preventive and therapeutic
protocols for clinical applicability, (which will include pharmacological and
non-pharmacological treatments, teeth brush, cryotherapy…) This is the aim of a new
biggest study that we have just begun.
P-609
FACTORS CONTRIBUTING TO PLACE OF DEATH IN CHILDREN AND
YOUNG PEOPLE DYING FROM CANCER: A SYSTEMATIC REVIEW OF THE
LITERATURE
D. McIntosh1, N. Osifodunrin2, D. Murphy2
1Royal Hospital for Sick Children-Yorkhill, Glasgow, United Kingdom; 2Royal Hospital
for Sick Children-Yorkhill, Paediatric Oncology, Glasgow, United Kingdom
Background/Objectives: Despite significant increases in survival from childhood cancer
it remains the most significant cause of death in children and young people. Paediatric
Palliative Care is an evolving subspecialty whose primary aim is to work with young
people and their families to improve their quality of both life and ultimately their
death. Internationally there is increasing emphasis on involving patients and carers in
decision making during palliation-including decisions regarding locations of death and
dying. The aim of this literature review was to determine the preferred place of death
and identify the factors influencing this decision.
Design/Methods: Embase, Medline and Cumulative Index to Nursing and Allied Health
Literature (CINAHL) were searched from 1998-2014 using the terms: ‘child’, ‘cancer’,
‘place’ and ‘death’. 3 independent reviewers assessed articles for relevance and inclusion.
Results: 22 studies were included from 15 countries. The majority of studies were
retrospective reviews of death certificates or medical records. Four studies used
semi-structured questionnaires given to bereaved parents and three were prospective
studies. Location of death varied significantly. Home deaths ranged from 9-79% and
hospital deaths from 27-81%. A minority of patients died in hospices, ranging from
3.1-35.5%.
Conclusion: Internationally there are significant differences in the location of death of
children and young people dying from cancer. This review identified many factors
contributing to place of death: patient demographics, disease diagnosis and stage, time
from diagnosis, geography, cultural beliefs and socioeconomic status. The most
significant were: Availability of Paediatric Palliative Care services and the ability to
provide end of life care in the preferred place of death. A key role of palliative care is to
facilitate parent and patient choices. Health professionals should ensure the
development of flexible services which can provide the care required at the location of
choice and be powerful advocates for this uniquely vulnerable group.
P-610
MANDATORY NATIONAL POLICY FOR RESUSCITATION PLANNING
IMPROVES DECISIONMAKING AND COMMUNICATION AT THE END OF
LIFE IN CHILDREN AND IS WELCOMED BY CLINICIANS
D. Murphy1, D. McIntosh2, J. Spiller3
1Glasgow, United Kingdom; 2Royal Hospital for Sick Children-Yorkhill, Oncology,
United Kingdom; 3Marie Curie Hospice, Palliative Care, Edinburgh, United Kingdom
Background/Objectives: In May 2010 National Health Service (NHS) Scotland
published Europe’s first fully integrated national policy for Do Not Attempt
Cardiopulmonary Resuscitation (DNACPR) decision making and communication. The
Scottish Government led the development of this policy. A Paediatric education
package was made available on line (Children and Young Adult Acute Deterioration
Management-CYPADM) and local champions appointed to provide training and
change working patterns.
Design/Methods: Using The Scottish Paediatric Surveillance Unit (an epidemiological
sub group of the Royal College of Paediatrics and Child Health) clinicians were sent a
monthly questionnaire asking if they had any end of life discussions with families.
Positive responses generated a follow up email asking about the consultation.
Results: Over 2 separate 1 year periods (2011-12 and 2013-14) 127 positive responses
were obtained and 99 follow up questionnaires completed (response rate 78%). The age
range of individuals involved was 0.5-27 years, with increased use of the form at the
extremes of the range. The form was useful in neonatal and transition settings. Uptake
reflected the population distribution across the nation, with most forms filled for people
living in the Central Belt. Over 95% of clinicians rated form use as easy or very easy. A
similar proportion rated the policy as very good or excellent.
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Conclusion: Policies which facilitate an integrated approach to DNACPR
decision-making and communication children have been implemented across Scotland.
Quality measures have been developed to assist Health Boards in further establishing
the impact of these policies on patient care.
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A MANAGED AND SUPPORTED TELEHEALTH NETWORK DELIVERS
EQUITABLE, HIGH QUALITY END OF LIFE CARE TO CHILDREN DYING OF
CANCER, ACROSS THE NATION, IRRESPECTIVE OF GEOGRAPHY
D. Murphy1, J. Miller2, H. Bishop3, M. Brougham4
1Glasgow, United Kingdom; 2Managed Service Network for Children and Young
Adults-Scotland, Clinical Support, Dundee, United Kingdom; 3Royal Hospital for Sick
Children-Aberdeen, Oncology, Aberdeen, United Kingdom; 4Royal Hospital for Sick
Children-Edinburgh, Oncology, United Kingdom
Background/Objectives: The Scottish Managed Service Network (MSN) for Children
and Young People with Cancer was established by the Scottish Government to ensure
equity of access to, and the provision of care to the population of Scotland irrespective
of location. Managerial and secretarial support was provided to the network
independent of health boards. Despite recent work suggesting the number of children
with a life limiting or threatening diagnosis is much greater than thought, it remains
rare and providers are often isolated both physically and intellectually. Weekly
telephone and monthly video multi disciplinary meetings began in May 2014, linking
professionals across disciplines and sites.
Design/Methods: A retrospective review of MDT attendance logs and review of service.
Results: A median of 7 professionals attended phone conferences (IQR 5-8) and a
median of 13 attended video conferences (IQR 10-15). Hospice, community, secondary
and tertiary care paediatric and nursing staff always attended. Allied health
professionals attended as the meetings became established. Paediatric Haematologists
did not attend. Professionals were clear that the meetings enhanced working practice
and welcomed the formal structure provided by the MSN. The meeting was universally
rated as “The most important MDT I attend”.
Conclusion: The use of proformas to frame case discussions was welcomed. The
meetings would not happen without managerial support from the MSN. More needs to
be done to engage with haematology colleagues Impact on practice: Improved
integration of care and development of quality indicators has rapidly improved practice
delivery to a uniquely vulnerable patient group.
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WHERE DO CHILDRENWITH CANCER DIE ANDWHAT FACTORS EFFECT
DECISIONMAKING ABOUT THIS? A SYSTEMATIC REVIEW OF THE
LITERATURE
D. Murphy1, N. Osifodunrin2, D. McIntosh3
1Glasgow, United Kingdom; 2Royal Hospital for Sick Children-Yorkhill-Glasgow,
Paediatrics, Glasgow, United Kingdom; 3Royal Hospital for Sick
Children-Yorkhill-Glasgow, Oncology, United Kingdom
Background/Objectives: Childhood cancer remains the single most common cause of
death in children and young adults in the developed world. As the survival rates have
improved, so too has the use and availability of paediatric palliative care. In the UK
and Europe there is an increasing emphasis on the facilitation of choice for patients and
carers. Factors believed to effect choice in regard to location of death include
availability of services, cultural beliefs, type of disease and socioeconomic status.
Design/Methods: Embase, Medline and Cumulative Index to Nursing and Allied Health
Literature (CINAHL) were searched from 1998-2014 using the terms: ‘child’, ‘cancer’,
‘place’ and ‘death’. Articles were assessed for relevance.
Results: Twenty two studies were included from 15 countries. The majority were
retrospective reviews of death certificates or medical records. Four studies used
semi-structured questionnaires, three were prospective studies.Location of death varied
significantly. Home deaths ranged from 9-79%, hospital deaths from 27-81% and
hospice deaths from 3.1-35.5%.
Conclusion: There are significant differences across the world and even between regions
within a single country, in the location of death of children and young people dying of
cancer. One of the key roles of palliative care professionals is to facilitate parent and
patient choices. A deep understanding of obstacles to optimum delivery of care is
required of clinicians delivering end of life care to children and their families. Where
absent/poor service provision or socio economic factors restrict choice, evidence should
be collected and presented to funding agencies to highlight gaps in the equitable
delivery of care to a uniquely vulnerable group.
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RISK FACTORS FOR SEVERE OUTCOME IN NEUTROPENIC
ENTEROCOLITIS; A SYSTEMATIC REVIEW
L. Naeije1, M. Van de Wetering2, L. Kremer2, E. Leclerq2
1Emma Children’s Hospital/Academic Medical Center, Amsterdam, Netherlands; 2Emma
Children’s Hospital/Academic Medical Center, Pediatric Oncology, Amsterdam,
Netherlands
Background/Objectives: A systematic literature review was carried out to evaluate best
existing evidence on prognostic factors for outcome of neutropenic enterocolitis (NEC)
or typhlitis. A well known potential life threatening complication of the treatment of
malignancies. The reported mortality rate in both adults and children varies from 8% -
50%.
Design/Methods: Databases (MEDLINE, CENTRAL and EMBASE) were searched
for relevant studies. All studies describing risk factors for outcome were included.
Information about study characteristics, treatment, outcome and prognostic analysis
were abstracted and the quality of each article was assessed.
Results: A total of 15 studies met the inclusion criteria and reported on risk factors for
the outcome of NEC. All had methodological limitations, regarding the internal and
external validity. Four studies evaluated possible prognostic factors in a multi- or
univariate analysis resulting in 8 potential relevant factors. Two studies with high quality
performed multivariate analysis showed that the diagnosis of Non Hodgkin Lymphoma
conditioning pretransplant with busulfan/cyclofosfamide and acute myeloid leukaemia
receiving high dose cytarabine indicated a significant prognostic factor for poor
outcome of the typhlitis episode. Two studies with univariate analysis showed that the
radiological finding of bowel wall thickening >10mm and the laboratory findings of
CRP>150 mg/L and IL-8 > 1000pg/ml were found as prognostic markers.
Conclusion: This systematic review summarizes the available evidence to identify the
prognostic factors relevant for the outcome of typhlitis/neutropenic enterocolitis and
provides the evidence on which to base further prospective studies and possibly create a
prediction rule for outcome of typhlitis/neutropenic enterocolitis in both adult and
paediatric oncology.
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DELIVERING BAD NEWS AND ADVANCED COMMUNICATION SKILLS
CURRICULUM FOR PEDIATRIC ONCOLOGY TRAINEES
A. Nageswara Rao1, S. Khan2
1Rochester, USA; 2Mayo Clinic, Pediatric Hematology/Oncology, Rochester, USA
Background/Objectives: Effective communication is the cornerstone of good patient
care. Pediatric oncologists are constantly faced with the challenge of delivering bad
news to patients and families. However, a study of pediatric oncologists showed that
they had received little training in delivering bad news other than learning from direct
observation and lectures. In a more recent survey of trainees in United States pediatric
hematology-oncology fellowship programs only 32% of trainees reported receiving
communication training. Herein, we present our communication skills curriculum and
our pediatric oncology trainees’ experience with the training module.
Design/Methods:We implemented a small-group communication skills training module
6 years ago with a goal of providing trainees with a non-threatening, and easily
engaging curriculum which allows for self-reflection and experiential learning. The
module consists of didactics followed by video recorded role-play sessions using
standardized patient actors. These video recorded sessions are followed by
self-reflection by the trainee and feedback from session facilitators(pediatric
oncologists), co-trainees, and the actor. Simulated scenarios include disclosure of a new
oncologic diagnosis, unexpected relapsed/recurrent disease, and caring for the dying
patient.
Results: The module focusses on conversation skills which include physician
questioning skills, assessing parental/patients’ knowledge, presenting information with
empathy and in an organized manner, thus aiding shared medical decision making.
Surveys were conducted to rate pre-and post-workshop knowledge/confidence levels of
trainees(n=18) for various case scenarios. Trainees reported high/very high knowledge
post-workshop compared to pre-workshop with scenarios involving discussion of a
newly diagnosed cancer, responding effectively to negative emotions and end of life
discussions and transition to palliative care(p=0.04, p=0.03, p=0.01; respectively). For
scenarios involving disclosure of unexpected cancer recurrence, there was no significant
difference in reported pre- and post-workshop knowledge levels(p=0.08).
Conclusion: Our study shows that small-group sessions with formal lectures and video
recorded simulated scenarios allowing self-reflection and feedback is an easily
implementable and effective training tool.
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RESPIRATORY VIRUSES, A COMMONMICROBIOLOGICAL FINDING IN
CHILDREN TREATED FOR CANCER IN SOUTH AFRICA
G. Naidu1, R. Wainwright1, D. MacKinnon1, S. Poiyadjis1, B. Rowe1, M. Nunes2,
S. Madhi2, A. Izu2
1University of the Witwatersrand and Chris Hani Baragwanath Academic Hospital,
Pediatric Oncology, Johannesburg, South Africa; 2Department of Science/National
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of the Witwatersrand- National Institute of Communicable Diseases, A Division of
NHLS- Sandringham, Johannesburg, South Africa
Background/Objectives: Febrile neutropenia is a common complication in children
undergoing therapy for malignant disease. A bacterial pathogen is only identified in 30-
40% of the septic episodes. To prospectively investigate viral infections as possible
etiologic agents in children with chemotherapy induced febrile neutropenia.
Design/Methods: Nasopharyngeal aspirates (NPAs) from patients presenting with fever
post therapy for a malignant disease were analysed with real time PCR (RT-PCR).
Results: The study included 169 children with cancer, 81 haematological cancer (HM)
and 88 solid tumours (ST) and 18 were HIV-infected. 60% were male with a mean age
of 7.2 years .There were 531 septic episodes, 332 in HM (mean = 4.10 episodes per
patient) 199 in solid tumours (mean = 2.26 episodes per patient) and 48 in the
HIV-infected group (mean = 2.67 episodes per patient). Viruses were identified in
60.4% of the septic episodes, 69.7% in HM, 30.2% in ST and 11.3% in the HIV-infected
group. Humanrhinovirus (42.6%), Coronavirus (29.6%), Polyomavirus (15.7%) and
Parainfluenzavirus (10.8%) were the most commonly observed viruses. 67.8% of viral
associated fevers had 1 virus detected and in 32.2% there were two or more viruses (
range 0 – 5). 7 (7.1%) of patients died due to a septic event ( 85.7% blood cancer, 16.7%
solid tumour and 28.6% HIV- infected). Eleven viruses were detected in the 7 patients
who died (5 Coronavirus, 3 Human-rhinovirus, 2 Influenza A, and 1
Metapneumovirus).
Conclusion: Respiratory viruses are found frequently during febrile episodes in children
with cancer. Further prospective studies with viral load determination may elucidate the
significance of these viral findings. Early detection of viral infections in this patient
group may help to reduce antimicrobial use and help to alleviate the critical issue of
microbial resistance.
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VIRAL AND BACTERIAL CO-INFECTIONS IN CHILDREN TREATED FOR
CANCER
G. Naidu1, R. Wainwright2, D. MacKinnon2, S. Poiyadjis2, B. Rowe2, M. Nunes3, Izu3,
S. Madhi4
1University of the Witwatersrand and Chris Hani Baragwanath Academic Hospital,
Johannesburg, South Africa; 2University of the Witwatersrand and Chris Hani
Baragwanath Academic Hospital, Pediatric Oncology, Johannesburg, South Africa;
3Department of Science/National Research Foundation: Vaccine Preventable Diseases-
Faculties of Health Sciences-University of the Witwatersrand: National Institute of
Communicable Diseases, A Division of NHLS- Sandringham, Johannesburg, South
Africa; 4Department of Science/National Research Foundation: Vaccine Preventable
Diseases- Faculties of Health Sciences-University of the Witwatersrand: National
Institute of Communicable Diseases: Medical Research Council: Respiratory and
Meningeal Pathogens Unit, A Division of NHLS- Sandringham, Johannesburg, South
Africa
Background/Objectives: The aim of the study was to prospectively explore the
prevalence of bacterial and viral coinfection in children with febrile episodes (FE).
Design/Methods: Individuals on treatment for cancer who presented with a FE had a
full blood count and differential, blood culture and nasopharyngeal aspirate (NPA) for
respiratory viruses tested. The NPA was tested using real-time reverse transcriptase
PCR.
Results: One hundred and thirty three patients (68% male, mean age 6.69years) with 398
FE (258 HM, 140 ST, 38 HIV-infected) were analyzed for bacterial and viral
coinfection. 264 NPAs tested positive for a respiratory virus. 54 were positive for only a
virus and 210 had coinfection with a virus and bacteria or fungus (109 gram-positive
and 85 gram-negative bacteria, 16 fungi). The odds for FE in a patient with a HM and
positive NPA was 1.63 (p=0.051). Amongst those with an absolute lymphocyte count
of <500 for longer than 7 days, the OR for coinfection was 1.92 (p=0.006).The OR for
coinfection with a positive NPA and blood culture in the HIV-infected patient was
0.376 (p=0.061) and OR for coinfection with Polyoma Ki virus was 0.358 (p=0.04).The
time to recovery from the FE was significantly longer in those that had coinfections
(p=0.004). 9/123 patients died due to FE. Twenty bacteria were cultured from any
septic episode of these patients (9 gram-positive, 7 gram-negative and 4 fungi) and 11
viruses were detected on NPA analysis. 6 patients had at least one positive test for
Human rhinovirus.
Conclusion: Bacterial infections are commonly associated with viral infections in
children with malignant disease. This study supports interactions between viruses and
bacteria in the pathogenesis of severe infections. Future prospective studies are required
to explore a temporal association between viral and secondary bacterial infections in
the immunocompromised patient.
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BACTERIAL INFECTIONS IN CHILDREN TREATED FOR
HAEMATOLOGICAL MALIGNANCY
G. Naidu1, R. Wainwright2, D. MacKinnon2, S. Poiyadjis2, B. Rowe2, A. Izu3, S. Madhi3
1University of the Witwatersrand and Chris Hani Baragwanath Academic Hospital,
Johannesburg, South Africa; 2University of the Witwatersrand and Chris Hani
Baragwanath Academic Hospital, Pediatric Oncology, Johannesburg, South Africa;
3Department of Science/National Research Foundation: Vaccine Preventable Diseases-
Faculties of Health Sciences-University of the Witwatersrand: National Institute of
Communicable Diseases: Medical Research Council: Respiratory and Meningeal
Pathogens Unit, A Division of NHLS - Sandringham, Johannesburg, South Africa
Background/Objectives: Childhood cancer cure rates have improved due to intensive
chemotherapy which leads to multiple disruptions in immunological protection and
increases susceptibility to life-threatening infections.
Design/Methods: Patients diagnosed with a haematological malignancy between April
2009 and March 2011 was prospectively evaluated. At each febrile episode (FE) bloods
taken for blood culture, full blood count, C-reactive protein, and procalcitonin and
urine sent for culture.
Results: Eighty one patients were enrolled (15 HIV-infected), 61% male, mean age 7.85
years. There were332 FE (4.1/patient); 78.8% with a positive blood culture (77
gram-positive and 181 gram-negative bacteria). 9.2% of FE had a proven fungal
infection. 40.9% of FE had one bacteria cultured, 20.2% had two and 38.9% had three
or more. 39 Escherichia coli were cultured ,79.4% extended spectrum ß-lactamase
producers (ESBL); 17 Klebsiella pneumonia, 59% ESBL; 12 Enterobacteraciae, 50%
resistant to Cephalosporins; 85.3% of Staphylococci sensitive to Vancomycin and 97.7%
resistant to Cloxacillin and 46.9% of Enterococcus sensitive to Vancomycin. Septic
complications: 26% UTI ( 39 gram-negative,21 gram-positive,12 fungi),24% clinical
pneumonia, 4.3% bacterial meningitis, 13.6% gastroenteritis, 28% mucositis, 30.1%
herpes stomatitis and 10% culture-proven tuberculosis. The mean white cell count was
2.7x 109/l, the mean absolute neutrophil; lymphocyte and monocyte counts were 2128,
652 and 252 respectively. The mean CRP was 151 mg/ml and PCT was 13 ng/ml. The
mean duration of fever was 4.76 days (median 4 days).9(11%) died of the septic
episode, only two were admitted to the ICU.
Conclusion: The very high rate of culture proven septic episodes is not recorded in the
developed world. Malnutrition, overcrowded wards, lack of adequate nursing
personnel, lack of isolation facilities, aseptic techniques and a high prevalence of HIV
disease may be contributory factors. In addition, there is a high incidence of
antimicrobial resistance. Intensive care facilities are a priority for children treated with
high-risk chemotherapy.
P-618
AN INTERVENTIONAL STUDY- NGOMAKING A DIFFERENCE IN THE
LIVES OF CHILDRENWITH CANCER : CONDUCTED IN COIMBATORE,
SOUTH INDIA
B. Nair1, H. Gokul.R2
1Aroh-Giving Hope, Coimbatore, India; 2Aroh-Giving Hope, Management, Coimbatore,
India
Background/Objectives: The incidence of childhood cancer is on the rise in India. But
India has less than 5 NGOs that work exclusively for children with cancer. The
treatment and the indirect expenses make it impossible for a middle-income or
lower-income family to afford the whole experience. Ignorance about the disease and
social stigma also play a part. Late diagnosis almost always results in death or relapse.
Most of the hospitals are also not equipped to treat childhood cancer. Very few
hospitals have social service teams or councilors. Not following the protocol, lack of
nutritious food and, very low personal hygiene contribute to the alarming relapse rate.
The researchers believe that the gaps in the entire spectrum of childhood cancer can be
efficiently filled with the services of an NGO. The authors run an NGO for children
with cancer and their families.
Design/Methods: This study was run for 18 months among 100 children with cancer and
their families. The state of the children before the intervention of the NGO was
documented. Then the NGO started working with the children in the key areas like
treatment, counseling, food, education, palliative care, and death and bereavement. And
after 18 months, the same 100 children were studied to see how the NGO has made a
difference in their lives.
Results: The result was that significant improvement was noted.
Conclusion: The authors have concluded that the services of the NGO make a
tremendous difference in the lives of the children with cancer.
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VIRIDANS GROUP STREPTOCOCCAL INFECTIONS IN CHILDREN
FOLLOWING CHEMOTHERAPY OR STEM CELL TRANSPLANTATION– A
TEN YEAR RETROSPECTIVE REVIEW FROM A TERTIARY PAEDIATRIC
HOSPITAL
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Background/Objectives: Viridans group streptococcal (VGS) infection is increasing and
is now the third most common cause of bacteraemia in paediatric haemato-oncology
patients. VGS is associated with high mortality rates due to the potential to cause
viridans group streptococcal shock syndrome (VSSS). Despite this, there are no recent
paediatric studies describing VGS in children with cancer in Europe to inform
antimicrobial therapy. The aim of this study was to describe the characteristics,
outcome and resistance patterns of children with VGS bacteraemia undergoing
treatment of malignancy or haematopoietic stem cell transplant (SCT) in a tertiary
referral centre in the UK.
Design/Methods: Patients aged 0-18 years admitted to a tertiary paediatric
haemato-oncology centre with VGS bacteraemia from 2003-2013 were included in the
study. All data was collected retrospectively from electronic records and case notes.
Results: 54 episodes occurred in 46 patients. The most common underlying diagnoses
were relapsed acute lymphoblastic leukaemia (ALL) [13 episodes], ALL [6 episodes]
and acute myeloid leukaemia (AML) [6 episodes]. Streptococcus mitis [35 episodes] was
the most frequent organism, followed by strep oralis [10 episodes]. Thirty percent of
isolates were resistant to penicillin and 100% sensitive to vancomycin. There were 8
episodes of VSSS (14.8%) – 4 in patients undergoing SCT; 3 in relapsed ALL and 1
with AML. Of these 8 patients, 6 required admission to intensive care and 3 died of
multi organ failure.
Conclusion: Patient characteristics were in keeping with known risk factors for VGS
bacteraemia although the high risk in relapsed ALL is of note. This observation
requires further investigation and may well have management implications. The
potentially fatal nature of VGS infection and high incidence of penicillin resistance are
confirmed. Research is needed to develop bedside risk stratification scores that identify
children at risk of VSSS to guide antimicrobial therapy.
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PHARMACOKINETICS AND ASSOCIATION OF HIGH-DOSE
CYCLOPHOSPHAMIDE AND ITS METABOLITES WITH CARDIAC TOXICITY
IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
T. Nishikawa1, E. Watanabe2, K. Ikawa3, Y. Kodama1, T. Tanabe1, Y. Okamoto1,
Y. Takeda2, Y. Kawano1
1Kagoshima University, Pediatrics, Kagoshima, Japan; 2Kagoshima University, Clinical
Pharmacy and Pharmacology, Kagoshima, Japan; 3Hiroshima University, Clinical
Pharmacotherapy, Hiroshima, Japan
Background/Objectives: Observed only after administration of high-dose, cardiotoxicity
is the dose-limiting effect of cyclophosphamide (CY). CY is activated by the
cytochrome P-450 enzymes to form 4-hydroxy-cyclophosphamide (HCY), which is in
equilibrium with aldocyclophosphamide. Depending on the cell type,
aldocyclophosphamide may decompose to form cytotoxic phosphoramide mustard and
the acrolein, or may be oxidized to the inactive metabolite
o-carboxyethylphosphoramide mustard (CEPM). This report investigates the
relationship between the pharmacokinetics of high-dose CY and the cardiotoxicity
observed when the drug is used for pediatric hematopoietic stem cell transplant
recipients.
Design/Methods: Ten consecutive children ranging from one to 18 years of age who
were receiving a high-dose CY ( 50 mg/kg/dose) were enrolled. The underlying
diseases were acute lymphoblastic leukemia (n = 3), acute myeloid leukemia (n = 2)
and others (n = 5). The pharmacokinetics of the CY, HCY and CEPM were evaluated
in each patient by analysis of the serial blood samples using liquid chromatography
coupled with electrospray tandem mass spectrometry. To evaluate the myocardial
damage, all the patients underwent an electrocardiogram (ECG) before every
administration of high-dose CY.
Results: No overt cardiac failures were recorded. Serial ECGs revealed a reduction in
T-wave and ST segment abnormalities with an increase in NT-proBNP level (1070
pg/ml) in one case. This patient had the lowest area under the concentration time curve
(AUC) for CEPM (55.3 μM×h) compared to the other patients (average AUC for
CEPM: 126 ± 32.8 μM×h). AUC variability was 2.0x for CY, 12.2x for HCY and 3.7x
for CEPM.
Conclusion:We speculate that the patient who developed cardiotoxicity might
metabolize CY into active metabolites such as acrolein, more than the inactive
metabolite, CEPM. Inter-individual differences in the pharmacokinetics of metabolism
of high-dose CY may explain variability in both patient response and cardiotoxicity. A
further large-scale trial will therefore be needed to confirm this hypothesis.
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SERVICE EVALUATION OF THE CLINICAL VALUE OF STOOL
MICROSCOPY AND CULTURE IN PAEDIATRIC ONCOLOGY UNIT
O. Oconnor1, R. Cooke2, N. Cunliffe3, B. Pizer4
1Institute of Child Health, Liverpool, United Kingdom; 2Alder Hey Children’s Hospital,
Microbiology, Liverpool, United Kingdom; 3University of Liverpool, Microbiology,
Liverpool, United Kingdom; 4Alder Hey Children’s Hospital, Oncology, Liverpool,
United Kingdom
Background/Objectives: Diarrhoea is a common symptom in paediatric oncology
patients. Although stool samples are still commonly sent for microscopy and culture,
the value of these tests in paediatric oncology patients with diarrhoea is not clear. A
number of studies suggested the limited role of attempting to isolate routine enteric
pathogens as a cause of diarrhoea in hospitalized patients, however the diagnostic value
of testing in children with oncological conditions has not been reported. Therefore, we
conducted a service evaluation to estimate diagnostic yield of stool cultures in oncology
patients.
Design/Methods: Records from the Microbiology Laboratory from September 2009 to
October 2014 were reviewed to collect data on the number of stool cultures performed
in patients treated at a Regional Paediatric Oncology Unit, Liverpool, UK.
Results: A total of 842 stool cultures from 250 paediatric oncology patients with
diarrhoea were performed over the 5-year study period. Ninety three percent (788
samples) of the workload was from inpatients, 6.4% (54 samples) was from oncology
day case ward. A significant number of children had more than one stool culture done
(average 3.4 samples per patient). Out of 842 samples tested over 5 years only 1 sample
was tested positive for Campylobacter (0.1 %). Medical records review of the patient
who was tested positive showed that the patient presented from the community with a
few weeks history of severe cramping abdominal pain, diarrhoea with mucus and
weight loss.
Conclusion: A comprehensive service evaluation of all stool culture tests performed in
paediatric oncology patients during a 5-year period have demonstrated very low utility
of routine stool cultures for patients with diarrhoea. We suggest that the
implementation of rational practice guidelines for ordering stool cultures could result in
cost savings of approximately £2,200 per year at our hospital and more efficient
utilisation of resources.
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AN ACTION RESEARCH: THE PROCESS OF CHANGE DIETARY
CONSIDERATIONS AND BEHAVIORS OF CHILDHOOD CANCER PATIENTS
AND PRACTICAL INTERVENTIONS FOR ENJOY EATING
M. Ogasawara1, A. Shiozaki2, Y. Murayama1, S. Nakamura1, M. Maruyama1,
K. Matsuura3, A. Nakazima1, A. Hayashibe1
1Nagano Children’s Hospital, Department of Nursing, Azumino, Japan; 2Nagano
Children’s Hospital, Department of Patient Support and Regional Collaboration,
Azumino, Japan; 3Nagano Children’s Hospital, Department of Nutrition Management,
Azumino, Japan
Background/Objectives: Childhood cancer patients lose their appetite due to the adverse
effects of the treatment. Sometimes they would no longer eat or have little interest in
eating even after the completion of treatment. In addition, hospital environment could
not arouse interest in foods and their eating behaviors. Therefore, it is important to
provide educational interventions to foster self-management skills on diet sustained
even after discharge. The purpose of this study is to provide interventions for childhood
cancer patients and to describe the process of change in their considerations and
behaviors.
Design/Methods: Participants were childhood cancer patients who were admitted to the
Hematology-Oncology ward in Nagano Children’s Hospital from May, 2013 to
December, 2014. Our interventions were (1) preparation of the environment for
enjoyable eating, (2) opening of dietary education classes for patients by
multidisciplinary team. In the class, participants were able to touch “the food of
today”, learn how each nutrient works in their bodies, cook and eat the food, and
experience serving participants’ cooking to friends who were in the same ward. We
collected the interviews of the participants before and after interventions and
observational records at the classes. We analyzed these records from the viewpoint of
how their dietary considerations and behaviors had changed by actions.
Results: Thirty-four childhood cancer patients participated. As the result of the
interventions, following changes were revealed; "trying to eat without their fastidious",
"respecting lives of foods”, “thinking about the meaning of nutrition", "increasing their
motivation to overcome their illness", "enjoying eating", "growing autonomy and
self-care" and "expressing their feelings about illness".
Conclusion: By improvement of the environment and educational interventions, the
participants showed changes not only just to enjoy eating but also to have interests
about nutritional balance and their eating habit.
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THE USE OF PROTHROMBIN COMPLEX CONCENTRATE TO TREAT
PURPURA FULMINANS CAUSED BY PROTEIN C AND S DEFICIENCY
AFTER VARICELLA INFECTION - A CASE REPORT
S. Ogden1, R. Keenan1
1Alder Hey Children’s Hospital, Haematology, Liverpool, United Kingdom
Background/Objectives: Purpura fulminans is a complication of varicella infection
causing haemorrhagic infiltration of the skin and increased risk of intravascular
thrombosis. It is often caused by a deficiency of protein C or protein S leading to a
prothrombotic state.
Design/Methods:We present the case of a 4 year old boy who developed purpura
fulminans 1 week after chicken pox infection. He presented with a circumferential skin
necrosis to both legs and disseminated intravascular coagulopathy. At diagnosis his
protein C and S levels were found to be low at 14.1% and undetectable respectively. He
was also found to have a heterozygous mutation for factor V Leiden.
Results: Treatment was started with an IV heparin infusion, IV Immunoglobulins, IV
antibiotics and regular infusions of fresh frozen plasma (FFP). It was not possible to
achieve adequate Protein S levels using FFP as post infusion his protein C and S levels
were 121% and 36% respectively. He also developed pulmonary oedema secondary to
volume overload so was switched to infusions of prothrombin complex concentrate
(Octaplex). The dose of this was 2ml/kg (25iu/kg) twice daily and his dose of heparin
was adjusted to compensate for the heparin this contained. Post Octaplex his post dose
protein S levels were 46% which improved to 90-100% over subsequent days. The dose
was successfully weaned and stopped after 19 days, following which he successfully
maintained his protein S levels independently. During his admission he developed a
deep vein thrombosis of his left arm. His heparin was changed to warfarin, without
loading. He has now made a full recovery without needing any plastic surgery to his
legs.
Conclusion: Purpura fulminans is a rare complication of varicella infection. This is the
first reported case where prothrombin complex concentrate has been used alongside
heparin to achieve a full recovery without any long term complications or sequelae.
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MANAGEMENT OF TUMOR LYSIS SYNDROMEWITHOUT RASBURICASE:
A MODEL FOR THE DEVELOPINGWORLD
A. Prakash1, P. Kowtal1, H. Rao1
1St Johns Medical College, Pediatrics, Bangalore, India
Background/Objectives: Tumour lysis syndrome (TLS) is a life threatening oncologic
emergency. Risk of TLS is determined by tumor type and tumour load and is
categorised as low, intermediate and high risk. International protocols for TLS
management mandate the use of rasburicase to decrease hyperuricemia mediated renal
dysfunction. As it is an expensive medication, we examined whether a judicious protocol
of fluid and electrolyte management could effectively manage TLS without rasburicase.
This protocol would be important in the resource constrained developing world.
Design/Methods: This prospective study was conducted in Pediatric
Hematology-Oncology Unit over a two year period. All the patients with risk for
developing TLS were included in the study and treatment was initiated as per our
protocol. The patients were categorised based on TLS risk stratification and
Cairo-Bishop score.
Results: Sixty patients were recruited in the study. Forty three had Acute Lymphoblastic
Leukemia, nine had Acute Myeloid Leukemia and eight had high grade Non-Hodgkins
lymphoma. Thirty seven were classified as high risk, 19 as intermediate and 4 as low
risk for TLS. Twelve developed hyperuricemia, 7 had hyperphosphatemia, 4 had
hypocalcemia and 4 had hyperkalemia. Chemotherapy was delayed due to renal
dysfunction in only one patient.Three required PICU care and only one required
dialysis. There was no mortality.
Conclusion: Judicious hydration, allopurinol, phosphate binders and frequent
laboratory monitoring was used in all our patients. We had an excellent outcome even
in the high risk group despite not using rasburicase.
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MIBG THERAPY IS AN ACCEPTABLE OPTION FOR
RELAPSED/REFRACTORY NEUROBLASTOMA(NB) IN A LOW/MIDDLE
INCOME COUNTRY (LMIC) SETTING: A 10-YEAR EXPERIENCE
M. Prasad1, R. Ranade2, G. Chinnaswamy1, S. Basu2, S. Shah3, B. Arora1, T. Vora1,
S. Qureshi4, S. Laskar5, N. Khanna5, S. Kembhavi6, M. Ramadwar7, M. Muckaden8,
P. Kurkure1
1Tata Memorial Hospital, Paediatric Oncology, Mumbai, India; 2Radiation Medicine
Centre, Mumbai, India; 3Tata Memorial Hospital, Nuclear Medicine, Mumbai, India;
4Tata Memorial Hospital, Surgical Oncology, Mumbai, India; 5Tata Memorial Hospital,
Radiation Oncology, Mumbai, India; 6Tata Memorial Hospital, Radiodiagnosis,
Mumbai, India; 7Tata Memorial Hospital, Pathology, Mumbai, India; 8Tata Memorial
Hospital, Palliative Care, Mumbai, India
Background/Objectives: 131-MIBG has been used in the treatment of
relapsed/refractory NB for the past 30years, with response rates of around 20-40%. It is
now used in frontline regimens, often in conjuction with chemotherapy or
myeloablative therapy. Data from LMICs is lacking. We describe here our experiences
with 131-MIBG therapy in the treatment of NB.
Design/Methods: Retrospective audit of patients with NB at a PaediatricOncology
referral centre in India, who received MIBGtherapy in frontline or relapsed/refractory
settings from 2005 to 2014.MIBG therapy was administered at the
RadiationMedicineCentre, a neighboring institution. Apart from the routine
evaluation, all patients underwent 131-MIBG scans and Urinary VanillylmandelicAcid
(VMA) levels prior to treatment. A few patients underwent
ComputerisedTomograms(CTScans) and/or Fluorodeoxyglucose Positron
EmissionTomography(FDG-PET scans). The dose of 131-I MIBG was 10-12mci/kg
body weight, and capped at 150mci. Children were isolated after treatment,and
caregivers screened for exposure to the agent. Reassessment was done by clinical
evaluation,MIBG scans and Urinary VMA levels.
Results: There was data on 31 children who received a total of 46 courses of MIBG
therapy(median 1;range1-6courses). Median age was 6years,and male:female ratio
20:11.Intent was palliative in 21patients (total 28courses); most were high risk NB and
had received multiple courses of treatment, including AutologousStemCellTranplant in
3/21. Response rate was 45%(12/28), with 4 patients alive at last followup. Median time
to progression was 7months.Ten patients received a total of 19 courses of MIBG
therapy as part of frontline therapy(inoperable mass- 4 patients, refractory disease- 2
patients, residual post-operative mass-4patients). Response rate was 40%,with 5/10 alive
at last followup. The most common toxicity was grade3/4cytopenia, documented in
20%patients, mainly seen in patients with bonemarrow disease.
Conclusion: 1.With the limitations of a retrospective study,MIBGtherapy appears
feasible both in relapsed/refractory as well as frontline NB in LMICs, with acceptable
toxicities. 2.MIBGtherapy offers a reasonable salvage strategy in LMIC settings,where
other aggressive salvage therapies(including High dose therapies) are often not possible.
3.We hope that incorporation of MIBGtherapy in the frontline treatment regimen at
our centre in the near future will help improve outcomes in HighRisk NB.
P-626
FEBRILE NEUTROPENIA IN PEDIATRIC ONCOLOGY: A REGIONAL
QUALITY IMPROVEMENT STUDY OF GUIDELINES FOR FEBRILE
NEUTROPENIA UPTAKE AND TARGETED KNOWLEDGE TRANSLATION
V. Price1, M. Bernstein2, T. MacDonald3, C. Digout4, C. Johnson5
1IWK Health Centre and Dalhousie University, Halifax, Canada; 2IWK Health Centre
and Dalhousie University, Pediatrics, Halifax, Canada; 3IWK Health Centre and
Dalhousie University, Pharmacy, Halifax, Canada; 4IWK Health Centre and Dalhousie
University, Division Pediatric Hematology/Oncology, Halifax, Canada; 5IWK Health
Centre and Dalhousie University, Quality Improvement, Halifax, Canada
Background/Objectives: Data was collected to determine knowledge translation
effectiveness related to the 2005 APPHON/ROHPPA (Atlantic Provinces Pediatric
Hematology Oncology Network) Guidelines for Febrile Neutropenia. These guidelines
were developed for the treatment of pediatric oncology patients with febrile
neutropenia at healthcare centres in Atlantic Canada. The overall study aim focused on
whether the APPHON/ ROHPPA Guidelines for Febrile Neutropenia and associated
education improved the treatment of febrile neutropenia in pediatric oncology patients
in Atlantic Canada.
Design/Methods: A retrospective chart audit was conducted in twenty-one regional
health centres in Atlantic Canada, for the period January 2005 until January 2011. A
focused audit of patient charts was conducted to determine health centres’ adherence
with the recommended Guidelines for Febrile Neutopenia and to assess if any quality
improvement opportunities for targeted febrile neutropenia education at health centres
in Atlantic Canada could be identified.
Results: In total, 429 cases met the definition of febrile neutropenia as per the indicators
outlined in the 2005 APPHON/ROHPPA Guidelines for Febrile Neutopenia. results
illustrated a statistically significant difference in “time to blood culture drawn” and “time
to administration of antibiotics” based both on the health centre’s (1) Levels of Care
designation (p< 0.001) and on (2) the treating department or point of entry (p< 0.001).
Centres and departments within centres who saw more pediatric oncology patients were
more likely to follow the recommended times for Febrile Neutopenia treatment.
Conclusion: APPHON/ROHPPA will utilize the results to clarify, communicate, educate
and advocate for compliance related to the recommended Guidelines for Febrile
Neutopenia. Guidelines for febrile neutropenia at all sites will be clarified, since all
require improvement. A re-audit is planned following a period devoted to this
clarification and training.
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PRESERVATION OF VARICELLA SEROLOGY TITERS IN PEDIATRIC
ONCOLOGY PATIENTS FOLLOWING CHEMOTHERAPY
P. De Gouveia1, S.W. Um2, A. Chiang2, C. Clarkstone2, R. Ramphal3
1McMaster University, Medicine, Toronto, Canada; 2University of Ottawa, Medicine,
Ottawa, Canada; 3children’s Hospital of Eastern Ontario, Pediatrics, Ottawa, Canada
Background/Objectives: For pediatric oncology patients, current practice includes
administering Varicella-Zoster Immunoglobulin (VZIG) as post-exposure prophylaxis
(PEP) against Varicella-Zoster Virus (VZV) and isolating patients for 8 to 21 days.
Pediatric oncology patients immune to VZV prior to their cancer diagnosis represent a
population likely to preserve immunity against the disease. For this population the need
for VZIG and isolation is poorly validated and may be an undue health care cost and
inconvenience to patients. Therefore, we assessed VZV serology post-chemotherapy as a
marker for persistence of immunity while on chemotherapy.
Design/Methods: Approval from the research ethics board at Children’s Hospital of
Eastern Ontario (CHEO) was obtained prior to this study. Varicella antibody titers
were collected from 500 pediatric oncology patients treated at CHEO. Patients included
in this study had positive titers at the time of their malignancy diagnosis and antibody
testing at 6-months or 1-year post-chemotherapy treatment.
Results: One hundred and eighty two patients had both positive VZV antibody titers at
diagnosis and repeat testing performed post-treatment. Post-treatment,160 (87.9%), 16
(8.8%), and 6 (3.3%) had positive, negative and equivocal VZV antibody titers,
respectively. Moreover, 19 (10.4%) had chickenpox and 11(6.0%) developed shingles
during chemotherapy or post-treatment but before re-testing for VZV antibody titers.
There was no correlation between age or tumour type with preservation of VZV
antibody titers.
Conclusion: The majority of pediatric oncology patients with prior VZV antibody titers
preserve their VZV immunity post chemotherapy. Consequently, for this population,
VZIG PEP and isolation if hospitalized may not be necessary. In Japan and the United
Kingdom, acyclovir is used as a cost-effective alternative. For patients VZV seropositive
prior to malignancy, further studies to determine the risk factors predisposing these
patients to breakthrough disease may identify a subgroup of patients for whom VZIG
PEP and isolation in hospital is necessary.
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EDUCATION PROGRAM IN PEDIATRIC PALLIATIVE CARE NURSING:
CULTURALLY RELEVANTWITHMETHODOLOGY TRAINING THE
TRAINER
S. Rivas1
1Unidad Nacional de Oncología Pediátrica, Guatemala, Guatemala
Background/Objectives: One of the programs associated with the care of Pediatric
Oncology patients are Palliative Care Programs. In many Latin American countries are
starting to be formed, lacking some places about programs related to this field of
medicine. In most of them there are policies that, sometimes, drive the few existing
programs.Latin America is composed of countries that share language, cultural traits
and deficiencies in the health system, that make us different as a region and with other
nations. Tested in other countries Palliative Care Programs may be partially successful
as it requires taking into account the multi-ethnic culture and the various
characteristics of each place spiritual expressions.
Design/Methods: In 2013, the program Training in Pediatric Palliative Care Nurses
starts (one local nurse). In 2014, the training of nurses in Central America and
Caribbean starts for two months rotation in Guatemala. The objective of the program
is to achieve qualities as early immersion Palliative Care of an oncological disease
although patients are curable (symptom management and emotional support of the
patient during the trajectory of the disease), cultural approach to patients in palliative
care, understand spiritual variables. It is characterized by professional trainers, and be
direct observers of training nurses for two consecutive months, plus a draft for their
countries. Methodology: training the trainers. The project will have a multiplier effect in
other countries. Be trained to train.
Results: 7 nurses trained. Different countries: Honduras, Haiti, Panama, Dominican
Republic, Nicaragua and Guatemala.
Conclusion: Trained nurses are advocates the implementation of palliative care in their
hospitals, promote the dissemination of culturally appropriate palliative care in
countries that do not yet have care programs for it.
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TOTAL PARENTERAL NUTRITION IN CHILDRENWITH CANCER
J. Roganovic1
1Clinical Hospital Centre Rijeka, Rijeka, Croatia
Background/Objectives: The incidence of malnutrition in children with cancer varies
between 8% and 60%, depending on the diagnosis and the extent of the disease as well
as the type of antineoplastic therapy. Malnutrition is associated with lower tolerance
and delay of chemotherapy, more frequent and severe side effects, and compromised
immune function. The aim of this study was to show our experience with total
parenteral nutrition (TPN) in children with cancer, and point out the importance of
nutritional support in pediatric oncology.
Design/Methods: Twenty four children who received TPN during the treatment of
cancer at the Children’s Hospital Rijeka were included in the study. Indications for
starting nutritional support were as follows: body weight below the 10th percentile for
age and/or body mass index below the 5th percentile for age at the diagnosis; body
weight loss greater than 5% prior to diagnosis or during the treatment; children who
refuse or are unable (mucositis, diarrhea) to take food.
Results: The average length of TPN was 19 days (range 6-59 days). Seventy six percent
of children had weight gain (median 7.4%; range 1-25%). In 7 (29%) patients mild
hepatotoxicity was observed, which did not require discontinuation of chemotherapy.
In three adolescents with concomitant steroid therapy, glucose intolerance and need for
insulin therapy was observed. Other side effects did not occur.
Conclusion: Our results confirm that TPN is an effective method of establishing
protein-energy balance in pediatric patients with cancer. Weight gain was satisfactory,
and complications rare and transitory.
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15-YEAR EXPERIENCE OF IMPLANTABLE VENOUS PORT USAGE AT
CHILDREN AND ADOLESCENCE: EXPERIENCE OF 4 RUSSIAN INSTITUTES
M. Rykov1, Y. Buydenok2, N. Vashakmadze3, A. Firsov4
1Institute of Pediatric Oncology and Hematology FSBSI "N.N. Blokhin RCRC", General
Oncology, Moscow, Russia; 2Institute of Clinical Oncology N.N. Blokhin, Anesthesiology,
Moscow, Russia; 3Scientific Centre of Children Health, Pediatric, Moscow, Russia;
4Children’s Clinical Hospital, Interventional radiology, Moscow, Russia
Background/Objectives: Intravenous injection is an integral part of the treatment of
cancer and many congenital diseases: mucopolysaccharidosis, cystic fibrosis,
glycogenosis. Implantable venous ports are the best long-term access to the venous
system.
Design/Methods: 3256 patients (3 months. - 17 years) underwent implantation of
venous ports: since 1998 2921 patients in the Institute of Clinical Oncology, since 2008
278 patients in the Institute of Pediatric Oncology and Hematology, since 2011 52
patients in Children’s Clinical Hospital, since 2012 5 patients in Scientific Centre of
Children Health. To access the superior vena cava in 3127 (96%) an internal jugular was
punctured, in 129 (4%) a subclavian vena was used. An ultrasound marking of veins
came before the puncturing. Using intraoperative fluoroscopic for positioning of distal
end of the catheter to the superior vena cava the ports were implanted in 2987 (91.7%)
patients, in 269 (8.3) for this purpose an endocardial ECG was made.
Results: Thromboses of port systems was observed in 75 (2.3%) patients, catheter
associated bloodstream infections - in 5 (0.15%), pneumothorax - in 5 (0.15%).
Migration of a catheter wire to the internal jugular against bloodstream was observed
in 138 (4.3%) to the subclavian vein in 92 (2.8%) to the internal jugular vena on the
opposite side - in 11 (0.3%). From the first attempt we managed to puncture IJV in 3248
(99.7%), to catheterize in 2915 (89.5%).
Conclusion: The use of ultrasonic marking permits the avoidance of injury to the
adjacent anatomical structures and the reduction of the duration of the surgery. The
use of an X-ray scanner during the positioning of the port catheter prevents its
migration into the cervical veins and enables to place a tip of the catheter into the v.
cava superior directly above a right atrium entry site.
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THE ROLE OF VENOUS ACCESS IN PEDIATRIC ONCOLOGY
M. Rykov1, V. Polyakov1
1Institute of Pediatric Oncology and Hematology FSBSI "N.N. Blokhin RCRC", General
Oncology, Moscow, Russia
Background/Objectives: The treatment of tumors is impossible without a venous access.
What kind of properties should it possess? It has to be safe, easy to use, implanted only
once during the treatment course and have minimal risks associated with implantation
and use. Our aim was to prevent complications of intravenous chemotherapeutic agent
administration.
Design/Methods: From 2010 to 2014 we were monitoring the treatment of 228 children
(aged 3 months to 17 years) with different tumors. 110 patients underwent 605
subclavian vein catheterization, 118 patients – 118 venous port implantation.
Results: Complications and technical difficulties during catheter insertion were
observed in 98.3% of cases, during venous port implantation – in 23% of cases.
Complications of subclavian catheter and venous port use were observed in 97.3% and
in only 11% of cases, respectively. Subclavian catheters compromised cancer treatment
in 45.9% of patients, implantable venous ports – in 1.7% of patients. Each patient with
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a subclavian catheter underwent central venous catheterization 4 to 19 times (mean 6
times) during treatment. Catheter dwell time exceeded the recommended limit in all
patients except for cases of catheter removal by patients. On multiple occasions all
patients were discharged with a subclavian catheter in place.
Conclusion: Venous ports obviously match the criteria mentioned in the introduction.
Subclavian catheter use resulted in cancer treatment protocol deviation in almost 50%
of cases, thus leading to a poorer prognosis and significantly increasing the number of
invasive procedures and instances where general anesthesia was needed.
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STENOTROPHOMONASMALTOPHILIA INFECTIONS IN PEDIATRIC
ONCOLOGY: EMERGING AND POTENTIALLY LIFE THREATENING
M. Saroha1, N. Radhakrishnan1, D. Thakkar1, J. Oberoi2, T. Khanna1, A. Sachdeva1
1Sir Gangaram Hospital, Pediatric Hematology Oncology and BMT Unit, New Delhi,
India; 2Sir Gangaram Hospital, Department of Microbiology, New Delhi, India
Background/Objectives: Stenotrophomonas maltophilia is an emerging multidrug
resistant gram-negative bacillus that is ubiquitous in nature. It is of concern in
immunocompromised hosts as it is potentially life threatening. We analyzed the clinical
characteristics, risk factors and outcomes of pediatric oncology patients with S.
maltophilia infection at our center.
Design/Methods:Microbiological data of pediatric oncology and BMT patients
between 2010-2014 were retrospectively analyzed. Hospital records were analyzed for
treatment received and outcome.
Results: S.maltophilia was isolated in blood culture of 5 patients. During the study
period, out of around 1000 febrile neutropenia episodes, 106 patients had a positive
blood culture. Age of patients ranged from 1 to 11 years. Underlying diagnosis was
ALL (1), Acute Promyelocytic Leukemia (1), Burkitt lymphoma (1), Aplastic anemia
(1), Thalassemia major post cord blood transplant (1). 3/5 had respiratory symptoms,
2/5 had grade 3-4 mucositis and one had chest wall abscess. Pus culture and
endotracheal secretions were positive in 2 cases. All had indwelling central venous
access device at this time of infection, which was subsequently removed in three. 4/5
patients were neutropenic at the onset of infection. Duration of neutropenia lasted for
>3 weeks in 4 patients. All patients received broad-spectrum antibiotics and 2 received
steroids prior to illness. Fall in WBC count was noticed in all 5 patients after the onset
of infection. The organism was sensitive to Levofloxacin (5/5), Cotrimoxazole (4/5) and
Ceftazidime (1/5). All were treated with Cotrimoxazole and 3 received Levofloxacin.
Two patients succumbed to the illness. Both patients did not have recovery of neutrophil
count till death. In the rest, neutropenia recovered with improvement of sepsis.
Conclusion: Although ubiquitous and less virulent, S.maltophilia can cause severe sepsis
and death in an immunocompromised host. Removal of indwelling catheter, prompt
initiation of appropriate antibiotics and recovery of neutropenia helped in survival.
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BONEMARROW EXAMINATION IN YIELDING CAUSE OF FEVER OF
UNKNOWN ORIGIN: EXPERIENCE FROM A TERTIARY CARE HOSPITAL
M. Saroha1, N. Radhakrishnan1, D. Thakkar1, J. Dass2, T. Khanna1, A. Sachdeva1
1Sir Gangaram Hospital, Pediatric Hematology Oncology and BMT Unit, New Delhi,
India; 2Sir Gangaram Hospital, Department of Hematology, New Delhi, India
Background/Objectives: Bone marrow (BM) examination remains a crucial test in
diagnostic approach for fever of unknown origin (PUO). Bone marrow aspiration
(BMA), biopsy, culture and other PCR based tests frequently prove helpful in reaching
to a diagnosis. We report data of 58 pediatric patients.
Design/Methods: A retrospective analysis of PUO patients admitted at our center
during January 2010 to March 2015 who underwent BM examination was done. All
patients underwent BMA, biopsy and microbiological tests viz. culture & sensitivity
and tests for isolation of mycobacteria viz. gene probe, AFB culture & sensitivity were
also sent depending on presenting complains of patient. The demographic and
laboratory profile were obtained from hospital records.
Results: During study period, 58 patients were admitted for PUO at our center. Out of
58 patients, 17 patients showed presence of blasts on peripheral smear examination
(29%) and thus, were not further analyzed. BM examination revealed diagnosis in 24/41
patients (58%); Hematological malignancy: 12 patients (29%), Hemophagocytic
lymphohistiocytosis or MAS: 7 patients (17%), 1 patient: Hodgkin lymphoma (2%), 1
patient (2%): encapsulated fungal spores on biopsy (Cryptococcus) and 1 patient: gene
probe for tuberculosis positivity (2%). Two patients showed prominent eosinophilia on
BMA and biopsy. None of the 8 patients for whom BM cultures were sent showed
growth. Overall, the diagnostic yield of BM examination was 58%. Among the tests for
BM examination, the yield of pathological examination was 91%.
Conclusion: BMA, biopsy and microbiological tests are useful for the diagnosis of
prolonged fever of unknown etiology in children. In resource constrained set up like
ours where extensive work up of PUO is expensive and at times unavailable, BM
examination is a relatively cost and time effective modality to help reach a diagnosis in
children with PUO. BM culture and other microbiological tests are of less diagnostic
significance.
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DIARRHOEA IN CHILDREN UNDERGOING TREATMENT FORMALIGNANT
HAEMATOLOGICAL, ONCOLOGICAL CONDITIONS AND BONEMARROW
TRANSPLANTATION (BMT) IN A SCOTTISH CHILDREN’S CANCER UNIT
N. Sasankan1, M. Ronghe1, D. Murphy1, B. Gibson2, E. Chalmers3, J. Sastry1
1Royal Hospital for Sick Children-Yorkhill, Oncology Department, Glasgow, United
Kingdom; 2Royal Hospital for Sick Children-Yorkhill, Haematology Department,
Glasgow, United Kingdom; 3Royal Hospital for Sick Children-Yorkhill, Department of
Haematology, Glasgow, United Kingdom
Background/Objectives: Diarrohea is a common, potentially serious complication in
children undergoing treatment for childhood malignant conditions. Screening of stool
is expected to help in management and source isolation of children to prevent spread to
others.
Design/Methods: This was a retrospective audit of diarrhoeal episodes over a period of
three months from August 2014 and October 2014. All children undergoing treatment
for a malignant condition or BMT in a Scottish tertiary treatment centre who had a
stool screening during the study period were included. We identified that multiple stool
samples were sent for each episode. Being symptom free for 48 hours was considered as
remission of an episode. We excluded asymptomatic neutropenic patients as routine
samples were sent weekly for this group. Data was obtained from electronic records and
case notes. Information collected included diagnosis, symptoms, stool culture &
virology results, treatment and outcome.
Results:We identified 35 patients with 63 episodes. Majority of our patients had a
haematological malignant condition. Episodes per patient ranged from 1 to 4 with a
mean of 1.8. Stool culture was positive in 24 out of 63 episodes with viral PCR being
positive in two cases. 13 episodes had vancomycin resistant enterococci and 5 had
extended spectrum beta lactamase producing organisms. In 14 episodes there was
persistent colonisation. Following the stool culture results, in 9 episodes the antibiotic
were changed. In 23 episodes patients were stem cell transplant recipients. These
patients had prolonged symptoms and persistent colonisation. Early isolation of
children with positive microbiological screen, prevented spread to other patients on the
ward.
Conclusion: Diarrhoea is a common side effect of chemotherapy, radiation therapy and
bone marrow transplantation. Stool screening was found useful in
immunocompromised patients to identify organisms, modify treatment and to isolate
patients to prevent spread to others.
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EFFECT OF NUTRITIONAL STATUS AT DIAGNOSES OF PATIENTS WITH
NEPHROBASTOMA AT A SINGLE INSTITUTION IN A DEVELOPING
COUNTRY OVER TWO 5 YEAR TIME PERIODS
J. Schoeman1, A. Buchner1, F. Omar1, M. Kruger2, D. Reynders1
1Steve Biko Academic Hospital & University of Pretoria, Paediatrics, Pretoria, South
Africa; 2Univerity of Stellenbosh, Peadiatrics and Child Health, Cape Town, South Africa
Background/Objectives: To compare the nutritional status at diagnosis and outcome of
patients with nephroblastoma with different stages and nutritional interventions in two
time periods.
Design/Methods: An audit was performed on the records of patients with
nephroblastoma treated at a single institution from January 2005 until December 2014.
The period was divided to compare outcome: group one (2005 until 2009) and Group 2
(2010 until 2014). The initial stage and final outcome were recorded. Anthropometric
assessment included: weight, height, triceps skin fold (TSF) and mid upper arm
circumference (MUAC). Severe malnutrition was defined as: below two standard
deviations of the Z-score; TSF and MUAC under 5th percentile according to Frisancho
tables. Nutritional intervention given as oral supplements, enteral (EN) and/or
parenteral nutrition (PN).
Results: In the first period there were 50 patients with a mean age of 47 months and in
the second were 48 patients with mean age of 49 months, The stages in the two periods
were respectively : stage I (36% vs. 29.2%), stage II (10% vs. 20.8%); stage III (32%
vs.31.2%); stage IV (12% vs.12.5%) and stage V (10% vs. 6.3%) and the nutritional
support given was: oral supplements (62% vs. 29.2%); EN (34% vs, 56.3%) and PN (4%
vs 14.5%).Stunting and underweight at diagnosis were more pronounced in first group
when compared to the second: 40% vs. 16.7% and 22.9% vs. 10.4% respectively. The fat
and muscle stores showed no difference according to WHO standards (33.3% vs.
34.3%), however, the Frisancho tables indicated increased malnutrition in second group
(38.3 vs. 56.3%). The overall survival rate increased in second period (60% vs. 75%).
Conclusion: Patients with depleted fat-and muscle stores and high risk disease at
diagnosis had a higher mortality. The superior outcome in the second group may be
attributed to better equipped and funded facility and more intensive nutritional
support.
Pediatr Blood Cancer DOI 10.1002/pbc
S392 SIOP ABSTRACTS
P-636
DISTORTION PRODUCT OTOACOUSTIC EMISSIONS (DPOAES) MAY SERVE
AS PREDICTORS OF INTERNATIONAL SOCIETY OF PEDIATRIC
ONCOLOGY (SIOP)-GRADED HEARING LOSS IN PEDIATRIC PATIENTS
WITH BRAIN TUMORS
M. Schuelke1, D. Sladen2, D. Warad3, J. Cole2, R. Neff2, A. NageswaraRao3
1Mayo Clinic, Medical Scientist Training Program, Rochester, USA; 2Mayo Clinic,
Department of Otorhinolaryngology, Rochester, USA; 3Mayo Clinic, Division of
Pediatric Hematology/Oncology, Rochester, USA
Background/Objectives: Cisplatin is an effective chemotherapeutic agent which carries a
significant risk of dose-dependent cochlear damage resulting in progressive high-
frequency hearing loss (HL). Various clinical ototoxicity grading scales are used to
detect HL and modify therapy. Distortion product otoacoustic emissions (DPOAEs)
are used to evaluate the function of individual cochlear hair cells independent of
patient participation, making it a reproducible assessment.
Design/Methods: A retrospective review of 8 pediatric brain tumor patients (6
medulloblastoma, 2 germ cell tumors) treated at our institution between 2007 and 2014
with radiation and cisplatin containing therapy was conducted. Audiograms and
DPOAEs for each ear (n= 16) at baseline (pre-cisplatin administration), at mid-therapy,
and near the end of therapy (375-400 mg/m2 cumulative dose) were reviewed. Hearing
loss in decibels was graded as per the International Society of Pediatric Oncology
(SIOP) grading scale.
Results: At baseline, five (31%) ears had absent DPOAEs at 8 kHz and DPOAEs were
present in all ears at 4 kHz. Grade 1 HL was noted in 1 ear. There was no correlation
between absent DPOAEs and HL by pure tone audiometry at baseline (p=0.31). Near
the end of therapy, 56% of ears were noted to have Grade 1 HL (6 grade 1, 1 grade 2,
2 grade 3) and DPOAEs were absent at 4 kHz and 8 kHz in 23% and 62% of ears.
Absence of DPOAEs at 4 kHz correlated with a  Grade 2 HL (p=0.004) and absence
of DPOAEs at 8 kHz correlated with  Grade 1 HL (p=0.005). Moreover, absence of
DPOAEs at 8 kHz at baseline was predictive of grade 1 HL near the end of therapy
(p=0.03).
Conclusion: By assessing individual cochlear hair cell function, DPOAEs can serve as a
predictor of progression to clinically-graded HL with time. Larger studies are required
to further define their clinical functionality.
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IMPROVING QUALITY OF SEXUAL LIFE IN CHILDRENWITH LYMPHOMA
IN DEVELOPING COUNTRIES: DISCUSSING THE UNDISCUSSED!
S. Jain1
1SMS Medical College & Attached Hospitals Jaipur, Radiation Oncology, Jaipur, India
Background/Objectives: Sex and cancer are two words that do not seem to belong in the
same sentence. Success in pediatric oncology requires attention to the psychosocial
consequences and quality of life. It is incumbent upon oncologists to conceive of
Lymphomas as more than just a disease that begins with diagnosis and ends when the
treatment protocol ends instead, it initiates a life-long trajectory of survival having
long-term implications for quality of life.
Design/Methods: Emotional needs are deeply frustrated in children, due to long
hospitalization, separation from parents, friends, painful tests, anxiety and anguish,
hours of loneliness without tenderness, this critical suspension from normal life and
shift to emergency survival delays growth of autonomy and independence and further
complicates e attainment of satisfying sexual identity and disrupts basic psychosexual
maturity process. Adolescent sexuality is very complex, and even more when serious
adverse event like cancer affects the individual well-being - sexual and non-sexual - in all
its dimensions.
Results: Young survivors are significantly different in specific domains to healthy, they
are less feminine in sexual identity have more restrictive and submissive images of
sexuality, lower confidence with masturbation. They have less experience of intercourse.
These effects can be better understood if put in perspectives with many changes and
challenges young cancer survivors have to face and cope with in different emotional,
affective, relational, cultural and existential domains. Cultural issues in our society, such
as the myth that children are too young to be interested in sexuality and presumption
that issues of survival overshadow sexuality, provide barriers to open communication
about sexuality.
Conclusion: Sexual function and fertility should no longer be regarded by oncologists as
frivolous or irrelevant issues, the very privileged relationship that oncologist have with
their patients should permit them to assist children in their journey of lymphoma.
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SERUM LEVELS OF GALACTOMAMMAM, BETA GLUCAN AND UTILITY OF
PCR FOR THE DIAGNOSIS OF INVASIVE FUNGUS INFECTION IN
PEDIATRIC PATIENTS WITH CANCER
L. Sherief1, O. Elsafy2, H. Mohtaday3, E. Abdelkalek4, M. Abd Elbasset1, W. Elsaeed1,
S. Saad1
1Zagazig University, Pediatric, Zagazig, Egypt; 2Zagazig University, Pediatric
Department, Zagazig, Egypt; 3Zagazig University, Microbiology, Zagazig, Egypt;
4Zagazig, Pediatric, Zagazig, Egypt
Background/Objectives: Invasive fungal infections (IFIs) are being increasingly
recognized in children with cancer, and delayed diagnosis can lead to death. Our
objective was to detect early Invasive fungal infections in immunocompromised
children with cancer using noninvasive tests including serum galactomannan(GM),
serum 1,3 beta glucan and Conventional PCR for pan fungal infection as recent
diagnostic method.
Design/Methods: we studied 50 febrile neutropenic cancer patient (54% with acute
lymphoblastic leukemia , 18% with acute non lymphoblastic leukemia, 16% with
lymphoma and 12% with neuroblastoma) treated at oncology unit in pediatric
department, zagazig university between November 2012 and April 2014. They were 34
female and 16 male, their age range from 2.5 to 15 year, blood samples were collected,
cultured for fungal infection and evaluated for noninvasive tests.
Results: :Eleven patients (22%) proved to have IFI, as defined by the 2008 European
Organization for Research and Treatment of Cancer/ Mycoses Study Group
(EORTC/MSG) criteria for IFI. Blood culture were positive in 12 patients; (11 with
candida and 1 aspergillus), the sensitivity, specificity, positive and negative predictive
values for positive and negative results of GM in patients with proven and probable IFI
were 75.9%, 85.7%, 58%, 88%; for 1,3 beta glucan they were 88.6%, 80.9%, 88.6%, 85%;
and for PCR they were 93.1%, 76.1%, 84.3%, 88.8%, respectively.
Conclusion: Invasive fungal infection is relatively frequent among febrile neutropenic
children with cancer. PCR is promising for early detection of fungal infection and
superior to other noninvasive tests in early diagnosis of IFI.
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HEPATITIS B AND C VIRUSES AMONG EGYPTIAN CHILDRENWITH
CANCER
E. Abdelkhalek1, L. Sherief1, N. Akeel1, N. Kamal2, A. El Shahat1
1Zagazig University, Pediatric, Zagazig, Egypt; 2Cairo University, Pediatric, Cairo, Egypt
Background/Objectives: Hepatitis B and C virus infections are major public health
problems in Egypt, both are hyperendemic. Egypt has the highest worldwide prevalence
of Hepatitis C virus infection, with 9% countrywide rate; and up to 50% rates in certain
rural areas. Children with cancer receiving repeated blood transfusions and
chemotherapy are at high risk for these infections. The present work aimed to study the
prevalence of hepatitis B and C viruses among children with cancer at the oncology
department of Zagazig University in Egypt during the period February 2014 to
February 2015.
Design/Methods: Sixty Five Egyptian children with cancer (mean age= 5.487+/-2.348)
and 30 healthy children age and sex matched as a control group were screened for HBV
and HCV. For all children, full clinical evaluation, Liver function tests, the number of
transfusions, HBV and HCV serology using the enzyme-linked immunosorbent assay
(ELISA) and polymerase chain reaction (PCR) were checked. In seropositive children,
HBV-DNA and HCV-RNA were measured. The relationships with study parameters
were statistically analyzed.
Results: HBV serology was negative in all patients and control group. HCV specific
antibody (anti-HCV) was detected in 31 (47.7%) patients but none had in the control
group. We find a statistical significant relation between socio-economic level, education
level, residence, longer hospitalization, surgical procedures and frequency of blood
transfusion and HCV infection.
Conclusion: In conclusion HBV infection is not common in Egyptian population and;
this may denote the success of the national vaccination programme. On the other hand
we observed an increased incidence of HCV infections among children with cancer.
This can be a serious cause of failure of treatment, morbidity and mortality, and point
to the importance of checking the anti-HCV status of the child at presentation, strict
HCV screening of blood donors and usage of disposable equipment.
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ADVANCE CARE PLANNING FOR PEDIATRIC CANCER ; A LITERATURE
REVIEW
K. Shiraishi1
1National Kyushu Cancer Center, fukuoka, Japan
Background/Objectives: Advance care planning (ACP) is increasingly regarded as the
standard in the care of patients with life-limiting illnesses. ACP use has been gradually
increasing with Japanese adult cancer patients.ACP is necessary for children with
cancer, but there is little research regarding pediatrics in the world, and nothing in
Japanese that I could find. I conducted a review on empirical literature on ACP
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pediatric cancer patients and families to assess current practices, effects, and
perspectives of pediatric ACP (pACP) regarding cancer.
Design/Methods: I searched PubMed for empirical literature on pACP concerning
cancer, published January 2000 through December 2014. Key words were “pediatric
cancer”, “advance care planning”, and “advance directive”.
Results: I examined 23 studies. Of those, only 6 were identified as pACP related to
cancer. These 6 studies focused exclusively on teens or adolescents. Of the 6 studies, 3
included family, 2 included end of life care, 2 referred to a way of providing pACP, and
4 referred to effectiveness. Preliminary data suggests that pACP, with cancer patients
and families, can successfully be implemented and is perceived as helpful. It may be
emotionally relieving, facilitate communication, and help to improve decision-making.
Conclusion: I think ACP process is helpfull for children with cancer as well as for teens
and adolescents. Research with children under 15 years of age is very difficult to find. In
most cases for children, basic conversation is all that is done. Of course there is a
difference in comprehension for children at different ages, and so we adjust our support
accordingly. In order to adopt ACP for children, building a trusting relationship and
starting from an early stage are needed. Therefore, I would like to conduct research
within that younger age bracket and find ways to apply pACP effectively.
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STEP DOWN ORAL ANTIBIOTIC AS OUTPATIENT FOR LOW RISK FEBRILE
NEUTROPENIA : AUDIT OF A SINGLE INSTITUTION PROTOCOL
G. Singh1, D. Strother1, V. Lewis2, G.M.T. Guilcher2, T. Truong2, R. Anderson1,
M. lippert1, S. Semmens1, L. Lafay-Cousin1
1Alberta Children’s Hospital, Pediatric Oncology, Calgary, Canada; 2Alberta Children’s
Hospital, Pediatric Oncology and BMT, Calgary, Canada
Background/Objectives:While febrile neutropenia(F/N) is a potentially serious event in
pediatric oncology, prolonged admission for IV antibiotics represents a significant
burden for the family and the health care system. Recent efforts have been directed
toward identifying patients at lower risk of complication who can safely be managed as
outpatient. We describe our preliminary experience of using a consensus-based low risk
F/N definition for outpatient management using our Hospital at Home
program(H@H).
Design/Methods: Patients, fulfilling medical, social and geographic low risk F/N criteria
were started on IV piperacillin-tazobactam, and discharged within 24 hr on oral
antibiotics(levofloxacin or ciprofloxacin/clavulin). Daily monitoring alternated between
nursing phone call, outpatient physician evaluation and nursing home visit. CBC was
performed every other day until ANC  100 and blood culture(BC) repeated if
persistent fever. Antibiotics were stopped when apyrexia >24 hr, BC negative and ANC
100. Readmission criteria included intolerance or non adherence to
treatment/monitoring, positive BC, clinical deterioration, fever > 5 days.
Results: From 2014-2015, 13 patients met the low risk F/N criteria, accounting for 22
episodes of F/N(10% of all F/N admission). Underlying diagnosis included Acute
lymphoblastic leukemia(30%) and solid tumors(70%). The median duration of fever
and neutropenia were respectively 2 days(range 1-4 days) and 4 days(range 1-7 days).
No adverse event(death, bacteraemia, modification of antibiotics, readmission) was
reported. For each F/N episode, the median number of H@H visit and outpatient clinic
visit were respectively 1(range 1-2) and 1(range 1-2) compared to 5 days of inpatient
admission with previous management.
Conclusion: Our preliminary experience of careful stepdown approach for low risk F/N
patients was associates with no adverse event. The support of our H@H program
allows for only one outpatient visit per F/N episode/patient. This strategy spared 4 days
of inpatient admission. Larger numbers of patients need to be evaluated to confirm the
safety of this approach.
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HEALTH-CARE PROVIDERS’ PERSPECTIVES ON COMPLEMENTARY
ALTERNATIVE MEDICINE IN CHILDHOOD CANCER IN INDONESIA
M. Sitaresmi1, D. Susilawati1, G. Kaspers2, S. Mostert2
1Sardjito General Hospital/ Gajah Mada University School of Medicine, Pediatric
Department, Yogyakarta, Indonesia; 2VU University Medical Center-Amsterdam-the
Netherlands, Oncology - Hematology, Amsterdam, Netherlands
Background/Objectives: The use of complementary and alternative medicine (CAM) is
prevalent among pediatric cancer patients. However, few studies on health belief and
perception on CAM among health care providers (HCP) have been studied. The aim of
this study is to investigate perspectives on CAM of HCP involved in the care of
children with cancer at Dr Sardjito Hospital in Yogyakarta, Indonesia.
Design/Methods: A cross-sectional study using a self-administered structured
questionnaire was conducted in Dr Sardjito Hospital from January to December 2014.
All HCPs: pediatric oncologist, pediatric resident, nurse, dietician, and psychologist
who work in Pediatric word were invited to participate the study.
Results: One hundred and seventy two HCP (response rate was 80%) completed the
questioner. Thirty six percent and 49%of HCP belief that CAM is helpful in childhood
cancer treatment and a combination of chemotherapy and CAM is the best way to cure
cancer.The most common CAM recommended by HCP was self-prayer (95%), support
group (82%) and vitamin-nutritional supplement (56%). The main concern raised from
HCP was lack of scientific evidence. Almost all (98%) of HCP agreed that parents
should receive guidance about beneficial or harmful effects of CAM, however most of
them (74%) stated that their knowledge about the safety and efficacy of CAM is
inadequate. Most HCP (80%) stated they discuss openly with parents the use of CAM,
and 61% HCP stated that discussion was initiated by the family.
Conclusion: This study found that most HCP accept common practices of CAMs in
Indonesia such as self-prayer, support group and vitamin-nutritional supplement.
Despite of inadequate knowledge of the safety and efficacy of CAM, they agreed that
parents should receive guidance about beneficial or harmful effects of CAM. CAM
should be included in the curriculum of health professional education.
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ADOPTIVE CELLULAR THERAPY IN PERSISTENT ADENOVIRAEMIA
P. Sivaprakasam1, J. Moppett2, M. Cummins1, C. Steward1,3, J. Cornish1, K. Gunter4,
A. Friedetzky5, H. Muller5, S. Dihanich5
1Bristol Royal Hospital for Children, Department of Paediatric Stem Cell
Transplantation, Bristol, United Kingdom; 2Bristol Royal Hospital for Children,
Deparment of Paediatric Stem Cell Transplantation, Bristol, United Kingdom;
3University of Bristol, Reader in Stem Cell Transplantation, Bristol, United Kingdom;
4Cell Medica Inc, Cell Medica, Houston, USA; 5Cell Medica Inc, Cell Medica, London,
United Kingdom
Background/Objectives: Adenoviraemia (AdV) is a significant complication of
haematopoietic stem cell transplant (HSCT). Antivirals control viraemia but T-cell
reconstitution is often required for viral clearance.
Design/Methods:We describe a patient with high level AdV post-transplant who failed
antivirals but responded to administration of expanded adenovirus-specific T-cells
(ADVT). A 12 year old boy in CR3 following extramedullary relapse of precursor-B
cell acute lymphoblastic leukaemia underwent a 9/10 A-antigenic mismatched sibling
donor HSCT (3.55 × 106/kg CD34) following Cyclophosphamide/ Total Body
Irradiation/ Alemtuzumab/ CNS boost conditioning. His transplant was complicated
by poor graft function with lymphopenia of <0.1x 109/L. He developed AdV from
D+33 with progressively worsening adenoviral levels (460 to 480,000 copies/ml) despite
antivirals (ribavirin and cidofovir) and stopping Ciclosporin by D+68. He remained
symptomatic with fever, nausea, diarrhoea and significant weight loss (>10%).
Chimerism was 100% donor in whole blood but with no signal in T-cells.
Results: 100ml of whole blood was collected from his donor after written informed
consent. Product was transported to the Centre for Cell, Gene and Tissue Therapeutics,
Royal Free Hospital, London. A one-touch rapid expansion process by exposing T cells
to overlapping peptides covering the entire adenoviral hexon V protein and a 10-day
expansion in the presence of cytokines without further intervention until ADVT were
harvested and cryopreserved. 104/kg ADVT with 95% purity was administered on
D+117. Patient became afebrile, tolerated oral feeds with AdV of 95 copies/ml by
D+135 allowing cessation of Cidofovir. Lymphopenia improved to >0.8 × 109/L; graft
function improved with 100% donor T-cell chimerism and no evidence of graft versus
host disease.
Conclusion: Adoptive anti-adenoviral cellular therapy has proven to be safe and
effective in this patient.
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THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE AMONG
CHILDRENWITH CANCER IN INDONESIA
D. Susilawati1, M. Mei N. Sitaresmi1, S. Saskia Mostert2, G. G.J.L. Kaspers2
1Sardjito General Hospital/ Gajah Mada University School of Medicine, Child Health
Department, Yogyakarta, Indonesia; 2VU University Medical Center, Pediatric
Oncology/Hematology, Amsterdam, Netherlands
Background/Objectives: The rate to use complementary and alternative medicine
(CAM) among children with cancer become increasingly. Little is known about the use
of CAM in Indonesia like another developed countries. The aim of the study was to
investigate the type, frequency, reason, component and expectations on use of CAM.
Design/Methods: A cross-sectional design was conducted using a semi-structured
questionnaire developed by the researchers. Parents of childhood cancer patients who
were requested to participate in the study between September 2013 to October 2014 in
Sardjito as one of tertiary hospital in Indonesia.
Results: One hundred and seventy-six of parents obtained in this study (respond rate =
85 %), women (73 %) more higher than men (27 %). Commonly use of type of CAM
before and during childhood cancer treatment were praying (91 %),
vitamin-supplement (48 %), and acupuncture (30 %). Some CAM become decreased
during treatment, such as acupuncture(30 % to 1 %), massage (29 % to 9 %), old-smart
people (29 % to 14 %).The most reasons using CAM were hope for improvement of
child’s condition (74 %) and hope for cure (70 %). Only 20 % doctor had ever asked
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parents to use of CAM. More half parent`s expectation include listen if they interested
to use of CAM (75 %), ask them whether interested to CAM (61 %), and doctor have
update information about CAM (60 %).
Conclusion: CAM is frequently used by parents of childhood cancer patient and the
most commonly CAM include praying, vitamin-supplement, and acupuncture.
Health-care provider should consider about parent`s perspectives toward CAM use.
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IMPROVING PEDIATRIC ONCOLOGY SERVICES IN A UNIVERSITY
HOSPITAL IN NORTH INDIA
A. Trehan1, S. Arumugavelu1, D. Bansal1, V. Jain2
1Postgraduate Institute of Medical Education & Research, Pediatrics, Chandigarh, India;
2Jiv Daya Foundation, Medical Oncology, Dallas-Texas, USA Background/Objectives:
Treatment of childhood cancer in developing countries is fraught with challenges. The
major challenges are accessibility to medical services and affordability. Consequently the
incidence of refusal and default of therapy is high. How do we improve?
Design/Methods: Three full time trainee fellows were added to the 3 consultants and 1
registrar running the unit towards end of 2009. In addition, a full time social worker
was assigned to counsel and assist patients in applying from governmental agencies for
financial support. Unit data was analyzed to evaluate improvement in patient care.
Results:We registered 3568 children with cancer from January 2004 – June 2014.
Refusal of Therapy: Twenty six percent patients refused therapy. Refusal was 29% till
2010 and 24% after 2010. Maximal refusal was seen in patients with Acute Myeloid
Leukemia and Neuroblastoma (NBL) (50 & 40%). Refusal in Acute Lymphoblastic
Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) decreased from 34% to 23%.
Wilms Tumour (WT), Germ Cell Tumour (GCT), Hodgkin Lymphoma have a refusal
rate of around 10%.Default of therapy: Twenty eight percent defaulted therapy before
2010; 17% defaulted after 2010 (p<0.05). Default diminished from 14 to 6.5 % in
children with ALL, and from 25% to 11.5% in AML. Nearly 30% of solid tumors
would lapse therapy, which decreased to 15-20%. Default in Retinoblastoma (RBL),
NBL and rhabdomyosarcoma remains high, decreasing from 50-60% to 30%-40%.
Most (80%) patients defaulted after 1-2 courses of chemotherapy. Three fourth of
defaulters had advanced stage disease. Patients with RBL, sarcomas & WT abandoned
therapy before surgery.
Conclusion:With the help of dedicated medical staff and social workers, we have
significantly decreased attrition and increased the number of patients taking therapy.
Developing a model for improving care requires enhancement of medical & ancillary
staff services and developing shared care with peripheral pediatricians in
resource-crunched countries.
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FERTILITY PRESERVATION IN PREPUBERTAL BOYS DIAGNOSEDWITH
CANCER
M. van de Wetering1, A. Meissner2, M. Uijldert2, A. de Melker3, A. van Pelt3, F. van der
Veen3, S. Repping3
1Emma Children’s Hospital/Academic Medical Center, Amsterdam, Netherlands;
2Academic Medical Center, Department Urology, Amsterdam, Netherlands; 3Academic
Medical Center, Center for Reproductive Medicine-Department of Obstetrics and
Gynaecology, Amsterdam, Netherlands
Background/Objectives: There is a high risk of infertility after successful childhood
cancer treatment. In prepubertal boys fertility preservation might be possible by
freezing a testicular biopsy before chemotherapy. Thanks to still ongoing research
spermatogonial stem cells (SSCs) can be isolated from the cryopreserved tissue,
propagated and autotransplanted in the adult patient to facilitate natural
conception.Although basic research is still needed the interval between biopsy and
autotransplantation legitimates starting cryopreservation in a research setting now with
approval of the Dutch Central Ethical Commission.
Design/Methods: Every prepubertal boy presenting to our children’s oncology
department because of a malignancy requiring chemotherapy with increased risk of
infertility will be considered for fertility preservation. Under general anesthesia a
unilateral testicular biopsy is taken using microsurgical technique .This is linked to
central line placement for chemotherapy, so that no separate anaesthesia is necessary.
Follow up of these patients includes postoperative examination for surgery related
complications and ultrasonography of the testis at predetermined time intervals. At 1 ,
6 and 12 months post-surgery the testes were evaluated for abnormalities in testis
parenchyma and testicular perfusion.
Results: From 18-03-2011 until 01-01-2015 the parents of 74 boys were asked to
participate, of which 24 declined. After signing informed consent in 50 of them a
testicular biopsy was performed without any complications. Spermatogonia were
preserved in all patients but one, in which no spermatogonia were found in the
biopsy.35 patients have been evaluated 1 year after surgery. 3 patients had minor
disturbances in testis parenchyma. All other 32 patients had normal testis parenchyma
with normal perfusion.
Conclusion: Fertility preservation by performing testicular biopsies prior to
chemotherapy in prepubertal boys with cancer is a safe procedure and should therefore
be routinely offered.
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CHILD BURDEN OF PARTICIPATION IN A CLINICAL TRIAL DURING THE
PALLIATIVE PHASE
I.M.M. van der Geest1, M.M. van den Heuvel-Eibrink1, C.M. Zwaan2, R. Pieters1,
J. Passchier3, A.S.E. Darlington4
1Princess Maxima Centre, Pediatric Oncology, Utrecht, Netherlands; 2Erasmus MC -
Sophia Children’s Hospital, Pediatric Oncology/Hematology, Rotterdam, Netherlands;
3VU University Amsterdam, Clinical Psychology, Amsterdam, Netherlands; 4University
of Southampton, Health Sciences, Southampton, United Kingdom
Background/Objectives: To test the value of novel, promising anti-cancer medication,
clinical trials in children are essential. Parents’ perspectives regarding clinical trial
participation of their child with incurable cancer, specifically the child’s burden, is an
important topic that warrants more attention. The aim of this study is to explore
parents’ perspectives of participation of their child with incurable cancer in a clinical
trial.
Design/Methods: A retrospective questionnaire was send to parents who lost a child to
cancer. Parents were requested whether their child with incurable cancer participated in
a clinical trial during the palliative phase, their motives for participation, the child’s
perceived burden (5-point Likert scale), and whether they would enrol again. Median
follow-up time was 5 years[3-8 years].
Results: Twenty-four/74 parents of 16/49 deceased children(33%) indicated that their
child participated in a clinical trial during the palliative phase. Parents’ reasoning for
their child’s participation was(more than one answers possible): treatment for future
patients(n=16); followed by hope for a cure(n=9); prolonging their child’s life(n=6)
and other reasons(n=5). To the question about the child’s burden of participation, 8
parents marked ’1’(not burdensome) and 4 parents ‘5’(very burdensome). Remaining
parents scored between ‘2’ and ‘4’. None of the parents would decline participation if
they would be in the same situation again.
Conclusion: Performing clinical trials, even in a vulnerable population as children with
cancer at the end of life, may not always lead to increased burden. None of the parents
would in future, given the same circumstances, decline participation in a clinical trial.
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PSYCHOSOCIAL OUTCOMES AMONG BEREAVED SIBLINGS OF
CHILDRENWITH CANCER
I.M.M. van der Geest1, A.S.E. Darlington2, M.M. van den Heuvel-Eibrink1
1Princess Maxima Centre, Pediatric Oncology, Utrecht, Netherlands; 2University of
Southampton, Health Sciences, Southampton, United Kingdom
Background/Objectives: The number of studies exploring long-term adjustment of
bereaved siblings are limited and lack conclusive evidence about the psychosocial
adjustment of siblings after the death of a brother or sister with cancer. Gaining
knowledge about long-term adjustment of siblings is important to be able to adequately
meet the needs of siblings.
Design/Methods: Parents who lost a child to cancer between 2000 and 2004 were asked
to retrospectively complete two statements about the well-being of siblings, which was
embedded in a larger study exploring parents’ perspectives on paediatric palliative care.
Parents were asked to rate both statements on a five-point Likert scale, ranging from ‘1’
(disagree) to ‘5’ (agree).
Results: Sixty-eight parents completed both questions about siblings’ well-being. In
total, 29/68 parents (43%) (somewhat) agreed with the statement that their other
children had experienced a lot of problems in the period before and after the death of
their brother/sister. Interestingly, most parents mentioned that the siblings still
experienced negative consequences as a result of the death of their brother/sister after a
median follow-up time of 5 years (31/68 parents (46%)).
Conclusion: Negative consequences of the child’s loss still occur in bereaved siblings,
even many years later. Though we here report findings of a small evaluation and we did
not use validated instruments to measure the siblings’ well-being, findings are valuable
in stressing the need to support siblings, which could improve future paediatric
palliative care. Considering the impact of a siblings’ loss, upcoming studies should
focus on developing supportive intervention strategies for siblings, and exploring
whether a potential effect of intervention strategies sustains over time.
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HOME-BASED PAEDIATRIC PALLIATIVE CARE FOR CHILDRENWITH
INCURABLE CANCER: PERSPECTIVES AND IMPACT ON GENERAL
PRACTITIONERS
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I. van der Geest1, P. Bindels2, S.M.F. Pluijm3, E. Michiels3, A. van der Heide4,
R. Pieters1, A.S.E. Darlington5, M.M. van den Heuvel-Eibrink6
1Princess Maxima Center, Pediatric Oncology, Utrecht, Netherlands; 2Erasmus MC,
General Practice, Rotterdam, Netherlands; 3Erasmus MC - Sophia Children’s Hospital,
Pediatric Oncology/Hematology, Rotterdam, Netherlands; 4Erasmus MC, Public Health,
Rotterdam, Netherlands; 5University of Southampton, Health Sciences, Southampton,
United Kingdom; 6Princess Maxima Centre, Pediatric Oncology, Utrecht, Netherlands
Background/Objectives: A substantial number of children with advanced cancer die at
home, implicating that the direct burden of care is delegated to general health care
professionals. So far, hardly any information is available on the quality of home-based
paediatric palliative care, and the impact of providing palliative care for children on
general practitioners (GPs) has never been established.
Design/Methods: Between 2001 and 2010, 150/264 (57%) children with cancer treated at
our hospital died at home. GPs of these children were approached to retrospectively
complete a questionnaire about their experiences with the quality of care, and the
impact of providing paediatric palliative care in a home-based setting.
Results: 91/112 GPs (81%) returned 93 questionnaires. GPs recognized the child’s
fatigue (n=60, 65%) and pain (n=54, 58%) as the most prevalent symptoms. Difficulties
with communication (14%), coordination (11%), collaboration (11%) and accessibility
(2%) were uncommon. The moment the child has passed away, as well as the
atmosphere around the child’s death were positively experienced. Hectic (7%) and
shocking (4%) situations were rare, even as panic (2%) around the child’s death. During
the terminal phase, GPs rated a median score on the distress thermometer of 6 [range
0-9.5]. Almost all GPs were able to come to terms with the child’s death. Being a female
GP (p=0.05), having observed the child’s nausea (p=0.04) or dyspnoea (p=0.04), and a
restless death (p<0.01) were associated with higher levels of distress in GPs during the
terminal phase.
Conclusion: In general, GPs were satisfied with the quality of paediatric palliative care.
The death of a child highly impacts GPs. The child’s suffering and the atmosphere
around the child’s death partly account for the impact on GPs during the terminal
phase.
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OUTBREAK OF INFLUENZA A/H1N1 IN AN OVERCROWDED PEDIATRIC
ONCOLOGYWARD
N. Verma1, A. Kumar1
1King George Medical University, Department of Pediatrics, Lucknow, India
Background/Objectives: Outbreaks of Influenza A/H1N1 in pediatric oncology patients
have been reported from many countries in the world, but the data from India and other
South-east Asian countries is deficient. We carried out a prospective observational
study in an overcrowded 30-bedded pediatric oncology ward in Northern India during
the H1N1 epidemic from January 2015 – March 2015. The clinical characteristics and
outcome of laboratory-proven H1N1 in children with cancer was studied.
Design/Methods: During the epidemic of H1N1 in India from January 2015 – March
2015, all the children in the pediatric cancer ward who had suspected influenza
(respiratory symptoms with or without fever) were tested for H1N1 by polymerase
chain reaction (PCR) in the nasopharyngeal swab. Clinical and laboratory data and
outcomes were recorded for all the laboratory confirmed H1N1 cases. A repeat PCR
was performed in all the cases to document viral clearance.
Results:We identified 75 episodes of suspected influenza in 65 children. Of all these
episodes, 8 (10%) tested positive for H1N1 (3 ALL, 2 Neuroblastoma, 1 Wilms tumor, 1
Ewings sarcoma, 1 Germ cell tumor). The common clinical features recorded were fever
(6/8), cough (6/8) and rhinorrhea (4/8). Three of these 8 H1N1 positive children
required hospitalization due to severe symptoms. One child developed
pneumomediastinum and subcutaneous emphysema and one developed severe upper
airway obstruction. Systemic antibiotics were given to 4 children. There was a delay in
planned chemotherapy in 2 children. Seven children improved on treatment, while one
with upper airway obstruction died after 10 days. Two children had persistent H1N1
positivity on repeat testing and required oseltamavir for 14 days and 18 days
respectively to clear the virus.
Conclusion: Influenza A/H1N1 results in increased hospitalization and antibiotic usage
in immunocompromised childhood cancer patients. These children can also have
unusual clinical manifestations and delayed viral clearance.
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DEVELOPMENT OF A ROLE-PLAYINGWORKSHOP TO TEACHMEDICAL
STUDENTS IN BOTSWANA HOW TO COMMUNICATE EFFECTIVELY AND
DELIVER BAD NEWS
K.D. Westmoreland1,2, F.M. Banda2, B.A. Fassl3, P.S. Mehta4, E. Isaksson5
1Children’s Hospital of Philadelphia, Pediatric Global Health, Philadelphia, USA;
2University of Botswana, Paediatric and Adolescent Medicine, Gaborone, Botswana;
3University of Utah, Pediatric Inpatient Medicine, Salt Lake City, USA; 4Texas
Children’s Cancer & Hematology Centers- Baylor College of Medicine, Pediatric
Hematology Oncology, Houston, USA; 5Holy Cross Hospice, Hospital Chaplain-
Palliative Care, Gaborone, Botswana
Background/Objectives: Delivering bad news is a task that doctors encounter often,
especially in low- and middle-income countries (LMIC) where morbidity and mortality
are high. Existing reports show doctors lack confidence and skill in performing this
task and most have never received formal training. This is the first report describing a
workshop teaching communication skills to medical students in a LMIC on delivering
bad news.
Design/Methods:We conducted 2-hour small group workshops to final year medical
students at the University of Botswana rotating through their pediatric clinical rotation.
The curriculum developed for this workshop included: overview of communication
basics with pediatric patients and families, end of life, HIV disclosure, and introduction
of the validated SPIKES protocol for delivering bad news. Education strategies
included didactic lecture, role-playing case sessions, open forum discussion, and
handouts. Pre- and post-training surveys were completed by participants using a
5-point Likert scale to determine 1) previous experience, 2) perception of skill and
confidence to deliver bad news, and 3) overall workshop effectiveness.
Results: 33 medical students attended the workshop and 82% (27/33) completed the pre-
and post-training survey. Medical students reported exposure to delivering bad news on
average 22 times monthly with 63% having delivered bad news themselves. The
preparedness to deliver bad news using a specific strategy increased from 29% to 100%,
and self perceived skill and confidence increased from 18% to 85%. Feedback after the
workshop demonstrated that 100% found the SPIKES approach helpful and plan to
use it in clinical practice, found role-playing helpful, and requested more sessions.
Conclusion: This workshop was effective in increasing medical student skill and
confidence in delivering bad news and has been successfully implemented into our
ongoing curriculum. Standardized role-playing communication workshops integrated
into medical school curriculum could be a low-cost, effective, and easily implemented
strategy to improve doctors’ communication skills in LMIC.
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DEVELOPMENT OF A PAEDIATRIC PALLIATIVE CARE OUTREACH
SERVICE IN N.W.CAMEROON
P. Wharin1, P. Hesseling2, M. Tamannai3, J. Kaah4, G. Mbah4
1Beryl Thyer Memorial Africa Trust, Trustee, Kettering, United Kingdom; 2Stellenbosch
University, Paediatrics and Child Health, Cape Town, South Africa; 3Charite Hospital,
Paediatric Oncology, Berlin, Germany; 4Cameroon Baptist Convention Health Board,
Banso Baptist Hospital, Kumbo, Cameroon
Background/Objectives:We have treated over 1,000 patients with Burkitt lymphoma
(BL). Approximately 40% of children treated are in need of palliative care(PC). A
survey in late 2012 showed that the majority of these children live beyond the range of
the 4-wheel drive vehicles used by the existing hospital palliative care team. Our
objective was to establish an effective outreach PC service to these children.
Design/Methods: A motorbike was purchased in 2012 and a male nurse with paediatric
nursing experience was appointed. Our nurse is undertaking further training in
paediatric palliative care. The outreach PC nurse spends over 50% of his time on the
ward getting to know patients and their guardians: he is an integral part of the hospital
team. The service has now extended to outreach from Mbingo Baptist Hospital.
Results:We abandoned the motorbike as a mode of transport in 2013 but the service
continues using public transport and lifts with other outreach hospital teams. For each
home visit the PC nurse completes a report of care given and details of sociological
information (carers, traditional medicine). In 2013 a visiting paediatric oncologist (Dr
Mona Tamannai) set out to assess quality of life issues for both children and guardians
in an attempt to find out how the new service affected these. We now have 2 years’
statistics covering home visits.
Conclusion: PC home visits have improved quality of life for children and their
guardians. Increasing numbers of children with other cancers, mostly Wilms tumour
and retinoblastoma, are now treated under established programmes at Mbingo Baptist
Hospital. The need for PC home visits is ever greater.
Posters: Surgery (IPSO)
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HUGE CERVICO-THORACIC MALIGNANT NERVE SHEATH TUMOR
(MPNST) IN A 10 YEAR GIRL - A RARE CLINICAL ENTITY
K. Kumar1, R. Seth2, A.K. Bishoi3, S. Agarwala4
1All India Institute of Medical Sciences, Pediatric Surgery, Delhi, India; 2All India
Institute of Medical Sciences, Pediatrics, Delhi, India; 3All India Institute of Medical
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Background/Objectives:Malignant peripheral nerve sheath tumors (MPNST) account
for 5-10% of soft tissue sarcomas and are more common in patients of
Neurofibromatosis type 1. Only 18 cases of intra thoracic MPNST have been reported
so far and that too mostly in adults. Herein, we report an unusual case of a 10 years old
girl with a huge dumbbell shaped intra-thoracic MPNST that proved to be a diagnostic
and therapeutic challenge.
Design/Methods: Retrospective review of case records.
Results: A 10 year old girl presented to us with a progressively increasing left axillary
and neck swelling for the last 9 months which was being treated with anti-tubercular
medications. The child had developed weakness of the left upper limb with Erb’s palsy
and progressive dyspnea and cough for the last 3 months. Further evaluation suggested
a large 15x 8 x7cm lobulated tumor in the left upper neck and thoracic region, encasing
the major vessels in the neck and superior mediastinum. Biopsy proved it to be a
MPNST. After 8 cycles of chemotherapy (Vincristine, Ifosfamide, Actinomycin D), the
tumor was deemed to be resectable, radiologically extending from the angle of the base
of the skull to the anterior mediastinum upto the pulmonary artery with intraspinal
extension. The child underwent median sternotomy and removal of a large dumbbell
shaped tumor measuring 18x 9cm (intra-thoracic component) and 5cmx8cm (neck
component). The neurological deficits drastically improved after resection and proper
physiotherapy of the left arm and hand. The patient was not given any post operative
chemotherapy or radiotherapy. The child presented with multiple local recurrences after
4 months.
Conclusion: This is one of the largest reported intra-thoracic MPNST in children. The
poor outcome and early recurrence despite chemotherapy and complete surgical
resection highlights the need for the role of post-operative adjuvant chemotherapy and
possibly radiotherapy.
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AMELOBLASTOMA - MANAGEMENT AND REVIEW OF LITERATURE
S. Bhatnagar1
1Mumbai, India
Background/Objectives: The purpose of this report is 1] To report the experience of the
department of Pediatric Surgery in the management of Ameloblastoma of the
mandible in children treated 2] To do a systematic review of the literature of last 10
years regarding the outcome of treatment of ameloblastoma in children.
Design/Methods: For the first part of the study, a retrospective review from the case
reports of the children treated in a single hospital in last 10 years from Jan 2005 till
December 2014 was done. The second part of the study was systematic review of
treatment of ameloblastoma in the developing and developed nations during the same
period.
Results: Three children (1 boy, 2 girls) < 16 years age with ameloblastoma were treated.
All 3 had unicystic lesions of the mandible, 2 on the left with loss of teeth at the siteof
the lesion and one on the right side. As primary treatment, all 3 children underwent
upfront enucleation. One child had remodeled bone graft filled after enulceation. One
child developed recurrence after about 1 year for which mandibular resection and
reconstruction was done. Literature review showed approximately 250 children and
adolescents with ameloblastoma, solid variant predominating.
Conclusion: Ameloblastoma in children has to be evaluated for the type, the extent and
the histology of the lesion which will dictate the treatment. While enucleation is a much
simpler procedure, it must be borne in mind that recurrence rate is high and the child
might require an extensive surgical reconstruction. Large series of long term results in
unicystic ameloblastoma are yet awaited. Enucleation is done in many centers upfront,
causing higher rate of recurrence variable from center to center ranging from 40% to
70%. Most have recommended bony excision and reconstruction with the disadvantage
of disfigurement and complex surgical intervention.
P-655
ANTERIOR APPROACH IN RETROPERITONEOSCOPIC REMOVAL OF A
NEUROBLASTIC TUMOR IN INFANCY
A.M. Fagnani1, A. Morandi1, S. Vallasciani2, R. Luksch3, R. Penati1, I. Borzani4,
F. Pallotti5, F. Mosca6, E. Leva1
1Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Department of
Pediatric Surgery, Milano, Italy; 2Fondazione IRCCS Ca’ Granda - Ospedale Maggiore
Policlinico, Department of Pediatric Surgery - Pediatric Urology Unit, Milano, Italy;
3IRCCS Istituto Nazionale dei Tumori, Department of Pediatrics, Milano, Italy;
4Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Radiology Unit,
Milano, Italy; 5Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico,
Anatomical Pathology Department, Milano, Italy; 6Fondazione IRCCS Ca’ Granda -
Ospedale Maggiore Policlinico, NICU Department of Clinical Science and Community
Health, Milano, Italy
Background/Objectives:Minimally invasive surgery (MIS) is an accepted approach for
neuroblastic tumors. The transperitoneal approach has been described in recent
pediatric literature, while no report concerning the retroperitoneoscopic anterior
approach in infants exists.
Design/Methods:We retrospectively reviewed the clinical records of a 5-month-old
infant operated on for a neuroblastic tumor.
Results: A newborn was delivered at term by caesarean section due to gestational
diabetes (birth weight 3080g). After two weeks she was readmitted with massive
abdominal distension and hepatomegaly. Abdominal ultrasound revealed a hyperhecoic
mass (49 × 34 mm) in left hypocondrium with multiple hepatic nodules, confirmed by
CT-scan, suggestive for aggressive metastatic neuroblastoma. Low haemoglobin and
platelet values, increased LDH, transaminases, NSE and pathologic urinary
cathecolamines were found.Considering the high bioptic risk we immediately started
chemotherapy (Carboplatin, Etoposide 1st cycle).Twenty days later open biopsy of the
adrenal mass and bone marrow aspirate were performed, and the 2nd chemotherapy
cycle was started. Based on histological/biological features the European
Neuroblastoma High-risk Protocol was adopted for two cycles. The lesion size was
reduced to 25 mm, so anterior approach retroperitoneoscopic adrenalectomy was
performed with 3-port 5 mm. The retroperitoneal space was created with a 10 mmHg
pressure. Adrenalectomy was performed and the mass was removed with an endobag.
No complications occurred. The baby, two months after surgery, is doing well,
completing the therapy protocol.
Conclusion: In carefully selected cases, MIS is a safe and effective method to resect
neuroblastic tumors. Retroperitoneoscopy provides direct access to the adrenal gland
and easy visualization of the adrenal vessels. Despite its limits, like significant small
working spaces and reverse orientation of the kidney, it minimizes the risk of injury to
other organs, especially liver and spleen, avoids colonic mobilization, and the risk of
adhesions.
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LAPAROSCOPIC “PNEUMOVESICUM” IN THE DIAGNOSIS AND
TREATMENT OF INTRAVESICAL TUMORS IN CHILDREN
M. Ilari1, G. Cobellis2, F. Nino1, I. Emelurumonye1, A. Martino1
1"G. Salesi" Children’s Hospital, Pediatric Surgery, Ancona, Italy; 2University of Ancona,
Pediatric Surgery, Ancona, Italy
Background/Objectives: In children, the diagnosis and treatment of the intravesical
tumors, sometimes are very difficult, mostly if they are perimeatal. The main criterion
for choice of a “particular” procedure has been the success of this procedure in the
hands of a “particular” surgeon. However, “open” surgery is not without its
complications. We have evaluated our results with a new method, using laparoscopic
pneumovesical approach in the diagnosis and treatment of intravesical tumors of their
uncertain “behavior” in children.
Design/Methods: From December 2013 we performed a laparoscopic “pneumovesicum”
in 3 male patients of 1, 7 and 14 years respectively. The procedure starts with
cystoscopic examination of the bladder.After a short skin incision the first 5 mm
diameter trocar is introduced suprapubically. The two laterals trocars (5 mm) are then
introduced trough the anterolateral wall of the bladder under cystoscopic or
vesicoscopic vision, depending on the surgeons’ preference.
Results: In the first case a biopsy of the primary tumor was performed; in the last two
cases it was possible the total removal of the papillomas that were “in close” connection
with the urethral meatus. There are no intraoperaitive complications. Patients from our
group had a mean hospital stay of 3 days.
Conclusion: The advent of minimally invasive surgery has changed the way of surgery is
practiced even if there is no consensus about the choice of technique to approach
perimeatal intravesical tumors in children. The laparoscopic pneumovesicum represents
an alternative to other “open” techniques and the major advantages include less
surgical trauma and faster operative recovery. A larger multicenter, prospective
randomized study to evaluate this new approach in comparison with the conventional
approach is warranted.
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MANAGEMENT OF GIANT HEPATIC HEMANGIOMA IN CHILDREN
M. Ilari1, F. Nino1, G. Cobellis2, D.A. Cozzi3, A. Martino1
1"G. Salesi" Children’s Hospital, Pediatric Surgery Unit, Ancona, Italy; 2University of
Ancona, Pediatric Surgery Unit, Ancona, Italy; 3University of Rome "Sapienza",
Pediatric Surgery Unit, Rome, Italy
Background/Objectives: Hemangioma is the most common benign tumor of the liver in
infancy and the prevalence ranged from 3-20% in autopsy series. Many of these lesions
are discovered incidentally and are localized and small enough to be of no clinical
significance. Even if, as with their cutaneous counterparts, hepatic hemangiomas exhibit
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multiple patterns of presentation and differing biologic behaviors. The severity of these
lesions varies widely, ranging from asymptomatic to life-threatening complications.
Design/Methods: The records of 3 infants and children of 3 days, 4 and 7 years old
respectively, with giant hepatic hemangioma, between December 2011 to February 2015
were collected. The clinical data including sex, age, symptoms, the size, number, and
location of the tumors, preoperative liver function test and complications were
retroactively reviewed and follow up information was available for all the patients.
Results: All three patients underwent therapy with propranolol (2 mg/Kg/die). In the
newborn, a repeat ultrasonography after 6 months, showed almost complete clearance
of hepatic focal lesion. There were no adverse events of the therapy during the entire
duration of treatment and the child now is off treatment for past two years and has no
evidence of disease recurrence. In the patient of 4 years old, indications for surgical
intervention, a left hepatic lobectomy, were abdominal pain and increased hemangioma
size after two months. In the third patient we are waiting for the results after one month
of therapy.
Conclusion:Many treatment options are available for hepatic hemangiomas. Close
observation should be reserved for a symptomatic tumors, and surgical resection is
offered for symptom relief of complicated hemangiomas or lesions in which the
diagnosis is uncertain. In our experience, hepatic hemangioma associated with prenatal
cardiac disorders, large volume and more than one enlarged hepatic vessel, have poorer
outcome and require specific perinatal multidisciplinary management.
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BILATERALWILMS’ TUMOR (WT) IN A HORSE SHOE KIDNEYWITHWAGR
SYNDROME: A RARE ASSOCIATION
B. Jindal1, B.K. Naredi1, M. Vuriti1, A. Rijhwani1, S.V. Chakkalakkoombil2,
B.A. Badhe3, J.C. Han4, D. Reyes-Capó4
1Jawaharlal Institute of Postgraduate Medical Education and Research, Department of
Pediatric Surgery, Pondicherry, India; 2Jawaharlal Institute of Postgraduate Medical
Education and Research, Department of Radiology, Pondicherry, India; 3Jawaharlal
Institute of Postgraduate Medical Education and Research, Department of Pathology,
Pondicherry, India; 4Eunice Kennedy Shriver National Institute of Child Health and
Human Development, Unit of Metabolism and Neuroendocrinology, Bethesda-MD, USA
Background/Objectives: In pediatric surgical practice the diagnosis of either horse shoe
kidney or bilateral WT is not uncommon, but their combination is extremely rare. We
here in share a rare association of bilateral WT in a horse shoe kidney associated with
WAGR syndrome (11p deletion syndrome) and its challenge in the course of
management.
Design/Methods: The child presented at 5 months of age with hypospadias and right
non-palpable undescended testis (UDT). He was also having aniridia with nystagmus
and was diagnosed as WAGR syndrome complex and was on regular 6 monthly follow
up. At one and half years of age he underwent laparoscopic Fowler’s Stephen’s I
orchidopexy elsewhere. At 2 years he presented with abdominal fullness with pain
during defecation and on evaluation was found to have bilateral WT in a horse shoe
kidney.
Results: The child received 9 weeks of neoadjuvant chemotherpay
(Vincristin+Dactinomycin+Doxorubicin) and then was subjected for surgery. Left
nephroureterectomy (for tumor involving the entire left moiety) with partial
nephrectomy on right side was performed. Post-operatively the child developed
hypertension with renal insufficiency for which he has to put on hemodialysis. While on
hemodialysis he was continued on chemotherapy with the plan of continuous
ambulatory peritoneal dialysis(CAPD) once chemotherapy was over. The child was
later admitted in emergency with loose stool and shock and succumbed to severe
unresponsive shock.
Conclusion: A patient with WAGR syndrome carries the higher risk (45%) of
developing WT and also the risk of end stage renal disease. This risk increases further
when the tumor is bilateral. We recommend frequent follow up of in the first 6 years for
early diagnosis, evaluation and surveillance of patients with WAGR syndrome.
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PULMONARYMETASTASECTOMY IN PAEDIATRIC SOLID TUMOURS IS
FEASIBLE, SAFE ANDMAY IMPROVE LONG TERM SURVIVAL
D. McIntosh1, J. Sastry2, M. Ronghe2, C. Wills2, F. Cowie2, R. Jones2, D. Murphy2,
A. Sabharwal3, A. Kirk4, P. Hammond3
1Royal Hospital for Sick Children-Yorkhill, Glasgow, United Kingdom; 2Royal Hospital
for Sick Children-Yorkhill, Paediatric Oncology, Glasgow, United Kingdom; 3Royal
Hospital for Sick Children-Yorkhill, Paediatric Surgery, Glasgow, United Kingdom;
4Golden Jubilee Hospital, Cardiothoracic Surgery, Glasgow, United Kingdom
Background/Objectives: Pulmonary metastases may be identified either at primary
diagnosis or relapse. We aimed to determine the feasibility, safety, any effect on
treatment decisions and long term outcome of pulmonary metastasectomy.
Design/Methods: All patients who underwent pulmonary metastasectomy were
identified from our institution’s pathology database and case notes were retrospectively
reviewed.
Results: Nineteen patients (12 males; median age 11 years 6 months (IQR: 4-16 years)
with solid tumours underwent metastasectomy between 1993 and 2015. Ten patients
underwent surgery at the end of first line therapy, 3 during treatment and 6 at relapse.
Eleven had metastases identifiable on both CXR and CT and 8 on CT only. At least 37
metastatic nodules were removed from 26 hemi-thoraces (12 patients unilateral, 7
bilateral of which 2 thoracoscopic). No major post-operative complications were
observed. In 14 patients excision was complete both pathologically and radiologically
(one patient underwent initial thoracoscopy but required subsequent open resection to
achieve this). Viable tumour was resected in 16 patients with the remaining 3 having
non-viable/necrotic tumour excised; this determined the need for lung radiotherapy or
changed chemotherapy in 9 patients. Nine patients, of whom 8 had complete resection,
are alive with median follow-up of 24 months (IQR: 6months-6years). Of the 10
patients who died only 5 achieved complete resection of nodules radiologically.
Conclusion: Our experience supports the evidence that pulmonary metastasectomy in
paediatric solid tumours is both feasible and safe. If complete excision can be achieved
both radiologically and pathologically this aids ongoing management decisions and
may contribute to an improved long term outcome. We therefore recommend that
careful consideration should be given to surgical resection of pulmonary metastatic
disease. The optimal surgical route is dependent on the number and location of
metastatic nodules; thoracoscopic excision being reserved for pleural metastases whilst
thoracotomy being employed for those within the lung parenchyma.
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EWING SARCOMA OF STERNUM - SURGICAL CHALLENGE IN A CHILD
S. Misra1, A. Tiwari2, K. Kumar3, S. Mehta4, G. Kapoor5
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Background/Objectives: Achieving R0 resection in Ewing sarcoma (ES) of the chest wall
is often challenging in children and reconstruction is even more exigent. We present a
child with localized ES arising from the body of sternum; managed with neoadjuvant
chemotherapy (NACT) followed by surgical resection and chest wall reconstruction.
Design/Methods: Retrospective case study.
Results: A 7-years-old boy presented with cough and chest pain for 2.5 months and
respiratory distress for 25 days. Chest X-ray showed a right sided opacity. CT chest
revealed 10 × 17 cms heterogenous anterior-mediastinal mass with necrotic areas,
displacing and compressing the mediastinal structures. Image guided biopsy confirmed
ES (CD-99 and FLI-1 positive on IHC). Metastatic workup was negative. Bone scan
revealed focal abnormal uptake in the sternum suggesting the origin of ES. He was
given NACT [Vincristine Doxorubicin and Cyclophosphamide alternating with
Etoposide Ifosphamide every 3 weeks (VDC/IE)]. Re-evaluation after week 12 showed
>60% reduction in tumor size (good PR). The tumor now measured 6.6 × 3.7 cms and
was abutting the great vessels. Resection of the tumor with 5 cms of the sternal body
and adjoining 3rd and 4th costal cartilages on either side was done. The sternal defect
was reconstruction with prosthetic material “Biopore” after confirming negative
margins on frozen section. Histopathology confirmed residual ES with 25% necrosis
and wide free margins. He had excellent cosmesis with no paradoxical movements of
the chest wall. He is currently on consolidation chemotherapy (week 24). Radiotherapy
was deferred since local control had been achieved by surgery alone.
Conclusion:Multimodality treatment of localized ES of chest wall can facilitate R0
resection after cytoreduction. Newer prosthetic materials are promising for sternal
reconstruction. However long term follow-up is essential to look for future chest wall
deformities.
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UTERINE TUMOR RESEMBLING OVARIAN SEX CORD STROMAL TUMOR -
AN UNUSUAL UTERINE TUMOR IN AN ADOLESCENT
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Background/Objectives: Uterine sarcomas are rare in adolescents and have a poor
outcome. We present a young girl with a rare variant of uterine tumor which was
managed conservatively.
Design/Methods: Retrospective case study.
Results: A 17-years-old girl presented with menorrhagia and dysmennorhoea for 6
months. Evaluation elsewhere showed sonographic evidence of 6.6 × 5.2 cms large
fibroid in posterior wall of uterus bulging into endometrial cavity. She underwent
laparoscopy at local hospital. However procedure was abandoned after biopsy since
incision on the posterior wall of myometrium revealed myxoid material.
Histopathology (HPE) showed mesenchymal tumor with extensive myxoid change, IHC
was inconclusive. She presented to us one month later. HPE review showed probable
smooth muscle tumor with low-to-intermediate aggressiveness. MRI pelvis confirmed
the lesion and PET-CT demonstrated non-metastatic disease. After counselling for
possible hysterectomy, she was re-explored. At surgery there was a well-defined
yellowish lesion in the posterior wall of uterus which was easily enucleated. Frozen
section revealed a spindle cell lesion. Giving the benefit of doubt to the young
unmarried patient, hysterectomy was deferred; and retroperitoneal with para-aortic
lymph node sampling was done. Final HPE showed neoplastic cells in sheets and cords
infiltrating the myometrium without tumor necrosis. IHC was positive for CD99, WT1,
ER, PR, CD56 and focally for CK and negative for calretinin, inhibin, SMA,
caldesmon, SMMH, EMA, S100, HMB-45 & desmin. The features were suggestive of
uterine tumor resembling ovarian sex cord stromal tumor (UTROSCT). The
institutional tumor board decided to keep her on regular and close follow-up as
UTROSCT is locally invasive but usually does not metastasize. She has been followed
for 4 months with no recurrence on imaging.
Conclusion: UTROSCT is a rare tumor in adolescents which must be differentiated
from uterine endometrial stromal sarcoma. Preservation of the uterus is possible due to
the less aggressive behavior of this tumor.
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ROBOTIC ASSISTED RESECTION OF LEFT ADRENAL GANGLIONEUROMA
IN A CHILD
S. Misra1, S. Rawal2
1Rajiv Gandhi Cancer Institute and Research Center, Pediatric Surgical Oncology, Delhi,
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Background/Objectives: The use minimally-invasive-surgery (MIS) for therapeutic
resection of solid tumors in children is limited in resource challenged nations. Ours is
one of the few institutes in the country where robotic assisted pediatric onco-surgeries
are performed. We report a child who underwent successful robotic excision of left
adrenal ganglioneuroma. Short video of the procedure is also presented.
Design/Methods: Retrospective case study.
Results: Eleven-years-old boy presented with an incidentally diagnosed left adrenal
mass. He was evaluated elsewhere for chest pain and cough of 1-month duration.
Imaging revealed a well-defined heterogeneous left adrenal mass measuring 5.5×4.2×6
cms without vascular invasion or calcification. His blood pressure and urinary
catecholamines were normal. CT-guided fine needle aspiration cytology (FNAC)
showed lipoma. Repeat endoscopic ultrasound (EUS) guided FNAC was suggestive of
a tumor of neural crest origin- ? neuroblastoma ? phaeochromocytoma. Metastatic
workup was negative. Since there were no image defined risk factors he was taken up for
upfront robotic surgery. Four-ports access with 12mm para-umbilical camera port and
three 5mm working ports, were used for the child in semi-lateral position. After
docking, the robotic arms of the da Vinci Si Surgical System assisted in resecting the
tumor. The adrenal mass was well encapsulated and could be easily separated from the
upper pole of kidney, pancreas and spleen. The adrenal vessels were clipped while
preserving the renal and splenic vessels. The specimen was removed through an
extended para-umbilical incision using an endo-bag. The operative time was 50 minutes
and blood loss was minimal. The child recovered smoothly and was discharged after 24
hours. Histopathology confirmed mature ganglioneuroma. He has been followed up for
3 months with no problems.
Conclusion: Robotic resection of pediatric tumors is a feasible option in selected cases.
The advantages of advanced three-dimensional high-definition magnified visualization;
and supra-human dexterity and range of motion of Endo-Wrist instruments cannot be
overemphasized.
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MUSCULO-SCELETAL TUMORS DEPARTMENT OF THE INSTITUTE OF
PEDIATRIC ONCOLOGY AND HEMATOLOGY: ANALYSIS OF THEWORK IN
2011 - 2013
M. Rykov1, E. Sengapova1, T. Men1, A. Dzampaev1
1Institute of Pediatric Oncology and Hematology FSBSI "N.N. Blokhin RCRC", General
Oncology, Moscow, Russia
Background/Objectives: Bone and soft tissue tumors are one of the most common
cancer in children.
Design/Methods: In 2011 – 2013 in the department of tumors of the musculoskeletal
system, which has 25 beds, 549 patients were treated at the age of 6 months up to 17
years.
Results: On each bed during the analyzed period were treated 22 people. It was carried
out in 1833 hospitalizations, the average time of hospital stay was 18 bed-days. Was
performed 408 surgeries, including 132 (32.3%) – arthroplasty replacements and 1 –
bladebone arthroplasty. Patients with different localizations osteosarcomas - 246
(44.9%), Ewing’s sarcoma family of tumors - 138 (25.1%), soft tissue tumors - 100
(18.2%) melanoma - 7 (1.3%), other tumor - 58 (10.5%).
Conclusion: Patients with osteosarcomas of different locations were dominated.
Prolonged hospital stay was due to a course of chemotherapy with high-dose
methotrexate. Carrying out of the chemotherapy for patients in the one day clinic can
increase the activity of surgical departments and the total number of patients.
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IS GLUTEAL REGION A FAVOURED SITE FOR AGGRESSIVE INFANTILE
FIBROMATOSIS?
Y.K. Sarin1
1Maulana Azad Medical College and LN Hospital, Delhi, India
Background/Objectives: Infantile aggressive fibromatosis, also known as desmoid type
fibromatosis, is a rare tumor of musculoaponeurotic tissue. Though benign, it is a
locally aggressive tumor with a high recurrence rate. Head and neck are the most
common site affected followed by shoulder, upper arm, chest wall and paraspinal
muscles. Gluteal involvement though reported in large series is not a favored site. We
present a series of three patients in last four years, all of them had gluteal fibromatosis.
Objectives: 1) To report the increasing incidence of aggressive infantile fibromatosis in
the gluteal region. 2) Gluteal site associated with high recurrence rate.
Design/Methods: Retrospective analysis of case records of patients with fibromatosis
was done. Last 4 years (July 2010 to June 2014) data was collected. All of these patients
had tumor in the gluteal region two on the right and one on the left side. Size of the
tumor ranged from 8-12 cm at initial presentation. Preoperative biopsy was done in all
the cases, and it reported fibromatosis. Excision of tumor was done with one-centimeter
rim of normal looking tissue.
Results: There were 3 patients, all boys of 1, 2 and 9 years of age. All the patients had
recurrence within one year of excision. One of them was lost to follow up. In other two,
one had re-excision of the tumor with postoperative radiotherapy and other had a gross
tumor with pelvic extension. The later patient is on chemotherapy for tumor size
reduction.
Conclusion:Gluteal region is the favored site for aggressive fibromatosis in children with
a very high recurrence rate. In children wherein fibromatoses occurs in this region, the
prognostication must be done as per the above observations.
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SURGERY OF NEPHROBLASTOMA EXPERIENCE OF THE DEPARTMENT
OF PEDIATRIC SURGERY IN SETIF, ALGERIA
Z. Soualili1, S. Ait Yahia1, M. Benmahmoud1, H. Choutri1, D. Achouri1, M. Mimoune1,
A. Haif1, S. Nedjar1, K. Bechouni1, S. Aggoun1
1Algerian Society of Pediatric Surgery, Pediatric Surgery Setif, SETIF, Algeria
Background/Objectives: To present the results of our experience in the surgery of
nephroblastoma and to analyze peroperative complications.
Design/Methods: A total of 47 children were referred to our departement of pediatric
surgery for surgical managment of wilm’s tumor between January 2000 and December
2011. All patients underwent total or subtotal ureteronephrectomy.
Results: Twenty girls and 27 boys with a mean age of 38 months were treated surgically
in our center. Nephroblastoma was in the right side in 24 cases and in the left side in 23
cases. Twenty five patients have had chimiotherapie wich decreases the tumor volume in
19 patients before surgery. The tumor resection was easier in the left side than in the
right side. Because of the huge tumor volume and to avoid tumor rupture in many
cases, we were not able to do an initial vessel aproach.
Conclusion: Surgery of nephroblastoma is a big challenge for pediatric surgeons.
Perspective 3D virtual tumorectomy will be part of the check list in the management of
wilm’s tumor.
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NEONATAL SACROCOCCYGEAL TERATOMA- EARLY COMPLICATION
AND LONG TERM OUTCOME
D. Yadav1, D. Bagga2, S. Acharya2
1All India Institute of Medical Sciences, Delhi, India; 2VMMC and Safdarjang Hospital,
Pediatric Surgery, Delhi, India
Background/Objectives: To evaluates the presentation, early and long term outcome of
neonatal sacrococcygeal teratoma.
Design/Methods: Retrospective analysis of consecutive cases of neonatal sacrococcygeal
teratoma presenting at VMMC and Safdarjang Hospital, New Delhi from2003 through
2013 was carried out. The age at presentation, significant pelvic extension (Palpable per
abdomen), treatment, histology, early complication, recurrence and long term outcome
were reviewed.
Results: Eighteen patients (14female, 4 male) were identified. Median age of
presentation was 3 days (range1-30 days). All presented with external mass. Significant
pelvic extension was found in two (11%). Posterior sacral approach in fifteen (83%), and
combined abdominal and sacral approach in three (17%), were used for excision.
Histologically sixteen (89%) were mature teratoma (MT), and two immature teratoma
(IMT). All underwent complete excision. Three (17%) developed wound infection (two
managed conservatively, one required diverting colostomy). Two (11%) had early
urinary dribbling and two (11%) had early fecal incontinence (resolved subsequently).
Recurrence (in pelvis and gluteal) developed in two (11%) [1 MT and 1 IMT at initial
diagnosis].Histology of recurrences were one [Yolk sac tumor (YST) (normal AFP,
histology YST, Given PEB-chemotherapy)] and one IMT (Complete excision). Mean
follow-up was 60 months (range 20-122 months). In the long term, one (6%) had
persistent urinary dribbling, none had fecal incontinence. one patient died after
colostomy closure at 4 month of age.
Conclusion: Neonatal sacrococcygeal teratoma presented with External mass. Overall
survival (94.4%) is good with a recurrence rate of 11%. Early complication (22%) and
Long term sequelae (6%) are acceptable and manageable.
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